<SEC-DOCUMENT>0000882095-23-000007.txt : 20230222
<SEC-HEADER>0000882095-23-000007.hdr.sgml : 20230222
<ACCEPTANCE-DATETIME>20230222161852
ACCESSION NUMBER:		0000882095-23-000007
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		124
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230222
DATE AS OF CHANGE:		20230222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		23653385

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>gild-20221231.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:138d9561-5f65-4b2f-b0c5-a8cb97862906,g:db888c96-90b0-4c6d-8008-49d88ed38ca7,d:6d96c727bd3e4a10969bbf6a84d64ce7--><html xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:gild="http://www.gilead.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>gild-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN180L2ZyYWc6Y2VhZDQ0MTRhYjMzNDczZmIyYmZiODVhMTUwYmZiNjgvdGFibGU6ZmIwMTNmNmI2MmM2NGZmNGE3NGIyYmQ3ZTZmZjJmY2YvdGFibGVyYW5nZTpmYjAxM2Y2YjYyYzY0ZmY0YTc0YjJiZDdlNmZmMmZjZl8zLTEtMS0xLTE2NzY2NQ_6cdf0acf-f23c-4394-871b-de8600fa1a78">0000882095</ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN180L2ZyYWc6Y2VhZDQ0MTRhYjMzNDczZmIyYmZiODVhMTUwYmZiNjgvdGFibGU6ZmIwMTNmNmI2MmM2NGZmNGE3NGIyYmQ3ZTZmZjJmY2YvdGFibGVyYW5nZTpmYjAxM2Y2YjYyYzY0ZmY0YTc0YjJiZDdlNmZmMmZjZl80LTEtMS0xLTE2NzY2NQ_e09c178b-6133-4aff-a32a-105047313bb8">2022</ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN180L2ZyYWc6Y2VhZDQ0MTRhYjMzNDczZmIyYmZiODVhMTUwYmZiNjgvdGFibGU6ZmIwMTNmNmI2MmM2NGZmNGE3NGIyYmQ3ZTZmZjJmY2YvdGFibGVyYW5nZTpmYjAxM2Y2YjYyYzY0ZmY0YTc0YjJiZDdlNmZmMmZjZl81LTEtMS0xLTE2NzY2NQ_d8ac8e9f-b5f9-4ac7-9700-b6f3dc72a135">FY</ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN180L2ZyYWc6Y2VhZDQ0MTRhYjMzNDczZmIyYmZiODVhMTUwYmZiNjgvdGFibGU6ZmIwMTNmNmI2MmM2NGZmNGE3NGIyYmQ3ZTZmZjJmY2YvdGFibGVyYW5nZTpmYjAxM2Y2YjYyYzY0ZmY0YTc0YjJiZDdlNmZmMmZjZl82LTEtMS0xLTE2NzY2NQ_e15a5759-80b6-4945-b206-1f0a345516e5">false</ix:nonNumeric><ix:nonNumeric contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtMi0xLTEtMTY3NjY1_2f4084d2-5259-4bc5-8b05-5f700b1f1a8a">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtNi0xLTEtMTY3NjY1_46ccc9b5-72b7-44ea-ba73-a4b1e8bd1b28">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtMi0xLTEtMjA2NjQ5_b7aba77a-d3a3-423b-9d31-3f7747775fae">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtNi0xLTEtMjA2NjQ5_bc98400a-c82d-4004-b4ed-25c8c3bfe4b2">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i9e6348bb4b5348819415c13456fd293e_D20220101-20221231" name="gild:DebtInstrumentCallFeaturePeriodBeforeMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEwOTk1MTE2MzcyNzc_a58a2f1f-515b-4f40-ba1a-00d6cf2d5f1b">P2M</ix:nonNumeric><ix:nonNumeric contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_8de7020f-9548-47c7-9a1e-4746afc67ea4">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_b3559456-f5cf-4d45-8c2a-793a81b2aed1">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_37e207dc-5857-47ab-bc75-5d95f77eba00">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_566a40c8-fefd-4cc7-be50-3313dae89a4d">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_083b769e-0d49-49bf-952b-f91005031157">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_6a8cd158-cdc0-45a1-ba9e-3851203d9cab">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i13cf4d57dd80444a9615d435346a008b_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTY3OTU_0304068a-3d69-42e3-a0cc-97d49217f440">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ied34c0fde1d440f0a671f6e6ead42d05_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTg2ODM_bb52c247-34d1-49f0-be7e-b07c8a217a78">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="gild-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2a52280e791949799892ada047e34d67_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8b93d3ce3b74726be0d91eed3869725_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if2acd853399e42529979a83d303e38d1_I20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i36be9f39e0e143cf97505efaec9d56a4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie98b1de291f04339b19d38631b6c5007_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5776967eec2e40169c93026e3f869e40_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdd0d2f0925f42e7889120dcf51249c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i549c720f0be04d399b280dc53ff6498d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3009f1cc5994ac0949727e755fef6fb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fd731dcc7c6442d9eb015fc7f92096b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ce29476464948ef99a1d86b1a2d50bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff509ac6299d48d6b6117ee9f80eea96_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabc34cf4f8374f479afced7f51e2c9fc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc9d4063e094f24aa7047cc3f2ade07_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea5153cc41ac4ad3909784ec5a03b75b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e8a156a2c184ca39b4834ed03243876_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0142ebb7458d4ec68ef2fa3254d6e76a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc446f587b564d3da2a7e92adf1f9212_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i605eee38c1414b2ebe50ecfda6aa08a7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c07a715073b4180a3d6350999b7c927_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9014eaa8515b42f5bf4fc221a5754f36_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d244df84ac4dea867eed31d805f681_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93bdf1e4730740ab8d4b26eb38235e1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7182ed726234760880abd2d15fcf97b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8646b81d562c4764b295900f43b19e19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i991524b7050f435c8e75c4ffc5a934c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f649babc4c4963a34bead50d8785d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i091822ada63940bfbcb5532bd0807fc2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i831d6d8c42f147b3af3fa768e1980ac4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8570b5642fc41c3b275ef064cd4fc5e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2bbd0596e084172b456bf6e816df644_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31982067c8ba46ccba2062f655093c96_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d65b154d20435bba2da402431f2156_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id41cdbe8321640c0bef3e78a54d341e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f2b6090dbb84a0da94eda0da3c2c7e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3255734b4164a248d1ae872f85437e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c6e110f0a74581baf5ef42159e7423_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i309e1278bed34922b7275c62cf3b74a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e9c39969dfb47c9bad7061e5500bbb8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f97bc74e5b74cff8c8def5c5e9058ce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2c49aec7474f71b15b7ba23892c798_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07be39de877c4dec919659b89dc15370_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ided187f87ec24a75b5f0f28661776608_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib24a5c6406f94acbab0fa346fc44c96d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22bb6ac875f8426a9e185ea79d9ed340_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c9fd7dab9954496aabbca76c556ef25_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic35cf517e1c44e6cb7eb51a11bc60ba9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if58ddd7e8b04461b92ae526d7f69766b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cff17f8e033479dbe6df66c5418db1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>gild:country</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>gild:segment</xbrli:measure></xbrli:unit><xbrli:context id="i1aa84a6eecd341f092eaee39012ec26a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2269762347243d582b0adac2360f5d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7fd9b86e7264c5c947746f574318575_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i390b60767b4e4998ba62331653915af0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88a6a37544df4d67aec58fa3bb44848e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09e8c6458f804b75b3ac5c526d0da3b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib71c43a2aa1f484d95e6e3501ae5b495_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic696402818f946ca8e766e2da5e21ac0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i286ee669e6484c499ce3f18c039cd90c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00413e506af84cb6b520644367a012ce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ac7bcb2b4b64c279d885fb620928589_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d7e0990ed454ca09ff79ece5703dfde_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56cc9ca37eb642478c269153aa683b08_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f70e4e6502d40f395271bf5dacfb004_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f74fe4a143c4a2c9d6b59c1d6a92719_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c25bac5ccf4ea4b63bb3ff8c487134_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e8df77801f4427b07c69bffbbb53f5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cca639743794954823700d44d77da39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cfd1d80d3ce4e1d81dd9cbad42783fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb859e1c4b7140e1bce378f02656f04f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e31ca129163441e8e9ea4ff5f95df21_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b5793c69ad54496bd31bcf75d0dc074_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9fccc1142b74901bc9e73819cdd9125_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b327175cb0442eab0262b47b930716e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a83bfeca0b4653adb38d1116db35d0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2f630b325964676ad13e1b62b9ace1d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if440505f622045a0ab8e2f08a2a84ff4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id47d4305b1ac49fcb94e0cdc18738baa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e56ec469d9f455285efc69b4c698e5c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15076f57d5f940d28b2718517e8b16f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22c3f886b1e7454faf57898572502064_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae0ac82ae7e44e389ab9b0b042115b90_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd4f275449048bdae7a5e135ab9aadb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93fde66711574d6bbab8f82da5df47b6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e1da3ce22e34b9d8b83601cc4c715da_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i964d48496e5a432ba68cb1dba5f31cc2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0071404988114bf68fb32b3baae96596_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69a61c1cbf1a41039ca8dd3bd871bccc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f2cf5628f8640368fe1236801410db4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67f16390de4f49cf950cd63ea38a892e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if72733c8f57e48839a1cec90953d943a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad56bba1d8dd4206abdf2a2ec6754899_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304b851b46d94cd2871b2b103c61252f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5ac5cc1e74843118ec886b8bf7ef582_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c5f8cda4ab4437b9355aa4d0ac8a973_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i740c73c876d84ead9b478bfac1e5c406_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02057a68acd8487089bcc3e13994ef8f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ae81470ee244b1bd11b567115b6709_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib23321b8060e4e9cb82713996e9cdccf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie28f325e4676479c9ae644fd3eb6dc67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0339bfc0225743a98310d7e4676b63a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff0215260a554fe1a70899059d81b451_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f3192435e8c448f8600dfb9c15a1180_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67f25f67445f4a4ab2ccdd05c60c4182_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee906e7856d488ca901f1010783b65d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i887e5599e4c94395876541937b39df84_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0505374d8f084ccba1175e3944dbd664_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida1cacafd04c44f093aad95b5b455f48_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib31ee1b39fb5499c81d8735285addc93_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbac4e022d8e464388f4a38bbf75756d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70473509ff904d01a46a345f05fea5da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf7892154f17434fbf26b8d35f055731_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee4be07fc0444b0c9a13b3199fe07055_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3caa5600f3c42d6a90eb349e4bd514f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca9bbc5fc664235853309bcafe09958_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3622543706a4a2ead1afac3ba8a644a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18db965aef5240089858bc62cf910c9f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd3b6a53fda1447db2fdec88c020c38a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35737905b7f54f96b51c229ab96133ca_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37d4b794616d455b92a951ae3e8edbdb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i036b934c4c424d27a375818415f5f565_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10d92f1839624521878f4e8fe7a4145e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0be6d27e8e284285916d1f631af87d93_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i272805c9851c4bfdb5a20f92f49d6fd0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98e924509b7e456cbae02bc97a737eba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17e5067a7fe24c2489a2377a45fe5b95_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie19185ddfd4c49b9aca949d6f1a89ec6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied3bdd8ecc264a9cb8aabcb280063543_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i633428932b804629900634cfca66947f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e76c6ce2104589bb819a55da49f0a1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i302fc8ea04774f47a2cf3fbb59d774c4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68de7e98cbfe48278b7e8e7b1ec961b2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09ef539a43334ebf8e611cf6caa5b1d3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e84d2367c3549a5bf92e42aa560380d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i058ee4cbf024433382a4b9568255bf56_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c7acb2c7cb04a5d8c5b81d0106790d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idba4864482334ff491facf75b1f78c6e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53b547cdffc54b5d8fd971f88c4b405a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36718df39e0a47c7a9984f2501ce84de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied0db1516b674b75a73389a4c97b931e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9af6895f54f43d2b2aee375ef4268d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50a22c11bafe49b492afdf6f074bf51c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56989cfa5ca9443592944384e4a662a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7d3d1785838487fa5864f6342945d52_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i483ed774b8694c0e9f7537a56e3d8723_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33140238ec544db4bf188fc5d80572b9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0fda03309d414a88c8d75b94de2c56_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic481237eae4e4a89a31528ac64b99866_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c625e43b4ea49c0aae317d5f95ced49_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id61421ab356146f5b9d4c0a367d00a97_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c3f9f82011a48019099652b6774bf3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36131c939960498fae7e0683985c0826_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39482d1ab7947dfbee72e97e6c80cb9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8417f39fd314af3973c6cffd12840ab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83cc8de84b324599b629478841ef5031_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibee89b9c9e4a4997a3e05c1360c968a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2710bb1e4e1a4da2bd3c71ff3d63d766_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d50bd550a3e4eda851933980c3b6015_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife622784ffa145f89df7c21f7e243720_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i995e08e1c0564adfa6e51134fcafcd8c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf67814543c7461d8fcb1cf0ed2a896a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i271f7c1121dc478784b60c3682272afc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c46fa85c0964613972809e212f5c052_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc70db5a1624cd9932fc54e3656a357_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf397fbe91ff4afab6f6016ac4dfc728_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if27e01c3738343ae828ddd82be4d291e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d9a8f22db57427db018ee661e6611ec_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23826be9a15045c7bb6572cf25f0aa6f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe24bb9f9af9476b962e3e4255a2fca0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5889f693afe94663b9bb93ada344fee3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i746f4ee74a48426283deb266e69bfe47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25fb84b127124bc9a930a78d394ae9ba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a531ef2bfa647ae80f2e7f581cb250a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i038b1c841f2c4a1f99edae58948bfc95_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8989bfdb504424e88c9fc5951e552e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i747dd2095bd84387a1b2cef2a08d4ce4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia623a13014414ceeb8b62e7b7d0307ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad8fc90a5cc743ac8164e9757643d7c7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef9373aea4d45da839ba8bd983d6d41_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i159b36366579482e833ac889d1de99c8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib77dccfb87744dc0bd019148750e21d3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i892ab04014c6452385a1231e4a398daf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic70bed0fa20348939ac81aac767a32c6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cdc513510df408a8c14ad0c77931ade_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e1551d2e994a7189a15b9f7e12f955_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3270ed2ab9af4df597819fe1d39f6066_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if566c62d193d4045a5d0d0bc3b4f89a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8e5cf6644584b59bef073ec6d2e077b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if603e181b6c147c1be2e679da1361347_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if161350d9f934bd5b9c69a9471693d6c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i224c38109cbc43f6bad2833a21c3d696_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3d5a1d3752041f4825d5ee38213b9f3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1889ca3a09446d1a27ffe2aacdca6bf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84af8bd3147d49149ce9becb6109e0f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dae9fa70cf84bab9cf15d4dd1ab1c25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca3edc2c8454bfe860b717853160f7c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i990aae18e5ac4dc19094dd84e771dffa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1385fad94f9646459a09390bebc1818f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64774209bf234606bd852b8efadecec2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i408f437468464bfb95a8a1c1592428a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a9586512d7c414fa31e0c58325277e9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i001f0a321e7a4cc9919c4b2d3cc488ef_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a7970864108404b9398d1c10e32861e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef5ab3d255d4d7d9f8adf8b51dc6060_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d762459c913449eb0f5d2ffcf4a8ab8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i842e95d3015c4566b5b99f7cd1c3766b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c8b88a32bcf490093fd7196fd827fdf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f6ac7fa58b641b9994e9e2ce1b1a394_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e5ee028ea914344923f044cfd129a25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e11ede728fc4b108eb991ae3d30fce7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7c70711ba3a452f8b82fa6d3959ed4a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e58f04355584a7b83ab6050a0f2f05e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d165787a07f4f2b974d0947bb5841d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if576a322818849af93ddf776061a8daa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13ecfda046a14b828b6b88d76ce34397_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0cd547725ff48868a0a2427edbdb26c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie44bc2b667f640c0a49ef7f1c0d6afad_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27d62848770f420584e5549e2f98494b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb21c9712fc547089da1e6a2b9444cc9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b6e79b7ca6d45d8865a7c9f5f63c09e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e3cb062c5154c10a3316d587eff126e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54e8d61cf6b54f18a3832db879c16f70_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id357c81bb4e5460ab1a7936bd0bc234a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9303626ac8f847eba23eb95d3525b36f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2436a0ce9352470798f7186a3a70c857_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8352ae8893d34956800ed3b7a48a48f7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4a7fcc37bdb46a8b48ab66e6c59272e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i316a0910d8e048a4843f027671f1598f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0ca5b4297e4ce5bb2fcad022831bd4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46b71f3a3fd84ae7b5f5562467d87974_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab7e60f505e04d06b0aa3dda75663f1f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadec57d70f694b2c9aeef1696ac8ec12_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb175d66081417f895e6a30847d0ec9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibee44c336571414b93118372858b768a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1cdd83824774e048ef83b228f4edbb4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9306bcc0ca3a42b3b7c50ee626394174_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccf53c215b7d4f7997810c9a06bcdd03_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dc553a8ada449298fffed4c28e2060f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic415777eefb04ed297d1241f612be3c7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie13c6aa1001243d89d2583a460ce4786_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib64f820871db47e3a10f78b9550bb92e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42cd1fcad93c4c6ea52dce4ae9e6c75f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b2bdd0ef7d94c5d9c5937ce2afd82fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aec2c5b53674a8e99a3fabeca154f63_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib20a0912ba52411597d240f59ee8a970_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if28852e0de5a4261bb649f5abaa6914b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ed29a62f86443fcb28feb3b67712b1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i752e7f4d5fcb4e0bbf8b49e33b38f59c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id94daf83394e47f9bb26f578ef1b6fd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e7228c11db24e9aa0d0a7aa03dfbb82_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44b50cd213f44bd3b7a2dc1a71945fa5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9225d954d484582b9642b85bcf59293_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib93f3e8abe7249e8bf7db00e4237ff24_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c19876953f4ca6b7fa9b0c8fdf5a9e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25424faa0377487b93010e5bde98b80b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f6d94f1fffe48978776b2d7573360e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53b03b0e23a24b88acb155327c8488ed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a165571ecc4a6a81d1a6a559f0c569_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icde54372e7c94f3cb372e6be0b78a13b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id464c7738d154fe99637211d865d3a53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i152e0d6d305445e59681826b69d85467_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c7a7e2316ac49c2a3524b858ab86c7e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7c74c57c8c0479082ce7a7dac084d27_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib769b5b3d70b46e892db64fc00f73c4c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ce38a9465334f39b1eb1623b8138d52_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if28c44bf664d40ecb1b0a3e548f23981_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59e34f35279744a9b950cebad2d0bc39_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09871c6ba3ae431c998271ba08136fe8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4170b5c1c1714d8f920993b6d2262d02_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6523d67294b4f8981a8e945c6b20785_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6f3c5b346184ba1b39b0710a6321e5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9d36441d753401c8d6ec0475559e780_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ed527ac9bdd4205809a16ca629aec11_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a9466b57eba44278c2bc11a50ea844e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd2376deb7144bd59b534ed53871b5ac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60812f2148b74064ae4b10afc339abc3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b257573b924383a6fd7a367622f923_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie21e023844a745bb8a3684cb9d194638_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idab285af921e41088931c917d2518003_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39beed2eccf74622bbc506893a5c1069_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4047a0aafd81455d991a4aeaa945def4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af0ff053a604ab5bda65ff903d0e784_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0570a9882284918847527738da8a490_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e1f9c9a4fe47a7bc9cbb56ef70b24f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7868f7368c3486d82227cdcaa76a33d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2d7e48b21f4489189057ca3a20ee5a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i552a5e98cd894d1f82b630e62cc1d7fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3d02401452d436da34605e1e142fa23_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57c3adbab8d849c5b912381e32fd4668_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb8d3f9aaf646d1ab94c2572cad9d97_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd11072ce9b8438f822f1f5b0f101e9d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icacbf61077d141f49fe6cfb43f3d6a64_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia435f9794a6b429f9e917b58fca423ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec37e2e6ec1a42e0a68b48238a81f664_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36bfd55ed5a14a94977376f9736657ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9976f07ed0ea4180a61ff830dd781cd2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9f3506be92642258438c218c9fefcab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc7adbea5d984ceca881d04a7c590ecd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic98c35b70a6d4caa9097cbd03988b94b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48bbf122b5a340cd9c41944387fcbf26_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8be13c495ea743bdb150e8a637348840_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f58bf4910d04410b4d8f3dee38fa563_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74057d7eaf294ff4a1f0ee3ed98656e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b1203b4aa444780be9b251625ed241b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c1cdc8fffbe411cb0781c91d13f40bb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eae0aa7e3b54e74ba47f8e7d11af81f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71b57df694f24969abcc922725bd4116_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4309bba638742288a3c3b3411782a64_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia68db9a0ea2f4c7390ec4cbc6e024d62_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f98a55a88cd4ff9a94405f8df480139_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10627c2c5eaf4c4a93e8853d80712680_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e0f9a67dff1450ea9e2f3abed91dfde_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bec111f16ad4191913cb9e0707b68d3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda1937d0695488d92eca8410b6b5ad0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id43ed2f32ec54108b2052f7c81e8dd87_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e173b6e94784412a1a9aba6693632f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20f103fc96db43f9871d8821af37e8d6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe90cf240bcb4039827d8ae3729b5f78_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9ea8631b9b348fc98164b8455c586a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55dcdd667a914130ac7f247f5ab8e970_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50c68ef9e2c94e88bc900f8445716b7f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15ca9a88790b41dab9dd09539fbfc66b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cc8f9b08eb949459f8922ebc6ecd590_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14d6f24068e64a7bb2e161b0ea089deb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie547a0920cc34aff9876297ca28ab3cd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9409f8c5614f464cac6ce5449dfc8a91_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibca6cbf239d149448f38489f25c6ac14_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3b79faef45f4559baf646714298411a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeb51c8c4ffd41489bda5887c0250688_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68234a1374f84b4b93207cb00261676d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a896e7fa0ea4692ab85773273ce8925_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fd408517b934aa38aa102382fee39f7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i720140b50665423d9ecf9cc4d23c024c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d26f0693aed4c998637a007f2a4df73_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bb9697cc7594310943f7cb04cffb997_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3cca4b1510b45f0a81e6c1ee81cd735_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43f061fd85154f68a9a577619edb8cf3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23c6213e809147e69336a3f6284317f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id94a3128eb634eb9a869ba096d445597_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie527ccfe78524f97b3646d01e7cdd88b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab43b5a322744bf29d7a74c4096dac3f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbdf5cd7eae14b92af352c6ab83988a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60a9443075964128a15a01c02e823b16_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67c8b2793e440f6b65336fc0aedd433_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifca680403c8f440e980e85b1a1536764_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ffac4669e6141d693435ad3d4c6baa5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e7eb9d47d3d45f1801328a82bcdb51c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79138071f14346498db0bdc4d20f7898_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8bf0dc9d6014d1b82589f892ae08671_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf42ac0f6b141f9b9a452ed3335a197_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b869318548494b9e06efac2a33eda5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d84e35cd15e4f45a75e3a912c6dc29b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a6ffb332c0e4d9fbb4397e67ceb91dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i738618c718414809ad145d0c367755aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icebf8365902241d8bdd0aa638c68bb3b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62346343776542ffb3989e6fdfdb861b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id85501d9727f4bd3a90aad68a5047f39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7981271263a0497385c106ee1d8586d4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11d9e7d23b4e44fca91e8f8a56cc640a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd5efc4fbfd4d47bbea341757531be6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6323c623d0145c9a4ab424c52f46d21_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91ac289724a141efb05295c0ae0c3206_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbde1bd79a61473584fdf4a131ea0893_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5901b8ecd56a493aab74941a2b2f9e23_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id160a09703b54e7685b93b162b95d162_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4729d87ad9f345eeadc62cb0f11ed0b5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64a427f3722a42e6afceb6d7c0ab324a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id402bd3c4ac1490b8201b3a308ef1e2f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib847a11c1e7f4aee9f52682db5c1f135_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91a7d5c54528430783128148bcd0b974_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3e2f8a83b0f4ae497dc2e5c8ba4927c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb1777596b9e486a9e19ecb95f8684eb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e0fa4aa3a554fbca7b6597772bae432_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b230c4abe241f88e888152fba0544e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icacf9afd500a448096edbd2f4cba2326_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01748bbcf6c24a2e85eb82ac7163747d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ided586c3fc76418f9cab15dce3540cb0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320ef6561a284511ac0240c964bc81a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia34d7b9624484238b55305a3f87daed8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib30d9baceb6a430eba29fc86bed3e18a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8000a2e754d4b178de03c4010ac094d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i191031ec2f8340fe8c4d6783e97231cc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47cec898f169483d9a78d908ee8ac54b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c17ca18fe8b4685bc8dbff8b0024fca_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c0214e29ea4b9282808e79f896a82b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i878929f1d5d34534bbf9576f56d5bffc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ca736187a154121b6128d87c38b83ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dbb6a36e59f4a65b7cd766dceaf5deb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3463ced19f543a6b038efda28937ed7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice19479778e74f7f859404303e2642b1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122092ce94ac4c349bc55b92090d0c7a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i895482d8185045179df5923b9434a992_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ded8cfb2f694a869b82b4f9ceb7481c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb0d53388f4d42a58ab06e6add14cb87_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbff194d4ca5433aa7e19eed529284a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i343fb20119ca4a0e8613c7e22a4b527e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia90efc3a95e5478c9d184b269d0ceecc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794d6401fe294df8a2c8c5f381e7766e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98fd41f3a3ce4161bf06001545fb251e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie276f108be5d41f7bf6f6aec108cc38a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbc48146b4d84e27bff9ab5d3c8388e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id83653adc14343229d0ecdf85dcc0b36_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55695bcefff74f4a90f76506bacb48c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44ec1db4248d428a8f326df992d5ba74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd5cf4c53b074c43b621eb8f8a9aa397_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6943cae579d9493b901bd4c64167f279_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4906ad8453c4207b906de6e1a183a7c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92af14de4d6e45c28faa18feca763fe7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86eb6bdf28e54e3cbf341a8b16bceb07_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0face3f5bfd147f59b55ecdd4534fa47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c332f0a85d243b0b2f856949a44e2d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28e35fde408143f1b5cdd3758261b912_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee00e346b51a47dca4aa5cc9604337d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9e8f79ffaa54a4f8353a2e74e70d2fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67a8beee1994fe2a9cfb4af6a2b4b81_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i133bd58bb3044e43b6e19b3c2019b2c9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b1a0954ab4c4c079b9fa4cff95a21bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c34d1a31564a41b639cee23ce6e2a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf9113abd39d46f397a0870bd4c9cdc8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bee5e30cfa2426f9d380bc5925fcac9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cfca0b59b604750a7f306bd9362a183_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c99e845b70436ca2df28ab68166418_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a483101b0c448358a8bd230e176fff0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3808d9c4a2e146bc9d87fcf438476f8c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bf751057be34c59b162ff5ec611226d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ad0ba308ad04f38a0ff215fa0aacb6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c405fdc93ac4546907dd695172e2ce9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb6db70d966741b8be2616a8bd67d2e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd515e9c1c6b4b0b8621d96b2531c80d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3dcf159fc7b46349235521b48359fa2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20ebe72fb6da4c999fc461851f94ee96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2478182a4b4e4e1487d776c80659bc45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdd0a17887254d5a9c770861de71e83e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie157b97ed1b142c8bfb14e1fcd0d779a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f394996de54d9db35d84fd2f8d9ef7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3900a5a96df424da8d5920aec948465_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4bdf8861d83422885dbc7a9b650a26b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib91c1acddeb04eea8c21245a6b6d170c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic45d2c331f304e139eb2373b4aeea8ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0983c44cb0734541a17aa9caaa5ab892_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cb3270aa34d4ff1b804ace86710f83c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib94f769c7f244c9e88d0a8e925d81a3b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i488df48c29e54b3593d5488e3d330c61_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db63b134cb94dcf9570583d7adafdf6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa4ad0ad8aba4b84beeeb124f4ea9111_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ea779af859f47d89962f097d7265f0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd1b17c5a8674218abaf2a1683840aaf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i618bd4f52005481f8b9ee51618d178c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbf59e9f2f2d4d67b113295c7b4d1089_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4374b3f59dcb41f88c069c68eef7cb1b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedcb3258e37243aa808a6fa8be5a770b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib47bca5eb2de4839b8e148ae5a0de84f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4eb920885a343a481088353353f3232_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88ec60685e024c9a9d982e1a4ff3ae64_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if92841c2bf314e908654618e08167aba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i773b7fbb6ae64c61836fd54bba47d25a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bf409fd77ce4f9a90bb11514b042cff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018a6b73fef648df813ad16b7e2eadb3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07414abcd214485880e84c068a03395f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie19dd55d40234f4aa0cb87ba2849918b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e2a4623b8824759a123ab21bf6411c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib084fcedcc844984a042bbb471e335d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i099761b72f8945b5941d06a0e1567729_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fcf55829c924deebe56a00be5ac0c2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf63565ba06a41a18d32952215669dc5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e733fc488aa402d8d8717e0955e5672_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e16303ba004af899fc51df2e60f7da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02675adb1f704219bbfa6df72958ccf9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic14516a4cc9c4cf4b87bc4e6c89da010_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i944a69baa46241a78832dfd6edb03619_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94e8996fcf904aefa7b45eb05d8a1b9f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41782720cc44450d8ecfa13b2c8eba6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39ea15b99df04bd1a91357ea2c784fb1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5c4c24154784954be6af020baa2783d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if72d0c8e59074c399a7a8d5de4a0d84c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69dc8a4d00924a239a188dc5ae14f7e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6ab0f463354216aaf151d6b3782c66_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeb19fd2013648c5b7c1b740c697a80f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1382e07fb1b3414fa219beccffc330e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cda06ee09b140cb827aed9e1a3df8bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f5633d790d049eb8451a5b270d77750_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied3cb02615a94f4a8ceb1be0e567f340_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d43b6e593fa4c628617fc5b9f8381e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ca783d57092471f8f9c2a0e850ac09c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ea06efd22dd4661bfb5cd9adaff66df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if89553c3611c4e288ce130b8d3ac5113_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08fcddcda0ac40758fc2ee38e6741a4a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f315354a63246aca5ced4ec8972897c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i327c843055444377ab16bab2849e6c00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide95ae75ed8c423695c053ecd6b2da97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd60b83d9abb419d9f60987e3d02e8cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i894b79ae5fbe43b2a34999235fe34725_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i983c7f539ca14293b59e2fe55bbce4b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a6894a7e98f4519a8f9e29d935836aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a77b8962a7b4133b9c80ea7b093866e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff764d89cbbe483ba2bacb34b6224c68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb43dd0a466b491faff2c751f3a877c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d985d4e3d9474ebcab3db7e6a6ee15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21959734d0a54ddcb46382c2339b2f8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib378be3a5b704e4ebb3dc87fcddff125_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9701ad4aac1b429ba132c36256901aa8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86d573d5c055472aa3815285608a7bfd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11ec8cf5f17e4fc1b6fbc896b8b377f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if89123ef0fcf45cebe2871f98a115ee8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56e6656d2b2349758ad1672abcde5f04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3056f9b6e43746a586f484704ba24280_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i177d34f888fa40768c93e77bd471d6ac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf1408e9098f40baa057cd1cfc7888f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ce378a3eb1f4ebba108c7b8e6e3fd0b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib233c60e47c6477a9eb3e08f380cda48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b61ed2454aa4bc2a404ffa25a550770_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e4adf40d5824c4fbe26cd8dcbfbf227_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie454a27fc82f4874b5cda233495e0206_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie78f1ffe90f34e168923153a6356d08e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief9bc9ff381a4854850cbd8345981bc5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3770d09680134e1792a2afb46bb64c8a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i258640a7c57747aeb519ee9e07186999_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39c7630058f7482b8663c73873f905cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if091fd24a2e744cc84af3abc98b8f3f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia14bcf8248ac4a89ac301d6111091e59_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dd2083018754b229660065eb3c2d886_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb7080a46984104933ddc77a231978a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a2c198018764025b669a401e4b72f02_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccefd6d5263c4c06812886b75ec30089_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ca5b496a82144a99398868f529cc733_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85d0914f5c72425b8a8d68428082805c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcaa8320537e4f41a1cac571eb1d4c4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ac85363bb5744b9a9f23b5639f332c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedbbc78ef8e242f2b89fc61cceca1611_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08f3914c4bd548ffa8c16f9da7bd4df7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7e357738293475089434472816fe934_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib93c734b7bfa468486822daca4f70209_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if172c306038b41f48386ed7ae399787a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i126cf5d37167408d897b7f47dbb2f508_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if398b36aa15c4bcdbd145f253add16fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aa74cadbdb34ed3b2763fe749e4a969_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7609fb41a434a248c259460823ebb48_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2efdf458554bab8ef48f6d397f4e6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if21d9ac9e987485c9b496bfee383aafa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10224614a2c4100ba6f83973aa40b07_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3f06b3794e74e00a49aace81e6036af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cd161b557064dc88ec5537ac6193a18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fdbe18128244987a1e36b0904391b66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99e1333e6d0f4c0a8d9fdea046b7eaf1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d0619bee4424bcc8f8609420f4cbb12_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50e2abe2412a45b18cf87a34c75a795b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ff5933035664d28975731dea852a94b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9084bff3951f442886fd602ca88f373d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0dc75bc453e4ab9a410488c8fa21a09_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia73cd273d0724e22a127a4de80a03fee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73bd05cee6434509a4a4f115c801d1c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01e13782ede9404eb98583a539f3ac04_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e9c57adbf444d65825f235837090240_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b5ae4a796da464bb370d53bae12c455_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e52c52611f24f8faac4fa92e65543f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i463626c5759146d08f5927f7e0b6683a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1634706b89014eebace618eae101eefc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eaf91c6ed454ec2900cd809519f9ae0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9928086fec14acfb7cf4385d987b680_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i198d532a8c074ac78f29a94fac0b9f33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4812222e45cd4cb69428c9cdba79819c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad7614ba24154118b1da72e576ca61e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ad61301e5ed420bb158a038204db320_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica09543c00fe4598ac8ce750d8afb1ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9443f1a550be401b9c00363c5d93d604_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if99033cbc8c044d3a0561d49bbba36b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gild:EquitySecuritiesDonationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gild:GileadFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1cc9513c77541668e0695e24152fbdf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gild:EquitySecuritiesDonationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gild:GileadFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c84aa3ba61245188fa2fc51e8e98ac1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i485ded3cb94b411881b8ee607e8a95fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id81c22c85dbc4822a7ef92c8c72ce5b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i669cfd4e64c242c1a8ef8796fd28b7cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bd1f9124d4d45ddb0aca9a2a42b8ae3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66b2c501c7c4411197427bc2b905865c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5dc98f71a34b989bdd92e74b03bcaf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i884916a0bf074d689e54307d3e38f85f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fedf80dcdf54b7ab0cf8db9b226197b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e415108242847aa9f7899559c4beb51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b1fc54addc74b608025b4442073733f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ddfa8ed452243918c264f684e03d322_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ff582c0bcd9440d8450644be10362de_D20220920-20220920"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:MiroBioLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-20</xbrli:startDate><xbrli:endDate>2022-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie636277d8cc8441891c35c55a8b0f84c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:MiroBioLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83300a86394449e3b64aed1970eda7d5_D20210304-20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-04</xbrli:startDate><xbrli:endDate>2021-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="icb5939cef17f48478fd4464ba9e5a0cc_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i510e50f0ac43478382e87ec9808db7ce_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28808546af3a44b5b726f97b0be6b62c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61be0ceaa2ff4374a907d95021e07080_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8747b96d361f490595133641ce6801bf_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f715f66b49c4eb3866d26fc054558bb_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e0b94afcd4a4e969f87632c645d0ab6_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i000f39fad6fc4888bca218c81bd4367a_D20210304-20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-04</xbrli:startDate><xbrli:endDate>2021-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4dce94d4803432ea623df9764cf4027_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4513e5ea422e4a229b71a42e1b842c21_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2d744e7509044cfb0669434445c9252_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab7b0de5a6c43d697d7858746732e0e_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i153abdf5024043579147bb4cf3dd2205_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8b805b1eef94fff97d2acef45332eaf_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e9d7f1885544506bd276d0c9126856f_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13dee278e6454433be1edc4ce1da6ed1_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f1965ab97c42069eb90ab5238a2ecd_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia565affd511f4d70ae37392429f48f4a_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4719e0d131f44a085886b933ab78bb6_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa9a93f5272a429bbdd06910a8637c97_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d561b8ae6b4a2f98da8f5dd0fa0d8a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1048a20244b4ce5bb8bf7d3be281065_D20201023-20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-23</xbrli:startDate><xbrli:endDate>2020-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie422be158b934364b7f415457625004b_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie215a497705b4a2fbfc864f7caeffd9d_D20200407-20200407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-07</xbrli:startDate><xbrli:endDate>2020-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia971b5b9fb3d4bd384e45480e81c75f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a7ef37e465543e5ad6a7b3828719842_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieff06bffa0844a9d8876ecd6c333e23c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44d47c74025d4cfdba50d1a8b27fc2b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i492e0765e063418f871681e4d0901a65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ba8e5a7781443694297bc65f7058d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf3325b9c814697b37f4edbe5de04de_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c7754ade07946249e798f443a00c1b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i181901e26e3e4c91a24f93e978ab1945_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44ccd0f6f6894efbb8cbf39df662d267_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89be91f170784317b4d65294841f9a30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf8e90e835654b89b0b240d8650e1eae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9d3cfbadc744a27b6406bc2824e189a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id42c17e537b943188ee815c6eb4724df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59824532c8ca4a779f76468f950efb0c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d0b0fcb16144c1485e4bb100851404c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i525ebc96796c4ef3b6ad07db88affd7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57236ea81268491a97d91341f26ba286_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cbbdf76bfd6400ebaa7f622c1e30073_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e1a6227be7f4425b549d4e5d0588c1c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i140e9b5aa60a4667b375867beadd9364_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i327df07e8ea64ce7a694e3e3b3ff882e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb58b983f5e14067bcbab9fc5db32341_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9bc6f335dac4058a61472d6b15e5fa0_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DragonflyTherapeuticsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gild:DragonflyTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i771f1a1172d84395889aa09f42795a08_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DragonflyTherapeuticsCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gild:DragonflyTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic189333a47cb4e74a306f790f89b7e3d_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i957b3f15755947a18bbf1e5b8d938645_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gild:MerckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia428e1ccf59043d4b741292e75fe250f_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OralFormulationProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35be91a902b1413ea429208ada936e60_D20210313-20210313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:InjectableFormulationProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-13</xbrli:startDate><xbrli:endDate>2021-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b7362839864e28ab937849b5b66936_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59caa7a2fafd4bcebc5b55c3446ffe7a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0604404ad083494e87385971ee52a834_D20200713-20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-13</xbrli:startDate><xbrli:endDate>2020-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be52f10430343af827d91922fb036f7_I20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f866f4b5345461795270bb2919d3ffb_D20200713-20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-13</xbrli:startDate><xbrli:endDate>2020-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6289804387bd4103907cc19f3c49ade8_I20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i740c686e35a541228a361dc29719f86c_D20200529-20200529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-29</xbrli:startDate><xbrli:endDate>2020-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3837ec2ec53d40948208538478b144fd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2135143e0b8a42c79094487f8538db87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5bf2b91bbf47619e2400e89b0617db_I20210208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15aa5080eeeb4755b9ee289447ef8c62_D20200527-20200527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-27</xbrli:startDate><xbrli:endDate>2020-05-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f56f1023e494483ab5622ea9a93b454_I20211118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>gild:program</xbrli:measure></xbrli:unit><xbrli:context id="i156971f265ed4b789964f0e884da2478_D20211221-20211221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-21</xbrli:startDate><xbrli:endDate>2021-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7645b620bfdd4f51895f7a3169f56f31_I20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfb2a3f5c657473bb9004b07b586f56e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i138aace7ae954687991de21bbcbf935f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01d11dc0f9a54ca5b5c8a9bb3d0e5538_I20200619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i016d7a91b5e04c58945de8f96fb29672_D20200713-20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-13</xbrli:startDate><xbrli:endDate>2020-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c6ac8024c8e4d0dba576efa9455806e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i200b7ebaf9d741dda60fabffb43ff601_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic28bdc6a3eb0421bb098c47b028e6ed7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id73ecb9294534bdda3109b865875a37a_I20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7b11be3257e4f40a3e503c8bc3746c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie187f099f6884416a506c2273b834248_I20200713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9841318d0cc04cdca6946b8f50b2d1e2_I20200717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71a5441f80434f7fb81b3ead03db9f77_D20200825-20200825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-25</xbrli:startDate><xbrli:endDate>2020-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2116fe68676542f08655b70510bcbc39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if64523d7bf4f4c6bbcf933b3fa695ad0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafaadd0b51b8476e9b35ffba851e4d74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70ddfe12d2d14dcd90c45e6ba0df7567_I20200825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57942f7799d54d7f9080cf71318c3ad9_I20200825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81f791b61360445b9d059ca216fb9e27_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TangoTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-17</xbrli:startDate><xbrli:endDate>2020-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c965202198f48ec9fd033a927a99823_D20200817-20200817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TangoTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-17</xbrli:startDate><xbrli:endDate>2020-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9369ae332d1495a882a011455d3dff2_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32bd6912cab14eadbb3318f66acae3dd_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98853617c7ee492bac67c931971fb5b8_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafbe177f342940c6bfb9527cc4113ba3_I20201215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021e03a868e241539ef14f9a4a5d5eff_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a34cfded76c4d25931ccbc7eb146801_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if22f3ebfb466459088b430f3aaf9fbe0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i561a20e735884dd09fd59922c428289f_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dd88b8c706745b7bfcd8184f6d34f23_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ff8d15cd938494a955c3470b06e15f7_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id348a415186e4a219b8e1335dc1ce1ae_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5f7160626e0482aa57280e46676f4b9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b27bce0f57f43408b5d6611ea6202b5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93636a3c58c408fbe02ea53965397ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3809906dea34eddb658b6eb681b0746_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dc6ff7bbfe146f790e94a1bf140cf21_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15224c301e61426ab8f8d27a3b9863f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d6fdb8767134660ae43cba1ca191838_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60eff7e7e8194d3ca2b0fe59c130421e_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d267ec0240944fe98ab627640747acb_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:EverestMedicinesAndImmunomedicsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4dccea757f34cada4ff7ad4f868097e_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:EverestMedicinesAndImmunomedicsAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gild:EverestMedicinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b13652ec49d451b9134a37a2d7ddd69_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:EverestMedicinesAndImmunomedicsAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gild:EverestMedicinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52460a4a2230491d8481379314fe3f77_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:EverestMedicinesAndImmunomedicsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e38b8bce9e8433699c11bb0d7911eaa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie041293ff2f94b94bb3eeae5382b1137_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica9f3e6a16e841fb807eb9deab1f16b7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94f7d5f595874e31babd47d1f943f03f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e682eb04f72495694ed3396a628d82d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a5ea21b1a1b43f288b70665cfbd4480_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id423610de99f429cadafe5a4274a7579_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46a7ff031bd6498c94ca9dd5f3025f99_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fbf6172d0c74ecf8b376de532d163ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72cca364459e4c9a9900d1ff55ebcbe1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife4410a1d3ac4f6db988c4f916e2bfec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfa5f7601c0344768c77f746163923e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if709c8f28db74549bd5a3161d97c21e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic140c268cb72480b99affba2d2903761_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0cddfe4bc224e0a87870c31c94df95e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68e57a3bf88e41bc8bcda7b3a61da0ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3619c4f682548ff8c69c3e69dd442e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42f508896a1f48ef818931672fc82b7f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4befda2944dd4e48bbf33cbb6a800b3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc01af360ccd4ed291a9c264b7a9d13d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d007723ea0d457f8381ae1dc771efe7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5968bcc3ccaf4e119907fba73d267d74_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12e3ef865c8244a080b985b6a3939718_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a23e70b82e64cc79b08ee71a5bd6b2f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie69a01e11be94336a2f8daa28bd70c35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4677adf6e0c14c858103e4db348e4694_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30e53bc1666b4c059c137ce292a94b11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6733ec0f5d1e4796b8f94c12c762b012_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14a47de090294df9b57b1251ef9289b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i175eed19d77e4a91a2d341be010e07f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d037f45ab54f7ca294996c4e283eb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72a08c81dba348df8500cc3742e5df5d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9ed8ad260cf481f964bb009ba049509_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1220d26ecab846bda8d60360ee0028bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3feeb01e0b754048b12295e1fbb184c9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2045Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52789550e4a34d6a81d8f70c1e195b8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2046Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i120a62d356e74c158afb261bb2ae839c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2046Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fe59d0908e34a159160b1e26b01fb15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dcdd5d44dfb41e08635c954c03f9520_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31faa9b303f543e78b0b2176fa8247c9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i259c5faa64504524b5634abd51d1fc38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic33e120250c747548d29ff0a8b4ff7cc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e2c900d6e514479b136e94cce379e22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d5cbf682a784526bc44e1be5f4b2591_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2aa040eb2c451cbda18a7f0add00c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic270da4b44c84a5db419c3cd7630f579_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id302c14527e54b03b1462a8b781c544d_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39f1a4a42b2e42c8b1adac714d4b3849_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6348bb4b5348819415c13456fd293e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58df36e70f7647cf876057727793fb70_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17fb44daa02d4c84b8bed20193956526_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7184a423cb03437a853dc81095f40d56_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ed58c535ccd4faa9176f654b65aaa5b_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bab656927b94fc98bcf55c11d946976_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4655f4b3112c42b5817c56a6a39a9b66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89095e70e7fa45458393451ccf83e29b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5fb8687e8cd4caea5f84599504664c8_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i381dbbaeb14842d0957d6f5cdf308d28_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9689ea2698f49518e3f35ebf341d9d2_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64a2deb2d3f347b89108aa1f51ac3e1b_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:PreExposureProphylaxisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>gild:agreement</xbrli:measure></xbrli:unit><xbrli:context id="ic183ba3839714584846a1a616db08cbd_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>gild:patent</xbrli:measure></xbrli:unit><xbrli:context id="i88bc63bfd5744353885db8517516f8c3_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5013c57ba1f641bd9a9a482a7a391bf2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2032ExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="opposingparty"><xbrli:measure>gild:opposingParty</xbrli:measure></xbrli:unit><xbrli:context id="iea228f095581408787a759595c70e968_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ProductLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>gild:lawsuit</xbrli:measure></xbrli:unit><xbrli:unit id="plaintiff"><xbrli:measure>gild:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i27765a75461d4d2081b2a23a1daaf601_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia23032332ced4abab639e98fc3486e66_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2016StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3967341da57b4f3caa9d502babffc1d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib808ed4dfe4e411999e03f92bc995798_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14329a4081124b6fbf3b38e4aae01606_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdde5e060f4745f89cb9aa85e12fd275_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ca1e84f12844d697f1ea6824ff7451_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i413b2fc67238496985ac43774e9116b6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad684e32333e4d028165723fb0a3c25d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie85479b87980466db067faedfa50f2bd_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ec4c04bdd21487da1fbeecdbf019611_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i925d522b8c534cdf821c642767a2b8c5_D20230202-20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0e2948c490453d8a2ebfca402b6cfb_D20220201-20220201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic65ba49cc6d24464998712864877bfbc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75a52e5d45f44bd2b61d1cbfd645a700_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39a3baccb6f4a489742ff823a82f45d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb52f2212bb54664833a43b8f1d3e792_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b9945ce2eae4b4db8bf21445b6ff8a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i225f3dbf9ef040efa82ebde15cfdcbfc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be022dd13814593bc19060ec3103aff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a8d242e2a254cb7a740cad8ec6484af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e2f8c526d704f298539af3a53a6ab31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4585b2391d2c42aaa5fcec24001b539d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i888ea767a9e646238e97fdafcff19aee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a43e9292cc34d47a7b84bc89666fdcc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1282cebfa404d25b44e39c3dee052f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc18bb50e5fb4827a108a43362008dbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i703dc9a954254418a5cecf9488a563fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ba96d4050347bdb58a1c83a817e40e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc1baff673f642548027f1b6b5d8e4af_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b483b2ee2e42d5a938318ae558e2e2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72eb2ca7a60f4cf19210a329bed5aa1f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia122869e81d74b249c7207040246de2f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41a0488268694a0ca64f483518e451cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id443da59986449869f984ba29bd052a0_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:GileadSciencesInc2022EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f202de25714586abb2bcfe7d406697_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:GileadSciencesInc2022EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13cf4d57dd80444a9615d435346a008b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41cc17b6454144eebfb7455e16f8e439_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief16c425ab394fcfaa9c8f247a26d1b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2061ba894de4be5b28c846ab2265609_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied34c0fde1d440f0a671f6e6ead42d05_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i580e59f939fd4c8388da4fdbdc6b58cb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03e3e50cbabd4bef8487336a456c1552_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba83b20f658a4a5b967cae95a8147d07_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3a53a5a5ed940069011952033f6937e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e116706429d4b6489792bf2fee6c8ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13414ce25cbc42b98829371034442897_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0fbfe8113ac4be684dbe7e6211e449f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gild:AcquisitionRelatedExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icca0a85ac6724ad4a26ba8cfb7d3e7aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gild:AcquisitionRelatedExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ed40d871ce41e2928bc9829eff5643_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gild:AcquisitionRelatedExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib345f0317e14471c87be46037d1c42bd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MiroBioLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gild:AcquisitionRelatedExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09a809a0f4a64f36887c2d0d12f7975f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gild:AcquisitionRelatedExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb5b9f9fcb9e410b9600826b343149ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gild:AcquisitionRelatedExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fd6c8b6cd2e488a9ef5cb0ed0ecd928_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifec682fbc5e74d0b9bb6f5a57a44ba23_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i767c3be8d79f4a58b2e54e5310c7404a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bf67c25be264122919d5db5b2238804_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6786edd5a2f463ba624fe8629254698_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16f8cd4d572b4630890ba497cb7ba380_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91dd25449865431396ad590df47902c2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d2e4dd234744ff0b8f9c4fbca89aac9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i246e5be9df34403b970d76a795c2a09e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia54f00a060494b7e8284daf41bb9942f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i306251c6f0a34cecb6731b34d196923e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb16b1a82cc04d97bc97982197e928b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b63e11ff4a246c388b2b8117a18b35f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd6b4cdafb5e493e8f88f2078b78eb38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05562b0ef6074645bd6d203b69cd9fe7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e2b914d4ec74b7d9487a6f371a25de3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf9a3708d6b74d5eb87c245216002834_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34b2763ca1054014af97296f08cfe8f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i016ea1213b884f66af6169c417c336f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f62493c696477b8cfbb9f960369e84_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GlobalStrategicCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcellxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2425a97f760f4c49bd6815b72167f203_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GlobalStrategicCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcellxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0056aa3d99a143b88dbc13d114cc84be_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GlobalStrategicCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcellxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">gild:ArcellxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f0e85f937584323a180e6f5054512c6_D20230222-20230222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882095</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:TmunityTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_1"></div><div style="min-height:18pt;width:100%"><div style="text-align:right"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.774%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">&#160;UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY184OQ_56aadc67-03e8-4df1-ad20-a4cccbf3ce57">10-K</ix:nonNumeric></span></div><div style="padding-left:218.25pt;padding-right:218.25pt;text-indent:-216pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6ZGUxM2E3ZTYwMjM1NDBiYzhjYzZmNDg5N2YzYmJiN2QvdGFibGVyYW5nZTpkZTEzYTdlNjAyMzU0MGJjOGNjNmY0ODk3ZjNiYmI3ZF8wLTAtMS0xLTE2NzY2NQ_f4cccf8f-a633-4bf1-8cd7-51dd0945f4dc">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18xMDk5NTExNjMxODUw_9ddd0d2b-58ef-4145-b8a9-74b6263b7eb5"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18xMDk5NTExNjMxODUw_22cf6078-a46a-4af5-a3b6-fe02672587dc">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6YmU5MzUyMzUxMzI0NGE3ZDkyYWNlNGU5NDExOTM0ZjUvdGFibGVyYW5nZTpiZTkzNTIzNTEzMjQ0YTdkOTJhY2U0ZTk0MTE5MzRmNV8wLTAtMS0xLTE2NzY2NQ_c6c01a24-e4c1-47ac-a243-999984cc1669">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:29.25pt;text-indent:-29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yMTY_054295ae-e76b-4e84-8e8b-bc8e6e445d92">000-19731</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yMjI_924b1e85-855e-435b-8806-2f2ca2c10539">GILEAD SCIENCES, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.161%"><tr><td style="width:1.0%"></td><td style="width:48.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6M2VkYjFhM2Y4MGYwNDJmYWI3YjI0MGE2NWQzMmY2NmEvdGFibGVyYW5nZTozZWRiMWEzZjgwZjA0MmZhYjdiMjQwYTY1ZDMyZjY2YV8wLTAtMS0xLTE2NzY2NQ_6e436a36-cad2-4ca1-8272-de0856faf3c6">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6M2VkYjFhM2Y4MGYwNDJmYWI3YjI0MGE2NWQzMmY2NmEvdGFibGVyYW5nZTozZWRiMWEzZjgwZjA0MmZhYjdiMjQwYTY1ZDMyZjY2YV8wLTEtMS0xLTE2NzY2NQ_5906fb9a-ffa8-40f2-9956-46b35dfcbfc1">94-3047598</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yODY_7107fca2-5a34-4318-a3be-feb243c47464">333 Lakeside Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yOTA_c47e6cc2-1f61-40b2-9037-f76e627619cb">Foster City</ix:nonNumeric>, <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yOTQ_dffd1ec8-2c19-41a9-a5de-f8fdc8c34c19">California</ix:nonNumeric> <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yOTc_804d1b9c-36d8-4437-a9cb-274e5df191d2">94404</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices, Including Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zNjI_d3cd0b44-e7fd-4bc8-b577-98149a12f3dd">650</ix:nonNumeric>-<ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zNjU_20cbab9c-4c8a-4c63-a37d-8dfa91dc49c5">574-3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.897%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.026%"><tr><td style="width:1.0%"></td><td style="width:36.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6M2M0MTA5NmU5YmEzNDcxMTlhM2ZmZDE1NmVlMzNiZTIvdGFibGVyYW5nZTozYzQxMDk2ZTliYTM0NzExOWEzZmZkMTU2ZWUzM2JlMl8xLTAtMS0xLTE2NzY2NQ_f87d6025-c640-4dd9-a27d-718897dc6629">Common Stock, par value, $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6M2M0MTA5NmU5YmEzNDcxMTlhM2ZmZDE1NmVlMzNiZTIvdGFibGVyYW5nZTozYzQxMDk2ZTliYTM0NzExOWEzZmZkMTU2ZWUzM2JlMl8xLTItMS0xLTE2NzY2NQ_20ef86e1-822b-4d92-8bc5-947922bffdf1">GILD</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6M2M0MTA5NmU5YmEzNDcxMTlhM2ZmZDE1NmVlMzNiZTIvdGFibGVyYW5nZTozYzQxMDk2ZTliYTM0NzExOWEzZmZkMTU2ZWUzM2JlMl8xLTQtMS0xLTE2NzY2NQ_a4edd668-6010-485b-8477-1c83a93a35cb">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Exchange Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> None</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY182OTE_0fc1bd0d-4c16-47f7-9f49-bbb12a352e7f">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY184NTA_7f5c3397-908c-4aab-a9bd-bad8de31ea98">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18xMTg1_4db28448-55e3-47ed-9bfa-11e71631d236">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18xNTEz_e2a99508-6003-4258-9691-10d55b7aad8e">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18xODcx_f70301a1-64c6-412b-9b74-c62fdc799309">Large accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated&#160;filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zODY0_b47a8288-afa9-4c82-bd3e-ca6ee4ab4a90">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zODY1_c17c4d09-7431-4c0d-9782-33026816ea5a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zODY2_1fbc6082-8fc4-42fd-beaf-2c6cdd38b6c5">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY185ODk1NjA0NjU0MTAz_3c2af349-ea84-4f84-b3d8-b5b40397ba37">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based upon the closing price of its Common Stock on the Nasdaq Global Select Market on June&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="if8b93d3ce3b74726be0d91eed3869725_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yOTM1_97abcefb-4477-467a-a3f9-7e59ac775706">55.9</ix:nonFraction> billion.* </span></div><div style="margin-top:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant&#8217;s Common Stock on February&#160;17, 2023 was <ix:nonFraction unitRef="shares" contextRef="if2acd853399e42529979a83d303e38d1_I20230217" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zMDE3_bc62645f-3710-42ef-b6bb-cc806ba2d0a9">1,247,105,154</ix:nonFraction></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE </span></div><div style="margin-top:2pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zODY5_ecc8f9c5-8565-42b0-952c-008fddfb0f1b" escape="true">Specified portions of the registrant&#8217;s proxy statement, which will be filed with the Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2023 Annual Meeting of Stockholders, to be held on May 3, 2023, are incorporated by reference into Part&#160;III of this Report.</ix:nonNumeric> </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Based on a closing price of $61.81 per share on June&#160;30, 2022. Excludes 350,109,572 shares of the registrant&#8217;s Common Stock held by executive officers, directors and any stockholders whose ownership exceeds 5% of registrant&#8217;s common stock outstanding at June&#160;30, 2022. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.</span></div><div style="padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.774%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 FORM 10-K ANNUAL REPORT</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_10">PART&#160;I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_13">Item&#160;1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_16">Item&#160;1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_16">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_19">Item 1B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_19">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_22">Item 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_22">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_25">Item 3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_25">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_28">Item 4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_28">30</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_31">PART&#160;II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_34">Item 5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_34">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_37">Item 6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_37">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_37">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_40">Item 7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_40">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_58">Item 7A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_58">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_58">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_61">Item 8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_61">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_61">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_145">Item 9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_145">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_145">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_151">Item 9A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_151">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_151">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_154">Item 9B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_154">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_154">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_157">Item 9C</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_157">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_157">96</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_160">PART&#160;III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_163">Item 10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_163">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_163">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_166">Item 11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_166">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_166">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_169">Item 12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_169">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_169">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_172">Item 13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_172">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_172">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_175">Item 14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_175">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_175">97</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_178">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_181">Item 15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_181">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_181">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_187">Item 16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_187">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_187">100</a></span></div></td></tr><tr style="height:6pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_190">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_190">101</a></span></div></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have rights to various trademarks and trade names used in our business, including the following: GILEAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GILEAD SCIENCES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, KITE&#8482;, AMBISOME</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ATRIPLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BIKTARVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CAYSTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, COMPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DESCOVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, DESCOVY FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EMTRIVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EPCLUSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, EVIPLERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GENVOYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HARVONI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HEPCLUDEX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, HEPSERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, JYSELECA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LETAIRIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ODEFSEY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RANEXA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SOVALDI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, STRIBILD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, SUNLENCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TECARTUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRODELVY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRUVADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TRUVADA FOR PREP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TYBOST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VEKLURY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VEMLIDY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VIREAD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VOSEVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, YESCARTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ZYDELIG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This report also refers to trademarks, service marks and trade names of other companies, which are the property of their respective owners.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K, including Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Words such as &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;project,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;might,&#8221; &#8220;forecast,&#8221; and variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, any statements other than statements of historical fact are forward-looking statements, including statements regarding overall trends; operating cost and revenue trends; liquidity and capital needs; plans and expectations with respect to products, product candidates, corporate strategy, business and operations, financial projections and the use of capital; collaboration and licensing arrangements; patent protection and estimated loss of exclusivity for our products and product candidates; ongoing litigation and investigation matters; statements regarding the anticipated future impact on our business of the coronavirus disease 2019 (&#8220;COVID-19&#8221;) and related public health measures; and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified in Part I, Item&#160;1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">of this Annual Report on Form 10-K. Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof unless otherwise specified. Except as required under federal securities laws and the rules and regulations of U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), we do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise. In evaluating our business, you should carefully consider the risks described under Part I, Item&#160;1A. Risk Factors of this Annual Report on Form 10-K. Any of the risks contained herein could materially and adversely affect our business, results of operations and financial condition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_13"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Our Business</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have transformed care for people around the world by discovering, developing and delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Our innovative medicines represent advancements by offering first-in-class therapies, greater efficacy, enhanced modes of delivery, more convenient treatment and prevention regimens, improved resistance profiles and reduced side effects.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, our primary revenue-generating products and the approved indications in the U.S. were as follows:</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HIV</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Biktarvy is a single-tablet regimen of a fixed-dose combination of our antiretroviral medications, bictegravir, emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;).</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Genvoya is a single-tablet regimen of a fixed-dose combination of our antiretroviral medications, elvitegravir, cobicistat, FTC and TAF.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in certain patients. Descovy is a fixed-dose combination of our antiretroviral medications, FTC and TAF. Descovy is also approved by U.S. Food and Drug Administration (&#8220;FDA&#8221;) for a pre-exposure prophylaxis (&#8220;PrEP&#8221;) indication to reduce the risk of sexually acquired HIV-1 infection in certain at-risk patients.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Odefsey is a single-tablet regimen of a fixed-dose combination of our antiretroviral medications, FTC and TAF, and rilpivirine marketed by Janssen Sciences Ireland Unlimited Company, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson (&#8220;Janssen&#8221;).</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">/Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. The product, marketed in the U.S. as Complera and in Europe as Eviplera, is a single-tablet regimen of a fixed-dose combination of our antiretroviral medications, tenofovir disoproxil fumarate (&#8220;TDF&#8221;) and FTC, and Janssen&#8217;s rilpivirine hydrochloride.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in certain patients. Truvada is a fixed-dose combination of our antiretroviral medications, TDF and FTC. Truvada is also approved by FDA for a PrEP indication to reduce the risk of sexually acquired HIV-1 infection in certain at-risk patients.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. Stribild is a single-tablet regimen of a fixed-dose combination of our antiretroviral medications, elvitegravir, cobicistat, TDF and FTC.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(remdesivir), an injection for intravenous use, is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (&#8220;COVID-19&#8221;) in certain adults and pediatric patients (28 days of age and older and weighing at least 3 kg) who are (i) hospitalized or (ii) not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Viral Hepatitis</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of a once-daily single-tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus (&#8220;HCV&#8221;) infection in adults and pediatric patients 3 years of age and older with genotype 1, 2, 3, 4, 5 or 6: (i) without cirrhosis or with compensated cirrhosis or (ii) with decompensated cirrhosis for use in combination with ribavirin. In addition, we have an authorized generic version of Epclusa distributed by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of TAF dosed once a day for the treatment of chronic hepatitis B virus (&#8220;HBV&#8221;) infection in adults and pediatric patients 12 years of age and older with compensated liver disease.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of a once-daily, single-tablet regimen of ledipasvir and sofosbuvir for the treatment of chronic HCV infection in adults and pediatric patients 3 years of age and older with: (i) genotype 1, 4, 5 or 6 without cirrhosis or with compensated cirrhosis, (ii) genotype 1 with decompensated cirrhosis, in combination with ribavirin, (iii) genotype 1 or 4 who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin. In addition, we have an authorized generic version of Harvoni distributed by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral formulation of TDF dosed once a day for the treatment of chronic HBV infection in adults and pediatric patients 2 years of age and older and weighing at least 10 kg. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Oncology</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (axicabtagene ciloleucel), a suspension for intravenous infusion, is a chimeric antigen receptor (&#8220;CAR&#8221;) T-cell therapy for the treatment of (i) adult patients with large B-cell lymphoma (&#8220;LBCL&#8221;) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, (ii) adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy, including diffuse LBCL (&#8220;DLBCL&#8221;) not otherwise specified, primary mediastinal LBCL, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma (&#8220;FL&#8221;), and (iii) adult patients with relapsed or refractory FL after two or more lines of systemic therapy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(sacituzumab govitecan-hziy), an injection for intravenous use, is a Trop-2 directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with (i) unresectable locally advanced or metastatic triple-negative breast cancer (&#8220;TNBC&#8221;) who have received two or more prior systemic therapies, at least one of them for metastatic disease, (ii) unresectable locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#8220;HR+/HER2-&#8221;) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (iii) locally advanced or metastatic urothelial cancer (&#8220;UC&#8221;) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (&#8220;PD-1&#8221;) or programmed death-ligand 1 (&#8220;PD-L1&#8221;) inhibitor.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brexucabtagene autoleucel), a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients with (i) relapsed or refractory mantle cell lymphoma (&#8220;MCL&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (&#8220;ALL&#8221;). </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This indication is approved under accelerated approval by FDA, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This indication received FDA approval in February 2023.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amphotericin B liposome for injection) is a proprietary liposomal formulation of amphotericin B, an antifungal agent, for the treatment of serious invasive fungal infections caused by various fungal species in adults.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ambrisentan) is an oral formulation of an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (&#8220;PAH&#8221;) (WHO Group I) (i) to improve exercise capacity and delay clinical worsening or (ii) in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the disaggregated revenue amounts contributed by the products listed above as well as the total product sales that include our other approved products, see Note 2. Revenues of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we received FDA approval for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sunlenca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(lenacapavir), a HIV-1 capsid inhibitor in tablet form for oral use and as an injection for subcutaneous use. Sunlenca, in combination with other antiretrovirals, is approved as a twice-yearly treatment option for HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Share and Other Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also generate revenues from other activities, including revenue share from combination products, royalties for outbound licenses of our intellectual property and other payments received from our collaborations with third-party partners. For example, pursuant to our collaboration with Janssen, we receive revenue share from cobicistat, FTC and TAF that are components of Symtuza (darunavir/cobicistat/FTC/TAF), a fixed-dose combination product commercialized by Janssen. We include our revenue share from Symtuza in our Product sales. For a description of our collaborations with Janssen and other partners, see Note 10. Collaborations and Other Arrangements of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Commercialization and Distribution</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have U.S. and international commercial sales operations, with marketing subsidiaries in more than 35 countries. Our products are marketed through our commercial teams and/or in conjunction with third-party distributors and corporate partners. Our commercial teams promote our products through direct field contact with physicians, hospitals, clinics and other healthcare providers. We generally grant our third-party distributors the exclusive right to promote our product in a territory for a specified period of time. Most of our agreements with these distributors provide for collaborative efforts between the distributor and Gilead in obtaining and maintaining regulatory approval for the product in the specified territory.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell and distribute most of our products in the U.S. exclusively through the wholesale channel. During the year ended December&#160;31, 2022, approximately 89% of our product sales in the U.S. and approximately 63% of our total worldwide revenues were from three large wholesalers: AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. We sell and distribute our products in Europe and countries outside the U.S. where the product is approved, either through our commercial teams, third-party distributors or corporate partners.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Competition</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive environment. Our products compete with other commercially available products based primarily on efficacy, safety, tolerability, acceptance by doctors, ease of patient compliance, ease of use, price, insurance and other reimbursement coverage, distribution and marketing. We also face significant competition as third parties pursue the development of products and technologies that may be competitive with our existing products or research programs. These third parties include large pharmaceutical and biotechnology companies and specialized pharmaceutical firms acting either independently or together with other such companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection or may establish collaborative arrangements for competitive products or programs. In addition, as our products mature, pricing pressures from private insurers and government payers often result in a reduction of the net product prices. Further, as new branded or generic products are introduced into major markets, our ability to maintain pricing and market share may be affected. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Research and Development</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development (&#8220;R&amp;D&#8221;) mission is to discover and develop transformational therapies in areas of high unmet medical need. Our product development efforts are focused primarily in viral diseases, oncology and inflammatory diseases. Our team of research scientists is engaged in the discovery and development of new molecules and technologies that we hope will lead to the approval of innovative medicines and therapies that will transform care for people around the world. We intend to continue committing significant resources to internal R&amp;D opportunities and external business development activity to drive innovation and growth of our business. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of product candidates and investigational therapies in our pipeline is subject to various risks and uncertainties. These risks and uncertainties include challenges in clinical trial protocol design, our ability to enroll patients in clinical trials, the possibility of unfavorable or inadequate trial results to support further development of our product candidates, including failure to meet a trial&#8217;s primary endpoint, safety issues arising from our clinical trials, and the need to modify or delay our clinical trials or to perform additional trials. As a result, we may be unable to successfully complete our clinical trials on our anticipated timelines, or at all. Based on trial results, it is possible that FDA and other regulatory authorities do not approve our product candidates, or that any market approvals include significant limitations on the products&#8217; use. Further, we may make a strategic decision to discontinue development of our product candidates if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline. Therefore, our product candidates may never be successfully commercialized, and we may be unable to recoup the significant R&amp;D and clinical trial expenses incurred. We expect to expend significant time and resources on our R&amp;D activities without any assurance that we will recoup our investments or that our efforts will be commercially successful. Drug development is inherently risky, and many product candidates and investigational therapies fail during the development process.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we continued to invest in and advance our R&amp;D pipeline across our therapeutic areas. Below is a summary of our product candidates that are in Phase 3 or registrational Phase 2 clinical trials or pending marketing authorization review by FDA or European Medicines Agency (&#8220;EMA&#8221;).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Candidates in Viral Diseases</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Candidates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulatory Filings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bulevirtide</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A Biologics License Application (&#8220;BLA&#8221;) has been filed with FDA for bulevirtide for the treatment of chronic hepatitis delta virus (&#8220;HDV&#8221;) infection. It has been granted both Orphan Drug and Breakthrough Therapy designations by FDA for this indication. Approval is pending resolution of certain manufacturing and delivery concerns cited in a complete response letter issued by FDA in October 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Europe, Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (bulevirtide) has been granted Conditional Marketing Authorization by the European Commission (&#8220;EC&#8221;) and PRIority MEdicines (&#8220;PRIME&#8221;) scheme eligibility by the EMA as the first approved treatment in adults with chronic HDV infection with compensated liver disease.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lenacapavir</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lenacapavir is being evaluated for an HIV PrEP indication. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GS-5245</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">GS-5245, a novel oral COVID-19 nucleoside, is being evaluated for the treatment of COVID-19 infection.</span></td></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Candidates in Oncology</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.240%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Candidates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulatory Filings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sacituzumab govitecan-hziy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A Type II variation Marketing Authorization Application has been filed with EMA for sacituzumab govitecan-hziy, a Trop-2 directed antibody and topoisomerase inhibitor conjugate, for the treatment of adult patients with unresectable or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. This indication received FDA approval in February 2023.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Axicabtagene ciloleucel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Axicabtagene ciloleucel, a CAR T-cell therapy, is being evaluated as a second-line and later treatment for high-risk follicular lymphoma.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sacituzumab govitecan-hziy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sacituzumab govitecan-hziy is being evaluated as (i) a second- or third-line treatment for non-small cell lung cancer (&#8220;NSCLC&#8221;); (ii) a first-line treatment for PD-L1 negative metastatic triple-negative breast cancer (&#8220;TNBC&#8221;); and (iii) a second-line treatment for metastatic urothelial cancer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In collaboration with Merck Sharp &amp; Dohme LLC (&#8220;Merck&#8221;),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sacituzumab govitecan-hziy is being evaluated in combination with Merck&#8217;s pembrolizumab as (i) a first-line treatment for PD-L1 positive metastatic TNBC and (ii) a first-line treatment for NSCLC. Sacituzumab govitecan-hziy is also being evaluated in combination with pembrolizumab as a treatment for adjuvant TNBC.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Magrolimab</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Magrolimab, an anti-CD47 monoclonal antibody, is being evaluated in combination with azacitidine as a first-line treatment for higher risk myelodysplastic syndrome (&#8220;MDS&#8221;). It has been granted Breakthrough Therapy designation by FDA and PRIME scheme eligibility for this indication.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Magrolimab is also being evaluated in combination with azacitidine as a first-line treatment for TP53m acute myeloid leukemia (&#8220;AML&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Magrolimab is also being evaluated in combination with venetoclax and azacitidine as a first-line treatment for unfit AML.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.240%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Domvanalimab and Zimberelimab</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In collaboration with Arcus Biosciences, Inc. (&#8220;Arcus&#8221;),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> the combination of zimberelimab, an anti-PD-1 monoclonal antibody, and domvanalimab, an Fc-silent anti-TIGIT antibody, is being evaluated as a first-line treatment for NSCLC. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In collaboration with Arcus,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> the combination of zimberelimab and domvanalimab with chemotherapy is also being evaluated as (i) a first-line treatment for NSCLC and (ii) a first-line treatment for upper gastrointestinal tract cancer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In collaboration with Arcus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and AstraZeneca, the combination of domvanalimab and durvalumab is being evaluated for the treatment of Stage 3 NSCLC.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Registrational Phase 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel, a CAR T-cell therapy, is being evaluated for the treatment of pediatric acute lymphoblastic leukemia.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For additional information regarding our collaborations with Merck and Arcus, see Note 10. Collaborations and Other Arrangements of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we also received regulatory approvals or authorizations from FDA and EC for new products and expanded indications of our products, including:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.866%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Regulatory Approval or Authorization</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sunlenca</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA and EC approved Sunlenca, a first-in-class, long-acting HIV capsid inhibitor, for the treatment of HIV infection, in combination with other antiretrovirals, in adults with multi-drug resistant HIV who are heavily treatment-experienced. Sunlenca is a new, twice-yearly treatment option for adults with HIV infection that is not adequately controlled by their current treatment regimen.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Yescarta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approved Yescarta for the treatment of adult patients with LBCL that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta is the first FDA-approved CAR T-cell therapy for the initial treatment of relapsed or refractory LBCL.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EC approved Yescarta for the treatment of adult patients with DLBCL and high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy approved for patients in Europe who do not respond to first-line treatment for DLBCL and high-grade B-cell lymphoma.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EC also approved Yescarta for the treatment of adult patients with relapsed or refractory FL after three or more lines of systemic therapy.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tecartus</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EC approved Tecartus for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor ALL.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Veklury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approved an expanded use of Veklury for the treatment of non-hospitalized patients who are at high risk of progression to severe COVID-19, including hospitalization and death.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA also expanded the approval of Veklury to include pediatric patients 28 days of age and older and weighing at least 3 kg.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biktarvy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EC approved a low-dose tablet dosage form of Biktarvy and an extension of the indication for Biktarvy to treat HIV infection in virologically suppressed children who are at least two years of age and weigh at least 14 kg.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Vemlidy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approved an expanded use of Vemlidy for the treatment of chronic HBV infection in pediatric patients 12 years of age and older with compensated liver disease.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Trodelvy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA approved Trodelvy for the treatment of unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. This indication received FDA approval in February 2023.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we seek to enhance our commercial portfolio and clinical pipeline across multiple therapeutic areas through acquisitions, in-licensing and strategic collaborations. In 2022, we announced multiple strategic collaborations, including (i) a research collaboration with Dragonfly Therapeutics, Inc. to develop natural killer cell engager-based immunotherapies in oncology and inflammation; (ii) a global strategic collaboration with Arcellx, Inc. to co-develop and co-commercialize Arcellx&#8217;s lead late-stage product candidate, CART-ddBCMA, for the treatment of relapsed or refractory multiple myeloma; and (iii) an oncology collaboration with MacroGenics, Inc. to develop bispecific antibodies, including Gilead&#8217;s exclusive option to license MGD024, a potential treatment for certain blood cancers. We also announced the acquisitions of (i) MiroBio, a private U.K.-based biotech company focused on restoring immune balance with agonists targeting immune inhibitory receptors; (ii) Tmunity Therapeutics, a clinical-stage, private biotech company focused on next-generation CAR T-cell therapies and technologies; and (iii) all remaining rights to GS-1811, an anti-CCR8 antibody in development as a potential treatment for solid tumors, from Jounce Therapeutics, Inc. Our strategic business development activity reflects our commitment to focus on transformative science, build a sustainable and diverse portfolio and position ourselves for the near-, medium- and long-term growth of our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Patents and Proprietary Rights</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. and European Patent Expiration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of U.S. and foreign patents, patent applications and rights to patents related to our compounds, products and technology, but we cannot be certain that issued patents will be enforceable or provide adequate protection or that pending patent applications will result in issued patents.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the estimated expiration dates (including patent term extensions, supplementary protection certificates and/or pediatric exclusivity where granted) in the U.S. and the European Union (&#8220;EU&#8221;) for the primary (typically compound) patents for our key product candidates as described above. For our product candidates that are fixed-dose combinations of single-tablet regimens, the estimated patent expiration date provided corresponds to the latest expiring compound patent for one of the active ingredients in the single-tablet regimen.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Key Product Candidates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Patent Expiration</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">U.S.</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">EU</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Viral Diseases:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lenacapavir</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2037</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2037</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Bulevirtide</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2029</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Inflammatory Diseases:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cilofexor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2032</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2032</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filgotinib</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2030</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Oncology:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Axicabtagene ciloleucel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2031</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Brexucabtagene autoleucel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sacituzumab govitecan-hziy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2029</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Magrolimab</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2031</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Zimberelimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2036)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Domvanalimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2037</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2037)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">The listed expiration dates do not include any potential additional exclusivity (e.g., patent term extensions, supplementary protection certificates or pediatric exclusivity) that has not yet been granted.</span></div></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;The composition of matter patent has expired in the EU. In the EU and the U.S., patent applications are pending relating to proprietary manufacturing processes of Kite, a Gilead company (&#8220;Kite&#8221;).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Regulatory exclusivity in the U.S. expires in 2032.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In collaboration with Arcus.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:107%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"> &#160;&#160;&#160;&#160;Dates in parentheses reflect the estimated expiration date of patents which may issue from currently pending applications. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the actual or estimated expiration dates (including patent term extensions, supplementary protection certificates and/or pediatric exclusivity where granted) in the U.S. and the EU for the primary (typically compound) patents for our principal products. For our products that are fixed-dose combinations or single-tablet regimens, the estimated patent expiration dates provided correspond to the latest expiring compound patent for one of the active ingredients in the single-tablet regimen.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Products</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Patent Expiration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">U.S.</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">EU</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Descovy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2031</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vemlidy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2031</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Zydelig</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Odefsey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stribild</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Genvoya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Harvoni</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Epclusa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2032</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Biktarvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vosevi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2034</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2033</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Veklury</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2035</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tecartus</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trodelvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jyseleca</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Hepcludex</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sunlenca</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2037</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2037</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">The listed expiration dates do not include any potential additional exclusivity (e.g., patent term extensions, supplementary protection certificates or pediatric exclusivity) that has not yet been granted.</span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Where applicable, settlement and license agreements with generic manufacturers relating to the patents that protect our principal products are noted. The nature and timing of loss of exclusivity for these products depends on a multitude of factors, and loss of exclusivity may be earlier under certain circumstances. For more information, see Item 1A. Risk Factors &#8220;Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.&#8221;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In September 2022, Gilead and five generic manufacturers (Lupin Ltd., Apotex Inc., Macleods Pharma Ltd., Hetero Labs Ltd., and Cipla Ltd.) reached agreements to settle the U.S. patent litigation concerning patents that protect TAF in our Descovy, Vemlidy and Odefsey products.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;The composition of matter patent has expired in the EU. In the EU and the U.S., patent applications are pending relating to proprietary manufacturing processes of Kite.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In 2018, Gilead and Mylan Pharmaceuticals reached an agreement to settle the patent litigation concerning patents that protect cobicistat in our Stribild and Genvoya products.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Regulatory exclusivity in the U.S. expires in 2032.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Protection and Certain Challenges </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are very important to our business. If we have a properly drafted and enforceable patent, it can be more difficult for our competitors to use our technology to create competitive products and more difficult for our competitors to obtain a patent that prevents us from using technology we create. As part of our business strategy, we actively seek patent protection both in the U.S. and internationally and file additional patent applications, when appropriate, to cover improvements in our compounds, products and technology.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents covering certain of the active pharmaceutical ingredients (&#8220;API&#8221;) of some of our products are held by third parties. We acquired exclusive rights to these patents in the agreements we have with these parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may obtain patents for certain products many years before marketing approval is obtained. As a result, the commercial value of the patent may be limited because the patent term is based on the date the patent application was filed, which may be prior to the regulatory approval and commercial sale of the related product. However, we may be able to apply for patent term extensions or supplementary protection certificates in some countries. For example, extensions for the patents or supplementary protection certificates on many of our products have been granted in the U.S. and in a number of European countries, compensating in part for delays in obtaining marketing approval. Similar patent term extensions may be available for other products we are developing, but we cannot be certain we will obtain them in some countries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also important that we do not infringe the valid patents of third parties. If we infringe the valid patents of third parties, our reputation may be harmed and we may be required to pay significant monetary damages, we may be prevented from commercializing products or we may be required to obtain licenses from these third parties. We may not be able to obtain alternative technologies or any required license on reasonable terms or at all. If we fail to obtain these licenses or alternative technologies, we may be unable to develop or commercialize some or all of our products. For example, we are aware of patents and patent applications owned by other parties that such parties may claim to cover the use of our products and research activities.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications are confidential for a period of time after filing, we may not know if our competitors have filed applications for technology covered by our pending applications or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent applications. Competitors may have filed patent applications or received patents and proprietary rights that block or compete with our products. In addition, if competitors file patent applications covering our technology, we may have to participate in litigation, post-grant proceedings before the U.S. Patent and Trademark Office or other proceedings to determine the right to a patent or validity of any patent granted. Such litigation and proceedings are unpredictable and expensive, and could divert management attention from other operations, such that, even if we are ultimately successful, we may be adversely impacted. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents relating to pharmaceutical, biopharmaceutical and biotechnology products, compounds and processes such as those that cover our existing compounds, products and processes and those that we will likely file in the future, do not always provide complete or adequate protection. Filing patent applications is a fact-intensive and complex process. We may file patent applications that ultimately do not result in patents or have patents that do not provide adequate protection for the related product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future litigation or other proceedings regarding the enforcement or validity of our existing patents or any future patents could result in the invalidation of our patents or substantially reduce their protection. From time to time, certain individuals or entities may challenge our patents.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending patent applications and the patent applications filed by our collaborative partners may not be able to prevent third parties from developing compounds or products that are closely related to those which we have developed or are developing. In addition, certain countries do not provide effective enforcement of our patents, and third-party manufacturers may be able to sell generic versions of our products in those countries.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face criticism as a result of our legitimate use of the patent systems to protect our investments in new and useful innovations in medicine. Further, incentives and exclusivities relating to our products and product candidates may change in the future. We are aware that several countries are considering changes to support sharing how to make and use new inventions that could impact the current patent systems and protections for innovation. Any such changes could also impact the voluntary licensing patent programs that we establish for our products to support access to medicines.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant pending legal proceedings, see Note 13. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. See also Item&#160;1A. Risk Factors &#8220;Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on unpatented trade secrets and improvements, unpatented internal know-how and technological innovation. For example, a great deal of our liposomal manufacturing expertise, which is a key component of our liposomal technology, is not covered by patents but is instead protected as a trade secret. We protect these rights mainly through confidentiality agreements with our corporate partners, employees, consultants and vendors. These agreements provide that all confidential information developed or made known to an individual during the course of their relationship with us will be kept confidential and will not be used or disclosed to third parties except in specified circumstances. In the case of employees, the agreements provide that all inventions made by an individual while employed by us will be our exclusive property. We cannot be certain that these parties will comply with these confidentiality agreements, that we have adequate remedies for any breach or that our trade secrets, internal know-how or technological innovation will not otherwise become known or be independently discovered by our competitors. Under some of our R&amp;D agreements, inventions become jointly owned by us and our corporate partners and in other cases become the exclusive property of one party. In certain circumstances, it can be difficult to determine who owns a particular invention and disputes could arise regarding those inventions. If our trade secrets or confidential information become known or independently discovered by competitors, or if we enter into disputes over ownership of inventions, our business and results of operations could be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Manufacturing and Raw Materials</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are manufactured either at our own facilities or by third-party contract manufacturers. We depend on third parties to perform manufacturing activities for the majority of our API and drug products. For most of our products, including our HIV and HCV products, we use multiple third-party contract manufacturers so that we have primary and back-up suppliers and manufacturing sites. For our cell therapy products, we have established clinical and commercial manufacturing facilities for cell processing activities. For our future products, we continue to develop additional manufacturing capabilities and establish additional third-party suppliers to manufacture sufficient quantities of our product candidates to undertake clinical trials and to manufacture sufficient quantities of any product that is approved for commercial sale.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Manufacturing Facilities </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease manufacturing facilities to manufacture and distribute certain products and API for clinical and/or commercial uses. As of the end of 2022, these facilities include:</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foster City, California: We conduct process chemistry research, analytical method development and formulation and device development activities, and manufacture API and drug product for our clinical trials.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">San Dimas and La Verne, California: We manufacture AmBisome and also package and label the majority of our commercial products for distribution to the Americas and the Pacific Rim.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Oceanside, California: We utilize the facility for commercial retroviral vector manufacturing and clinical manufacturing and process development of our biologics candidates.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">El Segundo, California: We utilize the facility for clinical and commercial manufacturing and processing of our cell therapy products.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Frederick, Maryland: We utilize the facility for clinical and commercial manufacturing and processing of our cell therapy products.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cork and Dublin, Ireland: We utilize the Cork facility for commercial manufacturing, packaging and labeling of our products. We also perform quality control testing, labeling, packaging and final release of many of our products at the Cork facility, which are distributed to the EU and other international markets through our facility in Dublin. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Edmonton, Canada: We conduct process chemistry research and scale-up activities for our clinical development candidates, manufacture API for both investigational and commercial products and conduct chemical development activities to improve existing commercial manufacturing processes.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Hoofddorp, Netherlands: We utilize the facility for commercial manufacturing and processing of our cell therapy products.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-Party Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the technology we use to manufacture our products is proprietary. For products manufactured by our third-party contract manufacturers, we have disclosed all necessary aspects of this technology to enable them to manufacture the products for us. We have agreements with these third-party manufacturers that are intended to restrict them from using or revealing this technology, but we cannot be certain that these third-party manufacturers will comply with these restrictions. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information about our third-party manufacturers, see Item&#160;1A. Risk Factors &#8220;We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation of Manufacturing Process</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for pharmaceutical products is highly regulated and regulators may shut down manufacturing facilities that they observe are not complying with regulations. We, our third-party manufacturers and our corporate partners are subject to current Good Manufacturing Practices (&#8220;GMP&#8221;), which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by FDA and EMA. Similar regulations are in effect in other jurisdictions. Our manufacturing operations are subject to routine inspections by regulatory agencies. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our cell therapy products, we are required by FDA to comply with the Risk Evaluation and Mitigation Strategy program, which includes educating and certifying medical personnel regarding the therapy procedures and the potential side effect profile of our therapy, such as the potential adverse side effects related to cytokine release syndrome and neurologic toxicities. Additionally, we are required to maintain a complex chain of identity and custody with respect to patient material as such material moves to the manufacturing facilities, through the manufacturing process, and back to the patient.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Access to Raw Materials </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need access to certain raw materials to conduct our clinical trials and manufacture our products. These raw materials are generally available from multiple sources, purchased worldwide and normally available in quantities adequate to meet the needs of our business. We attempt to manage the risks associated with our supply chain by inventory management, relationship management and evaluation of alternative sources when feasible. For more information, see Item&#160;1A. Risk Factors &#8220;We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Human Capital</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead&#8217;s success depends on the work of its dedicated employees who embrace a shared sense of purpose and a culture of excellence. Our human capital objective is to make Gilead an employer of choice for the best talent in our industry. Gilead&#8217;s key priorities for human capital management include inclusion and diversity, health and safety, total rewards, employee development and engagement. The Compensation and Talent Committee of our Board of Directors oversees our overall human capital management. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inclusion &amp; Diversity</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusion is a Gilead core value, and we believe building an inclusive and diverse workforce is critical to enabling Gilead&#8217;s mission. Our Global Inclusion and Diversity Council is responsible for governance of these matters, tracking progress on our goals and promoting a culture of inclusion. The Global Inclusion and Diversity Council is chaired by our Chairman and Chief Executive Officer and includes members of our leadership team. In 2020, we introduced our Advancing Black Leadership Strategy, a multi-year initiative that outlines our commitments to create internal and external pipelines for diverse talent and to build awareness, capabilities and accountability among our people managers. As part of this strategy, we set clear targets for representation within our overall workforce and executive populations, including goals to increase the percentage of female, Black and Hispanic employees with well-defined annual targets through 2025. Gilead also implemented multiple programs to train managers on inclusion and diversity topics, and created strategies and initiatives focused on attracting, developing and retaining diverse talent and driving an inclusive culture in our workplace, which organizational leaders were required to regularly review starting in 2021. In addition, our employee resource groups (&#8220;ERGs&#8221;) support diverse employees and aim to raise awareness of different cultures within the workplace, cultivate diversity as a business strength and support Gilead&#8217;s talent acquisition strategy to source, attract and recruit diverse candidates. Executive sponsors and leaders of our ERGs contribute to the advancement of our inclusion and diversity commitments through service on our Global Inclusion and Diversity Council.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Gilead&#8217;s inclusive and diverse workforce is the foundation for innovation and productivity. Gilead&#8217;s commitment to equal employment opportunity furthers its efforts to cultivate and celebrate an equitable culture of belonging. As of December&#160;31, 2022, Gilead had approximately 17,000 employees, and Gilead&#8217;s global workforce was approximately 53% female. Additionally, women represented 36% of Gilead&#8217;s leadership (defined as vice president level and above). In the U.S., based on our employees&#8217; voluntary self-identification, our workforce was 38% White, 37% Asian, 13% Hispanic, 8% Black and 4% Other.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health and Safety</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead is committed to providing a workplace for its employees that promotes health, safety, wellness and productivity. We have a workplace safety, training and security program together with various compliance protocols to support this commitment. We routinely train and educate our employees on workplace safety and security. In response to the COVID-19 pandemic, we implemented job site enhancements and risk protocols, including health screenings, COVID-19 testing and vaccine requirements, reconfiguration of work and common spaces to allow for physical distancing, in our effort to support the safe occupancy of our sites. Gilead also maintains a robust contact tracing and notification process for any employee who reports COVID-19 infection. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Rewards</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead&#8217;s compensation and benefits programs are designed to help attract, develop and retain the industry&#8217;s most talented workforce. Our Total Rewards program (which varies by country) includes competitive base salary and incentive compensation, stock awards, an employee stock purchase plan, a 401(k) savings plan with a company match that vests immediately, health and welfare and other valuable benefits, such as flexible work arrangements, flexible spending accounts, paid time off, family leave, family care resources, fertility, adoption and surrogacy assistance, student loan repayment and tuition assistance, employee assistance programs and global wellbeing reimbursement, among many others. Each year, we reassess our Total Rewards package to confirm whether it offers benefits and incentives that align with our total reward philosophy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a pay-for-performance company and are committed to addressing pay equity. Our employee salaries are informed by market-based ranges and are assessed annually through performance and career development reviews. Our policy is that compensation decisions are made without regard to personal characteristics such as gender, race, color, national or ethnic origin, age, disability, sexual orientation, gender identity or expression, genetic information, religion, or veteran status. We also conduct an annual pay equity review of employee compensation in an effort to strive to make our pay practices gender- and race-neutral. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Development and Engagement</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee development and engagement maximizes the potential and performance of each member of our workforce and is critical to achieving our business goals. Gilead offers a number of internal and external professional, management and leadership development training programs to help our employees develop technical, cross-functional and leadership skills and tools to grow their careers. In addition, employees can receive reimbursement for tuition expenses incurred while pursuing undergraduate, graduate or certificate courses at an accredited college or university.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we strive to be the employer of choice in our industry, our listening strategy gathers input from our employees to shape our engagement strategies and programs and measure our progress. In addition to ongoing internal and external data collection and benchmarking, we conducted comprehensive reviews of the employee experience in 2021 and again in 2022, including through the use of employee surveys. The results of these surveys play a key role in determining the direction of our culture as well as the company&#8217;s broader response to emerging developments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in response to the COVID-19 pandemic, we provided meaningful benefits to employees and refined our approach to flexible work arrangements. We believe our flexible work program positions us to be competitive for talent and support employee well-being while also creating the collaborative environment and connections that fuel innovation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Environmental, Social and Governance (&#8220;ESG&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in corporate responsibility is core to our business strategy and reflects our values of accountability, inclusion, teamwork, excellence and integrity. This is in service to our mission to advance global health by providing innovative therapeutics in areas of unmet need in a way that is socially responsible and environmentally sustainable. Gilead&#8217;s ESG programs reflect this commitment to our stakeholders. ESG strategy and performance are overseen by the Nominating and Corporate Governance Committee of our Board of Directors, and managed by a Corporate Responsibility Committee comprised of leaders from key departments across our company. The Corporate Responsibility Committee is responsible for reviewing ESG issues and, as appropriate, integrating them into our overall business strategy and operations. Additional information about this program and ESG highlights are available in Gilead&#8217;s 2021 year in review on Gilead&#8217;s website at https://www.gilead.com/-/media/files/pdfs/yir-2021-pdfs/2021-gilead-yir_desktop.pdf.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ESG goals are aspirational and may change. Statements regarding these goals and related initiatives are not guarantees or promises that they will be met.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Seasonality of Operations</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our worldwide product sales do not reflect any significant degree of seasonality in end-user demand. However, in the U.S., fluctuations in wholesaler inventory levels impact our product sales. We typically observe strong wholesaler and sub-wholesaler purchases of our products in the fourth quarter, resulting in inventory draw-down by wholesalers and sub-wholesalers in the subsequent first quarter. Several other factors, including government budgets, annual grant cycles for federal and state funds, adverse changes in economic conditions, increased competition and other buying patterns, also could impact the product sales recorded in a particular quarter. For more information, see Item&#160;1A. Risk Factors &#8220;We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories.&#8221;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Government Regulation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and activities are subject to extensive regulation by numerous government authorities in the U.S., the EU and other countries, including laws and regulations governing the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of our products. As a result of these regulations, product development and product approval processes are very expensive and time consuming, which has a significant impact on our capital expenditures and results of operations. The regulatory requirements applicable to drug development and approval are subject to change. Any legal and regulatory changes may impact our operations in the future.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A country&#8217;s regulatory agency, such as FDA in the U.S. and EMA and EC in the EU, as well as the national authorities of the EU member states, must approve a drug before it can be sold in the respective country or countries. The general process for drug approval in the U.S. is summarized below. Many other countries, including countries in the EU (and the EU under a centralized procedure), have similar regulatory structures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Testing</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can test a drug candidate in humans, we must study the drug in laboratory experiments and in animals to generate data to support the drug candidate&#8217;s potential benefits and safety. We submit this data to FDA in an Investigational New Drug (&#8220;IND&#8221;) application seeking its approval to test the compound in humans.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If FDA accepts the IND, the drug candidate can then be studied in human clinical trials to determine if the drug candidate is safe and effective. These clinical trials involve three separate phases that often overlap, can take many years and are very expensive. These three phases, which are subject to considerable regulation, are as follows:</span></div><div style="margin-bottom:3pt;margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1. The drug candidate is given to a small number of healthy human control subjects or patients suffering or at risk from the indicated disease, to test for safety, dose tolerance, pharmacokinetics, metabolism, distribution and excretion.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2. The drug candidate is given to a limited patient population to determine the effect of the drug candidate in treating or preventing the disease, the best dose of the drug candidate, and the possible side effects and safety risks of the drug candidate. It is not uncommon for a drug candidate that appears promising in Phase 1 clinical trials to fail in the more rigorous and extensive Phase 2 clinical trials.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3. If a drug candidate appears to be effective and have an appropriate safety profile in Phase 2 clinical trials, Phase 3 clinical trials are commenced to confirm those results. Phase 3 clinical trials are conducted over a longer term, involve a significantly larger population, are conducted at numerous sites in different geographic regions and are carefully designed to provide reliable and conclusive data regarding the safety and benefits of a drug candidate. It is not uncommon for a drug candidate that appears promising in Phase 2 clinical trials to fail in the more rigorous and extensive Phase 3 clinical trials.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Approval Process</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we believe that the data from our clinical trials show an acceptable benefit-risk profile, we submit the appropriate filing, usually in the form of a New Drug Application, Biologics License Application or supplemental application, with FDA, seeking approval to sell the drug candidate for a particular use. At FDA&#8217;s discretion, FDA may hold a public hearing where an independent advisory committee of expert advisors asks additional questions and makes recommendations regarding the drug candidate. This committee makes a recommendation to FDA that is not binding but is generally followed by FDA. If FDA agrees that the drug has met the required level of safety and efficacy for a particular use, it will approve the application and allow us to sell the drug in the U.S. for that use. It is not unusual, however, for FDA to decline to approve an application because it believes that the drug candidate is not safe enough or efficacious enough (i.e., does not have an appropriate benefit-risk profile) or because it does not believe that the data submitted is reliable or conclusive.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any point in this process, the development of a drug candidate can be stopped for a number of reasons, including safety concerns, lack of treatment benefit or manufacturing issues. We cannot be certain that any clinical trials that we are currently conducting or any that we conduct in the future will be completed successfully or within any specified time period. We may choose, or FDA may require us, to delay or suspend our clinical trials at any time if it appears that patients are being exposed to an unacceptable health risk or if the drug candidate does not appear to have sufficient treatment benefit.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after approving a drug, FDA may also require Phase 4 non-registrational studies to explore scientific questions to further characterize safety and efficacy during commercial use of our drug. FDA may also require us to provide additional data or information, improve our manufacturing processes, procedures or facilities or may require extensive surveillance to monitor the safety or benefits of our product candidates if it determines that our filing does not contain adequate evidence of the safety and benefits of the drug. In addition, even if FDA approves a drug, it could limit the uses of the drug. FDA can withdraw approvals if it does not believe that we are complying with regulatory standards or if concerns about the safety or efficacy are uncovered or occur after approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to obtaining FDA approval for each drug, we obtain FDA approval of the manufacturing facilities for any drug we sell, including those of companies who manufacture our drugs for us. All of these facilities are subject to periodic inspections by FDA. FDA must also approve foreign establishments that manufacture products to be sold in the U.S. and these facilities are subject to periodic regulatory inspection. Our manufacturing facilities located in California also must be licensed by the State of California in compliance with local regulatory requirements. Our manufacturing facilities in Canada, Ireland and Netherlands also must obtain local licenses and permits in compliance with local regulatory requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA may employ one of several tools to facilitate and expedite the development and review of a drug, including Fast Track designation, Breakthrough Therapy designation, Accelerated Approval designation and Priority Review designation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast Track designation is designed to facilitate the development and review of a drug that treats a serious condition and fills an unmet medical need. Breakthrough Therapy designation is designed to expedite the development and review of a drug that treats a serious condition where preliminary clinical evidence demonstrates substantial improvement over available therapies. Accelerated Approval of a drug may be granted by FDA where the drug treats a serious condition, fills an unmet medical need and has been studied for safety and efficacy. Priority Review designation means FDA&#8217;s goal is to take action on an application within six months of filing. FDA may grant Priority Review designation to a drug that would provide significant improvement in the safety or effectiveness of a treatment, diagnosis or prevention of a serious condition. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EU Regulatory System and Approval Proce</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ss</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, our products are subject to a variety of EU and EU member state regulations governing clinical trials, commercial sales and distribution. We are required to obtain a marketing authorization in the EU before we can market our medicinal products on the relevant market. The conduct of clinical trials in the EU is governed by, among others, Directive 2001/20/EC and Directive 2005/28/EC and the EU (ICH) Good Clinical Practice rules. These impose legal and regulatory obligations that are similar to those provided in applicable U.S. laws. The conduct of clinical trials in the EU must be approved by the competent authorities of each EU member states in which the clinical trials take place, and a positive opinion must be obtained from the relevant Ethics Committee in the relevant member state. In 2014, the EU legislator adopted Regulation (EU) No 536/2014 to replace Directive 2001/20/EC and to introduce a coordinated procedure for authorization of clinical trials. This Regulation entered into application in January 2022. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing authorization holders, manufacturers, importers, wholesalers and distributors of medicinal products placed on the market in the EU are required to comply with a number of regulatory requirements including pharmacovigilance, GMP compliance and the requirement to obtain manufacturing, import and/or distribution licenses issued by the competent authorities of the EU member states. Failure to comply with these requirements may lead to the imposition of civil, criminal or administrative sanctions, including suspension of marketing or manufacturing authorizations.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing and Reimbursement</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of our products depends, in part, on the availability of third-party payer reimbursement for the cost of such products and related treatments and medical services in the markets where we sell our products. Government health authorities, private health insurers and other organizations generally provide reimbursement. In the U.S., the EU and other significant or potentially significant markets for our products and product candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services. A significant portion of our sales of the majority of our products are subject to substantial discounts from their list prices, including rebates we may be required to pay to Medicaid agencies or discounts we may be required to pay to covered entities under Section 340B of the Public Health Service Act (&#8220;340B&#8221;). As a result, the price increases we implement from time to time on certain products may have a limited effect on our net product sales in certain markets. In addition, standard reimbursement structures may not adequately reimburse for innovative therapies.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our products mature, pricing pressures from private insurers and government payers often result in a reduction of the net product prices. Further, as new branded or generic products are introduced into major markets, our ability to maintain pricing and market share may be affected. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, see Item&#160;1A. Risk Factors &#8220;Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.&#8221; and &#8220;We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Fraud and Abuse Laws; Anti-Bribery Laws</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various U.S. federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claim laws. Anti-kickback laws make it illegal for a prescription drug manufacturer to knowingly and willingly solicit, offer, receive or pay any remuneration in exchange for, or to induce, the referral of business reimbursed by a federal healthcare program, including the purchase or prescription of a particular drug. False claims laws generally prohibit anyone from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment by federal and certain state payers (including Medicare and Medicaid), or knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim. In addition, FDA regulates written and verbal communications about our products. In addition to federal law, states also have consumer protection and false claims laws. Due to the breadth of the statutory provisions and the attention being given to them by law enforcement authorities, our sales, marketing, patient support, medical, clinical and public affairs activities may be subject to scrutiny under these laws. For example, recently there has been enhanced scrutiny by government enforcement authorities of company-sponsored patient assistance programs, including co-pay assistance programs and manufacturer donations to third-party charities that provide such assistance, reimbursement support offerings, clinical education programs and promotional speaker programs. Similarly, in Europe, interactions between pharmaceutical companies and physicians are subject to strict laws, regulations, industry self&#8209;regulation codes of conduct and physicians&#8217; codes of professional conduct, as applicable, including the EU member states anti-corruption laws and the UK Bribery Act 2010.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or retaining business. Our policies mandate compliance with these anti-bribery laws. We operate in parts of the world that have experienced governmental corruption to some degree. In certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state controlled, in a manner that is different than local custom. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our training and compliance program, our internal control policies and procedures may not protect us from unlawful acts committed by our employees or agents. Violations of fraud and abuse laws or anti-bribery laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as the possibility of exclusion from federal health care programs (including Medicare and Medicaid). Violations can also lead to the imposition of a Corporate Integrity Agreement or similar government oversight program, even if we disagree with the government&#8217;s perspective that we have violated any rules or guidance. Any similar violations by our competitors could also negatively impact the reputation of our industry and increase governmental and public scrutiny over our business and our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, see Item&#160;1A. Risk Factors &#8220;We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the health care industry.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Environment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of laws and regulations that require compliance with federal, state, and local regulations for the protection of the environment. The regulatory landscape continues to evolve, and we anticipate additional regulations in the future. Laws and regulations are implemented and under consideration to mitigate the effects of climate change mainly caused by greenhouse gas emissions. Our business is not energy intensive. Therefore, we do not anticipate being subject to a cap and trade system or other mitigation measure that would materially impact our capital expenditures, operations or competitive position. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Information</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the information requirements of the Securities Exchange Act of 1934 (&#8220;Exchange Act&#8221;). Therefore, we file periodic reports, proxy and information statements and other information with U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically with SEC.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website is www.gilead.com. Through a link on the &#8220;Investors&#8221; page of our website (under the &#8220;Financials - SEC Filings&#8221; section), we make available the following filings free of charge as soon as reasonably practicable after they are electronically filed with or furnished to SEC: our Annual Reports on Form 10-K; Quarterly Reports on Form 10-Q; Current Reports on Form 8-K; and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Website references are provided throughout this document for convenience. The content on the referenced websites does not constitute a part of and is not incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In evaluating our business, you should carefully consider the following discussion of material risks, events and uncertainties that make an investment in us speculative or risky in addition to the other information in this Annual Report on Form 10-K. A manifestation of any of the following risks and uncertainties could, in circumstances we may or may not be able to accurately predict, materially and adversely affect our business and operations, growth, reputation (including the commercial or scientific reputation of our products), prospects, product pipeline and sales, operating and financial results, financial condition, cash flows, liquidity and stock price. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. It is not possible to predict or identify all such factors; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product and Commercialization Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our products subject us to additional or heightened risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HIV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection. During the year ended December 31, 2022, sales of our HIV products accounted for approximately 64% of our total product sales. We may be unable to sustain or increase sales of our HIV products for any number of reasons, including market share gains by competitive products, including generics, or the inability to introduce new HIV medications necessary to remain competitive. In such case, we may need to scale back our operations, including our future drug development and spending on research and development (&#8220;R&amp;D&#8221;) efforts. For example, many of our HIV products contain tenofovir alafenamide (&#8220;TAF&#8221;), which belongs to the nucleoside class of antiviral therapeutics. If there are any changes to the treatment or prevention paradigm for HIV that cause nucleoside-based therapeutics to fall out of favor, our HIV product sales would be adversely impacted.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to our supply and distribution of Veklury, which was approved by U.S. Food and Drug Administration (&#8220;FDA&#8221;) in October 2020 as a treatment for patients hospitalized with coronavirus disease 2019 (&#8220;COVID-19&#8221;), in Janua</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ry 2022 as a treatment for non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death, and in April 2022 as a treatment for pediatric patients who are 28 days of age (and older), weighing at least 3 kg, and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered at high risk for progression to severe COVID-19, including hospitalization or death. While Veklury sales generally reflect COVID-19 related rates and severity of infections and hospitalizations, as well as the availability, uptake and effectiveness of vaccines and alternative treatments for COVID-19, we are unable to accurately predict our revenues or supply needs over the short- and long-term due to the dynamic nature of the COVID-19 pandemic. If we do not accurately forecast demand or manufacture Veklury at levels to align with actual demand, then we may experience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product shortages or build excess inventory that may need to be written off. We also remain subject to significant public attention and scrutiny over the complex decisions made regarding clinical data, supply, allocation, distribution and pricing of Veklury, all of which affects our corporate reputation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cell Therapy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advancing a novel and personalized therapy such as Yescarta or Tecartus, which are chimeric antigen receptor (&#8220;CAR&#8221;) T-cell therapies, creates significant challenges, including:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">educating and certifying medical personnel regarding the procedures and the potential side effects, such as cytokine release syndrome and neurologic toxicities, in compliance with the Risk Evaluation and Mitigation Strategy program required by FDA;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">securing sufficient supply of other medications to manage side effects, such as tocilizumab and corticosteroids, which may not be available in sufficient quantities, may not adequately control the side effects and/or may have detrimental impacts on the efficacy of cell therapy;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and maintaining a robust and reliable process for engineering a patient&#8217;s T cells in our facilities and infusing them back into the patient; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditioning patients with chemotherapy in advance of administering our therapy, which may increase the risk of adverse side effects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of engineered T cells as a potential cancer treatment is a recent development and may not be broadly accepted by physicians, patients, hospitals, cancer treatment centers, payers and others in the medical community. While FDA has approved some cell therapies, including Yescarta and Tecartus, we must continue to demonstrate to the medical community the potential advantages of cell therapy compared to existing and future therapeutics. For challenges related to the reimbursement of Yescarta and Tecartus, see also &#8220;Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.&#8221;</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party sites to collect patients&#8217; white blood cells, known as apheresis centers, as well as shippers, couriers, and hospitals for the logistical collection of patients&#8217; white blood cells and ultimate delivery of Yescarta and Tecartus to patients. These vendors may encounter disruptions or difficulties that could result in product loss and regulatory action. Apheresis centers may also choose not to participate in our quality certification process, or we may be unable to complete such certification in a timely manner or at all, which could delay or constrain our manufacturing and commercialization efforts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a new automated CAR T-cell therapy manufacturing facility in Frederick, Maryland, which received FDA approval for commercial production in April 2022. We have not previously manufactured our products in an automated facility on a commercial scale, and as a result, we may require additional time and resources in order to effectively increase manufacturing capacity. We also operate a new retroviral vector manufacturing facility in Oceanside, California, which received FDA approval for commercial production in October 2022. We also have not previously manufactured viral vectors on a commercial scale, and as a result, we may require additional time and resources in order to effectively increase manufacturing capacity. In addition, we may not be able to produce or otherwise obtain an amount of viral vector supply sufficient to satisfy demand for our finished products. If we are unable to meet product demand, we will have difficulty meeting sales forecasts for our finished products.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on developing and commercializing new products or expanding the indications for existing products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to launch commercially successful new products or new indications for existing products, our business will be adversely impacted. The launch of commercially successful products is necessary to grow our business, cover our substantial R&amp;D expenses, and offset revenue losses when existing products lose market share due to factors such as competition and loss of patent exclusivity. There are many difficulties and uncertainties inherent in drug development and the introduction of new products. The product development cycle is characterized by significant investments of resources, long lead times and unpredictable outcomes due to the nature of developing medicines for human use. We expend significant time and resources on our product pipeline without any assurance that we will recoup our investments or that our efforts will be commercially successful. A high rate of failure is inherent in the discovery and development of new products, and failure can occur at any point in the process, including late in the process after substantial investment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to accurately predict demand for our products, including the uptake of new products, as demand depends on a number of factors. For example, product demand may be adversely affected if physicians do not see the benefit of our products. Additionally, the non-retail sector in the U.S., which includes government institutions, including state AIDS Drug Assistance Programs, the U.S. Department of Veterans Affairs, correctional facilities and large health maintenance organizations, tends to be less consistent in terms of buying patterns and often causes quarter-over-quarter fluctuations that do not mirror actual patient demand for our products. Federal and state budget pressures, as well as the annual grant cycles for federal and state funds, may cause purchasing patterns to not reflect patient demand for our products. We expect to continue to experience fluctuations in the purchasing patterns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We believe these measures have caused some government agencies and other purchasers to reduce inventory of our products in the distribution channels, and we may continue to see this trend in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell and distribute most of our products in the U.S. exclusively through the wholesale channel. For the year ended December 31, 2022, approximately 89% of our product sales in the U.S. were to three wholesalers, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Corporation. The U.S. wholesalers with whom we have entered into inventory management agreements make estimates to determine end-user demand and may not be accurate in matching their inventory levels to actual end-user demand. As a result, changes in inventory levels held by those wholesalers can cause our operating results to fluctuate unexpectedly if our sales to these wholesalers do not match end-user demand. In addition, inventory is held at retail pharmacies and other non-wholesaler locations with whom we have no inventory management agreements and no control over buying patterns. Adverse changes in economic conditions, increased competition or other factors may cause retail pharmacies to reduce their inventories of our products, which would reduce their orders from wholesalers and, consequently, the wholesalers&#8217; orders from us, even if end-user demand has not changed. In addition, we have observed that strong wholesaler and sub-wholesaler purchases of our products in the fourth quarter typically results in inventory draw-down by wholesalers and sub-wholesalers in the subsequent first quarter. As inventory in the distribution channel fluctuates from quarter to quarter, we may continue to see fluctuations in our earnings and a mismatch between prescription demand for our products and our revenues. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New branded or generic products entering major markets affects our ability to maintain pricing and market share. Our products compete with other available products based primarily on efficacy, safety, tolerability, acceptance by doctors, ease of patient compliance, ease of use, price, insurance and other reimbursement coverage, distribution and marketing. A number of companies are pursuing the development of products and technologies that may be competitive with our existing products or research programs. These competing companies include large pharmaceutical and biotechnology companies and specialized pharmaceutical firms acting either independently or together with other such companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection or may establish collaborative arrangements for competitive products or programs. We may be adversely impacted if any of these competitors gain market share as a result of new technologies, commercialization strategies or otherwise.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Reimbursements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of our products depends, in part, on the availability and amount of third-party payer reimbursement for our products and related treatments and medical services in the markets where we sell our products. As our products mature, pricing pressures from private insurers and government payers often result in a reduction of the net product prices.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. For example, in September 2020, FDA issued a final rule implementing a pathway for the importation of certain prescription drugs from Canada. This rule is subject to ongoing litigation. We may be adversely impacted by any such legislative and regulatory actions, though it is difficult to predict the impact, if any, on the use and reimbursement of our products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Pricing, Discounts and Rebates</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the European Union (&#8220;EU&#8221;) and other significant or potentially significant markets for our products and pro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">duct candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services. The volume of drug pricing-related legislation has dramatically increased in recent years, including:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. Congress has enacted laws requiring manufacturer refunds on certain amounts of discarded drug from single-use vials beginning in 2023 and eliminating the existing cap on Medicaid rebate amounts beginning in 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. Congress has enacted the Inflation Reduction Act of 2022 (the &#8220;Act&#8221;), which, among other changes, (1) requires the Department of Health and Human Services to &#8220;negotiate&#8221; Medicare prices for certain drugs (starting with 10 drugs in 2026, adding 15 drugs in 2027 and 2028, and adding 20 drugs in 2029 and subsequent years), (2) imposes an inflation-based rebate on Medicare Part B utilization starting in 2023 and Part D utilization beginning October 1, 2022, and (3) restructures the Medicare Part D benefit to cap out-of-pocket expenses for Part D beneficiaries beginning in 2024 and, effective January 1, 2025, increases Part D plans&#8217; contributions in the catastrophic coverage phase and increase manufacturers&#8217; discount contributions across coverage phases such that manufacturers must pay a 10% discount in the initial coverage phase and a 20% discount in the catastrophic phase on drugs utilized by all Part D beneficiaries, including low income subsidy patients. We continue to evaluate the impact of the Act on our business but expect the Act will increase our payment obligations under the redesigned Part D discount program, limit the prices we can charge, and increase the rebates we must provide government programs for our products, thereby reducing our profitability and negatively impacting our financial results. In addition, it is unclear how certain provisions of the Act will be implemented, there may be additional legislation or rulemaking related to the Act and select provisions may become subject to legal challenges in the future. Therefore, the full impact of the Act on the profitability of our business and the pharmaceutical industry as a whole remains uncertain at this time.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many state legislatures are considering, or have already passed into law, legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as requiring manufacturers to publicly report proprietary pricing information, creating review boards for prices, and encouraging the use of generic drugs. These initiatives and such other legislation may cause added pricing pressures on our products, and the resulting impact on our business is uncertain.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many countries outside the U.S., including the EU member states, have established complex and lengthy procedures to obtain price approvals and coverage reimbursement and periodically review their pricing and reimbursement decisions. The outcome of these reviews cannot be predicted and could have an adverse effect on the pricing and reimbursement of our medical products in the EU member states. Reductions in the pricing of our medical products in one member state could affect the price in other member states and have a negative impact on our financial results. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our product sales is subject to significant discounts from list price, including rebates that we may be required to pay state Medicaid agencies and discounts provided to covered entities under Section 340B of the Public Health Service Act (&#8220;340B&#8221;). Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on our business. For example, the continued growth of the 340B program limits the prices we may charge on an increasing percentage of sales. Changes to the calculation of rebates under the Medicaid program could substantially increase our Medicaid rebate obligations and decrease the prices we charge 340B-covered entities. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently implemented a contract pharmacy integrity initiative for our branded hepatitis C virus (&#8220;HCV&#8221;) products. This integrity initiative will not involve any products from Asegua Therapeutics LLC. Our integrity initiative requires covered entities that enter into 340B bill to/ship to arrangements with contract pharmacies for our branded HCV products to provide claims level data for units dispensed from such contract pharmacies; covered entities without an in-house pharmacy that choose not to participate in the initiative can designate a single contract pharmacy for shipment. Certain manufacturers that have implemented other contract pharmacy integrity programs have received enforcement letters from the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) asserting that those programs violate the 340B statute, have been referred to the HHS Office of Inspector General for assessment of civil monetary penalties, and have been subject to administrative dispute resolution proceedings brought on behalf of covered entities. These manufacturers are currently challenging HHS&#8217; position in ongoing litigation. Although we believe that our integrity initiative complies with the requirements of the 340B statute, additional legal or legislative developments with respect to the 340B program, including potential litigation with HHS, may negatively impact our ability to implement or continue our integrity initiative. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, standard reimbursement structures may not adequately reimburse for innovative therapies. For example, beginning in fiscal year 2021, CMS established a new severity-adjusted diagnosis-related group (&#8220;DRG&#8221;) 018 for Medicare inpatient reimbursement of CAR T-cell products such as Yescarta and Tecartus. While the new DRG has a significantly higher base payment amount than the prior DRG 016, the payment available may not be sufficient to reimburse some hospitals for their cost of care for patients receiving Yescarta and Tecartus. When reimbursement is not aligned well to account for treatment costs, Medicare beneficiaries may be denied access as this misalignment could impact the willingness of some hospitals to offer the therapy and of doctors to recommend the therapy. Additionally, in the EU, there are barriers to reimbursement in individual countries that could limit the uptake of Yescarta and Tecartus.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we estimate the rebates we will be required to pay in connection with sales during a particular quarter based on claims data from prior quarters. In the U.S., actual rebate claims are typically made by payers one to three quarters in arrears. Actual claims and payments may vary significantly from our estimates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience adverse impacts resulting from the importation of our products from lower price markets or the distribution of illegally diverted or counterfeit versions of our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices for our products are based on local market economics and competition and sometimes differ from country to country. Our sales in countries with relatively higher prices may be reduced if products can be imported and resold into those countries from lower price markets. For example, U.S. sales could also be affected if FDA permits importation of drugs from Canada. We have entered into agreements with generic drug manufacturers as well as licensing agreements with the Medicines Patent Pool, a United Nations-backed public health organization, which allow generic drug manufacturers to manufacture generic versions of certain of our products for distribution in certain low- and middle-income countries. We may be adversely affected if any generic versions of our products, whether or not produced and/or distributed under these agreements, are exported to the U.S., the EU or markets with higher prices. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, we are required to permit products purchased in one EU member state to be sold in another member state. Purchases of our products in member states where our selling prices are relatively low for resale in member states in which our selling prices are relatively high can affect the inventory level held by our wholesalers and can cause the relative sales levels in the various countries to fluctuate from quarter to quarter and not reflect the actual consumer demand in any given quarter. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, diverted products may be used in countries where they have not been approved and patients may source the diverted products outside the legitimate supply chain. These diverted products may be handled, shipped and stored inappropriately, which may affect the efficacy of the products and could harm patients and adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of the existence of various suppliers around the world that, without Gilead&#8217;s authorization, purport to source our products and generic versions of our products and sell them for use in countries where those products have not been approved. As a result, patients may be at risk of taking unapproved medications that may not be what they purport to be, may not have the potency they claim to have or may contain harmful substances, which could harm patients and adversely impact us. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, third parties have illegally distributed and sold, and may continue to illegally distribute and sell, illegally diverted and counterfeit versions of our medicines, which do not meet the rigorous quality standards of our manufacturing and supply chain. For example, as part of a U.S. civil enforcement lawsuit in coordination with law enforcement, and pursuant to court order, we seized thousands of bottles of Gilead-labeled medication with counterfeit supply chain documentation. Our investigation revealed that pharmaceutical distributors that are not authorized by Gilead to sell Gilead medicine sold purportedly genuine Gilead medicine sourced from an illegal counterfeiting scheme to independent pharmacies nationwide.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Illegally diverted and counterfeit versions of Gilead-branded medicines exist and may pose a serious risk to patient health and safety. Our actions to stop or prevent the distribution and sale of illegally diverted and counterfeit versions of our medicines around the world may be costly and unsuccessful, which may adversely affect patients and our reputation and business, including our product revenues and financial results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Product Development and Supply Chain Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to demonstrate the safety and efficacy of product candidates that we develop for each intended use through extensive preclinical studies and clinical trials. The results from these studies do not always accurately predict results in later, large-scale clinical trials. Even successfully completed large-scale clinical trials may not result in marketable products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face numerous risks and uncertainties with our clinical trials that could result in delays or prevent completion of the development and approval of our product candidates, including challenges in clinical trial protocol design, our ability to enroll patients in clinical trials, the possibility of unfavorable or inadequate trial results to support further development of our product candidates, including failure to meet a trial&#8217;s primary endpoint, safety issues arising from our clinical trials, and the need to modify or delay our clinical trials or to perform additional trials. For example, in October 2022, we announced that FDA issued a complete response letter for our Biologics License Application for bulevirtide for the treatment of adults with hepatitis delta virus infection. In addition, see Note 8. Goodwill and Intangible Assets of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for a discussion of the partial in-process research and development impairment charge that we recognized during the three months ended March 31, 2022 related to assets we acquired from Immunomedics, Inc. (&#8220;Immunomedics&#8221;) in 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we may be unable to successfully complete our clinical trials on our anticipated timelines, or at all. Based on trial results, it is possible that FDA and other regulatory authorities do not approve our product candidates, or that any market approvals include significant limitations on the products&#8217; use. In addition, clinical trials involving our commercial products can raise new safety issues for our existing products, which could adversely impact our business. Further, we may make a strategic decision to discontinue development of our product candidates if, for example, we believe commercialization will be difficult relative to other opportunities in our pipeline. Therefore, our product candidates may never be successfully commercialized, and we may be unable to recoup the significant R&amp;D and clinical trial expenses incurred. We expect to expend significant time and resources on our clinical trial activities without any assurance that we will recoup our investments or that our efforts will be commercially successful. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also risks associated with the use of third parties in our clinical trial activities. We extensively outsource our clinical trial activities and usually perform only a small portion of the start-up activities in-house. We rely on independent third-party contract research organizations (&#8220;CROs&#8221;) to perform most of our clinical studies, including document preparation, site identification, screening and preparation, pre-study visits, training, program management, patient enrollment, ongoing monitoring, site management and bioanalytical analysis. Many important aspects of the services performed for us by the CROs are out of our direct control. If there is any dispute or disruption in our relationship with our CROs, our clinical trials may be delayed. Moreover, in our regulatory submissions, we rely on the quality and validity of the clinical work performed by third-party CROs. If any of our CROs&#8217; processes, methodologies or results were determined to be invalid or inadequate, our own clinical data and results and related regulatory approvals may be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products, which are manufactured at our own facilities or by third-party manufacturers and corporate partners, are the result of complex, highly regulated manufacturing processes. We depend on third-party manufacturers and corporate partners to perform manufacturing activities effectively and on a timely basis for the majority of our active pharmaceutical ingredients and drug products. These third parties are independent entities subject to their own unique operational and financial risks that are out of our control. We and our third-party manufacturers and corporate partners are subject to Good Manufacturing Practices (&#8220;GMP&#8221;), which are extensive regulations governing manufacturing processes, stability testing, record keeping and quality standards as defined by FDA and European Medicines Agency (&#8220;EMA&#8221;), as well as comparable regulations in other jurisdictions. Manufacturing operations are also subject to routine inspections by regulatory agencies.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting or resulting from our manufacturing operations or the operations of our third-party manufacturers and corporate partners may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We have incurred, and will continue to incur, inventory write-off charges and other expenses for products that fail to meet specifications and quality standards, and we may need to undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share and damage our reputation. In addition, manufacturing issues may cause delays in our clinical trials and applications for regulatory approval. For example, if we are unable to remedy any deficiencies cited by FDA or other regulatory agencies in their inspections, our existing products and the timing of regulatory approval of product candidates in development could be adversely affected. Further, there is risk that regulatory agencies in other countries where marketing applications are pending will undertake similar additional reviews or apply a heightened standard of review, which could delay the regulatory approvals for products in those countries. Our business may be adversely affected if approval of any of our product candidates were delayed or if production of our products were interrupted.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, which could limit our ability to generate revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need access to certain supplies and products to conduct our clinical trials and to manufacture and sell our products. If we are unable to purchase enough of these materials or find suitable alternative materials in a timely manner, our development efforts for our product candidates may be delayed or our ability to manufacture and sell our products could be limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suppliers of key components and materials must be named in the new drug application or marketing authorization application filed with the regulatory authority for any product candidate for which we are seeking marketing approval, and significant delays can occur if the qualification of a new supplier is required. Even after a manufacturer is qualified by the regulatory authority, the manufacturer must continue to expend time, money and effort in the area of production and quality control to maintain full compliance with GMP. Manufacturers are subject to regular periodic inspections by regulatory authorities following initial approval. If, as a result of these inspections, a regulatory authority determines that the equipment, facilities, laboratories or processes do not comply with applicable regulations and conditions of product approval, the regulatory authority may suspend the manufacturing operations. If the manufacturing operations of any of the single suppliers for our products are suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet market demand. In addition, if deliveries of materials from our suppliers are interrupted for any reason, we may be unable to ship certain of our products for commercial supply or to supply our product candidates in development for clinical trials. Also, some of our products and the materials that we utilize in our operations are manufactured by only one supplier or at only one facility, which we may not be able to replace in a timely manner and on commercially reasonable terms, or at all. Problems with any of the single suppliers or facilities we depend on, including in the event of a disaster, such as an earthquake, equipment failure or other difficulty, may negatively impact our development and commercialization efforts.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the raw materials and intermediates used to manufacture our antiviral products are supplied by third-party manufacturers and corporate partners outside of the U.S. As a result, any political or economic factors in a specific country or region, including any changes in or interpretations of trade regulations, compliance requirements or tax legislation, that would limit or prevent third parties outside of the U.S. from supplying these materials could adversely affect our ability to manufacture and supply our antiviral products to meet market needs and have a material and adverse effect on our operating results.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to encounter any of these difficulties, our ability to conduct clinical trials on product candidates and to manufacture and sell our products could be impaired.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Regulatory and Other Legal Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we develop must be approved for marketing and sale by regulatory authorities and, once approved, are subject to extensive regulation by FDA, EMA and comparable regulatory agencies in other countries. We have filed, and anticipate that we will continue to file, for marketing approval in additional countries and for additional indications and products. These and any future marketing applications we file may not be approved by the regulatory authorities on a timely basis, or at all. Even if marketing approval is granted for these products, there may be significant limitations on their use. We cannot state with certainty when or whether any of our product candidates under development will be approved or launched; whether we will be able to develop, license or acquire additional product candidates or products; or whether any products, once launched, will be commercially successful. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, how we manufacture and sell our products is subject to extensive regulation and review. For example, under FDA rules, we are often required to conduct post-approval clinical studies to assess a known serious risk, signals of serious risk or to identify an unexpected serious risk. In certain circumstances, we may be required to implement a Risk Evaluation and Mitigation Strategy program for our products, which could include a medication guide, patient package insert, a communication plan to healthcare providers, restrictions on distribution or use of a product and other elements FDA deems necessary to assure safe use of the drug. Discovery of previously unknown problems with our marketed products or product candidates, including serious safety, resistance or drug interaction issues, or problems with our manufacturing, safety reporting or promotional activities, may result in regulatory approvals being delayed, denied or granted with significant restrictions on our products, including limitations on or the withdrawal of the products from the market. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these or other requirements imposed by FDA could result in significant civil monetary penalties, fines, suspensions of regulatory approvals, product recalls, seizure of products and criminal prosecutions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the healthcare industry. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to various federal, state and international laws and regulations pertaining to drug reimbursement, rebates, price reporting, healthcare fraud and abuse, and data privacy and security. In the U.S., these laws include anti-kickback and false claims laws, laws and regulations relating to the Medicare and Medicaid programs and other federal and state programs, such as the Medicaid Rebate Statute and the 340B statute, laws that regulate written and verbal communications about our products, individual state laws relating to pricing and sales and marketing practices, the Health Insurance Portability and Accountability Act and other federal and state laws relating to the privacy and security of health information. Actual or alleged violations of these laws or any related regulations may be punishable by criminal and/or civil sanctions, including, in some instances, substantial fines, civil monetary penalties, exclusion from participation in federal and state healthcare programs, including Medicare, Medicaid and U.S. Department of Veterans Affairs and U.S. Department of Defense health programs, actions against executives overseeing our business and significant remediation measures, negative publicity or other consequences. These laws and regulations are broad in scope and subject to changing and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our sales or marketing practices. The resulting impact on our business is uncertain and could be material.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, government price reporting and payment regulations are complex, and we are continually assessing the methods by which we calculate and report pricing in accordance with these obligations. Our methodologies for calculations are inherently subjective and may be subject to review and challenge by various government agencies, which may disagree with our interpretation. If the government disagrees with our reported calculations, we may need to restate previously reported data and could be subject to additional financial and legal liability.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also continues to be enhanced scrutiny of company-sponsored patient assistance programs, including co-pay assistance programs and manufacturer donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments on reimbursement and other patient support offerings, clinical education programs and promotional speaker programs. If we, or our agents and vendors, are deemed to have failed to comply with laws, regulations or government guidance in any of these areas, we could be subject to criminal or civil sanctions. Any similar violations by our competitors could also negatively impact our industry reputation and increase scrutiny over our business and our products.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our government investigations and related litigation, see Note 13. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks if significant safety issues arise for our marketed products or our product candidates.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As additional studies are conducted after obtaining marketing approval for our products, and as our products are used over longer periods of time by many patients, including patients with underlying health problems or those taking other medicines, we expect to continue finding new issues related to safety, resistance or drug interactions. Any such issues may require changes to our product labels, such as additional warnings, contraindications or even narrowed indications, or to halt sales of a product.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have been moving towards more active and transparent pharmacovigilance and are making greater amounts of stand-alone safety information and clinical trial data directly available to the public through websites and other means, such as periodic safety update report summaries, risk management plan summaries and various adverse event data. Safety information, without the appropriate context and expertise, may be misinterpreted and lead to misperception or legal action.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are very important to our business. As part of our business strategy, we actively seek patent protection both in the U.S. and internationally and file additional patent applications, when appropriate, to cover improvements in our compounds, products and technology. Our success depends to a significant degree on our ability to:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patents and licenses to patent rights;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve trade secrets and internal know-how;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">defend against infringement of our patents and efforts to invalidate them; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing on the intellectual property of others.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications are confidential for a period of time after filing, we may not know if our competitors have filed applications for technology covered by our pending applications or if we were the first to invent or first to file an application directed toward the technology that is the subject of our patent applications. If competitors file patent applications covering our technology, we may have to participate in litigation, post-grant proceedings before the U.S. Patent and Trademark Office or other proceedings to determine the right to a patent or validity of any patent granted. Such litigation and proceedings are unpredictable and expensive, and could divert management attention from other operations, such that, even if we are ultimately successful, we may be adversely impacted.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents covering our existing compounds, products and processes, and those that we will likely file in the future, may not provide complete or adequate protection. Filing patent applications is a fact-intensive and complex process. We may file patent applications that ultimately do not result in patents or have patents that do not provide adequate protection for the related product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future litigation or other proceedings regarding the enforcement or validity of our existing patents or any future patents could result in the invalidation of our patents or substantially reduce their protection. In addition, we may face criticism as a result of our legitimate use of the patent systems to protect our investments in new and useful innovations in medicine.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic manufacturers have sought, and may continue to seek, FDA approval to market generic versions of our products through an abbreviated new drug application (&#8220;ANDA&#8221;), the application process typically used by manufacturers seeking approval of a generic drug. For a description of our ANDA litigation, see Note 13. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. ANDA litigation and related settlement and license agreements, in some cases, may result in a loss of exclusivity for our patents sooner than we would otherwise expect. In addition, loss of exclusivity may be earlier than expected under these settlement and license agreements under certain circumstances. For example, settlement and license agreements with generic manufacturers typically include acceleration clauses that permit generic entry before the agreed-upon entry date in certain circumstances, and generic manufacturers may continue to challenge the patents protecting our products. The entry of generic versions of our products has, and may in the future, lead to market share and price erosion. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe the valid patents of third parties, we may be required to pay significant monetary damages or we may be prevented from commercializing products or may be required to obtain licenses from these third parties. We may not be able to obtain alternative technologies or any required license on commercially reasonable terms or at all. If we fail to obtain these licenses or alternative technologies, we may be unable to develop or commercialize some or all of our products. For example, we are aware of patents and patent applications owned by other parties that such parties may claim to cover the use of our products and research activities. For a description of our pending patent litigation, see Note 13. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we also rely on unpatented trade secrets and improvements, unpatented internal know-how and technological innovation. We protect these rights mainly through confidentiality agreements with our corporate partners, employees, consultants and vendors. We cannot be certain that these parties will comply with these confidentiality agreements, that we have adequate remedies for any breach or that our trade secrets, internal know-how or technological innovation will not otherwise become known or be independently discovered by our competitors. Under some of our R&amp;D agreements, inventions become jointly owned by us and our corporate partner and in other cases become the exclusive property of one party. In certain circumstances, it can be difficult to determine who owns a particular invention and disputes could arise regarding those inventions. We could be adversely affected if our trade secrets, internal know-how, technological innovation or confidential information become known or independently discovered by competitors or if we enter into disputes over ownership of inventions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potentially significant liability and increased expenses from litigation and government investigations relating to our products and operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of litigation, investigation and other dispute-related matters that require us to expend substantial internal and financial resources. These matters could require us to pay significant monetary amounts, including royalty payments for past and future sales. For example, on February 1, 2022, we reached an agreement with ViiV Healthcare Company and related parties (collectively, &#8220;ViiV&#8221;) for a global resolution of all claims related to our sales of Biktarvy, pursuant to which (1) Gilead agreed to make a one-time payment of $1.25 billion and an ongoing royalty at a rate of 3% on future sales of Biktarvy and the bictegravir component of bictegravir-containing products in the U.S. until October 5, 2027, and (2) ViiV granted Gilead a broad worldwide license and covenant not to sue relating to any past, present or future development or commercialization of bictegravir.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect these matters will continue to require a high level of internal and financial resources for the foreseeable future. These matters have reduced, and are expected to continue to reduce, our earnings and require significant management attention. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the testing, manufacturing, marketing and use of our commercial products, as well as product candidates in development, involve substantial risk of product liability claims. These claims may be made directly by consumers, healthcare providers, pharmaceutical companies or others. We have limited insurance for product liabilities that may arise and claims may exceed our coverage.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our litigation, investigation and other dispute-related matters, see Note 13. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K. The outcome of such legal proceedings or any other legal proceedings that may be brought against us, the investigations or any other investigations that may be initiated and any other dispute-related matters, are inherently uncertain, and adverse developments or outcomes can result in significant expenses, monetary damages, penalties or injunctive relief against us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operational Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business has been, and may in the future be, adversely affected by outbreaks of epidemic, pandemic or contagious diseases, including the ongoing COVID-19 pandemic.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual or threatened outbreaks of epidemic, pandemic or contagious diseases, or other public health emergencies, may significantly disrupt our global operations and adversely affect our business, financial condition and results of operations. As we have seen with the COVID-19 pandemic, outbreaks can result in global supply chain and logistics disruptions and distribution constraints. The impact of an outbreak or other public health crisis on our results of operations and financial condition would depend on numerous evolving factors, but could involve higher operating expenses, lower demand for our products as a result of governmental, business and individuals&#8217; actions taken in response to such an event (including quarantines, travel restrictions and interruptions to healthcare services, which can impact enrollment in or operation of our clinical trials or limit patients&#8217; ability or willingness to access and seek care), challenges associated with the safety of our employees and safe occupancy of our job sites, and financial market volatility and significant macroeconomic uncertainty in global markets. An outbreak or public health emergency also could amplify many of the other risks described throughout the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. </span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks associated with our global operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations are accompanied by certain financial, political, economic and other risks, including those listed below:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Foreign C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">urrency Exchange: For the year ended December 31, 2022, approximately 31% of our product sales were outside the U.S. Because a significant percentage of our product sales is denominated in foreign currencies, primarily the Euro, we face exposure to adverse movements in foreign currency exchange rates. Overall, we are a net receiver of foreign currencies, and therefore, we benefit from a weaker U.S. dollar and are adversely affected by a stronger U.S. dollar. Our hedging program does not eliminate our exposure to currency fluctuations. We may be adversely impacted if the U.S. dollar appreciates significantly against certain currencies and our hedging program does not sufficiently offset the effects of such appreciation. For example, see Part II, Item 7 of this Annual Report on Form 10-K for a discussion of our exposure to movements in foreign currency exchange rates, primarily in the Euro, and the impacts from foreign currency exchange, net of hedges, for the year ended December 31, 2022.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest Rates and Inflation: We hold interest-generating assets and interest-bearing liabilities, including our available-for-sale debt securities and our senior unsecured notes and credit facilities. Fluctuations in interest rates, including the U.S. Federal Reserve&#8217;s recent increases in interest rates, could expose us to increased financial risk. In addition, high inflation, such as what we are seeing in the current economic environment, has adversely impacted and may continue to adversely impact our business and financial results.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-Bribery: We are subject to the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws that govern our international operations with respect to payments to government officials. Our international operations are heavily regulated and require significant interaction with foreign officials. We operate in parts of the world that have experienced governmental corruption to some degree. In certain circumstances, strict compliance with anti-bribery laws may conflict with local customs and practices or may require us to interact with doctors and hospitals, some of which may be state-controlled, in a manner that is different than local custom. It is possible that certain of our practices may be challenged under these laws. In addition, our internal control policies and procedures may not protect us from reckless or criminal acts committed by our employees and agents. Enforcement activities under anti-bribery laws could subject us to administrative and legal proceedings and actions, which could result in civil and criminal sanctions, including monetary penalties and exclusion from healthcare programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks inherent in conducting a global business include:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictive government actions against our intellectual property and other foreign assets such as nationalization, expropriation, the imposition of compulsory licenses or similar actions, including waiver of intellectual property protections.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Protective economic policies taken by foreign governments, such as trade protection measures and import and export licensing requirements, which may result in the imposition of trade sanctions or similar restrictions by the U.S. or other governments.</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Business interruptions stemming from natural or man-made disasters, such as climate change, earthquakes, hurricanes, flooding, fires, extreme heat, drought or actual or threatened public health emergencies, or efforts taken by third parties to prevent or mitigate such disasters, such as public safety power shutoffs and facility shutdowns, for which we may not have sufficient insurance. For example, our corporate headquarters in Foster City and certain R&amp;D and manufacturing facilities are located in California, a seismically active region. In the event of a major earthquake, we may not carry sufficient earthquake insurance, and significant recovery time could be required to resume operations. </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Political instability or disruption in a geographic region where we operate, regardless of cause, including war, terrorism, social unrest and political changes, including in China, Russia and Ukraine. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our aspirations, goals and disclosures related to environmental, social and governance (&#8220;ESG&#8221;) matters expose us to numerous risks, including risks to our reputation and stock price.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Institutional and individual investors are increasingly using ESG screening criteria to determine whether Gilead qualifies for inclusion in their investment portfolios. We are frequently asked by investors and other stakeholders to set ambitious ESG goals and provide new and more robust disclosure on goals, progress toward goals and other matters of interest to ESG stakeholders. In response, we have adapted the tracking and reporting of our corporate responsibility program to various evolving ESG frameworks, and we have established and announced goals and other objectives related to ESG matters. These goal statements reflect our current plans and aspirations and are not guarantees that we will be able to achieve them. Our efforts to accomplish and accurately report on these goals and objectives present numerous operational, reputational, financial, legal and other risks, any of which could have a material negative impact, including on our reputation and stock price. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to achieve any goal or objective, including with respect to environmental and diversity initiatives, is subject to numerous risks, many of which are outside of our control. Examples of such risks include: (1) the availability and cost of low- or non-carbon-based energy sources and technologies, (2) evolving regulatory requirements affecting ESG standards or disclosures, (3) the availability of suppliers that can meet our sustainability, diversity and other standards, (4) our ability to recruit, develop and retain diverse talent in our labor markets and (5) the impact of our organic growth and acquisitions or dispositions of businesses or operations. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standards for tracking and reporting on ESG matters are relatively new, have not been harmonized and continue to evolve. Our selection of disclosure frameworks that seek to align with various reporting standards may change from time to time and may result in a lack of consistent or meaningful comparative data from period to period. In addition, regulatory authorities may impose mandatory disclosure requirements with respect to ESG matters. For example, in March 2022, U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) proposed rule changes that would require companies to make certain climate-related disclosures, including information about climate-related risks, greenhouse gas emissions and certain climate-related financial statement metrics. Our processes and controls may not reflect evolving standards for identifying, measuring and reporting ESG matters, immediately or at all, our interpretation of reporting standards may differ from those of others, and such standards may change over time, any of which could result in significant revisions to our goals or reported progress in achieving such goals. In addition, enhancements to our processes and controls to reflect evolving reporting standards may be costly and require additional resources. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ESG practices do not meet evolving investor or other stakeholder expectations and standards, then our reputation, our ability to attract or retain employees and our attractiveness as an investment, business partner or acquiror could be negatively impacted. Similarly, our failure or perceived failure to pursue or fulfill our goals, targets and objectives or to satisfy various reporting standards within the timelines we announce, or at all, could also have similar negative impacts and expose us to government enforcement actions and private litigation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products. Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative relationships with third parties for our sales and marketing performance in certain territories. In some countries, we rely on international distributors for sales of certain of our products. Some of these relationships also involve the clinical development of these products by our partners. Reliance on collaborative relationships poses a number of risks, including the risk that:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are unable to control the resources our corporate partners devote to our programs or products;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of rights to technology developed with our corporate partners;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with our corporate partners could cause delays in, or termination of, the research, development or commercialization of product candidates or result in litigation or arbitration;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contracts with our corporate partners may fail to provide significant protection or may fail to be effectively enforced if one of these partners fails to perform;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners have considerable discretion in electing whether to pursue the development of any additional products and may pursue alternative technologies or products either on their own or in collaboration with our competitors;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our corporate partners with marketing rights may choose to pursue competing technologies or to devote fewer resources to the marketing of our products than they do to products of their own development; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our distributors and our corporate partners may be unable to pay us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is a great deal of uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the specialized and technical nature of our business, the failure to attract, develop and retain highly qualified personnel could adversely impact us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success will depend in large part on our continued ability to attract, develop and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, governmental regulation and commercialization. Our ability to do so also depends in part on how well we maintain a strong workplace culture that is attractive to employees. In addition, competition for qualified personnel in the biopharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Additionally, changes to U.S. immigration and work authorization laws and regulations could make it more difficult for employees to work in or transfer to one of the jurisdictions in which we operate. </span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant cybersecurity incidents could give rise to legal liability and regulatory action under data protection and privacy laws and adversely affect our business and operations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent upon information technology systems, infrastructure and data, including our Kite Konnect platform, which is critical to maintain chain of identity and chain of custody of Yescarta and Tecartus. The multitude and complexity of our computer systems make them inherently vulnerable to service interruption or destruction, malicious intrusion and ransomware attack. Likewise, data privacy or cybersecurity incidents or breaches by employees or others can result in the exposure of sensitive data, including our intellectual property or trade secrets or the personal information of our employees, patients, customers or other business partners to unauthorized persons or to the public. Cybersecurity attacks and incidents are increasing in their frequency, sophistication and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intensity. Malicious actors seek to steal money, gain unauthorized access to, destroy or manipulate data, and disrupt operations, and some of their attacks may not be recognized or discovered until launched or after initial entry into the environment, such as novel or zero-day attacks that are launched before patches are available and defenses can be readied. Malicious actors are also increasingly developing methods to avoid prevention, detection and alerting capabilities, including employing counter-forensic tactics making response activities more difficult. Such attacks and incidents include, for example, the deployment of harmful malware, ransomware, denial-of-service, social engineering and other means to affect service reliability and operatio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ns and threaten data confidentiality, integrity and availability. Our business and technology partners face similar risks and any security breach of their systems could adversely affect our security posture.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like many companies, we have experienced cybersecurity incidents, including data breaches and service interruptions. When cybersecurity incidents occur, our policy is to respond and address them in accordance with applicable governmental regulations and other legal requirements, including our cybersecurity protocols. There can be no assurance that our efforts in response to cybersecurity incidents, as well as our investments to protect our information technology infrastructure and data, will shield us from significant losses, brand and reputational harm and potential liability or prevent any future interruption or breach of our systems. Such cybersecurity incidents can cause the loss of critical or sensitive information, including personal information, and could give rise to legal liability and regulatory action under data protection and privacy laws. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators globally are also imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the General Data Protection Regulation (&#8220;GDPR&#8221;) established regulations regarding the handling of personal data, and non-compliance with the GDPR may result in monetary penalties of up to four percent of worldwide revenue. In addition, new domestic data privacy and security laws, such as the California Consumer Privacy Act and the California Privacy Rights Act and other laws that have been or may be passed, similarly introduce requirements with respect to personal information, and non-compliance with such laws may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Other changes or new laws or regulations associated with the enhanced protection of personal information, could greatly increase our cost of providing our products and services or even prevent us from offering certain services in jurisdictions in which we operate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Strategic and Financial Risks</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks associated with engaging in business acquisitions, licensing arrangements, collaborations, options, equity investments, asset divestitures and other strategic transactions.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have engaged in, and may in the future engage in, such transactions as part of our business strategy. We may not identify suitable transactions in the future and, if we do, we may not complete such transactions in a timely manner, on a cost-effective basis, or at all, including the possibility that a governmental entity or regulatory body may delay or refuse to grant approval for the consummation of the transaction. If we are successful in making an acquisition or closing a licensing arrangement or collaboration, the products, intellectual property and technologies that are acquired or licensed may not be successful or may require significantly greater resources and investments than anticipated. As part of our annual impairment testing of our goodwill and other indefinite-lived intangible assets in the fourth quarter, and earlier if impairment indicators exist, as required under U.S. generally accepted accounting principles, we may need to recognize impairment charges related to the products, intellectual property and technologies that are acquired or licensed. For example, as a result of an impairment analysis we conducted following our receipt of data in March 2022 from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with hormone receptor-positive, human epidermal growth receptor 2-negative metastatic breast cancer, we recognized a partial in-process research and development impairment charge on our Consolidated Statements of Income during 2022. For option structured deals, there is no assurance that we will elect to exercise our option right, and it is possible that disagreements, uncertainties or other circumstances may arise, including with respect to whether our option rights have been appropriately triggered, which may hinder our ability to realize the expected benefits. For equity investments in our strategic partners, such as in connection with our collaborations with Arcus Biosciences, Inc. and Galapagos NV, the value of our equity investments may fluctuate and decline in value. If we are not successful in the execution or implementation of these transactions, our financial condition, cash flows and results of operations may be adversely affected, and our stock price could decline.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid substantial amounts of cash and incurred additional debt to finance our strategic transactions. Additional indebtedness and a lower cash balance could result in a downgrade of our credit ratings, limit our ability to borrow additional funds or refinance existing debt on favorable terms, increase our vulnerability to adverse economic or industry conditions, and reduce our financial flexibility to continue with our capital investments, stock repurchases and dividend payments. For example, as a result of the cash used and the debt issued in connection with our acquisition of Immunomedics in 2020, S&amp;P Global Ratings downgraded our credit rating. We may be adversely impacted by any failure to overcome these additional risks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in our effective income tax rate could reduce our earnings.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the U.S. and various foreign jurisdictions. Due to economic and political conditions, various countries are actively considering and have made changes to existing tax laws, and we cannot predict the form or timing of such changes. Our effective tax rates are affected by changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, the introduction of new taxes, and changes in tax laws, regulations, administrative practices and interpretations, including in the U.S., Germany and Ireland.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the examination of our tax returns and other tax matters by the U.S. Internal Revenue Service and tax authorities in various foreign jurisdictions. There are differing interpretations of tax laws and regulations and, as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We may be adversely affected by the resolution of one or more of these exposures in any reporting period.</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_19"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNRESOLVED STAFF COMMENTS </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROPERTIES </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Foster City, California, where we house our administrative, manufacturing and R&amp;D activities. We also have administrative facilities in Raleigh, North Carolina and Washington, D.C., and we have R&amp;D facilities in Emeryville, Oceanside and Santa Monica, California; Seattle, Washington;</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Frederick, Maryland; Morris Plains, New Jersey; Edmonton, Canada; and Dublin, Ireland.</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal manufacturing facilities are in El Segundo, La Verne, Oceanside and San Dimas, California; Edmonton, Canada; Cork, Ireland and Hoofddorp, Netherlands.</span><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information about our manufacturing facilities, see Item&#160;1. Business &#8220;Our Manufacturing Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; Our global operations include offices in Europe, North America, Asia, South America, Africa, Australia and the Middle East.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing properties, including both owned and leased sites, are adequate and suitable for the conduct of our business. We believe our capital resources are sufficient to purchase, lease or construct any additional facilities required to meet our expected long-term growth needs.</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_25"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant pending legal proceedings, see&#160;Note 13. Commitments and Contingencies - Legal Proceedings of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_28"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MINE SAFETY DISCLOSURES </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_31"></div><div style="margin-top:13.5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_34"></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Market Information</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Select Market under the symbol &#8220;GILD.&#8221; </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Holders</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;17, 2023, we had approximately 1,452 stockholders of record of our common stock.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Dividends</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022 and </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we paid quarterly dividends. We expect to continue to pay quarterly dividends, although the amount and timing of any future dividends are subject to declaration by our Board of Directors. Additional information is included in Note 14. Stockholders&#8217; Equity of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Securities Authorized For Issuance Under Equity Compensation Plans</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information with respect to our equity compensation plans in effect as of December&#160;31, 2022:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of Common Shares to be Issued Upon Exercise of Outstanding Options and Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-average Exercise Price of Outstanding Options and Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of Common Shares Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(c) </span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Equity Incentive Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity compensation plans approved by security holders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 25.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">______________________________________________________&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes 25&#160;million restricted stock units, performance share units and phantom shares. These awards have no exercise price and are not included in the weighted-average exercise price of outstanding awards. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Under our Employee Stock Purchase Plan, participants are permitted to purchase our common stock at a discount on certain dates through payroll deductions within a pre-determined purchase period. Accordingly, these numbers are not determinable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Performance Graph</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares our cumulative total stockholder return for the past five years to&#160;two indices: the&#160;Standard&#160;&amp; Poor&#8217;s 500 Stock Index (&#8220;S&amp;P 500 Index&#8221;) and the Nasdaq Biotechnology Index (&#8220;NBI Index&#8221;). The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns. </span></div><div style="margin-top:4.5pt;text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of Cumulative Total Return on Investment for the Past Five Years</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><img src="gild-20221231_g1.jpg" alt="gild-20221231_g1.jpg" style="height:476px;margin-bottom:5pt;vertical-align:text-bottom;width:685px"/></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">______________________________________________________&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This section is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the Securities and Exchange Commission (&#8220;SEC&#8221;) and is not to be incorporated by reference in any of our filings under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) or the Securities Exchange Act of 1934 (&#8220;Exchange Act&#8221;) whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Shows the cumulative return on investment assuming an investment of $100 in our common stock, the NBI Index and the S&amp;P 500 Index on December&#160;31, 2017, and assuming that all dividends were reinvested.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Issuer Purchases of Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a new $5.0 billion&#160;stock repurchase program (&#8220;2020 Program&#8221;), with no fixed expiration. Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions. The $12.0 billion stock repurchase program authorized by our Board of Directors in the first quarter of 2016 (&#8220;2016 Program&#8221;) was completed in the fourth quarter of 2022. We started repurchases under the 2020 Program in December 2022. As of December&#160;31, 2022, the remaining authorized repurchase amount under the 2020 Program was $4.9 billion.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our stock repurchase activity for the three months ended December&#160;31, 2022:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:29.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average<br/>Price Paid<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of<br/>Shares Purchased<br/>as Part of a Publicly<br/>Announced Program (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Fair<br/>Value of Shares<br/>that May Yet Be<br/>Purchased Under<br/>the 2016 Program (in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Fair<br/>Value of Shares<br/>that May Yet Be<br/>Purchased Under<br/>the 2020 Program (in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 - October 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.91&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 - November 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 - December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,374&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">______________________________________________________&#160;</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The difference between the total number of shares purchased and the total number of shares purchased as part of a publicly announced program is due to shares of common stock withheld by us from employee restricted stock awards in order to satisfy applicable tax withholding obligations.</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_37"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">[RESERVED]</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis is intended to provide material information around events and uncertainties known</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to management relevant to an assessment of the financial condition and results of operations of Gilead and should therefore be read in conjunction with our audited Consolidated Financial Statements and the accompanying Notes to Consolidated Financial Statements and other disclosures included in this Annual Report on Form 10-K (including the disclosures under Part I, Item&#160;1A. Risk Factors) where other material events and uncertainties not otherwise discussed below are disclosed. Certain amounts and percentages herein may not sum or recalculate due to rounding. Additional information related to the comparison of our results of operations between the years 2021 and 2020 is included in Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of our <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/882095/000088209522000007/gild-20211231.htm">2021 Form 10-K</a> filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;)</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Management Overview</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategy and Outlook</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2019, our strategic ambitions have been to (i) bring 10+ transformative therapies to patients by 2030; (ii) be the biotech employer and partner of choice; and (iii) deliver shareholder value in a sustainable and responsible manner. Our strategic priorities for 2023 and beyond, reflecting how we plan to deliver those ambitions, are: (i) maximize near-term revenue growth; (ii) maximize impact of long-active HIV; (iii) expand and deliver on oncology programs; (iv) champion an environment of inclusion and employee growth; and (v) remove barriers to speed in execution. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to provide consistent execution on a portfolio with quality, depth and breadth, including continued growth in our leading HIV portfolio, which is poised to shape the long-acting market following our first lenacapavir approvals, as well as strong commercial performance and clinical momentum for our fast-growing oncology business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Business Updates</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we continued to advance our portfolio, receiving approvals across various therapeutic areas, indications and geographies. We ended the year with Sunlenca receiving its first approval in the U.S. for heavily-treatment experienced individuals, following the first European market approval by the European Commission (&#8220;EC&#8221;). This is the first twice-yearly, subcutaneous HIV medicine to be approved. We also continued to broaden therapies available in oncology, receiving approvals for additional indications of Yescarta and Tecartus, and the 2023 approval of Trodelvy for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#8220;HR+/HER2-&#8221;) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In terms of capital resources, we continued to invest in our business and research and development (&#8220;R&amp;D&#8221;) pipeline through acquisitions and collaborations. We also continued to provide shareholder returns in the form of dividends and share repurchases.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following highlights are taken from press releases recently issued. Readers are encouraged to review all press releases available on our website at www.gilead.com. The content on the referenced website does not constitute a part of and is not incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Virology</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In December 2022, we announced U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Sunlenca, in combination with other antiretroviral(s), for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In November 2022, we announced the EC authorized an extended indication and line extension for a low-dosage tablet form of Biktarvy for the treatment of HIV in virologically suppressed children who are at least 2 years of age and weigh at least 14 kg.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In November 2022, we announced FDA approval of Vemlidy for the treatment of chronic hepatitis B virus (&#8220;HBV&#8221;) infection in pediatric patients 12 years and older with compensated liver disease.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In October 2022, we announced that Merck &amp; Co., Inc. (&#8220;Merck&#8221;) and Gilead plan to resume their Phase 2 study under an amended protocol. The study will evaluate an investigational once-weekly oral combination treatment regimen of Merck&#8217;s islatravir at a lower weekly dose and Gilead&#8217;s lenacapavir.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In August 2022, we announced that EC has granted marketing authorization for Sunlenca (lenacapavir) for the treatment of HIV infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive antiviral regimen.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In July 2022, we received a positive opinion from European Medicines Agency&#8217;s (&#8220;EMA&#8221;) Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) for Veklury to be granted full marketing authorization for the treatment of coronavirus disease 2019 (&#8220;COVID-19&#8221;) in adults and adolescents with pneumonia requiring supplemental oxygen and adults who do not require supplemental oxygen and are at increased risk of developing severe COVID-19.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In May 2022, we announced FDA lifted the clinical hold placed on the Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and pre-exposure prophylaxis following the agency&#8217;s review of the storage and compatibility data of lenacapavir injection with an alternate vial made from aluminosilicate glass.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2022, FDA approved a supplemental new drug application for Veklury for the treatment of pediatric patients under 12 years of age for the treatment of COVID-19.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Oncology</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cell Therapy</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In December 2022, we entered into an agreement to acquire Tmunity Therapeutics Inc. (&#8220;Tmunity&#8221;), a clinical stage private biotech company, which will provide us with preclinical and clinical programs, including an &#8220;armored&#8221; CAR T technology platform that has the potential to be applied to a variety of CAR Ts to enhance anti-tumor activity, as well as rapid manufacturing processes. The transaction closed in February 2023.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In December 2022, we entered into a strategic collaboration with Arcellx, Inc. (&#8220;Arcellx&#8221;) to co-develop and co-commercialize CART-ddBCMA, a late-stage clinical asset in development for the treatment of multiple myeloma. The transaction closed in January 2023.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In December 2022, we announced the transfer of the marketing authorization for Yescarta in Japan from Daiichi Sankyo Co., Ltd. to Gilead K.K. in 2023.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In December 2022, we received approval from the Ministry of Health, Labour and Welfare in Japan for Yescarta for the initial treatment of relapsed or refractory (&#8220;R/R&#8221;) large B-cell lymphoma (&#8220;LBCL&#8221;).</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In October 2022, we received European marketing authorization for Yescarta use in adults with second-line diffuse LBCL. Additionally, EC granted marketing authorization for Tecartus for the treatment of adult R/R B-cell precursor acute lymphoblastic leukemia (&#8220;ALL&#8221;), and in Canada, we received conditional marketing authorization for Yescarta for R/R follicular lymphoma (&#8220;FL&#8221;) after two or more lines of systemic therapy.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In July 2022, we received a positive opinion from EMA&#8217;s CHMP for Tecartus for the treatment of adult patients 26 years of age and above with R/R B-cell precursor ALL.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In June 2022, EC approved Yescarta for the treatment of adult patients with R/R FL after three or more lines of systemic therapy.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2022, FDA approved commercial production at our new CAR T-cell therapy manufacturing facility in Frederick, Maryland.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2022, FDA granted approval to Yescarta as initial treatment for adults with LBCL that is refractory to or relapses within 12 months of first-line chemoimmunotherapy.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In February 2023, we announced that FDA has approved Trodelvy for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In January 2023, we announced that EMA has validated a Type II variation of the Marketing Authorization Application for Trodelvy for the treatment of adult patients unresectable or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In December 2022, we acquired the remaining rights to GS-1811, an anti-CCR8 antibody developed by Jounce Therapeutics, Inc. (&#8220;Jounce&#8221;) for the treatment of solid tumors.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In October 2022, we announced a strategic collaboration with MacroGenics, Inc. (&#8220;MacroGenics&#8221;) to develop bispecific antibodies to treat various cancers. The agreement includes an upfront payment by us of $60 million to MacroGenics and an exclusive option granted to us on MGD024, an investigational CD123 and CD3 bispecific.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In August 2022, we announced an agreement with Everest Medicines (&#8220;Everest&#8221;) to transfer all development and commercialization rights to Gilead for Trodelvy in Greater China, South Korea, and other Asian markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In April 2022, we entered into a strategic research collaboration agreement with Dragonfly Therapeutics, Inc. (&#8220;Dragonfly&#8221;) to develop natural killer cell engager-based immunotherapies for oncology and inflammation indications.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In March 2022, we announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- mBC who received prior endocrine therapy, cyclin-dependent kinase (&#8220;CDK&#8221;) 4/6 inhibitors and two to four lines of chemotherapy.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inflammation</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In January 2023, we announced a collaboration and licensing agreement with EVOQ Therapeutics, Inc. (&#8220;EVOQ&#8221;) to advance EVOQ&#8217;s proprietary NanoDisc technology for the treatment of rheumatoid arthritis and lupus.</span></div><div style="margin-top:3pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">In September 2022, we completed the acquisition of MiroBio Ltd. (&#8220;MiroBio&#8221;) for $414 million in cash. MiroBio is a U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Financial Results</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,281&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,305&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues were $27.3 billion in 2022 and remained relatively flat compared to 2021, primarily due to increased sales in HIV, cell therapy and Trodelvy, offset by lower sales of Veklury.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to Gilead was $4.6 billion or $3.64 diluted earnings per share attributable to Gilead in 2022, compared to $6.2 billion or $4.93 diluted earnings per share attributable to Gilead in 2021. The decrease was primarily due to the following items net of their related tax effect: a partial in-process research and development (&#8220;IPR&amp;D&#8221;) impairment charge of $2.7 billion during the three months ended March 31, 2022 related to assets we acquired from Immunomedics, Inc. (&#8220;Immunomedics&#8221;) in 2020, a $406 million charge related to the termination of the Trodelvy collaboration agreement with Everest and higher R&amp;D expenses, partially offset by a $1.25 billion charge for a settlement related to bictegravir litigation in the fourth quarter of 2021 that did not repeat in 2022.</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_46"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Total revenues:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HIV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HCV</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cell Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trodelvy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,716&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,342&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,924&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,982&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,176&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,678&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,008&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,884&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">See Note 2. Revenues of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for further disaggregation of revenue by product.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HIV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIV product sales increased by 5% to $17.2 billion in 2022, compared to 2021, primarily due to continued higher demand for Biktarvy worldwide and favorable pricing dynamics, partially offset by the impact of the loss of exclusivity for Truvada in the U.S., channel inventory dynamics and unfavorable foreign currency exchange impact. Part of our favorable pricing dynamics resulted from shifts in channel mix, and we expect channel mix to remain similar in 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Veklury</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Veklury product sales decreased by 30% to $3.9 billion in 2022, compared to 2021, primarily due to lower demand driven by reduced hospitalization rates in the U.S. and Europe, partially offset by higher demand in Other International. Sales of Veklury generally reflect COVID-19 related rates and severity of infections and hospitalizations, as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19. As a result, future sales of Veklury are difficult to predict and may vary significantly from one period to the next.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HCV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HCV product sales decreased by 4% to $1.8 billion in 2022, compared to 2021, primarily due to unfavorable foreign currency exchange impact, fewer patient starts and unfavorable pricing dynamics.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HBV / HDV</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HBV and HDV product sales increased by 2% to $988 million in 2022, compared to 2021, primarily due to higher demand for Vemlidy and the continued adoption of Hepcludex in Europe.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cell Therapy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell therapy product sales, which include Yescarta and Tecartus, increased by 68% to $1.5 billion in 2022, compared to 2021, primarily due to higher demand for Yescarta in R/R LBCL in the U.S. and Europe, as well as for Tecartus in R/R ALL and mantle cell lymphoma.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trodelvy</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trodelvy product sales increased by 79% to $680 million in 2022, compared to 2021, primarily due to the continued adoption in metastatic triple-negative breast cancer in the U.S. and Europe.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other product sales decreased by 8% to $946 million in 2022, as compared to 2021, primarily due to lower demand for AmBisome and loss of exclusivity for Letairis.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Gross-to-Net Deductions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in gross-to-net deductions:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,381&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross-to-net deductions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates and chargebacks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns, discounts and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross-to-net deductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,582&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,373&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of gross product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,982&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,008&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Exchange Impact</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally face exposure to movements in foreign currency exchange rates, primarily in the Euro. We use foreign currency exchange contracts to hedge a portion of our foreign currency exposures. Of our total product sales, 31% and 29% were generated outside the U.S. in 2022 and 2021, respectively. Foreign currency exchange, net of hedges, had an unfavorable impact on our total product sales of $608 million in 2022, based on a comparison using foreign currency exchange rates from 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs and Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our costs and expenses: </span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,657&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,601&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product gross margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">347 bps</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM - Not Meaningful</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Gross Margin</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product gross margin increased to 79.0% in 2022 as compared to 75.6% in 2021, primarily driven by a $1.25 billion charge for a settlement related to bictegravir litigation in the fourth quarter of 2021 that did not repeat in 2022. The increase was partially offset by higher royalty expenses driven by Biktarvy royalties, the reversal of a $175 million litigation reserve in the third quarter of 2021 that did not repeat in 2022, and changes in product mix.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $376 million in 2022 compared to 2021, primarily due to higher clinical development spend related mostly to Trodelvy and the Arcus Biosciences, Inc. (&#8220;Arcus&#8221;) collaboration, as well as inflationary increases.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquired In-Process Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development expenses of $944 million in 2022 were primarily related to a $389 million charge associated with our acquisition of MiroBio, a $315 million charge associated with the Dragonfly collaboration, an $82 million charge associated with the Jounce collaboration and acquisition of GS-1811, and a $60 million charge associated with the MacroGenics collaboration. Acquired in-process research and development expenses of $939 million in 2021 were primarily related to a $625 million charge associated with an option exercised under the Arcus collaboration. See Note 6. Acquisitions and Note 10. Collaborations and Other Arrangements of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">In-Process Research and Development Impairment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics in 2020, we allocated a portion of the purchase price to acquired IPR&amp;D intangible assets. Approximately $8.8&#160;billion was assigned to IPR&amp;D intangible assets related to Trodelvy for treatment of patients with HR+/HER2- breast cancer. In March 2022, we received data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- mBC who have received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy (&#8220;third-line plus patients&#8221;). Based on our evaluation of the study results, and in connection with the preparation of the financial statements for the first quarter, we updated our estimate of the fair value of our HR+/HER2- IPR&amp;D intangible asset to $6.1&#160;billion as of March 31, 2022. Our estimate of fair value used a probability weighted income approach that discounts expected future cash flows to the present value. The expected cash flows included cash flows from HR+/HER2- mBC for third-line plus patients and patients in earlier lines of therapy which are the subject of separate clinical studies. Our revised discounted cash flows were lower primarily due to a delay in launch timing for third-line plus patients which caused a decrease in our market share assumptions based on the expected competitive environment. There were no changes in our plans or assumptions related to our estimated cash flows for patients in the earlier lines of therapy. We determined the revised estimated fair value was below the carrying value of the asset and, as a result, we recognized a partial impairment charge of $2.7&#160;billion in In-process research and development impairment on our Consolidated Statements of Income during the three months ended March 31, 2022. The remaining balance of the HR+/HER2- IPR&amp;D intangible asset at the time of the assessment related to cash flows from earlier lines of therapy, where we have Phase 3 pivotal studies in development, in addition to the revised cash flows related to the third-line plus patient setting. If future events result in adverse changes in the key assumptions used in determining fair value, including the timing of product launches, information on the competitive landscape of treatments in this indication, changes to the probability of technical or regulatory success, failure to obtain anticipated regulatory approval or discount rate, among others, additional impairments may be recorded and could be material to our financial statements. No other IPR&amp;D impairment charges were recorded in 2022 or 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $427 million in 2022 compared to 2021, primarily due to a $406 million charge associated with the termination of the Trodelvy license collaboration agreement with Everest, which had provided Everest with broad commercialization and development rights to Trodelvy in certain Asia territories. We terminated the existing agreement and reacquired the Trodelvy rights in these territories. Other spending increases in 2022 included increased promotional and marketing investing, mostly in Trodelvy and cell therapy, as well as higher corporate activities and inflationary increases, slightly offset by a decrease in donations to the Gilead Foundation in 2022 as compared to 2021.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Expense and Other Income (Expense), Net</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Interest expense and Other income (expense), net:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:61.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(935)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,001)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(639)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased by $66 million in 2022 compared to 2021, primarily due to lower outstanding debt balances.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Other income (expense), net for 2022, compared to 2021, primarily reflects higher interest income due to rising interest rates, partially offset by higher net unrealized losses from equity securities.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the period-over-period changes in our Income tax expense:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:61.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,278&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(2,464)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our effective tax rate decreased in 2022, compared to 2021, primarily due to a beneficial change in jurisdictional mix of income and lower state taxes.</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_49"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidity and Capital Resources</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually evaluate our liquidity and capital resources, including our access to external capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to ensure that we can adequately and efficiently finance our operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable debt securities were $7.6 billion and $7.8 billion as of December&#160;31, 2022 and 2021, respectively. Cash and cash equivalents increased by $74 million from December&#160;31, 2021 to December&#160;31, 2022. The following table summarizes our cash flow activities:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities is derived by adjusting our net income for non-cash items and changes in operating assets and liabilities. Net cash provided by operating activities was $9.1 billion in 2022, compared to $11.4 billion in 2021. The decrease was primarily due to the $1.25 billion payment made in the first quarter of 2022 in connection with the legal settlement related to bictegravir litigation as well as higher income tax payments made and higher operating expenses in 2022.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $2.5 billion in 2022, compared to $3.1 billion in 2021. The decrease was primarily due to lower net purchases of marketable debt and equity securities, partially offset by higher capital expenditures and other acquisitions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $6.5 billion in 2022, compared to $8.9 billion in 2021. In 2022, we utilized cash for $1.5 billion of debt repayments, $3.7 billion of dividend payments and $1.4 billion of common stock repurchases. In 2021, we utilized cash for $4.75 billion of debt repayments, $3.6 billion of dividend payments, and $546 million of common stock repurchases.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Resources</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing capital resources, including cash and cash equivalents, marketable debt securities and our revolving credit facility, supplemented by cash flows generated from our operations, will be adequate to satisfy our capital needs for the foreseeable future.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our material cash requirements consisted primarily of the repayment of outstanding borrowings, income tax payments, including the remaining obligations for the one-time repatriation transition tax from the Tax Cuts and Jobs Act, purchases of inventory, operating lease obligations, capital expenditures and milestone and other payments related to our collaborative agreements. See Notes 6. Acquisitions, 10. Collaborations and Other Arrangements, 11. Debt and Credit Facilities, 12. Leases, 13. Commitments and Contingencies and 17. Income Taxes of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information. We enter into certain unconditional purchase obligations, capital expenditure projects and other commitments in the normal course of business. There have been no changes to these commitments during the year that would have a material impact on the company&#8217;s ability to meet either short-term or long-term cash requirements.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our future capital requirements will depend on many factors, including but not limited to the following:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the commercial performance of our current and future products;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the progress and scope of our R&amp;D efforts, including preclinical studies and clinical trials;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the cost, timing and outcome of regulatory reviews;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the expansion of our sales and marketing capabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the possibility of acquiring additional manufacturing capabilities or office facilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the possibility of acquiring other companies or new products;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">debt service requirements;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">future dividends subject to declaration by our Board of Directors;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the establishment of additional collaborative relationships with other companies; and</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">costs associated with the defense, settlement and adverse results of government investigations and litigation.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future require additional funding, which could be in the form of proceeds from equity or debt financings. If such funding is required, we cannot guarantee that it will be available to us on favorable terms, if at all. We may choose to repay certain of our long-term debt obligations prior to maturity dates based on our assessment of current and long-term liquidity and capital requirements</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_52"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Critical Accounting Estimates</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1. Organization and Summary of Significant Accounting Policies of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for information about our significant accounting policies and how estimates are involved in the preparation of our financial statements. We believe the following reflect the critical accounting estimates used in the preparation of our Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rebates and Chargebacks </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are determined using a complex estimation process and are subject to uncertainty in part due to the lag between the date of the product sales and the date the related rebates or chargeback claims are settled. In developing our estimates of rebates and chargebacks, we consider the following: </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product sales, including product mix and pricing;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">historical and estimated payer mix;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">statutory discount requirements and contractual terms;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">historical claims experience and processing time lags;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimated patient population;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">known market events or trends; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market research;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">channel inventory data obtained from our major U.S. wholesalers; and</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other pertinent internal or external information.</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consolidated activities and ending balances in our rebates and chargebacks accounts, including adjustments made relating to previous years&#8217; sales as a result of changes in estimates:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Decrease/(Increase) to Product Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2022:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2022 sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,442)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to sales prior to 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,622&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,509)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,028&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December&#160;31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to 2021 sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,714)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Activity related to sales prior to 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(617)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,691)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:21.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net product sales in 2022 include the impact of $418 million for changes in rebate and chargeback estimates related to sales prior to 2022. Historically, our actual rebates and chargebacks claimed for prior periods have varied by less than 5% from our estimates. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the fair values of intangible assets, whether as part of a business combination or impairment assessment, involves the use of a probability-weighted income approach that discounts expected future cash flows to present value and requires the use of critical estimated inputs, including:</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification of product candidates with sufficient substance requiring separate recognition;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of projected future cash flows, including revenues and operating profits related to the products or product candidates, which, for example, include significant inputs such as addressable patient population, treatment duration and projected market share;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the probability of technical and regulatory success for unapproved product candidates considering their stages of development;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and resources needed to complete the development and approval of product candidates;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an appropriate discount rate based on the estimated weighted-average cost of capital for companies with profiles similar to our profile, representing the rate that market participants would use to value the intangible assets;</span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the life of the potential commercialized products and associated risks, including the inherent difficulties and uncertainties in developing a product candidate such as obtaining FDA and other regulatory approvals; and</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">risks related to the viability of and potential alternative treatments in any future target markets.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates are subject to uncertainty due to the high rate of failure inherent in the discovery and development of new products; delays that can occur in development, approval and product launch processes; unanticipated decisions made by regulatory agencies; advent of competing products; unexpected changes in U.S. and global financial markets and other unanticipated events and circumstances. If future events result in adverse changes in the critical assumptions used in determining fair value, impairment charges on our intangible assets may be recorded and could be material to our financial statements. For example, in 2022, we recognized a $2.7 billion impairment charge related to our HR+/HER2- IPR&amp;D intangible asset related to an expected delay in launch timing which caused a decrease in our market share assumptions based on the expected competitive environment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. Certain significant matters are described in Note 13. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical inputs to the accruals recorded and disclosures provided in relation to these matters include the probability of a certain outcome of the case, the determination as to whether an exposure is reasonably estimable and the amount of potential exposure. These inputs are subject to uncertainty due to changes in the legal facts and circumstances of the case, status of the proceedings, applicable law, the views of legal counsel and the views of any judges or jury involved in the case. Upon the final resolution of such matters, it is possible that there may be a loss in excess of the amount recorded, and such amounts could have a material adverse effect on our results of operations, cash flows or financial position. We periodically reassess these matters when additional information becomes available and adjust our estimates and assumptions when facts and circumstances indicate the need for any changes. For example, in the fourth quarter of 2021, we recorded an accrual of $1.25 billion in Other current liabilities on our Consolidated Balance Sheets for the settlement related to bictegravir litigation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the U.S. and various foreign jurisdictions, including Ireland. Critical inputs in determining our provision for income taxes and related tax balances include forecasts of our future income and expenses, potential tax planning strategies and determination of the probability of certain tax positions being sustained upon examination by tax authorities. These inputs are subject to uncertainty due to potential changes in facts and circumstances, economic and political conditions, changes to existing tax laws and new regulations or interpretations by tax authorities. Changes in these conditions could have a material adverse impact on our results of operations and financial position.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:60.75pt;text-align:justify;text-indent:-60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks that may result from changes in foreign currency exchange rates, interest rates and credit, and equity prices. To reduce certain of these risks, we enter into various types of foreign currency derivative hedging transactions, follow investment guidelines and monitor outstanding receivables as part of our risk management program. We may also enter into other transactions, such as interest rate derivative hedges, as needed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Foreign Currency Exchange Rate Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in more than 35 countries worldwide. As a result, our financial results could be significantly affected by factors such as changes in foreign currency exchange rates or weak economic conditions in the foreign markets in which we distribute our products. Our operating results are exposed to changes in foreign currency exchange rates between the U.S. dollar and various foreign currencies, the most significant of which is the Euro. When the U.S. dollar strengthens against these currencies, the relative value of sales made in the respective foreign currency decreases. Conversely, when the U.S. dollar weakens against these currencies, the relative value of such sales increases. Overall, we are a net receiver of foreign currencies and, therefore, we benefit from a weaker U.S. dollar and are adversely affected by a stronger U.S. dollar. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 29% of our product sales were denominated in foreign currencies during 2022. To partially mitigate the impact of changes in currency exchange rates on net cash flows from our foreign currency denominated sales, we enter into foreign currency exchange forward contracts. We also hedge certain monetary assets and liabilities denominated in foreign currencies, which reduces but does not eliminate our exposure to currency fluctuations between the date a transaction is recorded and the date that cash is collected or paid. In general, the market risks of these contracts are offset by corresponding gains and losses on the transactions being hedged. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, we had open foreign currency forward contracts with notional amounts of $3.0 billion and $2.9 billion, respectively. A hypothetical 10% adverse movement in foreign currency exchange rates compared with the U.S. dollar relative to exchange rates as of December&#160;31, 2022 and 2021 would have resulted in a reduction in fair value of these contracts of approximately $299 million and $333 million, respectively, and if realized, would have negatively affected earnings over the remaining life of the contracts. The analysis does not consider the impact that hypothetical changes in foreign currency exchange rates would have on anticipated transactions that these foreign currency sensitive instruments were designed to offset.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Interest Rate and Credit Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of available-for-sale debt securities and our senior unsecured notes create an exposure to interest rate and credit risk. With respect to our investment portfolio, we adhere to an investment policy that requires us to limit amounts invested in securities based on credit rating, maturity, industry group and investment type and issuer, except for securities issued by the U.S. government. The goals of our investment policy, in order of priority, are as follows: </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> safety and preservation of principal and diversification of risk; </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> liquidity of investments sufficient to meet cash flow requirements; and </span></div><div style="margin-top:4.5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> a competitive after-tax rate of return. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the expected maturities and average interest rates of our interest-generating assets and interest-bearing liabilities as of December&#160;31, 2022:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.515%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expected Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior unsecured fixed rate notes, including current portion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Amounts represent principal balances. In addition to the senior unsecured fixed rate notes, we have a $2.5 billion five-year revolving credit facility that matures in June 2025. There were no amounts outstanding under the five-year revolving credit facility as of December&#160;31, 2022. See Note 11. Debt and Credit Facilities of the Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K for additional information. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Equity Price Risk </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold shares of common stock of certain publicly traded biotechnology companies primarily in connection with license and collaboration agreements. These equity securities are measured at fair value with any changes in fair value recognized in earnings. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of these equity securities was approximately $1.2 billion and $1.8 billion as of December&#160;31, 2022 and 2021, respectively. Changes in fair value of these equity securities are impacted by the volatility of the stock market and changes in general economic conditions, among other factors. A hypothetical 20% increase or decrease in the stock prices of these equity securities would have increased or decreased their fair value as of December&#160;31, 2022 and 2021 by approximately $239 million and $364 million, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span><br/></span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_64"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December&#160;31, 2022, 2021 and 2020 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_67">Report of Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN182NC9mcmFnOjI1YmY4YmMzNjk4NTQ0MWQ5YzY1YTMzNTFjZDNmMzBhL3RhYmxlOjQyODBjZDA3Yjc2NzRlNDhhNzI5ZDY5MDVmYWI5MDkwL3RhYmxlcmFuZ2U6NDI4MGNkMDdiNzY3NGU0OGE3MjlkNjkwNWZhYjkwOTBfMC0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjo0ZmQyYzQxNjlkYmU0NzlhYmJhYzJiMWJkZWVkMGIyZV83MQ_5a14d9ce-16da-45fd-9896-568284a50afa">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_67">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_67">46</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_70">Audited Consolidated Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_73">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_73">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_76">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_76">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_79">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_79">50</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_82">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_82">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_85">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_85">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_88">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_88">53</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Gilead Sciences, Inc.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Gilead Sciences, Inc. (the Company) as of December&#160;31, 2022 and 2021, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;22, 2023, expressed an unqualified opinion thereon.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate. </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Government and commercial rebates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully described in Note 1, the Company estimates reductions to its revenues for amounts payable to payers and healthcare providers in the United States under various government and commercial rebate programs in the period that the related sales occur. Rebates may vary by product, payer and individual payer plans, some of which may not be known at the point of sale. Estimated reductions to revenue are based on product sales, historical and expected payer mix, discount rates, and various other estimated and actual data, adjusted for current period expectations.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s estimated reductions to revenue for rebates was complex and involved significant judgment, particularly in assessing the reasonableness of estimated payer mix applied to sales during the period. This estimate relies heavily on historical data that is adjusted for changes in payer mix expectations over time.</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4.5pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated and tested the design and operating effectiveness of the Company&#8217;s internal controls over management&#8217;s estimation and review of reductions from revenue for rebate programs, including controls to assess the payer mix assumption. We also tested the completeness and accuracy of data utilized in the controls, and the accuracy of calculations supporting management&#8217;s estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test management&#8217;s estimation methodology for determining the payer mix, our audit procedures included, among others, analytically evaluating management&#8217;s estimates, evaluating evidence contrary to the estimated amounts, performing a sensitivity analysis on the rates used in the estimates and performing a comparison of actual payments related to amounts accrued during the current and prior years.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Valuation of in-process research and development intangible asset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company recognized a $2.7 billion impairment charge related to its in-process research and development (IPR&amp;D) intangible asset related to Trodelvy for treatment of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. At December 31, 2022, this intangible asset had a remaining carrying value of $6.1 billion. As discussed in Note 1, intangible assets with indefinite useful lives related to IPR&amp;D projects acquired in a business combination are measured at their respective fair values as of the acquisition date and are considered indefinite-lived until the completion or abandonment of the associated R&amp;D efforts. The Company tests indefinite-lived intangible assets for impairment on an annual basis and in between annual tests if they become aware of any events or changes that would indicate the fair values of the assets are below their carrying amounts. An impairment charge is recognized to the degree the carrying value exceeds the fair value. As discussed in Note 8, the Company estimated the fair value of the IPR&amp;D intangible asset related to Trodelvy for patients with HR+/HER2- breast cancer in connection with both an interim impairment assessment as of March 31, 2022, and an annual impairment assessment as of October 1, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the fair values of this IPR&amp;D intangible asset was complex due to the significant judgment required in estimating the fair values. In particular, the fair value estimates required the use of a valuation methodology that was sensitive to significant assumptions (e.g., discount rate, probability of technical and regulatory success, addressable patient population, treatment duration and projected market share), which were affected by expected future market or economic conditions.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated and tested the design and operating effectiveness of the Company&#8217;s internal controls over the determination of the estimated fair value of the IPR&amp;D intangible asset related to Trodelvy for patients with HR+/HER2- breast cancer for both the interim and annual impairment assessments. For example, we tested controls over management's review of the valuation methodology and the significant assumptions used to develop the fair value estimates. We also tested management's controls to validate that the data used in the fair value estimates were complete and accurate.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the estimated fair value of this asset at both the interim and annual assessment dates, our audit procedures, among others, included evaluating the Company's use of an appropriate valuation methodology with assistance from a valuation specialist, evaluating sensitivity analyses to determine which assumptions had the greatest impact on the fair value determination, and testing the completeness and accuracy of the underlying data. Our audit procedures over the most significant assumptions included comparing the assumptions to current industry, market and economic trends, to historical results of the Company's business and other guideline companies within the same industry and to other relevant factors. For example, we evaluated the probability of technical and regulatory success by considering the phase of development of the clinical projects and the Company's history of obtaining regulatory approval. In addition, we evaluated the expected addressable patient populations by comparing the Company&#8217;s estimates to external industry forecasts.</span></div></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN182Ny9mcmFnOjI4ZWM5NDY2ZGVlNzRkNzQ5NTQxOGZjYjNhNDIwYmE3L3RleHRyZWdpb246MjhlYzk0NjZkZWU3NGQ3NDk1NDE4ZmNiM2E0MjBiYTdfMzQzNg_3cf21250-d0f8-4df1-a87f-a898c601eac2">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1988.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN182Ny9mcmFnOjI4ZWM5NDY2ZGVlNzRkNzQ5NTQxOGZjYjNhNDIwYmE3L3RleHRyZWdpb246MjhlYzk0NjZkZWU3NGQ3NDk1NDE4ZmNiM2E0MjBiYTdfMzQzNw_d8329207-ace6-4e37-8e40-7629e108e516">San Jose, California</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;22, 2023</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_73"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC. </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNC0yLTEtMS0xNjc2NjU_87daa750-b12d-41f9-ab78-3ac5556c90e2">5,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNC00LTEtMS0xNjc2NjU_af18e15d-bb32-474e-acf7-d300a63134ba">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNS0yLTEtMS0xNjc2NjU_4405c21c-e9f1-4909-af5e-6850160e3c5d">973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNS00LTEtMS0xNjc2NjU_ad0f39eb-18e6-4cff-9af8-c1afafd3bcd1">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNi0yLTEtMS0xNjc2NjU_d1ab0282-f7a3-4f09-a4db-01b3844d1b0a">4,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNi00LTEtMS0xNjc2NjU_5f102b34-a534-4932-8406-a9854340148b">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNy0yLTEtMS0xNjc2NjU_9bdd67d9-d56f-4c1e-a35b-cbeaf4d32872">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNy00LTEtMS0xNjc2NjU_e005ec69-019a-4614-9edd-c225470c38a7">1,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfOC0yLTEtMS0xNjc2NjU_94452874-fbb0-42b9-a0f7-bfb8e16f1685">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfOC00LTEtMS0xNjc2NjU_a9870085-d735-46d1-90a3-c4821d7b3829">2,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfOS0yLTEtMS0xNjc2NjU_dbc6d49b-831e-4922-a758-07ded9c291bb">14,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfOS00LTEtMS0xNjc2NjU_bc975534-3807-44d3-a9f2-1cd47b246d59">14,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTAtMi0xLTEtMTY3NjY1_2d29ef7b-2cd3-41d6-9596-89c2c369850f">5,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTAtNC0xLTEtMTY3NjY1_0b0107e0-df06-477d-9fcd-8b3431105d1a">5,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTEtMi0xLTEtMTY3NjY1_bc2111d1-b4e4-437a-8090-6f4ae07efb37">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTEtNC0xLTEtMTY3NjY1_9b4e3a40-e657-4a5b-b3a9-4e5104dcf033">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTItMi0xLTEtMTY3NjY1_d834cd9a-2f73-4dee-a2f6-37bcfc991b2a">28,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTItNC0xLTEtMTY3NjY1_964c4036-4847-4a1d-b2b5-385eb4cd1db6">33,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTMtMi0xLTEtMTY3NjY1_c588bd02-2bc0-4340-bb01-7df224ce08d0">8,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTMtNC0xLTEtMTY3NjY1_16f902c8-2b22-4bc8-94e7-f0cda92cc5aa">8,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTQtMi0xLTEtMTY3NjY1_cc34d5a0-5b4c-4cf6-a041-77bd8b4605f2">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTQtNC0xLTEtMTY3NjY1_f26b83c9-534d-412f-9c9f-3d77078768a0">4,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTUtMi0xLTEtMTY3NjY1_575e195c-da7c-4809-a9a0-7416fca56d99">63,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTUtNC0xLTEtMTY3NjY1_9d4c0f88-d793-4cfc-8fe1-42809d9d90c6">67,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTgtMi0xLTEtMTY3NjY1_e85fa4ef-96a3-4efb-8a43-8010e32480f8">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTgtNC0xLTEtMTY3NjY1_a73011f2-a033-42ce-8185-c05a489c15b0">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:AccruedRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTktMi0xLTEtMTY3NjY1_1be76dea-e1c6-424e-b0a1-5c59806a8b80">3,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="gild:AccruedRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTktNC0xLTEtMTY3NjY1_370b9cdd-9148-4d85-aedf-47e9958a0f9f">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjAtMi0xLTEtMTY3NjY1_f056b6d8-9ff1-48d7-8a12-f277063f96ec">4,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjAtNC0xLTEtMTY3NjY1_d56d74f5-ac45-414d-952a-7ffdc665830d">6,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt and other obligations, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjEtMi0xLTEtMTY3NjY1_bf3a023f-28dc-41e0-8109-01a4a5a78b07">2,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjEtNC0xLTEtMTY3NjY1_7ead9847-c6e4-4b51-a757-593ba166e58d">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjItMi0xLTEtMTY3NjY1_0e2f999f-2de6-4f53-94ea-a5b45188ba4b">11,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjItNC0xLTEtMTY3NjY1_8493dcec-4b10-43b6-a7fc-c9cd5c31be97">11,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjMtMi0xLTEtMTY3NjY1_76aac610-1a91-4b1d-96a8-377f89a61892">22,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjMtNC0xLTEtMTY3NjY1_acc5582b-8131-43fc-b40f-af7c18e5015f">25,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjQtMi0xLTEtMTY3NjY1_b8562ec0-84fb-4228-b462-ab737c570e88">3,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjQtNC0xLTEtMTY3NjY1_e6e9b157-1a59-41b3-a712-cc8161da9797">4,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjUtMi0xLTEtMTY3NjY1_897b98fa-9aa3-428b-92b9-7be774cd8625">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjUtNC0xLTEtMTY3NjY1_871fdc84-40cd-47e8-9024-ac8ea1b064f7">4,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjYtMi0xLTEtMTY3NjY1_958a9d58-048c-465c-976c-6f4b7eeeb9ef">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjYtNC0xLTEtMTY3NjY1_9d86b7b9-a1aa-4f1c-af1d-0418ca798149">976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 13)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjctMi0xLTEtMTY3NjY1_10ddafb5-dba1-4169-b1a1-cf389f880fef"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjctNC0xLTEtMTY3NjY1_06510c42-ab64-4182-926b-fa9bfc8c7cf6"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#b6b6b6;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZGVhMGQxNjI5MjIzNDcxNDk1Zjg3NzQwOTk1YjYzZjRfMzE_478df680-1bd0-4e02-934f-5fd056433f4b"><ix:nonFraction unitRef="usdPerShare" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZGVhMGQxNjI5MjIzNDcxNDk1Zjg3NzQwOTk1YjYzZjRfMzE_d845cf67-a431-4e45-acb3-5ac58a30994b">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZGVhMGQxNjI5MjIzNDcxNDk1Zjg3NzQwOTk1YjYzZjRfNDU_1c820532-4735-4997-83f2-acd698936547"><ix:nonFraction unitRef="shares" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZGVhMGQxNjI5MjIzNDcxNDk1Zjg3NzQwOTk1YjYzZjRfNDU_20f3f5c0-6381-4986-bdef-2be464a844a6">5</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZGVhMGQxNjI5MjIzNDcxNDk1Zjg3NzQwOTk1YjYzZjRfNjc_5a1a16d1-72ff-40c8-8c5e-a6b17991ddb5"><ix:nonFraction unitRef="shares" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZGVhMGQxNjI5MjIzNDcxNDk1Zjg3NzQwOTk1YjYzZjRfNjc_c9f5647c-18ea-472d-8348-4749e66b2a8f">no</ix:nonFraction></ix:nonFraction>ne outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMi0xLTEtMTY3NjY1_127c4bf0-3511-4d2c-8ef4-e5d0542b60ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktNC0xLTEtMTY3NjY1_5b612731-c387-4999-aab7-3ad1fb67afc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfNzY5NjU4MTM5NDg0Ng_ae730a60-6908-4ba8-a59c-7f1e806f36ee"><ix:nonFraction unitRef="usdPerShare" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfNzY5NjU4MTM5NDg0Ng_e7253b32-d29d-46ab-a140-613c94d00ecc">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfNzY5NjU4MTM5NDgzNw_03e53a8b-5490-4678-a5f7-ed02e91bcc8b"><ix:nonFraction unitRef="shares" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfNzY5NjU4MTM5NDgzNw_06006b99-2755-49bd-a7b9-ed42aef3c933">5,600</ix:nonFraction></ix:nonFraction> authorized; <ix:nonFraction unitRef="shares" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfMTA5OTUxMTYyODE3Mw_b814779b-a1a1-4382-b3b9-3e2a7ffc8ea3"><ix:nonFraction unitRef="shares" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfMTA5OTUxMTYyODE3Mw_f8a903c7-a253-449b-8df4-be990b0ab364">1,247</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfMTA5OTUxMTYyODE2NA_5e7fdfdd-761f-4831-b537-b356b94fd7a9"><ix:nonFraction unitRef="shares" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfMTA5OTUxMTYyODE2NA_84e8e54e-9c2c-487b-917e-42200f136b21">1,254</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMi0xLTEtMTY3NjY1_2c502674-dc1b-4972-9e7a-afac17013e52">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtNC0xLTEtMTY3NjY1_13dd7a30-751a-4075-925d-006187e9e963">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzEtMi0xLTEtMTY3NjY1_86ed0f11-2ee6-446d-b429-82dcefaa27cb">5,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzEtNC0xLTEtMTY3NjY1_b3f0dbad-8927-4882-aa5c-ac303c55cf1c">4,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzItMi0xLTEtMTY3NjY1_37407bb8-59cd-4ff6-9c98-9153cbc1a3dd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzItNC0xLTEtMTY3NjY1_f5cb02a7-69f9-4664-811e-b4c35cfeacc6">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzMtMi0xLTEtMTY3NjY1_0cae36f4-c3f0-4162-894c-ac07673dfb33">15,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzMtNC0xLTEtMTY3NjY1_1cc3a661-a26c-4dca-bd6c-a2a417398166">16,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Gilead stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzQtMi0xLTEtMTY3NjY1_125c8d22-7c28-41a3-af05-2147a44ba3c0">21,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzQtNC0xLTEtMTY3NjY1_2e4e0601-ad34-406e-9a59-82477acb8982">21,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzUtMi0xLTEtMTY3NjY1_e9aceb63-d57e-4931-8c28-99f38523d96f">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzUtNC0xLTEtMTY3NjY1_104b7032-cda7-44ab-b8b8-a4aea275f677">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzYtMi0xLTEtMTY3NjY1_18cbfa3f-6601-49de-9541-7fba0ecdbbba">21,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzYtNC0xLTEtMTY3NjY1_0e6a54d5-f0fc-4238-925b-c636fcda34f4">21,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzctMi0xLTEtMTY3NjY1_114334ff-4689-4066-a829-400afe0d35e8">63,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzctNC0xLTEtMTY3NjY1_673d0f21-b626-44fe-88f5-19b200ba84b8">67,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC. </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776967eec2e40169c93026e3f869e40_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMy0yLTEtMS0xNjc2NjU_f8f420f2-9e66-48b7-a438-c72f2126dbab">26,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd0d2f0925f42e7889120dcf51249c1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMy00LTEtMS0xNjc2NjU_23acd1e7-c024-4a59-8f0b-eda9f0cfcfae">27,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i549c720f0be04d399b280dc53ff6498d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMy02LTEtMS0xNjc2NjU_c91b96b6-1677-41fe-acc6-734ae0da0cba">24,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3009f1cc5994ac0949727e755fef6fb_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNC0yLTEtMS0xNjc2NjU_d823e876-ef13-4c9b-9d73-c76159013d06">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fd731dcc7c6442d9eb015fc7f92096b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNC00LTEtMS0xNjc2NjU_c97f6157-839a-45e1-af32-8f2bbbad3920">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce29476464948ef99a1d86b1a2d50bf_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNC02LTEtMS0xNjc2NjU_567d789d-2564-44dd-be59-f4d09a851922">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNS0yLTEtMS0xNjc2NjU_705af443-5460-423e-b789-63214a755588">27,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNS00LTEtMS0xNjc2NjU_a7da044c-85a2-4c65-8725-8dbf903dc400">27,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNS02LTEtMS0xNjc2NjU_73906abe-cb67-4960-b6df-934ab095fc4d">24,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNy0yLTEtMS0xNjc2NjU_f3748581-e597-4880-b053-ea248e6ae822">5,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNy00LTEtMS0xNjc2NjU_b67d1c1a-a6f3-44a6-b9e8-2493609febfd">6,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNy02LTEtMS0xNjc2NjU_c62be3bc-27aa-4cfd-8b54-3e695e98cd40">4,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfOC0yLTEtMS0xNjc2NjU_64555f28-8443-4d95-bb3b-310de7907283">4,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfOC00LTEtMS0xNjc2NjU_07eca73e-90de-4525-a290-6a2da00cab75">4,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfOC02LTEtMS0xNjc2NjU_31df9952-63f3-4dec-a92f-6467327e4468">4,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfOS0yLTEtMS0xNjc2NjU_4e8861c2-d00c-4a3d-8355-2a91da19b90a">944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfOS00LTEtMS0xNjc2NjU_c113cf23-28b9-448b-9dee-9cfd2b6bd631">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfOS02LTEtMS0xNjc2NjU_2f5697c4-f6d0-4758-9db9-aa67c99d275d">5,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTAtMi0xLTEtMjAyODQ3_672db3f4-30b7-48ee-be18-720c9c57ee50">2,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTAtNC0xLTEtMjAyODQ3_7296e948-7ad6-467f-90f0-81029fe15726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTAtNi0xLTEtMjAyODQ3_0d0646b1-b3b8-41a6-9403-45fa9ac06f28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTAtMi0xLTEtMTY3NjY1_2823871e-2e38-4ba1-958e-85d66ef734e9">5,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTAtNC0xLTEtMTY3NjY1_55542c46-d99f-41b4-a88f-f7603e38264a">5,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTAtNi0xLTEtMTY3NjY1_81cf4990-a512-4c4e-a436-de550a7f51b0">5,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTEtMi0xLTEtMTY3NjY1_908dc39b-f600-4b87-9905-a54b04b03e40">19,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTEtNC0xLTEtMTY3NjY1_7d1c538d-4c15-45cd-bc18-5e6dc8bfb852">17,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTEtNi0xLTEtMTY3NjY1_292e38a0-83f7-4d5d-b7df-6ccf6086684e">20,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTItMi0xLTEtMTY3NjY1_df9bf41c-e840-461b-b176-53fda1c80f83">7,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTItNC0xLTEtMTY3NjY1_c25914f1-69ae-4bc5-ba6c-fc19e0b88df6">9,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTItNi0xLTEtMTY3NjY1_d3ee8612-e585-4ff4-a5c1-9dd6a3affddf">4,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTMtMi0xLTEtMTY3NjY1_97763fc8-0c17-4517-91d6-fee83676ce83">935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTMtNC0xLTEtMTY3NjY1_0e4f6961-ddd3-4bae-a3be-b6041729a795">1,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTMtNi0xLTEtMTY3NjY1_05d6e8e9-1477-4db2-96f2-afbf149d8a4b">984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTQtMi0xLTEtMTY3NjY1_4b714edf-ac33-4acf-9de7-cb1ec51bf817">581</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTQtNC0xLTEtMTY3NjY1_ce0aae50-83a4-487c-b93b-cb3586559c7c">639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTQtNi0xLTEtMTY3NjY1_5f6e88bd-9d1e-4469-b082-9d9a88f662eb">1,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTUtMi0xLTEtMTY3NjY1_f9c116bc-7741-4bc8-bd54-f247bbe7c24e">5,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTUtNC0xLTEtMTY3NjY1_6a7a20e7-6ea3-468a-bed7-88d247d696ec">8,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTUtNi0xLTEtMTY3NjY1_ed48e4ca-c767-49e3-a87f-1315f284c7a7">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTYtMi0xLTEtMTY3NjY1_ee9076a5-fae3-43ac-b20a-8056b031c40d">1,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTYtNC0xLTEtMTY3NjY1_d8ed3d19-da09-49ae-9038-2050af67e051">2,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTYtNi0xLTEtMTY3NjY1_61330962-0c4d-4b12-85b2-bc8a70678d8b">1,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTctMi0xLTEtMTY3NjY1_c740fe9f-facf-46c4-945f-a9d8b12b815d">4,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTctNC0xLTEtMTY3NjY1_2e7e5d80-bd45-42dc-9d1d-122b882d76bf">6,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTctNi0xLTEtMTY3NjY1_9f172a08-d204-439b-ba87-aafdb7a2a1e8">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTgtMi0xLTEtMTY3NjY1_019d1e28-9ef7-4bbb-8a55-ed7c82b16e53">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTgtNC0xLTEtMTY3NjY1_0f0f01dd-db53-45a3-86d5-2f85ce198c46">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTgtNi0xLTEtMTY3NjY1_dc2287fa-8384-4d57-af53-8b744fe32b59">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTktMi0xLTEtMTY3NjY1_3e38e7a0-6350-49f1-85bc-192612afa8c5">4,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTktNC0xLTEtMTY3NjY1_a0686f75-0cad-48e9-a6ca-34e5b986760b">6,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTktNi0xLTEtMTY3NjY1_c1438e93-8449-4b55-93ad-04d196782bd4">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjAtMi0xLTEtMTY3NjY1_f668b586-93b5-49df-aaa7-9e4a45a9963c">3.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjAtNC0xLTEtMTY3NjY1_d5333cdc-162c-4949-9b0d-615ec673b2e6">4.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjAtNi0xLTEtMTY3NjY1_9a03820a-297b-42d3-96ec-d80dc93c2475">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in basic earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjEtMi0xLTEtMTY3NjY1_cba4dff9-cd21-45d1-9fbc-05899c037b86">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjEtNC0xLTEtMTY3NjY1_ae2aee9e-3715-4661-98d8-a5ddeba71880">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjEtNi0xLTEtMTY3NjY1_d40dfe23-3dc3-4837-b05b-d98e4b90c858">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjItMi0xLTEtMTY3NjY1_ae05e343-668d-4901-9934-b335f5efb1ac">3.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjItNC0xLTEtMTY3NjY1_2df4161e-f717-40fb-81fa-8656d0a4f2e3">4.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjItNi0xLTEtMTY3NjY1_d13b1542-1bd1-402c-b561-ed2fdc44a253">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in diluted earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjMtMi0xLTEtMTY3NjY1_c1b066c8-e937-4723-97d8-c24b6a08c0b2">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjMtNC0xLTEtMTY3NjY1_30bb3a54-d7ee-40de-8916-be130187f418">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjMtNi0xLTEtMTY3NjY1_e7d47d8a-838d-44f8-9320-53bd24569d57">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMi0yLTEtMS0xNjc2NjU_c740fe9f-facf-46c4-945f-a9d8b12b815d">4,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMi00LTEtMS0xNjc2NjU_2e7e5d80-bd45-42dc-9d1d-122b882d76bf">6,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMi02LTEtMS0xNjc2NjU_9f172a08-d204-439b-ba87-aafdb7a2a1e8">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign currency translation loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNC0yLTEtMS0xNjc2NjU_1e8d3a02-d163-466c-9d33-dc0af952da08">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNC00LTEtMS0xNjc2NjU_3bedcbc1-e60a-4758-bd71-9a204a9ae9e2">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNC02LTEtMS0xNjc2NjU_e79031ed-23f7-4325-94e1-c93d220113c9">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss), net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNi0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjpiMDcwYTRhZjRkZjU0NjFmOGQ3ZTRmZDM2MzQyMjNjZl80Mzk4MDQ2NTExMTU3_af0304d9-b8e2-4133-9cda-3ad0450aba99">0</ix:nonFraction>, $(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNi0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjpiMDcwYTRhZjRkZjU0NjFmOGQ3ZTRmZDM2MzQyMjNjZl80Mzk4MDQ2NTExMTYy_d6fbeabe-95b2-4601-bb0b-c570d6c5a58c">1</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNi0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjpiMDcwYTRhZjRkZjU0NjFmOGQ3ZTRmZDM2MzQyMjNjZl80Mzk4MDQ2NTExMTcw_ea398c2a-148c-46bb-83b0-41d4dc7db5d8">12</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNi0yLTEtMS0xNjc2NjU_920617b2-0b45-4fdc-bf6d-f472980ac2b8">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNi00LTEtMS0xNjc2NjU_b0697b31-3859-4aac-97da-21037595440e">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNi02LTEtMS0xNjc2NjU_a79f8852-db33-4d74-b1e6-6a90b79becfb">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNy0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjoyNTEyZWFlOWJhMDQ0NDVlYWJjMWU2NDAyMjVkOTE3Zl80Mzk4MDQ2NTExMTYy_0510c133-7f4c-46b8-a3da-05fbf5543a7c">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNy0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjoyNTEyZWFlOWJhMDQ0NDVlYWJjMWU2NDAyMjVkOTE3Zl80Mzk4MDQ2NTExMTY3_07ebc29e-335c-412a-be42-2a601dead455">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNy0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjoyNTEyZWFlOWJhMDQ0NDVlYWJjMWU2NDAyMjVkOTE3Zl80Mzk4MDQ2NTExMTc1_a8272875-594f-4f03-b343-972eb4319de8">12</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNy0yLTEtMS0xNjc2NjU_43ee3911-cb69-4137-90b4-c3b5c2abe852">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNy00LTEtMS0xNjc2NjU_6a7e4587-96e6-435a-8e26-b7fb0e3ed4d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNy02LTEtMS0xNjc2NjU_95b50e6b-2234-4284-b171-9d60210b34b8">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfOC0yLTEtMS0xNjc2NjU_b36ed618-8f2c-4008-b049-cbdcd373cede">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfOC00LTEtMS0xNjc2NjU_5a3e3b5e-922f-42b1-9365-bf07e1076897">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfOC02LTEtMS0xNjc2NjU_e5c84a04-54bb-4492-b342-10121a85956f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss), net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YzE2NGI5ZWUwYWMzNDg1YThjY2JmMWY0YmQwYmJjZWJfNDM5ODA0NjUxMTE1Nw_0ce579de-1b5f-461a-9231-14d1b6a2c8df">20</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YzE2NGI5ZWUwYWMzNDg1YThjY2JmMWY0YmQwYmJjZWJfNDM5ODA0NjUxMTE2Mg_fcb88789-d3ba-438f-acac-80ef8e4ca2c3">18</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YzE2NGI5ZWUwYWMzNDg1YThjY2JmMWY0YmQwYmJjZWJfNDM5ODA0NjUxMTE3MA_f317b976-2227-4811-af0c-9cd0647123c0">15</ix:nonFraction>), respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTAtMi0xLTEtMTY3NjY1_9feae780-847f-4520-8056-d92d004ad34e">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTAtNC0xLTEtMTY3NjY1_d178b666-af1b-40cf-a437-f8197d2be331">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTAtNi0xLTEtMTY3NjY1_64647083-aff6-4f3a-a652-5ede8de29b87">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTEtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YWFhNGNmNzAwNTQ2NDBmOGI0NDA1NTI2Nzk3YzM5ZjRfNTQ5NzU1ODEzOTQ2_62a55e8c-8bf2-489f-ba40-27cf8beae971">25</ix:nonFraction>, $(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTEtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YWFhNGNmNzAwNTQ2NDBmOGI0NDA1NTI2Nzk3YzM5ZjRfNTQ5NzU1ODEzOTUx_68402e2c-8526-424d-99d3-1f7436ffafc4">9</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTEtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YWFhNGNmNzAwNTQ2NDBmOGI0NDA1NTI2Nzk3YzM5ZjRfNTQ5NzU1ODEzOTYz_352712aa-15a4-4fa5-bf36-942ec771aac1">6</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTEtMi0xLTEtMTY3NjY1_36b96d38-cca4-4c17-9a6b-885f6cb59a48">171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTEtNC0xLTEtMTY3NjY1_2b9ad264-a1ff-43ee-83d3-77dbe499386f">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTEtNi0xLTEtMTY3NjY1_770a0d80-955a-4d2d-8835-f61cd3500f5a">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTItMi0xLTEtMTY3NjY1_1991781c-aa8a-4915-b7f2-bae6c1d92726">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTItNC0xLTEtMTY3NjY1_577c542d-4da0-4fd2-b285-0c20b032584a">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTItNi0xLTEtMTY3NjY1_2c63da42-e0e7-4a31-8cb7-c72b360192c7">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTMtMi0xLTEtMTY3NjY1_014a1dcb-5386-4a20-8dd5-c6efc0b6f3f8">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTMtNC0xLTEtMTY3NjY1_59e430f0-4960-4a17-9290-8fe2619bc0ce">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTMtNi0xLTEtMTY3NjY1_6b6abeac-31de-485f-8271-ad76c9babbba">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTQtMi0xLTEtMTY3NjY1_230725fd-4cdf-4d15-8a61-ecff3edccec1">4,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTQtNC0xLTEtMTY3NjY1_f5c23953-b243-4ca1-a856-a768113dc6f2">6,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTQtNi0xLTEtMTY3NjY1_636a0802-b229-4fef-9923-927dbd52d989">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTUtMi0xLTEtMTY3NjY1_28e28955-11a5-4239-8138-5c24af49715a">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTUtNC0xLTEtMTY3NjY1_0051e8f1-889c-4a35-a96a-91790f3566e7">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTUtNi0xLTEtMTY3NjY1_95aa4b32-b5be-4115-ab4b-be6643385288">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTYtMi0xLTEtMTY3NjY1_52df4481-8401-4dd1-a0ad-c1ede1b76a14">4,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTYtNC0xLTEtMTY3NjY1_c2c40645-e512-4aa0-b467-488fe2a7c10b">6,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTYtNi0xLTEtMTY3NjY1_91dba5ef-1420-46b6-a62b-0560567f96ca">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC. </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.904%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gilead Stockholders&#8217; Equity&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; <br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Comprehensive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income (Loss)</span></div></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff509ac6299d48d6b6117ee9f80eea96_I20191231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItMi0xLTEtMTY3NjY1_4a63bdfb-51b5-4092-b27c-651930662aa0">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff509ac6299d48d6b6117ee9f80eea96_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItNC0xLTEtMTY3NjY1_2c349409-756c-4dbf-949c-bd7356a191d1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabc34cf4f8374f479afced7f51e2c9fc_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItNi0xLTEtMTY3NjY1_15ff5e98-dbe2-42b4-a5dc-6ff76f3fac6a">3,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc9d4063e094f24aa7047cc3f2ade07_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItOC0xLTEtMTY3NjY1_09404535-6bfb-4381-944d-8f9fe295bfa0">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea5153cc41ac4ad3909784ec5a03b75b_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItMTAtMS0xLTE2NzY2NQ_f1b7df98-d769-4394-8db7-54810e0e845a">19,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8a156a2c184ca39b4834ed03243876_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItMTItMS0xLTE2NzY2NQ_b7152085-ca1f-4f28-8a9c-3d174f934100">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0142ebb7458d4ec68ef2fa3254d6e76a_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItMTQtMS0xLTE2NzY2NQ_baa79540-acb1-4fc0-b8ed-1dd4dbccf0a1">22,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative effect from the adoption of new accounting standard </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc446f587b564d3da2a7e92adf1f9212_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTMtMTAtMS0xLTE2NzY2NQ_b800f0c0-c69e-424c-b063-1c6ec610efdc">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i605eee38c1414b2ebe50ecfda6aa08a7_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTMtMTQtMS0xLTE2NzY2NQ_6aa4a2cd-a282-418c-b5c4-5db8bd495852">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in noncontrolling interest </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c07a715073b4180a3d6350999b7c927_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTQtMTItMS0xLTE2NzY2NQ_fa13ac76-1d46-4f08-9113-ac0cc648f102">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTQtMTQtMS0xLTE2NzY2NQ_f7a7f3a1-c219-4a35-b33e-d24a6116952d">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9014eaa8515b42f5bf4fc221a5754f36_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTUtMTAtMS0xLTE2NzY2NQ_0b1cea1a-4c56-42fa-a284-e89135fbadd5">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c07a715073b4180a3d6350999b7c927_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTUtMTItMS0xLTE2NzY2NQ_8fb9076d-8562-44ed-9506-dd2dd0d9a26c">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTUtMTQtMS0xLTE2NzY2NQ_b8807bcd-a5e3-42ab-9625-d0e6d39ec010">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d244df84ac4dea867eed31d805f681_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTYtNi0xLTEtMTY3NjY1_41087402-55b7-4637-9c22-067ded300200">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93bdf1e4730740ab8d4b26eb38235e1d_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTYtOC0xLTEtMTY3NjY1_935c702d-8bf1-485a-984c-78a5e71f8d86">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9014eaa8515b42f5bf4fc221a5754f36_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTYtMTAtMS0xLTE2NzY2NQ_3d806d74-4f9e-478d-8a66-57e4e6f9588d">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTYtMTQtMS0xLTE2NzY2NQ_12f09e8c-1537-45a6-8c02-727d65899351">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7182ed726234760880abd2d15fcf97b_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTctMi0xLTEtMTY3NjY1_be417f7d-74ab-4725-93dc-3a09b7b9c358">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d244df84ac4dea867eed31d805f681_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTctNi0xLTEtMTY3NjY1_64424599-0850-40f5-a6c0-e01c59bc52ae">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTctMTQtMS0xLTE2NzY2NQ_b6ac10bc-029d-47fb-b8a0-e039beb92dff">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7182ed726234760880abd2d15fcf97b_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTgtMi0xLTEtMTY3NjY1_04d01c1f-49ad-4f96-902f-1799e378d8c5">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d244df84ac4dea867eed31d805f681_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTgtNi0xLTEtMTY3NjY1_d651c8e3-2e66-4afe-b48f-c4faff560dd1">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTgtMTQtMS0xLTE2NzY2NQ_b84bf5eb-466d-4fd0-a570-ac0757ac501f">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d244df84ac4dea867eed31d805f681_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTktNi0xLTEtMTY3NjY1_39140019-0cfd-405c-a088-51e5ebdc6c68">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTktMTQtMS0xLTE2NzY2NQ_d5ec6a6a-f1d2-4afb-a85a-41e6ee9857fc">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia7182ed726234760880abd2d15fcf97b_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjAtMi0xLTEtMTY3NjY1_05c63084-cddd-45a3-a6b6-65e1c9ee991d">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7d244df84ac4dea867eed31d805f681_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjAtNi0xLTEtMTY3NjY1_0b367277-551d-4fe3-8246-9354625176e0">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9014eaa8515b42f5bf4fc221a5754f36_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjAtMTAtMS0xLTE2NzY2NQ_4c10a64c-0bb3-4b4e-807a-396f5ae963de">1,658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjAtMTQtMS0xLTE2NzY2NQ_0298c5a8-71be-4c3b-8d95-c2059956e883">1,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjEtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZmFmNTc2ZmRmYTk5NDkzMjg0ZWFkNzg0MWMwYjQ4NDZfMTA5OTUxMTYyNzgxNA_3d8cfe1a-254e-43c7-bf8d-4d8058f85828">2.72</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9014eaa8515b42f5bf4fc221a5754f36_D20200101-20201231" decimals="-6" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjEtMTAtMS0xLTE2NzY2NQ_dfab5c8f-58c0-4676-85a7-94b0563560b0">3,464</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjEtMTQtMS0xLTE2NzY2NQ_3684e62b-bb59-4f5f-94dd-64fa0a20a87c">3,464</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8646b81d562c4764b295900f43b19e19_I20201231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItMi0xLTEtMTY3NjY1_b999b4ec-d766-4a72-9cac-4f63138234d1">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8646b81d562c4764b295900f43b19e19_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItNC0xLTEtMTY3NjY1_a2be2e9f-b4d8-4117-b7d6-9aa975b8d460">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i991524b7050f435c8e75c4ffc5a934c7_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItNi0xLTEtMTY3NjY1_3be82dc3-6f4d-4b40-aeb6-8b37b4460893">3,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6f649babc4c4963a34bead50d8785d8_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItOC0xLTEtMTY3NjY1_559d51b6-fcae-467f-a392-b2bfb8cf9f9c">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i091822ada63940bfbcb5532bd0807fc2_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItMTAtMS0xLTE2NzY2NQ_05b14760-2629-4bc5-8240-c56953d2dbb0">14,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i831d6d8c42f147b3af3fa768e1980ac4_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItMTItMS0xLTE2NzY2NQ_d00b1144-59ea-4df9-887f-8b5fc6f10a5f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItMTQtMS0xLTE2NzY2NQ_f28d5ce5-a62d-44b8-8ac1-881a386e3155">18,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8570b5642fc41c3b275ef064cd4fc5e_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjMtMTAtMS0xLTE2NzY2NQ_fe49a12e-8e7f-4b78-a704-0f02997d7136">6,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2bbd0596e084172b456bf6e816df644_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjMtMTItMS0xLTE2NzY2NQ_5fbc0859-3334-44c9-bf51-1072ce8b17fe">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjMtMTQtMS0xLTE2NzY2NQ_44665e0f-37fe-4742-b702-d5c0184b6973">6,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31982067c8ba46ccba2062f655093c96_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjQtOC0xLTEtMTY3NjY1_9dc41a8b-168e-4a14-a452-36bfe0d6792a">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjQtMTQtMS0xLTE2NzY2NQ_3ab32888-40f5-41c1-afa8-3604585e0a51">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21d65b154d20435bba2da402431f2156_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjUtMi0xLTEtMTY3NjY1_f3217dbd-9f36-49e8-9cc6-91e3735c4a17">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41cdbe8321640c0bef3e78a54d341e4_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjUtNi0xLTEtMTY3NjY1_2ea5573d-7485-466c-8aea-b30ba257f786">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjUtMTQtMS0xLTE2NzY2NQ_9fa426ad-ed4f-4e97-a9cb-76923c16af6f">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21d65b154d20435bba2da402431f2156_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjYtMi0xLTEtMTY3NjY1_ec0a479f-2e41-41a6-a5f3-93a9099836cf">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41cdbe8321640c0bef3e78a54d341e4_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjYtNi0xLTEtMTY3NjY1_789fdf10-613f-4acf-8a18-9dc6c3f3cb1f">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjYtMTQtMS0xLTE2NzY2NQ_79d6a14b-297a-4f5b-ab25-c4ea2c786f6e">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id41cdbe8321640c0bef3e78a54d341e4_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjctNi0xLTEtMTY3NjY1_26abff26-3d56-4b50-bc13-dfe4a7761b6a">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjctMTQtMS0xLTE2NzY2NQ_b3b3aba4-57d3-4358-a770-6f5b0e166805">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i21d65b154d20435bba2da402431f2156_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjgtMi0xLTEtMTY3NjY1_b1441e6e-3fed-4f81-b08e-e0709b956e0c">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id41cdbe8321640c0bef3e78a54d341e4_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjgtNi0xLTEtMTY3NjY1_84925146-c9d6-4250-8437-39f5281e20a2">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8570b5642fc41c3b275ef064cd4fc5e_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjgtMTAtMS0xLTE2NzY2NQ_b3c4b2e3-59ca-4762-92c8-c5455838df87">664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjgtMTQtMS0xLTE2NzY2NQ_c4cce1ae-8aeb-43a3-8499-e225835caad6">692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YTVlMzEyMzVhMWU5NGRiZWIzODMxYjMzYTRkYmNmMWJfMTA5OTUxMTYyNzgxNA_1d1b17ae-cfc1-4d8c-afeb-f8406a3e132f">2.84</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8570b5642fc41c3b275ef064cd4fc5e_D20210101-20211231" decimals="-6" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjktMTAtMS0xLTE2NzY2NQ_eadff01c-3406-41ed-8158-a6e71b97cd3c">3,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjktMTQtMS0xLTE2NzY2NQ_3b518bc7-e430-49aa-9db8-fd66b01b5139">3,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f2b6090dbb84a0da94eda0da3c2c7e9_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtMi0xLTEtMTY3NjY1_89723d0f-6d06-446a-be75-d2d1f7e94b17">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2b6090dbb84a0da94eda0da3c2c7e9_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtNC0xLTEtMTY3NjY1_f2bf2bdf-f0ce-4ca8-9922-4c59ff61a160">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3255734b4164a248d1ae872f85437e5_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtNi0xLTEtMTY3NjY1_aa381910-ecb0-43d3-8765-0e019da0a5e2">4,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c6e110f0a74581baf5ef42159e7423_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtOC0xLTEtMTY3NjY1_ba89c354-857a-4d99-9428-7de000a80c5d">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i309e1278bed34922b7275c62cf3b74a3_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtMTAtMS0xLTE2NzY2NQ_2f286c4d-f0da-4faa-81c9-1795bd890749">16,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e9c39969dfb47c9bad7061e5500bbb8_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtMTItMS0xLTE2NzY2NQ_41d290ab-d167-49e0-8bad-b035dd7cb2cd">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtMTQtMS0xLTE2NzY2NQ_33b9ee67-ae1c-4946-854f-f7dd8726dda0">21,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f97bc74e5b74cff8c8def5c5e9058ce_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzEtMTAtMS0xLTIwMjg4Nw_239d3da8-2c63-4552-b986-0ea7da4d0e94">4,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a2c49aec7474f71b15b7ba23892c798_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzEtMTItMS0xLTIwMjg4Nw_90c86757-35eb-4ce5-ae87-5a55c978a79f">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzEtMTQtMS0xLTIwMjg4Nw_50f97b2a-1518-4448-8a04-23c25963705d">4,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07be39de877c4dec919659b89dc15370_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzItOC0xLTEtMjAyODg3_948bcc4e-99f1-4ad9-9d56-9df0f373d0b5">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzItMTQtMS0xLTIwMjg4Nw_0901eb06-ad60-46fb-bbe0-084360a3207f">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided187f87ec24a75b5f0f28661776608_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzMtMi0xLTEtMjAyODg3_e09d0ee3-53b2-44a9-a851-1b6a6130853a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24a5c6406f94acbab0fa346fc44c96d_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzMtNi0xLTEtMjAyODg3_f5a6ae3f-e1d1-414d-9978-cf32bda1dc0a">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzMtMTQtMS0xLTIwMjg4Nw_90234629-7766-4926-b2c9-34e8c0511efe">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuances under equity incentive plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided187f87ec24a75b5f0f28661776608_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzQtMi0xLTEtMjAyODg3_ae7e231d-cb0f-4f49-9ce9-4d5775686d96">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24a5c6406f94acbab0fa346fc44c96d_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzQtNi0xLTEtMjAyODg3_de20b6c6-03ab-4cf0-8cf3-2b6e8ce06760">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzQtMTQtMS0xLTIwMjg4Nw_48a26716-d230-4017-a83a-df8bdb2d608f">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib24a5c6406f94acbab0fa346fc44c96d_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzUtNi0xLTEtMjAyODg3_f3deaae0-a708-4f27-97ae-d56f61d532b5">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzUtMTQtMS0xLTIwMjg4Nw_e5ff38d9-ba23-4ead-9e37-36e646d0fb0f">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ided187f87ec24a75b5f0f28661776608_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzYtMi0xLTEtMjAyODg3_b509f5ff-8922-4281-b9dd-5972f447ae7b">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib24a5c6406f94acbab0fa346fc44c96d_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzYtNi0xLTEtMjAyODg3_daa021bb-0550-496a-b52f-3d23b509115a">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f97bc74e5b74cff8c8def5c5e9058ce_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzYtMTAtMS0xLTIwMjg4Nw_59409f20-2d60-460f-a0db-52a60c1515e7">1,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzYtMTQtMS0xLTIwMjg4Nw_73eb0a3b-7c17-4852-a213-07a04eef669b">1,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzctMC0xLTEtMjAyODc3L3RleHRyZWdpb246ZmIyM2M5YTQxNzAyNDZhM2EzMzVkYjc2YmUxMmE5OGNfMTA5OTUxMTYyNzgyMQ_c0909df2-8a08-4d3a-924e-4674c6a21545">2.92</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f97bc74e5b74cff8c8def5c5e9058ce_D20220101-20221231" decimals="-6" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzctMTAtMS0xLTIwMjg4Nw_4844e8ae-3e4f-4f6e-9cca-a15549debc9a">3,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzctMTQtMS0xLTIwMjg4Nw_f91a9240-6643-47df-8420-789407943127">3,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22bb6ac875f8426a9e185ea79d9ed340_I20221231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtMi0xLTEtMjAyODg3_190d5c11-6069-489c-b627-00f764302f7b">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22bb6ac875f8426a9e185ea79d9ed340_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtNC0xLTEtMjAyODg3_2e045493-a900-4e31-b13a-a796a7948bbb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9fd7dab9954496aabbca76c556ef25_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtNi0xLTEtMjAyODg3_29b2b5a0-22a1-4429-ba9b-bc0af29d8d87">5,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35cf517e1c44e6cb7eb51a11bc60ba9_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtOC0xLTEtMjAyODg3_edb4c1d9-29d4-48c5-9264-9299744226c6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if58ddd7e8b04461b92ae526d7f69766b_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtMTAtMS0xLTIwMjg4Nw_eb534f5f-f2c7-48fa-9473-dd67356d668f">15,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cff17f8e033479dbe6df66c5418db1d_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtMTItMS0xLTIwMjg4Nw_36c66ae0-940d-4858-abbc-bf137562078e">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtMTQtMS0xLTIwMjg4Nw_c447e2ea-5674-4af1-9d23-a0fe3ae85b45">21,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES,&#160;INC. </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMy0yLTEtMS0xNjc2NjU_c740fe9f-facf-46c4-945f-a9d8b12b815d">4,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMy00LTEtMS0xNjc2NjU_2e7e5d80-bd45-42dc-9d1d-122b882d76bf">6,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMy02LTEtMS0xNjc2NjU_9f172a08-d204-439b-ba87-aafdb7a2a1e8">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNS0yLTEtMS0xNjc2NjU_3477a2b8-8946-446b-acf2-88e4652f1e3e">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNS00LTEtMS0xNjc2NjU_9d6a0c8d-e6aa-4e82-a51a-3809631d5987">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNS02LTEtMS0xNjc2NjU_bea3c194-8c22-4b6e-bf2c-3f9acec3c67f">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNi0yLTEtMS0xNjc2NjU_98717d8f-a274-427d-bc39-fd6a1989fbda">1,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNi00LTEtMS0xNjc2NjU_3c00e29a-16cb-47f4-bfde-0a6442a820e0">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNi02LTEtMS0xNjc2NjU_9dcaa3f7-5d6c-484a-be91-39ac8e4cbac2">1,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNy0yLTEtMS0xNjc2NjU_faebf387-2cb7-4d9c-9f09-4ac4d494af88">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNy00LTEtMS0xNjc2NjU_29cfebaf-9bc5-4390-8313-4aa396998bc9">635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNy02LTEtMS0xNjc2NjU_3d9dfcfc-e108-49dc-be22-3e271118d5c8">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfOC0yLTEtMS0xNjc2NjU_88129b29-5727-4e52-9838-a7d55107acbe">1,552</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfOC00LTEtMS0xNjc2NjU_38ccbe62-db3c-4eb6-a3d7-42af2101ef57">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfOC02LTEtMS0xNjc2NjU_013df50a-4e87-45a9-93a1-096cb90c1e85">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss from equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfOS0yLTEtMS0xNjc2NjU_c21e380a-b68d-4709-b137-1025f2f654f8">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfOS00LTEtMS0xNjc2NjU_f04ef4c8-d88f-4253-8c6e-4459bb9e261a">610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfOS02LTEtMS0xNjc2NjU_1b6d5d0f-dace-487c-825d-ee05f3a799a4">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTAtMi0xLTEtMTY3NjY1_a0833547-2c39-46bc-a692-da77c550199a">944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTAtNC0xLTEtMTY3NjY1_8c1a2f56-2858-44f6-934f-40b51bb79d64">939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTAtNi0xLTEtMTY3NjY1_0280b38b-5526-42ec-8a51-349099d653bc">5,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTEtMi0xLTEtMTY3NjY1_c6134ae6-eb7a-400d-8d74-bc644a8bc13b">2,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTEtNC0xLTEtMTY3NjY1_d2da1e6f-a84f-45e6-8a22-68c97682f83c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTEtNi0xLTEtMTY3NjY1_acbf7034-5720-4c06-af7a-2c62ad6cb298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTMtMi0xLTEtMTY3NjY1_c1a37393-b8f6-47f2-a7b6-9fa74f5a6b71">780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTMtNC0xLTEtMTY3NjY1_f7c9dd06-e3a2-46df-8a87-7ab3bce80f0b">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTMtNi0xLTEtMTY3NjY1_c486c075-683e-4794-b5b6-4a6c25b20f0d">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTUtMi0xLTEtMTY3NjY1_b023be84-3548-42aa-9c22-d901f1aada42">406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTUtNC0xLTEtMTY3NjY1_0c45255b-b353-42be-b716-691445f3c9ce">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTUtNi0xLTEtMTY3NjY1_c2be6521-d1d7-4a52-9c87-dd4f55032be3">1,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTYtMi0xLTEtMTY3NjY1_80b2dd89-6ee5-4aa9-a308-663e5667d87f">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTYtNC0xLTEtMTY3NjY1_fcbdcfba-01ca-486c-953c-228bfb77f147">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTYtNi0xLTEtMTY3NjY1_530cc50c-958b-4fac-89d8-a40e3ea964c1">195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTctMi0xLTEtMTY3NjY1_6d3a1e0a-8dcd-4b6c-8dc7-5d10fc0bc505">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTctNC0xLTEtMTY3NjY1_9d0978cf-19f8-4209-bdcb-2682d029a37b">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTctNi0xLTEtMTY3NjY1_ae64263b-c816-4a99-9bbe-eaea26f0a945">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTgtMi0xLTEtMTY3NjY1_987e98bd-f2a9-47f1-9386-1850c2e370f3">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTgtNC0xLTEtMTY3NjY1_ae273035-60eb-4764-a588-76a3962060d8">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTgtNi0xLTEtMTY3NjY1_3f2e9e7e-8d66-459a-b1be-ca04c1987fd2">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTktMi0xLTEtMTY3NjY1_d3bda90c-152d-4b8b-9ed4-6f31be362d6f">568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTktNC0xLTEtMTY3NjY1_295fde34-210f-4df1-8367-298190614218">364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTktNi0xLTEtMTY3NjY1_a29431db-969c-4594-a8e6-f412a73dd142">778</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjAtMi0xLTEtMTY3NjY1_9dbfd2c8-712f-48aa-b336-a144754da786">775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjAtNC0xLTEtMTY3NjY1_20b86392-2357-4e38-a8ff-4c36e8d649ba">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjAtNi0xLTEtMTY3NjY1_05b3b877-f7d1-42c2-8fe7-62f6c7813aa9">640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjEtMi0xLTEtMTY3NjY1_29d9fbf6-7280-4544-9903-20ed86873ca8">9,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjEtNC0xLTEtMTY3NjY1_fbc9bfd2-f69c-4eaf-a420-b64b312706c4">11,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjEtNi0xLTEtMTY3NjY1_9ab69aa2-0dac-4d11-8717-a4fad2ea8779">8,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjQtMi0xLTEtMTY3NjY1_5132eca6-a061-4ef2-b968-ef94c3b474be">1,770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjQtNC0xLTEtMTY3NjY1_edba330a-a319-46ca-9436-b6792f999b61">3,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjQtNi0xLTEtMTY3NjY1_526d511c-2c0e-4ab8-8a54-7bfa817c9915">20,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjUtMi0xLTEtMTY3NjY1_d47a29ff-5f8c-4216-87e8-123ca324f894">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjUtNC0xLTEtMTY3NjY1_c96f57cb-1f55-45f1-82ee-c88986ff3a91">730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjUtNi0xLTEtMTY3NjY1_2cbadd41-c1d8-4e7f-b634-fd5219504530">23,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjYtMi0xLTEtMTY3NjY1_eaa2c8fd-4bed-483c-af27-5b9cd004709e">1,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjYtNC0xLTEtMTY3NjY1_c5be48d9-0d0e-4e0d-a34d-9003d41c36ce">2,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjYtNi0xLTEtMTY3NjY1_1a14662b-8c4d-40db-b6c2-8c6b95d80c22">9,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, including in-process research and development, net of cash acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjctMi0xLTEtMTY3NjY1_517dba3b-1448-4ebb-a5ca-3cbcc22b1f9b">1,797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjctNC0xLTEtMTY3NjY1_ce7a357b-52ed-42c8-9c61-d3f64edaa791">1,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjctNi0xLTEtMTY3NjY1_ce3916b8-64a9-45de-9b04-217a2b81569d">25,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjgtMi0xLTEtMTY3NjY1_47284684-c11a-4a50-ab8f-6deee5459657">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjgtNC0xLTEtMTY3NjY1_39f2a576-9fbe-49b5-a567-f34935ccc4f8">380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjgtNi0xLTEtMTY3NjY1_e7f1306c-3faf-4177-bd3e-207bba879ded">455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjktMi0xLTEtMTY3NjY1_000e83b8-2d08-4857-8fde-7cc1a60765c7">728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjktNC0xLTEtMTY3NjY1_8d014499-34b2-499f-8315-fc294bdc174e">579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjktNi0xLTEtMTY3NjY1_33eb5420-5156-48d6-874f-ec603b940c17">650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzAtMi0xLTEtMTY3NjY1_2e9ba2a1-a76e-43ca-8866-48812b0d7548">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzAtNC0xLTEtMTY3NjY1_808c78b6-fbd1-4f0d-bcdd-af30b73e5978">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzAtNi0xLTEtMTY3NjY1_e6d4170a-8cb2-451a-b89a-4c21458f66ef">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzEtMi0xLTEtMTY3NjY1_68f68c72-bdf5-47df-859a-ef96ea6ce214">2,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzEtNC0xLTEtMTY3NjY1_c3ce40e5-6606-4286-8039-f0af9ad67ff2">3,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzEtNi0xLTEtMTY3NjY1_4e748026-10bb-4e22-be0d-90bf14a37e6c">14,615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from debt financing, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzQtMi0xLTEtMTY3NjY1_499eb82f-f903-4583-b1d1-6a83386c810a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzQtNC0xLTEtMTY3NjY1_5809c445-52ce-4953-ab53-07e7032da5dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzQtNi0xLTEtMTY3NjY1_2ec15fec-0df6-468a-8632-9b2a302ec4df">8,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuances of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzUtMi0xLTEtMTY3NjY1_0e731e0d-bd42-4f92-bbdf-2b103c39c54f">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzUtNC0xLTEtMTY3NjY1_ca9c5da2-d5a2-49d9-aa34-b2df62f47710">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzUtNi0xLTEtMTY3NjY1_25d362c6-77aa-4b9a-a808-bcb9bc7c89a9">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzYtMi0xLTEtMTY3NjY1_28c0a3fd-336d-47f8-a5dd-24cc27ebc781">1,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzYtNC0xLTEtMTY3NjY1_5f71e82f-3dae-4017-97ae-34596a8cff99">546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzYtNi0xLTEtMTY3NjY1_b20ae7b3-378e-454c-80ce-37f1a6a6a09a">1,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of debt and other obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzctMi0xLTEtMTY3NjY1_f4ff3cd8-0bca-4e05-a1b9-da56c261b2fc">1,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzctNC0xLTEtMTY3NjY1_646a88dc-3dc6-40b6-ab52-bfef77c172db">4,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzctNi0xLTEtMTY3NjY1_8396b8e9-9188-45d0-af6f-0d3ca029b846">2,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzgtMi0xLTEtMTY3NjY1_309b8ab3-9339-4661-9685-75418b83cf29">3,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzgtNC0xLTEtMTY3NjY1_6143a52e-08d5-499f-b9e0-23e1c5b0a8fe">3,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzgtNi0xLTEtMTY3NjY1_1617f13d-b297-40b3-81d0-3f9185acacc7">3,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzktMi0xLTEtMTY3NjY1_bda7914a-49fe-4acb-9006-f7b540cc62b3">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzktNC0xLTEtMTY3NjY1_aad8281a-0adf-445b-b41d-189dbad21f61">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzktNi0xLTEtMTY3NjY1_4f1f3688-1b5e-47e3-9db2-6530181da6c4">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDAtMi0xLTEtMTY3NjY1_4a28eb6e-64ad-4571-8ec2-0fe17e6e983d">6,469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDAtNC0xLTEtMTY3NjY1_a4bc3dbd-5834-475d-b0be-dcd4a13c8a05">8,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDAtNi0xLTEtMTY3NjY1_56118792-2f76-4828-a1bf-997158c910fd">770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDEtMi0xLTEtMTY3NjY1_13141be0-1dc8-48c7-b83b-3a35ebd7afdf">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDEtNC0xLTEtMTY3NjY1_c517aac6-7fb5-4e2d-b60f-24cf0b00e777">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDEtNi0xLTEtMTY3NjY1_9b1e7bab-5aef-470c-b90a-833177079cec">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDItMi0xLTEtMTY3NjY1_5e9e6d8c-8a3b-42f8-a27a-fe0ac9aba8e9">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDItNC0xLTEtMTY3NjY1_065d80f5-f4de-43c5-b6be-3b9053e63815">659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDItNi0xLTEtMTY3NjY1_07fc8b1e-30ee-4983-adc4-1e6cc640f96f">5,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDMtMi0xLTEtMTY3NjY1_ba403584-78b7-435c-8344-85a2828f05c1">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDMtNC0xLTEtMTY3NjY1_90a0cf18-54f3-4ca0-a9af-b2186dec5a0c">5,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0142ebb7458d4ec68ef2fa3254d6e76a_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDMtNi0xLTEtMTY3NjY1_5541d488-a505-4e8b-ac74-9c560b4ce3a5">11,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDQtMi0xLTEtMTY3NjY1_563fc159-b22d-4817-91e7-566a1fd4e7c9">5,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDQtNC0xLTEtMTY3NjY1_ba403584-78b7-435c-8344-85a2828f05c1">5,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDQtNi0xLTEtMTY3NjY1_59427aea-8126-4b7e-9c72-668b355abde0">5,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid, net of amounts capitalized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDctMi0xLTEtMTY3NjY1_5033df35-c438-4033-a9a3-10522b31269f">907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDctNC0xLTEtMTY3NjY1_ab833712-14c6-4e1d-8950-6f366cafb7b1">979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDctNi0xLTEtMTY3NjY1_5f1f6a17-2651-427a-850c-9a84ef618fce">951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDgtMi0xLTEtMTY3NjY1_51a4864a-65ba-4ad6-b398-76cfacbb3995">3,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDgtNC0xLTEtMTY3NjY1_2adf4f60-df28-4103-b59d-d4da38a3e928">2,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDgtNi0xLTEtMTY3NjY1_b718d35f-6d24-4c79-87c2-33bd4531dbe6">2,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GILEAD SCIENCES, INC.</span></div><div style="margin-top:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_91"></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzODY_0fa02eb1-5fbd-44cc-95bc-e581c445472b" continuedAt="i67a83c4dd5c541df838d552d3d7957cd" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i67a83c4dd5c541df838d552d3d7957cd" continuedAt="i80ded30d2de44f408109bb787364a806"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Organization</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than <ix:nonFraction unitRef="country" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="INF" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTY0OTI2NzUzODIzMQ_b4376237-919e-4d70-a61e-8f331f1cc791">35</ix:nonFraction> countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketed products includes AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cayston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Emtriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepsera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jyseleca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sovaldi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sunlenca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tybost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The approval status of Hepcludex and Jyseleca vary worldwide, and Hepcludex and Jyseleca are not approved in the U.S. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the U.S. through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="segment" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTA5OTUxMTcyNDMxNg_fd7a58ed-cf6e-4890-8cd5-960253a0ec1c">one</ix:nonFraction> operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need, scientific data, probability of technical and regulatory successful development, market potential and other considerations, and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Significant Accounting Policies</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE1MDU_60e460d1-e676-403c-bc37-57900bc821b3" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles and include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities (&#8220;VIEs&#8221;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates. Certain amounts and percentages herein may not sum or recalculate due to rounding.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2022, expenses related to development milestones and other collaboration payments made prior to regulatory approval of a developed product were reclassified from Research and development expenses to Acquired in-process research and development expenses on our Consolidated Statements of Income. Concurrently, we reclassified the cash payments related to these expenses from Other to Acquisitions, including in-process research and development, net of cash acquired within Investing Activities in the Consolidated Statements of Cash Flows. We believe this presentation assists users of the financial statements to better understand the total costs incurred to acquire in-process research and development (&#8220;IPR&amp;D&#8221;) projects. Prior periods have been revised to reflect this classification, resulting in a reduction of previously-reported Research and development expenses of $<ix:nonFraction unitRef="usd" contextRef="i1aa84a6eecd341f092eaee39012ec26a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTA5OTUxMTY3NTI5Ng_815322e4-8d07-4a57-bdc6-2a09f60da762">762</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic2269762347243d582b0adac2360f5d2_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTA5OTUxMTY3NTMxMQ_501b0be8-a4cd-49f5-9088-d90059bb0d2c">112</ix:nonFraction> million for the years ended December&#160;31, 2021 and 2020, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i80ded30d2de44f408109bb787364a806" continuedAt="ie91b1ee1f06a403ebf790f9f3eb73c7c"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0MDQ_244e003d-d349-4836-981c-74068c1e24cc" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales when control of the product transfers to the customer, which is generally upon shipment or delivery, or in certain cases, upon the corresponding sales by our customer to a third party. Revenues are recognized net of estimated rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a financing component. Shipping and handling activities are considered to be fulfillment activities and not a separate performance obligation.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Gross-to-Net Deductions </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are based on contractual arrangements or statutory requirements and include amounts due to payers and healthcare providers under various programs. These amounts may vary by product, payer and individual plans. Providers qualified under certain programs can purchase our products through wholesalers or other distributors at a discount. The wholesalers or distributors then charge the discount back to us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are estimated primarily based on product sales, including product mix and pricing, historical and estimated payer mix and discount rates, among other inputs, which require significant estimates and judgment. We assess and update our estimates each reporting period to reflect actual claims and other current information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Rebates that are payable to third party payers and healthcare providers are recorded in Accrued rebates on our Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor Fees</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually-determined covenants such as the maintenance of agreed-upon inventory levels. These distributor fees are based on a contractually-determined fixed percentage of sales.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for Sales Returns</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the U.S., we typically permit returns six months prior to and up to one year after the product expiration date. Outside the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Royalty, Contract and Other Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur. Contract and other revenues are recognized when the performance obligation is satisfied.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzNTM_74b2fcf6-eb84-431d-996a-97dd5761c5c6" continuedAt="i6b3b61bb76564c12bfa577f66ab9bc89" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are recorded when incurred and consist primarily of clinical studies performed by contract research organizations (&#8220;CROs&#8221;), materials and supplies, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations consisting of various support and infrastructure costs. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of Research and development expenses.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ie91b1ee1f06a403ebf790f9f3eb73c7c" continuedAt="i72fb187059b94b418c4ab414149b9e73"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6b3b61bb76564c12bfa577f66ab9bc89">Clinical study costs are a significant component of Research and development expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for R&amp;D services prior to the services being rendered are recorded as prepaid assets within Prepaid and other current assets on our Consolidated Balance Sheets and are expensed as the services are provided.</ix:continuation></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE1MTM_706775f0-ea7c-44aa-9ede-40c281724557" continuedAt="i07a6f8bd7133446588ada43674e11770" escape="true">Acquired In-Process Research and Development Expenses</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i07a6f8bd7133446588ada43674e11770">Acquired in-process research and development expenses are recorded when incurred and reflect costs of externally-developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront and milestone payments related to various collaborations and the costs of rights to IPR&amp;D projects.</ix:continuation> </span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0MTg_7d900cf1-efee-42a2-8be8-ca4be9ab6bff" continuedAt="i6b097d7752de4665b89744390e4236c9" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are recorded when incurred and consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs related to sales and marketing, finance, human resources, legal and other administrative activities. </span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6b097d7752de4665b89744390e4236c9">Advertising expenses within Selling, general and administrative expenses, including promotional expenses, are recorded when incurred and</ix:continuation> were $<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTI2Mjk_2e310bf2-90da-489e-9624-a3d1ec76b5a9">778</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTI2MzM_77f55146-fb70-42d5-98dd-0342869d7a2d">735</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTI2NDA_54e230f9-c623-4694-a24d-96a2ce3ff213">795</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTMxOTQxMzk2Mzk5OTg_c6ba9424-dbe4-4ce7-889a-ba574b4bfc22" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide stock-based compensation in the form of various types of equity-based awards, including restricted stock units (&#8220;RSUs&#8221;), performance share units (&#8220;PSUs&#8221;) and stock options, and through our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the &#8220;ESPP&#8221;). Stock-based compensation expense is based on the estimated fair value of the award on the grant date, or the first date of the ESPP purchase period, and recognized over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible or if an employee terminates due to death or disability.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of RSUs is based on the closing price of our common stock on the grant date. For PSUs, depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. For stock option and ESPP awards, estimated fair value is based on the Black-Scholes option valuation model. Estimated inputs to that model include (i) expected volatility, based on a blend of historical volatility of our common stock price along with implied volatility for traded options on our common stock, (ii) expected term in years, based on the weighted-average period awards are expected to remain outstanding using historical cancellation and exercise data, contractual terms and vesting terms of the award, (iii) risk-free interest rate, based on observed interest rates appropriate for the term of the stock-based awards, and (iv) expected dividend yield, based on our history and expectation of dividend payments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTMxOTQxMzk2Mzk5OTc_73cc6df1-bfe4-4aa2-856c-63901c6b87f6" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock outstanding during the period. Diluted earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents are determined under the treasury stock method.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0NDM_886fea8e-422f-45cf-aa83-1b6a8fa68e3c" continuedAt="i7f627419aa574983a44cc15f42f81503" escape="true">Cash and Cash Equivalents </ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f627419aa574983a44cc15f42f81503">We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents.</ix:continuation> </span></div></ix:continuation><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzOTA_e8ce618f-1286-4202-9533-b16649feb225" continuedAt="i85040ae5b4864aeaba75b14ef9dd585b" escape="true"></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i72fb187059b94b418c4ab414149b9e73" continuedAt="ic36facc21a8f43a486e18101c3548bea"><ix:continuation id="i85040ae5b4864aeaba75b14ef9dd585b"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our marketable debt securities are classified as available-for-sale and carried at estimated fair values. We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. Unrealized gains and losses on available-for-sale debt securities are reported in Accumulated other comprehensive income on our Consolidated Balance Sheets until realized, at which point they are reclassified into Other income (expense), net on our Consolidated Statements of Income. Interest, amortization of purchase premiums and discounts, and expected credit losses, if any, are also recorded in Other income (expense), net on our Consolidated Statements of Income. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost bases. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in Accumulated other comprehensive income.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzNzU_32f23dff-a2e8-4252-9b9d-14174fc222b7" continuedAt="i865f5732f3634497a8df72c7ad8dc5ec" escape="true">Accounts Receivable</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i865f5732f3634497a8df72c7ad8dc5ec">Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and estimated credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices.</ix:continuation> </span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzMzU_b778f54a-e7af-4858-af81-adf4d150c689" continuedAt="i43645d4fff6e46b6a5b43a72503dc8b3" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.</span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i43645d4fff6e46b6a5b43a72503dc8b3">When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends.</ix:continuation> </span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTMxOTQxMzk2Mzk5OTk_cd73af3c-7dc3-4d8b-9c17-7ef72bd0e67c" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair values, including those for which we have elected the fair value option, are recorded at fair market value, and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Any impairments or adjustments are recorded in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting, with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in equity securities are classified in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets, generally depending on marketability and whether the securities are subject to lock-up provisions. We regularly review our securities for indicators of impairment.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ic36facc21a8f43a486e18101c3548bea" continuedAt="i422070b5267e4e66aa9263711ab46f21"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0NzE_25db9e22-c96b-476c-8f66-1ac337ee629e" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="gild:PropertyPlantAndEquipmentUsefulLivesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0NjQ_51933601-be55-4be2-8679-1be457cf0b58" continuedAt="i9a76279e72614517ba64e8ae46dcdf9e" escape="true">Estimated useful lives in years are generally as follows: </ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i9a76279e72614517ba64e8ae46dcdf9e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated&#160;Useful&#160;Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;<ix:nonNumeric contextRef="ic7fd9b86e7264c5c947746f574318575_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RhYmxlOjQwNTYyZGVhMzg5ZjRkYjViYzQ1ZTg2ZTIyZjVjNDgzL3RhYmxlcmFuZ2U6NDA1NjJkZWEzODlmNGRiNWJjNDVlODZlMjJmNWM0ODNfMS0xLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjo0MzA1N2E4N2I0MDc0N2MyOGQ1MGEzYjU3OTgzYmY2OF8xNQ_3335a893-056f-42da-975f-858f24eebb40">35</ix:nonNumeric> years or useful&#160;life</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i390b60767b4e4998ba62331653915af0_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RhYmxlOjQwNTYyZGVhMzg5ZjRkYjViYzQ1ZTg2ZTIyZjVjNDgzL3RhYmxlcmFuZ2U6NDA1NjJkZWEzODlmNGRiNWJjNDVlODZlMjJmNWM0ODNfMi0xLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjo0ZDM4OWVmNzU4YjY0N2I2YTdhN2FkN2NhNzg3MDg1NV80_60971260-4fb9-403e-be1a-15f3a728742d">4</ix:nonNumeric>-<ix:nonNumeric contextRef="i88a6a37544df4d67aec58fa3bb44848e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RhYmxlOjQwNTYyZGVhMzg5ZjRkYjViYzQ1ZTg2ZTIyZjVjNDgzL3RhYmxlcmFuZ2U6NDA1NjJkZWEzODlmNGRiNWJjNDVlODZlMjJmNWM0ODNfMi0xLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjo0ZDM4OWVmNzU4YjY0N2I2YTdhN2FkN2NhNzg3MDg1NV83_5cdeacbc-cdae-4f51-8092-5c307aeceae7">10</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09e8c6458f804b75b3ac5c526d0da3b3_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RhYmxlOjQwNTYyZGVhMzg5ZjRkYjViYzQ1ZTg2ZTIyZjVjNDgzL3RhYmxlcmFuZ2U6NDA1NjJkZWEzODlmNGRiNWJjNDVlODZlMjJmNWM0ODNfMy0xLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjowZTM0YWRmMTlhMDA0YWQ5YTNkMjI4MDM2NWRmNDNlNl80_10f07a11-a451-4069-bfac-37dee7043dc4">3</ix:nonNumeric>-<ix:nonNumeric contextRef="ib71c43a2aa1f484d95e6e3501ae5b495_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RhYmxlOjQwNTYyZGVhMzg5ZjRkYjViYzQ1ZTg2ZTIyZjVjNDgzL3RhYmxlcmFuZ2U6NDA1NjJkZWEzODlmNGRiNWJjNDVlODZlMjJmNWM0ODNfMy0xLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjowZTM0YWRmMTlhMDA0YWQ5YTNkMjI4MDM2NWRmNDNlNl83_0339fd3f-7f41-4a59-a9ed-cddfdd4b38c0">15</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;useful&#160;life or lease&#160;term</span></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Impairment of Long-Lived Assets&#8221; for additional information.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0Mzc_e3645aaf-6023-479e-b925-1b5e43b56a6c" continuedAt="i7760ff70de90489aa315c942e8b0055a" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at inception and classify each lease as operating or financing. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.</span></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7760ff70de90489aa315c942e8b0055a">As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability.</ix:continuation> </span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0MjE_1731823a-a4ea-4b8e-bcb0-9f50d06d3642" continuedAt="ic7fe4af345be4ae9b986d2fb2c8cf276" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions, including Goodwill, Intangible Assets and Contingent Consideration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period, which may be up to one year from the acquisition date, with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the abandonment or completion of the associated R&amp;D efforts, which generally occurs when regulatory approval is obtained. Goodwill and indefinite-lived intangible assets are not amortized and, instead, are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and, are also periodically reviewed for changes in facts or circumstances resulting in a reduction to the estimated useful life of the asset, requiring the acceleration of amortization. See &#8220;Impairment of Long-Lived Assets&#8221; for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the initial fair value of an intangible asset, or when quantitative analysis is required to determine any impairment, we use a probability-weighted income approach that discounts expected future cash flows to present value using a discount rate that is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. These cash flow models require the use of Level 3 fair value measurements and inputs, including estimated revenues, which, for example, include significant inputs such as addressable patient population, treatment duration, projected market share, assessment of the asset&#8217;s life cycle, and competitive trends impacting the asset; costs and probability of technical and regulatory success, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value on our Consolidated Statements of Income until such time that the payment is made. Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i422070b5267e4e66aa9263711ab46f21" continuedAt="i67a364d6c00540368739a0a2bd1d85e7"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic7fe4af345be4ae9b986d2fb2c8cf276">When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and, therefore, no goodwill is recorded and contingent consideration generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are expensed as incurred on our Consolidated Statements of Income unless there is an alternative future use.</ix:continuation></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE1MDQ_06e3b414-769a-45d9-954e-2ccb73794f0a" continuedAt="ib6edcf0cb54d4f0db875f68bf35846b9" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib6edcf0cb54d4f0db875f68bf35846b9">Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset over its useful life to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</ix:continuation> </span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0MzI_00ef8600-7bcd-4d00-876e-881b29e45cd5" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Unrealized changes in the fair value of derivatives designated as part of a hedge transaction are recorded in Accumulated other comprehensive income. For our hedges related to forecasted product sales, the unrealized gains or losses in Accumulated other comprehensive income are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using regression analysis, we assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzOTI_13843253-912a-4ffa-8541-2f7273a27456" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize accruals for loss contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue the best estimate of loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzNTE_8a7757d9-51bd-4f6b-bc68-a3e9b89f53a8" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision is computed under the liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance to reduce our deferred tax assets to the amounts that are more likely than not to be realized. We consider future taxable income, ongoing tax planning strategies and our historical financial performance in assessing the need for a valuation allowance. If we expect to realize deferred tax assets for which we have previously recorded a valuation allowance, we will reduce the valuation allowance in the period in which such determination is first made.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (&#8220;UTB&#8221;) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax expense on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for the tax on Global Intangible Low-Taxed Income, enacted as part of the Tax Cuts and Jobs Act, as a component of tax expense in the period in which the tax is incurred.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i67a364d6c00540368739a0a2bd1d85e7"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTMxOTQxMzk2Mzk5OTU_ad9a9d19-d4fd-4214-8cb2-7c5fdf94fefa" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transactions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Financial Statements are presented in U.S. dollars. The functional currency for most of our foreign subsidiaries is their local currency. Revenues, expenses, gains and losses for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities for such entities are translated using exchange rates that approximate the rate at the balance sheet date. Foreign currency translation adjustments are recorded as a component of Accumulated other comprehensive income on our Consolidated Balance Sheets. Foreign currency transaction gains and losses on transactions not denominated in functional currency are recorded in Other income (expense), net, on our Consolidated Statements of Income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTMxOTQxMzk2Mzk5OTY_01b269ba-1fe3-41db-9f17-8a58627b8d79" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value accounting for all financial and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMjUzNw_b76287e3-688a-427b-a753-85de5d65dbd0" continuedAt="iae3eb84780ae4e10aa6757de327bf68f" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="iae3eb84780ae4e10aa6757de327bf68f" continuedAt="i6fb76018d38d4debb76dc2d21223d8f2"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Disaggregation of Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMjU0MQ_34fd82c6-8ed9-4a7f-b1c0-5a2aa2f54e6a" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Total revenues:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.930%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic696402818f946ca8e766e2da5e21ac0_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0yLTEtMS0xNjc2NjU_827b2b5a-c532-4917-b2c2-00a3d155a57d">8,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i286ee669e6484c499ce3f18c039cd90c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS00LTEtMS0xNjc2NjU_85feae0c-4487-4f5c-a562-697676213d41">1,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00413e506af84cb6b520644367a012ce_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS02LTEtMS0xNjc2NjU_41a83750-0265-4246-af42-081c10343907">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ac7bcb2b4b64c279d885fb620928589_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS04LTEtMS0xNjc2NjU_ae963350-c204-42bc-a6de-f388e8740ff1">10,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d7e0990ed454ca09ff79ece5703dfde_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0xMC0xLTEtMTY3NjY1_5973d02e-2cfa-4257-8d05-56b7d22444c2">7,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56cc9ca37eb642478c269153aa683b08_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0xMi0xLTEtMTY3NjY1_ace66840-4a0e-4d24-9423-f93167460230">969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f70e4e6502d40f395271bf5dacfb004_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0xNC0xLTEtMTY3NjY1_67445dbc-c81f-4587-8cc2-fee933f3346e">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f74fe4a143c4a2c9d6b59c1d6a92719_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0xNi0xLTEtMTY3NjY1_c8eb02a3-28b2-4907-919e-20fc83c470f1">8,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c25bac5ccf4ea4b63bb3ff8c487134_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0xOC0xLTEtMTY3NjY1_4204ba31-85cf-4a3c-b715-64be8aa93b8d">6,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e8df77801f4427b07c69bffbbb53f5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0yMC0xLTEtMTY3NjY1_ca143a7a-68eb-49e9-864e-3a3965996742">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cca639743794954823700d44d77da39_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0yMi0xLTEtMTY3NjY1_91307338-28c5-461f-abf2-952e300f26c6">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cfd1d80d3ce4e1d81dd9cbad42783fb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0yNC0xLTEtMTY3NjY1_57429eb8-2e1c-4334-981c-0ba2f0b018d2">7,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb859e1c4b7140e1bce378f02656f04f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0yLTEtMS0xNjc2NjU_4aed647a-323c-4b5b-9c27-8974abe6a281">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e31ca129163441e8e9ea4ff5f95df21_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi00LTEtMS0xNjc2NjU_70cb8c4e-902f-4908-82e3-1fff3f29c2c3">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5793c69ad54496bd31bcf75d0dc074_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi02LTEtMS0xNjc2NjU_a3601103-c837-4d0f-a498-d4e6c39064b5">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9fccc1142b74901bc9e73819cdd9125_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi04LTEtMS0xNjc2NjU_5788ad02-a56c-4a89-9ec0-9ba5fe01cd24">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b327175cb0442eab0262b47b930716e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0xMC0xLTEtMTY3NjY1_9f4634fa-edef-491e-887b-76b13bd50500">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a83bfeca0b4653adb38d1116db35d0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0xMi0xLTEtMTY3NjY1_e4a54159-722a-45fd-8cd0-64e01f14fd4e">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2f630b325964676ad13e1b62b9ace1d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0xNC0xLTEtMTY3NjY1_fe2be3cf-0f06-49ff-9ebe-09768f85b73e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if440505f622045a0ab8e2f08a2a84ff4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0xNi0xLTEtMTY3NjY1_dabd8cd8-cc06-4d25-8a6a-9142f3900efe">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47d4305b1ac49fcb94e0cdc18738baa_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0xOC0xLTEtMTY3NjY1_1611efdc-3814-4137-aff5-a01e2649476a">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e56ec469d9f455285efc69b4c698e5c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0yMC0xLTEtMTY3NjY1_6d5ca99a-c963-4448-a22b-937eb2bd4bb9">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15076f57d5f940d28b2718517e8b16f3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0yMi0xLTEtMTY3NjY1_8b47e615-9d44-40cb-89fc-fda37082c5a5">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22c3f886b1e7454faf57898572502064_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0yNC0xLTEtMTY3NjY1_1d8ab911-e47a-4658-b9e1-e0342697a243">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae0ac82ae7e44e389ab9b0b042115b90_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0yLTEtMS0xNjc2NjU_edf6c9b0-75c7-4695-bcbb-69150558788b">1,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd4f275449048bdae7a5e135ab9aadb_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy00LTEtMS0xNjc2NjU_b0f4f9ad-88ba-4fe7-90c7-a0af69a43a72">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93fde66711574d6bbab8f82da5df47b6_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy02LTEtMS0xNjc2NjU_cab9c392-6deb-4fb5-bf53-1dfb68de1f56">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e1da3ce22e34b9d8b83601cc4c715da_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy04LTEtMS0xNjc2NjU_e4cac694-8e7d-4c4b-ab18-4b8a4ffbdd38">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964d48496e5a432ba68cb1dba5f31cc2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0xMC0xLTEtMTY3NjY1_c676d774-5202-43cb-8519-4ac756f70cf1">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0071404988114bf68fb32b3baae96596_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0xMi0xLTEtMTY3NjY1_0b84ffdf-e4ee-4eeb-9fb5-1119f7c7adb3">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a61c1cbf1a41039ca8dd3bd871bccc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0xNC0xLTEtMTY3NjY1_aa1e61b5-f543-4f4c-8b33-fc8fd5b526d3">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f2cf5628f8640368fe1236801410db4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0xNi0xLTEtMTY3NjY1_e72108b8-3873-482d-b9bc-ec6f4baa321c">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67f16390de4f49cf950cd63ea38a892e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0xOC0xLTEtMTY3NjY1_c313354a-7323-47ee-9588-4ba0f94045d1">1,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72733c8f57e48839a1cec90953d943a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0yMC0xLTEtMTY3NjY1_47323efc-3af7-4381-ad82-56e0f5056206">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad56bba1d8dd4206abdf2a2ec6754899_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0yMi0xLTEtMTY3NjY1_0db41350-a6b2-443d-b8af-a3754721a5f5">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i304b851b46d94cd2871b2b103c61252f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0yNC0xLTEtMTY3NjY1_c22e5856-0dd6-418f-9705-6a09a1f32872">1,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ac5cc1e74843118ec886b8bf7ef582_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0yLTEtMS0xNjc2NjU_7e65c99a-df7f-449c-968a-0242d8e2fa29">1,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5f8cda4ab4437b9355aa4d0ac8a973_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC00LTEtMS0xNjc2NjU_0bf2630c-c620-4f9d-b42c-296615222aed">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i740c73c876d84ead9b478bfac1e5c406_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC02LTEtMS0xNjc2NjU_9ea2587c-e6d6-4989-b9ed-f52687a89104">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02057a68acd8487089bcc3e13994ef8f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC04LTEtMS0xNjc2NjU_61410fe3-3d96-47be-a0ec-ab09ef0825de">2,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0ae81470ee244b1bd11b567115b6709_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0xMC0xLTEtMTY3NjY1_63e6a9d0-a959-454c-94c0-b83385c35bdd">2,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23321b8060e4e9cb82713996e9cdccf_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0xMi0xLTEtMTY3NjY1_dcdad6e8-8566-4e98-a142-3a005a7ad2d3">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28f325e4676479c9ae644fd3eb6dc67_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0xNC0xLTEtMTY3NjY1_7f5a4336-5822-4d63-a834-99649750a7d1">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0339bfc0225743a98310d7e4676b63a1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0xNi0xLTEtMTY3NjY1_dd8d0048-4e7a-4f7b-bdc1-e404ee485664">2,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff0215260a554fe1a70899059d81b451_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0xOC0xLTEtMTY3NjY1_da7e7baf-5617-4278-bc74-dee811ad8943">2,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3192435e8c448f8600dfb9c15a1180_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0yMC0xLTEtMTY3NjY1_298634a7-9765-453a-a74b-ce20808b6303">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67f25f67445f4a4ab2ccdd05c60c4182_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0yMi0xLTEtMTY3NjY1_4f1ae97d-1474-4ffc-b762-850892035f35">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee906e7856d488ca901f1010783b65d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0yNC0xLTEtMTY3NjY1_e5662574-d093-42ee-a7b3-c7ac1bbf82d3">3,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i887e5599e4c94395876541937b39df84_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0yLTEtMS0xNjc2NjU_ce3d4c6a-9764-4ffc-9678-9c7311f1ad2d">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0505374d8f084ccba1175e3944dbd664_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS00LTEtMS0xNjc2NjU_1511eda5-87dd-48c5-a2a8-f9d0506171e2">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida1cacafd04c44f093aad95b5b455f48_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS02LTEtMS0xNjc2NjU_d1e3b328-9696-48d0-9443-077ad15e4219">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31ee1b39fb5499c81d8735285addc93_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS04LTEtMS0xNjc2NjU_f2fb40d8-ba4a-49d2-8bbb-281ed445513a">1,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbac4e022d8e464388f4a38bbf75756d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0xMC0xLTEtMTY3NjY1_72cf0a44-a6d0-47e3-b768-460468d04039">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70473509ff904d01a46a345f05fea5da_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0xMi0xLTEtMTY3NjY1_2798cac7-7b45-4ea9-839d-a0d1ddf761ee">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf7892154f17434fbf26b8d35f055731_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0xNC0xLTEtMTY3NjY1_b5e4052d-3bac-4ee7-a053-a9b3452b1c82">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4be07fc0444b0c9a13b3199fe07055_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0xNi0xLTEtMTY3NjY1_d9fb428e-90bb-4042-8446-210dd493bc5b">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3caa5600f3c42d6a90eb349e4bd514f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0xOC0xLTEtMTY3NjY1_0bdd966e-b271-4b43-a701-4f287cf609db">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca9bbc5fc664235853309bcafe09958_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0yMC0xLTEtMTY3NjY1_c6733b4c-c4e5-4f86-9f1b-c4bfa97699dd">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3622543706a4a2ead1afac3ba8a644a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0yMi0xLTEtMTY3NjY1_0233e8f8-bbce-4d96-adcc-187d1a7e644b">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18db965aef5240089858bc62cf910c9f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0yNC0xLTEtMTY3NjY1_fe96776f-8761-4200-88ba-fcdf3932c107">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3b6a53fda1447db2fdec88c020c38a_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMi0xLTEtMTY3NjY1_2719bbe3-b0ad-4368-99d5-0d4e8c35407d">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35737905b7f54f96b51c229ab96133ca_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtNC0xLTEtMTY3NjY1_2cf6b414-e2d9-4a89-be8d-c196baf61d64">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37d4b794616d455b92a951ae3e8edbdb_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtNi0xLTEtMTY3NjY1_9770b6f6-789a-475e-b702-59926f40630c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036b934c4c424d27a375818415f5f565_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtOC0xLTEtMTY3NjY1_5214b750-9a94-4546-9159-20039c4286e9">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d92f1839624521878f4e8fe7a4145e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMTAtMS0xLTE2NzY2NQ_c6427abf-8a66-463d-8928-1f67ee2230c0">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0be6d27e8e284285916d1f631af87d93_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMTItMS0xLTE2NzY2NQ_1d099657-8c70-4341-b5b2-63f3843b0d00">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i272805c9851c4bfdb5a20f92f49d6fd0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMTQtMS0xLTE2NzY2NQ_ee77ac34-3cdb-4241-b0e0-95e686fe5177">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e924509b7e456cbae02bc97a737eba_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMTYtMS0xLTE2NzY2NQ_8cfb39f9-3470-4a5b-aaaf-3ce2a828ae18">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e5067a7fe24c2489a2377a45fe5b95_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMTgtMS0xLTE2NzY2NQ_c0e2e879-c255-47ae-9f41-f67d0dd0dedb">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19185ddfd4c49b9aca949d6f1a89ec6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMjAtMS0xLTE2NzY2NQ_2fec4cf4-2d2d-4c52-b473-e231aad5c21a">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3bdd8ecc264a9cb8aabcb280063543_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMjItMS0xLTE2NzY2NQ_d176da59-b5d8-44a7-949a-8787f2cfe777">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i633428932b804629900634cfca66947f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMjQtMS0xLTE2NzY2NQ_3703c28d-3122-4a95-8e3c-65295e146061">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e76c6ce2104589bb819a55da49f0a1_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMi0xLTEtMTY3NjY1_53b28d84-de6d-400f-85d0-45f1f350266e">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i302fc8ea04774f47a2cf3fbb59d774c4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtNC0xLTEtMTY3NjY1_cac1a482-9f9e-4d01-a95c-893d4ead76a6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68de7e98cbfe48278b7e8e7b1ec961b2_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtNi0xLTEtMTY3NjY1_979ed947-a9f8-428b-88c0-05d4eb674759">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09ef539a43334ebf8e611cf6caa5b1d3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtOC0xLTEtMTY3NjY1_5c7db220-f2a7-45e4-a1db-19390351e0cc">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e84d2367c3549a5bf92e42aa560380d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMTAtMS0xLTE2NzY2NQ_6bc7035c-65a2-47a5-a2d1-daf2dff0fa00">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058ee4cbf024433382a4b9568255bf56_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMTItMS0xLTE2NzY2NQ_e7cf815f-182e-467d-bd13-01bdba5b4d19">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c7acb2c7cb04a5d8c5b81d0106790d3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMTQtMS0xLTE2NzY2NQ_779bfcba-e4cb-4f4c-8211-6e3324e0a4b9">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idba4864482334ff491facf75b1f78c6e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMTYtMS0xLTE2NzY2NQ_772af86c-ea4f-47bb-ac4f-36a3b2eec722">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b547cdffc54b5d8fd971f88c4b405a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMTgtMS0xLTE2NzY2NQ_f89bf893-c65a-45aa-b781-094c36aea2ed">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36718df39e0a47c7a9984f2501ce84de_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMjAtMS0xLTE2NzY2NQ_8bd03f33-24e4-4ddd-97f4-4abc4bbc75e7">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied0db1516b674b75a73389a4c97b931e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMjItMS0xLTE2NzY2NQ_ac2d8fce-b2e2-4734-9af9-abd0000e887c">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9af6895f54f43d2b2aee375ef4268d5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMjQtMS0xLTE2NzY2NQ_e6843c58-d5e1-4443-92b3-32e27c8f64dc">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a22c11bafe49b492afdf6f074bf51c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMi0xLTEtMTY3NjY1_539716b2-4587-44bc-8b5a-bb190951f02c">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56989cfa5ca9443592944384e4a662a3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItNC0xLTEtMTY3NjY1_afffd7b1-ff3b-4ccf-80d6-67f600cafa42">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d3d1785838487fa5864f6342945d52_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItNi0xLTEtMTY3NjY1_383cfd68-867b-49bd-b5d0-ad488ea22b63">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i483ed774b8694c0e9f7537a56e3d8723_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItOC0xLTEtMTY3NjY1_7fb35664-3786-46b4-a911-c267c3b5c4f0">530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33140238ec544db4bf188fc5d80572b9_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMTAtMS0xLTE2NzY2NQ_a078e185-4682-46ec-a966-2fbb96116ce7">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0fda03309d414a88c8d75b94de2c56_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMTItMS0xLTE2NzY2NQ_434fd464-9bda-42c7-b54a-0bad85711339">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic481237eae4e4a89a31528ac64b99866_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMTQtMS0xLTE2NzY2NQ_a8ce8ce0-1808-49e3-9b99-d9dad52d1cf4">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c625e43b4ea49c0aae317d5f95ced49_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMTYtMS0xLTE2NzY2NQ_2680cadc-1246-4037-8797-8efe6c1222ef">531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id61421ab356146f5b9d4c0a367d00a97_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMTgtMS0xLTE2NzY2NQ_0087a5f6-f74c-4eb9-b951-8d7700bd0a19">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3f9f82011a48019099652b6774bf3e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMjAtMS0xLTE2NzY2NQ_38aeb53c-7648-4260-b662-82852dbe1c02">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36131c939960498fae7e0683985c0826_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMjItMS0xLTE2NzY2NQ_384f9b4c-d8e0-4285-8080-bd24f8890631">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39482d1ab7947dfbee72e97e6c80cb9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMjQtMS0xLTE2NzY2NQ_88343f1a-4679-49dc-8b35-a4c67013f5fe">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8417f39fd314af3973c6cffd12840ab_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMi0xLTEtMTY3NjY1_3b97f9f6-29f1-4133-999e-0edb77ca9ef9">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83cc8de84b324599b629478841ef5031_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtNC0xLTEtMTY3NjY1_fd8c220c-21c8-45b9-b54d-24b6b8556bf5">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee89b9c9e4a4997a3e05c1360c968a3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtNi0xLTEtMTY3NjY1_1dc0f9ca-42dd-42b4-a0f8-7c1bfb3578a6">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2710bb1e4e1a4da2bd3c71ff3d63d766_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtOC0xLTEtMTY3NjY1_222e5db7-d992-4413-8dbd-ca96e9907b1a">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d50bd550a3e4eda851933980c3b6015_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMTAtMS0xLTE2NzY2NQ_83555d5a-1ecd-4b9b-8213-d143d75dcc23">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife622784ffa145f89df7c21f7e243720_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMTItMS0xLTE2NzY2NQ_b1d94015-fc09-4c05-8dca-31b1378eadee">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995e08e1c0564adfa6e51134fcafcd8c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMTQtMS0xLTE2NzY2NQ_60988555-feb2-467e-b0bf-3381ecf8c3b0">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf67814543c7461d8fcb1cf0ed2a896a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMTYtMS0xLTE2NzY2NQ_7dcd5bd7-9de3-45d4-8d7f-7256153c4bdd">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271f7c1121dc478784b60c3682272afc_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMTgtMS0xLTE2NzY2NQ_2c0c3d5a-90b8-41fd-b418-a86f9dcba97e">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c46fa85c0964613972809e212f5c052_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMjAtMS0xLTE2NzY2NQ_730550b1-ccab-4174-8bc5-52ac13f47d71">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdc70db5a1624cd9932fc54e3656a357_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMjItMS0xLTE2NzY2NQ_3458c40e-597d-426d-8259-ca531faf5f4c">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf397fbe91ff4afab6f6016ac4dfc728_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMjQtMS0xLTE2NzY2NQ_bdbe522e-b883-4820-9aa2-b4f6c4050030">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HIV </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27e01c3738343ae828ddd82be4d291e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMi0xLTEtMTY3NjY1_4d262d5b-b9e6-4568-b748-6f598a562f3e">13,820</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9a8f22db57427db018ee661e6611ec_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtNC0xLTEtMTY3NjY1_90748311-7068-4c96-805f-e83ed79e874d">2,219</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23826be9a15045c7bb6572cf25f0aa6f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtNi0xLTEtMTY3NjY1_9eff6b81-f3ef-43ee-bf64-4a80b2584f65">1,155</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe24bb9f9af9476b962e3e4255a2fca0_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtOC0xLTEtMTY3NjY1_4af74f63-b631-4b3c-8c27-22529d0cd5c0">17,194</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5889f693afe94663b9bb93ada344fee3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMTAtMS0xLTE2NzY2NQ_389d11bd-f13d-48d5-8953-982d80ad33ef">12,828</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i746f4ee74a48426283deb266e69bfe47_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMTItMS0xLTE2NzY2NQ_b703bc13-b535-404e-b60c-02531da828b4">2,366</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25fb84b127124bc9a930a78d394ae9ba_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMTQtMS0xLTE2NzY2NQ_5d7c32b8-172e-4cf6-aa13-ee72825b5f7c">1,121</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a531ef2bfa647ae80f2e7f581cb250a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMTYtMS0xLTE2NzY2NQ_5d8d602e-19fb-4494-bb6b-610a9b6b770b">16,315</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i038b1c841f2c4a1f99edae58948bfc95_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMTgtMS0xLTE2NzY2NQ_12977a20-99bb-41c2-9512-dce2b1eefaef">13,651</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8989bfdb504424e88c9fc5951e552e5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMjAtMS0xLTE2NzY2NQ_7ceaec22-04f4-45f5-9dd6-56b474f687f2">2,287</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i747dd2095bd84387a1b2cef2a08d4ce4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMjItMS0xLTE2NzY2NQ_54a39fee-6227-44af-a36b-8299cb2f0e83">1,000</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia623a13014414ceeb8b62e7b7d0307ed_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMjQtMS0xLTE2NzY2NQ_eda8b178-b1ac-462d-8ac2-dee67ae19fe6">16,938</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8fc90a5cc743ac8164e9757643d7c7_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMi0xLTEtMTY3NjY1_bb2dbe6b-3543-49f1-9fa0-8ef6d7bb89bd">1,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef9373aea4d45da839ba8bd983d6d41_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtNC0xLTEtMTY3NjY1_6c523ca6-fce7-4f0b-9c81-de57b297be19">702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i159b36366579482e833ac889d1de99c8_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtNi0xLTEtMTY3NjY1_c7dccec8-f0d8-47d4-b43d-06171d2c0556">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77dccfb87744dc0bd019148750e21d3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtOC0xLTEtMTY3NjY1_57ae2bfc-e3a9-4b9a-9591-6328c6cb42c1">3,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i892ab04014c6452385a1231e4a398daf_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMTAtMS0xLTE2NzY2NQ_403116b7-8d7f-4a75-ac99-27896b8b0bbb">3,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic70bed0fa20348939ac81aac767a32c6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMTItMS0xLTE2NzY2NQ_8448884f-e660-4d23-9ca6-9a5f8afd2395">1,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdc513510df408a8c14ad0c77931ade_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMTQtMS0xLTE2NzY2NQ_78bf78ab-410c-46d5-b229-99bfc9f56572">830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e1551d2e994a7189a15b9f7e12f955_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMTYtMS0xLTE2NzY2NQ_830f31f1-014b-4100-bec3-3552beeae76f">5,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3270ed2ab9af4df597819fe1d39f6066_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMTgtMS0xLTE2NzY2NQ_2b8213ed-d55f-4f39-a102-9ace3ceb92e0">2,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if566c62d193d4045a5d0d0bc3b4f89a2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMjAtMS0xLTE2NzY2NQ_0f2759a3-dc41-4d54-9efb-fe412549f6d3">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8e5cf6644584b59bef073ec6d2e077b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMjItMS0xLTE2NzY2NQ_59bd01b8-7ebd-4760-aacc-7f4679b08c75">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if603e181b6c147c1be2e679da1361347_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMjQtMS0xLTE2NzY2NQ_d6e264fb-7b35-44f0-85e3-cfbbfd60aadc">2,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ledipasvir/</span></div><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if161350d9f934bd5b9c69a9471693d6c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMi0xLTEtMTY3NjY1_5b84ff0e-bcc8-4be8-a123-e3a8a19dbf0f">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i224c38109cbc43f6bad2833a21c3d696_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktNC0xLTEtMTY3NjY1_f712cea9-e9ec-4e62-b4c7-7b4c6f83b3f1">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d5a1d3752041f4825d5ee38213b9f3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktNi0xLTEtMTY3NjY1_3560428f-2b88-4cb3-b5da-2bad0c2a49de">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1889ca3a09446d1a27ffe2aacdca6bf_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktOC0xLTEtMTY3NjY1_72539dc3-6c48-41f9-947c-5166e5d84447">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84af8bd3147d49149ce9becb6109e0f3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMTAtMS0xLTE2NzY2NQ_ddb5628b-ee9a-4a38-a466-08f9150a9de6">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dae9fa70cf84bab9cf15d4dd1ab1c25_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMTItMS0xLTE2NzY2NQ_12dde050-f78a-46c7-aff9-2b339ebc1030">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ca3edc2c8454bfe860b717853160f7c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMTQtMS0xLTE2NzY2NQ_a6ec9a44-72fb-4233-bb97-a6614eefac76">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i990aae18e5ac4dc19094dd84e771dffa_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMTYtMS0xLTE2NzY2NQ_a8a84988-045a-4a0f-8e84-7cc604c018cb">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1385fad94f9646459a09390bebc1818f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMTgtMS0xLTE2NzY2NQ_c2c7305d-88b5-4407-97c8-feeb6565a80f">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64774209bf234606bd852b8efadecec2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMjAtMS0xLTE2NzY2NQ_893b41db-efc3-4f57-8b39-646b4201d887">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i408f437468464bfb95a8a1c1592428a4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMjItMS0xLTE2NzY2NQ_d09c51bf-90e4-4579-a8ac-5cb51993b45e">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9586512d7c414fa31e0c58325277e9_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMjQtMS0xLTE2NzY2NQ_4f78f0ec-e065-4f33-889d-19a84471e54b">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001f0a321e7a4cc9919c4b2d3cc488ef_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMi0xLTEtMTY3NjY1_f49a4c2b-f9d0-4446-af26-c257bedf241c">844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7970864108404b9398d1c10e32861e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtNC0xLTEtMTY3NjY1_c894f92c-e19c-4248-aeee-c4b3bc2248da">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef5ab3d255d4d7d9f8adf8b51dc6060_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtNi0xLTEtMTY3NjY1_71677f7a-04ae-44a8-b94c-e75e9f4bb7b6">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d762459c913449eb0f5d2ffcf4a8ab8_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtOC0xLTEtMTY3NjY1_cdb1068b-c9fc-4326-8835-fd0701ebc17a">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i842e95d3015c4566b5b99f7cd1c3766b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMTAtMS0xLTE2NzY2NQ_a17c944e-7577-47a9-979c-58a211e39dc4">815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8b88a32bcf490093fd7196fd827fdf_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMTItMS0xLTE2NzY2NQ_99514b8b-77fb-42ec-b321-68cc3913ffd5">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6ac7fa58b641b9994e9e2ce1b1a394_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMTQtMS0xLTE2NzY2NQ_c3127ea7-2b3b-4341-95ce-41c25f718116">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e5ee028ea914344923f044cfd129a25_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMTYtMS0xLTE2NzY2NQ_fd2dd724-0684-4e27-8b54-4c8ee88f0ae2">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e11ede728fc4b108eb991ae3d30fce7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMTgtMS0xLTE2NzY2NQ_2ac36d6f-eb9f-494a-afb0-7fe48a7b4e17">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7c70711ba3a452f8b82fa6d3959ed4a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMjAtMS0xLTE2NzY2NQ_295786fc-dc75-4333-b6c4-ab2614bac1da">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58f04355584a7b83ab6050a0f2f05e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMjItMS0xLTE2NzY2NQ_9a428d08-51f6-42e3-b15c-582fa42f19c5">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d165787a07f4f2b974d0947bb5841d2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMjQtMS0xLTE2NzY2NQ_fe40d8e3-1503-4a9b-b845-a565ccf1a2f2">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if576a322818849af93ddf776061a8daa_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMi0xLTEtMTY3NjY1_577aa6bf-e18e-4a17-9f08-c31c59102dea">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13ecfda046a14b828b6b88d76ce34397_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtNC0xLTEtMTY3NjY1_da86bd29-b622-45bc-87f0-caedca23fc1b">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0cd547725ff48868a0a2427edbdb26c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtNi0xLTEtMTY3NjY1_c31d4780-e180-4d00-aaba-74ff1bf1c658">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44bc2b667f640c0a49ef7f1c0d6afad_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtOC0xLTEtMTY3NjY1_c0422185-4905-42f9-a034-64a586526cb7">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27d62848770f420584e5549e2f98494b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMTAtMS0xLTE2NzY2NQ_ead5d52a-de30-4eea-a8b9-e40a854caece">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb21c9712fc547089da1e6a2b9444cc9_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMTItMS0xLTE2NzY2NQ_2016da1a-6e4d-4a67-a9b3-0029ea619592">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b6e79b7ca6d45d8865a7c9f5f63c09e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMTQtMS0xLTE2NzY2NQ_71f031eb-c231-4851-ac3d-63b588b008da">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e3cb062c5154c10a3316d587eff126e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMTYtMS0xLTE2NzY2NQ_18eb724a-dd46-4614-8b7a-0a456d4dfcf3">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54e8d61cf6b54f18a3832db879c16f70_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMTgtMS0xLTE2NzY2NQ_0f62b0a8-95e2-41bd-8625-46e564fd56e0">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id357c81bb4e5460ab1a7936bd0bc234a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMjAtMS0xLTE2NzY2NQ_0dcacdfa-799e-46b0-84ac-ad1c7d7e3c4f">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9303626ac8f847eba23eb95d3525b36f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMjItMS0xLTE2NzY2NQ_29151f3d-0370-41b8-bdf9-099598976921">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2436a0ce9352470798f7186a3a70c857_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMjQtMS0xLTE2NzY2NQ_5abc435c-62ef-45d6-b814-205e56b41473">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8352ae8893d34956800ed3b7a48a48f7_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMi0xLTEtMTY3NjY1_f47e3192-43f7-4508-89bf-d612f3ab8bb3">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4a7fcc37bdb46a8b48ab66e6c59272e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItNC0xLTEtMTY3NjY1_f2322f3b-fb57-4207-a025-7b57f2483c0a">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i316a0910d8e048a4843f027671f1598f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItNi0xLTEtMTY3NjY1_44ec99d9-1419-4150-93ed-6edfca6a1bea">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0ca5b4297e4ce5bb2fcad022831bd4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItOC0xLTEtMTY3NjY1_948d4018-df83-4e8f-a7e1-c8369028e104">1,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46b71f3a3fd84ae7b5f5562467d87974_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMTAtMS0xLTE2NzY2NQ_77db6984-cd30-4424-9b08-a1758c48353b">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab7e60f505e04d06b0aa3dda75663f1f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMTItMS0xLTE2NzY2NQ_97841aa7-cc78-4fb4-9287-498fde0c4e63">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadec57d70f694b2c9aeef1696ac8ec12_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMTQtMS0xLTE2NzY2NQ_e5e2e69e-912b-4ecc-a567-6024d072785c">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb175d66081417f895e6a30847d0ec9_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMTYtMS0xLTE2NzY2NQ_3960ece3-3767-47c8-9a89-9b23021158f8">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee44c336571414b93118372858b768a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMTgtMS0xLTE2NzY2NQ_eab23075-7a38-4cb4-a260-d8dda92631e4">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cdd83824774e048ef83b228f4edbb4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMjAtMS0xLTE2NzY2NQ_4f5017be-7aed-498d-aa46-f9fba3c767c8">414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9306bcc0ca3a42b3b7c50ee626394174_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMjItMS0xLTE2NzY2NQ_a6972b3a-02f6-44bd-ad41-4e5fc38f6213">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf53c215b7d4f7997810c9a06bcdd03_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMjQtMS0xLTE2NzY2NQ_a10abae5-1bd9-432e-8e72-c962ef927826">2,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="27" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis Delta virus (&#8220;HDV&#8221;)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc553a8ada449298fffed4c28e2060f_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMi0xLTEtMTY3NjY1_c5816b10-5bba-4974-b959-a12a781f0ff7">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic415777eefb04ed297d1241f612be3c7_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtNC0xLTEtMTY3NjY1_b65ab1af-ae69-4a7f-b921-2662d31897b4">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie13c6aa1001243d89d2583a460ce4786_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtNi0xLTEtMTY3NjY1_798c6811-4d98-4b0c-8c21-d65646b24eec">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib64f820871db47e3a10f78b9550bb92e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtOC0xLTEtMTY3NjY1_8018446d-9e73-459b-881e-6994f87ee0e0">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42cd1fcad93c4c6ea52dce4ae9e6c75f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMTAtMS0xLTE2NzY2NQ_f3a1ca26-afb0-466d-888c-5acb76cb7981">384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2bdd0ef7d94c5d9c5937ce2afd82fa_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMTItMS0xLTE2NzY2NQ_d721663a-7b6c-4ed8-9b45-9b908de7b1ee">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aec2c5b53674a8e99a3fabeca154f63_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMTQtMS0xLTE2NzY2NQ_a464e41e-0327-493d-a4e2-f310f83dfd8f">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib20a0912ba52411597d240f59ee8a970_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMTYtMS0xLTE2NzY2NQ_ba42df45-2186-4754-8bf6-c31ae9de174c">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28852e0de5a4261bb649f5abaa6914b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMTgtMS0xLTE2NzY2NQ_830079d8-27e5-4619-942c-8ab89510754c">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed29a62f86443fcb28feb3b67712b1d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMjAtMS0xLTE2NzY2NQ_69444ed9-5c08-4fb0-b875-66748c09f75e">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i752e7f4d5fcb4e0bbf8b49e33b38f59c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMjItMS0xLTE2NzY2NQ_88db67a2-f74d-4256-943b-6dacf1cab500">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94daf83394e47f9bb26f578ef1b6fd7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMjQtMS0xLTE2NzY2NQ_12d0f874-41a7-4d92-88e0-c4004ebd7a9d">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e7228c11db24e9aa0d0a7aa03dfbb82_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMi0xLTEtMTY3NjY1_f1d86168-14ab-40bb-abd2-e4be63cc1334">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b50cd213f44bd3b7a2dc1a71945fa5_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtNC0xLTEtMTY3NjY1_af172626-ad70-404c-9bd3-80f6351b9453">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9225d954d484582b9642b85bcf59293_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtNi0xLTEtMTY3NjY1_525ce84b-9d33-42f4-a0a5-f2a89aa34c5a">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib93f3e8abe7249e8bf7db00e4237ff24_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtOC0xLTEtMTY3NjY1_b3b06128-8364-4f17-a808-8ee6b2fc1712">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c19876953f4ca6b7fa9b0c8fdf5a9e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMTAtMS0xLTE2NzY2NQ_ca79b763-db8c-45da-9306-ab6faff801c8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25424faa0377487b93010e5bde98b80b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMTItMS0xLTE2NzY2NQ_e46dbc3a-e54a-45b9-94c4-40e4e60699d9">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f6d94f1fffe48978776b2d7573360e4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMTQtMS0xLTE2NzY2NQ_7c93f1e9-84b8-468a-a99e-4785a1910eaa">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b03b0e23a24b88acb155327c8488ed_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMTYtMS0xLTE2NzY2NQ_44f73942-26fc-49c3-9a1b-1e776a17eea0">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a165571ecc4a6a81d1a6a559f0c569_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMTgtMS0xLTE2NzY2NQ_2742364c-797e-4a62-884c-b8daa0e6bc88">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icde54372e7c94f3cb372e6be0b78a13b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMjAtMS0xLTE2NzY2NQ_aae891a3-e416-48d2-a1e2-e216d781a49c">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id464c7738d154fe99637211d865d3a53_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMjItMS0xLTE2NzY2NQ_cd957422-0dbd-4274-983f-99a144224c89">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152e0d6d305445e59681826b69d85467_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMjQtMS0xLTE2NzY2NQ_f1927168-52ea-4305-b292-8db8c0a624bf">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c7a7e2316ac49c2a3524b858ab86c7e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMi0xLTEtMTY3NjY1_0fe881eb-8b64-46be-a5dc-87aa05da0fed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7c74c57c8c0479082ce7a7dac084d27_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctNC0xLTEtMTY3NjY1_e53ba5f6-1ca6-424b-aa30-f1526d04a390">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib769b5b3d70b46e892db64fc00f73c4c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctNi0xLTEtMTY3NjY1_7fb47b1b-d2ac-4fd3-8df7-9793e31dbba1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce38a9465334f39b1eb1623b8138d52_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctOC0xLTEtMTY3NjY1_9f21afb0-467e-4e4d-85c3-3570e3c93918">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28c44bf664d40ecb1b0a3e548f23981_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMTAtMS0xLTE2NzY2NQ_d5cc2871-1272-4fce-bf8d-bf015684d8a0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59e34f35279744a9b950cebad2d0bc39_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMTItMS0xLTE2NzY2NQ_e4dd746d-163e-4167-a485-552bac99db62">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09871c6ba3ae431c998271ba08136fe8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMTQtMS0xLTE2NzY2NQ_f7f325c5-408b-49dc-bf2a-989f6339f3a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4170b5c1c1714d8f920993b6d2262d02_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMTYtMS0xLTE2NzY2NQ_156c5770-d47c-4dbd-9bd7-49a86a07d137">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6523d67294b4f8981a8e945c6b20785_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMTgtMS0xLTE2NzY2NQ_8a823840-1263-4ca6-9efb-d2d161e7077a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f3c5b346184ba1b39b0710a6321e5a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMjAtMS0xLTE2NzY2NQ_ac1af59b-5143-4970-97c9-db8ad655e73f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d36441d753401c8d6ec0475559e780_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMjItMS0xLTE2NzY2NQ_4c09a757-3741-4846-a3da-4a180d38c7c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed527ac9bdd4205809a16ca629aec11_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMjQtMS0xLTE2NzY2NQ_b41227a4-9bf6-4f53-bd37-f49d806d31c2">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9466b57eba44278c2bc11a50ea844e_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMi0xLTEtMTY3NjY1_841680b4-5e61-4505-8ba0-06daed7f1235">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd2376deb7144bd59b534ed53871b5ac_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtNC0xLTEtMTY3NjY1_c15e5399-f480-471e-96a2-137b1d70ea64">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60812f2148b74064ae4b10afc339abc3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtNi0xLTEtMTY3NjY1_e18cbb0a-648f-4117-9038-990c50a2a3b4">441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b257573b924383a6fd7a367622f923_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtOC0xLTEtMTY3NjY1_34aa299c-bf66-40cf-81d2-9d102d1ab395">988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21e023844a745bb8a3684cb9d194638_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMTAtMS0xLTE2NzY2NQ_5bdc934c-9e24-4a6a-a2c2-a52a42340810">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idab285af921e41088931c917d2518003_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMTItMS0xLTE2NzY2NQ_7a6ad582-9eab-4257-be29-8d09ab1f2eec">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39beed2eccf74622bbc506893a5c1069_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMTQtMS0xLTE2NzY2NQ_2e18524b-412b-4d99-a0cf-d7f9e4e364d0">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4047a0aafd81455d991a4aeaa945def4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMTYtMS0xLTE2NzY2NQ_b8e68167-ee30-4502-b0a7-a511b76558c1">969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af0ff053a604ab5bda65ff903d0e784_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMTgtMS0xLTE2NzY2NQ_9bfa28a2-c212-4cfd-9aa1-cdd386e558d6">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0570a9882284918847527738da8a490_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMjAtMS0xLTE2NzY2NQ_ba1661c2-a087-4db2-90a2-4dd24ab0fc57">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e1f9c9a4fe47a7bc9cbb56ef70b24f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMjItMS0xLTE2NzY2NQ_94e9bb2f-fdf0-47ba-826f-4759139a9c93">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7868f7368c3486d82227cdcaa76a33d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMjQtMS0xLTE2NzY2NQ_5bbd62c3-81c2-44df-a17f-35437da6b204">860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cell therapy </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d7e48b21f4489189057ca3a20ee5a6_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMi0xLTEtMTY3NjY1_7499048d-4fb0-423f-8df2-6fb6da23cb07">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552a5e98cd894d1f82b630e62cc1d7fc_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtNC0xLTEtMTY3NjY1_2d825125-6d35-44f7-ab39-234325852f24">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d02401452d436da34605e1e142fa23_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtNi0xLTEtMTY3NjY1_5beeab56-8a84-432b-a84d-cdeb42fbfa76">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c3adbab8d849c5b912381e32fd4668_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtOC0xLTEtMTY3NjY1_63903fe8-ac59-454e-b51b-3a6c43a19bc4">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb8d3f9aaf646d1ab94c2572cad9d97_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMTAtMS0xLTE2NzY2NQ_7dff59f3-70db-4a45-804b-9a391ab5f694">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd11072ce9b8438f822f1f5b0f101e9d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMTItMS0xLTE2NzY2NQ_753d7c27-56a5-41d9-ab6b-3406a67b46d7">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacbf61077d141f49fe6cfb43f3d6a64_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMTQtMS0xLTE2NzY2NQ_d578bb2f-91e3-4aba-a0a2-58140c58f0ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia435f9794a6b429f9e917b58fca423ee_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMTYtMS0xLTE2NzY2NQ_64a57eb6-7e17-4ecf-b4fc-ca3e72fe7953">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec37e2e6ec1a42e0a68b48238a81f664_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMTgtMS0xLTE2NzY2NQ_800e5ace-db88-4ee5-9ab4-276898234610">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36bfd55ed5a14a94977376f9736657ad_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMjAtMS0xLTE2NzY2NQ_d55b2dc7-4159-4dda-990a-60d3f7d41939">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9976f07ed0ea4180a61ff830dd781cd2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMjItMS0xLTE2NzY2NQ_4e43424f-6dcf-4d47-8343-7a176384e25c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f3506be92642258438c218c9fefcab_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMjQtMS0xLTE2NzY2NQ_7b72cf06-ec31-4e7a-a6d1-ebeef6d4c9d5">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc7adbea5d984ceca881d04a7c590ecd_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMi0xLTEtMTY3NjY1_97bf9295-5fe1-420b-b2f5-ee525b7bf07b">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic98c35b70a6d4caa9097cbd03988b94b_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItNC0xLTEtMTY3NjY1_1525a7fa-87ab-40d7-b431-722040ed8c2e">355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bbf122b5a340cd9c41944387fcbf26_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItNi0xLTEtMTY3NjY1_4598cb32-400f-4df5-be56-6da79448ad92">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8be13c495ea743bdb150e8a637348840_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItOC0xLTEtMTY3NjY1_7020e8c3-1408-4e8c-a7a8-74427e652d00">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f58bf4910d04410b4d8f3dee38fa563_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMTAtMS0xLTE2NzY2NQ_4932a047-b32c-44af-9557-df46a12a7d3a">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74057d7eaf294ff4a1f0ee3ed98656e9_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMTItMS0xLTE2NzY2NQ_d343ab9e-2d7e-49d6-adb2-30aee184e9ff">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b1203b4aa444780be9b251625ed241b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMTQtMS0xLTE2NzY2NQ_9746d5f8-d403-4822-9b99-1c5bdb2ac899">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1cdc8fffbe411cb0781c91d13f40bb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMTYtMS0xLTE2NzY2NQ_3cd0f3ab-f24c-4edf-81da-860a9a323e19">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eae0aa7e3b54e74ba47f8e7d11af81f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMTgtMS0xLTE2NzY2NQ_1480ef5e-044f-4a69-9c43-399f527f8999">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71b57df694f24969abcc922725bd4116_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMjAtMS0xLTE2NzY2NQ_6f11a772-7414-4362-8f8d-8ec38a00a828">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4309bba638742288a3c3b3411782a64_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMjItMS0xLTE2NzY2NQ_cca5b219-b5b4-45c3-865e-4c1d607c3e72">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68db9a0ea2f4c7390ec4cbc6e024d62_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMjQtMS0xLTE2NzY2NQ_154a79ec-aac6-411a-9a54-d5c0d21ce06f">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total cell therapy </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f98a55a88cd4ff9a94405f8df480139_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMi0xLTEtMTY3NjY1_17c7e026-b31e-4d63-ade8-c6fd243c79cc">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10627c2c5eaf4c4a93e8853d80712680_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtNC0xLTEtMTY3NjY1_ed826572-2747-4d2c-a82c-971194e4df82">430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e0f9a67dff1450ea9e2f3abed91dfde_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtNi0xLTEtMTY3NjY1_5b7834d5-d7a6-4c89-94b5-a2730881474b">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bec111f16ad4191913cb9e0707b68d3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtOC0xLTEtMTY3NjY1_01cb5449-3329-4b07-a154-473265d29f13">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda1937d0695488d92eca8410b6b5ad0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMTAtMS0xLTE2NzY2NQ_d9993bc1-5a6a-4272-8597-3caccfee203f">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id43ed2f32ec54108b2052f7c81e8dd87_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMTItMS0xLTE2NzY2NQ_d46e5076-d409-44f7-b00c-120bb94ca226">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e173b6e94784412a1a9aba6693632f8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMTQtMS0xLTE2NzY2NQ_ea465efc-2628-4e0d-b928-c51a007ee931">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f103fc96db43f9871d8821af37e8d6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMTYtMS0xLTE2NzY2NQ_8fd91326-ff16-493e-9df4-0f649059b9ad">871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe90cf240bcb4039827d8ae3729b5f78_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMTgtMS0xLTE2NzY2NQ_ee60d5f3-c459-442d-8432-f312007f8e6a">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ea8631b9b348fc98164b8455c586a2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMjAtMS0xLTE2NzY2NQ_b0595877-ce8e-4e25-9a4e-183f6bc9b019">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dcdd667a914130ac7f247f5ab8e970_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMjItMS0xLTE2NzY2NQ_0408c722-2312-40a3-84b0-d672274d2fd2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c68ef9e2c94e88bc900f8445716b7f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMjQtMS0xLTE2NzY2NQ_fa0342a5-09e6-402e-9b6f-21e5dd2e6ef6">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15ca9a88790b41dab9dd09539fbfc66b_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMi0xLTEtMTY3NjY1_6b3d9b3e-1edd-4d93-883d-73818ba986f7">525</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cc8f9b08eb949459f8922ebc6ecd590_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtNC0xLTEtMTY3NjY1_e915bd3a-1374-446d-accd-0a03012569be">143</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d6f24068e64a7bb2e161b0ea089deb_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtNi0xLTEtMTY3NjY1_e78675c6-ca86-4300-8329-aa25abc9afa6">12</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie547a0920cc34aff9876297ca28ab3cd_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtOC0xLTEtMTY3NjY1_3337f757-8d5e-4546-845e-6d356e54a87d">680</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9409f8c5614f464cac6ce5449dfc8a91_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMTAtMS0xLTE2NzY2NQ_83c4396c-0a32-4698-81a0-c63dd9fc8420">370</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca6cbf239d149448f38489f25c6ac14_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMTItMS0xLTE2NzY2NQ_4c763554-2731-43e2-af04-fc5001b26785">10</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b79faef45f4559baf646714298411a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMTQtMS0xLTE2NzY2NQ_81c2a3ea-7574-4393-9a6b-0d32730afe83">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb51c8c4ffd41489bda5887c0250688_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMTYtMS0xLTE2NzY2NQ_c4e82039-0f39-4c26-be5b-df9bce20fe40">380</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68234a1374f84b4b93207cb00261676d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMTgtMS0xLTE2NzY2NQ_204e24ba-eb8a-4bfd-a147-10adb06afdd3">49</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a896e7fa0ea4692ab85773273ce8925_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMjAtMS0xLTE2NzY2NQ_eed967a4-0f7f-43ce-abbf-1a377c6a13b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fd408517b934aa38aa102382fee39f7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMjItMS0xLTE2NzY2NQ_94189d76-13dc-47ee-ae07-ca8b9420345e">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i720140b50665423d9ecf9cc4d23c024c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMjQtMS0xLTE2NzY2NQ_3dfabc3e-da64-4f9d-9623-ce604bce6929">49</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d26f0693aed4c998637a007f2a4df73_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMi0xLTEtMTY3NjY1_e6ab6faa-f688-41bf-830e-2d2ff6615dff">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb9697cc7594310943f7cb04cffb997_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtNC0xLTEtMTY3NjY1_849598c2-655e-4ca7-b3a8-dbda9b03eafa">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3cca4b1510b45f0a81e6c1ee81cd735_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtNi0xLTEtMTY3NjY1_620b5fe9-aa32-4813-a667-de67ea866321">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f061fd85154f68a9a577619edb8cf3_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtOC0xLTEtMTY3NjY1_8f2c242b-c99f-4b68-b5e9-f55dda07adbd">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23c6213e809147e69336a3f6284317f7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMTAtMS0xLTE2NzY2NQ_8fe4154a-d15a-4859-a246-10cc9f6cbd1e">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id94a3128eb634eb9a869ba096d445597_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMTItMS0xLTE2NzY2NQ_a5cc1135-fec2-424b-83dd-575e0db32730">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie527ccfe78524f97b3646d01e7cdd88b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMTQtMS0xLTE2NzY2NQ_b177aae5-e04f-4609-b50c-3c562dce8d84">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab43b5a322744bf29d7a74c4096dac3f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMTYtMS0xLTE2NzY2NQ_a105ef09-f1e8-4274-af4e-f99f54bb0a45">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbdf5cd7eae14b92af352c6ab83988a6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMTgtMS0xLTE2NzY2NQ_a53324c5-d791-4ed7-9be9-37b76e7f816b">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a9443075964128a15a01c02e823b16_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMjAtMS0xLTE2NzY2NQ_8d8f3001-a5df-496c-aa6f-ba824ea31a94">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67c8b2793e440f6b65336fc0aedd433_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMjItMS0xLTE2NzY2NQ_9d31b681-442a-45cb-b18d-40904d1b3dea">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca680403c8f440e980e85b1a1536764_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMjQtMS0xLTE2NzY2NQ_f652dab5-0e3a-44b2-a133-4316cade640c">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ffac4669e6141d693435ad3d4c6baa5_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMi0xLTEtMTY3NjY1_6e6e9a57-9657-4b6f-9350-e71ac693d309">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e7eb9d47d3d45f1801328a82bcdb51c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktNC0xLTEtMTY3NjY1_738518d7-59e7-4088-9ad8-c93293f2b8f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79138071f14346498db0bdc4d20f7898_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktNi0xLTEtMTY3NjY1_98840739-7695-4234-baa0-1561008f87ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8bf0dc9d6014d1b82589f892ae08671_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktOC0xLTEtMTY3NjY1_d398394c-86ad-41f7-b69f-5b78b60230d2">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf42ac0f6b141f9b9a452ed3335a197_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMTAtMS0xLTE2NzY2NQ_c782bb1f-7d86-40f4-bd6b-386f5fada6d3">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22b869318548494b9e06efac2a33eda5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMTItMS0xLTE2NzY2NQ_992d9382-b648-4303-a9cf-54de3b3740e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d84e35cd15e4f45a75e3a912c6dc29b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMTQtMS0xLTE2NzY2NQ_93945747-57c4-4c28-ab81-6639571809d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a6ffb332c0e4d9fbb4397e67ceb91dd_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMTYtMS0xLTE2NzY2NQ_79b48999-5b0a-4477-9459-3e0671467372">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i738618c718414809ad145d0c367755aa_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMTgtMS0xLTE2NzY2NQ_a1a5e72f-cdfa-4b54-b077-d060af75046a">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icebf8365902241d8bdd0aa638c68bb3b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMjAtMS0xLTE2NzY2NQ_d478e3f1-665b-4d68-87f7-36099d7c0e52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62346343776542ffb3989e6fdfdb861b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMjItMS0xLTE2NzY2NQ_9e4c4632-b89e-4163-b41c-6ec2719a3980">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id85501d9727f4bd3a90aad68a5047f39_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMjQtMS0xLTE2NzY2NQ_d609a241-c15f-4913-9ce5-ab76a2e0c814">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7981271263a0497385c106ee1d8586d4_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMi0xLTEtMTY3NjY1_5b5e0d0c-8cba-4313-a70c-e47f39b79dec">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d9e7d23b4e44fca91e8f8a56cc640a_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItNC0xLTEtMTY3NjY1_d18d43d5-0830-450c-a433-3fe5baff0b87">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fd5efc4fbfd4d47bbea341757531be6_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItNi0xLTEtMTY3NjY1_58fcb52e-4285-4d34-9704-98edd26137c0">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6323c623d0145c9a4ab424c52f46d21_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItOC0xLTEtMTY3NjY1_9bcd36e0-7c34-4103-892b-cdd08cbc3837">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ac289724a141efb05295c0ae0c3206_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMTAtMS0xLTE2NzY2NQ_cb916b98-5a36-46a3-8967-9ac1483d4122">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbde1bd79a61473584fdf4a131ea0893_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMTItMS0xLTE2NzY2NQ_5ac136e4-05d0-4429-928a-789b9253da39">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5901b8ecd56a493aab74941a2b2f9e23_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMTQtMS0xLTE2NzY2NQ_0984f897-5fa2-4ebf-88cd-a7d4371fff15">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id160a09703b54e7685b93b162b95d162_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMTYtMS0xLTE2NzY2NQ_b245559d-4ea8-4c9f-88a5-990ba13ba4c8">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4729d87ad9f345eeadc62cb0f11ed0b5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMTgtMS0xLTE2NzY2NQ_dce5a9aa-8716-4562-a9cc-3411d1e8504a">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a427f3722a42e6afceb6d7c0ab324a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMjAtMS0xLTE2NzY2NQ_b60d0bb5-1945-4ab4-b992-bf5d4609f14e">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id402bd3c4ac1490b8201b3a308ef1e2f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMjItMS0xLTE2NzY2NQ_dcebbe65-004d-4539-9e56-bdaaaeccf0f5">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib847a11c1e7f4aee9f52682db5c1f135_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMjQtMS0xLTE2NzY2NQ_2f503bca-5b8d-4465-a263-2f6baf06f607">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91a7d5c54528430783128148bcd0b974_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMi0xLTEtMTY3NjY1_e7da6159-db89-451a-b32a-9e79f8c6f666">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e2f8a83b0f4ae497dc2e5c8ba4927c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtNC0xLTEtMTY3NjY1_d94acf53-5f86-4ace-bfdb-2b746c970162">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1777596b9e486a9e19ecb95f8684eb_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtNi0xLTEtMTY3NjY1_30440272-dc0b-40f7-afd1-7b9de85a6251">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0fa4aa3a554fbca7b6597772bae432_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtOC0xLTEtMTY3NjY1_a7bc4d8f-237a-4235-b448-4fcba88fe35f">946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b230c4abe241f88e888152fba0544e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMTAtMS0xLTE2NzY2NQ_ce628f2b-59c9-417b-b96d-c15e2bec1a38">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacf9afd500a448096edbd2f4cba2326_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMTItMS0xLTE2NzY2NQ_71ea0d50-195b-4067-a980-7b22fcd24952">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01748bbcf6c24a2e85eb82ac7163747d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMTQtMS0xLTE2NzY2NQ_a7d6e580-c8c7-407a-8cc9-9ac410720294">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided586c3fc76418f9cab15dce3540cb0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMTYtMS0xLTE2NzY2NQ_e9378492-fea9-45f3-927d-0785e5501545">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320ef6561a284511ac0240c964bc81a4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMTgtMS0xLTE2NzY2NQ_f4230767-7bac-4393-9dd4-64654f875429">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34d7b9624484238b55305a3f87daed8_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMjAtMS0xLTE2NzY2NQ_b2dcadbb-be2d-4db9-9e6f-b55784b80fa3">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30d9baceb6a430eba29fc86bed3e18a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMjItMS0xLTE2NzY2NQ_693ebf83-b36b-43c0-a533-018abdd63df7">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8000a2e754d4b178de03c4010ac094d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMjQtMS0xLTE2NzY2NQ_d0f6f66c-c6c9-4cd8-95f4-8e332e821d40">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i191031ec2f8340fe8c4d6783e97231cc_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMi0xLTEtMTY3NjY1_66010dda-6add-4555-bfe3-e3c0613c2cb2">18,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47cec898f169483d9a78d908ee8ac54b_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtNC0xLTEtMTY3NjY1_a57f5d86-33b5-458b-9d4e-6077157d5592">4,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c17ca18fe8b4685bc8dbff8b0024fca_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtNi0xLTEtMTY3NjY1_735774c4-e6fb-4e0e-86f9-f112fe97b02f">3,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5776967eec2e40169c93026e3f869e40_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtOC0xLTEtMTY3NjY1_a2f94323-1bb7-4c37-a7d2-7e1672698613">26,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c0214e29ea4b9282808e79f896a82b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMTAtMS0xLTE2NzY2NQ_57b47bbd-a0be-43dc-a5e7-3fd8be38e971">19,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i878929f1d5d34534bbf9576f56d5bffc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMTItMS0xLTE2NzY2NQ_81bba0c2-b0c0-46b7-b56d-91171c07f3c6">4,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca736187a154121b6128d87c38b83ea_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMTQtMS0xLTE2NzY2NQ_d09264e7-77f1-4bb1-8ea5-b565746dec26">3,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd0d2f0925f42e7889120dcf51249c1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMTYtMS0xLTE2NzY2NQ_8677190e-b1ec-4282-b93e-2cb41e3e4b64">27,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dbb6a36e59f4a65b7cd766dceaf5deb_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMTgtMS0xLTE2NzY2NQ_c3a7eec2-3885-4bd5-b845-5dd4bf8c38b7">18,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3463ced19f543a6b038efda28937ed7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMjAtMS0xLTE2NzY2NQ_37774d97-e498-4fdd-b10d-fca066b9ee2c">3,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice19479778e74f7f859404303e2642b1_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMjItMS0xLTE2NzY2NQ_00503791-45f2-46db-a213-81d28821072e">2,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i549c720f0be04d399b280dc53ff6498d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMjQtMS0xLTE2NzY2NQ_b55d71cf-240e-4cfc-9d34-ca06832a8161">24,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122092ce94ac4c349bc55b92090d0c7a_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMi0xLTEtMTY3NjY1_c3e09c4d-d709-4f7a-8f95-350f18eb0f22">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i895482d8185045179df5923b9434a992_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtNC0xLTEtMTY3NjY1_b948109a-12e9-4cd2-8c5c-69e3bd7ae433">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ded8cfb2f694a869b82b4f9ceb7481c_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtNi0xLTEtMTY3NjY1_810f48b1-29f0-4aa0-a6f7-4a9383bc9f52">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3009f1cc5994ac0949727e755fef6fb_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtOC0xLTEtMTY3NjY1_00fcb2c7-7c38-4f46-bfe7-cd910a7877a4">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0d53388f4d42a58ab06e6add14cb87_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMTAtMS0xLTE2NzY2NQ_09afb792-4a9c-4ab8-b31f-14337dac416b">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbff194d4ca5433aa7e19eed529284a5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMTItMS0xLTE2NzY2NQ_4cf9d0c8-d220-4352-a9b3-12d4abf9b6e6">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i343fb20119ca4a0e8613c7e22a4b527e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMTQtMS0xLTE2NzY2NQ_2167f1a8-9d53-4928-8b72-85c8f8c89c7c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fd731dcc7c6442d9eb015fc7f92096b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMTYtMS0xLTE2NzY2NQ_6905cd3a-7522-4a93-896c-eeb4ea38868e">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90efc3a95e5478c9d184b269d0ceecc_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMTgtMS0xLTE2NzY2NQ_775f1ae2-5bb5-4301-a785-ec06d02b931e">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794d6401fe294df8a2c8c5f381e7766e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMjAtMS0xLTE2NzY2NQ_62f377f0-b36b-4d45-a6df-4429e498e0f3">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98fd41f3a3ce4161bf06001545fb251e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMjItMS0xLTE2NzY2NQ_a5fecfe3-c7d5-4e17-a820-4185a7b495a8">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce29476464948ef99a1d86b1a2d50bf_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMjQtMS0xLTE2NzY2NQ_bb380e8d-a093-451f-9713-ff19521609aa">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie276f108be5d41f7bf6f6aec108cc38a_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMi0xLTEtMTY3NjY1_82e7478d-02d1-4644-8175-4bb5e11dec03">18,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbc48146b4d84e27bff9ab5d3c8388e9_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtNC0xLTEtMTY3NjY1_f636b5f0-6295-4860-a943-2a5c8dbc86ab">4,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83653adc14343229d0ecdf85dcc0b36_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtNi0xLTEtMTY3NjY1_11e366eb-1064-411a-8117-574904d62cc4">3,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtOC0xLTEtMTY3NjY1_c957b0d4-f80a-4b3c-9067-1b8d32dbfe03">27,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55695bcefff74f4a90f76506bacb48c1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMTAtMS0xLTE2NzY2NQ_fd2f77af-5502-4fdc-a331-7963613313f7">19,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44ec1db4248d428a8f326df992d5ba74_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMTItMS0xLTE2NzY2NQ_8d9bd720-5f8e-4a78-abf4-c5263942d61f">4,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5cf4c53b074c43b621eb8f8a9aa397_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMTQtMS0xLTE2NzY2NQ_4841b541-766b-4d53-908b-f156a4afd1b3">3,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMTYtMS0xLTE2NzY2NQ_f05cef92-001a-49f0-a582-05752f8bc1fc">27,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6943cae579d9493b901bd4c64167f279_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMTgtMS0xLTE2NzY2NQ_a431c02e-3a19-434d-b615-6792b3d152fd">18,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4906ad8453c4207b906de6e1a183a7c_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMjAtMS0xLTE2NzY2NQ_5d80b833-40cf-43f0-b2ff-be53815f69b2">4,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92af14de4d6e45c28faa18feca763fe7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMjItMS0xLTE2NzY2NQ_1422212c-f29d-4f7c-9929-2f172c20b03d">2,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMjQtMS0xLTE2NzY2NQ_446ab151-a0ac-4113-9494-970d1a0df6aa">24,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#8220;Janssen&#8221;). See Note 10. Collaborations and Other Arrangements for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes Atripla, Emtriva, Sunlenca and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes Cayston, Jyseleca, Ranexa and Zydelig.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i6fb76018d38d4debb76dc2d21223d8f2" continuedAt="iaf59319d60df486d9d618842dbebb7df"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenues from Major Customers</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMjUzOA_63ad05c2-3bd1-4ac4-aa6f-5fd794be195b" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:61.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.699%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.699%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86eb6bdf28e54e3cbf341a8b16bceb07_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfMi0yLTEtMS0xNjc2NjU_67148e10-1022-400b-a20e-ca97def49b2a">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0face3f5bfd147f59b55ecdd4534fa47_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfMi00LTEtMS0xNjc2NjU_f412fd95-4f9c-44bf-8410-bc34cc3eb254">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c332f0a85d243b0b2f856949a44e2d2_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfMi02LTEtMS0xNjc2NjU_eb25157a-f2f4-4242-947f-fb8438d34e51">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i28e35fde408143f1b5cdd3758261b912_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfMy0yLTEtMS0xNjc2NjU_5798e691-410b-449a-81a7-2a0e267cae89">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee00e346b51a47dca4aa5cc9604337d3_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfMy00LTEtMS0xNjc2NjU_8e929028-c889-4379-be3e-032bc9362b6b">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9e8f79ffaa54a4f8353a2e74e70d2fa_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfMy02LTEtMS0xNjc2NjU_170b435f-1ac4-4882-8dbd-c78a3c55b487">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib67a8beee1994fe2a9cfb4af6a2b4b81_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfNC0yLTEtMS0xNjc2NjU_359e04b4-d6a5-442b-9793-093fb4863926">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i133bd58bb3044e43b6e19b3c2019b2c9_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfNC00LTEtMS0xNjc2NjU_e1beaa29-7cb5-4da0-9f46-15f975e722ca">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b1a0954ab4c4c079b9fa4cff95a21bf_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfNC02LTEtMS0xNjc2NjU_99b24a6b-2ca6-47f1-b5e9-2e9fe0e00c65">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenues Recognized from Performance Obligations Satisfied in Prior Periods</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMTMxOTQxMzk1NDM3MTI_fb1b1af2-57e6-4a45-988d-cd0c357bd630" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues recognized from performance obligations satisfied in prior periods:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:61.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue share with Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and royalties for licenses of intellectual property</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOjg2ZDNlMjExYWU4YjQzMjBhNmY1ZjBhN2UwNGEzYzFiL3RhYmxlcmFuZ2U6ODZkM2UyMTFhZThiNDMyMGE2ZjVmMGE3ZTA0YTNjMWJfMy0yLTEtMS0yMDQ5Nzc_2fe69acb-4739-4eb6-9860-e358cc03cf6b">783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOjg2ZDNlMjExYWU4YjQzMjBhNmY1ZjBhN2UwNGEzYzFiL3RhYmxlcmFuZ2U6ODZkM2UyMTFhZThiNDMyMGE2ZjVmMGE3ZTA0YTNjMWJfMy00LTEtMS0yMDQ5Nzc_d99d6c46-01ce-4bcf-b314-6cb2e480dd20">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOjg2ZDNlMjExYWU4YjQzMjBhNmY1ZjBhN2UwNGEzYzFiL3RhYmxlcmFuZ2U6ODZkM2UyMTFhZThiNDMyMGE2ZjVmMGE3ZTA0YTNjMWJfMy02LTEtMS0yMDQ5Nzc_aedaf745-956a-41e4-9fc4-d53c8b291264">841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOjg2ZDNlMjExYWU4YjQzMjBhNmY1ZjBhN2UwNGEzYzFiL3RhYmxlcmFuZ2U6ODZkM2UyMTFhZThiNDMyMGE2ZjVmMGE3ZTA0YTNjMWJfNC0yLTEtMS0yMDQ5Nzc_c382604c-a102-43c7-be24-c7be522697c3">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOjg2ZDNlMjExYWU4YjQzMjBhNmY1ZjBhN2UwNGEzYzFiL3RhYmxlcmFuZ2U6ODZkM2UyMTFhZThiNDMyMGE2ZjVmMGE3ZTA0YTNjMWJfNC00LTEtMS0yMDQ5Nzc_f572a1ee-310a-423c-91ab-2a84ca0459fa">856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOjg2ZDNlMjExYWU4YjQzMjBhNmY1ZjBhN2UwNGEzYzFiL3RhYmxlcmFuZ2U6ODZkM2UyMTFhZThiNDMyMGE2ZjVmMGE3ZTA0YTNjMWJfNC02LTEtMS0yMDQ5Nzc_08760180-18cc-4a38-98b0-36f1e59d7b53">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 10. Collaborations and Other Arrangements for additional information.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contract Balances</span></div></ix:continuation><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaf59319d60df486d9d618842dbebb7df">Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMTA5OTUxMTYzNjE5Mw_e0a2bef9-96b1-4170-984d-3e80c5a8f40c">171</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMTA5OTUxMTYzNjE4Ng_06500c02-7409-498a-acb4-3c89f3d7014a">174</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMTA5OTUxMTYzODExNQ_4678f705-6461-4bb7-b7a4-123de810f95b">102</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMTA5OTUxMTYzODExOA_02e5ab10-8f52-4a05-8b74-ed3095096b52">79</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfNzg0MA_3f9ceae0-c84a-41a6-be7d-09dcc9389b3f" continuedAt="i7c9b426ef48c4b24bcc047a35c6e674f" escape="true">FAIR VALUE MEASUREMENTS </ix:nonNumeric></span></div><ix:continuation id="i7c9b426ef48c4b24bcc047a35c6e674f" continuedAt="ic6595f90027b4bab9460abdbe19dbe4f"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfNzgyOA_0b4f1b8a-297e-44db-a499-53fd208430e9" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: </span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c34d1a31564a41b639cee23ce6e2a3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC0yLTEtMS0xNjc2NjU_869219cf-d25c-4eb0-afa2-3b1d8c0625ec">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf9113abd39d46f397a0870bd4c9cdc8_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC00LTEtMS0xNjc2NjU_8fad10bd-4792-4873-b93d-ad3eb465ed51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bee5e30cfa2426f9d380bc5925fcac9_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC02LTEtMS0xNjc2NjU_b2fd33b0-783f-40c8-a8e9-a2460c572a3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cfca0b59b604750a7f306bd9362a183_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC04LTEtMS0xNjc2NjU_7bbdff6e-c8d8-4b8d-a8fd-1423b91fbb6d">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c99e845b70436ca2df28ab68166418_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC0xMC0xLTEtMTY3NjY1_d7544d70-c865-4374-b7d0-41549d342245">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a483101b0c448358a8bd230e176fff0_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC0xMi0xLTEtMTY3NjY1_7d187e74-308e-4c93-9d4d-da5da20ad727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3808d9c4a2e146bc9d87fcf438476f8c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC0xNC0xLTEtMTY3NjY1_bfde0625-a3f8-4351-8d46-94852d919363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf751057be34c59b162ff5ec611226d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC0xNi0xLTEtMTY3NjY1_7d02e998-3e31-4eeb-b9d7-9160c66a79b2">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad0ba308ad04f38a0ff215fa0aacb6f_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS0yLTEtMS0xNjc2NjU_09a1ec28-4d5f-43c0-be9b-3ce351c74454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c405fdc93ac4546907dd695172e2ce9_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS00LTEtMS0xNjc2NjU_7c7c7b8c-481b-4713-8bb2-2b6f8070bba2">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb6db70d966741b8be2616a8bd67d2e8_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS02LTEtMS0xNjc2NjU_e3a4b2ef-b361-43a8-9113-910c9f6e1e5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd515e9c1c6b4b0b8621d96b2531c80d_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS04LTEtMS0xNjc2NjU_74700481-e8ad-4dfd-a9f2-ed27ece0894a">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3dcf159fc7b46349235521b48359fa2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS0xMC0xLTEtMTY3NjY1_1f796aa5-1843-456c-82bd-718e90fbdf5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20ebe72fb6da4c999fc461851f94ee96_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS0xMi0xLTEtMTY3NjY1_c69ce711-65c6-4366-9b9c-a69a7874e867">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2478182a4b4e4e1487d776c80659bc45_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS0xNC0xLTEtMTY3NjY1_5ecf41c6-babb-459f-9c26-a6b3ca81bd9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdd0a17887254d5a9c770861de71e83e_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS0xNi0xLTEtMTY3NjY1_4c62be33-3dd7-476d-a2e9-c764a5a4c774">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie157b97ed1b142c8bfb14e1fcd0d779a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi0yLTEtMS0xNjc2NjU_fb22c4f4-5553-456c-918d-8eb643ab14b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37f394996de54d9db35d84fd2f8d9ef7_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi00LTEtMS0xNjc2NjU_b9ea8cb7-d20f-46a6-8fa3-7e21f0c72c7b">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3900a5a96df424da8d5920aec948465_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi02LTEtMS0xNjc2NjU_22bb391f-1136-4763-a99e-49eb871c3587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4bdf8861d83422885dbc7a9b650a26b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi04LTEtMS0xNjc2NjU_eb9c6503-6272-4562-bab3-faa5eff1541f">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib91c1acddeb04eea8c21245a6b6d170c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi0xMC0xLTEtMTY3NjY1_7df58ee8-79b5-4b38-84bf-901aadf20d82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45d2c331f304e139eb2373b4aeea8ac_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi0xMi0xLTEtMTY3NjY1_c611d1d5-2e9e-4b8b-aef6-cb5303db4e53">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0983c44cb0734541a17aa9caaa5ab892_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi0xNC0xLTEtMTY3NjY1_d685c696-8bcd-45d7-9d6c-fb4f4ee40c4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cb3270aa34d4ff1b804ace86710f83c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi0xNi0xLTEtMTY3NjY1_b436460d-d40e-405d-a84a-dda7490ff17c">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94f769c7f244c9e88d0a8e925d81a3b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy0yLTEtMS0xNjc2NjU_a0ac2ec5-13ee-4424-8438-d62ee439ae76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488df48c29e54b3593d5488e3d330c61_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy00LTEtMS0xNjc2NjU_15ae8222-f3da-4974-ad20-30495ed110fc">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db63b134cb94dcf9570583d7adafdf6_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy02LTEtMS0xNjc2NjU_3f9596d1-957d-4d99-a49e-bae5c27983f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa4ad0ad8aba4b84beeeb124f4ea9111_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy04LTEtMS0xNjc2NjU_056e633e-f529-44d2-8541-15bc3fc3bc9b">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea779af859f47d89962f097d7265f0a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy0xMC0xLTEtMTY3NjY1_3ba930e4-0683-4c01-878e-2448888ab43b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd1b17c5a8674218abaf2a1683840aaf_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy0xMi0xLTEtMTY3NjY1_57f2ccc6-1be4-421f-b112-a331ff6111cf">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i618bd4f52005481f8b9ee51618d178c1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy0xNC0xLTEtMTY3NjY1_272b7c36-d4d6-453c-ad96-c30d4d752b2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf59e9f2f2d4d67b113295c7b4d1089_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy0xNi0xLTEtMTY3NjY1_38205a07-b0ff-453f-b9a7-3036b9f8e515">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4374b3f59dcb41f88c069c68eef7cb1b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC0yLTEtMS0xNjc2NjU_be0dc90c-84b0-43d4-b8dc-7b11171ffb81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcb3258e37243aa808a6fa8be5a770b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC00LTEtMS0xNjc2NjU_5510de87-18a9-4300-a1e7-9984ab52dba2">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47bca5eb2de4839b8e148ae5a0de84f_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC02LTEtMS0xNjc2NjU_219467e4-c4e4-4559-a10a-7e8e7c3602c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4eb920885a343a481088353353f3232_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC04LTEtMS0xNjc2NjU_ea3006c5-e10e-4070-af04-d1a01b72129b">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88ec60685e024c9a9d982e1a4ff3ae64_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC0xMC0xLTEtMTY3NjY1_9adfcfee-2fd8-48c0-9981-8fc43da41a54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if92841c2bf314e908654618e08167aba_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC0xMi0xLTEtMTY3NjY1_1749ac25-03a5-4f64-9369-6a48d7e22965">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i773b7fbb6ae64c61836fd54bba47d25a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC0xNC0xLTEtMTY3NjY1_e54ff0ba-092e-4a29-80c6-d1a165550275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bf409fd77ce4f9a90bb11514b042cff_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC0xNi0xLTEtMTY3NjY1_f01510fd-e3c4-4944-8e47-48bf1dcbc9a1">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018a6b73fef648df813ad16b7e2eadb3_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS0yLTEtMS0xNjc2NjU_b95d7633-043f-4e10-96cd-4745505aa86e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07414abcd214485880e84c068a03395f_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS00LTEtMS0xNjc2NjU_8616656c-5742-4315-a6c3-25e403129ce4">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19dd55d40234f4aa0cb87ba2849918b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS02LTEtMS0xNjc2NjU_d4bba44d-b48b-4d63-892e-b37f9e47fa02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2a4623b8824759a123ab21bf6411c1_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS04LTEtMS0xNjc2NjU_fd544916-9aa8-46cd-b9d3-d031e5d4c56d">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib084fcedcc844984a042bbb471e335d0_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS0xMC0xLTEtMTY3NjY1_4ff240ce-8b05-4b5b-82a3-3f9d7d89f8e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i099761b72f8945b5941d06a0e1567729_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS0xMi0xLTEtMTY3NjY1_1fb52e21-e60d-40cd-abb3-19be5f901060">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fcf55829c924deebe56a00be5ac0c2f_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS0xNC0xLTEtMTY3NjY1_0ceea604-0e16-4ad4-97fe-080dc057b943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf63565ba06a41a18d32952215669dc5_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS0xNi0xLTEtMTY3NjY1_c8b391e3-765a-4e15-a30f-d531a7047a8e">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e733fc488aa402d8d8717e0955e5672_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtMi0xLTEtMTY3NjY1_ea1bafc3-0394-4e41-be33-4be18d1fc909">3,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7e16303ba004af899fc51df2e60f7da_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtNC0xLTEtMTY3NjY1_0ffef966-df94-4642-9c7b-bf36aac16d07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02675adb1f704219bbfa6df72958ccf9_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtNi0xLTEtMTY3NjY1_f75104ae-a306-4c0a-8e34-8b4957c7d007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14516a4cc9c4cf4b87bc4e6c89da010_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtOC0xLTEtMTY3NjY1_3337784c-dc19-4b32-b706-875ba466037c">3,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i944a69baa46241a78832dfd6edb03619_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtMTAtMS0xLTE2NzY2NQ_f24816f9-aa63-4b80-9736-8007f3c45aa4">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e8996fcf904aefa7b45eb05d8a1b9f_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtMTItMS0xLTE2NzY2NQ_85c7ed0b-a75a-49f6-b7a3-ef1524319380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41782720cc44450d8ecfa13b2c8eba6a_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtMTQtMS0xLTE2NzY2NQ_d9f3fa94-0d7c-4680-ba1b-5283eb097fa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39ea15b99df04bd1a91357ea2c784fb1_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtMTYtMS0xLTE2NzY2NQ_6d604c0e-020b-4eac-9a4e-229178621070">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos NV (&#8220;Galapagos&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5c4c24154784954be6af020baa2783d_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItMi0xLTEtMTY3NjY1_dd292c2b-1808-440f-ae49-d19d8daf28d0">736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72d0c8e59074c399a7a8d5de4a0d84c_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItNC0xLTEtMTY3NjY1_2c219b6b-1502-4b94-b9e4-fa19bfdb7bfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69dc8a4d00924a239a188dc5ae14f7e8_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItNi0xLTEtMTY3NjY1_3c02a36a-8d91-4fb7-bb8e-f99b8d3359cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6ab0f463354216aaf151d6b3782c66_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItOC0xLTEtMTY3NjY1_5ced05d1-af10-46ca-a7c2-f8f89cdcb630">736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb19fd2013648c5b7c1b740c697a80f_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItMTAtMS0xLTE2NzY2NQ_1a9a6ccc-0681-4d39-8fe0-175eb0560be9">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1382e07fb1b3414fa219beccffc330e3_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItMTItMS0xLTE2NzY2NQ_8de0924f-bfbe-489c-a134-1b57b815af75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cda06ee09b140cb827aed9e1a3df8bf_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItMTQtMS0xLTE2NzY2NQ_95782666-0193-4169-b28b-17095078187e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f5633d790d049eb8451a5b270d77750_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItMTYtMS0xLTE2NzY2NQ_75472aa4-9c79-4f3c-bb03-6ff883fa4892">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3cb02615a94f4a8ceb1be0e567f340_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtMi0xLTEtMTY3NjY1_9e270e66-88db-470a-b66a-acc72be0761a">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d43b6e593fa4c628617fc5b9f8381e0_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtNC0xLTEtMTY3NjY1_81d2e08a-66b6-4946-a41a-644f3d8ab327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca783d57092471f8f9c2a0e850ac09c_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtNi0xLTEtMTY3NjY1_dc0fcf9e-f4c3-43fd-9510-f436a59b7c4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea06efd22dd4661bfb5cd9adaff66df_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtOC0xLTEtMTY3NjY1_6bb74321-3f34-4911-96b6-72efd53baebc">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89553c3611c4e288ce130b8d3ac5113_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtMTAtMS0xLTE2NzY2NQ_eac93ce7-5e9c-4a87-a3f3-7d6a8ac55174">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08fcddcda0ac40758fc2ee38e6741a4a_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtMTItMS0xLTE2NzY2NQ_5c52847d-bdf2-43cc-9353-73ec81d294ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f315354a63246aca5ced4ec8972897c_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtMTQtMS0xLTE2NzY2NQ_1d866973-5d50-4ca0-acfb-99c57d14dd68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i327c843055444377ab16bab2849e6c00_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtMTYtMS0xLTE2NzY2NQ_7a46a3dc-cbe4-4001-9615-431c28d2412f">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide95ae75ed8c423695c053ecd6b2da97_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtMi0xLTEtMTY3NjY1_57c0357c-b57f-4e83-b666-1818d977a814">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd60b83d9abb419d9f60987e3d02e8cd_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtNC0xLTEtMTY3NjY1_f9dc5f4d-a738-4ac5-af5f-6d43badab813">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894b79ae5fbe43b2a34999235fe34725_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtNi0xLTEtMTY3NjY1_6cd84751-a31b-4b2c-98b3-ecaa20bad567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i983c7f539ca14293b59e2fe55bbce4b0_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtOC0xLTEtMTY3NjY1_01c175be-0a56-4fe1-90b4-6e7483092ff9">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6894a7e98f4519a8f9e29d935836aa_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtMTAtMS0xLTE2NzY2NQ_3d1f4b4a-de7e-48cb-9752-674cc94a4b6c">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a77b8962a7b4133b9c80ea7b093866e_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtMTItMS0xLTE2NzY2NQ_f8002dcd-e7c6-4344-926f-ce99980267ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff764d89cbbe483ba2bacb34b6224c68_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtMTQtMS0xLTE2NzY2NQ_83b3fa63-2596-4493-ad25-403d696e0e6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb43dd0a466b491faff2c751f3a877c9_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtMTYtMS0xLTE2NzY2NQ_f26e8035-79fc-4dc0-86d3-1e2fd38ed592">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d985d4e3d9474ebcab3db7e6a6ee15_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtMi0xLTEtMTY3NjY1_2bbb7370-031c-4eb7-bf4d-109030963e70">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21959734d0a54ddcb46382c2339b2f8c_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtNC0xLTEtMTY3NjY1_0d39ac8e-e758-4781-9d3a-38b7b120d3c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib378be3a5b704e4ebb3dc87fcddff125_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtNi0xLTEtMTY3NjY1_08e06dd1-d869-4642-8f0d-3ff82bd70ee0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9701ad4aac1b429ba132c36256901aa8_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtOC0xLTEtMTY3NjY1_39951f47-4251-47e7-95d5-76494517397e">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86d573d5c055472aa3815285608a7bfd_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtMTAtMS0xLTE2NzY2NQ_70f16f1d-121c-477e-b1c0-9f36f8b1068a">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ec8cf5f17e4fc1b6fbc896b8b377f5_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtMTItMS0xLTE2NzY2NQ_c834794e-b525-4ea6-834d-a4c5a90abaab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89123ef0fcf45cebe2871f98a115ee8_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtMTQtMS0xLTE2NzY2NQ_ef05455b-0a88-437e-bf84-547dd8631d69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e6656d2b2349758ad1672abcde5f04_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtMTYtMS0xLTE2NzY2NQ_1b320656-2904-4ad7-92c5-8e5538938982">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3056f9b6e43746a586f484704ba24280_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtMi0xLTEtMTY3NjY1_386c34d6-e6d2-4906-a9cd-439e15275bcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i177d34f888fa40768c93e77bd471d6ac_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtNC0xLTEtMTY3NjY1_b2c80763-4956-40a3-9938-7c34d908226a">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1408e9098f40baa057cd1cfc7888f5_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtNi0xLTEtMTY3NjY1_a19a7d11-0634-4116-8959-73d01329aaab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce378a3eb1f4ebba108c7b8e6e3fd0b_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtOC0xLTEtMTY3NjY1_cc07fab6-464c-493e-a32e-49dda4bf5050">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib233c60e47c6477a9eb3e08f380cda48_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtMTAtMS0xLTE2NzY2NQ_a80d4556-3f90-41f4-8e22-555e7bb919b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b61ed2454aa4bc2a404ffa25a550770_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtMTItMS0xLTE2NzY2NQ_21367340-0ec7-436b-bdc5-1a6c3a540e2f">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4adf40d5824c4fbe26cd8dcbfbf227_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtMTQtMS0xLTE2NzY2NQ_59db7701-c104-409b-94c1-c09b56a45d0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie454a27fc82f4874b5cda233495e0206_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtMTYtMS0xLTE2NzY2NQ_23c0bab1-6719-4203-9eef-40cf8db12201">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie78f1ffe90f34e168923153a6356d08e_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctMi0xLTEtMTY3NjY1_6afef008-f26c-40b3-a2e3-26f4a6290a06">5,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9bc9ff381a4854850cbd8345981bc5_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctNC0xLTEtMTY3NjY1_376a5460-36ab-47d2-9657-4d7e4275c85a">1,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3770d09680134e1792a2afb46bb64c8a_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctNi0xLTEtMTY3NjY1_10fdad66-0310-4d1c-a3a0-33880fff210a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258640a7c57747aeb519ee9e07186999_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctOC0xLTEtMTY3NjY1_a9c4a984-d916-46c8-ad2e-ffa7e6c7d093">7,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39c7630058f7482b8663c73873f905cf_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctMTAtMS0xLTE2NzY2NQ_b38101cc-a1b8-454c-99f1-284835fd1a25">6,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if091fd24a2e744cc84af3abc98b8f3f5_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctMTItMS0xLTE2NzY2NQ_f7073205-94e8-4417-8299-119bef9141da">2,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14bcf8248ac4a89ac301d6111091e59_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctMTQtMS0xLTE2NzY2NQ_9b7d01bd-55ec-43b8-b4e2-2a72ac1d4588">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd2083018754b229660065eb3c2d886_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctMTYtMS0xLTE2NzY2NQ_d3e1ccff-f2f0-4c38-8aad-3f1cc83a8cb4">8,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb7080a46984104933ddc77a231978a_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktMi0xLTEtMTY3NjY1_8308f67d-a92a-4868-948d-cf06c9ed9428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2c198018764025b669a401e4b72f02_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktNC0xLTEtMTY3NjY1_d7f9f0d5-e694-4a95-a15d-87bbbf8fd0c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccefd6d5263c4c06812886b75ec30089_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktNi0xLTEtMTY3NjY1_2a792249-1fa3-4ac9-a2c7-75d1b3004ace">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca5b496a82144a99398868f529cc733_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktOC0xLTEtMTY3NjY1_982352e8-d8e9-4ecd-888c-42465879fd6b">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d0914f5c72425b8a8d68428082805c_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktMTAtMS0xLTE2NzY2NQ_2dbff62b-9827-4418-9075-bc4e45e6aa7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcaa8320537e4f41a1cac571eb1d4c4b_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktMTItMS0xLTE2NzY2NQ_32dc0019-5041-4c37-ac71-999c9e9dc37b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ac85363bb5744b9a9f23b5639f332c9_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktMTQtMS0xLTE2NzY2NQ_58690734-cd32-435d-b390-410aace59ea4">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedbbc78ef8e242f2b89fc61cceca1611_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktMTYtMS0xLTE2NzY2NQ_3401ddc4-2fa4-4991-bfbc-0bf7ccbee662">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d985d4e3d9474ebcab3db7e6a6ee15_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtMi0xLTEtMTY3NjY1_fc55e3cb-03de-4c5d-bd51-679abc8c94f2">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21959734d0a54ddcb46382c2339b2f8c_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtNC0xLTEtMTY3NjY1_a11f31c7-cf17-48bb-a6df-8860dbcf4b72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib378be3a5b704e4ebb3dc87fcddff125_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtNi0xLTEtMTY3NjY1_5480c245-5c76-4bc5-bf39-f51e08c0a512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9701ad4aac1b429ba132c36256901aa8_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtOC0xLTEtMTY3NjY1_d23d0d0f-c123-477e-97ae-e113d9d25237">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86d573d5c055472aa3815285608a7bfd_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtMTAtMS0xLTE2NzY2NQ_4c1ff52f-aea8-4a5a-b169-49df7b7efc5f">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ec8cf5f17e4fc1b6fbc896b8b377f5_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtMTItMS0xLTE2NzY2NQ_846209e1-cef0-49ca-8686-5475361fbc7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89123ef0fcf45cebe2871f98a115ee8_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtMTQtMS0xLTE2NzY2NQ_3ce5d923-a74e-4161-9552-f2126e02c037">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e6656d2b2349758ad1672abcde5f04_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtMTYtMS0xLTE2NzY2NQ_e6c415fe-346d-403c-b9b9-327c497a278f">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3056f9b6e43746a586f484704ba24280_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtMi0xLTEtMTY3NjY1_cba46e10-1dba-4866-ae09-455b87935b3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i177d34f888fa40768c93e77bd471d6ac_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtNC0xLTEtMTY3NjY1_85696489-210d-489b-bf38-1f1c6d63d258">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1408e9098f40baa057cd1cfc7888f5_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtNi0xLTEtMTY3NjY1_d34d91a9-16b3-421c-a621-d931dad86a95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce378a3eb1f4ebba108c7b8e6e3fd0b_I20221231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtOC0xLTEtMTY3NjY1_c8e6723f-b069-4881-a4fe-9a127514b8fa">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib233c60e47c6477a9eb3e08f380cda48_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtMTAtMS0xLTE2NzY2NQ_74931c87-88aa-41d2-ba97-6bc0bc57b1c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b61ed2454aa4bc2a404ffa25a550770_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtMTItMS0xLTE2NzY2NQ_08227898-4f48-4b82-93db-3b67258fc1ef">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4adf40d5824c4fbe26cd8dcbfbf227_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtMTQtMS0xLTE2NzY2NQ_d0ebd856-c216-4ef6-ad1c-ab788ecf5e59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie454a27fc82f4874b5cda233495e0206_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtMTYtMS0xLTE2NzY2NQ_00b3f51c-b986-4a06-b03b-5393e9ada7f8">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie78f1ffe90f34e168923153a6356d08e_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItMi0xLTEtMTY3NjY1_12120f28-0c8d-4445-961c-be7ecf93dc4c">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief9bc9ff381a4854850cbd8345981bc5_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItNC0xLTEtMTY3NjY1_cb803adb-91e7-45ef-bf4a-31fa7dee8cfa">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3770d09680134e1792a2afb46bb64c8a_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItNi0xLTEtMTY3NjY1_e32136cc-75c1-4498-ac0f-30ea8c422acd">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258640a7c57747aeb519ee9e07186999_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItOC0xLTEtMTY3NjY1_b0eee1d3-e0cb-4ef3-b912-8fd22d019a9c">538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39c7630058f7482b8663c73873f905cf_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItMTAtMS0xLTE2NzY2NQ_2bfe8b3d-b9d0-4558-8b39-906f90775ec0">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if091fd24a2e744cc84af3abc98b8f3f5_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItMTItMS0xLTE2NzY2NQ_f035706a-23ea-498b-b8ef-9cdf800ac345">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14bcf8248ac4a89ac301d6111091e59_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItMTQtMS0xLTE2NzY2NQ_3f5b7ce0-1b2e-4bdd-9eff-0f7d000dbc05">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd2083018754b229660065eb3c2d886_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItMTYtMS0xLTE2NzY2NQ_419e1716-9bc5-4f00-a4bb-75e1a6740da2">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 10. Collaborations and Other Arrangements for additional information.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfNzY5NjU4MTQxMzc1MA_b425bcb5-3b15-4f04-af27-2a4bdfc267cf" continuedAt="ia4f51e796056476097a603bb1f64cb8a" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Derivative Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an <ix:nonNumeric contextRef="i08f3914c4bd548ffa8c16f9da7bd4df7_D20220101-20221231" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfNzY5NjU4MTQxNTc1OA_de4fc7ef-142f-4590-96c4-d84157e3da42">18</ix:nonNumeric>-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ic6595f90027b4bab9460abdbe19dbe4f" continuedAt="ice5ebb560d6e401395ce743e6b129457"><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values, were approximately $<ix:nonFraction unitRef="usd" contextRef="if7e357738293475089434472816fe934_I20221231" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTYzNzkxNA_33b427da-d33f-42b0-ad37-2e53d159b4e0">21.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ib93c734b7bfa468486822daca4f70209_I20211231" decimals="-8" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTYzNzkwNw_b3ea4678-cbaf-46be-9912-0578fe21d2a9">28.6</ix:nonFraction> billion as of December&#160;31, 2022 and 2021, respectively, and the carrying values were $<ix:nonFraction unitRef="usd" contextRef="if172c306038b41f48386ed7ae399787a_I20221231" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTYzNzk0MQ_1ff830db-4d48-4323-b80a-6fa866c69588">24.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i126cf5d37167408d897b7f47dbb2f508_I20211231" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTYzNzk0OQ_e3ad324b-cdc1-408d-bf3a-a2d2d6eb1ebf">25.6</ix:nonFraction> billion as of December&#160;31, 2022 and 2021, respectively.</span></div><ix:continuation id="ia4f51e796056476097a603bb1f64cb8a"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 3 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our first quarter 2021 acquisition of MYR, we recorded a liability for contingent consideration, which is revalued each reporting period until the related contingency is resolved. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex.</span></div></ix:continuation><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTQyOTM2NTExODAzNjU_42fe3f36-7b1d-4ba9-a775-697db455fb3f" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in fair value of our contingent consideration: </span></div><div style="margin-top:4.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if398b36aa15c4bcdbd145f253add16fb_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfMi0yLTEtMS0yMDUyNzI_35b23a0d-90a2-41f1-8b58-9bd98aeba310">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aa74cadbdb34ed3b2763fe749e4a969_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfMi00LTEtMS0yMDUyNzI_d8a6e7bb-1270-42aa-9919-8cb506ced320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7609fb41a434a248c259460823ebb48_D20220101-20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfMy0yLTEtMS0yMDUyNzI_e5f81b9e-8b4a-4af1-a46b-d443ddcc52bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2efdf458554bab8ef48f6d397f4e6a_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfMy00LTEtMS0yMDUyNzI_82ae103d-09e7-4b4a-9a2b-24bbbba5eb29">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7609fb41a434a248c259460823ebb48_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfNC0yLTEtMS0yMDUyNzI_0471cb07-c8bd-458d-acf8-2c2fb7ddd2ea">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb2efdf458554bab8ef48f6d397f4e6a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfNC00LTEtMS0yMDUyNzI_b881638b-847e-4a4b-aaa8-cfbf8645a7e4">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange remeasurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7609fb41a434a248c259460823ebb48_D20220101-20221231" decimals="-6" sign="-" name="gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfNS0yLTEtMS0yMDUyNzI_a78b2ea6-7171-4118-b901-4e9ddba6d6d1">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb2efdf458554bab8ef48f6d397f4e6a_D20210101-20211231" decimals="-6" sign="-" name="gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfNS00LTEtMS0yMDUyNzI_fddecdb0-efb1-4c8e-aea3-3037dc9c5cce">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if21d9ac9e987485c9b496bfee383aafa_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfNi0yLTEtMS0yMDUyNzI_d5fcf8ae-1c10-4a01-bd6a-e2a92cf35d14">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if398b36aa15c4bcdbd145f253add16fb_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfNi00LTEtMS0yMDUyNzI_0ada7966-2394-469b-ae37-b016aa8bfe7f">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Included in Research and development expenses on our Consolidated Statements of Income and primarily related to increasing discount rates and updated probability rate estimates.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Included in Other income (expense), net on our Consolidated Statements of Income.</span></div></ix:nonNumeric><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a liability related to future royalties as part of our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;), which is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to future royalties were $<ix:nonFraction unitRef="usd" contextRef="ia10224614a2c4100ba6f83973aa40b07_I20221231" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTY0MTExMg_b8b96e0f-d9a6-41d4-a5d9-c487587d40ba">1.1</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ic3f06b3794e74e00a49aace81e6036af_I20211231" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTY0MTEwMw_193fd1f5-2af7-44ec-8755-57918a3ddd11">1.3</ix:nonFraction>&#160;billion as of December&#160;31, 2022 and 2021, respectively, and the carrying value was $<ix:nonFraction unitRef="usd" contextRef="i1cd161b557064dc88ec5537ac6193a18_I20221231" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTY0MTEzMw_9a4ce6ab-c0c6-432e-a245-0c66f218090d"><ix:nonFraction unitRef="usd" contextRef="i2fdbe18128244987a1e36b0904391b66_I20211231" decimals="-8" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTY0MTEzMw_f3d9cfc0-eb79-4288-b8b7-73ef37d20c57">1.1</ix:nonFraction></ix:nonFraction>&#160;billion as of December&#160;31, 2022 and 2021. See Note 11. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we recorded a partial impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i99e1333e6d0f4c0a8d9fdea046b7eaf1_D20220101-20221231" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTY0NzEwMA_267cdb16-932b-4bbf-92e9-e25b2c54a72f">2.7</ix:nonFraction>&#160;billion related to certain IPR&amp;D assets. See Note 8. Goodwill and Intangible Assets for additional information. There were no indicators of impairment noted during 2021.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fair Value Level Transfers</span></div></ix:continuation><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ice5ebb560d6e401395ce743e6b129457">There were no transfers between Level 1, Level 2 and Level 3 in the periods</ix:continuation> presented.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzYyNQ_21cc43cb-c086-4318-ab19-645a157a0a91" continuedAt="i08a20c5e4f7642ac9a01c4c84becc7cb" escape="true">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES </ix:nonNumeric></span></div><ix:continuation id="i08a20c5e4f7642ac9a01c4c84becc7cb" continuedAt="ice35d96572e54446b531f44c670e9f89"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU5MA_978639d4-8b3b-4175-8c37-27ddedb17641" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItMi0xLTEtMTY3NjY1_28c58804-457b-414d-b8ed-702604f0f325">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItNC0xLTEtMTY3NjY1_b1a7fa53-671f-4d75-a0aa-619a02e958b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItNi0xLTEtMTY3NjY1_8e51956e-55dc-4632-bc2f-5266e74ea4cb">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItOC0xLTEtMTY3NjY1_3d28f61a-7e0d-46a1-b9b7-ee70eed1af80">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItMTAtMS0xLTE2NzY2NQ_d89ab38b-7c26-4b82-ba94-5cae607f1502">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItMTItMS0xLTE2NzY2NQ_330a2a95-2e9b-46e5-8a0e-a545c82e70f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItMTQtMS0xLTE2NzY2NQ_a6948562-dba6-4ee7-badf-691fe3029692">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItMTYtMS0xLTE2NzY2NQ_949f989a-1a17-4bff-8ebc-be8fd0a1f905">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtMi0xLTEtMTY3NjY1_38a0ecde-5c29-45c6-a452-a147f450f7a8">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtNC0xLTEtMTY3NjY1_c2b8cb18-1032-4b65-b7c0-181b2e8aea4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtNi0xLTEtMTY3NjY1_43fb472f-dad1-4974-aba2-7b75d7261557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtOC0xLTEtMTY3NjY1_db0d7d45-cc01-4cd1-aede-b1737e51f757">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtMTAtMS0xLTE2NzY2NQ_82ae59a0-b613-4d32-92f3-ad1ea276689a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtMTItMS0xLTE2NzY2NQ_4e28a50b-ae04-4ca3-af48-5f8dfd470eb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtMTQtMS0xLTE2NzY2NQ_0a7935f9-41a7-4d31-93ed-30cc24d5e2fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtMTYtMS0xLTE2NzY2NQ_a2b5c952-f798-4e91-9282-31a25ab1318e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff5933035664d28975731dea852a94b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtMi0xLTEtMTY3NjY1_41857e25-977c-4b26-b444-eb29913f9f8d">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff5933035664d28975731dea852a94b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtNC0xLTEtMTY3NjY1_9a9c0189-a57f-47ca-8b2b-e1e46d053dc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff5933035664d28975731dea852a94b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtNi0xLTEtMTY3NjY1_b757d2ef-f3a6-4d4b-af9f-12ec2102448f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff5933035664d28975731dea852a94b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtOC0xLTEtMTY3NjY1_3c208ab1-e920-43ad-847a-741fde2a5266">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9084bff3951f442886fd602ca88f373d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtMTAtMS0xLTE2NzY2NQ_65afb9b2-faaa-4338-827b-74532bb47fc3">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9084bff3951f442886fd602ca88f373d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtMTItMS0xLTE2NzY2NQ_405cc7e1-d2aa-4791-9b97-f0f2e050afca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9084bff3951f442886fd602ca88f373d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtMTQtMS0xLTE2NzY2NQ_d0906b13-34ab-413a-89f9-f5b7d527d2b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9084bff3951f442886fd602ca88f373d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtMTYtMS0xLTE2NzY2NQ_6e800454-f0e8-408c-b087-f9594f076b1d">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtMi0xLTEtMTY3NjY1_0913744a-2ae2-47af-b572-9b688425a5f7">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtNC0xLTEtMTY3NjY1_c570b775-7ed9-48a1-bfc4-4fe2018dc200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtNi0xLTEtMTY3NjY1_1bf6f2b4-22f6-4e76-a808-9e238a01788b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtOC0xLTEtMTY3NjY1_d7e02bb6-44c7-48bd-89c0-51d5a26d0244">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtMTAtMS0xLTE2NzY2NQ_b37bc0eb-1530-4b45-b8c0-54b7493dd747">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtMTItMS0xLTE2NzY2NQ_4d949d38-f117-4f29-926c-3665c0e8e6d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtMTQtMS0xLTE2NzY2NQ_d529a0be-b868-4545-bb91-ae5b372e1af0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtMTYtMS0xLTE2NzY2NQ_380621ca-5ad1-484d-94f8-d5d35eaf9cba">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtMi0xLTEtMTY3NjY1_dee95293-086a-4c43-9ecc-96325727acf4">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtNC0xLTEtMTY3NjY1_6e4de0d2-f8af-46ca-9fd4-93b6027e8ced">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtNi0xLTEtMTY3NjY1_842530cc-f5e8-42bb-8175-c5a4ca78a9d6">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtOC0xLTEtMTY3NjY1_393b4a9f-eb69-4fea-892f-666804f1b891">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtMTAtMS0xLTE2NzY2NQ_07ecfba5-eb03-47ff-a768-453e7b963622">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtMTItMS0xLTE2NzY2NQ_61aea05e-221d-4063-944c-32a9b8cd5409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtMTQtMS0xLTE2NzY2NQ_508687ad-4f8b-4fd3-a561-a2988411735a">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtMTYtMS0xLTE2NzY2NQ_26b7cc37-9831-4773-b3d9-fa46fd24ee6b">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctMi0xLTEtMTY3NjY1_5c511e94-8b5e-4408-9250-ae41a6ae0569">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctNC0xLTEtMTY3NjY1_24791286-7e5e-4445-97d6-0da951f0399b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctNi0xLTEtMTY3NjY1_a5131ac6-008c-4bf7-bc69-61cec63c3d5d">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctOC0xLTEtMTY3NjY1_3ef06817-6d36-4007-ba18-12f3502b863d">333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9c57adbf444d65825f235837090240_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctMTAtMS0xLTE2NzY2NQ_9f6c6d88-00a8-4165-a1d0-dc5674250b17">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9c57adbf444d65825f235837090240_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctMTItMS0xLTE2NzY2NQ_137c9f53-8b94-4414-9881-173fd091dd80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e9c57adbf444d65825f235837090240_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctMTQtMS0xLTE2NzY2NQ_afa4540a-0093-49af-8ffd-0522e2dbdaef">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9c57adbf444d65825f235837090240_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctMTYtMS0xLTE2NzY2NQ_7bbcd9c0-adc6-475e-b744-144629e0d19c">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtMi0xLTEtMTY3NjY1_5766a1da-6dd2-43b8-ada6-50c50e1bed89">2,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtNC0xLTEtMTY3NjY1_e6baf5cc-88cc-4669-b88a-884264f4bbc9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtNi0xLTEtMTY3NjY1_1c1c94ed-5207-4f80-ba2d-f9ee50d3fd48">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtOC0xLTEtMTY3NjY1_71214195-c4d1-41aa-a0ab-2a2bac2505c1">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtMTAtMS0xLTE2NzY2NQ_8d87639f-9b53-449c-9d51-52b4033707a5">2,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtMTItMS0xLTE2NzY2NQ_099a05e1-6b5c-4b6c-8b63-fa7545976390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtMTQtMS0xLTE2NzY2NQ_3f057684-4ac1-45c7-8841-2ef9b44455ca">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtMTYtMS0xLTE2NzY2NQ_3b4c0c1a-b117-4564-81c8-dfc10187b456">2,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzEzMTk0MTM5NTQ3NDkw_98b997d3-c3d4-4202-9fe5-2b173678fd1f" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzItMi0xLTEtMjYyMjU3_16780e92-b891-4e50-8dd4-e854a518fb50">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzItNC0xLTEtMjYyMjU3_7a5811b2-29a1-4cde-8c35-78bbf8d08038">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzItNi0xLTEtMjYyMjU3_c3ccdac3-4a09-4d32-bab3-39f9f9ec1fc9">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzItOC0xLTEtMjYyMjU3_7fe5417f-23f0-4617-8449-ee5fe6f5ef50">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzItMTAtMS0xLTI2MjI1Nw_b994f93d-36ee-4e55-a1e9-c8f9a4d24ab1">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzItMTItMS0xLTI2MjI1Nw_1beaf047-c45f-4497-9cf5-b80ac891ed2d">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzMtMi0xLTEtMjYyMjU3_7838e10e-c50e-438d-b4b6-d307ea8f699a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzMtNC0xLTEtMjYyMjU3_ed821d04-7a2d-49ea-b4ef-0efeb263a9f3">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzMtNi0xLTEtMjYyMjU3_49da373c-1e6d-46c4-8648-f2eabc557e73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzMtOC0xLTEtMjYyMjU3_158b3198-4e63-46db-b1e6-ac3f23fab198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzMtMTAtMS0xLTI2MjI1Nw_ed164aaf-26f4-46cb-b3bc-f8e67dcca7de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzMtMTItMS0xLTI2MjI1Nw_6030941e-1e60-499d-a617-95546013a218">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff5933035664d28975731dea852a94b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzQtMi0xLTEtMjYyMjU3_23695b22-ec02-4cd1-8885-808720fb2a68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff5933035664d28975731dea852a94b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzQtNC0xLTEtMjYyMjU3_3ae3a604-b986-4d53-b725-74442d11e6fd">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff5933035664d28975731dea852a94b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzQtNi0xLTEtMjYyMjU3_9d44dab2-5856-4503-a612-a3a96ea21766">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff5933035664d28975731dea852a94b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzQtOC0xLTEtMjYyMjU3_6c0123a5-a7c2-4a5b-85fd-fdc404df68f6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff5933035664d28975731dea852a94b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzQtMTAtMS0xLTI2MjI1Nw_bbe86d74-1d6f-44da-9423-16222bf0b0b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff5933035664d28975731dea852a94b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzQtMTItMS0xLTI2MjI1Nw_5b37b17f-9cd6-4eb3-ab0e-4661e3d5160a">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzUtMi0xLTEtMjYyMjU3_04eba7b3-be79-40d8-bb96-eb033acda702">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzUtNC0xLTEtMjYyMjU3_827c0117-afa6-4f88-a572-247b56941c6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzUtNi0xLTEtMjYyMjU3_284cc675-8f3c-44d4-9212-30425d982cb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzUtOC0xLTEtMjYyMjU3_453e174b-e8aa-4387-8a5a-29de82b78de2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzUtMTAtMS0xLTI2MjI1Nw_40fcf21b-6c75-4594-8efe-a492c9e56f4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzUtMTItMS0xLTI2MjI1Nw_5fb91fb3-745e-49d9-962a-f2bb855ff9c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzYtMi0xLTEtMjYyMjU3_906fcc58-6c36-47e8-bb7f-3c561d011a5f">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzYtNC0xLTEtMjYyMjU3_afefca80-3f6e-4331-8b92-938c3d5f8e9c">774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzYtNi0xLTEtMjYyMjU3_000b51f2-77db-4655-be02-e90f99eafb29">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzYtOC0xLTEtMjYyMjU3_f6a11ac4-b4f4-45be-bc14-f5811587d5bb">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzYtMTAtMS0xLTI2MjI1Nw_7f1c96b4-f6fa-418f-a4e0-2bb97b183d06">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzYtMTItMS0xLTI2MjI1Nw_ac281e76-a1fe-448b-baab-0ef80c0dff5d">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzctMi0xLTEtMjYyMjU3_6a990e3f-438c-4076-a0e6-57cf70739b24">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzctNC0xLTEtMjYyMjU3_0ca3a8db-82b5-4bae-9c78-52c48d8830d8">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzctNi0xLTEtMjYyMjU3_2690e78a-1729-42ce-89ea-9b67c80513c3">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzctOC0xLTEtMjYyMjU3_a8aa4f7a-23e7-44f9-ba66-20d87eca7b92">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzctMTAtMS0xLTI2MjI1Nw_c0814cac-953e-4b11-8cd2-c43c2b94dfe2">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzctMTItMS0xLTI2MjI1Nw_f80939d4-d3f6-4ee3-ae31-4e01ba1c4e11">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzgtMi0xLTEtMjYyMjU3_bcba04f6-e9b7-424a-b2af-470293ba7a58">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzgtNC0xLTEtMjYyMjU3_cb485534-a1a3-4053-9104-cc6e16f86c48">1,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzgtNi0xLTEtMjYyMjU3_9df5d633-d368-4c8f-bf68-db65618ea1ea">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzgtOC0xLTEtMjYyMjU3_86375094-9ea9-44f8-9235-bb5a95a71bc2">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzgtMTAtMS0xLTI2MjI1Nw_14674fe5-1adf-4ab8-86b0-920df3a9e494">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzgtMTItMS0xLTI2MjI1Nw_6c20696d-be9e-4e5d-b4bf-24e5e78740a1">1,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzItMi0xLTEtMjYyMjU3_e6a5fcbf-5258-4b5e-9519-9c2660e1c071">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzItNC0xLTEtMjYyMjU3_c7fe77bc-415e-4fb9-a55f-767080ad1cfb">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzItNi0xLTEtMjYyMjU3_17e3fbc8-11f1-485b-a8bb-57dd9ca2c5f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzItOC0xLTEtMjYyMjU3_ef5137b8-9edb-4eac-8219-7099eff27399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzItMTAtMS0xLTI2MjI1Nw_b9e2db9b-daed-46bf-a657-884366b89c3c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzItMTItMS0xLTI2MjI1Nw_d486fabc-9d33-476e-baa2-023856c9f78d">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzMtMi0xLTEtMjYyMjU3_489fc612-6268-4901-91c2-7b0f3d926fa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzMtNC0xLTEtMjYyMjU3_9ab52359-0292-4fa3-bfd6-fab3f5606ca8">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzMtNi0xLTEtMjYyMjU3_8ca62030-7061-4304-b65c-7ee667d6149c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzMtOC0xLTEtMjYyMjU3_c26d2cc5-ffdf-4274-9792-e93df1bbb7ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzMtMTAtMS0xLTI2MjI1Nw_bc762072-78d5-4771-9089-ee530e28c0ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzMtMTItMS0xLTI2MjI1Nw_07a2e03c-0380-49e0-8070-829c6260c17f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9084bff3951f442886fd602ca88f373d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzQtMi0xLTEtMjYyMjU3_61bee9af-3251-4774-af70-430ffc8ae66f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9084bff3951f442886fd602ca88f373d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzQtNC0xLTEtMjYyMjU3_e46dfa4c-ebf7-482c-811e-d6752087e006">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9084bff3951f442886fd602ca88f373d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzQtNi0xLTEtMjYyMjU3_69c72848-e873-48d3-a43f-2ae9700a5333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9084bff3951f442886fd602ca88f373d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzQtOC0xLTEtMjYyMjU3_804995fd-ee65-4e9b-b40c-b55ca9cf60cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9084bff3951f442886fd602ca88f373d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzQtMTAtMS0xLTI2MjI1Nw_b3afe057-e19d-4020-ab4e-5bedba0400fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9084bff3951f442886fd602ca88f373d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzQtMTItMS0xLTI2MjI1Nw_1ec88a1d-bda8-44e7-8a60-040b1ed97727">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzUtMi0xLTEtMjYyMjU3_5498c302-d4d0-4ac4-94b6-95f8044bb86c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzUtNC0xLTEtMjYyMjU3_0d4c4249-e5c8-4700-a6a7-e6237794f7d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzUtNi0xLTEtMjYyMjU3_62216909-bbab-4ecf-8e92-c7256ecbb9e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzUtOC0xLTEtMjYyMjU3_1d69640e-ad3d-4c66-814f-e695a2c65f6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzUtMTAtMS0xLTI2MjI1Nw_cc536516-5ae6-4c05-9aaa-4020884fcfa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzUtMTItMS0xLTI2MjI1Nw_b2a82faf-ea32-47a7-8af7-9f2824120c96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzYtMi0xLTEtMjYyMjU3_d6be04c9-9079-4339-bbcb-004e6da25724">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzYtNC0xLTEtMjYyMjU3_06b530e4-138a-4df0-9547-89f9eee8b9bf">1,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzYtNi0xLTEtMjYyMjU3_e4ca6a1a-7c0b-4a79-ba23-216b13dfa7c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzYtOC0xLTEtMjYyMjU3_147305ab-0d3d-45ed-b653-fe93f048645b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzYtMTAtMS0xLTI2MjI1Nw_3f9a39c1-36e8-4c31-986b-ed024b1e9729">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzYtMTItMS0xLTI2MjI1Nw_83d57128-b59f-4fa2-a6b4-8e23dc52a5cf">1,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e9c57adbf444d65825f235837090240_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzctMi0xLTEtMjYyMjU3_1f125f33-9318-4c69-acac-17f6e3bdcf62">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9c57adbf444d65825f235837090240_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzctNC0xLTEtMjYyMjU3_5f8348a4-64a0-4f55-af9c-33cf7ca7a7f7">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9c57adbf444d65825f235837090240_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzctNi0xLTEtMjYyMjU3_02dcdfac-56c5-4833-92b9-62da2f76229a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9c57adbf444d65825f235837090240_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzctOC0xLTEtMjYyMjU3_dd0a574e-f5d2-4339-9355-cef3f7785df0">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e9c57adbf444d65825f235837090240_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzctMTAtMS0xLTI2MjI1Nw_f67a387f-ee68-497f-9470-f8ade9181edb">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e9c57adbf444d65825f235837090240_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzctMTItMS0xLTI2MjI1Nw_87155b75-58b3-49b7-bcdd-76482063a36c">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzgtMi0xLTEtMjYyMjU3_fd209151-eff7-4bd6-8c02-87e4d6d3e76a">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzgtNC0xLTEtMjYyMjU3_b05f2f15-a2f2-4b35-878b-a1a5e2c30808">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzgtNi0xLTEtMjYyMjU3_d08d314b-7831-4cfd-9704-80074f6c1b2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzgtOC0xLTEtMjYyMjU3_731a1bb5-c84e-4af9-862f-2504e08af069">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzgtMTAtMS0xLTI2MjI1Nw_9982e32b-120b-4e45-acd4-a7b3e560beee">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzgtMTItMS0xLTI2MjI1Nw_aa0730d9-ebdc-4419-adea-52420cff046f">2,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNTY2MA_0b2346d7-a4e8-4e69-93d8-c02c6324c741">No</ix:nonFraction> allowance for credit losses was recognized for investments with unrealized losses as of December&#160;31, 2022, as we do not currently intend to sell, and it is not more likely than not that we will be required to sell, such investments before recovery of their amortized cost bases. The unrealized losses were primarily driven by broader change in interest rates with no adverse conditions identified that would prevent the issuer from making scheduled principal and interest payments.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ice35d96572e54446b531f44c670e9f89"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzEzMTk0MTM5NTQ3NDkx_aedb54e9-99fb-40f1-a9ce-b4177e5c644d" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b5ae4a796da464bb370d53bae12c455_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzEtMi0xLTEtMjYyMjU3_3599b829-7db6-4123-be66-bc03ec0f42df">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e52c52611f24f8faac4fa92e65543f9_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzEtNC0xLTEtMjYyMjU3_91c7f4d6-bf3b-4b0c-b494-e1f97bcdf59c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463626c5759146d08f5927f7e0b6683a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzItMi0xLTEtMjYyMjU3_deece1be-280c-488f-955c-eb5990991794">973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1634706b89014eebace618eae101eefc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzItNC0xLTEtMjYyMjU3_60c5e906-7711-49c2-b8a1-4e90e7d6cc8b">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eaf91c6ed454ec2900cd809519f9ae0_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzMtMi0xLTEtMjYyMjU3_970c2e8c-72f8-4382-aeb8-d7d063cab9c9">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9928086fec14acfb7cf4385d987b680_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzMtNC0xLTEtMjYyMjU3_1b4ed19f-a847-49c1-ae91-72e6b4809075">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzQtMi0xLTEtMjYyMjU3_3048d4d5-eecb-461a-bc99-266ab6d072c8">2,293</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzQtNC0xLTEtMjYyMjU3_f2bf0716-2458-4c88-8684-a250a8cadcb7">2,497</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzEzMTk0MTM5NTQ3NDk0_02010b5a-9137-49f2-9ec5-51931bd6e0d9" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzItMi0xLTEtMjYyMjU3_90c6cefc-0ff7-4487-851e-cccadd4f351c">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzItNC0xLTEtMjYyMjU3_22a41993-dd49-4c70-ac1d-e4b69c9ce7db">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzMtMi0xLTEtMjYyMjU3_0a7056f6-f8ed-4811-8e3b-5cd3cfe97a00">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzMtNC0xLTEtMjYyMjU3_b70365fe-a183-4755-b7a4-05fde91fede4">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzQtMi0xLTEtMjYyMjU3_c7325e12-5b46-4215-8070-6d58291aa42c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzQtNC0xLTEtMjYyMjU3_bcec14e8-a018-411d-a121-55a6b612e876">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After ten years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzUtMi0xLTEtMjYyMjU3_df36ca42-9b02-42c7-97ae-1d180af80776">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzUtNC0xLTEtMjYyMjU3_b60edb94-6c75-4de4-be6a-667245191929">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzYtMi0xLTEtMjYyMjU3_ef7ed3ba-343a-4372-89bb-c497e1d7c88d">2,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzYtNC0xLTEtMjYyMjU3_a023e7b7-bfb3-44cb-9f90-ae68b71d6cba">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Equity Securities</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities Measured at Fair Value</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzEzMTk0MTM5NTQ3NDky_09199428-feb1-43f2-b27c-aa0ccf90e64c" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Consolidated Balance Sheets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b5ae4a796da464bb370d53bae12c455_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzEtMi0xLTEtMjYyMjU3_499cdf55-a935-4da9-89b4-48b2ede1f9a8">3,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e52c52611f24f8faac4fa92e65543f9_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzEtNC0xLTEtMjYyMjU3_e62218a6-6fd0-4f18-be91-3535daf28780">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i198d532a8c074ac78f29a94fac0b9f33_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzItMi0xLTEtMjYyMjU3_6e573fcc-fa25-4e6a-aa7d-40293f8f5fc3">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4812222e45cd4cb69428c9cdba79819c_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzItNC0xLTEtMjYyMjU3_bcd34361-bd16-43ef-974d-cd12e5d85db0">885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad7614ba24154118b1da72e576ca61e1_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzMtMi0xLTEtMjYyMjU3_19ef6b71-b5f6-4299-9d72-e4b46f746938">943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad61301e5ed420bb158a038204db320_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzMtNC0xLTEtMjYyMjU3_be904f78-704e-4f7e-8647-c77a43dc3b64">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica09543c00fe4598ac8ce750d8afb1ed_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzQtMi0xLTEtMjYyMjU3_83a2ee07-2745-4147-a023-b457afd6353e">5,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9443f1a550be401b9c00363c5d93d604_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzQtNC0xLTEtMjYyMjU3_e3160a69-a6bc-46f8-bdd5-46b261954efc">5,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is classified in Other long-term assets due to certain lock-up provisions in our amended subscription agreement with them, which extend to August 2024.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments and other equity investments without readily determinable fair values were $<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzA3NA_cde0dc2f-f394-4d0c-80d9-2f80c8115459">423</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzA3OQ_4f828f67-8880-43f4-93a3-afb631790f48">338</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively, and were excluded from the table above. These amounts were included in Other long-term assets on our Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrealized Gains and Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized losses recognized on equity securities were $<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzI4OA_ada04443-91cf-46e0-83d1-206fd6b57e82">657</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzI5Mw_bd7c43f5-bd8f-4191-b2f7-cf411af2eece">610</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-8" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzMwMQ_1632791f-238f-4f22-87a1-f11e9e36fdc6">1.7</ix:nonFraction> billion for the years ended December&#160;31, 2022, 2021 and 2020, respectively, and were included in Other income (expense), net on our Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transaction</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, Gilead donated certain equity securities at fair value to the Gilead Foundation, a California nonprofit public benefit corporation (the &#8220;Foundation&#8221;). The Foundation is a related party as certain of our officers also serve as directors of the Foundation. The donation expense of $<ix:nonFraction unitRef="usd" contextRef="if99033cbc8c044d3a0561d49bbba36b3_D20220101-20221231" decimals="-6" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzczNg_744a239c-5ce3-402f-b93e-a53de9fa0d35">85</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id1cc9513c77541668e0695e24152fbdf_D20210101-20211231" decimals="-6" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzc0NA_1ba3f57d-ef1c-431c-b0e8-91d67b814bc2">212</ix:nonFraction> million was recorded within Selling, general and administrative expenses on our Consolidated Statements of Income during the for the years ended December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzMzNTE_be3cf38a-da8d-4bc0-bcae-7cbf4d4ccccd" continuedAt="i44f7f63aa7c642c3aede1dcfacc8861e" escape="true">DERIVATIVE FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="i44f7f63aa7c642c3aede1dcfacc8861e" continuedAt="i7b95f08b870e40fe8f7bb4b15171a8fa"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative instruments we use to hedge our exposures for certain monetary assets and liabilities that are denominated in a non-functional currency are not designated as hedges. The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of <ix:nonNumeric contextRef="i08f3914c4bd548ffa8c16f9da7bd4df7_D20220101-20221231" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzEwOTk1MTE2MzE4NzA_9b9ad560-6454-4fce-b45a-75881d776717">18</ix:nonNumeric> months or less. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, we held foreign currency exchange contracts with outstanding notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzE2NDkyNjc0NDU3NDA_32cabc5a-f934-495c-974d-4d9dd971d5fd">3.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzE2NDkyNjc0NDU3NTA_612aa787-bfd0-4a10-82ea-73bc34d64949">2.9</ix:nonFraction> billion, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts in our Consolidated Balance Sheets on a gross basis. <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzMzNTU_9fc7cc56-d843-454a-8f44-14b5c5f9be0c" continuedAt="i414ac0e4ca4b434aa134cd7213352065" escape="true">The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting:</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-align:center"><ix:continuation id="i414ac0e4ca4b434aa134cd7213352065" continuedAt="idc9ab17aeaf245d39f13802f0d242982"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:42.474%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtMi0xLTEtMTY3NjY1_2f4084d2-5259-4bc5-8b05-5f700b1f1a8a">Derivative Assets</span></span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtNi0xLTEtMTY3NjY1_46ccc9b5-72b7-44ea-ba73-a4b1e8bd1b28">Derivative Liabilities</span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c84aa3ba61245188fa2fc51e8e98ac1_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzQtNC0xLTEtMTY3NjY1_cecd7926-c89e-4284-af09-4a280c203b7d">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485ded3cb94b411881b8ee607e8a95fe_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzQtOC0xLTEtMTY3NjY1_462d25de-2250-4a90-bf4d-0afe00edcd5b">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81c22c85dbc4822a7ef92c8c72ce5b4_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzUtNC0xLTEtMTY3NjY1_3e8c6ac4-9d53-4f65-90e6-8da7ff8ff736">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669cfd4e64c242c1a8ef8796fd28b7cc_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzUtOC0xLTEtMTY3NjY1_829d5973-6da6-425f-baba-e34f497f8dee">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bd1f9124d4d45ddb0aca9a2a42b8ae3_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzYtNC0xLTEtMTY3NjY1_6eab9b51-3341-41c1-9766-fe0a2ad375a3">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bd1f9124d4d45ddb0aca9a2a42b8ae3_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzYtOC0xLTEtMTY3NjY1_2e38f7e7-dc79-40eb-9714-7c2ce5230fb5">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b2c501c7c4411197427bc2b905865c_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzgtNC0xLTEtMTY3NjY1_4a14309e-8cab-4ad1-b545-87268992c913">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b2c501c7c4411197427bc2b905865c_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzgtOC0xLTEtMTY3NjY1_cdf1e20a-f691-496e-852d-a70b5d5d1a4d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b2c501c7c4411197427bc2b905865c_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzktNC0xLTEtMTY3NjY1_c9b2cb57-b41e-40e5-bc63-77b7f3c1bb0d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b2c501c7c4411197427bc2b905865c_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzktOC0xLTEtMTY3NjY1_0636be3f-09b0-44af-943e-8753f5a9ffc9">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives presented gross on the Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEwLTQtMS0xLTE2NzY2NQ_0053c2dd-470b-4216-9b2c-4426999fc7da">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEwLTgtMS0xLTE2NzY2NQ_e90a0b0e-ad53-44b2-9b7b-88ea4d5d94c2">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts not offset on the Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEyLTQtMS0xLTI2NTYzOA_baeff9ee-a236-41d6-b113-547c99542552">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEyLTgtMS0xLTI2NTY2MA_5b495abe-ccef-45a2-a04a-248b30da8a11">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash collateral received / pledged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEzLTQtMS0xLTI2NTY0OA_aa3f3bc5-6307-41da-b85b-3ba4d10f2b38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEzLTgtMS0xLTI2NTY1MQ_96bb18cf-c4fa-4b5e-adc4-a831e47048cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount (legal offset)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzE0LTQtMS0xLTI2NTY0NQ_114a2afe-eaf6-437c-a51b-caa19a2c3a20">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzE0LTgtMS0xLTI2NTY1NA_841c42de-8dd6-4322-a9f0-388fdcecfa78">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i7b95f08b870e40fe8f7bb4b15171a8fa"><div style="margin-top:9pt;text-align:center"><ix:continuation id="idc9ab17aeaf245d39f13802f0d242982"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:42.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtMi0xLTEtMjA2NjQ5_b7aba77a-d3a3-423b-9d31-3f7747775fae">Derivative Assets</span></span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtNi0xLTEtMjA2NjQ5_bc98400a-c82d-4004-b4ed-25c8c3bfe4b2">Derivative Liabilities</span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5dc98f71a34b989bdd92e74b03bcaf_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzQtNC0xLTEtMTY3NjY1_d1300c80-2412-4b98-8536-ed4588be79f2">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884916a0bf074d689e54307d3e38f85f_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzQtOC0xLTEtMTY3NjY1_6e990ca2-7062-4016-94ef-763798a7619d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fedf80dcdf54b7ab0cf8db9b226197b_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzUtNC0xLTEtMTY3NjY1_be042c40-059a-4eef-8887-df6c92e1c1f7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e415108242847aa9f7899559c4beb51_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzUtOC0xLTEtMTY3NjY1_86260115-2e76-4468-9dea-54300b14461d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1fc54addc74b608025b4442073733f_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzYtNC0xLTEtMTY3NjY1_1a985805-3bdd-4016-a481-e24f7ed01e90">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b1fc54addc74b608025b4442073733f_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzYtOC0xLTEtMTY3NjY1_5664f946-5f62-4991-b5dd-7cb873dff41e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ddfa8ed452243918c264f684e03d322_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzgtNC0xLTEtMTY3NjY1_b27d1efd-36a7-4949-9acc-726f28afa9b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ddfa8ed452243918c264f684e03d322_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzgtOC0xLTEtMTY3NjY1_fc2f6192-f7a6-4346-9b53-f72edfe8df4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ddfa8ed452243918c264f684e03d322_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzktNC0xLTEtMTY3NjY1_5d355c87-c730-4e54-b3a0-69a15aa90350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ddfa8ed452243918c264f684e03d322_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzktOC0xLTEtMTY3NjY1_cac27dff-bbe9-4593-8bc1-e4841da3f87b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives presented gross on the Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEwLTQtMS0xLTE2NzY2NQ_22d99656-39a2-4309-ae88-2cad23c072f9">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEwLTgtMS0xLTE2NzY2NQ_a5c69cd4-f1ca-4488-9ec5-d6c0b646d6ac">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts not offset on the Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEyLTQtMS0xLTI2NTc4OQ_abc40753-d714-48c9-9f16-f5a6da771e61">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEyLTgtMS0xLTI2NTc5Mg_08565978-eadd-46e0-a2bf-d9c628088aee">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash collateral received / pledged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEzLTQtMS0xLTI2NTc5NQ_56acd5fc-a927-488f-8f79-fd7d6f88611c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEzLTgtMS0xLTI2NTgwMQ_625211a6-0128-4b46-9b2c-2d9a7a7b0ca1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount (legal offset)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzE0LTQtMS0xLTI2NTc5OA_47f01800-9489-4203-bd89-603bfa4d0751">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzE0LTgtMS0xLTI2NTgwNA_a4e080b8-76fa-48ca-a815-f9fe0f1dd6b9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzMzNzM_9081a05e-faa7-4ee6-b25c-d3f42339037f" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our derivative contracts on our Consolidated Financial Statements:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:76.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Accumulated other comprehensive income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzMtMi0xLTEtMTY3NjY1_5c43220b-005b-45b4-8d02-2bf3bf27446d">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzMtNC0xLTEtMTY3NjY1_4b634e02-d33a-4d6d-8a04-2989d2c2fdd0">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzMtNi0xLTEtMTY3NjY1_51838a32-32d2-4076-82ae-e46a3aa571c3">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from Accumulated other comprehensive income to Product sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzQtMi0xLTEtMTY3NjY1_d97dc191-fe81-4bbd-922f-506a636b1931">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzQtNC0xLTEtMTY3NjY1_4776dc01-d02a-477a-a0e1-d0ec51b760cc">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzQtNi0xLTEtMTY3NjY1_5da06e2f-b788-4523-b3d1-feb363dbe586">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other income (expense), net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzYtMi0xLTEtMTY3NjY1_2e2562f2-6d21-402a-bedc-7cc7d834f5f0">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzYtNC0xLTEtMTY3NjY1_052f5d80-efef-475d-836a-f8a1d62b7a0e">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzYtNi0xLTEtMTY3NjY1_e445342f-f791-4db0-af41-1b6354b987e8">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of gains and losses related to the hedged forecasted transactions reported in Accumulated other comprehensive income as of December&#160;31, 2022 are expected to be reclassified to Product sales within <ix:nonNumeric contextRef="i08f3914c4bd548ffa8c16f9da7bd4df7_D20220101-20221231" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzEwOTk1MTE2Mzg5NzU_2e151778-4173-4ef4-953c-5226139d309a">12</ix:nonNumeric> months. There were <ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzE2NDkyNjc0NDU3MzM_135866ab-33d6-4df2-86d7-d28cfdaa8ed3"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzE2NDkyNjc0NDU3MzM_321f3a7d-8e28-4452-beb5-748ad8e3cc96">no</ix:nonFraction></ix:nonFraction> discontinuances of cash flow hedges for the years presented.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the years ended December&#160;31, 2022, 2021 and 2020 were included within Net cash provided by operating activities on our Consolidated Statements of Cash Flows.</span></div></ix:continuation><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_106"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEyMzcz_ecc406ea-80e4-459c-a697-8a8d1cd3d0bd" continuedAt="i3adfd3a354cd4cf4b08978f50730c1b1" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="i3adfd3a354cd4cf4b08978f50730c1b1" continuedAt="i0d96a2a8cd4e474e89a97116b84c577c"><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">MiroBio</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2022, we acquired all of the outstanding share capital of MiroBio Ltd. (&#8220;MiroBio&#8221;), a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for $<ix:nonFraction unitRef="usd" contextRef="i9ff582c0bcd9440d8450644be10362de_D20220920-20220920" decimals="-6" name="gild:PaymentsForAssetAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE2NjI0ODY_e116ea00-91f8-4d7f-8550-66aff5de3ae7">414</ix:nonFraction> million in cash. As a result, MiroBio became our wholly-owned subsidiary. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition and recorded a $<ix:nonFraction unitRef="usd" contextRef="ie636277d8cc8441891c35c55a8b0f84c_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE2NjI0OTM_c5b081eb-49bc-4439-89e4-b68f54a841fb">389</ix:nonFraction> million charge to Acquired in-process research and development expenses on our Consolidated Statements of Income during 2022. The remaining purchase price relates to various other assets acquired and liabilities assumed.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">MYR</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by European Medicines Agency (&#8220;EMA&#8221;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Consolidated Financial Statements from the date of the acquisition.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i0d96a2a8cd4e474e89a97116b84c577c" continuedAt="i34d032841e684c4398a9ad5238a01444"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate consideration for this acquisition of &#8364;<ix:nonFraction unitRef="eur" contextRef="i83300a86394449e3b64aed1970eda7d5_D20210304-20210304" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3NzE0Nw_9dd12aa4-de4b-4b0d-8b92-01f78cee63ce">1.3</ix:nonFraction> billion (or $<ix:nonFraction unitRef="usd" contextRef="i83300a86394449e3b64aed1970eda7d5_D20210304-20210304" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3NzE2Mg_812495fb-8aac-4cef-bfdb-d3e8dace0ffd">1.6</ix:nonFraction> billion) primarily consisted of &#8364;<ix:nonFraction unitRef="eur" contextRef="i83300a86394449e3b64aed1970eda7d5_D20210304-20210304" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3NzE3Nw_7a3cfd1c-b16f-4470-9722-c14e368c5e46">1.0</ix:nonFraction> billion (or $<ix:nonFraction unitRef="usd" contextRef="i83300a86394449e3b64aed1970eda7d5_D20210304-20210304" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3NzE5Mg_27aaadef-a5d4-47b9-9e5f-fff6dd96f03d">1.2</ix:nonFraction> billion) paid upon closing and contingent consideration of up to &#8364;<ix:nonFraction unitRef="eur" contextRef="icb5939cef17f48478fd4464ba9e5a0cc_I20210304" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3NzIwNw_93c834e2-009a-4a6e-8d9c-a382c08ccf6f">300</ix:nonFraction> million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $<ix:nonFraction unitRef="usd" contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3NzIyMg_9fceebd9-252f-42e5-bdee-e14eb1773202">341</ix:nonFraction> million as of the acquisition date. As of December&#160;31, 2021, the fair value of the liability was $<ix:nonFraction unitRef="usd" contextRef="i28808546af3a44b5b726f97b0be6b62c_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE3MTY_9b5d33d7-7131-4e4d-9154-0842691fe2cf">317</ix:nonFraction> million and was included in Other current liabilities on our Consolidated Balance Sheets. As of December&#160;31, 2022, the fair value of the liability was $<ix:nonFraction unitRef="usd" contextRef="i61be0ceaa2ff4374a907d95021e07080_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTgyMDY3NTA_ef4d6724-a958-4892-9ac0-de89f96e4f1c">275</ix:nonFraction> million and was included in Other long-term obligations. See Note 3. Fair Value Measurements for additional information.</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEzNzQzODk1NDIwMjc0_d56c66b6-3fc6-4f12-a7e0-01a18bb59e32" continuedAt="i7ab631f5f83e4658ad972608aa29e318" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8747b96d361f490595133641ce6801bf_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzItMi0xLTEtMjcxOTI0_935c3a69-9bd6-4c63-b417-1e68bb6dd244">845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f715f66b49c4eb3866d26fc054558bb_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzMtMi0xLTEtMjcxOTI0_9f8cf19e-1662-47c8-8e07-77ef4dfa58d7">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzQtMi0xLTEtMjcxOTI0_78866feb-8700-4130-bcc2-6bf2c35b6d63">513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304" decimals="-6" sign="-" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzUtMi0xLTEtMjcxOTI0_571b4353-b667-4e53-8324-c749a4b218f5">187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzYtMi0xLTEtMjcxOTI0_69e33ccb-a365-4aa3-8858-09c6b219058a">1,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304" decimals="-6" name="us-gaap:GoodwillGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzctMi0xLTEtMjcxOTI0_e8c808e8-ae86-43cd-b274-aeb0b6fda365">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzgtMi0xLTEtMjcxOTI0_c4b585a5-17bf-4774-8c74-56e74ce156d7">1,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $<ix:nonFraction unitRef="usd" contextRef="i8747b96d361f490595133641ce6801bf_I20210304" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2NTg_37892ae8-561f-442f-90bc-1b6d11da5854">845</ix:nonFraction>&#160;million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of <ix:nonFraction unitRef="number" contextRef="i5e0b94afcd4a4e969f87632c645d0ab6_I20210304" decimals="2" name="gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2NjY_e781e30e-ee43-4fe3-a31b-6dcb5a2bee26">12</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of <ix:nonNumeric contextRef="i000f39fad6fc4888bca218c81bd4367a_D20210304-20210304" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2NzQ_865fd0b4-a419-4972-803e-406a01077f15">10</ix:nonNumeric> years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D consists of Hepcludex for HDV in all other regions without regulatory approval, including the United States. The estimated aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="ie4dce94d4803432ea623df9764cf4027_I20210304" decimals="-7" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2ODA_54754bc5-0e26-4114-bd73-6ff3db72eee4">1.19</ix:nonFraction>&#160;billion as of the acquisition date was determined by applying the income approach using unobservable inputs (Level 3 under the fair value measurement and disclosure guidance) to estimate probability-weighted net cash flows attributable to this asset and a discount rate of <ix:nonFraction unitRef="number" contextRef="i5e0b94afcd4a4e969f87632c645d0ab6_I20210304" decimals="2" name="gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2NzA_e781e30e-ee43-4fe3-a31b-6dcb5a2bee26">12</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304" decimals="-6" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2ODc_44db19c2-a7c5-46d9-9550-2a4707807897">226</ix:nonFraction>&#160;million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is <ix:nonFraction unitRef="usd" contextRef="i61be0ceaa2ff4374a907d95021e07080_I20221231" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2OTQ_72f02a3c-c39d-4ab8-91f4-f6f2f2c7341b">no</ix:nonFraction>t expected to be deductible for income tax purposes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The one-year measurement period was completed in the first quarter of 2022, with adjustments recorded to the fair values of assets acquired and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i4513e5ea422e4a229b71a42e1b842c21_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTgyMDM0NzQ_48812f59-ac1e-4ae6-a405-0b1943257e60">18</ix:nonFraction> million. See Note 8. Goodwill and Intangible Assets for additional information.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Immunomedics</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we completed the acquisition of Immunomedics, a company focused on the development of antibody-drug conjugate technology, for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ic2d744e7509044cfb0669434445c9252_D20201023-20201023" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3MjkzMQ_c8d7d599-7af4-4fb7-ad9e-872c6e77a569">20.6</ix:nonFraction> billion. Upon closing, Immunomedics became a wholly-owned subsidiary of Gilead. The acquisition was financed with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $<ix:nonFraction unitRef="usd" contextRef="icab7b0de5a6c43d697d7858746732e0e_D20200901-20200930" decimals="-8" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDExNTI_f24357ab-4975-4d9b-8b90-7fab82d59401">1.0</ix:nonFraction>&#160;billion borrowing under a new senior unsecured term loan facility and cash on hand. In 2021, we repaid the borrowing under the senior unsecured term loan facility.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i34d032841e684c4398a9ad5238a01444" continuedAt="if99601def078456ea70a0582cfa8cc89"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded share-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i153abdf5024043579147bb4cf3dd2205_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDExNjE_04a6cd91-02fd-4cea-a1b4-05856a8c0a2e">289</ix:nonFraction>&#160;million related to the cash settlement of the accelerated share-based compensation expense attributable to the post-combination period, which was primarily recorded in Selling, general and administrative expenses and Research and development expenses on our Consolidated Statements of Income for the year ended December&#160;31, 2020. We also recorded other acquisition-related expenses of $<ix:nonFraction unitRef="usd" contextRef="i153abdf5024043579147bb4cf3dd2205_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDExNjk_ef26c415-61d5-4386-b655-e1b810e5d8ad">39</ix:nonFraction>&#160;million, primarily representing closing costs and related fees, in Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December&#160;31, 2020. </span></div><ix:continuation id="i7ab631f5f83e4658ad972608aa29e318"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Immunomedics was accounted for as a business combination using the acquisition method of accounting. The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzEtMi0xLTEtMjcxOTQz_ede0c6c7-cc8f-40a5-9c3c-a57ecafc8e49">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzItMi0xLTEtMjcxOTQz_af0a55c1-d9ce-410b-99a1-cf1cedb1ce2e">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9d7f1885544506bd276d0c9126856f_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzQtMi0xLTEtMjcxOTQz_3bb2b1f6-1626-4715-a421-654a9fd26c81">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dee278e6454433be1edc4ce1da6ed1_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzUtMi0xLTEtMjcxOTQz_f7cebb43-6136-4089-b39b-ebe312831040">15,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6f1965ab97c42069eb90ab5238a2ecd_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzYtMi0xLTEtMjcxOTQz_6a650a75-7562-433d-85da-835f1bb115b8">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzctMi0xLTEtMjcxOTQz_2e7675b5-3e99-4ca3-b9d0-63d2791593f2">4,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023" decimals="-6" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzgtMi0xLTEtMjcxOTQz_844c85db-7eae-43f4-ad2e-8fec60665c50">1,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023" decimals="-6" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzktMi0xLTEtMjcxOTQz_463cd6c8-0974-40cf-9384-e2ed79ff56c1">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzEwLTItMS0xLTI3MTk0Mw_44c1ba33-befc-4bde-8133-975ab0bfae65">16,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023" decimals="-6" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzExLTItMS0xLTI3MTk0Mw_d987cfd9-29a6-4995-a11f-dd3a21903866">3,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzEyLTItMS0xLTI3MTk0Mw_ff22d5ea-7025-4fe2-b706-a2194fa51fc4">20,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value step-up adjustment of $<ix:nonFraction unitRef="usd" contextRef="ic2d744e7509044cfb0669434445c9252_D20201023-20201023" decimals="-6" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDExODU_797a7969-84ed-43bb-a160-0a1ad5e00333">881</ix:nonFraction>&#160;million, included in inventories of $<ix:nonFraction unitRef="usd" contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDExOTI_e37092fe-1d23-4f1f-8687-ad5dae34f689">946</ix:nonFraction>&#160;million as of the acquisition date, was primarily determined by the estimated selling price of finished inventory less the cost to complete the manufacturing process and selling effort. The step-up adjustment was recorded in Cost of goods sold on our Consolidated Statements of Income as the inventory was sold to customers and in Research and development expenses on our Consolidated Statements of Income for inventory used for clinical purposes.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $<ix:nonFraction unitRef="usd" contextRef="i7e9d7f1885544506bd276d0c9126856f_I20201023" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMDA_1c6b1d1f-faa3-4ec4-bb44-124fc4cef376">4.6</ix:nonFraction>&#160;billion represents the estimated fair value of Trodelvy for metastatic triple-negative breast cancer (&#8220;TNBC&#8221;) as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Trodelvy for metastatic TNBC and a discount rate of <ix:nonFraction unitRef="number" contextRef="i7e9d7f1885544506bd276d0c9126856f_I20201023" decimals="3" name="gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMDg_5a65d244-e6f8-4735-a2bf-a89834913e86">7.0</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of <ix:nonNumeric contextRef="ia565affd511f4d70ae37392429f48f4a_D20201023-20201023" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMTY_db341be2-bbfc-4e3e-a4b0-c60dd473b098">12</ix:nonNumeric> years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D assets consist of Trodelvy for hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#8220;HR+/HER2-&#8221;) breast cancer, Trodelvy for non-small cell lung cancer and Trodelvy for urothelial cancer (&#8220;UC&#8221;). The estimated aggregate fair value of&#160;$<ix:nonFraction unitRef="usd" contextRef="i13dee278e6454433be1edc4ce1da6ed1_I20201023" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMTk_8f80d3a3-5046-4ce3-90dd-f94c452960ab">15.8</ix:nonFraction>&#160;billion&#160;as of the acquisition date was determined by applying the income approach using unobservable inputs (Level 3 under the fair value measurement and disclosure guidance) to estimate probability-weighted net cash flows attributable to these assets and a discount rate of <ix:nonFraction unitRef="number" contextRef="i7e9d7f1885544506bd276d0c9126856f_I20201023" decimals="3" name="gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMjk_5a65d244-e6f8-4735-a2bf-a89834913e86">7.0</ix:nonFraction>%. The discount rate used represents the estimated rate that market participants would use to value these intangible assets. Trodelvy for UC was granted accelerated approval by FDA in April 2021 and $<ix:nonFraction unitRef="usd" contextRef="ib4719e0d131f44a085886b933ab78bb6_I20210430" decimals="-8" sign="-" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMzc_80f55b5f-6ac5-43f4-9348-23ea1bf0e758"><ix:nonFraction unitRef="usd" contextRef="ifa9a93f5272a429bbdd06910a8637c97_I20210430" decimals="-8" name="gild:FiniteLivedIntangibleAssetsGrossReclassified" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMzc_c70e4d75-38c7-4e77-ab0d-7213470a2a46">1.0</ix:nonFraction></ix:nonFraction>&#160;billion was reclassified to finite-lived intangibles from IPR&amp;D. Trodelvy for HR+/HER2- breast cancer was partially impaired in the first quarter of 2022, but was subsequently granted approval by FDA in February 2023 and $<ix:nonFraction unitRef="usd" contextRef="i32d561b8ae6b4a2f98da8f5dd0fa0d8a_I20220331" decimals="-8" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE0NzM_cdd8b0fe-3165-4963-a449-788d71587cb6">6.1</ix:nonFraction>&#160;billion will be reclassified to finite-lived intangibles from IPR&amp;D in the first quarter of 2023. See Note 8. Goodwill and Intangible Assets for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recorded an intangible asset related to a license and supply agreement with Everest Medicines (&#8220;Everest&#8221;), which was entered into by Immunomedics prior to the acquisition. Under the agreement, Everest was granted an exclusive license to develop and commercialize Trodelvy in certain territories in Asia and make certain sales milestones and royalty payments to us. The acquisition date fair value of $<ix:nonFraction unitRef="usd" contextRef="ie6f1965ab97c42069eb90ab5238a2ecd_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE0ODE_4841af04-56f3-4a9a-ac1c-bff4b4074a9c">175</ix:nonFraction>&#160;million was determined by estimating the probability-weighted net cash flows attributable to the outlicense and a discount rate of <ix:nonFraction unitRef="number" contextRef="i7e9d7f1885544506bd276d0c9126856f_I20201023" decimals="3" name="gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMzQ_5a65d244-e6f8-4735-a2bf-a89834913e86">7.0</ix:nonFraction>%. The discount rate represents the estimated rate that market participants would use to value this intangible asset. This intangible asset was being amortized over an estimated useful life of <ix:nonNumeric contextRef="ic1048a20244b4ce5bb8bf7d3be281065_D20201023-20201023" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE0OTA_3a9d1dc8-1407-4e29-99d9-5f57c5a2b38d">15</ix:nonNumeric> years on a straight-line basis up until we reacquired the rights from Everest in the fourth quarter of 2022. See Note 10. Collaborations and Other Arrangements for additional information.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="if99601def078456ea70a0582cfa8cc89" continuedAt="icfc2061105c14fe99da8442c8545a4b3"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of Immunomedics.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust (&#8220;RPI&#8221;), prior to our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The acquisition date fair value of the liability was estimated as $<ix:nonFraction unitRef="usd" contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023" decimals="-8" name="gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE0OTM_a44728cd-e61f-4be0-9dd9-2bb3bcf539c9">1.1</ix:nonFraction>&#160;billion, which was primarily determined based on current estimates of future royalty payments to RPI over the life of the arrangement using the real options method and an effective annual interest rate of <ix:nonFraction unitRef="number" contextRef="ie422be158b934364b7f415457625004b_I20201023" decimals="3" name="gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE1MDE_d65f7779-933b-41bc-840b-940ead1ff9fa">2.5</ix:nonFraction>%. The inputs used for valuation of this liability are unobservable and are considered Level 3 under the fair value measurement and disclosure guidance. The liability related to future royalties was categorized as debt and primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Notes 3. Fair Value Measurements and 11. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The&#160;excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023" decimals="-8" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2NDE_3efba176-a8b8-4e78-a505-15b8dc92073b">4.0</ix:nonFraction>&#160;billion was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for Immunomedics is <ix:nonFraction unitRef="usd" contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2MzI_c99ce300-df0a-43e2-8f5b-864c3b301cf3">no</ix:nonFraction>t expected to be deductible for income tax purposes.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Forty Seven, Inc. (&#8220;Forty Seven&#8221;)</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icfc2061105c14fe99da8442c8545a4b3">In the second quarter of 2020, we completed the acquisition of Forty Seven, a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for total consideration of $<ix:nonFraction unitRef="usd" contextRef="ie215a497705b4a2fbfc864f7caeffd9d_D20200407-20200407" decimals="-8" name="gild:PaymentsToAcquireAssetsNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg1NjQ4MA_6bd0c24a-cd7d-4f84-8fbf-46f09f5dad87">4.7</ix:nonFraction> billion, net of acquired cash. Upon closing, Forty Seven became a wholly-owned subsidiary of Gilead. We accounted for the transaction as an asset acquisition since the lead asset, magrolimab, represented substantially all the fair value of the gross assets acquired. During the year ended December 31, 2020, we recorded a $<ix:nonFraction unitRef="usd" contextRef="ia971b5b9fb3d4bd384e45480e81c75f3_D20200101-20201231" decimals="-8" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg1NjQ5Ng_38efe009-6f32-4f13-9218-4b40b884d922">4.5</ix:nonFraction> billion charge representing an acquired IPR&amp;D asset with no alternative future use in Acquired in-process research and development expenses, and stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i9a7ef37e465543e5ad6a7b3828719842_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2NTA_ab3c8b07-1a42-4270-bce4-26c6e612fc78">144</ix:nonFraction>&#160;million primarily in Research and development expenses on our Consolidated Statements of Income.</ix:continuation> </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_112"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzY3NQ_79bd1806-ddbb-4251-b0e6-ac5f12891377" continuedAt="i981f059c7d914adaacde786730f99e77" escape="true">PROPERTY, PLANT AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i981f059c7d914adaacde786730f99e77"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzY3NA_b66ad555-5858-4cb3-89b1-88fe9479ed13" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Property, plant and equipment, net: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzItMi0xLTEtMTY3NjY1_2202f131-3589-4c1e-aebe-c930e5caee42">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:Land" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzItNC0xLTEtMTY3NjY1_807e3fa7-eb0d-4202-ba11-5e98a6c0078d">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements (including leasehold improvements)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzMtMi0xLTEtMTY3NjY1_cceb8061-621d-43ba-95e2-3c151c59a329">4,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:BuildingsAndImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzMtNC0xLTEtMTY3NjY1_19fc50ea-e698-480b-ae3d-63ad886abd91">3,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzQtMi0xLTEtMTY3NjY1_b8fe0895-ba80-48c3-b057-e40f16a90d43">1,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:MachineryAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzQtNC0xLTEtMTY3NjY1_ff175146-c891-46f0-b56a-46eda231db0b">952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzUtMi0xLTEtMTY3NjY1_c07e0b27-8309-4462-bc93-81cd435e9671">880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzUtNC0xLTEtMTY3NjY1_6062a307-638c-4a60-9fb3-9db43a6d4efd">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:ConstructionInProgressGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzYtMi0xLTEtMTY3NjY1_21b1a14d-7b23-4dbe-9c4c-d9014c027c58">719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzYtNC0xLTEtMTY3NjY1_a324a061-f5d3-4a3d-9851-3ab0b125358b">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzctMi0xLTEtMTY3NjY1_141b397b-de28-4f81-bb82-29aa82a449c5">7,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzctNC0xLTEtMTY3NjY1_d372c2c1-259e-461f-b636-0eda411a718c">7,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzgtMi0xLTEtMTY3NjY1_31b1c8d3-957b-4935-9cc2-87f82996d7fe">2,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzgtNC0xLTEtMTY3NjY1_4428c687-c38e-498b-b9f7-e93b797d9f1d">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzktMi0xLTEtMTY3NjY1_2023ce59-50d3-4d73-8ccc-e3756979a371">5,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzktNC0xLTEtMTY3NjY1_fefb998d-f857-41bf-810b-e79ef0ba1dcb">5,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes $<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzE2NDkyNjc0NDIzNTQ_71a609e9-73cd-49b9-bde3-7691648e3ffb">104</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzE2NDkyNjc0NDIzNDY_9f5d5835-aa71-4347-9858-acaf4b53824b">131</ix:nonFraction> million of unamortized capitalized software costs as of December&#160;31, 2022 and 2021, respectively.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net book value of our property, plant and equipment in the U.S. was $<ix:nonFraction unitRef="usd" contextRef="ieff06bffa0844a9d8876ecd6c333e23c_I20221231" decimals="-8" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzE2NDkyNjc0NDIzNjc_777e03fa-e3db-45eb-81c1-d6bff404069a">4.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i44d47c74025d4cfdba50d1a8b27fc2b9_I20211231" decimals="-8" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzE2NDkyNjc0NDIzNjE_83772223-eade-4d3f-bfec-e9b66acf8c9a">4.1</ix:nonFraction> billion as of December&#160;31, 2022 and 2021, respectively. The corresponding amount in international locations was $<ix:nonFraction unitRef="usd" contextRef="i492e0765e063418f871681e4d0901a65_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzE2NDkyNjc0NDIzODI_fda9ea37-6a8c-488a-846d-69cc5e3b9db7">973</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie0ba8e5a7781443694297bc65f7058d2_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzE2NDkyNjc0NDIzNzY_1de2a7b4-42c9-4e39-9cc1-fa0febd79099">963</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively. All individual international locations accounted for less than 10% of the total balances.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzM1MTI_c1c550ea-848c-4554-a117-37b657f2bb9f" continuedAt="id504e126e11643fcb77dba758f8e296b" escape="true">GOODWILL AND INTANGIBLE ASSETS </ix:nonNumeric></span></div><ix:continuation id="id504e126e11643fcb77dba758f8e296b" continuedAt="if3316244ae5540bea20b57c232f6fc31"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Goodwill</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzM1MTM_4fd911dd-13f2-42da-b282-e85c7e1f6834" escape="true"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of Goodwill:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzItMi0xLTEtMTY3NjY1_ba20cf8b-ddd8-41f5-b6f6-762f71b7f49f">8,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzItNC0xLTEtMTY3NjY1_33e14fc1-a2cb-4540-9010-3f808f9fde2b">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzMtMi0xLTEtMTY3NjY1_24a5b645-c663-44e2-99f4-de382095990e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzMtNC0xLTEtMTY3NjY1_ff4a4a49-83bd-4220-89c5-f402aa017077">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzQtMi0xLTEtMTY3NjY1_153b4f8e-4005-4e56-ba92-bc5661f3229b">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzQtNC0xLTEtMTY3NjY1_4e83d180-0b6e-4849-8a95-500b56e26f23">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzUtMi0xLTEtMTY3NjY1_e7d43fae-1acb-4f9e-86c6-4bde8572795f">8,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzUtNC0xLTEtMTY3NjY1_9a61f135-aabd-4c1d-b3fc-e510c49821e7">8,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, goodwill decreased by $<ix:nonFraction unitRef="usd" contextRef="icdf3325b9c814697b37f4edbe5de04de_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NDU4MzM_6302e19d-04b3-47d9-9bec-79078e4d3c35">18</ix:nonFraction>&#160;million as a result of finalizing the amount of acquired net operating losses of MYR, which resulted in a decrease to the net deferred tax liability acquired. As of December&#160;31, 2022, there were <ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NDU4NDQ_8f516f5b-e892-4b36-be7e-bcc6202c4434">no</ix:nonFraction> accumulated goodwill impairment losses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Intangible Assets</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzM0OTY_bbb18ef8-4dc0-4645-92b9-dcc089aeafb0" escape="true"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzM0NzQ_d679a21c-b79d-492d-a488-13abe1b2b9cb" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7754ade07946249e798f443a00c1b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtMi0xLTEtMTY3NjY1_83a4a5ea-eafe-45f7-8757-5760b912b120">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c7754ade07946249e798f443a00c1b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtNC0xLTEtMTY3NjY1_905dec9a-e7b1-4b5d-afc1-ab93018934e4">6,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7754ade07946249e798f443a00c1b4_I20221231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtNi0xLTEtMTY3NjY1_26ff22c0-29c2-4eb8-9a53-fc63d7c44bc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7754ade07946249e798f443a00c1b4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtOC0xLTEtMTY3NjY1_1f7608e7-e7bd-4b83-8393-b9c8942139fd">4,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i181901e26e3e4c91a24f93e978ab1945_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtMTAtMS0xLTE2NzY2NQ_8821d795-6970-4d8c-b65b-0107205e0102">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i181901e26e3e4c91a24f93e978ab1945_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtMTItMS0xLTE2NzY2NQ_59d42964-97c3-4f9d-837f-d7acb2a1826f">5,651</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i181901e26e3e4c91a24f93e978ab1945_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtMTQtMS0xLTE2NzY2NQ_0187e1dc-0d6d-4216-afbe-764db593170e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i181901e26e3e4c91a24f93e978ab1945_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtMTYtMS0xLTE2NzY2NQ_c677af71-b875-4df4-b88b-8e3c9989bc4b">5,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; axicabtagene ciloleucel</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44ccd0f6f6894efbb8cbf39df662d267_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtMi0xLTEtMTY3NjY1_7c047098-d93e-423f-bcfc-92a49c65bee4">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44ccd0f6f6894efbb8cbf39df662d267_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtNC0xLTEtMTY3NjY1_575b4a8c-4be4-49de-a203-603c34e3582d">1,908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44ccd0f6f6894efbb8cbf39df662d267_I20221231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtNi0xLTEtMTY3NjY1_4911fc1e-a547-464d-a9f6-23dcd8f49b28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44ccd0f6f6894efbb8cbf39df662d267_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtOC0xLTEtMTY3NjY1_be215e66-bbad-463f-9202-a696f5389c7f">5,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89be91f170784317b4d65294841f9a30_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtMTAtMS0xLTE2NzY2NQ_13c900d5-8875-4c2a-831e-dd0eb096346a">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89be91f170784317b4d65294841f9a30_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtMTItMS0xLTE2NzY2NQ_c5583f90-4c28-4803-8a27-4e9b78783154">1,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89be91f170784317b4d65294841f9a30_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtMTQtMS0xLTE2NzY2NQ_19e48863-85c1-4f38-99c0-6bb8c6eccf72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89be91f170784317b4d65294841f9a30_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtMTYtMS0xLTE2NzY2NQ_d359cc90-b8f6-4212-8b9f-e62fd1b17328">5,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf8e90e835654b89b0b240d8650e1eae_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtMi0xLTEtMTY3NjY1_46ce8e21-8af3-4f0a-9c22-b445455e70c0">5,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf8e90e835654b89b0b240d8650e1eae_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtNC0xLTEtMTY3NjY1_3836a418-abd3-45d0-9704-634f9fbab456">973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf8e90e835654b89b0b240d8650e1eae_I20221231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtNi0xLTEtMTY3NjY1_3404c127-03ac-41e5-a187-9acb7e6312e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf8e90e835654b89b0b240d8650e1eae_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtOC0xLTEtMTY3NjY1_618d5d21-4e73-4a90-9a74-243f4f1e073c">4,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d3cfbadc744a27b6406bc2824e189a_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtMTAtMS0xLTE2NzY2NQ_672eebdf-5373-4da2-8c65-dead4fa9d644">5,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9d3cfbadc744a27b6406bc2824e189a_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtMTItMS0xLTE2NzY2NQ_1c9a66c8-134a-4c0f-bdae-76fba9b6987c">507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d3cfbadc744a27b6406bc2824e189a_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtMTQtMS0xLTE2NzY2NQ_3349b42c-8576-4514-8890-b51cd6135933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d3cfbadc744a27b6406bc2824e189a_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtMTYtMS0xLTE2NzY2NQ_c73584cc-abcb-43c7-82ff-51fed7b9db7d">5,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; Hepcludex</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id42c17e537b943188ee815c6eb4724df_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtMi0xLTEtMTY3NjY1_4bb63e61-512b-4692-a7e9-a14a7d9e1686">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id42c17e537b943188ee815c6eb4724df_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtNC0xLTEtMTY3NjY1_94213b6e-82ca-4507-a773-89f118fa7553">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id42c17e537b943188ee815c6eb4724df_I20221231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtNi0xLTEtMTY3NjY1_5d8f2c13-85a2-446d-af7a-a00813acab1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id42c17e537b943188ee815c6eb4724df_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtOC0xLTEtMTY3NjY1_7643498a-1dbc-4078-82f6-e15526367cfe">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59824532c8ca4a779f76468f950efb0c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtMTAtMS0xLTE2NzY2NQ_46d1b36e-3625-49b3-9e13-6768670e1e8e">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59824532c8ca4a779f76468f950efb0c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtMTItMS0xLTE2NzY2NQ_77fab2f1-e2d0-4856-afa1-662de9a456fb">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59824532c8ca4a779f76468f950efb0c_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtMTQtMS0xLTE2NzY2NQ_59a8bf3e-7df7-4245-8117-c776424e530d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59824532c8ca4a779f76468f950efb0c_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtMTYtMS0xLTE2NzY2NQ_1cf97525-efb8-4173-923f-4398761c33af">773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0b0fcb16144c1485e4bb100851404c_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctMi0xLTEtMTY3NjY1_24e6d70f-6ad7-476c-a2fe-cb760f7f8c62">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d0b0fcb16144c1485e4bb100851404c_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctNC0xLTEtMTY3NjY1_3c4f9988-10b4-49cf-ad25-098396d92f9d">733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0b0fcb16144c1485e4bb100851404c_I20221231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctNi0xLTEtMTY3NjY1_d12d7c69-a3e0-4495-bbb9-d6e01001b0b9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d0b0fcb16144c1485e4bb100851404c_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctOC0xLTEtMTY3NjY1_c37ef5b7-7e0a-4ff8-b973-b1d030df1642">758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525ebc96796c4ef3b6ad07db88affd7b_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctMTAtMS0xLTE2NzY2NQ_faa7103f-7ccb-406e-8215-45fe2168a0c6">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i525ebc96796c4ef3b6ad07db88affd7b_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctMTItMS0xLTE2NzY2NQ_a5df5e36-e98e-4bc7-8790-102cef4a03ae">650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525ebc96796c4ef3b6ad07db88affd7b_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctMTQtMS0xLTE2NzY2NQ_1c48f376-85c9-4882-87bf-32c3b852a6fb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525ebc96796c4ef3b6ad07db88affd7b_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctMTYtMS0xLTE2NzY2NQ_fcc4903b-ad63-4288-a69d-d73073e63457">961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtMi0xLTEtMTY3NjY1_194f6f86-b28e-4ab6-9b75-dba91fb1da2c">25,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtNC0xLTEtMTY3NjY1_2313bef6-62d9-449a-ae2e-713aeb0544fc">10,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtNi0xLTEtMTY3NjY1_3c9d2d3e-ff14-4a2f-b05e-b3913b4d85fa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtOC0xLTEtMTY3NjY1_3ef34012-9919-4eb4-8548-d04f9b6a1d0c">15,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtMTAtMS0xLTE2NzY2NQ_150e4ef4-3e03-43db-b9db-8d16a5e771f9">25,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtMTItMS0xLTE2NzY2NQ_3acf957c-3d91-42fb-9316-8c3648605ea1">8,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtMTQtMS0xLTE2NzY2NQ_b2dcb7b7-7efb-49b7-9f3b-53eb50bd8891">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtMTYtMS0xLTE2NzY2NQ_6f53abd8-9a97-4d49-bdda-bb1af105790e">17,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets &#8211; IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzktMi0xLTEtMTY3NjY1_a6cbdf29-1d29-49c9-b5b4-f240c6b28004">13,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzktNi0xLTEtMTY3NjY1_f5740396-3506-4eed-82c9-0a9b2dbbea74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzktOC0xLTEtMTY3NjY1_d2f907fe-157a-4435-bce2-78466d2e59cc">13,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzktMTAtMS0xLTE2NzY2NQ_ca97a1b7-9b3b-410f-9b7a-85f639102cf8">15,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzktMTQtMS0xLTE2NzY2NQ_9fde7392-84fc-4c34-afcf-18b110c8bc55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzktMTYtMS0xLTE2NzY2NQ_355fb979-0f39-4c7d-b113-0c2d8f19c585">15,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTItMS0xLTE2NzY2NQ_8d1c65a1-76bb-4aaf-ab6e-e2a5525d2418">39,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTQtMS0xLTE2NzY2NQ_9722d1b7-25c2-4450-ad54-070317611633">10,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTYtMS0xLTE2NzY2NQ_d7693a8e-9152-4b77-9e96-28ab4fe35a8a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTgtMS0xLTE2NzY2NQ_e13a726f-02af-4e61-8efa-79356016b01c">28,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTEwLTEtMS0xNjc2NjU_82c8db73-3a74-4706-bb7a-1b4e0f97ee44">41,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTEyLTEtMS0xNjc2NjU_49b49e79-1b33-493b-9053-edb88a7aa780">8,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTE0LTEtMS0xNjc2NjU_23160cb0-4606-4921-bfeb-0e7a9ce6b086">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTE2LTEtMS0xNjc2NjU_270dd8a2-7dc4-43bb-b1ec-4aacb04d3025">33,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&amp;D intangible asset of $<ix:nonFraction unitRef="usd" contextRef="i57236ea81268491a97d91341f26ba286_I20221231" decimals="-8" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzEwOTk1MTE2NTUzNjA_ab6b342e-db90-4eb0-b140-a7103f82e714">6.1</ix:nonFraction> billion will be reclassified to finite-lived assets in the first quarter of 2023.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization Expense</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NDcwMzk_93b1ec22-4731-4fe0-8049-0d4c6bdb48a3">1.8</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NDcwMzI_8b7f7a67-5369-4dc4-b4a8-f4075a5c0e3a">1.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NDcwMjU_469c7bab-1712-4091-8823-17d9ddea2e06">1.2</ix:nonFraction> billion for the years ended December&#160;31, 2022, 2021 and 2020, respectively, and is primarily included in Cost of goods sold on our Consolidated Statements of Income.</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzEzMTk0MTM5NTU4NzEy_31edd875-6518-4593-a992-062644c32311" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2022:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzEtMi0xLTEtMjY1MTky_b467bfdb-43cb-4506-8381-7650c30f306e">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzItMi0xLTEtMjY1MTky_36ee1f8a-7ef1-4543-a744-4fb421d0f631">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzMtMi0xLTEtMjY1MTky_10ddcf49-8930-4981-a57d-b45e18490186">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzQtMi0xLTEtMjY1MTky_199ad010-1bcc-4c5e-8c35-8837f0a36ead">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzUtMi0xLTEtMjY1MTky_7db85d3e-5c24-4a6a-95fb-feb150327437">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzYtMi0xLTEtMjY1MTky_652ea547-9a55-46b0-bb3b-4d3cd1aff4c2">6,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzctMi0xLTEtMjY1MTky_f20b46c7-57b9-4252-adaa-32f4a06b5226">15,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="if3316244ae5540bea20b57c232f6fc31"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No indicators of impairment were noted for the years ended December&#160;31, 2022, 2021 and 2020, except as described under &#8220;2022 IPR&amp;D Impairment&#8221; below. The weighted-average discount rates used in our quantitative assessments for IPR&amp;D intangible assets during those years, other than for the assessment described below, were <ix:nonFraction unitRef="number" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="3" name="gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzU0OTc1NTgxNjEzMDQ_691e0f85-017b-43d0-9bdd-a485f65d5362">7.5</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="3" name="gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzU0OTc1NTgxNjEzMDk_f4d4b6a0-2750-48c1-b17c-0f57b0c4c23e">6.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231" decimals="3" name="gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzU0OTc1NTgxNjEzMTc_6a56f841-d5d3-4dac-8be9-13b0fc0dbeee">8.0</ix:nonFraction>%, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 IPR&amp;D Impairment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics in 2020, we allocated a portion of the purchase price to acquired IPR&amp;D intangible assets. Approximately $<ix:nonFraction unitRef="usd" contextRef="i3cbbdf76bfd6400ebaa7f622c1e30073_I20201231" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NTQwNjQ_4ef79441-c50d-4cab-982b-29ad3bf1b3ee">8.8</ix:nonFraction>&#160;billion was assigned to IPR&amp;D intangible assets related to Trodelvy for treatment of patients with HR+/HER2- breast cancer. In March 2022, we received data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- metastatic breast cancer who have received prior endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and two to four lines of chemotherapy (&#8220;third-line plus patients&#8221;). Based on our evaluation of the study results, and in connection with the preparation of the financial statements for the first quarter, we updated our estimate of the fair value of our HR+/HER2- IPR&amp;D intangible asset to $<ix:nonFraction unitRef="usd" contextRef="i32d561b8ae6b4a2f98da8f5dd0fa0d8a_I20220331" decimals="-8" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NTQwNzE_e253de21-e65e-4a02-88e4-c72687b27b3b">6.1</ix:nonFraction>&#160;billion as of March 31, 2022. Our estimate of fair value used a probability-weighted income approach that discounts expected future cash flows to the present value, which requires the use of Level 3 fair value measurements and inputs, including estimated revenues, costs, and probability of technical and regulatory success. The expected cash flows included cash flows from HR+/HER2- metastatic breast cancer for third-line plus patients and patients in earlier lines of therapy which are the subject of separate clinical studies. Our revised discounted cash flows were lower primarily due to a delay in launch timing for third-line plus patients which caused a decrease in our market share assumptions based on the expected competitive environment. As of March 2022, there were no changes in our plans or assumptions related to our estimated cash flows for patients in the earlier lines of therapy. We used a discount rate of <ix:nonFraction unitRef="number" contextRef="i8e1a6227be7f4425b549d4e5d0588c1c_I20220331" decimals="4" name="gild:IndefiniteLivedIntangibleAssetMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NTQwNzg_50142703-1aa8-4b96-b9f5-d780541f3719">6.75</ix:nonFraction>% which is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. We determined the revised estimated fair value was below the carrying value of the asset and, as a result, we recognized a partial impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i140e9b5aa60a4667b375867beadd9364_D20220101-20220331" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NTQwODI_740d464d-d655-4c44-ac7c-5daf934da1c7">2.7</ix:nonFraction>&#160;billion in In-process research and development impairment on our Consolidated Statements of Income during the three months ended March 31, 2022.</span></div></ix:continuation><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_118"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90ZXh0cmVnaW9uOjcwMDJhMDZmZGQwMTRjMjc4ZGFmZTdiZWE2ODVmNWVlXzE5MA_d903ab92-368f-456a-9635-f0938850c067" continuedAt="ibfcf40457e544126b1f4ef1d99315450" escape="true">OTHER FINANCIAL INFORMATION</ix:nonNumeric></span></div><ix:continuation id="ibfcf40457e544126b1f4ef1d99315450" continuedAt="if2c121922e0547e3a3755faa67818da2"><div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounts receivable, net</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90ZXh0cmVnaW9uOjcwMDJhMDZmZGQwMTRjMjc4ZGFmZTdiZWE2ODVmNWVlXzE5MQ_b1bdb360-71aa-4418-85f4-5fe23e727f96" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzItMi0xLTEtMTY3NjY1_6c2a3b9a-0175-472a-9223-18af1a0ca1dd">5,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AccountsReceivableGrossCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzItNC0xLTEtMTY3NjY1_6411ce4d-ff73-4dd1-bdbd-331bccf7793f">5,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzMtMi0xLTEtMTY3NjY1_12c2ea2f-f421-4df1-a580-c6a8f116eeb3">549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="gild:AccountsReceivableChargebacksCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzMtNC0xLTEtMTY3NjY1_92ae8866-7302-455c-9404-25d7c806c8ed">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzQtMi0xLTEtMTY3NjY1_94c45594-a953-4012-b764-e0369851df18">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="gild:AccountsReceivableCashDiscountsAndOtherCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzQtNC0xLTEtMTY3NjY1_dea7875f-f98a-438a-a15b-03f4369222c5">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzUtMi0xLTEtMTY3NjY1_a07a963a-ae5b-414e-9647-ce8db55f29f3">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzUtNC0xLTEtMTY3NjY1_a9e65bc8-a3c6-4892-bdf9-39e2877b9dee">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzYtMi0xLTEtMTY3NjY1_6f77dc52-20f5-4ee8-ab55-9091971a1077">4,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzYtNC0xLTEtMTY3NjY1_66dc246f-d08c-4a21-a126-89b05b60174d">4,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our trade accounts receivable arises from product sales in the U.S. and Europe.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Inventories</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90ZXh0cmVnaW9uOjcwMDJhMDZmZGQwMTRjMjc4ZGFmZTdiZWE2ODVmNWVlXzEzMTk0MTM5NTM1NzI3_511d5587-6a47-4419-870e-fbf04d8fb5b0" escape="true"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzItMi0xLTEtMjA2ODEz_35d6e0da-8aee-48b2-9703-915998390dca">1,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzItNC0xLTEtMjA2ODEz_43ae9104-87ea-4508-b747-30b9aaf5bcd6">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzMtMi0xLTEtMjA2ODEz_8aebed3a-1140-4791-9939-0c3e1866ed8d">577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzMtNC0xLTEtMjA2ODEz_d2d50708-6fb2-4802-b4b8-e23ac167cf2d">590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzQtMi0xLTEtMjA2ODEz_80eb9558-73a9-415f-87de-46e46f58983c">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzQtNC0xLTEtMjA2ODEz_7cce3cbd-9b90-461f-9bf4-3a37412ce7b8">1,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzUtMi0xLTEtMjA2ODEz_149c2019-5243-4ff5-a4d8-d1b9b8a191b9">2,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="gild:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzUtNC0xLTEtMjA2ODEz_5c49ef2d-1c99-40af-a046-0970d5d65784">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzgtMi0xLTEtMjA2ODEz_dedf1f5b-4502-424d-96ef-87d93766d640">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzgtNC0xLTEtMjA2ODEz_de6e4942-2ea3-4966-af2a-9f59f93727fa">1,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzktMi0xLTEtMjA2ODEz_c99bb0e9-1653-46dd-8465-31396e7768bd">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzktNC0xLTEtMjA2ODEz_38915212-a733-422e-a64e-52f75e26fd75">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzEwLTItMS0xLTIwNjgxMw_1fb1164b-b682-4fa9-b545-77ddcdeab9c3">2,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="gild:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzEwLTQtMS0xLTIwNjgxMw_8a2f8912-5cce-4a6f-bc24-3132d2279a16">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="if2c121922e0547e3a3755faa67818da2"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories as of December&#160;31, 2021 included $<ix:nonFraction unitRef="usd" contextRef="i327df07e8ea64ce7a694e3e3b3ff882e_I20211231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90ZXh0cmVnaW9uOjcwMDJhMDZmZGQwMTRjMjc4ZGFmZTdiZWE2ODVmNWVlXzU0OTc1NTgxNjc0NQ_403c6c88-1aa5-4c39-811c-e988c472d08d">294</ix:nonFraction> million of fair value adjustments resulting from the Immunomedics acquisition. There were <ix:nonFraction unitRef="usd" contextRef="ifb58b983f5e14067bcbab9fc5db32341_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90ZXh0cmVnaW9uOjcwMDJhMDZmZGQwMTRjMjc4ZGFmZTdiZWE2ODVmNWVlXzU0OTc1NTgxNjc2OQ_c46d172a-8953-4c1e-8684-2bdabaac1383">no</ix:nonFraction> fair value adjustments in total inventories as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other current liabilities</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90ZXh0cmVnaW9uOjcwMDJhMDZmZGQwMTRjMjc4ZGFmZTdiZWE2ODVmNWVlXzE5Mg_720821a6-5c50-494d-878b-82bb86e26cd0" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Other current liabilities:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzItMi0xLTEtMTY3NjY1_a8b49114-54cc-42cd-bc0c-f4f67c777397">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzItNC0xLTEtMTY3NjY1_b1251b61-8bfc-4a52-804c-1cfa22e4cd7e">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzMtMi0xLTEtMTY3NjY1_aa1c50a8-b860-4b72-892d-14edcd904632">959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzMtNC0xLTEtMTY3NjY1_2ab5c8e0-f001-417d-8bea-4735a6c72f8c">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzQtMi0xLTEtMTY3NjY1_2078ae20-b544-4294-ad39-0fbb4225610a">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzQtNC0xLTEtMTY3NjY1_965513f8-5d10-4481-af08-fb8830f61bd1">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for settlement related to bictegravir litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzUtMi0xLTEtMTY3NjY1_9d01031a-088b-4163-8968-69895949f9eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzUtNC0xLTEtMTY3NjY1_f7546071-793f-4505-976e-7a382b2d6ce7">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzYtMi0xLTEtMTY3NjY1_ff05e6d7-a50f-42d5-8976-3ecc756f1eed">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzYtNC0xLTEtMTY3NjY1_72460766-525c-4ca2-b489-361a9d2352f1">2,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzctMi0xLTEtMTY3NjY1_691c7853-6b5e-46b4-998f-6cfd12c0b953">4,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzctNC0xLTEtMTY3NjY1_995db15c-f830-45b6-a6d5-a17cafeacb99">6,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See Note 13. Commitments and Contingencies for additional information.</span></div></ix:nonNumeric></ix:continuation><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_121"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="gild:CollaborativeAndOtherArrangementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzMyMTAw_364d8c8d-c1be-4abe-b9fd-9be8d4937246" continuedAt="i1dae079d03564db0ac397663c9f76c21" escape="true">COLLABORATIONS AND OTHER ARRANGEMENTS </ix:nonNumeric></span></div><ix:continuation id="i1dae079d03564db0ac397663c9f76c21" continuedAt="ib3cf1536db994bc5bd015cb783c4927d"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements and equity investments.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the financial terms of these arrangements, we may be required to make payments upon achievement of various developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Consolidated Statements of Income when the corresponding events become probable. In connection with the regulatory approvals, milestone payments made will be capitalized as intangible assets and will be amortized to Cost of goods sold through the terms of these collaboration arrangements. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Dragonfly</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into a strategic research collaboration agreement (the &#8220;Dragonfly Collaboration Agreement&#8221;) with Dragonfly Therapeutics, Inc. (&#8220;Dragonfly&#8221;) to develop natural killer (&#8220;NK&#8221;) cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we received an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as options, after the completion of certain preclinical activities, to license exclusive, worldwide rights to develop and commercialize additional NK cell engager programs using the Dragonfly Tri-specific NK Engager platform. Upon the closing of the Dragonfly Collaboration Agreement, we made a $<ix:nonFraction unitRef="usd" contextRef="ib9bc6f335dac4058a61472d6b15e5fa0_D20220401-20220430" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0NDQ_c26df669-ef94-4e1d-908a-9ae47ce278b0">300</ix:nonFraction> million upfront payment to Dragonfly, and we made an additional $<ix:nonFraction unitRef="usd" contextRef="i771f1a1172d84395889aa09f42795a08_D20220101-20221231" decimals="-6" name="gild:PaymentsToAcquireAdditionalInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0NTE_dce5d32d-199c-4143-9072-f299336c454f">15</ix:nonFraction> million payment related to a target selection in connection with an August 2022 amendment to the agreement, which were recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December&#160;31, 2022. These payments were classified as Acquisitions, including in-process research and development, net of cash acquired in Investing Activities on our Consolidated Statements of Cash Flows for the year ended December&#160;31, 2022. In addition, Dragonfly is eligible to receive performance-based development and regulatory milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i771f1a1172d84395889aa09f42795a08_D20220101-20221231" decimals="-6" name="gild:PotentialFutureMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0NTg_f1331a28-017b-4c30-9939-d81da5bc0bf4">630</ix:nonFraction> million related to the DF7001 program with further commercial milestone payments and royalties on worldwide net sales if successful. If we exercise our options on additional NK cell engager programs, Dragonfly would be eligible to receive opt-in payments and performance-based development, regulatory and commercial milestone payments and royalties on worldwide net sales on these optioned programs as well.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Merck &amp; Co, Inc. (&#8220;Merck&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2021, we entered into a license and collaboration agreement with Merck Sharp &amp; Dohme Corp., a subsidiary of Merck to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#8217;s investigational capsid inhibitor, lenacapavir, and Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration is initially focused on long-acting oral and injectable formulations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ib3cf1536db994bc5bd015cb783c4927d" continuedAt="ia308d896cca6441baa17cc7858eec009"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Gilead and Merck share global development and commercialization costs at <ix:nonFraction unitRef="number" contextRef="ic189333a47cb4e74a306f790f89b7e3d_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0NjU_50a2d499-578d-4022-bd78-9fc8605dc926">60</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i957b3f15755947a18bbf1e5b8d938645_D20210313-20210313" decimals="2" name="gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4ODI0ODg_7bc504c2-483a-4d8d-bd18-f4dc1d8ffa23">40</ix:nonFraction>%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, Gilead would lead commercialization in the U.S., and Merck would lead commercialization in the European Union (&#8220;EU&#8221;) and rest of the world. For long-acting injectable products, if approved, Merck would lead commercialization in the U.S. and Gilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, Gilead and Merck would jointly promote the combination products in the U.S. and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $<ix:nonFraction unitRef="usd" contextRef="ia428e1ccf59043d4b741292e75fe250f_D20210313-20210313" decimals="-8" name="gild:CollaborationArrangementNetProductSalesThreshold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0NzM_d82bea8c-ed88-4665-b7cb-01b03a1d3a02">2.0</ix:nonFraction> billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to <ix:nonFraction unitRef="number" contextRef="ia428e1ccf59043d4b741292e75fe250f_D20210313-20210313" decimals="3" name="gild:CollaborationArrangementPercentOfGlobalProductRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0Njk_5adffe54-d344-4bc0-ab76-205e40f1120a">65</ix:nonFraction>% for any revenues above the threshold for such calendar year. Upon passing $<ix:nonFraction unitRef="usd" contextRef="i35be91a902b1413ea429208ada936e60_D20210313-20210313" decimals="-8" name="gild:CollaborationArrangementNetProductSalesThreshold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0Nzk_8bef2809-077e-4330-b828-47f20f507b7a">3.5</ix:nonFraction> billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to <ix:nonFraction unitRef="number" contextRef="i35be91a902b1413ea429208ada936e60_D20210313-20210313" decimals="3" name="gild:CollaborationArrangementPercentOfGlobalProductRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0ODc_af4fc720-46a1-448c-9ef7-fc666685ff8a">65</ix:nonFraction>% for any revenues above the threshold for such calendar year. Reimbursements of R&amp;D costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Income. Expenses recognized under the agreement were not material for the years ended December 31, 2022 and 2021. <ix:nonFraction unitRef="usd" contextRef="i49b7362839864e28ab937849b5b66936_D20220101-20221231" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA2ODUyOA_4862f622-b883-4cbc-9e2a-53721e7c65f2"><ix:nonFraction unitRef="usd" contextRef="i59caa7a2fafd4bcebc5b55c3446ffe7a_D20210101-20211231" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA2ODUyOA_89c244c4-1ca5-4382-a5fe-77d7faa97248">No</ix:nonFraction></ix:nonFraction> revenues have been recognized under the agreement for the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also have the option to license certain of Merck&#8217;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#8217;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first <ix:nonNumeric contextRef="ic189333a47cb4e74a306f790f89b7e3d_D20210313-20210313" name="gild:CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODAx_cf2e5cdc-218b-4433-ae6e-6bd30c735d99">five years</ix:nonNumeric> after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt out, in which case the non-exercising company will be paid a royalty.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Merck announced the decision of the parties to stop all dosing of participants in the Phase 2 clinical study evaluating an oral-weekly combination treatment regimen of lenacapavir and islatravir following the decision of FDA to place clinical holds on the Investigational New Drug applications for certain formulations of islatravir. In September 2022, Merck announced that the study would resume under an amended protocol with a lower dose of islatravir.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Arcus</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2020, we entered into a transaction with Arcus, a publicly traded oncology-focused biopharmaceutical company, which included entry into an option, license and collaboration agreement (the &#8220;Collaboration Agreement&#8221;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the &#8220;Stock Purchase Agreements&#8221;). In accordance with the terms of the Collaboration Agreement and Stock Purchase Agreements, which closed on July 13, 2020, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1MDk_548193fa-ee07-4b37-a9ce-af6564217738">175</ix:nonFraction> million and acquired approximately <ix:nonFraction unitRef="shares" contextRef="i7be52f10430343af827d91922fb036f7_I20200713" decimals="-5" name="gild:InvestmentOwnedBalanceAdditionalShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1MTc_5373e7cd-9ae8-4471-968b-3fd4cf7b9109">6.0</ix:nonFraction> million shares of Arcus common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1MzM_467807e8-f624-4b3f-a9f6-61e95487f317">200</ix:nonFraction> million. Of the total $<ix:nonFraction unitRef="usd" contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713" decimals="-6" name="gild:TotalUpfrontPaymentsMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1NDA_bab39964-1250-4131-be04-e2b51f036a4b">391</ix:nonFraction> million initial cash payments, including transactional costs, made under the agreements, we recorded $<ix:nonFraction unitRef="usd" contextRef="i7be52f10430343af827d91922fb036f7_I20200713" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1NTg_79b65341-7b20-4133-a461-b61828ec75c2">135</ix:nonFraction> million as an equity investment which was calculated based on Arcus&#8217; closing stock price on the closing date of the transaction. The remaining $<ix:nonFraction unitRef="usd" contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1OTQ_04a53a09-3bae-4493-bd29-3954d711f9d5">256</ix:nonFraction> million was attributed to (i) the acquired license and option rights of $<ix:nonFraction unitRef="usd" contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1NzY_a1805168-45d6-46d3-a746-fe69407d526a">175</ix:nonFraction> million representing IPR&amp;D assets with no alternative future use, (ii) $<ix:nonFraction unitRef="usd" contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713" decimals="-6" sign="-" name="gild:IssuanceDiscountPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY2MTE_16ad0916-0a92-4b52-bb70-997da8adb0af">65</ix:nonFraction> million of an issuance premium for the equity purchase and (iii) $<ix:nonFraction unitRef="usd" contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713" decimals="-6" name="gild:PaymentsForDirectTransactionalExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY2Mjg_998d0c56-81dd-4b5e-86c8-903be88da2ed">16</ix:nonFraction> million of direct transactional costs. These amounts were expensed as Acquired in-process research and development expenses during the year ended December 31, 2020 on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Stock Purchase Agreements, we have the right to purchase from Arcus additional shares up to a maximum of <ix:nonFraction unitRef="number" contextRef="i8f866f4b5345461795270bb2919d3ffb_D20200713-20200713" decimals="2" name="gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NTgzOTU1MzU_5b963da2-ec78-40a0-b7ee-06aa9ee040f2">35</ix:nonFraction>% of the outstanding voting stock of Arcus over a <ix:nonNumeric contextRef="i8f866f4b5345461795270bb2919d3ffb_D20200713-20200713" name="gild:EquitySecuritiesFVNIPurchasePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODEx_8d4f6f85-62f9-47db-ae6b-84d3c98f3e56">five-year</ix:nonNumeric> period ending in the third quarter of 2025. We are also subject to a <ix:nonNumeric contextRef="i8f866f4b5345461795270bb2919d3ffb_D20200713-20200713" name="gild:EquitySecuritiesFVNIRestrictionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODEz_8b072bc4-6b36-4b9a-82e7-89076fca9fad">three-year</ix:nonNumeric> standstill ending in the second quarter of 2023, restricting certain other activity on our part. On May 29, 2020, in a separate secondary equity offering, we acquired <ix:nonFraction unitRef="shares" contextRef="i6289804387bd4103907cc19f3c49ade8_I20200529" decimals="-5" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY2Njc_8d64ac87-4d5a-48e7-b7ee-41907a49f28d">2.2</ix:nonFraction> million shares of common stock of Arcus for approximately $<ix:nonFraction unitRef="usd" contextRef="i740c686e35a541228a361dc29719f86c_D20200529-20200529" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY2ODM_725c1ad6-48a7-4ae9-8073-00905654dcf9">61</ix:nonFraction> million. In the first quarter of 2021, we also acquired approximately <ix:nonFraction unitRef="shares" contextRef="i3837ec2ec53d40948208538478b144fd_D20210101-20210331" decimals="-5" name="gild:EquitySecuritiesFVNISharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3MDE_7a27dc37-cb8d-4b48-9458-0dead4d84067">5.7</ix:nonFraction> million additional shares of Arcus common stock for $<ix:nonFraction unitRef="usd" contextRef="i3837ec2ec53d40948208538478b144fd_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3MTk_ae091735-13e4-4d87-bae7-c7f80d40c37c">220</ix:nonFraction> million. As a result, we currently own a total of <ix:nonFraction unitRef="shares" contextRef="i2135143e0b8a42c79094487f8538db87_I20211231" decimals="-5" name="gild:EquitySecuritiesFVNIShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3MjY_1d3058b8-15c6-40fa-8a00-a9fe4db819d5">13.8</ix:nonFraction> million shares of Arcus, which represented approximately <ix:nonFraction unitRef="number" contextRef="idc5bf2b91bbf47619e2400e89b0617db_I20210208" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3MzU_df8151a4-7225-4748-8769-2a7b7e59c71d">19.5</ix:nonFraction>% of the issued and outstanding voting stock of Arcus immediately following the closing of the first quarter 2021 transaction. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ia308d896cca6441baa17cc7858eec009" continuedAt="i9e53a326099b4467b0c525f8acf02204"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Collaboration Agreement, Gilead had the right to opt in to all current and future clinical-stage product candidates for up to <ix:nonNumeric contextRef="i15aa5080eeeb4755b9ee289447ef8c62_D20200527-20200527" name="gild:CollaborativeAgreementOptInTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODE0_37ecfbf8-e7eb-4bae-84c6-3d955dc19d13">ten years</ix:nonNumeric> following the closing of the transaction. In November 2021, we exercised our options to <ix:nonFraction unitRef="program" contextRef="i0f56f1023e494483ab5622ea9a93b454_I20211118" decimals="INF" name="gild:NumberOfClinicalStageProgramsWithExercisedOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3NDU_e20d7807-2ff7-42b1-a1dc-6d9c11069f0f">three</ix:nonFraction> of Arcus&#8217; clinical stage programs and amended the Collaboration Agreement. The option exercise and amendment transaction closed in December 2021, triggering collaboration opt-in payments of $<ix:nonFraction unitRef="usd" contextRef="i156971f265ed4b789964f0e884da2478_D20211221-20211221" decimals="-6" name="gild:PaymentsToOptInTheCollaborativeAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3ODI_e84f8f7f-d622-4cc1-8797-d3873b1ee181">725</ix:nonFraction> million and waiving the $<ix:nonFraction unitRef="usd" contextRef="i7645b620bfdd4f51895f7a3169f56f31_I20200713" decimals="-6" name="gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4MjY_e4053f20-4ed6-409f-9452-dfbd4a397911">100</ix:nonFraction> million option continuation payment which would have been due to Arcus in the third quarter of 2022. The net option charge of $<ix:nonFraction unitRef="usd" contextRef="icfb2a3f5c657473bb9004b07b586f56e_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4MTU_b0044129-ef1f-45de-953f-f7e1ec138407">625</ix:nonFraction> million is included within Acquired in-process research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2021. The collaboration opt-in payments of $<ix:nonFraction unitRef="usd" contextRef="i156971f265ed4b789964f0e884da2478_D20211221-20211221" decimals="-6" name="gild:PaymentsToOptInTheCollaborativeAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3NjQ_e84f8f7f-d622-4cc1-8797-d3873b1ee181">725</ix:nonFraction> million were recorded in Other current liabilities on our Consolidated Balance Sheets as of December 31, 2021 and paid to Arcus in January 2022. Our payments to Arcus were included within Net cash used in investing activities on our Consolidated Statements of Cash Flows in the first quarter of 2022. Under the amended Collaboration Agreement, the companies co-develop and share the global costs related to these clinical programs. We recorded $<ix:nonFraction unitRef="usd" contextRef="i138aace7ae954687991de21bbcbf935f_D20220101-20221231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzQ5NDc4MDI1Nzk4Mjc_28f23885-d7a8-4198-af48-c148253f3545">187</ix:nonFraction> million of such costs in Research and development expenses on our Consolidated Statements of Income for the year ended December&#160;31, 2022. If the optioned molecules achieve regulatory approval, the companies will co-commercialize and equally share profits in the U.S. Gilead will hold exclusive commercialization rights outside the U.S., subject to any rights of Arcus&#8217;s existing collaboration partners, and will pay to Arcus tiered royalties as a percentage of net sales ranging from the mid teens to low twenties. Under the Collaboration Agreement, we may also pay an additional $<ix:nonFraction unitRef="usd" contextRef="i7645b620bfdd4f51895f7a3169f56f31_I20200713" decimals="-6" name="gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4MjI_e4337ec9-daf6-4639-8da2-f04b07b00ff6">100</ix:nonFraction> million at our option on each of the fourth, sixth and eighth anniversaries of the agreement, unless terminated early, to maintain the rights to opt in to future Arcus programs for the duration of the contact term. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pionyr</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, we entered into a transaction with Pionyr, a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate merger agreements, one contemplating the initial acquisition of a <ix:nonFraction unitRef="number" contextRef="i01d11dc0f9a54ca5b5c8a9bb3d0e5538_I20200619" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4MzM_bf123352-07b6-4f59-aa87-da188575760a">49.9</ix:nonFraction>% equity interest in Pionyr, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (together, the &#8220;Pionyr Merger and Option Agreements&#8221;) and a R&amp;D service agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2020, we closed the transaction and made cash payments of $<ix:nonFraction unitRef="usd" contextRef="i016d7a91b5e04c58945de8f96fb29672_D20200713-20200713" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4Mzc_102425f0-eee5-4bb6-8db8-3336fde1d52e">269</ix:nonFraction> million. We account for our investment in Pionyr using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Pionyr. Our investment in Pionyr, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Pionyr's net assets at transaction closing. We determined that the resulting basis difference primarily relates to Pionyr&#8217;s IPR&amp;D which has no alternative future use and that Pionyr is not a business as defined in accounting standards. As a result, we immediately recorded a charge for this basis difference of $<ix:nonFraction unitRef="usd" contextRef="i1c6ac8024c8e4d0dba576efa9455806e_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4NDQ_f5410550-bfca-46b2-9936-85b49824d3ca">215</ix:nonFraction> million in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. The carrying value of our equity method investment in Pionyr was <ix:nonFraction unitRef="usd" contextRef="i200b7ebaf9d741dda60fabffb43ff601_I20221231" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4NTE_72485c4e-30d9-4ff9-a34f-336cbb15433f"><ix:nonFraction unitRef="usd" contextRef="ic28bdc6a3eb0421bb098c47b028e6ed7_I20211231" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4NTE_931da3ff-c2f0-49cf-bf6c-1b524f959614">zero</ix:nonFraction></ix:nonFraction> as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Pionyr is approximately $<ix:nonFraction unitRef="usd" contextRef="id73ecb9294534bdda3109b865875a37a_I20200713" decimals="-6" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4NjE_2465bd78-6f80-453c-bf4b-df36c019595f">70</ix:nonFraction> million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount is recorded in Other long-term assets on our Consolidated Balance Sheets. We may choose to exercise our exclusive option to purchase the remaining equity interest from Pionyr&#8217;s current shareholders for a $<ix:nonFraction unitRef="usd" contextRef="id73ecb9294534bdda3109b865875a37a_I20200713" decimals="-6" name="gild:EquityMethodInvestmentOptionExerciseFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4Njg_26e489fe-50e9-40d1-b48e-ace40649858f">315</ix:nonFraction> million option exercise fee and up to $<ix:nonFraction unitRef="usd" contextRef="i016d7a91b5e04c58945de8f96fb29672_D20200713-20200713" decimals="-8" name="gild:PotentialFutureMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4NzQ_71a7f699-4916-471e-96b5-701e840704bb">1.2</ix:nonFraction> billion in potential future milestone payments upon achievement of certain development and regulatory milestones. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Pionyr. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the R&amp;D service agreement, we made an initial cash funding of $<ix:nonFraction unitRef="usd" contextRef="if7b11be3257e4f40a3e503c8bc3746c3_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4ODM_fbccbee9-e078-4535-ad68-59a31b4bd74f">80</ix:nonFraction> million and recorded a charge in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. In addition, we committed to provide additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="ie187f099f6884416a506c2273b834248_I20200713" decimals="-6" name="gild:ResearchAndDevelopmentFutureMaximumPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4OTA_3b1474d7-e0b2-45bd-bf4d-1c3060694066">115</ix:nonFraction> million to Pionyr upon achievement of certain development milestones. We accrued $<ix:nonFraction unitRef="usd" contextRef="if7b11be3257e4f40a3e503c8bc3746c3_D20200101-20201231" decimals="-6" name="gild:AdditionalResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4OTc_ed50fe09-5c42-4a40-bba9-1abb6cc5ea05">70</ix:nonFraction> million in milestone payments, related to the initiation of two Phase 1 studies, with a charge to Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020, and the payment was made in the first quarter of 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tizona</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, we entered into a transaction with Tizona, a privately held company developing cancer immunotherapies, which included entry into two separate merger agreements, one contemplating the initial acquisition of a <ix:nonFraction unitRef="number" contextRef="i9841318d0cc04cdca6946b8f50b2d1e2_I20200717" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5MDQ_9719f88b-07da-4b18-8256-b6857a8da681">49.9</ix:nonFraction>% equity interest in Tizona, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Tizona (together, the &#8220;Tizona Merger and Option Agreements&#8221;) and a development agreement. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i9e53a326099b4467b0c525f8acf02204" continuedAt="i33f17b7ccd39410bbace2ae380f90167"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, we closed the transaction with Tizona and made cash payments of $<ix:nonFraction unitRef="usd" contextRef="i71a5441f80434f7fb81b3ead03db9f77_D20200825-20200825" decimals="-6" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5MDg_b1c6c563-b444-487e-aaf7-a27f893c65b5">302</ix:nonFraction> million to Tizona&#8217;s shareholders in accordance with the terms of the Tizona Merger and Option Agreements. We account for our investment in Tizona using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Tizona. Our investment in Tizona, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Tizona&#8217;s net assets at transaction closing. We determined that the resulting basis difference primarily relates to Tizona&#8217;s IPR&amp;D with no alternative future use and that Tizona is not a business as defined in accounting standards. As a result, during the year ended December 31, 2020, we immediately recorded a charge for this basis difference of $<ix:nonFraction unitRef="usd" contextRef="i2116fe68676542f08655b70510bcbc39_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5MTU_9403abbf-1ca6-449e-8c57-ebf55fa71610">272</ix:nonFraction> million in Acquired in-process research and development expenses on our Consolidated Statements of Income. The carrying value of our equity method investment in Tizona was <ix:nonFraction unitRef="usd" contextRef="if64523d7bf4f4c6bbcf933b3fa695ad0_I20221231" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5MzQ_9423ab23-6fee-443b-90c4-2c6eeee9f346"><ix:nonFraction unitRef="usd" contextRef="iafaadd0b51b8476e9b35ffba851e4d74_I20211231" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5MzQ_ed06ffb5-d969-45bf-8847-f26f90cc2e4a">zero</ix:nonFraction></ix:nonFraction> as of December&#160;31, 2022 and 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Tizona is approximately $<ix:nonFraction unitRef="usd" contextRef="i70ddfe12d2d14dcd90c45e6ba0df7567_I20200825" decimals="-6" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5MjQ_c2893003-3213-489f-af6c-4da3af036b02">41</ix:nonFraction> million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount is recorded in Other long-term assets on our Consolidated Balance Sheets. We may choose to exercise our exclusive option to purchase the remaining equity interest from Tizona&#8217;s current shareholders for a $<ix:nonFraction unitRef="usd" contextRef="i70ddfe12d2d14dcd90c45e6ba0df7567_I20200825" decimals="-6" name="gild:EquityMethodInvestmentOptionExerciseFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5NDE_7e443e89-1055-4805-ae38-19bea4ea6c7f">100</ix:nonFraction> million option exercise fee and up to $<ix:nonFraction unitRef="usd" contextRef="i57942f7799d54d7f9080cf71318c3ad9_I20200825" decimals="-6" name="gild:EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5NDc_289c1849-f84e-4d92-87c0-ce9a642e7aab">1.2</ix:nonFraction> billion in potential future milestone payments upon achievement of certain development and regulatory milestones. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Tizona. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the development agreement, we committed to provide funding to Tizona of $<ix:nonFraction unitRef="usd" contextRef="i81f791b61360445b9d059ca216fb9e27_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzM4NDgyOTA5NTE4MzA_5e0f43ae-41da-4fd2-bcc0-338280eef251">115</ix:nonFraction> million, which was recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tango Therapeutics, Inc. (&#8220;Tango&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2020, we entered into a transaction with Tango, a privately held company pursuing innovative targeted immune evasion therapies for patients with cancer through its proprietary, CRISPR-enabled functional genomics target discovery platform, which included entry into an amended and restated research collaboration and license agreement and a stock purchase agreement (together, the &#8220;Tango Collaboration and Stock Purchase Agreements&#8221;). </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5NjQ_939ad9ab-e390-4aa0-bd46-1d99db1b83eb">125</ix:nonFraction> million and a $<ix:nonFraction unitRef="usd" contextRef="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817" decimals="-6" name="gild:CashPaymentsMadeRelatedToEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5ODY_3ff1195a-fe9e-47a9-87ec-5b636eefe727">20</ix:nonFraction> million equity investment in Tango. During the year ended December 31, 2020, we recorded the $<ix:nonFraction unitRef="usd" contextRef="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4OTUwMDQ_1a5511c8-ee81-48aa-ba0e-74c61ef5c357">125</ix:nonFraction> million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income. In the third quarter of 2021, we made an additional $<ix:nonFraction unitRef="usd" contextRef="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5OTM_5d3b731c-c829-4ffc-88d5-ccd31975606a">13</ix:nonFraction> million equity investment. Tango became a publicly traded company in 2021, and accordingly our equity investment has since been recorded in Prepaid and other current assets on our Consolidated Balance Sheets at fair market value.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tango Collaboration and Stock Purchase Agreements, Gilead has the right to option up to <ix:nonFraction unitRef="program" contextRef="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817" decimals="INF" name="gild:NumberOfPrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzcwMTA_926ef186-9cdf-40b2-ac49-a4a4658e2781">15</ix:nonFraction> programs over the <ix:nonNumeric contextRef="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817" name="gild:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODE1_0bf3a5a5-a342-4715-b60a-997913c48b49">seven-year</ix:nonNumeric> collaboration for up to $<ix:nonFraction unitRef="usd" contextRef="i0c965202198f48ec9fd033a927a99823_D20200817-20200817" decimals="-6" name="gild:EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzcwMDM_d940c99c-eae6-47f1-8903-05f41de9cc0f">410</ix:nonFraction> million per program in opt-in, extension and milestone payments. For the products that Tango opts to co-develop and co-promote, the parties will equally split profits and losses, as well as development costs in the U.S. For products that Tango does not opt to co-develop and co-promote, we will pay Tango up to low double-digit tiered royalties on net sales. We will provide Tango milestone payments and royalties on sales outside of the U.S. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Jounce Therapeutics, Inc. (&#8220;Jounce&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, we entered into a transaction with Jounce, a publicly traded company developing novel cancer immunotherapies, which included entry into license, registration rights and stock purchase agreements (together, &#8220;Jounce License and Stock Purchase Agreement&#8221;). In October 2020, we closed this transaction and made a total payment of $<ix:nonFraction unitRef="usd" contextRef="if9369ae332d1495a882a011455d3dff2_D20201001-20201031" decimals="-6" name="gild:TotalUpfrontPaymentsMade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzcwMzY_5fc8b2b3-4c7a-4bf3-a9d2-b24a164b10e2">120</ix:nonFraction> million. We recorded $<ix:nonFraction unitRef="usd" contextRef="if9369ae332d1495a882a011455d3dff2_D20201001-20201031" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzcwNTI_839fd925-faa1-45d6-ab56-8c76884d9157">64</ix:nonFraction> million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income and $<ix:nonFraction unitRef="usd" contextRef="if9369ae332d1495a882a011455d3dff2_D20201001-20201031" decimals="-6" name="gild:CashPaymentsMadeRelatedToEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzcwNjY_857f1203-3dad-4120-8f31-c19edce3c640">56</ix:nonFraction> million as an equity investment in Other long-term assets on our Consolidated Balance Sheets, representing approximately <ix:nonFraction unitRef="number" contextRef="i32bd6912cab14eadbb3318f66acae3dd_I20201031" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzcwNzg_36d9e786-3567-4a52-8808-58bf03f9f06e">14</ix:nonFraction>% of the issued and outstanding voting stock of Jounce immediately following the transaction, which was calculated based on Jounce&#8217;s closing stock price on the closing date of the transaction. In December 2022, we amended our existing license agreement with Jounce enabling us to buy out the remaining contingent payments potentially due under the license agreement for $<ix:nonFraction unitRef="usd" contextRef="i98853617c7ee492bac67c931971fb5b8_D20221201-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA3MDQxMg_04565a8a-3344-4c43-8a50-d2cba546c693">67</ix:nonFraction> million, which was expensed to Acquired in-process research and development expenses on our Consolidated Statements of Income and was paid in 2022. Going forward, we will be solely responsible for all further research, development and commercialization of the immunotherapy specified in the license agreement.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i33f17b7ccd39410bbace2ae380f90167" continuedAt="i2d66b290d0844e4b81f7187c43910e6a"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Galapagos</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Filgotinib Collaboration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we closed a license and collaboration agreement with Galapagos, a clinical-stage biotechnology company based in Belgium, for the development and commercialization of filgotinib, a JAK1-selective inhibitor being evaluated for inflammatory disease indications (the &#8220;filgotinib agreement&#8221;). Under the terms of the filgotinib agreement, as amended in 2019 (the &#8220;2019 Agreement&#8221;), we obtained an exclusive, worldwide, royalty-bearing, sublicensable license for filgotinib and products containing filgotinib. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Gilead and Galapagos amended their agreement to allow Galapagos to assume development, manufacturing, commercialization and certain other rights for filgotinib in Europe. In connection with the amendments to the 2019 Agreement, Gilead agreed to irrevocably pay Galapagos &#8364;<ix:nonFraction unitRef="eur" contextRef="iafbe177f342940c6bfb9527cc4113ba3_I20201215" decimals="-6" name="gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzczNTk_13db1d0f-e19b-42d9-8bc5-329bb77aee76">160</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="iafbe177f342940c6bfb9527cc4113ba3_I20201215" decimals="-6" name="gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzczNTM_19d82e02-0d78-4079-9090-9200a7c31be5">190</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Of this total amount, Gilead paid &#8364;<ix:nonFraction unitRef="eur" contextRef="i021e03a868e241539ef14f9a4a5d5eff_D20210101-20210131" decimals="-6" name="gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzczNzg_0d46d5eb-4037-4668-a2e1-eb418837d198">35</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="i021e03a868e241539ef14f9a4a5d5eff_D20210101-20210131" decimals="-6" name="gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzczOTY_f8542c6a-a19b-4332-a8b3-c45b7f450544">43</ix:nonFraction> million) in January 2021, an additional &#8364;<ix:nonFraction unitRef="eur" contextRef="i6a34cfded76c4d25931ccbc7eb146801_I20210430" decimals="-6" name="gild:AdjustmentsOfBudgetedDevelopmentCostsPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0MTM_0493c5f3-f0b1-4f61-a895-93a49ed5125f">75</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="i6a34cfded76c4d25931ccbc7eb146801_I20210430" decimals="-6" name="gild:AdjustmentsOfBudgetedDevelopmentCostsPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0MzA_369a3f99-704a-4821-8772-3cb0a6c27733">88</ix:nonFraction> million) in April 2021, and &#8364;<ix:nonFraction unitRef="eur" contextRef="if22f3ebfb466459088b430f3aaf9fbe0_I20221231" decimals="-6" name="gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0NDg_8b5f71ed-9c0e-4195-ac6a-d8330d73c369">50</ix:nonFraction> million (or approximately $<ix:nonFraction unitRef="usd" contextRef="if22f3ebfb466459088b430f3aaf9fbe0_I20221231" decimals="-6" name="gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0NjU_94800c9b-c845-4134-bb50-80c7eba2bd7b">60</ix:nonFraction> million) in 2022. We accrued the full amount of this liability with a charge to Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. In addition, Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Collaboration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In&#160;August 2019, we closed an option, license and collaboration agreement (the &#8220;Galapagos Collaboration Agreement&#8221;) and a subscription agreement (the &#8220;Galapagos Subscription Agreement&#8221;), each with Galapagos, pursuant to which the parties entered into a global collaboration that covers Galapagos&#8217; current and future product portfolio (other than filgotinib). </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Galapagos Subscription Agreement, we purchased <ix:nonFraction unitRef="shares" contextRef="i561a20e735884dd09fd59922c428289f_I20190831" decimals="-5" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA2ODUyMQ_1e4fe3dd-091f-4f89-b260-656ca72d4414">6.8</ix:nonFraction> million new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by Galapagos sufficient to bring the number of shares owned by us to <ix:nonFraction unitRef="number" contextRef="i561a20e735884dd09fd59922c428289f_I20190831" decimals="3" name="gild:MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0NzI_8536326c-d623-41e6-99e9-81dc64a7208e">29.9</ix:nonFraction>% of the issued and outstanding shares at the time of our exercises. We currently own <ix:nonFraction unitRef="shares" contextRef="i2dd88b8c706745b7bfcd8184f6d34f23_I20191231" decimals="-5" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0NzU_20d1749c-51c9-4418-aeac-49f35b412c37">16.7</ix:nonFraction> million shares or approximately <ix:nonFraction unitRef="number" contextRef="i561a20e735884dd09fd59922c428289f_I20190831" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0ODM_a59f98e5-d60d-4bd5-bdbf-3e21cde9ff8e">25.8</ix:nonFraction>% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a <ix:nonNumeric contextRef="i5ff8d15cd938494a955c3470b06e15f7_D20190801-20190831" name="gild:StandstillRestrictingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODE2_60f650fe-0484-4cc8-af5c-72f77cede3b7">10-year</ix:nonNumeric> standstill restricting our ability to acquire voting securities of Galapagos exceeding more than <ix:nonFraction unitRef="number" contextRef="i561a20e735884dd09fd59922c428289f_I20190831" decimals="3" name="gild:MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA2ODMxNA_3ffdaaf0-47f6-4528-a6e2-078f7c4d41be">29.9</ix:nonFraction>% of the then-issued and outstanding voting securities of Galapagos. We agreed not to, without the prior consent of Galapagos, dispose of any equity securities of Galapagos prior to the second anniversary of the closing of the Galapagos Subscription Agreement or dispose of any equity securities of Galapagos thereafter until the fifth anniversary of the closing of the Galapagos Subscription Agreement, if after such disposal we would own less than <ix:nonFraction unitRef="number" contextRef="i561a20e735884dd09fd59922c428289f_I20190831" decimals="3" name="gild:MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA2ODMxOA_bbdb1ae9-5f22-4c30-a4c3-16d332d41a04">20.1</ix:nonFraction>% of the then-issued and outstanding voting securities of Galapagos, subject to certain exceptions and termination events. In April 2021, we amended the Galapagos Subscription Agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to programs in Galapagos&#8217; current and future pipeline, if we exercise our option to a program, we will pay a $<ix:nonFraction unitRef="usd" contextRef="i561a20e735884dd09fd59922c428289f_I20190831" decimals="-6" name="gild:PotentialOptionExerciseFeePerProgram" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0ODc_d5b76d60-c68c-4795-9a2d-c3f8fe3d69f9">150</ix:nonFraction> million option exercise fee per program. In addition, Galapagos will receive tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="i561a20e735884dd09fd59922c428289f_I20190831" decimals="2" name="gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0OTY_719bc437-c6db-4e38-a39b-19a66973cfbb">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i561a20e735884dd09fd59922c428289f_I20190831" decimals="2" name="gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4ODI1MDA_ac2a3782-a67d-4879-872e-b0a92efec3b7">24</ix:nonFraction>% on net sales in our territories of each Galapagos product optioned by us. If we exercise our option for a program, the parties will share equally in development costs and mutually agreed commercialization costs incurred subsequent to our exercise of the option. We may terminate the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events. We have two designees appointed to Galapagos&#8217; board of directors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Janssen</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Complera/Eviplera and Odefsey</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, we entered into a license and collaboration agreement with Janssen, formerly Tibotec Pharmaceuticals, to develop and commercialize a fixed-dose combination of our Truvada and Janssen&#8217;s non-nucleoside reverse transcriptase inhibitor, rilpivirine, This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen&#8217;s rilpivirine and our emtricitabine and tenofovir alafenamide (&#8220;Odefsey&#8221;). </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i2d66b290d0844e4b81f7187c43910e6a" continuedAt="ida85543c88e94aaa9b09534d54dd9835"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party&#8217;s component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen&#8217;s share of revenues, including up to <ix:nonFraction unitRef="number" contextRef="id348a415186e4a219b8e1335dc1ce1ae_I20141231" decimals="2" name="gild:PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1MDA_836a0f2b-3383-4c55-8371-248ece73158a">30</ix:nonFraction>% in major markets. Sales of these products are included in Product sales and Janssen&#8217;s share of revenues is included in Cost of goods sold on our Consolidated Statements of Income. Cost of goods sold relating to Janssen&#8217;s share was $<ix:nonFraction unitRef="usd" contextRef="ic5f7160626e0482aa57280e46676f4b9_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1MjA_6e861952-ebc3-44d6-bd4c-54f093f18656">483</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7b27bce0f57f43408b5d6611ea6202b5_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1MDU_bee14e3e-852b-4086-a95d-7207f6a55e9b">530</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia93636a3c58c408fbe02ea53965397ff_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1MTE_628dce1b-024f-4645-bba4-065f7d814adb">570</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products, in which case Janssen has the right to become the selling party for such country if the product has launched but has been on the market for fewer than <ix:nonNumeric contextRef="ic3809906dea34eddb658b6eb681b0746_D20140101-20141231" name="gild:CollaborativeAgreementProductMarketPeriodSubjectToTermination" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1Mjk_1d45515d-6d3a-4913-ab42-e6bf23271e87">10</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Symtuza</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen&#8217;s darunavir and our cobicistat, emtricitabine and tenofovir alafenamide (&#8220;Gilead Compounds&#8221;). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the Gilead Compounds and are the exclusive supplier of the Gilead Compounds. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Symtuza. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party&#8217;s component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Income primarily because we supply the Gilead Compounds to Janssen for Symtuza.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than <ix:nonNumeric contextRef="ic3809906dea34eddb658b6eb681b0746_D20140101-20141231" name="gild:CollaborativeAgreementProductMarketPeriodSubjectToTermination" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1MzM_73c14033-b1ea-4ad1-857a-adfed21ed1b3">10</ix:nonNumeric> years. Janssen may also terminate the entire agreement without cause. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Japan Tobacco, Inc. (&#8220;Japan Tobacco&#8221;) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2005, Japan Tobacco granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Income. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Income. Royalty expenses recognized were $<ix:nonFraction unitRef="usd" contextRef="i8dc6ff7bbfe146f790e94a1bf140cf21_D20220101-20221231" decimals="-6" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1MzY_28a8fef2-ab8c-40df-a50d-fd413f08169d">198</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i15224c301e61426ab8f8d27a3b9863f8_D20210101-20211231" decimals="-6" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1NDU_4de07801-db21-4c89-94cc-34988be5bd53">250</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4d6fdb8767134660ae43cba1ca191838_D20200101-20201231" decimals="-6" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1NTI_c8b913e9-d3e4-4a87-8838-d9ddbc1334b4">291</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 agreement, we paid Japan Tobacco $<ix:nonFraction unitRef="usd" contextRef="i60eff7e7e8194d3ca2b0fe59c130421e_D20181201-20181231" decimals="-6" name="gild:InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1NTk_90b587c3-3555-4e4b-ac19-5ed7913bb177">559</ix:nonFraction> million in cash and recognized an intangible asset of $<ix:nonFraction unitRef="usd" contextRef="i60eff7e7e8194d3ca2b0fe59c130421e_D20181201-20181231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1NjY_04b7401c-6e98-4b83-b374-11f4b839bba4">550</ix:nonFraction> million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over <ix:nonNumeric contextRef="i60eff7e7e8194d3ca2b0fe59c130421e_D20181201-20181231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODE4_cd56060f-2ea6-449e-8e55-bc0a5100081b">nine years</ix:nonNumeric>, representing the period over which the majority of the benefits are expected to be derived from the applicable products in our HIV portfolio. The amortization expense is classified as selling expense and recorded as Selling, general and administrative expenses on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ida85543c88e94aaa9b09534d54dd9835" continuedAt="i424fc0fce7ef4df98e125acf6d587468"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Everest</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Everest and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia (the &#8220;Territories&#8221;). Gilead subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to be made to Gilead and was recorded as a $<ix:nonFraction unitRef="usd" contextRef="i1d267ec0240944fe98ab627640747acb_I20201023" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzM4NDgyOTA5NjA3NDY_57626e88-6206-40bb-ac94-0544f03463cb">175</ix:nonFraction> million finite-lived asset as part of the purchase accounting. In the fourth quarter of 2022, we reacquired all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, Gilead will make $<ix:nonFraction unitRef="usd" contextRef="ia4dccea757f34cada4ff7ad4f868097e_D20221001-20221231" decimals="-6" name="gild:UpfrontPaymentsToTerminatePreviousAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzQzOTgwNDY3NzM0MDg_ca5a87e0-6e1e-464f-b452-2f8c401fe0dc">280</ix:nonFraction> million in upfront termination payments to Everest, of which $<ix:nonFraction unitRef="usd" contextRef="ia4dccea757f34cada4ff7ad4f868097e_D20221001-20221231" decimals="-6" name="gild:PaymentsToTerminatePreviousAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzQzOTgwNDY3NzM0MjI_b2b44cd7-a7b9-4fd0-ad5c-8da5966d3fab">84</ix:nonFraction> million was made in 2022, with the remaining amounts included in Other current liabilities on our Consolidated Balance Sheets as of December&#160;31, 2022. In addition, Everest is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i1b13652ec49d451b9134a37a2d7ddd69_D20220101-20221231" decimals="-6" name="gild:PotentialFutureMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzQzOTgwNDY3NzM0Mzc_9e6e58e5-3bac-442e-92c5-32679d040b16">175</ix:nonFraction> million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $<ix:nonFraction unitRef="usd" contextRef="i52460a4a2230491d8481379314fe3f77_D20221001-20221231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzQzOTgwNDY3NzM0NTI_cc514772-cf52-479f-bd61-75de9c95b9ea">406</ix:nonFraction> million in Selling, general and administrative expenses on our Consolidated Statements of Income, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. In addition, we recorded an acquired finite-lived asset with a fair value of $<ix:nonFraction unitRef="usd" contextRef="i52460a4a2230491d8481379314fe3f77_D20221001-20221231" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA3NjYyMw_03d4c7a7-972b-4ac9-87b6-6e58182456d4">50</ix:nonFraction> million for the commercial rights reacquired for products approved in the Territories.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Collaboration Arrangements That Are Not Individually Significant</span></div></ix:continuation><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i424fc0fce7ef4df98e125acf6d587468">During 2022, 2021 and 2020, we entered into several collaborations, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements of $<ix:nonFraction unitRef="usd" contextRef="i1e38b8bce9e8433699c11bb0d7911eaa_D20220101-20221231" decimals="-6" name="gild:UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1Nzg_b3273a4e-03fc-4fb0-b480-e217c47713cb">86</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ie041293ff2f94b94bb3eeae5382b1137_D20210101-20211231" decimals="-6" name="gild:UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1ODc_2e767835-352f-4f09-bfd0-71fe30e59c7f">177</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica9f3e6a16e841fb807eb9deab1f16b7_D20200101-20201231" decimals="-6" name="gild:UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1OTE_407febeb-ffe9-4cfb-b946-8156729260d5">129</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, within Acquired in-process research and development expenses on our Consolidated Statements of Income.</ix:continuation> </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_124"></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzQ5NDU_e4784006-939c-474e-86f4-91604d2f4c61" continuedAt="ia560ef22ff5a4abbac2f78619455bfb1" escape="true">DEBT AND CREDIT FACILITIES</ix:nonNumeric></span></div><ix:continuation id="ia560ef22ff5a4abbac2f78619455bfb1" continuedAt="i52f108c317694dd8abf8fa0852f5f462"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzQ5NDY_1605f8eb-a8b2-4917-b110-23448888441f" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94f7d5f595874e31babd47d1f943f03f_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzItNi0xLTEtMTY3NjY1_f8fb8fb4-5b3a-43ca-a7c4-39698850e8bc">1.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f7d5f595874e31babd47d1f943f03f_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzItOC0xLTEtMTY3NjY1_cb18aea2-c480-4a8d-841f-55729efd4471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e682eb04f72495694ed3396a628d82d_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzItMTAtMS0xLTE2NzY2NQ_b070487c-afd3-4238-8358-e6f2c023d316">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a5ea21b1a1b43f288b70665cfbd4480_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzMtNi0xLTEtMTY3NjY1_ea7c97c7-d8ae-4d3b-b6c9-bccb6615ca27">3.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5ea21b1a1b43f288b70665cfbd4480_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzMtOC0xLTEtMTY3NjY1_091cbf8f-0f5a-446d-ad88-0362bcf17553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id423610de99f429cadafe5a4274a7579_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzMtMTAtMS0xLTE2NzY2NQ_ed05c836-35ed-49e4-9bdf-a697cd906da2">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46a7ff031bd6498c94ca9dd5f3025f99_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzQtNi0xLTEtMTY3NjY1_38b020f1-f838-44cc-b2a0-5ccfc355c6d6">2.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a7ff031bd6498c94ca9dd5f3025f99_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzQtOC0xLTEtMTY3NjY1_9e93c330-8086-48cf-971e-ac85841d2182">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fbf6172d0c74ecf8b376de532d163ad_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzQtMTAtMS0xLTE2NzY2NQ_4dbabae6-fe40-4ebc-b3be-78c9466ac6ed">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72cca364459e4c9a9900d1ff55ebcbe1_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzUtNi0xLTEtMTY3NjY1_7ff7be04-bfde-4e37-8c9d-b3df83bb8007">0.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72cca364459e4c9a9900d1ff55ebcbe1_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzUtOC0xLTEtMTY3NjY1_9d6e85e7-fc81-49e7-9c2e-a8ffc803336e">1,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife4410a1d3ac4f6db988c4f916e2bfec_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzUtMTAtMS0xLTE2NzY2NQ_0823aedb-c772-4168-b845-89d09c4d1faa">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfa5f7601c0344768c77f746163923e9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzYtNi0xLTEtMTY3NjY1_81d5ea12-d313-40fa-8b6d-938d745ecb3b">3.70</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa5f7601c0344768c77f746163923e9_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzYtOC0xLTEtMTY3NjY1_592ba96a-f442-4e92-b7cd-fdeb75d79365">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if709c8f28db74549bd5a3161d97c21e0_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzYtMTAtMS0xLTE2NzY2NQ_c3111b46-43b5-4dca-a243-cd8e25934a8e">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic140c268cb72480b99affba2d2903761_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzctNi0xLTEtMTY3NjY1_81a83cfd-5a1b-4add-be1e-d1d127a5c582">3.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic140c268cb72480b99affba2d2903761_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzctOC0xLTEtMTY3NjY1_09e249b9-8612-4af3-a568-eef02f12365a">1,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0cddfe4bc224e0a87870c31c94df95e_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzctMTAtMS0xLTE2NzY2NQ_54df0570-8c68-41d6-8969-e2b1c92d2155">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68e57a3bf88e41bc8bcda7b3a61da0ed_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzgtNi0xLTEtMTY3NjY1_6ece3d06-b3ee-4ce9-83b7-54399747a19e">3.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68e57a3bf88e41bc8bcda7b3a61da0ed_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzgtOC0xLTEtMTY3NjY1_9e0b5c3b-b84e-4406-8339-47ac7366ac97">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3619c4f682548ff8c69c3e69dd442e2_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzgtMTAtMS0xLTE2NzY2NQ_68085e32-43c6-445e-ba11-dbd62f60b65f">2,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42f508896a1f48ef818931672fc82b7f_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzktNi0xLTEtMTY3NjY1_90e7f05a-2a91-44d4-acff-e15f11a1d5a8">2.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f508896a1f48ef818931672fc82b7f_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzktOC0xLTEtMTY3NjY1_6c0d82b7-3a38-45c8-9e9a-36de6290e909">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4befda2944dd4e48bbf33cbb6a800b3b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzktMTAtMS0xLTE2NzY2NQ_c8de28e1-1e38-4883-9caa-9b7aa9957421">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc01af360ccd4ed291a9c264b7a9d13d_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEwLTYtMS0xLTE2NzY2NQ_b2c38ed2-2418-4d16-86b0-d92c2835e2c7">1.20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc01af360ccd4ed291a9c264b7a9d13d_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEwLTgtMS0xLTE2NzY2NQ_ce613245-e8df-4076-b0a8-4f4302e8bf70">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d007723ea0d457f8381ae1dc771efe7_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEwLTEwLTEtMS0xNjc2NjU_6c716cb7-ed72-408b-a287-0048fe437b4a">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5968bcc3ccaf4e119907fba73d267d74_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzExLTYtMS0xLTE2NzY2NQ_b59f8324-7b56-4181-9868-cd7ded4de9d7">1.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968bcc3ccaf4e119907fba73d267d74_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzExLTgtMS0xLTE2NzY2NQ_d373e988-33e7-4e22-a3a6-561af3938f01">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12e3ef865c8244a080b985b6a3939718_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzExLTEwLTEtMS0xNjc2NjU_ed9b369f-a318-461d-9837-429d4f2a9e46">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a23e70b82e64cc79b08ee71a5bd6b2f_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEyLTYtMS0xLTE2NzY2NQ_7fddf2e8-78c2-48d6-b39f-31cfb0f30eb1">4.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a23e70b82e64cc79b08ee71a5bd6b2f_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEyLTgtMS0xLTE2NzY2NQ_1866a6d6-84ea-4b16-b72c-a4e8271d996a">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie69a01e11be94336a2f8daa28bd70c35_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEyLTEwLTEtMS0xNjc2NjU_b198da0a-8737-4f90-868e-2e1b2810972e">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4677adf6e0c14c858103e4db348e4694_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEzLTYtMS0xLTE2NzY2NQ_05a825fc-80c4-407f-919e-0459b9395e8d">4.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4677adf6e0c14c858103e4db348e4694_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEzLTgtMS0xLTE2NzY2NQ_085d518e-55a4-4364-8b70-6e80c47f7b49">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e53bc1666b4c059c137ce292a94b11_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEzLTEwLTEtMS0xNjc2NjU_4ce303ff-b972-4b50-adea-0a5cb95b1f69">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6733ec0f5d1e4796b8f94c12c762b012_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE0LTYtMS0xLTE2NzY2NQ_2fcc1003-0bcb-4c61-a17e-f868635d0b9a">2.60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6733ec0f5d1e4796b8f94c12c762b012_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE0LTgtMS0xLTE2NzY2NQ_a29be6a3-1a29-4194-aa49-77a5c490b9dd">988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14a47de090294df9b57b1251ef9289b5_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE0LTEwLTEtMS0xNjc2NjU_c08123e7-da42-4864-b077-1efa62fc1f1c">987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i175eed19d77e4a91a2d341be010e07f7_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE1LTYtMS0xLTE2NzY2NQ_80a84e8b-546b-4b1f-a288-03af47907441">5.65</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i175eed19d77e4a91a2d341be010e07f7_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE1LTgtMS0xLTE2NzY2NQ_59a4ee32-ecb5-4c2c-9c48-30b92eff4c4f">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d037f45ab54f7ca294996c4e283eb2_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE1LTEwLTEtMS0xNjc2NjU_bcbc1110-4f2b-42ec-85b8-db587e8366c6">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72a08c81dba348df8500cc3742e5df5d_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE2LTYtMS0xLTE2NzY2NQ_d4e7b552-2b25-49fa-9504-d088d66a9d38">4.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72a08c81dba348df8500cc3742e5df5d_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE2LTgtMS0xLTE2NzY2NQ_e7379d6a-b3f5-4a41-bd7f-bf13a91d976b">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ed8ad260cf481f964bb009ba049509_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE2LTEwLTEtMS0xNjc2NjU_5a8b21eb-b2a7-4979-b6a4-887469cabeb2">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1220d26ecab846bda8d60360ee0028bd_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE3LTYtMS0xLTE2NzY2NQ_01d3477a-f051-43d5-a849-8a2253b0d197">4.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1220d26ecab846bda8d60360ee0028bd_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE3LTgtMS0xLTE2NzY2NQ_365c14af-c484-47f4-979d-f2a8cc7fa702">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3feeb01e0b754048b12295e1fbb184c9_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE3LTEwLTEtMS0xNjc2NjU_19dc53a9-39c7-4261-8f33-dfa47ce30e17">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i52789550e4a34d6a81d8f70c1e195b8c_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE4LTYtMS0xLTE2NzY2NQ_2a1bdcc2-672e-45a0-9536-27f4bb95e157">4.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52789550e4a34d6a81d8f70c1e195b8c_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE4LTgtMS0xLTE2NzY2NQ_a58c9cdc-a460-4a37-aac8-8af3cd60dfb3">2,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i120a62d356e74c158afb261bb2ae839c_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE4LTEwLTEtMS0xNjc2NjU_6b01d4a2-08f3-4841-9e19-6c9fd8cceeba">2,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2fe59d0908e34a159160b1e26b01fb15_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE5LTYtMS0xLTE2NzY2NQ_9771590b-2162-45af-9f6d-d12e6f111ccd">4.15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fe59d0908e34a159160b1e26b01fb15_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE5LTgtMS0xLTE2NzY2NQ_9f7f76a0-3ebb-43cf-973d-2ae8fecf6412">1,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dcdd5d44dfb41e08635c954c03f9520_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE5LTEwLTEtMS0xNjc2NjU_879e9286-d522-4c2e-8760-19a1a33876f6">1,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31faa9b303f543e78b0b2176fa8247c9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIwLTYtMS0xLTE2NzY2NQ_c0bcd64b-1a32-483c-811e-6ab7c9b5f65f">2.80</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31faa9b303f543e78b0b2176fa8247c9_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIwLTgtMS0xLTE2NzY2NQ_4808a4de-0ce8-4590-a263-4f18fe8a8102">1,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i259c5faa64504524b5634abd51d1fc38_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIwLTEwLTEtMS0xNjc2NjU_d27b33e0-d581-4138-80f6-5f4393211a92">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33e120250c747548d29ff0a8b4ff7cc_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIxLTgtMS0xLTE2NzY2NQ_ee267dc2-c327-4812-920f-4f2cd5bc24ab">24,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e2c900d6e514479b136e94cce379e22_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIxLTEwLTEtMS0xNjc2NjU_e060dc3d-b5dc-42c2-98cf-8d3dbcfa598e">25,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d5cbf682a784526bc44e1be5f4b2591_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIyLTgtMS0xLTE2NzY2NQ_240a0d28-d58e-492e-96f2-610680e06ccb">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2aa040eb2c451cbda18a7f0add00c0_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIyLTEwLTEtMS0xNjc2NjU_20b56071-664e-4983-ae8c-c5c71a3897fb">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIzLTgtMS0xLTE2NzY2NQ_a8270d34-7996-4ca1-9bfa-52e609cc1029">25,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIzLTEwLTEtMS0xNjc2NjU_e2436807-1305-44ec-a88a-1fc9eb3bf1e4">26,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzI0LTgtMS0xLTE2NzY2NQ_f82f8b5b-0c01-4457-8c55-0ec9d3d4e51d">2,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzI0LTEwLTEtMS0xNjc2NjU_e340d557-9890-4d8e-9ef7-69da24e0a792">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzI1LTgtMS0xLTE2NzY2NQ_0895e003-2158-473a-85c9-bc73f81e1db9">22,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzI1LTEwLTEtMS0xNjc2NjU_0a83f2b6-e250-4587-889b-2d3006de2f6c">25,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i52f108c317694dd8abf8fa0852f5f462" continuedAt="i96e70c6c47a04bfb9070eba2f3841428"><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we repaid $<ix:nonFraction unitRef="usd" contextRef="ic270da4b44c84a5db419c3cd7630f579_D20220201-20220228" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDcxNTY_f969275c-5d0b-4c55-9693-2d231d0919b6">500</ix:nonFraction> million of senior unsecured notes prior to the March 2022 maturity by exercising a par call option. Additionally, in July 2022, we repaid $<ix:nonFraction unitRef="usd" contextRef="id302c14527e54b03b1462a8b781c544d_D20220701-20220731" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NTExMjg_0fefaa1e-31c3-44b1-baf7-449b999fd1d5">1.0</ix:nonFraction> billion of senior unsecured notes prior to the September 2022 maturity by exercising a par call option. <ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDcyMzE_71d1140c-5508-4aed-978c-060b1157d12d">No</ix:nonFraction> new debt was issued in 2022. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our senior unsecured fixed rate notes may be redeemed at our option at a redemption price equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="i39f1a4a42b2e42c8b1adac714d4b3849_D20220101-20221231" decimals="3" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDgwNzA_4db154e7-ff1f-4fe3-941e-a74f07e67342">100</ix:nonFraction>% of the principal amount of the notes to be redeemed and (ii) the sum, as determined by an independent investment banker, of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium, which are defined in the terms of the notes. The senior unsecured fixed rate notes also have a par call feature, exercisable at our option, to redeem the notes at par in whole, or in part, on dates ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEwOTk1MTE2MzcyNzc_a58a2f1f-515b-4f40-ba1a-00d6cf2d5f1b">two</span> to <ix:nonNumeric contextRef="i58df36e70f7647cf876057727793fb70_D20220101-20221231" name="gild:DebtInstrumentCallFeaturePeriodBeforeMaturity" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEwOTk1MTE2MzcyODE_233ba983-2139-4659-aa70-baabd3df9bd8">six months</ix:nonNumeric> prior to maturity. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption. The $<ix:nonFraction unitRef="usd" contextRef="ife4410a1d3ac4f6db988c4f916e2bfec_I20211231" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEwOTk1MTE2Mzc1NTQ_47d602c8-335a-485f-930e-fd16cbc466f4">1.5</ix:nonFraction> billion of <ix:nonFraction unitRef="number" contextRef="i72cca364459e4c9a9900d1ff55ebcbe1_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEwOTk1MTE2MzcwMzI_7ff7be04-bfde-4e37-8c9d-b3df83bb8007">0.75</ix:nonFraction>% senior unsecured notes due September 2023 also have a different call feature, exercisable at our option, to redeem the notes at par, in whole or in part, at any time until maturity.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a change in control and a downgrade in the rating of our senior unsecured notes below investment grade by Moody&#8217;s Investors Service, Inc. and S&amp;P Global Ratings, the holders may require us to purchase all or a portion of their notes at a price equal to <ix:nonFraction unitRef="number" contextRef="i39f1a4a42b2e42c8b1adac714d4b3849_D20220101-20221231" decimals="3" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDgzNDY_2d9b7996-f5de-40be-964b-97aa7260fda7">101</ix:nonFraction>% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest to the date of repurchase. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of December&#160;31, 2022 and 2021, we were not in violation of any covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics, we assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust (&#8220;RPI&#8221;), prior to our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over <ix:nonFraction unitRef="number" contextRef="i17fb44daa02d4c84b8bed20193956526_I20201023" decimals="0" name="gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEzMTk0MTM5NTQ1Mjc5_11f1ec56-6197-458b-afb0-7917b81d752f">16</ix:nonFraction> years. The estimated timing and amount of future expected royalty payments over the estimated term will be re-assessed each reporting period. The impact from changes in estimates will be recognized in the liability and the related interest expense prospectively. The liability related to future royalties was primarily included in Long-term debt, net on our Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revolving Credit Facilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into a new $<ix:nonFraction unitRef="usd" contextRef="i7184a423cb03437a853dc81095f40d56_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDg5Nzg_a61c4295-752a-4fd5-a223-557da6eb22f8">2.5</ix:nonFraction> billion <ix:nonNumeric contextRef="i1ed58c535ccd4faa9176f654b65aaa5b_D20200601-20200630" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEzMTk0MTM5NTQyNTY1_b18bdb66-1119-4feb-bc95-c79c950dccca">five-year</ix:nonNumeric> revolving credit facility maturing in June 2025 (the &#8220;2020 Revolving Credit Facility&#8221;). The 2020 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of December&#160;31, 2022 and 2021, there were <ix:nonFraction unitRef="usd" contextRef="i7bab656927b94fc98bcf55c11d946976_I20221231" decimals="-6" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDg5OTg_4696b440-1045-4abb-a1d0-7d3a3f4a2f59"><ix:nonFraction unitRef="usd" contextRef="i4655f4b3112c42b5817c56a6a39a9b66_I20211231" decimals="-6" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDg5OTg_93297201-e207-4e86-abb6-c5a9c8a59f09">no</ix:nonFraction></ix:nonFraction> amounts outstanding under the 2020 Revolving Credit Facility.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Revolving Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default. As of December&#160;31, 2022, we were in compliance with all covenants. Loans under the 2020 Revolving Credit Facility bear interest at either (i) the Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) plus the Applicable Percentage, or (ii) the Base Rate plus the Applicable Percentage, each as defined in the 2020 Revolving Credit Facility agreement. We may terminate or reduce the commitments, and may prepay any loans under the credit facility in whole or in part at any time without premium or penalty.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contractual Maturities of Financing Obligations</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzQ5NTY_9b70c71d-45c2-46fb-bd29-1ab3eb0251c6" escape="true"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate future principal maturities of our senior unsecured notes as of December&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzEtMi0xLTEtMTY3NjY1_13883864-ff19-4588-b701-21e4a03f06f0">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzItMi0xLTEtMTY3NjY1_6bb4845b-bf4d-402b-845e-25ead5230235">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzMtMi0xLTEtMTY3NjY1_c235dcf8-8147-46f2-8f8d-7d97a304acb2">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzQtMi0xLTEtMTY3NjY1_837f58b9-6260-4f39-8d4a-ba0a153d318e">2,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzUtMi0xLTEtMTY3NjY1_b0d34697-aee0-4290-a7f9-0c45edc59b6a">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzYtMi0xLTEtMTY3NjY1_7a67dcbd-3290-4c9d-bae6-8025d5eb04c6">13,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzctMi0xLTEtMTY3NjY1_dbbc2a44-87e7-445e-bd47-2b270fd8629e">24,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:continuation id="i96e70c6c47a04bfb9070eba2f3841428" continuedAt="i5c3db130579643709e3dac8ba9e050b8">Interest Expense</ix:continuation></span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5c3db130579643709e3dac8ba9e050b8">Interest expense on our debt and credit facilities related to the contractual coupon rates and amortization of the debt discount and issuance costs was $<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDgwNTU_8bfacd4f-413b-43ef-b620-c2b64f746248">940</ix:nonFraction> million in 2022 and $<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-8" name="us-gaap:InterestExpenseLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDgwNjM_7655fa54-227a-46af-8a48-d6b3b7a6f297">1.0</ix:nonFraction> billion in 2021 and 2020.</ix:continuation> </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_127"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzgxNQ_d41c12fa-6bc3-422a-8e33-cd5aa5ed7c3d" continuedAt="ie0331a15e5854a3eb9ad120cfa7c2f07" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="ie0331a15e5854a3eb9ad120cfa7c2f07"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases consist primarily of properties and equipment for our administrative, manufacturing and R&amp;D activities. Some of our leases include options to extend the terms for up to <ix:nonNumeric contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzE2NDkyNjc0NDI0ODI_431444ff-1df8-45dc-b57f-3ebe3c571220">15</ix:nonNumeric> years and some include options to terminate the lease within <ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseOptionToTerminate" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzE2NDkyNjc0NDI0ODY_f08dc8d7-5e7a-4677-9453-ae9e0a0fc1c4">one year</ix:nonNumeric> after the lease commencement date. As of December&#160;31, 2022 and 2021, we did not have material finance leases. Operating lease expense, including variable costs and short-term leases, was $<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzE2NDkyNjc0NDI1MDM_d396cd17-28f7-47da-baf0-a543dd0f506f">162</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzE2NDkyNjc0NDI0OTc_9ccf7652-9d11-425d-a851-a9b58e418f4e">156</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzE2NDkyNjc0NDI0OTA_dc37efb8-0dcf-4cf6-b03f-27a1f46b4872">171</ix:nonFraction> million in 2022, 2021 and 2020, respectively. </span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzgxMw_227a9bb0-9a08-4a1e-94d0-a5de6f2cf6ce" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balance sheet and other information related to our operating leases:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.131%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except weighted average amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_8de7020f-9548-47c7-9a1e-4746afc67ea4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_b3559456-f5cf-4d45-8c2a-793a81b2aed1">Other long-term assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItNC0xLTEtMTY3NjY1_5cba5616-6678-4bda-be0c-b34100c43e9c">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItNi0xLTEtMTY3NjY1_fac64965-1cb1-416e-ac39-1b49d0c4fb64">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities &#8211; current</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_37e207dc-5857-47ab-bc75-5d95f77eba00"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_566a40c8-fefd-4cc7-be50-3313dae89a4d">Other accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtNC0xLTEtMTY3NjY1_eb6ed2a3-706a-4776-9f68-a1cd0e9624d3">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtNi0xLTEtMTY3NjY1_31c62f41-bd53-4345-b549-7c17656fac9d">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities &#8211; noncurrent</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_083b769e-0d49-49bf-952b-f91005031157"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_6a8cd158-cdc0-45a1-ba9e-3851203d9cab">Other long-term obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtNC0xLTEtMTY3NjY1_7f928a72-9790-4f9e-926b-511e8851ce15">467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtNi0xLTEtMTY3NjY1_4d41ee2c-58cb-4c49-a9b2-f778ee59ac08">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzUtNC0xLTEtMTY3NjY1_e11249f0-48e4-4b9b-9e3a-510b7d751358">8.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzUtNi0xLTEtMTY3NjY1_2490d778-e987-4e4e-a052-8c640461b7b8">8.5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzYtNC0xLTEtMTY3NjY1_1231cd63-deaf-4f30-bc0a-f2726c71fbaf">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzYtNi0xLTEtMTY3NjY1_e558ea2a-89d0-4eb6-b28b-eb0ec7c6b99d">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to our operating leases:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTpkMWFmMTkwN2RkNjY0OGYxYTU1Y2MzODYwOTY3ODZkNy90YWJsZXJhbmdlOmQxYWYxOTA3ZGQ2NjQ4ZjFhNTVjYzM4NjA5Njc4NmQ3XzItMi0xLTEtMTY3NjY1_ec943463-9b2d-43a4-aa73-f4b67df9fb55">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTpkMWFmMTkwN2RkNjY0OGYxYTU1Y2MzODYwOTY3ODZkNy90YWJsZXJhbmdlOmQxYWYxOTA3ZGQ2NjQ4ZjFhNTVjYzM4NjA5Njc4NmQ3XzItNC0xLTEtMTY3NjY1_b00e373a-fdb4-4ee6-bfef-96e341d64fec">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTpkMWFmMTkwN2RkNjY0OGYxYTU1Y2MzODYwOTY3ODZkNy90YWJsZXJhbmdlOmQxYWYxOTA3ZGQ2NjQ4ZjFhNTVjYzM4NjA5Njc4NmQ3XzMtMi0xLTEtMTY3NjY1_b596cb6b-bde6-421e-90fd-96806ade8340">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTpkMWFmMTkwN2RkNjY0OGYxYTU1Y2MzODYwOTY3ODZkNy90YWJsZXJhbmdlOmQxYWYxOTA3ZGQ2NjQ4ZjFhNTVjYzM4NjA5Njc4NmQ3XzMtNC0xLTEtMTY3NjY1_7bb8ab49-5c16-4be1-ab0b-3223535a294f">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzgxNA_cebbd016-79f5-406f-92d6-d144ca7ca1ef" escape="true"><div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzEtMi0xLTEtMTY3NjY1_e5b830ca-e360-4529-a109-0742a6680bce">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzItMi0xLTEtMTY3NjY1_deace6f0-b8b7-4df0-b4ce-32407720b82b">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzMtMi0xLTEtMTY3NjY1_b5706714-7633-4520-a1e9-ac51ee1947ed">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzQtMi0xLTEtMTY3NjY1_30ecd23c-d59b-415c-a7c5-9f7ff2683e17">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzUtMi0xLTEtMTY3NjY1_9a03c932-52c3-49a5-af48-9838c8065123">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzYtMi0xLTEtMTY3NjY1_2fb5b4a8-a4c6-4810-8eb0-1b6e1dc66ae9">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzctMi0xLTEtMTY3NjY1_7f84d911-2b78-43d2-8445-c7bf357f4152">651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzgtMi0xLTEtMTY3NjY1_1eae4d78-659a-4818-a9e6-f00e8057e226">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total discounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzktMi0xLTEtMTY3NjY1_c37aa38c-13e0-4780-9935-d996c57a3117">578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_130"></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzI0NjMx_f4cf0f2a-7381-4c18-b44e-3b8bd444dc30" continuedAt="i8f09e212388e43afba41aa7f20786420" escape="true">COMMITMENTS AND CONTINGENCIES </ix:nonNumeric></span></div><ix:continuation id="i8f09e212388e43afba41aa7f20786420" continuedAt="iebcf3c5a2d514911b25ff464bd78b309"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Legal Proceedings</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. Certain significant matters are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did <ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="INF" name="us-gaap:LitigationReserve" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUyNTQ_93f83c85-da20-49d6-9c00-dfb5209b9378">no</ix:nonFraction>t have any material accruals for the matters described below as of December&#160;31, 2022. As of December&#160;31, 2021, we recorded an accrual of $<ix:nonFraction unitRef="usd" contextRef="ib5fb8687e8cd4caea5f84599504664c8_D20220201-20220228" decimals="-7" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUyMzQ_204660a6-58f4-4a74-827c-848e08856752"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-7" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUyMzQ_67ccb8f7-dbf4-4d47-9ec8-d98f49dd4607">1.25</ix:nonFraction></ix:nonFraction> billion in Accrued and other current liabilities on our Consolidated Balance Sheets for the previously disclosed legal settlement related to the bictegravir litigation, which we paid in February 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="iebcf3c5a2d514911b25ff464bd78b309" continuedAt="ia49e156837e84b0e82227a7af7100ee5"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of HCV. In 2013, we received approval from FDA for sofosbuvir, sold under the brand name Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concluded the inter partes review that it had initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#8217;s patent invalid. In July 2021, the University appealed this decision, and oral arguments before the Court of Appeals for the Federal Circuit were held in January 2023. The litigation in the U.S. District Court will remain stayed through the appeal proceedings.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with NuCana plc. (&#8220;NuCana&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuCana has obtained European Patent No. 2,955,190 (the &#8220;EP &#8217;190 patent&#8221;) that allegedly covers sofosbuvir. In opposition proceedings before the European Patent Office (&#8220;EPO&#8221;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#8217;190 patent in amended form. The EPO has now scheduled the appeal hearing for March 2023. We continue to believe that the amended EP &#8217;190 patent claims are invalid. Subsequent to the EPO opposition decision, we initiated proceedings to invalidate the U.K. counterparts of the EP &#8217;190 patent and a related patent, European Patent No. 3,904,365 (the EP &#8216;365 patent) in the High Court of England &amp; Wales. NuCana has also filed counterclaims against us in the High Court of England &amp; Wales alleging patent infringement of the U.K. counterparts and seeking damages and other relief. The U.K. case was heard in January and early February 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#252;sseldorf alleging patent infringement of the German counterpart of the EP &#8217;190 patent and seeking damages and injunctive relief. In April 2022, we filed an action for grant of a compulsory license before the Federal Patent Court in Germany. In July 2022, the D&#252;sseldorf court determined that NuCana&#8217;s German counterpart of the EP &#8217;190 patent is infringed and granted an injunction. In August 2022, Gilead filed a notice of appeal regarding the D&#252;sseldorf court&#8217;s decision, and a hearing is scheduled for August 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Related to Axicabtagene Ciloleucel</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes U.S. Patent No. 7,446,190 (the &#8220;&#8217;190 patent&#8221;). A jury trial was held on the &#8217;190 patent, and in December 2019, the jury found that the asserted claims of the &#8217;190 patent were valid, and that we willfully infringed the asserted claims of the &#8217;190 patent. The jury also awarded Juno damages in amounts of $<ix:nonFraction unitRef="usd" contextRef="i381dbbaeb14842d0957d6f5cdf308d28_D20191201-20191231" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUyNzQ_9190ebd6-4a8c-47b9-8005-dcdc5c38e7c3">585</ix:nonFraction> million in an upfront payment and a <ix:nonFraction unitRef="number" contextRef="i381dbbaeb14842d0957d6f5cdf308d28_D20191201-20191231" decimals="3" name="gild:JudgmentRoyaltyRateFromOctober2017" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUyODU_a83af996-1a8f-43ac-a790-c9be2c039dcf">27.6</ix:nonFraction>% running royalty from October 2017 through the date of the jury&#8217;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#8217;s verdict, enhanced the past damages by <ix:nonFraction unitRef="number" contextRef="ib9689ea2698f49518e3f35ebf341d9d2_I20200430" decimals="2" name="gild:JudgmentEnhancedDamagesOnPastSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzMDE_02dba917-7e7c-40cb-9566-fcd92d734942">50</ix:nonFraction>% and maintained the royalties on future Yescarta sales at <ix:nonFraction unitRef="number" contextRef="ib9689ea2698f49518e3f35ebf341d9d2_I20200430" decimals="3" name="gild:JudgmentRoyaltyRateOnFutureSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUyOTM_274843b6-85a8-4acb-a6fe-4c5b972659f3">27.6</ix:nonFraction>%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge, and in July 2021, the appeals court heard oral arguments. In August 2021, the Court of Appeals for the Federal Circuit (the &#8220;CAFC&#8221;) reversed the jury verdict, finding the asserted claims of Juno&#8217;s patent invalid. In October 2021, Juno filed a petition for rehearing with the CAFC. In January 2022, the CAFC denied Juno&#8217;s petition for rehearing. In June 2022, Juno filed a petition for certiorari seeking a review by the Supreme Court. The Supreme Court rejected Juno&#8217;s petition in January 2023, making the CAFC judgment final.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ia49e156837e84b0e82227a7af7100ee5" continuedAt="id0f6b2c7e21d45128753b72981dd9e6b"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of FTC and tenofovir disoproxil fumarate (&#8220;TDF&#8221;) or TAF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the U.S. Court of Federal Claims, alleging violations of <ix:nonFraction unitRef="agreement" contextRef="i64a2deb2d3f347b89108aa1f51ac3e1b_I20200430" decimals="INF" name="gild:LossContingencyMaterialTransferAgreementsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzMDU_ac727347-40d7-47c3-ac52-5978ca427f10">three</ix:nonFraction> material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and two clinical trial agreements (&#8220;CTAs&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of each of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial for the bifurcated portion of the lawsuit in the Court of Federal Claims was held in June 2022, and in November 2022, the Court determined that the government breached the three MTAs. The Court also made findings of fact relating to the CTAs but declined to issue a decision on breach of the CTAs until after trial in the Delaware District Court. A trial date for the lawsuit in the Delaware District Court has been set for May 2023. A separate trial at the Court of Federal Claims to determine the damages Gilead is owed based on the government&#8217;s breach has yet to be set.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our products will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we received a letter from Lupin Ltd. (&#8220;Lupin&#8221;) indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen (&#8220;Janssen&#8221;), filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Lupin asserting infringement of <ix:nonFraction unitRef="patent" contextRef="ic183ba3839714584846a1a616db08cbd_D20211001-20211031" decimals="INF" name="gild:LossContingencyAdditionalPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzMzA_1fa58f5a-53a3-49ff-95d7-014469853b8d">two</ix:nonFraction> additional patents in the same court. This second case has been stayed. Trial has been scheduled for October 2023. In September 2022, we received a letter from Apotex Inc. and Apotex Corp. (&#8220;Apotex&#8221;) stating that they have submitted an ANDA for a generic version of Symtuza. In October 2022, we, along with Janssen, filed a patent infringement lawsuit against Apotex as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Apotex asserting infringement of two additional patents in the same court. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in March 2022, we received letters from Lupin, Laurus Labs (&#8220;Laurus&#8221;) and Cipla Ltd. (&#8220;Cipla&#8221;), indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of <ix:nonFraction unitRef="patent" contextRef="i88bc63bfd5744353885db8517516f8c3_D20220301-20220331" decimals="INF" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzNDM_b36f9b03-6e50-48bf-b6ec-ea8d7feab38c">three</ix:nonFraction> of the <ix:nonFraction unitRef="patent" contextRef="i88bc63bfd5744353885db8517516f8c3_D20220301-20220331" decimals="INF" name="gild:LossContingencyNumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzNDc_e4ebaa28-8521-4a00-b487-e37bb24df8f7">five</ix:nonFraction> patents listed in the Orange Book as associated with Biktarvy. We filed a lawsuit against Lupin, Laurus and Cipla in May 2022 in the U.S. District Court of Delaware, and intend to enforce and defend our intellectual property. Trial has been scheduled for December 2024.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal hearing was held in November 2022, but a final decision regarding the validity of the claims has not yet been announced.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. The original opposing parties have appealed, requesting full revocation. The hearing for the appeal has been scheduled for September 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="id0f6b2c7e21d45128753b72981dd9e6b" continuedAt="i6275e5408172447aa6f75418093d28d8"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. <ix:nonFraction unitRef="opposingparty" contextRef="i5013c57ba1f641bd9a9a482a7a391bf2_I20191231" decimals="INF" name="gild:LossContingencyPartiesAppealedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzNzM_8d06d6ca-7497-46ba-b010-afa6c37cfdb1">Three</ix:nonFraction> parties have appealed this decision. The hearing for the appeal has been scheduled for March 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir and TAF hemifumarate in the EU could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and Johnson &amp; Johnson, Inc., have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of direct purchasers consisting largely of wholesalers and indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the second half of 2021 and first half of 2022, several plaintiffs filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the putative classes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These cases have been coordinated with the class actions. Trial has been set for May 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we, along with BMS and Janssen Products, L.P., were named as defendants in a lawsuit filed in the Superior Court of the State of California, County of San Mateo, by Aetna, Inc. on behalf of itself and its affiliates and subsidiaries that effectively opts the Aetna plaintiffs out of the above class actions. The allegations are substantively the same as those in the class actions. The Aetna plaintiffs seek damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we, along with generic manufacturers Cipla and Cipla USA Inc. (together, &#8220;Cipla Defendants&#8221;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and the Cipla Defendants, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we, along with BMS and Teva Pharmaceutical Industries Ltd., were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="iea228f095581408787a759595c70e968_D20220101-20221231" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzODA_701a1db9-4fd9-4e6a-b214-4d7079523d44">one</ix:nonFraction> class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Florida, Missouri and New York, involve more than <ix:nonFraction unitRef="plaintiff" contextRef="iea228f095581408787a759595c70e968_D20220101-20221231" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzODY_661eb1d9-71a9-4040-8562-99b64e0f0bc2">26,000</ix:nonFraction> plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. The first bellwether trial in California state court was scheduled to begin in October 2022, but is currently stayed while the California First District Court of Appeal considers the merits of plaintiffs&#8217; theories of liability. The first bellwether trial in California federal court is scheduled to begin in January 2024. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Investigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i6275e5408172447aa6f75418093d28d8"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead&#8217;s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The relator seeks all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice Advocates, LLC (&#8220;Health Choice&#8221;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#8217;s dismissal.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. In September 2021, the Texas Court of Appeals for the Sixth Court Appeals District granted our request to stay the Texas litigation pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. In June 2022, plaintiffs filed their Motion for Class Certification, and Immunomedics submitted its Opposition in July 2022. The parties have agreed to settle this litigation. A motion seeking preliminary approval of the settlement was granted in February 2023. The court has not yet entered a final order approving the settlement. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated financial position, results of operations or cash flows.</span></div></ix:continuation><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_133"></div><div style="margin-top:13.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzI3Mjg_9bfef954-6802-42b0-9924-6350ba48e096" continuedAt="i74d94384f07f40b380cd69dbc4c8ddb7" escape="true">STOCKHOLDERS&#8217; EQUITY </ix:nonNumeric></span></div><ix:continuation id="i74d94384f07f40b380cd69dbc4c8ddb7" continuedAt="i185d2f6c234c492a81804c835eb21ebf"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a $<ix:nonFraction unitRef="usd" contextRef="i27765a75461d4d2081b2a23a1daaf601_I20200331" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzE2NDkyNjc0NDQ0NzM_aaec4085-5121-4311-b875-d62a23a99cf5">5.0</ix:nonFraction> billion&#160;stock repurchase program (&#8220;2020 Program&#8221;). Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions. The $<ix:nonFraction unitRef="usd" contextRef="ia23032332ced4abab639e98fc3486e66_I20160331" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzU0OTc1NTgyMTEzMg_808bbcc4-914f-40aa-82cf-e27d067f24ef">12.0</ix:nonFraction> billion stock repurchase program authorized by our Board of Directors in the first quarter of 2016 was completed in the fourth quarter of 2022. We started repurchases under the 2020 Program in December 2022. As of December&#160;31, 2022, the remaining authorized repurchase amount under the 2020 Program was $<ix:nonFraction unitRef="usd" contextRef="i3967341da57b4f3caa9d502babffc1d5_I20221231" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzE2NDkyNjc0NDQ0ODA_2c69e01b-9428-4f08-81ca-0bb89bc233bd">4.9</ix:nonFraction> billion.</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzI3NDA_5a6eb522-f90b-4769-8b43-a46805f2037f" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock repurchases through open market transactions under these programs:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased and retired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzItMi0xLTEtMTY3NjY1_f22cdc03-a2d7-4d6c-be30-f8c07ec39a38">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzItNC0xLTEtMTY3NjY1_e02b3b08-1300-403d-9cb6-25903edc458b">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzItNi0xLTEtMTY3NjY1_ba8af475-2dd8-46da-9874-5575498b100e">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzMtMi0xLTEtMTY3NjY1_c276dfb9-66db-4227-9cb7-7dea4df941cf">1,396</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzMtNC0xLTEtMTY3NjY1_ead07804-716d-45c8-992c-9cc72b5f2a64">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzMtNi0xLTEtMTY3NjY1_664d79bb-487a-496d-b76c-0347ae4c4c7e">1,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzQtMi0xLTEtMTY3NjY1_50fa55bb-1bf4-4606-9d35-cdb94c2ba6aa">73.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzQtNC0xLTEtMTY3NjY1_63964f0a-2c8d-410f-985a-a539644dd439">66.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzQtNi0xLTEtMTY3NjY1_b8992b18-2e1b-461b-b7e5-3cfb376c575d">70.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to repurchases from the stock repurchase programs, we repurchased shares of common stock withheld by us from employee restricted stock awards to satisfy our applicable tax withholding obligations. These shares are excluded from the table above. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i185d2f6c234c492a81804c835eb21ebf"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the par value method of accounting for our stock repurchases. Under the par value method, common stock is first charged with the par value of the shares involved. The excess of the cost of shares acquired over the par value is allocated to Additional paid-in capital based on an estimated average sales price per issued share with the excess amounts charged to Retained earnings. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Dividends</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:DividendsDeclaredTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzI3NTg_e261d37b-1be6-4dd9-8109-b729b72b3edc" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash dividends declared on our common stock:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib808ed4dfe4e411999e03f92bc995798_D20220101-20220331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzItMi0xLTEtMTY3NjY1_b8369dab-efc2-4e33-9e9e-baa6c6b01b5e">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib808ed4dfe4e411999e03f92bc995798_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzItNC0xLTEtMTY3NjY1_e2472282-1e76-4770-bbd2-b4d3192ffbc4">932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i14329a4081124b6fbf3b38e4aae01606_D20210101-20210331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzItNi0xLTEtMTY3NjY1_9c456134-b7cb-4476-b586-8c76d055f4ae">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14329a4081124b6fbf3b38e4aae01606_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzItOC0xLTEtMTY3NjY1_5919a7f7-cae0-4462-82c6-271957262879">906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifdde5e060f4745f89cb9aa85e12fd275_D20220401-20220630" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzMtMi0xLTEtMTY3NjY1_27ce4a42-cc9a-4daa-8582-9fcb7cbed4a1">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdde5e060f4745f89cb9aa85e12fd275_D20220401-20220630" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzMtNC0xLTEtMTY3NjY1_8dfdca4b-2444-49c1-82d5-9cd78ceebc55">932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9ca1e84f12844d697f1ea6824ff7451_D20210401-20210630" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzMtNi0xLTEtMTY3NjY1_e06117aa-3dd8-4bc9-811b-4a2bfedb6675">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ca1e84f12844d697f1ea6824ff7451_D20210401-20210630" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzMtOC0xLTEtMTY3NjY1_001590a2-ea64-4e18-80c4-97474447a139">903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i413b2fc67238496985ac43774e9116b6_D20220701-20220930" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzQtMi0xLTEtMTY3NjY1_4eb5d2e9-eeae-4cc8-8c0c-c3e79f5d868b">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i413b2fc67238496985ac43774e9116b6_D20220701-20220930" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzQtNC0xLTEtMTY3NjY1_f40da00a-b844-46e9-b225-30604612b3f1">933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iad684e32333e4d028165723fb0a3c25d_D20210701-20210930" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzQtNi0xLTEtMTY3NjY1_4b079be2-02ca-4e5f-899a-b42768cbcf44">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad684e32333e4d028165723fb0a3c25d_D20210701-20210930" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzQtOC0xLTEtMTY3NjY1_04da6a3f-22ec-48bd-98ba-50687816f838">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie85479b87980466db067faedfa50f2bd_D20221001-20221231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzUtMi0xLTEtMTY3NjY1_95c8defc-6742-45bf-bed6-fd34723cddd5">0.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85479b87980466db067faedfa50f2bd_D20221001-20221231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzUtNC0xLTEtMTY3NjY1_98a0e99c-820b-4478-926e-13c262c466ca">928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ec4c04bdd21487da1fbeecdbf019611_D20211001-20211231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzUtNi0xLTEtMTY3NjY1_9a3ff3bb-4037-4ebe-98a9-ede7049802ae">0.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ec4c04bdd21487da1fbeecdbf019611_D20211001-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzUtOC0xLTEtMTY3NjY1_27092290-a365-4987-bc06-ef76883f962c">904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzYtMi0xLTEtMTY3NjY1_84e1de31-291d-4048-9a88-466f94667c90">2.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzYtNC0xLTEtMTY3NjY1_f6f63e40-6037-4f25-aa70-ec48dae51dd0">3,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzYtNi0xLTEtMTY3NjY1_b6344430-1abe-4ea3-afe8-1996a10500df">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzYtOC0xLTEtMTY3NjY1_0b156839-5fd9-4897-ab23-dd732e255e3e">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RSUs and PSUs have dividend equivalent rights entitling holders to dividend equivalents to be paid upon vesting for each share of the underlying unit.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;2, 2023, we announced that our Board of Directors declared a quarterly cash dividend increase of <ix:nonFraction unitRef="number" contextRef="i925d522b8c534cdf821c642767a2b8c5_D20230202-20230202" decimals="3" name="gild:ChangeInDividendsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzU0OTc1NTgxOTY0OQ_509f6d6c-dd7b-4cc3-ae49-e5fac5697c79">2.7</ix:nonFraction>% from $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc0e2948c490453d8a2ebfca402b6cfb_D20220201-20220201" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzU0OTc1NTgxOTY0Mg_673ede39-0c96-4b63-b0a7-787cb6ba243a">0.73</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i925d522b8c534cdf821c642767a2b8c5_D20230202-20230202" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzU0OTc1NTgxNzIyNQ_8caf0f12-6afa-476a-a424-9d3103c7c730">0.75</ix:nonFraction> per share of our common stock, with a payment date of March&#160;30, 2023 to all stockholders of record as of the close of business on March&#160;15, 2023. Future dividends are subject to declaration by our Board of Directors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Preferred Stock</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="shares" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzE2NDkyNjc0NDQ0OTI_5a1dcaf5-d237-468b-9ea2-40a6d9b818bf">5</ix:nonFraction> million shares of authorized preferred stock issuable in series. Our Board is authorized to determine the designation, powers, preferences and rights of any such series. There was <ix:nonFraction unitRef="shares" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzE2NDkyNjc0NDQ1MDA_42b52ee4-f861-4c8b-bc62-66590ccec517"><ix:nonFraction unitRef="shares" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzE2NDkyNjc0NDQ1MDA_cea36019-1048-4a6e-a6fc-2ea43f431a70">no</ix:nonFraction></ix:nonFraction> preferred stock outstanding as of December&#160;31, 2022 and 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accumulated Other Comprehensive Income </span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzI3NTk_3dc0d424-1c4f-42d8-9100-a0bebf01f3e5" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in Accumulated other comprehensive income by component, net of tax:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65ba49cc6d24464998712864877bfbc_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEtMi0xLTEtMTY3NjY1_0fefc82c-7584-463e-ad10-146506bc4df5">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a52e5d45f44bd2b61d1cbfd645a700_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEtNC0xLTEtMTY3NjY1_62868ff7-beb8-468b-b08d-dfbe4de25ea5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39a3baccb6f4a489742ff823a82f45d_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEtNi0xLTEtMTY3NjY1_22bcda5b-6315-481a-ab38-08dc788e234d">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc9d4063e094f24aa7047cc3f2ade07_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEtOC0xLTEtMTY3NjY1_b0edf419-21dc-46f6-ba42-04cfa5a9272b">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb52f2212bb54664833a43b8f1d3e792_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzItMi0xLTEtMTY3NjY1_be5badf1-05e1-4366-ab81-8fb57fb0edb5">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b9945ce2eae4b4db8bf21445b6ff8a9_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzItNC0xLTEtMTY3NjY1_e52c0113-9f96-45fc-8526-36935be1af5f">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i225f3dbf9ef040efa82ebde15cfdcbfc_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzItNi0xLTEtMTY3NjY1_81085c05-bfc3-40d0-83d2-e9ebc6e58509">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzItOC0xLTEtMTY3NjY1_4997875d-94b6-468a-9406-17632f45f0f9">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb52f2212bb54664833a43b8f1d3e792_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzMtMi0xLTEtMTY3NjY1_2f4903d6-a168-4ad2-beb3-dd22d99ddf12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b9945ce2eae4b4db8bf21445b6ff8a9_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzMtNC0xLTEtMTY3NjY1_7464e080-5e30-4c1d-a2c7-34ba7f9aa17a">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i225f3dbf9ef040efa82ebde15cfdcbfc_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzMtNi0xLTEtMTY3NjY1_39e90a3d-5570-4e2f-acf8-f22f3138582a">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzMtOC0xLTEtMTY3NjY1_86775091-f98c-4c6d-a5ae-0301c0c27814">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb52f2212bb54664833a43b8f1d3e792_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzQtMi0xLTEtMTY3NjY1_55b91b52-41d2-4475-9504-06b35818adba">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b9945ce2eae4b4db8bf21445b6ff8a9_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzQtNC0xLTEtMTY3NjY1_0c8303e9-705f-408d-be0f-727619fd3b95">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i225f3dbf9ef040efa82ebde15cfdcbfc_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzQtNi0xLTEtMTY3NjY1_846c9d46-4860-4e39-a01a-a7bb6666be00">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzQtOC0xLTEtMTY3NjY1_a2bc9d99-f58e-4047-880a-0541a66bbc78">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be022dd13814593bc19060ec3103aff_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzUtMi0xLTEtMTY3NjY1_a3104504-2a2f-4fd2-b867-ec2823977260">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a8d242e2a254cb7a740cad8ec6484af_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzUtNC0xLTEtMTY3NjY1_8519d8f3-1a21-499a-8ae6-f03be90d110f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e2f8c526d704f298539af3a53a6ab31_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzUtNi0xLTEtMTY3NjY1_fd76e8f2-ce88-44da-a292-24d43ea282a9">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6f649babc4c4963a34bead50d8785d8_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzUtOC0xLTEtMTY3NjY1_98c47778-a56d-4b59-a782-831013911fb0">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4585b2391d2c42aaa5fcec24001b539d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzYtMi0xLTEtMTY3NjY1_fdeee50f-fd20-444c-b0bf-344c126a5b5a">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i888ea767a9e646238e97fdafcff19aee_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzYtNC0xLTEtMTY3NjY1_08e9418f-5bef-4808-a515-fb8031baea36">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a43e9292cc34d47a7b84bc89666fdcc_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzYtNi0xLTEtMTY3NjY1_05906d2a-18be-4be1-af04-430d84ba59ec">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzYtOC0xLTEtMTY3NjY1_febaa9e6-1b1d-43f3-9509-105852e39f37">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4585b2391d2c42aaa5fcec24001b539d_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzctMi0xLTEtMTY3NjY1_888ec807-4305-485f-acba-063827b2d467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i888ea767a9e646238e97fdafcff19aee_D20210101-20211231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzctNC0xLTEtMTY3NjY1_4395a885-58b2-4bf7-84a1-644c0f7d3aa3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a43e9292cc34d47a7b84bc89666fdcc_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzctNi0xLTEtMTY3NjY1_9f018601-a41c-4bde-a5ff-49a7074971c4">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzctOC0xLTEtMTY3NjY1_d670e857-6e7b-4d0a-8faa-4f3a7929de77">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4585b2391d2c42aaa5fcec24001b539d_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzgtMi0xLTEtMTY3NjY1_bc9831c0-5d56-422d-b0cf-ce9e605b2a89">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i888ea767a9e646238e97fdafcff19aee_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzgtNC0xLTEtMTY3NjY1_d55de0f2-e26b-4dd1-9e4b-88d253fd4508">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a43e9292cc34d47a7b84bc89666fdcc_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzgtNi0xLTEtMTY3NjY1_84b29b1b-5816-467d-83de-bbb1dd19c6fc">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzgtOC0xLTEtMTY3NjY1_1a596c91-09ac-49ff-9564-bf68a6288269">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1282cebfa404d25b44e39c3dee052f3_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzktMi0xLTEtMTY3NjY1_76fcdba4-8ffe-4b11-a513-1eae6c48720f">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc18bb50e5fb4827a108a43362008dbb_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzktNC0xLTEtMTY3NjY1_96dc67c7-db72-463b-bcf7-415d6681ef61">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i703dc9a954254418a5cecf9488a563fa_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzktNi0xLTEtMTY3NjY1_121d5d40-e06c-44ee-86c7-5a94bcefe50d">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c6e110f0a74581baf5ef42159e7423_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzktOC0xLTEtMTY3NjY1_af8d93b4-31e0-4b35-aeb4-bff301d9d55c">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89ba96d4050347bdb58a1c83a817e40e_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEwLTItMS0xLTE2NzY2NQ_d4ef1006-49d1-4814-8204-4e1e3e367c41">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc1baff673f642548027f1b6b5d8e4af_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEwLTQtMS0xLTE2NzY2NQ_54564d22-a681-4537-ad9c-4306ad23b4f5">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b483b2ee2e42d5a938318ae558e2e2_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEwLTYtMS0xLTE2NzY2NQ_f91dffe0-6bb4-454c-85ae-d39bab5fb815">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEwLTgtMS0xLTE2NzY2NQ_80f9acc1-292a-4ea2-81cd-87484d4f21a8">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ba96d4050347bdb58a1c83a817e40e_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzExLTItMS0xLTE2NzY2NQ_61d28c1a-510c-4dcd-a7ba-f7f6c4332aa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc1baff673f642548027f1b6b5d8e4af_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzExLTQtMS0xLTE2NzY2NQ_4884d601-120b-4232-9ec8-a5d0d222a668">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5b483b2ee2e42d5a938318ae558e2e2_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzExLTYtMS0xLTE2NzY2NQ_46984f84-f43a-4ca1-b3d5-372bfb6437d4">171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzExLTgtMS0xLTE2NzY2NQ_d9594a52-22d9-4ec3-b607-991afdea9a80">170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89ba96d4050347bdb58a1c83a817e40e_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEyLTItMS0xLTE2NzY2NQ_a24ded8a-0541-4017-b5f0-e12269c8d50a">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc1baff673f642548027f1b6b5d8e4af_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEyLTQtMS0xLTE2NzY2NQ_02fed9bb-a248-462e-946c-b70fbdc0a931">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5b483b2ee2e42d5a938318ae558e2e2_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEyLTYtMS0xLTE2NzY2NQ_01c27f5a-aed6-4d79-bb50-a2eb779eae9f">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEyLTgtMS0xLTE2NzY2NQ_813f88c4-28c4-4b05-8faf-26d0009ddb9c">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72eb2ca7a60f4cf19210a329bed5aa1f_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEzLTItMS0xLTE2NzY2NQ_2b7417ad-110e-428f-b866-0a104230fc35">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia122869e81d74b249c7207040246de2f_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEzLTQtMS0xLTE2NzY2NQ_81c463e8-dbe8-4ab3-9056-ec91e4b10b1d">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a0488268694a0ca64f483518e451cd_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEzLTYtMS0xLTE2NzY2NQ_3616ab3c-6bab-4dad-a577-6fe98acc78d8">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35cf517e1c44e6cb7eb51a11bc60ba9_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEzLTgtMS0xLTE2NzY2NQ_7d6046e7-8537-4296-9830-86a188b822f7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzk4NTU_afd318db-519d-4d5c-b6e8-4dbf9ede5238" continuedAt="i7827da2b57d5471096c796c364484a8c" escape="true">EMPLOYEE BENEFITS </ix:nonNumeric></span></div><ix:continuation id="i7827da2b57d5471096c796c364484a8c" continuedAt="ifa354cd593e14a5fa453b94d2775a210"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans Summary</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2004, our stockholders approved and we adopted the Gilead Sciences, Inc. 2004 Equity Incentive Plan (as amended, the &#8220;2004 Plan&#8221;). As part of our acquisition of Forty Seven in 2020, we assumed the Forty Seven, Inc. 2018 Equity Incentive Plan, which we subsequently amended and restated as the Gilead Sciences, Inc. 2018 Equity Incentive Plan (as amended and restated, the &#8220;2018 Plan&#8221;). As part of the Immunomedics acquisition, we assumed the Immunomedics Amended and Restated 2014 Long-Term Incentive Plan, which we subsequently merged into the 2004 Plan.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, our stockholders approved and we adopted the Gilead Sciences, Inc. 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan authorized the issuance of a total of <ix:nonFraction unitRef="shares" contextRef="id443da59986449869f984ba29bd052a0_I20220531" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzU0OTc1NTgxNzU3MDY_2ec0e47c-4c0f-4221-883e-26c6e5582498">132</ix:nonFraction> million shares of common stock. No awards may be granted under the 2004 Plan or the 2018 Plan since the approval of the 2022 Plan.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These are broad-based incentive plans that provide for the grant of equity-based awards, including RSUs, PSUs, stock options and other restricted stock and performance awards, to employees, directors and consultants. As of December&#160;31, 2022, a total of <ix:nonFraction unitRef="shares" contextRef="ic8f202de25714586abb2bcfe7d406697_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTkxMzg_f853368c-03d2-4ab2-a89a-68c345f7b56b">101</ix:nonFraction> million shares remain available for future grant under the 2022 Plan.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">RSUs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant time-based RSUs to certain employees as part of our annual employee equity compensation review program as well as to new hire employees and to non-employee members of our Board. RSUs are share-based awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. RSUs generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTY3OTU_0304068a-3d69-42e3-a0cc-97d49217f440">three</span> or <ix:nonNumeric contextRef="i41cc17b6454144eebfb7455e16f8e439_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzc2OTY1ODE0NDY3ODM_3079b50e-e08b-4706-bdc6-f5637f56fd2b">four years</ix:nonNumeric> from the date of grant.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PSUs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant PSUs that vest upon the achievement of specified market or performance goals, which could include achieving a total shareholder return compared to a pre-determined peer group or achieving revenue targets. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from <ix:nonFraction unitRef="number" contextRef="ief16c425ab394fcfaa9c8f247a26d1b8_I20221231" decimals="3" name="gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTc3MTc_e2981404-7aa0-4b43-a51f-c9d148bbf7a5">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic2061ba894de4be5b28c846ab2265609_I20221231" decimals="3" name="gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTc3MjQ_f61c17cc-7c10-494d-984a-3995117c58c2">200</ix:nonFraction>%, and these awards generally vest only when a committee (or subcommittee) of our Board has determined that the specified market and performance goals have been achieved. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants are designated as either non-statutory or incentive stock options. The exercise price of stock options may not be less than the fair market value of our common stock on the grant date and no stock option may have a term in excess of <ix:nonNumeric contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTg2MzU_2bf9c02f-5c0e-4eb1-8f4d-f6e2b5fa9069">10</ix:nonNumeric> years. Employee stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTg2ODM_bb52c247-34d1-49f0-be7e-b07c8a217a78">three</span> or <ix:nonNumeric contextRef="i580e59f939fd4c8388da4fdbdc6b58cb_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzc2OTY1ODE0NDY3ODQ_86c9649d-6372-424e-8e81-e9d596611be3">four years</ix:nonNumeric>. Stock options may be settled in cash or in shares of our common stock, including a net issuance using shares otherwise purchasable under the option to pay the exercise price. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP Summary</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our ESPP, employees can purchase shares of our common stock based on a percentage of their compensation subject to certain limits. The purchase price per share is equal to the lower of <ix:nonFraction unitRef="number" contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjI5MTk_230f9129-9f39-4f00-bdcf-592d65cbb901">85</ix:nonFraction>% of the fair market value of our common stock on the offering date or the purchase date. The ESPP offers a six-month look-back feature. ESPP purchases are settled with common stock from the ESPP&#8217;s previously authorized and available pool of shares. A total of <ix:nonFraction unitRef="shares" contextRef="i03e3e50cbabd4bef8487336a456c1552_I20221231" decimals="-6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjI5MjM_a042383b-f17f-41fa-96df-59e1fb406c1d">79</ix:nonFraction> million shares of common stock have been authorized for issuance under the ESPP, and there were <ix:nonFraction unitRef="shares" contextRef="i03e3e50cbabd4bef8487336a456c1552_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjI5Mjc_89276b5f-c1b9-452f-bcf3-3c1e3baf8fef">3</ix:nonFraction> million shares available for issuance under the ESPP as of December&#160;31, 2022.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ifa354cd593e14a5fa453b94d2775a210" continuedAt="i3126e2ec838247d9b9cc170c25e25b15"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzEx_36a76df3-6a66-4ba7-a57f-d741e671ca8a" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize total stock-based compensation expense included on our Consolidated Statements of Income as broken down by award type and by expense type:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzItMi0xLTEtMjM5MzQy_a72547b2-a26f-47a1-a6b2-7de22b45527c">557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba83b20f658a4a5b967cae95a8147d07_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzItNC0xLTEtMjM5MzQy_d1e7e64b-a1be-4a93-ada7-9e7016d6643c">558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a53a5a5ed940069011952033f6937e_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzItNi0xLTEtMjM5MzQy_e35afc95-28d5-4bb5-92ad-5d76eef648f5">546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzMtMi0xLTEtMjM5MzQy_387d51ff-eaad-4e46-9319-7a62ad0648f7">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e116706429d4b6489792bf2fee6c8ae_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzMtNC0xLTEtMjM5MzQy_9a43c148-4779-452f-af7d-5853e832cff5">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13414ce25cbc42b98829371034442897_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzMtNi0xLTEtMjM5MzQy_67b450ec-b2ad-4368-a7c8-ef7d278a0336">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzQtMi0xLTEtMjQwMzIw_f4e40486-c9d8-40f9-8586-9671f85452c5">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzQtNC0xLTEtMjQwMzIw_80966f5f-8066-4f9b-8bad-62b44185d4fd">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzQtNi0xLTEtMjQwMzIw_958e19c6-2f90-4a7c-8025-82e2e92f265b">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzQtMi0xLTEtMjM5MzQy_250c5bf0-0c7f-4b0d-acb1-4bc9fa818923">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzQtNC0xLTEtMjM5MzQy_e4f14cdb-6881-4e65-a3a8-ac4a553a1674">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzQtNi0xLTEtMjM5MzQy_479c2e75-1728-482c-ae87-accb5a99cfe7">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0fbfe8113ac4be684dbe7e6211e449f_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzctMi0xLTEtMjQwMzIw_b2a90c57-1320-4b80-b349-ac58b336c532">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icca0a85ac6724ad4a26ba8cfb7d3e7aa_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzctNC0xLTEtMjQwMzIw_d65f4274-9ac5-4cd9-945f-cc926997e4e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ed40d871ce41e2928bc9829eff5643_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzctNi0xLTEtMjQwMTMz_77222ffb-40e4-4fdf-b3b5-caa5f2ac2041">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in total costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzctMi0xLTEtMjM5MzQy_0f89a66a-e5a6-452e-8d8d-4d343d3617d6">645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzctNC0xLTEtMjM5MzQy_2a2753b3-1123-4da1-b629-fefa411e92c3">635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzctNi0xLTEtMjM5MzQy_e7e08df8-6e01-45ba-82df-1db1b1db5785">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accelerated post-acquisition stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="ib345f0317e14471c87be46037d1c42bd_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjU0OTU_10a56fec-6698-4af2-bb1e-d1be4765df8f">8</ix:nonFraction> million related to the MiroBio acquisition in 2022, and $<ix:nonFraction unitRef="usd" contextRef="i09a809a0f4a64f36887c2d0d12f7975f_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjI5Mzc_85d9c69a-20c5-4e31-be6e-651f68ea2c3a">289</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idb5b9f9fcb9e410b9600826b343149ed_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjI5NDU_b407976a-3b14-488a-94db-4d7e40ed8757">144</ix:nonFraction> million related to the acquisitions of Immunomedics and Forty Seven, respectively, in 2020.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fd6c8b6cd2e488a9ef5cb0ed0ecd928_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzItMi0xLTEtMjM5Mjkz_d8f39057-d4a0-4a20-bd34-cfe02e27f547">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec682fbc5e74d0b9bb6f5a57a44ba23_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzItNC0xLTEtMjM5Mjkz_19020b79-178b-422d-b8a8-231514b01a12">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767c3be8d79f4a58b2e54e5310c7404a_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzItNi0xLTEtMjM5Mjkz_adf39458-7083-4bb0-b4d2-ed9640e702e4">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bf67c25be264122919d5db5b2238804_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzMtMi0xLTEtMjM5Mjkz_4da69965-f033-4fd8-8870-a761a4469a2f">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6786edd5a2f463ba624fe8629254698_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzMtNC0xLTEtMjM5Mjkz_38364301-7a59-4328-b259-9903ca1b7ecc">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f8cd4d572b4630890ba497cb7ba380_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzMtNi0xLTEtMjM5Mjkz_81150701-dcd0-4f45-920c-abee5ce436ed">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91dd25449865431396ad590df47902c2_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzQtMi0xLTEtMjM5Mjkz_acb81c42-76b2-4ff1-a1ea-f55b3861f24a">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2e4dd234744ff0b8f9c4fbca89aac9_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzQtNC0xLTEtMjM5Mjkz_1ee7c03c-bf22-4043-bf13-f07e7aa4f879">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i246e5be9df34403b970d76a795c2a09e_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzQtNi0xLTEtMjM5Mjkz_72586197-b92b-4772-b04a-d21b7a8e3a6f">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in total costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzUtMi0xLTEtMjM5Mjkz_53ca98f8-a97b-4b2c-8e17-ca84ea8b1bad">645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzUtNC0xLTEtMjM5Mjkz_e67ef0ed-05b8-4c75-a038-b818532a324c">635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzUtNi0xLTEtMjM5Mjkz_53a012f6-14f4-46ff-a08f-afb75987f4aa">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzYtMi0xLTEtMjM5Mjkz_9d67feae-9d63-4ae1-ae3c-69aa1a815aa1">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzYtNC0xLTEtMjM5Mjkz_1b19a728-1cd1-4727-84d2-36e4c8ed0b84">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzYtNi0xLTEtMjM5Mjkz_96ef1231-6237-4b01-9041-78bd34c66bd2">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzctMi0xLTEtMjM5Mjkz_732ad64a-fce7-4df9-883f-cc226cd92593">553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzctNC0xLTEtMjM5Mjkz_95328e17-df5a-4f83-ae4b-f5c37795516c">535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzctNi0xLTEtMjM5Mjkz_021fce42-8b35-4c11-b0b1-b0dfce30cc71">854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzk4NjI_bde64c41-a633-456f-a378-af045435933f" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our RSU activity:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia54f00a060494b7e8284daf41bb9942f_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzItMi0xLTEtMTY3NjY1_3be8081b-c39e-4fc7-a45b-52f3655acd8f">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia54f00a060494b7e8284daf41bb9942f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzItNC0xLTEtMTY3NjY1_de5b827b-cde3-4972-9223-cf912633e961">67.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzMtMi0xLTEtMTY3NjY1_9238844d-5b28-40ab-818f-01f85d945d30">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzMtNC0xLTEtMTY3NjY1_56ee7dde-5f83-4499-bd31-6ece39546ea4">60.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzQtMi0xLTEtMTY3NjY1_4c6bf93e-4dbb-40a0-9505-b80e5b727472">8.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzQtNC0xLTEtMTY3NjY1_617f04b9-7c9d-42e2-b733-63cd48e23e3f">67.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzUtMi0xLTEtMTY3NjY1_903ab704-6e87-49e1-a9b2-5b57ef688c8e">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzUtNC0xLTEtMTY3NjY1_f85086e6-27a6-4d8b-8228-e9347c6498b2">63.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i306251c6f0a34cecb6731b34d196923e_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzYtMi0xLTEtMTY3NjY1_509e63be-3b6b-4a87-b763-80e086585017">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i306251c6f0a34cecb6731b34d196923e_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzYtNC0xLTEtMTY3NjY1_b98d02e8-cb4d-4952-9b57-d52f7412fe50">63.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value of RSUs granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjYTczNDVlZTUxMDY0NmY3YWIxM2NlZDZkZWU1NzZkZC90YWJsZXJhbmdlOmNhNzM0NWVlNTEwNjQ2ZjdhYjEzY2VkNmRlZTU3NmRkXzItMi0xLTEtMjE1MjYw_09163fcf-2a5d-49f2-97a7-0b745e7ab153">60.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iba83b20f658a4a5b967cae95a8147d07_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjYTczNDVlZTUxMDY0NmY3YWIxM2NlZDZkZWU1NzZkZC90YWJsZXJhbmdlOmNhNzM0NWVlNTEwNjQ2ZjdhYjEzY2VkNmRlZTU3NmRkXzItNC0xLTEtMjE1MjYz_64006f07-3de4-45f1-8809-d88e272e1617">65.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3a53a5a5ed940069011952033f6937e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjYTczNDVlZTUxMDY0NmY3YWIxM2NlZDZkZWU1NzZkZC90YWJsZXJhbmdlOmNhNzM0NWVlNTEwNjQ2ZjdhYjEzY2VkNmRlZTU3NmRkXzItNi0xLTEtMjE1MjY1_75b951f1-d7fd-4235-ad7f-0bb3c67a601a">70.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of RSUs as of the respective vesting dates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjYTczNDVlZTUxMDY0NmY3YWIxM2NlZDZkZWU1NzZkZC90YWJsZXJhbmdlOmNhNzM0NWVlNTEwNjQ2ZjdhYjEzY2VkNmRlZTU3NmRkXzUtMi0xLTEtMjE1Mjgz_dceb7ff3-28c0-466e-b079-6e62c23cf340">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba83b20f658a4a5b967cae95a8147d07_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjYTczNDVlZTUxMDY0NmY3YWIxM2NlZDZkZWU1NzZkZC90YWJsZXJhbmdlOmNhNzM0NWVlNTEwNjQ2ZjdhYjEzY2VkNmRlZTU3NmRkXzUtNC0xLTEtMjE1Mjg1_cb0f7022-031a-4aff-afa2-23bd9c4a5ecf">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a53a5a5ed940069011952033f6937e_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjYTczNDVlZTUxMDY0NmY3YWIxM2NlZDZkZWU1NzZkZC90YWJsZXJhbmdlOmNhNzM0NWVlNTEwNjQ2ZjdhYjEzY2VkNmRlZTU3NmRkXzUtNi0xLTEtMjE1Mjg3_207bc713-a62c-4bb9-b639-ab98b6dd0178">444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i306251c6f0a34cecb6731b34d196923e_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjI5NjE_414f6d47-90bd-4c77-a21e-3ca2c2329f63">948</ix:nonFraction> million of unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzE2_c30983c4-86fa-4c3e-88b1-93747fd2ae7c">2.3</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i3126e2ec838247d9b9cc170c25e25b15" continuedAt="i7f70d4060e81430fa7a197cdc3d30be5"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PSUs</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzE0_d3265644-4351-4d60-9fab-084242a4052f" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our PSU activity:</span></div><div style="margin-top:4.5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb16b1a82cc04d97bc97982197e928b8_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzItNi0xLTEtMjM5NDI4_32bfcce5-cc29-4afb-b45c-b4aae540c703">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb16b1a82cc04d97bc97982197e928b8_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzItOC0xLTEtMjM5NDI4_e3f84372-4b3e-45d1-a28f-ad20ca4d5a66">79.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzMtNi0xLTEtMjM5NDI4_21630d8d-7243-4410-85c3-fd9a405bdbdf">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzMtOC0xLTEtMjM5NDI4_97e02b44-97d9-4138-a03c-36e0101aab20">60.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzQtNi0xLTEtMjM5NDI4_d1568258-3df5-4163-bbbc-3b0d8480c13d">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzQtOC0xLTEtMjM5NDI4_b78b9876-ccb8-4dd6-84a6-bd300ad7f28a">68.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzUtNi0xLTEtMjM5NDI4_5b4d814c-21b0-47cf-83b6-837c0d14d1c8">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzUtOC0xLTEtMjM5NDI4_637cc218-2b40-4e06-9737-6355614d769c">59.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b63e11ff4a246c388b2b8117a18b35f_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzYtNi0xLTEtMjM5NDI4_bc2d3347-c7ce-4494-8bd2-fcab99751c84">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b63e11ff4a246c388b2b8117a18b35f_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzYtOC0xLTEtMjM5NDI4_b9123ec4-1a24-4954-a711-e147afac8bd1">64.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value of PSUs granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZGQ3OTYwNmEwNWQ0ZDAyYmY1ZjUyMmVkZjYyZWJkNS90YWJsZXJhbmdlOjZkZDc5NjA2YTA1ZDRkMDJiZjVmNTIyZWRmNjJlYmQ1XzItMi0xLTEtMjM5NDI4_12148a14-da46-4125-b813-1c969d7db755">60.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e116706429d4b6489792bf2fee6c8ae_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZGQ3OTYwNmEwNWQ0ZDAyYmY1ZjUyMmVkZjYyZWJkNS90YWJsZXJhbmdlOjZkZDc5NjA2YTA1ZDRkMDJiZjVmNTIyZWRmNjJlYmQ1XzItNC0xLTEtMjM5NDI4_d221c9e5-fdd0-4ca4-8320-f7109ab3f504">71.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i13414ce25cbc42b98829371034442897_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZGQ3OTYwNmEwNWQ0ZDAyYmY1ZjUyMmVkZjYyZWJkNS90YWJsZXJhbmdlOjZkZDc5NjA2YTA1ZDRkMDJiZjVmNTIyZWRmNjJlYmQ1XzItNi0xLTEtMjM5NDI4_71ff8f7a-d95f-49d6-a014-3f90a3693bae">83.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of PSUs as of the respective vesting dates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZGQ3OTYwNmEwNWQ0ZDAyYmY1ZjUyMmVkZjYyZWJkNS90YWJsZXJhbmdlOjZkZDc5NjA2YTA1ZDRkMDJiZjVmNTIyZWRmNjJlYmQ1XzUtMi0xLTEtMjM5NDI4_14dcfe21-37a9-4a25-b6f3-a0f11a1ebed5">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e116706429d4b6489792bf2fee6c8ae_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZGQ3OTYwNmEwNWQ0ZDAyYmY1ZjUyMmVkZjYyZWJkNS90YWJsZXJhbmdlOjZkZDc5NjA2YTA1ZDRkMDJiZjVmNTIyZWRmNjJlYmQ1XzUtNC0xLTEtMjM5NDI4_8b9c13d4-1697-40bc-93f9-58eae68e37aa">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13414ce25cbc42b98829371034442897_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZGQ3OTYwNmEwNWQ0ZDAyYmY1ZjUyMmVkZjYyZWJkNS90YWJsZXJhbmdlOjZkZDc5NjA2YTA1ZDRkMDJiZjVmNTIyZWRmNjJlYmQ1XzUtNi0xLTEtMjM5NDI4_acedcec5-6635-4752-8b36-9e0aad1b202f">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i1b63e11ff4a246c388b2b8117a18b35f_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjMwMTE_8daab2f0-3f6a-4ccb-9f91-4cb232fa9fb3">29</ix:nonFraction> million of unrecognized compensation cost related to unvested PSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzE4_7bf48d29-e764-4e56-a5f4-6844bf244f42">1.4</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzIw_b2288ade-851f-4d59-9911-e3109505cf61" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize activity and other information related to our stock options: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>(in dollars)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd6b4cdafb5e493e8f88f2078b78eb38_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzEtMi0xLTEtMjM5Mzc5_0651d6d4-cbc6-4e00-96e7-cc044537eb7c">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifd6b4cdafb5e493e8f88f2078b78eb38_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzEtNC0xLTEtMjM5Mzc5_c953e709-cf95-40c0-8764-0fbf3db91ed7">70.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzItMi0xLTEtMjM5Mzc5_9a7beb50-157a-4ee1-a3cf-593e175d2190">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzItNC0xLTEtMjM5Mzc5_69adfac8-cfb5-4095-8f28-b75f5fa23137">58.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzMtMi0xLTEtMjM5Mzc5_c7540644-2e1a-432b-8022-03dde59d29d4">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzMtNC0xLTEtMjM5Mzc5_2b4b02f0-8112-4b36-982b-bf3ea9ccfbd2">62.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzQtMi0xLTEtMjM5Mzc5_a971bf41-b2d6-49de-8ece-a88fd34105ee">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzQtNC0xLTEtMjM5Mzc5_915dcb68-6d01-440b-b728-f6f2772a58b9">82.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzUtMi0xLTEtMjM5Mzc5_6fefef9f-d46d-4391-b62b-43f31c909761">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzUtNC0xLTEtMjM5Mzc5_3a407e62-28a9-4e00-97d3-bdbbc2b0923b">61.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzYtMi0xLTEtMjM5Mzc5_32325902-e682-4daa-b882-46ea19a5c9a8">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzYtNC0xLTEtMjM5Mzc5_7cc3551c-1cc7-4409-8c0e-f65dd7193605">67.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzYtNi0xLTEtMjM5Mzc5_787826ad-5df6-41e5-ae1b-0516f554f8df">6.61</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzYtOC0xLTEtMjM5Mzc5_020729cf-5a8c-49b2-bb2d-63addfcbffaa">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzctMi0xLTEtMjM5Mzc5_5140be8a-f985-4d71-8aa7-02dd45ae3864">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzctNC0xLTEtMjM5Mzc5_10190672-1c3c-4d8e-aa0d-34d665ef57a8">72.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzctNi0xLTEtMjM5Mzc5_2ba52ac1-da10-40a9-a7d8-0b87eb9f74f6">5.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzctOC0xLTEtMjM5Mzc5_f205603b-18c2-4ccf-bde6-111588dfc98c">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest, net of estimated forfeitures as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzgtMi0xLTEtMjM5Mzc5_beda5a71-1ae9-46a7-a8b7-b8229d4c3ded">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzgtNC0xLTEtMjM5Mzc5_d1f6b89d-4bcd-4b62-9c76-bf0fb4ff80ec">62.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzgtNi0xLTEtMjM5Mzc5_0647139e-87fd-4317-8f08-12c9dd03fd89">8.55</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzgtOC0xLTEtMjM5Mzc5_9ada1f80-3e90-4985-9244-03a1913417bc">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjZDMzNjJmNDljM2E0NmU1OTgzYmM2ZWVmYjhiYTk0OC90YWJsZXJhbmdlOmNkMzM2MmY0OWMzYTQ2ZTU5ODNiYzZlZWZiOGJhOTQ4XzItMi0xLTEtMjM5NTUz_ad11643a-7249-4b2b-a9e8-ebaad03d65b1">9.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjZDMzNjJmNDljM2E0NmU1OTgzYmM2ZWVmYjhiYTk0OC90YWJsZXJhbmdlOmNkMzM2MmY0OWMzYTQ2ZTU5ODNiYzZlZWZiOGJhOTQ4XzItNC0xLTEtMjM5NTUz_fdc56a93-381b-4bbd-9bfe-c960cc870d7b">10.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjZDMzNjJmNDljM2E0NmU1OTgzYmM2ZWVmYjhiYTk0OC90YWJsZXJhbmdlOmNkMzM2MmY0OWMzYTQ2ZTU5ODNiYzZlZWZiOGJhOTQ4XzItNi0xLTEtMjM5NTUz_015b9772-d75c-4af8-8a07-2f6fbf286b7c">11.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjZDMzNjJmNDljM2E0NmU1OTgzYmM2ZWVmYjhiYTk0OC90YWJsZXJhbmdlOmNkMzM2MmY0OWMzYTQ2ZTU5ODNiYzZlZWZiOGJhOTQ4XzMtMi0xLTEtMjM5NTYw_1e3eeedc-7275-46e3-b42d-858cfd3973c8">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjZDMzNjJmNDljM2E0NmU1OTgzYmM2ZWVmYjhiYTk0OC90YWJsZXJhbmdlOmNkMzM2MmY0OWMzYTQ2ZTU5ODNiYzZlZWZiOGJhOTQ4XzMtNC0xLTEtMjM5NTYw_d80166ed-214c-41de-820e-319f23195a62">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjZDMzNjJmNDljM2E0NmU1OTgzYmM2ZWVmYjhiYTk0OC90YWJsZXJhbmdlOmNkMzM2MmY0OWMzYTQ2ZTU5ODNiYzZlZWZiOGJhOTQ4XzMtNi0xLTEtMjM5NTYw_358d5a22-0139-4c4f-abac-1eae6f074c7a">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="gild:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzIx_48c3017c-7695-433c-a031-db363c1faa32" continuedAt="if9edb764dd5c42af8261d17fe114167f" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the stock option awards:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzItMi0xLTEtMjM5NjEy_e1631257-6a37-4014-ac6e-d0f8e07df21b">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzItNC0xLTEtMjM5NjEy_8dcab7b0-e229-4625-8fba-b9aaa7ebe821">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzItNi0xLTEtMjM5NjEy_58b4b5f2-03f4-403c-99a4-f0479a48b170">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected terms in years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzMtMi0xLTEtMjM5NjE2_2b741f4d-462e-49d3-8ffc-2f9041e3fcfd">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzMtNC0xLTEtMjM5NjE2_a8176ef9-fa38-4cc8-a588-8ffe86e8e10f">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzMtNi0xLTEtMjM5NjE2_9e0a9ae0-83d2-4371-87ae-b8ab62ed8941">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzQtMi0xLTEtMjQwMjMz_69b9eae6-2e35-4fda-8a49-066394104657">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzQtNC0xLTEtMjQwMjMz_e5f7c432-8c22-401e-86d3-456fd7c698fa">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzQtNi0xLTEtMjQwMjMz_32472b5b-12c3-4c1e-8e7c-b7a0e4cb5318">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzUtMi0xLTEtMjM5NjIy_57bfc228-48ef-4ffb-8000-078f7cfa3ffc">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzUtNC0xLTEtMjM5NjIy_dcf3bade-7977-4170-b438-6e51f9c04a95">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzUtNi0xLTEtMjM5NjIy_492516cf-49ac-42c2-b792-5d04f8ca1f81">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i7f70d4060e81430fa7a197cdc3d30be5"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjMwNzY_cf398a68-886d-48ed-ba80-ed13887bd1b5">48</ix:nonFraction> million of unrecognized compensation cost related to stock options, which is expected to be recognized over an estimated weighted-average period of <ix:nonNumeric contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzIy_6f85888f-045a-400e-ba55-6a42942e5088">2.4</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzNzQzODk1Mzg0NjEx_226e7cea-c25b-4907-b4b2-91d0af926040" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our ESPP activity:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzItMi0xLTEtMjY1ODQz_155f421a-a132-430b-a80e-f9675060743d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzItNC0xLTEtMjY3MzI3_5d8236be-961d-44dd-b389-c81bd0a92413">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzItNi0xLTEtMjY3MzI3_ff0b1e1c-da25-47d3-9e94-3ea5a6addb83">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount paid by employees for shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzMtMi0xLTEtMjY1ODQ2_780dd00c-22e8-4313-8bbc-0501b1044532">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzMtNC0xLTEtMjY3MzI3_7456b5e9-d9bc-49d2-a44e-09765d43df18">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzMtNi0xLTEtMjY3MzI3_f1cb300f-b03a-444e-a65d-345e99345ae0">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value of ESPP shares granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231" decimals="2" name="gild:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzItMi0xLTEtMjM5ODAy_ef855703-1601-44c3-8053-6eda1a4a5295">13.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231" decimals="2" name="gild:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzItNC0xLTEtMjM5ODAy_2201f8d6-14ba-4210-98ba-ed7b71175735">14.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231" decimals="2" name="gild:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzItNi0xLTEtMjM5ODAy_0d348dfb-75ce-4bc3-b744-a505815e4367">15.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of ESPP shares as of the respective vesting dates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzMtMi0xLTEtMjM5ODAy_7fda62be-b9bb-4ba0-8ae5-8edbf5a3a755">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzMtNC0xLTEtMjM5ODAy_ad2f273a-85c0-4865-bd8d-4381e3fee584">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzMtNi0xLTEtMjM5ODAy_a456634f-6b84-4884-abbf-9e3b0f16b75d">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="if9edb764dd5c42af8261d17fe114167f"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the ESPP awards:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzQtMi0xLTEtMTY3NjY1_8dbbd317-b162-42df-a189-60b13c98b61b">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzQtNC0xLTEtMTY3NjY1_6f73cbea-cf4d-4adb-a12c-baff4faae1d5">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzQtNi0xLTEtMTY3NjY1_33525411-aa05-4411-b785-6144f09c4eb3">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected terms in years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzctMi0xLTEtMTY3NjY1_31d48970-54e5-47f1-8ef3-54ff3cc60580">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzctNC0xLTEtMTY3NjY1_6a7f5040-6d99-47b7-b3a8-d22fd423eb70">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzctNi0xLTEtMTY3NjY1_f2d7de4b-a248-450e-a43b-1c9397fb3957">0.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzEwLTItMS0xLTE2NzY2NQ_d3fa5ecf-936f-48ce-9c7c-ddbfb53221e4">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzEwLTQtMS0xLTE2NzY2NQ_1a87762f-9606-49a6-b7db-62f224d5e348">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzEwLTYtMS0xLTE2NzY2NQ_cfb00a5f-79d5-4168-95a5-94d9e9e8b01e">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzExLTItMS0xLTE2NzY2NQ_3f0cd206-2d67-4816-b934-451c55b99ad2">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzExLTQtMS0xLTE2NzY2NQ_b3c67694-79a9-45f7-b578-c71434db7696">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzExLTYtMS0xLTE2NzY2NQ_65c4ee6f-1e0c-4501-89aa-c7454317ecc9">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Deferred Compensation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a retirement saving plan under which eligible U.S. employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (the &#8220;Gilead Sciences 401k Plan&#8221;). In certain foreign subsidiaries, we maintain defined benefit plans as required by local regulatory requirements. Our total matching contribution expense under the Gilead Sciences 401k Plan and other defined benefit plans was $<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjMxMTU_a60ac989-9d8b-45b6-9f05-861457c2ad98">176</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjMxMjM_f924cce1-237d-4097-955c-2ce60fb9cfd0">166</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjMxMzA_488eceda-73d1-4ea1-83d1-4609a2eee5e4">144</ix:nonFraction> million during 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a deferred compensation plan under which our directors and key employees may defer compensation. Amounts deferred by participants are deposited into a rabbi trust. The total assets and liabilities associated with the deferred compensation plan were $<ix:nonFraction unitRef="usd" contextRef="i0e2b914d4ec74b7d9487a6f371a25de3_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzU0OTc1NTg1MTMwNQ_e0294ed2-1056-43b1-957f-a901ecb21b16">220</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idf9a3708d6b74d5eb87c245216002834_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjMxNDU_26e7775e-f310-437f-8fdc-51fbb76fdbe2">261</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_139"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90ZXh0cmVnaW9uOmYxYWU1YTkwZThiMDRiMjVhNGQ5MDE1ZTY5MDk5MzNhXzk3Mg_543be3c0-d332-4685-973a-bfcfbe7b3678" continuedAt="i2cc58a1d93724c70a955065ba9d940df" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i2cc58a1d93724c70a955065ba9d940df"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90ZXh0cmVnaW9uOmYxYWU1YTkwZThiMDRiMjVhNGQ5MDE1ZTY5MDk5MzNhXzk2Nw_d05e62fb-541c-4773-bdd7-b3c1cded8113" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted earnings per share attributable to Gilead:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:63.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.046%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzItMi0xLTEtMTY3NjY1_3e38e7a0-6350-49f1-85bc-192612afa8c5">4,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzItNC0xLTEtMTY3NjY1_a0686f75-0cad-48e9-a6ca-34e5b986760b">6,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzItNi0xLTEtMTY3NjY1_c1438e93-8449-4b55-93ad-04d196782bd4">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in basic earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzMtMi0xLTEtMTY3NjY1_cba4dff9-cd21-45d1-9fbc-05899c037b86">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzMtNC0xLTEtMTY3NjY1_ae2aee9e-3715-4661-98d8-a5ddeba71880">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzMtNi0xLTEtMTY3NjY1_d40dfe23-3dc3-4837-b05b-d98e4b90c858">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzQtMi0xLTEtMTY3NjY1_39cddccc-2877-4f52-8388-941ec701097e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzQtNC0xLTEtMTY3NjY1_6d454dfd-438f-4b36-8c8e-cba3d5d04bf2">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzQtNi0xLTEtMTY3NjY1_a481d49b-1380-495e-83f0-24b820b1058c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in diluted earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzUtMi0xLTEtMTY3NjY1_c1b066c8-e937-4723-97d8-c24b6a08c0b2">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzUtNC0xLTEtMTY3NjY1_0f82b954-a474-4676-b096-7a775f06e778">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzUtNi0xLTEtMTY3NjY1_e7d47d8a-838d-44f8-9320-53bd24569d57">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzYtMi0xLTEtMTY3NjY1_7810b9a5-71be-4f17-996f-e950fe61dc78">3.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzYtNC0xLTEtMTY3NjY1_d5333cdc-162c-4949-9b0d-615ec673b2e6">4.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzYtNi0xLTEtMTY3NjY1_9a03820a-297b-42d3-96ec-d80dc93c2475">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzctMi0xLTEtMTY3NjY1_5110ccb8-7038-4d12-bc10-9526946bd1ce">3.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzctNC0xLTEtMTY3NjY1_2df4161e-f717-40fb-81fa-8656d0a4f2e3">4.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzctNi0xLTEtMTY3NjY1_d13b1542-1bd1-402c-b561-ed2fdc44a253">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of Diluted earnings per share attributable to Gilead because their effect would have been antidilutive were <ix:nonFraction unitRef="shares" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90ZXh0cmVnaW9uOmYxYWU1YTkwZThiMDRiMjVhNGQ5MDE1ZTY5MDk5MzNhXzEwOTk1MTE2Mjk1Njk_d4211531-ec92-4ac6-9296-725a870be9f1">12</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90ZXh0cmVnaW9uOmYxYWU1YTkwZThiMDRiMjVhNGQ5MDE1ZTY5MDk5MzNhXzEwOTk1MTE2Mjk1NzU_b32dc9ac-f2dd-4d46-925d-55d093b88852">15</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90ZXh0cmVnaW9uOmYxYWU1YTkwZThiMDRiMjVhNGQ5MDE1ZTY5MDk5MzNhXzEwOTk1MTE2Mjk1ODM_5734d427-32a4-453f-bb50-86bb86196331">13</ix:nonFraction> million during 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQ3MTM_2318eef3-bdf6-4ae3-be3d-75c4e47087c4" continuedAt="i5b24dc66642f4306b432933110ca7693" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i5b24dc66642f4306b432933110ca7693" continuedAt="i26a93af967fd4db8a2d6a8f8c316d738"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQ3MTY_b7003666-2ed9-4d9b-aa11-0fef31702b49" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes consists of the following:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzItMi0xLTEtMTY3NjY1_adf8e152-d033-4865-b312-2fff51891c3d">4,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzItNC0xLTEtMTY3NjY1_74364703-07de-4393-889d-1418142b63e9">8,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzItNi0xLTEtMTY3NjY1_ca23e288-2561-4621-87ee-33395ec6ee20">2,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzMtMi0xLTEtMTY3NjY1_c6675add-9d9d-4417-9c38-66ec901e8cf8">1,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzMtNC0xLTEtMTY3NjY1_61e270ec-abd8-4e15-a179-ddcac67e6d42">309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzMtNi0xLTEtMTY3NjY1_eec28579-b72e-4c01-89f0-4dae5a04f7f9">836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzQtMi0xLTEtMTY3NjY1_e6737d8e-1310-4782-8e01-43bd0e158f09">5,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzQtNC0xLTEtMTY3NjY1_ba72beca-6a3d-40a5-80ea-2b75bbc084f4">8,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzQtNi0xLTEtMTY3NjY1_c11e8300-a2cf-400f-9ceb-0cc7836d7d9f">1,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQ2OTQ_6ecee9e3-40bb-4e47-a764-f9350f721372" escape="true"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense consists of the following:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzMtMi0xLTEtMTY3NjY1_a99a1184-d0dd-454e-9f70-320cd938bce7">2,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzMtNC0xLTEtMTY3NjY1_90250e3d-6d92-43ba-9530-d79edb586ad1">1,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzMtNi0xLTEtMTY3NjY1_53051f67-eb03-4c8a-9464-51c7dc1b2eae">1,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzQtMi0xLTEtMTY3NjY1_3993bd51-662c-4c73-ba41-2a8048ba93f1">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzQtNC0xLTEtMTY3NjY1_afaaddeb-8e28-4226-9aa6-5b93fe4c3b88">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzQtNi0xLTEtMTY3NjY1_8e9ccbe2-8e41-447d-890f-057803e1eea0">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzUtMi0xLTEtMTY3NjY1_293498c9-b41e-45fd-ac00-d9cc53615f1f">1,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzUtNC0xLTEtMTY3NjY1_ec092d55-d2b6-4397-8855-6d9419e03173">1,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzUtNi0xLTEtMTY3NjY1_459aa33e-aec0-4ec2-a193-191b33c40011">1,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzctMi0xLTEtMTY3NjY1_0ac1e851-6852-48a6-9d8d-7ae95818e135">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzctNC0xLTEtMTY3NjY1_affc473d-f922-4a9f-9524-e300715c5238">228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzctNi0xLTEtMTY3NjY1_f18309e3-c43b-4194-bc8d-3425754648e2">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzgtMi0xLTEtMTY3NjY1_4eb1babd-30c5-4008-bece-dfda66b4bd39">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzgtNC0xLTEtMTY3NjY1_aa7a204f-8c34-4bbd-8b1a-cf90bc2d0d66">185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzgtNi0xLTEtMTY3NjY1_f3416cf6-5927-4b08-89f6-f163eca7a584">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzktMi0xLTEtMTY3NjY1_b7a9430f-ccca-4dfa-afa5-29ba62650dc0">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzktNC0xLTEtMTY3NjY1_fb449a86-9476-430d-a37e-0ef38bee24c8">413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzktNi0xLTEtMTY3NjY1_c904a6c1-f803-4b7e-bb76-239548237ef6">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzExLTItMS0xLTE2NzY2NQ_664a2267-c9aa-49d4-aeec-43955b468290">232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzExLTQtMS0xLTE2NzY2NQ_9af2dbf9-4e4d-4ece-a349-306f24f3490a">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzExLTYtMS0xLTE2NzY2NQ_e678655e-8dc7-4be7-bebe-fe4233774fa5">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzEyLTItMS0xLTE2NzY2NQ_8d16b6c4-6f9d-4cf6-a0dd-99d7fb80cccd">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzEyLTQtMS0xLTE2NzY2NQ_cc7f2d88-ade8-4e7b-9fc7-ac0f34c70575">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzEyLTYtMS0xLTE2NzY2NQ_cdb50c1d-1e32-4a45-938a-5ae0034c7c7b">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzEzLTItMS0xLTE2NzY2NQ_cb3ed1fc-5d10-40b8-9631-ed34f3c0d806">333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzEzLTQtMS0xLTE2NzY2NQ_44faf781-6fa6-458f-8434-32d083768fed">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzEzLTYtMS0xLTE2NzY2NQ_aea4da12-1802-4427-b3e7-bfcb9392c0e2">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzE0LTItMS0xLTE2NzY2NQ_07e0beb2-a2c5-4618-8006-865b7419f982">1,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzE0LTQtMS0xLTE2NzY2NQ_9e6d2583-d8e5-4124-bdc0-831624a4be9d">2,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzE0LTYtMS0xLTE2NzY2NQ_7e52b9ed-e72a-4799-a7e3-63673ba90a89">1,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQ3MTQ_9631442b-78d2-40ce-b27f-8ad61172c918" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the federal statutory tax rate applied to Income before income taxes and our effective tax rate is summarized as follows:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzItMi0xLTEtMTY3NjY1_a761d3bb-4899-41e5-b136-b5be4e592bc0">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzItNC0xLTEtMTY3NjY1_d2f0cb54-7874-4207-9bda-bf06e5e7502c">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzItNi0xLTEtMTY3NjY1_577aefa7-7d55-436f-a7b6-cf631b736c59">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzMtMi0xLTEtMTY3NjY1_5c23c934-d516-4322-adea-48dd3ac122eb">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzMtNC0xLTEtMTY3NjY1_027f8fc8-0b2c-4517-bb62-c055bb7aa255">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzMtNi0xLTEtMTY3NjY1_588c5747-7ed7-4b4d-99d3-28aa06ec2691">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at different rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzQtMi0xLTEtMTY3NjY1_dd588e1b-6c3c-47e5-8c0c-13e04fbb3822">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzQtNC0xLTEtMTY3NjY1_eed6c81e-8116-4323-9b12-dcda7a436172">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzQtNi0xLTEtMTY3NjY1_3e653599-0ece-49d7-85b0-ffd3e8d16a2e">10.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzUtMi0xLTEtMTY3NjY1_2eaee813-9acf-43ed-9938-7e285540ed24">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzUtNC0xLTEtMTY3NjY1_c5aa1cb0-ebe0-4dc7-aa94-efed3fac136d">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzUtNi0xLTEtMTY3NjY1_5e00f817-a8e4-4196-8899-f904b1bb27fe">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US tax on foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzYtMi0xLTEtMTY3NjY1_ba0becb2-9e0a-42a5-88cd-3b9e154ed9f3">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzYtNC0xLTEtMTY3NjY1_850417bd-1a8d-4170-916a-1be0743ffbce">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzYtNi0xLTEtMTY3NjY1_63233ae3-2cda-4f60-ac41-d61371f0466c">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzctMi0xLTEtMTY3NjY1_5b79de84-ae03-4651-aee1-070c29284ea3">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzctNC0xLTEtMTY3NjY1_14420dd9-4c6f-48a3-b5b7-dbd7085ca803">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzctNi0xLTEtMTY3NjY1_4ea32d71-7f38-4588-b5ba-457c10ccab99">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of tax examinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzktMi0xLTEtMTY3NjY1_1ebe54c0-897a-4570-99d3-cefc454c2e49">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzktNC0xLTEtMTY3NjY1_265b52a5-2dae-49c3-a829-4582e4dc142b">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzktNi0xLTEtMTY3NjY1_bcad329e-4ab1-45a1-ad89-1dda15fda518">10.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D &amp; related charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEwLTItMS0xLTE2NzY2NQ_71ebf9b3-bd29-496b-86b9-5cf3f99e4434">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEwLTQtMS0xLTE2NzY2NQ_1aadff04-3c8b-48f8-b542-61847536cd93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEwLTYtMS0xLTE2NzY2NQ_4d764d3e-3011-4789-815c-f1f4b044ff66">56.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzExLTItMS0xLTE2NzY2NQ_e1b7339f-b9e9-466f-a584-f6f09be23f79">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzExLTQtMS0xLTE2NzY2NQ_fe4191df-484d-44e2-8350-d696f4a0ea39">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzExLTYtMS0xLTE2NzY2NQ_e213c275-ba53-4619-b748-d6d310353bba">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable unrealized loss on investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEyLTItMS0xLTE2NzY2NQ_3816604a-fad2-4ec8-9a90-35f1f9325c9b">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEyLTQtMS0xLTE2NzY2NQ_27fbf2e4-a5ec-4001-8575-9df8185e6c17">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEyLTYtMS0xLTE2NzY2NQ_e1e44706-a070-4577-93e0-e399e831e4ba">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEzLTItMS0xLTE2NzY2NQ_01c91d4b-3d4c-4296-9d19-426d93cb8b1d">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEzLTQtMS0xLTE2NzY2NQ_c69e9a5d-e478-48c4-a5f8-79b5589240fa">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEzLTYtMS0xLTE2NzY2NQ_02e22243-7eb2-4b32-9210-2b874bb1c1f4">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzE0LTItMS0xLTE2NzY2NQ_50905175-fbe0-48c0-99c5-8a387997fd27">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzE0LTQtMS0xLTE2NzY2NQ_d17a057c-e1f3-41a6-b45d-234556455e3e">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzE0LTYtMS0xLTE2NzY2NQ_7ad47998-30eb-4afd-b17e-b3ab9ca5bc0f">94.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i26a93af967fd4db8a2d6a8f8c316d738" continuedAt="i84a23f80573d499fabce170d249ddb37"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQ2OTM_453c2481-d7fc-4e0d-9b23-2dd16fdb94c4" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzMtMi0xLTEtMTY3NjY1_82d51e21-bd46-47b2-a2be-8362725cfbf8">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzMtNC0xLTEtMTY3NjY1_a1bf8e1b-3ff8-4f04-afc0-8842787af418">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzQtMi0xLTEtMTY3NjY1_956c8660-de8e-4e82-9a89-e64e33f3edb2">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzQtNC0xLTEtMTY3NjY1_bcd16378-3b61-4d49-93ad-fa6fae5d4b1b">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals not currently deductible</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzUtMi0xLTEtMTY3NjY1_48f3f308-13fa-4949-ac31-aecf00c131c2">645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzUtNC0xLTEtMTY3NjY1_8c82bce7-eacc-40b6-b269-348e89f84cb2">700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of tax basis over book basis of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzYtMi0xLTEtMTY3NjY1_91c082ba-63d1-43dc-9d60-c760104cb122">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzYtNC0xLTEtMTY3NjY1_e4abcb7e-cbbf-4832-859d-155c5a05b9c3">1,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront and milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:DeferredTaxAssetsUpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzctMi0xLTEtMTY3NjY1_a616c696-7311-4da8-9b5d-72332d55d512">1,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="gild:DeferredTaxAssetsUpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzctNC0xLTEtMTY3NjY1_b7ce6042-4ec1-4f3e-9250-33e67cc19dcb">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzgtMi0xLTEtMTY3NjY1_556075a1-14ca-40c8-ad0e-f6c5f4a47a1a">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzgtNC0xLTEtMTY3NjY1_1fca0b37-876d-40cf-991c-ce312560a2ef">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzktMi0xLTEtMTY3NjY1_ae4d3cfa-7d4c-4fed-b061-c4729cff8f23">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzktNC0xLTEtMTY3NjY1_e41c303e-fc89-4c94-81f9-fe30106c6a0e">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to sale of future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzEwLTItMS0xLTE2NzY2NQ_a109fd9b-198b-4218-bb1f-91384b86ad26">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzEwLTQtMS0xLTE2NzY2NQ_20b25271-e47d-450a-8b76-b0d5df9e757e">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzExLTItMS0xLTI1NDA0MA_a13288eb-8388-4a4d-b38b-182ccf6c3db5">784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzExLTQtMS0xLTI1NDIzNA_1b6b9ffe-c3e1-406d-b950-8c0c7e9468a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzExLTItMS0xLTE2NzY2NQ_cad6b4a9-0c88-417a-9ff3-841c90d40ac1">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzExLTQtMS0xLTE2NzY2NQ_0a6e0e6b-c587-44a4-baec-8e839374adc0">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzEyLTItMS0xLTE2NzY2NQ_e53361b8-e94a-4bb6-a2e6-c4194343060d">5,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzEyLTQtMS0xLTE2NzY2NQ_ea28c1c8-acf3-4b91-8c78-fe2b3c5e13e2">4,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzEzLTItMS0xLTE2NzY2NQ_e179e3c3-4ac3-4fa3-92f9-b72d6f422861">599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzEzLTQtMS0xLTE2NzY2NQ_c24247b9-d402-4c6d-a1a4-6053fe93207f">520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE0LTItMS0xLTE2NzY2NQ_54031278-7285-4bc8-93ca-f1d698ce9b59">4,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE0LTQtMS0xLTE2NzY2NQ_87ccb388-c70f-4be0-a81a-a4e9bd9bda46">4,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE2LTItMS0xLTE2NzY2NQ_8bdb572b-a8ca-442f-9359-e031d00013be">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE2LTQtMS0xLTE2NzY2NQ_527c4b96-4614-43ae-bc89-165be4f2193d">227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of book basis over tax basis of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE3LTItMS0xLTE2NzY2NQ_f15b523f-7e9d-4e49-84af-a82d68275100">5,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE3LTQtMS0xLTE2NzY2NQ_c549de3d-7a98-4a0e-82e0-d31be852e1dc">6,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE4LTItMS0xLTE2NzY2NQ_d96ed39f-615c-4e66-93d8-44021600f470">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE4LTQtMS0xLTE2NzY2NQ_97130312-2a0f-45c7-9d6d-1489ec520da9">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE5LTItMS0xLTE2NzY2NQ_eac2143a-8cf5-4e60-a38a-9802effd8002">6,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE5LTQtMS0xLTE2NzY2NQ_a24ea961-2e7d-4c88-a6d9-fab628c372e2">7,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzIwLTItMS0xLTE2NzY2NQ_96429529-b4b5-4946-8933-700f04d7baef">1,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzIwLTQtMS0xLTE2NzY2NQ_4b599afb-d8b5-4fcb-a905-6ee5e2ca3b55">3,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance increased from $<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzU0OTc1NTgxNTMzODY_63b0e600-5e40-4b4d-9925-f11e0a31a579">520</ix:nonFraction> million as of December&#160;31, 2021 to $<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1ODU_b088dbb4-fbb3-4ef9-add6-aa000bd92bc4">599</ix:nonFraction> million as of December&#160;31, 2022, primarily due to unrealized losses on our equity investments which are subject to a full valuation allowance, and increased from $<ix:nonFraction unitRef="usd" contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzU0OTc1NTgxNTM1MjA_3eaf6e9e-d557-41b2-a68a-6257b5791318">398</ix:nonFraction> million as of December&#160;31, 2020 to $<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1Njk_63b0e600-5e40-4b4d-9925-f11e0a31a579">520</ix:nonFraction> million as of December&#160;31, 2021, primarily due to California research and development tax credits.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had U.S. federal net operating loss and tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i34b2763ca1054014af97296f08cfe8f9_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1MjY_f5ffc73b-4892-419f-970f-3a5cbb38df66">199</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i34b2763ca1054014af97296f08cfe8f9_I20221231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1Mzc_e61aa6f0-c4e0-4ef0-803f-d341a18a3282">7</ix:nonFraction> million, respectively, which will start to expire in 2023, if not utilized. In addition, we had state net operating loss and tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i016ea1213b884f66af6169c417c336f8_I20221231" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1NDQ_4aee8f16-6afa-4d64-9fd0-4ec93df1dc41">2.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i016ea1213b884f66af6169c417c336f8_I20221231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1NTM_a7cec877-c1d1-45f2-89ae-0ca23f1d9bf1">879</ix:nonFraction> million, respectively, which will start to expire in 2024 and 2023, respectively, if not utilized. Utilization of net operating losses and tax credits may be subject to an annual limitation due to ownership change limitations provided in the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file federal, state and foreign income tax returns in the U.S. and in many foreign jurisdictions. For federal income tax purposes, the statute of limitations is open for 2016 and onwards and 2013 and onwards for California income tax purposes. For certain acquired entities, the statute of limitations is open for all years from inception due to our utilization of their net operating losses and credits carried over from prior years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service and Irish tax authorities for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.</span><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total unrecognized tax benefits, $<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1MTc_bc8f49a5-85d6-4195-9348-04246f2e3f6c">946</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1MTA_72f51cd8-9d06-4637-8efe-0769c575697d">800</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively, if recognized, would reduce our effective tax rate in the period of recognition. Interest and penalties related to unrecognized tax benefits included income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQzOTgwNDY1MjU0MTI_c7d4c936-6ee8-42d7-b15e-7ef9e7cca0e6">3</ix:nonFraction> million, income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY0OTQ_c7ed80ed-5dcf-401b-b07d-ab5c060199ad">41</ix:nonFraction> million and income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY0NzM_6407ed55-9e08-474e-872e-0cdfa9c84ac7">82</ix:nonFraction> million on our Consolidated Statements of Income for the years ended December&#160;31, 2022, 2021 and 2020 respectively. Accrued interest and penalties related to unrecognized tax benefits were $<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY0NTA_905e5891-6377-43bc-a07a-4daa6a92b163">215</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY0NDM_55c6a949-3e25-45a2-a062-0f87b6722dc8">218</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022, we do not believe that it is reasonably possible that our unrecognized tax benefits will significantly change in the next 12 months. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i84a23f80573d499fabce170d249ddb37"><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQ3MjA_e5324b71-892c-4454-b074-7860006986d4" escape="true"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our total gross unrecognized tax benefits:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzItMi0xLTEtMTY3NjY1_38e8a4e3-75c7-44cf-9a6d-b013742662ee">1,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzItNC0xLTEtMTY3NjY1_89bf7ee2-3596-4ea0-89b6-182bf04d7323">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0142ebb7458d4ec68ef2fa3254d6e76a_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzItNi0xLTEtMTY3NjY1_38d02b4c-b5d9-4e37-889c-a06132c91853">2,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzQtMi0xLTEtMTY3NjY1_6ee8ac76-4743-4028-b60e-f67686361d28">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzQtNC0xLTEtMTY3NjY1_642a4e9a-4718-4e52-9394-b2dbf37d92da">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzQtNi0xLTEtMTY3NjY1_578619d3-6674-4c07-9e55-6906b6dc1fd1">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzUtMi0xLTEtMTY3NjY1_e1adc627-ccf3-4644-a57a-6c0b6c629568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzUtNC0xLTEtMTY3NjY1_0eb0e9b6-7662-4114-941a-49080d8b09d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzUtNi0xLTEtMTY3NjY1_a6a5d5a5-e656-469d-8d90-2ecb5230ae66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzctMi0xLTEtMTY3NjY1_a8fd930f-0ce4-4308-84cb-e829d113db2a">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzctNC0xLTEtMTY3NjY1_838d925e-ab92-4dde-a7f3-2413af982aea">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzctNi0xLTEtMTY3NjY1_655b83bc-2626-4c6a-8cdb-9874dc98160c">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzgtMi0xLTEtMTY3NjY1_c6bb8dee-c83a-4356-9699-c078554fd2d3">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzgtNC0xLTEtMTY3NjY1_adc7f210-509c-43e4-a79b-26cdb3a48988">179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzgtNi0xLTEtMTY3NjY1_4d843855-b0be-45ac-b40f-869119adf764">481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzktMi0xLTEtMTY3NjY1_5bd517ba-0aba-4379-acc6-d724901550f2">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzktNC0xLTEtMTY3NjY1_f40afb7f-fdf9-4095-bfa6-5ef4dafe138f">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzktNi0xLTEtMTY3NjY1_cb94168b-1d12-4768-87e3-1c567210da1d">454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzEwLTItMS0xLTE2NzY2NQ_bb731164-b23c-4f4d-90e0-34c3bfdc3172">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzEwLTQtMS0xLTE2NzY2NQ_2370e718-dded-4dd6-b49a-f20441020fac">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzEwLTYtMS0xLTE2NzY2NQ_15f21b47-089b-41d1-842c-18874c72375d">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzExLTItMS0xLTE2NzY2NQ_165fabb1-01ed-4271-be4a-a3ed071def85">1,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzExLTQtMS0xLTE2NzY2NQ_d4c24ebe-c6af-41e5-ac80-829ac58fdeb6">1,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzExLTYtMS0xLTE2NzY2NQ_88d20275-1588-4043-803d-6fabbc1dedd0">1,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Tax Cuts and Jobs Act, we recorded a federal income tax payable for transition tax on the mandatory deemed repatriation of foreign earnings that is payable over an eight-year period. Federal income tax payable for transition tax was $<ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-8" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzU0OTc1NTgxNTM4ODQ_4a607926-30a5-4942-8204-4efebfc6e94a">3.5</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231" decimals="-8" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzU0OTc1NTgxNTM4OTI_5d5f8e09-3b61-4515-9c8e-a66630ebcbaf">4.0</ix:nonFraction> billion as of December&#160;31, 2022 and 2021, respectively. </span></div><ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="gild:ScheduleOfTransitionTaxTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzEzNzQzODk1MzU3Mzk5_7dcf2cd1-e391-4fa5-83d2-9b15e5574c5b" escape="true"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the anticipated timing of payments associated with this transition tax as of December&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTo0MDhjNGE3NTkwNDY0MjMzOGIxMzg2ZTk5MTZmZTM2NC90YWJsZXJhbmdlOjQwOGM0YTc1OTA0NjQyMzM4YjEzODZlOTkxNmZlMzY0XzEtMi0xLTEtMjIyNzUz_6b9818e2-af38-49dc-9b8d-e2b566b08ced">886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTo0MDhjNGE3NTkwNDY0MjMzOGIxMzg2ZTk5MTZmZTM2NC90YWJsZXJhbmdlOjQwOGM0YTc1OTA0NjQyMzM4YjEzODZlOTkxNmZlMzY0XzItMi0xLTEtMjIyNzUz_b528040d-0dfd-4e97-a823-c75d54bb326c">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="gild:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTo0MDhjNGE3NTkwNDY0MjMzOGIxMzg2ZTk5MTZmZTM2NC90YWJsZXJhbmdlOjQwOGM0YTc1OTA0NjQyMzM4YjEzODZlOTkxNmZlMzY0XzMtMi0xLTEtMjIyNzUz_18117b23-a339-465d-9df9-66bbb3da6952">1,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231" decimals="-6" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTo0MDhjNGE3NTkwNDY0MjMzOGIxMzg2ZTk5MTZmZTM2NC90YWJsZXJhbmdlOjQwOGM0YTc1OTA0NjQyMzM4YjEzODZlOTkxNmZlMzY0XzctMi0xLTEtMjIyNzUz_b8062da8-182b-4d0c-97af-2f750a3399c7">3,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_549755815568"></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN181NDk3NTU4MTU1NjgvZnJhZzpmZTZhYTdlYzY5OWU0YzA2ODJkNTI1ZDRkYWQwOTAxNy90ZXh0cmVnaW9uOmZlNmFhN2VjNjk5ZTRjMDY4MmQ1MjVkNGRhZDA5MDE3XzEzNzQzODk1MzYyOTcx_a63f703e-67fb-4d89-bba2-a075e9dc65e4" continuedAt="i4b26bd5d301e4304b36fbbb2efd9f1fc" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i4b26bd5d301e4304b36fbbb2efd9f1fc"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Arcellx</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, Inc. (&#8220;Arcellx&#8221;) to co-develop and co-commercialize Arcellx&#8217;s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Under the terms of the agreement, Arcellx will receive an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="ie3f62493c696477b8cfbb9f960369e84_D20230101-20230131" decimals="-6" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN181NDk3NTU4MTU1NjgvZnJhZzpmZTZhYTdlYzY5OWU0YzA2ODJkNTI1ZDRkYWQwOTAxNy90ZXh0cmVnaW9uOmZlNmFhN2VjNjk5ZTRjMDY4MmQ1MjVkNGRhZDA5MDE3XzU0OTc1NTgzNDAwNQ_5be2a6b4-e961-4a9e-aff3-0a22dc238bde">225</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie3f62493c696477b8cfbb9f960369e84_D20230101-20230131" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN181NDk3NTU4MTU1NjgvZnJhZzpmZTZhYTdlYzY5OWU0YzA2ODJkNTI1ZDRkYWQwOTAxNy90ZXh0cmVnaW9uOmZlNmFhN2VjNjk5ZTRjMDY4MmQ1MjVkNGRhZDA5MDE3XzU0OTc1NTgzNDAwOQ_0764a6fd-a442-4a8b-bd34-faa32e881633">100</ix:nonFraction>&#160;million equity investment as well as other potential contingent payments. The companies will share development, clinical trial, and commercialization costs for CART-ddBCMA and will jointly commercialize the product and split U.S. profits <ix:nonFraction unitRef="number" contextRef="i2425a97f760f4c49bd6815b72167f203_I20230131" decimals="2" name="gild:RevenuePerformanceObligationPercentageOfUSProfits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN181NDk3NTU4MTU1NjgvZnJhZzpmZTZhYTdlYzY5OWU0YzA2ODJkNTI1ZDRkYWQwOTAxNy90ZXh0cmVnaW9uOmZlNmFhN2VjNjk5ZTRjMDY4MmQ1MjVkNGRhZDA5MDE3XzU0OTc1NTgzNjgwNw_93ca0d94-9bb8-4937-b1e2-7ec422b6975c">50</ix:nonFraction>/<ix:nonFraction unitRef="number" contextRef="i0056aa3d99a143b88dbc13d114cc84be_I20230131" decimals="2" name="gild:RevenuePerformanceObligationPercentageOfUSProfits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN181NDk3NTU4MTU1NjgvZnJhZzpmZTZhYTdlYzY5OWU0YzA2ODJkNTI1ZDRkYWQwOTAxNy90ZXh0cmVnaW9uOmZlNmFhN2VjNjk5ZTRjMDY4MmQ1MjVkNGRhZDA5MDE3XzU0OTc1NTgzNjgxMw_19706b49-1655-4015-ad73-152c0a93fc62">50</ix:nonFraction>. Outside the U.S., we will commercialize the product and Arcellx will receive royalties on sales.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tmunity</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we closed an agreement to acquire Tmunity Therapeutics (&#8220;Tmunity&#8221;), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. Under the terms of the agreement, we acquired all outstanding shares of Tmunity other than those already owned by Gilead for approximately $<ix:nonFraction unitRef="usd" contextRef="i0f0e85f937584323a180e6f5054512c6_D20230222-20230222" decimals="-6" name="gild:PaymentsForAssetAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN181NDk3NTU4MTU1NjgvZnJhZzpmZTZhYTdlYzY5OWU0YzA2ODJkNTI1ZDRkYWQwOTAxNy90ZXh0cmVnaW9uOmZlNmFhN2VjNjk5ZTRjMDY4MmQ1MjVkNGRhZDA5MDE3XzU0OTc1NTgzNDA0OQ_2d3b9251-9f0c-46f2-b805-48904e485479">300</ix:nonFraction>&#160;million in cash consideration.</span></div></ix:continuation><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Gilead Sciences, Inc. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Gilead Sciences, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Gilead Sciences, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2022, based on the COSO criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2022 and 2021, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2022, and the related notes and our report dated February&#160;22, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;22, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Evaluation of Disclosure Controls and Procedures </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation as of December&#160;31, 2022 was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our &#8220;disclosure controls and procedures,&#8221; which are defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as controls and other procedures of a company that are designed to ensure that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to the company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December&#160;31, 2022. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Management&#8217;s Report on Internal Control over Financial Reporting </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule&#160;13a-15(f) and 15d-15(f) of the Exchange Act. Our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of financial statements for external purposes in accordance with generally accepted accounting principles. All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable assurance that the objectives of the internal control system are met. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting, based on criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in its 2013 Internal Control-Integrated Framework. Based on our evaluation, we concluded that our internal control over financial reporting was effective as of December&#160;31, 2022. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm, Ernst&#160;&amp; Young LLP, has audited our Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10-K and have issued a report on our internal control over financial reporting as of December&#160;31, 2022. Its report on the audit of internal control over financial reporting appears above. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Changes in Internal Control over Financial Reporting </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, has evaluated any changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2022, and has concluded that there was no change during such quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_154"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_157"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_160"></div><div style="margin-top:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_163"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item concerning our directors and executive officers is incorporated by reference to the sections of our Definitive Proxy Statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with our 2023 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;) under the headings &#8220;The Gilead Board of Directors - Nominees,&#8221; &#8220;Board Structure,&#8221; &#8220;Executive Officers,&#8221; and, if applicable, &#8220;Delinquent Section&#160;16(a) Reports.&#8221; </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our written Code of Ethics applies to all of our directors and employees, including our executive officers, including without limitation our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions. The Code of Ethics is available on our website at www.gilead.com in the &#8220;Investors&#8221; section under &#8220;Governance - Governance Documents&#8221; We intend to disclose future amendments to certain provisions of the Code of Ethics, and waivers of the Code of Ethics granted to executive officers and directors, on the website within four business days following the date of the amendment or waiver.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the sections of the Proxy Statement under the headings &#8220;Executive Compensation,&#8221; &#8220;Committees of our Board of Directors,&#8221; &#8220;Compensation and Talent Committee Report,&#8221; and &#8220;Compensation of Non-Employee Board Members.&#8221; </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_169"></div><div style="margin-top:13.5pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to Item 5 of our Annual Report on Form 10-K under the heading &#8220;Securities Authorized For Issuance Under Equity Compensation Plans&#8221; and the section of the Proxy Statement under the heading &#8220;Security Ownership of Certain Beneficial Owners and Management.&#8221;</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_172"></div><div style="margin-top:13.5pt;padding-left:60.75pt;text-align:justify;text-indent:-60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the sections of the Proxy Statement under the headings &#8220;The Gilead Board of Directors,&#8221; and &#8220;Board Processes.&#8221; </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_175"></div><div style="margin-top:13.5pt;padding-left:60.75pt;text-align:justify;text-indent:-60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL ACCOUNTANT FEES AND SERVICES </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the section&#160;of the Proxy Statement under the heading &#8220;Principal Accountant Fees and Services.&#8221; </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_178"></div><div style="margin-top:13.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV </span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_181"></div><div style="margin-top:13.5pt;padding-left:60.75pt;text-align:justify;text-indent:-60.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_184"></div><div style="-sec-extract:summary;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The following documents are filed as part of this Annual Report on Form 10-K: </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Index list to Consolidated Financial Statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_67">Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_67">46</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_70">Audited Consolidated Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_73">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_73">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_76">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_76">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_79">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_79">50</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_82">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_82">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_85">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_85">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_88">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_88">53</a></span></div></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) All other schedules are omitted because they are not required or the required information is included in the financial statements or notes thereto. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Exhibits.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed herewith or incorporated by reference:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit<br/>Footnote</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465919028215/a19-9678_1ex3d2.htm">Restated Certificate of Incorporation of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465923011167/tm235492d1_ex3-1.htm">Amended and Restated Bylaws of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Reference is made to Exhibit 3.1 and Exhibit 3.2</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex41.htm">Indenture related to Senior Notes, dated as of March&#160;30, 2011, between Registrant and Wells Fargo, National Association, as Trustee</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex42.htm">First Supplemental Indenture related to Senior Notes, dated as of March 30, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including form of Senior Notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511339157/d269235dex41.htm">Second Supplemental Indenture related to Senior Notes, dated as of December 13, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2041 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514089047/d688498dex41.htm">Third Supplemental Indenture related to Senior Notes, dated as of March 7, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2024 Note and Form of 2044 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312514415184/d821656dex41.htm">Fourth Supplemental Indenture related to Senior Notes, dated as of November 17, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2025 Note and Form of 2045 Note)</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312515319560/d68529dex41.htm">Fifth Supplemental Indenture, dated as of September 14, 2015, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2026 Note, Form of 2035 Note and Form of 2046 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312516714926/d259911dex41.htm">Sixth Supplemental Indenture, dated as of September 20, 2016, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2023 Note, Form of 2027 Note, Form of 2036 Note and Form of 2047 Note)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465920110185/tm2031940d2_ex4-1.htm">Eighth Supplemental Indenture, dated as of September 30, 2020, between the Registrant and Wells Fargo Bank, National Association, as Trustee (including form of notes)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000006/gild2019form10-kex49.htm">Description of Registrant&#8217;s Securities</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312517168672/d396034dex101.htm">Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000008/gild20ormex102amendmentto2.htm">Amendment No. 1 to Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(12)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465922056435/tm2213708d1_ex10-1.htm">Gilead Sciences, Inc. 2022 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1042.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex104.htm">Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex105.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex1072021employe.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex1072021employe.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex1072021employe.htm"> in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex1082022employe.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10102022employ.htm">Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants commencing in 202</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10102022employ.htm">2</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10102022employ.htm">)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(20)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312509165506/dex1019.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2009 through 2012)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1043.htm">Form of non-employee director stock option agreement (U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(21)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.13*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000038/gildq21310-qex1044.htm">Form of non-employee director stock option agreement (non-U.S.) under 2004 Equity Incentive Plan (for grants made in 2013)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(22)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.14*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209514000038/ex1045-stockoptionagreement.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2014 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex109.htm"> in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(23)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.16*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm"> in 2020</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm"> and 2021</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10262020no.htm">)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10172022non-ee.htm">Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants commencing in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1012.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.19*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1013.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10162021psuagr.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10162021psuagr.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10162021psuagr.htm"> in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.21*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex10182022psuagr.htm">Form of performance share award agreement - TSR Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.22*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1015.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1017.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants made in 2020)</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.24*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10192021psuagr.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10192021psuagr.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10192021psuagr.htm"> in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.25*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex10222022psuagr.htm">Form of performance share award agreement - Revenue Goals (U.S.) under 2004 Equity Incentive Plan (for grants commencing in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.26*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312511132405/dex1057.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.27*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1017.htm">Form of employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.28*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1020.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.29*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1024.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(17)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.30*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209521000013/gildq12021ex10242021employ.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for grants commencing in 2021)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(18)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.31*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000013/gildq12022ex10282022employ.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.32*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10322022employ.htm">Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for certain </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10322022employ.htm">grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10322022employ.htm">commencing in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(23)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.33*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm">Form of non-employee director restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants </a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm">made</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm"> in 202</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm">1</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10112020no.htm">)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(19)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.34*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209522000019/gildq22022ex10342022non-ee.htm">Form of non-employee director restricted stock unit issuance agreement under 2004 Equity Incentive Plan (for grants commencing in 2022)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(23)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.35*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex10272018eq.htm">Gilead Sciences, Inc. 2018 Equity Incentive Plan, amended and restated April 7, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(24) </span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.36*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000015/exhibit101-espp.htm">Gilead Sciences, Inc. Employee Stock Purchase Plan, amended and restated January 22, 2015</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.37*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1020.htm">Gilead Sciences, Inc. 2005 Deferred Compensation Plan, amended and restated April 19, 2016</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(23)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.38*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1030severa.htm">Gilead Sciences, Inc. Severance Plan, amended and restated May 5, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1028.htm">Gilead Sciences, Inc. Corporate Annual Incentive Plan, amended and restated January 1, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(25)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.40*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000110465918072098/a18-41320_1ex99d2.htm">Offer Letter between Registrant and Daniel O&#8217;Day, dated November 30, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.41*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1027.htm">Stock option agreement for Daniel O&#8217;Day under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.42*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1028.htm">Performance share award agreement for Daniel O&#8217;Day (for TSR Goals in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.43*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1029.htm">Performance share award agreement for Daniel O&#8217;Day (for Revenue Goals in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.44*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1030.htm">Form of restricted stock unit issuance agreement for Daniel O&#8217;Day (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(14)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.45*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000020/gildq22019ex1026.htm">Offer Letter between Registrant and Johanna Mercier, dated May 21, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(23)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.46*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000019/gildq22020ex1043housin.htm">Letter Agreement between Registrant and Johanna Mercier, dated May 4, 2020</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.47*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1040.htm">Global stock option agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.48*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1041.htm">Restricted stock unit issuance agreement for Johanna Mercier (for Performance Objectives in 2019-2020) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.49*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1042.htm">Global restricted stock unit issuance agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.50*,**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="gild2022formex1050offerlet.htm">Offer Letter between Registrant and Merdad Parsey, dated September 29, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.51*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1044.htm">Global stock option agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(16)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.52*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209520000013/gildq12020ex1045.htm">Global restricted stock unit issuance agreement for Merdad Parsey (in 2019) under 2004 Equity Incentive Plan</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(26)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.53*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Indemnity Agreement entered into between Registrant and its directors and executive officers</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(26)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.54*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(27)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.55*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312507041203/dex103.htm">Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees (revised September&#160;2006)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(28)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amendment Agreement, dated October&#160;25, 1993, between Registrant, the Institute of Organic Chemistry and Biochemistry (IOCB) and Rega Stichting v.z.w. (REGA), together with the following exhibits: the License Agreement, dated December&#160;15, 1991, between Registrant, IOCB and REGA (the 1991 License Agreement); the License Agreement, dated October&#160;15, 1992, between Registrant, IOCB and REGA (the October 1992 License Agreement); and the License Agreement, dated December&#160;1, 1992, between Registrant, IOCB and REGA (the December 1992 License Agreement)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(29)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000091205701007841/a2041233zex-10_13.txt">Amendment Agreement between Registrant and IOCB/REGA, dated December&#160;27, 2000, amending the 1991 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(30)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.58</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312506223996/dex103.htm">Sixth Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated August&#160;18, 2006, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(31)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.59</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209513000046/q313form10-qxexhibit1078.htm">Seventh Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated July 1, 2013, amending the October 1992 License Agreement and the December 1992 License Agreement</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(32)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.60</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1022622/000091205799003190/0000912057-99-003190.txt">Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University, dated May&#160;6, 1999</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(33)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.61</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Royalty Sale Agreement by and among Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;18, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">+(33)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.62</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000119312505216649/dex102.htm">Amended and Restated License Agreement by and between Registrant, Emory University and Investors Trust &amp; Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July&#160;21, 2005</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(34)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.63</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1042.htm">Amended and Restated EVG License Agreement by and between Japan Tobacco Inc. and Registrant, dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">++(34)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.64</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000008/gild2018form10-kaexhibit1043.htm">Master Agreement by and between Registrant, Gilead Sciences K.K. and Japan Tobacco Inc., dated November 29, 2018</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(35)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.65</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209515000008/ex1076-arcollaborationagre.htm">Amended and Restated Collaboration Agreement by and among Registrant, Gilead Sciences Ireland UC (formerly Gilead Sciences Limited) and Janssen R&amp;D Ireland, dated December 23, 2014</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;+(36)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.66</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1510580/000119312514239257/d705296dex1017.htm">License Agreement by and among Kite Pharma, Inc., Cabaret Biotech Ltd. and Dr. Zelig Eshhar, dated December 12, 2013</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;++(15)</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10.67</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/882095/000088209519000027/gildq32019ex1050.htm">Option, License and Collaboration Agreement by and between Galapagos NV and Registrant, dated July 14, 2019</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">21.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2022form10-kexhibit211.htm">Subsidiaries of Registrant</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">23.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2022form10-kexhibit231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">24.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i6d96c727bd3e4a10969bbf6a84d64ce7_190">Power of Attorney (included on the signature page of this report)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2022form10-kexhibit311.htm">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2022form10-kexhibit312.htm">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">32***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="gild2022form10-kexhibit32.htm">Certifications of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.INS**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.SCH**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.CAL**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.DEF**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.LAB**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101.PRE**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">Cover Page Interactive Data File, formatted in Inline XBRL (included as Exhibit 101)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 9, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on April&#160;1, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 13, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on March 7, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on November 17, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 14, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 20, 2016, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on September 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 12, 2017, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(11)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(12)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 5, 2022, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2011, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(14)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(15)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(16)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(17)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">(18)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%">Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(19)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(20)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2009, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(21)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, and incorporated herein by reference</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(22)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(23)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(24)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on May 8, 2015, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(25)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Current Report on Form 8-K filed on December 10, 2018, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(26)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Registration Statement on Form S-1 (No. 33-55680), as amended, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(27)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(28)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended March&#160;31, 1994, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(20)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2000, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(30)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2006, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(31)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(32)&#160;&#160;&#160;&#160;Filed as an exhibit to Triangle Pharmaceuticals, Inc.&#8217;s Quarterly Report on Form 10-Q/A filed on November&#160;3, 1999, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(33)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2005, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(34)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Amendment No. 1 to Annual Report on Form 10-K/A filed on April 18, 2019, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(35)&#160;&#160;&#160;&#160;Filed as an exhibit to Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2014, and incorporated herein by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(36)&#160;&#160;&#160;&#160;Filed as an exhibit to Kite Pharma, Inc.&#8217;s Registration Statement on Form S-1/A (No. 333-196081) filed on June 17, 2014, and incorporated herein by reference.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Certain confidential portions of this Exhibit were omitted by means of marking such portions with an asterisk (the Mark). This Exhibit has been filed separately with the Secretary of the Securities and Exchange Commission without the Mark pursuant to Registrant&#8217;s Application Requesting Confidential Treatment under Rule 24b-2 under the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">++&#160;&#160;&#160;&#160;Certain portions of this Exhibit were omitted by means of marking such portions with the Mark because the identified portions are (i) private or confidential and (ii) not material.</span></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_187"></div><div style="margin-top:13.5pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i6d96c727bd3e4a10969bbf6a84d64ce7_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.859%"><tr><td style="width:1.0%"></td><td style="width:10.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GILEAD SCIENCES, INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daniel P. O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Day</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</span></div></td></tr></table></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Daniel P. O&#8217;Day and Deborah H. Telman, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel P. O&#8217;Day</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Andrew D. Dickinson</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DIANE E. WILFONG</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diane E. Wilfong</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;JACQUELINE K. BARTON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqueline K. Barton, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;JEFFREY A. BLUESTONE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey A. Bluestone, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;SANDRA J. HORNING</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra J. Horning, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;KELLY A. KRAMER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kelly A. Kramer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;KEVIN E. LOFTON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin E. Lofton</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;HARISH MANWANI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harish Manwani</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JAVIER J. RODRIGUEZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Javier J. Rodriguez</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;ANTHONY WELTERS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthony Welters</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.50
<SEQUENCE>2
<FILENAME>gild2022formex1050offerlet.htm
<DESCRIPTION>OFFER LETTER (PARSEY)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i06562e95f6ec45a1af2d9361d1a7036f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 10.50</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Certain information has been excluded from this exhibit pursuant to Item 601(a)(6) of Regulation S-K because disclosure of such information would constitute a clearly unwarranted invasion of personal privacy. The following symbol is included in this exhibit to indicate where such information has been omitted&#58; &#91;*&#93;</font></div><div style="margin-bottom:6pt;text-align:right"><img alt="image_1.jpg" src="image_1.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 29, 2019</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REVISED</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merdad Parsey </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;*&#93;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dear Merdad,</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead&#8221;) is pleased to offer you the position of Chief Medical Officer. In this role you will report to Gilead&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), Daniel O&#8217;Day, and will have responsibility for Gilead&#8217;s core drug development and medical affairs initiatives, other than those of Kite Pharma, Inc. You will join Gilead&#8217;s Leadership Team and be based in our Foster City, California headquarters. We would expect you to start on November 4, 2019 or such earlier date as may be agreed to by the CEO (such date, the &#8220;Start Date&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are very excited about the possibility of you joining Gilead, and we look forward to working with you in our innovative company. The following outlines the specific terms of our offer&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Compensation.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Your base salary on an annualized basis will be </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$1,000,000</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, less taxes, payable bi-- weekly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You will be eligible to participate in Gilead&#8217;s annual corporate bonus program, commencing with the 2020 bonus year. Your target bonus will be </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100%</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of annual base salary. Based on your starting annualized base salary, your target bonus would be $1,000,000. Under current plan terms your actual bonus payout can range from 0% to 150% of this target based on the achievement of individual and corporate performance goals as established by the Compensation Committee (the &#8220;Compensation Committee&#8221;) of Gilead&#8217;s Board of Directors (the &#8220;Board&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to an initial equity award as described below, you will be eligible to participate in Gilead&#8217;s annual equity award program, under which awards are typically granted in the first quarter of the year. For 2020, the aggregate target grant date value for your equity awards will be </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$4,000,000</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Currently, 25% of the aggregate target value of such annual equity awards is comprised of stock options, 25% is comprised of restricted stock units (RSUs), and the remaining 50% is comprised of performance share unit awards (PSUs). The actual award breakdown will be determined by the Compensation Committee prior to grant, and the number of shares subject to each of these grants will be determined based on the assumptions used by Gilead at the time of grant to value equity awards for purposes of Gilead&#8217;s financial reporting. These awards will be subject to the standard terms utilized for grants to the Gilead Leadership Team. The target grant values and equity vehicles are reviewed on an annual basis and subject to change as determined by the Compensation Committee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New-Hire Equity Awards.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> You will be granted equity awards with an aggregate target grant date value of</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$2,000,000</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following your Start Date (your &#8220;New-Hire Equity Awards&#8221;). Your New Hire Equity Awards will be made under the Gilead Sciences, Inc. 2004 Equity Incentive Plan, as amended (the &#8220;Equity Incentive Plan&#8221;), </font></div><div style="height:45.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with $1,000,000 of the awards granted in the form of restricted stock units (RSUs) and $1,000,000 granted in the form of stock options, intended to replace the value of unvested equity awards forfeited from your current employer. The actual number of shares subject to each of these grants will be determined based on the assumptions used by Gilead at the time of grant to value equity awards for purposes of Gilead&#8217;s financial reporting. Your New-Hire Equity Awards will be subject to the standard terms utilized for grants to the Gilead Leadership Team under the Equity Incentive Plan as approved by the Compensation Committee prior to the time of this offer, including the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The exercise price for your stock options will be no less than the fair market value per share of Gilead common stock on the grant date. The fair market value per share for that date will be determined in accordance with the provisions of the Equity Incentive Plan. You will be notified of the details after your options have been granted. Your options will vest and become exercisable for 25% of the option shares upon your completion of one year of employment with Gilead, measured from the grant date, and will vest and become exercisable for the balance of the option shares in a series of successive equal quarterly installments upon your completion of each successive three-month period of continued employment with Gilead over the next three years. The options will have a maximum term of ten years, subject to earlier termination upon or following your cessation of employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Your RSUs will vest, and the underlying shares of Gilead common stock issued to you, in a series of three successive annual installments upon your completion of each year of continued employment with Gilead over the three-year period measured from the award date. Each RSU that vests will entitle you to one share of Gilead common stock.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sign-On Bonus.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To offset the value of your annual bonus and unvested equity awards forfeited from your current employer, you will receive a one-time cash payment of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$2,000,000</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Sign-On Bonus&#8221;). Your Sign-On Bonus will be paid to you in two equal installments. The first installment of $1,000,000 will be paid with your first payroll check subsequent to the Start Date and, subject to your continued employment, the second installment of $1,000,000 will paid with the first payroll check subsequent to the first anniversary of the Start Date. In the event that your employment is terminated by Gilead for Cause (as defined in the Equity Incentive Plan) or by you without Good Reason (as defined below), prior to your completion of one year of service, you will be required to repay the first installment of the Sign-On Bonus to Gilead. Your repayment obligation, if applicable, is due in full to Gilead within ninety days following your employment termination date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that, during your first two years with Gilead, your employment is terminated by Gilead without Cause (as defined in the Equity Incentive Plan), if you voluntarily terminate for Good Reason (as defined below) or if your employment with Gilead terminates due to your death or Disability (as defined below), you will become 100% vested in any of your remaining unvested New Hire Equity Awards and the full Sign-On Bonus, subject to your execution and non-revocation of a waiver and general release of claims within the time period specified by and in the form then provided by Gilead. In such circumstances, any stock options granted as part of your New Hire Equity Awards will remain exercisable until the first anniversary of your termination date. Any unpaid portion of the Sign-On Bonus will be paid to you within 60 days of such termination date. The stock options and RSUs will be subject, in all respects except as specifically set forth herein, to the terms and conditions of an award agreement that will be provided to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this letter, &#8220;Good Reason&#8221; means the occurrence of any of the following events or conditions&#58; (i) an adverse change in your employment status, title, position or responsibilities as Chief Medical Officer (including reporting responsibilities)&#59; (ii) a reduction in your annual base compensation or any failure to pay you any compensation or benefits to which you are entitled within 30 days of the date due&#59; (iii) a reduction in your target bonus or annual equity award opportunity prior to the first anniversary of the Start Date&#59; or (iv) Gilead requires you to relocate to any place outside a 50 mile radius of the greater Foster City, California area, except for reasonably required travel on the business of Gilead or any subsidiary.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this letter, &#8220;Disability&#8221; means a physical or mental impairment which renders you unable to perform the essential functions of your employment with Gilead, even with reasonable accommodation that does not impose undue hardship on Gilead, for more than 90 days in any 180-day period.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Benefits.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gilead provides a comprehensive company-paid benefits package including health, dental, vision, life, and long-term disability insurance plans. You are eligible for health and welfare benefits if you are a full-time employee working 30 hours or more (unless otherwise specified). You will need to enroll for medical, dental and vision coverage within 31 days of your hire date, or you will not be eligible to enroll until the next open enrollment, unless you have a qualifying life event. Upon completion of enrollment within such 31 day period, your coverage begins effective as of your Start Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the next enrollment date, you will be eligible to participate in our Employee Stock Purchase Plan (&#8220;ESPP&#8221;) that offers you the opportunity to contribute up to 15% of your earnings, up to the IRS maximum, through payroll deductions to purchase Gilead stock at 85% of the lower of the closing price at the date of enrollment or purchase. ESPP enrollment occurs two times a year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we offer a 401(k) plan, which provides you with the opportunity for Pre-tax, Roth After-tax and Additional After-tax savings by deferring from 1-50% of your annual salary, subject to IRS maximums. Gilead will match 100% of your Pre-tax and&#47;or Roth After-tax contributions to the plan up to a maximum company contribution of $12,000 per year (which increases to $15,000 beginning in 2020). More detailed information regarding your benefits will be provided at your New Employee Orientation, shortly after you begin employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an employee, you are covered under Gilead&#8217;s Workers Compensation insurance policy. This policy applies to all employees who become ill or injured on the job. Gilead&#8217;s Workers Compensation carrier is XL Insurance America, Inc. Claims are handled by Sedgwick, a Third Party Administrator, at 1-855-336-0983.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You will be entitled to severance benefits in accordance with the terms and conditions of the Gilead Sciences, Inc. Severance Plan, as amended (the &#8220;Severance Plan&#8221;) and in the amounts set forth in Appendix B thereto&#59; provided, however, that notwithstanding anything to the contrary in the Severance Plan, a termination of your employment by Gilead without Cause (as defined above) or by you for Good Reason (as defined above) will be considered &#8220;an involuntary termination&#8221; that entitles you to the Severance Pay Benefit for purposes of Section IV(a)(i)(1) of the Severance Plan, subject to your execution and delivery to Gilead of a release as provided for by the Severance Plan. A copy of this plan has been provided to you.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For your information, we have enclosed a Benefits Summary outlining Gilead&#8217;s benefits programs. We will arrange for you to meet with a member of our benefits staff to review your benefits package and enroll in the various programs. Please note that, as an executive, you will not accrue paid time-off but will instead have the flexibility of taking time off at your discretion in accordance with the business needs of the corporation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Terms.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All compensation provided to you, including any cash or equity-based compensation, will be subject to Gilead&#8217;s collection of the applicable withholding taxes, and unless otherwise specifically stated above, Gilead will not gross-up or make whole for any such taxes.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead intends to honor your ongoing confidentiality obligations and you agree to abide by Gilead&#8217;s strict company policy that prohibits any new employee from using or bringing with them from any prior employer any proprietary information, trade secrets, proprietary materials or processes of such former employers. Upon starting employment with Gilead, you will be required to sign Gilead&#8217;s Confidential Information and Inventions Agreement (&#8220;CIIA&#8221;) for Employees indicating your agreement with this policy. At the termination of your employment, you will be reminded of your continuing duties under the CIIA. Please read this policy and the CIIA carefully.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You and Gilead will also enter into Gilead&#8217;s standard form of indemnification agreement with its executive officers. During your employment with Gilead and for a period of not less than six (6) years after your employment with Gilead terminates, Gilead will cover you under directors and officers liability insurance in the same amount and to the same extent as Gilead covers its other executive officers and directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You will also be required to fill out the electronic Employment Eligibility Verification (Form 1-9). This electronic form will be sent to you via email. On your first day of employment please bring the necessary documents that establish your identity and employment eligibility.</font></div><div style="height:45.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You understand and agree that Gilead does not desire or intend to acquire from you any trade secrets or confidential proprietary information you may have acquired from others, including former employers. Therefore, you agree that during the term of your employment with Gilead, you will not bring to Gilead any such trade secrets or confidential proprietary information, nor will you use or disclose any trade secrets or confidential proprietary information of any former or concurrent employer, or any other person or entity with whom you have an agreement or to whom you owe a duty to keep such information in confidence. Further, you agree and represent to Gilead by signing below that as of the Start Date you will not be subject to any other agreement or any other previous or existing business relationship which conflicts with or restricts the full performance of your duties and obligations to Gilead (including your duties and obligations under this or any other agreement) during the term of your employment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, you agree and represent to Gilead by signing below that you have never been terminated, suspended, or otherwise disciplined by an employer or organization for conduct that was alleged to be in violation of that employer&#47;organization&#8217;s personnel policies, including but not limited to policies concerning harassment, discrimination, or other misconduct.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You agree by signing below that Gilead has made no other promises other than what is outlined in this letter. It contains the entire offer Gilead is making to you. In case of any conflict between this letter and the terms of any other letter or agreement, this letter will be controlling. Our agreement can only be modified by written agreement signed by you and Gilead&#8217;s representative. You also agree that should you accept a position at Gilead, the employment relationship is based on the mutual consent of the employee and Gilead. Accordingly, either you or Gilead can terminate the employment relationship at will, at any time, with or without cause or</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advance notice. You should also note that Gilead may modify wages and benefits from time to time at its discretion.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This offer of employment is effective for 10 days from the date of this letter. The offer is also contingent upon successful background and reference checks and Gilead&#8217;s review. If all of the foregoing is satisfactory, please sign and date within 10 days .</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I am excited to have you join the Gilead Leadership Team as the Chief Medical Officer and look forward to working with you on the organization&#8217;s short and long-term success.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sincerely,</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Daniel O&#8217;Day</font></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Daniel O&#8217;Day</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">CEO and Chairman</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foregoing terms and conditions hereby accepted&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Signature&#58;   &#47;s&#47; Merdad Parsey                                  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Name&#58;               Merdad Parsey                                  </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Date&#58;                 29 Sept 2019                                      </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                               </font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:45.35pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>gild2022form10-kexhibit211.htm
<DESCRIPTION>EXHIBIT 21.1 LISTING OF SUBSIDIARIES
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icf306b12418d4fbab0c9e408cb13199c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.903%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUBSIDIARIES OF GILEAD SCIENCES, INC.</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(as of December 31, 2022)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NAME OF SUBSIDIARY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COUNTRY OF FORMATION</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asegua Therapeutics LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forty Seven, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forty Seven Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Alberta, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Apollo, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Biopharmaceutics US LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Calistoga, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Connecticut, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Holdings, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Pharmasset LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Holding, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunomedics, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IBC Pharmaceuticals, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">neoKite, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Argentina S.R.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cytopia Pty. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Pty. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences YM Australia Pty. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">YM BioSciences Australia Pty. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences GesmbH.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Belgium BVBA</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Farmac&#234;utica do Brasil Ltda.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Alberta ULC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Canada, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead YM ULC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fosun Pharma Kite Biotechnology Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences (Shanghai) Consulting Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Hangzhou Pharmaceutical Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Colombia S.A.S.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Columbia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences s.r.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EpiTherapeutics ApS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Denmark ApS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Finland Oy</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences SAS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunomedics GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MYR GmbH</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Hellas EPE</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Hong Kong Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences India Private Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.903%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUBSIDIARIES OF GILEAD SCIENCES, INC. (continued)</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(as of December 31, 2022)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NAME OF SUBSIDIARY</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COUNTRY OF FORMATION</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Apollo Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Biopharmaceutics Ireland UC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Ireland Research UC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Oncology Ireland UC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Ireland Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Therapeutics A1 Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Therapeutics A2 Unlimited Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Israel Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences S.r.l.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences KK</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Luxembourg S.a.r.l.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Malaysia Sdn. Bhd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Mexico S. de R.L. de C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Netherlands BV</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma EU B.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KP EU C.V.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences (NZ)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Norway AS</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Americas S. de R.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Poland Sp. z o.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Lda.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences (GSR) S.R.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Romania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Russia LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Singapore Pte. Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Slovakia s.r.o.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences South Africa (Pty) Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Korea Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences S.L.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Sweden AB</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Switzerland Sarl</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gilead Sciences Ilac Ticaret Limited Sirketi</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Europe Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences International Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilead Sciences Limited</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MiroBio Ltd.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>gild2022form10-kexhibit231.htm
<DESCRIPTION>EXHIBIT 23.1 CONSENT OF INDEPENDANT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib8d285cb36464b0d8f9e9cf2df762fc9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 33-81670, 33-46058, 333-58893, 333-84719, 333-117480, 333-126012, 333-135412, 333-143920, 333-151624, 333-161069, 333-163871, 333-207813, 333-219772, 333-223248, 333-238525, 333-264713 and 333-249836) pertaining to the Employee Stock Purchase Plan, the International Employee Stock Purchase Plan, the 2004 Equity Incentive Plan, the 2018 Equity Incentive Plan and the 2022 Equity Incentive Plan of Gilead Sciences, Inc. and the Amended &#38; Restated 2014 Long-Term Incentive Plan of Immunomedics, Inc., and the Registration Statement on Form S-3 (No. 333-242321) of Gilead Sciences, Inc. and in the related Prospectuses, as applicable, of our reports dated February&#160;22, 2023, with respect to the consolidated financial statements of Gilead Sciences, Inc., and the effectiveness of internal control over financial reporting of Gilead Sciences, Inc., included in this Annual Report (Form 10-K) for the year ended December&#160;31, 2022.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;22, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>gild2022form10-kexhibit311.htm
<DESCRIPTION>CEO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2da65c99fbda43e9b1bb519f573ed4be_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel P. O&#8217;Day, certify that&#58;</font></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this annual report on Form 10-K of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O&#8217;Day<br>Chairman and Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>gild2022form10-kexhibit312.htm
<DESCRIPTION>CFO CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0d48f89431f64dccafc41e92ee2f0464_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Andrew D. Dickinson, certify that&#58;</font></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this annual report on Form 10-K of Gilead Sciences, Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:24.75pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 22, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>gild2022form10-kexhibit32.htm
<DESCRIPTION>SECTION 906 CERTIFICATIONS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ifb838536752b42a0a2ab296415cd38c1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Exhibit 32</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. &#167; 1350, as adopted), Daniel P. O&#8217;Day, the Chairman and Chief Executive Officer of Gilead Sciences, Inc. (the Company), and Andrew D. Dickinson, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58; </font></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Company&#8217;s Annual Report on Form&#160;10-K for the annual period ended December&#160;31, 2022 (the Report) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;22, 2023 </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:47.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;DANIEL P. O&#8217;DAY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;ANDREW D. DICKINSON</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Daniel P. O&#8217;Day<br>Chairman and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Andrew D. Dickinson<br>Chief Financial Officer</font></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>gild-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:138d9561-5f65-4b2f-b0c5-a8cb97862906,g:db888c96-90b0-4c6d-8008-49d88ed38ca7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gild="http://www.gilead.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.gilead.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gild-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.gilead.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.gilead.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>0000009 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000010 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.gilead.com/role/Revenues">
        <link:definition>0000012 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.gilead.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforsaleDebtSecuritiesandEquitySecurities" roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecurities">
        <link:definition>0000014 - Disclosure - Available-for-sale Debt Securities and Equity Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstruments" roleURI="http://www.gilead.com/role/DerivativeFinancialInstruments">
        <link:definition>0000015 - Disclosure - Derivative Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.gilead.com/role/Acquisitions">
        <link:definition>0000016 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.gilead.com/role/PropertyPlantandEquipment">
        <link:definition>0000017 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000018 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.gilead.com/role/OtherFinancialInformation">
        <link:definition>0000019 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangements" roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangements">
        <link:definition>0000020 - Disclosure - Collaborations and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilities" roleURI="http://www.gilead.com/role/DebtandCreditFacilities">
        <link:definition>0000021 - Disclosure - Debt and Credit Facilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.gilead.com/role/Leases">
        <link:definition>0000022 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.gilead.com/role/CommitmentsandContingencies">
        <link:definition>0000023 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.gilead.com/role/StockholdersEquity">
        <link:definition>0000024 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefits" roleURI="http://www.gilead.com/role/EmployeeBenefits">
        <link:definition>0000025 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.gilead.com/role/EarningsPerShare">
        <link:definition>0000026 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.gilead.com/role/IncomeTaxes">
        <link:definition>0000027 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.gilead.com/role/SubsequentEvents">
        <link:definition>0000028 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000029 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000030 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.gilead.com/role/RevenuesTables">
        <link:definition>0000031 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.gilead.com/role/FairValueMeasurementsTables">
        <link:definition>0000032 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforsaleDebtSecuritiesandEquitySecuritiesTables" roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesTables">
        <link:definition>0000033 - Disclosure - Available-for-sale Debt Securities and Equity Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsTables" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables">
        <link:definition>0000034 - Disclosure - Derivative Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.gilead.com/role/AcquisitionsTables">
        <link:definition>0000035 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentTables">
        <link:definition>0000036 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000037 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.gilead.com/role/OtherFinancialInformationTables">
        <link:definition>0000038 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilitiesTables" roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesTables">
        <link:definition>0000039 - Disclosure - Debt and Credit Facilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.gilead.com/role/LeasesTables">
        <link:definition>0000040 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.gilead.com/role/StockholdersEquityTables">
        <link:definition>0000041 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsTables" roleURI="http://www.gilead.com/role/EmployeeBenefitsTables">
        <link:definition>0000042 - Disclosure - Employee Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.gilead.com/role/EarningsPerShareTables">
        <link:definition>0000043 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.gilead.com/role/IncomeTaxesTables">
        <link:definition>0000044 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000045 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDisaggregationofRevenuesDetails" roleURI="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails">
        <link:definition>0000046 - Disclosure - Revenues - Disaggregation of Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesSummarizedRevenuesfromMajorCustomersDetails" roleURI="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails">
        <link:definition>0000047 - Disclosure - Revenues - Summarized Revenues from Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesPerformanceObligationsDetails" roleURI="http://www.gilead.com/role/RevenuesPerformanceObligationsDetails">
        <link:definition>0000048 - Disclosure - Revenues - Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.gilead.com/role/RevenuesNarrativeDetails">
        <link:definition>0000049 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails">
        <link:definition>0000050 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>0000051 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofContingentConsiderationDetails" roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails">
        <link:definition>0000052 - Disclosure - Fair Value Measurements - Summary of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
        <link:definition>0000053 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails">
        <link:definition>0000054 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails" roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails">
        <link:definition>0000055 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
        <link:definition>0000056 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails">
        <link:definition>0000057 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails" roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails">
        <link:definition>0000058 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of Classification of Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsAdditionalInformationDetails" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>0000059 - Disclosure - Derivative Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
        <link:definition>0000060 - Disclosure - Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails">
        <link:definition>0000061 - Disclosure - Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.gilead.com/role/AcquisitionsNarrativeDetails">
        <link:definition>0000062 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>0000063 - Disclosure - Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>0000064 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNarrativeDetails" roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails">
        <link:definition>0000065 - Disclosure - Property, Plant and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsGoodwillDetails" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails">
        <link:definition>0000066 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails">
        <link:definition>0000067 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails">
        <link:definition>0000068 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1">
        <link:definition>0000068 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails">
        <link:definition>0000069 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccountsReceivableNetDetails" roleURI="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails">
        <link:definition>0000070 - Disclosure - Other Financial Information - Accounts Receivable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationInventoriesDetails" roleURI="http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails">
        <link:definition>0000071 - Disclosure - Other Financial Information - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationInventoriesDetails_1" roleURI="http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails_1">
        <link:definition>0000071 - Disclosure - Other Financial Information - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationNarrativeDetails" roleURI="http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails">
        <link:definition>0000072 - Disclosure - Other Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationOtherAccruedLiabilitiesDetails" roleURI="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails">
        <link:definition>0000073 - Disclosure - Other Financial Information - Other Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandOtherArrangementsDetails" roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails">
        <link:definition>0000074 - Disclosure - Collaborations and Other Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails">
        <link:definition>0000075 - Disclosure - Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilitiesNarrativeDetails" roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails">
        <link:definition>0000076 - Disclosure - Debt and Credit Facilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails">
        <link:definition>0000077 - Disclosure - Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.gilead.com/role/LeasesNarrativeDetails">
        <link:definition>0000078 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalanceSheetLocationandOtherInformationDetails" roleURI="http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails">
        <link:definition>0000079 - Disclosure - Leases - Balance Sheet Location and Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalInformationRelatedtoLeasesDetails" roleURI="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails">
        <link:definition>0000080 - Disclosure - Leases - Supplemental Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails">
        <link:definition>0000081 - Disclosure - Leases - Summary of Operating Lease Liabilities Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1">
        <link:definition>0000081 - Disclosure - Leases - Summary of Operating Lease Liabilities Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.gilead.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000082 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRepurchasesofCommonStockDetails" roleURI="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails">
        <link:definition>0000083 - Disclosure - Stockholders' Equity - Repurchases of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDividendsDetails" roleURI="http://www.gilead.com/role/StockholdersEquityDividendsDetails">
        <link:definition>0000084 - Disclosure - Stockholders' Equity - Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPreferredStockDetails" roleURI="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails">
        <link:definition>0000085 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>0000086 - Disclosure - Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsNarrativeDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails">
        <link:definition>0000087 - Disclosure - Employee Benefits - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsSummaryofStockBasedCompensationDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails">
        <link:definition>0000088 - Disclosure - Employee Benefits - Summary of Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsRestrictedStockDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails">
        <link:definition>0000089 - Disclosure - Employee Benefits - Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsPerformanceShareAwardsDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails">
        <link:definition>0000090 - Disclosure - Employee Benefits - Performance Share Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsStockOptionsDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails">
        <link:definition>0000091 - Disclosure - Employee Benefits - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails">
        <link:definition>0000092 - Disclosure - Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsESPPActivityDetails" roleURI="http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails">
        <link:definition>0000093 - Disclosure - Employee Benefits - ESPP Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" roleURI="http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails">
        <link:definition>0000094 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://www.gilead.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>0000095 - Disclosure - Earnings Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>0000096 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxExpenseDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails">
        <link:definition>0000097 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails">
        <link:definition>0000098 - Disclosure - Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000099 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.gilead.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000100 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" roleURI="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails">
        <link:definition>0000101 - Disclosure - Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofTransitionTaxDetails" roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails">
        <link:definition>0000102 - Disclosure - Income Taxes - Schedule of Transition Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.gilead.com/role/SubsequentEventsDetails">
        <link:definition>0000103 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="gild_InvestmentOwnedBalanceAdditionalShares" abstract="false" name="InvestmentOwnedBalanceAdditionalShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gild_OtherInternationalMember" abstract="true" name="OtherInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" abstract="true" name="AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2027Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2026Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ArcusBiosciencesIncMember" abstract="true" name="ArcusBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" abstract="false" name="PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_PotentialOptionExerciseFeePerProgram" abstract="false" name="PotentialOptionExerciseFeePerProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_NumberOfClinicalStageProgramsWithExercisedOptions" abstract="false" name="NumberOfClinicalStageProgramsWithExercisedOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_TmunityTherapeuticsMember" abstract="true" name="TmunityTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" abstract="true" name="UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_ResidentialMortgageAndAssetBackedSecuritiesMember" abstract="true" name="ResidentialMortgageAndAssetBackedSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_StandstillRestrictingTerm" abstract="false" name="StandstillRestrictingTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_EverestMedicinesAndImmunomedicsAgreementMember" abstract="true" name="EverestMedicinesAndImmunomedicsAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" abstract="false" name="CollaborativeAgreementProductMarketPeriodSubjectToTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_PaymentsToAcquireAssetsNetOfCashAcquired" abstract="false" name="PaymentsToAcquireAssetsNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne" abstract="false" name="TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ArcusCollaborationAgreementMember" abstract="true" name="ArcusCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AmerisourcebergenCorpMember" abstract="true" name="AmerisourcebergenCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DevelopmentAgreementMember" abstract="true" name="DevelopmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ResearchAndDevelopmentServiceAgreementMember" abstract="true" name="ResearchAndDevelopmentServiceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2035Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepcludexMember" abstract="true" name="HepcludexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_JanssenPharmaceuticalsMember" abstract="true" name="JanssenPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="gild_ScheduleofInventoryTable" abstract="true" name="ScheduleofInventoryTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_ContingentConsiderationLiabilityMember" abstract="true" name="ContingentConsiderationLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CellTherapyProductsTotalCellTherapyProductSalesMember" abstract="true" name="CellTherapyProductsTotalCellTherapyProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AgreementWithJapanTobaccoIncMember" abstract="true" name="AgreementWithJapanTobaccoIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MiroBioLtdMember" abstract="true" name="MiroBioLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" abstract="true" name="AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" abstract="true" name="FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A120SeniorUnsecuredNotesDueOctober2027Member" abstract="true" name="A120SeniorUnsecuredNotesDueOctober2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_RevenuePerformanceObligationPercentageOfUSProfits" abstract="false" name="RevenuePerformanceObligationPercentageOfUSProfits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_PaymentsForAssetAcquisitions" abstract="false" name="PaymentsForAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CollaborativeandOtherArrangementsAbstract" abstract="true" name="CollaborativeandOtherArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_OtherProductsTotalOtherProductSalesMember" abstract="true" name="OtherProductsTotalOtherProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" abstract="false" name="PaymentForAdjustmentsOfBudgetedDevelopmentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" abstract="false" name="DebtInstrumentCallFeaturePeriodBeforeMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_MckessonCorpMember" abstract="true" name="MckessonCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsDescovyMember" abstract="true" name="HIVProductsDescovyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement" abstract="false" name="MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_JudgmentRoyaltyRateFromOctober2017" abstract="false" name="JudgmentRoyaltyRateFromOctober2017" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant" abstract="false" name="UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" abstract="false" name="AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_InjectableFormulationProductMember" abstract="true" name="InjectableFormulationProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ForeignCurrencyDerivativeContractsMember" abstract="true" name="ForeignCurrencyDerivativeContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" abstract="false" name="EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_IntangibleAssetSofosbuvirMember" abstract="true" name="IntangibleAssetSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinFebruary2045Member" abstract="true" name="SeniorUnsecuredNotesDueinFebruary2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" abstract="false" name="AdjustmentsOfBudgetedDevelopmentCostsPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_TotalUpfrontPaymentsMade" abstract="false" name="TotalUpfrontPaymentsMade" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" abstract="false" name="EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_PaymentsToOptInTheCollaborativeAgreement" abstract="false" name="PaymentsToOptInTheCollaborativeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2023Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2036Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" abstract="true" name="JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" abstract="true" name="LicenseRegistrationRightsAndStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DragonflyTherapeuticsCollaborationAgreementMember" abstract="true" name="DragonflyTherapeuticsCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2022Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ResearchAndDevelopmentFutureMaximumPayments" abstract="false" name="ResearchAndDevelopmentFutureMaximumPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ImmunomedicsIncMember" abstract="true" name="ImmunomedicsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIShares" abstract="false" name="EquitySecuritiesFVNIShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gild_AccruedRebates" abstract="false" name="AccruedRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" abstract="false" name="TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_GileadSciencesInc2022EquityIncentivePlanMember" abstract="true" name="GileadSciencesInc2022EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A195SeniorUnsecuredNotesDueMarch2022Member" abstract="true" name="A195SeniorUnsecuredNotesDueMarch2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HCVProductsLedipasvirSofosbuvirMember" abstract="true" name="HCVProductsLedipasvirSofosbuvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_MarketableSecuritiesCurrentMember" abstract="true" name="MarketableSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherCollaborationArrangementsMember" abstract="true" name="OtherCollaborationArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" abstract="true" name="MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsGrossReclassified" abstract="false" name="FiniteLivedIntangibleAssetsGrossReclassified" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueDecember2041Member" abstract="true" name="SeniorUnsecuredNotesDueDecember2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" abstract="false" name="PotentialSalesBasedTieredRoyaltyLowEndPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2047Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_GalapagosMember" abstract="true" name="GalapagosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A280SeniorUnsecuredNotesDueOctober2050Member" abstract="true" name="A280SeniorUnsecuredNotesDueOctober2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIRestrictionPeriod" abstract="false" name="EquitySecuritiesFVNIRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetMeasurementInput" abstract="false" name="IndefiniteLivedIntangibleAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_HIVProductSalesMember" abstract="true" name="HIVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FortySevenIncMember" abstract="true" name="FortySevenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" abstract="false" name="EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_AcquisitionRelatedExpenseMember" abstract="true" name="AcquisitionRelatedExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree" abstract="false" name="TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_GileadFoundationMember" abstract="true" name="GileadFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyMaterialTransferAgreementsNumber" abstract="false" name="LossContingencyMaterialTransferAgreementsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_AccountsReceivableChargebacksCurrent" abstract="false" name="AccountsReceivableChargebacksCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_EquitySecuritiesDonationMember" abstract="true" name="EquitySecuritiesDonationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OtherHCVMember" abstract="true" name="OtherHCVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" abstract="false" name="BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="gild_OtherProductsOtherMember" abstract="true" name="OtherProductsOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PotentialFutureMilestonePaymentsMaximum" abstract="false" name="PotentialFutureMilestonePaymentsMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A165SeniorUnsecuredNotesDueOctober2030Member" abstract="true" name="A165SeniorUnsecuredNotesDueOctober2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DeferredCompensationPlanMember" abstract="true" name="DeferredCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PionyrImmunotherapeuticsIncMember" abstract="true" name="PionyrImmunotherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ScheduleOfTransitionTaxTableTextBlock" abstract="false" name="ScheduleOfTransitionTaxTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gild_OtherProductsYescartaMember" abstract="true" name="OtherProductsYescartaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HIVProductsBiktarvyMember" abstract="true" name="HIVProductsBiktarvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PaymentsToTerminatePreviousAgreement" abstract="false" name="PaymentsToTerminatePreviousAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_A325SeniorUnsecuredNotesDueSeptember2022Member" abstract="true" name="A325SeniorUnsecuredNotesDueSeptember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan" abstract="false" name="InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_PreExposureProphylaxisMember" abstract="true" name="PreExposureProphylaxisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gild_MerckMember" abstract="true" name="MerckMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborativeAndOtherArrangementsTextBlock" abstract="false" name="CollaborativeAndOtherArrangementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_ProductsOtherHIVMember" abstract="true" name="ProductsOtherHIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" abstract="false" name="CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_MYRGmbHMember" abstract="true" name="MYRGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" abstract="false" name="IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIPurchasePeriod" abstract="false" name="EquitySecuritiesFVNIPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_JudgmentRoyaltyRateOnFutureSales" abstract="false" name="JudgmentRoyaltyRateOnFutureSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_ChangeInDividendsPercentage" abstract="false" name="ChangeInDividendsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" abstract="true" name="ThreeYearSeniorUnsecuredTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborationArrangementNetProductSalesThreshold" abstract="false" name="CollaborationArrangementNetProductSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" abstract="false" name="EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_CollaborationArrangementPercentOfGlobalProductRevenues" abstract="false" name="CollaborationArrangementPercentOfGlobalProductRevenues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_CashPaymentsMadeRelatedToEquityInvestments" abstract="false" name="CashPaymentsMadeRelatedToEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_TizonaMergerAndOptionAgreementsMember" abstract="true" name="TizonaMergerAndOptionAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_ProductLiabilityMember" abstract="true" name="ProductLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PionyrMergerAndOptionAgreementsMember" abstract="true" name="PionyrMergerAndOptionAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PaymentsForDirectTransactionalExpense" abstract="false" name="PaymentsForDirectTransactionalExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HIVProductsOdefseyMember" abstract="true" name="HIVProductsOdefseyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborativeAgreementOptInTerm" abstract="false" name="CollaborativeAgreementOptInTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_HIVProductsGenvoyaMember" abstract="true" name="HIVProductsGenvoyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_TangoTherapeuticsIncMember" abstract="true" name="TangoTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinFebruary2025Member" abstract="true" name="SeniorUnsecuredNotesDueinFebruary2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AccountsReceivableCashDiscountsAndOtherCurrent" abstract="false" name="AccountsReceivableCashDiscountsAndOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_ScheduleOfInventoryLineItems" abstract="true" name="ScheduleOfInventoryLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage" abstract="false" name="PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_OralFormulationProductMember" abstract="true" name="OralFormulationProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" abstract="false" name="LossContingencyAdditionalPatentsAllegedlyInfringedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_ProductsRevenueShareSymtuzaMember" abstract="true" name="ProductsRevenueShareSymtuzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_HIVProductsTruvadaMember" abstract="true" name="HIVProductsTruvadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" abstract="false" name="PotentialSalesBasedTieredRoyaltiesHighEndPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" abstract="true" name="ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_VekluryMember" abstract="true" name="VekluryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CreditFacilityDueJune2025Member" abstract="true" name="CreditFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A260SeniorUnsecuredNotesDueOctober2040Member" abstract="true" name="A260SeniorUnsecuredNotesDueOctober2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductVireadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A2020StockRepurchaseProgramMember" abstract="true" name="A2020StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HCVProductSalesMember" abstract="true" name="HCVProductSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EuropeanPatentClaims2032ExpirationMember" abstract="true" name="EuropeanPatentClaims2032ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A2016StockRepurchaseProgramMember" abstract="true" name="A2016StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyPartiesAppealedNumber" abstract="false" name="LossContingencyPartiesAppealedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_HIVProductsStribildMember" abstract="true" name="HIVProductsStribildMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" abstract="true" name="HepatitisBVirusHepatitisDeltaVirusProductOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_ArcellxIncMember" abstract="true" name="ArcellxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" abstract="false" name="IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_OtherProductsLetairisMember" abstract="true" name="OtherProductsLetairisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MarketableSecuritiesNoncurrentMember" abstract="true" name="MarketableSecuritiesNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_GlobalStrategicCollaborationAgreementMember" abstract="true" name="GlobalStrategicCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinApril2024Member" abstract="true" name="SeniorUnsecuredNotesDueinApril2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DeferredTaxAssetsUpfrontAndMilestonePayments" abstract="false" name="DeferredTaxAssetsUpfrontAndMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinApril2044Member" abstract="true" name="SeniorUnsecuredNotesDueinApril2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" abstract="true" name="A075SeniorUnsecuredNotesDueInSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorNotesAndMediumTermNotesMember" abstract="true" name="SeniorNotesAndMediumTermNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" abstract="false" name="MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNISharesAcquired" abstract="false" name="EquitySecuritiesFVNISharesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="gild_HCVProductsSofosbuvirVelpatasvirMember" abstract="true" name="HCVProductsSofosbuvirVelpatasvirMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" abstract="true" name="InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinMarch2046Member" abstract="true" name="SeniorUnsecuredNotesDueinMarch2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_NumberOfPrograms" abstract="false" name="NumberOfPrograms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_GalapagosSubscriptionAgreementMember" abstract="true" name="GalapagosSubscriptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_IssuanceDiscountPremium" abstract="false" name="IssuanceDiscountPremium" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_JounceTherapeuticsIncMember" abstract="true" name="JounceTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="gild_ArcusStockPurchaseAgreementMember" abstract="true" name="ArcusStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_RoyaltyContractAndOtherMember" abstract="true" name="RoyaltyContractAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_DragonflyTherapeuticsIncMember" abstract="true" name="DragonflyTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_UpfrontPaymentsToTerminatePreviousAgreement" abstract="false" name="UpfrontPaymentsToTerminatePreviousAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_OtherProductsAmBisomeMember" abstract="true" name="OtherProductsAmBisomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AxicabtageneciloleucelDLBCLMember" abstract="true" name="AxicabtageneciloleucelDLBCLMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" abstract="false" name="AcquiredFiniteLivedIntangibleAssetsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_CellTherapyProductsTecartusMember" abstract="true" name="CellTherapyProductsTecartusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_LossContingencyNumberOfPatents" abstract="false" name="LossContingencyNumberOfPatents" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="gild_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_EquityMethodInvestmentOptionExerciseFee" abstract="false" name="EquityMethodInvestmentOptionExerciseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" abstract="false" name="EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_TizonaTherapeuticsIncMember" abstract="true" name="TizonaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_AdditionalResearchAndDevelopmentInProcess" abstract="false" name="AdditionalResearchAndDevelopmentInProcess" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_HIVProductsCompleraEvipleraMember" abstract="true" name="HIVProductsCompleraEvipleraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_EverestMedicinesMember" abstract="true" name="EverestMedicinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_InventoryNetAndInventoryNoncurrent" abstract="false" name="InventoryNetAndInventoryNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_JudgmentEnhancedDamagesOnPastSales" abstract="false" name="JudgmentEnhancedDamagesOnPastSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment" abstract="false" name="PaymentsToAcquireAdditionalInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo" abstract="false" name="TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" abstract="true" name="UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="gild_SeniorUnsecuredNotesDueinSeptember2022Member" abstract="true" name="SeniorUnsecuredNotesDueinSeptember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" abstract="false" name="CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="gild_TrodelvyMember" abstract="true" name="TrodelvyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>gild-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:138d9561-5f65-4b2f-b0c5-a8cb97862906,g:db888c96-90b0-4c6d-8008-49d88ed38ca7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0e1c6070-182c-4e3f-b4d4-f529a155f769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_acd95419-9b86-49f8-8b34-c001c796e41a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0e1c6070-182c-4e3f-b4d4-f529a155f769" xlink:to="loc_us-gaap_StockholdersEquity_acd95419-9b86-49f8-8b34-c001c796e41a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8de20898-2e44-42c7-8fcf-887e3a480e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0e1c6070-182c-4e3f-b4d4-f529a155f769" xlink:to="loc_us-gaap_MinorityInterest_8de20898-2e44-42c7-8fcf-887e3a480e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_01db8c2b-f52f-4144-8277-f81e6671a266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b26192f8-4f0b-4a47-a62b-6bb6b0924f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01db8c2b-f52f-4144-8277-f81e6671a266" xlink:to="loc_us-gaap_AssetsCurrent_b26192f8-4f0b-4a47-a62b-6bb6b0924f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1b4e970d-3c79-4465-b0c7-5f26cb39a637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01db8c2b-f52f-4144-8277-f81e6671a266" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1b4e970d-3c79-4465-b0c7-5f26cb39a637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_0f3cc200-5e64-4daa-8b02-2b284a35af3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01db8c2b-f52f-4144-8277-f81e6671a266" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_0f3cc200-5e64-4daa-8b02-2b284a35af3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_48b48bf8-1f13-422e-9f9b-eeb1086d6a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01db8c2b-f52f-4144-8277-f81e6671a266" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_48b48bf8-1f13-422e-9f9b-eeb1086d6a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_eb9d3ff1-32d4-4992-9d9a-9a21c9c25e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01db8c2b-f52f-4144-8277-f81e6671a266" xlink:to="loc_us-gaap_Goodwill_eb9d3ff1-32d4-4992-9d9a-9a21c9c25e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9a49611e-8601-4bba-8a03-e8437fffff5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_01db8c2b-f52f-4144-8277-f81e6671a266" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9a49611e-8601-4bba-8a03-e8437fffff5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4819186e-4322-4915-90a4-a20258d646b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b7c53661-67d4-454e-9d36-3f89f72ef610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4819186e-4322-4915-90a4-a20258d646b7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b7c53661-67d4-454e-9d36-3f89f72ef610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_028d57fd-2184-4213-9dc7-ef705632d11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4819186e-4322-4915-90a4-a20258d646b7" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_028d57fd-2184-4213-9dc7-ef705632d11a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cc7b6e5c-4422-401d-9da8-d2acfccc2e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4819186e-4322-4915-90a4-a20258d646b7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cc7b6e5c-4422-401d-9da8-d2acfccc2e3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_313785e1-eac8-427e-aae9-f32a4a7ddd70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4819186e-4322-4915-90a4-a20258d646b7" xlink:to="loc_us-gaap_InventoryNet_313785e1-eac8-427e-aae9-f32a4a7ddd70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8eb9e789-c29f-49ba-a19e-5deab15f28f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4819186e-4322-4915-90a4-a20258d646b7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8eb9e789-c29f-49ba-a19e-5deab15f28f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b7a05cac-905a-4bd5-9304-ea37e2c334bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c8658515-2553-4d53-9647-f1ce64b18926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b7a05cac-905a-4bd5-9304-ea37e2c334bf" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c8658515-2553-4d53-9647-f1ce64b18926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedRebates_5b4558bb-a0bf-455a-9544-dd6b992d123b" xlink:href="gild-20221231.xsd#gild_AccruedRebates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b7a05cac-905a-4bd5-9304-ea37e2c334bf" xlink:to="loc_gild_AccruedRebates_5b4558bb-a0bf-455a-9544-dd6b992d123b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_591a0b9f-f723-4a06-b652-572d31bb3c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b7a05cac-905a-4bd5-9304-ea37e2c334bf" xlink:to="loc_us-gaap_AccountsPayableCurrent_591a0b9f-f723-4a06-b652-572d31bb3c88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_99a80e98-324b-47e8-b226-9354d3354ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b7a05cac-905a-4bd5-9304-ea37e2c334bf" xlink:to="loc_us-gaap_DebtCurrent_99a80e98-324b-47e8-b226-9354d3354ae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f61414b6-9a42-4b9f-837d-24b1b0c64b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_723893a5-6125-4172-bb00-9c9ed4c664e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f61414b6-9a42-4b9f-837d-24b1b0c64b04" xlink:to="loc_us-gaap_LiabilitiesCurrent_723893a5-6125-4172-bb00-9c9ed4c664e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ef0074dc-1860-4962-94c1-62fc02959fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f61414b6-9a42-4b9f-837d-24b1b0c64b04" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ef0074dc-1860-4962-94c1-62fc02959fef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_a76eca95-5607-4663-987c-600a95c73908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f61414b6-9a42-4b9f-837d-24b1b0c64b04" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_a76eca95-5607-4663-987c-600a95c73908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7fa719fc-3dc0-4bca-93f4-3d33dd963975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f61414b6-9a42-4b9f-837d-24b1b0c64b04" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7fa719fc-3dc0-4bca-93f4-3d33dd963975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_91a753b8-1f61-45ee-91fc-f479fbbdbf55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f61414b6-9a42-4b9f-837d-24b1b0c64b04" xlink:to="loc_us-gaap_CommitmentsAndContingencies_91a753b8-1f61-45ee-91fc-f479fbbdbf55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b86f7b49-f961-42a9-b6e5-43a95d9be649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f61414b6-9a42-4b9f-837d-24b1b0c64b04" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b86f7b49-f961-42a9-b6e5-43a95d9be649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bcb0199f-dc5d-4fbb-b5b0-ccbbc41744b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f61414b6-9a42-4b9f-837d-24b1b0c64b04" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_bcb0199f-dc5d-4fbb-b5b0-ccbbc41744b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cada3217-7219-432b-ad43-12ec5fdfd405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_072bc1b0-f679-4025-b376-2c8493ff756a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cada3217-7219-432b-ad43-12ec5fdfd405" xlink:to="loc_us-gaap_PreferredStockValue_072bc1b0-f679-4025-b376-2c8493ff756a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4daf0412-1711-4a36-9e3c-767648f3672f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cada3217-7219-432b-ad43-12ec5fdfd405" xlink:to="loc_us-gaap_CommonStockValue_4daf0412-1711-4a36-9e3c-767648f3672f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_866a0105-12a1-40e1-8a80-e60cb50fe8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cada3217-7219-432b-ad43-12ec5fdfd405" xlink:to="loc_us-gaap_AdditionalPaidInCapital_866a0105-12a1-40e1-8a80-e60cb50fe8a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b680f307-6a44-4b11-882e-0a751b0892a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cada3217-7219-432b-ad43-12ec5fdfd405" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b680f307-6a44-4b11-882e-0a751b0892a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5ff49cdf-fbce-4040-9539-cd78b8f163af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cada3217-7219-432b-ad43-12ec5fdfd405" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5ff49cdf-fbce-4040-9539-cd78b8f163af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0a91722f-63a2-4423-a6e9-36dc69453208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fd65a5ba-6336-4690-810d-a11335d5a4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0a91722f-63a2-4423-a6e9-36dc69453208" xlink:to="loc_us-gaap_ProfitLoss_fd65a5ba-6336-4690-810d-a11335d5a4c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_455dd8a8-6e88-468b-976f-0f52cf7bab12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0a91722f-63a2-4423-a6e9-36dc69453208" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_455dd8a8-6e88-468b-976f-0f52cf7bab12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_21d9d85c-5574-4029-89ab-4351e1d135bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_69849f83-a896-49c7-8c77-4ab045ec1997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21d9d85c-5574-4029-89ab-4351e1d135bb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_69849f83-a896-49c7-8c77-4ab045ec1997" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3c6b45ff-d6ec-4a50-b069-55a20722b59b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21d9d85c-5574-4029-89ab-4351e1d135bb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3c6b45ff-d6ec-4a50-b069-55a20722b59b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bbf87279-c18c-4897-83a0-3cf882550293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21d9d85c-5574-4029-89ab-4351e1d135bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bbf87279-c18c-4897-83a0-3cf882550293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e704becf-f6c5-44bf-a715-01362752469b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21d9d85c-5574-4029-89ab-4351e1d135bb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e704becf-f6c5-44bf-a715-01362752469b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_42164fac-d72b-4303-9e38-daf0d70063a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_21d9d85c-5574-4029-89ab-4351e1d135bb" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_42164fac-d72b-4303-9e38-daf0d70063a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3532334b-c713-4d59-b6b3-1a84b9c1a10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e5475279-2b86-4f6e-997e-fe02b6d671a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3532334b-c713-4d59-b6b3-1a84b9c1a10c" xlink:to="loc_us-gaap_CostsAndExpenses_e5475279-2b86-4f6e-997e-fe02b6d671a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ddf210ba-9ffb-4d7d-887a-d5964d72ecdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3532334b-c713-4d59-b6b3-1a84b9c1a10c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ddf210ba-9ffb-4d7d-887a-d5964d72ecdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a9440e5-1963-490b-8364-0805fef7ce09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_627d6fa8-f7df-4b7d-a198-fe51a5a2dae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a9440e5-1963-490b-8364-0805fef7ce09" xlink:to="loc_us-gaap_OperatingIncomeLoss_627d6fa8-f7df-4b7d-a198-fe51a5a2dae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_94c14490-aada-4397-b78e-a02a29de0ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a9440e5-1963-490b-8364-0805fef7ce09" xlink:to="loc_us-gaap_InterestExpense_94c14490-aada-4397-b78e-a02a29de0ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b0b1f1a9-5be3-4173-8705-b7c880d382d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a9440e5-1963-490b-8364-0805fef7ce09" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b0b1f1a9-5be3-4173-8705-b7c880d382d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a1ac210a-ec85-448d-8eac-babe234afab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2dfe3cff-f067-47e7-985e-d2c9dae58fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_a1ac210a-ec85-448d-8eac-babe234afab0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2dfe3cff-f067-47e7-985e-d2c9dae58fbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2fcb46f4-725e-4631-b85b-c58ef404bf98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_a1ac210a-ec85-448d-8eac-babe234afab0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2fcb46f4-725e-4631-b85b-c58ef404bf98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e85144c-184c-4c54-b978-2111594564c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_af701d8b-2dfc-47dd-963c-331e256e80c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e85144c-184c-4c54-b978-2111594564c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_af701d8b-2dfc-47dd-963c-331e256e80c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4876b44e-a2a5-423b-9550-b593ff5229af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e85144c-184c-4c54-b978-2111594564c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4876b44e-a2a5-423b-9550-b593ff5229af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e41f7f71-ba62-4718-a0ce-713d626b1f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e85144c-184c-4c54-b978-2111594564c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e41f7f71-ba62-4718-a0ce-713d626b1f8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d1aea7e8-6ef4-4b5f-9b31-385617aa4f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c33d0fb7-8731-429b-96c4-b07c40afd676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d1aea7e8-6ef4-4b5f-9b31-385617aa4f0c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c33d0fb7-8731-429b-96c4-b07c40afd676" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_45fe35f0-4089-41a2-bf1d-c6dced930783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d1aea7e8-6ef4-4b5f-9b31-385617aa4f0c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_45fe35f0-4089-41a2-bf1d-c6dced930783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3c8fea38-ad8b-44ac-88ba-5dbd98764163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_78ee7549-802b-42a0-9c9c-1a5c2485b973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3c8fea38-ad8b-44ac-88ba-5dbd98764163" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_78ee7549-802b-42a0-9c9c-1a5c2485b973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_53064560-841e-4175-9141-dbad51ad6674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3c8fea38-ad8b-44ac-88ba-5dbd98764163" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_53064560-841e-4175-9141-dbad51ad6674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4f084de5-cf90-4a26-a878-12f8ff6e49f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_c2c8b1f2-2f0a-4a98-bd9b-6b1836dc5fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4f084de5-cf90-4a26-a878-12f8ff6e49f9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_c2c8b1f2-2f0a-4a98-bd9b-6b1836dc5fb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c5b73b8b-fb05-45a0-b4e4-3362240be6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4f084de5-cf90-4a26-a878-12f8ff6e49f9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_c5b73b8b-fb05-45a0-b4e4-3362240be6fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_493b762d-3314-4e6e-a182-285d531d7f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3d0ac8df-b442-42d2-9396-451b826764e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_493b762d-3314-4e6e-a182-285d531d7f95" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3d0ac8df-b442-42d2-9396-451b826764e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_09b00500-4f64-4bd3-afc9-7d024a861f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_493b762d-3314-4e6e-a182-285d531d7f95" xlink:to="loc_us-gaap_ProfitLoss_09b00500-4f64-4bd3-afc9-7d024a861f4c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_51eb45d7-e9b4-448d-a785-e880402fa543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_Depreciation_51eb45d7-e9b4-448d-a785-e880402fa543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f2f01b0b-2722-4233-a126-efbdce73b336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f2f01b0b-2722-4233-a126-efbdce73b336" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9b10f58c-9d68-4c33-a327-296446952309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_9b10f58c-9d68-4c33-a327-296446952309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c82e5fd3-d3a5-42d6-af49-f07a1c62b710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c82e5fd3-d3a5-42d6-af49-f07a1c62b710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_5d47b4d5-e059-4735-a60a-aa698914b943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_5d47b4d5-e059-4735-a60a-aa698914b943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9a3353ae-84bc-456a-bdff-4c6acce4294e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_ShareBasedCompensation_9a3353ae-84bc-456a-bdff-4c6acce4294e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3d14a4ae-40dd-48ab-91ec-41df8ccd4915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3d14a4ae-40dd-48ab-91ec-41df8ccd4915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d8a55a83-b5ba-4712-82b7-83d2df63852f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d8a55a83-b5ba-4712-82b7-83d2df63852f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8da9f88c-1314-446b-b290-09ec5437981d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8da9f88c-1314-446b-b290-09ec5437981d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_ae28ecd8-c498-4547-b58f-8e1d7b16c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_ae28ecd8-c498-4547-b58f-8e1d7b16c16b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_7ac40d8b-aa69-41fc-b540-1944ce577964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_AdjustmentForAmortization_7ac40d8b-aa69-41fc-b540-1944ce577964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6f189c18-5678-47f1-ad9f-043a080fcd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_6f189c18-5678-47f1-ad9f-043a080fcd6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ed7460a2-ca87-44d7-83e3-1894103a50c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_ProfitLoss_ed7460a2-ca87-44d7-83e3-1894103a50c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_add3623a-d2ea-4f3e-afc8-fd6dd1da118d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_add3623a-d2ea-4f3e-afc8-fd6dd1da118d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cbf110ec-f0c4-4bc6-ab8d-bd3091bc326b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b29faf31-2253-49de-93b6-b6062d0306a7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cbf110ec-f0c4-4bc6-ab8d-bd3091bc326b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_21261dad-21fb-4f18-b0b5-eb9d0683ad6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e015abaa-ef0d-4648-a27b-75bcb3afcd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_21261dad-21fb-4f18-b0b5-eb9d0683ad6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e015abaa-ef0d-4648-a27b-75bcb3afcd23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c959f92c-f5c6-48b4-93a2-92412c3b44f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_21261dad-21fb-4f18-b0b5-eb9d0683ad6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c959f92c-f5c6-48b4-93a2-92412c3b44f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc79355a-f5c5-4159-ba68-abbf4b138936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_21261dad-21fb-4f18-b0b5-eb9d0683ad6b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc79355a-f5c5-4159-ba68-abbf4b138936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a503abec-021e-42ec-8558-4d0e44d68f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_21261dad-21fb-4f18-b0b5-eb9d0683ad6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a503abec-021e-42ec-8558-4d0e44d68f69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259ccccb-775e-4dd1-800a-cc6cc1368092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_9e7c5662-d513-494d-a4ff-1be184ec022b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259ccccb-775e-4dd1-800a-cc6cc1368092" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_9e7c5662-d513-494d-a4ff-1be184ec022b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2ef7a733-8ef2-43e3-8961-3158b22038d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259ccccb-775e-4dd1-800a-cc6cc1368092" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2ef7a733-8ef2-43e3-8961-3158b22038d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3a9860b4-cf3e-4d6c-a07f-3d5c320bfa93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259ccccb-775e-4dd1-800a-cc6cc1368092" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3a9860b4-cf3e-4d6c-a07f-3d5c320bfa93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_3a507036-d8c3-4986-831f-c239f2468ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259ccccb-775e-4dd1-800a-cc6cc1368092" xlink:to="loc_us-gaap_RepaymentsOfDebt_3a507036-d8c3-4986-831f-c239f2468ee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_2cccf1fa-dfa4-41f5-98e3-f8b1e527f7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259ccccb-775e-4dd1-800a-cc6cc1368092" xlink:to="loc_us-gaap_PaymentsOfDividends_2cccf1fa-dfa4-41f5-98e3-f8b1e527f7bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_24e04102-66b0-4975-87c5-e5a1d6998a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_259ccccb-775e-4dd1-800a-cc6cc1368092" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_24e04102-66b0-4975-87c5-e5a1d6998a7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ff7b79f-0d2d-45a1-953e-8e8f7f7050e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e1d4555c-3538-4346-a7ab-7f79e7ffd85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ff7b79f-0d2d-45a1-953e-8e8f7f7050e4" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e1d4555c-3538-4346-a7ab-7f79e7ffd85d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d163fde9-6717-4a32-b8f0-cc1dd3fdbbff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ff7b79f-0d2d-45a1-953e-8e8f7f7050e4" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d163fde9-6717-4a32-b8f0-cc1dd3fdbbff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_32ce2f16-a4ca-4c8c-b494-69a981afc010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ff7b79f-0d2d-45a1-953e-8e8f7f7050e4" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_32ce2f16-a4ca-4c8c-b494-69a981afc010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b1482f94-f537-482b-864e-b10e96ba01d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ff7b79f-0d2d-45a1-953e-8e8f7f7050e4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b1482f94-f537-482b-864e-b10e96ba01d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_c88ac83a-d148-43ef-8de6-bcae5303684c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ff7b79f-0d2d-45a1-953e-8e8f7f7050e4" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_c88ac83a-d148-43ef-8de6-bcae5303684c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_81587dd0-533a-4577-b54b-f9bb54eed200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ff7b79f-0d2d-45a1-953e-8e8f7f7050e4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_81587dd0-533a-4577-b54b-f9bb54eed200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c994db07-0706-48c9-9f67-dd9455a05c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6ff7b79f-0d2d-45a1-953e-8e8f7f7050e4" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c994db07-0706-48c9-9f67-dd9455a05c71" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_570ea463-513b-4d5e-bf9b-998f4a10a73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_82ebfed1-30df-4e59-89a1-25bca39499cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_570ea463-513b-4d5e-bf9b-998f4a10a73a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_82ebfed1-30df-4e59-89a1-25bca39499cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_686edc3a-3d16-42bd-9afe-16131a8cef24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_570ea463-513b-4d5e-bf9b-998f4a10a73a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_686edc3a-3d16-42bd-9afe-16131a8cef24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_66d52d71-aaaf-4afb-a483-25713870d4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_570ea463-513b-4d5e-bf9b-998f4a10a73a" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_66d52d71-aaaf-4afb-a483-25713870d4ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_3922c9f6-b630-47f2-a909-921382237bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_012bc8fc-e0ee-4ae9-aa7b-81115b32e3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_3922c9f6-b630-47f2-a909-921382237bbd" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_012bc8fc-e0ee-4ae9-aa7b-81115b32e3fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_4648dea9-9a0a-4799-a9a0-0f841b5a18a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_3922c9f6-b630-47f2-a909-921382237bbd" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_4648dea9-9a0a-4799-a9a0-0f841b5a18a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_17e1fcbb-91d1-4fb3-8519-9c8e66de471e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_3922c9f6-b630-47f2-a909-921382237bbd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_17e1fcbb-91d1-4fb3-8519-9c8e66de471e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ad835f75-9cd9-4f31-9f9c-5fe6b5f3c64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c5cc7fc7-3805-49f0-81d6-62e13aa59a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ad835f75-9cd9-4f31-9f9c-5fe6b5f3c64c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c5cc7fc7-3805-49f0-81d6-62e13aa59a21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_49191513-7ec9-4535-a094-28c326bb6e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ad835f75-9cd9-4f31-9f9c-5fe6b5f3c64c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_49191513-7ec9-4535-a094-28c326bb6e1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6b796678-46e7-4145-b332-8a22794fbf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_ad835f75-9cd9-4f31-9f9c-5fe6b5f3c64c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6b796678-46e7-4145-b332-8a22794fbf5f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1f571d57-39ea-4bb5-8a18-81cf2ffef566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_ea133345-5136-46ea-bd4b-2a87d3fcc6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1f571d57-39ea-4bb5-8a18-81cf2ffef566" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_ea133345-5136-46ea-bd4b-2a87d3fcc6ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_285f8d6c-f9ab-4233-b251-8c79dad4b59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1f571d57-39ea-4bb5-8a18-81cf2ffef566" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_285f8d6c-f9ab-4233-b251-8c79dad4b59c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b20968e0-2822-44d5-b216-13b3689ecd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a1d42d88-4624-4f3d-96df-cab85435b972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b20968e0-2822-44d5-b216-13b3689ecd2d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a1d42d88-4624-4f3d-96df-cab85435b972" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_cb22a820-0e9a-401e-8ff0-e1299854090c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b20968e0-2822-44d5-b216-13b3689ecd2d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_cb22a820-0e9a-401e-8ff0-e1299854090c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a0be5e0b-f163-4bbf-a488-ade76a20ec7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_bb4db969-753d-44dc-afcf-460fc88b30b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a0be5e0b-f163-4bbf-a488-ade76a20ec7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_bb4db969-753d-44dc-afcf-460fc88b30b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_05abe2b1-c251-45f8-8476-4e7ff21f8d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a0be5e0b-f163-4bbf-a488-ade76a20ec7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_05abe2b1-c251-45f8-8476-4e7ff21f8d34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0ffbb342-c128-4544-bb28-5428163bffe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a0be5e0b-f163-4bbf-a488-ade76a20ec7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0ffbb342-c128-4544-bb28-5428163bffe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_12d58ff5-99fa-426f-b0f0-b9d1b276177f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a0be5e0b-f163-4bbf-a488-ade76a20ec7c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_12d58ff5-99fa-426f-b0f0-b9d1b276177f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_cca5f415-c155-4aa4-b7a1-081df3d86762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5af28cd6-3647-4d32-8983-83bba3194f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_cca5f415-c155-4aa4-b7a1-081df3d86762" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5af28cd6-3647-4d32-8983-83bba3194f05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_a74f561a-35cc-4b0f-a479-1f359d29341b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_cca5f415-c155-4aa4-b7a1-081df3d86762" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_a74f561a-35cc-4b0f-a479-1f359d29341b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1de65655-5d1a-456a-96c3-94175f2bfcef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_cca5f415-c155-4aa4-b7a1-081df3d86762" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1de65655-5d1a-456a-96c3-94175f2bfcef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_0a84a692-d767-44ce-97aa-fba1cb45dad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_cca5f415-c155-4aa4-b7a1-081df3d86762" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_0a84a692-d767-44ce-97aa-fba1cb45dad7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_30665b2b-7278-49d1-9a16-a98dd1ede831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_bc6ca65d-c7a7-4a78-965f-c5e7c0f8ce94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_30665b2b-7278-49d1-9a16-a98dd1ede831" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_bc6ca65d-c7a7-4a78-965f-c5e7c0f8ce94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6f11d212-b0c4-42d0-aee6-a50fd8b15a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_080bee65-1407-4d40-82f5-6afa61dd2ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6f11d212-b0c4-42d0-aee6-a50fd8b15a38" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_080bee65-1407-4d40-82f5-6afa61dd2ba5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_18b0f231-cdad-46c8-9205-64fa0419be8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_6f11d212-b0c4-42d0-aee6-a50fd8b15a38" xlink:to="loc_us-gaap_GoodwillGross_18b0f231-cdad-46c8-9205-64fa0419be8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ef418eb1-eba0-4fe8-b2f0-a4b4131271b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_0ae30f35-a77f-474e-95f7-77613e55b21e" xlink:href="gild-20221231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ef418eb1-eba0-4fe8-b2f0-a4b4131271b0" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_0ae30f35-a77f-474e-95f7-77613e55b21e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0d5628fa-1842-4828-9a4b-eefdde258320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ef418eb1-eba0-4fe8-b2f0-a4b4131271b0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0d5628fa-1842-4828-9a4b-eefdde258320" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_db36caf2-620d-4baa-a807-d6342c3cd8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ef418eb1-eba0-4fe8-b2f0-a4b4131271b0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_db36caf2-620d-4baa-a807-d6342c3cd8f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d72877a4-ee17-4f02-8343-c6a3a37c2ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ef418eb1-eba0-4fe8-b2f0-a4b4131271b0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d72877a4-ee17-4f02-8343-c6a3a37c2ac2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_29920fda-9cd5-4d2a-aa4e-860b554c3ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_fef7accb-589d-4aa4-89a3-cfbd6dd5a4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_29920fda-9cd5-4d2a-aa4e-860b554c3ec8" xlink:to="loc_us-gaap_Land_fef7accb-589d-4aa4-89a3-cfbd6dd5a4a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_452d3609-96f6-44f2-8ea8-e9f2d3908f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_29920fda-9cd5-4d2a-aa4e-860b554c3ec8" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_452d3609-96f6-44f2-8ea8-e9f2d3908f5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_4be4b05c-c2c1-4c65-89aa-2f28fb319ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_29920fda-9cd5-4d2a-aa4e-860b554c3ec8" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_4be4b05c-c2c1-4c65-89aa-2f28fb319ed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_66e86007-735b-4de5-818a-a8aeff35be30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_29920fda-9cd5-4d2a-aa4e-860b554c3ec8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_66e86007-735b-4de5-818a-a8aeff35be30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_17a5fe8a-3826-47e0-aea5-85a3173913c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_29920fda-9cd5-4d2a-aa4e-860b554c3ec8" xlink:to="loc_us-gaap_ConstructionInProgressGross_17a5fe8a-3826-47e0-aea5-85a3173913c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_db5f5619-9009-4717-8818-981546275374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c7a74921-bd33-493a-8dfa-96c93b14d03f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_db5f5619-9009-4717-8818-981546275374" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c7a74921-bd33-493a-8dfa-96c93b14d03f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fefdf33c-39bc-472d-8bdb-3ad1e5ad9af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_db5f5619-9009-4717-8818-981546275374" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fefdf33c-39bc-472d-8bdb-3ad1e5ad9af3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f5865100-ecb2-4a4e-a378-2f5e66121c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c4cb9566-d37e-455b-af1f-e192708526f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f5865100-ecb2-4a4e-a378-2f5e66121c9d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c4cb9566-d37e-455b-af1f-e192708526f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4bf7cd28-06da-4a5c-b6ad-73862f5b9830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f5865100-ecb2-4a4e-a378-2f5e66121c9d" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4bf7cd28-06da-4a5c-b6ad-73862f5b9830" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_d4bebbf1-5613-4d9f-b2c8-f4733cd1bb00" xlink:href="gild-20221231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f5865100-ecb2-4a4e-a378-2f5e66121c9d" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_d4bebbf1-5613-4d9f-b2c8-f4733cd1bb00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f657044e-d808-4113-9d2c-06ce9dd5b309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d8ce0a8-67fb-46e9-aa87-d9651c286283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f657044e-d808-4113-9d2c-06ce9dd5b309" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d8ce0a8-67fb-46e9-aa87-d9651c286283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_93d7f785-5604-4dec-8358-8a8bec23da5d" xlink:href="gild-20221231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f657044e-d808-4113-9d2c-06ce9dd5b309" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_93d7f785-5604-4dec-8358-8a8bec23da5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a91519ab-3404-4e86-bac5-d6eca133323f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f657044e-d808-4113-9d2c-06ce9dd5b309" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a91519ab-3404-4e86-bac5-d6eca133323f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_49cbd10a-e715-4a7f-891d-d6c95ef69762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2fd78332-d16b-42f7-b1a4-5d757952a8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_49cbd10a-e715-4a7f-891d-d6c95ef69762" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2fd78332-d16b-42f7-b1a4-5d757952a8e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c3ce1112-cd3f-4f03-8909-cda1f2bea464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_49cbd10a-e715-4a7f-891d-d6c95ef69762" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c3ce1112-cd3f-4f03-8909-cda1f2bea464" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_8c97816d-09aa-4add-9bc6-9646787c887e" xlink:href="gild-20221231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_05abe139-f9de-4907-903e-cb84dfb65f09" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_8c97816d-09aa-4add-9bc6-9646787c887e" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_05abe139-f9de-4907-903e-cb84dfb65f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_c5753fb1-96d4-4da6-93fd-bceda39ed310" xlink:href="gild-20221231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_8c97816d-09aa-4add-9bc6-9646787c887e" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_c5753fb1-96d4-4da6-93fd-bceda39ed310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d5d98bb9-13bf-4328-9fcd-9e8c52b92c42" xlink:href="gild-20221231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9a7c0ae6-7805-4d85-b6d2-911166ccf69c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d5d98bb9-13bf-4328-9fcd-9e8c52b92c42" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9a7c0ae6-7805-4d85-b6d2-911166ccf69c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_e801a85c-3007-43db-95de-b0df222f8c77" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_d5d98bb9-13bf-4328-9fcd-9e8c52b92c42" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_e801a85c-3007-43db-95de-b0df222f8c77" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="gild-20221231.xsd#GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_eb01ecaf-a4b1-4eb8-8949-7be684054a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_86ab780e-f1fd-43b7-a749-b21e7b22e642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_eb01ecaf-a4b1-4eb8-8949-7be684054a08" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_86ab780e-f1fd-43b7-a749-b21e7b22e642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_e2c78a80-377b-4ec7-a1bb-9a4df93e46e0" xlink:href="gild-20221231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_eb01ecaf-a4b1-4eb8-8949-7be684054a08" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_e2c78a80-377b-4ec7-a1bb-9a4df93e46e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97ceeeed-a59d-45c2-80cb-0ffa30b6dffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_41823f13-0cf1-4326-9b93-cda3b09be093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97ceeeed-a59d-45c2-80cb-0ffa30b6dffc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_41823f13-0cf1-4326-9b93-cda3b09be093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ac5b615b-5940-4356-b41a-d9aa9f2c3c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97ceeeed-a59d-45c2-80cb-0ffa30b6dffc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ac5b615b-5940-4356-b41a-d9aa9f2c3c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6e03538f-ade5-4d5f-a1f8-7bad81cc7687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97ceeeed-a59d-45c2-80cb-0ffa30b6dffc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6e03538f-ade5-4d5f-a1f8-7bad81cc7687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f8c56ba6-2d97-46f2-9af7-2a4dd2beea89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97ceeeed-a59d-45c2-80cb-0ffa30b6dffc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f8c56ba6-2d97-46f2-9af7-2a4dd2beea89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3c80f098-6647-4a34-9b01-30eaf3f9898c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97ceeeed-a59d-45c2-80cb-0ffa30b6dffc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3c80f098-6647-4a34-9b01-30eaf3f9898c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9a1cc329-fec7-4b31-8e3a-0cd3ea7f9f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97ceeeed-a59d-45c2-80cb-0ffa30b6dffc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9a1cc329-fec7-4b31-8e3a-0cd3ea7f9f3e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#OtherFinancialInformationAccountsReceivableNetDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_155e85fc-4980-472e-8837-e43f2581d0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a9fe6cdb-498f-490b-9930-4c7235dbb8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_155e85fc-4980-472e-8837-e43f2581d0a8" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_a9fe6cdb-498f-490b-9930-4c7235dbb8b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_a1559fa0-8c6f-4acc-b2fa-30f686d57e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_155e85fc-4980-472e-8837-e43f2581d0a8" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_a1559fa0-8c6f-4acc-b2fa-30f686d57e7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_3a09020e-7d58-45ea-9176-143860371228" xlink:href="gild-20221231.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_155e85fc-4980-472e-8837-e43f2581d0a8" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_3a09020e-7d58-45ea-9176-143860371228" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_f4d0a104-c0ee-4962-9b35-3ebe973e5c9d" xlink:href="gild-20221231.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_155e85fc-4980-472e-8837-e43f2581d0a8" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_f4d0a104-c0ee-4962-9b35-3ebe973e5c9d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#OtherFinancialInformationInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_07e9defd-48cb-4cf5-acb8-33be765b9327" xlink:href="gild-20221231.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_85c3534c-b5fe-4efa-a816-77630890224e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_07e9defd-48cb-4cf5-acb8-33be765b9327" xlink:to="loc_us-gaap_InventoryNet_85c3534c-b5fe-4efa-a816-77630890224e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_202b24c5-021a-42b2-8011-d9d6316456f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_07e9defd-48cb-4cf5-acb8-33be765b9327" xlink:to="loc_us-gaap_InventoryNoncurrent_202b24c5-021a-42b2-8011-d9d6316456f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails_1" xlink:type="simple" xlink:href="gild-20221231.xsd#OtherFinancialInformationInventoriesDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_b2eb1933-f46b-48ad-9702-e7eb4a97403e" xlink:href="gild-20221231.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_42d39988-4fb6-48e0-af52-4442be4c0463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_b2eb1933-f46b-48ad-9702-e7eb4a97403e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_42d39988-4fb6-48e0-af52-4442be4c0463" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_20e5adf5-2a1d-464a-b9f2-dde78a7138a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_b2eb1933-f46b-48ad-9702-e7eb4a97403e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_20e5adf5-2a1d-464a-b9f2-dde78a7138a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b555a751-cde9-4dbe-a075-32a784efa218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent_b2eb1933-f46b-48ad-9702-e7eb4a97403e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b555a751-cde9-4dbe-a075-32a784efa218" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#OtherFinancialInformationOtherAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3ec54f27-63f9-4598-b391-172fc6bc88a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_7bcc9c9e-c01e-4246-906a-e518f2df39f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_3ec54f27-63f9-4598-b391-172fc6bc88a1" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_7bcc9c9e-c01e-4246-906a-e518f2df39f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0beffa2f-336e-4587-9f23-263e14894b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_3ec54f27-63f9-4598-b391-172fc6bc88a1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0beffa2f-336e-4587-9f23-263e14894b0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_a6961eef-f86d-4ca1-aa95-d2cee638ff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_3ec54f27-63f9-4598-b391-172fc6bc88a1" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_a6961eef-f86d-4ca1-aa95-d2cee638ff2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_be994567-74f7-4991-b362-71c057d2a9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_3ec54f27-63f9-4598-b391-172fc6bc88a1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_be994567-74f7-4991-b362-71c057d2a9be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_ef30e25d-733a-4bba-a781-8e4cb087cae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_3ec54f27-63f9-4598-b391-172fc6bc88a1" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_ef30e25d-733a-4bba-a781-8e4cb087cae4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fb732169-5da3-440e-9773-66a7ac5eeae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_3df6110c-7eb8-4832-8792-ad37c52b6f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_fb732169-5da3-440e-9773-66a7ac5eeae5" xlink:to="loc_us-gaap_LongTermDebtCurrent_3df6110c-7eb8-4832-8792-ad37c52b6f46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_dbe99c15-fd82-4eb9-a8d8-6a7693db306f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_fb732169-5da3-440e-9773-66a7ac5eeae5" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_dbe99c15-fd82-4eb9-a8d8-6a7693db306f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c17976ca-8f29-443a-b4d1-bc92ad30bed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f68d2972-8bff-4c17-bd64-50364ebfaedc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c17976ca-8f29-443a-b4d1-bc92ad30bed4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f68d2972-8bff-4c17-bd64-50364ebfaedc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_acc15aa3-5852-499e-abcf-e7b6fba452ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c17976ca-8f29-443a-b4d1-bc92ad30bed4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_acc15aa3-5852-499e-abcf-e7b6fba452ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_297eb283-ddd0-465c-822b-0ec8231f2286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c17976ca-8f29-443a-b4d1-bc92ad30bed4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_297eb283-ddd0-465c-822b-0ec8231f2286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_662f31a2-9f35-49d4-bbce-ab1cbf23b760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c17976ca-8f29-443a-b4d1-bc92ad30bed4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_662f31a2-9f35-49d4-bbce-ab1cbf23b760" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e9d47127-a123-4a5b-ae71-8770b13a198f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c17976ca-8f29-443a-b4d1-bc92ad30bed4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e9d47127-a123-4a5b-ae71-8770b13a198f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2fbd9aa4-3ee2-44b5-a59c-94eda19cd8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c17976ca-8f29-443a-b4d1-bc92ad30bed4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2fbd9aa4-3ee2-44b5-a59c-94eda19cd8e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9995819e-b47d-467d-9b84-bba2f964b7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d284d289-4c80-4c6c-a812-7a4e3090ac8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9995819e-b47d-467d-9b84-bba2f964b7a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d284d289-4c80-4c6c-a812-7a4e3090ac8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bbb8be5e-d201-4c3b-b420-0be0553e66bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9995819e-b47d-467d-9b84-bba2f964b7a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bbb8be5e-d201-4c3b-b420-0be0553e66bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c97cbe69-5046-41e5-91c5-379bc5af880c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9995819e-b47d-467d-9b84-bba2f964b7a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c97cbe69-5046-41e5-91c5-379bc5af880c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1aacfa8a-c1c1-44e5-a2b3-24cda67d23b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9995819e-b47d-467d-9b84-bba2f964b7a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1aacfa8a-c1c1-44e5-a2b3-24cda67d23b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_71b03518-b872-45af-ba3e-96af7635a21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9995819e-b47d-467d-9b84-bba2f964b7a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_71b03518-b872-45af-ba3e-96af7635a21a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b963a042-635d-4333-a4d4-adcaedb4c192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9995819e-b47d-467d-9b84-bba2f964b7a1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b963a042-635d-4333-a4d4-adcaedb4c192" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" xlink:type="simple" xlink:href="gild-20221231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_297d5d7d-5ff5-42c0-b2d3-925474784cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c104c7f0-758a-4d74-bd69-369eca2451c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_297d5d7d-5ff5-42c0-b2d3-925474784cc9" xlink:to="loc_us-gaap_OperatingLeaseLiability_c104c7f0-758a-4d74-bd69-369eca2451c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_36620c5c-40fc-48b4-ae30-694ad49a7f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_297d5d7d-5ff5-42c0-b2d3-925474784cc9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_36620c5c-40fc-48b4-ae30-694ad49a7f4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e2fbe14-c425-4420-92d1-9c4d7fb22107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1f3df96f-6643-47e1-98f4-5f7d14636a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e2fbe14-c425-4420-92d1-9c4d7fb22107" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1f3df96f-6643-47e1-98f4-5f7d14636a2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_eeb3cb9e-d06b-4c48-af69-b70f33a27452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e2fbe14-c425-4420-92d1-9c4d7fb22107" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_eeb3cb9e-d06b-4c48-af69-b70f33a27452" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsSummaryofStockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_aa5d99ca-f790-4c89-bb56-f4c9f51f279b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b70563f0-9a54-428e-8c96-d7e74c45fcae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_aa5d99ca-f790-4c89-bb56-f4c9f51f279b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b70563f0-9a54-428e-8c96-d7e74c45fcae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_567ccd9a-2c45-4e1c-8722-b6ee99160339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_aa5d99ca-f790-4c89-bb56-f4c9f51f279b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_567ccd9a-2c45-4e1c-8722-b6ee99160339" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ff80fb07-1f03-41a7-94da-8eebde8ebe6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6fc87a22-a5ac-47d8-9e9f-c9d4a0ebe04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ff80fb07-1f03-41a7-94da-8eebde8ebe6a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6fc87a22-a5ac-47d8-9e9f-c9d4a0ebe04d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ac0559e8-40a5-4722-87de-d6f786a7da62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ff80fb07-1f03-41a7-94da-8eebde8ebe6a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ac0559e8-40a5-4722-87de-d6f786a7da62" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d5b79c3-c946-4e75-b57f-d37ea68110a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b897ed52-521e-4e2b-be67-1138612ccfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d5b79c3-c946-4e75-b57f-d37ea68110a3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b897ed52-521e-4e2b-be67-1138612ccfe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_13885dc0-68ff-44d8-a746-286aed319fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5d5b79c3-c946-4e75-b57f-d37ea68110a3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_13885dc0-68ff-44d8-a746-286aed319fff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesScheduleofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_c47fce25-b167-43e8-a212-1373ac8e0790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_005cde83-9dad-4530-ab25-88da07ac0fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_c47fce25-b167-43e8-a212-1373ac8e0790" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_005cde83-9dad-4530-ab25-88da07ac0fdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a7c240f0-7121-43e3-9ce9-1dd745563468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_c47fce25-b167-43e8-a212-1373ac8e0790" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a7c240f0-7121-43e3-9ce9-1dd745563468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f9b2290d-edd4-44f1-a5fe-0fe6ab6898bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_7300eeef-d459-42b2-aac8-333232b0af62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f9b2290d-edd4-44f1-a5fe-0fe6ab6898bd" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_7300eeef-d459-42b2-aac8-333232b0af62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_bec2861f-d59a-493c-847e-bc979eb1eb50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f9b2290d-edd4-44f1-a5fe-0fe6ab6898bd" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_bec2861f-d59a-493c-847e-bc979eb1eb50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_25547a6a-cd0c-4a17-86dd-3a2e2290e7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f9b2290d-edd4-44f1-a5fe-0fe6ab6898bd" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_25547a6a-cd0c-4a17-86dd-3a2e2290e7d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_7202b9c0-a857-49fe-8b6a-c36b82a7aa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_41f15190-f31f-48a3-93c1-f3ad97b4e574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_7202b9c0-a857-49fe-8b6a-c36b82a7aa8d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_41f15190-f31f-48a3-93c1-f3ad97b4e574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_df9a268d-2546-4b90-8d49-e33f18f72f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_7202b9c0-a857-49fe-8b6a-c36b82a7aa8d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_df9a268d-2546-4b90-8d49-e33f18f72f10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_23e74b84-745e-4736-a6f8-555278770571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b73d8304-684e-4e55-809b-5898cc1ea50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_23e74b84-745e-4736-a6f8-555278770571" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b73d8304-684e-4e55-809b-5898cc1ea50b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2836895d-5dc1-48c5-9a97-3576ef6ea372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_23e74b84-745e-4736-a6f8-555278770571" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2836895d-5dc1-48c5-9a97-3576ef6ea372" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7808f3-4620-4b0d-b1ec-752c2e407f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_45be042c-6693-40df-84ca-fa135dec9127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7808f3-4620-4b0d-b1ec-752c2e407f35" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_45be042c-6693-40df-84ca-fa135dec9127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_5ea92bc4-645c-48e9-8464-be10bdf46857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7808f3-4620-4b0d-b1ec-752c2e407f35" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_5ea92bc4-645c-48e9-8464-be10bdf46857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5276ae1b-70c2-4c60-b453-d46f2cc544dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7808f3-4620-4b0d-b1ec-752c2e407f35" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5276ae1b-70c2-4c60-b453-d46f2cc544dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_12a76964-05d7-47f4-8e68-594ee12e8475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7808f3-4620-4b0d-b1ec-752c2e407f35" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_12a76964-05d7-47f4-8e68-594ee12e8475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_0ad3f05f-2429-4e2a-8de6-0e73a53bb6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7808f3-4620-4b0d-b1ec-752c2e407f35" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_0ad3f05f-2429-4e2a-8de6-0e73a53bb6b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_974a6717-817a-45a9-a293-8d7dcba79c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7808f3-4620-4b0d-b1ec-752c2e407f35" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_974a6717-817a-45a9-a293-8d7dcba79c47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion_c94c7ee1-4348-4a86-9f32-d51e85db2c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7808f3-4620-4b0d-b1ec-752c2e407f35" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion_c94c7ee1-4348-4a86-9f32-d51e85db2c92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_772374d8-a6f7-44e7-bcc1-3eeb532e3c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7808f3-4620-4b0d-b1ec-752c2e407f35" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_772374d8-a6f7-44e7-bcc1-3eeb532e3c1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_29e52df3-207f-4304-b10f-8bd012952786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7808f3-4620-4b0d-b1ec-752c2e407f35" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_29e52df3-207f-4304-b10f-8bd012952786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_259c001e-6182-43f6-855a-fec8569d8403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7808f3-4620-4b0d-b1ec-752c2e407f35" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_259c001e-6182-43f6-855a-fec8569d8403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_10876e8e-27ed-416b-8b6e-9e4ed820e869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba7808f3-4620-4b0d-b1ec-752c2e407f35" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_10876e8e-27ed-416b-8b6e-9e4ed820e869" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_92dcb28a-b0b2-48aa-a73d-9508ccced8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c2d4e9b7-15fd-4b44-97a6-831222d8dd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_92dcb28a-b0b2-48aa-a73d-9508ccced8fa" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c2d4e9b7-15fd-4b44-97a6-831222d8dd4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d61d272b-1ffe-48a4-8f02-a59dba0a1455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_92dcb28a-b0b2-48aa-a73d-9508ccced8fa" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d61d272b-1ffe-48a4-8f02-a59dba0a1455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_8ef00c5f-a5d8-42d5-9bf5-0d7e5e786aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_92dcb28a-b0b2-48aa-a73d-9508ccced8fa" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_8ef00c5f-a5d8-42d5-9bf5-0d7e5e786aa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ac841fdf-f067-4a8b-baa1-130e5de557cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3e5fa1b4-1b4a-4e67-a3d5-f59f11a211a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ac841fdf-f067-4a8b-baa1-130e5de557cc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3e5fa1b4-1b4a-4e67-a3d5-f59f11a211a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_4e89ebb0-020d-49bb-b1c9-0e2caf6a3cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ac841fdf-f067-4a8b-baa1-130e5de557cc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_4e89ebb0-020d-49bb-b1c9-0e2caf6a3cf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fb9580b8-a08b-47a4-9432-2efd11ebf74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ac841fdf-f067-4a8b-baa1-130e5de557cc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_fb9580b8-a08b-47a4-9432-2efd11ebf74d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_ee4da48b-ce20-4a1d-a33e-73c01dfc4598" xlink:href="gild-20221231.xsd#gild_DeferredTaxAssetsUpfrontAndMilestonePayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ac841fdf-f067-4a8b-baa1-130e5de557cc" xlink:to="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_ee4da48b-ce20-4a1d-a33e-73c01dfc4598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_0ed695df-0480-4c7b-ac66-20b39f64d96f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ac841fdf-f067-4a8b-baa1-130e5de557cc" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_0ed695df-0480-4c7b-ac66-20b39f64d96f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_75a82ede-5f3c-4be8-ad51-62ffca50425a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ac841fdf-f067-4a8b-baa1-130e5de557cc" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_75a82ede-5f3c-4be8-ad51-62ffca50425a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ba2bccb8-5a0a-4924-a940-e974e9669bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ac841fdf-f067-4a8b-baa1-130e5de557cc" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ba2bccb8-5a0a-4924-a940-e974e9669bc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_78bb60a0-775f-462c-9b91-1152a40b34fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ac841fdf-f067-4a8b-baa1-130e5de557cc" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_78bb60a0-775f-462c-9b91-1152a40b34fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_b6266b40-5bd7-434d-aa65-8e3905592669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ac841fdf-f067-4a8b-baa1-130e5de557cc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_b6266b40-5bd7-434d-aa65-8e3905592669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8422be5f-9098-4284-935b-ebac4f175bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_ac841fdf-f067-4a8b-baa1-130e5de557cc" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8422be5f-9098-4284-935b-ebac4f175bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_ad46be19-78d7-42de-9529-de1473bf737a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_83b32836-023e-44db-9f8b-ddc0d0f111e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ad46be19-78d7-42de-9529-de1473bf737a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_83b32836-023e-44db-9f8b-ddc0d0f111e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_dce0a373-6309-411e-87e8-f1fe6863b459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ad46be19-78d7-42de-9529-de1473bf737a" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_dce0a373-6309-411e-87e8-f1fe6863b459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8a7c4552-fcbb-4d9b-938d-f58f197af38f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ddab9677-13b8-4b00-ac93-729605a58557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_8a7c4552-fcbb-4d9b-938d-f58f197af38f" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ddab9677-13b8-4b00-ac93-729605a58557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9631a581-8adb-4f2d-b104-3aca61c9ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_8a7c4552-fcbb-4d9b-938d-f58f197af38f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9631a581-8adb-4f2d-b104-3aca61c9ceca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesScheduleofTransitionTaxDetails"/>
  <link:calculationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_b928c947-76d0-48fe-b67f-56c9b06da9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo_1c0bd45f-201c-4c2b-b43f-041ea5ff7b80" xlink:href="gild-20221231.xsd#gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_b928c947-76d0-48fe-b67f-56c9b06da9b6" xlink:to="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo_1c0bd45f-201c-4c2b-b43f-041ea5ff7b80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree_17f93b1c-7694-46c6-bbc7-2f289d9a5c5a" xlink:href="gild-20221231.xsd#gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_b928c947-76d0-48fe-b67f-56c9b06da9b6" xlink:to="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree_17f93b1c-7694-46c6-bbc7-2f289d9a5c5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne_a98b286f-ef5a-4d78-87e0-66ee1380d5df" xlink:href="gild-20221231.xsd#gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_b928c947-76d0-48fe-b67f-56c9b06da9b6" xlink:to="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne_a98b286f-ef5a-4d78-87e0-66ee1380d5df" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>gild-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:138d9561-5f65-4b2f-b0c5-a8cb97862906,g:db888c96-90b0-4c6d-8008-49d88ed38ca7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended" id="i1ed6d4c661584854a60df14070ce6b3c_CONSOLIDATEDSTATEMENTSOFINCOME">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d0be36b7-28f7-4817-a4ab-d208c2273655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_RevenuesAbstract_d0be36b7-28f7-4817-a4ab-d208c2273655" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a1221ea2-86a1-4ce0-bc43-b026f3433a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_d0be36b7-28f7-4817-a4ab-d208c2273655" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a1221ea2-86a1-4ce0-bc43-b026f3433a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6bb81f78-8d3c-441c-8fd1-ab6b558a9ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6bb81f78-8d3c-441c-8fd1-ab6b558a9ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_016ccd26-ecbb-4bff-910a-4402697a9ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_016ccd26-ecbb-4bff-910a-4402697a9ea3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_1f5450a9-92df-4195-991c-cb376b971a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_1f5450a9-92df-4195-991c-cb376b971a60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e06b1ca3-33f7-4018-9ccf-ce60588b7e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e06b1ca3-33f7-4018-9ccf-ce60588b7e54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c37ce407-ee9d-4178-9ea5-2d4e57589265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c37ce407-ee9d-4178-9ea5-2d4e57589265" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1e7c6fd0-9889-47ff-858d-5db30a30b193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:to="loc_us-gaap_CostsAndExpenses_1e7c6fd0-9889-47ff-858d-5db30a30b193" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2f57376b-3a19-4f73-a685-77249d8e3c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_OperatingIncomeLoss_2f57376b-3a19-4f73-a685-77249d8e3c63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_993d32a2-719f-482e-956a-966e27f21db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_InterestExpense_993d32a2-719f-482e-956a-966e27f21db6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5a341870-c570-4888-b8b5-be9c94a67033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5a341870-c570-4888-b8b5-be9c94a67033" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a01dc33c-d67d-42cc-ac4d-0e4db54e1bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a01dc33c-d67d-42cc-ac4d-0e4db54e1bfa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c8ebd8e8-4b6b-42cb-8fd8-829a98cb88e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c8ebd8e8-4b6b-42cb-8fd8-829a98cb88e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ba85c183-c363-41b2-ba17-08a9bc421d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_ProfitLoss_ba85c183-c363-41b2-ba17-08a9bc421d80" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e4f7b2ee-20c7-4384-b275-be04b892e5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e4f7b2ee-20c7-4384-b275-be04b892e5b5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cc3af065-1182-40ec-b36a-d96619faaed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_NetIncomeLoss_cc3af065-1182-40ec-b36a-d96619faaed8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e3767324-f22f-4286-a435-ff3221f1ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_EarningsPerShareBasic_e3767324-f22f-4286-a435-ff3221f1ee48" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91f3a819-9174-4b0e-86c0-ccaec321c913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91f3a819-9174-4b0e-86c0-ccaec321c913" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f8383083-affb-4854-b29b-9e8a55f534bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f8383083-affb-4854-b29b-9e8a55f534bf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f66293af-ae03-4490-bb3b-677eabd9ba74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f66293af-ae03-4490-bb3b-677eabd9ba74" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b682824e-63c8-4505-a144-cf3523934cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_StatementTable_b682824e-63c8-4505-a144-cf3523934cad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4ba58ed8-840f-4184-9b45-dcf7ae49bcc3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b682824e-63c8-4505-a144-cf3523934cad" xlink:to="loc_srt_ProductOrServiceAxis_4ba58ed8-840f-4184-9b45-dcf7ae49bcc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4ba58ed8-840f-4184-9b45-dcf7ae49bcc3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4ba58ed8-840f-4184-9b45-dcf7ae49bcc3" xlink:to="loc_srt_ProductsAndServicesDomain_4ba58ed8-840f-4184-9b45-dcf7ae49bcc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ebd224be-1c9d-4e09-9e34-bba938e51215" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4ba58ed8-840f-4184-9b45-dcf7ae49bcc3" xlink:to="loc_srt_ProductsAndServicesDomain_ebd224be-1c9d-4e09-9e34-bba938e51215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_bbfd2c6f-34c3-443e-90de-7a8e871dc2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ebd224be-1c9d-4e09-9e34-bba938e51215" xlink:to="loc_us-gaap_ProductMember_bbfd2c6f-34c3-443e-90de-7a8e871dc2f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_29acb681-9b8d-4a0d-b6ee-843f9d9f749f" xlink:href="gild-20221231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ebd224be-1c9d-4e09-9e34-bba938e51215" xlink:to="loc_gild_RoyaltyContractAndOtherMember_29acb681-9b8d-4a0d-b6ee-843f9d9f749f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i8af95d26f8ec43a59acd498bea5ef0f0_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e08cb80f-4b18-410b-a57d-f9bd1c534809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e08cb80f-4b18-410b-a57d-f9bd1c534809" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_54de0056-6eac-4f65-97dd-ed7c58b0d0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_54de0056-6eac-4f65-97dd-ed7c58b0d0a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee44464c-2407-40b6-aec5-2fe7dfd18db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee44464c-2407-40b6-aec5-2fe7dfd18db5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_105e6f61-f659-4983-8593-a4ba7a1d4488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_105e6f61-f659-4983-8593-a4ba7a1d4488" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_328ca4e5-689d-4e3e-aafb-cd2b4da6b85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_ProfitLoss_328ca4e5-689d-4e3e-aafb-cd2b4da6b85e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b0fc7226-7dab-4bf8-a57e-9ad15641c2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b0fc7226-7dab-4bf8-a57e-9ad15641c2ce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b2a99b53-e557-4ad2-b0a1-4cec33677ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b2a99b53-e557-4ad2-b0a1-4cec33677ae1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a4af525e-b831-41bb-b186-7b04f672029b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a4af525e-b831-41bb-b186-7b04f672029b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_380c0de5-963a-40a9-972b-7536360be40c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_380c0de5-963a-40a9-972b-7536360be40c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0e9d9170-0e21-48de-9d39-14e6e0447826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0e9d9170-0e21-48de-9d39-14e6e0447826" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_027a917e-5c16-490f-ade1-dd7f26b94291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_027a917e-5c16-490f-ade1-dd7f26b94291" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_e5cc9593-52b5-4532-a527-be445cbe39c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_e5cc9593-52b5-4532-a527-be445cbe39c6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f5399d9a-853e-415e-8cae-a8fbdc749978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f5399d9a-853e-415e-8cae-a8fbdc749978" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_3c1e118f-8084-43e0-8bc7-abc0319065b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_Dividends_3c1e118f-8084-43e0-8bc7-abc0319065b5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5b609695-9112-4e51-b488-1f6ffa63f256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_651b84dc-4d59-4789-84c4-a3d9ea32787d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cc1bc568-34a9-4e82-8567-107e4eaeb027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e08cb80f-4b18-410b-a57d-f9bd1c534809" xlink:to="loc_us-gaap_StatementTable_cc1bc568-34a9-4e82-8567-107e4eaeb027" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_49c44461-c613-43cd-b38b-b24d6be9bd59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cc1bc568-34a9-4e82-8567-107e4eaeb027" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_49c44461-c613-43cd-b38b-b24d6be9bd59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_49c44461-c613-43cd-b38b-b24d6be9bd59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_49c44461-c613-43cd-b38b-b24d6be9bd59" xlink:to="loc_us-gaap_EquityComponentDomain_49c44461-c613-43cd-b38b-b24d6be9bd59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_49c44461-c613-43cd-b38b-b24d6be9bd59" xlink:to="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_00c549f7-f8e6-4e2c-b902-4a2602fdaea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:to="loc_us-gaap_CommonStockMember_00c549f7-f8e6-4e2c-b902-4a2602fdaea6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_55302ac9-8978-413b-89f6-5e9536295fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_55302ac9-8978-413b-89f6-5e9536295fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d8c0a79c-87c7-49a4-9ec5-82dc65b8d37e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d8c0a79c-87c7-49a4-9ec5-82dc65b8d37e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9d127c19-776e-4710-8b1b-9f1e70e5de39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:to="loc_us-gaap_RetainedEarningsMember_9d127c19-776e-4710-8b1b-9f1e70e5de39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_293f45af-c153-4e01-8a52-2c9499cd6fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_293f45af-c153-4e01-8a52-2c9499cd6fab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d63fa6f6-417e-4645-b674-35921707ce03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cc1bc568-34a9-4e82-8567-107e4eaeb027" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d63fa6f6-417e-4645-b674-35921707ce03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d63fa6f6-417e-4645-b674-35921707ce03_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d63fa6f6-417e-4645-b674-35921707ce03" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d63fa6f6-417e-4645-b674-35921707ce03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dd2ce558-cdca-4455-bf77-08794d58a6c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d63fa6f6-417e-4645-b674-35921707ce03" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dd2ce558-cdca-4455-bf77-08794d58a6c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1800e675-80f7-4872-899f-36ebe3b6cdf4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dd2ce558-cdca-4455-bf77-08794d58a6c1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1800e675-80f7-4872-899f-36ebe3b6cdf4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i1fcccb83b29e4fc49ad0263122c46da0_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:href="gild-20221231.xsd#gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_58888417-e30b-4e11-b301-b46b84ce242b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_58888417-e30b-4e11-b301-b46b84ce242b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2fce756f-f7fd-48ef-9d53-7bb231120bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2fce756f-f7fd-48ef-9d53-7bb231120bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e2e322a-374c-41d3-95b9-abda9655c1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e2e322a-374c-41d3-95b9-abda9655c1fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_5b7475a6-1e5c-445f-a35b-3ac7c1c4c014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:to="loc_us-gaap_AdvertisingExpense_5b7475a6-1e5c-445f-a35b-3ac7c1c4c014" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e152a264-e676-4d5c-a06b-23fbea1ba6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e152a264-e676-4d5c-a06b-23fbea1ba6f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SummaryOfSignificantAccountingPoliciesTable_3d57f523-5f96-4942-8d3a-1b211370954e" xlink:href="gild-20221231.xsd#gild_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:to="loc_gild_SummaryOfSignificantAccountingPoliciesTable_3d57f523-5f96-4942-8d3a-1b211370954e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d94076f-6b2e-4f72-9c6b-e080675f5b2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_3d57f523-5f96-4942-8d3a-1b211370954e" xlink:to="loc_srt_RangeAxis_8d94076f-6b2e-4f72-9c6b-e080675f5b2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d94076f-6b2e-4f72-9c6b-e080675f5b2b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8d94076f-6b2e-4f72-9c6b-e080675f5b2b" xlink:to="loc_srt_RangeMember_8d94076f-6b2e-4f72-9c6b-e080675f5b2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1cdd3ce2-920d-42c6-9ad9-53d8f678d61b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8d94076f-6b2e-4f72-9c6b-e080675f5b2b" xlink:to="loc_srt_RangeMember_1cdd3ce2-920d-42c6-9ad9-53d8f678d61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3bde6aaf-db9b-4d71-af21-5fd462487110" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1cdd3ce2-920d-42c6-9ad9-53d8f678d61b" xlink:to="loc_srt_MinimumMember_3bde6aaf-db9b-4d71-af21-5fd462487110" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e444e66-7e02-4a4c-91a3-a7bc98879ef9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1cdd3ce2-920d-42c6-9ad9-53d8f678d61b" xlink:to="loc_srt_MaximumMember_7e444e66-7e02-4a4c-91a3-a7bc98879ef9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0f2a3910-49c3-48aa-a188-09f0d5a21263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_3d57f523-5f96-4942-8d3a-1b211370954e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0f2a3910-49c3-48aa-a188-09f0d5a21263" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0f2a3910-49c3-48aa-a188-09f0d5a21263_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0f2a3910-49c3-48aa-a188-09f0d5a21263" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0f2a3910-49c3-48aa-a188-09f0d5a21263_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8044ebb-9109-4f2c-8664-c49a9ec756e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0f2a3910-49c3-48aa-a188-09f0d5a21263" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8044ebb-9109-4f2c-8664-c49a9ec756e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_a37d0cd7-3bf7-493a-afc8-7f89448f249a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8044ebb-9109-4f2c-8664-c49a9ec756e0" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_a37d0cd7-3bf7-493a-afc8-7f89448f249a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_ca0f1a81-ef2d-405f-bdde-7e08642a4b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8044ebb-9109-4f2c-8664-c49a9ec756e0" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_ca0f1a81-ef2d-405f-bdde-7e08642a4b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d3c5352e-2e40-4193-9793-347c81c5d745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8044ebb-9109-4f2c-8664-c49a9ec756e0" xlink:to="loc_us-gaap_ComputerEquipmentMember_d3c5352e-2e40-4193-9793-347c81c5d745" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_7ebadfc8-5782-467d-98a3-242f076be191" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_3d57f523-5f96-4942-8d3a-1b211370954e" xlink:to="loc_srt_RestatementAxis_7ebadfc8-5782-467d-98a3-242f076be191" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_7ebadfc8-5782-467d-98a3-242f076be191_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_7ebadfc8-5782-467d-98a3-242f076be191" xlink:to="loc_srt_RestatementDomain_7ebadfc8-5782-467d-98a3-242f076be191_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_c82d8596-bfb6-42e8-8c54-95f8629731a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_7ebadfc8-5782-467d-98a3-242f076be191" xlink:to="loc_srt_RestatementDomain_c82d8596-bfb6-42e8-8c54-95f8629731a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_483d004b-6c4e-4fcf-9ec9-6efdc0c14c79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_c82d8596-bfb6-42e8-8c54-95f8629731a6" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_483d004b-6c4e-4fcf-9ec9-6efdc0c14c79" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#RevenuesDisaggregationofRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="extended" id="i9b29505f4c6c4810a9af4849e91bf75f_RevenuesDisaggregationofRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_41309a3a-abda-4720-9107-8641c4f0c3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08676d75-129a-4e16-949f-4d42fea1bd70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_41309a3a-abda-4720-9107-8641c4f0c3cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08676d75-129a-4e16-949f-4d42fea1bd70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b8aba6d3-2572-4195-a805-068a5dd9782f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_41309a3a-abda-4720-9107-8641c4f0c3cf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b8aba6d3-2572-4195-a805-068a5dd9782f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bd0183dd-112d-4a00-90f9-7fc7df67b9fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b8aba6d3-2572-4195-a805-068a5dd9782f" xlink:to="loc_srt_ProductOrServiceAxis_bd0183dd-112d-4a00-90f9-7fc7df67b9fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bd0183dd-112d-4a00-90f9-7fc7df67b9fd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bd0183dd-112d-4a00-90f9-7fc7df67b9fd" xlink:to="loc_srt_ProductsAndServicesDomain_bd0183dd-112d-4a00-90f9-7fc7df67b9fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96466de1-a1cb-4bd1-8736-f3652d4aecb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bd0183dd-112d-4a00-90f9-7fc7df67b9fd" xlink:to="loc_srt_ProductsAndServicesDomain_96466de1-a1cb-4bd1-8736-f3652d4aecb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_96466de1-a1cb-4bd1-8736-f3652d4aecb3" xlink:to="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:href="gild-20221231.xsd#gild_HIVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_05c3d5e4-d2c8-45ab-b716-d265d81beabf" xlink:href="gild-20221231.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsBiktarvyMember_05c3d5e4-d2c8-45ab-b716-d265d81beabf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_dda0547f-9804-4efe-b1a0-28de60337981" xlink:href="gild-20221231.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_dda0547f-9804-4efe-b1a0-28de60337981" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_e655b14c-a43c-41ae-b9a7-66998ee2e071" xlink:href="gild-20221231.xsd#gild_HIVProductsDescovyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsDescovyMember_e655b14c-a43c-41ae-b9a7-66998ee2e071" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_fe5e90c5-6402-41cb-97a3-51771f0eff2f" xlink:href="gild-20221231.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsGenvoyaMember_fe5e90c5-6402-41cb-97a3-51771f0eff2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_7b7f5167-fb0e-4ba1-bf77-24a2a9b927ab" xlink:href="gild-20221231.xsd#gild_HIVProductsOdefseyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsOdefseyMember_7b7f5167-fb0e-4ba1-bf77-24a2a9b927ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_d392e328-8d74-4a83-8c98-4a3b24ad3e7c" xlink:href="gild-20221231.xsd#gild_HIVProductsStribildMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsStribildMember_d392e328-8d74-4a83-8c98-4a3b24ad3e7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_756d7187-3c63-419d-a362-736f5aaea626" xlink:href="gild-20221231.xsd#gild_HIVProductsTruvadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsTruvadaMember_756d7187-3c63-419d-a362-736f5aaea626" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_2f0884ea-13b6-4752-93f7-c9cbc6a5d177" xlink:href="gild-20221231.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_2f0884ea-13b6-4752-93f7-c9cbc6a5d177" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_76f29593-8a7f-4582-9748-2c013ea3f77c" xlink:href="gild-20221231.xsd#gild_ProductsOtherHIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_ProductsOtherHIVMember_76f29593-8a7f-4582-9748-2c013ea3f77c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember_03c910dd-4ce7-4f2c-9c69-63606b0b9937" xlink:href="gild-20221231.xsd#gild_VekluryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_VekluryMember_03c910dd-4ce7-4f2c-9c69-63606b0b9937" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_75ddc2f1-382e-4fd8-a123-dc7b8e57d475" xlink:href="gild-20221231.xsd#gild_HCVProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_HCVProductSalesMember_75ddc2f1-382e-4fd8-a123-dc7b8e57d475" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_8b9ee560-d619-4555-9276-b492ffb86625" xlink:href="gild-20221231.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_75ddc2f1-382e-4fd8-a123-dc7b8e57d475" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_8b9ee560-d619-4555-9276-b492ffb86625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_5322ed44-a951-417f-aaa9-e19a73f2e246" xlink:href="gild-20221231.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_75ddc2f1-382e-4fd8-a123-dc7b8e57d475" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_5322ed44-a951-417f-aaa9-e19a73f2e246" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHCVMember_468d350e-a6fa-4e34-bf10-1aa7294e4f32" xlink:href="gild-20221231.xsd#gild_OtherHCVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HCVProductSalesMember_75ddc2f1-382e-4fd8-a123-dc7b8e57d475" xlink:to="loc_gild_OtherHCVMember_468d350e-a6fa-4e34-bf10-1aa7294e4f32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_5caad235-b990-42be-a081-a230bfdc6dad" xlink:href="gild-20221231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_5caad235-b990-42be-a081-a230bfdc6dad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_2e36cdbb-0506-4e48-b23d-caa210e6e6fe" xlink:href="gild-20221231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_5caad235-b990-42be-a081-a230bfdc6dad" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_2e36cdbb-0506-4e48-b23d-caa210e6e6fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_543e1db9-641b-4a1b-b740-15da629b02aa" xlink:href="gild-20221231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_5caad235-b990-42be-a081-a230bfdc6dad" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_543e1db9-641b-4a1b-b740-15da629b02aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_8b0618c1-ce3b-4163-a374-ffd9cd62a40b" xlink:href="gild-20221231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_5caad235-b990-42be-a081-a230bfdc6dad" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_8b0618c1-ce3b-4163-a374-ffd9cd62a40b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ea3837b0-5a88-4c26-992c-6fa397c9b291" xlink:href="gild-20221231.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ea3837b0-5a88-4c26-992c-6fa397c9b291" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_058fec26-b8c0-4274-b08e-534d8e2834d5" xlink:href="gild-20221231.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ea3837b0-5a88-4c26-992c-6fa397c9b291" xlink:to="loc_gild_CellTherapyProductsTecartusMember_058fec26-b8c0-4274-b08e-534d8e2834d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsYescartaMember_67412e7f-8ec6-49f2-b320-57852f022581" xlink:href="gild-20221231.xsd#gild_OtherProductsYescartaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ea3837b0-5a88-4c26-992c-6fa397c9b291" xlink:to="loc_gild_OtherProductsYescartaMember_67412e7f-8ec6-49f2-b320-57852f022581" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_9e368858-8123-431b-a990-1095ebdc30ac" xlink:href="gild-20221231.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_TrodelvyMember_9e368858-8123-431b-a990-1095ebdc30ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_cb6075b2-7823-47ad-8e34-b6fade2d7456" xlink:href="gild-20221231.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_cb6075b2-7823-47ad-8e34-b6fade2d7456" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_35751aff-82a8-48c5-9065-a05568b28684" xlink:href="gild-20221231.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_cb6075b2-7823-47ad-8e34-b6fade2d7456" xlink:to="loc_gild_OtherProductsAmBisomeMember_35751aff-82a8-48c5-9065-a05568b28684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_2daaa4c4-194a-415a-bb63-11092fb5d0f9" xlink:href="gild-20221231.xsd#gild_OtherProductsLetairisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_cb6075b2-7823-47ad-8e34-b6fade2d7456" xlink:to="loc_gild_OtherProductsLetairisMember_2daaa4c4-194a-415a-bb63-11092fb5d0f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_246af3e4-a788-4d13-85a5-51a08a2cd5a4" xlink:href="gild-20221231.xsd#gild_OtherProductsOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_cb6075b2-7823-47ad-8e34-b6fade2d7456" xlink:to="loc_gild_OtherProductsOtherMember_246af3e4-a788-4d13-85a5-51a08a2cd5a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_5ccbc6ca-1d2a-4d55-8c3a-59f6bed73f38" xlink:href="gild-20221231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_96466de1-a1cb-4bd1-8736-f3652d4aecb3" xlink:to="loc_gild_RoyaltyContractAndOtherMember_5ccbc6ca-1d2a-4d55-8c3a-59f6bed73f38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_79186a15-80ff-44b8-a9ce-99b0456a6193" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b8aba6d3-2572-4195-a805-068a5dd9782f" xlink:to="loc_srt_StatementGeographicalAxis_79186a15-80ff-44b8-a9ce-99b0456a6193" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_79186a15-80ff-44b8-a9ce-99b0456a6193_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_79186a15-80ff-44b8-a9ce-99b0456a6193" xlink:to="loc_srt_SegmentGeographicalDomain_79186a15-80ff-44b8-a9ce-99b0456a6193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e33a645d-3694-414d-aede-f80562a7295a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_79186a15-80ff-44b8-a9ce-99b0456a6193" xlink:to="loc_srt_SegmentGeographicalDomain_e33a645d-3694-414d-aede-f80562a7295a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a22da078-d7c5-4b60-9095-1688057b610b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e33a645d-3694-414d-aede-f80562a7295a" xlink:to="loc_country_US_a22da078-d7c5-4b60-9095-1688057b610b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_b5abd97d-a2b8-42a4-85fc-e1262ab27366" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e33a645d-3694-414d-aede-f80562a7295a" xlink:to="loc_srt_EuropeMember_b5abd97d-a2b8-42a4-85fc-e1262ab27366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_c229ff39-23fe-4d0a-9859-adf267b992b1" xlink:href="gild-20221231.xsd#gild_OtherInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e33a645d-3694-414d-aede-f80562a7295a" xlink:to="loc_gild_OtherInternationalMember_c229ff39-23fe-4d0a-9859-adf267b992b1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#RevenuesSummarizedRevenuesfromMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="extended" id="i540e11eeae7f4cc5ac831746e4149d7f_RevenuesSummarizedRevenuesfromMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b557ca45-e55e-447f-a18e-256c91249aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f3d2ae77-3829-4dba-9010-d4bbee1bfbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b557ca45-e55e-447f-a18e-256c91249aaa" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f3d2ae77-3829-4dba-9010-d4bbee1bfbf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7e08220e-c0c3-41f1-a982-faf54f202a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b557ca45-e55e-447f-a18e-256c91249aaa" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7e08220e-c0c3-41f1-a982-faf54f202a58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f22bcb0d-66ed-4a44-83ea-72036f5b03da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7e08220e-c0c3-41f1-a982-faf54f202a58" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f22bcb0d-66ed-4a44-83ea-72036f5b03da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f22bcb0d-66ed-4a44-83ea-72036f5b03da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f22bcb0d-66ed-4a44-83ea-72036f5b03da" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f22bcb0d-66ed-4a44-83ea-72036f5b03da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_143c6292-931e-4afe-863e-2aca9105fe98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f22bcb0d-66ed-4a44-83ea-72036f5b03da" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_143c6292-931e-4afe-863e-2aca9105fe98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_bd077812-ab39-4ae0-9549-f436c97a6410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_143c6292-931e-4afe-863e-2aca9105fe98" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_bd077812-ab39-4ae0-9549-f436c97a6410" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_34c8508f-f347-4da3-af2f-f10cad7223ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7e08220e-c0c3-41f1-a982-faf54f202a58" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_34c8508f-f347-4da3-af2f-f10cad7223ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_34c8508f-f347-4da3-af2f-f10cad7223ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_34c8508f-f347-4da3-af2f-f10cad7223ec" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_34c8508f-f347-4da3-af2f-f10cad7223ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_77933c67-2261-447c-9844-c81096bfd342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_34c8508f-f347-4da3-af2f-f10cad7223ec" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_77933c67-2261-447c-9844-c81096bfd342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d1b824d3-1852-4b0e-8038-46f3a1ad7bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_77933c67-2261-447c-9844-c81096bfd342" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d1b824d3-1852-4b0e-8038-46f3a1ad7bfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fa359992-6b11-41b1-83e6-1b72098dbcc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7e08220e-c0c3-41f1-a982-faf54f202a58" xlink:to="loc_srt_MajorCustomersAxis_fa359992-6b11-41b1-83e6-1b72098dbcc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fa359992-6b11-41b1-83e6-1b72098dbcc9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_fa359992-6b11-41b1-83e6-1b72098dbcc9" xlink:to="loc_srt_NameOfMajorCustomerDomain_fa359992-6b11-41b1-83e6-1b72098dbcc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_83cf9ae8-7805-4774-9763-c77ea5bcdf26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_fa359992-6b11-41b1-83e6-1b72098dbcc9" xlink:to="loc_srt_NameOfMajorCustomerDomain_83cf9ae8-7805-4774-9763-c77ea5bcdf26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_8996cbdd-7f4e-479e-9a96-0fe8f4b67386" xlink:href="gild-20221231.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_83cf9ae8-7805-4774-9763-c77ea5bcdf26" xlink:to="loc_gild_AmerisourcebergenCorpMember_8996cbdd-7f4e-479e-9a96-0fe8f4b67386" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_600d644f-d4d4-408b-ab0d-5baeebf5326d" xlink:href="gild-20221231.xsd#gild_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_83cf9ae8-7805-4774-9763-c77ea5bcdf26" xlink:to="loc_gild_CardinalHealthIncMember_600d644f-d4d4-408b-ab0d-5baeebf5326d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_894f8236-65a3-416e-9186-9bc7868d3e23" xlink:href="gild-20221231.xsd#gild_MckessonCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_83cf9ae8-7805-4774-9763-c77ea5bcdf26" xlink:to="loc_gild_MckessonCorpMember_894f8236-65a3-416e-9186-9bc7868d3e23" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended" id="id7730626fc5b430c960b63b5063bb9f9_FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ff70d016-a6b0-40ea-b76b-58762b86a2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8ddfc574-e29b-4480-8566-d0a2179c185a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ff70d016-a6b0-40ea-b76b-58762b86a2b0" xlink:to="loc_us-gaap_AssetsAbstract_8ddfc574-e29b-4480-8566-d0a2179c185a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3e1bb20d-877b-482a-b292-c104eb8aace4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8ddfc574-e29b-4480-8566-d0a2179c185a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3e1bb20d-877b-482a-b292-c104eb8aace4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7922a339-9665-4ff7-90ca-57b2b2bde2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8ddfc574-e29b-4480-8566-d0a2179c185a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7922a339-9665-4ff7-90ca-57b2b2bde2d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_a2e66148-9822-4a8e-b35b-6e0cc11ab807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8ddfc574-e29b-4480-8566-d0a2179c185a" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_a2e66148-9822-4a8e-b35b-6e0cc11ab807" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_717ef47c-04b1-4e2c-a959-9b2be923b562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8ddfc574-e29b-4480-8566-d0a2179c185a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_717ef47c-04b1-4e2c-a959-9b2be923b562" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_a93e8714-015a-49c5-a7cf-7af17c5c1a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ff70d016-a6b0-40ea-b76b-58762b86a2b0" xlink:to="loc_us-gaap_LiabilitiesAbstract_a93e8714-015a-49c5-a7cf-7af17c5c1a32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e735e400-10c2-4dcb-ad6d-017fea9e4eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_a93e8714-015a-49c5-a7cf-7af17c5c1a32" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e735e400-10c2-4dcb-ad6d-017fea9e4eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_58e847fa-d775-45a5-a20a-a7375260cbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_a93e8714-015a-49c5-a7cf-7af17c5c1a32" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_58e847fa-d775-45a5-a20a-a7375260cbe6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_adb7de1b-6cb1-4ab8-8efe-f71bbd31688b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_a93e8714-015a-49c5-a7cf-7af17c5c1a32" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_adb7de1b-6cb1-4ab8-8efe-f71bbd31688b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ce22e9f8-6d0d-4e20-b983-0aeb0fb5f1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_a93e8714-015a-49c5-a7cf-7af17c5c1a32" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_ce22e9f8-6d0d-4e20-b983-0aeb0fb5f1cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ff70d016-a6b0-40ea-b76b-58762b86a2b0" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ab3fd3fb-fc13-408c-9faa-346fafa68b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ab3fd3fb-fc13-408c-9faa-346fafa68b54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab3fd3fb-fc13-408c-9faa-346fafa68b54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ab3fd3fb-fc13-408c-9faa-346fafa68b54" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ab3fd3fb-fc13-408c-9faa-346fafa68b54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2a38eda0-2d9a-43c5-beee-f038c0e18a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ab3fd3fb-fc13-408c-9faa-346fafa68b54" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2a38eda0-2d9a-43c5-beee-f038c0e18a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_32af3724-62f6-40e7-bb7f-901c6bc4ad90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2a38eda0-2d9a-43c5-beee-f038c0e18a05" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_32af3724-62f6-40e7-bb7f-901c6bc4ad90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299bc415-a68e-4c26-83b4-26d371b71e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299bc415-a68e-4c26-83b4-26d371b71e28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_299bc415-a68e-4c26-83b4-26d371b71e28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299bc415-a68e-4c26-83b4-26d371b71e28" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_299bc415-a68e-4c26-83b4-26d371b71e28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b2eb316a-b2e8-4efd-b1b5-442e7af54419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299bc415-a68e-4c26-83b4-26d371b71e28" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b2eb316a-b2e8-4efd-b1b5-442e7af54419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_23830173-7d27-4d4e-8833-b5b6816c5ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b2eb316a-b2e8-4efd-b1b5-442e7af54419" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_23830173-7d27-4d4e-8833-b5b6816c5ed3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b35d16a0-6082-4a39-9e33-f7a26dc3d4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b2eb316a-b2e8-4efd-b1b5-442e7af54419" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b35d16a0-6082-4a39-9e33-f7a26dc3d4a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7f5db702-03ac-4d4d-9beb-a097449250fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b2eb316a-b2e8-4efd-b1b5-442e7af54419" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7f5db702-03ac-4d4d-9beb-a097449250fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_171b7bf9-ffb0-4e0c-994e-4be4c447ec2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_171b7bf9-ffb0-4e0c-994e-4be4c447ec2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_171b7bf9-ffb0-4e0c-994e-4be4c447ec2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_171b7bf9-ffb0-4e0c-994e-4be4c447ec2a" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_171b7bf9-ffb0-4e0c-994e-4be4c447ec2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26a3f6b7-5e54-4bc8-b88a-6d9368e7b641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_171b7bf9-ffb0-4e0c-994e-4be4c447ec2a" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26a3f6b7-5e54-4bc8-b88a-6d9368e7b641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a5a22763-c434-4cd1-81dc-ecf6b5b57d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26a3f6b7-5e54-4bc8-b88a-6d9368e7b641" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a5a22763-c434-4cd1-81dc-ecf6b5b57d69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8b2f9a15-8f21-444e-83a5-1bb90dee79be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a5a22763-c434-4cd1-81dc-ecf6b5b57d69" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8b2f9a15-8f21-444e-83a5-1bb90dee79be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0be097da-1b30-4652-814f-1c506bfcdc59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0be097da-1b30-4652-814f-1c506bfcdc59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0be097da-1b30-4652-814f-1c506bfcdc59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0be097da-1b30-4652-814f-1c506bfcdc59" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0be097da-1b30-4652-814f-1c506bfcdc59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0be097da-1b30-4652-814f-1c506bfcdc59" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8103a338-8fbe-4ec9-895a-b1240bd2525c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8103a338-8fbe-4ec9-895a-b1240bd2525c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_98e47e96-b502-498f-866d-baab45534139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_98e47e96-b502-498f-866d-baab45534139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_2ee0ff06-542a-4555-93e2-74f2651fa256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_2ee0ff06-542a-4555-93e2-74f2651fa256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_24c1492d-a3fd-4557-bb55-59eb0bf773c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_CertificatesOfDepositMember_24c1492d-a3fd-4557-bb55-59eb0bf773c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_739aad82-edca-427c-8dba-07bb926e4df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_739aad82-edca-427c-8dba-07bb926e4df9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_b649e4b4-9ad1-4302-8091-5a3ecbede538" xlink:href="gild-20221231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_b649e4b4-9ad1-4302-8091-5a3ecbede538" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_66af51b8-b304-48f5-b649-9efb9fb52503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_MoneyMarketFundsMember_66af51b8-b304-48f5-b649-9efb9fb52503" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_13bdbee6-c0d8-4aeb-abed-c8003b8b5807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_EquitySecuritiesMember_13bdbee6-c0d8-4aeb-abed-c8003b8b5807" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_a1b12b2c-0cd1-4908-a549-585ced44f2ed" xlink:href="gild-20221231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_gild_DeferredCompensationPlanMember_a1b12b2c-0cd1-4908-a549-585ced44f2ed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_8817ee0c-30ec-478f-921a-8424d85eee64" xlink:href="gild-20221231.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_8817ee0c-30ec-478f-921a-8424d85eee64" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_13f565f4-eb2a-4b9f-8648-58fc8bcc1f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_13f565f4-eb2a-4b9f-8648-58fc8bcc1f8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_13f565f4-eb2a-4b9f-8648-58fc8bcc1f8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_13f565f4-eb2a-4b9f-8648-58fc8bcc1f8e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_13f565f4-eb2a-4b9f-8648-58fc8bcc1f8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0caeb5d-7461-4c17-9692-c2a67bfadeed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_13f565f4-eb2a-4b9f-8648-58fc8bcc1f8e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0caeb5d-7461-4c17-9692-c2a67bfadeed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_fa2a85c6-e701-4d17-ad56-a0049c200703" xlink:href="gild-20221231.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0caeb5d-7461-4c17-9692-c2a67bfadeed" xlink:to="loc_gild_MYRGmbHMember_fa2a85c6-e701-4d17-ad56-a0049c200703" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_50876216-596c-424b-9101-3a773f6ca9e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_50876216-596c-424b-9101-3a773f6ca9e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_50876216-596c-424b-9101-3a773f6ca9e9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_50876216-596c-424b-9101-3a773f6ca9e9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_50876216-596c-424b-9101-3a773f6ca9e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_da84331c-2945-4f0f-8ea1-8d6dc455fbe3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_50876216-596c-424b-9101-3a773f6ca9e9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_da84331c-2945-4f0f-8ea1-8d6dc455fbe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_e6700fa4-ea51-42ba-a5db-04a78b9af167" xlink:href="gild-20221231.xsd#gild_GalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84331c-2945-4f0f-8ea1-8d6dc455fbe3" xlink:to="loc_gild_GalapagosMember_e6700fa4-ea51-42ba-a5db-04a78b9af167" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_4dff86ee-fb85-4109-93f6-53bb4e48db21" xlink:href="gild-20221231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84331c-2945-4f0f-8ea1-8d6dc455fbe3" xlink:to="loc_gild_ArcusBiosciencesIncMember_4dff86ee-fb85-4109-93f6-53bb4e48db21" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" id="id3e0b6895f02453a948f551adbd29bc6_FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_f9fbd4ba-3151-41ee-a6e4-20008eb5928d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_f9fbd4ba-3151-41ee-a6e4-20008eb5928d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_90702517-1bd9-4c6a-9dc9-49aca2a43cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:to="loc_us-gaap_LongTermDebtFairValue_90702517-1bd9-4c6a-9dc9-49aca2a43cdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_730d1e94-6cdd-4631-bb78-dc7eac7a7388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_730d1e94-6cdd-4631-bb78-dc7eac7a7388" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_a27e486f-8e0e-4187-b955-0fddd95c714a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_a27e486f-8e0e-4187-b955-0fddd95c714a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_11221ef8-84d2-474d-81c6-8675a3eb33d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_11221ef8-84d2-474d-81c6-8675a3eb33d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_eda859d2-ded9-49b2-b288-b00a0e5a599a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_eda859d2-ded9-49b2-b288-b00a0e5a599a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_eda859d2-ded9-49b2-b288-b00a0e5a599a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_eda859d2-ded9-49b2-b288-b00a0e5a599a" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_eda859d2-ded9-49b2-b288-b00a0e5a599a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_682bb9cc-a808-4f8d-8e41-825e4295b560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_eda859d2-ded9-49b2-b288-b00a0e5a599a" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_682bb9cc-a808-4f8d-8e41-825e4295b560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2444adaa-945c-42a5-bf49-53fc7a0766af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_682bb9cc-a808-4f8d-8e41-825e4295b560" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2444adaa-945c-42a5-bf49-53fc7a0766af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d42fab76-53ae-46cd-bb49-c6f04ddce75d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2444adaa-945c-42a5-bf49-53fc7a0766af" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d42fab76-53ae-46cd-bb49-c6f04ddce75d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_259f27aa-70c6-4066-a816-433c2eb053a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2444adaa-945c-42a5-bf49-53fc7a0766af" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_259f27aa-70c6-4066-a816-433c2eb053a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_974e0b30-7972-4cda-9a7e-85d141af6b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_974e0b30-7972-4cda-9a7e-85d141af6b5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_974e0b30-7972-4cda-9a7e-85d141af6b5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_974e0b30-7972-4cda-9a7e-85d141af6b5d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_974e0b30-7972-4cda-9a7e-85d141af6b5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e841c2dc-290d-4e9c-9bc2-06d4921e9fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_974e0b30-7972-4cda-9a7e-85d141af6b5d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e841c2dc-290d-4e9c-9bc2-06d4921e9fec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a80ff87e-7f31-445b-80e5-a9b556d927b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e841c2dc-290d-4e9c-9bc2-06d4921e9fec" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a80ff87e-7f31-445b-80e5-a9b556d927b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f32ada29-e485-4fa7-909f-4a209ca54c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e841c2dc-290d-4e9c-9bc2-06d4921e9fec" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f32ada29-e485-4fa7-909f-4a209ca54c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_82a66182-25f5-4140-b53b-5e98728f24e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_82a66182-25f5-4140-b53b-5e98728f24e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_82a66182-25f5-4140-b53b-5e98728f24e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_82a66182-25f5-4140-b53b-5e98728f24e6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_82a66182-25f5-4140-b53b-5e98728f24e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f757f985-7d56-4c75-9ccc-c6ffc5e9ba9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_82a66182-25f5-4140-b53b-5e98728f24e6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f757f985-7d56-4c75-9ccc-c6ffc5e9ba9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_784b367d-71d1-4492-8e7a-4ff5532ac5c3" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f757f985-7d56-4c75-9ccc-c6ffc5e9ba9a" xlink:to="loc_gild_ImmunomedicsIncMember_784b367d-71d1-4492-8e7a-4ff5532ac5c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ab9ee36-e308-464a-9c8a-f22055007c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ab9ee36-e308-464a-9c8a-f22055007c3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5ab9ee36-e308-464a-9c8a-f22055007c3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ab9ee36-e308-464a-9c8a-f22055007c3d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5ab9ee36-e308-464a-9c8a-f22055007c3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3bdf12dd-9c6b-41bf-b9b4-f506711e2759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ab9ee36-e308-464a-9c8a-f22055007c3d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3bdf12dd-9c6b-41bf-b9b4-f506711e2759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_ef1e0ac3-cb5a-45d8-ae97-ac2800c01d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3bdf12dd-9c6b-41bf-b9b4-f506711e2759" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_ef1e0ac3-cb5a-45d8-ae97-ac2800c01d8a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#FairValueMeasurementsSummaryofContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails" xlink:type="extended" id="i2e9ace753acc4b7b8f4cd13226445de2_FairValueMeasurementsSummaryofContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f8f5779-da50-4f59-9c11-b0e80f77b756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f8f5779-da50-4f59-9c11-b0e80f77b756" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4a538042-fd85-48a6-bb89-79857e3eb427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4a538042-fd85-48a6-bb89-79857e3eb427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8a9278d2-4475-4ae5-bc87-75e15e18359b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8a9278d2-4475-4ae5-bc87-75e15e18359b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6fd30e66-4ac4-47e0-b2a4-ea8650ff8f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6fd30e66-4ac4-47e0-b2a4-ea8650ff8f19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_4a48425b-0113-4f73-89de-3fb7ecf46341" xlink:href="gild-20221231.xsd#gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:to="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_4a48425b-0113-4f73-89de-3fb7ecf46341" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e22bf453-8831-44a1-b889-9c532c47a02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_70816147-39b3-4183-a3a5-7b0249f67e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f8f5779-da50-4f59-9c11-b0e80f77b756" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_70816147-39b3-4183-a3a5-7b0249f67e0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_8d27452e-be87-4634-adce-bbae1f70c13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_70816147-39b3-4183-a3a5-7b0249f67e0a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_8d27452e-be87-4634-adce-bbae1f70c13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8d27452e-be87-4634-adce-bbae1f70c13b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_8d27452e-be87-4634-adce-bbae1f70c13b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8d27452e-be87-4634-adce-bbae1f70c13b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c18f87ea-5d45-4977-82da-6fced2b0b6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_8d27452e-be87-4634-adce-bbae1f70c13b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c18f87ea-5d45-4977-82da-6fced2b0b6a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContingentConsiderationLiabilityMember_669b562b-1cc0-4621-b292-4dcf8416ef41" xlink:href="gild-20221231.xsd#gild_ContingentConsiderationLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c18f87ea-5d45-4977-82da-6fced2b0b6a5" xlink:to="loc_gild_ContingentConsiderationLiabilityMember_669b562b-1cc0-4621-b292-4dcf8416ef41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a93e0ced-4f8b-4743-a62f-d8ce1cd662ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_70816147-39b3-4183-a3a5-7b0249f67e0a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a93e0ced-4f8b-4743-a62f-d8ce1cd662ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a93e0ced-4f8b-4743-a62f-d8ce1cd662ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a93e0ced-4f8b-4743-a62f-d8ce1cd662ad" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a93e0ced-4f8b-4743-a62f-d8ce1cd662ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e42d5d30-0131-44ff-8bca-4a99971b56e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a93e0ced-4f8b-4743-a62f-d8ce1cd662ad" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e42d5d30-0131-44ff-8bca-4a99971b56e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_fc19de5d-e55d-423b-ad84-bd93a461be6a" xlink:href="gild-20221231.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e42d5d30-0131-44ff-8bca-4a99971b56e9" xlink:to="loc_gild_MYRGmbHMember_fc19de5d-e55d-423b-ad84-bd93a461be6a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended" id="i4749e217c8a84a5c9c44b930a527bfb1_AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1ac84f81-1e8e-487f-b89b-475073f95313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4c45b97c-a488-42ff-8b54-6c5bf15e3856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1ac84f81-1e8e-487f-b89b-475073f95313" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4c45b97c-a488-42ff-8b54-6c5bf15e3856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a07228d5-4ea0-4163-a167-c232b3bd7b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1ac84f81-1e8e-487f-b89b-475073f95313" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a07228d5-4ea0-4163-a167-c232b3bd7b65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_259050fe-9b7e-45cb-91c2-806d9d9e7c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1ac84f81-1e8e-487f-b89b-475073f95313" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_259050fe-9b7e-45cb-91c2-806d9d9e7c56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_58d3813f-387b-4b2a-ac21-989101dac677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1ac84f81-1e8e-487f-b89b-475073f95313" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_58d3813f-387b-4b2a-ac21-989101dac677" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c07fb7c4-a51c-464e-a4f7-571a64a56e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1ac84f81-1e8e-487f-b89b-475073f95313" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c07fb7c4-a51c-464e-a4f7-571a64a56e57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_94a4f81d-0c07-4beb-a08d-2af621ac1eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c07fb7c4-a51c-464e-a4f7-571a64a56e57" xlink:to="loc_us-gaap_FinancialInstrumentAxis_94a4f81d-0c07-4beb-a08d-2af621ac1eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94a4f81d-0c07-4beb-a08d-2af621ac1eb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_94a4f81d-0c07-4beb-a08d-2af621ac1eb2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_94a4f81d-0c07-4beb-a08d-2af621ac1eb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_94a4f81d-0c07-4beb-a08d-2af621ac1eb2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4620e716-ff70-495f-8c17-8361b9eedb21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4620e716-ff70-495f-8c17-8361b9eedb21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5434d609-db5c-481c-b784-459bb31fe88e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5434d609-db5c-481c-b784-459bb31fe88e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_8e8d2587-bcfe-43c9-a51a-1afd3ae94bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_8e8d2587-bcfe-43c9-a51a-1afd3ae94bf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7776e306-c819-48a4-b6a5-82e5e0cbb127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7776e306-c819-48a4-b6a5-82e5e0cbb127" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7daee531-2ff6-46c5-b16b-eaa2e458db43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7daee531-2ff6-46c5-b16b-eaa2e458db43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_bba18daf-7765-4c9e-864c-7d95b3cdedba" xlink:href="gild-20221231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_bba18daf-7765-4c9e-864c-7d95b3cdedba" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" xlink:type="extended" id="i5c8a84c50e904cd4bfb1edf990443e29_AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c4c52da4-9329-4725-9ded-c3af2564e6db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_39b0fae9-ebc1-42d4-8372-9bd44530cced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c4c52da4-9329-4725-9ded-c3af2564e6db" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_39b0fae9-ebc1-42d4-8372-9bd44530cced" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3ca547d0-ba03-434e-9452-c64531edb21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_39b0fae9-ebc1-42d4-8372-9bd44530cced" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3ca547d0-ba03-434e-9452-c64531edb21a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6bd82af2-4035-498b-86ed-2af0644a1b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_39b0fae9-ebc1-42d4-8372-9bd44530cced" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6bd82af2-4035-498b-86ed-2af0644a1b1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_31cb4425-6b20-44e1-8c6e-001c6bc48d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_39b0fae9-ebc1-42d4-8372-9bd44530cced" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_31cb4425-6b20-44e1-8c6e-001c6bc48d9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_3100892d-c39e-4e74-818f-fca9123480f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c4c52da4-9329-4725-9ded-c3af2564e6db" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_3100892d-c39e-4e74-818f-fca9123480f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_233dc9b5-c06c-4280-a737-568c47c7a0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_3100892d-c39e-4e74-818f-fca9123480f3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_233dc9b5-c06c-4280-a737-568c47c7a0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_03a771e7-4100-4741-81f2-2223604e97bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_3100892d-c39e-4e74-818f-fca9123480f3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_03a771e7-4100-4741-81f2-2223604e97bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0e278b21-f715-4301-bc2d-662b3d394a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_3100892d-c39e-4e74-818f-fca9123480f3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0e278b21-f715-4301-bc2d-662b3d394a36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57bab801-6d6c-4055-a473-772c4832924e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c4c52da4-9329-4725-9ded-c3af2564e6db" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57bab801-6d6c-4055-a473-772c4832924e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2ed68361-ff2b-4620-81f7-41b3e1f1e964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57bab801-6d6c-4055-a473-772c4832924e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2ed68361-ff2b-4620-81f7-41b3e1f1e964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2ed68361-ff2b-4620-81f7-41b3e1f1e964_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2ed68361-ff2b-4620-81f7-41b3e1f1e964" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2ed68361-ff2b-4620-81f7-41b3e1f1e964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2ed68361-ff2b-4620-81f7-41b3e1f1e964" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8a96c6d4-c271-4cdd-b937-be8d7b0fd700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8a96c6d4-c271-4cdd-b937-be8d7b0fd700" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6733641b-ac15-47ed-bbe2-65c68669279e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6733641b-ac15-47ed-bbe2-65c68669279e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_2a3deee1-9fa4-4f59-ae0b-3d5fdaa781c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_2a3deee1-9fa4-4f59-ae0b-3d5fdaa781c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6bf64bd4-1aae-40be-850e-b0143d2b9128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6bf64bd4-1aae-40be-850e-b0143d2b9128" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1183b78d-1306-4550-b867-321e9f145d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1183b78d-1306-4550-b867-321e9f145d18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_6c7f9e06-eba8-4c0d-9064-b90c1977e696" xlink:href="gild-20221231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_6c7f9e06-eba8-4c0d-9064-b90c1977e696" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails" xlink:type="extended" id="i97c3cca0e8994390939ad9c7f7f4cbdf_AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2d202bab-8e82-4251-8c0c-3910f5af2730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_1efc0dcd-f9a3-4907-8fbc-f0afad4d7343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2d202bab-8e82-4251-8c0c-3910f5af2730" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_1efc0dcd-f9a3-4907-8fbc-f0afad4d7343" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3c1a3e8-5916-44b9-bb93-12b67715580d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2d202bab-8e82-4251-8c0c-3910f5af2730" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3c1a3e8-5916-44b9-bb93-12b67715580d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_7ee7976b-32fd-4c45-9c91-3b6ab320b7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3c1a3e8-5916-44b9-bb93-12b67715580d" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_7ee7976b-32fd-4c45-9c91-3b6ab320b7c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_7ee7976b-32fd-4c45-9c91-3b6ab320b7c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_7ee7976b-32fd-4c45-9c91-3b6ab320b7c6" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_7ee7976b-32fd-4c45-9c91-3b6ab320b7c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3ad06a1a-9132-4118-995b-0f4918200a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_7ee7976b-32fd-4c45-9c91-3b6ab320b7c6" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3ad06a1a-9132-4118-995b-0f4918200a6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesDonationMember_e8394fc0-d228-452e-96ff-564febaa7e87" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesDonationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3ad06a1a-9132-4118-995b-0f4918200a6c" xlink:to="loc_gild_EquitySecuritiesDonationMember_e8394fc0-d228-452e-96ff-564febaa7e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31c53680-0410-46a2-b796-b70af5807c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3c1a3e8-5916-44b9-bb93-12b67715580d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31c53680-0410-46a2-b796-b70af5807c03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_31c53680-0410-46a2-b796-b70af5807c03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31c53680-0410-46a2-b796-b70af5807c03" xlink:to="loc_us-gaap_RelatedPartyDomain_31c53680-0410-46a2-b796-b70af5807c03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_02397305-e31f-4c91-ba3d-45e49685ea34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31c53680-0410-46a2-b796-b70af5807c03" xlink:to="loc_us-gaap_RelatedPartyDomain_02397305-e31f-4c91-ba3d-45e49685ea34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadFoundationMember_9065b88b-c533-415c-8e76-421903b5a074" xlink:href="gild-20221231.xsd#gild_GileadFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_02397305-e31f-4c91-ba3d-45e49685ea34" xlink:to="loc_gild_GileadFoundationMember_9065b88b-c533-415c-8e76-421903b5a074" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended" id="i329086c1e71a4bf4b333737295241f5b_AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af8ac5f9-c069-4bc0-aa5c-28b11571591f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ff6b56f8-9dd4-4f74-a15b-d014256c162d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af8ac5f9-c069-4bc0-aa5c-28b11571591f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ff6b56f8-9dd4-4f74-a15b-d014256c162d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5f03adc-3700-4e78-8126-7f3c9a9b65e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af8ac5f9-c069-4bc0-aa5c-28b11571591f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5f03adc-3700-4e78-8126-7f3c9a9b65e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2ba2a643-9ebd-452d-b04d-1ca5365663ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5f03adc-3700-4e78-8126-7f3c9a9b65e9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2ba2a643-9ebd-452d-b04d-1ca5365663ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2ba2a643-9ebd-452d-b04d-1ca5365663ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2ba2a643-9ebd-452d-b04d-1ca5365663ea" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2ba2a643-9ebd-452d-b04d-1ca5365663ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_24915fcb-ea6e-4953-9fd7-2674e5c25141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2ba2a643-9ebd-452d-b04d-1ca5365663ea" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_24915fcb-ea6e-4953-9fd7-2674e5c25141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_e8923aab-3620-48aa-9f6e-daed0a59f579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24915fcb-ea6e-4953-9fd7-2674e5c25141" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_e8923aab-3620-48aa-9f6e-daed0a59f579" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_e1f8aee2-b3e3-44a8-b223-11f370a90409" xlink:href="gild-20221231.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24915fcb-ea6e-4953-9fd7-2674e5c25141" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_e1f8aee2-b3e3-44a8-b223-11f370a90409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_dc319796-4c8e-409e-beae-e79b5c053513" xlink:href="gild-20221231.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24915fcb-ea6e-4953-9fd7-2674e5c25141" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_dc319796-4c8e-409e-beae-e79b5c053513" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended" id="i154356f3199448d293c31af5c7a1e7ad_AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc10c3d2-93d0-4930-bd99-ec4403415cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a7c4ff4b-99ce-4e86-b2f8-9596aaedb23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc10c3d2-93d0-4930-bd99-ec4403415cff" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a7c4ff4b-99ce-4e86-b2f8-9596aaedb23a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ec4cfe85-4da2-4d49-9048-db151830fa49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc10c3d2-93d0-4930-bd99-ec4403415cff" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ec4cfe85-4da2-4d49-9048-db151830fa49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36004d00-6332-4ccf-ae67-0ab71877f0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc10c3d2-93d0-4930-bd99-ec4403415cff" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36004d00-6332-4ccf-ae67-0ab71877f0c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_033c4956-4297-465d-9603-ddd1ba0db815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36004d00-6332-4ccf-ae67-0ab71877f0c8" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_033c4956-4297-465d-9603-ddd1ba0db815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_033c4956-4297-465d-9603-ddd1ba0db815_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_033c4956-4297-465d-9603-ddd1ba0db815" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_033c4956-4297-465d-9603-ddd1ba0db815_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d191ce0f-bfde-4163-b206-2bbb74b9a301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_033c4956-4297-465d-9603-ddd1ba0db815" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d191ce0f-bfde-4163-b206-2bbb74b9a301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_d52fed96-8153-4dd3-94e4-429223f6ce2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d191ce0f-bfde-4163-b206-2bbb74b9a301" xlink:to="loc_us-gaap_EquitySecuritiesMember_d52fed96-8153-4dd3-94e4-429223f6ce2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_45323a62-5711-4b6a-b7d1-e311dc002c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36004d00-6332-4ccf-ae67-0ab71877f0c8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_45323a62-5711-4b6a-b7d1-e311dc002c57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_45323a62-5711-4b6a-b7d1-e311dc002c57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_45323a62-5711-4b6a-b7d1-e311dc002c57" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_45323a62-5711-4b6a-b7d1-e311dc002c57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_eb9fe626-801d-4b0b-b45a-ea0584d5de37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_45323a62-5711-4b6a-b7d1-e311dc002c57" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_eb9fe626-801d-4b0b-b45a-ea0584d5de37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_2235cac1-c2ed-45bf-8661-fb8388bc1c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_eb9fe626-801d-4b0b-b45a-ea0584d5de37" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_2235cac1-c2ed-45bf-8661-fb8388bc1c3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_50f0bf83-a603-4986-9079-98f60eab01e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_eb9fe626-801d-4b0b-b45a-ea0584d5de37" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_50f0bf83-a603-4986-9079-98f60eab01e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_09e26721-94b6-4e18-b460-f57510be9503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_eb9fe626-801d-4b0b-b45a-ea0584d5de37" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_09e26721-94b6-4e18-b460-f57510be9503" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DerivativeFinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended" id="iea0566858c1c41be9662cf563380c780_DerivativeFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a7037efb-4ae8-4cda-930c-891bad0290d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_319337ae-fc43-4411-b609-72a9f8904767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a7037efb-4ae8-4cda-930c-891bad0290d5" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_319337ae-fc43-4411-b609-72a9f8904767" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_c7e4484e-fc62-41e9-bd17-0a2c91ffe6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a7037efb-4ae8-4cda-930c-891bad0290d5" xlink:to="loc_us-gaap_DerivativeNotionalAmount_c7e4484e-fc62-41e9-bd17-0a2c91ffe6e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_bf7f9fd0-6457-4ec8-a106-72a4f8911ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a7037efb-4ae8-4cda-930c-891bad0290d5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_bf7f9fd0-6457-4ec8-a106-72a4f8911ce3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_ccd0eb23-fb45-48d2-91b8-14d020dc9a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a7037efb-4ae8-4cda-930c-891bad0290d5" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_ccd0eb23-fb45-48d2-91b8-14d020dc9a12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f106248f-27bf-42d9-82c7-acb32c406120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_a7037efb-4ae8-4cda-930c-891bad0290d5" xlink:to="loc_us-gaap_DerivativeTable_f106248f-27bf-42d9-82c7-acb32c406120" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3b4e774a-9283-4495-b7a2-1836c13a0472" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f106248f-27bf-42d9-82c7-acb32c406120" xlink:to="loc_srt_RangeAxis_3b4e774a-9283-4495-b7a2-1836c13a0472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b4e774a-9283-4495-b7a2-1836c13a0472_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3b4e774a-9283-4495-b7a2-1836c13a0472" xlink:to="loc_srt_RangeMember_3b4e774a-9283-4495-b7a2-1836c13a0472_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_40ced589-0d01-4ff1-b5c8-3dcfd54d52b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3b4e774a-9283-4495-b7a2-1836c13a0472" xlink:to="loc_srt_RangeMember_40ced589-0d01-4ff1-b5c8-3dcfd54d52b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c6fec6b7-5073-4169-9406-7bbae62c4679" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_40ced589-0d01-4ff1-b5c8-3dcfd54d52b9" xlink:to="loc_srt_MaximumMember_c6fec6b7-5073-4169-9406-7bbae62c4679" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended" id="id869f39aadfe4216af54b353fe4a10ed_DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_4ecd5ea9-42ee-4d7b-baed-b5a8f654fa12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_4ecd5ea9-42ee-4d7b-baed-b5a8f654fa12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_52470f5a-dfda-427d-a035-e20047007050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_52470f5a-dfda-427d-a035-e20047007050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_4877f388-ae2f-4e56-a354-8d2a624280cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_4877f388-ae2f-4e56-a354-8d2a624280cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_0d85075e-6f86-4a04-bb45-1bfc0087efc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_0d85075e-6f86-4a04-bb45-1bfc0087efc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_81a5176b-49c3-481d-a94e-3d57602f247f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_81a5176b-49c3-481d-a94e-3d57602f247f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_5c349d4a-f35e-4e81-9963-f28774d315aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_5c349d4a-f35e-4e81-9963-f28774d315aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_3bd312e1-fa2f-47f2-9b20-1785825bb12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_3bd312e1-fa2f-47f2-9b20-1785825bb12b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_52d60c5c-ef2d-46d1-9e87-293b981580d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_52d60c5c-ef2d-46d1-9e87-293b981580d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_79ad46b0-f681-460a-9259-f0b870bc4e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_79ad46b0-f681-460a-9259-f0b870bc4e6a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_92216b71-b82a-4c50-9081-2a680ed0397b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_92216b71-b82a-4c50-9081-2a680ed0397b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0080bc96-19d5-4ec2-a40f-cbe1a6aabf16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0080bc96-19d5-4ec2-a40f-cbe1a6aabf16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_26515827-45d8-4260-9165-316274a9e756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0080bc96-19d5-4ec2-a40f-cbe1a6aabf16" xlink:to="loc_us-gaap_HedgingDesignationAxis_26515827-45d8-4260-9165-316274a9e756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_26515827-45d8-4260-9165-316274a9e756_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_26515827-45d8-4260-9165-316274a9e756" xlink:to="loc_us-gaap_HedgingDesignationDomain_26515827-45d8-4260-9165-316274a9e756_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2e9c475c-0360-4d8b-a2a3-559283bdbb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_26515827-45d8-4260-9165-316274a9e756" xlink:to="loc_us-gaap_HedgingDesignationDomain_2e9c475c-0360-4d8b-a2a3-559283bdbb2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9eb172ed-3b9e-4691-a790-11d23ce48b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2e9c475c-0360-4d8b-a2a3-559283bdbb2f" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9eb172ed-3b9e-4691-a790-11d23ce48b0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_609edcca-25ea-48d1-af3f-2011551a36ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2e9c475c-0360-4d8b-a2a3-559283bdbb2f" xlink:to="loc_us-gaap_NondesignatedMember_609edcca-25ea-48d1-af3f-2011551a36ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8af97805-39ef-44ac-8f49-bbed7a086581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0080bc96-19d5-4ec2-a40f-cbe1a6aabf16" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8af97805-39ef-44ac-8f49-bbed7a086581" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8af97805-39ef-44ac-8f49-bbed7a086581_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8af97805-39ef-44ac-8f49-bbed7a086581" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8af97805-39ef-44ac-8f49-bbed7a086581_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_62d5127f-8381-4352-8be8-250ade90e055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8af97805-39ef-44ac-8f49-bbed7a086581" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_62d5127f-8381-4352-8be8-250ade90e055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8b6b71fa-6a48-4169-9dd0-0727699e539d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_62d5127f-8381-4352-8be8-250ade90e055" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8b6b71fa-6a48-4169-9dd0-0727699e539d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_ee02a1b4-c65b-43b5-b6a1-2de74a3b964a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_62d5127f-8381-4352-8be8-250ade90e055" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_ee02a1b4-c65b-43b5-b6a1-2de74a3b964a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_6a9acf90-2011-4415-84cb-d39ffdc27d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_62d5127f-8381-4352-8be8-250ade90e055" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_6a9acf90-2011-4415-84cb-d39ffdc27d2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_99c47a4a-dec8-4ac2-8017-7a7ca3125340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_62d5127f-8381-4352-8be8-250ade90e055" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_99c47a4a-dec8-4ac2-8017-7a7ca3125340" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="extended" id="ia490dc4400b2442e87e239eb6486b92d_AcquisitionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForAssetAcquisitions_103a1211-1bfb-4fc8-ab81-14b9f2788e34" xlink:href="gild-20221231.xsd#gild_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_PaymentsForAssetAcquisitions_103a1211-1bfb-4fc8-ab81-14b9f2788e34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3e4cadb6-d3d0-42a1-9248-719eb18b7e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3e4cadb6-d3d0-42a1-9248-719eb18b7e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f34de86d-729a-4eae-84f1-e30c1a22316a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f34de86d-729a-4eae-84f1-e30c1a22316a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_53432cfd-7c61-47ca-af57-725196cbab17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_53432cfd-7c61-47ca-af57-725196cbab17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0af7ccf4-95c2-485d-adff-9a2cef07cac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0af7ccf4-95c2-485d-adff-9a2cef07cac4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_d934262f-aa1f-411d-838a-1df8dd03ff40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_d934262f-aa1f-411d-838a-1df8dd03ff40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f86ed65c-e3ec-4082-bffd-f0d7f6e23e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f86ed65c-e3ec-4082-bffd-f0d7f6e23e77" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_f9780b11-bebe-4e02-9711-2356cce7ae7c" xlink:href="gild-20221231.xsd#gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_f9780b11-bebe-4e02-9711-2356cce7ae7c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8c6f0c9d-a29c-471e-869a-b135da0505f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8c6f0c9d-a29c-471e-869a-b135da0505f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ef416ed8-06e4-4a73-8cfb-0cdd22eb75d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ef416ed8-06e4-4a73-8cfb-0cdd22eb75d7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_c87a694f-5858-49ef-b48d-945a7f5b8e78" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_c87a694f-5858-49ef-b48d-945a7f5b8e78" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_385c1eaf-63fd-4ca3-b6a7-35e5da9eadcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_GoodwillGross_385c1eaf-63fd-4ca3-b6a7-35e5da9eadcb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_e2a130f8-e063-4c15-8da1-2bda6022d9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_e2a130f8-e063-4c15-8da1-2bda6022d9b4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_1268afdc-1382-4ba0-b023-d4d314575da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_1268afdc-1382-4ba0-b023-d4d314575da1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5cc3dc79-c5a1-4305-83c3-7b0b3f330afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5cc3dc79-c5a1-4305-83c3-7b0b3f330afd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c8eb0b4b-6802-469b-b19e-3f010b7855da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c8eb0b4b-6802-469b-b19e-3f010b7855da" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_05a05905-709b-45af-b6b1-0259d72b338c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_05a05905-709b-45af-b6b1-0259d72b338c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_f9b93b22-2cfd-44c1-a184-f9c184de85dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_f9b93b22-2cfd-44c1-a184-f9c184de85dd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_b89f41d7-9285-4df6-90e1-71ecc60c09b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_b89f41d7-9285-4df6-90e1-71ecc60c09b9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_c1b61699-2317-4377-a8f8-920ac1535611" xlink:href="gild-20221231.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_c1b61699-2317-4377-a8f8-920ac1535611" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_66cc3cf4-b5e5-427d-8773-f6dcb98d5dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_66cc3cf4-b5e5-427d-8773-f6dcb98d5dce" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_8ca6dd0e-1f33-4f6d-b28f-7983d02ae4a3" xlink:href="gild-20221231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_8ca6dd0e-1f33-4f6d-b28f-7983d02ae4a3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_43d08146-bf21-4f76-955f-42059cffdcb3" xlink:href="gild-20221231.xsd#gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_43d08146-bf21-4f76-955f-42059cffdcb3" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired_1d2d85db-3ff6-4869-93d5-310e7d6d650c" xlink:href="gild-20221231.xsd#gild_PaymentsToAcquireAssetsNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired_1d2d85db-3ff6-4869-93d5-310e7d6d650c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1bc062a3-e949-48ce-9965-81fc0a6be304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1bc062a3-e949-48ce-9965-81fc0a6be304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_1bc062a3-e949-48ce-9965-81fc0a6be304_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1bc062a3-e949-48ce-9965-81fc0a6be304" xlink:to="loc_us-gaap_AssetAcquisitionDomain_1bc062a3-e949-48ce-9965-81fc0a6be304_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_332f1f66-aaef-41c4-8e03-56f936396815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1bc062a3-e949-48ce-9965-81fc0a6be304" xlink:to="loc_us-gaap_AssetAcquisitionDomain_332f1f66-aaef-41c4-8e03-56f936396815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MiroBioLtdMember_ef503a5a-922a-46d2-9818-3be19e8d9925" xlink:href="gild-20221231.xsd#gild_MiroBioLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_332f1f66-aaef-41c4-8e03-56f936396815" xlink:to="loc_gild_MiroBioLtdMember_ef503a5a-922a-46d2-9818-3be19e8d9925" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_c354f592-12c6-4060-b255-2e01f3dd8f58" xlink:href="gild-20221231.xsd#gild_FortySevenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_332f1f66-aaef-41c4-8e03-56f936396815" xlink:to="loc_gild_FortySevenIncMember_c354f592-12c6-4060-b255-2e01f3dd8f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7f6c46dc-6f79-4877-b466-d02b2247a84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7f6c46dc-6f79-4877-b466-d02b2247a84e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7f6c46dc-6f79-4877-b466-d02b2247a84e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7f6c46dc-6f79-4877-b466-d02b2247a84e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7f6c46dc-6f79-4877-b466-d02b2247a84e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e9fe52cc-8e0c-431b-be71-4ac8b9e98da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7f6c46dc-6f79-4877-b466-d02b2247a84e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e9fe52cc-8e0c-431b-be71-4ac8b9e98da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_f8e589a5-06fe-4f29-acb6-fe7c5b62de3f" xlink:href="gild-20221231.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e9fe52cc-8e0c-431b-be71-4ac8b9e98da5" xlink:to="loc_gild_MYRGmbHMember_f8e589a5-06fe-4f29-acb6-fe7c5b62de3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_d047308d-0eca-4023-8e20-eccdd701c06a" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e9fe52cc-8e0c-431b-be71-4ac8b9e98da5" xlink:to="loc_gild_ImmunomedicsIncMember_d047308d-0eca-4023-8e20-eccdd701c06a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f5a927d-bbd1-4811-9f19-c77af1d66938" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_srt_RangeAxis_3f5a927d-bbd1-4811-9f19-c77af1d66938" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f5a927d-bbd1-4811-9f19-c77af1d66938_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3f5a927d-bbd1-4811-9f19-c77af1d66938" xlink:to="loc_srt_RangeMember_3f5a927d-bbd1-4811-9f19-c77af1d66938_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_017ee3f9-f946-4f69-9f9b-fcbcc4ecfe8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3f5a927d-bbd1-4811-9f19-c77af1d66938" xlink:to="loc_srt_RangeMember_017ee3f9-f946-4f69-9f9b-fcbcc4ecfe8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_72e6c383-a0d1-42bc-9854-f92b135f75bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_017ee3f9-f946-4f69-9f9b-fcbcc4ecfe8a" xlink:to="loc_srt_MaximumMember_72e6c383-a0d1-42bc-9854-f92b135f75bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d2678689-dede-46f6-95c3-ff94c16cc9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d2678689-dede-46f6-95c3-ff94c16cc9fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d2678689-dede-46f6-95c3-ff94c16cc9fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d2678689-dede-46f6-95c3-ff94c16cc9fe" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d2678689-dede-46f6-95c3-ff94c16cc9fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_86b09e8c-ab10-462c-8601-8a64cc6df515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d2678689-dede-46f6-95c3-ff94c16cc9fe" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_86b09e8c-ab10-462c-8601-8a64cc6df515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_be0cc559-e205-41e4-80d1-849b9fefa553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_86b09e8c-ab10-462c-8601-8a64cc6df515" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_be0cc559-e205-41e4-80d1-849b9fefa553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_bd0f5103-9a14-4579-8ca3-f567e7c6b3f4" xlink:href="gild-20221231.xsd#gild_HepcludexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_86b09e8c-ab10-462c-8601-8a64cc6df515" xlink:to="loc_gild_HepcludexMember_bd0f5103-9a14-4579-8ca3-f567e7c6b3f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_21e17dd6-b38f-47ac-a71f-dd04074190ce" xlink:href="gild-20221231.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_86b09e8c-ab10-462c-8601-8a64cc6df515" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_21e17dd6-b38f-47ac-a71f-dd04074190ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54d435b6-7a05-44ff-b3ab-00f2bfd623d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54d435b6-7a05-44ff-b3ab-00f2bfd623d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54d435b6-7a05-44ff-b3ab-00f2bfd623d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54d435b6-7a05-44ff-b3ab-00f2bfd623d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54d435b6-7a05-44ff-b3ab-00f2bfd623d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0ba097c-429e-4c28-ad4d-49ac64900308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54d435b6-7a05-44ff-b3ab-00f2bfd623d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0ba097c-429e-4c28-ad4d-49ac64900308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_1ddd5802-6036-466a-83d5-61e347e73e4a" xlink:href="gild-20221231.xsd#gild_HepcludexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0ba097c-429e-4c28-ad4d-49ac64900308" xlink:to="loc_gild_HepcludexMember_1ddd5802-6036-466a-83d5-61e347e73e4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_0a536eb6-6c87-4c48-b904-8ddd59bff71c" xlink:href="gild-20221231.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0ba097c-429e-4c28-ad4d-49ac64900308" xlink:to="loc_gild_TrodelvyMember_0a536eb6-6c87-4c48-b904-8ddd59bff71c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_684976e9-f94f-406e-bbba-4ab997f76220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0ba097c-429e-4c28-ad4d-49ac64900308" xlink:to="loc_us-gaap_LicensingAgreementsMember_684976e9-f94f-406e-bbba-4ab997f76220" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_af6a0574-311c-481b-a118-afa252cd0972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_af6a0574-311c-481b-a118-afa252cd0972" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_af6a0574-311c-481b-a118-afa252cd0972_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_af6a0574-311c-481b-a118-afa252cd0972" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_af6a0574-311c-481b-a118-afa252cd0972_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0e1d3566-bd01-4ae7-84a9-93dc0b9dfd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_af6a0574-311c-481b-a118-afa252cd0972" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0e1d3566-bd01-4ae7-84a9-93dc0b9dfd0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d2ec5e76-adc8-4b23-b33f-c150fe9ded3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0e1d3566-bd01-4ae7-84a9-93dc0b9dfd0f" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d2ec5e76-adc8-4b23-b33f-c150fe9ded3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_54b4f128-f969-4633-ae8d-d9d5efb0f91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0e1d3566-bd01-4ae7-84a9-93dc0b9dfd0f" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_54b4f128-f969-4633-ae8d-d9d5efb0f91c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9a57bc4d-9ff5-41b7-be5c-987e765619c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9a57bc4d-9ff5-41b7-be5c-987e765619c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9a57bc4d-9ff5-41b7-be5c-987e765619c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9a57bc4d-9ff5-41b7-be5c-987e765619c9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9a57bc4d-9ff5-41b7-be5c-987e765619c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f3bd9de3-23c3-418a-b555-5e8de1703b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9a57bc4d-9ff5-41b7-be5c-987e765619c9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f3bd9de3-23c3-418a-b555-5e8de1703b47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_d5398859-783d-46b3-8b4b-8eddf62b6300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f3bd9de3-23c3-418a-b555-5e8de1703b47" xlink:to="loc_us-gaap_MediumTermNotesMember_d5398859-783d-46b3-8b4b-8eddf62b6300" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b6c0a2cc-1727-4bf9-ad73-7621651924ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_DebtInstrumentAxis_b6c0a2cc-1727-4bf9-ad73-7621651924ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b6c0a2cc-1727-4bf9-ad73-7621651924ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b6c0a2cc-1727-4bf9-ad73-7621651924ca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b6c0a2cc-1727-4bf9-ad73-7621651924ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e496909-9ae4-4fc7-91d0-4376b387365b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b6c0a2cc-1727-4bf9-ad73-7621651924ca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e496909-9ae4-4fc7-91d0-4376b387365b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_ee3e0861-0575-4b42-887e-b75923946f7d" xlink:href="gild-20221231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4e496909-9ae4-4fc7-91d0-4376b387365b" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_ee3e0861-0575-4b42-887e-b75923946f7d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="id3a44da208bb49d7b8d9ae2b589b5c74_AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0fd37daf-3385-4fef-bb9b-d1173840c11b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0fd37daf-3385-4fef-bb9b-d1173840c11b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_eecd80aa-ccbc-4a51-ae84-0ca35cc8c804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_eecd80aa-ccbc-4a51-ae84-0ca35cc8c804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e5766cfa-29cb-44ed-9efb-3f17b4337839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e5766cfa-29cb-44ed-9efb-3f17b4337839" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_84063e29-182b-4a9f-aaf5-4832ed161cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e5766cfa-29cb-44ed-9efb-3f17b4337839" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_84063e29-182b-4a9f-aaf5-4832ed161cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_b2bb39e5-9a33-48e9-b9c3-1786ccaaa5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e5766cfa-29cb-44ed-9efb-3f17b4337839" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_b2bb39e5-9a33-48e9-b9c3-1786ccaaa5e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e03100fa-2096-46e8-b622-2464a830592f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e03100fa-2096-46e8-b622-2464a830592f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_6d16b890-7593-4301-9545-067ff76e612b" xlink:href="gild-20221231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_6d16b890-7593-4301-9545-067ff76e612b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_ee98f739-32b6-4eb7-949b-90610e8c76e4" xlink:href="gild-20221231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_ee98f739-32b6-4eb7-949b-90610e8c76e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b96b0dc9-a79b-48df-88f4-43f6b7b6a313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b96b0dc9-a79b-48df-88f4-43f6b7b6a313" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_7fdd32c6-8257-452e-9b0b-b2ce97a7e364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_GoodwillGross_7fdd32c6-8257-452e-9b0b-b2ce97a7e364" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e36c6660-3636-471e-891e-553e43c453e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e36c6660-3636-471e-891e-553e43c453e6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f39ae95-bfa9-4ed6-970a-2922c8a784f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f39ae95-bfa9-4ed6-970a-2922c8a784f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f47b0185-854c-4b19-9df8-73b263bc9da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f39ae95-bfa9-4ed6-970a-2922c8a784f4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f47b0185-854c-4b19-9df8-73b263bc9da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f47b0185-854c-4b19-9df8-73b263bc9da8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f47b0185-854c-4b19-9df8-73b263bc9da8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f47b0185-854c-4b19-9df8-73b263bc9da8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65712cea-cbaa-4295-a651-8617311f2790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f47b0185-854c-4b19-9df8-73b263bc9da8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65712cea-cbaa-4295-a651-8617311f2790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_3950d0ad-b03f-4149-9769-a146196319dd" xlink:href="gild-20221231.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65712cea-cbaa-4295-a651-8617311f2790" xlink:to="loc_gild_MYRGmbHMember_3950d0ad-b03f-4149-9769-a146196319dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_db21c8a6-9221-461c-be2c-8479246b9578" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65712cea-cbaa-4295-a651-8617311f2790" xlink:to="loc_gild_ImmunomedicsIncMember_db21c8a6-9221-461c-be2c-8479246b9578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9b994086-05ac-4da5-be7c-53a520e802f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f39ae95-bfa9-4ed6-970a-2922c8a784f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9b994086-05ac-4da5-be7c-53a520e802f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b994086-05ac-4da5-be7c-53a520e802f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9b994086-05ac-4da5-be7c-53a520e802f1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9b994086-05ac-4da5-be7c-53a520e802f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff19bb1a-d2e5-4ecd-92d5-515d6eac1322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9b994086-05ac-4da5-be7c-53a520e802f1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff19bb1a-d2e5-4ecd-92d5-515d6eac1322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_a18f2608-ee3b-403c-b4e8-775f843307ec" xlink:href="gild-20221231.xsd#gild_HepcludexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff19bb1a-d2e5-4ecd-92d5-515d6eac1322" xlink:to="loc_gild_HepcludexMember_a18f2608-ee3b-403c-b4e8-775f843307ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_a65f4de7-cf3f-454c-b7b9-aa7b19beeaa9" xlink:href="gild-20221231.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff19bb1a-d2e5-4ecd-92d5-515d6eac1322" xlink:to="loc_gild_TrodelvyMember_a65f4de7-cf3f-454c-b7b9-aa7b19beeaa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_1dbf8075-c0db-4690-8f85-e3877dce0e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff19bb1a-d2e5-4ecd-92d5-515d6eac1322" xlink:to="loc_us-gaap_LicensingAgreementsMember_1dbf8075-c0db-4690-8f85-e3877dce0e9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5a82d82-6ec3-4a72-aefd-35b171d1a0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f39ae95-bfa9-4ed6-970a-2922c8a784f4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5a82d82-6ec3-4a72-aefd-35b171d1a0cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c5a82d82-6ec3-4a72-aefd-35b171d1a0cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5a82d82-6ec3-4a72-aefd-35b171d1a0cf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c5a82d82-6ec3-4a72-aefd-35b171d1a0cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c0795a7b-b3da-4cf8-b242-9b782d2ba805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5a82d82-6ec3-4a72-aefd-35b171d1a0cf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c0795a7b-b3da-4cf8-b242-9b782d2ba805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_33445b98-4fd3-4551-b22b-4f9bfa86c5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c0795a7b-b3da-4cf8-b242-9b782d2ba805" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_33445b98-4fd3-4551-b22b-4f9bfa86c5af" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended" id="i602c363888374969b148db647aa719a3_PropertyPlantandEquipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d95c5c5b-5878-4aa8-9832-e0dd8c484196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_8f38073c-a42e-4424-9214-fcf3209eb41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d95c5c5b-5878-4aa8-9832-e0dd8c484196" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_8f38073c-a42e-4424-9214-fcf3209eb41b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3177a864-e7b9-4bca-88de-e77a600e4a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d95c5c5b-5878-4aa8-9832-e0dd8c484196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3177a864-e7b9-4bca-88de-e77a600e4a20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0bdfc7c4-9888-4138-8496-c45d384cee76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d95c5c5b-5878-4aa8-9832-e0dd8c484196" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0bdfc7c4-9888-4138-8496-c45d384cee76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f5ad97d1-3760-4fab-91b7-82cbd5bf9f0a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0bdfc7c4-9888-4138-8496-c45d384cee76" xlink:to="loc_srt_StatementGeographicalAxis_f5ad97d1-3760-4fab-91b7-82cbd5bf9f0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f5ad97d1-3760-4fab-91b7-82cbd5bf9f0a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f5ad97d1-3760-4fab-91b7-82cbd5bf9f0a" xlink:to="loc_srt_SegmentGeographicalDomain_f5ad97d1-3760-4fab-91b7-82cbd5bf9f0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f1ab74ff-ae38-4562-8af2-f912d664d53b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f5ad97d1-3760-4fab-91b7-82cbd5bf9f0a" xlink:to="loc_srt_SegmentGeographicalDomain_f1ab74ff-ae38-4562-8af2-f912d664d53b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c9344e71-ca01-4d23-b93c-fb82d7bea21d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f1ab74ff-ae38-4562-8af2-f912d664d53b" xlink:to="loc_country_US_c9344e71-ca01-4d23-b93c-fb82d7bea21d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_c3a2dc60-b7b0-4f42-a144-4476bd727b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f1ab74ff-ae38-4562-8af2-f912d664d53b" xlink:to="loc_us-gaap_NonUsMember_c3a2dc60-b7b0-4f42-a144-4476bd727b51" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended" id="i2c20b7d994c2427ab623f9c57b933b0c_GoodwillandIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_a0331a8a-a594-4d59-954f-5c39f7038add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_a0331a8a-a594-4d59-954f-5c39f7038add" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_a0206d99-4d0e-40e8-9976-c8038fd02673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_a0206d99-4d0e-40e8-9976-c8038fd02673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_89afa668-463d-4853-bc09-50d2bfda3f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_89afa668-463d-4853-bc09-50d2bfda3f56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_f3a013ac-7bbd-4e24-a98e-451749942be2" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_f3a013ac-7bbd-4e24-a98e-451749942be2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_fab1b5ac-3944-4a66-b08f-c77592a5dae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_fab1b5ac-3944-4a66-b08f-c77592a5dae8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_88cfd20e-19eb-4303-9f27-2de2e2309118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_88cfd20e-19eb-4303-9f27-2de2e2309118" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput_76422553-c6cf-4eed-9911-8f39f03c742a" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput_76422553-c6cf-4eed-9911-8f39f03c742a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0efc8810-0d66-4219-a666-7787d3168ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0efc8810-0d66-4219-a666-7787d3168ea2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9ab6a9c0-da47-4be7-b023-50b43a19fcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9ab6a9c0-da47-4be7-b023-50b43a19fcb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9ab6a9c0-da47-4be7-b023-50b43a19fcb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9ab6a9c0-da47-4be7-b023-50b43a19fcb5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9ab6a9c0-da47-4be7-b023-50b43a19fcb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6463662e-df5d-4c10-8df4-1f2dd6104df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9ab6a9c0-da47-4be7-b023-50b43a19fcb5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6463662e-df5d-4c10-8df4-1f2dd6104df0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_c778d906-9905-4207-af41-b5a786c2c966" xlink:href="gild-20221231.xsd#gild_MYRGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6463662e-df5d-4c10-8df4-1f2dd6104df0" xlink:to="loc_gild_MYRGmbHMember_c778d906-9905-4207-af41-b5a786c2c966" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_dbbb481a-cb7c-4526-b7a9-f00013a77d4e" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6463662e-df5d-4c10-8df4-1f2dd6104df0" xlink:to="loc_gild_ImmunomedicsIncMember_dbbb481a-cb7c-4526-b7a9-f00013a77d4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_db67ec6f-088c-4d26-9ef9-495c1c4ca38d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_db67ec6f-088c-4d26-9ef9-495c1c4ca38d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_db67ec6f-088c-4d26-9ef9-495c1c4ca38d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_db67ec6f-088c-4d26-9ef9-495c1c4ca38d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_db67ec6f-088c-4d26-9ef9-495c1c4ca38d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8d289859-2dec-415f-a398-3128075974fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_db67ec6f-088c-4d26-9ef9-495c1c4ca38d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8d289859-2dec-415f-a398-3128075974fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_eb1a6f30-9866-48aa-9bb7-8de7430b41ea" xlink:href="gild-20221231.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8d289859-2dec-415f-a398-3128075974fb" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_eb1a6f30-9866-48aa-9bb7-8de7430b41ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_74a83209-216b-40e1-9157-5eb50f550fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_74a83209-216b-40e1-9157-5eb50f550fca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_74a83209-216b-40e1-9157-5eb50f550fca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_74a83209-216b-40e1-9157-5eb50f550fca" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_74a83209-216b-40e1-9157-5eb50f550fca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_002f1ded-95f6-4e29-bf00-0dff8df76242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_74a83209-216b-40e1-9157-5eb50f550fca" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_002f1ded-95f6-4e29-bf00-0dff8df76242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_336e9ac3-1a00-4c07-a00a-cf41470365dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_002f1ded-95f6-4e29-bf00-0dff8df76242" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_336e9ac3-1a00-4c07-a00a-cf41470365dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04a98172-6431-4110-86cb-8ff4ef144379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04a98172-6431-4110-86cb-8ff4ef144379" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_04a98172-6431-4110-86cb-8ff4ef144379_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04a98172-6431-4110-86cb-8ff4ef144379" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_04a98172-6431-4110-86cb-8ff4ef144379_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5c644b7c-bf58-4db3-b6fa-6f1fbc68fbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04a98172-6431-4110-86cb-8ff4ef144379" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5c644b7c-bf58-4db3-b6fa-6f1fbc68fbbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_edba6aee-c861-4406-b9de-c8c2356f56af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5c644b7c-bf58-4db3-b6fa-6f1fbc68fbbe" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_edba6aee-c861-4406-b9de-c8c2356f56af" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" xlink:type="extended" id="iaba2afe69c3141299fe31c744df88d80_GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_741506fd-89b6-4b8f-b9ec-1b616c5d484a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_741506fd-89b6-4b8f-b9ec-1b616c5d484a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_06453adb-3e38-4e24-a698-f151d612fd24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_06453adb-3e38-4e24-a698-f151d612fd24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_51c06903-ff1d-4270-8b61-886da8b92521" xlink:href="gild-20221231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_51c06903-ff1d-4270-8b61-886da8b92521" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41a0850-650b-496b-be9c-a9cccd887ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41a0850-650b-496b-be9c-a9cccd887ed6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c1615472-fa63-49c1-917e-821fc20df718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c1615472-fa63-49c1-917e-821fc20df718" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_55e40f0a-47bf-446e-8e37-6bd53a91fd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c1615472-fa63-49c1-917e-821fc20df718" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_55e40f0a-47bf-446e-8e37-6bd53a91fd79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_c1444b87-87bc-421c-a873-6529a898f5aa" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c1615472-fa63-49c1-917e-821fc20df718" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_c1444b87-87bc-421c-a873-6529a898f5aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_40f346d3-0d52-4bce-a894-4c6ad8b6f312" xlink:href="gild-20221231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c1615472-fa63-49c1-917e-821fc20df718" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_40f346d3-0d52-4bce-a894-4c6ad8b6f312" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8fd6c9fb-622e-41dc-a90d-b596f2daa85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8fd6c9fb-622e-41dc-a90d-b596f2daa85e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e75a3aec-d0c4-4464-aa1a-6ef10284777b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8fd6c9fb-622e-41dc-a90d-b596f2daa85e" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e75a3aec-d0c4-4464-aa1a-6ef10284777b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_21617700-493e-4fcf-956f-2b69dbf5ed62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_50a036f9-79e8-4eb2-8a84-856e02fec85c" xlink:href="gild-20221231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8fd6c9fb-622e-41dc-a90d-b596f2daa85e" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_50a036f9-79e8-4eb2-8a84-856e02fec85c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a152e74c-e85e-43b0-9362-922d75e8305c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8fd6c9fb-622e-41dc-a90d-b596f2daa85e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a152e74c-e85e-43b0-9362-922d75e8305c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_57b88116-bd27-46c1-b755-b1ec8c5b8384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_57b88116-bd27-46c1-b755-b1ec8c5b8384" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_84d214e0-8dc1-425a-977c-550501324319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_84d214e0-8dc1-425a-977c-550501324319" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ea82376-110a-47dc-b3ad-211c9c64bd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_84d214e0-8dc1-425a-977c-550501324319" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ea82376-110a-47dc-b3ad-211c9c64bd8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ea82376-110a-47dc-b3ad-211c9c64bd8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ea82376-110a-47dc-b3ad-211c9c64bd8b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6ea82376-110a-47dc-b3ad-211c9c64bd8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ea82376-110a-47dc-b3ad-211c9c64bd8b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_e8590daa-6533-429e-a5e5-43f3940e681e" xlink:href="gild-20221231.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_e8590daa-6533-429e-a5e5-43f3940e681e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember_9a3299d8-4d3d-42e8-abb5-1f6e510902ce" xlink:href="gild-20221231.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:to="loc_gild_AxicabtageneciloleucelDLBCLMember_9a3299d8-4d3d-42e8-abb5-1f6e510902ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_380b3720-3ab7-492f-9b15-82a4de211bae" xlink:href="gild-20221231.xsd#gild_TrodelvyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:to="loc_gild_TrodelvyMember_380b3720-3ab7-492f-9b15-82a4de211bae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_ae452856-1ace-451a-a547-53d5d592031f" xlink:href="gild-20221231.xsd#gild_HepcludexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:to="loc_gild_HepcludexMember_ae452856-1ace-451a-a547-53d5d592031f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_7a4e60d6-449f-4624-bd8d-4dd7b438ad60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_7a4e60d6-449f-4624-bd8d-4dd7b438ad60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4303468b-9008-4128-ad9c-0e90d5a4d9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_84d214e0-8dc1-425a-977c-550501324319" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4303468b-9008-4128-ad9c-0e90d5a4d9dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4303468b-9008-4128-ad9c-0e90d5a4d9dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4303468b-9008-4128-ad9c-0e90d5a4d9dd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4303468b-9008-4128-ad9c-0e90d5a4d9dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_254fc3bf-8eaa-415f-8d61-3c604af3de04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4303468b-9008-4128-ad9c-0e90d5a4d9dd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_254fc3bf-8eaa-415f-8d61-3c604af3de04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_cd4cf98e-9291-4a6d-bc67-ca1dcf0712b2" xlink:href="gild-20221231.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_254fc3bf-8eaa-415f-8d61-3c604af3de04" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_cd4cf98e-9291-4a6d-bc67-ca1dcf0712b2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended" id="i25d47b19b56e4281a51d40f6327a8d3e_OtherFinancialInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleOfInventoryLineItems_0ca68545-779a-4b96-9dc5-444736ac572c" xlink:href="gild-20221231.xsd#gild_ScheduleOfInventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0caf2504-4ecd-4b9f-bfe3-f01040605160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ScheduleOfInventoryLineItems_0ca68545-779a-4b96-9dc5-444736ac572c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0caf2504-4ecd-4b9f-bfe3-f01040605160" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable_811d85b1-5175-473d-a858-d4b64c8d9ebe" xlink:href="gild-20221231.xsd#gild_ScheduleofInventoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_gild_ScheduleOfInventoryLineItems_0ca68545-779a-4b96-9dc5-444736ac572c" xlink:to="loc_gild_ScheduleofInventoryTable_811d85b1-5175-473d-a858-d4b64c8d9ebe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_103b3435-462f-4187-9015-903135944997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_gild_ScheduleofInventoryTable_811d85b1-5175-473d-a858-d4b64c8d9ebe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_103b3435-462f-4187-9015-903135944997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_103b3435-462f-4187-9015-903135944997_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_103b3435-462f-4187-9015-903135944997" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_103b3435-462f-4187-9015-903135944997_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a1f38b51-33da-4657-a03c-26ad918b22b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_103b3435-462f-4187-9015-903135944997" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a1f38b51-33da-4657-a03c-26ad918b22b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_316927a4-cab9-46b0-8f1f-60d5dde3b2a4" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a1f38b51-33da-4657-a03c-26ad918b22b9" xlink:to="loc_gild_ImmunomedicsIncMember_316927a4-cab9-46b0-8f1f-60d5dde3b2a4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended" id="i721edf45b9b54225a1ed3be1b8e2b782_CollaborationsandOtherArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_d8781734-f57b-4b85-ba3c-b5e36a73d999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_d8781734-f57b-4b85-ba3c-b5e36a73d999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment_dc903cf5-cd7e-4c9d-a0ea-38fe6add55c7" xlink:href="gild-20221231.xsd#gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment_dc903cf5-cd7e-4c9d-a0ea-38fe6add55c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum_58f0fd74-2832-4f2d-aa36-c1d62007aa0d" xlink:href="gild-20221231.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PotentialFutureMilestonePaymentsMaximum_58f0fd74-2832-4f2d-aa36-c1d62007aa0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_204fbf34-dab1-45b6-b5d8-1b55b514c3d4" xlink:href="gild-20221231.xsd#gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_204fbf34-dab1-45b6-b5d8-1b55b514c3d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementNetProductSalesThreshold_946b1e87-cfc0-489d-b785-d017ee3e4172" xlink:href="gild-20221231.xsd#gild_CollaborationArrangementNetProductSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborationArrangementNetProductSalesThreshold_946b1e87-cfc0-489d-b785-d017ee3e4172" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_78ad026e-02bb-4dfa-8f14-4adf527b9d16" xlink:href="gild-20221231.xsd#gild_CollaborationArrangementPercentOfGlobalProductRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_78ad026e-02bb-4dfa-8f14-4adf527b9d16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_07eacabe-89dd-4f87-8221-0c9931e401df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_07eacabe-89dd-4f87-8221-0c9931e401df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_310b3e79-9a1f-47a9-802f-f509d049e2bf" xlink:href="gild-20221231.xsd#gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_310b3e79-9a1f-47a9-802f-f509d049e2bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InvestmentOwnedBalanceAdditionalShares_c331ef45-b0d0-434a-a4d1-ea067f937bb2" xlink:href="gild-20221231.xsd#gild_InvestmentOwnedBalanceAdditionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_InvestmentOwnedBalanceAdditionalShares_c331ef45-b0d0-434a-a4d1-ea067f937bb2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_02e7d257-7ae3-4a57-a28e-25ff64a31497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_02e7d257-7ae3-4a57-a28e-25ff64a31497" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalUpfrontPaymentsMade_00ed8a1f-30a4-4732-b17c-ffef9a169f70" xlink:href="gild-20221231.xsd#gild_TotalUpfrontPaymentsMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_TotalUpfrontPaymentsMade_00ed8a1f-30a4-4732-b17c-ffef9a169f70" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_bb44abcc-1966-44e7-b347-d8da7f795963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_bb44abcc-1966-44e7-b347-d8da7f795963" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c098e565-7540-49d5-b512-876795a09d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c098e565-7540-49d5-b512-876795a09d5f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IssuanceDiscountPremium_e9236bc1-3146-4247-95f2-a5365400ed75" xlink:href="gild-20221231.xsd#gild_IssuanceDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_IssuanceDiscountPremium_e9236bc1-3146-4247-95f2-a5365400ed75" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForDirectTransactionalExpense_5e0131ff-da7d-47b0-8c61-a219c3700de5" xlink:href="gild-20221231.xsd#gild_PaymentsForDirectTransactionalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PaymentsForDirectTransactionalExpense_5e0131ff-da7d-47b0-8c61-a219c3700de5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_2a97e9b7-6042-4583-8b52-102042714e27" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_2a97e9b7-6042-4583-8b52-102042714e27" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod_4554ef25-749d-4986-8828-91931c06b237" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNIPurchasePeriod_4554ef25-749d-4986-8828-91931c06b237" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_a5db2fab-798a-46a6-a763-0768fa06a242" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_a5db2fab-798a-46a6-a763-0768fa06a242" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_0474356c-4128-47f1-8021-45e532cf7c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_0474356c-4128-47f1-8021-45e532cf7c46" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNISharesAcquired_ff66888d-508f-4d30-b0c6-960af66e7193" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNISharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNISharesAcquired_ff66888d-508f-4d30-b0c6-960af66e7193" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIShares_0ddc4546-af32-479e-aac9-128c4c7281d1" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNIShares_0ddc4546-af32-479e-aac9-128c4c7281d1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5a841fe1-c23a-48ad-858d-64a379129e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5a841fe1-c23a-48ad-858d-64a379129e01" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementOptInTerm_2aa2fcf9-e413-4206-bc3d-7063a1d86702" xlink:href="gild-20221231.xsd#gild_CollaborativeAgreementOptInTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborativeAgreementOptInTerm_2aa2fcf9-e413-4206-bc3d-7063a1d86702" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions_19c51fe0-88ef-4d5b-bce5-c5f0e9e17298" xlink:href="gild-20221231.xsd#gild_NumberOfClinicalStageProgramsWithExercisedOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions_19c51fe0-88ef-4d5b-bce5-c5f0e9e17298" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToOptInTheCollaborativeAgreement_a00d10a7-f1bb-43dd-9d4e-9a71ea800256" xlink:href="gild-20221231.xsd#gild_PaymentsToOptInTheCollaborativeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PaymentsToOptInTheCollaborativeAgreement_a00d10a7-f1bb-43dd-9d4e-9a71ea800256" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_d481a160-326c-492c-a86b-c8b974a7d019" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_d481a160-326c-492c-a86b-c8b974a7d019" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ef03f52d-678d-41dd-8f6e-14ed2b5db646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ef03f52d-678d-41dd-8f6e-14ed2b5db646" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e15fb96f-6cf1-4989-82e0-11d7c1257c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e15fb96f-6cf1-4989-82e0-11d7c1257c70" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_4775a422-fa8a-41ff-8fed-8195ff4e79f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_4775a422-fa8a-41ff-8fed-8195ff4e79f0" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_93e5bc97-929a-4b8e-9da8-de5ad280e3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_EquityMethodInvestments_93e5bc97-929a-4b8e-9da8-de5ad280e3cd" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_fb00050d-a7a7-4a9c-9c77-cae622f23927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_fb00050d-a7a7-4a9c-9c77-cae622f23927" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionExerciseFee_9d7d7a6b-f998-47af-8191-b10cdf8a363b" xlink:href="gild-20221231.xsd#gild_EquityMethodInvestmentOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquityMethodInvestmentOptionExerciseFee_9d7d7a6b-f998-47af-8191-b10cdf8a363b" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentFutureMaximumPayments_0a1d1482-1c65-4d84-8eeb-2ed7ff2df85e" xlink:href="gild-20221231.xsd#gild_ResearchAndDevelopmentFutureMaximumPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_ResearchAndDevelopmentFutureMaximumPayments_0a1d1482-1c65-4d84-8eeb-2ed7ff2df85e" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdditionalResearchAndDevelopmentInProcess_66d0a88c-d5b6-45b3-862a-32133783408b" xlink:href="gild-20221231.xsd#gild_AdditionalResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_AdditionalResearchAndDevelopmentInProcess_66d0a88c-d5b6-45b3-862a-32133783408b" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_d6a6ef4e-e922-4619-b411-67c37e0dd952" xlink:href="gild-20221231.xsd#gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_d6a6ef4e-e922-4619-b411-67c37e0dd952" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_e48321e6-f623-4c4d-9f12-465f3c7cde14" xlink:href="gild-20221231.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_e48321e6-f623-4c4d-9f12-465f3c7cde14" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfPrograms_e4fbaf7f-2ff0-439f-9e86-a196429b4b62" xlink:href="gild-20221231.xsd#gild_NumberOfPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_NumberOfPrograms_e4fbaf7f-2ff0-439f-9e86-a196429b4b62" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeArrangementTerm_4ae5ee93-dd81-477f-afcd-6772f733f68c" xlink:href="gild-20221231.xsd#gild_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborativeArrangementTerm_4ae5ee93-dd81-477f-afcd-6772f733f68c" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_9f8b2596-afeb-4a4e-8e7c-936112347da7" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_9f8b2596-afeb-4a4e-8e7c-936112347da7" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_a50afe01-8aba-4cec-b770-bb67f2014179" xlink:href="gild-20221231.xsd#gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_a50afe01-8aba-4cec-b770-bb67f2014179" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_ce4446e2-ca45-4be3-ac4a-f2bfd55167f6" xlink:href="gild-20221231.xsd#gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_ce4446e2-ca45-4be3-ac4a-f2bfd55167f6" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_d5090eab-935a-42e2-8daf-c418f91f3142" xlink:href="gild-20221231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_d5090eab-935a-42e2-8daf-c418f91f3142" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_b02d36a0-bd92-496b-9054-0a45b4b76132" xlink:href="gild-20221231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_b02d36a0-bd92-496b-9054-0a45b4b76132" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement_74e93f83-3e14-4e8f-940e-70f9263831ed" xlink:href="gild-20221231.xsd#gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement_74e93f83-3e14-4e8f-940e-70f9263831ed" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_StandstillRestrictingTerm_d7b3f6b7-beb5-480f-96b9-ba5e5bf1f4f7" xlink:href="gild-20221231.xsd#gild_StandstillRestrictingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_StandstillRestrictingTerm_d7b3f6b7-beb5-480f-96b9-ba5e5bf1f4f7" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_30c08a96-2867-4c8f-9b81-064eb1f3add9" xlink:href="gild-20221231.xsd#gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_30c08a96-2867-4c8f-9b81-064eb1f3add9" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialOptionExerciseFeePerProgram_757d89ee-9257-46e8-8496-30f088423299" xlink:href="gild-20221231.xsd#gild_PotentialOptionExerciseFeePerProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PotentialOptionExerciseFeePerProgram_757d89ee-9257-46e8-8496-30f088423299" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_cfae79a0-4c1e-49cc-8542-297a75da8216" xlink:href="gild-20221231.xsd#gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_cfae79a0-4c1e-49cc-8542-297a75da8216" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_002b7fba-1f13-41dd-82a7-1e9b4455a02e" xlink:href="gild-20221231.xsd#gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_002b7fba-1f13-41dd-82a7-1e9b4455a02e" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage_75682106-cf43-4310-b9f0-8d4963ef98dd" xlink:href="gild-20221231.xsd#gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage_75682106-cf43-4310-b9f0-8d4963ef98dd" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_66ced04e-97ac-4d2a-9c27-2ea48e6e11ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_66ced04e-97ac-4d2a-9c27-2ea48e6e11ca" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_b2a85f8d-69ed-4f08-80bf-2b3638a10971" xlink:href="gild-20221231.xsd#gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_b2a85f8d-69ed-4f08-80bf-2b3638a10971" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_1aa96cf0-b18d-4e6e-8a44-dbf1c71993ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_RoyaltyExpense_1aa96cf0-b18d-4e6e-8a44-dbf1c71993ae" xlink:type="arc" order="52"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan_548e3b91-3699-483d-91fc-859cf0dabcca" xlink:href="gild-20221231.xsd#gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan_548e3b91-3699-483d-91fc-859cf0dabcca" xlink:type="arc" order="53"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_c30bec8c-9839-4f75-9aec-e39f34041d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_c30bec8c-9839-4f75-9aec-e39f34041d0d" xlink:type="arc" order="54"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_69024f05-bf43-4ab4-8397-e5feaa60982c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_69024f05-bf43-4ab4-8397-e5feaa60982c" xlink:type="arc" order="55"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_82b88c9f-73d5-446a-817b-865be80dbbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_82b88c9f-73d5-446a-817b-865be80dbbcf" xlink:type="arc" order="56"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontPaymentsToTerminatePreviousAgreement_5ee52ec4-8912-4046-91df-5edfeb7f16c6" xlink:href="gild-20221231.xsd#gild_UpfrontPaymentsToTerminatePreviousAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_UpfrontPaymentsToTerminatePreviousAgreement_5ee52ec4-8912-4046-91df-5edfeb7f16c6" xlink:type="arc" order="57"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToTerminatePreviousAgreement_35f09bf4-11d6-4e0c-b1e6-0ae123260644" xlink:href="gild-20221231.xsd#gild_PaymentsToTerminatePreviousAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PaymentsToTerminatePreviousAgreement_35f09bf4-11d6-4e0c-b1e6-0ae123260644" xlink:type="arc" order="58"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b398ff6c-8e37-4749-8a33-e6bb5908db1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b398ff6c-8e37-4749-8a33-e6bb5908db1e" xlink:type="arc" order="59"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant_d65cc0bc-e76b-48ed-81bc-f86ce212564c" xlink:href="gild-20221231.xsd#gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant_d65cc0bc-e76b-48ed-81bc-f86ce212564c" xlink:type="arc" order="60"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a1af53b3-5bda-4754-9ed3-88b8fe5822fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_srt_CounterpartyNameAxis_a1af53b3-5bda-4754-9ed3-88b8fe5822fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a1af53b3-5bda-4754-9ed3-88b8fe5822fe_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a1af53b3-5bda-4754-9ed3-88b8fe5822fe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a1af53b3-5bda-4754-9ed3-88b8fe5822fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab9ff633-ecd0-43ca-beb8-79d49bc8cff8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a1af53b3-5bda-4754-9ed3-88b8fe5822fe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab9ff633-ecd0-43ca-beb8-79d49bc8cff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DragonflyTherapeuticsIncMember_919383ba-c651-43ce-8417-c362e8c5bd1c" xlink:href="gild-20221231.xsd#gild_DragonflyTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab9ff633-ecd0-43ca-beb8-79d49bc8cff8" xlink:to="loc_gild_DragonflyTherapeuticsIncMember_919383ba-c651-43ce-8417-c362e8c5bd1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EverestMedicinesMember_65d58eaf-367c-440c-89b6-a72c010af5be" xlink:href="gild-20221231.xsd#gild_EverestMedicinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab9ff633-ecd0-43ca-beb8-79d49bc8cff8" xlink:to="loc_gild_EverestMedicinesMember_65d58eaf-367c-440c-89b6-a72c010af5be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d70f478c-5ee1-465f-9b06-cc5c7d8be579" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d70f478c-5ee1-465f-9b06-cc5c7d8be579" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d70f478c-5ee1-465f-9b06-cc5c7d8be579_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d70f478c-5ee1-465f-9b06-cc5c7d8be579" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d70f478c-5ee1-465f-9b06-cc5c7d8be579_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d70f478c-5ee1-465f-9b06-cc5c7d8be579" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_e0251d73-51ae-4560-8d70-3d51ec8d3834" xlink:href="gild-20221231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:to="loc_gild_ArcusBiosciencesIncMember_e0251d73-51ae-4560-8d70-3d51ec8d3834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrImmunotherapeuticsIncMember_6359bd82-30f6-4711-8def-444637609c64" xlink:href="gild-20221231.xsd#gild_PionyrImmunotherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:to="loc_gild_PionyrImmunotherapeuticsIncMember_6359bd82-30f6-4711-8def-444637609c64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaTherapeuticsIncMember_2e9a01ac-c7c1-427e-a40b-dbfa43beb21f" xlink:href="gild-20221231.xsd#gild_TizonaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:to="loc_gild_TizonaTherapeuticsIncMember_2e9a01ac-c7c1-427e-a40b-dbfa43beb21f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember_8004b1d8-3cd7-40f1-88f6-50c3f83b0186" xlink:href="gild-20221231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:to="loc_gild_TangoTherapeuticsIncMember_8004b1d8-3cd7-40f1-88f6-50c3f83b0186" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember_a6a109f8-5bf9-47bc-a9f6-8746046abb8f" xlink:href="gild-20221231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:to="loc_gild_JounceTherapeuticsIncMember_a6a109f8-5bf9-47bc-a9f6-8746046abb8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_85dd756a-516e-4e8a-aacd-0fd98cb5c440" xlink:href="gild-20221231.xsd#gild_GalapagosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:to="loc_gild_GalapagosMember_85dd756a-516e-4e8a-aacd-0fd98cb5c440" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dfa6038a-1194-45e9-8586-f9e408478ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dfa6038a-1194-45e9-8586-f9e408478ba8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dfa6038a-1194-45e9-8586-f9e408478ba8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dfa6038a-1194-45e9-8586-f9e408478ba8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dfa6038a-1194-45e9-8586-f9e408478ba8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dfa6038a-1194-45e9-8586-f9e408478ba8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DragonflyTherapeuticsCollaborationAgreementMember_e1db7b88-50b6-4a92-afc9-80b0ffbdee04" xlink:href="gild-20221231.xsd#gild_DragonflyTherapeuticsCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_DragonflyTherapeuticsCollaborationAgreementMember_e1db7b88-50b6-4a92-afc9-80b0ffbdee04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_b2c5ff39-39c6-43f5-b0bf-1e95553920e7" xlink:href="gild-20221231.xsd#gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_b2c5ff39-39c6-43f5-b0bf-1e95553920e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_943f5db5-61ef-4bfb-844b-8b7159769029" xlink:href="gild-20221231.xsd#gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_943f5db5-61ef-4bfb-844b-8b7159769029" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember_dbb2dca4-cf30-48f3-9047-23297cd265c5" xlink:href="gild-20221231.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_ArcusStockPurchaseAgreementMember_dbb2dca4-cf30-48f3-9047-23297cd265c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementMember_4d2386ac-ed5b-420f-89dc-771feaebc210" xlink:href="gild-20221231.xsd#gild_ArcusCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_ArcusCollaborationAgreementMember_4d2386ac-ed5b-420f-89dc-771feaebc210" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrMergerAndOptionAgreementsMember_7468adb3-3791-440c-961e-a6b6a2b927a6" xlink:href="gild-20221231.xsd#gild_PionyrMergerAndOptionAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_PionyrMergerAndOptionAgreementsMember_7468adb3-3791-440c-961e-a6b6a2b927a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentServiceAgreementMember_ea3ba795-d8a1-4767-af8c-da46a684fd6d" xlink:href="gild-20221231.xsd#gild_ResearchAndDevelopmentServiceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_ResearchAndDevelopmentServiceAgreementMember_ea3ba795-d8a1-4767-af8c-da46a684fd6d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaMergerAndOptionAgreementsMember_76f5c102-0236-470c-ab76-e88e65ef8a0d" xlink:href="gild-20221231.xsd#gild_TizonaMergerAndOptionAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_TizonaMergerAndOptionAgreementsMember_76f5c102-0236-470c-ab76-e88e65ef8a0d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DevelopmentAgreementMember_b7457d4a-7238-43b7-ada9-b7d7f0432cce" xlink:href="gild-20221231.xsd#gild_DevelopmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_DevelopmentAgreementMember_b7457d4a-7238-43b7-ada9-b7d7f0432cce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_267d4854-30a2-48db-8fc3-65b891ff05f1" xlink:href="gild-20221231.xsd#gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_267d4854-30a2-48db-8fc3-65b891ff05f1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_cad60768-5c1a-4176-abae-c57537434e75" xlink:href="gild-20221231.xsd#gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_cad60768-5c1a-4176-abae-c57537434e75" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_ca02d7b0-20f0-47b4-9c1d-e1bcbf0cb289" xlink:href="gild-20221231.xsd#gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_ca02d7b0-20f0-47b4-9c1d-e1bcbf0cb289" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosSubscriptionAgreementMember_9e84fb43-1d8e-4f49-aad0-36de13fc1a2a" xlink:href="gild-20221231.xsd#gild_GalapagosSubscriptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_GalapagosSubscriptionAgreementMember_9e84fb43-1d8e-4f49-aad0-36de13fc1a2a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JanssenPharmaceuticalsMember_347667b0-3435-45ff-a4d0-affe34a4a265" xlink:href="gild-20221231.xsd#gild_JanssenPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_JanssenPharmaceuticalsMember_347667b0-3435-45ff-a4d0-affe34a4a265" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AgreementWithJapanTobaccoIncMember_55173402-90db-47b4-aae6-73cfa92a0fd0" xlink:href="gild-20221231.xsd#gild_AgreementWithJapanTobaccoIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_AgreementWithJapanTobaccoIncMember_55173402-90db-47b4-aae6-73cfa92a0fd0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EverestMedicinesAndImmunomedicsAgreementMember_af4a630b-06eb-4562-a330-d890f9f6611f" xlink:href="gild-20221231.xsd#gild_EverestMedicinesAndImmunomedicsAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_EverestMedicinesAndImmunomedicsAgreementMember_af4a630b-06eb-4562-a330-d890f9f6611f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember_e371fe67-bd3d-45b7-8503-c917d626faba" xlink:href="gild-20221231.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_OtherCollaborationArrangementsMember_e371fe67-bd3d-45b7-8503-c917d626faba" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_8a167715-146b-4ec4-9dc1-e3345577ae12" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_srt_OwnershipAxis_8a167715-146b-4ec4-9dc1-e3345577ae12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_8a167715-146b-4ec4-9dc1-e3345577ae12_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_8a167715-146b-4ec4-9dc1-e3345577ae12" xlink:to="loc_srt_OwnershipDomain_8a167715-146b-4ec4-9dc1-e3345577ae12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9e2935be-7067-4dcc-9244-876a1572816a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_8a167715-146b-4ec4-9dc1-e3345577ae12" xlink:to="loc_srt_OwnershipDomain_9e2935be-7067-4dcc-9244-876a1572816a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_bca4874f-39e5-4bdd-8b45-f3d4f4d9a571" xlink:href="gild-20221231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_9e2935be-7067-4dcc-9244-876a1572816a" xlink:to="loc_gild_ArcusBiosciencesIncMember_bca4874f-39e5-4bdd-8b45-f3d4f4d9a571" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember_43fdbe9f-7672-460a-9f8c-7c3ff872dc87" xlink:href="gild-20221231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_9e2935be-7067-4dcc-9244-876a1572816a" xlink:to="loc_gild_TangoTherapeuticsIncMember_43fdbe9f-7672-460a-9f8c-7c3ff872dc87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4f14985c-7014-4c79-8713-a1c009742cb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_srt_ProductOrServiceAxis_4f14985c-7014-4c79-8713-a1c009742cb3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4f14985c-7014-4c79-8713-a1c009742cb3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4f14985c-7014-4c79-8713-a1c009742cb3" xlink:to="loc_srt_ProductsAndServicesDomain_4f14985c-7014-4c79-8713-a1c009742cb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cae66158-f69b-4cca-acd1-fb205d0d5ef2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4f14985c-7014-4c79-8713-a1c009742cb3" xlink:to="loc_srt_ProductsAndServicesDomain_cae66158-f69b-4cca-acd1-fb205d0d5ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OralFormulationProductMember_bea712bb-c868-4ef4-9ddf-e7a2b9fb0261" xlink:href="gild-20221231.xsd#gild_OralFormulationProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cae66158-f69b-4cca-acd1-fb205d0d5ef2" xlink:to="loc_gild_OralFormulationProductMember_bea712bb-c868-4ef4-9ddf-e7a2b9fb0261" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InjectableFormulationProductMember_16e784fa-a46a-4492-a4ac-494c364e9841" xlink:href="gild-20221231.xsd#gild_InjectableFormulationProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cae66158-f69b-4cca-acd1-fb205d0d5ef2" xlink:to="loc_gild_InjectableFormulationProductMember_16e784fa-a46a-4492-a4ac-494c364e9841" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8cdd964c-285e-4e39-b8b3-29757607cf78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_srt_RangeAxis_8cdd964c-285e-4e39-b8b3-29757607cf78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8cdd964c-285e-4e39-b8b3-29757607cf78_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8cdd964c-285e-4e39-b8b3-29757607cf78" xlink:to="loc_srt_RangeMember_8cdd964c-285e-4e39-b8b3-29757607cf78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba49f97c-44f6-41fa-a5b7-df139d04eb19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8cdd964c-285e-4e39-b8b3-29757607cf78" xlink:to="loc_srt_RangeMember_ba49f97c-44f6-41fa-a5b7-df139d04eb19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f9565bfd-6923-45ba-9835-bca09af3ccda" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ba49f97c-44f6-41fa-a5b7-df139d04eb19" xlink:to="loc_srt_MaximumMember_f9565bfd-6923-45ba-9835-bca09af3ccda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_950d58a6-a234-4bd9-a363-2ebb1aa385de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_dei_LegalEntityAxis_950d58a6-a234-4bd9-a363-2ebb1aa385de" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_950d58a6-a234-4bd9-a363-2ebb1aa385de_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_950d58a6-a234-4bd9-a363-2ebb1aa385de" xlink:to="loc_dei_EntityDomain_950d58a6-a234-4bd9-a363-2ebb1aa385de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6f1198b6-999d-4428-99c0-9f73f829db85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_950d58a6-a234-4bd9-a363-2ebb1aa385de" xlink:to="loc_dei_EntityDomain_6f1198b6-999d-4428-99c0-9f73f829db85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckMember_5cf361df-e78f-4e23-aba6-68acda435665" xlink:href="gild-20221231.xsd#gild_MerckMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6f1198b6-999d-4428-99c0-9f73f829db85" xlink:to="loc_gild_MerckMember_5cf361df-e78f-4e23-aba6-68acda435665" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_75689e7c-87df-4701-862b-cc0bdc2bca09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_75689e7c-87df-4701-862b-cc0bdc2bca09" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75689e7c-87df-4701-862b-cc0bdc2bca09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_75689e7c-87df-4701-862b-cc0bdc2bca09" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75689e7c-87df-4701-862b-cc0bdc2bca09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8570bac9-c587-49a1-a0a3-8d3f37d4b013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_75689e7c-87df-4701-862b-cc0bdc2bca09" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8570bac9-c587-49a1-a0a3-8d3f37d4b013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_6b6451db-34ac-4446-a016-4a5dc5b237ac" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8570bac9-c587-49a1-a0a3-8d3f37d4b013" xlink:to="loc_gild_ImmunomedicsIncMember_6b6451db-34ac-4446-a016-4a5dc5b237ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f475d1d-6781-4dfc-8f0a-13e549d94cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f475d1d-6781-4dfc-8f0a-13e549d94cce" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f475d1d-6781-4dfc-8f0a-13e549d94cce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f475d1d-6781-4dfc-8f0a-13e549d94cce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0f475d1d-6781-4dfc-8f0a-13e549d94cce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09a9fab0-6163-4e64-9ffd-475779b3be99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f475d1d-6781-4dfc-8f0a-13e549d94cce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09a9fab0-6163-4e64-9ffd-475779b3be99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3563e001-885c-4c2b-94da-16d6b49d764b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09a9fab0-6163-4e64-9ffd-475779b3be99" xlink:to="loc_us-gaap_LicensingAgreementsMember_3563e001-885c-4c2b-94da-16d6b49d764b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="extended" id="i1bc35c505c5444259d7df510b70fd744_DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_61c85e88-8641-4f9c-bc91-9185a7e1c2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_61c85e88-8641-4f9c-bc91-9185a7e1c2b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_960d5fb8-ad96-43bb-87e9-4c5e93e93542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:to="loc_us-gaap_LongTermDebt_960d5fb8-ad96-43bb-87e9-4c5e93e93542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c1dfab00-d4bf-45fc-b049-5b2806ba129f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c1dfab00-d4bf-45fc-b049-5b2806ba129f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9f4dbb76-dfe1-4e1c-b587-aa69a4469beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:to="loc_us-gaap_LongTermDebtCurrent_9f4dbb76-dfe1-4e1c-b587-aa69a4469beb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5d22469e-8480-4974-b6a9-bcc36857fa7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5d22469e-8480-4974-b6a9-bcc36857fa7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cd57681f-d923-43e0-81fb-50448b8e3338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:to="loc_us-gaap_DebtInstrumentTable_cd57681f-d923-43e0-81fb-50448b8e3338" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f80b30ab-4b2d-4580-93cd-9c1c80db1520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cd57681f-d923-43e0-81fb-50448b8e3338" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f80b30ab-4b2d-4580-93cd-9c1c80db1520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f80b30ab-4b2d-4580-93cd-9c1c80db1520_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f80b30ab-4b2d-4580-93cd-9c1c80db1520" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f80b30ab-4b2d-4580-93cd-9c1c80db1520_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1ca2423-7a86-496d-9573-e87b7546e721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f80b30ab-4b2d-4580-93cd-9c1c80db1520" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1ca2423-7a86-496d-9573-e87b7546e721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_9700999d-acde-4333-b555-9a6d42677c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1ca2423-7a86-496d-9573-e87b7546e721" xlink:to="loc_us-gaap_SeniorNotesMember_9700999d-acde-4333-b555-9a6d42677c37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember_0d37509f-1ba2-4a95-8760-79941a6786a6" xlink:href="gild-20221231.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1ca2423-7a86-496d-9573-e87b7546e721" xlink:to="loc_gild_SeniorNotesAndMediumTermNotesMember_0d37509f-1ba2-4a95-8760-79941a6786a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_edf4c165-6f71-4fb7-81ca-a2e3c2370c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1ca2423-7a86-496d-9573-e87b7546e721" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_edf4c165-6f71-4fb7-81ca-a2e3c2370c7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_43743ede-b713-4492-a170-079de29e6b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cd57681f-d923-43e0-81fb-50448b8e3338" xlink:to="loc_us-gaap_DebtInstrumentAxis_43743ede-b713-4492-a170-079de29e6b09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_43743ede-b713-4492-a170-079de29e6b09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_43743ede-b713-4492-a170-079de29e6b09" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_43743ede-b713-4492-a170-079de29e6b09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_43743ede-b713-4492-a170-079de29e6b09" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_2af55799-03cf-4594-aa29-586abc0d98da" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_2af55799-03cf-4594-aa29-586abc0d98da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member_9d9e58f3-1032-4601-a9d2-111f8731f758" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member_9d9e58f3-1032-4601-a9d2-111f8731f758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member_39ceeefb-82e3-4b80-82ad-cf431540d74a" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member_39ceeefb-82e3-4b80-82ad-cf431540d74a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_6bff6c0d-e27d-4e90-8b93-531cacca643e" xlink:href="gild-20221231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_6bff6c0d-e27d-4e90-8b93-531cacca643e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2024Member_a30327a8-9774-4e78-b8e3-3c33943b001b" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinApril2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinApril2024Member_a30327a8-9774-4e78-b8e3-3c33943b001b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member_1e08e50e-e833-45ce-a089-c700c2c5f806" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member_1e08e50e-e833-45ce-a089-c700c2c5f806" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member_b4fe1e14-30f8-4cba-8447-7a30bf7384e9" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member_b4fe1e14-30f8-4cba-8447-7a30bf7384e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member_613d345f-5312-4acb-93ba-bca5e910d1c6" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member_613d345f-5312-4acb-93ba-bca5e910d1c6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_787ced2d-2dba-458e-94ca-29545fcc5260" xlink:href="gild-20221231.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_787ced2d-2dba-458e-94ca-29545fcc5260" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_ffa61eda-7c95-41d3-bc7b-dd7506953a4b" xlink:href="gild-20221231.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_ffa61eda-7c95-41d3-bc7b-dd7506953a4b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member_3d27ea69-d855-4610-960a-0b279fe2d2c5" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member_3d27ea69-d855-4610-960a-0b279fe2d2c5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member_e4512992-f1d5-4ddf-b905-89a68c032e35" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member_e4512992-f1d5-4ddf-b905-89a68c032e35" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_b58bdf3d-c764-4f98-a4e9-bb0308323e50" xlink:href="gild-20221231.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_b58bdf3d-c764-4f98-a4e9-bb0308323e50" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2041Member_576228c2-179f-4ce5-b8f0-59019f96a817" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueDecember2041Member_576228c2-179f-4ce5-b8f0-59019f96a817" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2044Member_ddd14091-a4ab-4e62-8079-26af295f92ca" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinApril2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinApril2044Member_ddd14091-a4ab-4e62-8079-26af295f92ca" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member_6ab849f2-5262-41f6-b037-7911e2e167b0" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member_6ab849f2-5262-41f6-b037-7911e2e167b0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member_e682822e-8b08-4a8c-851d-2f88286e9639" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member_e682822e-8b08-4a8c-851d-2f88286e9639" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member_9f665045-9859-43b4-8f54-dad2342dd199" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member_9f665045-9859-43b4-8f54-dad2342dd199" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_b8aa5d28-2e5f-465c-95db-ddf3181ecdf8" xlink:href="gild-20221231.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_b8aa5d28-2e5f-465c-95db-ddf3181ecdf8" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DebtandCreditFacilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="extended" id="ia1eb16b11a9c48b1b41102fd7537a10f_DebtandCreditFacilitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_e6b2a488-1414-430b-ae1f-93cd3788c610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_RepaymentsOfDebt_e6b2a488-1414-430b-ae1f-93cd3788c610" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_82a7fbd3-5742-44cd-9f28-1bbe6d65bb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_82a7fbd3-5742-44cd-9f28-1bbe6d65bb9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_66437ecd-d9c0-43a9-ac44-be0375dc342a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_66437ecd-d9c0-43a9-ac44-be0375dc342a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_b723e37d-ba01-48f0-892f-efefc003dd65" xlink:href="gild-20221231.xsd#gild_DebtInstrumentCallFeaturePeriodBeforeMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_b723e37d-ba01-48f0-892f-efefc003dd65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f0fdee9b-99ed-4593-8d0a-c44a1774bcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_LongTermDebt_f0fdee9b-99ed-4593-8d0a-c44a1774bcd0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a7e7c334-0aaa-4e36-a911-4fdc6e766a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a7e7c334-0aaa-4e36-a911-4fdc6e766a6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_62316117-ba7c-4e45-88ed-42f2a9c73291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_62316117-ba7c-4e45-88ed-42f2a9c73291" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_7a8a865c-e748-4af9-a90b-6a4483db89aa" xlink:href="gild-20221231.xsd#gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_7a8a865c-e748-4af9-a90b-6a4483db89aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ab2a89d0-2f77-4435-931c-2f24cee654b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ab2a89d0-2f77-4435-931c-2f24cee654b3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_da53764c-3495-452c-a0cf-9a11abec6659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_DebtInstrumentTerm_da53764c-3495-452c-a0cf-9a11abec6659" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_c4fad347-da55-484c-b4ce-35bacb9ddc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_LineOfCredit_c4fad347-da55-484c-b4ce-35bacb9ddc8e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt_580b866e-c601-4ff6-870b-d6b5db3d5762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_InterestExpenseLongTermDebt_580b866e-c601-4ff6-870b-d6b5db3d5762" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a4d717ef-9ac2-48a9-9da9-c9831f1168bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_us-gaap_DebtInstrumentAxis_a4d717ef-9ac2-48a9-9da9-c9831f1168bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a4d717ef-9ac2-48a9-9da9-c9831f1168bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a4d717ef-9ac2-48a9-9da9-c9831f1168bc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a4d717ef-9ac2-48a9-9da9-c9831f1168bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a4d717ef-9ac2-48a9-9da9-c9831f1168bc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_bdda4405-dc7d-4ba5-b47c-eefbe2bc514a" xlink:href="gild-20221231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_bdda4405-dc7d-4ba5-b47c-eefbe2bc514a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_214f39be-1c9f-4053-ba42-65be7bde00ff" xlink:href="gild-20221231.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:to="loc_gild_CreditFacilityDueJune2025Member_214f39be-1c9f-4053-ba42-65be7bde00ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_7e46c67c-44fc-434c-8a04-971071c76c47" xlink:href="gild-20221231.xsd#gild_A195SeniorUnsecuredNotesDueMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:to="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_7e46c67c-44fc-434c-8a04-971071c76c47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_8ef2ac71-731d-4d14-bf76-611b2a1bf996" xlink:href="gild-20221231.xsd#gild_A325SeniorUnsecuredNotesDueSeptember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:to="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_8ef2ac71-731d-4d14-bf76-611b2a1bf996" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_5c7a7319-06fd-4b6c-84cd-53fa30271f17" xlink:href="gild-20221231.xsd#gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:to="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_5c7a7319-06fd-4b6c-84cd-53fa30271f17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0910ac79-40a6-4abc-903e-f0d921b8e482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0910ac79-40a6-4abc-903e-f0d921b8e482" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0910ac79-40a6-4abc-903e-f0d921b8e482_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0910ac79-40a6-4abc-903e-f0d921b8e482" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0910ac79-40a6-4abc-903e-f0d921b8e482_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d457a591-3a11-46ea-914f-7822e806a528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0910ac79-40a6-4abc-903e-f0d921b8e482" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d457a591-3a11-46ea-914f-7822e806a528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_17bce074-c919-4fe4-894b-ab5caca8cf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d457a591-3a11-46ea-914f-7822e806a528" xlink:to="loc_us-gaap_SeniorNotesMember_17bce074-c919-4fe4-894b-ab5caca8cf2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_309b6152-1b60-4743-9f38-f3fef0824598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d457a591-3a11-46ea-914f-7822e806a528" xlink:to="loc_us-gaap_LineOfCreditMember_309b6152-1b60-4743-9f38-f3fef0824598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_55def4cb-9fb0-4caa-84f0-a815080c5b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_us-gaap_CreditFacilityAxis_55def4cb-9fb0-4caa-84f0-a815080c5b81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_55def4cb-9fb0-4caa-84f0-a815080c5b81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_55def4cb-9fb0-4caa-84f0-a815080c5b81" xlink:to="loc_us-gaap_CreditFacilityDomain_55def4cb-9fb0-4caa-84f0-a815080c5b81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_935cdbfe-6bf8-482b-83a5-e73e22e19f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_55def4cb-9fb0-4caa-84f0-a815080c5b81" xlink:to="loc_us-gaap_CreditFacilityDomain_935cdbfe-6bf8-482b-83a5-e73e22e19f80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_5826914b-3e33-4283-adf1-802dee029628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_935cdbfe-6bf8-482b-83a5-e73e22e19f80" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_5826914b-3e33-4283-adf1-802dee029628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_700de1da-c47a-462e-879c-24b889e4ccaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_srt_RangeAxis_700de1da-c47a-462e-879c-24b889e4ccaa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_700de1da-c47a-462e-879c-24b889e4ccaa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_700de1da-c47a-462e-879c-24b889e4ccaa" xlink:to="loc_srt_RangeMember_700de1da-c47a-462e-879c-24b889e4ccaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0490819-9443-4029-b29a-43596e9f3ebf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_700de1da-c47a-462e-879c-24b889e4ccaa" xlink:to="loc_srt_RangeMember_c0490819-9443-4029-b29a-43596e9f3ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6f408e22-26dd-4968-9c5f-c8942ea8ad49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c0490819-9443-4029-b29a-43596e9f3ebf" xlink:to="loc_srt_MaximumMember_6f408e22-26dd-4968-9c5f-c8942ea8ad49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0418666f-401d-4f2e-baa9-6f19ce706a11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c0490819-9443-4029-b29a-43596e9f3ebf" xlink:to="loc_srt_MinimumMember_0418666f-401d-4f2e-baa9-6f19ce706a11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_11ea3f35-bf55-4e53-af6f-1a28064c2be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_11ea3f35-bf55-4e53-af6f-1a28064c2be8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11ea3f35-bf55-4e53-af6f-1a28064c2be8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11ea3f35-bf55-4e53-af6f-1a28064c2be8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11ea3f35-bf55-4e53-af6f-1a28064c2be8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d51ea115-2123-4ab4-b4b4-03b47ece6228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11ea3f35-bf55-4e53-af6f-1a28064c2be8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d51ea115-2123-4ab4-b4b4-03b47ece6228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_39d6ac50-0239-4857-a55f-05d881d2d06e" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d51ea115-2123-4ab4-b4b4-03b47ece6228" xlink:to="loc_gild_ImmunomedicsIncMember_39d6ac50-0239-4857-a55f-05d881d2d06e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3aacfdda-72dc-4260-8895-1aea257a6483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3aacfdda-72dc-4260-8895-1aea257a6483" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3aacfdda-72dc-4260-8895-1aea257a6483_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3aacfdda-72dc-4260-8895-1aea257a6483" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3aacfdda-72dc-4260-8895-1aea257a6483_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_068d51c7-32bf-41ff-8fc0-eda57997523c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3aacfdda-72dc-4260-8895-1aea257a6483" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_068d51c7-32bf-41ff-8fc0-eda57997523c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_619fd35d-73fd-4a51-9517-c31c98582e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_068d51c7-32bf-41ff-8fc0-eda57997523c" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_619fd35d-73fd-4a51-9517-c31c98582e4c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="extended" id="i177577ddb3954c8e8af25adbd9c5fc91_DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8e75fec8-d354-49c3-985d-ef5a74c058b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8e75fec8-d354-49c3-985d-ef5a74c058b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9e2d146c-60c4-46ba-be78-509ebc545ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9e2d146c-60c4-46ba-be78-509ebc545ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f6cc88c-93b5-4ec4-a43d-ce52ae3d5d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f6cc88c-93b5-4ec4-a43d-ce52ae3d5d4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4a0431e2-4bb8-4d40-9cdd-c8ed9d76cb56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4a0431e2-4bb8-4d40-9cdd-c8ed9d76cb56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_382892a1-1b24-458d-88ac-c9ad429ac07b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_382892a1-1b24-458d-88ac-c9ad429ac07b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2a42877f-065f-44eb-8272-d7052c863ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2a42877f-065f-44eb-8272-d7052c863ffa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_58331615-313b-44bc-a0a7-0315be7b0d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebt_58331615-313b-44bc-a0a7-0315be7b0d28" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0de272a1-c84a-47a0-866f-054f2d261ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_DebtInstrumentTable_0de272a1-c84a-47a0-866f-054f2d261ffa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3d90fc1b-f612-4a4c-8546-b5b0325b3992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0de272a1-c84a-47a0-866f-054f2d261ffa" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3d90fc1b-f612-4a4c-8546-b5b0325b3992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3d90fc1b-f612-4a4c-8546-b5b0325b3992_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3d90fc1b-f612-4a4c-8546-b5b0325b3992" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3d90fc1b-f612-4a4c-8546-b5b0325b3992_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9ef77f45-6ddd-4b02-922b-105ef1a291be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3d90fc1b-f612-4a4c-8546-b5b0325b3992" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9ef77f45-6ddd-4b02-922b-105ef1a291be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5be2703b-7e19-411c-bcd9-b5ec7bde19b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9ef77f45-6ddd-4b02-922b-105ef1a291be" xlink:to="loc_us-gaap_SeniorNotesMember_5be2703b-7e19-411c-bcd9-b5ec7bde19b1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ic62194ef24fc42939d639ced82390d8b_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_fdb4875b-5f48-42d9-b920-b0419b928ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_LitigationReserve_fdb4875b-5f48-42d9-b920-b0419b928ecb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_e6e84d59-6945-4f1c-8fa6-d5d03f3d3fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_e6e84d59-6945-4f1c-8fa6-d5d03f3d3fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_8a7a10ca-27a2-47b7-97bb-1dc0c4a86649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_8a7a10ca-27a2-47b7-97bb-1dc0c4a86649" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017_f88d05bb-e93e-4bdd-9d77-6bcbfde78300" xlink:href="gild-20221231.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_JudgmentRoyaltyRateFromOctober2017_f88d05bb-e93e-4bdd-9d77-6bcbfde78300" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales_e33cc88d-cf5a-4697-97df-064646fdf166" xlink:href="gild-20221231.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_JudgmentEnhancedDamagesOnPastSales_e33cc88d-cf5a-4697-97df-064646fdf166" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales_027c4992-fcbb-4066-9383-8bf4fefde671" xlink:href="gild-20221231.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_JudgmentRoyaltyRateOnFutureSales_027c4992-fcbb-4066-9383-8bf4fefde671" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber_1aac6863-6f85-4d0e-84aa-746a634d29f2" xlink:href="gild-20221231.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_LossContingencyMaterialTransferAgreementsNumber_1aac6863-6f85-4d0e-84aa-746a634d29f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_75c16f2c-69ad-4fe6-ae86-7f1c4238160d" xlink:href="gild-20221231.xsd#gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_75c16f2c-69ad-4fe6-ae86-7f1c4238160d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_b018b190-905f-4201-a7f3-1eabfdbafe67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_b018b190-905f-4201-a7f3-1eabfdbafe67" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyNumberOfPatents_a925e9c0-c427-43cd-ba25-a21050ab0020" xlink:href="gild-20221231.xsd#gild_LossContingencyNumberOfPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_LossContingencyNumberOfPatents_a925e9c0-c427-43cd-ba25-a21050ab0020" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber_73dba3e2-f22e-481d-9de8-8c633e303383" xlink:href="gild-20221231.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_LossContingencyPartiesAppealedNumber_73dba3e2-f22e-481d-9de8-8c633e303383" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_ed1024a5-39e9-49c7-9921-d5899e4ed258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_ed1024a5-39e9-49c7-9921-d5899e4ed258" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_cfc3c207-7c05-44b1-ab9e-e9a21c4b7985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_cfc3c207-7c05-44b1-ab9e-e9a21c4b7985" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_2f7eafdb-e4bd-4590-b854-5f64d2941650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_OtherCommitmentsTable_2f7eafdb-e4bd-4590-b854-5f64d2941650" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a42672f4-baf2-42d6-8e51-12dfe2b81e87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_2f7eafdb-e4bd-4590-b854-5f64d2941650" xlink:to="loc_srt_LitigationCaseAxis_a42672f4-baf2-42d6-8e51-12dfe2b81e87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a42672f4-baf2-42d6-8e51-12dfe2b81e87_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a42672f4-baf2-42d6-8e51-12dfe2b81e87" xlink:to="loc_srt_LitigationCaseTypeDomain_a42672f4-baf2-42d6-8e51-12dfe2b81e87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ec4fb49f-a885-4320-9294-edbf4a2d074d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a42672f4-baf2-42d6-8e51-12dfe2b81e87" xlink:to="loc_srt_LitigationCaseTypeDomain_ec4fb49f-a885-4320-9294-edbf4a2d074d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_6e4d472f-7fe6-4911-b1f4-3e90baa17b85" xlink:href="gild-20221231.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ec4fb49f-a885-4320-9294-edbf4a2d074d" xlink:to="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_6e4d472f-7fe6-4911-b1f4-3e90baa17b85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember_c6d59990-a358-44ea-972b-4e9ac3154a82" xlink:href="gild-20221231.xsd#gild_PreExposureProphylaxisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ec4fb49f-a885-4320-9294-edbf4a2d074d" xlink:to="loc_gild_PreExposureProphylaxisMember_c6d59990-a358-44ea-972b-4e9ac3154a82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember_8366b009-d5b0-483c-8ceb-4b2c2a7e40c9" xlink:href="gild-20221231.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ec4fb49f-a885-4320-9294-edbf4a2d074d" xlink:to="loc_gild_EuropeanPatentClaims2032ExpirationMember_8366b009-d5b0-483c-8ceb-4b2c2a7e40c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember_a33c8592-cd18-49ca-9b9e-803e08f23df8" xlink:href="gild-20221231.xsd#gild_ProductLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ec4fb49f-a885-4320-9294-edbf4a2d074d" xlink:to="loc_gild_ProductLiabilityMember_a33c8592-cd18-49ca-9b9e-803e08f23df8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#StockholdersEquityRepurchasesofCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="extended" id="i0cdc66c33b2e4d669bac03726b563c43_StockholdersEquityRepurchasesofCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7df81a4d-9a45-431d-aa3d-76ea43607f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7df81a4d-9a45-431d-aa3d-76ea43607f92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_319c6d4e-bde7-4b17-a4a5-3ee865bd7951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_319c6d4e-bde7-4b17-a4a5-3ee865bd7951" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_636e70cb-138f-436d-89d5-06d47fe9191d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_636e70cb-138f-436d-89d5-06d47fe9191d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_14be0858-0928-4832-8947-99549f574077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_14be0858-0928-4832-8947-99549f574077" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_00be1cbf-7093-42b6-986b-d4025ccd8b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_00be1cbf-7093-42b6-986b-d4025ccd8b24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bbc26c90-77e3-4733-b455-7c72083c8408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bbc26c90-77e3-4733-b455-7c72083c8408" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_51058a7c-fe25-44b6-b5c9-2af3247e2868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bbc26c90-77e3-4733-b455-7c72083c8408" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_51058a7c-fe25-44b6-b5c9-2af3247e2868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_51058a7c-fe25-44b6-b5c9-2af3247e2868_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_51058a7c-fe25-44b6-b5c9-2af3247e2868" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_51058a7c-fe25-44b6-b5c9-2af3247e2868_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_8c269fba-e11b-4d01-ad16-4babca2e018a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_51058a7c-fe25-44b6-b5c9-2af3247e2868" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_8c269fba-e11b-4d01-ad16-4babca2e018a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember_922184a1-2320-40b2-927f-1330996df2c9" xlink:href="gild-20221231.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8c269fba-e11b-4d01-ad16-4babca2e018a" xlink:to="loc_gild_A2020StockRepurchaseProgramMember_922184a1-2320-40b2-927f-1330996df2c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember_b35539de-e7ad-4b1a-8326-5b7e76150e1a" xlink:href="gild-20221231.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8c269fba-e11b-4d01-ad16-4babca2e018a" xlink:to="loc_gild_A2016StockRepurchaseProgramMember_b35539de-e7ad-4b1a-8326-5b7e76150e1a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#StockholdersEquityDividendsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="extended" id="ic6becfe7b9934a63b9d11ce27d2453c8_StockholdersEquityDividendsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_e93a0bab-c65e-461c-a321-0215765f2f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_0f916bb3-3430-48fd-ba01-c35358449efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e93a0bab-c65e-461c-a321-0215765f2f12" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_0f916bb3-3430-48fd-ba01-c35358449efc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_5c3dbd42-115f-474a-b774-df88a6ad8472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e93a0bab-c65e-461c-a321-0215765f2f12" xlink:to="loc_us-gaap_DividendsCommonStockCash_5c3dbd42-115f-474a-b774-df88a6ad8472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ChangeInDividendsPercentage_5a0bb2ff-7913-4eba-ae86-79c9720368f7" xlink:href="gild-20221231.xsd#gild_ChangeInDividendsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_e93a0bab-c65e-461c-a321-0215765f2f12" xlink:to="loc_gild_ChangeInDividendsPercentage_5a0bb2ff-7913-4eba-ae86-79c9720368f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a7621484-9e20-4450-b8fe-bf7d059591dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_e93a0bab-c65e-461c-a321-0215765f2f12" xlink:to="loc_us-gaap_SubsequentEventTable_a7621484-9e20-4450-b8fe-bf7d059591dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_11e660ca-f8bf-4cf2-9c78-0d7c224cc1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a7621484-9e20-4450-b8fe-bf7d059591dd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_11e660ca-f8bf-4cf2-9c78-0d7c224cc1b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_11e660ca-f8bf-4cf2-9c78-0d7c224cc1b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_11e660ca-f8bf-4cf2-9c78-0d7c224cc1b7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_11e660ca-f8bf-4cf2-9c78-0d7c224cc1b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e59ab288-3a43-45af-af4d-2a21dad3261f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_11e660ca-f8bf-4cf2-9c78-0d7c224cc1b7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e59ab288-3a43-45af-af4d-2a21dad3261f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0c546b58-640f-4480-bc64-82258f9d9a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e59ab288-3a43-45af-af4d-2a21dad3261f" xlink:to="loc_us-gaap_SubsequentEventMember_0c546b58-640f-4480-bc64-82258f9d9a08" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="ie93b042dc7984204aa903989926a7ef4_StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4c0131f6-5d37-48ee-b096-47ed1a2d0181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4c0131f6-5d37-48ee-b096-47ed1a2d0181" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff2dd907-79ca-45cb-a328-6130f831ad57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff2dd907-79ca-45cb-a328-6130f831ad57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8e9b2329-a5aa-4cf1-8639-d65ac5e2aed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8e9b2329-a5aa-4cf1-8639-d65ac5e2aed7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_74aa8fda-0c01-4d18-a0ce-0b0454a7f17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_74aa8fda-0c01-4d18-a0ce-0b0454a7f17d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e3f332c7-0bca-4a63-bc14-ed7953af62e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e3f332c7-0bca-4a63-bc14-ed7953af62e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bc594774-bdd6-4f28-b7bf-e1fa39ec4046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9c01c797-5a5c-4a17-8c33-0660650193a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4c0131f6-5d37-48ee-b096-47ed1a2d0181" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9c01c797-5a5c-4a17-8c33-0660650193a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5447fecf-9bbd-4024-bb1e-b3304b2e9852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9c01c797-5a5c-4a17-8c33-0660650193a4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5447fecf-9bbd-4024-bb1e-b3304b2e9852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5447fecf-9bbd-4024-bb1e-b3304b2e9852_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5447fecf-9bbd-4024-bb1e-b3304b2e9852" xlink:to="loc_us-gaap_EquityComponentDomain_5447fecf-9bbd-4024-bb1e-b3304b2e9852_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_35d72351-9161-45e2-aadd-cde2b996a3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5447fecf-9bbd-4024-bb1e-b3304b2e9852" xlink:to="loc_us-gaap_EquityComponentDomain_35d72351-9161-45e2-aadd-cde2b996a3db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9699b97e-a585-4ea5-b3ca-d82aa9818426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_35d72351-9161-45e2-aadd-cde2b996a3db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9699b97e-a585-4ea5-b3ca-d82aa9818426" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7e27e2c9-e3d6-41c0-9864-676745319622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9699b97e-a585-4ea5-b3ca-d82aa9818426" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7e27e2c9-e3d6-41c0-9864-676745319622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d93aae97-9405-433a-ac62-ec561db0c042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9699b97e-a585-4ea5-b3ca-d82aa9818426" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d93aae97-9405-433a-ac62-ec561db0c042" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_77b8c24e-04c0-4a6e-b4f9-17ead18e2a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9699b97e-a585-4ea5-b3ca-d82aa9818426" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_77b8c24e-04c0-4a6e-b4f9-17ead18e2a24" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="extended" id="ib52fa5a034cc4acba376cfbff3ddc480_EmployeeBenefitsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_593f0af7-eca4-4dcb-99be-8e57b1284797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_593f0af7-eca4-4dcb-99be-8e57b1284797" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bf71a5dd-6072-41ca-8866-88ac69ec6d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bf71a5dd-6072-41ca-8866-88ac69ec6d14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_355cfd4f-a577-4fa2-a106-58ea27e74464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_355cfd4f-a577-4fa2-a106-58ea27e74464" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_90b100ed-d0e8-4fc8-a3c4-6fc907d82ba1" xlink:href="gild-20221231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_90b100ed-d0e8-4fc8-a3c4-6fc907d82ba1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cbcfe39b-08f4-4f87-8ce0-abc148e7490c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cbcfe39b-08f4-4f87-8ce0-abc148e7490c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5546a10b-ae09-4f77-8c90-904369c1bcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5546a10b-ae09-4f77-8c90-904369c1bcbd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b8a1d8cb-5afa-4fe7-954d-92ff16ee4d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b8a1d8cb-5afa-4fe7-954d-92ff16ee4d82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_53fbea74-d7ff-4d27-9112-b44c2a700db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_53fbea74-d7ff-4d27-9112-b44c2a700db0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0dd86c19-6956-481f-b64d-d77794a214e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0dd86c19-6956-481f-b64d-d77794a214e7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_7971b45a-51a8-42ae-87a2-82ca6c382900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_7971b45a-51a8-42ae-87a2-82ca6c382900" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7854f3b5-c4c7-4548-a9f3-8799005bbb43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7854f3b5-c4c7-4548-a9f3-8799005bbb43" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b2e04dae-7a78-43c4-858a-c40466aeedf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b2e04dae-7a78-43c4-858a-c40466aeedf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b2e04dae-7a78-43c4-858a-c40466aeedf3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b2e04dae-7a78-43c4-858a-c40466aeedf3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b2e04dae-7a78-43c4-858a-c40466aeedf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a440d89c-3bb3-4f87-894c-9838a848fc09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b2e04dae-7a78-43c4-858a-c40466aeedf3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a440d89c-3bb3-4f87-894c-9838a848fc09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_a7d3533a-5a7d-466f-a316-34f7ac94b60d" xlink:href="gild-20221231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a440d89c-3bb3-4f87-894c-9838a848fc09" xlink:to="loc_gild_DeferredCompensationPlanMember_a7d3533a-5a7d-466f-a316-34f7ac94b60d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b2df2f01-2ce7-4f89-bfc4-e85ab6c43c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b2df2f01-2ce7-4f89-bfc4-e85ab6c43c10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2df2f01-2ce7-4f89-bfc4-e85ab6c43c10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b2df2f01-2ce7-4f89-bfc4-e85ab6c43c10" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2df2f01-2ce7-4f89-bfc4-e85ab6c43c10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e288a7dc-4894-470f-9ecf-4e5b5299e353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b2df2f01-2ce7-4f89-bfc4-e85ab6c43c10" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e288a7dc-4894-470f-9ecf-4e5b5299e353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a9e34470-5d41-4824-9a57-5eda17dfeac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e288a7dc-4894-470f-9ecf-4e5b5299e353" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a9e34470-5d41-4824-9a57-5eda17dfeac6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_31aa49d4-272b-4d23-8148-39f5f6c3ca01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_AwardTypeAxis_31aa49d4-272b-4d23-8148-39f5f6c3ca01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31aa49d4-272b-4d23-8148-39f5f6c3ca01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_31aa49d4-272b-4d23-8148-39f5f6c3ca01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31aa49d4-272b-4d23-8148-39f5f6c3ca01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51ce548f-e8da-447a-9325-2e151b5e211b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_31aa49d4-272b-4d23-8148-39f5f6c3ca01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51ce548f-e8da-447a-9325-2e151b5e211b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5218795e-314c-4af2-acfc-a3183180bec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51ce548f-e8da-447a-9325-2e151b5e211b" xlink:to="loc_us-gaap_EmployeeStockMember_5218795e-314c-4af2-acfc-a3183180bec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e8788f52-0391-47d8-9d4d-5a4acce7aeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51ce548f-e8da-447a-9325-2e151b5e211b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e8788f52-0391-47d8-9d4d-5a4acce7aeb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7219555c-ceba-4af3-b311-5d02d15df7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51ce548f-e8da-447a-9325-2e151b5e211b" xlink:to="loc_us-gaap_PerformanceSharesMember_7219555c-ceba-4af3-b311-5d02d15df7dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_085ff01d-fa15-407d-a118-fecb08929999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51ce548f-e8da-447a-9325-2e151b5e211b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_085ff01d-fa15-407d-a118-fecb08929999" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_af648e62-45ce-4421-a951-9a2e3d8e1c79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_srt_RangeAxis_af648e62-45ce-4421-a951-9a2e3d8e1c79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af648e62-45ce-4421-a951-9a2e3d8e1c79_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_af648e62-45ce-4421-a951-9a2e3d8e1c79" xlink:to="loc_srt_RangeMember_af648e62-45ce-4421-a951-9a2e3d8e1c79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f8fb57a-fb0a-478a-bcb4-be1942a76597" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_af648e62-45ce-4421-a951-9a2e3d8e1c79" xlink:to="loc_srt_RangeMember_6f8fb57a-fb0a-478a-bcb4-be1942a76597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_108f3b9c-3c73-4a0e-b012-c1aac4386db1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6f8fb57a-fb0a-478a-bcb4-be1942a76597" xlink:to="loc_srt_MinimumMember_108f3b9c-3c73-4a0e-b012-c1aac4386db1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e8593fa2-2fea-4fdd-9ff8-791ee73d28fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6f8fb57a-fb0a-478a-bcb4-be1942a76597" xlink:to="loc_srt_MaximumMember_e8593fa2-2fea-4fdd-9ff8-791ee73d28fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8df0f2de-4ba6-40a4-a9a9-e2cb50a0f898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_PlanNameAxis_8df0f2de-4ba6-40a4-a9a9-e2cb50a0f898" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8df0f2de-4ba6-40a4-a9a9-e2cb50a0f898_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8df0f2de-4ba6-40a4-a9a9-e2cb50a0f898" xlink:to="loc_us-gaap_PlanNameDomain_8df0f2de-4ba6-40a4-a9a9-e2cb50a0f898_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2fcd93c9-f049-4992-9278-ddd58f4b950c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8df0f2de-4ba6-40a4-a9a9-e2cb50a0f898" xlink:to="loc_us-gaap_PlanNameDomain_2fcd93c9-f049-4992-9278-ddd58f4b950c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2022EquityIncentivePlanMember_c0d78999-faf0-440c-8182-8b676a434e93" xlink:href="gild-20221231.xsd#gild_GileadSciencesInc2022EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2fcd93c9-f049-4992-9278-ddd58f4b950c" xlink:to="loc_gild_GileadSciencesInc2022EquityIncentivePlanMember_c0d78999-faf0-440c-8182-8b676a434e93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dfd4364b-812a-481f-bed1-eee741d41c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dfd4364b-812a-481f-bed1-eee741d41c5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dfd4364b-812a-481f-bed1-eee741d41c5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dfd4364b-812a-481f-bed1-eee741d41c5f" xlink:to="loc_us-gaap_ClassOfStockDomain_dfd4364b-812a-481f-bed1-eee741d41c5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8bde8965-4edb-4fc5-8cc3-5e64113c3f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dfd4364b-812a-481f-bed1-eee741d41c5f" xlink:to="loc_us-gaap_ClassOfStockDomain_8bde8965-4edb-4fc5-8cc3-5e64113c3f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b2786c8b-4197-4d79-abcf-001715c72bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8bde8965-4edb-4fc5-8cc3-5e64113c3f21" xlink:to="loc_us-gaap_CommonStockMember_b2786c8b-4197-4d79-abcf-001715c72bf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_4db21f52-7e62-4328-b09a-3c1456f02156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_4db21f52-7e62-4328-b09a-3c1456f02156" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4db21f52-7e62-4328-b09a-3c1456f02156_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_4db21f52-7e62-4328-b09a-3c1456f02156" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4db21f52-7e62-4328-b09a-3c1456f02156_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_30c9c671-db20-41a5-bbd0-fd2ce8f911e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_4db21f52-7e62-4328-b09a-3c1456f02156" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_30c9c671-db20-41a5-bbd0-fd2ce8f911e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a771073f-bea3-400a-b282-c7ccab819994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_30c9c671-db20-41a5-bbd0-fd2ce8f911e3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a771073f-bea3-400a-b282-c7ccab819994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0db415e6-4f63-4baa-9f76-d677cdf2196c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a771073f-bea3-400a-b282-c7ccab819994" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0db415e6-4f63-4baa-9f76-d677cdf2196c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsSummaryofStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="extended" id="ic5c035fa2f6f4b648aff3a4f333a4bb2_EmployeeBenefitsSummaryofStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_82950d97-480f-4178-be45-1c60ffce2865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e21ef832-83c3-4d49-ae78-79814e80858e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_82950d97-480f-4178-be45-1c60ffce2865" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e21ef832-83c3-4d49-ae78-79814e80858e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3e3c2981-8441-4455-bfdc-91a9fe84432a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_82950d97-480f-4178-be45-1c60ffce2865" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3e3c2981-8441-4455-bfdc-91a9fe84432a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_b90c9a0c-ba9a-4e62-9606-2b44187c1073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_82950d97-480f-4178-be45-1c60ffce2865" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_b90c9a0c-ba9a-4e62-9606-2b44187c1073" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2bd93151-1590-44dd-b6bf-e6936df2150f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_82950d97-480f-4178-be45-1c60ffce2865" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2bd93151-1590-44dd-b6bf-e6936df2150f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_54a800aa-c855-4a15-bd6f-f597fd5f278f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2bd93151-1590-44dd-b6bf-e6936df2150f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_54a800aa-c855-4a15-bd6f-f597fd5f278f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_54a800aa-c855-4a15-bd6f-f597fd5f278f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_54a800aa-c855-4a15-bd6f-f597fd5f278f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_54a800aa-c855-4a15-bd6f-f597fd5f278f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a414b02f-8ca2-4567-9189-450cedef6a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_54a800aa-c855-4a15-bd6f-f597fd5f278f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a414b02f-8ca2-4567-9189-450cedef6a22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AcquisitionRelatedExpenseMember_34a513a3-c6f3-42d0-96b8-fbe23b5267c7" xlink:href="gild-20221231.xsd#gild_AcquisitionRelatedExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a414b02f-8ca2-4567-9189-450cedef6a22" xlink:to="loc_gild_AcquisitionRelatedExpenseMember_34a513a3-c6f3-42d0-96b8-fbe23b5267c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_aab75f7b-4850-4563-ae57-57faf5305575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a414b02f-8ca2-4567-9189-450cedef6a22" xlink:to="loc_us-gaap_CostOfSalesMember_aab75f7b-4850-4563-ae57-57faf5305575" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4d6ddf7a-aab2-4cca-979a-7deea868e4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a414b02f-8ca2-4567-9189-450cedef6a22" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4d6ddf7a-aab2-4cca-979a-7deea868e4b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fab8606e-e048-4650-bb80-7807291bc636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a414b02f-8ca2-4567-9189-450cedef6a22" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fab8606e-e048-4650-bb80-7807291bc636" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6408dada-b55e-4482-b5c8-6a45e21a3d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2bd93151-1590-44dd-b6bf-e6936df2150f" xlink:to="loc_us-gaap_AwardTypeAxis_6408dada-b55e-4482-b5c8-6a45e21a3d61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6408dada-b55e-4482-b5c8-6a45e21a3d61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6408dada-b55e-4482-b5c8-6a45e21a3d61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6408dada-b55e-4482-b5c8-6a45e21a3d61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539bc776-ff17-4eea-946f-5ac7b271e048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6408dada-b55e-4482-b5c8-6a45e21a3d61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539bc776-ff17-4eea-946f-5ac7b271e048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e34487ad-ba06-4a4f-a81a-646466cc8b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539bc776-ff17-4eea-946f-5ac7b271e048" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e34487ad-ba06-4a4f-a81a-646466cc8b8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c156937e-4677-4029-8b8b-5f59464bf09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539bc776-ff17-4eea-946f-5ac7b271e048" xlink:to="loc_us-gaap_PerformanceSharesMember_c156937e-4677-4029-8b8b-5f59464bf09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_44b8cc7d-5579-43da-bf61-7a31307164e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539bc776-ff17-4eea-946f-5ac7b271e048" xlink:to="loc_us-gaap_EmployeeStockOptionMember_44b8cc7d-5579-43da-bf61-7a31307164e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_92c58656-1aca-417d-8b32-89f764381ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539bc776-ff17-4eea-946f-5ac7b271e048" xlink:to="loc_us-gaap_EmployeeStockMember_92c58656-1aca-417d-8b32-89f764381ec8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_866b51f2-aef5-4bf5-ae21-79530f5d2812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2bd93151-1590-44dd-b6bf-e6936df2150f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_866b51f2-aef5-4bf5-ae21-79530f5d2812" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_866b51f2-aef5-4bf5-ae21-79530f5d2812_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_866b51f2-aef5-4bf5-ae21-79530f5d2812" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_866b51f2-aef5-4bf5-ae21-79530f5d2812_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20fe8d43-3b5c-43ca-a0c6-f56a5bc5cdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_866b51f2-aef5-4bf5-ae21-79530f5d2812" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20fe8d43-3b5c-43ca-a0c6-f56a5bc5cdd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MiroBioLtdMember_894dbb3c-bcaa-47e0-a750-ebbae6badc54" xlink:href="gild-20221231.xsd#gild_MiroBioLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20fe8d43-3b5c-43ca-a0c6-f56a5bc5cdd9" xlink:to="loc_gild_MiroBioLtdMember_894dbb3c-bcaa-47e0-a750-ebbae6badc54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_23172559-03df-4417-a057-6cefc1cf1882" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20fe8d43-3b5c-43ca-a0c6-f56a5bc5cdd9" xlink:to="loc_gild_ImmunomedicsIncMember_23172559-03df-4417-a057-6cefc1cf1882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_65c63f6f-d977-4b9e-90ff-91aa22fd0160" xlink:href="gild-20221231.xsd#gild_FortySevenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20fe8d43-3b5c-43ca-a0c6-f56a5bc5cdd9" xlink:to="loc_gild_FortySevenIncMember_65c63f6f-d977-4b9e-90ff-91aa22fd0160" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails" xlink:type="extended" id="i7b82cb223baa4112b055e5eacb02d688_EmployeeBenefitsRestrictedStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b59b576-1f46-49c4-ba6f-2085ecdd98c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b59b576-1f46-49c4-ba6f-2085ecdd98c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d23e9ac6-11cd-4602-bbb0-7a0b3a821d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d23e9ac6-11cd-4602-bbb0-7a0b3a821d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_49f6048c-6261-40e4-a029-1b3e80076443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_49f6048c-6261-40e4-a029-1b3e80076443" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00cceb0b-59cd-465b-bf96-32453eac216e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00cceb0b-59cd-465b-bf96-32453eac216e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0363af81-b27b-4770-96a0-05cb65cb5427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0363af81-b27b-4770-96a0-05cb65cb5427" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c95e2a63-d8f6-4810-a11e-9e2cd94a1dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:href="gild-20221231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b59b576-1f46-49c4-ba6f-2085ecdd98c0" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4545bf2a-a86b-4826-a537-4ce303d426f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4545bf2a-a86b-4826-a537-4ce303d426f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5840f762-dc39-49e8-bb0b-ac97cd04e4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5840f762-dc39-49e8-bb0b-ac97cd04e4e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c9742acb-bbfc-4ae5-9b23-4ce3e9b975fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c9742acb-bbfc-4ae5-9b23-4ce3e9b975fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9008b237-7878-4687-ad75-afcd6f9353a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9008b237-7878-4687-ad75-afcd6f9353a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_66af9538-f147-47b7-9640-9438650f9c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f780a7bf-83dd-40e7-9574-719a68b97583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b59b576-1f46-49c4-ba6f-2085ecdd98c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f780a7bf-83dd-40e7-9574-719a68b97583" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_780c5383-8dbf-471d-9ecc-ba3ca15d8b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b59b576-1f46-49c4-ba6f-2085ecdd98c0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_780c5383-8dbf-471d-9ecc-ba3ca15d8b70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5bf8415b-008c-4a05-9894-335ff90ac807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_780c5383-8dbf-471d-9ecc-ba3ca15d8b70" xlink:to="loc_us-gaap_AwardTypeAxis_5bf8415b-008c-4a05-9894-335ff90ac807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5bf8415b-008c-4a05-9894-335ff90ac807_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5bf8415b-008c-4a05-9894-335ff90ac807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5bf8415b-008c-4a05-9894-335ff90ac807_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381ca982-55de-485e-b08b-c196557e2075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5bf8415b-008c-4a05-9894-335ff90ac807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381ca982-55de-485e-b08b-c196557e2075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d49e19de-96d6-4a57-93c6-8b0f16d2fb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381ca982-55de-485e-b08b-c196557e2075" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d49e19de-96d6-4a57-93c6-8b0f16d2fb52" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsPerformanceShareAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails" xlink:type="extended" id="icb4fbe0b31a947f08fe6e2ae9d660d8c_EmployeeBenefitsPerformanceShareAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a561219-e6f7-4f06-938c-f6bc3316f432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a561219-e6f7-4f06-938c-f6bc3316f432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7e4b03b-b330-4415-bcd8-ada1914bf277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7e4b03b-b330-4415-bcd8-ada1914bf277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10d3f675-875c-4eb3-a324-35972e910ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10d3f675-875c-4eb3-a324-35972e910ada" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f4e891f4-b752-4811-82fb-bbcd811b702a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f4e891f4-b752-4811-82fb-bbcd811b702a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dc3eb416-961a-41bb-bc01-459f70ff5a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dc3eb416-961a-41bb-bc01-459f70ff5a70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3376d4f4-d2e4-4119-9d2c-cac553824ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:href="gild-20221231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a561219-e6f7-4f06-938c-f6bc3316f432" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bc936c5f-4da6-44aa-b90b-0bca2d95d304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bc936c5f-4da6-44aa-b90b-0bca2d95d304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_546232b8-4be2-4367-a210-32df9aa36275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_546232b8-4be2-4367-a210-32df9aa36275" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8b5f921c-c218-44a1-a8d3-1f71d94373b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8b5f921c-c218-44a1-a8d3-1f71d94373b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_08fc4bab-7434-4920-a12e-681d050c7b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_08fc4bab-7434-4920-a12e-681d050c7b59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d1ff7d46-4031-499b-9187-71f9234235e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_433b9e00-9b79-43aa-98bb-1cd01190807c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a561219-e6f7-4f06-938c-f6bc3316f432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_433b9e00-9b79-43aa-98bb-1cd01190807c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd8cc578-580d-499a-8ef0-282eab259b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a561219-e6f7-4f06-938c-f6bc3316f432" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd8cc578-580d-499a-8ef0-282eab259b35" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dd769a78-790d-491a-876e-9fa95bec5cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd8cc578-580d-499a-8ef0-282eab259b35" xlink:to="loc_us-gaap_AwardTypeAxis_dd769a78-790d-491a-876e-9fa95bec5cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd769a78-790d-491a-876e-9fa95bec5cd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dd769a78-790d-491a-876e-9fa95bec5cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd769a78-790d-491a-876e-9fa95bec5cd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec5aa7e0-d3bf-4b34-9a78-8a7f460e279b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dd769a78-790d-491a-876e-9fa95bec5cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec5aa7e0-d3bf-4b34-9a78-8a7f460e279b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7e16bad7-f4e8-42e6-848c-ca62ba30e77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec5aa7e0-d3bf-4b34-9a78-8a7f460e279b" xlink:to="loc_us-gaap_PerformanceSharesMember_7e16bad7-f4e8-42e6-848c-ca62ba30e77f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="extended" id="i048f5ca4c8894332bfeba2e183b05b7c_EmployeeBenefitsStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8cdcceb8-f201-421e-8236-2f98ca57dfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8cdcceb8-f201-421e-8236-2f98ca57dfbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_de9a95cf-f554-42c4-a7fb-d60c9bce249c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_de9a95cf-f554-42c4-a7fb-d60c9bce249c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1cf45be7-b70e-4483-a961-b2b271d5ab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1cf45be7-b70e-4483-a961-b2b271d5ab7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ae365df2-9e70-48c5-b873-aa84a095707f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ae365df2-9e70-48c5-b873-aa84a095707f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e8705b41-010b-4387-b690-9de1cd44b184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e8705b41-010b-4387-b690-9de1cd44b184" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fce3edd1-0741-44d8-bce2-7642e957aaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fc98e04f-ef0d-481c-8e15-cb96852e7acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fc98e04f-ef0d-481c-8e15-cb96852e7acb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8e72c13c-7f3c-4522-ba39-7bc429a8c91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8e72c13c-7f3c-4522-ba39-7bc429a8c91c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:href="gild-20221231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5238887-caef-4c20-9324-7131f9d857a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5238887-caef-4c20-9324-7131f9d857a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d7b6b347-bc48-43a6-9b0b-e523078f8087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d7b6b347-bc48-43a6-9b0b-e523078f8087" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e44a420a-6fd9-4487-81d8-1cc5a39f1ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e44a420a-6fd9-4487-81d8-1cc5a39f1ea4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e48368f3-6c71-4ce2-92c0-9b7bd6d40e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e48368f3-6c71-4ce2-92c0-9b7bd6d40e5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_38cceb80-8ea7-4aaf-ab6b-a7fd9a3b2b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_38cceb80-8ea7-4aaf-ab6b-a7fd9a3b2b1d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89dbf25c-b9ac-4d7c-b37c-309b2da21b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c0fcf360-07dd-467f-8afc-4f81ba06d7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c0fcf360-07dd-467f-8afc-4f81ba06d7e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_13b9fad0-792f-4f3e-9f5e-1b4119360ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_13b9fad0-792f-4f3e-9f5e-1b4119360ef8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6d98e5b8-6d3b-4e6a-9bda-6d06e62a5af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6d98e5b8-6d3b-4e6a-9bda-6d06e62a5af4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_56d39722-bd26-4f32-b1e5-c7951c6e1d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6d98e5b8-6d3b-4e6a-9bda-6d06e62a5af4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_56d39722-bd26-4f32-b1e5-c7951c6e1d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_597f1568-1a7a-483d-9c9b-a17123321c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6d98e5b8-6d3b-4e6a-9bda-6d06e62a5af4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_597f1568-1a7a-483d-9c9b-a17123321c13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6de42851-5c34-4de2-98d9-c8c21c16ad62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6d98e5b8-6d3b-4e6a-9bda-6d06e62a5af4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6de42851-5c34-4de2-98d9-c8c21c16ad62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_75867a4b-9a57-4c4f-9f09-10adf6656861" xlink:href="gild-20221231.xsd#gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_75867a4b-9a57-4c4f-9f09-10adf6656861" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40d57651-e90c-4d44-8d59-b3a0438860dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_75867a4b-9a57-4c4f-9f09-10adf6656861" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40d57651-e90c-4d44-8d59-b3a0438860dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d3d553a8-b3ed-4735-ad1b-257980a4e9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_75867a4b-9a57-4c4f-9f09-10adf6656861" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d3d553a8-b3ed-4735-ad1b-257980a4e9d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ae8a73ac-163e-46ea-accb-f869ab24f845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_75867a4b-9a57-4c4f-9f09-10adf6656861" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ae8a73ac-163e-46ea-accb-f869ab24f845" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_972143fc-f50b-4d0d-a896-4059015b331f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_972143fc-f50b-4d0d-a896-4059015b331f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_755e237b-2c17-4784-bb33-41c2c4fac5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_755e237b-2c17-4784-bb33-41c2c4fac5c1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa95db45-613a-4d3e-9178-6100915cc776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa95db45-613a-4d3e-9178-6100915cc776" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ad6c9223-c1c3-4485-8c34-2f55259c7762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa95db45-613a-4d3e-9178-6100915cc776" xlink:to="loc_us-gaap_AwardTypeAxis_ad6c9223-c1c3-4485-8c34-2f55259c7762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad6c9223-c1c3-4485-8c34-2f55259c7762_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ad6c9223-c1c3-4485-8c34-2f55259c7762" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad6c9223-c1c3-4485-8c34-2f55259c7762_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25419398-492e-4be0-984c-20c5126d2e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ad6c9223-c1c3-4485-8c34-2f55259c7762" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25419398-492e-4be0-984c-20c5126d2e41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_35249967-8fbf-4e5d-a74c-8aea7928f445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25419398-492e-4be0-984c-20c5126d2e41" xlink:to="loc_us-gaap_EmployeeStockOptionMember_35249967-8fbf-4e5d-a74c-8aea7928f445" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="extended" id="i8188ecc9fd4a432db89914cecb59c713_EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_157701c3-5c01-400e-aa99-b22875f44bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_21b3df2b-7fc5-4a1c-8a93-db22f92d88c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_157701c3-5c01-400e-aa99-b22875f44bdb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_21b3df2b-7fc5-4a1c-8a93-db22f92d88c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_05c2b097-822e-4b9c-8ed4-da51690799ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_157701c3-5c01-400e-aa99-b22875f44bdb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_05c2b097-822e-4b9c-8ed4-da51690799ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_129e05e2-c836-4c47-959c-a4c990d5a028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_157701c3-5c01-400e-aa99-b22875f44bdb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_129e05e2-c836-4c47-959c-a4c990d5a028" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_04685da1-2b89-4289-a020-aefb7f5f71e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_157701c3-5c01-400e-aa99-b22875f44bdb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_04685da1-2b89-4289-a020-aefb7f5f71e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f812aa85-cd6d-40f0-9641-36f1e0aa4e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_157701c3-5c01-400e-aa99-b22875f44bdb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f812aa85-cd6d-40f0-9641-36f1e0aa4e21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_81a1f8c8-5af1-4044-acc7-d6591eb02709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f812aa85-cd6d-40f0-9641-36f1e0aa4e21" xlink:to="loc_us-gaap_AwardTypeAxis_81a1f8c8-5af1-4044-acc7-d6591eb02709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81a1f8c8-5af1-4044-acc7-d6591eb02709_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_81a1f8c8-5af1-4044-acc7-d6591eb02709" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81a1f8c8-5af1-4044-acc7-d6591eb02709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd756ae-e5be-4e99-97e0-dfed35e72e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_81a1f8c8-5af1-4044-acc7-d6591eb02709" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd756ae-e5be-4e99-97e0-dfed35e72e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ecd9bcbb-be0c-45b2-873d-f0c75987c040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd756ae-e5be-4e99-97e0-dfed35e72e02" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ecd9bcbb-be0c-45b2-873d-f0c75987c040" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1857c2cb-bcdc-4e5d-b0a7-863d8d5f12e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd756ae-e5be-4e99-97e0-dfed35e72e02" xlink:to="loc_us-gaap_EmployeeStockMember_1857c2cb-bcdc-4e5d-b0a7-863d8d5f12e3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsESPPActivityDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails" xlink:type="extended" id="i2d00af42b33f4bcebb22f01791644870_EmployeeBenefitsESPPActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2b26db-5cd4-40b6-a7d1-be30faa5ea88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b288130b-ec3e-4d95-9bfe-7e8c01b81cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2b26db-5cd4-40b6-a7d1-be30faa5ea88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b288130b-ec3e-4d95-9bfe-7e8c01b81cc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2a8bec4a-7203-46f7-9cc2-d15e91025962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2b26db-5cd4-40b6-a7d1-be30faa5ea88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2a8bec4a-7203-46f7-9cc2-d15e91025962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare_97fde441-f0f0-49e5-808b-74d2e2ef875b" xlink:href="gild-20221231.xsd#gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2b26db-5cd4-40b6-a7d1-be30faa5ea88" xlink:to="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare_97fde441-f0f0-49e5-808b-74d2e2ef875b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_156d5e39-e27d-4ab2-aded-bddebc4fb918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2b26db-5cd4-40b6-a7d1-be30faa5ea88" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_156d5e39-e27d-4ab2-aded-bddebc4fb918" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19f4706d-3164-446d-b19a-d8ad959dcb21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2b26db-5cd4-40b6-a7d1-be30faa5ea88" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19f4706d-3164-446d-b19a-d8ad959dcb21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05a3fd06-5181-4a72-8386-f8d0364d4026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19f4706d-3164-446d-b19a-d8ad959dcb21" xlink:to="loc_us-gaap_AwardTypeAxis_05a3fd06-5181-4a72-8386-f8d0364d4026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05a3fd06-5181-4a72-8386-f8d0364d4026_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_05a3fd06-5181-4a72-8386-f8d0364d4026" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05a3fd06-5181-4a72-8386-f8d0364d4026_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd9ac61e-78ae-4cb7-8cf6-a8782bf722eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_05a3fd06-5181-4a72-8386-f8d0364d4026" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd9ac61e-78ae-4cb7-8cf6-a8782bf722eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_135500db-16ac-4d13-ad58-a07aed4bfa54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd9ac61e-78ae-4cb7-8cf6-a8782bf722eb" xlink:to="loc_us-gaap_EmployeeStockMember_135500db-16ac-4d13-ad58-a07aed4bfa54" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i8d4e56e36fd7477199a2056af19dfa28_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_67afd268-8c98-4b47-9b6f-156376ba52a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_67afd268-8c98-4b47-9b6f-156376ba52a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_dcdcfa00-e5e7-4269-b737-aa93b0a3ccc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_dcdcfa00-e5e7-4269-b737-aa93b0a3ccc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0a3e843f-8360-484e-854b-6d7cc89b9f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_0a3e843f-8360-484e-854b-6d7cc89b9f88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_cfd40077-b889-491c-be74-eea8df3cb79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_cfd40077-b889-491c-be74-eea8df3cb79c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3e65b35a-324d-4810-98e8-94866c6ee616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3e65b35a-324d-4810-98e8-94866c6ee616" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_80b47080-359a-4f78-8943-e4f00030031b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_80b47080-359a-4f78-8943-e4f00030031b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7caad3ef-cbd4-4d96-87c7-204a8b96347b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7caad3ef-cbd4-4d96-87c7-204a8b96347b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_622852b8-20f9-4634-a275-21c08174e85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_622852b8-20f9-4634-a275-21c08174e85c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e11f7f18-afcd-47a0-b33c-2130007f398f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_622852b8-20f9-4634-a275-21c08174e85c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e11f7f18-afcd-47a0-b33c-2130007f398f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e11f7f18-afcd-47a0-b33c-2130007f398f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e11f7f18-afcd-47a0-b33c-2130007f398f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e11f7f18-afcd-47a0-b33c-2130007f398f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a311c125-9c61-4733-9532-6afdce2a370f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e11f7f18-afcd-47a0-b33c-2130007f398f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a311c125-9c61-4733-9532-6afdce2a370f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_16f36767-92cc-45e6-8095-39e8e6638638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a311c125-9c61-4733-9532-6afdce2a370f" xlink:to="loc_us-gaap_DomesticCountryMember_16f36767-92cc-45e6-8095-39e8e6638638" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_8cd1566f-f8be-4b79-85f3-840cd718a82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a311c125-9c61-4733-9532-6afdce2a370f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_8cd1566f-f8be-4b79-85f3-840cd718a82b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.gilead.com/role/SubsequentEventsDetails" xlink:type="extended" id="i9b9e65a6571b40a6b38d763fab0015b5_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b8cc8a99-50e3-4044-9340-aaecd810e673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7c4cfa4b-9974-4e7f-9099-8197d857e248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b8cc8a99-50e3-4044-9340-aaecd810e673" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7c4cfa4b-9974-4e7f-9099-8197d857e248" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_c741de98-bd93-4655-9088-22668b702177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b8cc8a99-50e3-4044-9340-aaecd810e673" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_c741de98-bd93-4655-9088-22668b702177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuePerformanceObligationPercentageOfUSProfits_4cfbffd4-723c-460b-9fd6-a3a8fe8084d3" xlink:href="gild-20221231.xsd#gild_RevenuePerformanceObligationPercentageOfUSProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b8cc8a99-50e3-4044-9340-aaecd810e673" xlink:to="loc_gild_RevenuePerformanceObligationPercentageOfUSProfits_4cfbffd4-723c-460b-9fd6-a3a8fe8084d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForAssetAcquisitions_6c62981f-1866-48b4-852d-d5197584f01f" xlink:href="gild-20221231.xsd#gild_PaymentsForAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b8cc8a99-50e3-4044-9340-aaecd810e673" xlink:to="loc_gild_PaymentsForAssetAcquisitions_6c62981f-1866-48b4-852d-d5197584f01f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_b8cc8a99-50e3-4044-9340-aaecd810e673" xlink:to="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8216b93f-7016-4c9b-a5ec-b8c9e913a9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8216b93f-7016-4c9b-a5ec-b8c9e913a9ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8216b93f-7016-4c9b-a5ec-b8c9e913a9ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8216b93f-7016-4c9b-a5ec-b8c9e913a9ff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8216b93f-7016-4c9b-a5ec-b8c9e913a9ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a1ad2d4d-1015-463f-ab57-6a34ec3924b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8216b93f-7016-4c9b-a5ec-b8c9e913a9ff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a1ad2d4d-1015-463f-ab57-6a34ec3924b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9c3f2ca3-b02d-4349-8c31-ab17cccb20b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a1ad2d4d-1015-463f-ab57-6a34ec3924b2" xlink:to="loc_us-gaap_SubsequentEventMember_9c3f2ca3-b02d-4349-8c31-ab17cccb20b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f87c8a5b-724c-479f-ad93-d318c409f2cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f87c8a5b-724c-479f-ad93-d318c409f2cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f87c8a5b-724c-479f-ad93-d318c409f2cf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f87c8a5b-724c-479f-ad93-d318c409f2cf" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f87c8a5b-724c-479f-ad93-d318c409f2cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_83acc63c-9498-4d59-b627-378b563dadb7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f87c8a5b-724c-479f-ad93-d318c409f2cf" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_83acc63c-9498-4d59-b627-378b563dadb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcellxIncMember_6043bf9a-60cf-4b6b-88e2-de0f9ea7195e" xlink:href="gild-20221231.xsd#gild_ArcellxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_83acc63c-9498-4d59-b627-378b563dadb7" xlink:to="loc_gild_ArcellxIncMember_6043bf9a-60cf-4b6b-88e2-de0f9ea7195e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e590b969-58e6-4ced-a06b-dd5cdea8d865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e590b969-58e6-4ced-a06b-dd5cdea8d865" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e590b969-58e6-4ced-a06b-dd5cdea8d865_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e590b969-58e6-4ced-a06b-dd5cdea8d865" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e590b969-58e6-4ced-a06b-dd5cdea8d865_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee03ff79-136a-4598-8eed-acdddabd38c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e590b969-58e6-4ced-a06b-dd5cdea8d865" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee03ff79-136a-4598-8eed-acdddabd38c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GlobalStrategicCollaborationAgreementMember_678179a4-7023-4e3c-80b9-b08a9aa0959b" xlink:href="gild-20221231.xsd#gild_GlobalStrategicCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee03ff79-136a-4598-8eed-acdddabd38c1" xlink:to="loc_gild_GlobalStrategicCollaborationAgreementMember_678179a4-7023-4e3c-80b9-b08a9aa0959b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c95bb65a-6d79-4ea6-a8f0-48d5e5957782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c95bb65a-6d79-4ea6-a8f0-48d5e5957782" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c95bb65a-6d79-4ea6-a8f0-48d5e5957782_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c95bb65a-6d79-4ea6-a8f0-48d5e5957782" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c95bb65a-6d79-4ea6-a8f0-48d5e5957782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_6209e1b3-eab3-49c9-aaff-76276ab20bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c95bb65a-6d79-4ea6-a8f0-48d5e5957782" xlink:to="loc_us-gaap_AssetAcquisitionDomain_6209e1b3-eab3-49c9-aaff-76276ab20bfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TmunityTherapeuticsMember_1b31d917-10b0-4b17-a1b8-7ffb922c0ed6" xlink:href="gild-20221231.xsd#gild_TmunityTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_6209e1b3-eab3-49c9-aaff-76276ab20bfe" xlink:to="loc_gild_TmunityTherapeuticsMember_1b31d917-10b0-4b17-a1b8-7ffb922c0ed6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019609b8-6e64-43e4-91f1-1b8c9f7f1ca9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:to="loc_dei_LegalEntityAxis_019609b8-6e64-43e4-91f1-1b8c9f7f1ca9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_019609b8-6e64-43e4-91f1-1b8c9f7f1ca9_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_019609b8-6e64-43e4-91f1-1b8c9f7f1ca9" xlink:to="loc_dei_EntityDomain_019609b8-6e64-43e4-91f1-1b8c9f7f1ca9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a910bd10-9990-4401-83ff-0be1e3ea33a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_019609b8-6e64-43e4-91f1-1b8c9f7f1ca9" xlink:to="loc_dei_EntityDomain_a910bd10-9990-4401-83ff-0be1e3ea33a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcellxIncMember_f124eab3-c725-45c1-9bcb-819785cd883a" xlink:href="gild-20221231.xsd#gild_ArcellxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a910bd10-9990-4401-83ff-0be1e3ea33a6" xlink:to="loc_gild_ArcellxIncMember_f124eab3-c725-45c1-9bcb-819785cd883a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>gild-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:138d9561-5f65-4b2f-b0c5-a8cb97862906,g:db888c96-90b0-4c6d-8008-49d88ed38ca7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_092f18a5-e654-42e7-a046-a2834d665287_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_f58b15fc-c5a2-4d50-9f44-6ebcf017f81b_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_d32cafb2-357b-406e-a804-34dd8405b33e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b35adf44-4f4b-47bc-b869-cfae1039d899_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation and Transaction</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_d38103b5-637c-43a8-ac56-dd5c8aebb9ef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_160d806b-16ba-49c2-ad9e-e48c803f6596_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total senior unsecured notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_03055802-d353-43f1-ba1a-26598d1f8802_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_c851bd59-e8f2-4930-aec5-9f3037c09524_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local income tax expense (benefit), continuing operations</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_d1068e25-b977-46b2-85d3-81221d165a84_terseLabel_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Running royalty rate on future sales</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_label_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate on Future Sales</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateOnFutureSales_documentation_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate on Future Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales" xlink:href="gild-20221231.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentRoyaltyRateOnFutureSales" xlink:to="lab_gild_JudgmentRoyaltyRateOnFutureSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_d2e687e7-e58b-413e-9bf0-d303ba7f17c0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a8bc1e2f-32e5-4a5e-b85f-5bfaad8a4cb6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_4a66c841-6283-4021-be98-abfddca67d59_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_fe4a595e-975d-453d-85c6-33a2d3f7b72e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b36ed1e6-6eb2-49cc-9e0f-4f2d736b087e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_c3fb2ef4-291a-4d67-b020-d5417ee10b8d_terseLabel_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:href="gild-20221231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:to="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_66f18a72-30a1-4893-96b1-763846bd1e08_terseLabel_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 stock repurchase program</link:label>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_label_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_gild_A2020StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_gild_A2020StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember" xlink:href="gild-20221231.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A2020StockRepurchaseProgramMember" xlink:to="lab_gild_A2020StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_37565976-fbff-40bd-aa07-b48785b4c080_terseLabel_en-US" xlink:label="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties, measurement Input</link:label>
    <link:label id="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_label_en-US" xlink:label="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Future Royalties, Liability, Measurement Input</link:label>
    <link:label id="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Future Royalties, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:href="gild-20221231.xsd#gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:to="lab_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsYescartaMember_2a8e5efd-5530-4749-8d5c-db94ffd64f4a_terseLabel_en-US" xlink:label="lab_gild_OtherProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Yescarta</link:label>
    <link:label id="lab_gild_OtherProductsYescartaMember_label_en-US" xlink:label="lab_gild_OtherProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Yescarta [Member]</link:label>
    <link:label id="lab_gild_OtherProductsYescartaMember_documentation_en-US" xlink:label="lab_gild_OtherProductsYescartaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Yescarta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsYescartaMember" xlink:href="gild-20221231.xsd#gild_OtherProductsYescartaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsYescartaMember" xlink:to="lab_gild_OtherProductsYescartaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_ec1493c2-b68e-4690-9338-07d1261dc6c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_acd2177d-7f66-4134-867a-49d8cf95fb5e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4bea1ada-16f5-44e2-a3ad-df7c13d5464b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_28d0f980-9816-4b68-815e-fbda33bfb128_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time estimate for gains (losses) to be reclassified from AOCI to product sales</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InjectableFormulationProductMember_9208215f-9c73-4d67-93d2-6465b7041f9d_terseLabel_en-US" xlink:label="lab_gild_InjectableFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation Product</link:label>
    <link:label id="lab_gild_InjectableFormulationProductMember_label_en-US" xlink:label="lab_gild_InjectableFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation Product [Member]</link:label>
    <link:label id="lab_gild_InjectableFormulationProductMember_documentation_en-US" xlink:label="lab_gild_InjectableFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Injectable Formulation Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InjectableFormulationProductMember" xlink:href="gild-20221231.xsd#gild_InjectableFormulationProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InjectableFormulationProductMember" xlink:to="lab_gild_InjectableFormulationProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b7217577-45c6-49a6-a1fc-6a2ba2045737_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_14b91783-2613-496e-bfa2-ea8fd0d0a5d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_f892fa0c-a7aa-40ce-a71f-e674ddda2e33_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_56eeb24b-c25a-48ba-a2f0-edfc1a85526b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_51f95572-1e78-4982-8f80-f9ba01d52cb3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_90b26279-7979-427b-8ae7-bf0b00411981_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_44ed6bd9-33ca-4304-8441-4f787f898965_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_c5aa4e76-85d3-4326-a32a-c226076f9c71_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_985d3b64-f80b-41f4-9db1-2cf46dbd4985_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5ec46a4e-ac8a-4982-bab0-8765bb8d5a2e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Effect of Foreign Currency Exchange Contracts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_84b5f43d-c737-47f1-b5eb-849009e4ffe8_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_cca1c9a7-634c-4d00-9b3b-16a225b76651_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_b4023912-4cca-4473-9243-b486bb405a0a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, statement of financial position</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_59f9d3f3-088c-4f0a-80a8-753ce86bce2b_terseLabel_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus collaboration agreement and stock purchase agreements</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_label_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement and Stock Purchase Agreements [Member]</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_documentation_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement and Stock Purchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:href="gild-20221231.xsd#gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:to="lab_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1f84182c-9ea9-4e21-a869-02580143004c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_4bc5273e-d88d-4e9e-9c0e-1928c2fedd25_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_475cb264-b074-4d0e-adba-1373224e7a95_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_3c85ae65-7b28-4a01-9c0f-31f0be293013_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3a9f40f0-1d61-465e-855d-1d7ac59f024e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_9258d13e-1d69-4a3a-a4fa-3257e06c4de4_terseLabel_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmBisome</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_label_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:label id="lab_gild_OtherProductsAmBisomeMember_documentation_en-US" xlink:label="lab_gild_OtherProductsAmBisomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, AmBisome [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember" xlink:href="gild-20221231.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsAmBisomeMember" xlink:to="lab_gild_OtherProductsAmBisomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_797ecaf7-258d-4c8a-93ec-e90d23760873_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income, net of tax impact of $0, $0 and $12, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_4970fbc0-e0a1-4b59-9585-76675245c6f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_b57a14b3-1d49-4d59-9704-b8240dacf815_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GileadSciencesInc2022EquityIncentivePlanMember_5b5bc9ff-8fcd-482b-b228-1cbd67a6c3e6_terseLabel_en-US" xlink:label="lab_gild_GileadSciencesInc2022EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Equity Incentive Plan</link:label>
    <link:label id="lab_gild_GileadSciencesInc2022EquityIncentivePlanMember_label_en-US" xlink:label="lab_gild_GileadSciencesInc2022EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences, Inc. 2022 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_gild_GileadSciencesInc2022EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_gild_GileadSciencesInc2022EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Sciences, Inc. 2022 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2022EquityIncentivePlanMember" xlink:href="gild-20221231.xsd#gild_GileadSciencesInc2022EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GileadSciencesInc2022EquityIncentivePlanMember" xlink:to="lab_gild_GileadSciencesInc2022EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_27607b0c-1d05-47f3-a99d-1cfbc293b30c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ac952dab-b105-4c25-ab3c-5842c21fdee7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b64fa727-fe3b-4aa8-86ae-51b9521bbf80_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_b89b2c5b-30e1-42d9-afc3-e9cb7d895963_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_6c651661-7347-49e3-84ac-ccf1a6ab7e24_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_44535c47-9856-479b-aa62-89be2fa29e04_terseLabel_en-US" xlink:label="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in millions)</link:label>
    <link:label id="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_label_en-US" xlink:label="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:href="gild-20221231.xsd#gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_ece41c28-6c06-43f5-be62-a81c77bebed0_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_dcdc743a-c333-443e-9910-c3aed7aa11af_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_8dc91f5a-cd74-4e3f-a7ac-4c86cd813004_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EverestMedicinesMember_50751122-795d-4408-b11f-9bc658ca4b47_terseLabel_en-US" xlink:label="lab_gild_EverestMedicinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Everest Medicines</link:label>
    <link:label id="lab_gild_EverestMedicinesMember_label_en-US" xlink:label="lab_gild_EverestMedicinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Everest Medicines [Member]</link:label>
    <link:label id="lab_gild_EverestMedicinesMember_documentation_en-US" xlink:label="lab_gild_EverestMedicinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Everest Medicines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EverestMedicinesMember" xlink:href="gild-20221231.xsd#gild_EverestMedicinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EverestMedicinesMember" xlink:to="lab_gild_EverestMedicinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_a710ddc6-4a44-4c06-90a2-c205e79b4bee_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8ba6034b-da3b-41ec-8e92-b9429e17a9e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_95ef745e-79f8-4b61-b82a-01d1c6751495_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeArrangementTerm_5b018baa-a9f8-49a0-9196-424e4a7624a6_terseLabel_en-US" xlink:label="lab_gild_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration term</link:label>
    <link:label id="lab_gild_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_gild_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_gild_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_gild_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeArrangementTerm" xlink:href="gild-20221231.xsd#gild_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeArrangementTerm" xlink:to="lab_gild_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c0d55160-4b40-4946-8d8d-344c3b7322f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, current, statement of financial position, extensible enumeration</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_9a1487c8-8863-492a-afec-16c61972cf13_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_277a3a1c-471f-4bb4-a70b-54bce080b381_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MckessonCorpMember_575a54c4-8b51-4f19-a73b-44899e71b2b0_terseLabel_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_gild_MckessonCorpMember_label_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:label id="lab_gild_MckessonCorpMember_documentation_en-US" xlink:label="lab_gild_MckessonCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember" xlink:href="gild-20221231.xsd#gild_MckessonCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MckessonCorpMember" xlink:to="lab_gild_MckessonCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_3658660d-e89d-4f84-9a93-c21ed446237c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_8bcc45fd-fb68-43c9-9b9f-b2b13c166a8d_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_b31875de-9a4f-4b96-82f0-fb19384c3d9f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts outstanding under the facility</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2f552b22-f7e9-457a-aef7-b36595bb2dd9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_8a087056-cbf4-4a02-b03a-c35b25b2866f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_3cf8c57a-e1a1-49f9-85ef-ce0aaca0266e_terseLabel_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of tiered royalties, high-end percentage</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_label_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalties High-end, Percentage</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_documentation_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalties High-end, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:href="gild-20221231.xsd#gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:to="lab_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5d353109-916a-44c7-9d09-f00fd1a41c70_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_34bd1f32-419b-40d1-95a4-9782ae7240ea_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_8d330967-35e4-4ee7-8fca-5c938a71bd7f_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowances for chargebacks</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableChargebacksCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Chargebacks, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent" xlink:href="gild-20221231.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableChargebacksCurrent" xlink:to="lab_gild_AccountsReceivableChargebacksCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_104fea98-f52a-4f7b-a751-568600be1d22_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In Process Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9be1de76-0ab3-4cbb-b3dc-18e0df1ea3b4_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_be302e18-943a-43aa-9d68-2ba07d6b46d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_3c142555-635c-4ef3-8054-e06371164443_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities &#8211; current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_77002f5a-0e51-4a77-b016-4884af1e4249_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_94f3ca89-0e0d-4f2e-9812-413f5187d2a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_6001c5a7-0d1d-4910-a6bd-9b380aece0bc_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_efa8e4c5-29e7-42e6-9d04-dd2e7b97ba86_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restriction period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restriction Period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIRestrictionPeriod_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:to="lab_gild_EquitySecuritiesFVNIRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_afb32c69-058a-40f3-85b2-d4f03a7819a0_terseLabel_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genvoya</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_label_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:label id="lab_gild_HIVProductsGenvoyaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsGenvoyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Genvoya [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember" xlink:href="gild-20221231.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsGenvoyaMember" xlink:to="lab_gild_HIVProductsGenvoyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_36e4d836-7a7c-4f61-9af9-d4f688a788a7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_15bec10a-09aa-488f-9fef-a335f64ce7db_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialOptionExerciseFeePerProgram_448e1572-75f5-4132-97b9-486096ac2dad_terseLabel_en-US" xlink:label="lab_gild_PotentialOptionExerciseFeePerProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential option exercise fee</link:label>
    <link:label id="lab_gild_PotentialOptionExerciseFeePerProgram_label_en-US" xlink:label="lab_gild_PotentialOptionExerciseFeePerProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Option Exercise Fee Per Program</link:label>
    <link:label id="lab_gild_PotentialOptionExerciseFeePerProgram_documentation_en-US" xlink:label="lab_gild_PotentialOptionExerciseFeePerProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Option Exercise Fee Per Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialOptionExerciseFeePerProgram" xlink:href="gild-20221231.xsd#gild_PotentialOptionExerciseFeePerProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialOptionExerciseFeePerProgram" xlink:to="lab_gild_PotentialOptionExerciseFeePerProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_d3b31d58-7b16-4db5-9821-9f9b4b5e70d7_terseLabel_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for adjustments of budgeted development costs in 2022</link:label>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months</link:label>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_documentation_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:href="gild-20221231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:to="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5b5d31c8-359b-484b-8872-cd327da8732b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21d5644c-f787-4b2c-9f97-f43076c030c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_ef3ce1eb-66ae-4743-b113-72d722357241_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_e0b6fc8e-d7fa-4784-bbee-de8218d387e9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7b589cf4-8f00-4e3e-be92-2ca4c09dd3c9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2041Member_c64cbbfc-1f9c-47b3-89ca-af88bb024dc4_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.65% Senior Unsecured Notes Due in December 2041</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2041Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueDecember2041Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due December 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueDecember2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3fade976-6cf8-48bd-a143-fee6edb38a49_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fb806fa5-45d7-4845-bc94-76d0c1aaebcf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_61304136-b31f-4a50-be54-af7c8483f554_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent_3b53341c-c035-490f-b4b9-d9d58fa221e6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for settlement related to bictegravir litigation</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_65728d1a-32d9-4645-924b-14e1bfce8143_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree_c54c354e-3e70-4cb6-b338-11543f9c475b_terseLabel_en-US" xlink:label="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree_label_en-US" xlink:label="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year Three</link:label>
    <link:label id="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree_documentation_en-US" xlink:label="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree" xlink:href="gild-20221231.xsd#gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree" xlink:to="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_27941ac2-edd2-44af-8f55-17df7dfc7c6e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5c00a953-2f3b-4a6c-b5d8-7d9679ee130c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_d8ba90e8-0f81-4204-88da-1128e7267bfd_terseLabel_en-US" xlink:label="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">the "2020 Fixed Rate Notes"</link:label>
    <link:label id="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_label_en-US" xlink:label="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Rate Senior Unsecured Note Issued September 2020 [Member]</link:label>
    <link:label id="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_documentation_en-US" xlink:label="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Rate Senior Unsecured Note Issued September 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:href="gild-20221231.xsd#gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:to="lab_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ScheduleofInventoryTable_6ce7e097-a3f9-40d0-802e-dde7e5bb99f0_terseLabel_en-US" xlink:label="lab_gild_ScheduleofInventoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Table]</link:label>
    <link:label id="lab_gild_ScheduleofInventoryTable_label_en-US" xlink:label="lab_gild_ScheduleofInventoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Table]</link:label>
    <link:label id="lab_gild_ScheduleofInventoryTable_documentation_en-US" xlink:label="lab_gild_ScheduleofInventoryTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about inventory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable" xlink:href="gild-20221231.xsd#gild_ScheduleofInventoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ScheduleofInventoryTable" xlink:to="lab_gild_ScheduleofInventoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_458979fc-1798-4660-acef-d08585f09f6b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_fd1fc3bf-b66f-4c93-9186-3fa7c79fc0ba_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for sales returns</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2f592a7a-2799-47b7-b5c5-72994af96f8e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9f1be8ee-c865-4683-b032-9ad00152c965_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_63b037c7-8718-4fe1-8e68-27a0bddb8c28_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_14d50833-1224-4b03-a4c5-1e5aec492bc7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_ca540532-1a60-4d51-a3d4-9e68dfb67e24_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_46f90742-68bf-4ed3-9a46-04bc008ddc10_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TrodelvyMember_2e766b48-82da-4b91-9576-0ad942e3f988_terseLabel_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:label id="lab_gild_TrodelvyMember_4ed647e8-9bd1-4f96-b17a-41862a2eeddd_verboseLabel_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset &#8211; Trodelvy</link:label>
    <link:label id="lab_gild_TrodelvyMember_label_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy [Member]</link:label>
    <link:label id="lab_gild_TrodelvyMember_documentation_en-US" xlink:label="lab_gild_TrodelvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trodelvy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember" xlink:href="gild-20221231.xsd#gild_TrodelvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TrodelvyMember" xlink:to="lab_gild_TrodelvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ScheduleOfInventoryLineItems_f843fd91-7468-4323-a70c-3862b52a55cb_terseLabel_en-US" xlink:label="lab_gild_ScheduleOfInventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Line Items]</link:label>
    <link:label id="lab_gild_ScheduleOfInventoryLineItems_label_en-US" xlink:label="lab_gild_ScheduleOfInventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Line Items]</link:label>
    <link:label id="lab_gild_ScheduleOfInventoryLineItems_documentation_en-US" xlink:label="lab_gild_ScheduleOfInventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleOfInventoryLineItems" xlink:href="gild-20221231.xsd#gild_ScheduleOfInventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ScheduleOfInventoryLineItems" xlink:to="lab_gild_ScheduleOfInventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_65e23ad0-0e8c-40cd-9811-bea7e271b4be_terseLabel_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_label_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:label id="lab_gild_CollaborativeandOtherArrangementsAbstract_documentation_en-US" xlink:label="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract" xlink:href="gild-20221231.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract" xlink:to="lab_gild_CollaborativeandOtherArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_e38422be-7242-4527-9242-f6f202061a56_terseLabel_en-US" xlink:label="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential payment for adjustments of budgeted development costs</link:label>
    <link:label id="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_label_en-US" xlink:label="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Payment for Adjustments of Budgeted Development Costs</link:label>
    <link:label id="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_documentation_en-US" xlink:label="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Payment for Adjustments of Budgeted Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:href="gild-20221231.xsd#gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:to="lab_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b5efe712-af6d-4ba0-b19b-b371b59fdef3_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9218db65-ddbe-4613-a4ce-5f796718a3f1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_6028df71-ec3e-4ced-b710-082c2e1d314f_terseLabel_en-US" xlink:label="lab_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Life</link:label>
    <link:label id="lab_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_label_en-US" xlink:label="lab_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_documentation_en-US" xlink:label="lab_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Lives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:href="gild-20221231.xsd#gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="lab_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_020b4abf-2f4d-4255-9bdb-98c19141d970_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_375346da-10c3-49c9-952c-160c65c57c6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_5fb22b75-e87e-416d-86f8-f3fde5d198b1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_5e174b70-6417-466a-80d5-d41db92a1753_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca5231f9-12a7-4e61-b64e-7d255cbed037_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0c3b6a64-f192-4011-887e-8b10d11a27d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_38369ce2-f0a5-4778-b780-837c1f656c8a_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20221231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_df791c34-6bc7-48ff-96f4-2ff0f70b6242_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dd03439f-36f2-4a83-bfde-0112a1ba772c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a0a29358-b27f-4a58-8070-e08f36e0dca7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings at different rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_6909e913-1e23-43c1-a4c6-92d22926bd24_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_55afec01-19f5-46ee-aabe-28e6cbdd34ec_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member_09fee03c-62e1-41bc-b4b9-8a8ded79eda7_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Senior Unsecured Notes Due in March 2027</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2027 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_437060a1-26f2-4954-9b15-c1c46cf0988a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;long-term&#160;obligations</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d88c45c4-d8b0-4919-9439-2082508d88d3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_f010fd5a-9ffd-40b5-9d8c-6ee73d0f4bf2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact of net unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherInternationalMember_cacecf35-21ed-4e33-a6a7-c3392c50e9dd_terseLabel_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International</link:label>
    <link:label id="lab_gild_OtherInternationalMember_label_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:label id="lab_gild_OtherInternationalMember_documentation_en-US" xlink:label="lab_gild_OtherInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember" xlink:href="gild-20221231.xsd#gild_OtherInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherInternationalMember" xlink:to="lab_gild_OtherInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_5529d642-67ef-40fd-84ff-155b91d811fe_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_45381124-2226-4c7b-ac5c-2eed291caeb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_1335ddda-a19e-4e2b-89b2-3f3fd6e996ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Classification and Fair Value of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e0993387-699b-4f3e-b90a-3691489b1164_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_3d725380-1f81-4dce-abc9-8eb247d3a89b_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements (including leasehold improvements)</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_bafb1afe-aba8-4f8c-9c14-2a75e7e17358_terseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets (and liabilities), net</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_label_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_documentation_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:href="gild-20221231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:to="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a05e4d95-32d7-4a8c-b041-56a0690c4d26_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_672e31db-ff28-442b-84ac-42ae1d1faa34_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1dddc28e-8c17-45bd-827e-789af8f56c8d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_63e77256-5c07-4967-8f7f-1983f01e4429_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_76f13e33-8ae3-4870-8fb2-46ad9a8f92f0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_7d0dcdcb-da0f-46e2-a63c-8c8ecb46e21e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_12d2ac47-1595-49e1-bba4-997230b40994_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3332af16-b029-4a10-a3ef-97e38bdb4354_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_2321b11e-c251-4799-b242-6d909557e13d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TizonaMergerAndOptionAgreementsMember_fa855bdd-360e-42fc-a9ef-82489dee5f85_terseLabel_en-US" xlink:label="lab_gild_TizonaMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona merger and option agreements</link:label>
    <link:label id="lab_gild_TizonaMergerAndOptionAgreementsMember_label_en-US" xlink:label="lab_gild_TizonaMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona Merger and Option Agreements [Member]</link:label>
    <link:label id="lab_gild_TizonaMergerAndOptionAgreementsMember_documentation_en-US" xlink:label="lab_gild_TizonaMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona Merger and Option Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaMergerAndOptionAgreementsMember" xlink:href="gild-20221231.xsd#gild_TizonaMergerAndOptionAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TizonaMergerAndOptionAgreementsMember" xlink:to="lab_gild_TizonaMergerAndOptionAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_d830068d-e8c0-4f6d-9202-791f7b0775af_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_138fc503-e5bf-459d-933f-093eec21e8e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_8b8a359c-4bb8-4165-b03b-9ce93679617e_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tecartus</link:label>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Tecartus [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsTecartusMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsTecartusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Tecartus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember" xlink:href="gild-20221231.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsTecartusMember" xlink:to="lab_gild_CellTherapyProductsTecartusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseLongTermDebt_41fc8de9-9cee-4f04-9682-46f05a743f99_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseLongTermDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseLongTermDebt" xlink:to="lab_us-gaap_InterestExpenseLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_f94bd820-298c-463c-998e-ede00b3d126d_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_9227060c-69fe-4415-894d-edaf7915664d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3392702-5ef2-4b01-ad88-1f6cfdb355de_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20a3ecc5-3e72-47df-8094-a658cd76aae7_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3b061c4c-cb72-436c-98a6-90be6adbfaab_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b0dc3288-9c95-4063-a5d6-7c03b7accaa3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5978f3af-ce84-4f4b-8932-8ee36b97abde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_174fbd62-5bfe-4e6b-8a3f-38ef5aef9f5d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_acc15c42-3f7a-4668-83db-13cc57859471_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt financing, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_7c32e44b-d090-4f07-be61-1bc320a0dcf1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_01f13686-d48d-4a29-ab9f-f806591a6645_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b4a3d6a1-6fed-4ab2-99a3-a7b67b72ab78_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_cdfa02f7-d559-40dc-a702-f8e41b48808e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss), net of tax impact of $20, $18 and $(15), respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1fea3994-93cf-451f-baa1-e9f44bdbc6b3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b5ec1bec-2f6b-4e90-9909-5861a3055fcb_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3db62701-5057-46cf-9a7c-c619c41e1662_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_051ddabd-d0ae-4951-97de-e26c097c02dd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2c2909e8-c177-4559-b33a-71e68a95310b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_69bae589-43c9-4160-a368-16ab9379aa39_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_d6039841-0cd1-401c-9d31-fe94c15b11b9_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d28ec92a-97ff-477e-a1d4-1226d06d141e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_300fb4cb-ef21-4559-84a6-355ee7a3e90d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c0330410-d449-4be7-9e9b-e9d892c4fdd1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3bc68e9e-5250-417e-9498-6f61c3b5370e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e965089c-25e1-4ad7-a75f-b4e924094281_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_e22ae9fc-b666-403e-b2f8-dcf361656b3e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a67d84cc-7e34-4821-ae6f-06a51f9f6673_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_71b01549-31c0-4af3-938f-5485dca74586_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementNetProductSalesThreshold_0f714888-0a24-4463-96e8-03c9e414e580_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales threshold</link:label>
    <link:label id="lab_gild_CollaborationArrangementNetProductSalesThreshold_label_en-US" xlink:label="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Net Product Sales Threshold</link:label>
    <link:label id="lab_gild_CollaborationArrangementNetProductSalesThreshold_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Net Product Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementNetProductSalesThreshold" xlink:href="gild-20221231.xsd#gild_CollaborationArrangementNetProductSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementNetProductSalesThreshold" xlink:to="lab_gild_CollaborationArrangementNetProductSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_694bf351-2ba6-42e1-9d8e-1cb8fd525432_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo_87ff9f54-9628-42d0-8d3c-a6de188f53cd_terseLabel_en-US" xlink:label="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo_label_en-US" xlink:label="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year Two</link:label>
    <link:label id="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo_documentation_en-US" xlink:label="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo" xlink:href="gild-20221231.xsd#gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo" xlink:to="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_729833c4-229e-40d1-be23-f05595daa9df_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6bc29a0e-9a17-4562-ab05-0e99ac48a915_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5a925264-1d7a-4478-9673-24e9b66d0db0_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_14f8a71d-0199-41de-983c-a3b7ac1ad1de_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_70e499ba-97e7-4177-8e68-a2ff96af9437_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_6412f8f5-ef66-4166-ade2-dd4e34821374_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_35e2f837-d19b-430f-81f4-862a558c5a0d_terseLabel_en-US" xlink:label="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax positions related to prior years:</link:label>
    <link:label id="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_label_en-US" xlink:label="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Prior Period Tax Positions [Abstract]</link:label>
    <link:label id="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_documentation_en-US" xlink:label="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" xlink:href="gild-20221231.xsd#gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" xlink:to="lab_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_45b24598-99d7-42db-be44-64b5708605c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_02dcb070-63d4-4159-a688-6be690ffbda1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member_20f58635-35a9-4e8a-996d-d55256ead8bd_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due in March 2022</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2022 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2e755949-63a3-4d00-be23-42806de553aa_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeAndOtherArrangementsTextBlock_e7aa6c0d-b7b1-444c-b2c6-63b4b6bd6cc9_terseLabel_en-US" xlink:label="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and Other Arrangements</link:label>
    <link:label id="lab_gild_CollaborativeAndOtherArrangementsTextBlock_label_en-US" xlink:label="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative And Other Arrangements [Text Block]</link:label>
    <link:label id="lab_gild_CollaborativeAndOtherArrangementsTextBlock_documentation_en-US" xlink:label="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Arrangements [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:href="gild-20221231.xsd#gild_CollaborativeAndOtherArrangementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:to="lab_gild_CollaborativeAndOtherArrangementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_ae5583e0-9fde-4854-936f-30b2fd552cde_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_749d1324-f223-4107-aecc-6f27fd710f4d_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4a5783e9-a938-4d6c-a4ca-6bfdf0d069ce_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Gilead (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_2e1dd94c-38db-457d-8f41-96b085014165_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact of reclassifications to net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_ed1fc2d5-a33f-4573-947b-daebd16034d0_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9a703912-117d-4f98-8c21-f1364656400a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of RSUs as of the respective vesting dates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4700f520-a36b-44b4-b265-142b6f83f76e_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_4b895330-63ee-40ad-85e1-6adbc5f440cf_totalLabel_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_label_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:label id="lab_gild_InventoryNetAndInventoryNoncurrent_documentation_en-US" xlink:label="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent" xlink:href="gild-20221231.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InventoryNetAndInventoryNoncurrent" xlink:to="lab_gild_InventoryNetAndInventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abba9ace-a93d-44d2-a348-142c773b1b5c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_c68770f2-c92d-4b3c-858b-2026c795810a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign:</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_41c92a49-d9af-481e-9a76-c1016123fe53_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_a22ff15f-44c0-4024-a046-a64d2dc5c7a3_terseLabel_en-US" xlink:label="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax positions related to current year:</link:label>
    <link:label id="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_label_en-US" xlink:label="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Current Period Tax Positions [Abstract]</link:label>
    <link:label id="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_documentation_en-US" xlink:label="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" xlink:href="gild-20221231.xsd#gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" xlink:to="lab_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_640ee0fb-beda-4e7d-b6a7-912b13de437f_terseLabel_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassified intangible assets</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_label_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross, Reclassified</link:label>
    <link:label id="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified_documentation_en-US" xlink:label="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross, Reclassified</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:href="gild-20221231.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:to="lab_gild_FiniteLivedIntangibleAssetsGrossReclassified" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_634ab916-1c0d-4dab-acae-0ddd8220dce7_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d20e67d6-051c-4c54-bec5-ec04dfb2e981_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyNumberOfPatents_7d01f0f6-9613-4db3-b201-f6899b4a7608_terseLabel_en-US" xlink:label="lab_gild_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents</link:label>
    <link:label id="lab_gild_LossContingencyNumberOfPatents_label_en-US" xlink:label="lab_gild_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:label id="lab_gild_LossContingencyNumberOfPatents_documentation_en-US" xlink:label="lab_gild_LossContingencyNumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyNumberOfPatents" xlink:href="gild-20221231.xsd#gild_LossContingencyNumberOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyNumberOfPatents" xlink:to="lab_gild_LossContingencyNumberOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_ee9c7203-3970-48ea-a12d-cc893d336dc1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7a1fae9-9297-4151-965b-ba15e54e667b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_480058f5-39cc-4918-9712-e820ccf2108e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2fb44569-a528-40dc-8dea-4129418a5af2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_b97ed8d6-948f-45ee-8859-00b48729c6c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated stock-based expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_161a5cfa-692d-4b02-8b65-c399142f786e_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_c81d98b4-897d-457d-b954-56cae22a13a5_terseLabel_en-US" xlink:label="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due September 2022</link:label>
    <link:label id="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_label_en-US" xlink:label="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due September 2022 [Member]</link:label>
    <link:label id="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_documentation_en-US" xlink:label="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due September 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:href="gild-20221231.xsd#gild_A325SeniorUnsecuredNotesDueSeptember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:to="lab_gild_A325SeniorUnsecuredNotesDueSeptember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_720fe205-0200-4d78-974a-2d9d33e6844c_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_776ec44e-5e69-4dff-9d57-8aa8e6efe022_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable debt securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember" xlink:href="gild-20221231.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesCurrentMember" xlink:to="lab_gild_MarketableSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member_58e1e7d3-7a58-4fe6-8303-a10fd16520c4_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.65% Senior Unsecured Notes Due in March 2026</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2026 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_06b35ff7-f030-41f3-84b1-f56c51da1f95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Expenses -Included in Consolidated Statement of Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c43e6e71-3098-4e65-946a-3297ff460898_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_eafeee5f-c28a-446a-90ca-536b16a75c84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_01060b1a-95cf-4d6a-8537-f703464d826a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_add73df4-f663-4e28-8f53-272678151379_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_d0746fe3-0843-43e9-8deb-68916f7dffee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_38e09b4b-d107-4b5d-a386-bec6bd320606_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_VekluryMember_2c24e868-ca56-4ffd-a2d2-863870e84184_terseLabel_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:label id="lab_gild_VekluryMember_label_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury [Member]</link:label>
    <link:label id="lab_gild_VekluryMember_documentation_en-US" xlink:label="lab_gild_VekluryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Veklury</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember" xlink:href="gild-20221231.xsd#gild_VekluryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_VekluryMember" xlink:to="lab_gild_VekluryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_bdfd5d92-0a57-46de-ba4f-69831ef58a5f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term extension</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_4b4fdb7c-3b49-42cb-8f61-406597e8722a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FortySevenIncMember_21683866-ddbc-4b23-96c1-3d03ac5d038e_terseLabel_en-US" xlink:label="lab_gild_FortySevenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Seven, Inc.</link:label>
    <link:label id="lab_gild_FortySevenIncMember_label_en-US" xlink:label="lab_gild_FortySevenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Seven, Inc. [Member]</link:label>
    <link:label id="lab_gild_FortySevenIncMember_documentation_en-US" xlink:label="lab_gild_FortySevenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forty Seven, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember" xlink:href="gild-20221231.xsd#gild_FortySevenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FortySevenIncMember" xlink:to="lab_gild_FortySevenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_fba16064-bb09-4e2b-b8bb-985ad665c6fb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_964321c1-db8a-4268-8331-0a35773c61c0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax penalties and interest (benefit) expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_084e8d7c-bf25-460c-acea-6ea68357f515_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_b6101f01-bb8c-4e0c-91ad-b58951ce0d15_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_141927fc-5159-452d-aa79-53a60dd801a6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_aa079087-8b6a-4874-b32f-9d21dade1a3e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a9d6208c-14ca-4441-95ff-7d7279eb6791_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b79c7aff-3336-4e58-bebd-9ed4f056e7d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a614eca1-40fb-49e2-bc57-dc0ea09b13ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsOtherHIVMember_1109c57d-e9c8-4c56-9fa9-7fac9846e0de_terseLabel_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HIV</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_label_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:label id="lab_gild_ProductsOtherHIVMember_documentation_en-US" xlink:label="lab_gild_ProductsOtherHIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Other HIV [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember" xlink:href="gild-20221231.xsd#gild_ProductsOtherHIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsOtherHIVMember" xlink:to="lab_gild_ProductsOtherHIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e193dc6b-5222-4017-817c-b694259cd1c0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_9cdc1788-4f73-4233-81dd-6557061fb9a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact of reclassifications to net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7dd242e5-1c96-4d84-83ea-a97a698415fa_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e4ab8200-db3a-494c-b395-ba6e94639ded_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_30d96e42-e153-4ad9-b205-a3ab8e0ed3b8_terseLabel_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 stock repurchase program</link:label>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_label_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_gild_A2016StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_gild_A2016StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember" xlink:href="gild-20221231.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A2016StockRepurchaseProgramMember" xlink:to="lab_gild_A2016StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8c7a620d-7bf2-4ca0-8435-901105af66e5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized R&amp;D expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_UpfrontPaymentsToTerminatePreviousAgreement_32c314c3-a3d6-4f17-8e63-048e95f96752_terseLabel_en-US" xlink:label="lab_gild_UpfrontPaymentsToTerminatePreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront termination payments</link:label>
    <link:label id="lab_gild_UpfrontPaymentsToTerminatePreviousAgreement_label_en-US" xlink:label="lab_gild_UpfrontPaymentsToTerminatePreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments To Terminate Previous Agreement</link:label>
    <link:label id="lab_gild_UpfrontPaymentsToTerminatePreviousAgreement_documentation_en-US" xlink:label="lab_gild_UpfrontPaymentsToTerminatePreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments To Terminate Previous Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontPaymentsToTerminatePreviousAgreement" xlink:href="gild-20221231.xsd#gild_UpfrontPaymentsToTerminatePreviousAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_UpfrontPaymentsToTerminatePreviousAgreement" xlink:to="lab_gild_UpfrontPaymentsToTerminatePreviousAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract_f73b8607-d4f2-4781-9bcd-dcc65653f1e5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_632771df-db80-4e73-a98b-b4c9fa1459ce_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office, computer equipment and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOther_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOther" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOther" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_99a8a2f6-afef-42fd-8cd2-e87790f288ee_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in, extension and milestone payments</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:to="lab_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b58dfc9-846d-4cbe-bbbb-114869603618_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_2c312629-80d4-45c9-9401-17d8edd5c9e6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5b02595e-6771-4787-b815-53e20a81d566_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_418a6ecd-50c9-4fbb-8528-02d77eed3331_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_dc581d0c-5e13-4a63-b7ff-fb2bbc6a9986_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_b9f01ca1-84f2-4fd9-99d1-d23ea01ed674_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AdditionalResearchAndDevelopmentInProcess_f8b82946-943c-41b4-a467-a0b9c4e020d8_terseLabel_en-US" xlink:label="lab_gild_AdditionalResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional acquired in-process research and development expenses</link:label>
    <link:label id="lab_gild_AdditionalResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_gild_AdditionalResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Research And Development In Process</link:label>
    <link:label id="lab_gild_AdditionalResearchAndDevelopmentInProcess_documentation_en-US" xlink:label="lab_gild_AdditionalResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Research And Development In Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdditionalResearchAndDevelopmentInProcess" xlink:href="gild-20221231.xsd#gild_AdditionalResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AdditionalResearchAndDevelopmentInProcess" xlink:to="lab_gild_AdditionalResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_03c64331-a322-45b5-a61e-8e247cd3fba9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_aac859b9-b5ce-4527-ab9f-b03753796d14_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_00028c13-d0fc-4253-b0d2-eb269d91c055_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2dc64fd3-79a4-4b07-82d9-48ae11b116ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ad056e05-7df1-4b1a-82d7-0a3382e2ccf5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_cc0b6f73-a658-4655-9e06-66fddfb193b9_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_d24b9fc0-a0db-45f5-b083-950b2e167a93_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_0a5733a3-fe11-4cbe-bb67-d94de66b4ce2_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_78282e4e-edc2-407d-bdcc-31190077512e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_30015670-3423-44b3-96a1-81d36bb9e338_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_5ea2418c-fa8d-416e-a348-c4f608afc133_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Donation expense</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b60f8182-648a-4439-903d-edd97bc6e3c6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_355c17d6-e7ba-43b1-abad-994da46ee672_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_19cc346e-3e08-472e-adef-faeae867ee29_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_23c356ba-f658-4488-805b-58f11947bbba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1d8f2bb7-3ac4-4fa1-9014-a0caa0fd44ac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_4c19babd-87ab-4f23-95b0-1c3435a24b11_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_b6e6225f-251f-48c4-beae-648df75d75e4_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_b0ed7482-0552-41a1-b68c-c91fc22f2aca_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_a8934f68-92f6-42e9-a1ec-fd02a90d3607_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, statement of financial position</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_4a32ec66-939f-44ce-a13c-dd2227a96422_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_67878d07-7e96-4791-9872-4f7c8a6a0b87_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_5fc1840b-8eb2-4db1-9c08-8258c60d170d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received / pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_f9113a72-2566-451e-b15e-51e3b7ec7009_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional option fee on fourth, sixth, and eighth anniversaries</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:to="lab_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6dc325e7-4bb4-4f13-8933-6a163c31b203_verboseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a9fb9f5d-9e11-443d-b90d-68d2fbd6caba_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_57924a05-9586-4cd7-8cc4-acd7ee0255f7_terseLabel_en-US" xlink:label="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum ownership percentage</link:label>
    <link:label id="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_label_en-US" xlink:label="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</link:label>
    <link:label id="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_documentation_en-US" xlink:label="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:href="gild-20221231.xsd#gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:to="lab_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_8fc804f1-f773-48f5-bd1f-d80a9f205e92_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_afc8cb8f-d38e-4a06-afb0-7ea27ad3b4d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.001 per share; 5,600 authorized; 1,247 and 1,254 shares issued and outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8f228992-5b0a-40e8-9387-e2cce9e4e9c9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9c12bfd7-a576-4a25-b765-1c65eaa57f57_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_aabaf1e8-b4a3-4510-b2fc-952d7da6e168_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents challenged</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_a2fce896-95af-4d16-86a3-fe085b8431d6_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_f027ded2-fb18-4584-bccd-89715672eeb0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_4980e52b-8d2c-489a-9e7d-c08afc5477d3_terseLabel_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhanced damages on past sales</link:label>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_label_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Enhanced Damages On Past Sales</link:label>
    <link:label id="lab_gild_JudgmentEnhancedDamagesOnPastSales_documentation_en-US" xlink:label="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Enhanced Damages On Past Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales" xlink:href="gild-20221231.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentEnhancedDamagesOnPastSales" xlink:to="lab_gild_JudgmentEnhancedDamagesOnPastSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7ccbc7a7-5182-4a5f-af24-db182956d8c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_2ba6faba-25a5-48c3-8774-eadcf3ebcc42_terseLabel_en-US" xlink:label="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jounce license and stock purchase agreement</link:label>
    <link:label id="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_label_en-US" xlink:label="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Registration Rights and Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Registration Rights and Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:href="gild-20221231.xsd#gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:to="lab_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_0b6eac56-5186-4fe4-b613-7938de8530dc_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e62bbb7d-be80-4f76-a379-9397a36f6b44_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd85b5cc-3836-4e4c-b1ec-f482c20725a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_34d348e2-6b56-4051-a342-791846ed04bd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_936ef496-4607-46e0-a88d-ec334172cdfd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9530eeb9-c5e1-4c71-912a-30d773ebc3a3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_3dcb2e46-cf6d-4063-81a0-945a4ee85f20_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_e026d89e-ff79-4f8f-b303-a12e52aeee25_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan_4744cb61-6eef-4f9e-86b1-2a4366a07bb1_terseLabel_en-US" xlink:label="lab_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid</link:label>
    <link:label id="lab_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan_label_en-US" xlink:label="lab_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Consideration For Acquisition Of Rights To Market And Distribute Certain Products In Japan</link:label>
    <link:label id="lab_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan_documentation_en-US" xlink:label="lab_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial consideration for acquisition of rights to market and distribute certain products in Japan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan" xlink:href="gild-20221231.xsd#gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan" xlink:to="lab_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_fb805763-d023-45ea-bdad-3020db536cc8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_01d91cdc-c70b-4bd2-97c9-4a4e21a04702_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option period to license certain inhibitors</link:label>
    <link:label id="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_label_en-US" xlink:label="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period</link:label>
    <link:label id="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:href="gild-20221231.xsd#gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:to="lab_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_329e2e97-81d4-413a-b828-31b1efe61846_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4bb80a7e-0ce2-4f22-a271-af2e924ff527_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_73362349-84ec-4340-a92b-18a9031acbd0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_832c5ce7-6129-4536-a3e1-9608985c0905_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount (legal offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_61da2cef-bbd7-4060-a6e1-22e7e93263f3_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_870a8db6-5263-4006-8ec9-5b97cdab3e02_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_a4ae7a63-e18b-4406-b13e-3c4699764f5d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_a8b5bcb5-4e4d-41b6-a92e-644bec57f138_terseLabel_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_gild_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_gild_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract" xlink:href="gild-20221231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherFinancialInformationAbstract" xlink:to="lab_gild_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_f36edac1-37ed-4b1a-afe4-ef7ee732c736_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill resulting from acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_69beffaa-efd5-4ed6-8714-5ddf7be05d44_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_08f1c896-4b7d-47f7-a964-bc8aec38710b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6f147578-1ca2-4bbc-849e-63be0a56059e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_bf690818-ec25-4cbf-afc4-ed99c4bd6eaf_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Purchase Period</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIPurchasePeriod_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:to="lab_gild_EquitySecuritiesFVNIPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8f4c54d1-953b-4c1e-84c9-f44732170548_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_4407c44d-15f6-4bab-bcfd-7750357a33c6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock (percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_c8808789-865b-4a6e-a3ec-aedfe831a574_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6ad21bf0-7d4e-4c2a-aae9-4e31089e4b0b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_bef4f008-dd77-4723-afd3-b65b3da7be07_netLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6e9c8591-e3f7-4c01-bb73-c379d771a0fb_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_db59fabf-9920-4b4b-8b21-2c8b56f309fb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a6f14b99-8ab3-446e-af1c-2a19dd1cccd9_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_fea8820f-5a66-4bc7-bbfb-005c24c41402_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_bb0c4556-bcbf-45e2-bbd9-3a4b186d97c2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ae9ecc69-1e27-477a-a0b2-d2d3c2c01f4b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f12e24ac-06ac-4d94-a44a-cdbcab61bec1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_be6b4caa-68d2-43fb-992f-2822e2beda07_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2aa692b4-7710-4d6a-ab79-890ddf031aa1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_b025d1f9-a778-48b2-89d1-9698be1f916d_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Dividends Declared</link:label>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Declared [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:to="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_69bc550c-55aa-4483-ae1e-44af0098bc81_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets, fair value</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c42364a4-4ed5-4b5d-b55e-8929dba7a596_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d34a013b-2fce-4085-8556-a226ba2f55c2_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowances for credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_815c5570-54b8-4c17-9cd8-1ce26214d46a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e15d33a0-7417-4638-8828-4b16368a69f3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_aeb9c226-9967-43e7-bd89-d7b30b35dac2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_a6b9a62a-335f-41d7-bffd-268216e3d24f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f16f75ba-c860-4562-90c5-31966675d45b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a60be504-68a2-4c23-a741-da9965c33c6b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_8e061c54-4a09-4d5c-8e16-d38b317f8538_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_ec385816-f946-4f8a-bd2f-e0e451597e02_terseLabel_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_label_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_gild_ArcusBiosciencesIncMember_documentation_en-US" xlink:label="lab_gild_ArcusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember" xlink:href="gild-20221231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusBiosciencesIncMember" xlink:to="lab_gild_ArcusBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5dba11f-06d1-4b4b-ab45-ccaf88bf4e6a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ChangeInDividendsPercentage_88ce9fac-bff3-4de6-ae33-ae81593ef131_terseLabel_en-US" xlink:label="lab_gild_ChangeInDividendsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of change in dividends</link:label>
    <link:label id="lab_gild_ChangeInDividendsPercentage_label_en-US" xlink:label="lab_gild_ChangeInDividendsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Dividends, Percentage</link:label>
    <link:label id="lab_gild_ChangeInDividendsPercentage_documentation_en-US" xlink:label="lab_gild_ChangeInDividendsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Dividends, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ChangeInDividendsPercentage" xlink:href="gild-20221231.xsd#gild_ChangeInDividendsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ChangeInDividendsPercentage" xlink:to="lab_gild_ChangeInDividendsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_c1e47a41-73d6-4354-a2f2-c533dea79103_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e43205d-18a3-4dcb-93af-81cc5bed8d03_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialFutureMilestonePaymentsMaximum_04ac916a-bca2-4435-8ae1-609711c497c1_terseLabel_en-US" xlink:label="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential future milestone payments</link:label>
    <link:label id="lab_gild_PotentialFutureMilestonePaymentsMaximum_label_en-US" xlink:label="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments, Maximum</link:label>
    <link:label id="lab_gild_PotentialFutureMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum" xlink:href="gild-20221231.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialFutureMilestonePaymentsMaximum" xlink:to="lab_gild_PotentialFutureMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_bb540805-22d2-4907-b90a-86a0ff1a8463_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_7afc9aa7-855e-4117-8063-5936af91abc5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right-of-use asset, statement of financial position, extensible enumeration</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_4f08d3bf-3932-48a5-975c-f9373016b71b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_4a42cf71-ff10-44e4-928e-180087d40660_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsDescovyMember_15e6596f-ccff-4b37-8f7f-1f2a5392193d_terseLabel_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Descovy</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_label_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsDescovyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsDescovyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Descovy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember" xlink:href="gild-20221231.xsd#gild_HIVProductsDescovyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsDescovyMember" xlink:to="lab_gild_HIVProductsDescovyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_6916cee6-e138-4b30-b97e-387ad2b88ccc_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ImmunomedicsIncMember_bef6bad7-fd3b-4e62-accf-2eb284153c45_terseLabel_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc.</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_label_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. [Member]</link:label>
    <link:label id="lab_gild_ImmunomedicsIncMember_documentation_en-US" xlink:label="lab_gild_ImmunomedicsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunomedics, Inc. (&#8220;Immunomedics&#8221;), a leading company in antibody-drug conjugate (&#8220;ADC&#8221;) technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ImmunomedicsIncMember" xlink:to="lab_gild_ImmunomedicsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e00039df-6f8a-4602-8c88-4cd9914ccd60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f95cac4a-1a77-444c-b37c-b4ca6f7d4115_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquityMethodInvestmentOptionExerciseFee_b1dd8859-5284-4839-8087-ba80c524cfa0_terseLabel_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_gild_EquityMethodInvestmentOptionExerciseFee_label_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Option Exercise Fee</link:label>
    <link:label id="lab_gild_EquityMethodInvestmentOptionExerciseFee_documentation_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionExerciseFee" xlink:href="gild-20221231.xsd#gild_EquityMethodInvestmentOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquityMethodInvestmentOptionExerciseFee" xlink:to="lab_gild_EquityMethodInvestmentOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_0bb1fc92-e0c1-461c-9f45-d1872c842540_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_0a245cdb-1363-4839-894e-66fd28a5214d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_d0ed8905-3f8a-4e53-85b7-f3e09c04865b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AuditInformationAbstract_label_en-US" xlink:label="lab_gild_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_gild_AuditInformationAbstract_documentation_en-US" xlink:label="lab_gild_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AuditInformationAbstract" xlink:href="gild-20221231.xsd#gild_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AuditInformationAbstract" xlink:to="lab_gild_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_bbdf5dc3-e6fc-4fc6-9198-42448ddada39_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_baf75ff4-b6a5-4169-9847-ddf1cd36ce1d_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate of acquired IPR&amp;D</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired, Discount Rate</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_f200f303-4bf7-45b4-96b2-38a2442fb7ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased and retired (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_a0f1e536-9efa-4003-8df4-168da9bb3b98_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value step-up adjustment of inventories acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5959d6bf-f5b1-4462-9fa9-1bb03c00bd16_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d40d2fe2-b95b-4f8c-8c10-eb287a366072_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResearchAndDevelopmentServiceAgreementMember_365d0c31-8144-459d-bd4e-ea6bef7521df_terseLabel_en-US" xlink:label="lab_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development service agreement</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentServiceAgreementMember_label_en-US" xlink:label="lab_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Service Agreement [Member]</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentServiceAgreementMember_documentation_en-US" xlink:label="lab_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Service Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:href="gild-20221231.xsd#gild_ResearchAndDevelopmentServiceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:to="lab_gild_ResearchAndDevelopmentServiceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_f7db17d4-e8ec-44d5-8381-f508ccf770cc_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by noncontrolling owners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DevelopmentAgreementMember_fa3fe2eb-2265-4202-9a0f-e87dac0dd71b_terseLabel_en-US" xlink:label="lab_gild_DevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development agreement</link:label>
    <link:label id="lab_gild_DevelopmentAgreementMember_label_en-US" xlink:label="lab_gild_DevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreement [Member]</link:label>
    <link:label id="lab_gild_DevelopmentAgreementMember_documentation_en-US" xlink:label="lab_gild_DevelopmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DevelopmentAgreementMember" xlink:href="gild-20221231.xsd#gild_DevelopmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DevelopmentAgreementMember" xlink:to="lab_gild_DevelopmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput_e6395b98-b7ca-4af6-b713-178557fde6f8_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate, measurement input</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Asset, Measurement Input</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_e1815e5a-1a97-4681-b9d7-c08549ee62db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_a79a4647-ea4d-42c4-bed6-196c9ce4a573_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares (in millions)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_2926f03f-a436-47a8-9860-8cdef65a31cd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_87e7e932-0076-4d30-87b7-db303c631442_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member_7282cb29-3aec-423a-926b-9cf3b2d16040_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.50% Senior Unsecured Notes Due in September 2023</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_73f6b0fd-f6bc-43e2-b99d-09f03286cdac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JounceTherapeuticsIncMember_79a0c826-d359-44ea-92de-603bc2b1a61c_terseLabel_en-US" xlink:label="lab_gild_JounceTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jounce</link:label>
    <link:label id="lab_gild_JounceTherapeuticsIncMember_label_en-US" xlink:label="lab_gild_JounceTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jounce Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_JounceTherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_JounceTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jounce Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember" xlink:href="gild-20221231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JounceTherapeuticsIncMember" xlink:to="lab_gild_JounceTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_53b6b7d3-b66d-4692-93e9-fc58483a3876_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c3551506-0a65-4fe1-8717-73723450f920_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_da0e4eb7-eaa7-4292-b3e2-95506b79c06f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1578f762-8765-40da-b1af-335766002deb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8117e04a-7eba-4c92-8bca-bd607e810860_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_5a4370e7-f1a1-4432-b879-12aea711b070_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_dd64093e-ef64-4bd0-8269-d3967f2de0e3_terseLabel_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_label_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration [Member]</link:label>
    <link:label id="lab_gild_EuropeanPatentClaims2032ExpirationMember_documentation_en-US" xlink:label="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Patent Claims 2032 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember" xlink:href="gild-20221231.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EuropeanPatentClaims2032ExpirationMember" xlink:to="lab_gild_EuropeanPatentClaims2032ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_15c885d5-3bff-47d9-a558-9f7568731ef8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_a5646ab7-f64b-4521-8b74-a5b65e8988b1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_dc72bf86-240f-4e92-a40f-69ddb0cdc20f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_2ab25cc0-a3c6-48d5-a1e8-9f928c80bbf1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f5a134ec-e02b-4185-b51e-e20e462cc771_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_55221ecf-a1ad-4cf6-8d18-d2f3633459b8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_1c8eca81-3520-4ab2-96ab-dee76ca1cc4e_terseLabel_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_label_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:label id="lab_gild_ForeignCurrencyDerivativeContractsMember_documentation_en-US" xlink:label="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:href="gild-20221231.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ForeignCurrencyDerivativeContractsMember" xlink:to="lab_gild_ForeignCurrencyDerivativeContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6b78c174-602e-4031-98d4-ff693a0aeec4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_NumberOfPrograms_6006602a-b85e-47ec-aa11-dcf39ffbeeaf_terseLabel_en-US" xlink:label="lab_gild_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of programs</link:label>
    <link:label id="lab_gild_NumberOfPrograms_label_en-US" xlink:label="lab_gild_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Programs</link:label>
    <link:label id="lab_gild_NumberOfPrograms_documentation_en-US" xlink:label="lab_gild_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfPrograms" xlink:href="gild-20221231.xsd#gild_NumberOfPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_NumberOfPrograms" xlink:to="lab_gild_NumberOfPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member_a251f0d1-55b6-4555-8f34-b47d124b7a9b_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.15% Senior Unsecured Notes Due in March 2047</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2047 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2044Member_0d86aceb-e306-4a10-8df5-8f8dcab60049_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80% Senior Unsecured Notes Due in April 2044</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2044Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in April 2044 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2044Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in April 2044 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinApril2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinApril2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_bad78f6a-7a41-4417-a901-0e128b4b623f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b5f78e6a-c706-4c8f-a991-c50d7fcbe025_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in basic earnings per share attributable to Gilead calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_6499aa65-788e-4ab7-9b50-90ee00546bbe_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_7ac90690-73e1-4047-b9a1-0771d4a6fd6d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6f8e1722-15d8-4517-880c-ed37bddab89c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_e9198375-54e4-439b-a255-e5c031ad8a02_terseLabel_en-US" xlink:label="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research And Development Trodelvy For HR+/HER2-</link:label>
    <link:label id="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_label_en-US" xlink:label="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research And Development Trodelvy For HR+/HER2- [Member]</link:label>
    <link:label id="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_documentation_en-US" xlink:label="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research And Development Trodelvy For HR+/HER2-</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:href="gild-20221231.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:to="lab_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_33e2544e-4dc4-4468-a6bb-586bd9a5a34c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount (legal offset)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_6ab6ec62-c796-4b8a-8a2a-f25fac6ad8cc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding notional amounts on foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b7d88785-e3b9-4e02-97c4-d4b47a669e93_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_f3dd3940-acc7-4516-97a7-f2304f070177_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_d0dbca9f-0047-4c82-9c6b-d391dcffc5a9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3bcbec1f-2771-4965-a96e-abaeb38aca57_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues_ce8c3252-c458-43a0-bf99-11e72dd82354_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of global product revenues</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues_label_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Product Revenues</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Product Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:href="gild-20221231.xsd#gild_CollaborationArrangementPercentOfGlobalProductRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:to="lab_gild_CollaborationArrangementPercentOfGlobalProductRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_c7d1fc4a-696e-4e4e-bdb4-ad117932e740_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PionyrMergerAndOptionAgreementsMember_2b7a0771-01e5-42d3-875f-453ea0ceb241_terseLabel_en-US" xlink:label="lab_gild_PionyrMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr merger and option agreements</link:label>
    <link:label id="lab_gild_PionyrMergerAndOptionAgreementsMember_label_en-US" xlink:label="lab_gild_PionyrMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Merger and Option Agreements [Member]</link:label>
    <link:label id="lab_gild_PionyrMergerAndOptionAgreementsMember_documentation_en-US" xlink:label="lab_gild_PionyrMergerAndOptionAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Merger and Option Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrMergerAndOptionAgreementsMember" xlink:href="gild-20221231.xsd#gild_PionyrMergerAndOptionAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PionyrMergerAndOptionAgreementsMember" xlink:to="lab_gild_PionyrMergerAndOptionAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_b28b0ad2-03d6-4ebd-83fa-60e1ba873864_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_7588e655-4f9f-4ac3-a71b-b82411b8c6d5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt and other obligations, net</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_551038ca-c222-4000-a329-accc28e5c896_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_20f626a3-8ba5-4600-80cc-c09335b960ef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_ab2bcd7a-4eb8-48a6-9276-0993f9757089_terseLabel_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes and Medium-Term Notes</link:label>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_label_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes And Medium-Term Notes [Member]</link:label>
    <link:label id="lab_gild_SeniorNotesAndMediumTermNotesMember_documentation_en-US" xlink:label="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes And Medium-Term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember" xlink:href="gild-20221231.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorNotesAndMediumTermNotesMember" xlink:to="lab_gild_SeniorNotesAndMediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_809a8a9e-2ce6-4699-b583-c7ff2296b579_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1a337188-ff07-4f7d-b1eb-4ebb803b3e87_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_da6d4ef8-04b3-41ed-89db-c881c5be2412_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_255023f3-fb17-444c-9817-76940d049755_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_72545cf2-a27e-4617-b925-2de9e8d9a32c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductSalesMember_1179394f-15e7-4991-9211-9d4e27d1b826_terseLabel_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HCV</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_label_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HCVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HCVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember" xlink:href="gild-20221231.xsd#gild_HCVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductSalesMember" xlink:to="lab_gild_HCVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4e180537-4cee-4e7d-ad29-d83f5f5fa5f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_8fa6fbf6-4a32-483a-b2e7-f8743774fd27_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_8d4486d3-ec29-47f0-bf97-26d295926fb1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIShares_9f31da43-49cf-47e7-ae60-fee6e7b3eb74_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIShares_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIShares_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIShares" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIShares" xlink:to="lab_gild_EquitySecuritiesFVNIShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_5a92271e-a611-4a5c-828c-298802a3d19a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_38f2a1f8-8294-45a6-bcf3-3687208f186f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7f012409-1a19-4f34-bbe8-13c21d84569a_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of stock options and equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8bea8360-108f-450b-84fc-2474a887955d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, including in-process research and development, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_f509a237-6fe5-463d-9fe4-72b358572134_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill expected to be deductible for tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8444a245-3466-490e-8ea2-419b0cc584a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7bdcc833-3682-4021-a8b9-345fda11540f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CardinalHealthIncMember_cb36633d-ac4d-4d35-8494-9e529f6ea872_terseLabel_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_label_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_gild_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_gild_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember" xlink:href="gild-20221231.xsd#gild_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CardinalHealthIncMember" xlink:to="lab_gild_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_70e11eda-6700-499d-8ef2-7e23206cba7e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable debt securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_f96d6a98-26ed-45ae-a12e-52b9149c5af4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ee5a6ac2-d8bb-4e5c-88bb-a2401e4b10b3_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_90cc9d62-430d-478d-90cd-1f948d0164b3_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_798aaaaa-8efd-40f1-9116-76a0d8987432_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_9f104405-730b-4570-84f8-27ca5b977622_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3cb181bb-374e-4ad4-9b56-1ee3ad3c7d07_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AgreementWithJapanTobaccoIncMember_1642f8d9-2f97-4c9a-8dd9-ec460fc19acb_terseLabel_en-US" xlink:label="lab_gild_AgreementWithJapanTobaccoIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan tobacco</link:label>
    <link:label id="lab_gild_AgreementWithJapanTobaccoIncMember_label_en-US" xlink:label="lab_gild_AgreementWithJapanTobaccoIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with Japan Tobacco, Inc. [Member]</link:label>
    <link:label id="lab_gild_AgreementWithJapanTobaccoIncMember_documentation_en-US" xlink:label="lab_gild_AgreementWithJapanTobaccoIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement with Japan Tobacco, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AgreementWithJapanTobaccoIncMember" xlink:href="gild-20221231.xsd#gild_AgreementWithJapanTobaccoIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AgreementWithJapanTobaccoIncMember" xlink:to="lab_gild_AgreementWithJapanTobaccoIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepcludexMember_2b83c3fd-b9a9-43a3-9cff-d4af3be1d4f8_terseLabel_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex</link:label>
    <link:label id="lab_gild_HepcludexMember_4a7a9089-ee35-49d4-bfb1-6c95b2327f8d_verboseLabel_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset &#8211; Hepcludex</link:label>
    <link:label id="lab_gild_HepcludexMember_label_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex [Member]</link:label>
    <link:label id="lab_gild_HepcludexMember_documentation_en-US" xlink:label="lab_gild_HepcludexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepcludex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember" xlink:href="gild-20221231.xsd#gild_HepcludexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepcludexMember" xlink:to="lab_gild_HepcludexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_a7f0883d-1c7a-4f51-b327-9a8a56df196c_terseLabel_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ledipasvir/Sofosbuvir</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_label_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsLedipasvirSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Ledipasvir/Sofosbuvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:href="gild-20221231.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:to="lab_gild_HCVProductsLedipasvirSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_0e69b903-55fa-4857-88de-52a5531c3b1a_terseLabel_en-US" xlink:label="lab_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions to Calculate the Estimated Fair Value of Awards</link:label>
    <link:label id="lab_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Stock Options And Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and ESPP, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="gild-20221231.xsd#gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_140ab433-fee0-4fcb-ad5a-e84cb92a8f47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_8be2d272-6214-40e9-b6ea-3d8a44c6eff8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_9f164bdc-49ee-40c6-a870-4dd8f5b18671_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_e08ae9f2-a5d1-49fd-914d-5a2516f368c7_terseLabel_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_label_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050 [Member]</link:label>
    <link:label id="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member_documentation_en-US" xlink:label="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.80% Senior Unsecured Notes Due October 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:href="gild-20221231.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:to="lab_gild_A280SeniorUnsecuredNotesDueOctober2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d6308d0a-4fef-415d-8b7d-ab58baa6eab2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_37869738-27b3-4d70-adcb-aa975c6190dd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4451eef4-4113-4275-b82e-c52bbb44a6e7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_fffc98e8-5882-441d-a51e-6e4386e3837b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_77f3ad02-fd7a-4c00-9d87-b68ca6e04d0e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. government securities</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_aabc8cae-0245-4ffb-bc60-a710e1f6ed7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Revenues from Major Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_30f0568e-0103-47db-bd3b-7c7a1cf16c5d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d9331496-9a46-4603-9055-b28780274cdf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_c7ab459e-c352-4e9b-8354-db8f4a0b196a_terseLabel_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payout percentage</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_label_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_documentation_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:href="gild-20221231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:to="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeAgreementOptInTerm_5df2fa73-aa04-4523-a265-5ae7112d7e98_terseLabel_en-US" xlink:label="lab_gild_CollaborativeAgreementOptInTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt-in term</link:label>
    <link:label id="lab_gild_CollaborativeAgreementOptInTerm_label_en-US" xlink:label="lab_gild_CollaborativeAgreementOptInTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Opt-In Term</link:label>
    <link:label id="lab_gild_CollaborativeAgreementOptInTerm_documentation_en-US" xlink:label="lab_gild_CollaborativeAgreementOptInTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Opt-In Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementOptInTerm" xlink:href="gild-20221231.xsd#gild_CollaborativeAgreementOptInTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeAgreementOptInTerm" xlink:to="lab_gild_CollaborativeAgreementOptInTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_db42da54-3cab-41ab-9636-56fd5238e285_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_2b672ac7-ae36-4348-9303-613dc54d3f8b_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_90de71a2-6637-4747-8ebf-a9d77fcaaa83_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received / pledged</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_bd9d4ea5-e9ea-499a-88c6-9ef746fe9457_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TizonaTherapeuticsIncMember_482d4c81-123c-4cee-b8c1-7270fbca0a3f_terseLabel_en-US" xlink:label="lab_gild_TizonaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona</link:label>
    <link:label id="lab_gild_TizonaTherapeuticsIncMember_label_en-US" xlink:label="lab_gild_TizonaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_TizonaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_TizonaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tizona Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaTherapeuticsIncMember" xlink:href="gild-20221231.xsd#gild_TizonaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TizonaTherapeuticsIncMember" xlink:to="lab_gild_TizonaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_85db89c2-d5f7-4ba3-9ef1-2fd12ddb2cb6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_e115b847-dcd6-4dac-942d-5c56ee7dce5e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member_2968beda-c566-4181-8234-74ca5f5db2fb_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Unsecured Notes Due in March 2046</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2046 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in March 2046</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinMarch2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_819d0ec7-4d63-4cd9-8fb2-2bc61a084999_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss), net of tax impact of $0, $(1) and $12, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_6351d534-5a0d-4f84-a6f9-04d4e849eb96_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare_1e71fdff-ae32-4df3-a173-6f31b5c580d5_terseLabel_en-US" xlink:label="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of ESPP shares granted (in dollars per share)</link:label>
    <link:label id="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare_label_en-US" xlink:label="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Shares Issued In Period, Weighted Average Price Per Share</link:label>
    <link:label id="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Shares Issued In Period, Weighted Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare" xlink:href="gild-20221231.xsd#gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare" xlink:to="lab_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsLetairisMember_bfa87aeb-2460-40ed-b8d6-1d60bb315acd_terseLabel_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letairis</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_label_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:label id="lab_gild_OtherProductsLetairisMember_documentation_en-US" xlink:label="lab_gild_OtherProductsLetairisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Letairis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember" xlink:href="gild-20221231.xsd#gild_OtherProductsLetairisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsLetairisMember" xlink:to="lab_gild_OtherProductsLetairisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_9fb67a8c-8e95-4053-aa47-e4adabfb5b16_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6d7cf1db-d930-4ca9-bad2-a308c1f35d52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JanssenPharmaceuticalsMember_19229ce2-676e-41af-91e1-453e1fc73697_terseLabel_en-US" xlink:label="lab_gild_JanssenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen pharmaceuticals</link:label>
    <link:label id="lab_gild_JanssenPharmaceuticalsMember_label_en-US" xlink:label="lab_gild_JanssenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals [Member]</link:label>
    <link:label id="lab_gild_JanssenPharmaceuticalsMember_documentation_en-US" xlink:label="lab_gild_JanssenPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the collaboration with Janssen Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JanssenPharmaceuticalsMember" xlink:href="gild-20221231.xsd#gild_JanssenPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JanssenPharmaceuticalsMember" xlink:to="lab_gild_JanssenPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_902ff974-f2f1-422b-b068-b0f1daae0a16_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_de49186a-9f48-4aa5-a005-6f94b3ef48c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_67116f81-381f-4d4e-afe6-7527cae89189_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_ef27724a-64aa-4c34-937b-4fc92b8587ef_terseLabel_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of parties appealed</link:label>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_label_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Appealed, Number</link:label>
    <link:label id="lab_gild_LossContingencyPartiesAppealedNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyPartiesAppealedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Parties Appealed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber" xlink:href="gild-20221231.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyPartiesAppealedNumber" xlink:to="lab_gild_LossContingencyPartiesAppealedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_85f89070-10a5-41dc-b31a-4110f389cc1c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3d631c70-13d3-477f-930e-0e9eaff88c87_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_663fe272-cbc1-4a2a-a5e8-07d06c70f245_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Difference Between Provision for Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7276e5eb-7375-43fa-825a-cf0c89bdce27_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c69103e1-d349-451c-b50f-6393c51aa71e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_66efced5-dd2a-4d51-a3b9-3368202aa51c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D &amp; related charges</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GalapagosSubscriptionAgreementMember_0ecc0afb-3d62-40d3-9b2a-42f0d6b30b1b_terseLabel_en-US" xlink:label="lab_gild_GalapagosSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos subscription agreement</link:label>
    <link:label id="lab_gild_GalapagosSubscriptionAgreementMember_label_en-US" xlink:label="lab_gild_GalapagosSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos Subscription Agreement [Member]</link:label>
    <link:label id="lab_gild_GalapagosSubscriptionAgreementMember_documentation_en-US" xlink:label="lab_gild_GalapagosSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosSubscriptionAgreementMember" xlink:href="gild-20221231.xsd#gild_GalapagosSubscriptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GalapagosSubscriptionAgreementMember" xlink:to="lab_gild_GalapagosSubscriptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4506be04-188b-4cca-bbad-5c8fb3f86dfa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cbabede2-336d-47eb-b64e-56907465bd96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_ed151778-1576-4bae-b133-cc2d4b3bf98f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_0b68be87-cd8d-4207-b855-f35155f62d97_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_97c4a6c1-30a2-4c07-b6de-8636d59f10bb_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_eaf3b3ea-a033-4d9f-8ed1-be6e7fbd1deb_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized capitalized software costs</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8b2ebb49-3474-4fe9-a760-fb1d1e2d0b80_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0d4d4c10-6f6d-4f87-b156-3cd72a936e71_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_b7d85cfe-12bb-453b-a882-d6a826b0ec2e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_81ef1b87-b331-46b7-b3af-b0f4c949b775_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on discontinuance of cash flow hedges</link:label>
    <link:label id="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_label_en-US" xlink:label="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:to="lab_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_5fd6003f-b303-496a-9348-a10afb6e8e9d_terseLabel_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir/Velpatasvir</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_label_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir [Member]</link:label>
    <link:label id="lab_gild_HCVProductsSofosbuvirVelpatasvirMember_documentation_en-US" xlink:label="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HCV Products, Sofosbuvir/Velpatasvir</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:href="gild-20221231.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:to="lab_gild_HCVProductsSofosbuvirVelpatasvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e9135f87-05e6-4bf7-9e7d-34b833b05cd5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_9a63df4c-5106-4774-9a69-825a403cbb2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_290959b1-84dc-41be-b643-edb1cee033b8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_97ca92c0-d754-41a1-8b76-62e282598483_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6468ec4c-f146-4b6c-ab17-0b24314e0a10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_4ce80bb7-a542-41d8-84de-507e4ffd3630_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire equity method investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5cc5c255-a489-4a76-a398-105055bfbca4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a2e9993a-6e63-4446-946e-0c1692a66661_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a5b4dd36-c6c1-485e-a6bc-f97d3e15c23b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_a9b9e9e7-354c-4d72-9acf-29fd1576b7e0_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_us-gaap_MachineryAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_83f55bbc-458a-4d6f-ae57-0dfd94c78d26_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ea0d40bc-a730-484e-a91f-1f0cf2523c3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_95ebcddc-032d-4fbd-9dc1-181333fe4ccd_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_4806f1a5-2f33-44a5-bc33-627dd1092d49_terseLabel_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, contract and other revenues</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_label_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:label id="lab_gild_RoyaltyContractAndOtherMember_documentation_en-US" xlink:label="lab_gild_RoyaltyContractAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Contract, And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember" xlink:href="gild-20221231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RoyaltyContractAndOtherMember" xlink:to="lab_gild_RoyaltyContractAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_f877ce84-0ddf-4de5-8d79-111704dbe2ee_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_ec893fbe-2a3c-49bf-811e-1c2bafcd28a9_terseLabel_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset &#8211; sofosbuvir</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_label_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset - Sofosbuvir [Member]</link:label>
    <link:label id="lab_gild_IntangibleAssetSofosbuvirMember_documentation_en-US" xlink:label="lab_gild_IntangibleAssetSofosbuvirMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sofosbuvir [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember" xlink:href="gild-20221231.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IntangibleAssetSofosbuvirMember" xlink:to="lab_gild_IntangibleAssetSofosbuvirMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a3a77d60-a352-43da-8741-dcb227069518_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_e6b70427-4bf5-4ec4-9a55-b6adcf62c69f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c35e8c23-8d55-4544-a201-4070beeec4c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4241f3d7-6c65-43a2-8fa2-3560854e55d0_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_10b0e6bf-3abe-4373-a994-f77cacfce3e3_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_ad196423-384a-4279-bbde-c4a61e67e123_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_cc80e745-5712-4abe-a2fd-53ef79933c02_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member_07a5e3f2-7490-488d-8923-3406382947e9_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.25% Senior Unsecured Notes Due in September 2022</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2022 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bc3c7777-c1e5-409f-abe8-0af63e484a70_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_cba64c87-f39e-451f-a31b-c1d7f8634192_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3f8773d2-ff59-4b1f-9e40-3080ddf8eb03_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ef4ea427-09ec-48db-b209-900b89075eb9_terseLabel_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cell therapy</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_label_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales [Member]</link:label>
    <link:label id="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_documentation_en-US" xlink:label="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cell Therapy Products, Total Cell Therapy Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:href="gild-20221231.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:to="lab_gild_CellTherapyProductsTotalCellTherapyProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TmunityTherapeuticsMember_c8e73521-be00-49eb-adbf-32b8e87b76e9_terseLabel_en-US" xlink:label="lab_gild_TmunityTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tmunity Therapeutics</link:label>
    <link:label id="lab_gild_TmunityTherapeuticsMember_label_en-US" xlink:label="lab_gild_TmunityTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tmunity Therapeutics [Member]</link:label>
    <link:label id="lab_gild_TmunityTherapeuticsMember_documentation_en-US" xlink:label="lab_gild_TmunityTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tmunity Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TmunityTherapeuticsMember" xlink:href="gild-20221231.xsd#gild_TmunityTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TmunityTherapeuticsMember" xlink:to="lab_gild_TmunityTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_0e9ac70c-d9bb-4ede-89b3-5a26dc461969_terseLabel_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of material transfer agreements</link:label>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_label_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Material Transfer Agreements, Number</link:label>
    <link:label id="lab_gild_LossContingencyMaterialTransferAgreementsNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Material Transfer Agreements, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:href="gild-20221231.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:to="lab_gild_LossContingencyMaterialTransferAgreementsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusCollaborationAgreementMember_c704a045-030b-4b86-b663-4e3a80e148d5_terseLabel_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus collaboration agreement</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_ArcusCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_ArcusCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementMember" xlink:href="gild-20221231.xsd#gild_ArcusCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusCollaborationAgreementMember" xlink:to="lab_gild_ArcusCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_34229df1-e7cd-4b4c-b814-ca6382116798_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, including Goodwill, Intangible Assets and Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9b5b0f49-c598-4933-b7a4-bd4bfd290db5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_7aedfc7a-c41e-4db1-b057-dc11d1380262_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7734b516-9af2-4178-be48-73e214125f98_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_17167a6a-485f-4d62-8245-2d347ea4ebd7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-taxable unrealized loss on investment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_279c5c46-ea9e-458e-ac02-cdf30af0130c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_65ad628f-660f-40b2-bbe1-768b5c7cf940_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue share with Janssen and royalties for licenses of intellectual property</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_70567567-8a0a-4e88-a024-2ff7bf6575da_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire in process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_7c026063-9a93-4dac-8d00-6f24cc82e046_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HB/HDV</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Other [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:href="gild-20221231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_ad96bfc4-bd0c-498b-89d4-3d31ca9049a6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8852dc00-df15-43ad-8292-40b31025f18c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f0064cd2-9cac-4da0-8d3d-f6d78adc999d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_35ab7154-51b6-4166-821d-f0a0c8c84d7c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_f5652a7c-8aa5-4c3e-8c1a-ae616b76b33c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issued</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_483836d5-4589-445d-a38e-3e09df91a3c6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_9b673385-3738-4d3b-8d96-bbeb187c377a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_68a6b50b-6f59-4791-b371-569d49851e02_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic tax authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_0c16347a-dc5d-4933-af1b-186d78ffdde8_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt and other obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_2c228a76-6121-48b7-8265-92fa8752c757_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_826791e2-237d-4e04-b7fe-846a1d7aa1dd_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_84239284-160d-4873-b0c8-af4edfd7ed54_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7c865b6f-20d5-4f78-a63c-085be7aebf5d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResearchAndDevelopmentFutureMaximumPayments_2c4d6b3a-4f96-48f5-aa76-32f576a31fc4_terseLabel_en-US" xlink:label="lab_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development future maximum payments</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentFutureMaximumPayments_label_en-US" xlink:label="lab_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Future Maximum Payments</link:label>
    <link:label id="lab_gild_ResearchAndDevelopmentFutureMaximumPayments_documentation_en-US" xlink:label="lab_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Future Maximum Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:href="gild-20221231.xsd#gild_ResearchAndDevelopmentFutureMaximumPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:to="lab_gild_ResearchAndDevelopmentFutureMaximumPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7b344333-af89-478d-8800-ccb079c98e87_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_2255a715-43fc-4813-8864-3ddbf169c17f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_a12bc617-f5b4-4039-abf5-0d9a0b463cba_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_34708969-7f2a-45e8-af65-612289e19f50_terseLabel_en-US" xlink:label="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call feature, period prior to maturity</link:label>
    <link:label id="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_label_en-US" xlink:label="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Call Feature, Period Before Maturity</link:label>
    <link:label id="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_documentation_en-US" xlink:label="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Call Feature, Period Before Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:href="gild-20221231.xsd#gild_DebtInstrumentCallFeaturePeriodBeforeMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:to="lab_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f53f074e-2151-4711-b719-4a25a751b99f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contractual Maturities of Financing Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_38219da5-64aa-4482-9253-47f7c0dc19c7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_844d8d8b-b6a4-4c22-a931-50eb8c4473d1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGrossCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_6f99ef4d-950e-4b6b-940a-59af7ec02cb7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MerckMember_d1c423d2-8fc0-419d-bc72-42b020c5ffac_terseLabel_en-US" xlink:label="lab_gild_MerckMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_gild_MerckMember_label_en-US" xlink:label="lab_gild_MerckMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_gild_MerckMember_documentation_en-US" xlink:label="lab_gild_MerckMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckMember" xlink:href="gild-20221231.xsd#gild_MerckMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MerckMember" xlink:to="lab_gild_MerckMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5ab6c6f9-c949-4ebc-bcfa-67413742b0de_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_a700b37d-e359-4e33-86c2-f5009487117e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_fca89539-3b5d-4b90-adbe-96da8b75066f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductSalesMember_d17cbe63-704f-4bc0-8ab7-1f48b5cb4f9e_terseLabel_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HIV</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_label_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales [Member]</link:label>
    <link:label id="lab_gild_HIVProductSalesMember_documentation_en-US" xlink:label="lab_gild_HIVProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember" xlink:href="gild-20221231.xsd#gild_HIVProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductSalesMember" xlink:to="lab_gild_HIVProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9cdcb913-fd74-4ea1-a905-8afb9248f206_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a43605a7-f2d1-4197-b0b2-f86b51ad2df1_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_78c87dab-ca63-424e-a43b-4d9eaab8c04b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_9ea9db9f-caf8-4b58-abd6-cb72bcad7f03_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of tax examinations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_38477a55-cb42-4016-bc89-0d3155c29649_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AcquisitionRelatedExpenseMember_3bf08634-1c77-4a17-92a0-71d34e68bc38_terseLabel_en-US" xlink:label="lab_gild_AcquisitionRelatedExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related expense</link:label>
    <link:label id="lab_gild_AcquisitionRelatedExpenseMember_label_en-US" xlink:label="lab_gild_AcquisitionRelatedExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Related Expense [Member]</link:label>
    <link:label id="lab_gild_AcquisitionRelatedExpenseMember_documentation_en-US" xlink:label="lab_gild_AcquisitionRelatedExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AcquisitionRelatedExpenseMember" xlink:href="gild-20221231.xsd#gild_AcquisitionRelatedExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AcquisitionRelatedExpenseMember" xlink:to="lab_gild_AcquisitionRelatedExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_182a9db9-32fa-4be9-9124-1450650c7ce1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_75441510-7a10-472e-a11c-3fe14348ac96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_6c7c3692-cb97-4ead-8a86-5120bb89d7bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage_929d68a9-dd3b-41d5-9203-b42fc2d4c044_terseLabel_en-US" xlink:label="lab_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of goods less specified amount, maximum percentage</link:label>
    <link:label id="lab_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage_label_en-US" xlink:label="lab_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Goods Less Specified Amount, Maximum Percentage</link:label>
    <link:label id="lab_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage_documentation_en-US" xlink:label="lab_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Goods Less Specified Amount, Maximum Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage" xlink:href="gild-20221231.xsd#gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage" xlink:to="lab_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_cf76f7d2-f6f0-47b5-931d-a402fda1c463_terseLabel_en-US" xlink:label="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period subject to termination</link:label>
    <link:label id="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_label_en-US" xlink:label="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Product Market Period Subject To Termination</link:label>
    <link:label id="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_documentation_en-US" xlink:label="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Product Market Period Subject To Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" xlink:href="gild-20221231.xsd#gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" xlink:to="lab_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_04a25bf3-b4e0-46ea-a58f-776f3ec23f2a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6280b288-fa6b-4b6f-a495-24901d91fa9e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Classification of Available-for-Sale Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_d2560c32-e255-4750-97fe-233d14912545_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_6fe6ad6e-558c-40fc-a14c-c883a800e4e5_terseLabel_en-US" xlink:label="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2019 agreement</link:label>
    <link:label id="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_label_en-US" xlink:label="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Filgotinib License and Collaboration Agreement in December 2020 [Member]</link:label>
    <link:label id="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_documentation_en-US" xlink:label="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Filgotinib License and Collaboration Agreement in December 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:href="gild-20221231.xsd#gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:to="lab_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member_4f57c6eb-1f01-4d25-b122-ac9e008ac0b1_terseLabel_en-US" xlink:label="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due March 2022</link:label>
    <link:label id="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member_label_en-US" xlink:label="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due March 2022 [Member]</link:label>
    <link:label id="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member_documentation_en-US" xlink:label="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.95% Senior Unsecured Notes Due March 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:href="gild-20221231.xsd#gild_A195SeniorUnsecuredNotesDueMarch2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:to="lab_gild_A195SeniorUnsecuredNotesDueMarch2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_ffe60a9f-9a2e-40ec-8a2a-c0cd877b5b2f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_6059afe3-4c8f-4ef2-b659-ca9e86ae74ba_terseLabel_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_442647eb-db4b-4297-b82a-51278be053dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_9291d288-6782-469d-96fe-0d02b7e4d82a_terseLabel_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_label_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:label id="lab_gild_AmerisourcebergenCorpMember_documentation_en-US" xlink:label="lab_gild_AmerisourcebergenCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corp [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember" xlink:href="gild-20221231.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmerisourcebergenCorpMember" xlink:to="lab_gild_AmerisourcebergenCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_18d6e8d2-361f-4b34-9546-4fab72379c57_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_2ef5f24c-e25d-4efc-806d-88e4b7109aad_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_ec29eb5a-f5af-4851-abf4-0b53cf0abe5d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_981a8903-6a44-432d-a6e2-9095db6b5c64_terseLabel_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus stock purchase agreement</link:label>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_label_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_gild_ArcusStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gild_ArcusStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcus Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember" xlink:href="gild-20221231.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcusStockPurchaseAgreementMember" xlink:to="lab_gild_ArcusStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_1712ca80-4f3f-4da9-9cc8-d561702fc787_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_fc22f24e-a589-4c2c-a024-5e7b2ea7c6c8_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d225b20b-2a77-402e-93b7-94cbb8bc5fae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) reclassified from Accumulated other comprehensive income to Product sales</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_8b91640a-8a85-4cba-a41e-4bf109b4cfe8_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsOtherMember_dd0a06f9-1bcc-4310-948e-d11a3c0f9089_terseLabel_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_label_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:label id="lab_gild_OtherProductsOtherMember_documentation_en-US" xlink:label="lab_gild_OtherProductsOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember" xlink:href="gild-20221231.xsd#gild_OtherProductsOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsOtherMember" xlink:to="lab_gild_OtherProductsOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions_a2ac616e-fe31-4b56-90d1-2040e38fd49f_terseLabel_en-US" xlink:label="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical stage programs with exercise options</link:label>
    <link:label id="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions_label_en-US" xlink:label="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Stage Programs With Exercised Options</link:label>
    <link:label id="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions_documentation_en-US" xlink:label="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Stage Programs With Exercised Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:href="gild-20221231.xsd#gild_NumberOfClinicalStageProgramsWithExercisedOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:to="lab_gild_NumberOfClinicalStageProgramsWithExercisedOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_23616e81-242e-4eab-9524-1a5b7be30a1f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsToTerminatePreviousAgreement_f5953e45-f6c9-4fc7-aa24-b1b064d55691_terseLabel_en-US" xlink:label="lab_gild_PaymentsToTerminatePreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination payments</link:label>
    <link:label id="lab_gild_PaymentsToTerminatePreviousAgreement_label_en-US" xlink:label="lab_gild_PaymentsToTerminatePreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Terminate Previous Agreement</link:label>
    <link:label id="lab_gild_PaymentsToTerminatePreviousAgreement_documentation_en-US" xlink:label="lab_gild_PaymentsToTerminatePreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Terminate Previous Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToTerminatePreviousAgreement" xlink:href="gild-20221231.xsd#gild_PaymentsToTerminatePreviousAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsToTerminatePreviousAgreement" xlink:to="lab_gild_PaymentsToTerminatePreviousAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member_4f8000ba-e314-4c1e-ab6f-dcec61b42e05_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes Due in February 2045</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in February 2045 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in February 2045 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinFebruary2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d2887e50-0a14-492e-9490-fe35a7d743a4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_aaafb100-84d8-4694-9b52-1b603d192ee1_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity on derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7ae77d56-807d-425b-91ff-12c013dc7cbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_371a7bf8-3dd4-4dd2-9dcc-17ccfd1139d2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_1b138667-5cfc-4c7d-a8b3-449cbfc2d3d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Credit Facilities</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ed1d5a00-f0b8-45c5-87a3-3fc72703ede6_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsToOptInTheCollaborativeAgreement_bfd3ee29-28e2-493b-b119-a6d319411ff9_terseLabel_en-US" xlink:label="lab_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration opt-in payments</link:label>
    <link:label id="lab_gild_PaymentsToOptInTheCollaborativeAgreement_label_en-US" xlink:label="lab_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Opt-In The Collaborative Agreement</link:label>
    <link:label id="lab_gild_PaymentsToOptInTheCollaborativeAgreement_documentation_en-US" xlink:label="lab_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Opt-In The Collaborative Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:href="gild-20221231.xsd#gild_PaymentsToOptInTheCollaborativeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:to="lab_gild_PaymentsToOptInTheCollaborativeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9d4c4c7a-f5fb-402e-a16c-1c4d396aca41_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_044472fe-968a-4441-aa3c-93fcc6cced2b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_dff3d94b-c21d-4075-a15f-33e95105393c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_253bec97-f157-4900-964d-cf0ae1b090a9_terseLabel_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_label_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030 [Member]</link:label>
    <link:label id="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member_documentation_en-US" xlink:label="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.65% Senior Unsecured Notes Due October 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:href="gild-20221231.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:to="lab_gild_A165SeniorUnsecuredNotesDueOctober2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_3455e38a-7d7d-43aa-81f2-bd1d4e24da42_terseLabel_en-US" xlink:label="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for adjustments of budgeted development costs</link:label>
    <link:label id="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_label_en-US" xlink:label="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Adjustments of Budgeted Development Costs</link:label>
    <link:label id="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_documentation_en-US" xlink:label="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Adjustments of Budgeted Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:href="gild-20221231.xsd#gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:to="lab_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8e2b92ec-a1ae-4a98-908c-dc47680a72f4_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign income tax expense (benefit), continuing operations</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_facc9aee-29d9-4395-9e5e-ab41666a6f9a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MediumTermNotesMember_1b2fd441-d06c-42f2-b718-e08797b515f1_terseLabel_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term notes</link:label>
    <link:label id="lab_us-gaap_MediumTermNotesMember_label_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MediumTermNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MediumTermNotesMember" xlink:to="lab_us-gaap_MediumTermNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired_84c58bb9-fb56-41f8-ab3d-6b95ca37dec8_terseLabel_en-US" xlink:label="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration, net of acquired cash</link:label>
    <link:label id="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired_label_en-US" xlink:label="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Assets, Net Of Cash Acquired</link:label>
    <link:label id="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired_documentation_en-US" xlink:label="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Assets, Net Of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:href="gild-20221231.xsd#gild_PaymentsToAcquireAssetsNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:to="lab_gild_PaymentsToAcquireAssetsNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_ca346b25-2c30-47b5-bed2-4695d71886b7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_f371a64b-f4bb-4e0a-9bb6-b73927e087af_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8d67b949-ca28-49fa-a21b-c10d653df316_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_334e8c36-d264-42ef-87d9-32625fad8c02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, noncurrent, statement of financial position, extensible enumeration</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_e7a36966-7668-4d81-8109-023e95cc3ed0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_98c4437c-5b6c-494d-9e95-4c2aa981b863_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsForDirectTransactionalExpense_bc0639ad-8b41-4a04-b5a9-a693b648e0fb_terseLabel_en-US" xlink:label="lab_gild_PaymentsForDirectTransactionalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct transactional costs</link:label>
    <link:label id="lab_gild_PaymentsForDirectTransactionalExpense_label_en-US" xlink:label="lab_gild_PaymentsForDirectTransactionalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Direct Transactional Expense</link:label>
    <link:label id="lab_gild_PaymentsForDirectTransactionalExpense_documentation_en-US" xlink:label="lab_gild_PaymentsForDirectTransactionalExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Direct Transactional Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForDirectTransactionalExpense" xlink:href="gild-20221231.xsd#gild_PaymentsForDirectTransactionalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsForDirectTransactionalExpense" xlink:to="lab_gild_PaymentsForDirectTransactionalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f366c2e6-5aae-425c-90b3-42c7e7abfdd5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated OCI by Component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_73116e1f-1697-4215-862f-b78a0af302d2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b741e513-9dd1-4b99-9234-a55c10150d8b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_0d5b84f5-bc27-4886-a8f8-4e67385ea3e2_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EverestMedicinesAndImmunomedicsAgreementMember_62b72d21-28d2-4941-8d0e-dd5bcf09119f_terseLabel_en-US" xlink:label="lab_gild_EverestMedicinesAndImmunomedicsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Everest Medicines</link:label>
    <link:label id="lab_gild_EverestMedicinesAndImmunomedicsAgreementMember_label_en-US" xlink:label="lab_gild_EverestMedicinesAndImmunomedicsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Everest Medicines And Immunomedics Agreement [Member]</link:label>
    <link:label id="lab_gild_EverestMedicinesAndImmunomedicsAgreementMember_documentation_en-US" xlink:label="lab_gild_EverestMedicinesAndImmunomedicsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Everest Medicines And Immunomedics Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EverestMedicinesAndImmunomedicsAgreementMember" xlink:href="gild-20221231.xsd#gild_EverestMedicinesAndImmunomedicsAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EverestMedicinesAndImmunomedicsAgreementMember" xlink:to="lab_gild_EverestMedicinesAndImmunomedicsAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_503f9744-9e36-44ff-a271-ab2d5ec786d4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_b78f6251-f550-42ad-aff1-d84e9df16fcb_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_029ec250-e9ba-4d9b-840c-eb1ab4e63c33_terseLabel_en-US" xlink:label="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional patents allegedly infringed</link:label>
    <link:label id="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Additional Patents Allegedly Infringed, Number</link:label>
    <link:label id="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_documentation_en-US" xlink:label="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Additional Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:href="gild-20221231.xsd#gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:to="lab_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8cf36d14-23a9-4289-8e96-031e091d08ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f7a076bb-a361-4e82-88de-162c6fb7dbf0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ContingentConsiderationLiabilityMember_01f97b3d-d2a1-431b-8794-52a7f88517a2_terseLabel_en-US" xlink:label="lab_gild_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_gild_ContingentConsiderationLiabilityMember_label_en-US" xlink:label="lab_gild_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Liability [Member]</link:label>
    <link:label id="lab_gild_ContingentConsiderationLiabilityMember_documentation_en-US" xlink:label="lab_gild_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContingentConsiderationLiabilityMember" xlink:href="gild-20221231.xsd#gild_ContingentConsiderationLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ContingentConsiderationLiabilityMember" xlink:to="lab_gild_ContingentConsiderationLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_3452e451-3a5e-42cc-8372-3162e8f81f47_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_e1f7f9b8-f5c4-41c8-9732-481fc8b626dd_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_017b177b-edf2-4ed8-a2f6-1e7516e1d551_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4975ad4e-6e32-4694-b718-1bb391b9ab6a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d58e6148-24f8-4841-bfae-f66741afa32c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_8a2b3f09-7835-4b36-b54c-42455e896138_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2024Member_04dbc440-acd4-4caf-896a-a9578a7939e7_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Senior Unsecured Notes Due in April 2024</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2024Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in April 2024 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinApril2024Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in April 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinApril2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinApril2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_2ccc0357-380f-48cd-94ea-195b029e2784_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_e4194c88-67e7-4060-b53b-93ba7e2d5bba_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_a5291adf-6546-4539-8871-e244676db8a9_terseLabel_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue share - Symtuza</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_label_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:label id="lab_gild_ProductsRevenueShareSymtuzaMember_documentation_en-US" xlink:label="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products, Revenue Share-Symtuza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:href="gild-20221231.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductsRevenueShareSymtuzaMember" xlink:to="lab_gild_ProductsRevenueShareSymtuzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_34f55463-5fa7-4541-9d4e-2817fef0e10b_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal:</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_41782347-046a-45d8-bac2-d1fe1dddb4d1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0fb7a827-92a6-4eb5-937c-18968afb8af6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_091e25bf-f483-43ea-be1b-648bed84d536_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GlobalStrategicCollaborationAgreementMember_60c5cdc7-aab8-4f99-a2fd-16a5a25b5576_terseLabel_en-US" xlink:label="lab_gild_GlobalStrategicCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Strategic Collaboration Agreement</link:label>
    <link:label id="lab_gild_GlobalStrategicCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_GlobalStrategicCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Strategic Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_GlobalStrategicCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_GlobalStrategicCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Strategic Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GlobalStrategicCollaborationAgreementMember" xlink:href="gild-20221231.xsd#gild_GlobalStrategicCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GlobalStrategicCollaborationAgreementMember" xlink:to="lab_gild_GlobalStrategicCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_e9002f5d-b3ed-408e-9e2f-12c586a63284_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office, computer equipment and other</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsTruvadaMember_b7c15a40-03e7-4740-81e8-da64dd8231b9_terseLabel_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Truvada</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_label_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:label id="lab_gild_HIVProductsTruvadaMember_documentation_en-US" xlink:label="lab_gild_HIVProductsTruvadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Truvada [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember" xlink:href="gild-20221231.xsd#gild_HIVProductsTruvadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsTruvadaMember" xlink:to="lab_gild_HIVProductsTruvadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_9fffba0e-3cdc-4c44-8a11-1dcaceb8f06b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Equity Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_2a27a3e1-73ff-409e-a46e-c2fe8b51402c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_1332c9b2-6d3a-4797-8793-bc0314da1efd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2c001996-2b6d-425c-8c80-ddb18b954d5a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_32cf6ef2-fa3f-435e-ad17-0eb2d9e0e2f8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_3390cf2b-4f16-4882-91c4-eda3cf3f7181_terseLabel_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_label_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040 [Member]</link:label>
    <link:label id="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member_documentation_en-US" xlink:label="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.60% Senior Unsecured Notes Due October 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:href="gild-20221231.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:to="lab_gild_A260SeniorUnsecuredNotesDueOctober2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MYRGmbHMember_2ba627a3-1f79-44da-b57a-dcf9581405e3_terseLabel_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR</link:label>
    <link:label id="lab_gild_MYRGmbHMember_label_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH [Member]</link:label>
    <link:label id="lab_gild_MYRGmbHMember_documentation_en-US" xlink:label="lab_gild_MYRGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MYR GmbH (&#8220;MYR&#8221;), a German biotechnology company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember" xlink:href="gild-20221231.xsd#gild_MYRGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MYRGmbHMember" xlink:to="lab_gild_MYRGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsForAssetAcquisitions_f5be2e32-2523-435a-a788-072c5adde95a_terseLabel_en-US" xlink:label="lab_gild_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration</link:label>
    <link:label id="lab_gild_PaymentsForAssetAcquisitions_label_en-US" xlink:label="lab_gild_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Asset Acquisitions</link:label>
    <link:label id="lab_gild_PaymentsForAssetAcquisitions_documentation_en-US" xlink:label="lab_gild_PaymentsForAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForAssetAcquisitions" xlink:href="gild-20221231.xsd#gild_PaymentsForAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsForAssetAcquisitions" xlink:to="lab_gild_PaymentsForAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_57c3b37f-84c5-475a-b187-1a58c5261e68_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7dfd23a5-2dd5-4eef-8bb8-dbabf6871ac3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_ba029c02-adb3-4708-9091-1429bdc6e6bc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ProductLiabilityMember_c7f85804-f5cf-4862-a32f-c49b62ee430a_terseLabel_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_gild_ProductLiabilityMember_label_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Member]</link:label>
    <link:label id="lab_gild_ProductLiabilityMember_documentation_en-US" xlink:label="lab_gild_ProductLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember" xlink:href="gild-20221231.xsd#gild_ProductLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ProductLiabilityMember" xlink:to="lab_gild_ProductLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_0130805d-6723-4fb2-8499-b394ba370119_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_9c64cda1-926c-42f1-ab2f-83467c35b1d0_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_4ed428c4-2805-4b5e-9c16-5a0fa433e6bb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_7412d656-3fcb-44dc-bec3-36919f55f46e_terseLabel_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of tiered royalties, low-end percentage</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_label_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalty, Low-end, Percentage</link:label>
    <link:label id="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_documentation_en-US" xlink:label="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Sales Based Tiered Royalty, Low-end, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:href="gild-20221231.xsd#gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:to="lab_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_5846643d-a7cb-4ab2-a8df-322d6339d52a_terseLabel_en-US" xlink:label="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharp &amp; Dohme Corp</link:label>
    <link:label id="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharp &amp; Dohme Corp License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck Sharp &amp; Dohme Corp License And Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:href="gild-20221231.xsd#gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:to="lab_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_b1afac84-d912-4bb5-b0dc-fae579ad46e1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3eea6615-175b-488e-9056-b04a7d6912bd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne_1f2873b4-0dea-4925-bc59-ab7ca59dca08_terseLabel_en-US" xlink:label="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne_label_en-US" xlink:label="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year One</link:label>
    <link:label id="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne_documentation_en-US" xlink:label="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne" xlink:href="gild-20221231.xsd#gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne" xlink:to="lab_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_795896f0-fc9e-4f9b-b6d7-5cdf19471db8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_afcdf2da-4740-42c9-b6b6-9b1b5ec3b91c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, net of estimated forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_6950f198-c627-4e8e-836f-8926aad3c3bc_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total HBV/HDV</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:href="gild-20221231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_a16a15df-5594-47bf-b266-26aa71ba8258_terseLabel_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowances for cash discounts and other</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_label_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:label id="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent_documentation_en-US" xlink:label="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Cash Discounts and Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:href="gild-20221231.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:to="lab_gild_AccountsReceivableCashDiscountsAndOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_48c95faa-4e33-445c-a868-c2b551a077e6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_108c33ea-0dc5-4842-91db-4c63ef5b2630_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_ca534916-9e59-4c8a-bb2f-2db4937180c1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Debt Securities and Equity Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d6487d8d-8033-4f48-8700-6ee4995ef28f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_4f216dfc-74c4-4f40-a691-5c23df63dc26_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_f21ae640-fc12-4343-8c7b-8c380a976875_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amortization expense related to finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_791b7a27-9c27-48cf-9f83-44020671f65c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_c558b2b5-3d53-4f91-934b-1d5fd100dcfe_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid, net of amounts capitalized</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ArcellxIncMember_4ceeb8ee-70d6-46e4-86cf-a13fcd8d68fb_terseLabel_en-US" xlink:label="lab_gild_ArcellxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcellx, Inc</link:label>
    <link:label id="lab_gild_ArcellxIncMember_label_en-US" xlink:label="lab_gild_ArcellxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcellx, Inc [Member]</link:label>
    <link:label id="lab_gild_ArcellxIncMember_documentation_en-US" xlink:label="lab_gild_ArcellxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arcellx, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcellxIncMember" xlink:href="gild-20221231.xsd#gild_ArcellxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ArcellxIncMember" xlink:to="lab_gild_ArcellxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c5ca319d-64e1-4db2-ae9f-0c109bf74059_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract_77d9199a-ca6e-4a13-85a3-310d57689cde_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_089795df-1c89-4ea7-abc5-3c732fa0b110_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_2861b974-5f33-45e5-8f9b-27278096357e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c03fdd30-2fa6-415e-a07b-aa34ce520ef6_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7e3cef57-cdf3-4fbb-a137-3ebe0b656460_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gilead stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_e5cd6eab-d674-41ea-b8f7-3bb8844c8bfb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized from Performance Obligations Satisfied in Prior Periods</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_e68bac70-0624-4e8b-9b31-8ed9bd8fa5fc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_8581c83a-b3ee-4812-b5f1-85a6f5159b4a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4c529fee-0911-43fb-b9a6-3d811ef5f2ea_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_6c760ca2-9f53-4cdf-beeb-c7d12e310374_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member_d7fca364-9307-4753-9a7f-ee387dd09e9a_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.00% Senior Unsecured Notes Due in September 2036</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2036 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_IssuanceDiscountPremium_24f9c61f-4505-49df-bad1-27ee0090e7bb_terseLabel_en-US" xlink:label="lab_gild_IssuanceDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance discount (premium)</link:label>
    <link:label id="lab_gild_IssuanceDiscountPremium_label_en-US" xlink:label="lab_gild_IssuanceDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Discount (Premium)</link:label>
    <link:label id="lab_gild_IssuanceDiscountPremium_documentation_en-US" xlink:label="lab_gild_IssuanceDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IssuanceDiscountPremium" xlink:href="gild-20221231.xsd#gild_IssuanceDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_IssuanceDiscountPremium" xlink:to="lab_gild_IssuanceDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bc410fda-8ef9-4396-85c1-4f79b35a6d9e_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_26681ad9-b9be-4525-8018-ca004eb3071f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e487a872-b414-48d4-b05c-644ce5020c95_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_5f7888f9-2007-4a52-906f-5938f0d1bb29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Change in Fair Value of Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5de31d56-e1ae-4a46-ad13-2959ad789d76_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1b44d3d4-2a59-47fa-8249-465004434ffb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_726247f9-04bf-44bb-a96f-7928b97e2e66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8a842882-4c9b-4c05-8d4f-23877d08f77b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e2a0e7dc-01ad-439c-838e-f600f4b8f44f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_a6dac53a-8dfb-4a68-9a09-7f198e01b0e0_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_032fd780-dc1d-4110-81a6-c00901b03d4d_totalLabel_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Indefinite Lived Intangible Assets Excluding Goodwill</link:label>
    <link:label id="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_documentation_en-US" xlink:label="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="gild-20221231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2eb527e8-2829-4330-84b7-d7ed68198632_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock&#160;</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_b4352612-c1f7-41fc-9e2a-5589dc6c833c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Information Related to Operating Leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_25c48ead-3feb-4e54-954c-0233807fade2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_575573f6-ee49-4826-933a-490ace0ac411_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c49fa61a-f615-4d5a-b9ae-327bb4c79d0d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2652de55-2b2e-4eb3-bb01-84471b303370_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member_75148e6c-38aa-42d5-9265-52bb6c264761_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Senior Unsecured Notes Due in February 2025</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in February 2025 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in February 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinFebruary2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_f43cbe4b-87f6-48bb-a119-e6dbd2523a5e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage of principal amount repurchased</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_d3f2dbf2-917e-4676-8912-cfb0fbd5c7dc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c305683e-500b-4007-b7f6-ff436f795748_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities &#8211; noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_14b4b8fa-8c49-4ba7-bdef-ae507d2b15f8_terseLabel_en-US" xlink:label="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate of finite-lived intangible asset acquired</link:label>
    <link:label id="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_label_en-US" xlink:label="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_documentation_en-US" xlink:label="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:href="gild-20221231.xsd#gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:to="lab_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_ac1a3346-345d-49bb-9502-cd0335d24b41_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and other credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_25871250-ce55-45a4-880f-ffd8e8944bdf_terseLabel_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable debt securities</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_label_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:label id="lab_gild_MarketableSecuritiesNoncurrentMember_documentation_en-US" xlink:label="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:href="gild-20221231.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MarketableSecuritiesNoncurrentMember" xlink:to="lab_gild_MarketableSecuritiesNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b84df54b-7b43-462a-8a54-c30c5034b3c7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f29ac3da-0ba1-49ad-9a8e-ef7f0e27b2af_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_252b291b-7556-4216-b659-b5ef5c286842_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f32b2420-af70-4104-85e4-b0c3102023c2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6d467127-df8c-42e4-b971-a570d934af22_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_176a8087-adc3-4b8c-a2ae-acb4299ab30c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f787d23d-7d26-4fe4-b5ec-dde8d2e97982_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_2df78107-da24-4937-919b-800f1aee72aa_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_fbf4cc6e-984e-47d4-9c04-060736d8600e_terseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_50b091a4-8405-4420-970b-76c28c814b6a_negatedTerseLabel_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_label_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</link:label>
    <link:label id="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_documentation_en-US" xlink:label="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:href="gild-20221231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:to="lab_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_9ae161bb-5c0d-4e73-adbc-39c96c27ac2d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_49e75753-c3e8-4da6-aa55-47adfb103dfa_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement_9d56f85d-08d2-475a-9315-0b3231b754f5_terseLabel_en-US" xlink:label="lab_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage</link:label>
    <link:label id="lab_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement_label_en-US" xlink:label="lab_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Ownership Percentage In Galapagos Based On The Terms Of The Subscription Agreement</link:label>
    <link:label id="lab_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement_documentation_en-US" xlink:label="lab_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Ownership Percentage In Galapagos Based On The Terms Of The Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement" xlink:href="gild-20221231.xsd#gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement" xlink:to="lab_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_88dfecf7-ea4b-4dc6-afeb-df35ae3584d4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_50497f45-ae46-4088-b12c-a6f608dd2ae3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f3275605-441f-4ff8-875e-ace49f4bc600_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_ee8aaa2b-09fd-43f3-9050-09251912e25a_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6ccbfc18-d3e4-423e-a3ac-917a3218813c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160; Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f64aaebb-b00b-4b39-8734-6e6605c8652c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6d80b81b-bb8f-4608-952d-753a5a0368ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5d338d7d-99e2-4944-b602-c796f32506eb_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_3f45ca21-c710-401b-bd9d-a1b84fde996c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e5791ef1-00b8-411a-a6f6-fa930476e938_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7010b89b-e54a-4584-ad5f-4767c17dfda9_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_6d99863d-7e46-4ab4-a2d7-2791770bd70c_terseLabel_en-US" xlink:label="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tango collaboration and stock purchase agreement</link:label>
    <link:label id="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_label_en-US" xlink:label="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Research Collaboration and License Agreement and Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended and Restated Research Collaboration and License Agreement and Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:href="gild-20221231.xsd#gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:to="lab_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_2a8a7152-86fe-4369-85ab-c4954b448dd1_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_a07a15f3-d8a9-4f4f-89de-deef9f071e8f_terseLabel_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 revolving credit facility</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_label_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_gild_CreditFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_gild_CreditFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Due June 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member" xlink:href="gild-20221231.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CreditFacilityDueJune2025Member" xlink:to="lab_gild_CreditFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7f3f96e4-025d-4155-ba40-84fbd189a48c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1db5e20d-b1e0-42df-b0ca-39bc08d6f130_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7300081b-04b8-46bf-8a1e-da08af0940b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity Under Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_11abbae2-8c30-48c3-9d63-49c7be4d9f71_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4422eb99-62d2-48a9-8d2e-9266faccff43_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_868f5c44-f6fe-4329-9381-a3512d042a71_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member_9273e3b7-db39-4eb5-a34f-21546a844cfa_terseLabel_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.60% Senior Unsecured Notes Due in September 2035</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member_label_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2035 [Member]</link:label>
    <link:label id="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member_documentation_en-US" xlink:label="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due in September 2035</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:to="lab_gild_SeniorUnsecuredNotesDueinSeptember2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_dbfe4e61-044d-43dd-b68c-1f3f438f7a5d_terseLabel_en-US" xlink:label="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments</link:label>
    <link:label id="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_label_en-US" xlink:label="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Upfront and Milestone Payments</link:label>
    <link:label id="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_documentation_en-US" xlink:label="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Upfront and Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:href="gild-20221231.xsd#gild_DeferredTaxAssetsUpfrontAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:to="lab_gild_DeferredTaxAssetsUpfrontAndMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_b58f89ff-a9de-492d-9b31-b433ed242ae0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investment of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_5a0fdfd3-1d88-4fc9-9430-e428a14045fb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_ec54e743-b909-49fe-b335-813c8c8e4750_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_caad5028-72a8-4765-b88c-296769b8a0e9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_92c2e63b-70ce-4cb6-b43b-ad7b781b1f15_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNISharesAcquired_7496741e-0549-4fc0-bfc9-d51da7420ea4_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares acquired (in shares)</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNISharesAcquired_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares Acquired</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNISharesAcquired_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNISharesAcquired" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNISharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNISharesAcquired" xlink:to="lab_gild_EquitySecuritiesFVNISharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8a5246fe-e22e-405f-b29d-3ef9753f54c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8d91463d-bcb8-42ac-b2a2-0cb60660bb66_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d9f5a38f-679c-4f5d-a975-c2c1995cd28e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_14134837-170d-42c3-b581-83dab8d4466b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5c9e40b9-8b0b-4f8e-9b80-dafed2bcac66_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fbbabe5f-246c-415f-9250-88d7137ec840_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_11b7781c-6e97-4f1e-8e02-48b2911f9f42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_45e078e8-2cd3-4a16-b0be-db9a2a2dffaf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_59a120ff-d63b-466b-8a2a-955b46b698f6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_bc123c50-6cd3-4a93-86ec-d99e19460220_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8d4760f5-9135-4a24-bc65-871ef625855e_terseLabel_en-US" xlink:label="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="gild-20221231.xsd#gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_fd0613cb-2f8a-4ac0-9959-6814e3cb4493_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5505c541-fae0-4cc5-9978-82e927e684a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_7e8629cc-06f3-4969-88f2-eb14597bab5e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_11ea48aa-6862-41be-a163-e97839b2b455_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in diluted earnings per share attributable to Gilead calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0fcd9be0-9f8a-4130-b593-0206d98bd122_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in diluted earnings per share attributable to Gilead calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e47001cb-7543-4a2d-91a4-3a427c7fcc1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4c6437e1-01fe-499a-85fe-b424aa416fb2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected terms in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f96c8c56-28ec-4587-817d-5958e1139cd0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_dde26939-165b-414b-94a6-627a9ffa2ea1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_8d791f4d-7349-4f7f-8bc4-aa1dbcad0771_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f2195c3e-242c-485e-a734-d5e501cd78c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt Securities at Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_ef3eb0bb-2b4c-4293-9fab-7f4a40bceaeb_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_4ac42e81-a3ce-4bb2-beda-6b08ac75bb26_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f57815e3-8970-474a-9366-9db9e5062cc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DragonflyTherapeuticsIncMember_e7cff883-f5bc-410f-8568-bfa16933d271_terseLabel_en-US" xlink:label="lab_gild_DragonflyTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dragonfly Therapeutics, Inc.</link:label>
    <link:label id="lab_gild_DragonflyTherapeuticsIncMember_label_en-US" xlink:label="lab_gild_DragonflyTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dragonfly Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_DragonflyTherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_DragonflyTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dragonfly Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DragonflyTherapeuticsIncMember" xlink:href="gild-20221231.xsd#gild_DragonflyTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DragonflyTherapeuticsIncMember" xlink:to="lab_gild_DragonflyTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_85cfa6cb-967f-4434-9493-0549653782db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3aa5ea91-12bd-4bdd-bad7-a4228d1dee62_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_87d901bd-e8fe-4d6a-a8e6-122d780a249b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_edc2abe5-06ef-49d7-82c6-3094743cd226_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from equity securities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AccruedRebates_4c8f6ba2-c764-4689-9d49-627cb9dff9f6_terseLabel_en-US" xlink:label="lab_gild_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates</link:label>
    <link:label id="lab_gild_AccruedRebates_label_en-US" xlink:label="lab_gild_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates</link:label>
    <link:label id="lab_gild_AccruedRebates_documentation_en-US" xlink:label="lab_gild_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedRebates" xlink:href="gild-20221231.xsd#gild_AccruedRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AccruedRebates" xlink:to="lab_gild_AccruedRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_57afa83f-06ec-4197-93c9-6189f6e5ae84_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_38a04022-b7ec-459e-a10a-438cd272015e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dd6987ce-29d7-4705-8b55-58d7cf1e95d6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fbcf763b-4162-45ec-a409-a1bbd963ee37_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment losses</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_4f093d58-25aa-4b45-a90b-9d8c6361deb0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSU Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_63b053c5-def1-4b0d-acd1-d00f9ee576b3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_3ce5e9d0-dd9f-4b87-b58d-a2a4d3b6c259_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_4effbb85-b1d8-4c8f-8c26-407ec5605e9a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6aaac614-0c0b-4fa0-8a9d-4897aa59f24c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_78c0b04f-a70c-459f-861e-77d85af2ac50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OralFormulationProductMember_9f244e26-a61e-45ad-bc2c-ed5b1350acc3_terseLabel_en-US" xlink:label="lab_gild_OralFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation Product</link:label>
    <link:label id="lab_gild_OralFormulationProductMember_label_en-US" xlink:label="lab_gild_OralFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation Product [Member]</link:label>
    <link:label id="lab_gild_OralFormulationProductMember_documentation_en-US" xlink:label="lab_gild_OralFormulationProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Formulation Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OralFormulationProductMember" xlink:href="gild-20221231.xsd#gild_OralFormulationProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OralFormulationProductMember" xlink:to="lab_gild_OralFormulationProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c01b1b1-c7a2-4f8c-bd46-5b131bb29c46_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_25f73586-a916-491a-8601-a19b4454499e_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of outstanding stock allowed to be purchased</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_label_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</link:label>
    <link:label id="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:to="lab_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_583a68c3-62ef-4d70-95e2-c7339db3fe74_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_ca94b42a-39a2-4c14-befb-c96bc1d40554_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_1e585e55-b2cf-4122-8d50-fff184a8fdfa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_ef42b01a-b519-45cc-8ae1-0e719a367794_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing under the senior unsecured term loan facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_f887ce55-a209-4440-8968-77acd246191a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_adc134db-6e66-4391-bbb6-896224d623de_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Gilead</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_31d3e243-424b-4675-afa3-831fe579f12a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_24ad6c76-0966-4fec-99ed-58a83510cf2e_terseLabel_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complera/Eviplera</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_label_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:label id="lab_gild_HIVProductsCompleraEvipleraMember_documentation_en-US" xlink:label="lab_gild_HIVProductsCompleraEvipleraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Complera/Eviplera [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember" xlink:href="gild-20221231.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsCompleraEvipleraMember" xlink:to="lab_gild_HIVProductsCompleraEvipleraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_dbfeb810-d49a-4352-ae00-72275db9896e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_55b806c8-880b-4325-86a9-3e643cdef074_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_90282c3e-9035-4c4f-947d-ec12d3546eba_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits_b3418338-3049-4a5b-8917-de9786b05675_terseLabel_en-US" xlink:label="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of profits earned</link:label>
    <link:label id="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits_label_en-US" xlink:label="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage Of U.S. Profits</link:label>
    <link:label id="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits_documentation_en-US" xlink:label="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage Of U.S. Profits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuePerformanceObligationPercentageOfUSProfits" xlink:href="gild-20221231.xsd#gild_RevenuePerformanceObligationPercentageOfUSProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_RevenuePerformanceObligationPercentageOfUSProfits" xlink:to="lab_gild_RevenuePerformanceObligationPercentageOfUSProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TangoTherapeuticsIncMember_dda3b751-75fa-4016-a975-fbd906f575fa_terseLabel_en-US" xlink:label="lab_gild_TangoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tango</link:label>
    <link:label id="lab_gild_TangoTherapeuticsIncMember_label_en-US" xlink:label="lab_gild_TangoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tango Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_TangoTherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_TangoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tango Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember" xlink:href="gild-20221231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TangoTherapeuticsIncMember" xlink:to="lab_gild_TangoTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_eaa9f806-6988-4ba5-8257-404f46db75e4_terseLabel_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Running royalty rate from October 2017</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_label_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate from October 2017</link:label>
    <link:label id="lab_gild_JudgmentRoyaltyRateFromOctober2017_documentation_en-US" xlink:label="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judgment: Royalty Rate from October 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017" xlink:href="gild-20221231.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JudgmentRoyaltyRateFromOctober2017" xlink:to="lab_gild_JudgmentRoyaltyRateFromOctober2017" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_a65d9957-940d-4d1c-88af-7ef201d9bb10_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_c931410b-8019-4a32-a98d-e5bfa09266ca_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_dc74e617-60ba-489b-9e44-847166d732ca_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c19b3a42-68ac-41b4-b432-ef53c1ba08aa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_0c38311c-5695-4d50-b35b-c86aeb2d856d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Fair Values of Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_4f1a50c6-d506-4aaf-844a-957854da8b63_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_947aa1b0-4035-487c-a1e6-cbbb8f165ec5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f18d2742-789c-41a2-b543-f86a9261f451_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant_9356e2c9-29d1-4cdd-84ab-e8ffd60cf4ee_terseLabel_en-US" xlink:label="lab_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront collaboration expenses</link:label>
    <link:label id="lab_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant_label_en-US" xlink:label="lab_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-Front Collaboration And Licensing Expenses Related To Other Collaboration Arrangements That Are Not Individually Significant</link:label>
    <link:label id="lab_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant_documentation_en-US" xlink:label="lab_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-Front Collaboration And Licensing Expenses Related To Other Collaboration Arrangements That Are Not Individually Significant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:href="gild-20221231.xsd#gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:to="lab_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherHCVMember_57d979c7-60aa-40ed-a6f3-9c186ba405f5_terseLabel_en-US" xlink:label="lab_gild_OtherHCVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV</link:label>
    <link:label id="lab_gild_OtherHCVMember_label_en-US" xlink:label="lab_gild_OtherHCVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV [Member]</link:label>
    <link:label id="lab_gild_OtherHCVMember_documentation_en-US" xlink:label="lab_gild_OtherHCVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other HCV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHCVMember" xlink:href="gild-20221231.xsd#gild_OtherHCVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherHCVMember" xlink:to="lab_gild_OtherHCVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_5326fd65-2448-4dc7-bbb7-396c31863c9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Repurchases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1268d58b-0e29-4637-aa08-1a063f6168da_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_4f4d98b5-b7cd-4a83-90b0-6a92679278ca_terseLabel_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price (in dollars)</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:href="gild-20221231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:to="lab_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_efc161f6-5328-40b4-9256-0adf949f554b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_73db6f32-b8c8-462f-a9d6-bf60c186dc48_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9cb687e2-280b-49ea-9cf8-864453ad226e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_df4b5bc9-7800-45cb-87ac-34f7a098a84b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d1b1446c-98d6-47d7-8468-b29585bfd3d0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_216c3db1-297b-47fe-a181-2fd17792db4b_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2765a60c-d6f9-4796-9e11-4b8156381f45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future Amortization Expense of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b46657df-83c4-4970-b624-d0ffa235ced7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in valuation assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_MiroBioLtdMember_24f161ba-0674-4c26-ba9a-658c75ee2308_terseLabel_en-US" xlink:label="lab_gild_MiroBioLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MiroBio Ltd.</link:label>
    <link:label id="lab_gild_MiroBioLtdMember_label_en-US" xlink:label="lab_gild_MiroBioLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MiroBio Ltd. [Member]</link:label>
    <link:label id="lab_gild_MiroBioLtdMember_documentation_en-US" xlink:label="lab_gild_MiroBioLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MiroBio Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MiroBioLtdMember" xlink:href="gild-20221231.xsd#gild_MiroBioLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_MiroBioLtdMember" xlink:to="lab_gild_MiroBioLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_114de8d4-981c-41cb-adb1-65ffbc92d386_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to future royalties</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_5f5ea087-f9ab-4242-bf03-d8e197c4a9db_terseLabel_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of global and development and commercialization costs</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_label_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Development And Commercialization Costs</link:label>
    <link:label id="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_documentation_en-US" xlink:label="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Percent Of Global Development And Commercialization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:href="gild-20221231.xsd#gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:to="lab_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_f268b0fc-82f0-4dcd-89db-b80b3fab0a8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_107df0ba-9fe1-4f1c-a96f-eebc1c11dcad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_1a4898a8-0af0-4086-96d9-c4b74cff0498_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_37aac68c-319f-4b04-a3bb-13f1b0350f2b_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a3a34723-67b7-4376-8174-d3142af5ce2a_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_62935acc-3620-4dd5-8944-77e9e4ee095e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_3d48fe12-239a-4dc3-ac4b-f7f012678cb8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_27245434-7d78-4631-90cd-7f42da2551e8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesDonationMember_dc711d25-671b-4bda-8838-3e0bd9094c4b_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesDonationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Donation</link:label>
    <link:label id="lab_gild_EquitySecuritiesDonationMember_label_en-US" xlink:label="lab_gild_EquitySecuritiesDonationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Donation [Member]</link:label>
    <link:label id="lab_gild_EquitySecuritiesDonationMember_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesDonationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Donation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesDonationMember" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesDonationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesDonationMember" xlink:to="lab_gild_EquitySecuritiesDonationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PreExposureProphylaxisMember_0d83f400-4ef8-42cd-b49e-222f55d9341a_terseLabel_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis</link:label>
    <link:label id="lab_gild_PreExposureProphylaxisMember_label_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis [Member]</link:label>
    <link:label id="lab_gild_PreExposureProphylaxisMember_documentation_en-US" xlink:label="lab_gild_PreExposureProphylaxisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Exposure Prophylaxis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember" xlink:href="gild-20221231.xsd#gild_PreExposureProphylaxisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PreExposureProphylaxisMember" xlink:to="lab_gild_PreExposureProphylaxisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_902a8e09-b39f-484e-aff9-5268993e4726_terseLabel_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_label_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023 [Member]</link:label>
    <link:label id="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_documentation_en-US" xlink:label="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.75% Senior Unsecured Notes Due in September 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:href="gild-20221231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:to="lab_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_493748d0-53a6-4c9c-a000-f382c04b110a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_c39128c5-7ffc-42ce-9710-cac76c90e712_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_b02e6ea3-717f-470d-96da-5765b4b2fd47_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact of net unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3d1e4723-e0bc-4257-939c-a8ba1d4cc7cc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion_393f4d0c-c367-4ec0-be65-664586bd69db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign-derived intangible income deduction</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Extraterritorial Income Exclusion, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_99c8ffbe-616d-4969-be34-d6949e64f77b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_TotalUpfrontPaymentsMade_690d894b-cef9-4060-81fe-073b630a7f3d_terseLabel_en-US" xlink:label="lab_gild_TotalUpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront payments made</link:label>
    <link:label id="lab_gild_TotalUpfrontPaymentsMade_label_en-US" xlink:label="lab_gild_TotalUpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Upfront Payments Made</link:label>
    <link:label id="lab_gild_TotalUpfrontPaymentsMade_documentation_en-US" xlink:label="lab_gild_TotalUpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Upfront Payments Made</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalUpfrontPaymentsMade" xlink:href="gild-20221231.xsd#gild_TotalUpfrontPaymentsMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_TotalUpfrontPaymentsMade" xlink:to="lab_gild_TotalUpfrontPaymentsMade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_fa8c102c-e071-4513-a9aa-73d734089863_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_1691e82f-947e-42ad-ae2f-c925d4802067_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State:</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_0fded79f-b5e3-4b69-aa4c-42ca18baf411_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_13c767de-a459-499e-97cd-f66189626629_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_878980b4-fed9-46d5-a12e-681b61009ebb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_30fd8821-7ba4-428f-869d-24e61856b392_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_61072cb4-7e3f-4c6f-9434-5cfc4c846e7c_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b18ace1a-b327-4604-9b6c-8f37da9d0ca5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7640e64c-54cf-4913-aa5c-0dd94e07fc03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0e4a0f19-345a-4002-9b63-b5cfb815a1d3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_daa3efc7-d3fe-49a9-a84e-1c4c1539ffb5_terseLabel_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno</link:label>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_label_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center [Member]</link:label>
    <link:label id="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_documentation_en-US" xlink:label="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:href="gild-20221231.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:to="lab_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_a7353f9a-3619-4cc0-9e2b-0236f2fc7850_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax expense (benefit), continuing operations</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_e6e960f5-628c-4fc6-b393-fda04cd086dd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US tax on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_66164688-134f-4d07-964c-2007dac45365_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_1fb4fa28-8d40-4758-9c35-6d863a4dd5b3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued repatriation of foreign earnings</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_dd1b2a7d-9aac-442f-a3d0-2c7262809c86_totalLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_64e78bd5-6b94-4623-b897-b535e7454a3b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_1bc0a643-015d-4010-bfcf-bbf2c67fb22b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PionyrImmunotherapeuticsIncMember_fd2082a6-e818-4f0d-aed2-81399f291927_terseLabel_en-US" xlink:label="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr</link:label>
    <link:label id="lab_gild_PionyrImmunotherapeuticsIncMember_label_en-US" xlink:label="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Immunotherapeutics, Inc. [Member]</link:label>
    <link:label id="lab_gild_PionyrImmunotherapeuticsIncMember_documentation_en-US" xlink:label="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pionyr Immunotherapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrImmunotherapeuticsIncMember" xlink:href="gild-20221231.xsd#gild_PionyrImmunotherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PionyrImmunotherapeuticsIncMember" xlink:to="lab_gild_PionyrImmunotherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ee30613b-4feb-4a66-a657-9aaa01830fcc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GileadFoundationMember_54881415-9d33-4f17-b835-81013e04411c_terseLabel_en-US" xlink:label="lab_gild_GileadFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Foundation</link:label>
    <link:label id="lab_gild_GileadFoundationMember_label_en-US" xlink:label="lab_gild_GileadFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Foundation [Member]</link:label>
    <link:label id="lab_gild_GileadFoundationMember_documentation_en-US" xlink:label="lab_gild_GileadFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gilead Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadFoundationMember" xlink:href="gild-20221231.xsd#gild_GileadFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GileadFoundationMember" xlink:to="lab_gild_GileadFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f2fd1460-8f2c-423d-9a19-0b68aff7e4a2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total discounted lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ea4f5650-fa90-4dbc-9f12-f98fb8d1a756_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_ab06cb21-a0b0-4087-a19b-b480331a0c8b_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_4b41892b-ba22-44d8-a791-8f2087a2c7f1_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and land improvements</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_5a0d7449-e69e-4ed4-82e1-78ad0fb787a6_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vemlidy</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:href="gild-20221231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b179b2ea-4454-43f7-ae8f-ed0e72cbafaa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_39062536-7fbb-49e7-aa57-f7dc38830a8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_2a27af29-43d9-4067-bd30-aa85681e0e60_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves and accruals not currently deductible</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_b2876d47-d74d-41e8-9148-3f06c44119fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_143a2a3d-2b10-45fa-85bc-96df26365a5f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_bbff3a5e-2d34-4b2d-86b0-16b013a0f5bb_terseLabel_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_label_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027 [Member]</link:label>
    <link:label id="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member_documentation_en-US" xlink:label="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.20% Senior Unsecured Notes Due October 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:href="gild-20221231.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:to="lab_gild_A120SeniorUnsecuredNotesDueOctober2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_bf70ab2c-446b-456f-8325-26116d5bbd0b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_86d33dcd-cf40-4798-8fbc-82a362b55a4c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_667588d6-8efc-468f-9718-b7bc6b32160a_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_416a248a-35cb-4c8c-be5b-308fc7a8ddbf_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_af06b888-af2e-4041-9f83-8394343f6a2b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_a9e4f19a-191a-4911-860e-7fc7800d4fed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_4d3df8f5-a708-43ce-9ecb-c1ab54c7b403_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_6760b124-bd7c-439c-9ae5-6d4908f2b95c_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3c612454-7e14-42eb-aeff-1c53a20878ac_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_5eaf89e0-5d1d-4f68-8bbb-6c5aa94533c4_terseLabel_en-US" xlink:label="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments and equity method investments without readily determinable fair values</link:label>
    <link:label id="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount</link:label>
    <link:label id="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_documentation_en-US" xlink:label="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_03fd4d42-166b-4a4b-a48d-831a0d515131_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_bddeccff-5bf4-4f87-8cfc-edc5f0a509a0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_df63bc9b-41a4-4125-a941-be996b993b14_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a04a7a47-b60d-43a5-ae3c-c6c9402b6547_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c0f54651-3798-410c-ba1f-90d2f8510219_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_5d3904b5-9440-4040-a7d1-d0b1383be380_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of finite-lived intangible asset acquired</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f46f1c94-97f6-4e3e-b08d-ec46a49793d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_a6ce09ce-7043-4a7d-a6ea-3876b8fe299b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to net income, net of tax impact of $25, $(9) and $6, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c546a7c4-dc1b-471b-81ac-c8ffea278565_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f6fc6d19-267a-43a7-8fd9-6cc6160ada7d_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DeferredCompensationPlanMember_7eacf35f-d442-430e-80f8-4e0cc5ade903_terseLabel_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_label_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:label id="lab_gild_DeferredCompensationPlanMember_documentation_en-US" xlink:label="lab_gild_DeferredCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember" xlink:href="gild-20221231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DeferredCompensationPlanMember" xlink:to="lab_gild_DeferredCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember_077680c4-c0c0-4fbf-bb61-7ef70dad319b_terseLabel_en-US" xlink:label="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dragonfly Therapeutics Collaboration Agreement</link:label>
    <link:label id="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember_label_en-US" xlink:label="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dragonfly Therapeutics Collaboration Agreement [Member]</link:label>
    <link:label id="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember_documentation_en-US" xlink:label="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dragonfly Therapeutics Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DragonflyTherapeuticsCollaborationAgreementMember" xlink:href="gild-20221231.xsd#gild_DragonflyTherapeuticsCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_DragonflyTherapeuticsCollaborationAgreementMember" xlink:to="lab_gild_DragonflyTherapeuticsCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3153e64b-e63b-47b7-8f35-28d9740bc859_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_3d0ecbe4-01d5-4545-af43-ffb9d6910d2c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_df64bc93-40e0-4fdc-9567-f9ad9c5e23e9_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_f8dc3055-4166-45d9-a606-c3f22bcd369e_terseLabel_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other collaboration arrangements</link:label>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_label_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Arrangements [Member]</link:label>
    <link:label id="lab_gild_OtherCollaborationArrangementsMember_documentation_en-US" xlink:label="lab_gild_OtherCollaborationArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Collaboration Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember" xlink:href="gild-20221231.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherCollaborationArrangementsMember" xlink:to="lab_gild_OtherCollaborationArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ScheduleOfTransitionTaxTableTextBlock_b3dae1c4-512b-48aa-8e82-4b9aa5e28481_terseLabel_en-US" xlink:label="lab_gild_ScheduleOfTransitionTaxTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transition Tax</link:label>
    <link:label id="lab_gild_ScheduleOfTransitionTaxTableTextBlock_label_en-US" xlink:label="lab_gild_ScheduleOfTransitionTaxTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transition Tax [Table Text Block]</link:label>
    <link:label id="lab_gild_ScheduleOfTransitionTaxTableTextBlock_documentation_en-US" xlink:label="lab_gild_ScheduleOfTransitionTaxTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transition Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleOfTransitionTaxTableTextBlock" xlink:href="gild-20221231.xsd#gild_ScheduleOfTransitionTaxTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ScheduleOfTransitionTaxTableTextBlock" xlink:to="lab_gild_ScheduleOfTransitionTaxTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_6a95aa78-e757-4376-8f5e-825fbb1d1b0d_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsStribildMember_c70ff1d2-1bce-40ed-a168-be42ebed2417_terseLabel_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stribild</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_label_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:label id="lab_gild_HIVProductsStribildMember_documentation_en-US" xlink:label="lab_gild_HIVProductsStribildMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Stribild [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember" xlink:href="gild-20221231.xsd#gild_HIVProductsStribildMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsStribildMember" xlink:to="lab_gild_HIVProductsStribildMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1991c1c8-8a07-4974-a926-d0ce29140597_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and other credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_2a8fb409-220e-47c3-987e-10f49aa7e36d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_bf611cc5-df8c-4994-9444-fd500ace6ec9_terseLabel_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biktarvy</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_label_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:label id="lab_gild_HIVProductsBiktarvyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsBiktarvyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Biktarvy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember" xlink:href="gild-20221231.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsBiktarvyMember" xlink:to="lab_gild_HIVProductsBiktarvyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_c315cbc2-0dca-44d9-a95f-743ec6ceffbe_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_979f2a51-1daa-418f-a154-c75cec9479b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_GalapagosMember_10272f54-6ccc-47b1-a0b8-804f533c5e32_terseLabel_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos</link:label>
    <link:label id="lab_gild_GalapagosMember_label_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos [Member]</link:label>
    <link:label id="lab_gild_GalapagosMember_documentation_en-US" xlink:label="lab_gild_GalapagosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galapagos, a clinical-stage biotechnology company based in Belgium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember" xlink:href="gild-20221231.xsd#gild_GalapagosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_GalapagosMember" xlink:to="lab_gild_GalapagosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_7649fccb-b2b2-4462-a276-4e7b140b0ad9_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ad3df370-fc60-4d89-bbcc-86c0c2c3d998_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_StandstillRestrictingTerm_a12b16fc-8dc8-44f7-9daa-86967e6bebf0_terseLabel_en-US" xlink:label="lab_gild_StandstillRestrictingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill restricting term</link:label>
    <link:label id="lab_gild_StandstillRestrictingTerm_label_en-US" xlink:label="lab_gild_StandstillRestrictingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill Restricting Term</link:label>
    <link:label id="lab_gild_StandstillRestrictingTerm_documentation_en-US" xlink:label="lab_gild_StandstillRestrictingTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill Restricting Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_StandstillRestrictingTerm" xlink:href="gild-20221231.xsd#gild_StandstillRestrictingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_StandstillRestrictingTerm" xlink:to="lab_gild_StandstillRestrictingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_e71ffe0f-fae2-430d-ab15-f6a0fbb9e710_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of ESPP shares as of the respective vesting dates</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_b8c9e63e-319b-4f97-a0db-904ee5a99930_terseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_9209ed8a-8f57-4263-95fb-07123b69d63f_verboseLabel_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential mortgage and asset-backed securities</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_label_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:label id="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_documentation_en-US" xlink:label="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage And Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:href="gild-20221231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:to="lab_gild_ResidentialMortgageAndAssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_5eb94848-b724-4af2-8d03-1139a53d2543_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment_0689316d-7872-4e06-a750-a9550c455c66_terseLabel_en-US" xlink:label="lab_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payments to acquire in process research and development</link:label>
    <link:label id="lab_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Additional In Process Research And Development</link:label>
    <link:label id="lab_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Additional In Process Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment" xlink:href="gild-20221231.xsd#gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment" xlink:to="lab_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_4f28a1c3-6b68-49c5-b5e4-10c9a0811ff7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2bd8b804-bac7-4131-a767-2baf2e06346a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of tax basis over book basis of intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_28ee8fe7-638a-478b-a7dd-d21119424a36_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HIVProductsOdefseyMember_e258957b-3cb1-403f-afcd-052195716149_terseLabel_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Odefsey</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_label_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:label id="lab_gild_HIVProductsOdefseyMember_documentation_en-US" xlink:label="lab_gild_HIVProductsOdefseyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIV Products, Odefsey [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember" xlink:href="gild-20221231.xsd#gild_HIVProductsOdefseyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HIVProductsOdefseyMember" xlink:to="lab_gild_HIVProductsOdefseyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_97e54814-5019-4920-92de-ab8269ef58d5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_04a225c3-475d-4847-84a9-c62d2dbead83_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_28336747-6f22-490e-a06f-f0abc41f5ae7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income (Loss) Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_86b38071-49ca-4997-95ce-da50b434051c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_112fe6ce-04a1-40f9-bbb3-78272052eb12_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and income tax penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_f8e61f54-1116-4736-84a0-ce31f5e19d4c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized&#160;Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1ef8a7eb-d730-409f-a2e8-d8f582f20ef6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f6e39991-77e4-46ce-9f0f-8516e9d1c8e9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Gilead (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c723c14a-c1fa-4e99-8afc-fdfce152d6d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_32f8a958-0b6f-480b-8656-098f79a63fc2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_2c80d960-e70d-419b-a0de-83a1ac6ff06e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Repurchases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d6a7c241-9507-457d-aee7-f8f231a89c47_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_3a31b6cc-af0f-427f-9ed4-35b8e67a27ba_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_0420a582-7ec6-460c-8974-3afeca7cfcbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_46d797c3-1d01-4524-adce-a305031b45b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1047e550-589f-4a0a-b9f8-2c992d5ccbf4_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_55ee86de-8ec2-4b38-a52e-f6cb2df05c86_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_9d384a2f-9f01-42e3-b225-314142dbe8ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of book basis over tax basis of intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_0fde71c8-fc4e-4dfa-9c14-7ebb924fa49a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_a89716f7-4065-4537-8b5b-4e097b118c21_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_SummaryOfSignificantAccountingPoliciesTable_cf3ae519-2137-43ee-bbed-1c2304988372_terseLabel_en-US" xlink:label="lab_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gild_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_gild_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:href="gild-20221231.xsd#gild_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_gild_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_efa874fd-290b-49b0-b8af-703eecbccea3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ce782062-d1c2-4576-a328-eeb3d6b910d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_e06b709b-0637-4e4f-98c8-18b8f8c48b53_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_45e53667-9f3b-4073-88a1-23d656b59eda_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_65efc62c-619e-4b77-b466-a46439d92461_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_99634373-69d0-4a27-8766-6f6483dbf4be_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect from the adoption of new accounting standard</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_55532156-e278-4914-bb60-3379cdc645cf_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0c98ab9d-20b4-4161-9905-498cf2bec5d0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Aggregate Future Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c74ed881-d97d-4a95-a217-2de98a25d472_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_ed81c350-8fc9-4d03-bef8-9533a65deea0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d572cd4e-ed1f-4c92-831f-206455175588_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_beb44499-46fc-474a-94d2-3804550993ee_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_InvestmentOwnedBalanceAdditionalShares_99f0b0e5-8038-4628-8f5c-7d0b0f4aefe4_terseLabel_en-US" xlink:label="lab_gild_InvestmentOwnedBalanceAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares acquired (in shares)</link:label>
    <link:label id="lab_gild_InvestmentOwnedBalanceAdditionalShares_label_en-US" xlink:label="lab_gild_InvestmentOwnedBalanceAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Additional Shares</link:label>
    <link:label id="lab_gild_InvestmentOwnedBalanceAdditionalShares_documentation_en-US" xlink:label="lab_gild_InvestmentOwnedBalanceAdditionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Additional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InvestmentOwnedBalanceAdditionalShares" xlink:href="gild-20221231.xsd#gild_InvestmentOwnedBalanceAdditionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_InvestmentOwnedBalanceAdditionalShares" xlink:to="lab_gild_InvestmentOwnedBalanceAdditionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c82481cf-eded-4730-a218-b7e9c92acbb2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_9c68176b-3d46-4d0c-861f-4807f8425147_terseLabel_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viread</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_label_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]</link:label>
    <link:label id="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_documentation_en-US" xlink:label="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:href="gild-20221231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:to="lab_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_8b128d40-faee-4a7f-992e-a240cad528b6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_d14bbbbf-8197-4a06-9f93-27e6a6165461_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_fc5a16ba-8121-4f4a-a903-3b93900eb836_terseLabel_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three year senior unsecured term loan facility</link:label>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_label_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Year Senior Unsecured Term Loan Facility [Member]</link:label>
    <link:label id="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_documentation_en-US" xlink:label="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Year Senior Unsecured Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:href="gild-20221231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:to="lab_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_180a698e-94f1-4a51-8740-ff0af1bb5d4d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long term assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2653e18e-a9d1-4186-9104-15fa391f45e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financing Arrangements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_9df29db3-3628-426e-8a95-c0651ba56095_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_b0f90c3f-97f3-466f-996d-9534bdb73174_terseLabel_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments made related to equity investments</link:label>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_label_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments Made Related To Equity Investments</link:label>
    <link:label id="lab_gild_CashPaymentsMadeRelatedToEquityInvestments_documentation_en-US" xlink:label="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments Made Related To Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:href="gild-20221231.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:to="lab_gild_CashPaymentsMadeRelatedToEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_138a3c57-7de7-4cfe-bb1f-2c848212b28a_terseLabel_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payment for adjustments of budgeted development costs in 2021</link:label>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_label_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments of Budgeted Development Costs, Payments</link:label>
    <link:label id="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_documentation_en-US" xlink:label="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments of Budgeted Development Costs, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" xlink:href="gild-20221231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" xlink:to="lab_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_e295ff8c-ffaa-42c0-aef0-8cb35de53d40_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_8f339397-8822-402b-a2d5-469e323a4f88_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a7b3e00b-9715-481b-bef6-e0095e971526_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_e7b1f644-15ab-4014-80f9-5cddec3ff554_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_dedaa528-38bd-4ac4-8ed5-11fd47ee3586_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_9575c552-6e96-4e16-8725-a83305c32a42_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_88c498fd-57bd-4be4-a8b4-bdbf4e3e5a1a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire shares</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_c3e9adc0-4a27-42a4-83fe-3a813d0df34e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e088c929-7bff-433d-bcc4-51758480788d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_faab0ef4-1504-400a-b393-58ce91a539a4_totalLabel_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_label_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:label id="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_documentation_en-US" xlink:label="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:href="gild-20221231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:to="lab_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_049f5ee4-8e78-4a98-88a5-219e29e56758_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d22e4127-11fa-4fcf-9f6a-95252f5085bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_06289753-fe93-4097-8ba7-b5f0b82c27d1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_35356dc2-0699-4c18-a9ef-9eb97c7746a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_bad74a54-c9e0-48da-8e7e-887d424143f1_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_aec4d3a9-eded-431c-9efc-d34444845d9d_terseLabel_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset &#8211; axicabtagene ciloleucel</link:label>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_label_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:label id="lab_gild_AxicabtageneciloleucelDLBCLMember_documentation_en-US" xlink:label="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">axicabtagene ciloleucel (DLBCL) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember" xlink:href="gild-20221231.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_AxicabtageneciloleucelDLBCLMember" xlink:to="lab_gild_AxicabtageneciloleucelDLBCLMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_e2fc53bf-0ebd-40e4-85aa-8c0229802f2f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_22521c8d-4a0a-4a22-a33a-06979b855ae5_terseLabel_en-US" xlink:label="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange remeasurement</link:label>
    <link:label id="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_label_en-US" xlink:label="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement</link:label>
    <link:label id="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_documentation_en-US" xlink:label="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:href="gild-20221231.xsd#gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:to="lab_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_310379fa-33cf-41de-a851-48901f7b2c79_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8c92468d-098d-47b8-8a7e-9ff9f7834558_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_342116de-b730-462a-ad4e-c4f0b8699033_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_104c0790-783e-412d-9674-093b23e326e7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_52980916-65c5-4782-b40a-56714b240623_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_518ac469-c26c-48c3-a9c0-536728c236d8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_582c9e49-150c-4ef2-89b8-d411034ab318_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching contribution expense</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_b1cf46bc-3f1f-400c-a025-30a015a7267a_terseLabel_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_label_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales [Member]</link:label>
    <link:label id="lab_gild_OtherProductsTotalOtherProductSalesMember_documentation_en-US" xlink:label="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products, Total Other product sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:href="gild-20221231.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember" xlink:to="lab_gild_OtherProductsTotalOtherProductSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_5bc8fdf2-41ef-43c7-a5b1-25038eab2aeb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimates</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_29f769c3-240d-47d7-ba75-30d5744e3668_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_db64dd49-1a4a-482f-9159-4af60bb39ce1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_c54794a0-55bb-42ec-93b9-8d5d2a37fdbe_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_62da0b19-83e5-45fd-ba7a-b54d917a991f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_9ab51c26-aec8-42be-8c3c-6ef16fee4f69_terseLabel_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option fee and potential future milestone payments</link:label>
    <link:label id="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_label_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Option Fee And Potential Future Milestone Payments</link:label>
    <link:label id="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_documentation_en-US" xlink:label="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Option Fee And Potential Future Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:href="gild-20221231.xsd#gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:to="lab_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>gild-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:138d9561-5f65-4b2f-b0c5-a8cb97862906,g:db888c96-90b0-4c6d-8008-49d88ed38ca7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.gilead.com/role/Cover" xlink:type="simple" xlink:href="gild-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_151e0668-d681-45f2-bc4d-cc54ce593589" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_DocumentType_151e0668-d681-45f2-bc4d-cc54ce593589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_650372ad-69d5-4ede-97ec-9b8d3ae25266" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_DocumentAnnualReport_650372ad-69d5-4ede-97ec-9b8d3ae25266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ba6538b8-081d-47da-b5b8-fd1ae5a9248b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_DocumentPeriodEndDate_ba6538b8-081d-47da-b5b8-fd1ae5a9248b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9672b889-1de6-487a-9436-cf0331e30e33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_CurrentFiscalYearEndDate_9672b889-1de6-487a-9436-cf0331e30e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_60c53da1-9c96-4b23-9eaf-6f70cfb8d45e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_DocumentTransitionReport_60c53da1-9c96-4b23-9eaf-6f70cfb8d45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7aa47abb-3a4c-418f-a04f-3127e40a61c5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityFileNumber_7aa47abb-3a4c-418f-a04f-3127e40a61c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fbbf41ca-3de1-4ecc-a525-427dab6164eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityRegistrantName_fbbf41ca-3de1-4ecc-a525-427dab6164eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2d31301b-0177-4f33-9086-5f2d169805ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2d31301b-0177-4f33-9086-5f2d169805ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_96b8ecc6-0567-4c12-a400-77cf79279ce2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityTaxIdentificationNumber_96b8ecc6-0567-4c12-a400-77cf79279ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d4333e5e-d504-4026-b3e6-9d22ca9ed2f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityAddressAddressLine1_d4333e5e-d504-4026-b3e6-9d22ca9ed2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_310884a5-b3e1-474b-b293-65dd3bd76fae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityAddressCityOrTown_310884a5-b3e1-474b-b293-65dd3bd76fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5f0aae66-1aca-4ec8-a227-12935ccda719" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityAddressStateOrProvince_5f0aae66-1aca-4ec8-a227-12935ccda719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_07cb6b48-828e-45eb-81b9-656bab35a7af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityAddressPostalZipCode_07cb6b48-828e-45eb-81b9-656bab35a7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_66ee7fc4-9e7c-4cb7-a357-8431f8bf6dec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_CityAreaCode_66ee7fc4-9e7c-4cb7-a357-8431f8bf6dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_347c4d9d-6e43-44f9-8363-d5263868541d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_LocalPhoneNumber_347c4d9d-6e43-44f9-8363-d5263868541d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_737ef3a0-a0d8-4a60-bf3f-c9495947ebcb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_Security12bTitle_737ef3a0-a0d8-4a60-bf3f-c9495947ebcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b37fa923-a799-4303-bf06-48057ce381b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_TradingSymbol_b37fa923-a799-4303-bf06-48057ce381b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9ca761a8-8746-4f78-84d0-ed0c8f834178" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_SecurityExchangeName_9ca761a8-8746-4f78-84d0-ed0c8f834178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_d5acd543-6ce6-400a-ab38-e6bce141e639" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_d5acd543-6ce6-400a-ab38-e6bce141e639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_122fdc45-94c6-470d-873f-89c1e2716bf0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityVoluntaryFilers_122fdc45-94c6-470d-873f-89c1e2716bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f8f6401c-a6e9-40ac-9448-9eee21a6e4f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityCurrentReportingStatus_f8f6401c-a6e9-40ac-9448-9eee21a6e4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_59313e53-80af-4322-8bfb-3618611096db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityInteractiveDataCurrent_59313e53-80af-4322-8bfb-3618611096db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c0cff5fc-11c7-4418-ad2e-8a95c1cc5536" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityFilerCategory_c0cff5fc-11c7-4418-ad2e-8a95c1cc5536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6e6b4b79-4a51-4651-8c05-39d863b01cee" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntitySmallBusiness_6e6b4b79-4a51-4651-8c05-39d863b01cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9c86e83e-d059-48b4-bb04-d3e9f4c600d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityEmergingGrowthCompany_9c86e83e-d059-48b4-bb04-d3e9f4c600d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_c603490b-cfc4-4058-9213-425dac4e922d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_IcfrAuditorAttestationFlag_c603490b-cfc4-4058-9213-425dac4e922d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e36ef53b-2dee-4b8a-a357-0e0033723269" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityShellCompany_e36ef53b-2dee-4b8a-a357-0e0033723269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_d7c818b7-f2bf-48a2-b8bb-0c0d1c058ed2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityPublicFloat_d7c818b7-f2bf-48a2-b8bb-0c0d1c058ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2898066f-4205-442d-881a-69bb652fb55a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2898066f-4205-442d-881a-69bb652fb55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_347a1c64-78f0-4cc2-831e-c770c025f9a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_347a1c64-78f0-4cc2-831e-c770c025f9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b02a4d93-ae22-4c1b-bbb9-245c10671487" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_EntityCentralIndexKey_b02a4d93-ae22-4c1b-bbb9-245c10671487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_637bbdb3-9916-4054-a678-cbf06f82f8d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_DocumentFiscalYearFocus_637bbdb3-9916-4054-a678-cbf06f82f8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_aafe670b-5042-423c-8eeb-2b5803f6103a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_DocumentFiscalPeriodFocus_aafe670b-5042-423c-8eeb-2b5803f6103a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_819c7723-a573-4d9b-825d-6be913b80f36" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49a2c337-0b99-4bb4-a718-705a636992ce" xlink:to="loc_dei_AmendmentFlag_819c7723-a573-4d9b-825d-6be913b80f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AuditInformation" xlink:type="simple" xlink:href="gild-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_AuditInformationAbstract_8ce25a92-8c2f-4e8e-99c2-9f4e1f7daab4" xlink:href="gild-20221231.xsd#gild_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_a301f685-13be-454b-95c5-bfffa9e1c7c4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_AuditInformationAbstract_8ce25a92-8c2f-4e8e-99c2-9f4e1f7daab4" xlink:to="loc_dei_AuditorName_a301f685-13be-454b-95c5-bfffa9e1c7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_81c3782f-665f-4889-a6f8-271524b0387e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_AuditInformationAbstract_8ce25a92-8c2f-4e8e-99c2-9f4e1f7daab4" xlink:to="loc_dei_AuditorLocation_81c3782f-665f-4889-a6f8-271524b0387e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_c7821c17-5ab9-4e10-b158-76a0760b59b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_AuditInformationAbstract_8ce25a92-8c2f-4e8e-99c2-9f4e1f7daab4" xlink:to="loc_dei_AuditorFirmId_c7821c17-5ab9-4e10-b158-76a0760b59b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e1dba3e6-7497-4d09-975f-48b8019892ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e1a74d56-b512-42bf-96ca-4e8b4a5c4606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1dba3e6-7497-4d09-975f-48b8019892ca" xlink:to="loc_us-gaap_AssetsAbstract_e1a74d56-b512-42bf-96ca-4e8b4a5c4606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b2f9c4c9-2f15-42a2-a639-7dc92a6a4c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1a74d56-b512-42bf-96ca-4e8b4a5c4606" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b2f9c4c9-2f15-42a2-a639-7dc92a6a4c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a41a6dcd-d1db-4e78-9e90-8274758691bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b2f9c4c9-2f15-42a2-a639-7dc92a6a4c5b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a41a6dcd-d1db-4e78-9e90-8274758691bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b4922f4c-56da-4b68-908c-f7313d71bf25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b2f9c4c9-2f15-42a2-a639-7dc92a6a4c5b" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b4922f4c-56da-4b68-908c-f7313d71bf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f4cb6ded-43de-4885-a56b-5ebc1654aeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b2f9c4c9-2f15-42a2-a639-7dc92a6a4c5b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f4cb6ded-43de-4885-a56b-5ebc1654aeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1aa31e1e-ab40-4444-be41-43329a23f479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b2f9c4c9-2f15-42a2-a639-7dc92a6a4c5b" xlink:to="loc_us-gaap_InventoryNet_1aa31e1e-ab40-4444-be41-43329a23f479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e40df926-43b7-4205-9112-9bbb45e274b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b2f9c4c9-2f15-42a2-a639-7dc92a6a4c5b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e40df926-43b7-4205-9112-9bbb45e274b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_75f1e355-afe9-48fe-8de3-89e209bff71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b2f9c4c9-2f15-42a2-a639-7dc92a6a4c5b" xlink:to="loc_us-gaap_AssetsCurrent_75f1e355-afe9-48fe-8de3-89e209bff71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0ebb8163-9ae1-4db9-b193-9f4c59523760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1a74d56-b512-42bf-96ca-4e8b4a5c4606" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0ebb8163-9ae1-4db9-b193-9f4c59523760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_c65d814c-f20a-42d9-837a-e1f008172155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1a74d56-b512-42bf-96ca-4e8b4a5c4606" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_c65d814c-f20a-42d9-837a-e1f008172155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c9b5fa14-eb33-49ee-a6a9-985fcb1dd2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1a74d56-b512-42bf-96ca-4e8b4a5c4606" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c9b5fa14-eb33-49ee-a6a9-985fcb1dd2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f3db01ef-284b-4e1e-83e7-ffc662023fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1a74d56-b512-42bf-96ca-4e8b4a5c4606" xlink:to="loc_us-gaap_Goodwill_f3db01ef-284b-4e1e-83e7-ffc662023fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5df17592-541d-4b09-99f4-9d21c6936f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1a74d56-b512-42bf-96ca-4e8b4a5c4606" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5df17592-541d-4b09-99f4-9d21c6936f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9c593286-0b7e-4f2f-9bbc-f11cfa3e1a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e1a74d56-b512-42bf-96ca-4e8b4a5c4606" xlink:to="loc_us-gaap_Assets_9c593286-0b7e-4f2f-9bbc-f11cfa3e1a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27ff422a-e4c8-46f5-bbba-bec653b86519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e1dba3e6-7497-4d09-975f-48b8019892ca" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27ff422a-e4c8-46f5-bbba-bec653b86519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_87d41f47-adb4-4088-9fd9-37f64d3dd98f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27ff422a-e4c8-46f5-bbba-bec653b86519" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_87d41f47-adb4-4088-9fd9-37f64d3dd98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c1591a4c-9195-49e7-bab1-d8dad1d58432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87d41f47-adb4-4088-9fd9-37f64d3dd98f" xlink:to="loc_us-gaap_AccountsPayableCurrent_c1591a4c-9195-49e7-bab1-d8dad1d58432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccruedRebates_47b29c78-cc2e-4284-8c05-b567c46b14dc" xlink:href="gild-20221231.xsd#gild_AccruedRebates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87d41f47-adb4-4088-9fd9-37f64d3dd98f" xlink:to="loc_gild_AccruedRebates_47b29c78-cc2e-4284-8c05-b567c46b14dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_42f916c4-cf37-44a6-b79d-d1d6b13608fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87d41f47-adb4-4088-9fd9-37f64d3dd98f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_42f916c4-cf37-44a6-b79d-d1d6b13608fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_3bc38227-0e4b-430c-9a2f-7e01b0c64dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87d41f47-adb4-4088-9fd9-37f64d3dd98f" xlink:to="loc_us-gaap_DebtCurrent_3bc38227-0e4b-430c-9a2f-7e01b0c64dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ba36fb04-55af-42ca-9f78-f31d2fa7f365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87d41f47-adb4-4088-9fd9-37f64d3dd98f" xlink:to="loc_us-gaap_LiabilitiesCurrent_ba36fb04-55af-42ca-9f78-f31d2fa7f365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c3f6432c-fd85-4754-8e6f-b6341ae73a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27ff422a-e4c8-46f5-bbba-bec653b86519" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c3f6432c-fd85-4754-8e6f-b6341ae73a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_9d28df66-2574-4bce-9819-093a5a36fd44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27ff422a-e4c8-46f5-bbba-bec653b86519" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_9d28df66-2574-4bce-9819-093a5a36fd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b5e50bdc-a67d-4f5e-b6ea-aad1248e1374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27ff422a-e4c8-46f5-bbba-bec653b86519" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b5e50bdc-a67d-4f5e-b6ea-aad1248e1374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_89433922-9a71-47cc-8c8f-10b465914f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27ff422a-e4c8-46f5-bbba-bec653b86519" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_89433922-9a71-47cc-8c8f-10b465914f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9b9b2382-1f75-4c7f-82b0-8663779a32c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27ff422a-e4c8-46f5-bbba-bec653b86519" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9b9b2382-1f75-4c7f-82b0-8663779a32c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_18b639d6-a81e-40aa-925d-0ad436c33f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27ff422a-e4c8-46f5-bbba-bec653b86519" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_18b639d6-a81e-40aa-925d-0ad436c33f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_969e1545-769d-49f1-a615-d6c410d594d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_18b639d6-a81e-40aa-925d-0ad436c33f06" xlink:to="loc_us-gaap_PreferredStockValue_969e1545-769d-49f1-a615-d6c410d594d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ce4b0149-1ed2-4077-85dd-501c8bc41617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_18b639d6-a81e-40aa-925d-0ad436c33f06" xlink:to="loc_us-gaap_CommonStockValue_ce4b0149-1ed2-4077-85dd-501c8bc41617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e8d078ed-0803-4f17-82d1-6020ca9202a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_18b639d6-a81e-40aa-925d-0ad436c33f06" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e8d078ed-0803-4f17-82d1-6020ca9202a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_375f7665-da75-4bcc-a54d-c0d2f31710fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_18b639d6-a81e-40aa-925d-0ad436c33f06" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_375f7665-da75-4bcc-a54d-c0d2f31710fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7c3684b4-59cf-4133-b113-82e480e8384a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_18b639d6-a81e-40aa-925d-0ad436c33f06" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7c3684b4-59cf-4133-b113-82e480e8384a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5db3b4cb-297e-4433-8e8c-968507c6f5db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_18b639d6-a81e-40aa-925d-0ad436c33f06" xlink:to="loc_us-gaap_StockholdersEquity_5db3b4cb-297e-4433-8e8c-968507c6f5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_12ce437b-e58e-4a82-a956-671d5d88e38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_18b639d6-a81e-40aa-925d-0ad436c33f06" xlink:to="loc_us-gaap_MinorityInterest_12ce437b-e58e-4a82-a956-671d5d88e38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf66fa6f-6804-429d-80f5-33e60393cff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_18b639d6-a81e-40aa-925d-0ad436c33f06" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf66fa6f-6804-429d-80f5-33e60393cff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e2d213e8-7d7a-4f8f-8d8f-97a6410a39aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_27ff422a-e4c8-46f5-bbba-bec653b86519" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e2d213e8-7d7a-4f8f-8d8f-97a6410a39aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d3a9141f-2645-47eb-8dcf-d558866d9643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94095aa-5adb-4c3c-a034-7c44d4155fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d3a9141f-2645-47eb-8dcf-d558866d9643" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94095aa-5adb-4c3c-a034-7c44d4155fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_89d64309-6e69-40da-833c-65b9faa65576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94095aa-5adb-4c3c-a034-7c44d4155fa4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_89d64309-6e69-40da-833c-65b9faa65576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_877506a5-ad90-49ad-abb6-177387aaef60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_89d64309-6e69-40da-833c-65b9faa65576" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_877506a5-ad90-49ad-abb6-177387aaef60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_14ea2a36-a080-4285-98fc-a9f4ddd27fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_89d64309-6e69-40da-833c-65b9faa65576" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_14ea2a36-a080-4285-98fc-a9f4ddd27fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5e6b7e38-389a-41e5-b839-46c6d727fc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_89d64309-6e69-40da-833c-65b9faa65576" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5e6b7e38-389a-41e5-b839-46c6d727fc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_19db961c-9fa2-45d2-8594-21b478ca8d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_89d64309-6e69-40da-833c-65b9faa65576" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_19db961c-9fa2-45d2-8594-21b478ca8d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d8c1be62-a0c5-40a8-963f-0d16086e4544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_89d64309-6e69-40da-833c-65b9faa65576" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d8c1be62-a0c5-40a8-963f-0d16086e4544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_605db0db-1df9-4d6e-ad48-9a0d7d96a8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_89d64309-6e69-40da-833c-65b9faa65576" xlink:to="loc_us-gaap_CommonStockSharesIssued_605db0db-1df9-4d6e-ad48-9a0d7d96a8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_63663820-c602-4885-8144-50971b550a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_89d64309-6e69-40da-833c-65b9faa65576" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_63663820-c602-4885-8144-50971b550a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_43de56a6-d1f0-44e4-aefd-03cfd27c9f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b682824e-63c8-4505-a144-cf3523934cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_43de56a6-d1f0-44e4-aefd-03cfd27c9f90" xlink:to="loc_us-gaap_StatementTable_b682824e-63c8-4505-a144-cf3523934cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4ba58ed8-840f-4184-9b45-dcf7ae49bcc3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b682824e-63c8-4505-a144-cf3523934cad" xlink:to="loc_srt_ProductOrServiceAxis_4ba58ed8-840f-4184-9b45-dcf7ae49bcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ebd224be-1c9d-4e09-9e34-bba938e51215" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4ba58ed8-840f-4184-9b45-dcf7ae49bcc3" xlink:to="loc_srt_ProductsAndServicesDomain_ebd224be-1c9d-4e09-9e34-bba938e51215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_bbfd2c6f-34c3-443e-90de-7a8e871dc2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ebd224be-1c9d-4e09-9e34-bba938e51215" xlink:to="loc_us-gaap_ProductMember_bbfd2c6f-34c3-443e-90de-7a8e871dc2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_29acb681-9b8d-4a0d-b6ee-843f9d9f749f" xlink:href="gild-20221231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ebd224be-1c9d-4e09-9e34-bba938e51215" xlink:to="loc_gild_RoyaltyContractAndOtherMember_29acb681-9b8d-4a0d-b6ee-843f9d9f749f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b682824e-63c8-4505-a144-cf3523934cad" xlink:to="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d0be36b7-28f7-4817-a4ab-d208c2273655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_RevenuesAbstract_d0be36b7-28f7-4817-a4ab-d208c2273655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a1221ea2-86a1-4ce0-bc43-b026f3433a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d0be36b7-28f7-4817-a4ab-d208c2273655" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a1221ea2-86a1-4ce0-bc43-b026f3433a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6bb81f78-8d3c-441c-8fd1-ab6b558a9ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6bb81f78-8d3c-441c-8fd1-ab6b558a9ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_016ccd26-ecbb-4bff-910a-4402697a9ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_016ccd26-ecbb-4bff-910a-4402697a9ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_1f5450a9-92df-4195-991c-cb376b971a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_1f5450a9-92df-4195-991c-cb376b971a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e06b1ca3-33f7-4018-9ccf-ce60588b7e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e06b1ca3-33f7-4018-9ccf-ce60588b7e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c37ce407-ee9d-4178-9ea5-2d4e57589265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c37ce407-ee9d-4178-9ea5-2d4e57589265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1e7c6fd0-9889-47ff-858d-5db30a30b193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b24c1f1b-6e33-495e-912b-4afdc1a77907" xlink:to="loc_us-gaap_CostsAndExpenses_1e7c6fd0-9889-47ff-858d-5db30a30b193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2f57376b-3a19-4f73-a685-77249d8e3c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_OperatingIncomeLoss_2f57376b-3a19-4f73-a685-77249d8e3c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_993d32a2-719f-482e-956a-966e27f21db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_InterestExpense_993d32a2-719f-482e-956a-966e27f21db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5a341870-c570-4888-b8b5-be9c94a67033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5a341870-c570-4888-b8b5-be9c94a67033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a01dc33c-d67d-42cc-ac4d-0e4db54e1bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a01dc33c-d67d-42cc-ac4d-0e4db54e1bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c8ebd8e8-4b6b-42cb-8fd8-829a98cb88e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c8ebd8e8-4b6b-42cb-8fd8-829a98cb88e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ba85c183-c363-41b2-ba17-08a9bc421d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_ProfitLoss_ba85c183-c363-41b2-ba17-08a9bc421d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e4f7b2ee-20c7-4384-b275-be04b892e5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e4f7b2ee-20c7-4384-b275-be04b892e5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cc3af065-1182-40ec-b36a-d96619faaed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_NetIncomeLoss_cc3af065-1182-40ec-b36a-d96619faaed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e3767324-f22f-4286-a435-ff3221f1ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_EarningsPerShareBasic_e3767324-f22f-4286-a435-ff3221f1ee48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91f3a819-9174-4b0e-86c0-ccaec321c913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91f3a819-9174-4b0e-86c0-ccaec321c913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f8383083-affb-4854-b29b-9e8a55f534bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f8383083-affb-4854-b29b-9e8a55f534bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f66293af-ae03-4490-bb3b-677eabd9ba74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e92b09a1-5baa-4c8c-a385-eeea5dd1e0bb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f66293af-ae03-4490-bb3b-677eabd9ba74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f6937d2-81b3-4c4c-b91c-543f3eb96ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ff4ae4d2-23b6-4b95-8b73-d4ad800a665f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f6937d2-81b3-4c4c-b91c-543f3eb96ab8" xlink:to="loc_us-gaap_ProfitLoss_ff4ae4d2-23b6-4b95-8b73-d4ad800a665f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9b121b07-8d75-4bbf-a0cc-2f2043a5e661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f6937d2-81b3-4c4c-b91c-543f3eb96ab8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9b121b07-8d75-4bbf-a0cc-2f2043a5e661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cacfa0a2-85fb-49c5-b8d2-c80e1fff5d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9b121b07-8d75-4bbf-a0cc-2f2043a5e661" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cacfa0a2-85fb-49c5-b8d2-c80e1fff5d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_8cec5a6a-2c10-4251-8267-ef52bebfe296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9b121b07-8d75-4bbf-a0cc-2f2043a5e661" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_8cec5a6a-2c10-4251-8267-ef52bebfe296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41faed29-a813-4b30-8a26-77b5b7babd68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_8cec5a6a-2c10-4251-8267-ef52bebfe296" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_41faed29-a813-4b30-8a26-77b5b7babd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_da5b66a2-a076-4156-b7bf-9fc766bf953b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_8cec5a6a-2c10-4251-8267-ef52bebfe296" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_da5b66a2-a076-4156-b7bf-9fc766bf953b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_574094b1-63c8-4462-b8c9-d49b7195776d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_8cec5a6a-2c10-4251-8267-ef52bebfe296" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_574094b1-63c8-4462-b8c9-d49b7195776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_2d617117-7572-475d-9d42-4447196028e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9b121b07-8d75-4bbf-a0cc-2f2043a5e661" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_2d617117-7572-475d-9d42-4447196028e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_3d2bd2dc-9c35-46da-af28-911c89592456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_2d617117-7572-475d-9d42-4447196028e9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_3d2bd2dc-9c35-46da-af28-911c89592456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_17fbc111-32f2-46fc-9ae1-5936e9fa679e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_2d617117-7572-475d-9d42-4447196028e9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_17fbc111-32f2-46fc-9ae1-5936e9fa679e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_11a26e6a-e171-4841-8d3e-d1599121cdba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract_2d617117-7572-475d-9d42-4447196028e9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_11a26e6a-e171-4841-8d3e-d1599121cdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9a62bee1-714d-426c-be7d-8242183e560c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9b121b07-8d75-4bbf-a0cc-2f2043a5e661" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9a62bee1-714d-426c-be7d-8242183e560c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_88306e39-5bea-40cb-8303-17405e078d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f6937d2-81b3-4c4c-b91c-543f3eb96ab8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_88306e39-5bea-40cb-8303-17405e078d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ea4cf630-4244-4e8d-9011-54b24055aac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f6937d2-81b3-4c4c-b91c-543f3eb96ab8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ea4cf630-4244-4e8d-9011-54b24055aac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_71a8eb11-64a8-4213-bf3f-1ce89bdd533e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8f6937d2-81b3-4c4c-b91c-543f3eb96ab8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_71a8eb11-64a8-4213-bf3f-1ce89bdd533e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59aa6d8c-2115-4c24-891c-2f4d7bfff92d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract_74197863-5caa-41aa-8f28-b923b6d46e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59aa6d8c-2115-4c24-891c-2f4d7bfff92d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract_74197863-5caa-41aa-8f28-b923b6d46e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_c5b1de96-206a-4afe-8e71-6f00397d2624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract_74197863-5caa-41aa-8f28-b923b6d46e19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_c5b1de96-206a-4afe-8e71-6f00397d2624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_2758a9ff-34a6-43e6-8615-dc4987b592a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract_74197863-5caa-41aa-8f28-b923b6d46e19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_2758a9ff-34a6-43e6-8615-dc4987b592a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract_18ad28c5-c9b5-4b20-9189-34ec90b8a0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59aa6d8c-2115-4c24-891c-2f4d7bfff92d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract_18ad28c5-c9b5-4b20-9189-34ec90b8a0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_2968e9bf-05af-4884-9f0f-cc765de1bc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract_18ad28c5-c9b5-4b20-9189-34ec90b8a0bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_2968e9bf-05af-4884-9f0f-cc765de1bc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_e0cf1c94-b82d-4ef7-9047-f7a29d298322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract_18ad28c5-c9b5-4b20-9189-34ec90b8a0bd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_e0cf1c94-b82d-4ef7-9047-f7a29d298322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_292bd747-4c94-48df-9e54-0a8117b9a56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cc1bc568-34a9-4e82-8567-107e4eaeb027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_292bd747-4c94-48df-9e54-0a8117b9a56c" xlink:to="loc_us-gaap_StatementTable_cc1bc568-34a9-4e82-8567-107e4eaeb027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_49c44461-c613-43cd-b38b-b24d6be9bd59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc1bc568-34a9-4e82-8567-107e4eaeb027" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_49c44461-c613-43cd-b38b-b24d6be9bd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_49c44461-c613-43cd-b38b-b24d6be9bd59" xlink:to="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_00c549f7-f8e6-4e2c-b902-4a2602fdaea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:to="loc_us-gaap_CommonStockMember_00c549f7-f8e6-4e2c-b902-4a2602fdaea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_55302ac9-8978-413b-89f6-5e9536295fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_55302ac9-8978-413b-89f6-5e9536295fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d8c0a79c-87c7-49a4-9ec5-82dc65b8d37e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d8c0a79c-87c7-49a4-9ec5-82dc65b8d37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9d127c19-776e-4710-8b1b-9f1e70e5de39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:to="loc_us-gaap_RetainedEarningsMember_9d127c19-776e-4710-8b1b-9f1e70e5de39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_293f45af-c153-4e01-8a52-2c9499cd6fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_26ceb583-af06-4ea1-89c1-015ce88592e3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_293f45af-c153-4e01-8a52-2c9499cd6fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d63fa6f6-417e-4645-b674-35921707ce03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc1bc568-34a9-4e82-8567-107e4eaeb027" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d63fa6f6-417e-4645-b674-35921707ce03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dd2ce558-cdca-4455-bf77-08794d58a6c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_d63fa6f6-417e-4645-b674-35921707ce03" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dd2ce558-cdca-4455-bf77-08794d58a6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1800e675-80f7-4872-899f-36ebe3b6cdf4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_dd2ce558-cdca-4455-bf77-08794d58a6c1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1800e675-80f7-4872-899f-36ebe3b6cdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e08cb80f-4b18-410b-a57d-f9bd1c534809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc1bc568-34a9-4e82-8567-107e4eaeb027" xlink:to="loc_us-gaap_StatementLineItems_e08cb80f-4b18-410b-a57d-f9bd1c534809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e08cb80f-4b18-410b-a57d-f9bd1c534809" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_54de0056-6eac-4f65-97dd-ed7c58b0d0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_54de0056-6eac-4f65-97dd-ed7c58b0d0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee44464c-2407-40b6-aec5-2fe7dfd18db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee44464c-2407-40b6-aec5-2fe7dfd18db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_105e6f61-f659-4983-8593-a4ba7a1d4488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_105e6f61-f659-4983-8593-a4ba7a1d4488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_328ca4e5-689d-4e3e-aafb-cd2b4da6b85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_ProfitLoss_328ca4e5-689d-4e3e-aafb-cd2b4da6b85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b0fc7226-7dab-4bf8-a57e-9ad15641c2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b0fc7226-7dab-4bf8-a57e-9ad15641c2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b2a99b53-e557-4ad2-b0a1-4cec33677ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b2a99b53-e557-4ad2-b0a1-4cec33677ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a4af525e-b831-41bb-b186-7b04f672029b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a4af525e-b831-41bb-b186-7b04f672029b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_380c0de5-963a-40a9-972b-7536360be40c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_380c0de5-963a-40a9-972b-7536360be40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0e9d9170-0e21-48de-9d39-14e6e0447826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0e9d9170-0e21-48de-9d39-14e6e0447826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_027a917e-5c16-490f-ade1-dd7f26b94291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_027a917e-5c16-490f-ade1-dd7f26b94291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_e5cc9593-52b5-4532-a527-be445cbe39c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_e5cc9593-52b5-4532-a527-be445cbe39c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f5399d9a-853e-415e-8cae-a8fbdc749978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f5399d9a-853e-415e-8cae-a8fbdc749978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_3c1e118f-8084-43e0-8bc7-abc0319065b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_Dividends_3c1e118f-8084-43e0-8bc7-abc0319065b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5b609695-9112-4e51-b488-1f6ffa63f256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5b609695-9112-4e51-b488-1f6ffa63f256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_651b84dc-4d59-4789-84c4-a3d9ea32787d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0947f6ba-d701-4f54-8611-8d4975b9e035" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_651b84dc-4d59-4789-84c4-a3d9ea32787d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d6ab6c41-3e7a-44c5-99c1-e07662afd0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_f3354fa7-f429-403f-967c-037214796950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d6ab6c41-3e7a-44c5-99c1-e07662afd0e0" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_f3354fa7-f429-403f-967c-037214796950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="gild-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0302b332-ba45-4f35-8d18-1ec71d61dd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_908eff79-2320-4f49-b381-0b05afaf24ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0302b332-ba45-4f35-8d18-1ec71d61dd9a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_908eff79-2320-4f49-b381-0b05afaf24ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c0d61b23-e484-4e51-a6e9-31b739cd14e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_908eff79-2320-4f49-b381-0b05afaf24ad" xlink:to="loc_us-gaap_ProfitLoss_c0d61b23-e484-4e51-a6e9-31b739cd14e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a22bd05c-3cd7-4fc8-a6e3-8b0c7319643b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_908eff79-2320-4f49-b381-0b05afaf24ad" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a22bd05c-3cd7-4fc8-a6e3-8b0c7319643b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_5c0ff979-fd5a-49e5-8540-cbf2becfc211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a22bd05c-3cd7-4fc8-a6e3-8b0c7319643b" xlink:to="loc_us-gaap_Depreciation_5c0ff979-fd5a-49e5-8540-cbf2becfc211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_2a5e3f50-330a-4c4f-90f2-157a5859e0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a22bd05c-3cd7-4fc8-a6e3-8b0c7319643b" xlink:to="loc_us-gaap_AdjustmentForAmortization_2a5e3f50-330a-4c4f-90f2-157a5859e0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ecc231ed-7ee0-4724-ba62-baffc4141ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a22bd05c-3cd7-4fc8-a6e3-8b0c7319643b" xlink:to="loc_us-gaap_ShareBasedCompensation_ecc231ed-7ee0-4724-ba62-baffc4141ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_81e3fb55-03e7-4642-8845-c1a68343178a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a22bd05c-3cd7-4fc8-a6e3-8b0c7319643b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_81e3fb55-03e7-4642-8845-c1a68343178a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_1fb49211-a0b1-4aa8-a69c-3d278c969616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a22bd05c-3cd7-4fc8-a6e3-8b0c7319643b" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_1fb49211-a0b1-4aa8-a69c-3d278c969616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_fda8079d-3846-4d23-b269-4fef70374ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a22bd05c-3cd7-4fc8-a6e3-8b0c7319643b" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_fda8079d-3846-4d23-b269-4fef70374ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6abeeded-9027-4786-8518-3a313ab1c6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a22bd05c-3cd7-4fc8-a6e3-8b0c7319643b" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_6abeeded-9027-4786-8518-3a313ab1c6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_a1d0d760-3f3b-42ca-ac6c-67bf7564cf18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a22bd05c-3cd7-4fc8-a6e3-8b0c7319643b" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_a1d0d760-3f3b-42ca-ac6c-67bf7564cf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c5680e1-ac89-41ad-aea3-71e9407410b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a22bd05c-3cd7-4fc8-a6e3-8b0c7319643b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c5680e1-ac89-41ad-aea3-71e9407410b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c4ac37c4-cf75-4713-bf6b-e2f76e6cc5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c5680e1-ac89-41ad-aea3-71e9407410b5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c4ac37c4-cf75-4713-bf6b-e2f76e6cc5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_406d9030-9ecd-4b56-9500-0d98f2395f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c5680e1-ac89-41ad-aea3-71e9407410b5" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_406d9030-9ecd-4b56-9500-0d98f2395f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5f74a332-b48e-4018-92c9-26c6b9d458ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c5680e1-ac89-41ad-aea3-71e9407410b5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5f74a332-b48e-4018-92c9-26c6b9d458ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_990c8614-1b91-400e-9af9-c7aa39d80db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c5680e1-ac89-41ad-aea3-71e9407410b5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_990c8614-1b91-400e-9af9-c7aa39d80db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_06c0f879-3bb5-45b9-af61-8a942d90f2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c5680e1-ac89-41ad-aea3-71e9407410b5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_06c0f879-3bb5-45b9-af61-8a942d90f2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_98a7c883-c825-43ae-965f-4a171c776ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c5680e1-ac89-41ad-aea3-71e9407410b5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_98a7c883-c825-43ae-965f-4a171c776ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_184a8492-3753-46ae-b412-4e8cd86affe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c5680e1-ac89-41ad-aea3-71e9407410b5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_184a8492-3753-46ae-b412-4e8cd86affe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3bd6d36-0dfc-42df-90e6-92644c64d2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0302b332-ba45-4f35-8d18-1ec71d61dd9a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3bd6d36-0dfc-42df-90e6-92644c64d2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e670ed74-4d97-4512-bc8e-50249b3f8b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3bd6d36-0dfc-42df-90e6-92644c64d2d3" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e670ed74-4d97-4512-bc8e-50249b3f8b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2bbada36-e91c-4c51-b9ff-fa489163ef88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3bd6d36-0dfc-42df-90e6-92644c64d2d3" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2bbada36-e91c-4c51-b9ff-fa489163ef88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_de580fda-aac7-4b54-bc1f-15c344aad475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3bd6d36-0dfc-42df-90e6-92644c64d2d3" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_de580fda-aac7-4b54-bc1f-15c344aad475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e4b4cb4-77fe-48fa-923b-6a8c58c820a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3bd6d36-0dfc-42df-90e6-92644c64d2d3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e4b4cb4-77fe-48fa-923b-6a8c58c820a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_01e1e8bf-cdb0-4cbc-ae42-0286d953ea5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3bd6d36-0dfc-42df-90e6-92644c64d2d3" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_01e1e8bf-cdb0-4cbc-ae42-0286d953ea5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9710101b-bac3-4cc1-9301-c0cf5e848cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3bd6d36-0dfc-42df-90e6-92644c64d2d3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9710101b-bac3-4cc1-9301-c0cf5e848cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_03eb62fd-2582-4ad5-9d6f-d53b02aa595d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3bd6d36-0dfc-42df-90e6-92644c64d2d3" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_03eb62fd-2582-4ad5-9d6f-d53b02aa595d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_72ab002e-2918-4a2c-9045-e786dd8615a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d3bd6d36-0dfc-42df-90e6-92644c64d2d3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_72ab002e-2918-4a2c-9045-e786dd8615a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9620294-c979-46ed-9dc9-ef46e1f2b05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0302b332-ba45-4f35-8d18-1ec71d61dd9a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9620294-c979-46ed-9dc9-ef46e1f2b05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_7eb921d5-f576-4f99-99b2-bef6398e54a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9620294-c979-46ed-9dc9-ef46e1f2b05c" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_7eb921d5-f576-4f99-99b2-bef6398e54a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_042d1fd3-44b0-4b7f-9a06-9aa1144e429f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9620294-c979-46ed-9dc9-ef46e1f2b05c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_042d1fd3-44b0-4b7f-9a06-9aa1144e429f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_234483b9-9dc3-47f4-89f5-0528648a675f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9620294-c979-46ed-9dc9-ef46e1f2b05c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_234483b9-9dc3-47f4-89f5-0528648a675f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_a35c5ad0-9cc0-4ac3-9974-d9f8c0f48560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9620294-c979-46ed-9dc9-ef46e1f2b05c" xlink:to="loc_us-gaap_RepaymentsOfDebt_a35c5ad0-9cc0-4ac3-9974-d9f8c0f48560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_50004d32-5328-4598-98ac-2e5a26eafe4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9620294-c979-46ed-9dc9-ef46e1f2b05c" xlink:to="loc_us-gaap_PaymentsOfDividends_50004d32-5328-4598-98ac-2e5a26eafe4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1d166946-dd69-44a4-a825-482b9a661b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9620294-c979-46ed-9dc9-ef46e1f2b05c" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_1d166946-dd69-44a4-a825-482b9a661b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e54786b-d626-4da5-a757-865305c95567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d9620294-c979-46ed-9dc9-ef46e1f2b05c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e54786b-d626-4da5-a757-865305c95567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4c6f9911-ed48-48b6-980d-4237757d3518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0302b332-ba45-4f35-8d18-1ec71d61dd9a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4c6f9911-ed48-48b6-980d-4237757d3518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52566b03-627f-48f3-8639-99de5bc8063a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0302b332-ba45-4f35-8d18-1ec71d61dd9a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_52566b03-627f-48f3-8639-99de5bc8063a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ba5a7a5-e607-4e83-8da0-0ef8ea73fb64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0302b332-ba45-4f35-8d18-1ec71d61dd9a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0ba5a7a5-e607-4e83-8da0-0ef8ea73fb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5432842b-7865-4627-9f33-9b844a2caf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0302b332-ba45-4f35-8d18-1ec71d61dd9a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5432842b-7865-4627-9f33-9b844a2caf9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_49bcec02-f5b9-49d8-9305-8397605e1077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0302b332-ba45-4f35-8d18-1ec71d61dd9a" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_49bcec02-f5b9-49d8-9305-8397605e1077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_04a05465-8407-481a-965d-c09fe69d56d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_49bcec02-f5b9-49d8-9305-8397605e1077" xlink:to="loc_us-gaap_InterestPaidNet_04a05465-8407-481a-965d-c09fe69d56d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_fa112506-6ba3-4d07-bb0d-33873cbf2294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_49bcec02-f5b9-49d8-9305-8397605e1077" xlink:to="loc_us-gaap_IncomeTaxesPaid_fa112506-6ba3-4d07-bb0d-33873cbf2294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="gild-20221231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1d3f2d45-f826-4682-9d4f-1b1ac050743a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_a7d2195c-263b-4503-875b-01f517e27b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d3f2d45-f826-4682-9d4f-1b1ac050743a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_a7d2195c-263b-4503-875b-01f517e27b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Revenues" xlink:type="simple" xlink:href="gild-20221231.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_31c63e4c-c28c-481e-8b3b-f0f4fea85afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2ae5475b-c2f3-420a-9a75-41c994d2189c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_31c63e4c-c28c-481e-8b3b-f0f4fea85afc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2ae5475b-c2f3-420a-9a75-41c994d2189c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="gild-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8e62cad7-95f5-4085-8848-5f1e9e0ca6be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4497658d-b265-448d-87a3-4361dbf79522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8e62cad7-95f5-4085-8848-5f1e9e0ca6be" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4497658d-b265-448d-87a3-4361dbf79522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecurities" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecurities"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3a8754f5-2c87-4cdc-85f4-3fbd50a62550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_8f3a3a7f-bc05-48f0-a02d-04e01c5d6aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3a8754f5-2c87-4cdc-85f4-3fbd50a62550" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_8f3a3a7f-bc05-48f0-a02d-04e01c5d6aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstruments" xlink:type="simple" xlink:href="gild-20221231.xsd#DerivativeFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_226ae667-f640-41f7-aa30-b0466eb3c879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_23de23c5-e426-4a25-973f-905782cc504c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_226ae667-f640-41f7-aa30-b0466eb3c879" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_23de23c5-e426-4a25-973f-905782cc504c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Acquisitions" xlink:type="simple" xlink:href="gild-20221231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_36c702be-533f-4b90-a14b-7d866e99d642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_4a264637-5137-471f-ba45-55cf7a6d3807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_36c702be-533f-4b90-a14b-7d866e99d642" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_4a264637-5137-471f-ba45-55cf7a6d3807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="gild-20221231.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e00b519e-591b-4f7b-97af-94d7e2f06c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_803b95db-531c-4faf-b951-48cd946e33c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e00b519e-591b-4f7b-97af-94d7e2f06c7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_803b95db-531c-4faf-b951-48cd946e33c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="gild-20221231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75be9680-6841-41ba-b20e-e691c306562e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_330a5399-8d06-49f6-88d9-5bf47ef328f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75be9680-6841-41ba-b20e-e691c306562e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_330a5399-8d06-49f6-88d9-5bf47ef328f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="gild-20221231.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_d7a1f0a8-0364-4fd6-987a-f0510cc27956" xlink:href="gild-20221231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_689613c9-06fd-4865-bddf-d96a17330cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d7a1f0a8-0364-4fd6-987a-f0510cc27956" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_689613c9-06fd-4865-bddf-d96a17330cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangements" xlink:type="simple" xlink:href="gild-20221231.xsd#CollaborationsandOtherArrangements"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CollaborationsandOtherArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract_c81ffc8f-2a36-4b22-b85e-a56f9e4e2ec9" xlink:href="gild-20221231.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAndOtherArrangementsTextBlock_f5145d64-40b3-445b-a338-ad1fc66b20bf" xlink:href="gild-20221231.xsd#gild_CollaborativeAndOtherArrangementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract_c81ffc8f-2a36-4b22-b85e-a56f9e4e2ec9" xlink:to="loc_gild_CollaborativeAndOtherArrangementsTextBlock_f5145d64-40b3-445b-a338-ad1fc66b20bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilities" xlink:type="simple" xlink:href="gild-20221231.xsd#DebtandCreditFacilities"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_52fd22a8-3907-41b3-9155-feacb60af13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_af582367-2c43-4547-96a6-ac3ee22fba2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_52fd22a8-3907-41b3-9155-feacb60af13c" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_af582367-2c43-4547-96a6-ac3ee22fba2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/Leases" xlink:type="simple" xlink:href="gild-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_512d64a9-e93c-439c-a4fc-6b92f963bb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_4352bae0-2938-423b-8d20-0575bc8f5a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_512d64a9-e93c-439c-a4fc-6b92f963bb4f" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_4352bae0-2938-423b-8d20-0575bc8f5a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="gild-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_af1720a0-acc9-46c8-9188-2bb4258cee67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3976c831-b0be-42c1-9b16-d542e23c70d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_af1720a0-acc9-46c8-9188-2bb4258cee67" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3976c831-b0be-42c1-9b16-d542e23c70d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquity" xlink:type="simple" xlink:href="gild-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_647f1959-0bd3-4cd4-80c9-6357be85959d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_41c81340-f751-4e25-8f0d-d4ae49a53c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_647f1959-0bd3-4cd4-80c9-6357be85959d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_41c81340-f751-4e25-8f0d-d4ae49a53c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefits" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefits"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b309434f-8b29-4a14-87db-a3cddff4e537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d1f691a0-a183-4b34-a7ba-203c1679e3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b309434f-8b29-4a14-87db-a3cddff4e537" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d1f691a0-a183-4b34-a7ba-203c1679e3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EarningsPerShare" xlink:type="simple" xlink:href="gild-20221231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c38b24e5-9d6e-4db0-9f31-4fb7a1ef0f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_955db995-460a-4aa1-ada3-fbffeeb8521f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c38b24e5-9d6e-4db0-9f31-4fb7a1ef0f45" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_955db995-460a-4aa1-ada3-fbffeeb8521f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxes" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a8813951-d21a-4c4d-945c-f0f56dc8f228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0afb6e95-804a-482d-b544-2bc793f28055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a8813951-d21a-4c4d-945c-f0f56dc8f228" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0afb6e95-804a-482d-b544-2bc793f28055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SubsequentEvents" xlink:type="simple" xlink:href="gild-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d95aaf5c-2440-46ce-9c39-53fb9b40964f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ff03f8a6-a1f6-4738-8298-df4258b143c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d95aaf5c-2440-46ce-9c39-53fb9b40964f" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ff03f8a6-a1f6-4738-8298-df4258b143c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="gild-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a34688ba-c1d5-4a96-ab9d-aaa101f317f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a34688ba-c1d5-4a96-ab9d-aaa101f317f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d708efa8-805a-429d-acfd-2db596b4ede6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d708efa8-805a-429d-acfd-2db596b4ede6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_99a8b129-ca33-4573-9c6a-0a6d29707549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_99a8b129-ca33-4573-9c6a-0a6d29707549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_24112adf-8f66-4e09-bbdf-6e4deeccb144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_24112adf-8f66-4e09-bbdf-6e4deeccb144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_4339269e-bc8b-4c8f-aa96-5ab9b6784a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_4339269e-bc8b-4c8f-aa96-5ab9b6784a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_d020100a-b389-47fd-a11b-a86e331ba691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_d020100a-b389-47fd-a11b-a86e331ba691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_6aa71837-8657-4f68-9c43-9a3cfd4b72a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_6aa71837-8657-4f68-9c43-9a3cfd4b72a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_68432ca6-d871-4154-84f6-ccfb9a8aab56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_68432ca6-d871-4154-84f6-ccfb9a8aab56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_5b511842-cc4e-420c-b3cd-87ebf6bed28f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_5b511842-cc4e-420c-b3cd-87ebf6bed28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_3ea0c831-5c85-4fd9-8d81-cc0c2dd2c7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_3ea0c831-5c85-4fd9-8d81-cc0c2dd2c7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_c430ad5b-e223-4bc9-a2fe-2de0c9993051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_c430ad5b-e223-4bc9-a2fe-2de0c9993051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_01c55764-b2c3-448a-8e2f-79a8ffbd171c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_01c55764-b2c3-448a-8e2f-79a8ffbd171c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a967bb1b-3862-475f-ac99-0824452a2c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a967bb1b-3862-475f-ac99-0824452a2c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_e75d134d-e3e5-46c6-aec1-18f746b7a9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_e75d134d-e3e5-46c6-aec1-18f746b7a9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_e75087d7-19e7-4bb2-a0d8-7d72d67ff6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_e75087d7-19e7-4bb2-a0d8-7d72d67ff6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b9616598-465c-40e7-a375-3886c5881e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b9616598-465c-40e7-a375-3886c5881e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_b27904cd-5625-43c0-a2ed-32843a9d810a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_b27904cd-5625-43c0-a2ed-32843a9d810a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_cbd1e96b-d2b3-4a58-9ea1-8915e2506139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_cbd1e96b-d2b3-4a58-9ea1-8915e2506139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_2b95d5a6-49af-409c-808c-a623e22226e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_2b95d5a6-49af-409c-808c-a623e22226e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_090a96a2-d901-4fad-bcca-0ea8ccbccce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_090a96a2-d901-4fad-bcca-0ea8ccbccce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9e558388-39af-4261-8f00-a3f82a3c3e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9e558388-39af-4261-8f00-a3f82a3c3e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d328230d-6e79-4c5a-bce3-13eadd1b8cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37b8a6a0-36c1-49d1-9b32-3853014e438d" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d328230d-6e79-4c5a-bce3-13eadd1b8cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="gild-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_533d81a8-a5eb-4b32-a978-001adecfd67f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_f1f1e267-7151-49e1-ae3d-335805adef2c" xlink:href="gild-20221231.xsd#gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_533d81a8-a5eb-4b32-a978-001adecfd67f" xlink:to="loc_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_f1f1e267-7151-49e1-ae3d-335805adef2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesTables" xlink:type="simple" xlink:href="gild-20221231.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f43e44f8-954f-491b-86c0-4447c35f4e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1be4234d-9c3e-48b5-84b5-06fdb9159f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f43e44f8-954f-491b-86c0-4447c35f4e91" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1be4234d-9c3e-48b5-84b5-06fdb9159f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_d6a78ed8-8826-44c1-b698-54b79763676c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f43e44f8-954f-491b-86c0-4447c35f4e91" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_d6a78ed8-8826-44c1-b698-54b79763676c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_509c0b0f-20c7-43e6-8f51-b31c858f3aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f43e44f8-954f-491b-86c0-4447c35f4e91" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_509c0b0f-20c7-43e6-8f51-b31c858f3aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="gild-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a617a57c-ec63-4f83-a54e-969b936745b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b5747cd5-dde1-47ed-a4b0-a6e94c1301b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a617a57c-ec63-4f83-a54e-969b936745b3" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b5747cd5-dde1-47ed-a4b0-a6e94c1301b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e1a168a9-be22-46ea-a616-68c6b45edc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a617a57c-ec63-4f83-a54e-969b936745b3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e1a168a9-be22-46ea-a616-68c6b45edc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesTables" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e595205f-d599-4e66-9f34-08bbc13b0cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_967c5a8b-aeac-43eb-82e8-8b8f847a05f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e595205f-d599-4e66-9f34-08bbc13b0cf6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_967c5a8b-aeac-43eb-82e8-8b8f847a05f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_6d2ff377-3fb8-4e1b-8e8f-388d4351e111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e595205f-d599-4e66-9f34-08bbc13b0cf6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_6d2ff377-3fb8-4e1b-8e8f-388d4351e111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_97f6928c-a126-420e-90f0-0ab67d61072c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e595205f-d599-4e66-9f34-08bbc13b0cf6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_97f6928c-a126-420e-90f0-0ab67d61072c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_fa231520-aac9-4aa6-a243-f7d42d1ac54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e595205f-d599-4e66-9f34-08bbc13b0cf6" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_fa231520-aac9-4aa6-a243-f7d42d1ac54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_51e2f7ed-46fe-444a-9197-8d3b43988b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_e595205f-d599-4e66-9f34-08bbc13b0cf6" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_51e2f7ed-46fe-444a-9197-8d3b43988b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables" xlink:type="simple" xlink:href="gild-20221231.xsd#DerivativeFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35afc0e5-5d88-4ef1-b461-4fd8b43ddd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_6dc6f45e-dfd2-4450-ba82-fc0c1c97eccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35afc0e5-5d88-4ef1-b461-4fd8b43ddd47" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_6dc6f45e-dfd2-4450-ba82-fc0c1c97eccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2d226b5d-ec55-4028-a03b-8cbc98cb472f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35afc0e5-5d88-4ef1-b461-4fd8b43ddd47" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_2d226b5d-ec55-4028-a03b-8cbc98cb472f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="gild-20221231.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a8338416-860c-4148-8222-e141c06a2725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_a5721d91-663a-43ae-aa03-bd0663d06927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a8338416-860c-4148-8222-e141c06a2725" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_a5721d91-663a-43ae-aa03-bd0663d06927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="gild-20221231.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1620f707-ed89-40d3-90d5-0cbd6e8109d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_59dcc971-f912-4e43-bded-1c2138818b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1620f707-ed89-40d3-90d5-0cbd6e8109d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_59dcc971-f912-4e43-bded-1c2138818b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="gild-20221231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_547c2d27-269f-467b-a8a2-8ab7304a98b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_1f0a2b42-c3f1-414a-b8c5-84bd452f601a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_547c2d27-269f-467b-a8a2-8ab7304a98b8" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_1f0a2b42-c3f1-414a-b8c5-84bd452f601a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_938c84a8-3677-4d68-969f-a0162b2b3b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_547c2d27-269f-467b-a8a2-8ab7304a98b8" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_938c84a8-3677-4d68-969f-a0162b2b3b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_73a71b7a-599f-447d-9458-8ffce9d0a9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_547c2d27-269f-467b-a8a2-8ab7304a98b8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_73a71b7a-599f-447d-9458-8ffce9d0a9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b818a320-c4bc-4d5a-aaa7-f1a321cba27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_547c2d27-269f-467b-a8a2-8ab7304a98b8" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b818a320-c4bc-4d5a-aaa7-f1a321cba27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="gild-20221231.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_90c27c6c-0898-46ed-a7b2-ca7154ae0bb5" xlink:href="gild-20221231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_596f8c33-e4fb-4eff-81e4-626a167f49a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_90c27c6c-0898-46ed-a7b2-ca7154ae0bb5" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_596f8c33-e4fb-4eff-81e4-626a167f49a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_853ab5e5-a625-454a-96ef-77965e215f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_90c27c6c-0898-46ed-a7b2-ca7154ae0bb5" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_853ab5e5-a625-454a-96ef-77965e215f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_52b60384-c2cc-47ca-bf4e-e57eaf868ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_90c27c6c-0898-46ed-a7b2-ca7154ae0bb5" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_52b60384-c2cc-47ca-bf4e-e57eaf868ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesTables" xlink:type="simple" xlink:href="gild-20221231.xsd#DebtandCreditFacilitiesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_90ff1ed5-4d0f-47ab-9f6e-da9faf54a668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f3c4e671-b1e7-4c94-87a0-1a142410a927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_90ff1ed5-4d0f-47ab-9f6e-da9faf54a668" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f3c4e671-b1e7-4c94-87a0-1a142410a927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d8da3392-28f8-406c-9d1b-fdae16ad9f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_90ff1ed5-4d0f-47ab-9f6e-da9faf54a668" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d8da3392-28f8-406c-9d1b-fdae16ad9f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesTables" xlink:type="simple" xlink:href="gild-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_de7ee5ce-dc95-4657-8a49-87176562e53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_995bbedd-2c1d-4767-8bf8-34eb0aa37296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_de7ee5ce-dc95-4657-8a49-87176562e53a" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_995bbedd-2c1d-4767-8bf8-34eb0aa37296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_85c62602-72a3-417f-8a07-e2b9aeec50cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_de7ee5ce-dc95-4657-8a49-87176562e53a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_85c62602-72a3-417f-8a07-e2b9aeec50cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="gild-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6f4434c9-f52e-4a9e-93f7-357ca0f4b14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_09ffb0f4-69be-43fd-b696-425f2cf4d679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6f4434c9-f52e-4a9e-93f7-357ca0f4b14e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_09ffb0f4-69be-43fd-b696-425f2cf4d679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock_c8cf3d92-0ad5-45b1-9005-37ba0cdf48d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6f4434c9-f52e-4a9e-93f7-357ca0f4b14e" xlink:to="loc_us-gaap_DividendsDeclaredTableTextBlock_c8cf3d92-0ad5-45b1-9005-37ba0cdf48d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3bbf3c37-d23e-47ea-96fa-1ad229915d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6f4434c9-f52e-4a9e-93f7-357ca0f4b14e" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3bbf3c37-d23e-47ea-96fa-1ad229915d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsTables" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3072199e-efae-4dd2-ace8-a705db818295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6b61bc0b-7ac9-4e07-9de1-601506135e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3072199e-efae-4dd2-ace8-a705db818295" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6b61bc0b-7ac9-4e07-9de1-601506135e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_0f471123-f468-4948-8e19-cb78b788bab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3072199e-efae-4dd2-ace8-a705db818295" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_0f471123-f468-4948-8e19-cb78b788bab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_ce29c1d5-33eb-423d-9298-c6f5f43407e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3072199e-efae-4dd2-ace8-a705db818295" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_ce29c1d5-33eb-423d-9298-c6f5f43407e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_cc4b25e5-c7c6-4e03-9f84-330092fecb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3072199e-efae-4dd2-ace8-a705db818295" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_cc4b25e5-c7c6-4e03-9f84-330092fecb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_bbfdb9f4-0b23-405c-91e6-12dd1e7e56fb" xlink:href="gild-20221231.xsd#gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3072199e-efae-4dd2-ace8-a705db818295" xlink:to="loc_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_bbfdb9f4-0b23-405c-91e6-12dd1e7e56fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_332ad2b0-d828-4239-9c28-1a9bdb7ca500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3072199e-efae-4dd2-ace8-a705db818295" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_332ad2b0-d828-4239-9c28-1a9bdb7ca500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="gild-20221231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d6790d02-7d33-4a6c-81cb-8ad32a881137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_97bb915a-eef7-4129-a97c-b9aec95d44c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d6790d02-7d33-4a6c-81cb-8ad32a881137" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_97bb915a-eef7-4129-a97c-b9aec95d44c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cd64599e-356c-4233-ad7f-8d476733148f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2ad55ab4-d29e-4988-bca0-86f632acede9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd64599e-356c-4233-ad7f-8d476733148f" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_2ad55ab4-d29e-4988-bca0-86f632acede9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5fce8559-ca95-41b9-9755-c4e91fbcd43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd64599e-356c-4233-ad7f-8d476733148f" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_5fce8559-ca95-41b9-9755-c4e91fbcd43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7165cb38-6d9a-46a1-9962-ce46dd0bc6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd64599e-356c-4233-ad7f-8d476733148f" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7165cb38-6d9a-46a1-9962-ce46dd0bc6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c065a76e-20c5-43a1-ade7-95e012838611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd64599e-356c-4233-ad7f-8d476733148f" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c065a76e-20c5-43a1-ade7-95e012838611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5a90183f-d86b-4b5e-9052-64bb5f35d530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd64599e-356c-4233-ad7f-8d476733148f" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5a90183f-d86b-4b5e-9052-64bb5f35d530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleOfTransitionTaxTableTextBlock_ebb781c4-fdff-443a-8ae0-2d7c21d2f46e" xlink:href="gild-20221231.xsd#gild_ScheduleOfTransitionTaxTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd64599e-356c-4233-ad7f-8d476733148f" xlink:to="loc_gild_ScheduleOfTransitionTaxTableTextBlock_ebb781c4-fdff-443a-8ae0-2d7c21d2f46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dacf9507-1b49-435d-8aa6-89a17b1d970a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SummaryOfSignificantAccountingPoliciesTable_3d57f523-5f96-4942-8d3a-1b211370954e" xlink:href="gild-20221231.xsd#gild_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dacf9507-1b49-435d-8aa6-89a17b1d970a" xlink:to="loc_gild_SummaryOfSignificantAccountingPoliciesTable_3d57f523-5f96-4942-8d3a-1b211370954e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d94076f-6b2e-4f72-9c6b-e080675f5b2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_3d57f523-5f96-4942-8d3a-1b211370954e" xlink:to="loc_srt_RangeAxis_8d94076f-6b2e-4f72-9c6b-e080675f5b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1cdd3ce2-920d-42c6-9ad9-53d8f678d61b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8d94076f-6b2e-4f72-9c6b-e080675f5b2b" xlink:to="loc_srt_RangeMember_1cdd3ce2-920d-42c6-9ad9-53d8f678d61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3bde6aaf-db9b-4d71-af21-5fd462487110" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1cdd3ce2-920d-42c6-9ad9-53d8f678d61b" xlink:to="loc_srt_MinimumMember_3bde6aaf-db9b-4d71-af21-5fd462487110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e444e66-7e02-4a4c-91a3-a7bc98879ef9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1cdd3ce2-920d-42c6-9ad9-53d8f678d61b" xlink:to="loc_srt_MaximumMember_7e444e66-7e02-4a4c-91a3-a7bc98879ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0f2a3910-49c3-48aa-a188-09f0d5a21263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_3d57f523-5f96-4942-8d3a-1b211370954e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0f2a3910-49c3-48aa-a188-09f0d5a21263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8044ebb-9109-4f2c-8664-c49a9ec756e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0f2a3910-49c3-48aa-a188-09f0d5a21263" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8044ebb-9109-4f2c-8664-c49a9ec756e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_a37d0cd7-3bf7-493a-afc8-7f89448f249a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8044ebb-9109-4f2c-8664-c49a9ec756e0" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_a37d0cd7-3bf7-493a-afc8-7f89448f249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_ca0f1a81-ef2d-405f-bdde-7e08642a4b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8044ebb-9109-4f2c-8664-c49a9ec756e0" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_ca0f1a81-ef2d-405f-bdde-7e08642a4b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d3c5352e-2e40-4193-9793-347c81c5d745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c8044ebb-9109-4f2c-8664-c49a9ec756e0" xlink:to="loc_us-gaap_ComputerEquipmentMember_d3c5352e-2e40-4193-9793-347c81c5d745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_7ebadfc8-5782-467d-98a3-242f076be191" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_3d57f523-5f96-4942-8d3a-1b211370954e" xlink:to="loc_srt_RestatementAxis_7ebadfc8-5782-467d-98a3-242f076be191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_c82d8596-bfb6-42e8-8c54-95f8629731a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_7ebadfc8-5782-467d-98a3-242f076be191" xlink:to="loc_srt_RestatementDomain_c82d8596-bfb6-42e8-8c54-95f8629731a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_483d004b-6c4e-4fcf-9ec9-6efdc0c14c79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_c82d8596-bfb6-42e8-8c54-95f8629731a6" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_483d004b-6c4e-4fcf-9ec9-6efdc0c14c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:href="gild-20221231.xsd#gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SummaryOfSignificantAccountingPoliciesTable_3d57f523-5f96-4942-8d3a-1b211370954e" xlink:to="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_58888417-e30b-4e11-b301-b46b84ce242b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_58888417-e30b-4e11-b301-b46b84ce242b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2fce756f-f7fd-48ef-9d53-7bb231120bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2fce756f-f7fd-48ef-9d53-7bb231120bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e2e322a-374c-41d3-95b9-abda9655c1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e2e322a-374c-41d3-95b9-abda9655c1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_5b7475a6-1e5c-445f-a35b-3ac7c1c4c014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:to="loc_us-gaap_AdvertisingExpense_5b7475a6-1e5c-445f-a35b-3ac7c1c4c014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e152a264-e676-4d5c-a06b-23fbea1ba6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ddbceab8-8ff8-4fdc-a238-5dd048c50f91" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e152a264-e676-4d5c-a06b-23fbea1ba6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#RevenuesDisaggregationofRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19a1781e-b0d1-4e89-b9be-ea3e180ce17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b8aba6d3-2572-4195-a805-068a5dd9782f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19a1781e-b0d1-4e89-b9be-ea3e180ce17d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b8aba6d3-2572-4195-a805-068a5dd9782f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bd0183dd-112d-4a00-90f9-7fc7df67b9fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b8aba6d3-2572-4195-a805-068a5dd9782f" xlink:to="loc_srt_ProductOrServiceAxis_bd0183dd-112d-4a00-90f9-7fc7df67b9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96466de1-a1cb-4bd1-8736-f3652d4aecb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bd0183dd-112d-4a00-90f9-7fc7df67b9fd" xlink:to="loc_srt_ProductsAndServicesDomain_96466de1-a1cb-4bd1-8736-f3652d4aecb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_96466de1-a1cb-4bd1-8736-f3652d4aecb3" xlink:to="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:href="gild-20221231.xsd#gild_HIVProductSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsBiktarvyMember_05c3d5e4-d2c8-45ab-b716-d265d81beabf" xlink:href="gild-20221231.xsd#gild_HIVProductsBiktarvyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsBiktarvyMember_05c3d5e4-d2c8-45ab-b716-d265d81beabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsCompleraEvipleraMember_dda0547f-9804-4efe-b1a0-28de60337981" xlink:href="gild-20221231.xsd#gild_HIVProductsCompleraEvipleraMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsCompleraEvipleraMember_dda0547f-9804-4efe-b1a0-28de60337981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsDescovyMember_e655b14c-a43c-41ae-b9a7-66998ee2e071" xlink:href="gild-20221231.xsd#gild_HIVProductsDescovyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsDescovyMember_e655b14c-a43c-41ae-b9a7-66998ee2e071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsGenvoyaMember_fe5e90c5-6402-41cb-97a3-51771f0eff2f" xlink:href="gild-20221231.xsd#gild_HIVProductsGenvoyaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsGenvoyaMember_fe5e90c5-6402-41cb-97a3-51771f0eff2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsOdefseyMember_7b7f5167-fb0e-4ba1-bf77-24a2a9b927ab" xlink:href="gild-20221231.xsd#gild_HIVProductsOdefseyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsOdefseyMember_7b7f5167-fb0e-4ba1-bf77-24a2a9b927ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsStribildMember_d392e328-8d74-4a83-8c98-4a3b24ad3e7c" xlink:href="gild-20221231.xsd#gild_HIVProductsStribildMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsStribildMember_d392e328-8d74-4a83-8c98-4a3b24ad3e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HIVProductsTruvadaMember_756d7187-3c63-419d-a362-736f5aaea626" xlink:href="gild-20221231.xsd#gild_HIVProductsTruvadaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_HIVProductsTruvadaMember_756d7187-3c63-419d-a362-736f5aaea626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsRevenueShareSymtuzaMember_2f0884ea-13b6-4752-93f7-c9cbc6a5d177" xlink:href="gild-20221231.xsd#gild_ProductsRevenueShareSymtuzaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_ProductsRevenueShareSymtuzaMember_2f0884ea-13b6-4752-93f7-c9cbc6a5d177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductsOtherHIVMember_76f29593-8a7f-4582-9748-2c013ea3f77c" xlink:href="gild-20221231.xsd#gild_ProductsOtherHIVMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HIVProductSalesMember_65f98237-871b-423e-8810-cec891196f04" xlink:to="loc_gild_ProductsOtherHIVMember_76f29593-8a7f-4582-9748-2c013ea3f77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_VekluryMember_03c910dd-4ce7-4f2c-9c69-63606b0b9937" xlink:href="gild-20221231.xsd#gild_VekluryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_VekluryMember_03c910dd-4ce7-4f2c-9c69-63606b0b9937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductSalesMember_75ddc2f1-382e-4fd8-a123-dc7b8e57d475" xlink:href="gild-20221231.xsd#gild_HCVProductSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_HCVProductSalesMember_75ddc2f1-382e-4fd8-a123-dc7b8e57d475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsLedipasvirSofosbuvirMember_8b9ee560-d619-4555-9276-b492ffb86625" xlink:href="gild-20221231.xsd#gild_HCVProductsLedipasvirSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_75ddc2f1-382e-4fd8-a123-dc7b8e57d475" xlink:to="loc_gild_HCVProductsLedipasvirSofosbuvirMember_8b9ee560-d619-4555-9276-b492ffb86625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_5322ed44-a951-417f-aaa9-e19a73f2e246" xlink:href="gild-20221231.xsd#gild_HCVProductsSofosbuvirVelpatasvirMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_75ddc2f1-382e-4fd8-a123-dc7b8e57d475" xlink:to="loc_gild_HCVProductsSofosbuvirVelpatasvirMember_5322ed44-a951-417f-aaa9-e19a73f2e246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherHCVMember_468d350e-a6fa-4e34-bf10-1aa7294e4f32" xlink:href="gild-20221231.xsd#gild_OtherHCVMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HCVProductSalesMember_75ddc2f1-382e-4fd8-a123-dc7b8e57d475" xlink:to="loc_gild_OtherHCVMember_468d350e-a6fa-4e34-bf10-1aa7294e4f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_5caad235-b990-42be-a081-a230bfdc6dad" xlink:href="gild-20221231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_5caad235-b990-42be-a081-a230bfdc6dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_2e36cdbb-0506-4e48-b23d-caa210e6e6fe" xlink:href="gild-20221231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_5caad235-b990-42be-a081-a230bfdc6dad" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember_2e36cdbb-0506-4e48-b23d-caa210e6e6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_543e1db9-641b-4a1b-b740-15da629b02aa" xlink:href="gild-20221231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_5caad235-b990-42be-a081-a230bfdc6dad" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember_543e1db9-641b-4a1b-b740-15da629b02aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_8b0618c1-ce3b-4163-a374-ffd9cd62a40b" xlink:href="gild-20221231.xsd#gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductMember_5caad235-b990-42be-a081-a230bfdc6dad" xlink:to="loc_gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember_8b0618c1-ce3b-4163-a374-ffd9cd62a40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ea3837b0-5a88-4c26-992c-6fa397c9b291" xlink:href="gild-20221231.xsd#gild_CellTherapyProductsTotalCellTherapyProductSalesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ea3837b0-5a88-4c26-992c-6fa397c9b291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CellTherapyProductsTecartusMember_058fec26-b8c0-4274-b08e-534d8e2834d5" xlink:href="gild-20221231.xsd#gild_CellTherapyProductsTecartusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ea3837b0-5a88-4c26-992c-6fa397c9b291" xlink:to="loc_gild_CellTherapyProductsTecartusMember_058fec26-b8c0-4274-b08e-534d8e2834d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsYescartaMember_67412e7f-8ec6-49f2-b320-57852f022581" xlink:href="gild-20221231.xsd#gild_OtherProductsYescartaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CellTherapyProductsTotalCellTherapyProductSalesMember_ea3837b0-5a88-4c26-992c-6fa397c9b291" xlink:to="loc_gild_OtherProductsYescartaMember_67412e7f-8ec6-49f2-b320-57852f022581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_9e368858-8123-431b-a990-1095ebdc30ac" xlink:href="gild-20221231.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_TrodelvyMember_9e368858-8123-431b-a990-1095ebdc30ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsTotalOtherProductSalesMember_cb6075b2-7823-47ad-8e34-b6fade2d7456" xlink:href="gild-20221231.xsd#gild_OtherProductsTotalOtherProductSalesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_0a02cf35-3c4d-495f-94bf-31d185bfa93e" xlink:to="loc_gild_OtherProductsTotalOtherProductSalesMember_cb6075b2-7823-47ad-8e34-b6fade2d7456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsAmBisomeMember_35751aff-82a8-48c5-9065-a05568b28684" xlink:href="gild-20221231.xsd#gild_OtherProductsAmBisomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_cb6075b2-7823-47ad-8e34-b6fade2d7456" xlink:to="loc_gild_OtherProductsAmBisomeMember_35751aff-82a8-48c5-9065-a05568b28684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsLetairisMember_2daaa4c4-194a-415a-bb63-11092fb5d0f9" xlink:href="gild-20221231.xsd#gild_OtherProductsLetairisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_cb6075b2-7823-47ad-8e34-b6fade2d7456" xlink:to="loc_gild_OtherProductsLetairisMember_2daaa4c4-194a-415a-bb63-11092fb5d0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherProductsOtherMember_246af3e4-a788-4d13-85a5-51a08a2cd5a4" xlink:href="gild-20221231.xsd#gild_OtherProductsOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherProductsTotalOtherProductSalesMember_cb6075b2-7823-47ad-8e34-b6fade2d7456" xlink:to="loc_gild_OtherProductsOtherMember_246af3e4-a788-4d13-85a5-51a08a2cd5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RoyaltyContractAndOtherMember_5ccbc6ca-1d2a-4d55-8c3a-59f6bed73f38" xlink:href="gild-20221231.xsd#gild_RoyaltyContractAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_96466de1-a1cb-4bd1-8736-f3652d4aecb3" xlink:to="loc_gild_RoyaltyContractAndOtherMember_5ccbc6ca-1d2a-4d55-8c3a-59f6bed73f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_79186a15-80ff-44b8-a9ce-99b0456a6193" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b8aba6d3-2572-4195-a805-068a5dd9782f" xlink:to="loc_srt_StatementGeographicalAxis_79186a15-80ff-44b8-a9ce-99b0456a6193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e33a645d-3694-414d-aede-f80562a7295a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_79186a15-80ff-44b8-a9ce-99b0456a6193" xlink:to="loc_srt_SegmentGeographicalDomain_e33a645d-3694-414d-aede-f80562a7295a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a22da078-d7c5-4b60-9095-1688057b610b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e33a645d-3694-414d-aede-f80562a7295a" xlink:to="loc_country_US_a22da078-d7c5-4b60-9095-1688057b610b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_b5abd97d-a2b8-42a4-85fc-e1262ab27366" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e33a645d-3694-414d-aede-f80562a7295a" xlink:to="loc_srt_EuropeMember_b5abd97d-a2b8-42a4-85fc-e1262ab27366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherInternationalMember_c229ff39-23fe-4d0a-9859-adf267b992b1" xlink:href="gild-20221231.xsd#gild_OtherInternationalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e33a645d-3694-414d-aede-f80562a7295a" xlink:to="loc_gild_OtherInternationalMember_c229ff39-23fe-4d0a-9859-adf267b992b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_41309a3a-abda-4720-9107-8641c4f0c3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b8aba6d3-2572-4195-a805-068a5dd9782f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_41309a3a-abda-4720-9107-8641c4f0c3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08676d75-129a-4e16-949f-4d42fea1bd70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_41309a3a-abda-4720-9107-8641c4f0c3cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08676d75-129a-4e16-949f-4d42fea1bd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#RevenuesSummarizedRevenuesfromMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0d1197b9-3107-4307-a637-622bc93d2771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7e08220e-c0c3-41f1-a982-faf54f202a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0d1197b9-3107-4307-a637-622bc93d2771" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7e08220e-c0c3-41f1-a982-faf54f202a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f22bcb0d-66ed-4a44-83ea-72036f5b03da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7e08220e-c0c3-41f1-a982-faf54f202a58" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f22bcb0d-66ed-4a44-83ea-72036f5b03da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_143c6292-931e-4afe-863e-2aca9105fe98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_f22bcb0d-66ed-4a44-83ea-72036f5b03da" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_143c6292-931e-4afe-863e-2aca9105fe98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_bd077812-ab39-4ae0-9549-f436c97a6410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_143c6292-931e-4afe-863e-2aca9105fe98" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_bd077812-ab39-4ae0-9549-f436c97a6410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_34c8508f-f347-4da3-af2f-f10cad7223ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7e08220e-c0c3-41f1-a982-faf54f202a58" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_34c8508f-f347-4da3-af2f-f10cad7223ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_77933c67-2261-447c-9844-c81096bfd342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_34c8508f-f347-4da3-af2f-f10cad7223ec" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_77933c67-2261-447c-9844-c81096bfd342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d1b824d3-1852-4b0e-8038-46f3a1ad7bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_77933c67-2261-447c-9844-c81096bfd342" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d1b824d3-1852-4b0e-8038-46f3a1ad7bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fa359992-6b11-41b1-83e6-1b72098dbcc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7e08220e-c0c3-41f1-a982-faf54f202a58" xlink:to="loc_srt_MajorCustomersAxis_fa359992-6b11-41b1-83e6-1b72098dbcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_83cf9ae8-7805-4774-9763-c77ea5bcdf26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_fa359992-6b11-41b1-83e6-1b72098dbcc9" xlink:to="loc_srt_NameOfMajorCustomerDomain_83cf9ae8-7805-4774-9763-c77ea5bcdf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmerisourcebergenCorpMember_8996cbdd-7f4e-479e-9a96-0fe8f4b67386" xlink:href="gild-20221231.xsd#gild_AmerisourcebergenCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_83cf9ae8-7805-4774-9763-c77ea5bcdf26" xlink:to="loc_gild_AmerisourcebergenCorpMember_8996cbdd-7f4e-479e-9a96-0fe8f4b67386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CardinalHealthIncMember_600d644f-d4d4-408b-ab0d-5baeebf5326d" xlink:href="gild-20221231.xsd#gild_CardinalHealthIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_83cf9ae8-7805-4774-9763-c77ea5bcdf26" xlink:to="loc_gild_CardinalHealthIncMember_600d644f-d4d4-408b-ab0d-5baeebf5326d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MckessonCorpMember_894f8236-65a3-416e-9186-9bc7868d3e23" xlink:href="gild-20221231.xsd#gild_MckessonCorpMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_83cf9ae8-7805-4774-9763-c77ea5bcdf26" xlink:to="loc_gild_MckessonCorpMember_894f8236-65a3-416e-9186-9bc7868d3e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b557ca45-e55e-447f-a18e-256c91249aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_7e08220e-c0c3-41f1-a982-faf54f202a58" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b557ca45-e55e-447f-a18e-256c91249aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f3d2ae77-3829-4dba-9010-d4bbee1bfbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_b557ca45-e55e-447f-a18e-256c91249aaa" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f3d2ae77-3829-4dba-9010-d4bbee1bfbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesPerformanceObligationsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#RevenuesPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ae3f5b5c-2c0d-48c3-a13f-c20b87b49c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_b767c370-2501-429c-962f-70b2039644a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ae3f5b5c-2c0d-48c3-a13f-c20b87b49c64" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_b767c370-2501-429c-962f-70b2039644a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_8a30507b-28d6-4a4f-893e-0b31f240a480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ae3f5b5c-2c0d-48c3-a13f-c20b87b49c64" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_8a30507b-28d6-4a4f-893e-0b31f240a480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_55bb21e1-3fb6-4c2f-a089-468c207868e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_b4ef3c52-0d8e-40f3-aed1-f997ceb7e42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_55bb21e1-3fb6-4c2f-a089-468c207868e4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_b4ef3c52-0d8e-40f3-aed1-f997ceb7e42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_8f3caded-9381-4b10-a1e9-24fd537bb21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_55bb21e1-3fb6-4c2f-a089-468c207868e4" xlink:to="loc_us-gaap_ContractWithCustomerLiability_8f3caded-9381-4b10-a1e9-24fd537bb21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3fd9790a-61a4-42ff-a193-59bfaef5a130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3fd9790a-61a4-42ff-a193-59bfaef5a130" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ab3fd3fb-fc13-408c-9faa-346fafa68b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ab3fd3fb-fc13-408c-9faa-346fafa68b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2a38eda0-2d9a-43c5-beee-f038c0e18a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ab3fd3fb-fc13-408c-9faa-346fafa68b54" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2a38eda0-2d9a-43c5-beee-f038c0e18a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_32af3724-62f6-40e7-bb7f-901c6bc4ad90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2a38eda0-2d9a-43c5-beee-f038c0e18a05" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_32af3724-62f6-40e7-bb7f-901c6bc4ad90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299bc415-a68e-4c26-83b4-26d371b71e28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299bc415-a68e-4c26-83b4-26d371b71e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b2eb316a-b2e8-4efd-b1b5-442e7af54419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_299bc415-a68e-4c26-83b4-26d371b71e28" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b2eb316a-b2e8-4efd-b1b5-442e7af54419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_23830173-7d27-4d4e-8833-b5b6816c5ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b2eb316a-b2e8-4efd-b1b5-442e7af54419" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_23830173-7d27-4d4e-8833-b5b6816c5ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b35d16a0-6082-4a39-9e33-f7a26dc3d4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b2eb316a-b2e8-4efd-b1b5-442e7af54419" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b35d16a0-6082-4a39-9e33-f7a26dc3d4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7f5db702-03ac-4d4d-9beb-a097449250fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b2eb316a-b2e8-4efd-b1b5-442e7af54419" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7f5db702-03ac-4d4d-9beb-a097449250fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_171b7bf9-ffb0-4e0c-994e-4be4c447ec2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_171b7bf9-ffb0-4e0c-994e-4be4c447ec2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26a3f6b7-5e54-4bc8-b88a-6d9368e7b641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_171b7bf9-ffb0-4e0c-994e-4be4c447ec2a" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26a3f6b7-5e54-4bc8-b88a-6d9368e7b641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a5a22763-c434-4cd1-81dc-ecf6b5b57d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_26a3f6b7-5e54-4bc8-b88a-6d9368e7b641" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a5a22763-c434-4cd1-81dc-ecf6b5b57d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8b2f9a15-8f21-444e-83a5-1bb90dee79be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a5a22763-c434-4cd1-81dc-ecf6b5b57d69" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8b2f9a15-8f21-444e-83a5-1bb90dee79be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_0be097da-1b30-4652-814f-1c506bfcdc59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_0be097da-1b30-4652-814f-1c506bfcdc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_0be097da-1b30-4652-814f-1c506bfcdc59" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8103a338-8fbe-4ec9-895a-b1240bd2525c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8103a338-8fbe-4ec9-895a-b1240bd2525c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_98e47e96-b502-498f-866d-baab45534139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_98e47e96-b502-498f-866d-baab45534139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_2ee0ff06-542a-4555-93e2-74f2651fa256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_2ee0ff06-542a-4555-93e2-74f2651fa256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_24c1492d-a3fd-4557-bb55-59eb0bf773c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_CertificatesOfDepositMember_24c1492d-a3fd-4557-bb55-59eb0bf773c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_739aad82-edca-427c-8dba-07bb926e4df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_739aad82-edca-427c-8dba-07bb926e4df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_b649e4b4-9ad1-4302-8091-5a3ecbede538" xlink:href="gild-20221231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_b649e4b4-9ad1-4302-8091-5a3ecbede538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_66af51b8-b304-48f5-b649-9efb9fb52503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_MoneyMarketFundsMember_66af51b8-b304-48f5-b649-9efb9fb52503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_13bdbee6-c0d8-4aeb-abed-c8003b8b5807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_us-gaap_EquitySecuritiesMember_13bdbee6-c0d8-4aeb-abed-c8003b8b5807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_a1b12b2c-0cd1-4908-a549-585ced44f2ed" xlink:href="gild-20221231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_gild_DeferredCompensationPlanMember_a1b12b2c-0cd1-4908-a549-585ced44f2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ForeignCurrencyDerivativeContractsMember_8817ee0c-30ec-478f-921a-8424d85eee64" xlink:href="gild-20221231.xsd#gild_ForeignCurrencyDerivativeContractsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_81d1ba92-6603-4a46-9dad-fef2519ff3ee" xlink:to="loc_gild_ForeignCurrencyDerivativeContractsMember_8817ee0c-30ec-478f-921a-8424d85eee64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_13f565f4-eb2a-4b9f-8648-58fc8bcc1f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_13f565f4-eb2a-4b9f-8648-58fc8bcc1f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0caeb5d-7461-4c17-9692-c2a67bfadeed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_13f565f4-eb2a-4b9f-8648-58fc8bcc1f8e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0caeb5d-7461-4c17-9692-c2a67bfadeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_fa2a85c6-e701-4d17-ad56-a0049c200703" xlink:href="gild-20221231.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f0caeb5d-7461-4c17-9692-c2a67bfadeed" xlink:to="loc_gild_MYRGmbHMember_fa2a85c6-e701-4d17-ad56-a0049c200703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_50876216-596c-424b-9101-3a773f6ca9e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_50876216-596c-424b-9101-3a773f6ca9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_da84331c-2945-4f0f-8ea1-8d6dc455fbe3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_50876216-596c-424b-9101-3a773f6ca9e9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_da84331c-2945-4f0f-8ea1-8d6dc455fbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_e6700fa4-ea51-42ba-a5db-04a78b9af167" xlink:href="gild-20221231.xsd#gild_GalapagosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84331c-2945-4f0f-8ea1-8d6dc455fbe3" xlink:to="loc_gild_GalapagosMember_e6700fa4-ea51-42ba-a5db-04a78b9af167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_4dff86ee-fb85-4109-93f6-53bb4e48db21" xlink:href="gild-20221231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84331c-2945-4f0f-8ea1-8d6dc455fbe3" xlink:to="loc_gild_ArcusBiosciencesIncMember_4dff86ee-fb85-4109-93f6-53bb4e48db21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ff70d016-a6b0-40ea-b76b-58762b86a2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ecc6c705-9ef5-41a0-a53c-1ecf29cea717" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ff70d016-a6b0-40ea-b76b-58762b86a2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8ddfc574-e29b-4480-8566-d0a2179c185a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ff70d016-a6b0-40ea-b76b-58762b86a2b0" xlink:to="loc_us-gaap_AssetsAbstract_8ddfc574-e29b-4480-8566-d0a2179c185a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3e1bb20d-877b-482a-b292-c104eb8aace4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8ddfc574-e29b-4480-8566-d0a2179c185a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_3e1bb20d-877b-482a-b292-c104eb8aace4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7922a339-9665-4ff7-90ca-57b2b2bde2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8ddfc574-e29b-4480-8566-d0a2179c185a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7922a339-9665-4ff7-90ca-57b2b2bde2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_a2e66148-9822-4a8e-b35b-6e0cc11ab807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8ddfc574-e29b-4480-8566-d0a2179c185a" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_a2e66148-9822-4a8e-b35b-6e0cc11ab807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_717ef47c-04b1-4e2c-a959-9b2be923b562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8ddfc574-e29b-4480-8566-d0a2179c185a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_717ef47c-04b1-4e2c-a959-9b2be923b562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_a93e8714-015a-49c5-a7cf-7af17c5c1a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ff70d016-a6b0-40ea-b76b-58762b86a2b0" xlink:to="loc_us-gaap_LiabilitiesAbstract_a93e8714-015a-49c5-a7cf-7af17c5c1a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e735e400-10c2-4dcb-ad6d-017fea9e4eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a93e8714-015a-49c5-a7cf-7af17c5c1a32" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e735e400-10c2-4dcb-ad6d-017fea9e4eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_58e847fa-d775-45a5-a20a-a7375260cbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a93e8714-015a-49c5-a7cf-7af17c5c1a32" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_58e847fa-d775-45a5-a20a-a7375260cbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_adb7de1b-6cb1-4ab8-8efe-f71bbd31688b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a93e8714-015a-49c5-a7cf-7af17c5c1a32" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_adb7de1b-6cb1-4ab8-8efe-f71bbd31688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ce22e9f8-6d0d-4e20-b983-0aeb0fb5f1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_a93e8714-015a-49c5-a7cf-7af17c5c1a32" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_ce22e9f8-6d0d-4e20-b983-0aeb0fb5f1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_060519b9-cb88-47f9-8f16-9aafa33c1454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_060519b9-cb88-47f9-8f16-9aafa33c1454" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_eda859d2-ded9-49b2-b288-b00a0e5a599a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_eda859d2-ded9-49b2-b288-b00a0e5a599a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_682bb9cc-a808-4f8d-8e41-825e4295b560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_eda859d2-ded9-49b2-b288-b00a0e5a599a" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_682bb9cc-a808-4f8d-8e41-825e4295b560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2444adaa-945c-42a5-bf49-53fc7a0766af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_682bb9cc-a808-4f8d-8e41-825e4295b560" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2444adaa-945c-42a5-bf49-53fc7a0766af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d42fab76-53ae-46cd-bb49-c6f04ddce75d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2444adaa-945c-42a5-bf49-53fc7a0766af" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d42fab76-53ae-46cd-bb49-c6f04ddce75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_259f27aa-70c6-4066-a816-433c2eb053a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2444adaa-945c-42a5-bf49-53fc7a0766af" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_259f27aa-70c6-4066-a816-433c2eb053a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_974e0b30-7972-4cda-9a7e-85d141af6b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_974e0b30-7972-4cda-9a7e-85d141af6b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e841c2dc-290d-4e9c-9bc2-06d4921e9fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_974e0b30-7972-4cda-9a7e-85d141af6b5d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e841c2dc-290d-4e9c-9bc2-06d4921e9fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a80ff87e-7f31-445b-80e5-a9b556d927b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e841c2dc-290d-4e9c-9bc2-06d4921e9fec" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a80ff87e-7f31-445b-80e5-a9b556d927b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f32ada29-e485-4fa7-909f-4a209ca54c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e841c2dc-290d-4e9c-9bc2-06d4921e9fec" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f32ada29-e485-4fa7-909f-4a209ca54c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_82a66182-25f5-4140-b53b-5e98728f24e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_82a66182-25f5-4140-b53b-5e98728f24e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f757f985-7d56-4c75-9ccc-c6ffc5e9ba9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_82a66182-25f5-4140-b53b-5e98728f24e6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f757f985-7d56-4c75-9ccc-c6ffc5e9ba9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_784b367d-71d1-4492-8e7a-4ff5532ac5c3" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f757f985-7d56-4c75-9ccc-c6ffc5e9ba9a" xlink:to="loc_gild_ImmunomedicsIncMember_784b367d-71d1-4492-8e7a-4ff5532ac5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ab9ee36-e308-464a-9c8a-f22055007c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ab9ee36-e308-464a-9c8a-f22055007c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3bdf12dd-9c6b-41bf-b9b4-f506711e2759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ab9ee36-e308-464a-9c8a-f22055007c3d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3bdf12dd-9c6b-41bf-b9b4-f506711e2759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_ef1e0ac3-cb5a-45d8-ae97-ac2800c01d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3bdf12dd-9c6b-41bf-b9b4-f506711e2759" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_ef1e0ac3-cb5a-45d8-ae97-ac2800c01d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ec3db74e-8ed4-4589-93a6-506010453a59" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_f9fbd4ba-3151-41ee-a6e4-20008eb5928d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_f9fbd4ba-3151-41ee-a6e4-20008eb5928d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_90702517-1bd9-4c6a-9dc9-49aca2a43cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:to="loc_us-gaap_LongTermDebtFairValue_90702517-1bd9-4c6a-9dc9-49aca2a43cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_730d1e94-6cdd-4631-bb78-dc7eac7a7388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_730d1e94-6cdd-4631-bb78-dc7eac7a7388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_a27e486f-8e0e-4187-b955-0fddd95c714a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_a27e486f-8e0e-4187-b955-0fddd95c714a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_11221ef8-84d2-474d-81c6-8675a3eb33d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3a1084d-f247-4972-970b-e0d5288f2a30" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_11221ef8-84d2-474d-81c6-8675a3eb33d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#FairValueMeasurementsSummaryofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_11e7e3ab-35db-4eec-b1bc-a1ed91938484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_70816147-39b3-4183-a3a5-7b0249f67e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_11e7e3ab-35db-4eec-b1bc-a1ed91938484" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_70816147-39b3-4183-a3a5-7b0249f67e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_8d27452e-be87-4634-adce-bbae1f70c13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_70816147-39b3-4183-a3a5-7b0249f67e0a" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_8d27452e-be87-4634-adce-bbae1f70c13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c18f87ea-5d45-4977-82da-6fced2b0b6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_8d27452e-be87-4634-adce-bbae1f70c13b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c18f87ea-5d45-4977-82da-6fced2b0b6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ContingentConsiderationLiabilityMember_669b562b-1cc0-4621-b292-4dcf8416ef41" xlink:href="gild-20221231.xsd#gild_ContingentConsiderationLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c18f87ea-5d45-4977-82da-6fced2b0b6a5" xlink:to="loc_gild_ContingentConsiderationLiabilityMember_669b562b-1cc0-4621-b292-4dcf8416ef41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a93e0ced-4f8b-4743-a62f-d8ce1cd662ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_70816147-39b3-4183-a3a5-7b0249f67e0a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a93e0ced-4f8b-4743-a62f-d8ce1cd662ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e42d5d30-0131-44ff-8bca-4a99971b56e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a93e0ced-4f8b-4743-a62f-d8ce1cd662ad" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e42d5d30-0131-44ff-8bca-4a99971b56e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_fc19de5d-e55d-423b-ad84-bd93a461be6a" xlink:href="gild-20221231.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e42d5d30-0131-44ff-8bca-4a99971b56e9" xlink:to="loc_gild_MYRGmbHMember_fc19de5d-e55d-423b-ad84-bd93a461be6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f8f5779-da50-4f59-9c11-b0e80f77b756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_70816147-39b3-4183-a3a5-7b0249f67e0a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f8f5779-da50-4f59-9c11-b0e80f77b756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9f8f5779-da50-4f59-9c11-b0e80f77b756" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4a538042-fd85-48a6-bb89-79857e3eb427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4a538042-fd85-48a6-bb89-79857e3eb427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8a9278d2-4475-4ae5-bc87-75e15e18359b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8a9278d2-4475-4ae5-bc87-75e15e18359b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6fd30e66-4ac4-47e0-b2a4-ea8650ff8f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6fd30e66-4ac4-47e0-b2a4-ea8650ff8f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_4a48425b-0113-4f73-89de-3fb7ecf46341" xlink:href="gild-20221231.xsd#gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:to="loc_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement_4a48425b-0113-4f73-89de-3fb7ecf46341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e22bf453-8831-44a1-b889-9c532c47a02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a908f19e-ba8d-4429-8ed8-be09f27a482c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e22bf453-8831-44a1-b889-9c532c47a02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dbeb45ed-821c-4cef-9179-c25c81d7e35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c07fb7c4-a51c-464e-a4f7-571a64a56e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_dbeb45ed-821c-4cef-9179-c25c81d7e35a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c07fb7c4-a51c-464e-a4f7-571a64a56e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_94a4f81d-0c07-4beb-a08d-2af621ac1eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c07fb7c4-a51c-464e-a4f7-571a64a56e57" xlink:to="loc_us-gaap_FinancialInstrumentAxis_94a4f81d-0c07-4beb-a08d-2af621ac1eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_94a4f81d-0c07-4beb-a08d-2af621ac1eb2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4620e716-ff70-495f-8c17-8361b9eedb21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4620e716-ff70-495f-8c17-8361b9eedb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5434d609-db5c-481c-b784-459bb31fe88e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_5434d609-db5c-481c-b784-459bb31fe88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_8e8d2587-bcfe-43c9-a51a-1afd3ae94bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_8e8d2587-bcfe-43c9-a51a-1afd3ae94bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7776e306-c819-48a4-b6a5-82e5e0cbb127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7776e306-c819-48a4-b6a5-82e5e0cbb127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7daee531-2ff6-46c5-b16b-eaa2e458db43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7daee531-2ff6-46c5-b16b-eaa2e458db43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_bba18daf-7765-4c9e-864c-7d95b3cdedba" xlink:href="gild-20221231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_09809ed3-8d3d-450c-83ba-1055fe284d97" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_bba18daf-7765-4c9e-864c-7d95b3cdedba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1ac84f81-1e8e-487f-b89b-475073f95313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c07fb7c4-a51c-464e-a4f7-571a64a56e57" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1ac84f81-1e8e-487f-b89b-475073f95313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4c45b97c-a488-42ff-8b54-6c5bf15e3856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1ac84f81-1e8e-487f-b89b-475073f95313" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_4c45b97c-a488-42ff-8b54-6c5bf15e3856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a07228d5-4ea0-4163-a167-c232b3bd7b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1ac84f81-1e8e-487f-b89b-475073f95313" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a07228d5-4ea0-4163-a167-c232b3bd7b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_259050fe-9b7e-45cb-91c2-806d9d9e7c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1ac84f81-1e8e-487f-b89b-475073f95313" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_259050fe-9b7e-45cb-91c2-806d9d9e7c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_58d3813f-387b-4b2a-ac21-989101dac677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1ac84f81-1e8e-487f-b89b-475073f95313" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_58d3813f-387b-4b2a-ac21-989101dac677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_70b83536-d464-4607-aade-dea2975337b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57bab801-6d6c-4055-a473-772c4832924e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_70b83536-d464-4607-aade-dea2975337b7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57bab801-6d6c-4055-a473-772c4832924e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2ed68361-ff2b-4620-81f7-41b3e1f1e964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57bab801-6d6c-4055-a473-772c4832924e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2ed68361-ff2b-4620-81f7-41b3e1f1e964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2ed68361-ff2b-4620-81f7-41b3e1f1e964" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8a96c6d4-c271-4cdd-b937-be8d7b0fd700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8a96c6d4-c271-4cdd-b937-be8d7b0fd700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6733641b-ac15-47ed-bbe2-65c68669279e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6733641b-ac15-47ed-bbe2-65c68669279e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_2a3deee1-9fa4-4f59-ae0b-3d5fdaa781c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_2a3deee1-9fa4-4f59-ae0b-3d5fdaa781c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6bf64bd4-1aae-40be-850e-b0143d2b9128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6bf64bd4-1aae-40be-850e-b0143d2b9128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1183b78d-1306-4550-b867-321e9f145d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1183b78d-1306-4550-b867-321e9f145d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_6c7f9e06-eba8-4c0d-9064-b90c1977e696" xlink:href="gild-20221231.xsd#gild_ResidentialMortgageAndAssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da0c57fe-cb7b-4754-82d9-e14315e9c4db" xlink:to="loc_gild_ResidentialMortgageAndAssetBackedSecuritiesMember_6c7f9e06-eba8-4c0d-9064-b90c1977e696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c4c52da4-9329-4725-9ded-c3af2564e6db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_57bab801-6d6c-4055-a473-772c4832924e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c4c52da4-9329-4725-9ded-c3af2564e6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_39b0fae9-ebc1-42d4-8372-9bd44530cced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c4c52da4-9329-4725-9ded-c3af2564e6db" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_39b0fae9-ebc1-42d4-8372-9bd44530cced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3ca547d0-ba03-434e-9452-c64531edb21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_39b0fae9-ebc1-42d4-8372-9bd44530cced" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3ca547d0-ba03-434e-9452-c64531edb21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6bd82af2-4035-498b-86ed-2af0644a1b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_39b0fae9-ebc1-42d4-8372-9bd44530cced" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6bd82af2-4035-498b-86ed-2af0644a1b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_31cb4425-6b20-44e1-8c6e-001c6bc48d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_39b0fae9-ebc1-42d4-8372-9bd44530cced" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_31cb4425-6b20-44e1-8c6e-001c6bc48d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_3100892d-c39e-4e74-818f-fca9123480f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c4c52da4-9329-4725-9ded-c3af2564e6db" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_3100892d-c39e-4e74-818f-fca9123480f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_233dc9b5-c06c-4280-a737-568c47c7a0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_3100892d-c39e-4e74-818f-fca9123480f3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_233dc9b5-c06c-4280-a737-568c47c7a0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_03a771e7-4100-4741-81f2-2223604e97bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_3100892d-c39e-4e74-818f-fca9123480f3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_03a771e7-4100-4741-81f2-2223604e97bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0e278b21-f715-4301-bc2d-662b3d394a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract_3100892d-c39e-4e74-818f-fca9123480f3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0e278b21-f715-4301-bc2d-662b3d394a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f4a42e01-9ff2-4901-9f25-2327b86c4ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_8f63eeeb-faa7-4244-abfd-9a3413336123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f4a42e01-9ff2-4901-9f25-2327b86c4ab1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest_8f63eeeb-faa7-4244-abfd-9a3413336123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_6600ce6a-f762-4560-a516-6a5071676bad" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f4a42e01-9ff2-4901-9f25-2327b86c4ab1" xlink:to="loc_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount_6600ce6a-f762-4560-a516-6a5071676bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_cddc7fa8-5213-4c4d-9011-aa8ada210830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f4a42e01-9ff2-4901-9f25-2327b86c4ab1" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_cddc7fa8-5213-4c4d-9011-aa8ada210830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3c1a3e8-5916-44b9-bb93-12b67715580d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f4a42e01-9ff2-4901-9f25-2327b86c4ab1" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3c1a3e8-5916-44b9-bb93-12b67715580d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_7ee7976b-32fd-4c45-9c91-3b6ab320b7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3c1a3e8-5916-44b9-bb93-12b67715580d" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_7ee7976b-32fd-4c45-9c91-3b6ab320b7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3ad06a1a-9132-4118-995b-0f4918200a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_7ee7976b-32fd-4c45-9c91-3b6ab320b7c6" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3ad06a1a-9132-4118-995b-0f4918200a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesDonationMember_e8394fc0-d228-452e-96ff-564febaa7e87" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesDonationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3ad06a1a-9132-4118-995b-0f4918200a6c" xlink:to="loc_gild_EquitySecuritiesDonationMember_e8394fc0-d228-452e-96ff-564febaa7e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31c53680-0410-46a2-b796-b70af5807c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3c1a3e8-5916-44b9-bb93-12b67715580d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31c53680-0410-46a2-b796-b70af5807c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_02397305-e31f-4c91-ba3d-45e49685ea34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_31c53680-0410-46a2-b796-b70af5807c03" xlink:to="loc_us-gaap_RelatedPartyDomain_02397305-e31f-4c91-ba3d-45e49685ea34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadFoundationMember_9065b88b-c533-415c-8e76-421903b5a074" xlink:href="gild-20221231.xsd#gild_GileadFoundationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_02397305-e31f-4c91-ba3d-45e49685ea34" xlink:to="loc_gild_GileadFoundationMember_9065b88b-c533-415c-8e76-421903b5a074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2d202bab-8e82-4251-8c0c-3910f5af2730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e3c1a3e8-5916-44b9-bb93-12b67715580d" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2d202bab-8e82-4251-8c0c-3910f5af2730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_1efc0dcd-f9a3-4907-8fbc-f0afad4d7343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2d202bab-8e82-4251-8c0c-3910f5af2730" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_1efc0dcd-f9a3-4907-8fbc-f0afad4d7343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_15e15b27-a63e-433f-88f2-ac5d59d2775c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5f03adc-3700-4e78-8126-7f3c9a9b65e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_15e15b27-a63e-433f-88f2-ac5d59d2775c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5f03adc-3700-4e78-8126-7f3c9a9b65e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2ba2a643-9ebd-452d-b04d-1ca5365663ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5f03adc-3700-4e78-8126-7f3c9a9b65e9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2ba2a643-9ebd-452d-b04d-1ca5365663ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_24915fcb-ea6e-4953-9fd7-2674e5c25141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2ba2a643-9ebd-452d-b04d-1ca5365663ea" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_24915fcb-ea6e-4953-9fd7-2674e5c25141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_e8923aab-3620-48aa-9f6e-daed0a59f579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24915fcb-ea6e-4953-9fd7-2674e5c25141" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_e8923aab-3620-48aa-9f6e-daed0a59f579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesCurrentMember_e1f8aee2-b3e3-44a8-b223-11f370a90409" xlink:href="gild-20221231.xsd#gild_MarketableSecuritiesCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24915fcb-ea6e-4953-9fd7-2674e5c25141" xlink:to="loc_gild_MarketableSecuritiesCurrentMember_e1f8aee2-b3e3-44a8-b223-11f370a90409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MarketableSecuritiesNoncurrentMember_dc319796-4c8e-409e-beae-e79b5c053513" xlink:href="gild-20221231.xsd#gild_MarketableSecuritiesNoncurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24915fcb-ea6e-4953-9fd7-2674e5c25141" xlink:to="loc_gild_MarketableSecuritiesNoncurrentMember_dc319796-4c8e-409e-beae-e79b5c053513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af8ac5f9-c069-4bc0-aa5c-28b11571591f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a5f03adc-3700-4e78-8126-7f3c9a9b65e9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af8ac5f9-c069-4bc0-aa5c-28b11571591f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ff6b56f8-9dd4-4f74-a15b-d014256c162d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_af8ac5f9-c069-4bc0-aa5c-28b11571591f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ff6b56f8-9dd4-4f74-a15b-d014256c162d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f72a6869-3c1f-446c-9235-0ff508d5cad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1e194dd7-26ff-4b85-b43c-e906c892e4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f72a6869-3c1f-446c-9235-0ff508d5cad5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1e194dd7-26ff-4b85-b43c-e906c892e4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_341c530d-07b3-483f-a7c8-1ad00db88bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1e194dd7-26ff-4b85-b43c-e906c892e4ee" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_341c530d-07b3-483f-a7c8-1ad00db88bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_1b68439d-aab6-4803-8b66-190877ba7a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1e194dd7-26ff-4b85-b43c-e906c892e4ee" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_1b68439d-aab6-4803-8b66-190877ba7a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_ed45e6ef-5554-43f4-bfc1-47be10991da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1e194dd7-26ff-4b85-b43c-e906c892e4ee" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_ed45e6ef-5554-43f4-bfc1-47be10991da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_0907a96d-840b-4dcc-a910-70287108bd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1e194dd7-26ff-4b85-b43c-e906c892e4ee" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_0907a96d-840b-4dcc-a910-70287108bd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_bfacd156-34f2-44cf-b482-feeb8c13cb99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_1e194dd7-26ff-4b85-b43c-e906c892e4ee" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_bfacd156-34f2-44cf-b482-feeb8c13cb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_3f2ce7e8-9892-4d3b-9e11-a9e7b9704a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f72a6869-3c1f-446c-9235-0ff508d5cad5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_3f2ce7e8-9892-4d3b-9e11-a9e7b9704a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9629d8c8-426d-477c-a3c7-c096c77ce0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_3f2ce7e8-9892-4d3b-9e11-a9e7b9704a3c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9629d8c8-426d-477c-a3c7-c096c77ce0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8feb99f2-2022-424b-8544-eaa666b87e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_3f2ce7e8-9892-4d3b-9e11-a9e7b9704a3c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8feb99f2-2022-424b-8544-eaa666b87e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_88187771-413b-45d8-b9a0-5958c87ac26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_3f2ce7e8-9892-4d3b-9e11-a9e7b9704a3c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_88187771-413b-45d8-b9a0-5958c87ac26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_44341fe4-54a1-4228-871e-5ce88e202c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_3f2ce7e8-9892-4d3b-9e11-a9e7b9704a3c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_44341fe4-54a1-4228-871e-5ce88e202c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a7ab91ca-9756-4ae3-b69b-5db84cf0e740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_3f2ce7e8-9892-4d3b-9e11-a9e7b9704a3c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_a7ab91ca-9756-4ae3-b69b-5db84cf0e740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9d694cd2-06cb-4971-b079-cd97092d341f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36004d00-6332-4ccf-ae67-0ab71877f0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_9d694cd2-06cb-4971-b079-cd97092d341f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36004d00-6332-4ccf-ae67-0ab71877f0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_033c4956-4297-465d-9603-ddd1ba0db815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36004d00-6332-4ccf-ae67-0ab71877f0c8" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_033c4956-4297-465d-9603-ddd1ba0db815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d191ce0f-bfde-4163-b206-2bbb74b9a301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_033c4956-4297-465d-9603-ddd1ba0db815" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d191ce0f-bfde-4163-b206-2bbb74b9a301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_d52fed96-8153-4dd3-94e4-429223f6ce2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d191ce0f-bfde-4163-b206-2bbb74b9a301" xlink:to="loc_us-gaap_EquitySecuritiesMember_d52fed96-8153-4dd3-94e4-429223f6ce2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_45323a62-5711-4b6a-b7d1-e311dc002c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36004d00-6332-4ccf-ae67-0ab71877f0c8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_45323a62-5711-4b6a-b7d1-e311dc002c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_eb9fe626-801d-4b0b-b45a-ea0584d5de37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_45323a62-5711-4b6a-b7d1-e311dc002c57" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_eb9fe626-801d-4b0b-b45a-ea0584d5de37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_2235cac1-c2ed-45bf-8661-fb8388bc1c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_eb9fe626-801d-4b0b-b45a-ea0584d5de37" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_2235cac1-c2ed-45bf-8661-fb8388bc1c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_50f0bf83-a603-4986-9079-98f60eab01e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_eb9fe626-801d-4b0b-b45a-ea0584d5de37" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_50f0bf83-a603-4986-9079-98f60eab01e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_09e26721-94b6-4e18-b460-f57510be9503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_eb9fe626-801d-4b0b-b45a-ea0584d5de37" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_09e26721-94b6-4e18-b460-f57510be9503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc10c3d2-93d0-4930-bd99-ec4403415cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36004d00-6332-4ccf-ae67-0ab71877f0c8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc10c3d2-93d0-4930-bd99-ec4403415cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a7c4ff4b-99ce-4e86-b2f8-9596aaedb23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc10c3d2-93d0-4930-bd99-ec4403415cff" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a7c4ff4b-99ce-4e86-b2f8-9596aaedb23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ec4cfe85-4da2-4d49-9048-db151830fa49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cc10c3d2-93d0-4930-bd99-ec4403415cff" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ec4cfe85-4da2-4d49-9048-db151830fa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DerivativeFinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0cc3d71e-254a-44b6-8dda-0678de3f163c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f106248f-27bf-42d9-82c7-acb32c406120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0cc3d71e-254a-44b6-8dda-0678de3f163c" xlink:to="loc_us-gaap_DerivativeTable_f106248f-27bf-42d9-82c7-acb32c406120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3b4e774a-9283-4495-b7a2-1836c13a0472" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f106248f-27bf-42d9-82c7-acb32c406120" xlink:to="loc_srt_RangeAxis_3b4e774a-9283-4495-b7a2-1836c13a0472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_40ced589-0d01-4ff1-b5c8-3dcfd54d52b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3b4e774a-9283-4495-b7a2-1836c13a0472" xlink:to="loc_srt_RangeMember_40ced589-0d01-4ff1-b5c8-3dcfd54d52b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c6fec6b7-5073-4169-9406-7bbae62c4679" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_40ced589-0d01-4ff1-b5c8-3dcfd54d52b9" xlink:to="loc_srt_MaximumMember_c6fec6b7-5073-4169-9406-7bbae62c4679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a7037efb-4ae8-4cda-930c-891bad0290d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f106248f-27bf-42d9-82c7-acb32c406120" xlink:to="loc_us-gaap_DerivativeLineItems_a7037efb-4ae8-4cda-930c-891bad0290d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_319337ae-fc43-4411-b609-72a9f8904767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a7037efb-4ae8-4cda-930c-891bad0290d5" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_319337ae-fc43-4411-b609-72a9f8904767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_c7e4484e-fc62-41e9-bd17-0a2c91ffe6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a7037efb-4ae8-4cda-930c-891bad0290d5" xlink:to="loc_us-gaap_DerivativeNotionalAmount_c7e4484e-fc62-41e9-bd17-0a2c91ffe6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_bf7f9fd0-6457-4ec8-a106-72a4f8911ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a7037efb-4ae8-4cda-930c-891bad0290d5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1_bf7f9fd0-6457-4ec8-a106-72a4f8911ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_ccd0eb23-fb45-48d2-91b8-14d020dc9a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a7037efb-4ae8-4cda-930c-891bad0290d5" xlink:to="loc_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet_ccd0eb23-fb45-48d2-91b8-14d020dc9a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_57918770-1f3b-4995-93c7-3035d6f4523d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0080bc96-19d5-4ec2-a40f-cbe1a6aabf16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_57918770-1f3b-4995-93c7-3035d6f4523d" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0080bc96-19d5-4ec2-a40f-cbe1a6aabf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_26515827-45d8-4260-9165-316274a9e756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0080bc96-19d5-4ec2-a40f-cbe1a6aabf16" xlink:to="loc_us-gaap_HedgingDesignationAxis_26515827-45d8-4260-9165-316274a9e756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2e9c475c-0360-4d8b-a2a3-559283bdbb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_26515827-45d8-4260-9165-316274a9e756" xlink:to="loc_us-gaap_HedgingDesignationDomain_2e9c475c-0360-4d8b-a2a3-559283bdbb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9eb172ed-3b9e-4691-a790-11d23ce48b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2e9c475c-0360-4d8b-a2a3-559283bdbb2f" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9eb172ed-3b9e-4691-a790-11d23ce48b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_609edcca-25ea-48d1-af3f-2011551a36ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2e9c475c-0360-4d8b-a2a3-559283bdbb2f" xlink:to="loc_us-gaap_NondesignatedMember_609edcca-25ea-48d1-af3f-2011551a36ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8af97805-39ef-44ac-8f49-bbed7a086581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0080bc96-19d5-4ec2-a40f-cbe1a6aabf16" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8af97805-39ef-44ac-8f49-bbed7a086581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_62d5127f-8381-4352-8be8-250ade90e055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8af97805-39ef-44ac-8f49-bbed7a086581" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_62d5127f-8381-4352-8be8-250ade90e055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8b6b71fa-6a48-4169-9dd0-0727699e539d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_62d5127f-8381-4352-8be8-250ade90e055" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8b6b71fa-6a48-4169-9dd0-0727699e539d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_ee02a1b4-c65b-43b5-b6a1-2de74a3b964a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_62d5127f-8381-4352-8be8-250ade90e055" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_ee02a1b4-c65b-43b5-b6a1-2de74a3b964a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_6a9acf90-2011-4415-84cb-d39ffdc27d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_62d5127f-8381-4352-8be8-250ade90e055" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_6a9acf90-2011-4415-84cb-d39ffdc27d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_99c47a4a-dec8-4ac2-8017-7a7ca3125340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_62d5127f-8381-4352-8be8-250ade90e055" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_99c47a4a-dec8-4ac2-8017-7a7ca3125340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0080bc96-19d5-4ec2-a40f-cbe1a6aabf16" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_4ecd5ea9-42ee-4d7b-baed-b5a8f654fa12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement_4ecd5ea9-42ee-4d7b-baed-b5a8f654fa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_52470f5a-dfda-427d-a035-e20047007050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_52470f5a-dfda-427d-a035-e20047007050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_4877f388-ae2f-4e56-a354-8d2a624280cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_4877f388-ae2f-4e56-a354-8d2a624280cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_0d85075e-6f86-4a04-bb45-1bfc0087efc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_0d85075e-6f86-4a04-bb45-1bfc0087efc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_81a5176b-49c3-481d-a94e-3d57602f247f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement_81a5176b-49c3-481d-a94e-3d57602f247f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_5c349d4a-f35e-4e81-9963-f28774d315aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_5c349d4a-f35e-4e81-9963-f28774d315aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_3bd312e1-fa2f-47f2-9b20-1785825bb12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_3bd312e1-fa2f-47f2-9b20-1785825bb12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_52d60c5c-ef2d-46d1-9e87-293b981580d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_52d60c5c-ef2d-46d1-9e87-293b981580d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_79ad46b0-f681-460a-9259-f0b870bc4e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_79ad46b0-f681-460a-9259-f0b870bc4e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_92216b71-b82a-4c50-9081-2a680ed0397b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_655686ef-9213-43ed-afcd-026e5f275cdb" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_92216b71-b82a-4c50-9081-2a680ed0397b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2a5f18b1-f2c9-4af3-a41d-64a95280a519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_e1f4135c-817d-419e-8c58-a5a854ff0cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2a5f18b1-f2c9-4af3-a41d-64a95280a519" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_e1f4135c-817d-419e-8c58-a5a854ff0cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_688782f5-3e49-44f7-9e25-c453111b0f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2a5f18b1-f2c9-4af3-a41d-64a95280a519" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_688782f5-3e49-44f7-9e25-c453111b0f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_8fbbcab5-397c-4880-8969-8531597fcaca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2a5f18b1-f2c9-4af3-a41d-64a95280a519" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_8fbbcab5-397c-4880-8969-8531597fcaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_45646a3b-d180-4713-a9fb-688604ebba35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_45646a3b-d180-4713-a9fb-688604ebba35" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_1bc062a3-e949-48ce-9965-81fc0a6be304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_AssetAcquisitionAxis_1bc062a3-e949-48ce-9965-81fc0a6be304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_332f1f66-aaef-41c4-8e03-56f936396815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_1bc062a3-e949-48ce-9965-81fc0a6be304" xlink:to="loc_us-gaap_AssetAcquisitionDomain_332f1f66-aaef-41c4-8e03-56f936396815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MiroBioLtdMember_ef503a5a-922a-46d2-9818-3be19e8d9925" xlink:href="gild-20221231.xsd#gild_MiroBioLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_332f1f66-aaef-41c4-8e03-56f936396815" xlink:to="loc_gild_MiroBioLtdMember_ef503a5a-922a-46d2-9818-3be19e8d9925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_c354f592-12c6-4060-b255-2e01f3dd8f58" xlink:href="gild-20221231.xsd#gild_FortySevenIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_332f1f66-aaef-41c4-8e03-56f936396815" xlink:to="loc_gild_FortySevenIncMember_c354f592-12c6-4060-b255-2e01f3dd8f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7f6c46dc-6f79-4877-b466-d02b2247a84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7f6c46dc-6f79-4877-b466-d02b2247a84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e9fe52cc-8e0c-431b-be71-4ac8b9e98da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7f6c46dc-6f79-4877-b466-d02b2247a84e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e9fe52cc-8e0c-431b-be71-4ac8b9e98da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_f8e589a5-06fe-4f29-acb6-fe7c5b62de3f" xlink:href="gild-20221231.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e9fe52cc-8e0c-431b-be71-4ac8b9e98da5" xlink:to="loc_gild_MYRGmbHMember_f8e589a5-06fe-4f29-acb6-fe7c5b62de3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_d047308d-0eca-4023-8e20-eccdd701c06a" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e9fe52cc-8e0c-431b-be71-4ac8b9e98da5" xlink:to="loc_gild_ImmunomedicsIncMember_d047308d-0eca-4023-8e20-eccdd701c06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f5a927d-bbd1-4811-9f19-c77af1d66938" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_srt_RangeAxis_3f5a927d-bbd1-4811-9f19-c77af1d66938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_017ee3f9-f946-4f69-9f9b-fcbcc4ecfe8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3f5a927d-bbd1-4811-9f19-c77af1d66938" xlink:to="loc_srt_RangeMember_017ee3f9-f946-4f69-9f9b-fcbcc4ecfe8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_72e6c383-a0d1-42bc-9854-f92b135f75bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_017ee3f9-f946-4f69-9f9b-fcbcc4ecfe8a" xlink:to="loc_srt_MaximumMember_72e6c383-a0d1-42bc-9854-f92b135f75bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d2678689-dede-46f6-95c3-ff94c16cc9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d2678689-dede-46f6-95c3-ff94c16cc9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_86b09e8c-ab10-462c-8601-8a64cc6df515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d2678689-dede-46f6-95c3-ff94c16cc9fe" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_86b09e8c-ab10-462c-8601-8a64cc6df515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_be0cc559-e205-41e4-80d1-849b9fefa553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_86b09e8c-ab10-462c-8601-8a64cc6df515" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_be0cc559-e205-41e4-80d1-849b9fefa553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_bd0f5103-9a14-4579-8ca3-f567e7c6b3f4" xlink:href="gild-20221231.xsd#gild_HepcludexMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_86b09e8c-ab10-462c-8601-8a64cc6df515" xlink:to="loc_gild_HepcludexMember_bd0f5103-9a14-4579-8ca3-f567e7c6b3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_21e17dd6-b38f-47ac-a71f-dd04074190ce" xlink:href="gild-20221231.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_86b09e8c-ab10-462c-8601-8a64cc6df515" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_21e17dd6-b38f-47ac-a71f-dd04074190ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54d435b6-7a05-44ff-b3ab-00f2bfd623d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54d435b6-7a05-44ff-b3ab-00f2bfd623d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0ba097c-429e-4c28-ad4d-49ac64900308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_54d435b6-7a05-44ff-b3ab-00f2bfd623d5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0ba097c-429e-4c28-ad4d-49ac64900308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_1ddd5802-6036-466a-83d5-61e347e73e4a" xlink:href="gild-20221231.xsd#gild_HepcludexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0ba097c-429e-4c28-ad4d-49ac64900308" xlink:to="loc_gild_HepcludexMember_1ddd5802-6036-466a-83d5-61e347e73e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_0a536eb6-6c87-4c48-b904-8ddd59bff71c" xlink:href="gild-20221231.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0ba097c-429e-4c28-ad4d-49ac64900308" xlink:to="loc_gild_TrodelvyMember_0a536eb6-6c87-4c48-b904-8ddd59bff71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_684976e9-f94f-406e-bbba-4ab997f76220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c0ba097c-429e-4c28-ad4d-49ac64900308" xlink:to="loc_us-gaap_LicensingAgreementsMember_684976e9-f94f-406e-bbba-4ab997f76220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_af6a0574-311c-481b-a118-afa252cd0972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_af6a0574-311c-481b-a118-afa252cd0972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0e1d3566-bd01-4ae7-84a9-93dc0b9dfd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_af6a0574-311c-481b-a118-afa252cd0972" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0e1d3566-bd01-4ae7-84a9-93dc0b9dfd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d2ec5e76-adc8-4b23-b33f-c150fe9ded3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0e1d3566-bd01-4ae7-84a9-93dc0b9dfd0f" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d2ec5e76-adc8-4b23-b33f-c150fe9ded3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_54b4f128-f969-4633-ae8d-d9d5efb0f91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0e1d3566-bd01-4ae7-84a9-93dc0b9dfd0f" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_54b4f128-f969-4633-ae8d-d9d5efb0f91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9a57bc4d-9ff5-41b7-be5c-987e765619c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9a57bc4d-9ff5-41b7-be5c-987e765619c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f3bd9de3-23c3-418a-b555-5e8de1703b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9a57bc4d-9ff5-41b7-be5c-987e765619c9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f3bd9de3-23c3-418a-b555-5e8de1703b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_d5398859-783d-46b3-8b4b-8eddf62b6300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MediumTermNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f3bd9de3-23c3-418a-b555-5e8de1703b47" xlink:to="loc_us-gaap_MediumTermNotesMember_d5398859-783d-46b3-8b4b-8eddf62b6300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b6c0a2cc-1727-4bf9-ad73-7621651924ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_DebtInstrumentAxis_b6c0a2cc-1727-4bf9-ad73-7621651924ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e496909-9ae4-4fc7-91d0-4376b387365b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b6c0a2cc-1727-4bf9-ad73-7621651924ca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e496909-9ae4-4fc7-91d0-4376b387365b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_ee3e0861-0575-4b42-887e-b75923946f7d" xlink:href="gild-20221231.xsd#gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4e496909-9ae4-4fc7-91d0-4376b387365b" xlink:to="loc_gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember_ee3e0861-0575-4b42-887e-b75923946f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable_ba2a2b51-8306-446d-b96e-be78931f55e7" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForAssetAcquisitions_103a1211-1bfb-4fc8-ab81-14b9f2788e34" xlink:href="gild-20221231.xsd#gild_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_PaymentsForAssetAcquisitions_103a1211-1bfb-4fc8-ab81-14b9f2788e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3e4cadb6-d3d0-42a1-9248-719eb18b7e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3e4cadb6-d3d0-42a1-9248-719eb18b7e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f34de86d-729a-4eae-84f1-e30c1a22316a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f34de86d-729a-4eae-84f1-e30c1a22316a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_53432cfd-7c61-47ca-af57-725196cbab17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_53432cfd-7c61-47ca-af57-725196cbab17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0af7ccf4-95c2-485d-adff-9a2cef07cac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0af7ccf4-95c2-485d-adff-9a2cef07cac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_d934262f-aa1f-411d-838a-1df8dd03ff40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability_d934262f-aa1f-411d-838a-1df8dd03ff40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f86ed65c-e3ec-4082-bffd-f0d7f6e23e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f86ed65c-e3ec-4082-bffd-f0d7f6e23e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_f9780b11-bebe-4e02-9711-2356cce7ae7c" xlink:href="gild-20221231.xsd#gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate_f9780b11-bebe-4e02-9711-2356cce7ae7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8c6f0c9d-a29c-471e-869a-b135da0505f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8c6f0c9d-a29c-471e-869a-b135da0505f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ef416ed8-06e4-4a73-8cfb-0cdd22eb75d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_ef416ed8-06e4-4a73-8cfb-0cdd22eb75d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_c87a694f-5858-49ef-b48d-945a7f5b8e78" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_c87a694f-5858-49ef-b48d-945a7f5b8e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_385c1eaf-63fd-4ca3-b6a7-35e5da9eadcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_GoodwillGross_385c1eaf-63fd-4ca3-b6a7-35e5da9eadcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_e2a130f8-e063-4c15-8da1-2bda6022d9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_e2a130f8-e063-4c15-8da1-2bda6022d9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_1268afdc-1382-4ba0-b023-d4d314575da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_1268afdc-1382-4ba0-b023-d4d314575da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5cc3dc79-c5a1-4305-83c3-7b0b3f330afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5cc3dc79-c5a1-4305-83c3-7b0b3f330afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c8eb0b4b-6802-469b-b19e-3f010b7855da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_c8eb0b4b-6802-469b-b19e-3f010b7855da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_05a05905-709b-45af-b6b1-0259d72b338c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_05a05905-709b-45af-b6b1-0259d72b338c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_f9b93b22-2cfd-44c1-a184-f9c184de85dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory_f9b93b22-2cfd-44c1-a184-f9c184de85dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_b89f41d7-9285-4df6-90e1-71ecc60c09b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_b89f41d7-9285-4df6-90e1-71ecc60c09b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_c1b61699-2317-4377-a8f8-920ac1535611" xlink:href="gild-20221231.xsd#gild_FiniteLivedIntangibleAssetsGrossReclassified"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_FiniteLivedIntangibleAssetsGrossReclassified_c1b61699-2317-4377-a8f8-920ac1535611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_66cc3cf4-b5e5-427d-8773-f6dcb98d5dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_66cc3cf4-b5e5-427d-8773-f6dcb98d5dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_8ca6dd0e-1f33-4f6d-b28f-7983d02ae4a3" xlink:href="gild-20221231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_8ca6dd0e-1f33-4f6d-b28f-7983d02ae4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_43d08146-bf21-4f76-955f-42059cffdcb3" xlink:href="gild-20221231.xsd#gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_43d08146-bf21-4f76-955f-42059cffdcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired_1d2d85db-3ff6-4869-93d5-310e7d6d650c" xlink:href="gild-20221231.xsd#gild_PaymentsToAcquireAssetsNetOfCashAcquired"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems_a4b8863a-7c49-4ddd-b25a-3c1fbc19b291" xlink:to="loc_gild_PaymentsToAcquireAssetsNetOfCashAcquired_1d2d85db-3ff6-4869-93d5-310e7d6d650c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b9beb439-74cb-4e5f-8be3-752e765794c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f39ae95-bfa9-4ed6-970a-2922c8a784f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b9beb439-74cb-4e5f-8be3-752e765794c6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f39ae95-bfa9-4ed6-970a-2922c8a784f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f47b0185-854c-4b19-9df8-73b263bc9da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f39ae95-bfa9-4ed6-970a-2922c8a784f4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f47b0185-854c-4b19-9df8-73b263bc9da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65712cea-cbaa-4295-a651-8617311f2790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f47b0185-854c-4b19-9df8-73b263bc9da8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65712cea-cbaa-4295-a651-8617311f2790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_3950d0ad-b03f-4149-9769-a146196319dd" xlink:href="gild-20221231.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65712cea-cbaa-4295-a651-8617311f2790" xlink:to="loc_gild_MYRGmbHMember_3950d0ad-b03f-4149-9769-a146196319dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_db21c8a6-9221-461c-be2c-8479246b9578" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65712cea-cbaa-4295-a651-8617311f2790" xlink:to="loc_gild_ImmunomedicsIncMember_db21c8a6-9221-461c-be2c-8479246b9578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9b994086-05ac-4da5-be7c-53a520e802f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f39ae95-bfa9-4ed6-970a-2922c8a784f4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9b994086-05ac-4da5-be7c-53a520e802f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff19bb1a-d2e5-4ecd-92d5-515d6eac1322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9b994086-05ac-4da5-be7c-53a520e802f1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff19bb1a-d2e5-4ecd-92d5-515d6eac1322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_a18f2608-ee3b-403c-b4e8-775f843307ec" xlink:href="gild-20221231.xsd#gild_HepcludexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff19bb1a-d2e5-4ecd-92d5-515d6eac1322" xlink:to="loc_gild_HepcludexMember_a18f2608-ee3b-403c-b4e8-775f843307ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_a65f4de7-cf3f-454c-b7b9-aa7b19beeaa9" xlink:href="gild-20221231.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff19bb1a-d2e5-4ecd-92d5-515d6eac1322" xlink:to="loc_gild_TrodelvyMember_a65f4de7-cf3f-454c-b7b9-aa7b19beeaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_1dbf8075-c0db-4690-8f85-e3877dce0e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff19bb1a-d2e5-4ecd-92d5-515d6eac1322" xlink:to="loc_us-gaap_LicensingAgreementsMember_1dbf8075-c0db-4690-8f85-e3877dce0e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5a82d82-6ec3-4a72-aefd-35b171d1a0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f39ae95-bfa9-4ed6-970a-2922c8a784f4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5a82d82-6ec3-4a72-aefd-35b171d1a0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c0795a7b-b3da-4cf8-b242-9b782d2ba805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c5a82d82-6ec3-4a72-aefd-35b171d1a0cf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c0795a7b-b3da-4cf8-b242-9b782d2ba805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_33445b98-4fd3-4551-b22b-4f9bfa86c5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c0795a7b-b3da-4cf8-b242-9b782d2ba805" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_33445b98-4fd3-4551-b22b-4f9bfa86c5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0f39ae95-bfa9-4ed6-970a-2922c8a784f4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0fd37daf-3385-4fef-bb9b-d1173840c11b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0fd37daf-3385-4fef-bb9b-d1173840c11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_eecd80aa-ccbc-4a51-ae84-0ca35cc8c804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_eecd80aa-ccbc-4a51-ae84-0ca35cc8c804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e5766cfa-29cb-44ed-9efb-3f17b4337839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e5766cfa-29cb-44ed-9efb-3f17b4337839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_84063e29-182b-4a9f-aaf5-4832ed161cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e5766cfa-29cb-44ed-9efb-3f17b4337839" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_84063e29-182b-4a9f-aaf5-4832ed161cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_b2bb39e5-9a33-48e9-b9c3-1786ccaaa5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e5766cfa-29cb-44ed-9efb-3f17b4337839" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_b2bb39e5-9a33-48e9-b9c3-1786ccaaa5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e03100fa-2096-46e8-b622-2464a830592f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e03100fa-2096-46e8-b622-2464a830592f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_6d16b890-7593-4301-9545-067ff76e612b" xlink:href="gild-20221231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability_6d16b890-7593-4301-9545-067ff76e612b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_ee98f739-32b6-4eb7-949b-90610e8c76e4" xlink:href="gild-20221231.xsd#gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet_ee98f739-32b6-4eb7-949b-90610e8c76e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b96b0dc9-a79b-48df-88f4-43f6b7b6a313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b96b0dc9-a79b-48df-88f4-43f6b7b6a313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_7fdd32c6-8257-452e-9b0b-b2ce97a7e364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_GoodwillGross_7fdd32c6-8257-452e-9b0b-b2ce97a7e364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e36c6660-3636-471e-891e-553e43c453e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dff889c0-88a5-4ef0-a50b-abb82808a6dd" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e36c6660-3636-471e-891e-553e43c453e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7af9f10a-3859-4ddd-84ea-6dc94dce3ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_707a2d1e-9e74-4e96-8876-434ff8516a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Land"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7af9f10a-3859-4ddd-84ea-6dc94dce3ced" xlink:to="loc_us-gaap_Land_707a2d1e-9e74-4e96-8876-434ff8516a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_8004343c-aa51-48e5-afac-cb2859627ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingsAndImprovementsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7af9f10a-3859-4ddd-84ea-6dc94dce3ced" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_8004343c-aa51-48e5-afac-cb2859627ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_01921f27-d819-45d3-8b35-a2d520783cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7af9f10a-3859-4ddd-84ea-6dc94dce3ced" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_01921f27-d819-45d3-8b35-a2d520783cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOther_86e5bfda-2dc5-4e52-99a1-e0c196ad444f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7af9f10a-3859-4ddd-84ea-6dc94dce3ced" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOther_86e5bfda-2dc5-4e52-99a1-e0c196ad444f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_14964546-ac9d-48c8-a1eb-9dc5fd7aa35f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7af9f10a-3859-4ddd-84ea-6dc94dce3ced" xlink:to="loc_us-gaap_ConstructionInProgressGross_14964546-ac9d-48c8-a1eb-9dc5fd7aa35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3724d693-3d82-40d4-a728-2f950c570c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7af9f10a-3859-4ddd-84ea-6dc94dce3ced" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3724d693-3d82-40d4-a728-2f950c570c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b4d9bd51-75b6-41d4-b829-e6d07d5a7df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7af9f10a-3859-4ddd-84ea-6dc94dce3ced" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b4d9bd51-75b6-41d4-b829-e6d07d5a7df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_08689ab3-775d-46ed-ac9d-d2ea3070c4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7af9f10a-3859-4ddd-84ea-6dc94dce3ced" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_08689ab3-775d-46ed-ac9d-d2ea3070c4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d1a52e09-143d-4126-ad12-ab5131683d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0bdfc7c4-9888-4138-8496-c45d384cee76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d1a52e09-143d-4126-ad12-ab5131683d57" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0bdfc7c4-9888-4138-8496-c45d384cee76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f5ad97d1-3760-4fab-91b7-82cbd5bf9f0a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0bdfc7c4-9888-4138-8496-c45d384cee76" xlink:to="loc_srt_StatementGeographicalAxis_f5ad97d1-3760-4fab-91b7-82cbd5bf9f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f1ab74ff-ae38-4562-8af2-f912d664d53b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f5ad97d1-3760-4fab-91b7-82cbd5bf9f0a" xlink:to="loc_srt_SegmentGeographicalDomain_f1ab74ff-ae38-4562-8af2-f912d664d53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c9344e71-ca01-4d23-b93c-fb82d7bea21d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f1ab74ff-ae38-4562-8af2-f912d664d53b" xlink:to="loc_country_US_c9344e71-ca01-4d23-b93c-fb82d7bea21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_c3a2dc60-b7b0-4f42-a144-4476bd727b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f1ab74ff-ae38-4562-8af2-f912d664d53b" xlink:to="loc_us-gaap_NonUsMember_c3a2dc60-b7b0-4f42-a144-4476bd727b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d95c5c5b-5878-4aa8-9832-e0dd8c484196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0bdfc7c4-9888-4138-8496-c45d384cee76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d95c5c5b-5878-4aa8-9832-e0dd8c484196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_8f38073c-a42e-4424-9214-fcf3209eb41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d95c5c5b-5878-4aa8-9832-e0dd8c484196" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_8f38073c-a42e-4424-9214-fcf3209eb41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3177a864-e7b9-4bca-88de-e77a600e4a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d95c5c5b-5878-4aa8-9832-e0dd8c484196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3177a864-e7b9-4bca-88de-e77a600e4a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#GoodwillandIntangibleAssetsGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2ec7ee53-aac9-419b-b8f7-d70768a8eb13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_3e847f47-743c-4bc0-9ed0-52f98d59c2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2ec7ee53-aac9-419b-b8f7-d70768a8eb13" xlink:to="loc_us-gaap_GoodwillRollForward_3e847f47-743c-4bc0-9ed0-52f98d59c2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dd3372c3-413d-4ded-b6de-824fb820b583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3e847f47-743c-4bc0-9ed0-52f98d59c2b1" xlink:to="loc_us-gaap_Goodwill_dd3372c3-413d-4ded-b6de-824fb820b583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_f4c827e8-1733-4809-bf37-24e9aa627649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3e847f47-743c-4bc0-9ed0-52f98d59c2b1" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_f4c827e8-1733-4809-bf37-24e9aa627649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_530e0b5f-2cb8-4b83-bcf7-b03c2e813f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3e847f47-743c-4bc0-9ed0-52f98d59c2b1" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_530e0b5f-2cb8-4b83-bcf7-b03c2e813f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ec5cce91-2720-4626-88a3-80efbb78dace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_3e847f47-743c-4bc0-9ed0-52f98d59c2b1" xlink:to="loc_us-gaap_Goodwill_ec5cce91-2720-4626-88a3-80efbb78dace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1a7e592-e57e-446f-b274-4469a8f98d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1a7e592-e57e-446f-b274-4469a8f98d84" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9ab6a9c0-da47-4be7-b023-50b43a19fcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9ab6a9c0-da47-4be7-b023-50b43a19fcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6463662e-df5d-4c10-8df4-1f2dd6104df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9ab6a9c0-da47-4be7-b023-50b43a19fcb5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6463662e-df5d-4c10-8df4-1f2dd6104df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MYRGmbHMember_c778d906-9905-4207-af41-b5a786c2c966" xlink:href="gild-20221231.xsd#gild_MYRGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6463662e-df5d-4c10-8df4-1f2dd6104df0" xlink:to="loc_gild_MYRGmbHMember_c778d906-9905-4207-af41-b5a786c2c966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_dbbb481a-cb7c-4526-b7a9-f00013a77d4e" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6463662e-df5d-4c10-8df4-1f2dd6104df0" xlink:to="loc_gild_ImmunomedicsIncMember_dbbb481a-cb7c-4526-b7a9-f00013a77d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_db67ec6f-088c-4d26-9ef9-495c1c4ca38d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_db67ec6f-088c-4d26-9ef9-495c1c4ca38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8d289859-2dec-415f-a398-3128075974fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_db67ec6f-088c-4d26-9ef9-495c1c4ca38d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8d289859-2dec-415f-a398-3128075974fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_eb1a6f30-9866-48aa-9bb7-8de7430b41ea" xlink:href="gild-20221231.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8d289859-2dec-415f-a398-3128075974fb" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_eb1a6f30-9866-48aa-9bb7-8de7430b41ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_74a83209-216b-40e1-9157-5eb50f550fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_74a83209-216b-40e1-9157-5eb50f550fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_002f1ded-95f6-4e29-bf00-0dff8df76242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_74a83209-216b-40e1-9157-5eb50f550fca" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_002f1ded-95f6-4e29-bf00-0dff8df76242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_336e9ac3-1a00-4c07-a00a-cf41470365dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_002f1ded-95f6-4e29-bf00-0dff8df76242" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_336e9ac3-1a00-4c07-a00a-cf41470365dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04a98172-6431-4110-86cb-8ff4ef144379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04a98172-6431-4110-86cb-8ff4ef144379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5c644b7c-bf58-4db3-b6fa-6f1fbc68fbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04a98172-6431-4110-86cb-8ff4ef144379" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5c644b7c-bf58-4db3-b6fa-6f1fbc68fbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_edba6aee-c861-4406-b9de-c8c2356f56af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5c644b7c-bf58-4db3-b6fa-6f1fbc68fbbe" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_edba6aee-c861-4406-b9de-c8c2356f56af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ef91b072-895e-4486-963c-b996f472c8fe" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_a0331a8a-a594-4d59-954f-5c39f7038add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_a0331a8a-a594-4d59-954f-5c39f7038add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_a0206d99-4d0e-40e8-9976-c8038fd02673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_a0206d99-4d0e-40e8-9976-c8038fd02673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_89afa668-463d-4853-bc09-50d2bfda3f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_89afa668-463d-4853-bc09-50d2bfda3f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_f3a013ac-7bbd-4e24-a98e-451749942be2" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate_f3a013ac-7bbd-4e24-a98e-451749942be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_fab1b5ac-3944-4a66-b08f-c77592a5dae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_fab1b5ac-3944-4a66-b08f-c77592a5dae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_88cfd20e-19eb-4303-9f27-2de2e2309118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_88cfd20e-19eb-4303-9f27-2de2e2309118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput_76422553-c6cf-4eed-9911-8f39f03c742a" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetMeasurementInput"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetMeasurementInput_76422553-c6cf-4eed-9911-8f39f03c742a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0efc8810-0d66-4219-a666-7787d3168ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b4cdd74-afcc-47cf-b8a7-036e875b7f39" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0efc8810-0d66-4219-a666-7787d3168ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2bfc2d1d-da5e-43bf-a5d7-f253408999ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_84d214e0-8dc1-425a-977c-550501324319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2bfc2d1d-da5e-43bf-a5d7-f253408999ce" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_84d214e0-8dc1-425a-977c-550501324319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ea82376-110a-47dc-b3ad-211c9c64bd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_84d214e0-8dc1-425a-977c-550501324319" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ea82376-110a-47dc-b3ad-211c9c64bd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6ea82376-110a-47dc-b3ad-211c9c64bd8b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IntangibleAssetSofosbuvirMember_e8590daa-6533-429e-a5e5-43f3940e681e" xlink:href="gild-20221231.xsd#gild_IntangibleAssetSofosbuvirMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:to="loc_gild_IntangibleAssetSofosbuvirMember_e8590daa-6533-429e-a5e5-43f3940e681e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AxicabtageneciloleucelDLBCLMember_9a3299d8-4d3d-42e8-abb5-1f6e510902ce" xlink:href="gild-20221231.xsd#gild_AxicabtageneciloleucelDLBCLMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:to="loc_gild_AxicabtageneciloleucelDLBCLMember_9a3299d8-4d3d-42e8-abb5-1f6e510902ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TrodelvyMember_380b3720-3ab7-492f-9b15-82a4de211bae" xlink:href="gild-20221231.xsd#gild_TrodelvyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:to="loc_gild_TrodelvyMember_380b3720-3ab7-492f-9b15-82a4de211bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_HepcludexMember_ae452856-1ace-451a-a547-53d5d592031f" xlink:href="gild-20221231.xsd#gild_HepcludexMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:to="loc_gild_HepcludexMember_ae452856-1ace-451a-a547-53d5d592031f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_7a4e60d6-449f-4624-bd8d-4dd7b438ad60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1427391f-abcb-4fa7-9326-5770c2757f43" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_7a4e60d6-449f-4624-bd8d-4dd7b438ad60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4303468b-9008-4128-ad9c-0e90d5a4d9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_84d214e0-8dc1-425a-977c-550501324319" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4303468b-9008-4128-ad9c-0e90d5a4d9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_254fc3bf-8eaa-415f-8d61-3c604af3de04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4303468b-9008-4128-ad9c-0e90d5a4d9dd" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_254fc3bf-8eaa-415f-8d61-3c604af3de04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_cd4cf98e-9291-4a6d-bc67-ca1dcf0712b2" xlink:href="gild-20221231.xsd#gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_254fc3bf-8eaa-415f-8d61-3c604af3de04" xlink:to="loc_gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member_cd4cf98e-9291-4a6d-bc67-ca1dcf0712b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_84d214e0-8dc1-425a-977c-550501324319" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_741506fd-89b6-4b8f-b9ec-1b616c5d484a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_741506fd-89b6-4b8f-b9ec-1b616c5d484a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_06453adb-3e38-4e24-a698-f151d612fd24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_06453adb-3e38-4e24-a698-f151d612fd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_51c06903-ff1d-4270-8b61-886da8b92521" xlink:href="gild-20221231.xsd#gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_51c06903-ff1d-4270-8b61-886da8b92521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41a0850-650b-496b-be9c-a9cccd887ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41a0850-650b-496b-be9c-a9cccd887ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c1615472-fa63-49c1-917e-821fc20df718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c1615472-fa63-49c1-917e-821fc20df718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_55e40f0a-47bf-446e-8e37-6bd53a91fd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c1615472-fa63-49c1-917e-821fc20df718" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_55e40f0a-47bf-446e-8e37-6bd53a91fd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_c1444b87-87bc-421c-a873-6529a898f5aa" xlink:href="gild-20221231.xsd#gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c1615472-fa63-49c1-917e-821fc20df718" xlink:to="loc_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_c1444b87-87bc-421c-a873-6529a898f5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_40f346d3-0d52-4bce-a894-4c6ad8b6f312" xlink:href="gild-20221231.xsd#gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c1615472-fa63-49c1-917e-821fc20df718" xlink:to="loc_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill_40f346d3-0d52-4bce-a894-4c6ad8b6f312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8fd6c9fb-622e-41dc-a90d-b596f2daa85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8fd6c9fb-622e-41dc-a90d-b596f2daa85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e75a3aec-d0c4-4464-aa1a-6ef10284777b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8fd6c9fb-622e-41dc-a90d-b596f2daa85e" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e75a3aec-d0c4-4464-aa1a-6ef10284777b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_21617700-493e-4fcf-956f-2b69dbf5ed62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8fd6c9fb-622e-41dc-a90d-b596f2daa85e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_21617700-493e-4fcf-956f-2b69dbf5ed62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_50a036f9-79e8-4eb2-8a84-856e02fec85c" xlink:href="gild-20221231.xsd#gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8fd6c9fb-622e-41dc-a90d-b596f2daa85e" xlink:to="loc_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss_50a036f9-79e8-4eb2-8a84-856e02fec85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a152e74c-e85e-43b0-9362-922d75e8305c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_8fd6c9fb-622e-41dc-a90d-b596f2daa85e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a152e74c-e85e-43b0-9362-922d75e8305c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_57b88116-bd27-46c1-b755-b1ec8c5b8384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_859ae791-b0e2-42fb-830a-4c45c90b68ea" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_57b88116-bd27-46c1-b755-b1ec8c5b8384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="gild-20221231.xsd#GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc0806c3-ae8e-414b-b676-22cb71bb3fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c3fbfc06-a5b8-4448-85a7-18f3a0d68f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc0806c3-ae8e-414b-b676-22cb71bb3fd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c3fbfc06-a5b8-4448-85a7-18f3a0d68f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_41b5f143-3104-4349-93c4-541def28f80a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc0806c3-ae8e-414b-b676-22cb71bb3fd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_41b5f143-3104-4349-93c4-541def28f80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a4e17059-5714-463e-b291-7cb6b8bd39fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc0806c3-ae8e-414b-b676-22cb71bb3fd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a4e17059-5714-463e-b291-7cb6b8bd39fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_98a9d43d-1d43-432e-b5c9-9b5ccb4face9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc0806c3-ae8e-414b-b676-22cb71bb3fd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_98a9d43d-1d43-432e-b5c9-9b5ccb4face9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_73bcb845-a126-48b2-bda4-5f99c85caa72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc0806c3-ae8e-414b-b676-22cb71bb3fd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_73bcb845-a126-48b2-bda4-5f99c85caa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_54ca715a-ef99-445c-b8fb-76c26d5d3d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc0806c3-ae8e-414b-b676-22cb71bb3fd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_54ca715a-ef99-445c-b8fb-76c26d5d3d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6461cc32-2adb-4ebe-8c84-d41415d4115c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fc0806c3-ae8e-414b-b676-22cb71bb3fd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6461cc32-2adb-4ebe-8c84-d41415d4115c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#OtherFinancialInformationAccountsReceivableNetDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_db4a70a5-6451-4218-8d48-b09771760290" xlink:href="gild-20221231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_2976fc81-adcb-484e-ab19-27e8dc9c6c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_db4a70a5-6451-4218-8d48-b09771760290" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_2976fc81-adcb-484e-ab19-27e8dc9c6c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableChargebacksCurrent_a4b9e51b-9dfa-4924-a1fe-8aed3a62c3dd" xlink:href="gild-20221231.xsd#gild_AccountsReceivableChargebacksCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_db4a70a5-6451-4218-8d48-b09771760290" xlink:to="loc_gild_AccountsReceivableChargebacksCurrent_a4b9e51b-9dfa-4924-a1fe-8aed3a62c3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_9d70538a-f96a-4ecc-84f5-a9d81d671842" xlink:href="gild-20221231.xsd#gild_AccountsReceivableCashDiscountsAndOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_db4a70a5-6451-4218-8d48-b09771760290" xlink:to="loc_gild_AccountsReceivableCashDiscountsAndOtherCurrent_9d70538a-f96a-4ecc-84f5-a9d81d671842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_818bfed9-0b7b-477a-a4a8-b7090ea1d954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_db4a70a5-6451-4218-8d48-b09771760290" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_818bfed9-0b7b-477a-a4a8-b7090ea1d954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f5b992d2-e039-49e4-a49d-e694f3c3f3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_db4a70a5-6451-4218-8d48-b09771760290" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f5b992d2-e039-49e4-a49d-e694f3c3f3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#OtherFinancialInformationInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_81b63dd9-a839-45fd-bfcd-89a4be72efd5" xlink:href="gild-20221231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5e92cf9d-a240-4823-ad40-5acdd55c87ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_81b63dd9-a839-45fd-bfcd-89a4be72efd5" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5e92cf9d-a240-4823-ad40-5acdd55c87ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_56b477bd-2f29-4236-a94c-f1822f79466c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_81b63dd9-a839-45fd-bfcd-89a4be72efd5" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_56b477bd-2f29-4236-a94c-f1822f79466c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e615cd70-3aa1-4e0c-beb9-5b7ffe8b2c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_81b63dd9-a839-45fd-bfcd-89a4be72efd5" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e615cd70-3aa1-4e0c-beb9-5b7ffe8b2c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_a7ec4410-719a-49ca-8641-f6f7b80722dc" xlink:href="gild-20221231.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_81b63dd9-a839-45fd-bfcd-89a4be72efd5" xlink:to="loc_gild_InventoryNetAndInventoryNoncurrent_a7ec4410-719a-49ca-8641-f6f7b80722dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_895c8a54-d46a-48c8-b3d5-09fd41744573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_81b63dd9-a839-45fd-bfcd-89a4be72efd5" xlink:to="loc_us-gaap_InventoryNet_895c8a54-d46a-48c8-b3d5-09fd41744573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_fbdcd71b-ea1d-465b-b52e-856933d32e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_81b63dd9-a839-45fd-bfcd-89a4be72efd5" xlink:to="loc_us-gaap_InventoryNoncurrent_fbdcd71b-ea1d-465b-b52e-856933d32e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InventoryNetAndInventoryNoncurrent_bc25b50b-9fa8-411f-907e-71d964f8c748" xlink:href="gild-20221231.xsd#gild_InventoryNetAndInventoryNoncurrent"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails_1" xlink:type="simple" xlink:href="gild-20221231.xsd#OtherFinancialInformationInventoriesDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_47f6d8c1-8f2a-450e-a913-cdb50508c447" xlink:href="gild-20221231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleofInventoryTable_811d85b1-5175-473d-a858-d4b64c8d9ebe" xlink:href="gild-20221231.xsd#gild_ScheduleofInventoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_47f6d8c1-8f2a-450e-a913-cdb50508c447" xlink:to="loc_gild_ScheduleofInventoryTable_811d85b1-5175-473d-a858-d4b64c8d9ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_103b3435-462f-4187-9015-903135944997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryTable_811d85b1-5175-473d-a858-d4b64c8d9ebe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_103b3435-462f-4187-9015-903135944997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a1f38b51-33da-4657-a03c-26ad918b22b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_103b3435-462f-4187-9015-903135944997" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a1f38b51-33da-4657-a03c-26ad918b22b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_316927a4-cab9-46b0-8f1f-60d5dde3b2a4" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a1f38b51-33da-4657-a03c-26ad918b22b9" xlink:to="loc_gild_ImmunomedicsIncMember_316927a4-cab9-46b0-8f1f-60d5dde3b2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ScheduleOfInventoryLineItems_0ca68545-779a-4b96-9dc5-444736ac572c" xlink:href="gild-20221231.xsd#gild_ScheduleOfInventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleofInventoryTable_811d85b1-5175-473d-a858-d4b64c8d9ebe" xlink:to="loc_gild_ScheduleOfInventoryLineItems_0ca68545-779a-4b96-9dc5-444736ac572c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0caf2504-4ecd-4b9f-bfe3-f01040605160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ScheduleOfInventoryLineItems_0ca68545-779a-4b96-9dc5-444736ac572c" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0caf2504-4ecd-4b9f-bfe3-f01040605160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#OtherFinancialInformationOtherAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherFinancialInformationAbstract_d38821fc-9b43-4943-a6cb-e8e834077373" xlink:href="gild-20221231.xsd#gild_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b9053d1b-0886-4cb1-8d74-4ac90f6618df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d38821fc-9b43-4943-a6cb-e8e834077373" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b9053d1b-0886-4cb1-8d74-4ac90f6618df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_f7d8f789-cd40-4bdf-9c15-aa7ffeb30daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d38821fc-9b43-4943-a6cb-e8e834077373" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_f7d8f789-cd40-4bdf-9c15-aa7ffeb30daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_e6e7ecf9-ea92-4ba7-b44d-ec85f01d24a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d38821fc-9b43-4943-a6cb-e8e834077373" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_e6e7ecf9-ea92-4ba7-b44d-ec85f01d24a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_cd80db98-a121-460f-8b89-528dd13f7388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d38821fc-9b43-4943-a6cb-e8e834077373" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_cd80db98-a121-460f-8b89-528dd13f7388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3c9b20be-a239-4406-9778-25f9f9e58323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d38821fc-9b43-4943-a6cb-e8e834077373" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3c9b20be-a239-4406-9778-25f9f9e58323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c29b3f85-7ec4-4f33-9a55-49c1be0453e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_OtherFinancialInformationAbstract_d38821fc-9b43-4943-a6cb-e8e834077373" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c29b3f85-7ec4-4f33-9a55-49c1be0453e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#CollaborationsandOtherArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeandOtherArrangementsAbstract_117d312f-3580-4253-8339-77ea9d2fdb17" xlink:href="gild-20221231.xsd#gild_CollaborativeandOtherArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_CollaborativeandOtherArrangementsAbstract_117d312f-3580-4253-8339-77ea9d2fdb17" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a1af53b3-5bda-4754-9ed3-88b8fe5822fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_srt_CounterpartyNameAxis_a1af53b3-5bda-4754-9ed3-88b8fe5822fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab9ff633-ecd0-43ca-beb8-79d49bc8cff8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a1af53b3-5bda-4754-9ed3-88b8fe5822fe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab9ff633-ecd0-43ca-beb8-79d49bc8cff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DragonflyTherapeuticsIncMember_919383ba-c651-43ce-8417-c362e8c5bd1c" xlink:href="gild-20221231.xsd#gild_DragonflyTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab9ff633-ecd0-43ca-beb8-79d49bc8cff8" xlink:to="loc_gild_DragonflyTherapeuticsIncMember_919383ba-c651-43ce-8417-c362e8c5bd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EverestMedicinesMember_65d58eaf-367c-440c-89b6-a72c010af5be" xlink:href="gild-20221231.xsd#gild_EverestMedicinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab9ff633-ecd0-43ca-beb8-79d49bc8cff8" xlink:to="loc_gild_EverestMedicinesMember_65d58eaf-367c-440c-89b6-a72c010af5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d70f478c-5ee1-465f-9b06-cc5c7d8be579" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d70f478c-5ee1-465f-9b06-cc5c7d8be579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d70f478c-5ee1-465f-9b06-cc5c7d8be579" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_e0251d73-51ae-4560-8d70-3d51ec8d3834" xlink:href="gild-20221231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:to="loc_gild_ArcusBiosciencesIncMember_e0251d73-51ae-4560-8d70-3d51ec8d3834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrImmunotherapeuticsIncMember_6359bd82-30f6-4711-8def-444637609c64" xlink:href="gild-20221231.xsd#gild_PionyrImmunotherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:to="loc_gild_PionyrImmunotherapeuticsIncMember_6359bd82-30f6-4711-8def-444637609c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaTherapeuticsIncMember_2e9a01ac-c7c1-427e-a40b-dbfa43beb21f" xlink:href="gild-20221231.xsd#gild_TizonaTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:to="loc_gild_TizonaTherapeuticsIncMember_2e9a01ac-c7c1-427e-a40b-dbfa43beb21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember_8004b1d8-3cd7-40f1-88f6-50c3f83b0186" xlink:href="gild-20221231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:to="loc_gild_TangoTherapeuticsIncMember_8004b1d8-3cd7-40f1-88f6-50c3f83b0186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JounceTherapeuticsIncMember_a6a109f8-5bf9-47bc-a9f6-8746046abb8f" xlink:href="gild-20221231.xsd#gild_JounceTherapeuticsIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:to="loc_gild_JounceTherapeuticsIncMember_a6a109f8-5bf9-47bc-a9f6-8746046abb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosMember_85dd756a-516e-4e8a-aacd-0fd98cb5c440" xlink:href="gild-20221231.xsd#gild_GalapagosMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_da84d662-8632-460a-b393-693bc811e465" xlink:to="loc_gild_GalapagosMember_85dd756a-516e-4e8a-aacd-0fd98cb5c440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dfa6038a-1194-45e9-8586-f9e408478ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dfa6038a-1194-45e9-8586-f9e408478ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dfa6038a-1194-45e9-8586-f9e408478ba8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DragonflyTherapeuticsCollaborationAgreementMember_e1db7b88-50b6-4a92-afc9-80b0ffbdee04" xlink:href="gild-20221231.xsd#gild_DragonflyTherapeuticsCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_DragonflyTherapeuticsCollaborationAgreementMember_e1db7b88-50b6-4a92-afc9-80b0ffbdee04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_b2c5ff39-39c6-43f5-b0bf-1e95553920e7" xlink:href="gild-20221231.xsd#gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember_b2c5ff39-39c6-43f5-b0bf-1e95553920e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_943f5db5-61ef-4bfb-844b-8b7159769029" xlink:href="gild-20221231.xsd#gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember_943f5db5-61ef-4bfb-844b-8b7159769029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusStockPurchaseAgreementMember_dbb2dca4-cf30-48f3-9047-23297cd265c5" xlink:href="gild-20221231.xsd#gild_ArcusStockPurchaseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_ArcusStockPurchaseAgreementMember_dbb2dca4-cf30-48f3-9047-23297cd265c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusCollaborationAgreementMember_4d2386ac-ed5b-420f-89dc-771feaebc210" xlink:href="gild-20221231.xsd#gild_ArcusCollaborationAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_ArcusCollaborationAgreementMember_4d2386ac-ed5b-420f-89dc-771feaebc210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PionyrMergerAndOptionAgreementsMember_7468adb3-3791-440c-961e-a6b6a2b927a6" xlink:href="gild-20221231.xsd#gild_PionyrMergerAndOptionAgreementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_PionyrMergerAndOptionAgreementsMember_7468adb3-3791-440c-961e-a6b6a2b927a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentServiceAgreementMember_ea3ba795-d8a1-4767-af8c-da46a684fd6d" xlink:href="gild-20221231.xsd#gild_ResearchAndDevelopmentServiceAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_ResearchAndDevelopmentServiceAgreementMember_ea3ba795-d8a1-4767-af8c-da46a684fd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TizonaMergerAndOptionAgreementsMember_76f5c102-0236-470c-ab76-e88e65ef8a0d" xlink:href="gild-20221231.xsd#gild_TizonaMergerAndOptionAgreementsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_TizonaMergerAndOptionAgreementsMember_76f5c102-0236-470c-ab76-e88e65ef8a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DevelopmentAgreementMember_b7457d4a-7238-43b7-ada9-b7d7f0432cce" xlink:href="gild-20221231.xsd#gild_DevelopmentAgreementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_DevelopmentAgreementMember_b7457d4a-7238-43b7-ada9-b7d7f0432cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_267d4854-30a2-48db-8fc3-65b891ff05f1" xlink:href="gild-20221231.xsd#gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember_267d4854-30a2-48db-8fc3-65b891ff05f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_cad60768-5c1a-4176-abae-c57537434e75" xlink:href="gild-20221231.xsd#gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember_cad60768-5c1a-4176-abae-c57537434e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_ca02d7b0-20f0-47b4-9c1d-e1bcbf0cb289" xlink:href="gild-20221231.xsd#gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member_ca02d7b0-20f0-47b4-9c1d-e1bcbf0cb289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GalapagosSubscriptionAgreementMember_9e84fb43-1d8e-4f49-aad0-36de13fc1a2a" xlink:href="gild-20221231.xsd#gild_GalapagosSubscriptionAgreementMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_GalapagosSubscriptionAgreementMember_9e84fb43-1d8e-4f49-aad0-36de13fc1a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JanssenPharmaceuticalsMember_347667b0-3435-45ff-a4d0-affe34a4a265" xlink:href="gild-20221231.xsd#gild_JanssenPharmaceuticalsMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_JanssenPharmaceuticalsMember_347667b0-3435-45ff-a4d0-affe34a4a265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AgreementWithJapanTobaccoIncMember_55173402-90db-47b4-aae6-73cfa92a0fd0" xlink:href="gild-20221231.xsd#gild_AgreementWithJapanTobaccoIncMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_AgreementWithJapanTobaccoIncMember_55173402-90db-47b4-aae6-73cfa92a0fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EverestMedicinesAndImmunomedicsAgreementMember_af4a630b-06eb-4562-a330-d890f9f6611f" xlink:href="gild-20221231.xsd#gild_EverestMedicinesAndImmunomedicsAgreementMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_EverestMedicinesAndImmunomedicsAgreementMember_af4a630b-06eb-4562-a330-d890f9f6611f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OtherCollaborationArrangementsMember_e371fe67-bd3d-45b7-8503-c917d626faba" xlink:href="gild-20221231.xsd#gild_OtherCollaborationArrangementsMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_60bee137-4559-4ada-b2b6-3513732cbf80" xlink:to="loc_gild_OtherCollaborationArrangementsMember_e371fe67-bd3d-45b7-8503-c917d626faba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_8a167715-146b-4ec4-9dc1-e3345577ae12" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_srt_OwnershipAxis_8a167715-146b-4ec4-9dc1-e3345577ae12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9e2935be-7067-4dcc-9244-876a1572816a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_8a167715-146b-4ec4-9dc1-e3345577ae12" xlink:to="loc_srt_OwnershipDomain_9e2935be-7067-4dcc-9244-876a1572816a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcusBiosciencesIncMember_bca4874f-39e5-4bdd-8b45-f3d4f4d9a571" xlink:href="gild-20221231.xsd#gild_ArcusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_9e2935be-7067-4dcc-9244-876a1572816a" xlink:to="loc_gild_ArcusBiosciencesIncMember_bca4874f-39e5-4bdd-8b45-f3d4f4d9a571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TangoTherapeuticsIncMember_43fdbe9f-7672-460a-9f8c-7c3ff872dc87" xlink:href="gild-20221231.xsd#gild_TangoTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_9e2935be-7067-4dcc-9244-876a1572816a" xlink:to="loc_gild_TangoTherapeuticsIncMember_43fdbe9f-7672-460a-9f8c-7c3ff872dc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4f14985c-7014-4c79-8713-a1c009742cb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_srt_ProductOrServiceAxis_4f14985c-7014-4c79-8713-a1c009742cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cae66158-f69b-4cca-acd1-fb205d0d5ef2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4f14985c-7014-4c79-8713-a1c009742cb3" xlink:to="loc_srt_ProductsAndServicesDomain_cae66158-f69b-4cca-acd1-fb205d0d5ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_OralFormulationProductMember_bea712bb-c868-4ef4-9ddf-e7a2b9fb0261" xlink:href="gild-20221231.xsd#gild_OralFormulationProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cae66158-f69b-4cca-acd1-fb205d0d5ef2" xlink:to="loc_gild_OralFormulationProductMember_bea712bb-c868-4ef4-9ddf-e7a2b9fb0261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InjectableFormulationProductMember_16e784fa-a46a-4492-a4ac-494c364e9841" xlink:href="gild-20221231.xsd#gild_InjectableFormulationProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cae66158-f69b-4cca-acd1-fb205d0d5ef2" xlink:to="loc_gild_InjectableFormulationProductMember_16e784fa-a46a-4492-a4ac-494c364e9841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8cdd964c-285e-4e39-b8b3-29757607cf78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_srt_RangeAxis_8cdd964c-285e-4e39-b8b3-29757607cf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba49f97c-44f6-41fa-a5b7-df139d04eb19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8cdd964c-285e-4e39-b8b3-29757607cf78" xlink:to="loc_srt_RangeMember_ba49f97c-44f6-41fa-a5b7-df139d04eb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f9565bfd-6923-45ba-9835-bca09af3ccda" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ba49f97c-44f6-41fa-a5b7-df139d04eb19" xlink:to="loc_srt_MaximumMember_f9565bfd-6923-45ba-9835-bca09af3ccda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_950d58a6-a234-4bd9-a363-2ebb1aa385de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_dei_LegalEntityAxis_950d58a6-a234-4bd9-a363-2ebb1aa385de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6f1198b6-999d-4428-99c0-9f73f829db85" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_950d58a6-a234-4bd9-a363-2ebb1aa385de" xlink:to="loc_dei_EntityDomain_6f1198b6-999d-4428-99c0-9f73f829db85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MerckMember_5cf361df-e78f-4e23-aba6-68acda435665" xlink:href="gild-20221231.xsd#gild_MerckMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6f1198b6-999d-4428-99c0-9f73f829db85" xlink:to="loc_gild_MerckMember_5cf361df-e78f-4e23-aba6-68acda435665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_75689e7c-87df-4701-862b-cc0bdc2bca09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_75689e7c-87df-4701-862b-cc0bdc2bca09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8570bac9-c587-49a1-a0a3-8d3f37d4b013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_75689e7c-87df-4701-862b-cc0bdc2bca09" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8570bac9-c587-49a1-a0a3-8d3f37d4b013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_6b6451db-34ac-4446-a016-4a5dc5b237ac" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8570bac9-c587-49a1-a0a3-8d3f37d4b013" xlink:to="loc_gild_ImmunomedicsIncMember_6b6451db-34ac-4446-a016-4a5dc5b237ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f475d1d-6781-4dfc-8f0a-13e549d94cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f475d1d-6781-4dfc-8f0a-13e549d94cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09a9fab0-6163-4e64-9ffd-475779b3be99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f475d1d-6781-4dfc-8f0a-13e549d94cce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09a9fab0-6163-4e64-9ffd-475779b3be99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3563e001-885c-4c2b-94da-16d6b49d764b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_09a9fab0-6163-4e64-9ffd-475779b3be99" xlink:to="loc_us-gaap_LicensingAgreementsMember_3563e001-885c-4c2b-94da-16d6b49d764b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ecb885e0-9d99-4b29-ae39-9467f4e6f23c" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_d8781734-f57b-4b85-ba3c-b5e36a73d999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_d8781734-f57b-4b85-ba3c-b5e36a73d999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment_dc903cf5-cd7e-4c9d-a0ea-38fe6add55c7" xlink:href="gild-20221231.xsd#gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment_dc903cf5-cd7e-4c9d-a0ea-38fe6add55c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialFutureMilestonePaymentsMaximum_58f0fd74-2832-4f2d-aa36-c1d62007aa0d" xlink:href="gild-20221231.xsd#gild_PotentialFutureMilestonePaymentsMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PotentialFutureMilestonePaymentsMaximum_58f0fd74-2832-4f2d-aa36-c1d62007aa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_204fbf34-dab1-45b6-b5d8-1b55b514c3d4" xlink:href="gild-20221231.xsd#gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts_204fbf34-dab1-45b6-b5d8-1b55b514c3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementNetProductSalesThreshold_946b1e87-cfc0-489d-b785-d017ee3e4172" xlink:href="gild-20221231.xsd#gild_CollaborationArrangementNetProductSalesThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborationArrangementNetProductSalesThreshold_946b1e87-cfc0-489d-b785-d017ee3e4172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_78ad026e-02bb-4dfa-8f14-4adf527b9d16" xlink:href="gild-20221231.xsd#gild_CollaborationArrangementPercentOfGlobalProductRevenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborationArrangementPercentOfGlobalProductRevenues_78ad026e-02bb-4dfa-8f14-4adf527b9d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_07eacabe-89dd-4f87-8221-0c9931e401df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_07eacabe-89dd-4f87-8221-0c9931e401df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_310b3e79-9a1f-47a9-802f-f509d049e2bf" xlink:href="gild-20221231.xsd#gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod_310b3e79-9a1f-47a9-802f-f509d049e2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InvestmentOwnedBalanceAdditionalShares_c331ef45-b0d0-434a-a4d1-ea067f937bb2" xlink:href="gild-20221231.xsd#gild_InvestmentOwnedBalanceAdditionalShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_InvestmentOwnedBalanceAdditionalShares_c331ef45-b0d0-434a-a4d1-ea067f937bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_02e7d257-7ae3-4a57-a28e-25ff64a31497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_02e7d257-7ae3-4a57-a28e-25ff64a31497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TotalUpfrontPaymentsMade_00ed8a1f-30a4-4732-b17c-ffef9a169f70" xlink:href="gild-20221231.xsd#gild_TotalUpfrontPaymentsMade"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_TotalUpfrontPaymentsMade_00ed8a1f-30a4-4732-b17c-ffef9a169f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_bb44abcc-1966-44e7-b347-d8da7f795963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_bb44abcc-1966-44e7-b347-d8da7f795963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c098e565-7540-49d5-b512-876795a09d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c098e565-7540-49d5-b512-876795a09d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_IssuanceDiscountPremium_e9236bc1-3146-4247-95f2-a5365400ed75" xlink:href="gild-20221231.xsd#gild_IssuanceDiscountPremium"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_IssuanceDiscountPremium_e9236bc1-3146-4247-95f2-a5365400ed75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForDirectTransactionalExpense_5e0131ff-da7d-47b0-8c61-a219c3700de5" xlink:href="gild-20221231.xsd#gild_PaymentsForDirectTransactionalExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PaymentsForDirectTransactionalExpense_5e0131ff-da7d-47b0-8c61-a219c3700de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_2a97e9b7-6042-4583-8b52-102042714e27" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased_2a97e9b7-6042-4583-8b52-102042714e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIPurchasePeriod_4554ef25-749d-4986-8828-91931c06b237" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIPurchasePeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNIPurchasePeriod_4554ef25-749d-4986-8828-91931c06b237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_a5db2fab-798a-46a6-a763-0768fa06a242" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIRestrictionPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNIRestrictionPeriod_a5db2fab-798a-46a6-a763-0768fa06a242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_0474356c-4128-47f1-8021-45e532cf7c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_0474356c-4128-47f1-8021-45e532cf7c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNISharesAcquired_ff66888d-508f-4d30-b0c6-960af66e7193" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNISharesAcquired"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNISharesAcquired_ff66888d-508f-4d30-b0c6-960af66e7193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIShares_0ddc4546-af32-479e-aac9-128c4c7281d1" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIShares"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNIShares_0ddc4546-af32-479e-aac9-128c4c7281d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5a841fe1-c23a-48ad-858d-64a379129e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_5a841fe1-c23a-48ad-858d-64a379129e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementOptInTerm_2aa2fcf9-e413-4206-bc3d-7063a1d86702" xlink:href="gild-20221231.xsd#gild_CollaborativeAgreementOptInTerm"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborativeAgreementOptInTerm_2aa2fcf9-e413-4206-bc3d-7063a1d86702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions_19c51fe0-88ef-4d5b-bce5-c5f0e9e17298" xlink:href="gild-20221231.xsd#gild_NumberOfClinicalStageProgramsWithExercisedOptions"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_NumberOfClinicalStageProgramsWithExercisedOptions_19c51fe0-88ef-4d5b-bce5-c5f0e9e17298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToOptInTheCollaborativeAgreement_a00d10a7-f1bb-43dd-9d4e-9a71ea800256" xlink:href="gild-20221231.xsd#gild_PaymentsToOptInTheCollaborativeAgreement"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PaymentsToOptInTheCollaborativeAgreement_a00d10a7-f1bb-43dd-9d4e-9a71ea800256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_d481a160-326c-492c-a86b-c8b974a7d019" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries_d481a160-326c-492c-a86b-c8b974a7d019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ef03f52d-678d-41dd-8f6e-14ed2b5db646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ef03f52d-678d-41dd-8f6e-14ed2b5db646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e15fb96f-6cf1-4989-82e0-11d7c1257c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e15fb96f-6cf1-4989-82e0-11d7c1257c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_4775a422-fa8a-41ff-8fed-8195ff4e79f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_4775a422-fa8a-41ff-8fed-8195ff4e79f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_93e5bc97-929a-4b8e-9da8-de5ad280e3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_EquityMethodInvestments_93e5bc97-929a-4b8e-9da8-de5ad280e3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_fb00050d-a7a7-4a9c-9c77-cae622f23927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_fb00050d-a7a7-4a9c-9c77-cae622f23927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionExerciseFee_9d7d7a6b-f998-47af-8191-b10cdf8a363b" xlink:href="gild-20221231.xsd#gild_EquityMethodInvestmentOptionExerciseFee"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquityMethodInvestmentOptionExerciseFee_9d7d7a6b-f998-47af-8191-b10cdf8a363b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ResearchAndDevelopmentFutureMaximumPayments_0a1d1482-1c65-4d84-8eeb-2ed7ff2df85e" xlink:href="gild-20221231.xsd#gild_ResearchAndDevelopmentFutureMaximumPayments"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_ResearchAndDevelopmentFutureMaximumPayments_0a1d1482-1c65-4d84-8eeb-2ed7ff2df85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdditionalResearchAndDevelopmentInProcess_66d0a88c-d5b6-45b3-862a-32133783408b" xlink:href="gild-20221231.xsd#gild_AdditionalResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_AdditionalResearchAndDevelopmentInProcess_66d0a88c-d5b6-45b3-862a-32133783408b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_d6a6ef4e-e922-4619-b411-67c37e0dd952" xlink:href="gild-20221231.xsd#gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments_d6a6ef4e-e922-4619-b411-67c37e0dd952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_e48321e6-f623-4c4d-9f12-465f3c7cde14" xlink:href="gild-20221231.xsd#gild_CashPaymentsMadeRelatedToEquityInvestments"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CashPaymentsMadeRelatedToEquityInvestments_e48321e6-f623-4c4d-9f12-465f3c7cde14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_NumberOfPrograms_e4fbaf7f-2ff0-439f-9e86-a196429b4b62" xlink:href="gild-20221231.xsd#gild_NumberOfPrograms"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_NumberOfPrograms_e4fbaf7f-2ff0-439f-9e86-a196429b4b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeArrangementTerm_4ae5ee93-dd81-477f-afcd-6772f733f68c" xlink:href="gild-20221231.xsd#gild_CollaborativeArrangementTerm"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborativeArrangementTerm_4ae5ee93-dd81-477f-afcd-6772f733f68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_9f8b2596-afeb-4a4e-8e7c-936112347da7" xlink:href="gild-20221231.xsd#gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments_9f8b2596-afeb-4a4e-8e7c-936112347da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_a50afe01-8aba-4cec-b770-bb67f2014179" xlink:href="gild-20221231.xsd#gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts_a50afe01-8aba-4cec-b770-bb67f2014179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_ce4446e2-ca45-4be3-ac4a-f2bfd55167f6" xlink:href="gild-20221231.xsd#gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts_ce4446e2-ca45-4be3-ac4a-f2bfd55167f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_d5090eab-935a-42e2-8daf-c418f91f3142" xlink:href="gild-20221231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPayments"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments_d5090eab-935a-42e2-8daf-c418f91f3142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_b02d36a0-bd92-496b-9054-0a45b4b76132" xlink:href="gild-20221231.xsd#gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths_b02d36a0-bd92-496b-9054-0a45b4b76132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement_74e93f83-3e14-4e8f-940e-70f9263831ed" xlink:href="gild-20221231.xsd#gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement_74e93f83-3e14-4e8f-940e-70f9263831ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_StandstillRestrictingTerm_d7b3f6b7-beb5-480f-96b9-ba5e5bf1f4f7" xlink:href="gild-20221231.xsd#gild_StandstillRestrictingTerm"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_StandstillRestrictingTerm_d7b3f6b7-beb5-480f-96b9-ba5e5bf1f4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_30c08a96-2867-4c8f-9b81-064eb1f3add9" xlink:href="gild-20221231.xsd#gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement_30c08a96-2867-4c8f-9b81-064eb1f3add9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialOptionExerciseFeePerProgram_757d89ee-9257-46e8-8496-30f088423299" xlink:href="gild-20221231.xsd#gild_PotentialOptionExerciseFeePerProgram"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PotentialOptionExerciseFeePerProgram_757d89ee-9257-46e8-8496-30f088423299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_cfae79a0-4c1e-49cc-8542-297a75da8216" xlink:href="gild-20221231.xsd#gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage_cfae79a0-4c1e-49cc-8542-297a75da8216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_002b7fba-1f13-41dd-82a7-1e9b4455a02e" xlink:href="gild-20221231.xsd#gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage_002b7fba-1f13-41dd-82a7-1e9b4455a02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage_75682106-cf43-4310-b9f0-8d4963ef98dd" xlink:href="gild-20221231.xsd#gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage_75682106-cf43-4310-b9f0-8d4963ef98dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_66ced04e-97ac-4d2a-9c27-2ea48e6e11ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_66ced04e-97ac-4d2a-9c27-2ea48e6e11ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_b2a85f8d-69ed-4f08-80bf-2b3638a10971" xlink:href="gild-20221231.xsd#gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination_b2a85f8d-69ed-4f08-80bf-2b3638a10971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_1aa96cf0-b18d-4e6e-8a44-dbf1c71993ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_RoyaltyExpense_1aa96cf0-b18d-4e6e-8a44-dbf1c71993ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan_548e3b91-3699-483d-91fc-859cf0dabcca" xlink:href="gild-20221231.xsd#gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan_548e3b91-3699-483d-91fc-859cf0dabcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_c30bec8c-9839-4f75-9aec-e39f34041d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_c30bec8c-9839-4f75-9aec-e39f34041d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_69024f05-bf43-4ab4-8397-e5feaa60982c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="56" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_69024f05-bf43-4ab4-8397-e5feaa60982c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_82b88c9f-73d5-446a-817b-865be80dbbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="57" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_82b88c9f-73d5-446a-817b-865be80dbbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpfrontPaymentsToTerminatePreviousAgreement_5ee52ec4-8912-4046-91df-5edfeb7f16c6" xlink:href="gild-20221231.xsd#gild_UpfrontPaymentsToTerminatePreviousAgreement"/>
    <link:presentationArc order="58" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_UpfrontPaymentsToTerminatePreviousAgreement_5ee52ec4-8912-4046-91df-5edfeb7f16c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsToTerminatePreviousAgreement_35f09bf4-11d6-4e0c-b1e6-0ae123260644" xlink:href="gild-20221231.xsd#gild_PaymentsToTerminatePreviousAgreement"/>
    <link:presentationArc order="59" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_PaymentsToTerminatePreviousAgreement_35f09bf4-11d6-4e0c-b1e6-0ae123260644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b398ff6c-8e37-4749-8a33-e6bb5908db1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b398ff6c-8e37-4749-8a33-e6bb5908db1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant_d65cc0bc-e76b-48ed-81bc-f86ce212564c" xlink:href="gild-20221231.xsd#gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant"/>
    <link:presentationArc order="61" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_dbe88e14-74fa-470f-825f-c1eaa2e18308" xlink:to="loc_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant_d65cc0bc-e76b-48ed-81bc-f86ce212564c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c6728b5b-5fd7-4ffa-ad1b-34dc77af3410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cd57681f-d923-43e0-81fb-50448b8e3338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c6728b5b-5fd7-4ffa-ad1b-34dc77af3410" xlink:to="loc_us-gaap_DebtInstrumentTable_cd57681f-d923-43e0-81fb-50448b8e3338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f80b30ab-4b2d-4580-93cd-9c1c80db1520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cd57681f-d923-43e0-81fb-50448b8e3338" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f80b30ab-4b2d-4580-93cd-9c1c80db1520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1ca2423-7a86-496d-9573-e87b7546e721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f80b30ab-4b2d-4580-93cd-9c1c80db1520" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1ca2423-7a86-496d-9573-e87b7546e721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_9700999d-acde-4333-b555-9a6d42677c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1ca2423-7a86-496d-9573-e87b7546e721" xlink:to="loc_us-gaap_SeniorNotesMember_9700999d-acde-4333-b555-9a6d42677c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorNotesAndMediumTermNotesMember_0d37509f-1ba2-4a95-8760-79941a6786a6" xlink:href="gild-20221231.xsd#gild_SeniorNotesAndMediumTermNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1ca2423-7a86-496d-9573-e87b7546e721" xlink:to="loc_gild_SeniorNotesAndMediumTermNotesMember_0d37509f-1ba2-4a95-8760-79941a6786a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_edf4c165-6f71-4fb7-81ca-a2e3c2370c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1ca2423-7a86-496d-9573-e87b7546e721" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_edf4c165-6f71-4fb7-81ca-a2e3c2370c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_43743ede-b713-4492-a170-079de29e6b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cd57681f-d923-43e0-81fb-50448b8e3338" xlink:to="loc_us-gaap_DebtInstrumentAxis_43743ede-b713-4492-a170-079de29e6b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_43743ede-b713-4492-a170-079de29e6b09" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_2af55799-03cf-4594-aa29-586abc0d98da" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2022Member_2af55799-03cf-4594-aa29-586abc0d98da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member_9d9e58f3-1032-4601-a9d2-111f8731f758" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2022Member_9d9e58f3-1032-4601-a9d2-111f8731f758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member_39ceeefb-82e3-4b80-82ad-cf431540d74a" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2023Member_39ceeefb-82e3-4b80-82ad-cf431540d74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_6bff6c0d-e27d-4e90-8b93-531cacca643e" xlink:href="gild-20221231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_6bff6c0d-e27d-4e90-8b93-531cacca643e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2024Member_a30327a8-9774-4e78-b8e3-3c33943b001b" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinApril2024Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinApril2024Member_a30327a8-9774-4e78-b8e3-3c33943b001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member_1e08e50e-e833-45ce-a089-c700c2c5f806" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2025Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinFebruary2025Member_1e08e50e-e833-45ce-a089-c700c2c5f806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member_b4fe1e14-30f8-4cba-8447-7a30bf7384e9" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2026Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2026Member_b4fe1e14-30f8-4cba-8447-7a30bf7384e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member_613d345f-5312-4acb-93ba-bca5e910d1c6" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2027Member_613d345f-5312-4acb-93ba-bca5e910d1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_787ced2d-2dba-458e-94ca-29545fcc5260" xlink:href="gild-20221231.xsd#gild_A120SeniorUnsecuredNotesDueOctober2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_A120SeniorUnsecuredNotesDueOctober2027Member_787ced2d-2dba-458e-94ca-29545fcc5260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_ffa61eda-7c95-41d3-bc7b-dd7506953a4b" xlink:href="gild-20221231.xsd#gild_A165SeniorUnsecuredNotesDueOctober2030Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_A165SeniorUnsecuredNotesDueOctober2030Member_ffa61eda-7c95-41d3-bc7b-dd7506953a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member_3d27ea69-d855-4610-960a-0b279fe2d2c5" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2035Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2035Member_3d27ea69-d855-4610-960a-0b279fe2d2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member_e4512992-f1d5-4ddf-b905-89a68c032e35" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinSeptember2036Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinSeptember2036Member_e4512992-f1d5-4ddf-b905-89a68c032e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_b58bdf3d-c764-4f98-a4e9-bb0308323e50" xlink:href="gild-20221231.xsd#gild_A260SeniorUnsecuredNotesDueOctober2040Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_A260SeniorUnsecuredNotesDueOctober2040Member_b58bdf3d-c764-4f98-a4e9-bb0308323e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueDecember2041Member_576228c2-179f-4ce5-b8f0-59019f96a817" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueDecember2041Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueDecember2041Member_576228c2-179f-4ce5-b8f0-59019f96a817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinApril2044Member_ddd14091-a4ab-4e62-8079-26af295f92ca" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinApril2044Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinApril2044Member_ddd14091-a4ab-4e62-8079-26af295f92ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member_6ab849f2-5262-41f6-b037-7911e2e167b0" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinFebruary2045Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinFebruary2045Member_6ab849f2-5262-41f6-b037-7911e2e167b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member_e682822e-8b08-4a8c-851d-2f88286e9639" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2046Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2046Member_e682822e-8b08-4a8c-851d-2f88286e9639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member_9f665045-9859-43b4-8f54-dad2342dd199" xlink:href="gild-20221231.xsd#gild_SeniorUnsecuredNotesDueinMarch2047Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_SeniorUnsecuredNotesDueinMarch2047Member_9f665045-9859-43b4-8f54-dad2342dd199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_b8aa5d28-2e5f-465c-95db-ddf3181ecdf8" xlink:href="gild-20221231.xsd#gild_A280SeniorUnsecuredNotesDueOctober2050Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa9b4db3-ae71-4745-984f-eff151de1daa" xlink:to="loc_gild_A280SeniorUnsecuredNotesDueOctober2050Member_b8aa5d28-2e5f-465c-95db-ddf3181ecdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cd57681f-d923-43e0-81fb-50448b8e3338" xlink:to="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_61c85e88-8641-4f9c-bc91-9185a7e1c2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_61c85e88-8641-4f9c-bc91-9185a7e1c2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_960d5fb8-ad96-43bb-87e9-4c5e93e93542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:to="loc_us-gaap_LongTermDebt_960d5fb8-ad96-43bb-87e9-4c5e93e93542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c1dfab00-d4bf-45fc-b049-5b2806ba129f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c1dfab00-d4bf-45fc-b049-5b2806ba129f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9f4dbb76-dfe1-4e1c-b587-aa69a4469beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:to="loc_us-gaap_LongTermDebtCurrent_9f4dbb76-dfe1-4e1c-b587-aa69a4469beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5d22469e-8480-4974-b6a9-bcc36857fa7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_89da3f6e-fdfd-4969-b5b9-0d669ea1b7a4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5d22469e-8480-4974-b6a9-bcc36857fa7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DebtandCreditFacilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d1b6bd0b-7518-4a61-af1d-9fdf24dcd310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d1b6bd0b-7518-4a61-af1d-9fdf24dcd310" xlink:to="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a4d717ef-9ac2-48a9-9da9-c9831f1168bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_us-gaap_DebtInstrumentAxis_a4d717ef-9ac2-48a9-9da9-c9831f1168bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a4d717ef-9ac2-48a9-9da9-c9831f1168bc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_bdda4405-dc7d-4ba5-b47c-eefbe2bc514a" xlink:href="gild-20221231.xsd#gild_A075SeniorUnsecuredNotesDueInSeptember2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:to="loc_gild_A075SeniorUnsecuredNotesDueInSeptember2023Member_bdda4405-dc7d-4ba5-b47c-eefbe2bc514a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_CreditFacilityDueJune2025Member_214f39be-1c9f-4053-ba42-65be7bde00ff" xlink:href="gild-20221231.xsd#gild_CreditFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:to="loc_gild_CreditFacilityDueJune2025Member_214f39be-1c9f-4053-ba42-65be7bde00ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_7e46c67c-44fc-434c-8a04-971071c76c47" xlink:href="gild-20221231.xsd#gild_A195SeniorUnsecuredNotesDueMarch2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:to="loc_gild_A195SeniorUnsecuredNotesDueMarch2022Member_7e46c67c-44fc-434c-8a04-971071c76c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_8ef2ac71-731d-4d14-bf76-611b2a1bf996" xlink:href="gild-20221231.xsd#gild_A325SeniorUnsecuredNotesDueSeptember2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:to="loc_gild_A325SeniorUnsecuredNotesDueSeptember2022Member_8ef2ac71-731d-4d14-bf76-611b2a1bf996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_5c7a7319-06fd-4b6c-84cd-53fa30271f17" xlink:href="gild-20221231.xsd#gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4134a632-fec3-4df2-962b-b4090967860b" xlink:to="loc_gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member_5c7a7319-06fd-4b6c-84cd-53fa30271f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_0910ac79-40a6-4abc-903e-f0d921b8e482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_0910ac79-40a6-4abc-903e-f0d921b8e482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d457a591-3a11-46ea-914f-7822e806a528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_0910ac79-40a6-4abc-903e-f0d921b8e482" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d457a591-3a11-46ea-914f-7822e806a528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_17bce074-c919-4fe4-894b-ab5caca8cf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d457a591-3a11-46ea-914f-7822e806a528" xlink:to="loc_us-gaap_SeniorNotesMember_17bce074-c919-4fe4-894b-ab5caca8cf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_309b6152-1b60-4743-9f38-f3fef0824598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d457a591-3a11-46ea-914f-7822e806a528" xlink:to="loc_us-gaap_LineOfCreditMember_309b6152-1b60-4743-9f38-f3fef0824598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_55def4cb-9fb0-4caa-84f0-a815080c5b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_us-gaap_CreditFacilityAxis_55def4cb-9fb0-4caa-84f0-a815080c5b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_935cdbfe-6bf8-482b-83a5-e73e22e19f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_55def4cb-9fb0-4caa-84f0-a815080c5b81" xlink:to="loc_us-gaap_CreditFacilityDomain_935cdbfe-6bf8-482b-83a5-e73e22e19f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_5826914b-3e33-4283-adf1-802dee029628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_935cdbfe-6bf8-482b-83a5-e73e22e19f80" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_5826914b-3e33-4283-adf1-802dee029628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_700de1da-c47a-462e-879c-24b889e4ccaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_srt_RangeAxis_700de1da-c47a-462e-879c-24b889e4ccaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0490819-9443-4029-b29a-43596e9f3ebf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_700de1da-c47a-462e-879c-24b889e4ccaa" xlink:to="loc_srt_RangeMember_c0490819-9443-4029-b29a-43596e9f3ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6f408e22-26dd-4968-9c5f-c8942ea8ad49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c0490819-9443-4029-b29a-43596e9f3ebf" xlink:to="loc_srt_MaximumMember_6f408e22-26dd-4968-9c5f-c8942ea8ad49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0418666f-401d-4f2e-baa9-6f19ce706a11" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c0490819-9443-4029-b29a-43596e9f3ebf" xlink:to="loc_srt_MinimumMember_0418666f-401d-4f2e-baa9-6f19ce706a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_11ea3f35-bf55-4e53-af6f-1a28064c2be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_11ea3f35-bf55-4e53-af6f-1a28064c2be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d51ea115-2123-4ab4-b4b4-03b47ece6228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11ea3f35-bf55-4e53-af6f-1a28064c2be8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d51ea115-2123-4ab4-b4b4-03b47ece6228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_39d6ac50-0239-4857-a55f-05d881d2d06e" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d51ea115-2123-4ab4-b4b4-03b47ece6228" xlink:to="loc_gild_ImmunomedicsIncMember_39d6ac50-0239-4857-a55f-05d881d2d06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_3aacfdda-72dc-4260-8895-1aea257a6483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_3aacfdda-72dc-4260-8895-1aea257a6483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_068d51c7-32bf-41ff-8fc0-eda57997523c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_3aacfdda-72dc-4260-8895-1aea257a6483" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_068d51c7-32bf-41ff-8fc0-eda57997523c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_619fd35d-73fd-4a51-9517-c31c98582e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_068d51c7-32bf-41ff-8fc0-eda57997523c" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_619fd35d-73fd-4a51-9517-c31c98582e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a92371d6-6962-43f7-b7a5-865b9caeab31" xlink:to="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_e6b2a488-1414-430b-ae1f-93cd3788c610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_RepaymentsOfDebt_e6b2a488-1414-430b-ae1f-93cd3788c610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_82a7fbd3-5742-44cd-9f28-1bbe6d65bb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_82a7fbd3-5742-44cd-9f28-1bbe6d65bb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_66437ecd-d9c0-43a9-ac44-be0375dc342a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_66437ecd-d9c0-43a9-ac44-be0375dc342a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_b723e37d-ba01-48f0-892f-efefc003dd65" xlink:href="gild-20221231.xsd#gild_DebtInstrumentCallFeaturePeriodBeforeMaturity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity_b723e37d-ba01-48f0-892f-efefc003dd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f0fdee9b-99ed-4593-8d0a-c44a1774bcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_LongTermDebt_f0fdee9b-99ed-4593-8d0a-c44a1774bcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a7e7c334-0aaa-4e36-a911-4fdc6e766a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a7e7c334-0aaa-4e36-a911-4fdc6e766a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_62316117-ba7c-4e45-88ed-42f2a9c73291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_62316117-ba7c-4e45-88ed-42f2a9c73291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_7a8a865c-e748-4af9-a90b-6a4483db89aa" xlink:href="gild-20221231.xsd#gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput_7a8a865c-e748-4af9-a90b-6a4483db89aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ab2a89d0-2f77-4435-931c-2f24cee654b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ab2a89d0-2f77-4435-931c-2f24cee654b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_da53764c-3495-452c-a0cf-9a11abec6659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_DebtInstrumentTerm_da53764c-3495-452c-a0cf-9a11abec6659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_c4fad347-da55-484c-b4ce-35bacb9ddc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_LineOfCredit_c4fad347-da55-484c-b4ce-35bacb9ddc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseLongTermDebt_580b866e-c601-4ff6-870b-d6b5db3d5762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseLongTermDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_69210e84-cc9e-426f-830e-e8d5247a8ecd" xlink:to="loc_us-gaap_InterestExpenseLongTermDebt_580b866e-c601-4ff6-870b-d6b5db3d5762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f74eabfe-1548-4e1d-88a3-2af48b6cb894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0de272a1-c84a-47a0-866f-054f2d261ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f74eabfe-1548-4e1d-88a3-2af48b6cb894" xlink:to="loc_us-gaap_DebtInstrumentTable_0de272a1-c84a-47a0-866f-054f2d261ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3d90fc1b-f612-4a4c-8546-b5b0325b3992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0de272a1-c84a-47a0-866f-054f2d261ffa" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3d90fc1b-f612-4a4c-8546-b5b0325b3992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9ef77f45-6ddd-4b02-922b-105ef1a291be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3d90fc1b-f612-4a4c-8546-b5b0325b3992" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9ef77f45-6ddd-4b02-922b-105ef1a291be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5be2703b-7e19-411c-bcd9-b5ec7bde19b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9ef77f45-6ddd-4b02-922b-105ef1a291be" xlink:to="loc_us-gaap_SeniorNotesMember_5be2703b-7e19-411c-bcd9-b5ec7bde19b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0de272a1-c84a-47a0-866f-054f2d261ffa" xlink:to="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8e75fec8-d354-49c3-985d-ef5a74c058b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8e75fec8-d354-49c3-985d-ef5a74c058b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9e2d146c-60c4-46ba-be78-509ebc545ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9e2d146c-60c4-46ba-be78-509ebc545ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f6cc88c-93b5-4ec4-a43d-ce52ae3d5d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f6cc88c-93b5-4ec4-a43d-ce52ae3d5d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4a0431e2-4bb8-4d40-9cdd-c8ed9d76cb56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4a0431e2-4bb8-4d40-9cdd-c8ed9d76cb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_382892a1-1b24-458d-88ac-c9ad429ac07b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_382892a1-1b24-458d-88ac-c9ad429ac07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2a42877f-065f-44eb-8272-d7052c863ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2a42877f-065f-44eb-8272-d7052c863ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_58331615-313b-44bc-a0a7-0315be7b0d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d08d61-7822-4f91-ab2e-abc436502056" xlink:to="loc_us-gaap_LongTermDebt_58331615-313b-44bc-a0a7-0315be7b0d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e959cfdf-3df4-4634-8fb9-82e50ca094b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_210c683d-dce8-413e-896c-5f73256e551f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e959cfdf-3df4-4634-8fb9-82e50ca094b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_210c683d-dce8-413e-896c-5f73256e551f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_58d0a85e-7587-4818-87f0-585a05731ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e959cfdf-3df4-4634-8fb9-82e50ca094b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_58d0a85e-7587-4818-87f0-585a05731ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_a19e545d-ed2d-4f6a-af8e-6d0aada5e236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e959cfdf-3df4-4634-8fb9-82e50ca094b5" xlink:to="loc_us-gaap_OperatingLeaseExpense_a19e545d-ed2d-4f6a-af8e-6d0aada5e236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#LeasesBalanceSheetLocationandOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6039aff3-3f4b-4c0c-988e-defdfd0fdf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5cdb89a7-0f5a-4299-be8c-0d00cd87266f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6039aff3-3f4b-4c0c-988e-defdfd0fdf8b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5cdb89a7-0f5a-4299-be8c-0d00cd87266f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_55f88516-85cf-4cee-8018-aa71143ee811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6039aff3-3f4b-4c0c-988e-defdfd0fdf8b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_55f88516-85cf-4cee-8018-aa71143ee811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_96edd99a-1ef0-4ebb-a9cd-a032499b8468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6039aff3-3f4b-4c0c-988e-defdfd0fdf8b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_96edd99a-1ef0-4ebb-a9cd-a032499b8468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_775dcf6f-7c82-413e-9682-470da7d56be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6039aff3-3f4b-4c0c-988e-defdfd0fdf8b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_775dcf6f-7c82-413e-9682-470da7d56be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_97acf304-4bb8-4c6b-82ee-efad6dacfa90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6039aff3-3f4b-4c0c-988e-defdfd0fdf8b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_97acf304-4bb8-4c6b-82ee-efad6dacfa90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_0cc46bd6-7663-48b6-87cc-2b5217ec666f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6039aff3-3f4b-4c0c-988e-defdfd0fdf8b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_0cc46bd6-7663-48b6-87cc-2b5217ec666f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_4061d3f5-7517-48c1-9f64-6d223582848d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6039aff3-3f4b-4c0c-988e-defdfd0fdf8b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_4061d3f5-7517-48c1-9f64-6d223582848d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_7cafa6ed-f057-445c-9bc4-4c9848fba8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6039aff3-3f4b-4c0c-988e-defdfd0fdf8b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_7cafa6ed-f057-445c-9bc4-4c9848fba8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#LeasesSupplementalInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e6e94a4a-adb2-42dc-810e-d9ecc6c20192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9e3e4f46-9f3d-4dc6-811c-133e83f4363a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e6e94a4a-adb2-42dc-810e-d9ecc6c20192" xlink:to="loc_us-gaap_OperatingLeasePayments_9e3e4f46-9f3d-4dc6-811c-133e83f4363a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_724694ac-8869-47b6-b8d6-6f8b63c08c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e6e94a4a-adb2-42dc-810e-d9ecc6c20192" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_724694ac-8869-47b6-b8d6-6f8b63c08c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_74f865bb-dc6e-4ff9-916d-268e8e4270ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ed748bdf-74af-4e72-9c3a-ed7c5e68f5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_74f865bb-dc6e-4ff9-916d-268e8e4270ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ed748bdf-74af-4e72-9c3a-ed7c5e68f5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_207c602e-bdaa-4557-af56-ecde47fd94b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_74f865bb-dc6e-4ff9-916d-268e8e4270ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_207c602e-bdaa-4557-af56-ecde47fd94b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e0362d5a-e065-4a8d-b35c-ce7012dc1f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_74f865bb-dc6e-4ff9-916d-268e8e4270ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e0362d5a-e065-4a8d-b35c-ce7012dc1f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9f28e15d-872f-459e-886d-8f79e7f001b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_74f865bb-dc6e-4ff9-916d-268e8e4270ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9f28e15d-872f-459e-886d-8f79e7f001b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bcebaf72-d8ea-4edd-aa67-d33d64397ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_74f865bb-dc6e-4ff9-916d-268e8e4270ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bcebaf72-d8ea-4edd-aa67-d33d64397ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a6cedf3f-910d-4d36-b03a-8b1916bf2c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_74f865bb-dc6e-4ff9-916d-268e8e4270ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a6cedf3f-910d-4d36-b03a-8b1916bf2c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_965e62cc-ad19-45e9-8c01-90863d77e3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_74f865bb-dc6e-4ff9-916d-268e8e4270ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_965e62cc-ad19-45e9-8c01-90863d77e3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fe1b4ea7-b491-4402-9adb-d141e524118e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_74f865bb-dc6e-4ff9-916d-268e8e4270ae" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fe1b4ea7-b491-4402-9adb-d141e524118e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4bf2a913-ab23-4f59-9195-ead44c464f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_74f865bb-dc6e-4ff9-916d-268e8e4270ae" xlink:to="loc_us-gaap_OperatingLeaseLiability_4bf2a913-ab23-4f59-9195-ead44c464f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" xlink:type="simple" xlink:href="gild-20221231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72b9e1f8-9ec5-46e5-9e1e-f9f85c27aadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_2f7eafdb-e4bd-4590-b854-5f64d2941650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72b9e1f8-9ec5-46e5-9e1e-f9f85c27aadd" xlink:to="loc_us-gaap_OtherCommitmentsTable_2f7eafdb-e4bd-4590-b854-5f64d2941650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a42672f4-baf2-42d6-8e51-12dfe2b81e87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2f7eafdb-e4bd-4590-b854-5f64d2941650" xlink:to="loc_srt_LitigationCaseAxis_a42672f4-baf2-42d6-8e51-12dfe2b81e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ec4fb49f-a885-4320-9294-edbf4a2d074d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a42672f4-baf2-42d6-8e51-12dfe2b81e87" xlink:to="loc_srt_LitigationCaseTypeDomain_ec4fb49f-a885-4320-9294-edbf4a2d074d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_6e4d472f-7fe6-4911-b1f4-3e90baa17b85" xlink:href="gild-20221231.xsd#gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ec4fb49f-a885-4320-9294-edbf4a2d074d" xlink:to="loc_gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember_6e4d472f-7fe6-4911-b1f4-3e90baa17b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PreExposureProphylaxisMember_c6d59990-a358-44ea-972b-4e9ac3154a82" xlink:href="gild-20221231.xsd#gild_PreExposureProphylaxisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ec4fb49f-a885-4320-9294-edbf4a2d074d" xlink:to="loc_gild_PreExposureProphylaxisMember_c6d59990-a358-44ea-972b-4e9ac3154a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_EuropeanPatentClaims2032ExpirationMember_8366b009-d5b0-483c-8ceb-4b2c2a7e40c9" xlink:href="gild-20221231.xsd#gild_EuropeanPatentClaims2032ExpirationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ec4fb49f-a885-4320-9294-edbf4a2d074d" xlink:to="loc_gild_EuropeanPatentClaims2032ExpirationMember_8366b009-d5b0-483c-8ceb-4b2c2a7e40c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ProductLiabilityMember_a33c8592-cd18-49ca-9b9e-803e08f23df8" xlink:href="gild-20221231.xsd#gild_ProductLiabilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ec4fb49f-a885-4320-9294-edbf4a2d074d" xlink:to="loc_gild_ProductLiabilityMember_a33c8592-cd18-49ca-9b9e-803e08f23df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2f7eafdb-e4bd-4590-b854-5f64d2941650" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_fdb4875b-5f48-42d9-b920-b0419b928ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_LitigationReserve_fdb4875b-5f48-42d9-b920-b0419b928ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_e6e84d59-6945-4f1c-8fa6-d5d03f3d3fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_e6e84d59-6945-4f1c-8fa6-d5d03f3d3fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_8a7a10ca-27a2-47b7-97bb-1dc0c4a86649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_8a7a10ca-27a2-47b7-97bb-1dc0c4a86649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateFromOctober2017_f88d05bb-e93e-4bdd-9d77-6bcbfde78300" xlink:href="gild-20221231.xsd#gild_JudgmentRoyaltyRateFromOctober2017"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_JudgmentRoyaltyRateFromOctober2017_f88d05bb-e93e-4bdd-9d77-6bcbfde78300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentEnhancedDamagesOnPastSales_e33cc88d-cf5a-4697-97df-064646fdf166" xlink:href="gild-20221231.xsd#gild_JudgmentEnhancedDamagesOnPastSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_JudgmentEnhancedDamagesOnPastSales_e33cc88d-cf5a-4697-97df-064646fdf166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_JudgmentRoyaltyRateOnFutureSales_027c4992-fcbb-4066-9383-8bf4fefde671" xlink:href="gild-20221231.xsd#gild_JudgmentRoyaltyRateOnFutureSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_JudgmentRoyaltyRateOnFutureSales_027c4992-fcbb-4066-9383-8bf4fefde671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyMaterialTransferAgreementsNumber_1aac6863-6f85-4d0e-84aa-746a634d29f2" xlink:href="gild-20221231.xsd#gild_LossContingencyMaterialTransferAgreementsNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_LossContingencyMaterialTransferAgreementsNumber_1aac6863-6f85-4d0e-84aa-746a634d29f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_75c16f2c-69ad-4fe6-ae86-7f1c4238160d" xlink:href="gild-20221231.xsd#gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber_75c16f2c-69ad-4fe6-ae86-7f1c4238160d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_b018b190-905f-4201-a7f3-1eabfdbafe67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_b018b190-905f-4201-a7f3-1eabfdbafe67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyNumberOfPatents_a925e9c0-c427-43cd-ba25-a21050ab0020" xlink:href="gild-20221231.xsd#gild_LossContingencyNumberOfPatents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_LossContingencyNumberOfPatents_a925e9c0-c427-43cd-ba25-a21050ab0020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_LossContingencyPartiesAppealedNumber_73dba3e2-f22e-481d-9de8-8c633e303383" xlink:href="gild-20221231.xsd#gild_LossContingencyPartiesAppealedNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_gild_LossContingencyPartiesAppealedNumber_73dba3e2-f22e-481d-9de8-8c633e303383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_ed1024a5-39e9-49c7-9921-d5899e4ed258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_ed1024a5-39e9-49c7-9921-d5899e4ed258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_cfc3c207-7c05-44b1-ab9e-e9a21c4b7985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_5b879971-cd88-40b8-aa9a-7a021d370f42" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_cfc3c207-7c05-44b1-ab9e-e9a21c4b7985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#StockholdersEquityRepurchasesofCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_07ebb235-8fa2-42dd-ae81-90112656c317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bbc26c90-77e3-4733-b455-7c72083c8408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_07ebb235-8fa2-42dd-ae81-90112656c317" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bbc26c90-77e3-4733-b455-7c72083c8408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_51058a7c-fe25-44b6-b5c9-2af3247e2868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bbc26c90-77e3-4733-b455-7c72083c8408" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_51058a7c-fe25-44b6-b5c9-2af3247e2868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_8c269fba-e11b-4d01-ad16-4babca2e018a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_51058a7c-fe25-44b6-b5c9-2af3247e2868" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_8c269fba-e11b-4d01-ad16-4babca2e018a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2020StockRepurchaseProgramMember_922184a1-2320-40b2-927f-1330996df2c9" xlink:href="gild-20221231.xsd#gild_A2020StockRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8c269fba-e11b-4d01-ad16-4babca2e018a" xlink:to="loc_gild_A2020StockRepurchaseProgramMember_922184a1-2320-40b2-927f-1330996df2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_A2016StockRepurchaseProgramMember_b35539de-e7ad-4b1a-8326-5b7e76150e1a" xlink:href="gild-20221231.xsd#gild_A2016StockRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8c269fba-e11b-4d01-ad16-4babca2e018a" xlink:to="loc_gild_A2016StockRepurchaseProgramMember_b35539de-e7ad-4b1a-8326-5b7e76150e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bbc26c90-77e3-4733-b455-7c72083c8408" xlink:to="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7df81a4d-9a45-431d-aa3d-76ea43607f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7df81a4d-9a45-431d-aa3d-76ea43607f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_319c6d4e-bde7-4b17-a4a5-3ee865bd7951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_319c6d4e-bde7-4b17-a4a5-3ee865bd7951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_636e70cb-138f-436d-89d5-06d47fe9191d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_636e70cb-138f-436d-89d5-06d47fe9191d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_14be0858-0928-4832-8947-99549f574077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_14be0858-0928-4832-8947-99549f574077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_00be1cbf-7093-42b6-986b-d4025ccd8b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_08d8ee67-f189-4b4b-82fe-90986233d0ed" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_00be1cbf-7093-42b6-986b-d4025ccd8b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#StockholdersEquityDividendsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityDividendsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a6c0ddb1-eeaa-4743-8216-daaeb2ec2f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a7621484-9e20-4450-b8fe-bf7d059591dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a6c0ddb1-eeaa-4743-8216-daaeb2ec2f12" xlink:to="loc_us-gaap_SubsequentEventTable_a7621484-9e20-4450-b8fe-bf7d059591dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_11e660ca-f8bf-4cf2-9c78-0d7c224cc1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a7621484-9e20-4450-b8fe-bf7d059591dd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_11e660ca-f8bf-4cf2-9c78-0d7c224cc1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e59ab288-3a43-45af-af4d-2a21dad3261f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_11e660ca-f8bf-4cf2-9c78-0d7c224cc1b7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e59ab288-3a43-45af-af4d-2a21dad3261f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0c546b58-640f-4480-bc64-82258f9d9a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e59ab288-3a43-45af-af4d-2a21dad3261f" xlink:to="loc_us-gaap_SubsequentEventMember_0c546b58-640f-4480-bc64-82258f9d9a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_e93a0bab-c65e-461c-a321-0215765f2f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a7621484-9e20-4450-b8fe-bf7d059591dd" xlink:to="loc_us-gaap_SubsequentEventLineItems_e93a0bab-c65e-461c-a321-0215765f2f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_0f916bb3-3430-48fd-ba01-c35358449efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e93a0bab-c65e-461c-a321-0215765f2f12" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_0f916bb3-3430-48fd-ba01-c35358449efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_5c3dbd42-115f-474a-b774-df88a6ad8472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e93a0bab-c65e-461c-a321-0215765f2f12" xlink:to="loc_us-gaap_DividendsCommonStockCash_5c3dbd42-115f-474a-b774-df88a6ad8472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ChangeInDividendsPercentage_5a0bb2ff-7913-4eba-ae86-79c9720368f7" xlink:href="gild-20221231.xsd#gild_ChangeInDividendsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_e93a0bab-c65e-461c-a321-0215765f2f12" xlink:to="loc_gild_ChangeInDividendsPercentage_5a0bb2ff-7913-4eba-ae86-79c9720368f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_3c0c75ca-f53a-420d-8397-7df3221e1ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_04e13313-0b9e-4316-8935-c055a04fe094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3c0c75ca-f53a-420d-8397-7df3221e1ed0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_04e13313-0b9e-4316-8935-c055a04fe094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6d21bd58-433e-48ee-a285-d23b3f8a191b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3c0c75ca-f53a-420d-8397-7df3221e1ed0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6d21bd58-433e-48ee-a285-d23b3f8a191b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_43575f21-7284-400a-aa74-e6c153c147cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9c01c797-5a5c-4a17-8c33-0660650193a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_43575f21-7284-400a-aa74-e6c153c147cf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9c01c797-5a5c-4a17-8c33-0660650193a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5447fecf-9bbd-4024-bb1e-b3304b2e9852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9c01c797-5a5c-4a17-8c33-0660650193a4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5447fecf-9bbd-4024-bb1e-b3304b2e9852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_35d72351-9161-45e2-aadd-cde2b996a3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5447fecf-9bbd-4024-bb1e-b3304b2e9852" xlink:to="loc_us-gaap_EquityComponentDomain_35d72351-9161-45e2-aadd-cde2b996a3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9699b97e-a585-4ea5-b3ca-d82aa9818426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_35d72351-9161-45e2-aadd-cde2b996a3db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9699b97e-a585-4ea5-b3ca-d82aa9818426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7e27e2c9-e3d6-41c0-9864-676745319622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9699b97e-a585-4ea5-b3ca-d82aa9818426" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7e27e2c9-e3d6-41c0-9864-676745319622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d93aae97-9405-433a-ac62-ec561db0c042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9699b97e-a585-4ea5-b3ca-d82aa9818426" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d93aae97-9405-433a-ac62-ec561db0c042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_77b8c24e-04c0-4a6e-b4f9-17ead18e2a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9699b97e-a585-4ea5-b3ca-d82aa9818426" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_77b8c24e-04c0-4a6e-b4f9-17ead18e2a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4c0131f6-5d37-48ee-b096-47ed1a2d0181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9c01c797-5a5c-4a17-8c33-0660650193a4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4c0131f6-5d37-48ee-b096-47ed1a2d0181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4c0131f6-5d37-48ee-b096-47ed1a2d0181" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff2dd907-79ca-45cb-a328-6130f831ad57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ff2dd907-79ca-45cb-a328-6130f831ad57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8e9b2329-a5aa-4cf1-8639-d65ac5e2aed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8e9b2329-a5aa-4cf1-8639-d65ac5e2aed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_74aa8fda-0c01-4d18-a0ce-0b0454a7f17d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_74aa8fda-0c01-4d18-a0ce-0b0454a7f17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e3f332c7-0bca-4a63-bc14-ed7953af62e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e3f332c7-0bca-4a63-bc14-ed7953af62e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bc594774-bdd6-4f28-b7bf-e1fa39ec4046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_d94f3394-6a1d-4746-ac25-07ec70da4bab" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bc594774-bdd6-4f28-b7bf-e1fa39ec4046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d324ef67-3cdc-4baf-acce-8acaeac37889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d324ef67-3cdc-4baf-acce-8acaeac37889" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_b2e04dae-7a78-43c4-858a-c40466aeedf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_b2e04dae-7a78-43c4-858a-c40466aeedf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a440d89c-3bb3-4f87-894c-9838a848fc09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_b2e04dae-7a78-43c4-858a-c40466aeedf3" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a440d89c-3bb3-4f87-894c-9838a848fc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredCompensationPlanMember_a7d3533a-5a7d-466f-a316-34f7ac94b60d" xlink:href="gild-20221231.xsd#gild_DeferredCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a440d89c-3bb3-4f87-894c-9838a848fc09" xlink:to="loc_gild_DeferredCompensationPlanMember_a7d3533a-5a7d-466f-a316-34f7ac94b60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b2df2f01-2ce7-4f89-bfc4-e85ab6c43c10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b2df2f01-2ce7-4f89-bfc4-e85ab6c43c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e288a7dc-4894-470f-9ecf-4e5b5299e353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b2df2f01-2ce7-4f89-bfc4-e85ab6c43c10" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e288a7dc-4894-470f-9ecf-4e5b5299e353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a9e34470-5d41-4824-9a57-5eda17dfeac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e288a7dc-4894-470f-9ecf-4e5b5299e353" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a9e34470-5d41-4824-9a57-5eda17dfeac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_31aa49d4-272b-4d23-8148-39f5f6c3ca01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_AwardTypeAxis_31aa49d4-272b-4d23-8148-39f5f6c3ca01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51ce548f-e8da-447a-9325-2e151b5e211b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_31aa49d4-272b-4d23-8148-39f5f6c3ca01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51ce548f-e8da-447a-9325-2e151b5e211b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5218795e-314c-4af2-acfc-a3183180bec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51ce548f-e8da-447a-9325-2e151b5e211b" xlink:to="loc_us-gaap_EmployeeStockMember_5218795e-314c-4af2-acfc-a3183180bec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e8788f52-0391-47d8-9d4d-5a4acce7aeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51ce548f-e8da-447a-9325-2e151b5e211b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e8788f52-0391-47d8-9d4d-5a4acce7aeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7219555c-ceba-4af3-b311-5d02d15df7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51ce548f-e8da-447a-9325-2e151b5e211b" xlink:to="loc_us-gaap_PerformanceSharesMember_7219555c-ceba-4af3-b311-5d02d15df7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_085ff01d-fa15-407d-a118-fecb08929999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51ce548f-e8da-447a-9325-2e151b5e211b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_085ff01d-fa15-407d-a118-fecb08929999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_af648e62-45ce-4421-a951-9a2e3d8e1c79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_srt_RangeAxis_af648e62-45ce-4421-a951-9a2e3d8e1c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f8fb57a-fb0a-478a-bcb4-be1942a76597" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_af648e62-45ce-4421-a951-9a2e3d8e1c79" xlink:to="loc_srt_RangeMember_6f8fb57a-fb0a-478a-bcb4-be1942a76597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_108f3b9c-3c73-4a0e-b012-c1aac4386db1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6f8fb57a-fb0a-478a-bcb4-be1942a76597" xlink:to="loc_srt_MinimumMember_108f3b9c-3c73-4a0e-b012-c1aac4386db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e8593fa2-2fea-4fdd-9ff8-791ee73d28fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6f8fb57a-fb0a-478a-bcb4-be1942a76597" xlink:to="loc_srt_MaximumMember_e8593fa2-2fea-4fdd-9ff8-791ee73d28fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8df0f2de-4ba6-40a4-a9a9-e2cb50a0f898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_PlanNameAxis_8df0f2de-4ba6-40a4-a9a9-e2cb50a0f898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2fcd93c9-f049-4992-9278-ddd58f4b950c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8df0f2de-4ba6-40a4-a9a9-e2cb50a0f898" xlink:to="loc_us-gaap_PlanNameDomain_2fcd93c9-f049-4992-9278-ddd58f4b950c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GileadSciencesInc2022EquityIncentivePlanMember_c0d78999-faf0-440c-8182-8b676a434e93" xlink:href="gild-20221231.xsd#gild_GileadSciencesInc2022EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2fcd93c9-f049-4992-9278-ddd58f4b950c" xlink:to="loc_gild_GileadSciencesInc2022EquityIncentivePlanMember_c0d78999-faf0-440c-8182-8b676a434e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_dfd4364b-812a-481f-bed1-eee741d41c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_StatementClassOfStockAxis_dfd4364b-812a-481f-bed1-eee741d41c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8bde8965-4edb-4fc5-8cc3-5e64113c3f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_dfd4364b-812a-481f-bed1-eee741d41c5f" xlink:to="loc_us-gaap_ClassOfStockDomain_8bde8965-4edb-4fc5-8cc3-5e64113c3f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b2786c8b-4197-4d79-abcf-001715c72bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8bde8965-4edb-4fc5-8cc3-5e64113c3f21" xlink:to="loc_us-gaap_CommonStockMember_b2786c8b-4197-4d79-abcf-001715c72bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_4db21f52-7e62-4328-b09a-3c1456f02156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_4db21f52-7e62-4328-b09a-3c1456f02156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_30c9c671-db20-41a5-bbd0-fd2ce8f911e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_4db21f52-7e62-4328-b09a-3c1456f02156" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_30c9c671-db20-41a5-bbd0-fd2ce8f911e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a771073f-bea3-400a-b282-c7ccab819994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_30c9c671-db20-41a5-bbd0-fd2ce8f911e3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a771073f-bea3-400a-b282-c7ccab819994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0db415e6-4f63-4baa-9f76-d677cdf2196c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a771073f-bea3-400a-b282-c7ccab819994" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0db415e6-4f63-4baa-9f76-d677cdf2196c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98925294-b924-4f28-8703-ccb2d7516e71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_593f0af7-eca4-4dcb-99be-8e57b1284797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_593f0af7-eca4-4dcb-99be-8e57b1284797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bf71a5dd-6072-41ca-8866-88ac69ec6d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bf71a5dd-6072-41ca-8866-88ac69ec6d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_355cfd4f-a577-4fa2-a106-58ea27e74464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_355cfd4f-a577-4fa2-a106-58ea27e74464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_90b100ed-d0e8-4fc8-a3c4-6fc907d82ba1" xlink:href="gild-20221231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage_90b100ed-d0e8-4fc8-a3c4-6fc907d82ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cbcfe39b-08f4-4f87-8ce0-abc148e7490c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cbcfe39b-08f4-4f87-8ce0-abc148e7490c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5546a10b-ae09-4f77-8c90-904369c1bcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5546a10b-ae09-4f77-8c90-904369c1bcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b8a1d8cb-5afa-4fe7-954d-92ff16ee4d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b8a1d8cb-5afa-4fe7-954d-92ff16ee4d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_53fbea74-d7ff-4d27-9112-b44c2a700db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_53fbea74-d7ff-4d27-9112-b44c2a700db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0dd86c19-6956-481f-b64d-d77794a214e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0dd86c19-6956-481f-b64d-d77794a214e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_7971b45a-51a8-42ae-87a2-82ca6c382900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_7971b45a-51a8-42ae-87a2-82ca6c382900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7854f3b5-c4c7-4548-a9f3-8799005bbb43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_893f61d8-1209-4ec6-be70-175a146a2e00" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7854f3b5-c4c7-4548-a9f3-8799005bbb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsSummaryofStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18efe2d3-462c-4d69-8cae-d0db60a15a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2bd93151-1590-44dd-b6bf-e6936df2150f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18efe2d3-462c-4d69-8cae-d0db60a15a16" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2bd93151-1590-44dd-b6bf-e6936df2150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_54a800aa-c855-4a15-bd6f-f597fd5f278f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2bd93151-1590-44dd-b6bf-e6936df2150f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_54a800aa-c855-4a15-bd6f-f597fd5f278f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a414b02f-8ca2-4567-9189-450cedef6a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_54a800aa-c855-4a15-bd6f-f597fd5f278f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a414b02f-8ca2-4567-9189-450cedef6a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_AcquisitionRelatedExpenseMember_34a513a3-c6f3-42d0-96b8-fbe23b5267c7" xlink:href="gild-20221231.xsd#gild_AcquisitionRelatedExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a414b02f-8ca2-4567-9189-450cedef6a22" xlink:to="loc_gild_AcquisitionRelatedExpenseMember_34a513a3-c6f3-42d0-96b8-fbe23b5267c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_aab75f7b-4850-4563-ae57-57faf5305575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a414b02f-8ca2-4567-9189-450cedef6a22" xlink:to="loc_us-gaap_CostOfSalesMember_aab75f7b-4850-4563-ae57-57faf5305575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4d6ddf7a-aab2-4cca-979a-7deea868e4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a414b02f-8ca2-4567-9189-450cedef6a22" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4d6ddf7a-aab2-4cca-979a-7deea868e4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fab8606e-e048-4650-bb80-7807291bc636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a414b02f-8ca2-4567-9189-450cedef6a22" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fab8606e-e048-4650-bb80-7807291bc636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6408dada-b55e-4482-b5c8-6a45e21a3d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2bd93151-1590-44dd-b6bf-e6936df2150f" xlink:to="loc_us-gaap_AwardTypeAxis_6408dada-b55e-4482-b5c8-6a45e21a3d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539bc776-ff17-4eea-946f-5ac7b271e048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6408dada-b55e-4482-b5c8-6a45e21a3d61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539bc776-ff17-4eea-946f-5ac7b271e048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e34487ad-ba06-4a4f-a81a-646466cc8b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539bc776-ff17-4eea-946f-5ac7b271e048" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e34487ad-ba06-4a4f-a81a-646466cc8b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c156937e-4677-4029-8b8b-5f59464bf09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539bc776-ff17-4eea-946f-5ac7b271e048" xlink:to="loc_us-gaap_PerformanceSharesMember_c156937e-4677-4029-8b8b-5f59464bf09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_44b8cc7d-5579-43da-bf61-7a31307164e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539bc776-ff17-4eea-946f-5ac7b271e048" xlink:to="loc_us-gaap_EmployeeStockOptionMember_44b8cc7d-5579-43da-bf61-7a31307164e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_92c58656-1aca-417d-8b32-89f764381ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_539bc776-ff17-4eea-946f-5ac7b271e048" xlink:to="loc_us-gaap_EmployeeStockMember_92c58656-1aca-417d-8b32-89f764381ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_866b51f2-aef5-4bf5-ae21-79530f5d2812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2bd93151-1590-44dd-b6bf-e6936df2150f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_866b51f2-aef5-4bf5-ae21-79530f5d2812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20fe8d43-3b5c-43ca-a0c6-f56a5bc5cdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_866b51f2-aef5-4bf5-ae21-79530f5d2812" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20fe8d43-3b5c-43ca-a0c6-f56a5bc5cdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_MiroBioLtdMember_894dbb3c-bcaa-47e0-a750-ebbae6badc54" xlink:href="gild-20221231.xsd#gild_MiroBioLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20fe8d43-3b5c-43ca-a0c6-f56a5bc5cdd9" xlink:to="loc_gild_MiroBioLtdMember_894dbb3c-bcaa-47e0-a750-ebbae6badc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ImmunomedicsIncMember_23172559-03df-4417-a057-6cefc1cf1882" xlink:href="gild-20221231.xsd#gild_ImmunomedicsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20fe8d43-3b5c-43ca-a0c6-f56a5bc5cdd9" xlink:to="loc_gild_ImmunomedicsIncMember_23172559-03df-4417-a057-6cefc1cf1882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_FortySevenIncMember_65c63f6f-d977-4b9e-90ff-91aa22fd0160" xlink:href="gild-20221231.xsd#gild_FortySevenIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20fe8d43-3b5c-43ca-a0c6-f56a5bc5cdd9" xlink:to="loc_gild_FortySevenIncMember_65c63f6f-d977-4b9e-90ff-91aa22fd0160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_82950d97-480f-4178-be45-1c60ffce2865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2bd93151-1590-44dd-b6bf-e6936df2150f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_82950d97-480f-4178-be45-1c60ffce2865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e21ef832-83c3-4d49-ae78-79814e80858e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_82950d97-480f-4178-be45-1c60ffce2865" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e21ef832-83c3-4d49-ae78-79814e80858e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3e3c2981-8441-4455-bfdc-91a9fe84432a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_82950d97-480f-4178-be45-1c60ffce2865" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3e3c2981-8441-4455-bfdc-91a9fe84432a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_b90c9a0c-ba9a-4e62-9606-2b44187c1073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_82950d97-480f-4178-be45-1c60ffce2865" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_b90c9a0c-ba9a-4e62-9606-2b44187c1073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04e6b1c8-e57e-49e4-81ad-295cfbf7a456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_780c5383-8dbf-471d-9ecc-ba3ca15d8b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04e6b1c8-e57e-49e4-81ad-295cfbf7a456" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_780c5383-8dbf-471d-9ecc-ba3ca15d8b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5bf8415b-008c-4a05-9894-335ff90ac807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_780c5383-8dbf-471d-9ecc-ba3ca15d8b70" xlink:to="loc_us-gaap_AwardTypeAxis_5bf8415b-008c-4a05-9894-335ff90ac807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381ca982-55de-485e-b08b-c196557e2075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5bf8415b-008c-4a05-9894-335ff90ac807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381ca982-55de-485e-b08b-c196557e2075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d49e19de-96d6-4a57-93c6-8b0f16d2fb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_381ca982-55de-485e-b08b-c196557e2075" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d49e19de-96d6-4a57-93c6-8b0f16d2fb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b59b576-1f46-49c4-ba6f-2085ecdd98c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_780c5383-8dbf-471d-9ecc-ba3ca15d8b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b59b576-1f46-49c4-ba6f-2085ecdd98c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b59b576-1f46-49c4-ba6f-2085ecdd98c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d23e9ac6-11cd-4602-bbb0-7a0b3a821d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d23e9ac6-11cd-4602-bbb0-7a0b3a821d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_49f6048c-6261-40e4-a029-1b3e80076443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_49f6048c-6261-40e4-a029-1b3e80076443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00cceb0b-59cd-465b-bf96-32453eac216e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_00cceb0b-59cd-465b-bf96-32453eac216e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0363af81-b27b-4770-96a0-05cb65cb5427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0363af81-b27b-4770-96a0-05cb65cb5427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c95e2a63-d8f6-4810-a11e-9e2cd94a1dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b1a3f9d4-3f26-4cba-a3a0-fb9ab29cad8c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c95e2a63-d8f6-4810-a11e-9e2cd94a1dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:href="gild-20221231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b59b576-1f46-49c4-ba6f-2085ecdd98c0" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4545bf2a-a86b-4826-a537-4ce303d426f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4545bf2a-a86b-4826-a537-4ce303d426f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5840f762-dc39-49e8-bb0b-ac97cd04e4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5840f762-dc39-49e8-bb0b-ac97cd04e4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c9742acb-bbfc-4ae5-9b23-4ce3e9b975fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c9742acb-bbfc-4ae5-9b23-4ce3e9b975fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9008b237-7878-4687-ad75-afcd6f9353a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9008b237-7878-4687-ad75-afcd6f9353a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_66af9538-f147-47b7-9640-9438650f9c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_ef0328c8-45b0-4bef-8bba-ec79e51e87cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_66af9538-f147-47b7-9640-9438650f9c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f780a7bf-83dd-40e7-9574-719a68b97583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b59b576-1f46-49c4-ba6f-2085ecdd98c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_f780a7bf-83dd-40e7-9574-719a68b97583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsPerformanceShareAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec31d934-838e-471a-9a5b-70d07ac8f4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd8cc578-580d-499a-8ef0-282eab259b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec31d934-838e-471a-9a5b-70d07ac8f4ed" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd8cc578-580d-499a-8ef0-282eab259b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dd769a78-790d-491a-876e-9fa95bec5cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd8cc578-580d-499a-8ef0-282eab259b35" xlink:to="loc_us-gaap_AwardTypeAxis_dd769a78-790d-491a-876e-9fa95bec5cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec5aa7e0-d3bf-4b34-9a78-8a7f460e279b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dd769a78-790d-491a-876e-9fa95bec5cd7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec5aa7e0-d3bf-4b34-9a78-8a7f460e279b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7e16bad7-f4e8-42e6-848c-ca62ba30e77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec5aa7e0-d3bf-4b34-9a78-8a7f460e279b" xlink:to="loc_us-gaap_PerformanceSharesMember_7e16bad7-f4e8-42e6-848c-ca62ba30e77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a561219-e6f7-4f06-938c-f6bc3316f432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd8cc578-580d-499a-8ef0-282eab259b35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a561219-e6f7-4f06-938c-f6bc3316f432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a561219-e6f7-4f06-938c-f6bc3316f432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7e4b03b-b330-4415-bcd8-ada1914bf277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d7e4b03b-b330-4415-bcd8-ada1914bf277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10d3f675-875c-4eb3-a324-35972e910ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10d3f675-875c-4eb3-a324-35972e910ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f4e891f4-b752-4811-82fb-bbcd811b702a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f4e891f4-b752-4811-82fb-bbcd811b702a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dc3eb416-961a-41bb-bc01-459f70ff5a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dc3eb416-961a-41bb-bc01-459f70ff5a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3376d4f4-d2e4-4119-9d2c-cac553824ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1c23a77e-707b-42a2-838b-f4f2cb5c62fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3376d4f4-d2e4-4119-9d2c-cac553824ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:href="gild-20221231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a561219-e6f7-4f06-938c-f6bc3316f432" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bc936c5f-4da6-44aa-b90b-0bca2d95d304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bc936c5f-4da6-44aa-b90b-0bca2d95d304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_546232b8-4be2-4367-a210-32df9aa36275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_546232b8-4be2-4367-a210-32df9aa36275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8b5f921c-c218-44a1-a8d3-1f71d94373b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8b5f921c-c218-44a1-a8d3-1f71d94373b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_08fc4bab-7434-4920-a12e-681d050c7b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_08fc4bab-7434-4920-a12e-681d050c7b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d1ff7d46-4031-499b-9187-71f9234235e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward_8b489da0-e247-43ce-996d-52c415f10834" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d1ff7d46-4031-499b-9187-71f9234235e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_433b9e00-9b79-43aa-98bb-1cd01190807c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a561219-e6f7-4f06-938c-f6bc3316f432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_433b9e00-9b79-43aa-98bb-1cd01190807c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d48585a-26c9-489c-8ada-6f1222621786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa95db45-613a-4d3e-9178-6100915cc776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d48585a-26c9-489c-8ada-6f1222621786" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa95db45-613a-4d3e-9178-6100915cc776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ad6c9223-c1c3-4485-8c34-2f55259c7762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa95db45-613a-4d3e-9178-6100915cc776" xlink:to="loc_us-gaap_AwardTypeAxis_ad6c9223-c1c3-4485-8c34-2f55259c7762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25419398-492e-4be0-984c-20c5126d2e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ad6c9223-c1c3-4485-8c34-2f55259c7762" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25419398-492e-4be0-984c-20c5126d2e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_35249967-8fbf-4e5d-a74c-8aea7928f445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_25419398-492e-4be0-984c-20c5126d2e41" xlink:to="loc_us-gaap_EmployeeStockOptionMember_35249967-8fbf-4e5d-a74c-8aea7928f445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa95db45-613a-4d3e-9178-6100915cc776" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8cdcceb8-f201-421e-8236-2f98ca57dfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8cdcceb8-f201-421e-8236-2f98ca57dfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_de9a95cf-f554-42c4-a7fb-d60c9bce249c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_de9a95cf-f554-42c4-a7fb-d60c9bce249c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1cf45be7-b70e-4483-a961-b2b271d5ab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1cf45be7-b70e-4483-a961-b2b271d5ab7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ae365df2-9e70-48c5-b873-aa84a095707f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_ae365df2-9e70-48c5-b873-aa84a095707f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e8705b41-010b-4387-b690-9de1cd44b184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e8705b41-010b-4387-b690-9de1cd44b184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fce3edd1-0741-44d8-bce2-7642e957aaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_068d32d9-f2a1-46d4-99af-6279c0b4f54c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fce3edd1-0741-44d8-bce2-7642e957aaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fc98e04f-ef0d-481c-8e15-cb96852e7acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fc98e04f-ef0d-481c-8e15-cb96852e7acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8e72c13c-7f3c-4522-ba39-7bc429a8c91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8e72c13c-7f3c-4522-ba39-7bc429a8c91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:href="gild-20221231.xsd#gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5238887-caef-4c20-9324-7131f9d857a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5238887-caef-4c20-9324-7131f9d857a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d7b6b347-bc48-43a6-9b0b-e523078f8087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d7b6b347-bc48-43a6-9b0b-e523078f8087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e44a420a-6fd9-4487-81d8-1cc5a39f1ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e44a420a-6fd9-4487-81d8-1cc5a39f1ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e48368f3-6c71-4ce2-92c0-9b7bd6d40e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e48368f3-6c71-4ce2-92c0-9b7bd6d40e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_38cceb80-8ea7-4aaf-ab6b-a7fd9a3b2b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_38cceb80-8ea7-4aaf-ab6b-a7fd9a3b2b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89dbf25c-b9ac-4d7c-b37c-309b2da21b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward_15cf65ec-d531-47f3-901d-e37789b08f48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_89dbf25c-b9ac-4d7c-b37c-309b2da21b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c0fcf360-07dd-467f-8afc-4f81ba06d7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c0fcf360-07dd-467f-8afc-4f81ba06d7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_13b9fad0-792f-4f3e-9f5e-1b4119360ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_13b9fad0-792f-4f3e-9f5e-1b4119360ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6d98e5b8-6d3b-4e6a-9bda-6d06e62a5af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6d98e5b8-6d3b-4e6a-9bda-6d06e62a5af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_56d39722-bd26-4f32-b1e5-c7951c6e1d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6d98e5b8-6d3b-4e6a-9bda-6d06e62a5af4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_56d39722-bd26-4f32-b1e5-c7951c6e1d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_597f1568-1a7a-483d-9c9b-a17123321c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6d98e5b8-6d3b-4e6a-9bda-6d06e62a5af4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_597f1568-1a7a-483d-9c9b-a17123321c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6de42851-5c34-4de2-98d9-c8c21c16ad62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_6d98e5b8-6d3b-4e6a-9bda-6d06e62a5af4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6de42851-5c34-4de2-98d9-c8c21c16ad62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_75867a4b-9a57-4c4f-9f09-10adf6656861" xlink:href="gild-20221231.xsd#gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_75867a4b-9a57-4c4f-9f09-10adf6656861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40d57651-e90c-4d44-8d59-b3a0438860dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_75867a4b-9a57-4c4f-9f09-10adf6656861" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40d57651-e90c-4d44-8d59-b3a0438860dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d3d553a8-b3ed-4735-ad1b-257980a4e9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_75867a4b-9a57-4c4f-9f09-10adf6656861" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d3d553a8-b3ed-4735-ad1b-257980a4e9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ae8a73ac-163e-46ea-accb-f869ab24f845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_75867a4b-9a57-4c4f-9f09-10adf6656861" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ae8a73ac-163e-46ea-accb-f869ab24f845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_972143fc-f50b-4d0d-a896-4059015b331f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_972143fc-f50b-4d0d-a896-4059015b331f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_755e237b-2c17-4784-bb33-41c2c4fac5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09814a37-b01b-4537-acad-dff449d06cac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_755e237b-2c17-4784-bb33-41c2c4fac5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7fd5eb11-25dd-4290-ae57-442578a91958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f812aa85-cd6d-40f0-9641-36f1e0aa4e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7fd5eb11-25dd-4290-ae57-442578a91958" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f812aa85-cd6d-40f0-9641-36f1e0aa4e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_81a1f8c8-5af1-4044-acc7-d6591eb02709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f812aa85-cd6d-40f0-9641-36f1e0aa4e21" xlink:to="loc_us-gaap_AwardTypeAxis_81a1f8c8-5af1-4044-acc7-d6591eb02709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd756ae-e5be-4e99-97e0-dfed35e72e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_81a1f8c8-5af1-4044-acc7-d6591eb02709" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd756ae-e5be-4e99-97e0-dfed35e72e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ecd9bcbb-be0c-45b2-873d-f0c75987c040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd756ae-e5be-4e99-97e0-dfed35e72e02" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ecd9bcbb-be0c-45b2-873d-f0c75987c040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1857c2cb-bcdc-4e5d-b0a7-863d8d5f12e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd756ae-e5be-4e99-97e0-dfed35e72e02" xlink:to="loc_us-gaap_EmployeeStockMember_1857c2cb-bcdc-4e5d-b0a7-863d8d5f12e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_157701c3-5c01-400e-aa99-b22875f44bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f812aa85-cd6d-40f0-9641-36f1e0aa4e21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_157701c3-5c01-400e-aa99-b22875f44bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_21b3df2b-7fc5-4a1c-8a93-db22f92d88c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_157701c3-5c01-400e-aa99-b22875f44bdb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_21b3df2b-7fc5-4a1c-8a93-db22f92d88c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_05c2b097-822e-4b9c-8ed4-da51690799ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_157701c3-5c01-400e-aa99-b22875f44bdb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_05c2b097-822e-4b9c-8ed4-da51690799ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_129e05e2-c836-4c47-959c-a4c990d5a028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_157701c3-5c01-400e-aa99-b22875f44bdb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_129e05e2-c836-4c47-959c-a4c990d5a028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_04685da1-2b89-4289-a020-aefb7f5f71e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_157701c3-5c01-400e-aa99-b22875f44bdb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_04685da1-2b89-4289-a020-aefb7f5f71e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EmployeeBenefitsESPPActivityDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_470a6997-b870-4c47-bc51-c15ecd45838e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19f4706d-3164-446d-b19a-d8ad959dcb21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_470a6997-b870-4c47-bc51-c15ecd45838e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19f4706d-3164-446d-b19a-d8ad959dcb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05a3fd06-5181-4a72-8386-f8d0364d4026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19f4706d-3164-446d-b19a-d8ad959dcb21" xlink:to="loc_us-gaap_AwardTypeAxis_05a3fd06-5181-4a72-8386-f8d0364d4026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd9ac61e-78ae-4cb7-8cf6-a8782bf722eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_05a3fd06-5181-4a72-8386-f8d0364d4026" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd9ac61e-78ae-4cb7-8cf6-a8782bf722eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_135500db-16ac-4d13-ad58-a07aed4bfa54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd9ac61e-78ae-4cb7-8cf6-a8782bf722eb" xlink:to="loc_us-gaap_EmployeeStockMember_135500db-16ac-4d13-ad58-a07aed4bfa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2b26db-5cd4-40b6-a7d1-be30faa5ea88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19f4706d-3164-446d-b19a-d8ad959dcb21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2b26db-5cd4-40b6-a7d1-be30faa5ea88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b288130b-ec3e-4d95-9bfe-7e8c01b81cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2b26db-5cd4-40b6-a7d1-be30faa5ea88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b288130b-ec3e-4d95-9bfe-7e8c01b81cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2a8bec4a-7203-46f7-9cc2-d15e91025962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2b26db-5cd4-40b6-a7d1-be30faa5ea88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2a8bec4a-7203-46f7-9cc2-d15e91025962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare_97fde441-f0f0-49e5-808b-74d2e2ef875b" xlink:href="gild-20221231.xsd#gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2b26db-5cd4-40b6-a7d1-be30faa5ea88" xlink:to="loc_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare_97fde441-f0f0-49e5-808b-74d2e2ef875b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_156d5e39-e27d-4ab2-aded-bddebc4fb918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e2b26db-5cd4-40b6-a7d1-be30faa5ea88" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_156d5e39-e27d-4ab2-aded-bddebc4fb918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b692a9ea-1b60-46d6-a31d-11a8091bae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0beec46f-6cb0-4e69-bed0-b45615bc4db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b692a9ea-1b60-46d6-a31d-11a8091bae4f" xlink:to="loc_us-gaap_NetIncomeLoss_0beec46f-6cb0-4e69-bed0-b45615bc4db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cee0d499-f5c0-4fcd-a956-2788922a27ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b692a9ea-1b60-46d6-a31d-11a8091bae4f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cee0d499-f5c0-4fcd-a956-2788922a27ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f34a6487-b0b1-47cb-8b04-8bf07d13a752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b692a9ea-1b60-46d6-a31d-11a8091bae4f" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f34a6487-b0b1-47cb-8b04-8bf07d13a752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dfe4bbfd-c52a-42c9-81eb-ebf66e6df622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b692a9ea-1b60-46d6-a31d-11a8091bae4f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dfe4bbfd-c52a-42c9-81eb-ebf66e6df622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b08ba085-88c0-436d-aa78-ac813693e5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b692a9ea-1b60-46d6-a31d-11a8091bae4f" xlink:to="loc_us-gaap_EarningsPerShareBasic_b08ba085-88c0-436d-aa78-ac813693e5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1a85e354-7b9e-4f1e-9918-c8f609330b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b692a9ea-1b60-46d6-a31d-11a8091bae4f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1a85e354-7b9e-4f1e-9918-c8f609330b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ec9b0bb8-1e7c-4691-885d-5c6dd79831eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a95bd7ef-f78f-42a7-b7d4-0db8dff97863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ec9b0bb8-1e7c-4691-885d-5c6dd79831eb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a95bd7ef-f78f-42a7-b7d4-0db8dff97863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6c63801c-d875-4cce-ae78-b8ac42b68b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e9b14dda-e814-456b-91a0-d316f6122c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c63801c-d875-4cce-ae78-b8ac42b68b88" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e9b14dda-e814-456b-91a0-d316f6122c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_30c41883-a1e0-4ebf-af07-9bf268575415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c63801c-d875-4cce-ae78-b8ac42b68b88" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_30c41883-a1e0-4ebf-af07-9bf268575415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_73083d63-c44f-484a-866d-974ff0f142b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c63801c-d875-4cce-ae78-b8ac42b68b88" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_73083d63-c44f-484a-866d-974ff0f142b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesScheduleofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_10d290e4-e5de-431f-946c-323c8b4ac2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_e524af09-04c2-4bc3-836f-405e2ca24b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_10d290e4-e5de-431f-946c-323c8b4ac2cb" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_e524af09-04c2-4bc3-836f-405e2ca24b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5e3a17a7-596a-455b-83ec-594d8bf9f25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_e524af09-04c2-4bc3-836f-405e2ca24b88" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5e3a17a7-596a-455b-83ec-594d8bf9f25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1ee73fcb-deff-482f-90d8-71abb4bb05c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_e524af09-04c2-4bc3-836f-405e2ca24b88" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1ee73fcb-deff-482f-90d8-71abb4bb05c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_05e920f0-6602-426c-b5f4-adc57a4e684c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_e524af09-04c2-4bc3-836f-405e2ca24b88" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_05e920f0-6602-426c-b5f4-adc57a4e684c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c9c8bf7-85d5-41f9-95bb-2162d1ab2143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_10d290e4-e5de-431f-946c-323c8b4ac2cb" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c9c8bf7-85d5-41f9-95bb-2162d1ab2143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7161e472-0c8c-4f97-85c3-0699520b5de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c9c8bf7-85d5-41f9-95bb-2162d1ab2143" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7161e472-0c8c-4f97-85c3-0699520b5de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_325a4780-4a78-4e23-87bb-5bfda81b2913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c9c8bf7-85d5-41f9-95bb-2162d1ab2143" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_325a4780-4a78-4e23-87bb-5bfda81b2913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_4a6233e9-f25d-44c3-9982-eee57bc86821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c9c8bf7-85d5-41f9-95bb-2162d1ab2143" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_4a6233e9-f25d-44c3-9982-eee57bc86821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_b459703b-7cb7-457d-9468-dd8c031d4f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_10d290e4-e5de-431f-946c-323c8b4ac2cb" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_b459703b-7cb7-457d-9468-dd8c031d4f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cc7e5ef9-e25b-46eb-a46a-1bfeb9714ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_b459703b-7cb7-457d-9468-dd8c031d4f6e" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_cc7e5ef9-e25b-46eb-a46a-1bfeb9714ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8a9f2061-1be1-4323-b480-4384d74aeca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_b459703b-7cb7-457d-9468-dd8c031d4f6e" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8a9f2061-1be1-4323-b480-4384d74aeca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_127141cd-97c8-449c-9bae-7d553f44f0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract_b459703b-7cb7-457d-9468-dd8c031d4f6e" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_127141cd-97c8-449c-9bae-7d553f44f0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bf35c3ef-90c1-40aa-a153-4eda4975693c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_10d290e4-e5de-431f-946c-323c8b4ac2cb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bf35c3ef-90c1-40aa-a153-4eda4975693c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e2e537d0-40e2-4a15-8986-cc615f079199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e2e537d0-40e2-4a15-8986-cc615f079199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b6a65c90-3f08-452a-bf53-fd6dad1442c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b6a65c90-3f08-452a-bf53-fd6dad1442c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1fbde81e-2b84-43a4-98bf-68a320cf8c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1fbde81e-2b84-43a4-98bf-68a320cf8c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5b223ad4-f7f6-4278-b544-d876c4040cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5b223ad4-f7f6-4278-b544-d876c4040cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_55a7159b-e488-432a-a3c4-402822ff839d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings_55a7159b-e488-432a-a3c4-402822ff839d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion_6c3d851d-92dc-4a7e-83ed-330286336915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion_6c3d851d-92dc-4a7e-83ed-330286336915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_3283bd7c-b4c8-4ed7-8ce3-4566abb4213a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_3283bd7c-b4c8-4ed7-8ce3-4566abb4213a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_d9c4a71c-0eda-403a-b025-5053161e6813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_d9c4a71c-0eda-403a-b025-5053161e6813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_09bdde61-c377-41a4-86d5-075c627b95a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_09bdde61-c377-41a4-86d5-075c627b95a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_fc68dcca-64b1-4524-898a-1cf8588ef823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_fc68dcca-64b1-4524-898a-1cf8588ef823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_eb59af0d-7266-4bda-bfd9-e2ea18c8a6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_eb59af0d-7266-4bda-bfd9-e2ea18c8a6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_15349382-4d0f-4193-a8d8-6785aa918fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0fae884-a075-4c2e-b31c-81b14a592bc4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_15349382-4d0f-4193-a8d8-6785aa918fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f6c519da-b6df-46be-b260-6cfc84d342fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f6c519da-b6df-46be-b260-6cfc84d342fd" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_38387d8d-bfe5-454e-b92d-4411045571cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_38387d8d-bfe5-454e-b92d-4411045571cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0dfb85f3-a68a-4a69-9d26-8d0a9a458ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0dfb85f3-a68a-4a69-9d26-8d0a9a458ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_8048ff90-8847-44bb-9fe8-21509df78f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_8048ff90-8847-44bb-9fe8-21509df78f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_216475fd-9655-41a1-a883-8bee4839abc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_216475fd-9655-41a1-a883-8bee4839abc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_709dc292-35c3-4ff2-9255-ef5f92cea4f7" xlink:href="gild-20221231.xsd#gild_DeferredTaxAssetsUpfrontAndMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_gild_DeferredTaxAssetsUpfrontAndMilestonePayments_709dc292-35c3-4ff2-9255-ef5f92cea4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e98f2fba-6e37-4166-afac-d8dd52335c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e98f2fba-6e37-4166-afac-d8dd52335c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_f71a8c88-8683-4d9c-88e3-2f3fb11717ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_f71a8c88-8683-4d9c-88e3-2f3fb11717ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_a3ac7272-0753-46b4-9a5c-c203e801417f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_a3ac7272-0753-46b4-9a5c-c203e801417f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2a282897-e3be-4a90-bf2d-07f1d303dec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_2a282897-e3be-4a90-bf2d-07f1d303dec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d2eb16b7-8cc3-482b-aac4-5c74800bbaca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d2eb16b7-8cc3-482b-aac4-5c74800bbaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_35aed073-3d83-426c-b1ed-bab8b37f5631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_35aed073-3d83-426c-b1ed-bab8b37f5631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e8c5a6e8-35fe-4f99-81d7-c5ee8a4b3ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e8c5a6e8-35fe-4f99-81d7-c5ee8a4b3ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2415c66b-4cde-458d-8772-3e76dfd7a944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_d24c3fef-46a7-42a5-8734-131d96afad9e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2415c66b-4cde-458d-8772-3e76dfd7a944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_13e73484-39cc-48d3-9e95-91f90bc8b98f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f6c519da-b6df-46be-b260-6cfc84d342fd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_13e73484-39cc-48d3-9e95-91f90bc8b98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0408fce5-cd5a-4c80-be4c-d1b621c86d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_13e73484-39cc-48d3-9e95-91f90bc8b98f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0408fce5-cd5a-4c80-be4c-d1b621c86d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_fcc99378-949a-4516-baf0-d68e42d9f6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_13e73484-39cc-48d3-9e95-91f90bc8b98f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_fcc99378-949a-4516-baf0-d68e42d9f6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_0cf2743a-1e71-4d05-8f7b-21e7a7a0bee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_13e73484-39cc-48d3-9e95-91f90bc8b98f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_0cf2743a-1e71-4d05-8f7b-21e7a7a0bee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b9cee7f2-f36c-4be8-981c-4d53a68c7d37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_13e73484-39cc-48d3-9e95-91f90bc8b98f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b9cee7f2-f36c-4be8-981c-4d53a68c7d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_c0b7d9f7-6afe-41fe-ba48-edbe46deff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f6c519da-b6df-46be-b260-6cfc84d342fd" xlink:to="loc_us-gaap_DeferredTaxLiabilities_c0b7d9f7-6afe-41fe-ba48-edbe46deff2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1ac82cb6-521d-4a0a-bf0d-af6532baa7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_622852b8-20f9-4634-a275-21c08174e85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1ac82cb6-521d-4a0a-bf0d-af6532baa7e5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_622852b8-20f9-4634-a275-21c08174e85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e11f7f18-afcd-47a0-b33c-2130007f398f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_622852b8-20f9-4634-a275-21c08174e85c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e11f7f18-afcd-47a0-b33c-2130007f398f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a311c125-9c61-4733-9532-6afdce2a370f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e11f7f18-afcd-47a0-b33c-2130007f398f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a311c125-9c61-4733-9532-6afdce2a370f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_16f36767-92cc-45e6-8095-39e8e6638638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a311c125-9c61-4733-9532-6afdce2a370f" xlink:to="loc_us-gaap_DomesticCountryMember_16f36767-92cc-45e6-8095-39e8e6638638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_8cd1566f-f8be-4b79-85f3-840cd718a82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_a311c125-9c61-4733-9532-6afdce2a370f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_8cd1566f-f8be-4b79-85f3-840cd718a82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_622852b8-20f9-4634-a275-21c08174e85c" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_67afd268-8c98-4b47-9b6f-156376ba52a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_67afd268-8c98-4b47-9b6f-156376ba52a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_dcdcfa00-e5e7-4269-b737-aa93b0a3ccc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_dcdcfa00-e5e7-4269-b737-aa93b0a3ccc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_0a3e843f-8360-484e-854b-6d7cc89b9f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_0a3e843f-8360-484e-854b-6d7cc89b9f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_cfd40077-b889-491c-be74-eea8df3cb79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_cfd40077-b889-491c-be74-eea8df3cb79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3e65b35a-324d-4810-98e8-94866c6ee616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3e65b35a-324d-4810-98e8-94866c6ee616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_80b47080-359a-4f78-8943-e4f00030031b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_80b47080-359a-4f78-8943-e4f00030031b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7caad3ef-cbd4-4d96-87c7-204a8b96347b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_e7ae1d07-07bf-4bde-94e8-1fe93599253a" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7caad3ef-cbd4-4d96-87c7-204a8b96347b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_740b6a8b-d850-4826-9735-86e048306138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0c4e192f-bbe6-4aac-9471-2b0f2b1ad097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_740b6a8b-d850-4826-9735-86e048306138" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0c4e192f-bbe6-4aac-9471-2b0f2b1ad097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_88ae74ba-098c-4ad4-95bb-de62c6a11f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0c4e192f-bbe6-4aac-9471-2b0f2b1ad097" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_88ae74ba-098c-4ad4-95bb-de62c6a11f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_56d3508f-a211-4e32-9185-687880370521" xlink:href="gild-20221231.xsd#gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0c4e192f-bbe6-4aac-9471-2b0f2b1ad097" xlink:to="loc_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_56d3508f-a211-4e32-9185-687880370521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_83c6c973-5aa9-410b-8f33-d0a13074d382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_56d3508f-a211-4e32-9185-687880370521" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_83c6c973-5aa9-410b-8f33-d0a13074d382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_cab6a63e-7cd5-4c9b-a234-046e74ee4ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract_56d3508f-a211-4e32-9185-687880370521" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_cab6a63e-7cd5-4c9b-a234-046e74ee4ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_20cc9068-1e02-4485-91a9-23a2ba966d04" xlink:href="gild-20221231.xsd#gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0c4e192f-bbe6-4aac-9471-2b0f2b1ad097" xlink:to="loc_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_20cc9068-1e02-4485-91a9-23a2ba966d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_33421799-fb17-4e07-a9d4-66a49ebdf973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_20cc9068-1e02-4485-91a9-23a2ba966d04" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_33421799-fb17-4e07-a9d4-66a49ebdf973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_14f206df-dd64-43a7-97fe-1790c03656f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract_20cc9068-1e02-4485-91a9-23a2ba966d04" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_14f206df-dd64-43a7-97fe-1790c03656f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_3e2ae70d-ce8a-4c43-84e9-0c452034aa91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0c4e192f-bbe6-4aac-9471-2b0f2b1ad097" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_3e2ae70d-ce8a-4c43-84e9-0c452034aa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_40d546b2-16d7-46b9-8b0e-ebe21986b4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0c4e192f-bbe6-4aac-9471-2b0f2b1ad097" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_40d546b2-16d7-46b9-8b0e-ebe21986b4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_644c70f7-c89f-4e53-b32b-0f0e5aa022d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0c4e192f-bbe6-4aac-9471-2b0f2b1ad097" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_644c70f7-c89f-4e53-b32b-0f0e5aa022d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#IncomeTaxesScheduleofTransitionTaxDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2e64e02e-ba10-4dda-ab79-343c6fb43c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne_b735e5ad-270b-47af-80f4-c23938410126" xlink:href="gild-20221231.xsd#gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e64e02e-ba10-4dda-ab79-343c6fb43c18" xlink:to="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne_b735e5ad-270b-47af-80f4-c23938410126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo_a5436b42-c9c9-4e64-b1d5-a2eee7247ccc" xlink:href="gild-20221231.xsd#gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e64e02e-ba10-4dda-ab79-343c6fb43c18" xlink:to="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo_a5436b42-c9c9-4e64-b1d5-a2eee7247ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree_69afb4a7-b854-478d-809c-0caef26ec7e2" xlink:href="gild-20221231.xsd#gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e64e02e-ba10-4dda-ab79-343c6fb43c18" xlink:to="loc_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree_69afb4a7-b854-478d-809c-0caef26ec7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_e0dc50fd-5fd2-4c7b-9775-48132eb80fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e64e02e-ba10-4dda-ab79-343c6fb43c18" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_e0dc50fd-5fd2-4c7b-9775-48132eb80fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.gilead.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="gild-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.gilead.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3417a776-9403-4631-b217-1eb18b3124b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3417a776-9403-4631-b217-1eb18b3124b9" xlink:to="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8216b93f-7016-4c9b-a5ec-b8c9e913a9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8216b93f-7016-4c9b-a5ec-b8c9e913a9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a1ad2d4d-1015-463f-ab57-6a34ec3924b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8216b93f-7016-4c9b-a5ec-b8c9e913a9ff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a1ad2d4d-1015-463f-ab57-6a34ec3924b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9c3f2ca3-b02d-4349-8c31-ab17cccb20b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a1ad2d4d-1015-463f-ab57-6a34ec3924b2" xlink:to="loc_us-gaap_SubsequentEventMember_9c3f2ca3-b02d-4349-8c31-ab17cccb20b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f87c8a5b-724c-479f-ad93-d318c409f2cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f87c8a5b-724c-479f-ad93-d318c409f2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_83acc63c-9498-4d59-b627-378b563dadb7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f87c8a5b-724c-479f-ad93-d318c409f2cf" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_83acc63c-9498-4d59-b627-378b563dadb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcellxIncMember_6043bf9a-60cf-4b6b-88e2-de0f9ea7195e" xlink:href="gild-20221231.xsd#gild_ArcellxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_83acc63c-9498-4d59-b627-378b563dadb7" xlink:to="loc_gild_ArcellxIncMember_6043bf9a-60cf-4b6b-88e2-de0f9ea7195e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e590b969-58e6-4ced-a06b-dd5cdea8d865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e590b969-58e6-4ced-a06b-dd5cdea8d865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee03ff79-136a-4598-8eed-acdddabd38c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e590b969-58e6-4ced-a06b-dd5cdea8d865" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee03ff79-136a-4598-8eed-acdddabd38c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_GlobalStrategicCollaborationAgreementMember_678179a4-7023-4e3c-80b9-b08a9aa0959b" xlink:href="gild-20221231.xsd#gild_GlobalStrategicCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ee03ff79-136a-4598-8eed-acdddabd38c1" xlink:to="loc_gild_GlobalStrategicCollaborationAgreementMember_678179a4-7023-4e3c-80b9-b08a9aa0959b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c95bb65a-6d79-4ea6-a8f0-48d5e5957782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c95bb65a-6d79-4ea6-a8f0-48d5e5957782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_6209e1b3-eab3-49c9-aaff-76276ab20bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c95bb65a-6d79-4ea6-a8f0-48d5e5957782" xlink:to="loc_us-gaap_AssetAcquisitionDomain_6209e1b3-eab3-49c9-aaff-76276ab20bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_TmunityTherapeuticsMember_1b31d917-10b0-4b17-a1b8-7ffb922c0ed6" xlink:href="gild-20221231.xsd#gild_TmunityTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_6209e1b3-eab3-49c9-aaff-76276ab20bfe" xlink:to="loc_gild_TmunityTherapeuticsMember_1b31d917-10b0-4b17-a1b8-7ffb922c0ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_019609b8-6e64-43e4-91f1-1b8c9f7f1ca9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:to="loc_dei_LegalEntityAxis_019609b8-6e64-43e4-91f1-1b8c9f7f1ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a910bd10-9990-4401-83ff-0be1e3ea33a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_019609b8-6e64-43e4-91f1-1b8c9f7f1ca9" xlink:to="loc_dei_EntityDomain_a910bd10-9990-4401-83ff-0be1e3ea33a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_ArcellxIncMember_f124eab3-c725-45c1-9bcb-819785cd883a" xlink:href="gild-20221231.xsd#gild_ArcellxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a910bd10-9990-4401-83ff-0be1e3ea33a6" xlink:to="loc_gild_ArcellxIncMember_f124eab3-c725-45c1-9bcb-819785cd883a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b8cc8a99-50e3-4044-9340-aaecd810e673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_32a22874-f7fd-48af-9c03-418e53778ce8" xlink:to="loc_us-gaap_SubsequentEventLineItems_b8cc8a99-50e3-4044-9340-aaecd810e673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7c4cfa4b-9974-4e7f-9099-8197d857e248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b8cc8a99-50e3-4044-9340-aaecd810e673" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_7c4cfa4b-9974-4e7f-9099-8197d857e248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_c741de98-bd93-4655-9088-22668b702177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b8cc8a99-50e3-4044-9340-aaecd810e673" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_c741de98-bd93-4655-9088-22668b702177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_RevenuePerformanceObligationPercentageOfUSProfits_4cfbffd4-723c-460b-9fd6-a3a8fe8084d3" xlink:href="gild-20221231.xsd#gild_RevenuePerformanceObligationPercentageOfUSProfits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b8cc8a99-50e3-4044-9340-aaecd810e673" xlink:to="loc_gild_RevenuePerformanceObligationPercentageOfUSProfits_4cfbffd4-723c-460b-9fd6-a3a8fe8084d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_gild_PaymentsForAssetAcquisitions_6c62981f-1866-48b4-852d-d5197584f01f" xlink:href="gild-20221231.xsd#gild_PaymentsForAssetAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b8cc8a99-50e3-4044-9340-aaecd810e673" xlink:to="loc_gild_PaymentsForAssetAcquisitions_6c62981f-1866-48b4-852d-d5197584f01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gild-20221231_g1.jpg
<DESCRIPTION>PERFORMANCE GRAPH
<TEXT>
begin 644 gild-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO;B!+<G5E
M9V5R   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,Y-P  DI(
M @    ,Y-P  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( F,#;@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M_GS\0?\ A.:A_P#&*/\ A/-(_P"?/Q!_X3FH?_&* .DHKF_^$\TC_GS\0?\
MA.:A_P#&*/\ A/-(_P"?/Q!_X3FH?_&* .DHKF_^$\TC_GS\0?\ A.:A_P#&
M*/\ A/-(_P"?/Q!_X3FH?_&* .DHKF_^$\TC_GS\0?\ A.:A_P#&*/\ A/-(
M_P"?/Q!_X3FH?_&* .DHKF_^$\TC_GS\0?\ A.:A_P#&*/\ A/-(_P"?/Q!_
MX3FH?_&* .DHKF_^$\TC_GS\0?\ A.:A_P#&*BN?B+H-G:RW5Y%KD%O"ADEE
ME\/7ZI&H&2S$PX  &230!U-%<W_PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\
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M\0?^$YJ'_P 8H Z2BN;_ .$\TC_GS\0?^$YJ'_QBC_A/-(_Y\_$'_A.:A_\
M&* .DHKF_P#A/-(_Y\_$'_A.:A_\8H_X3S2/^?/Q!_X3FH?_ !B@#I**YO\
MX3S2/^?/Q!_X3FH?_&*/^$\TC_GS\0?^$YJ'_P 8H Z2BN;_ .$\TC_GS\0?
M^$YJ'_QBC_A/-(_Y\_$'_A.:A_\ &* .DHKF_P#A/-(_Y\_$'_A.:A_\8H_X
M3S2/^?/Q!_X3FH?_ !B@#I**YO\ X3S2/^?/Q!_X3FH?_&*/^$\TC_GS\0?^
M$YJ'_P 8H Z2BN6N/B+H-K&)+J+7(49TC#2>'K]06=@JKDP]2S  =R0.]2_\
M)YI'_/GX@_\ "<U#_P",4 =)17-_\)YI'_/GX@_\)S4/_C%'_">:1_SY^(/_
M  G-0_\ C% '245S?_">:1_SY^(/_"<U#_XQ1_PGFD?\^?B#_P )S4/_ (Q0
M!TE%<W_PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\ "<U#_P",4 =)17-_\)YI
M'_/GX@_\)S4/_C%'_">:1_SY^(/_  G-0_\ C% '245S?_">:1_SY^(/_"<U
M#_XQ1_PGFD?\^?B#_P )S4/_ (Q0!TE%<W_PGFD?\^?B#_PG-0_^,4?\)YI'
M_/GX@_\ "<U#_P",4 =)17-_\)YI'_/GX@_\)S4/_C%'_">:1_SY^(/_  G-
M0_\ C% '245S?_">:1_SY^(/_"<U#_XQ1_PGFD?\^?B#_P )S4/_ (Q0!TE%
M<W_PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\ "<U#_P",4 =)17-_\)YI'_/G
MX@_\)S4/_C%11?$709Y)HX(M<D>W<1S*GAZ_)C;:&VL!#P=K*<'LP/>@#J:*
MYO\ X3S2/^?/Q!_X3FH?_&*/^$\TC_GS\0?^$YJ'_P 8H Z2BN;_ .$\TC_G
MS\0?^$YJ'_QBC_A/-(_Y\_$'_A.:A_\ &* .DHKF_P#A/-(_Y\_$'_A.:A_\
M8H_X3S2/^?/Q!_X3FH?_ !B@#I**YO\ X3S2/^?/Q!_X3FH?_&*/^$\TC_GS
M\0?^$YJ'_P 8H Z2BN;_ .$\TC_GS\0?^$YJ'_QBC_A/-(_Y\_$'_A.:A_\
M&* .DHKF_P#A/-(_Y\_$'_A.:A_\8H_X3S2/^?/Q!_X3FH?_ !B@#I**YO\
MX3S2/^?/Q!_X3FH?_&*/^$\TC_GS\0?^$YJ'_P 8H Z2BN;_ .$\TC_GS\0?
M^$YJ'_QBC_A/-(_Y\_$'_A.:A_\ &* .DHKF_P#A/-(_Y\_$'_A.:A_\8H_X
M3S2/^?/Q!_X3FH?_ !B@#I**YO\ X3S2/^?/Q!_X3FH?_&*DM/&VCWFIVM@J
MZI!<7CM'!]LT>[MDD8(SE0\D2KG:C'&?X30!T%%%% !7/:AX&T74]6N-2NO[
M2%U<HL<K0:O=PJZ+G";$E"[>6.,8RS'J370T4 8[>%-&;7%U<V9%VK*X F<1
M%U78LAB#>67"X4.5W  #. *63PMH\NOC69+5C>AQ)GSG$;2!=@D,6[89 ORA
MRNX  9P!6O10 5S=C_R5/7?^P+IO_H^^KI*YNQ_Y*GKO_8%TW_T??4 =)111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6)XU8)X!\0.\D$2
MKIER3)<Q>9$@\IN73!W*.XP<CC!Z5MUB>-)?(\!:_*9GM_+TRY;SHXA(T>(F
M.X(2 Q'7!(STH VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ,2T8'Q]JJ"2 L-,LB8UBQ*H,MURSXY4X.!DX(8X&[)VZQ+67/CW5
M8O.=MNF63>28@%3,MT-P?.23C!&.-H/.XXVZ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** ,3Q:P31;<M)!&/[3T\;IXO,4DWD(  P?F/1
M3CAB#D8R-NL3Q9+Y.C0,9GASJ=@NY(A(3F\A&W!(X.<$]@2><8K;H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q-!8-K7B8+) Y74T!
M6*+:R'[';'#G W-SG.3\I49XP-NL30I?,UGQ*OG/)Y>IHNUH@HC_ -#MSM!S
M\PYSDXY8CMD@&W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7-^*/^1B\&_P#8:D_]-]Y725S?BC_D8O!G_8:D_P#3?>4 =)1110 4444
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M+(_-T:!?)DFQJ=@VV.41D8O(3NR0>!C)'\0! (SFMJ@ HHHH **** "BBB@
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M "2OJ "<9H VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,2T0#Q]JK^5"&.F60,BRYD8"6ZX9,_*HSPV!DEAD[>-NL2T*_\ "?:J
M UON_LRRRJJ?- \VZP6.,;>NT YR'SC(SMT %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 8GBU ^BVX:*&4?VGIYVSR^6H(O(3D'(RPZJN
M?F8 8.<';K$\6E1HMOO:W4?VGI_-PI*Y^V0X P#\W]T] VW.!S6W0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7'^*?&<EG=C1O#D7VW5Y3MP
MHW+#]??VZ#O537_%M[JVI-H'@P>;<'B>\4_+$.^#_P"S?EDUN^%O"=IX9M#L
M_?WLHS/<L/F8^@]!_DU-[[''*I*L^2EMU?Z+S_(S= \ VEM"]UXB5-3U*X.Z
M5YOF53Z#/7ZT[1_#.BS:IKT<VD:>4AOUCB"D.0OV:!OF7)V'<S?+@<8;'S9/
M75B:"5.M>)MK6Y(U--PA4A@?L=MQ)D<MTY&1MV]\@.R-HT*4591,77? KI>_
MVOX1F_L[45)8QJ<1R^V.@SZ=#^M2^'?'275U_97B*'^S=40[2)!M24^V>A]N
MA[&NPK'\0^%]-\2VOEW\6)5&(YTX>/\ 'N/8TK6V,I490?/1T\NC_P F;%%>
M=0:SKG@*X2S\1J^HZ22%BO8QEHQZ'_ _@37>V-_:ZG9I=6$Z3P/]UT.1]/8^
MU-.YI2K1J:;-="Q1113-PHHHH **** "BBB@ HHHH **** "BBB@ KF_%'_(
MQ>#?^PU)_P"F^\KI*YOQ1_R,7@S_ +#4G_IOO* .DHHHH ***P-7\32Z7XOT
M'1/[+EEBUB26/[=YJ*D+)"\FW;RS$B/T  /4GB@#?HKC9/'DX\52Z=%I,<EC
M;ZG%I<TPN_\ 2!+)$) X@V<QX898N#@.V"%YFF\;M%JLY&GJ=$MK^/3)M1-Q
MAQ<.RH,1;<&,/(B%RP(;/RD#- '65S=C_P E3UW_ + NF_\ H^^KI*YNQ_Y*
MGKO_ &!=-_\ 1]]0!TE%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %8GC600^ ?$$KRI"J:9<L99(1*J 1-\Q0@AP.NTC!Z5MUC>,7>/P-K
MKQ2W$+KIMP5DM4WS(?*;!1<C+#L,C)QR* -FBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#$M) ?'VJQ"5"RZ99,8A" R@RW7S%\98
M'! 7.%VDC[QSMUC6KN?'.J(9;@H--LR(V3$*DRW.2K9Y8X&X8& J<G/&S0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B>+9!%HMNS2I$
M#J>GKN>$2@DWD("X(."<X#=5)##!&:VZQO%+NFCP&.6XB/\ :5B-ULFYB#=Q
M @C(^4C(8]E+'!Q@[- !1110 4444 %%%% !1110 4444 %%%% !114-Y>6]
MA:275[,L,$8R[N< "@3:2NR1Y$BC:25E1%!+,QP /4FO/=3US4_&^H2:/X5+
M0:<AVW5^00&'H/;VZGV%1RS:K\2;UH;,R6'AZ)\/*1AIR/Y_3H.^3@5WNF:9
M::/I\=EI\*PPQC@#J3ZD]S[U.YQWEB=(Z0[]_3R*V@>'['PYIJVFGQXSS)*W
MWI&]2?Z=JU***HZXQ45RQV"L309 ^M>)E$J2&/4T4JL(0QG[';':2!\YYSN.
M3@A>B@5MUC:&[MK'B,/+<.%U) JS)A4'V2W.(SDY7))SQ\Q88XR0HV:*** (
M[BWANK=X+F))8I!M='&0P]Q7!WWA;5O"=X^J>"Y&EMV.Z;37)8,/;U_F.V:]
M HI-7,:M&-3?1K9]3GO#/C'3_$D?EH?LU\@_>6LA^88ZX]1_DUT-<OXE\$6F
MMR?;;)SI^J(=R7,7&X]MV/YCGZ]*R]*\:7NBWJZ1XWA^SRXQ%>@?)*/4XX_$
M?B!2O;<R5:5)\M;[^GS['>44B.LB*\;!E895E.01ZTM4=84444 %%%% !111
M0 4444 %%%% !7-^*/\ D8O!G_8:D_\ 3?>5TE<WXH_Y&+P;_P!AJ3_TWWE
M'24444 %<?XKM=4G\;>$;K3]&NKVUTZ[FFNIXI856-7@DA'#R*Q(+@G / .,
MGBNPHH \TOO#.N3_ !&75X]-E34(M03[/K<4\0@73MJ^9;2Q[@[DXDQ\C89E
M8.H!Q9NO#.K/]M\.1V+'3;[6TU0ZGYL>R.+STN)(BF=_F%T91A2NU@V[(*UZ
M%10 V2,2Q/&Q8*ZE258J<'T(Y!]Q7 Z7X2TZ#XG:S&ESK!6/1[$@OK=XY.^2
M]5LDRDG  QG[IR5P237H%<W8_P#)4]=_[ NF_P#H^^H LCPEIP15%SK&%A,
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M;=;O%("  8(E^4\<D8+');))K;HH QG\+:>\DCM<:L#).L[;=8NP PS@ "7
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M"#G/F\-Q]_[Q&1G!-;=% ''Q^%K2;Q9JL,C:ZL#:=9 3#6+I48J\ZX1@X8,
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M$0'_ (G=YG:"#G/F\-Q]_P"\1D9P36W10!B2>$M.E656N=8 E5$;;K=XI 0
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M/K.CVVG>+/"D]O+>N\^LL'%Q?33J,:?>8VK(Y">^T#/?-=G7-^*/^1B\&?\
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M@8VZQ+1@?'VJH)("PTRR)C6+$J@RW7+/CE3@X&3@AC@;LG;H **** "BBB@
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M^P+IO_H^^H Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1MP2.#G!/8$GG&*VZQ_%!E&D0>1]KW?VC8Y^R9W[?M<6[./X,9W_ .QNK8H
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M=2DC\U+(SJ)F3GY@F=Q'!YQC@T 7*YNQ_P"2IZ[_ -@73?\ T??5TE<W8_\
M)4]=_P"P+IO_ */OJ .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K%\9Q^=X#U^+R9)]^F7*^5%*(V?,3?*'((4GID@XZXK:K$\:H)/
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ME4,Y61EU64E8>,.!]G&6Z_+D 8'S'/&S10!B1W?BHK%YVC:.I*N90NKRMM8
M[ /]&&X$XR3C'8-TH%WXJV*3HVCAO)+,!J\N!+DX4'[-RN,'=U!)&TXR=NB@
M#$:[\5!9-FC:.6$*% =7E :0[=ZG_1N%'S8;DG ^5<G!+=>*1YODZ/I#X9!%
MOU:5=ZX.XM_HQVD'& ,YR>1C!VZ* ,<W/B7S\#2=*\K[3MW?VI)N\C/W\?9_
MOX_@SC_;IL=UXH/E>=H^D+EW$NW5I6VJ -A'^C#<2<Y!QC P6S@;5% &(EWX
MJ*Q^9HVCJQB<R!=7E(609V*/]&Y4_+EN",G"MCD-WXJV-C1M'W>2& _M>7!E
MR,KG[-]W&3NZY &T9R-NB@#C8KKQ"/&6K&WTS0Y+P:;8_N3J,J-C?<9+2?9S
M\NXR!0 3\I)QNP-E[KQ,))!'I&DL@G58RVJR@M%SN<C[.<,/EPN2#D_,,<MM
M) ?'VJQ"5"RZ99,8A" R@RW7S%\98'! 7.%VDC[QSMT 8R77B8R1B32-)5#.
M5D9=5E)6'C#@?9QENORY &!\QSPV.[\5%8O.T;1U)5S*%U>5MK '8!_HPW G
M&2<8[!NE;=% &(+OQ5L4G1M'#>268#5Y<"7)PH/V;E<8.[J"2-IQDC7?BH+)
MLT;1RPA0H#J\H#2';O4_Z-PH^;#<DX'RKDXVZ* ,26Z\4CS?)T?2'PR"+?JT
MJ[UP=Q;_ $8[2#C &<Y/(Q@O-SXE\_ TG2O*^T[=W]J2;O(S]_'V?[^/X,X_
MVZV** ,6.Z\4'RO.T?2%R[B7;JTK;5 &PC_1AN).<@XQ@8+9P$2[\5%8_,T;
M1U8Q.9 NKRD+(,[%'^C<J?ERW!&3A6QSMT4 8AN_%6QL:-H^[R0P']KRX,N1
ME<_9ONXR=W7( VC.027?BH++Y.C:.S!4,8;5Y5#,0-X/^C' !R >=P )"YP-
MNB@#&>Z\3"201Z1I+()U6,MJLH+1<[G(^SG##Y<+D@Y/S#'(EUXF,D8DTC25
M0SE9&75925AXPX'V<9;K\N0!@?,<\;-% &)'=^*BL7G:-HZDJYE"ZO*VU@#L
M _T8;@3C).,=@W2@7?BK8I.C:.&\DLP&KRX$N3A0?LW*XP=W4$D;3C)VZ* ,
M1KOQ4%DV:-HY80H4!U>4!I#MWJ?]&X4?-AN2<#Y5R<$MUXI'F^3H^D/AD$6_
M5I5WK@[BW^C':0<8 SG)Y&,';HH QS<^)?/P-)TKROM.W=_:DF[R,_?Q]G^_
MC^#./]NFQW7B@^5YVCZ0N7<2[=6E;:H V$?Z,-Q)SD'&,#!;.!M44 <3XIN_
M$_\ 8=H9](T"/-]9E_.U29T67[9'Y:+BVR=QV ,<;6;."%YVS=^*MC8T;1]W
MDA@/[7EP9<C*Y^S?=QD[NN0!M&<@\6R"+1;=FE2('4]/7<\(E!)O(0%P0<$Y
MP&ZJ2&&",UMT 8DEWXJ"R^3HVCLP5#&&U>50S$#>#_HQP <@'G< "0N<!SW7
MB822"/2-)9!.JQEM5E!:+G<Y'V<X8?+A<D')^88YV:* ,9+KQ,9(Q)I&DJAG
M*R,NJRDK#QAP/LXRW7Y<@# ^8YXR=9\6:QX=L8;G6=+TF/>'#10ZM([E@/E"
M VXW G&2=NW_ &NAO^*?%UIX;M@N/M%_*,06J'ECV)]!_/M6-X?\(7>H:@-?
M\8MY]XWS0VK?=A';(]O3MWR:EOHCFJ59.7LZ6K_!?UV,B/0_$WBV_BUO6+*U
MELPC/;:?<7;P#/&T'$;_ "GN>O3@BNS^T>)XX66#1-& 2!/*3^UI5!D^7<AQ
M;<*!NPPR3@?*N>-VBFE8NE2C37=O=]S$ENO%(\WR='TA\,@BWZM*N]<'<6_T
M8[2#C &<Y/(Q@O-SXE\_ TG2O*^T[=W]J2;O(S]_'V?[^/X,X_VZV**9L8L=
MUXH/E>=H^D+EW$NW5I6VJ -A'^C#<2<Y!QC P6S@(EWXJ*Q^9HVCJQB<R!=7
ME(609V*/]&Y4_+EN",G"MCG;HH Q#=^*MC8T;1]WDA@/[7EP9<C*Y^S?=QD[
MNN0!M&<@DN_%067R=&T=F"H8PVKRJ&8@;P?]&. #D \[@ 2%S@;=% &,]UXF
M$D@CTC2603JL9;5906BYW.1]G.&'RX7)!R?F&.1+KQ,9(Q)I&DJAG*R,NJRD
MK#QAP/LXRW7Y<@# ^8YXV:* ,2.[\5%8O.T;1U)5S*%U>5MK '8!_HPW G&2
M<8[!NE N_%6Q2=&T<-Y)9@-7EP)<G"@_9N5Q@[NH)(VG&3MT4 8C7?BH+)LT
M;1RPA0H#J\H#2';O4_Z-PH^;#<DX'RKDX);KQ2/-\G1](?#((M^K2KO7!W%O
M]&.T@XP!G.3R,8.W10!CFY\2^?@:3I7E?:=N[^U)-WD9^_C[/]_'\&<?[=8N
M@W7B ZMK>W3-#,C:G_I:PZC*##BTM]F2;?\ >,1@G[H52H^;!KLJQ-!D#ZUX
MF42I(8]312JPA#&?L=L=I('SGG.XY."%Z*!0 )=^*BL?F:-HZL8G,@75Y2%D
M&=BC_1N5/RY;@C)PK8Y#=^*MC8T;1]WDA@/[7EP9<C*Y^S?=QD[NN0!M&<C;
MHH Q)+OQ4%E\G1M'9@J&,-J\JAF(&\'_ $8X .0#SN !(7. Y[KQ,))!'I&D
ML@G58RVJR@M%SN<C[.<,/EPN2#D_,,<[-% &,EUXF,D8DTC250SE9&75925A
MXPX'V<9;K\N0!@?,<\-CN_%16+SM&T=25<RA=7E;:P!V ?Z,-P)QDG&.P;I6
MW10!B"[\5;%)T;1PWDEF U>7 ER<*#]FY7&#NZ@DC:<9(UWXJ"R;-&T<L(4*
M ZO* TAV[U/^C<*/FPW).!\JY.-NB@#$ENO%(\WR='TA\,@BWZM*N]<'<6_T
M8[2#C &<Y/(Q@O-SXE\_ TG2O*^T[=W]J2;O(S]_'V?[^/X,X_VZV** ,6.Z
M\4'RO.T?2%R[B7;JTK;5 &PC_1AN).<@XQ@8+9P$2[\5%8_,T;1U8Q.9 NKR
MD+(,[%'^C<J?ERW!&3A6QSMT4 8AN_%6QL:-H^[R0P']KRX,N1E<_9ONXR=W
M7( VC.027?BH++Y.C:.S!4,8;5Y5#,0-X/\ HQP <@'G< "0N<#;HH QGNO$
MPDD$>D:2R"=5C+:K*"T7.YR/LYPP^7"Y(.3\PQR)=>)C)&)-(TE4,Y61EU64
ME8>,.!]G&6Z_+D 8'S'/&S10!STX\0ZA9K;ZEH&B212HXGC.JRN <'8!FV&<
MG&3P5ZC=BN1@T/Q9X-+:CI5O;M:,-]QIL5T]P%.3G:6C0D8V_,!GD@@@9/I]
M%)JYC5HQJ:[-;,XO1/&NI^(X[@Z3IFE&6.-2L%QJLD<A?(W!@+<X4#=A@6S@
M A<\+K,VK2>+/"BZG965O NLMY#V]X\S/_Q+[S=N4Q(%QVP6S[5-XD\#0ZE<
M?VGHLO\ 9VK(=RRQG:KG_:QT/N/QS7'ZUXQU6TNM(@U^P,>IZ1?BZ\Q<!9D,
M4D1XZ<K*W(X_*E>VY@\0Z.E?[UL_\F>NT5%;7$5W:Q7-NX>*9 Z,.X(R#4M4
M=NX4444 %%%% !7-V/\ R5/7?^P+IO\ Z/OJZ2N;L?\ DJ>N_P#8%TW_ -'W
MU '24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>,7>/P
M-KKQ2W$+KIMP5DM4WS(?*;!1<C+#L,C)QR*V:QO&*/)X&UU(HKF9VTVX"QVC
M;9G/E-@(<'#'L<'G'!H V:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,:U=SXYU1#+<%!IMF1&R8A4F6YR5;/+' W# P%3DYXV:QK
M5''CG5',5R$;3;,"1F_<L1+<Y"C'##(W')R"G QSLT %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 8WBEW31X#'+<1'^TK$;K9-S$&[B!!
M&1\I&0Q[*6.#C!V:QO%*/)H\ CBN93_:5B2MLVU@!=Q$D\'Y0 2P[J&&1U&S
M0 5RGBKQFNE2C2]&C^VZQ,=J1(-PC)[M[^WYU3\1^,;BYO\ ^P/"*_:=1D)6
M2=>5@'?GID>O0?6M3PKX.M?#D1GD;[5J4HS-=/R<GJ%ST'OU/>IO?1')*I*K
M+DI?-_Y>?Y%3PMX+_L^Y.KZ]+]MUB4[B[G<(B?3W]^W05UU%%-*QO3IQIQY8
MA1113- HHHH **** "BBB@ HHHH **** "BBB@ K&T-W;6/$8>6X<+J2!5F3
M"H/LEN<1G)RN23GCYBPQQD[-8VAHZZQXC+Q7*!]20HTS95Q]DMQF/@87((QS
M\P<YYP #9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ'
MQ;I/B'5/$RW-YI\D;:A<&WLXV=>=L;N%Z]=D;'\#7MU<WXH_Y&+P;_V&I/\
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M* "BBB@ HHHH **** "BBB@ HHHH *Q-!C":UXF80K&9-31BRRAS)_H=L-Q
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M.XP<CC!Z5MUB>-)?(\!:_*9GM_+TRY;SHXA(T>(F.X(2 Q'7!(STH VZ***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,2T8'Q]JJ"2
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M]J?Y2?\ QVC_ (5WXA_Z'[4_RD_^.T?5<+_T$+_P&7^0>TJ_R?BCT&BO/O\
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M8$1)8QCY?NDDG'3))H;P5X5=9%?PUH[++"D#@V$1#QIMV(?EY4;5P.@VCT%
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M_)4]=_[ NF_^C[ZNDKF['_DJ>N_]@73?_1]]0!TE%%% !1110 4444 %%%%
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MVAN[:QXC#RW#A=20*LR85!]DMSB,Y.5R2<\?,6&.,D V:*** "BBB@ HHHH
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M/S5*OPZ+OU,_1?AUYUX-5\9W1U;4&P?*8YB3VQ_%].![5W2JJ(%10JJ,  8
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MS=C_ ,E3UW_L"Z;_ .C[ZNDKF['_ )*GKO\ V!=-_P#1]]0!TE%%% !1110
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M*-(@\C[7N_M&QS]DSOV_:XMV<?P8SO\ ]C=6Q0 4444 %%%% !1110 4444
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MZ?H5F;C4[E84_A!Y9SZ =37%-JGB7QVQBT6-M(T@G#74G#R#VQ_)?Q-7M(\
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M@" 1G-;58GBU ^BVX:*&4?VGIYVSR^6H(O(3D'(RPZJN?F8 8.<';H ****
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M_P!Y^N/88'M72445PSG*<N:3NRM@K%T*/9K/B5O)DC\S4T;<\H<2?Z';C<H
M^4<8P<\J3GD ;58F@H%UKQ,1%"A;4T):*7>SG[';#+C)V-QC;@?*%./FR9 V
MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOQ1_R,7@S_
M +#4G_IOO*Z2N;\4?\C%X-_[#4G_ *;[R@#I**** "BBB@ HHHH *YNQ_P"2
MIZ[_ -@73?\ T??5TE<W8_\ )4]=_P"P+IO_ */OJ .DHHHH **** "BBB@
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M98'! 7.%VDC[QSMT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW?\ +'7[WLOE<CVDZG\-:=W_ )&%_;'C3QG\NAV@T/36_P"7J<_O&'J#C/\
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M;@G4TW&%B68_8[;F3)P&Q@8&!M"GJ22 ;=%%% !1110 4444 %%%% !1110
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M* "N;\4?\C%X-_[#4G_IOO*Z2N;\4?\ (Q>#/^PU)_Z;[R@#I**** "BBB@
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MH Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L3QJ@D\
M^($:*&56TRY!CN)?*C<>4W#OD;5/=LC YR*VZQ/&I4> ?$!=K=5&F7.6NE+1
M >4W+@ DKZ@ G&: -NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHH *YOQ1_P C%X-_[#4G_IOO*Z2N;\4?\C%X,_[#4G_IOO* .DHHHH ****
M/*-:L-1_X6=/J5GI]_%J2WUHEM#%9N]A?V@50\T\F-BS)OFVL65@(XU ;/S6
M],TR^\K0?"[6-VEQH^KR7MS=M;NL!@5I61EE(VNS^8@VJ2PR^0,&O3** &R*
M7B=%D:-F4@.H&5/J,@C/U!K@=+T'48OB=K*OXLUB9ET>Q)=XK,%]TEZJ@X@
M^0@L, <D[MPP!Z!7-V/_ "5/7?\ L"Z;_P"C[Z@"R-!U$(JGQ9K!(A,18Q6>
M68DGS#^XQN (&/NX RI.21M!U%ED \6:PI>%(P1%9Y1EVYD&8/O-@YSE?F.
M.,;=% &)+H6HR>;L\5ZO%YC(R[(K/]V ""JY@/#9R<Y/ P1SEYT2_P#/\S_A
M)]5"_:?.\ORK3;LS_J?]1G9[YW_[5;%% &+'H6HIY6[Q7J\FQW9MT5G^\#
M*<0#A<$C&#R<D\ (F@ZBJQAO%FL.4B>-BT5GEV;.'.(/O+D8QA?E&0><[=%
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M9_PD^JA?M/G>7Y5IMV9_U/\ J,[/?.__ &J;'H6HIY6[Q7J\FQW9MT5G^\#
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MX2?50OVGSO+\JTV[,_ZG_49V>^=_^U38]"U%/*W>*]7DV.[-NBL_W@8 !3B
M<+@D8P>3DG@#:HH Q$T'456,-XLUARD3QL6BL\NS9PYQ!]Y<C&,+\HR#SD.@
MZB48?\)9K )A$0;RK/(8$'S/]1]XXQC[N"?ES@C;HH XV+2KV;QEJUI'XJU&
M*8:;8OOCM;02H-]PN=Y@(8,48[2#M+/C 8 ;+Z'J#22,OBC5D#SK*J+%:811
MG,8S!G:<C).6^488<Y+5W/CG5$,MP4&FV9$;)B%29;G)5L\L<#<,# 5.3GC9
MH QDT/4%DC9O%&K.$G,K(T5IAU./W1Q!G:,'D$-R<L>,-CT'446(-XLUB0HK
MABT5G^\+ @$X@'*YR,8''.[I6W10!B#0=1"*I\6:P2(3$6,5GEF))\P_N,;@
M"!C[N ,J3DD;0=199 /%FL*7A2,$16>49=N9!F#[S8.<Y7YC@#C&W10!B2Z%
MJ,GF[/%>KQ>8R,NR*S_=@ @JN8#PV<G.3P,$<Y>=$O\ S_,_X2?50OVGSO+\
MJTV[,_ZG_49V>^=_^U6Q10!BQZ%J*>5N\5ZO)L=V;=%9_O P "G$ X7!(Q@\
MG)/ ")H.HJL8;Q9K#E(GC8M%9Y=FSASB#[RY&,87Y1D'G.W10!B'0=1*,/\
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M45PQ:*S_ 'A8$ G$ Y7.1C XYW=*!H.HA%4^+-8)$)B+&*SRS$D^8?W&-P!
MQ]W &5)R3MT4 8C:#J++(!XLUA2\*1@B*SRC+MS(,P?>;!SG*_,< <8)="U&
M3S=GBO5XO,9&79%9_NP 057,!X;.3G)X&".<[=% &.=$O_/\S_A)]5"_:?.\
MORK3;LS_ *G_ %&=GOG?_M5BZ#I=Z^K:W&/%6HR-::GME*VMHC2[K2W8+(1!
M\Q4$$,NTX(4YVUV58VAN[:QXC#RW#A=20*LR85!]DMSB,Y.5R2<\?,6&.,D
M:F@ZBJQAO%FL.4B>-BT5GEV;.'.(/O+D8QA?E&0><AT'42C#_A+-8!,(B#>5
M9Y# @^9_J/O'&,?=P3\N<$;=% &))H.HNLH7Q9K$9=452L5GF,J "PS >6QD
MYR,D[0HP*<^AZ@TDC+XHU9 \ZRJBQ6F$49S&,P9VG(R3EOE&&'.=FB@#&30]
M062-F\4:LX2<RLC16F'4X_='$&=HP>00W)RQXPV/0=118@WBS6)"BN&+16?[
MPL" 3B <KG(Q@<<[NE;=% &(-!U$(JGQ9K!(A,18Q6>68DGS#^XQN (&/NX
MRI.21M!U%ED \6:PI>%(P1%9Y1EVYD&8/O-@YSE?F. .,;=% &)+H6HR>;L\
M5ZO%YC(R[(K/]V ""JY@/#9R<Y/ P1SEYT2_\_S/^$GU4+]I\[R_*M-NS/\
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MOF)OE+G 4'IN/3K0!MT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 8UJCCQSJCF*Y"-IMF!(S?N6(EN<A1CAAD;CDY!3@8YV:Q+2,#
MQ]JLODJ"VF62F42@LV);KY2G50,YW=]Q'\)K;H **** "BBB@ HHHH ****
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M !7-^*/^1B\&_P#8:D_]-]Y725S?BC_D8O!G_8:D_P#3?>4 =)1110 4444
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M^SK/;OSY&[S+G.S_ &\;=WMY=;% !1110 4444 %%%% !1110 4444 %%%%
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MKPG*^3N ^88)&#R 3M./1*J1Z9;Q:U<ZH@;[3<V\5M(=W&R)I&7CUS,_Z>E
M&-_PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\ "<U#_P",5TE% '-_\)YI'_/G
MX@_\)S4/_C%'_">:1_SY^(/_  G-0_\ C%=)10!S?_">:1_SY^(/_"<U#_XQ
M1_PGFD?\^?B#_P )S4/_ (Q7244 <W_PGFD?\^?B#_PG-0_^,4?\)YI'_/GX
M@_\ "<U#_P",5TE% '-_\)YI'_/GX@_\)S4/_C%'_">:1_SY^(/_  G-0_\
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M8KI** .;_P"$\TC_ )\_$'_A.:A_\8H_X3S2/^?/Q!_X3FH?_&*Z2B@#F_\
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M%4- T*T\.Z1'I]B9'56+R33.7DFD8Y:1V/5B>2?Z5I4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5@^(SX@GFM+#PU<VM@\PDDFOKJV,ZQJFW
M"*@9<LQ;J3P%;OBMZB@#S6RCU^SN9KVXL;?5;+5I)+;6-'5U4BX0&-IK<2,
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MGA>"WM]&NM73[9JNEVAMH;J<[I$4X!)/3>0J@L.O/.":Z&BB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** *VI7,MGI=W<VT#7,T,+R1PJ>9&"D
MA1]2,5Y_J&D^.)M1LOM.L:9)JL*/>Z=<V]J\,*N,++:2@NQ>-U<$-PP*9QD
M5Z36!XJ\.W7B)+.WM]2DT^W61A>-!Q++"5P8T;^ DX!8<@9Q@X( ,?1]&.MZ
MM>:O=:3+I46KZ:UKJEN+B-X[M_E$<J/&QS\C2#?P2&7H5P.OL;&UTS3X+'3K
M>.VM;=!'%#$NU44= !3K.TM]/L8+.RA2"VMXUBAB085$4850/0  5-0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\
MO_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\
M)5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%
M<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J
M_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X
M@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I
M_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'
M_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]
M")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\
MO_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\
M)5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%
M<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J
M_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X
M@_[_ .G_ /R51_PE&K_]")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I
M_P#\E4?\)1J__0B>(/\ O_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'
M_"4:O_T(GB#_ +_Z?_\ )5 '245S?_"4:O\ ]")X@_[_ .G_ /R51_PE&K_]
M")X@_P"_^G__ "50!TE%<W_PE&K_ /0B>(/^_P#I_P#\E4?\)1J__0B>(/\
MO_I__P E4 =)17-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\
M)5 '245S?_"4:O\ ]")X@_[_ .G_ /R56EH&M1^(-(6_BM;BT_?30/!<[/,C
M>*5XG!V,R_>1N02,4 :5%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMY;V-I%K+^9<7,JQQIFPNP,LQ &20/J:L_\ "QO!'_0Y>'__  :0?_%5TE%
M'-_\+&\$?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5TE% '-_\+&\$
M?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5TE% '-_\+&\$?]#EX?\
M_!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5TE% '-_\+&\$?]#EX?\ _!I!_P#%
M4?\ "QO!'_0Y>'__  :0?_%5TE% '-_\+&\$?]#EX?\ _!I!_P#%4?\ "QO!
M'_0Y>'__  :0?_%5TE% '-_\+&\$?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__
M  :0?_%5TE% '-_\+&\$?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5
MTE% '-_\+&\$?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5TE% '-_\
M+&\$?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5TE% '-_\+&\$?]#E
MX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5TE% '-_\+&\$?]#EX?\ _!I!
M_P#%4?\ "QO!'_0Y>'__  :0?_%5TE% '-_\+&\$?]#EX?\ _!I!_P#%4?\
M"QO!'_0Y>'__  :0?_%5TE% '-_\+&\$?]#EX?\ _!I!_P#%4?\ "QO!'_0Y
M>'__  :0?_%5TE% '-_\+&\$?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0
M?_%5TE% '-_\+&\$?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5TE%
M'-_\+&\$?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5TE% '-_\+&\$
M?]#EX?\ _!I!_P#%4?\ "QO!'_0Y>'__  :0?_%5TE% '-_\+&\$?]#EX?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_1.jpg
<DESCRIPTION>EXHIBIT 10.50 GRAPHIC
<TEXT>
begin 644 image_1.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  I )8# 2(  A$! Q$!_\0
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M;7XF>88C#5\35RW)X*G1I0G*4H_%)PBW\6[5]-]=]58^BZ**\>_:4_:2T?\
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AV'P@4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278875440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GILEAD SCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3047598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">333 Lakeside Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">574-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value, $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GILD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,247,105,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Specified portions of the registrant&#8217;s proxy statement, which will be filed with the Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2023 Annual Meeting of Stockholders, to be held on May 3, 2023, are incorporated by reference into Part&#160;III of this Report.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278866752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460277493888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,412<span></span>
</td>
<td class="nump">$ 5,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">973<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">4,777<span></span>
</td>
<td class="nump">4,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,507<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,774<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">14,443<span></span>
</td>
<td class="nump">14,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,475<span></span>
</td>
<td class="nump">5,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">1,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">28,894<span></span>
</td>
<td class="nump">33,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,314<span></span>
</td>
<td class="nump">8,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">4,963<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">63,171<span></span>
</td>
<td class="nump">67,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">3,479<span></span>
</td>
<td class="nump">3,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">4,580<span></span>
</td>
<td class="nump">6,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of long-term debt and other obligations, net</a></td>
<td class="nump">2,273<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,237<span></span>
</td>
<td class="nump">11,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">22,957<span></span>
</td>
<td class="nump">25,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable</a></td>
<td class="nump">3,916<span></span>
</td>
<td class="nump">4,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">2,673<span></span>
</td>
<td class="nump">4,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share; 5,600 authorized; 1,247 and 1,254 shares issued and outstanding, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">5,550<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">15,687<span></span>
</td>
<td class="nump">16,324<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Gilead stockholders&#8217; equity</a></td>
<td class="nump">21,240<span></span>
</td>
<td class="nump">21,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">21,209<span></span>
</td>
<td class="nump">21,064<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 63,171<span></span>
</td>
<td class="nump">$ 67,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Rebates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278200448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">5,600,000,000<span></span>
</td>
<td class="nump">5,600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">1,247,000,000<span></span>
</td>
<td class="nump">1,254,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">1,247,000,000<span></span>
</td>
<td class="nump">1,254,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460284359008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 27,281<span></span>
</td>
<td class="nump">$ 27,305<span></span>
</td>
<td class="nump">$ 24,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">5,657<span></span>
</td>
<td class="nump">6,601<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">4,977<span></span>
</td>
<td class="nump">4,601<span></span>
</td>
<td class="nump">4,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="nump">5,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">5,673<span></span>
</td>
<td class="nump">5,246<span></span>
</td>
<td class="nump">5,151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">19,951<span></span>
</td>
<td class="nump">17,387<span></span>
</td>
<td class="nump">20,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">7,330<span></span>
</td>
<td class="nump">9,918<span></span>
</td>
<td class="nump">4,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
<td class="num">(984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(581)<span></span>
</td>
<td class="num">(639)<span></span>
</td>
<td class="num">(1,418)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">5,814<span></span>
</td>
<td class="nump">8,278<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(1,248)<span></span>
</td>
<td class="num">(2,077)<span></span>
</td>
<td class="num">(1,580)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,566<span></span>
</td>
<td class="nump">6,201<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Gilead</a></td>
<td class="nump">$ 4,592<span></span>
</td>
<td class="nump">$ 6,225<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Gilead (in dollars per share)</a></td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="nump">$ 4.96<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in basic earnings per share attributable to Gilead calculation (in shares)</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Gilead (in dollars per share)</a></td>
<td class="nump">$ 3.64<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in diluted earnings per share attributable to Gilead calculation (in shares)</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 26,982<span></span>
</td>
<td class="nump">$ 27,008<span></span>
</td>
<td class="nump">$ 24,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278245168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,566<span></span>
</td>
<td class="nump">$ 6,201<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation loss</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss), net of tax impact of $0, $(1) and $12, respectively</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to net income, net of tax impact of $0, $0 and $12, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Net unrealized gain (loss), net of tax impact of $20, $18 and $(15), respectively</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to net income, net of tax impact of $25, $(9) and $6, respectively</a></td>
<td class="num">(171)<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="num">(41)<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(81)<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="nump">4,485<span></span>
</td>
<td class="nump">6,344<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interest</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Gilead</a></td>
<td class="nump">$ 4,511<span></span>
</td>
<td class="nump">$ 6,368<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278996224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract', window );"><strong>Available-for-sale debt securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Tax impact of net unrealized gain (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Tax impact of reclassifications to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract', window );"><strong>Cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Tax impact of net unrealized gain (loss)</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax', window );">Tax impact of reclassifications to net income</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460277952944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect from the adoption of new accounting standard</div></th>
<th class="th"><div>Common Stock&#160;</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative effect from the adoption of new accounting standard</div>
</th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 22,650<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 3,051<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 19,388<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Change in noncontrolling interest</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(1,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(3,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">18,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">14,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">6,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (3,618)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,618)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 21,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">16,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">4,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuances under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances under equity incentive plans</a></td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of common stock</a></td>
<td class="num">(1,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (3,725)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,725)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 21,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 5,550<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 15,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278204768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared (in dollars per share)</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 2.92<span></span>
</td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278965712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,566<span></span>
</td>
<td class="nump">$ 6,201<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
<td class="nump">1,780<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">635<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(1,552)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Net loss from equity securities</a></td>
<td class="nump">657<span></span>
</td>
<td class="nump">610<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="nump">5,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(406)<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="num">(1,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(310)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="nump">70<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">226<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(568)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
<td class="num">(778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(775)<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">9,072<span></span>
</td>
<td class="nump">11,384<span></span>
</td>
<td class="nump">8,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable debt securities</a></td>
<td class="num">(1,770)<span></span>
</td>
<td class="num">(3,517)<span></span>
</td>
<td class="num">(20,315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable debt securities</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">730<span></span>
</td>
<td class="nump">23,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable debt securities</a></td>
<td class="nump">1,590<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
<td class="nump">9,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, including in-process research and development, net of cash acquired</a></td>
<td class="num">(1,797)<span></span>
</td>
<td class="num">(1,584)<span></span>
</td>
<td class="num">(25,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchases of equity securities</a></td>
<td class="num">(172)<span></span>
</td>
<td class="num">(380)<span></span>
</td>
<td class="num">(455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(728)<span></span>
</td>
<td class="num">(579)<span></span>
</td>
<td class="num">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,466)<span></span>
</td>
<td class="num">(3,131)<span></span>
</td>
<td class="num">(14,615)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt financing, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(1,396)<span></span>
</td>
<td class="num">(546)<span></span>
</td>
<td class="num">(1,583)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt and other obligations</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="num">(4,750)<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="num">(3,709)<span></span>
</td>
<td class="num">(3,605)<span></span>
</td>
<td class="num">(3,449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(173)<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(6,469)<span></span>
</td>
<td class="num">(8,877)<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">74<span></span>
</td>
<td class="num">(659)<span></span>
</td>
<td class="num">(5,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">5,997<span></span>
</td>
<td class="nump">11,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">5,412<span></span>
</td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">5,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid, net of amounts capitalized</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="nump">951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">$ 3,136<span></span>
</td>
<td class="nump">$ 2,509<span></span>
</td>
<td class="nump">$ 2,639<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285104656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Organization</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (&#8220;Gilead,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketed products includes AmBisome</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Atripla</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biktarvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cayston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Complera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Descovy for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Emtriva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epclusa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Eviplera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Genvoya</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Harvoni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepcludex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Hepsera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jyseleca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Letairis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Odefsey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ranexa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sovaldi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Stribild</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Sunlenca</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tecartus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trodelvy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Truvada for PrEP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tybost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vemlidy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Viread</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vosevi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Yescarta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zydelig</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The approval status of Hepcludex and Jyseleca vary worldwide, and Hepcludex and Jyseleca are not approved in the U.S. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the U.S. through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#8220;R&amp;D&#8221;) projects based on unmet medical need, scientific data, probability of technical and regulatory successful development, market potential and other considerations, and, as necessary, reallocate resources among our internal R&amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Significant Accounting Policies</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles and include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities (&#8220;VIEs&#8221;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates. Certain amounts and percentages herein may not sum or recalculate due to rounding.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2022, expenses related to development milestones and other collaboration payments made prior to regulatory approval of a developed product were reclassified from Research and development expenses to Acquired in-process research and development expenses on our Consolidated Statements of Income. Concurrently, we reclassified the cash payments related to these expenses from Other to Acquisitions, including in-process research and development, net of cash acquired within Investing Activities in the Consolidated Statements of Cash Flows. We believe this presentation assists users of the financial statements to better understand the total costs incurred to acquire in-process research and development (&#8220;IPR&amp;D&#8221;) projects. Prior periods have been revised to reflect this classification, resulting in a reduction of previously-reported Research and development expenses of $762 million and $112 million for the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales when control of the product transfers to the customer, which is generally upon shipment or delivery, or in certain cases, upon the corresponding sales by our customer to a third party. Revenues are recognized net of estimated rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a financing component. Shipping and handling activities are considered to be fulfillment activities and not a separate performance obligation.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Gross-to-Net Deductions </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are based on contractual arrangements or statutory requirements and include amounts due to payers and healthcare providers under various programs. These amounts may vary by product, payer and individual plans. Providers qualified under certain programs can purchase our products through wholesalers or other distributors at a discount. The wholesalers or distributors then charge the discount back to us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are estimated primarily based on product sales, including product mix and pricing, historical and estimated payer mix and discount rates, among other inputs, which require significant estimates and judgment. We assess and update our estimates each reporting period to reflect actual claims and other current information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Rebates that are payable to third party payers and healthcare providers are recorded in Accrued rebates on our Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor Fees</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually-determined covenants such as the maintenance of agreed-upon inventory levels. These distributor fees are based on a contractually-determined fixed percentage of sales.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for Sales Returns</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the U.S., we typically permit returns six months prior to and up to one year after the product expiration date. Outside the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Royalty, Contract and Other Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur. Contract and other revenues are recognized when the performance obligation is satisfied.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are recorded when incurred and consist primarily of clinical studies performed by contract research organizations (&#8220;CROs&#8221;), materials and supplies, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations consisting of various support and infrastructure costs. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of Research and development expenses.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical study costs are a significant component of Research and development expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for R&amp;D services prior to the services being rendered are recorded as prepaid assets within Prepaid and other current assets on our Consolidated Balance Sheets and are expensed as the services are provided.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-Process Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development expenses are recorded when incurred and reflect costs of externally-developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront and milestone payments related to various collaborations and the costs of rights to IPR&amp;D projects. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are recorded when incurred and consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs related to sales and marketing, finance, human resources, legal and other administrative activities. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expenses within Selling, general and administrative expenses, including promotional expenses, are recorded when incurred and were $778 million, $735 million and $795 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide stock-based compensation in the form of various types of equity-based awards, including restricted stock units (&#8220;RSUs&#8221;), performance share units (&#8220;PSUs&#8221;) and stock options, and through our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the &#8220;ESPP&#8221;). Stock-based compensation expense is based on the estimated fair value of the award on the grant date, or the first date of the ESPP purchase period, and recognized over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible or if an employee terminates due to death or disability.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of RSUs is based on the closing price of our common stock on the grant date. For PSUs, depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. For stock option and ESPP awards, estimated fair value is based on the Black-Scholes option valuation model. Estimated inputs to that model include (i) expected volatility, based on a blend of historical volatility of our common stock price along with implied volatility for traded options on our common stock, (ii) expected term in years, based on the weighted-average period awards are expected to remain outstanding using historical cancellation and exercise data, contractual terms and vesting terms of the award, (iii) risk-free interest rate, based on observed interest rates appropriate for the term of the stock-based awards, and (iv) expected dividend yield, based on our history and expectation of dividend payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock outstanding during the period. Diluted earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents are determined under the treasury stock method.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our marketable debt securities are classified as available-for-sale and carried at estimated fair values. We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. Unrealized gains and losses on available-for-sale debt securities are reported in Accumulated other comprehensive income on our Consolidated Balance Sheets until realized, at which point they are reclassified into Other income (expense), net on our Consolidated Statements of Income. Interest, amortization of purchase premiums and discounts, and expected credit losses, if any, are also recorded in Other income (expense), net on our Consolidated Statements of Income. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost bases. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in Accumulated other comprehensive income.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and estimated credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair values, including those for which we have elected the fair value option, are recorded at fair market value, and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Any impairments or adjustments are recorded in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting, with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in equity securities are classified in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets, generally depending on marketability and whether the securities are subject to lock-up provisions. We regularly review our securities for indicators of impairment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated&#160;Useful&#160;Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;35 years or useful&#160;life</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;useful&#160;life or lease&#160;term</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Impairment of Long-Lived Assets&#8221; for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at inception and classify each lease as operating or financing. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions, including Goodwill, Intangible Assets and Contingent Consideration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period, which may be up to one year from the acquisition date, with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the abandonment or completion of the associated R&amp;D efforts, which generally occurs when regulatory approval is obtained. Goodwill and indefinite-lived intangible assets are not amortized and, instead, are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and, are also periodically reviewed for changes in facts or circumstances resulting in a reduction to the estimated useful life of the asset, requiring the acceleration of amortization. See &#8220;Impairment of Long-Lived Assets&#8221; for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the initial fair value of an intangible asset, or when quantitative analysis is required to determine any impairment, we use a probability-weighted income approach that discounts expected future cash flows to present value using a discount rate that is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. These cash flow models require the use of Level 3 fair value measurements and inputs, including estimated revenues, which, for example, include significant inputs such as addressable patient population, treatment duration, projected market share, assessment of the asset&#8217;s life cycle, and competitive trends impacting the asset; costs and probability of technical and regulatory success, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value on our Consolidated Statements of Income until such time that the payment is made. Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and, therefore, no goodwill is recorded and contingent consideration generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are expensed as incurred on our Consolidated Statements of Income unless there is an alternative future use.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset over its useful life to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Unrealized changes in the fair value of derivatives designated as part of a hedge transaction are recorded in Accumulated other comprehensive income. For our hedges related to forecasted product sales, the unrealized gains or losses in Accumulated other comprehensive income are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using regression analysis, we assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize accruals for loss contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue the best estimate of loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision is computed under the liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance to reduce our deferred tax assets to the amounts that are more likely than not to be realized. We consider future taxable income, ongoing tax planning strategies and our historical financial performance in assessing the need for a valuation allowance. If we expect to realize deferred tax assets for which we have previously recorded a valuation allowance, we will reduce the valuation allowance in the period in which such determination is first made.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (&#8220;UTB&#8221;) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax expense on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for the tax on Global Intangible Low-Taxed Income, enacted as part of the Tax Cuts and Jobs Act, as a component of tax expense in the period in which the tax is incurred.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transactions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Financial Statements are presented in U.S. dollars. The functional currency for most of our foreign subsidiaries is their local currency. Revenues, expenses, gains and losses for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities for such entities are translated using exchange rates that approximate the rate at the balance sheet date. Foreign currency translation adjustments are recorded as a component of Accumulated other comprehensive income on our Consolidated Balance Sheets. Foreign currency transaction gains and losses on transactions not denominated in functional currency are recorded in Other income (expense), net, on our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value accounting for all financial and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285162736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text">REVENUES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Disaggregation of Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Total revenues:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HIV </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,820&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,194&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,828&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,315&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,651&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ledipasvir/</span></div><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,810&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="27" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis Delta virus (&#8220;HDV&#8221;)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cell therapy </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total cell therapy </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,884&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#8220;Janssen&#8221;). See Note 10. Collaborations and Other Arrangements for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes Atripla, Emtriva, Sunlenca and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes Cayston, Jyseleca, Ranexa and Zydelig.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenues from Major Customers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:61.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenues Recognized from Performance Obligations Satisfied in Prior Periods</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues recognized from performance obligations satisfied in prior periods:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:61.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue share with Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and royalties for licenses of intellectual property</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 10. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contract Balances</span></div>Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $171 million and $174 million as of December&#160;31, 2022 and 2021, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $102 million and $79 million as of December&#160;31, 2022 and 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285168896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS <div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: </span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos NV (&#8220;Galapagos&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,658&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,600&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,320&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 10. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Derivative Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimated fair values of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values, were approximately $21.9 billion and $28.6 billion as of December&#160;31, 2022 and 2021, respectively, and the carrying values were $24.1 billion and $25.6 billion as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 3 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our first quarter 2021 acquisition of MYR, we recorded a liability for contingent consideration, which is revalued each reporting period until the related contingency is resolved. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in fair value of our contingent consideration: </span></div><div style="margin-top:4.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange remeasurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Included in Research and development expenses on our Consolidated Statements of Income and primarily related to increasing discount rates and updated probability rate estimates.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Included in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a liability related to future royalties as part of our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#8220;Immunomedics&#8221;), which is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to future royalties were $1.1&#160;billion and $1.3&#160;billion as of December&#160;31, 2022 and 2021, respectively, and the carrying value was $1.1&#160;billion as of December&#160;31, 2022 and 2021. See Note 11. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we recorded a partial impairment charge of $2.7&#160;billion related to certain IPR&amp;D assets. See Note 8. Goodwill and Intangible Assets for additional information. There were no indicators of impairment noted during 2021.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fair Value Level Transfers</span></div>There were no transfers between Level 1, Level 2 and Level 3 in the periods<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460284665328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-sale Debt Securities and Equity Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Available-for-sale Debt Securities and Equity Securities</a></td>
<td class="text">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Available-for-Sale Debt Securities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:40.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:40.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No allowance for credit losses was recognized for investments with unrealized losses as of December&#160;31, 2022, as we do not currently intend to sell, and it is not more likely than not that we will be required to sell, such investments before recovery of their amortized cost bases. The unrealized losses were primarily driven by broader change in interest rates with no adverse conditions identified that would prevent the issuer from making scheduled principal and interest payments.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After ten years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Equity Securities</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities Measured at Fair Value</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Consolidated Balance Sheets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is classified in Other long-term assets due to certain lock-up provisions in our amended subscription agreement with them, which extend to August 2024.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Equity Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments and other equity investments without readily determinable fair values were $423 million and $338&#160;million as of December&#160;31, 2022 and 2021, respectively, and were excluded from the table above. These amounts were included in Other long-term assets on our Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrealized Gains and Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized losses recognized on equity securities were $657 million, $610 million and $1.7 billion for the years ended December&#160;31, 2022, 2021 and 2020, respectively, and were included in Other income (expense), net on our Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transaction</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, Gilead donated certain equity securities at fair value to the Gilead Foundation, a California nonprofit public benefit corporation (the &#8220;Foundation&#8221;). The Foundation is a related party as certain of our officers also serve as directors of the Foundation. The donation expense of $85 million and $212 million was recorded within Selling, general and administrative expenses on our Consolidated Statements of Income during the for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285155376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">DERIVATIVE FINANCIAL INSTRUMENTS<div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative instruments we use to hedge our exposures for certain monetary assets and liabilities that are denominated in a non-functional currency are not designated as hedges. The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of 18 months or less. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, we held foreign currency exchange contracts with outstanding notional amounts of $3.0 billion and $2.9 billion, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts in our Consolidated Balance Sheets on a gross basis. The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:42.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.437%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtMi0xLTEtMTY3NjY1_2f4084d2-5259-4bc5-8b05-5f700b1f1a8a">Derivative Assets</span></span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtNi0xLTEtMTY3NjY1_46ccc9b5-72b7-44ea-ba73-a4b1e8bd1b28">Derivative Liabilities</span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives presented gross on the Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts not offset on the Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash collateral received / pledged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount (legal offset)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:42.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtMi0xLTEtMjA2NjQ5_b7aba77a-d3a3-423b-9d31-3f7747775fae">Derivative Assets</span></span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtNi0xLTEtMjA2NjQ5_bc98400a-c82d-4004-b4ed-25c8c3bfe4b2">Derivative Liabilities</span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives presented gross on the Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts not offset on the Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash collateral received / pledged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount (legal offset)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our derivative contracts on our Consolidated Financial Statements:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Accumulated other comprehensive income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from Accumulated other comprehensive income to Product sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other income (expense), net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of gains and losses related to the hedged forecasted transactions reported in Accumulated other comprehensive income as of December&#160;31, 2022 are expected to be reclassified to Product sales within 12 months. There were no discontinuances of cash flow hedges for the years presented.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flow effects of our derivative contracts for the years ended December&#160;31, 2022, 2021 and 2020 were included within Net cash provided by operating activities on our Consolidated Statements of Cash Flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285228880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">ACQUISITIONS<div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">MiroBio</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2022, we acquired all of the outstanding share capital of MiroBio Ltd. (&#8220;MiroBio&#8221;), a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for $414 million in cash. As a result, MiroBio became our wholly-owned subsidiary. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the transaction as an asset acquisition and recorded a $389 million charge to Acquired in-process research and development expenses on our Consolidated Statements of Income during 2022. The remaining purchase price relates to various other assets acquired and liabilities assumed.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">MYR</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by European Medicines Agency (&#8220;EMA&#8221;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Consolidated Financial Statements from the date of the acquisition.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate consideration for this acquisition of &#8364;1.3 billion (or $1.6 billion) primarily consisted of &#8364;1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to &#8364;300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $341 million as of the acquisition date. As of December&#160;31, 2021, the fair value of the liability was $317 million and was included in Other current liabilities on our Consolidated Balance Sheets. As of December&#160;31, 2022, the fair value of the liability was $275 million and was included in Other long-term obligations. See Note 3. Fair Value Measurements for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $845&#160;million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 10 years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D consists of Hepcludex for HDV in all other regions without regulatory approval, including the United States. The estimated aggregate fair value of $1.19&#160;billion as of the acquisition date was determined by applying the income approach using unobservable inputs (Level 3 under the fair value measurement and disclosure guidance) to estimate probability-weighted net cash flows attributable to this asset and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $226&#160;million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is not expected to be deductible for income tax purposes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The one-year measurement period was completed in the first quarter of 2022, with adjustments recorded to the fair values of assets acquired and liabilities assumed of $18 million. See Note 8. Goodwill and Intangible Assets for additional information.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Immunomedics</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we completed the acquisition of Immunomedics, a company focused on the development of antibody-drug conjugate technology, for cash consideration of $20.6 billion. Upon closing, Immunomedics became a wholly-owned subsidiary of Gilead. The acquisition was financed with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $1.0&#160;billion borrowing under a new senior unsecured term loan facility and cash on hand. In 2021, we repaid the borrowing under the senior unsecured term loan facility.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded share-based compensation expense of $289&#160;million related to the cash settlement of the accelerated share-based compensation expense attributable to the post-combination period, which was primarily recorded in Selling, general and administrative expenses and Research and development expenses on our Consolidated Statements of Income for the year ended December&#160;31, 2020. We also recorded other acquisition-related expenses of $39&#160;million, primarily representing closing costs and related fees, in Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December&#160;31, 2020. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Immunomedics was accounted for as a business combination using the acquisition method of accounting. The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value step-up adjustment of $881&#160;million, included in inventories of $946&#160;million as of the acquisition date, was primarily determined by the estimated selling price of finished inventory less the cost to complete the manufacturing process and selling effort. The step-up adjustment was recorded in Cost of goods sold on our Consolidated Statements of Income as the inventory was sold to customers and in Research and development expenses on our Consolidated Statements of Income for inventory used for clinical purposes.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The finite-lived intangible asset of $4.6&#160;billion represents the estimated fair value of Trodelvy for metastatic triple-negative breast cancer (&#8220;TNBC&#8221;) as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Trodelvy for metastatic TNBC and a discount rate of 7.0%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 12 years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired IPR&amp;D assets consist of Trodelvy for hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#8220;HR+/HER2-&#8221;) breast cancer, Trodelvy for non-small cell lung cancer and Trodelvy for urothelial cancer (&#8220;UC&#8221;). The estimated aggregate fair value of&#160;$15.8&#160;billion&#160;as of the acquisition date was determined by applying the income approach using unobservable inputs (Level 3 under the fair value measurement and disclosure guidance) to estimate probability-weighted net cash flows attributable to these assets and a discount rate of 7.0%. The discount rate used represents the estimated rate that market participants would use to value these intangible assets. Trodelvy for UC was granted accelerated approval by FDA in April 2021 and $1.0&#160;billion was reclassified to finite-lived intangibles from IPR&amp;D. Trodelvy for HR+/HER2- breast cancer was partially impaired in the first quarter of 2022, but was subsequently granted approval by FDA in February 2023 and $6.1&#160;billion will be reclassified to finite-lived intangibles from IPR&amp;D in the first quarter of 2023. See Note 8. Goodwill and Intangible Assets for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recorded an intangible asset related to a license and supply agreement with Everest Medicines (&#8220;Everest&#8221;), which was entered into by Immunomedics prior to the acquisition. Under the agreement, Everest was granted an exclusive license to develop and commercialize Trodelvy in certain territories in Asia and make certain sales milestones and royalty payments to us. The acquisition date fair value of $175&#160;million was determined by estimating the probability-weighted net cash flows attributable to the outlicense and a discount rate of 7.0%. The discount rate represents the estimated rate that market participants would use to value this intangible asset. This intangible asset was being amortized over an estimated useful life of 15 years on a straight-line basis up until we reacquired the rights from Everest in the fourth quarter of 2022. See Note 10. Collaborations and Other Arrangements for additional information.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of Immunomedics.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust (&#8220;RPI&#8221;), prior to our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The acquisition date fair value of the liability was estimated as $1.1&#160;billion, which was primarily determined based on current estimates of future royalty payments to RPI over the life of the arrangement using the real options method and an effective annual interest rate of 2.5%. The inputs used for valuation of this liability are unobservable and are considered Level 3 under the fair value measurement and disclosure guidance. The liability related to future royalties was categorized as debt and primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Notes 3. Fair Value Measurements and 11. Debt and Credit Facilities for additional information.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The&#160;excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $4.0&#160;billion was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for Immunomedics is not expected to be deductible for income tax purposes.</span></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Forty Seven, Inc. (&#8220;Forty Seven&#8221;)</span></div>In the second quarter of 2020, we completed the acquisition of Forty Seven, a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for total consideration of $4.7 billion, net of acquired cash. Upon closing, Forty Seven became a wholly-owned subsidiary of Gilead. We accounted for the transaction as an asset acquisition since the lead asset, magrolimab, represented substantially all the fair value of the gross assets acquired. During the year ended December 31, 2020, we recorded a $4.5 billion charge representing an acquired IPR&amp;D asset with no alternative future use in Acquired in-process research and development expenses, and stock-based compensation expense of $144&#160;million primarily in Research and development expenses on our Consolidated Statements of Income.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285228880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Property, plant and equipment, net: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements (including leasehold improvements)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,661&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,014&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes $104 million and $131 million of unamortized capitalized software costs as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net book value of our property, plant and equipment in the U.S. was $4.5 billion and $4.1 billion as of December&#160;31, 2022 and 2021, respectively. The corresponding amount in international locations was $973 million and $963 million as of December&#160;31, 2022 and 2021, respectively. All individual international locations accounted for less than 10% of the total balances.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285265536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Goodwill</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of Goodwill:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,314&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, goodwill decreased by $18&#160;million as a result of finalizing the amount of acquired net operating losses of MYR, which resulted in a decrease to the net deferred tax liability acquired. As of December&#160;31, 2022, there were no accumulated goodwill impairment losses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Intangible Assets</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; axicabtagene ciloleucel</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; Hepcludex</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,794&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,121)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,674&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,915&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,535&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets &#8211; IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,121)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,894&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&amp;D intangible asset of $6.1 billion will be reclassified to finite-lived assets in the first quarter of 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization Expense</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense related to finite-lived intangible assets was $1.8 billion, $1.7 billion and $1.2 billion for the years ended December&#160;31, 2022, 2021 and 2020, respectively, and is primarily included in Cost of goods sold on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2022:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessments</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No indicators of impairment were noted for the years ended December&#160;31, 2022, 2021 and 2020, except as described under &#8220;2022 IPR&amp;D Impairment&#8221; below. The weighted-average discount rates used in our quantitative assessments for IPR&amp;D intangible assets during those years, other than for the assessment described below, were 7.5%, 6.5% and 8.0%, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 IPR&amp;D Impairment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics in 2020, we allocated a portion of the purchase price to acquired IPR&amp;D intangible assets. Approximately $8.8&#160;billion was assigned to IPR&amp;D intangible assets related to Trodelvy for treatment of patients with HR+/HER2- breast cancer. In March 2022, we received data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- metastatic breast cancer who have received prior endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and two to four lines of chemotherapy (&#8220;third-line plus patients&#8221;). Based on our evaluation of the study results, and in connection with the preparation of the financial statements for the first quarter, we updated our estimate of the fair value of our HR+/HER2- IPR&amp;D intangible asset to $6.1&#160;billion as of March 31, 2022. Our estimate of fair value used a probability-weighted income approach that discounts expected future cash flows to the present value, which requires the use of Level 3 fair value measurements and inputs, including estimated revenues, costs, and probability of technical and regulatory success. The expected cash flows included cash flows from HR+/HER2- metastatic breast cancer for third-line plus patients and patients in earlier lines of therapy which are the subject of separate clinical studies. Our revised discounted cash flows were lower primarily due to a delay in launch timing for third-line plus patients which caused a decrease in our market share assumptions based on the expected competitive environment. As of March 2022, there were no changes in our plans or assumptions related to our estimated cash flows for patients in the earlier lines of therapy. We used a discount rate of 6.75% which is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. We determined the revised estimated fair value was below the carrying value of the asset and, as a result, we recognized a partial impairment charge of $2.7&#160;billion in In-process research and development impairment on our Consolidated Statements of Income during the three months ended March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285018400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Financial Information</a></td>
<td class="text">OTHER FINANCIAL INFORMATION<div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accounts receivable, net</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,278&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our trade accounts receivable arises from product sales in the U.S. and Europe.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Inventories</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories as of December&#160;31, 2021 included $294 million of fair value adjustments resulting from the Immunomedics acquisition. There were no fair value adjustments in total inventories as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other current liabilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Other current liabilities:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for settlement related to bictegravir litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See Note 13. Commitments and Contingencies for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285220496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CollaborativeandOtherArrangementsAbstract', window );"><strong>Collaborative and Other Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CollaborativeAndOtherArrangementsTextBlock', window );">Collaborations and Other Arrangements</a></td>
<td class="text">COLLABORATIONS AND OTHER ARRANGEMENTS <div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements and equity investments.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the financial terms of these arrangements, we may be required to make payments upon achievement of various developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Consolidated Statements of Income when the corresponding events become probable. In connection with the regulatory approvals, milestone payments made will be capitalized as intangible assets and will be amortized to Cost of goods sold through the terms of these collaboration arrangements. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Dragonfly</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into a strategic research collaboration agreement (the &#8220;Dragonfly Collaboration Agreement&#8221;) with Dragonfly Therapeutics, Inc. (&#8220;Dragonfly&#8221;) to develop natural killer (&#8220;NK&#8221;) cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we received an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as options, after the completion of certain preclinical activities, to license exclusive, worldwide rights to develop and commercialize additional NK cell engager programs using the Dragonfly Tri-specific NK Engager platform. Upon the closing of the Dragonfly Collaboration Agreement, we made a $300 million upfront payment to Dragonfly, and we made an additional $15 million payment related to a target selection in connection with an August 2022 amendment to the agreement, which were recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December&#160;31, 2022. These payments were classified as Acquisitions, including in-process research and development, net of cash acquired in Investing Activities on our Consolidated Statements of Cash Flows for the year ended December&#160;31, 2022. In addition, Dragonfly is eligible to receive performance-based development and regulatory milestone payments of up to $630 million related to the DF7001 program with further commercial milestone payments and royalties on worldwide net sales if successful. If we exercise our options on additional NK cell engager programs, Dragonfly would be eligible to receive opt-in payments and performance-based development, regulatory and commercial milestone payments and royalties on worldwide net sales on these optioned programs as well.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Merck &amp; Co, Inc. (&#8220;Merck&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2021, we entered into a license and collaboration agreement with Merck Sharp &amp; Dohme Corp., a subsidiary of Merck to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#8217;s investigational capsid inhibitor, lenacapavir, and Merck&#8217;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration is initially focused on long-acting oral and injectable formulations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Gilead and Merck share global development and commercialization costs at 60% and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, Gilead would lead commercialization in the U.S., and Merck would lead commercialization in the European Union (&#8220;EU&#8221;) and rest of the world. For long-acting injectable products, if approved, Merck would lead commercialization in the U.S. and Gilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, Gilead and Merck would jointly promote the combination products in the U.S. and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of R&amp;D costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Income. Expenses recognized under the agreement were not material for the years ended December 31, 2022 and 2021. No revenues have been recognized under the agreement for the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also have the option to license certain of Merck&#8217;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#8217;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first five years after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt out, in which case the non-exercising company will be paid a royalty.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Merck announced the decision of the parties to stop all dosing of participants in the Phase 2 clinical study evaluating an oral-weekly combination treatment regimen of lenacapavir and islatravir following the decision of FDA to place clinical holds on the Investigational New Drug applications for certain formulations of islatravir. In September 2022, Merck announced that the study would resume under an amended protocol with a lower dose of islatravir.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Arcus</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2020, we entered into a transaction with Arcus, a publicly traded oncology-focused biopharmaceutical company, which included entry into an option, license and collaboration agreement (the &#8220;Collaboration Agreement&#8221;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the &#8220;Stock Purchase Agreements&#8221;). In accordance with the terms of the Collaboration Agreement and Stock Purchase Agreements, which closed on July 13, 2020, we made an upfront payment of $175 million and acquired approximately 6.0 million shares of Arcus common stock for approximately $200 million. Of the total $391 million initial cash payments, including transactional costs, made under the agreements, we recorded $135 million as an equity investment which was calculated based on Arcus&#8217; closing stock price on the closing date of the transaction. The remaining $256 million was attributed to (i) the acquired license and option rights of $175 million representing IPR&amp;D assets with no alternative future use, (ii) $65 million of an issuance premium for the equity purchase and (iii) $16 million of direct transactional costs. These amounts were expensed as Acquired in-process research and development expenses during the year ended December 31, 2020 on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Stock Purchase Agreements, we have the right to purchase from Arcus additional shares up to a maximum of 35% of the outstanding voting stock of Arcus over a five-year period ending in the third quarter of 2025. We are also subject to a three-year standstill ending in the second quarter of 2023, restricting certain other activity on our part. On May 29, 2020, in a separate secondary equity offering, we acquired 2.2 million shares of common stock of Arcus for approximately $61 million. In the first quarter of 2021, we also acquired approximately 5.7 million additional shares of Arcus common stock for $220 million. As a result, we currently own a total of 13.8 million shares of Arcus, which represented approximately 19.5% of the issued and outstanding voting stock of Arcus immediately following the closing of the first quarter 2021 transaction. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Collaboration Agreement, Gilead had the right to opt in to all current and future clinical-stage product candidates for up to ten years following the closing of the transaction. In November 2021, we exercised our options to three of Arcus&#8217; clinical stage programs and amended the Collaboration Agreement. The option exercise and amendment transaction closed in December 2021, triggering collaboration opt-in payments of $725 million and waiving the $100 million option continuation payment which would have been due to Arcus in the third quarter of 2022. The net option charge of $625 million is included within Acquired in-process research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2021. The collaboration opt-in payments of $725 million were recorded in Other current liabilities on our Consolidated Balance Sheets as of December 31, 2021 and paid to Arcus in January 2022. Our payments to Arcus were included within Net cash used in investing activities on our Consolidated Statements of Cash Flows in the first quarter of 2022. Under the amended Collaboration Agreement, the companies co-develop and share the global costs related to these clinical programs. We recorded $187 million of such costs in Research and development expenses on our Consolidated Statements of Income for the year ended December&#160;31, 2022. If the optioned molecules achieve regulatory approval, the companies will co-commercialize and equally share profits in the U.S. Gilead will hold exclusive commercialization rights outside the U.S., subject to any rights of Arcus&#8217;s existing collaboration partners, and will pay to Arcus tiered royalties as a percentage of net sales ranging from the mid teens to low twenties. Under the Collaboration Agreement, we may also pay an additional $100 million at our option on each of the fourth, sixth and eighth anniversaries of the agreement, unless terminated early, to maintain the rights to opt in to future Arcus programs for the duration of the contact term. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pionyr</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, we entered into a transaction with Pionyr, a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate merger agreements, one contemplating the initial acquisition of a 49.9% equity interest in Pionyr, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (together, the &#8220;Pionyr Merger and Option Agreements&#8221;) and a R&amp;D service agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2020, we closed the transaction and made cash payments of $269 million. We account for our investment in Pionyr using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Pionyr. Our investment in Pionyr, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Pionyr's net assets at transaction closing. We determined that the resulting basis difference primarily relates to Pionyr&#8217;s IPR&amp;D which has no alternative future use and that Pionyr is not a business as defined in accounting standards. As a result, we immediately recorded a charge for this basis difference of $215 million in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. The carrying value of our equity method investment in Pionyr was zero as of December&#160;31, 2022 and 2021.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Pionyr is approximately $70 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount is recorded in Other long-term assets on our Consolidated Balance Sheets. We may choose to exercise our exclusive option to purchase the remaining equity interest from Pionyr&#8217;s current shareholders for a $315 million option exercise fee and up to $1.2 billion in potential future milestone payments upon achievement of certain development and regulatory milestones. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Pionyr. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the R&amp;D service agreement, we made an initial cash funding of $80 million and recorded a charge in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. In addition, we committed to provide additional payments of up to $115 million to Pionyr upon achievement of certain development milestones. We accrued $70 million in milestone payments, related to the initiation of two Phase 1 studies, with a charge to Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020, and the payment was made in the first quarter of 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tizona</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, we entered into a transaction with Tizona, a privately held company developing cancer immunotherapies, which included entry into two separate merger agreements, one contemplating the initial acquisition of a 49.9% equity interest in Tizona, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Tizona (together, the &#8220;Tizona Merger and Option Agreements&#8221;) and a development agreement. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, we closed the transaction with Tizona and made cash payments of $302 million to Tizona&#8217;s shareholders in accordance with the terms of the Tizona Merger and Option Agreements. We account for our investment in Tizona using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Tizona. Our investment in Tizona, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Tizona&#8217;s net assets at transaction closing. We determined that the resulting basis difference primarily relates to Tizona&#8217;s IPR&amp;D with no alternative future use and that Tizona is not a business as defined in accounting standards. As a result, during the year ended December 31, 2020, we immediately recorded a charge for this basis difference of $272 million in Acquired in-process research and development expenses on our Consolidated Statements of Income. The carrying value of our equity method investment in Tizona was zero as of December&#160;31, 2022 and 2021. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Tizona is approximately $41 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount is recorded in Other long-term assets on our Consolidated Balance Sheets. We may choose to exercise our exclusive option to purchase the remaining equity interest from Tizona&#8217;s current shareholders for a $100 million option exercise fee and up to $1.2 billion in potential future milestone payments upon achievement of certain development and regulatory milestones. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Tizona. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the development agreement, we committed to provide funding to Tizona of $115 million, which was recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tango Therapeutics, Inc. (&#8220;Tango&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2020, we entered into a transaction with Tango, a privately held company pursuing innovative targeted immune evasion therapies for patients with cancer through its proprietary, CRISPR-enabled functional genomics target discovery platform, which included entry into an amended and restated research collaboration and license agreement and a stock purchase agreement (together, the &#8220;Tango Collaboration and Stock Purchase Agreements&#8221;). </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering into this transaction, we made an upfront payment of $125 million and a $20 million equity investment in Tango. During the year ended December 31, 2020, we recorded the $125 million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income. In the third quarter of 2021, we made an additional $13 million equity investment. Tango became a publicly traded company in 2021, and accordingly our equity investment has since been recorded in Prepaid and other current assets on our Consolidated Balance Sheets at fair market value.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Tango Collaboration and Stock Purchase Agreements, Gilead has the right to option up to 15 programs over the seven-year collaboration for up to $410 million per program in opt-in, extension and milestone payments. For the products that Tango opts to co-develop and co-promote, the parties will equally split profits and losses, as well as development costs in the U.S. For products that Tango does not opt to co-develop and co-promote, we will pay Tango up to low double-digit tiered royalties on net sales. We will provide Tango milestone payments and royalties on sales outside of the U.S. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Jounce Therapeutics, Inc. (&#8220;Jounce&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, we entered into a transaction with Jounce, a publicly traded company developing novel cancer immunotherapies, which included entry into license, registration rights and stock purchase agreements (together, &#8220;Jounce License and Stock Purchase Agreement&#8221;). In October 2020, we closed this transaction and made a total payment of $120 million. We recorded $64 million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income and $56 million as an equity investment in Other long-term assets on our Consolidated Balance Sheets, representing approximately 14% of the issued and outstanding voting stock of Jounce immediately following the transaction, which was calculated based on Jounce&#8217;s closing stock price on the closing date of the transaction. In December 2022, we amended our existing license agreement with Jounce enabling us to buy out the remaining contingent payments potentially due under the license agreement for $67 million, which was expensed to Acquired in-process research and development expenses on our Consolidated Statements of Income and was paid in 2022. Going forward, we will be solely responsible for all further research, development and commercialization of the immunotherapy specified in the license agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Galapagos</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Filgotinib Collaboration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we closed a license and collaboration agreement with Galapagos, a clinical-stage biotechnology company based in Belgium, for the development and commercialization of filgotinib, a JAK1-selective inhibitor being evaluated for inflammatory disease indications (the &#8220;filgotinib agreement&#8221;). Under the terms of the filgotinib agreement, as amended in 2019 (the &#8220;2019 Agreement&#8221;), we obtained an exclusive, worldwide, royalty-bearing, sublicensable license for filgotinib and products containing filgotinib. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Gilead and Galapagos amended their agreement to allow Galapagos to assume development, manufacturing, commercialization and certain other rights for filgotinib in Europe. In connection with the amendments to the 2019 Agreement, Gilead agreed to irrevocably pay Galapagos &#8364;160 million (or approximately $190 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Of this total amount, Gilead paid &#8364;35 million (or approximately $43 million) in January 2021, an additional &#8364;75 million (or approximately $88 million) in April 2021, and &#8364;50 million (or approximately $60 million) in 2022. We accrued the full amount of this liability with a charge to Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. In addition, Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Collaboration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In&#160;August 2019, we closed an option, license and collaboration agreement (the &#8220;Galapagos Collaboration Agreement&#8221;) and a subscription agreement (the &#8220;Galapagos Subscription Agreement&#8221;), each with Galapagos, pursuant to which the parties entered into a global collaboration that covers Galapagos&#8217; current and future product portfolio (other than filgotinib). </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Galapagos Subscription Agreement, we purchased 6.8 million new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by Galapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of Galapagos exceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We agreed not to, without the prior consent of Galapagos, dispose of any equity securities of Galapagos prior to the second anniversary of the closing of the Galapagos Subscription Agreement or dispose of any equity securities of Galapagos thereafter until the fifth anniversary of the closing of the Galapagos Subscription Agreement, if after such disposal we would own less than 20.1% of the then-issued and outstanding voting securities of Galapagos, subject to certain exceptions and termination events. In April 2021, we amended the Galapagos Subscription Agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to programs in Galapagos&#8217; current and future pipeline, if we exercise our option to a program, we will pay a $150 million option exercise fee per program. In addition, Galapagos will receive tiered royalties ranging from 20% to 24% on net sales in our territories of each Galapagos product optioned by us. If we exercise our option for a program, the parties will share equally in development costs and mutually agreed commercialization costs incurred subsequent to our exercise of the option. We may terminate the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events. We have two designees appointed to Galapagos&#8217; board of directors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Janssen</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Complera/Eviplera and Odefsey</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, we entered into a license and collaboration agreement with Janssen, formerly Tibotec Pharmaceuticals, to develop and commercialize a fixed-dose combination of our Truvada and Janssen&#8217;s non-nucleoside reverse transcriptase inhibitor, rilpivirine, This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen&#8217;s rilpivirine and our emtricitabine and tenofovir alafenamide (&#8220;Odefsey&#8221;). </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party&#8217;s component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen&#8217;s share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen&#8217;s share of revenues is included in Cost of goods sold on our Consolidated Statements of Income. Cost of goods sold relating to Janssen&#8217;s share was $483 million, $530 million and $570 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products, in which case Janssen has the right to become the selling party for such country if the product has launched but has been on the market for fewer than 10 years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Symtuza</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen&#8217;s darunavir and our cobicistat, emtricitabine and tenofovir alafenamide (&#8220;Gilead Compounds&#8221;). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the Gilead Compounds and are the exclusive supplier of the Gilead Compounds. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Symtuza. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party&#8217;s component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Income primarily because we supply the Gilead Compounds to Janssen for Symtuza.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Japan Tobacco, Inc. (&#8220;Japan Tobacco&#8221;) </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2005, Japan Tobacco granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Income. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Income. Royalty expenses recognized were $198 million, $250 million and $291 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are expected to be derived from the applicable products in our HIV portfolio. The amortization expense is classified as selling expense and recorded as Selling, general and administrative expenses on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Everest</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, Everest and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia (the &#8220;Territories&#8221;). Gilead subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to be made to Gilead and was recorded as a $175 million finite-lived asset as part of the purchase accounting. In the fourth quarter of 2022, we reacquired all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, Gilead will make $280 million in upfront termination payments to Everest, of which $84 million was made in 2022, with the remaining amounts included in Other current liabilities on our Consolidated Balance Sheets as of December&#160;31, 2022. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $406 million in Selling, general and administrative expenses on our Consolidated Statements of Income, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. In addition, we recorded an acquired finite-lived asset with a fair value of $50 million for the commercial rights reacquired for products approved in the Territories.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Collaboration Arrangements That Are Not Individually Significant</span></div>During 2022, 2021 and 2020, we entered into several collaborations, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements of $86 million, $177 million and $129 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, within Acquired in-process research and development expenses on our Consolidated Statements of Income.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeAndOtherArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Arrangements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeAndOtherArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeandOtherArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative and Other Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeandOtherArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285190688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt and Credit Facilities</a></td>
<td class="text">DEBT AND CREDIT FACILITIES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.551%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,088&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,571&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,229&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,695&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,957&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,179&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Senior Unsecured Notes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we repaid $500 million of senior unsecured notes prior to the March 2022 maturity by exercising a par call option. Additionally, in July 2022, we repaid $1.0 billion of senior unsecured notes prior to the September 2022 maturity by exercising a par call option. No new debt was issued in 2022. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our senior unsecured fixed rate notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed and (ii) the sum, as determined by an independent investment banker, of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium, which are defined in the terms of the notes. The senior unsecured fixed rate notes also have a par call feature, exercisable at our option, to redeem the notes at par in whole, or in part, on dates ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEwOTk1MTE2MzcyNzc_a58a2f1f-515b-4f40-ba1a-00d6cf2d5f1b">two</span> to six months prior to maturity. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption. The $1.5 billion of 0.75% senior unsecured notes due September 2023 also have a different call feature, exercisable at our option, to redeem the notes at par, in whole or in part, at any time until maturity.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a change in control and a downgrade in the rating of our senior unsecured notes below investment grade by Moody&#8217;s Investors Service, Inc. and S&amp;P Global Ratings, the holders may require us to purchase all or a portion of their notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest to the date of repurchase. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of December&#160;31, 2022 and 2021, we were not in violation of any covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liability Related to Future Royalties</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Immunomedics, we assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust (&#8220;RPI&#8221;), prior to our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over 16 years. The estimated timing and amount of future expected royalty payments over the estimated term will be re-assessed each reporting period. The impact from changes in estimates will be recognized in the liability and the related interest expense prospectively. The liability related to future royalties was primarily included in Long-term debt, net on our Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revolving Credit Facilities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into a new $2.5 billion five-year revolving credit facility maturing in June 2025 (the &#8220;2020 Revolving Credit Facility&#8221;). The 2020 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of December&#160;31, 2022 and 2021, there were no amounts outstanding under the 2020 Revolving Credit Facility.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Revolving Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default. As of December&#160;31, 2022, we were in compliance with all covenants. Loans under the 2020 Revolving Credit Facility bear interest at either (i) the Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) plus the Applicable Percentage, or (ii) the Base Rate plus the Applicable Percentage, each as defined in the 2020 Revolving Credit Facility agreement. We may terminate or reduce the commitments, and may prepay any loans under the credit facility in whole or in part at any time without premium or penalty.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contractual Maturities of Financing Obligations</span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate future principal maturities of our senior unsecured notes as of December&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Interest ExpenseInterest expense on our debt and credit facilities related to the contractual coupon rates and amortization of the debt discount and issuance costs was $940 million in 2022 and $1.0 billion in 2021 and 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285166464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases consist primarily of properties and equipment for our administrative, manufacturing and R&amp;D activities. Some of our leases include options to extend the terms for up to 15 years and some include options to terminate the lease within one year after the lease commencement date. As of December&#160;31, 2022 and 2021, we did not have material finance leases. Operating lease expense, including variable costs and short-term leases, was $162 million, $156 million and $171 million in 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balance sheet and other information related to our operating leases:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.131%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except weighted average amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_8de7020f-9548-47c7-9a1e-4746afc67ea4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_b3559456-f5cf-4d45-8c2a-793a81b2aed1">Other long-term assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities &#8211; current</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_37e207dc-5857-47ab-bc75-5d95f77eba00"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_566a40c8-fefd-4cc7-be50-3313dae89a4d">Other accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities &#8211; noncurrent</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_083b769e-0d49-49bf-952b-f91005031157"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_6a8cd158-cdc0-45a1-ba9e-3851203d9cab">Other long-term obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to our operating leases:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total discounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285018400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Legal Proceedings</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions. Certain significant matters are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any material accruals for the matters described below as of December&#160;31, 2022. As of December&#160;31, 2021, we recorded an accrual of $1.25 billion in Accrued and other current liabilities on our Consolidated Balance Sheets for the previously disclosed legal settlement related to the bictegravir litigation, which we paid in February 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Related to Sofosbuvir</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of HCV. In 2013, we received approval from FDA for sofosbuvir, sold under the brand name Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with the University of Minnesota</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The University of Minnesota (the &#8220;University&#8221;) has obtained U.S. Patent No. 8,815,830 (the &#8220;&#8217;830 patent&#8221;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#8217;830 patent. We believe the &#8217;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#8220;PTAB&#8221;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concluded the inter partes review that it had initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#8217;s patent invalid. In July 2021, the University appealed this decision, and oral arguments before the Court of Appeals for the Federal Circuit were held in January 2023. The litigation in the U.S. District Court will remain stayed through the appeal proceedings.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Litigation with NuCana plc. (&#8220;NuCana&#8221;)</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuCana has obtained European Patent No. 2,955,190 (the &#8220;EP &#8217;190 patent&#8221;) that allegedly covers sofosbuvir. In opposition proceedings before the European Patent Office (&#8220;EPO&#8221;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#8217;190 patent in amended form. The EPO has now scheduled the appeal hearing for March 2023. We continue to believe that the amended EP &#8217;190 patent claims are invalid. Subsequent to the EPO opposition decision, we initiated proceedings to invalidate the U.K. counterparts of the EP &#8217;190 patent and a related patent, European Patent No. 3,904,365 (the EP &#8216;365 patent) in the High Court of England &amp; Wales. NuCana has also filed counterclaims against us in the High Court of England &amp; Wales alleging patent infringement of the U.K. counterparts and seeking damages and other relief. The U.K. case was heard in January and early February 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#252;sseldorf alleging patent infringement of the German counterpart of the EP &#8217;190 patent and seeking damages and injunctive relief. In April 2022, we filed an action for grant of a compulsory license before the Federal Patent Court in Germany. In July 2022, the D&#252;sseldorf court determined that NuCana&#8217;s German counterpart of the EP &#8217;190 patent is infringed and granted an injunction. In August 2022, Gilead filed a notice of appeal regarding the D&#252;sseldorf court&#8217;s decision, and a hearing is scheduled for August 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Related to Axicabtagene Ciloleucel</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#8220;Juno&#8221;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes U.S. Patent No. 7,446,190 (the &#8220;&#8217;190 patent&#8221;). A jury trial was held on the &#8217;190 patent, and in December 2019, the jury found that the asserted claims of the &#8217;190 patent were valid, and that we willfully infringed the asserted claims of the &#8217;190 patent. The jury also awarded Juno damages in amounts of $585 million in an upfront payment and a 27.6% running royalty from October 2017 through the date of the jury&#8217;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#8217;s verdict, enhanced the past damages by 50% and maintained the royalties on future Yescarta sales at 27.6%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge, and in July 2021, the appeals court heard oral arguments. In August 2021, the Court of Appeals for the Federal Circuit (the &#8220;CAFC&#8221;) reversed the jury verdict, finding the asserted claims of Juno&#8217;s patent invalid. In October 2021, Juno filed a petition for rehearing with the CAFC. In January 2022, the CAFC denied Juno&#8217;s petition for rehearing. In June 2022, Juno filed a petition for certiorari seeking a review by the Supreme Court. The Supreme Court rejected Juno&#8217;s petition in January 2023, making the CAFC judgment final.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Relating to Pre-Exposure Prophylaxis</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#8220;HHS Patents&#8221;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of FTC and tenofovir disoproxil fumarate (&#8220;TDF&#8221;) or TAF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#8220;PrEP&#8221;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the U.S. Court of Federal Claims, alleging violations of three material transfer agreements (&#8220;MTAs&#8221;) related to the research underlying the HHS Patents and two clinical trial agreements (&#8220;CTAs&#8221;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of each of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#8217;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial for the bifurcated portion of the lawsuit in the Court of Federal Claims was held in June 2022, and in November 2022, the Court determined that the government breached the three MTAs. The Court also made findings of fact relating to the CTAs but declined to issue a decision on breach of the CTAs until after trial in the Delaware District Court. A trial date for the lawsuit in the Delaware District Court has been set for May 2023. A separate trial at the Court of Federal Claims to determine the damages Gilead is owed based on the government&#8217;s breach has yet to be set.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation with Generic Manufacturers</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our products will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we received a letter from Lupin Ltd. (&#8220;Lupin&#8221;) indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen (&#8220;Janssen&#8221;), filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Lupin asserting infringement of two additional patents in the same court. This second case has been stayed. Trial has been scheduled for October 2023. In September 2022, we received a letter from Apotex Inc. and Apotex Corp. (&#8220;Apotex&#8221;) stating that they have submitted an ANDA for a generic version of Symtuza. In October 2022, we, along with Janssen, filed a patent infringement lawsuit against Apotex as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Apotex asserting infringement of two additional patents in the same court. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in March 2022, we received letters from Lupin, Laurus Labs (&#8220;Laurus&#8221;) and Cipla Ltd. (&#8220;Cipla&#8221;), indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of three of the five patents listed in the Orange Book as associated with Biktarvy. We filed a lawsuit against Lupin, Laurus and Cipla in May 2022 in the U.S. District Court of Delaware, and intend to enforce and defend our intellectual property. Trial has been scheduled for December 2024.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European Patent Claims</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal hearing was held in November 2022, but a final decision regarding the validity of the claims has not yet been announced.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. The original opposing parties have appealed, requesting full revocation. The hearing for the appeal has been scheduled for September 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. The hearing for the appeal has been scheduled for March 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir and TAF hemifumarate in the EU could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antitrust and Consumer Protection</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with Bristol-Myers Squibb Company (&#8220;BMS&#8221;) and Johnson &amp; Johnson, Inc., have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of direct purchasers consisting largely of wholesalers and indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the second half of 2021 and first half of 2022, several plaintiffs filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the putative classes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These cases have been coordinated with the class actions. Trial has been set for May 2023.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we, along with BMS and Janssen Products, L.P., were named as defendants in a lawsuit filed in the Superior Court of the State of California, County of San Mateo, by Aetna, Inc. on behalf of itself and its affiliates and subsidiaries that effectively opts the Aetna plaintiffs out of the above class actions. The allegations are substantively the same as those in the class actions. The Aetna plaintiffs seek damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we, along with generic manufacturers Cipla and Cipla USA Inc. (together, &#8220;Cipla Defendants&#8221;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#8220;Jacksonville Trust&#8221;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and the Cipla Defendants, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we, along with BMS and Teva Pharmaceutical Industries Ltd., were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages, permanent injunctive relief and other relief.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named as a defendant in one class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Florida, Missouri and New York, involve more than 26,000 plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. The first bellwether trial in California state court was scheduled to begin in October 2022, but is currently stayed while the California First District Court of Appeal considers the merits of plaintiffs&#8217; theories of liability. The first bellwether trial in California federal court is scheduled to begin in January 2024. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Investigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#8217;s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead&#8217;s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The relator seeks all available relief under these statutes.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice Advocates, LLC (&#8220;Health Choice&#8221;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#8217;s dismissal.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#8217;s Office&#8217;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#8220;TMFPA&#8221;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. In September 2021, the Texas Court of Appeals for the Sixth Court Appeals District granted our request to stay the Texas litigation pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#8217; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. In June 2022, plaintiffs filed their Motion for Class Certification, and Immunomedics submitted its Opposition in July 2022. The parties have agreed to settle this litigation. A motion seeking preliminary approval of the settlement was granted in February 2023. The court has not yet entered a final order approving the settlement. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460282985312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Stock Repurchase Programs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, our Board of Directors authorized a $5.0 billion&#160;stock repurchase program (&#8220;2020 Program&#8221;). Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions. The $12.0 billion stock repurchase program authorized by our Board of Directors in the first quarter of 2016 was completed in the fourth quarter of 2022. We started repurchases under the 2020 Program in December 2022. As of December&#160;31, 2022, the remaining authorized repurchase amount under the 2020 Program was $4.9 billion.</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock repurchases through open market transactions under these programs:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased and retired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to repurchases from the stock repurchase programs, we repurchased shares of common stock withheld by us from employee restricted stock awards to satisfy our applicable tax withholding obligations. These shares are excluded from the table above. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the par value method of accounting for our stock repurchases. Under the par value method, common stock is first charged with the par value of the shares involved. The excess of the cost of shares acquired over the par value is allocated to Additional paid-in capital based on an estimated average sales price per issued share with the excess amounts charged to Retained earnings. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Dividends</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash dividends declared on our common stock:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our RSUs and PSUs have dividend equivalent rights entitling holders to dividend equivalents to be paid upon vesting for each share of the underlying unit.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;2, 2023, we announced that our Board of Directors declared a quarterly cash dividend increase of 2.7% from $0.73 to $0.75 per share of our common stock, with a payment date of March&#160;30, 2023 to all stockholders of record as of the close of business on March&#160;15, 2023. Future dividends are subject to declaration by our Board of Directors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Preferred Stock</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 5 million shares of authorized preferred stock issuable in series. Our Board is authorized to determine the designation, powers, preferences and rights of any such series. There was no preferred stock outstanding as of December&#160;31, 2022 and 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Accumulated Other Comprehensive Income </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in Accumulated other comprehensive income by component, net of tax:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285145184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Employee Benefits</a></td>
<td class="text">EMPLOYEE BENEFITS <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Stock-Based Compensation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans Summary</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2004, our stockholders approved and we adopted the Gilead Sciences, Inc. 2004 Equity Incentive Plan (as amended, the &#8220;2004 Plan&#8221;). As part of our acquisition of Forty Seven in 2020, we assumed the Forty Seven, Inc. 2018 Equity Incentive Plan, which we subsequently amended and restated as the Gilead Sciences, Inc. 2018 Equity Incentive Plan (as amended and restated, the &#8220;2018 Plan&#8221;). As part of the Immunomedics acquisition, we assumed the Immunomedics Amended and Restated 2014 Long-Term Incentive Plan, which we subsequently merged into the 2004 Plan.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, our stockholders approved and we adopted the Gilead Sciences, Inc. 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan authorized the issuance of a total of 132 million shares of common stock. No awards may be granted under the 2004 Plan or the 2018 Plan since the approval of the 2022 Plan.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These are broad-based incentive plans that provide for the grant of equity-based awards, including RSUs, PSUs, stock options and other restricted stock and performance awards, to employees, directors and consultants. As of December&#160;31, 2022, a total of 101 million shares remain available for future grant under the 2022 Plan.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">RSUs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant time-based RSUs to certain employees as part of our annual employee equity compensation review program as well as to new hire employees and to non-employee members of our Board. RSUs are share-based awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. RSUs generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTY3OTU_0304068a-3d69-42e3-a0cc-97d49217f440">three</span> or four years from the date of grant.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PSUs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant PSUs that vest upon the achievement of specified market or performance goals, which could include achieving a total shareholder return compared to a pre-determined peer group or achieving revenue targets. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%, and these awards generally vest only when a committee (or subcommittee) of our Board has determined that the specified market and performance goals have been achieved. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Options</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants are designated as either non-statutory or incentive stock options. The exercise price of stock options may not be less than the fair market value of our common stock on the grant date and no stock option may have a term in excess of 10 years. Employee stock options generally vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTg2ODM_bb52c247-34d1-49f0-be7e-b07c8a217a78">three</span> or four years. Stock options may be settled in cash or in shares of our common stock, including a net issuance using shares otherwise purchasable under the option to pay the exercise price. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP Summary</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our ESPP, employees can purchase shares of our common stock based on a percentage of their compensation subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of our common stock on the offering date or the purchase date. The ESPP offers a six-month look-back feature. ESPP purchases are settled with common stock from the ESPP&#8217;s previously authorized and available pool of shares. A total of 79 million shares of common stock have been authorized for issuance under the ESPP, and there were 3 million shares available for issuance under the ESPP as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize total stock-based compensation expense included on our Consolidated Statements of Income as broken down by award type and by expense type:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in total costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accelerated post-acquisition stock-based compensation expense of $8 million related to the MiroBio acquisition in 2022, and $289 million and $144 million related to the acquisitions of Immunomedics and Forty Seven, respectively, in 2020.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in total costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our RSU activity:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.48&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value of RSUs granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.36&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.42&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.94&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of RSUs as of the respective vesting dates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $948 million of unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a weighted-average period of 2.3 years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PSUs</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our PSU activity:</span></div><div style="margin-top:4.5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value of PSUs granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.04&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.31&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.64&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of PSUs as of the respective vesting dates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, there was $29 million of unrecognized compensation cost related to unvested PSUs, which is expected to be recognized over a weighted-average period of 1.4 years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize activity and other information related to our stock options: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>(in dollars)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest, net of estimated forfeitures as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.08&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.05&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.69&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the stock option awards:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.015%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected terms in years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $48 million of unrecognized compensation cost related to stock options, which is expected to be recognized over an estimated weighted-average period of 2.4 years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our ESPP activity:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount paid by employees for shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value of ESPP shares granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of ESPP shares as of the respective vesting dates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the ESPP awards:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected terms in years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Deferred Compensation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a retirement saving plan under which eligible U.S. employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (the &#8220;Gilead Sciences 401k Plan&#8221;). In certain foreign subsidiaries, we maintain defined benefit plans as required by local regulatory requirements. Our total matching contribution expense under the Gilead Sciences 401k Plan and other defined benefit plans was $176 million, $166 million and $144 million during 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a deferred compensation plan under which our directors and key employees may defer compensation. Amounts deferred by participants are deposited into a rabbi trust. The total assets and liabilities associated with the deferred compensation plan were $220&#160;million and $261 million as of December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285162736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">EARNINGS PER SHARE<div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted earnings per share attributable to Gilead:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,592&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,225&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in basic earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in diluted earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.66&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.96&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential shares of common stock excluded from the computation of Diluted earnings per share attributable to Gilead because their effect would have been antidilutive were 12 million, 15 million and 13 million during 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285362480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes consists of the following:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,587&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,505&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense consists of the following:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,526)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,286)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,248)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,580)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the federal statutory tax rate applied to Income before income taxes and our effective tax rate is summarized as follows:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at different rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US tax on foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of tax examinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D &amp; related charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable unrealized loss on investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals not currently deductible</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of tax basis over book basis of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront and milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to sale of future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,289&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,641&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,690&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of book basis over tax basis of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,728)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,122)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,138)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,432)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,017)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance increased from $520 million as of December&#160;31, 2021 to $599 million as of December&#160;31, 2022, primarily due to unrealized losses on our equity investments which are subject to a full valuation allowance, and increased from $398 million as of December&#160;31, 2020 to $520 million as of December&#160;31, 2021, primarily due to California research and development tax credits.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had U.S. federal net operating loss and tax credit carryforwards of approximately $199 million and $7 million, respectively, which will start to expire in 2023, if not utilized. In addition, we had state net operating loss and tax credit carryforwards of approximately $2.7 billion and $879 million, respectively, which will start to expire in 2024 and 2023, respectively, if not utilized. Utilization of net operating losses and tax credits may be subject to an annual limitation due to ownership change limitations provided in the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file federal, state and foreign income tax returns in the U.S. and in many foreign jurisdictions. For federal income tax purposes, the statute of limitations is open for 2016 and onwards and 2013 and onwards for California income tax purposes. For certain acquired entities, the statute of limitations is open for all years from inception due to our utilization of their net operating losses and credits carried over from prior years.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service and Irish tax authorities for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.</span><span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total unrecognized tax benefits, $946 million and $800 million as of December&#160;31, 2022 and 2021, respectively, if recognized, would reduce our effective tax rate in the period of recognition. Interest and penalties related to unrecognized tax benefits included income tax benefit of $3 million, income tax expense of $41 million and income tax benefit of $82 million on our Consolidated Statements of Income for the years ended December&#160;31, 2022, 2021 and 2020 respectively. Accrued interest and penalties related to unrecognized tax benefits were $215 million and $218 million as of December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022, we do not believe that it is reasonably possible that our unrecognized tax benefits will significantly change in the next 12 months. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our total gross unrecognized tax benefits:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Tax Cuts and Jobs Act, we recorded a federal income tax payable for transition tax on the mandatory deemed repatriation of foreign earnings that is payable over an eight-year period. Federal income tax payable for transition tax was $3.5 billion and $4.0 billion as of December&#160;31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the anticipated timing of payments associated with this transition tax as of December&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285400768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Arcellx</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, Inc. (&#8220;Arcellx&#8221;) to co-develop and co-commercialize Arcellx&#8217;s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Under the terms of the agreement, Arcellx will receive an upfront cash payment of $225&#160;million and $100&#160;million equity investment as well as other potential contingent payments. The companies will share development, clinical trial, and commercialization costs for CART-ddBCMA and will jointly commercialize the product and split U.S. profits 50/50. Outside the U.S., we will commercialize the product and Arcellx will receive royalties on sales.</span></div><div style="margin-top:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tmunity</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we closed an agreement to acquire Tmunity Therapeutics (&#8220;Tmunity&#8221;), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. Under the terms of the agreement, we acquired all outstanding shares of Tmunity other than those already owned by Gilead for approximately $300&#160;million in cash consideration.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278046016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles and include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities (&#8220;VIEs&#8221;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates. Certain amounts and percentages herein may not sum or recalculate due to rounding.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2022, expenses related to development milestones and other collaboration payments made prior to regulatory approval of a developed product were reclassified from Research and development expenses to Acquired in-process research and development expenses on our Consolidated Statements of Income. Concurrently, we reclassified the cash payments related to these expenses from Other to Acquisitions, including in-process research and development, net of cash acquired within Investing Activities in the Consolidated Statements of Cash Flows. We believe this presentation assists users of the financial statements to better understand the total costs incurred to acquire in-process research and development (&#8220;IPR&amp;D&#8221;) projects. Prior periods have been revised to reflect this classification, resulting in a reduction of previously-reported Research and development expenses of $762 million and $112 million for the years ended December&#160;31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Sales</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue from product sales when control of the product transfers to the customer, which is generally upon shipment or delivery, or in certain cases, upon the corresponding sales by our customer to a third party. Revenues are recognized net of estimated rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a financing component. Shipping and handling activities are considered to be fulfillment activities and not a separate performance obligation.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Gross-to-Net Deductions </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are based on contractual arrangements or statutory requirements and include amounts due to payers and healthcare providers under various programs. These amounts may vary by product, payer and individual plans. Providers qualified under certain programs can purchase our products through wholesalers or other distributors at a discount. The wholesalers or distributors then charge the discount back to us.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and chargebacks are estimated primarily based on product sales, including product mix and pricing, historical and estimated payer mix and discount rates, among other inputs, which require significant estimates and judgment. We assess and update our estimates each reporting period to reflect actual claims and other current information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Rebates that are payable to third party payers and healthcare providers are recorded in Accrued rebates on our Consolidated Balance Sheets.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributor Fees</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually-determined covenants such as the maintenance of agreed-upon inventory levels. These distributor fees are based on a contractually-determined fixed percentage of sales.</span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Allowance for Sales Returns</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the U.S., we typically permit returns six months prior to and up to one year after the product expiration date. Outside the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Royalty, Contract and Other Revenues</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur. Contract and other revenues are recognized when the performance obligation is satisfied.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are recorded when incurred and consist primarily of clinical studies performed by contract research organizations (&#8220;CROs&#8221;), materials and supplies, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations consisting of various support and infrastructure costs. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of Research and development expenses.</span></div>Clinical study costs are a significant component of Research and development expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for R&amp;D services prior to the services being rendered are recorded as prepaid assets within Prepaid and other current assets on our Consolidated Balance Sheets and are expensed as the services are provided.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In Process Research and Development Expenses</a></td>
<td class="text">Acquired In-Process Research and Development ExpensesAcquired in-process research and development expenses are recorded when incurred and reflect costs of externally-developed IPR&amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront and milestone payments related to various collaborations and the costs of rights to IPR&amp;D projects.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses are recorded when incurred and consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs related to sales and marketing, finance, human resources, legal and other administrative activities. </span></div>Advertising expenses within Selling, general and administrative expenses, including promotional expenses, are recorded when incurred and<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide stock-based compensation in the form of various types of equity-based awards, including restricted stock units (&#8220;RSUs&#8221;), performance share units (&#8220;PSUs&#8221;) and stock options, and through our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the &#8220;ESPP&#8221;). Stock-based compensation expense is based on the estimated fair value of the award on the grant date, or the first date of the ESPP purchase period, and recognized over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible or if an employee terminates due to death or disability.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of RSUs is based on the closing price of our common stock on the grant date. For PSUs, depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. For stock option and ESPP awards, estimated fair value is based on the Black-Scholes option valuation model. Estimated inputs to that model include (i) expected volatility, based on a blend of historical volatility of our common stock price along with implied volatility for traded options on our common stock, (ii) expected term in years, based on the weighted-average period awards are expected to remain outstanding using historical cancellation and exercise data, contractual terms and vesting terms of the award, (iii) risk-free interest rate, based on observed interest rates appropriate for the term of the stock-based awards, and (iv) expected dividend yield, based on our history and expectation of dividend payments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock outstanding during the period. Diluted earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents are determined under the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash Equivalents We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Marketable Debt Securities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our marketable debt securities are classified as available-for-sale and carried at estimated fair values. We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. Unrealized gains and losses on available-for-sale debt securities are reported in Accumulated other comprehensive income on our Consolidated Balance Sheets until realized, at which point they are reclassified into Other income (expense), net on our Consolidated Statements of Income. Interest, amortization of purchase premiums and discounts, and expected credit losses, if any, are also recorded in Other income (expense), net on our Consolidated Statements of Income. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost bases. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in Accumulated other comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">Accounts ReceivableTrade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and estimated credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.</span></div>When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#8217;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Securities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities with readily determinable fair values, including those for which we have elected the fair value option, are recorded at fair market value, and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Any impairments or adjustments are recorded in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting, with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in equity securities are classified in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets, generally depending on marketability and whether the securities are subject to lock-up provisions. We regularly review our securities for indicators of impairment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated&#160;Useful&#160;Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;35 years or useful&#160;life</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;useful&#160;life or lease&#160;term</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Impairment of Long-Lived Assets&#8221; for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement contains a lease at inception and classify each lease as operating or financing. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.</span></div>As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions, including Goodwill, Intangible Assets and Contingent Consideration</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions, including Goodwill, Intangible Assets and Contingent Consideration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period, which may be up to one year from the acquisition date, with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the abandonment or completion of the associated R&amp;D efforts, which generally occurs when regulatory approval is obtained. Goodwill and indefinite-lived intangible assets are not amortized and, instead, are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and, are also periodically reviewed for changes in facts or circumstances resulting in a reduction to the estimated useful life of the asset, requiring the acceleration of amortization. See &#8220;Impairment of Long-Lived Assets&#8221; for additional information.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the initial fair value of an intangible asset, or when quantitative analysis is required to determine any impairment, we use a probability-weighted income approach that discounts expected future cash flows to present value using a discount rate that is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. These cash flow models require the use of Level 3 fair value measurements and inputs, including estimated revenues, which, for example, include significant inputs such as addressable patient population, treatment duration, projected market share, assessment of the asset&#8217;s life cycle, and competitive trends impacting the asset; costs and probability of technical and regulatory success, among other factors.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value on our Consolidated Statements of Income until such time that the payment is made. Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates.</span></div>When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and, therefore, no goodwill is recorded and contingent consideration generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are expensed as incurred on our Consolidated Statements of Income unless there is an alternative future use.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset over its useful life to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Unrealized changes in the fair value of derivatives designated as part of a hedge transaction are recorded in Accumulated other comprehensive income. For our hedges related to forecasted product sales, the unrealized gains or losses in Accumulated other comprehensive income are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in Other income (expense), net on our Consolidated Statements of Income.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using regression analysis, we assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize accruals for loss contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue the best estimate of loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax provision is computed under the liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance to reduce our deferred tax assets to the amounts that are more likely than not to be realized. We consider future taxable income, ongoing tax planning strategies and our historical financial performance in assessing the need for a valuation allowance. If we expect to realize deferred tax assets for which we have previously recorded a valuation allowance, we will reduce the valuation allowance in the period in which such determination is first made.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (&#8220;UTB&#8221;) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax expense on our Consolidated Statements of Income. </span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for the tax on Global Intangible Low-Taxed Income, enacted as part of the Tax Cuts and Jobs Act, as a component of tax expense in the period in which the tax is incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Transaction</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transactions</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Consolidated Financial Statements are presented in U.S. dollars. The functional currency for most of our foreign subsidiaries is their local currency. Revenues, expenses, gains and losses for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities for such entities are translated using exchange rates that approximate the rate at the balance sheet date. Foreign currency translation adjustments are recorded as a component of Accumulated other comprehensive income on our Consolidated Balance Sheets. Foreign currency transaction gains and losses on transactions not denominated in functional currency are recorded in Other income (expense), net, on our Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value accounting for all financial and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Level 1 inputs include quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 2 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale Debt Securities</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Derivative Contracts</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;P Global Ratings, Moody&#8217;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Level 3 Inputs</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our first quarter 2021 acquisition of MYR, we recorded a liability for contingent consideration, which is revalued each reporting period until the related contingency is resolved. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval of Hepcludex.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285367024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Property, Plant and Equipment, Estimated Useful Life</a></td>
<td class="text">Estimated useful lives in years are generally as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Estimated&#160;Useful&#160;Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;35 years or useful&#160;life</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4-10</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-15</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter&#160;of&#160;useful&#160;life or lease&#160;term</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Useful Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285346544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Total revenues:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.930%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other International</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Product sales:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">HIV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biktarvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Complera/Eviplera</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Descovy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genvoya</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Odefsey</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stribild</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Truvada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue share - Symtuza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HIV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HIV </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,820&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,194&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,828&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,315&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,651&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:4.5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Hepatitis C virus (&#8220;HCV&#8221;)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ledipasvir/</span></div><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sofosbuvir/Velpatasvir</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HCV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HCV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,810&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">442&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,064&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="27" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Hepatitis B virus (&#8220;HBV&#8221;) / Hepatitis Delta virus (&#8220;HDV&#8221;)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vemlidy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Viread</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other HBV/HDV</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total HBV/HDV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cell therapy </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tecartus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Yescarta</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total cell therapy </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Trodelvy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AmBisome</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Letairis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Royalty, contract and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,884&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,305&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,135&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,689&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents our revenue from cobicistat (&#8220;C&#8221;), emtricitabine (&#8220;FTC&#8221;) and tenofovir alafenamide (&#8220;TAF&#8221;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#8220;Janssen&#8221;). See Note 10. Collaborations and Other Arrangements for additional information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes Atripla, Emtriva, Sunlenca and Tybost.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes Vosevi and Sovaldi.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes Hepcludex and Hepsera.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes Cayston, Jyseleca, Ranexa and Zydelig.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Summarized Revenues from Major Customers</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:61.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.699%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(as a percentage of total revenues)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Revenues Recognized from Performance Obligations Satisfied in Prior Periods</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes revenues recognized from performance obligations satisfied in prior periods:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:61.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue share with Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and royalties for licenses of intellectual property</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 10. Collaborations and Other Arrangements for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460284481984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: </span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.661%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Galapagos NV (&#8220;Galapagos&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment in Arcus Biosciences, Inc. (&#8220;Arcus&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,658&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,600&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,150&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,320&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency derivative contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Note 10. Collaborations and Other Arrangements for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Change in Fair Value of Contingent Consideration</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the change in fair value of our contingent consideration: </span></div><div style="margin-top:4.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange remeasurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Included in Research and development expenses on our Consolidated Statements of Income and primarily related to increasing discount rates and updated probability rate estimates.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Included in Other income (expense), net on our Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278168176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-sale Debt Securities and Equity Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Available-for-Sale Debt Securities at Estimated Fair Value</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:40.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,204&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,908&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:40.481%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential mortgage and asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of the Classification of Available-for-Sale Debt Securities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Available-for-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity: </span></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized&#160;Cost</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After ten years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Equity Securities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Consolidated Balance Sheets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is classified in Other long-term assets due to certain lock-up provisions in our amended subscription agreement with them, which extend to August 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460281666400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of Classification and Fair Value of Derivative Instruments</a></td>
<td class="text">The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:42.474%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.437%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtMi0xLTEtMTY3NjY1_2f4084d2-5259-4bc5-8b05-5f700b1f1a8a">Derivative Assets</span></span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtNi0xLTEtMTY3NjY1_46ccc9b5-72b7-44ea-ba73-a4b1e8bd1b28">Derivative Liabilities</span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives presented gross on the Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts not offset on the Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash collateral received / pledged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount (legal offset)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:42.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtMi0xLTEtMjA2NjQ5_b7aba77a-d3a3-423b-9d31-3f7747775fae">Derivative Assets</span></span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtNi0xLTEtMjA2NjQ5_bc98400a-c82d-4004-b4ed-25c8c3bfe4b2">Derivative Liabilities</span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other&#160;long-term&#160;obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives designated as hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives not designated as hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total derivatives presented gross on the Consolidated Balance Sheets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross amounts not offset on the Consolidated Balance Sheets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash collateral received / pledged</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net amount (legal offset)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Effect of Foreign Currency Exchange Contracts</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the effect of our derivative contracts on our Consolidated Financial Statements:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives designated as hedges:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Accumulated other comprehensive income</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) reclassified from Accumulated other comprehensive income to Product sales</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives not designated as hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other income (expense), net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285308272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summarized Fair Values of Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Immunomedics was accounted for as a business combination using the acquisition method of accounting. The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="margin-bottom:1pt;margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.399%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outlicense contract</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets (and liabilities), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,606&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,597&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285335232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Property, plant and equipment, net: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements (including leasehold improvements)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office, computer equipment and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,661&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,014&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Includes $104 million and $131 million of unamortized capitalized software costs as of December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460277994320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of Goodwill:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill resulting from acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,314&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,332&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; axicabtagene ciloleucel</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; Hepcludex</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,794&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,121)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,674&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,915&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,535&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets &#8211; IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,121)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,894&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&amp;D intangible asset of $6.1 billion will be reclassified to finite-lived assets in the first quarter of 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Intangible assets, net:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.156%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross&#160;<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; sofosbuvir</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; axicabtagene ciloleucel</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,501)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; Trodelvy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset &#8211; Hepcludex</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(650)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,794&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,121)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,674&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,915&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,535&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived assets &#8211; IPR&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,121)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,894&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,835&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,381)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,455&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated Future Amortization Expense of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2022:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278962640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Accounts Receivable, net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Accounts receivable, net: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,278&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for cash discounts and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowances for credit losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our Inventories:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of Other current liabilities:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and employee benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for sales returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual for settlement related to bictegravir litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,145&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;See Note 13. Commitments and Contingencies for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460279191152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Financing Arrangements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of our borrowings under various financing arrangements:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.551%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type of Borrowing</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issue Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.65%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2036</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2040</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2011</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.65%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2044</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2045</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2046</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2047</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Unsecured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2050</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior unsecured notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,088&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,571&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,229&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,695&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other obligations, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Long-term debt, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,957&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,179&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Contractual Maturities of Financing Obligations</a></td>
<td class="text"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate future principal maturities of our senior unsecured notes as of December&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460275031248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Supplemental Information Related to Operating Leases</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balance sheet and other information related to our operating leases:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.131%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except weighted average amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_8de7020f-9548-47c7-9a1e-4746afc67ea4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_b3559456-f5cf-4d45-8c2a-793a81b2aed1">Other long-term assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities &#8211; current</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_37e207dc-5857-47ab-bc75-5d95f77eba00"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_566a40c8-fefd-4cc7-be50-3313dae89a4d">Other accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities &#8211; noncurrent</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_083b769e-0d49-49bf-952b-f91005031157"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_6a8cd158-cdc0-45a1-ba9e-3851203d9cab">Other long-term obligations</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to our operating leases:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Aggregate Future Lease Payments</a></td>
<td class="text"><div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total discounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285152848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Stock Repurchases</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our stock repurchases through open market transactions under these programs:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares repurchased and retired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsDeclaredTableTextBlock', window );">Schedule of Dividends Declared</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes cash dividends declared on our common stock:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dividend Per Share</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third quarter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth quarter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated OCI by Component</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in Accumulated other comprehensive income by component, net of tax:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassifications to net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsDeclaredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsDeclaredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460277581600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based Compensation Expenses -Included in Consolidated Statement of Income</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize total stock-based compensation expense included on our Consolidated Statements of Income as broken down by award type and by expense type:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in total costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accelerated post-acquisition stock-based compensation expense of $8 million related to the MiroBio acquisition in 2022, and $289 million and $144 million related to the acquisitions of Immunomedics and Forty Seven, respectively, in 2020.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in total costs and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">RSU Activity</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our RSU activity:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.48&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value of RSUs granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.36&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.42&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.94&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of RSUs as of the respective vesting dates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">PSU Activity</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our PSU activity:</span></div><div style="margin-top:4.5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value of PSUs granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.04&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.31&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.64&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of PSUs as of the respective vesting dates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Activity Under Stock Option Plans</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize activity and other information related to our stock options: </span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price<br/>(in dollars)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.60&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest, net of estimated forfeitures as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.08&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.05&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.69&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of options exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions to Calculate the Estimated Fair Value of Awards</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the stock option awards:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.015%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected terms in years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the ESPP awards:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected terms in years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">ESPP Activity</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our ESPP activity:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount paid by employees for shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value of ESPP shares granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of ESPP shares as of the respective vesting dates</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and ESPP, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460285348896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the calculation of basic and diluted earnings per share attributable to Gilead:</span></div><div style="margin-top:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:63.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.046%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,592&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,225&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in basic earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in diluted earnings per share attributable to Gilead calculation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.66&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.96&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Gilead</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.93&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460282677184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) Before Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes consists of the following:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,587&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,505&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expense</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense consists of the following:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,526)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,286)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,248)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,580)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Difference Between Provision for Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the federal statutory tax rate applied to Income before income taxes and our effective tax rate is summarized as follows:</span></div><div style="margin-top:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at different rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US tax on foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of tax examinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D &amp; related charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable unrealized loss on investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities are as follows:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves and accruals not currently deductible</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of tax basis over book basis of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront and milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and other credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to sale of future royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized R&amp;D expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,289&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,641&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,690&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess of book basis over tax basis of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,728)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,719)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,122)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,138)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,432)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,017)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a rollforward of our total gross unrecognized tax benefits:</span></div><div style="margin-top:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to current year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax positions related to prior years:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_ScheduleOfTransitionTaxTableTextBlock', window );">Schedule of Transition Tax</a></td>
<td class="text"><div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the anticipated timing of payments associated with this transition tax as of December&#160;31, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ScheduleOfTransitionTaxTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Transition Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ScheduleOfTransitionTaxTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460281523648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>country</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which entity operates | country</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Decrease in research and development</a></td>
<td class="num">$ (4,977)<span></span>
</td>
<td class="num">$ (4,601)<span></span>
</td>
<td class="num">$ (4,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 778<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Decrease in research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 762<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">35 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Office, computer equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Office, computer equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460268454576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Disaggregation of Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 27,281<span></span>
</td>
<td class="nump">$ 27,305<span></span>
</td>
<td class="nump">$ 24,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18,884<span></span>
</td>
<td class="nump">19,267<span></span>
</td>
<td class="nump">18,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,469<span></span>
</td>
<td class="nump">4,874<span></span>
</td>
<td class="nump">4,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember', window );">Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,928<span></span>
</td>
<td class="nump">3,164<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">26,982<span></span>
</td>
<td class="nump">27,008<span></span>
</td>
<td class="nump">24,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18,716<span></span>
</td>
<td class="nump">19,176<span></span>
</td>
<td class="nump">18,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">4,342<span></span>
</td>
<td class="nump">4,678<span></span>
</td>
<td class="nump">3,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,924<span></span>
</td>
<td class="nump">3,154<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">17,194<span></span>
</td>
<td class="nump">16,315<span></span>
</td>
<td class="nump">16,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13,820<span></span>
</td>
<td class="nump">12,828<span></span>
</td>
<td class="nump">13,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,219<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember', window );">Total HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,155<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10,390<span></span>
</td>
<td class="nump">8,624<span></span>
</td>
<td class="nump">7,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8,510<span></span>
</td>
<td class="nump">7,049<span></span>
</td>
<td class="nump">6,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,103<span></span>
</td>
<td class="nump">969<span></span>
</td>
<td class="nump">735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember', window );">Biktarvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">606<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember', window );">Complera/Eviplera | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,872<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,631<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember', window );">Descovy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,404<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">3,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">2,267<span></span>
</td>
<td class="nump">2,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember', window );">Genvoya | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,469<span></span>
</td>
<td class="nump">1,568<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,058<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">1,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember', window );">Odefsey | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember', window );">Stribild | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="nump">1,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember', window );">Truvada | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember', window );">Revenue share - Symtuza | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember', window );">Other HIV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,905<span></span>
</td>
<td class="nump">5,565<span></span>
</td>
<td class="nump">2,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,575<span></span>
</td>
<td class="nump">3,640<span></span>
</td>
<td class="nump">2,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_VekluryMember', window );">Veklury | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,628<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,810<span></span>
</td>
<td class="nump">1,881<span></span>
</td>
<td class="nump">2,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember', window );">Total HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember', window );">Ledipasvir/Sofosbuvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,530<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">1,599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">844<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember', window );">Sofosbuvir/Velpatasvir | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHCVMember', window );">Other HCV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHCVMember', window );">Other HCV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHCVMember', window );">Other HCV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherHCVMember', window );">Other HCV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">988<span></span>
</td>
<td class="nump">969<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember', window );">Total HBV/HDV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">441<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">814<span></span>
</td>
<td class="nump">657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember', window );">Vemlidy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember', window );">Viread | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HB/HDV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HB/HDV | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HB/HDV | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember', window );">Other HB/HDV | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total cell therapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="nump">871<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total cell therapy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">542<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total cell therapy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember', window );">Total cell therapy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember', window );">Tecartus | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember', window );">Yescarta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">695<span></span>
</td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember', window );">Yescarta | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">747<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember', window );">Yescarta | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember', window );">Yescarta | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_TrodelvyMember', window );">Trodelvy | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">946<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember', window );">Total Other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">497<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember', window );">AmBisome | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember', window );">Letairis | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember', window );">Other | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember', window );">Royalty, contract and other revenues | Other International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=gild_OtherInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=gild_OtherInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsStribildMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsStribildMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_VekluryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_VekluryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherHCVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherHCVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OtherProductsOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OtherProductsOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460279238096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Summarized Revenues from Major Customers (Details) - Revenue benchmark - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Cardinal Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_AmerisourcebergenCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=gild_MckessonCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=gild_MckessonCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460284500592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Performance Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue share with Janssen and royalties for licenses of intellectual property</a></td>
<td class="nump">$ 783<span></span>
</td>
<td class="nump">$ 851<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Changes in estimates</a></td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460281546304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460274293376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 2,293<span></span>
</td>
<td class="nump">$ 2,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,248<span></span>
</td>
<td class="nump">5,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">8,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">3,831<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Fair value | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,658<span></span>
</td>
<td class="nump">6,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">3,831<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 1 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,943<span></span>
</td>
<td class="nump">2,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 2 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Galapagos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Other publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Deferred compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Deferred compensation plan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, recurring | Level 3 | Foreign currency derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Foreign currency derivative contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_ForeignCurrencyDerivativeContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460277557936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Short-term and long-term debt</a></td>
<td class="nump">21,900<span></span>
</td>
<td class="nump">28,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair value | Level 3 | Immunomedics, Inc. | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Future royalties</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying value | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Short-term and long-term debt</a></td>
<td class="nump">24,100<span></span>
</td>
<td class="nump">25,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying value | Level 3 | Immunomedics, Inc. | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Future royalties</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460279239088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Contingent Consideration (Details) - Contingent Consideration - MYR - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in valuation assumptions</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement', window );">Effect of foreign exchange remeasurement</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=gild_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=gild_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460268406240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 2,325<span></span>
</td>
<td class="nump">$ 2,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">2,293<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember', window );">Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">$ 333<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460274322240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">$ (22)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">1,204<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">1,908<span></span>
</td>
<td class="nump">2,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agencies securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">774<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember', window );">Residential mortgage and asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">$ 261<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gild_ResidentialMortgageAndAssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460281562096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-sale Debt Securities and Equity Securities - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount', window );">Equity investments and equity method investments without readily determinable fair values</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss on investment of equity securities</a></td>
<td class="nump">657<span></span>
</td>
<td class="nump">610<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=gild_EquitySecuritiesDonationMember', window );">Equity Securities Donation | Gilead Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Donation expense</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=gild_EquitySecuritiesDonationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=gild_EquitySecuritiesDonationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gild_GileadFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gild_GileadFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460274221920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-sale Debt Securities and Equity Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 2,293<span></span>
</td>
<td class="nump">$ 2,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember', window );">Short-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">973<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember', window );">Long-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Total</a></td>
<td class="nump">$ 1,245<span></span>
</td>
<td class="nump">$ 1,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=gild_MarketableSecuritiesNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460280368800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized&#160;Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within one year</a></td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">After one year through five years</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">After five years through ten years</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">After ten years</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">2,325<span></span>
</td>
<td class="nump">$ 2,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one year through five years</a></td>
<td class="nump">1,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">After five years through ten years</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">After ten years</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 2,293<span></span>
</td>
<td class="nump">$ 2,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460280369840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-sale Debt Securities and Equity Securities - Summary of Classification of Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">$ 3,831<span></span>
</td>
<td class="nump">$ 3,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 5,248<span></span>
</td>
<td class="nump">$ 5,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460282248528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Outstanding notional amounts on foreign currency exchange contracts</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet', window );">Gain (loss) on discontinuance of cash flow hedges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Maturity on derivative instruments</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1', window );">Time estimate for gains (losses) to be reclassified from AOCI to product sales</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460274059280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Derivative financial instruments</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received / pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amount (legal offset)</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Derivative financial instruments</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash collateral received / pledged</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amount (legal offset)</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative asset, statement of financial position</a></td>
<td class="text">Other long-term assets, Prepaid and other current assets<span></span>
</td>
<td class="text">Other long-term assets, Prepaid and other current assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative liability, statement of financial position</a></td>
<td class="text">Other current liabilities, Other long-term obligations<span></span>
</td>
<td class="text">Other current liabilities, Other long-term obligations<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Prepaid and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as hedging instrument | Other&#160;long-term&#160;obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement', window );">Derivative Liabilities</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460279253808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Gain (loss) recognized in Accumulated other comprehensive income</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="num">$ (118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Gain (loss) reclassified from Accumulated other comprehensive income to Product sales</a></td>
<td class="nump">196<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gain (loss) recognized in Other income (expense), net</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="num">$ (51)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460273481040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 23, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 07, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 944,000,000<span></span>
</td>
<td class="nump">$ 939,000,000<span></span>
</td>
<td class="nump">$ 5,968,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate', window );">Discount rate of acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Decrease in goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember', window );">Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsGrossReclassified', window );">Reclassified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member', window );">In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Indefinite-lived intangible assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000,000<span></span>
</td>
<td class="nump">6,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="nump">&#8364; 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">317,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability', window );">Fair value of contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Decrease in goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Hepcludex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 845,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Hepcludex | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate', window );">Discount rate of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Aggregate fair value of acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Hepcludex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Aggregate fair value of acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability for MYR GmbH (&#8220;MYR&#8221;) contingent consideration | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,991,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Accelerated stock-based expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory', window );">Fair value step-up adjustment of inventories acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 294,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability', window );">Liability related to future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Medium-term notes | Three year senior unsecured term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowing under the senior unsecured term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput', window );">Liability related to future royalties, measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate', window );">Discount rate of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of finite-lived intangible asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Aggregate fair value of acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,760,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Aggregate fair value of acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gild_MiroBioLtdMember', window );">MiroBio Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PaymentsForAssetAcquisitions', window );">Cash consideration</a></td>
<td class="nump">$ 414,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 389,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember', window );">Forty Seven, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Accelerated stock-based expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PaymentsToAcquireAssetsNetOfCashAcquired', window );">Total consideration, net of acquired cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember', window );">Forty Seven, Inc. | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems', window );"><strong>Business Combination, Separately Recognized Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired Finite-lived Intangible Assets, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Future Royalties, Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsGrossReclassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Gross, Reclassified</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsGrossReclassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite-lived Intangible Assets Acquired, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsToAcquireAssetsNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Assets, Net Of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsToAcquireAssetsNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gild_MiroBioLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gild_MiroBioLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gild_FortySevenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460282338000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet', window );">Other assets (and liabilities), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR | Intangible asset &#8211; Hepcludex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income taxes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability', window );">Liability related to future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet', window );">Other assets (and liabilities), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460277616240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land and land improvements</a></td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings and improvements (including leasehold improvements)</a></td>
<td class="nump">4,390<span></span>
</td>
<td class="nump">3,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Laboratory and manufacturing equipment</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Office, computer equipment and other</a></td>
<td class="nump">880<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Subtotal</a></td>
<td class="nump">7,661<span></span>
</td>
<td class="nump">7,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="nump">2,186<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">$ 5,475<span></span>
</td>
<td class="nump">$ 5,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460283001456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Unamortized capitalized software costs</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,475<span></span>
</td>
<td class="nump">5,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 973<span></span>
</td>
<td class="nump">$ 963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460282826160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 8,332<span></span>
</td>
<td class="nump">$ 8,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill resulting from acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustments</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 8,314<span></span>
</td>
<td class="nump">$ 8,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460277395136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Decrease in goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense related to finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate', window );">Discount rate of acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member', window );">In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Indefinite-lived intangible assets, fair value</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member', window );">In Process Research And Development Trodelvy For HR+/HER2- | Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">In-process research and development impairment</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember', window );">MYR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Decrease in goodwill</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Aggregate fair value of acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | In Process Research And Development Trodelvy For HR+/HER2- | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetMeasurementInput', window );">Discount rate, measurement input</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite-Lived Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite-lived Intangible Assets Acquired, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MYRGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460277875040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">$ 25,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(10,121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">15,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">13,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">13,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">39,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(10,121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,381)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">28,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member', window );">In Process Research And Development Trodelvy For HR+/HER2-</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Indefinite-lived intangible assets, fair value</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember', window );">Intangible asset &#8211; sofosbuvir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">10,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(6,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,651)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">4,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(6,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,651)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember', window );">Intangible asset &#8211; axicabtagene ciloleucel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">7,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">5,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,501)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember', window );">Intangible asset &#8211; Trodelvy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">5,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">4,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(507)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember', window );">Intangible asset &#8211; Hepcludex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross&#160; Carrying Amount</a></td>
<td class="nump">1,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(733)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss', window );">Foreign Currency Translation Adjustment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Including Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (733)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (650)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_IntangibleAssetSofosbuvirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_AxicabtageneciloleucelDLBCLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_TrodelvyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gild_HepcludexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460282184640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">1,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">1,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">1,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">1,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">6,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 15,674<span></span>
</td>
<td class="nump">$ 17,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460378097632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accounts Receivable, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 5,464<span></span>
</td>
<td class="nump">$ 5,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_AccountsReceivableChargebacksCurrent', window );">Less: allowances for chargebacks</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent', window );">Less: allowances for cash discounts and other</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowances for credit losses</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 4,777<span></span>
</td>
<td class="nump">$ 4,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableCashDiscountsAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Cash Discounts and Other, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableCashDiscountsAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AccountsReceivableChargebacksCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Chargebacks, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AccountsReceivableChargebacksCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460282055456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,177<span></span>
</td>
<td class="nump">$ 1,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_InventoryNetAndInventoryNoncurrent', window );">Total</a></td>
<td class="nump">2,820<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">1,507<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other long term assets</a></td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">$ 1,116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InventoryNetAndInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Net And Inventory Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InventoryNetAndInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460284224096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_ScheduleOfInventoryLineItems', window );"><strong>Schedule of Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ScheduleOfInventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Inventory [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ScheduleOfInventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460282208000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Other Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and employee benefits</a></td>
<td class="nump">$ 1,018<span></span>
</td>
<td class="nump">$ 927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">959<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Allowance for sales returns</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueCurrent', window );">Accrual for settlement related to bictegravir litigation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,182<span></span>
</td>
<td class="nump">2,930<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 4,580<span></span>
</td>
<td class="nump">$ 6,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 27<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130611-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460255167760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations and Other Arrangements (Details)<br> &#8364; in Millions, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 25, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 17, 2020 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Jul. 13, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 29, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>May 27, 2020</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Nov. 18, 2021 </div>
<div>program</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Feb. 08, 2021</div></th>
<th class="th">
<div>Dec. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 15, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 23, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 17, 2020</div></th>
<th class="th"><div>Jun. 19, 2020</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 944,000,000<span></span>
</td>
<td class="nump">$ 939,000,000<span></span>
</td>
<td class="nump">$ 5,968,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,977,000,000<span></span>
</td>
<td class="nump">4,601,000,000<span></span>
</td>
<td class="nump">4,927,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,657,000,000<span></span>
</td>
<td class="nump">6,601,000,000<span></span>
</td>
<td class="nump">4,572,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,673,000,000<span></span>
</td>
<td class="nump">5,246,000,000<span></span>
</td>
<td class="nump">5,151,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts', window );">Percent of global and development and commercialization costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenues recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod', window );">Option period to license certain inhibitors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp | Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts', window );">Percent of global and development and commercialization costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp | Oral Formulation Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CollaborationArrangementNetProductSalesThreshold', window );">Net product sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalProductRevenues', window );">Percent of global product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember', window );">Merck Sharp &amp; Dohme Corp | Injectable Formulation Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CollaborationArrangementNetProductSalesThreshold', window );">Net product sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CollaborationArrangementPercentOfGlobalProductRevenues', window );">Percent of global product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember', window );">Arcus stock purchase agreement | Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember', window );">Janssen pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage', window );">Purchase price of goods less specified amount, maximum percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,000,000<span></span>
</td>
<td class="nump">530,000,000<span></span>
</td>
<td class="nump">570,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination', window );">Period subject to termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember', window );">Japan tobacco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">291,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 559,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_EverestMedicinesAndImmunomedicsAgreementMember', window );">Everest Medicines | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-lived intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember', window );">Other collaboration arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant', window );">Upfront collaboration expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000,000<span></span>
</td>
<td class="nump">177,000,000<span></span>
</td>
<td class="nump">129,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares of common stock acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus collaboration agreement and stock purchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to acquire in process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_InvestmentOwnedBalanceAdditionalShares', window );">Additional shares acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_TotalUpfrontPaymentsMade', window );">Total upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_IssuanceDiscountPremium', window );">Issuance discount (premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PaymentsForDirectTransactionalExpense', window );">Direct transactional costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CollaborativeAgreementOptInTerm', window );">Opt-in term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_NumberOfClinicalStageProgramsWithExercisedOptions', window );">Number of clinical stage programs with exercise options | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PaymentsToOptInTheCollaborativeAgreement', window );">Collaboration opt-in payments</a></td>
<td class="nump">$ 725,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased', window );">Maximum percentage of outstanding stock allowed to be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIPurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIRestrictionPeriod', window );">Restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_EquitySecuritiesFVNISharesAcquired', window );">Additional shares acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIShares', window );">Number of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember', window );">Arcus | Arcus collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries', window );">Additional option fee on fourth, sixth, and eighth anniversaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember', window );">Pionyr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember', window );">Pionyr | Pionyr merger and option agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PotentialFutureMilestonePaymentsMaximum', window );">Maximum potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_EquityMethodInvestmentOptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember', window );">Pionyr | Research and development service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_ResearchAndDevelopmentFutureMaximumPayments', window );">Research and development future maximum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_AdditionalResearchAndDevelopmentInProcess', window );">Additional acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember', window );">Tizona</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember', window );">Tizona | Tizona merger and option agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_EquityMethodInvestmentOptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember', window );">Tizona | Tizona merger and option agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments', window );">Option fee and potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember', window );">Tizona | Development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember', window );">Tango | Tango collaboration and stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to acquire in process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CashPaymentsMadeRelatedToEquityInvestments', window );">Cash payments made related to equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_NumberOfPrograms', window );">Number of programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CollaborativeArrangementTerm', window );">Collaboration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember', window );">Tango | Tango collaboration and stock purchase agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments', window );">Opt-in, extension and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_JounceTherapeuticsIncMember', window );">Jounce | Jounce license and stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to acquire in process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_TotalUpfrontPaymentsMade', window );">Total upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_CashPaymentsMadeRelatedToEquityInvestments', window );">Cash payments made related to equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember', window );">Galapagos | Amended 2019 agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts', window );">Potential payment for adjustments of budgeted development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000,000<span></span>
</td>
<td class="nump">&#8364; 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts', window );">Payment for adjustments of budgeted development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000,000<span></span>
</td>
<td class="nump">&#8364; 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments', window );">Additional payment for adjustments of budgeted development costs in 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000,000<span></span>
</td>
<td class="nump">&#8364; 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths', window );">Payment for adjustments of budgeted development costs in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember', window );">Galapagos | Galapagos subscription agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares of common stock acquired (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement', window );">Maximum ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_StandstillRestrictingTerm', window );">Standstill restricting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement', window );">Minimum ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PotentialOptionExerciseFeePerProgram', window );">Potential option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage', window );">Payment of tiered royalties, low-end percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage', window );">Payment of tiered royalties, high-end percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gild_DragonflyTherapeuticsIncMember', window );">Dragonfly Therapeutics, Inc. | Dragonfly Therapeutics Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to acquire in process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment', window );">Additional payments to acquire in process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PotentialFutureMilestonePaymentsMaximum', window );">Maximum potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=gild_EverestMedicinesMember', window );">Everest Medicines | Everest Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PotentialFutureMilestonePaymentsMaximum', window );">Maximum potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_UpfrontPaymentsToTerminatePreviousAgreement', window );">Upfront termination payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PaymentsToTerminatePreviousAgreement', window );">Termination payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AdditionalResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Research And Development In Process</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AdditionalResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AdjustmentsOfBudgetedDevelopmentCostsPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments of Budgeted Development Costs, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AdjustmentsOfBudgetedDevelopmentCostsPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CashPaymentsMadeRelatedToEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Payments Made Related To Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CashPaymentsMadeRelatedToEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementNetProductSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Net Product Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementNetProductSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Percent Of Global Development And Commercialization Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborationArrangementPercentOfGlobalProductRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Percent Of Global Product Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborationArrangementPercentOfGlobalProductRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeAgreementOptInTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Opt-In Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeAgreementOptInTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Product Market Period Subject To Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquityMethodInvestmentOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquityMethodInvestmentOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Option Fee And Potential Future Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Restriction Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNIShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNIShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_EquitySecuritiesFVNISharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_EquitySecuritiesFVNISharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial consideration for acquisition of rights to market and distribute certain products in Japan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_InvestmentOwnedBalanceAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment Owned, Balance, Additional Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_InvestmentOwnedBalanceAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_IssuanceDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Discount (Premium)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_IssuanceDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Ownership Percentage In Galapagos Based On The Terms Of The Subscription Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_NumberOfClinicalStageProgramsWithExercisedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Clinical Stage Programs With Exercised Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_NumberOfClinicalStageProgramsWithExercisedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_NumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_NumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for Adjustments of Budgeted Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsForDirectTransactionalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Direct Transactional Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsForDirectTransactionalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Additional In Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsToOptInTheCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Opt-In The Collaborative Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsToOptInTheCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsToTerminatePreviousAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Terminate Previous Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsToTerminatePreviousAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialFutureMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialFutureMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialOptionExerciseFeePerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Option Exercise Fee Per Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialOptionExerciseFeePerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Payment for Adjustments of Budgeted Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Sales Based Tiered Royalties High-end, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Sales Based Tiered Royalty, Low-end, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Goods Less Specified Amount, Maximum Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ResearchAndDevelopmentFutureMaximumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Future Maximum Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ResearchAndDevelopmentFutureMaximumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_StandstillRestrictingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standstill Restricting Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_StandstillRestrictingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TotalUpfrontPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Upfront Payments Made</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TotalUpfrontPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Up-Front Collaboration And Licensing Expenses Related To Other Collaboration Arrangements That Are Not Individually Significant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_UpfrontPaymentsToTerminatePreviousAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payments To Terminate Previous Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_UpfrontPaymentsToTerminatePreviousAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126960272&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gild_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gild_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_OralFormulationProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_OralFormulationProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_EverestMedicinesAndImmunomedicsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_EverestMedicinesAndImmunomedicsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_PionyrMergerAndOptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_PionyrMergerAndOptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_ResearchAndDevelopmentServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_ResearchAndDevelopmentServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_TizonaMergerAndOptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_TizonaMergerAndOptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_DevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_DevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_JounceTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_JounceTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gild_DragonflyTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gild_DragonflyTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_DragonflyTherapeuticsCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_DragonflyTherapeuticsCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gild_EverestMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gild_EverestMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460274371296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Summary of Debt Carrying Amount (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 25,229<span></span>
</td>
<td class="nump">$ 26,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt and other obligations, net</a></td>
<td class="nump">2,273<span></span>
</td>
<td class="nump">1,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total Long-term debt, net</a></td>
<td class="nump">22,957<span></span>
</td>
<td class="nump">25,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 24,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 1.95% Senior Unsecured Notes Due in March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.25% Senior Unsecured Notes Due in September 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.50% Senior Unsecured Notes Due in September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 0.75% Senior Unsecured Notes Due in September 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,498<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.70% Senior Unsecured Notes Due in April 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,748<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.50% Senior Unsecured Notes Due in February 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,748<span></span>
</td>
<td class="nump">1,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.65% Senior Unsecured Notes Due in March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 2,742<span></span>
</td>
<td class="nump">2,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.95% Senior Unsecured Notes Due in March 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,247<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 1.20% Senior Unsecured Notes Due October 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 747<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 1.65% Senior Unsecured Notes Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.60% Senior Unsecured Notes Due in September 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.00% Senior Unsecured Notes Due in September 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.60% Senior Unsecured Notes Due October 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 988<span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.65% Senior Unsecured Notes Due in December 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">5.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 996<span></span>
</td>
<td class="nump">996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.80% Senior Unsecured Notes Due in April 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.50% Senior Unsecured Notes Due in February 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,733<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.75% Senior Unsecured Notes Due in March 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 2,221<span></span>
</td>
<td class="nump">2,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.15% Senior Unsecured Notes Due in March 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,728<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 2.80% Senior Unsecured Notes Due October 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,477<span></span>
</td>
<td class="nump">1,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember', window );">Senior Notes and Medium-Term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total senior unsecured notes</a></td>
<td class="nump">24,088<span></span>
</td>
<td class="nump">25,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Liability related to future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 1,141<span></span>
</td>
<td class="nump">$ 1,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueInSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueInSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinApril2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinApril2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinFebruary2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinFebruary2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A120SeniorUnsecuredNotesDueOctober2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A165SeniorUnsecuredNotesDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinSeptember2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A260SeniorUnsecuredNotesDueOctober2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueDecember2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinApril2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinApril2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinFebruary2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinFebruary2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_SeniorUnsecuredNotesDueinMarch2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A280SeniorUnsecuredNotesDueOctober2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=gild_SeniorNotesAndMediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460268305760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Credit Facilities - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="nump">$ 4,750,000,000<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Debt issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,229,000,000<span></span>
</td>
<td class="nump">26,695,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLongTermDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940,000,000<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember', window );">Immunomedics, Inc. | Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput', window );">Liability related to future royalties, measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption price, percentage of principal amount repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueInSeptember2023Member', window );">0.75% Senior Unsecured Notes Due in September 2023 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,498,000,000<span></span>
</td>
<td class="nump">1,496,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member', window );">2020 revolving credit facility | Line of credit | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under the facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A195SeniorUnsecuredNotesDueMarch2022Member', window );">1.95% Senior Unsecured Notes Due March 2022 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_A325SeniorUnsecuredNotesDueSeptember2022Member', window );">3.25% Senior Unsecured Notes Due September 2022 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member', window );">the "2020 Fixed Rate Notes" | Senior notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity', window );">Call feature, period prior to maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member', window );">the "2020 Fixed Rate Notes" | Senior notes | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity', window );">Call feature, period prior to maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Future Royalties, Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DebtInstrumentCallFeaturePeriodBeforeMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Call Feature, Period Before Maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DebtInstrumentCallFeaturePeriodBeforeMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest paid or due on all long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueInSeptember2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A075SeniorUnsecuredNotesDueInSeptember2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_CreditFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A195SeniorUnsecuredNotesDueMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A195SeniorUnsecuredNotesDueMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_A325SeniorUnsecuredNotesDueSeptember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_A325SeniorUnsecuredNotesDueSeptember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460277443552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 25,229<span></span>
</td>
<td class="nump">$ 26,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">13,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">$ 24,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460275027664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease term extension</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Termination period</a></td>
<td class="text">one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460282215440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Location and Other Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">$ 542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities &#8211; current</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities &#8211; noncurrent</a></td>
<td class="nump">$ 467<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating lease, right-of-use asset, statement of financial position, extensible enumeration</a></td>
<td class="text">Other long-term assets<span></span>
</td>
<td class="text">Other long-term assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, current, statement of financial position, extensible enumeration</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, noncurrent, statement of financial position, extensible enumeration</a></td>
<td class="text">Other long-term obligations<span></span>
</td>
<td class="text">Other long-term obligations<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460282218368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Information Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460282461328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Operating Lease Liabilities Maturity (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total discounted lease payments</a></td>
<td class="nump">$ 578<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460274244288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>patent</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>patent</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>opposingParty</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>lawsuit </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Accrued litigation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber', window );">Number of additional patents allegedly infringed | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents challenged | patent</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_LossContingencyNumberOfPatents', window );">Number of patents | patent</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember', window );">Juno</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_JudgmentRoyaltyRateFromOctober2017', window );">Running royalty rate from October 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_JudgmentEnhancedDamagesOnPastSales', window );">Enhanced damages on past sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_JudgmentRoyaltyRateOnFutureSales', window );">Running royalty rate on future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember', window );">Pre-Exposure Prophylaxis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_LossContingencyMaterialTransferAgreementsNumber', window );">Number of material transfer agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember', window );">European Patent Claims 2032 Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_LossContingencyPartiesAppealedNumber', window );">Number of parties appealed | opposingParty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=gild_ProductLiabilityMember', window );">Product Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of claims filed | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentEnhancedDamagesOnPastSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Judgment: Enhanced Damages On Past Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentEnhancedDamagesOnPastSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentRoyaltyRateFromOctober2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Judgment: Royalty Rate from October 2017</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentRoyaltyRateFromOctober2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_JudgmentRoyaltyRateOnFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Judgment: Royalty Rate on Future Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_JudgmentRoyaltyRateOnFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Additional Patents Allegedly Infringed, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyMaterialTransferAgreementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Material Transfer Agreements, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyMaterialTransferAgreementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyNumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Patents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyNumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_LossContingencyPartiesAppealedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Parties Appealed, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_LossContingencyPartiesAppealedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_PreExposureProphylaxisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_EuropeanPatentClaims2032ExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gild_ProductLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gild_ProductLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460280307280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Repurchases of Common Stock (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares repurchased and retired (in shares)</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Amount</a></td>
<td class="nump">$ 1,396,000,000<span></span>
</td>
<td class="nump">$ 546,000,000<span></span>
</td>
<td class="nump">$ 1,583,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average price per share (in dollars per share)</a></td>
<td class="nump">$ 73.77<span></span>
</td>
<td class="nump">$ 66.58<span></span>
</td>
<td class="nump">$ 70.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember', window );">2020 stock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized amount</a></td>
<td class="nump">$ 4,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember', window );">2016 stock repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_A2020StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=gild_A2016StockRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278133472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Dividends (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Feb. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 2.92<span></span>
</td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 928<span></span>
</td>
<td class="nump">$ 933<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
<td class="nump">$ 904<span></span>
</td>
<td class="nump">$ 905<span></span>
</td>
<td class="nump">$ 903<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
<td class="nump">$ 3,725<span></span>
</td>
<td class="nump">$ 3,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_ChangeInDividendsPercentage', window );">Percentage of change in dividends</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ChangeInDividendsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Dividends, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ChangeInDividendsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460279149824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Preferred Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460282395152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 21,064<span></span>
</td>
<td class="nump">$ 18,221<span></span>
</td>
<td class="nump">$ 22,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="num">(170)<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(81)<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">21,209<span></span>
</td>
<td class="nump">21,064<span></span>
</td>
<td class="nump">18,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">83<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(81)<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">74<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Net unrealized gain (loss)</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="num">(171)<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(41)<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="num">$ (113)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460274094000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Narrative (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Matching contribution expense</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gild_GileadSciencesInc2022EquityIncentivePlanMember', window );">2022 Equity Incentive Plan | Common Stock&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant (in shares)</a></td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant (in shares)</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock (percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Capital shares reserved for future issuance (in shares)</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage', window );">Payout percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage', window );">Payout percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember', window );">Deferred compensation plan | Fair value, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember', window );">Deferred compensation plan | Fair value, recurring | Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable equity securities</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gild_GileadSciencesInc2022EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gild_GileadSciencesInc2022EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=gild_DeferredCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460277736976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Summary of Stock-Based Compensation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">$ 645<span></span>
</td>
<td class="nump">$ 635<span></span>
</td>
<td class="nump">$ 1,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Stock-based compensation expense, net of tax</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="nump">854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">558<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=gild_AcquisitionRelatedExpenseMember', window );">Acquisition-related expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=gild_AcquisitionRelatedExpenseMember', window );">Acquisition-related expense | MiroBio Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=gild_AcquisitionRelatedExpenseMember', window );">Acquisition-related expense | Immunomedics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=gild_AcquisitionRelatedExpenseMember', window );">Acquisition-related expense | Forty Seven, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in total costs and expenses</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 505<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=gild_AcquisitionRelatedExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=gild_AcquisitionRelatedExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_MiroBioLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_MiroBioLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=gild_FortySevenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=gild_FortySevenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460273379344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Restricted Stock (Details) - RSUs - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">20.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(8.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">20.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Weighted- Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 67.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">60.36<span></span>
</td>
<td class="nump">$ 65.42<span></span>
</td>
<td class="nump">$ 70.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">67.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">63.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 63.62<span></span>
</td>
<td class="nump">$ 67.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of RSUs as of the respective vesting dates</a></td>
<td class="nump">$ 554<span></span>
</td>
<td class="nump">$ 463<span></span>
</td>
<td class="nump">$ 444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460268425856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Performance Share Awards (Details) - PSUs - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Weighted- Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 79.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">60.04<span></span>
</td>
<td class="nump">$ 71.31<span></span>
</td>
<td class="nump">$ 83.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">68.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">59.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 64.28<span></span>
</td>
<td class="nump">$ 79.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of RSUs as of the respective vesting dates</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460280354064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Stock Options (Details) - Stock options - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Shares (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Expected to vest, net of estimated forfeitures (in shares)</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward', window );"><strong>Weighted- Average Exercise Price (in dollars)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 70.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">58.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">62.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">82.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">61.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">67.69<span></span>
</td>
<td class="nump">$ 70.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">72.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Expected to vest, net of estimated forfeitures (in dollars per share)</a></td>
<td class="nump">$ 62.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">6 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Expected to vest, net of estimated forfeitures</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Expected to vest, net of estimated forfeitures</a></td>
<td class="text">8 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 9.08<span></span>
</td>
<td class="nump">$ 10.05<span></span>
</td>
<td class="nump">$ 11.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460274054832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms in years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460273412928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - ESPP Activity (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuances under employee stock purchase plan</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare', window );">Weighted-average grant date fair value of ESPP shares granted (in dollars per share)</a></td>
<td class="nump">$ 13.40<span></span>
</td>
<td class="nump">$ 14.58<span></span>
</td>
<td class="nump">$ 15.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Total fair value of ESPP shares as of the respective vesting dates</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Shares Issued In Period, Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278010016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Gilead</a></td>
<td class="nump">$ 4,592<span></span>
</td>
<td class="nump">$ 6,225<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in basic earnings per share attributable to Gilead calculation (in shares)</a></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of stock options and equivalents (in shares)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in diluted earnings per share attributable to Gilead calculation (in shares)</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Gilead (in dollars per share)</a></td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="nump">$ 4.96<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Gilead (in dollars per share)</a></td>
<td class="nump">$ 3.64<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460279201456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460278838592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 4,439<span></span>
</td>
<td class="nump">$ 8,587<span></span>
</td>
<td class="nump">$ 2,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">1,375<span></span>
</td>
<td class="num">(309)<span></span>
</td>
<td class="num">(836)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">$ 5,814<span></span>
</td>
<td class="nump">$ 8,278<span></span>
</td>
<td class="nump">$ 1,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460274192784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="num">$ (2,539)<span></span>
</td>
<td class="num">$ (1,776)<span></span>
</td>
<td class="num">$ (1,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">1,502<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal income tax expense (benefit), continuing operations</a></td>
<td class="num">(1,037)<span></span>
</td>
<td class="num">(1,526)<span></span>
</td>
<td class="num">(1,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
<td class="num">(198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">154<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State and local income tax expense (benefit), continuing operations</a></td>
<td class="nump">122<span></span>
</td>
<td class="num">(413)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Foreign:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="num">(101)<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Foreign income tax expense (benefit), continuing operations</a></td>
<td class="num">(333)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (1,248)<span></span>
</td>
<td class="num">$ (2,077)<span></span>
</td>
<td class="num">$ (1,580)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460268404128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings at different rates</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(10.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Research and other credits</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(6.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings', window );">US tax on foreign earnings</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion', window );">Foreign-derived intangible income deduction</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Settlement of tax examinations</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(10.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Acquired IPR&amp;D &amp; related charges</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">56.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary', window );">Non-taxable unrealized loss on investment</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">21.50%<span></span>
</td>
<td class="nump">25.10%<span></span>
</td>
<td class="nump">94.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for extraterritorial income exclusion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460279147744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 430<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and accruals not currently deductible</a></td>
<td class="nump">645<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Excess of tax basis over book basis of intangible assets</a></td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">1,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_DeferredTaxAssetsUpfrontAndMilestonePayments', window );">Upfront and milestone payments</a></td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and other credit carryforwards</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments', window );">Equity investments</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies', window );">Liability related to sale of future royalties</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;D expenditures</a></td>
<td class="nump">784<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">5,289<span></span>
</td>
<td class="nump">4,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(599)<span></span>
</td>
<td class="num">(520)<span></span>
</td>
<td class="num">$ (398)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">4,690<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Excess of book basis over tax basis of intangible assets</a></td>
<td class="num">(5,728)<span></span>
</td>
<td class="num">(6,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(160)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(6,122)<span></span>
</td>
<td class="num">(7,138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets (liabilities)</a></td>
<td class="num">$ (1,432)<span></span>
</td>
<td class="num">$ (3,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_DeferredTaxAssetsUpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Upfront and Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_DeferredTaxAssetsUpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460281533456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 599<span></span>
</td>
<td class="nump">$ 520<span></span>
</td>
<td class="nump">$ 398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits</a></td>
<td class="nump">946<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Income tax penalties and interest (benefit) expense</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">$ (82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and income tax penalties</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Accrued repatriation of foreign earnings</a></td>
<td class="nump">3,546<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460279145088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 1,713<span></span>
</td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">$ 2,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract', window );"><strong>Tax positions related to current year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Reductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract', window );"><strong>Tax positions related to prior years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(179)<span></span>
</td>
<td class="num">(481)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 1,959<span></span>
</td>
<td class="nump">$ 1,713<span></span>
</td>
<td class="nump">$ 1,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Current Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460279273920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Transition Tax (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne', window );">2023</a></td>
<td class="nump">$ 886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo', window );">2024</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree', window );">2025</a></td>
<td class="nump">1,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Total</a></td>
<td class="nump">$ 3,546<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140460281909280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent event - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 22, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Tmunity Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_PaymentsForAssetAcquisitions', window );">Cash consideration</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Arcellx, Inc | Global Strategic Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to acquire in process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_RevenuePerformanceObligationPercentageOfUSProfits', window );">Percentage of profits earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Arcellx, Inc | Global Strategic Collaboration Agreement | Arcellx, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gild_RevenuePerformanceObligationPercentageOfUSProfits', window );">Percentage of profits earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_PaymentsForAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_PaymentsForAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gild_RevenuePerformanceObligationPercentageOfUSProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Percentage Of U.S. Profits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gild_RevenuePerformanceObligationPercentageOfUSProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gild_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcellxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcellxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gild_GlobalStrategicCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gild_GlobalStrategicCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=gild_ArcellxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=gild_ArcellxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>gild-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:gild="http://www.gilead.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gild-20221231.xsd" xlink:type="simple"/>
    <context id="i2a52280e791949799892ada047e34d67_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if8b93d3ce3b74726be0d91eed3869725_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if2acd853399e42529979a83d303e38d1_I20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2023-02-17</instant>
        </period>
    </context>
    <context id="i36be9f39e0e143cf97505efaec9d56a4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie98b1de291f04339b19d38631b6c5007_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5776967eec2e40169c93026e3f869e40_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibdd0d2f0925f42e7889120dcf51249c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i549c720f0be04d399b280dc53ff6498d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3009f1cc5994ac0949727e755fef6fb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2fd731dcc7c6442d9eb015fc7f92096b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ce29476464948ef99a1d86b1a2d50bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff509ac6299d48d6b6117ee9f80eea96_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iabc34cf4f8374f479afced7f51e2c9fc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5bc9d4063e094f24aa7047cc3f2ade07_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea5153cc41ac4ad3909784ec5a03b75b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e8a156a2c184ca39b4834ed03243876_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0142ebb7458d4ec68ef2fa3254d6e76a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc446f587b564d3da2a7e92adf1f9212_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i605eee38c1414b2ebe50ecfda6aa08a7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c07a715073b4180a3d6350999b7c927_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9014eaa8515b42f5bf4fc221a5754f36_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7d244df84ac4dea867eed31d805f681_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i93bdf1e4730740ab8d4b26eb38235e1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia7182ed726234760880abd2d15fcf97b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8646b81d562c4764b295900f43b19e19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i991524b7050f435c8e75c4ffc5a934c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia6f649babc4c4963a34bead50d8785d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i091822ada63940bfbcb5532bd0807fc2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i831d6d8c42f147b3af3fa768e1980ac4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8570b5642fc41c3b275ef064cd4fc5e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2bbd0596e084172b456bf6e816df644_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i31982067c8ba46ccba2062f655093c96_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i21d65b154d20435bba2da402431f2156_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id41cdbe8321640c0bef3e78a54d341e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f2b6090dbb84a0da94eda0da3c2c7e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id3255734b4164a248d1ae872f85437e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33c6e110f0a74581baf5ef42159e7423_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i309e1278bed34922b7275c62cf3b74a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e9c39969dfb47c9bad7061e5500bbb8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f97bc74e5b74cff8c8def5c5e9058ce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1a2c49aec7474f71b15b7ba23892c798_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i07be39de877c4dec919659b89dc15370_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ided187f87ec24a75b5f0f28661776608_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib24a5c6406f94acbab0fa346fc44c96d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i22bb6ac875f8426a9e185ea79d9ed340_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c9fd7dab9954496aabbca76c556ef25_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic35cf517e1c44e6cb7eb51a11bc60ba9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if58ddd7e8b04461b92ae526d7f69766b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7cff17f8e033479dbe6df66c5418db1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1aa84a6eecd341f092eaee39012ec26a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2269762347243d582b0adac2360f5d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7fd9b86e7264c5c947746f574318575_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i390b60767b4e4998ba62331653915af0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i88a6a37544df4d67aec58fa3bb44848e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09e8c6458f804b75b3ac5c526d0da3b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib71c43a2aa1f484d95e6e3501ae5b495_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic696402818f946ca8e766e2da5e21ac0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i286ee669e6484c499ce3f18c039cd90c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i00413e506af84cb6b520644367a012ce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4ac7bcb2b4b64c279d885fb620928589_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d7e0990ed454ca09ff79ece5703dfde_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56cc9ca37eb642478c269153aa683b08_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f70e4e6502d40f395271bf5dacfb004_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f74fe4a143c4a2c9d6b59c1d6a92719_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70c25bac5ccf4ea4b63bb3ff8c487134_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9e8df77801f4427b07c69bffbbb53f5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0cca639743794954823700d44d77da39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0cfd1d80d3ce4e1d81dd9cbad42783fb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsBiktarvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb859e1c4b7140e1bce378f02656f04f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3e31ca129163441e8e9ea4ff5f95df21_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0b5793c69ad54496bd31bcf75d0dc074_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if9fccc1142b74901bc9e73819cdd9125_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8b327175cb0442eab0262b47b930716e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i93a83bfeca0b4653adb38d1116db35d0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2f630b325964676ad13e1b62b9ace1d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if440505f622045a0ab8e2f08a2a84ff4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id47d4305b1ac49fcb94e0cdc18738baa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e56ec469d9f455285efc69b4c698e5c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15076f57d5f940d28b2718517e8b16f3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i22c3f886b1e7454faf57898572502064_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsCompleraEvipleraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae0ac82ae7e44e389ab9b0b042115b90_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2cd4f275449048bdae7a5e135ab9aadb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i93fde66711574d6bbab8f82da5df47b6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e1da3ce22e34b9d8b83601cc4c715da_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i964d48496e5a432ba68cb1dba5f31cc2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0071404988114bf68fb32b3baae96596_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69a61c1cbf1a41039ca8dd3bd871bccc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f2cf5628f8640368fe1236801410db4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67f16390de4f49cf950cd63ea38a892e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if72733c8f57e48839a1cec90953d943a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad56bba1d8dd4206abdf2a2ec6754899_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i304b851b46d94cd2871b2b103c61252f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsDescovyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5ac5cc1e74843118ec886b8bf7ef582_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8c5f8cda4ab4437b9355aa4d0ac8a973_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i740c73c876d84ead9b478bfac1e5c406_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i02057a68acd8487089bcc3e13994ef8f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if0ae81470ee244b1bd11b567115b6709_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib23321b8060e4e9cb82713996e9cdccf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie28f325e4676479c9ae644fd3eb6dc67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0339bfc0225743a98310d7e4676b63a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff0215260a554fe1a70899059d81b451_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8f3192435e8c448f8600dfb9c15a1180_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i67f25f67445f4a4ab2ccdd05c60c4182_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaee906e7856d488ca901f1010783b65d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsGenvoyaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i887e5599e4c94395876541937b39df84_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0505374d8f084ccba1175e3944dbd664_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida1cacafd04c44f093aad95b5b455f48_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib31ee1b39fb5499c81d8735285addc93_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifbac4e022d8e464388f4a38bbf75756d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70473509ff904d01a46a345f05fea5da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf7892154f17434fbf26b8d35f055731_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iee4be07fc0444b0c9a13b3199fe07055_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia3caa5600f3c42d6a90eb349e4bd514f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idca9bbc5fc664235853309bcafe09958_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3622543706a4a2ead1afac3ba8a644a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18db965aef5240089858bc62cf910c9f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsOdefseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd3b6a53fda1447db2fdec88c020c38a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i35737905b7f54f96b51c229ab96133ca_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i37d4b794616d455b92a951ae3e8edbdb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i036b934c4c424d27a375818415f5f565_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i10d92f1839624521878f4e8fe7a4145e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0be6d27e8e284285916d1f631af87d93_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i272805c9851c4bfdb5a20f92f49d6fd0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i98e924509b7e456cbae02bc97a737eba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i17e5067a7fe24c2489a2377a45fe5b95_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie19185ddfd4c49b9aca949d6f1a89ec6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied3bdd8ecc264a9cb8aabcb280063543_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i633428932b804629900634cfca66947f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsStribildMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87e76c6ce2104589bb819a55da49f0a1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i302fc8ea04774f47a2cf3fbb59d774c4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i68de7e98cbfe48278b7e8e7b1ec961b2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09ef539a43334ebf8e611cf6caa5b1d3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6e84d2367c3549a5bf92e42aa560380d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i058ee4cbf024433382a4b9568255bf56_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c7acb2c7cb04a5d8c5b81d0106790d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idba4864482334ff491facf75b1f78c6e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53b547cdffc54b5d8fd971f88c4b405a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36718df39e0a47c7a9984f2501ce84de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied0db1516b674b75a73389a4c97b931e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9af6895f54f43d2b2aee375ef4268d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductsTruvadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i50a22c11bafe49b492afdf6f074bf51c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i56989cfa5ca9443592944384e4a662a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib7d3d1785838487fa5864f6342945d52_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i483ed774b8694c0e9f7537a56e3d8723_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i33140238ec544db4bf188fc5d80572b9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4f0fda03309d414a88c8d75b94de2c56_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic481237eae4e4a89a31528ac64b99866_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c625e43b4ea49c0aae317d5f95ced49_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id61421ab356146f5b9d4c0a367d00a97_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c3f9f82011a48019099652b6774bf3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36131c939960498fae7e0683985c0826_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic39482d1ab7947dfbee72e97e6c80cb9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsRevenueShareSymtuzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id8417f39fd314af3973c6cffd12840ab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i83cc8de84b324599b629478841ef5031_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibee89b9c9e4a4997a3e05c1360c968a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2710bb1e4e1a4da2bd3c71ff3d63d766_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d50bd550a3e4eda851933980c3b6015_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife622784ffa145f89df7c21f7e243720_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i995e08e1c0564adfa6e51134fcafcd8c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf67814543c7461d8fcb1cf0ed2a896a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i271f7c1121dc478784b60c3682272afc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c46fa85c0964613972809e212f5c052_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifdc70db5a1624cd9932fc54e3656a357_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf397fbe91ff4afab6f6016ac4dfc728_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:ProductsOtherHIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if27e01c3738343ae828ddd82be4d291e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1d9a8f22db57427db018ee661e6611ec_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i23826be9a15045c7bb6572cf25f0aa6f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibe24bb9f9af9476b962e3e4255a2fca0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5889f693afe94663b9bb93ada344fee3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i746f4ee74a48426283deb266e69bfe47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25fb84b127124bc9a930a78d394ae9ba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a531ef2bfa647ae80f2e7f581cb250a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i038b1c841f2c4a1f99edae58948bfc95_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8989bfdb504424e88c9fc5951e552e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i747dd2095bd84387a1b2cef2a08d4ce4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia623a13014414ceeb8b62e7b7d0307ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HIVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad8fc90a5cc743ac8164e9757643d7c7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5ef9373aea4d45da839ba8bd983d6d41_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i159b36366579482e833ac889d1de99c8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib77dccfb87744dc0bd019148750e21d3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i892ab04014c6452385a1231e4a398daf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic70bed0fa20348939ac81aac767a32c6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0cdc513510df408a8c14ad0c77931ade_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70e1551d2e994a7189a15b9f7e12f955_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3270ed2ab9af4df597819fe1d39f6066_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if566c62d193d4045a5d0d0bc3b4f89a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id8e5cf6644584b59bef073ec6d2e077b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if603e181b6c147c1be2e679da1361347_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:VekluryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if161350d9f934bd5b9c69a9471693d6c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i224c38109cbc43f6bad2833a21c3d696_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if3d5a1d3752041f4825d5ee38213b9f3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1889ca3a09446d1a27ffe2aacdca6bf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i84af8bd3147d49149ce9becb6109e0f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7dae9fa70cf84bab9cf15d4dd1ab1c25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ca3edc2c8454bfe860b717853160f7c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i990aae18e5ac4dc19094dd84e771dffa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1385fad94f9646459a09390bebc1818f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64774209bf234606bd852b8efadecec2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i408f437468464bfb95a8a1c1592428a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a9586512d7c414fa31e0c58325277e9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsLedipasvirSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i001f0a321e7a4cc9919c4b2d3cc488ef_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8a7970864108404b9398d1c10e32861e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8ef5ab3d255d4d7d9f8adf8b51dc6060_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d762459c913449eb0f5d2ffcf4a8ab8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i842e95d3015c4566b5b99f7cd1c3766b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c8b88a32bcf490093fd7196fd827fdf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f6ac7fa58b641b9994e9e2ce1b1a394_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8e5ee028ea914344923f044cfd129a25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e11ede728fc4b108eb991ae3d30fce7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7c70711ba3a452f8b82fa6d3959ed4a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e58f04355584a7b83ab6050a0f2f05e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0d165787a07f4f2b974d0947bb5841d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductsSofosbuvirVelpatasvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if576a322818849af93ddf776061a8daa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i13ecfda046a14b828b6b88d76ce34397_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib0cd547725ff48868a0a2427edbdb26c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie44bc2b667f640c0a49ef7f1c0d6afad_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i27d62848770f420584e5549e2f98494b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb21c9712fc547089da1e6a2b9444cc9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b6e79b7ca6d45d8865a7c9f5f63c09e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8e3cb062c5154c10a3316d587eff126e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i54e8d61cf6b54f18a3832db879c16f70_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id357c81bb4e5460ab1a7936bd0bc234a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9303626ac8f847eba23eb95d3525b36f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2436a0ce9352470798f7186a3a70c857_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherHCVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8352ae8893d34956800ed3b7a48a48f7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id4a7fcc37bdb46a8b48ab66e6c59272e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i316a0910d8e048a4843f027671f1598f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4f0ca5b4297e4ce5bb2fcad022831bd4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i46b71f3a3fd84ae7b5f5562467d87974_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab7e60f505e04d06b0aa3dda75663f1f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iadec57d70f694b2c9aeef1696ac8ec12_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3cb175d66081417f895e6a30847d0ec9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibee44c336571414b93118372858b768a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if1cdd83824774e048ef83b228f4edbb4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9306bcc0ca3a42b3b7c50ee626394174_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iccf53c215b7d4f7997810c9a06bcdd03_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HCVProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2dc553a8ada449298fffed4c28e2060f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic415777eefb04ed297d1241f612be3c7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie13c6aa1001243d89d2583a460ce4786_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib64f820871db47e3a10f78b9550bb92e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42cd1fcad93c4c6ea52dce4ae9e6c75f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b2bdd0ef7d94c5d9c5937ce2afd82fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4aec2c5b53674a8e99a3fabeca154f63_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib20a0912ba52411597d240f59ee8a970_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if28852e0de5a4261bb649f5abaa6914b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ed29a62f86443fcb28feb3b67712b1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i752e7f4d5fcb4e0bbf8b49e33b38f59c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id94daf83394e47f9bb26f578ef1b6fd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e7228c11db24e9aa0d0a7aa03dfbb82_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i44b50cd213f44bd3b7a2dc1a71945fa5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib9225d954d484582b9642b85bcf59293_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib93f3e8abe7249e8bf7db00e4237ff24_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i84c19876953f4ca6b7fa9b0c8fdf5a9e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25424faa0377487b93010e5bde98b80b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6f6d94f1fffe48978776b2d7573360e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53b03b0e23a24b88acb155327c8488ed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42a165571ecc4a6a81d1a6a559f0c569_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icde54372e7c94f3cb372e6be0b78a13b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id464c7738d154fe99637211d865d3a53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i152e0d6d305445e59681826b69d85467_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductVireadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0c7a7e2316ac49c2a3524b858ab86c7e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib7c74c57c8c0479082ce7a7dac084d27_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib769b5b3d70b46e892db64fc00f73c4c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1ce38a9465334f39b1eb1623b8138d52_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if28c44bf664d40ecb1b0a3e548f23981_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i59e34f35279744a9b950cebad2d0bc39_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i09871c6ba3ae431c998271ba08136fe8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4170b5c1c1714d8f920993b6d2262d02_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id6523d67294b4f8981a8e945c6b20785_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if6f3c5b346184ba1b39b0710a6321e5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia9d36441d753401c8d6ec0475559e780_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1ed527ac9bdd4205809a16ca629aec11_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a9466b57eba44278c2bc11a50ea844e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibd2376deb7144bd59b534ed53871b5ac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i60812f2148b74064ae4b10afc339abc3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id3b257573b924383a6fd7a367622f923_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie21e023844a745bb8a3684cb9d194638_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idab285af921e41088931c917d2518003_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i39beed2eccf74622bbc506893a5c1069_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4047a0aafd81455d991a4aeaa945def4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7af0ff053a604ab5bda65ff903d0e784_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if0570a9882284918847527738da8a490_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4e1f9c9a4fe47a7bc9cbb56ef70b24f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7868f7368c3486d82227cdcaa76a33d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:HepatitisBVirusHepatitisDeltaVirusProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic2d7e48b21f4489189057ca3a20ee5a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i552a5e98cd894d1f82b630e62cc1d7fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia3d02401452d436da34605e1e142fa23_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i57c3adbab8d849c5b912381e32fd4668_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0cb8d3f9aaf646d1ab94c2572cad9d97_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd11072ce9b8438f822f1f5b0f101e9d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icacbf61077d141f49fe6cfb43f3d6a64_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia435f9794a6b429f9e917b58fca423ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec37e2e6ec1a42e0a68b48238a81f664_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36bfd55ed5a14a94977376f9736657ad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9976f07ed0ea4180a61ff830dd781cd2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9f3506be92642258438c218c9fefcab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTecartusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc7adbea5d984ceca881d04a7c590ecd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic98c35b70a6d4caa9097cbd03988b94b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i48bbf122b5a340cd9c41944387fcbf26_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8be13c495ea743bdb150e8a637348840_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1f58bf4910d04410b4d8f3dee38fa563_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i74057d7eaf294ff4a1f0ee3ed98656e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b1203b4aa444780be9b251625ed241b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c1cdc8fffbe411cb0781c91d13f40bb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3eae0aa7e3b54e74ba47f8e7d11af81f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71b57df694f24969abcc922725bd4116_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if4309bba638742288a3c3b3411782a64_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia68db9a0ea2f4c7390ec4cbc6e024d62_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsYescartaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f98a55a88cd4ff9a94405f8df480139_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i10627c2c5eaf4c4a93e8853d80712680_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e0f9a67dff1450ea9e2f3abed91dfde_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1bec111f16ad4191913cb9e0707b68d3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idda1937d0695488d92eca8410b6b5ad0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id43ed2f32ec54108b2052f7c81e8dd87_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e173b6e94784412a1a9aba6693632f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20f103fc96db43f9871d8821af37e8d6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibe90cf240bcb4039827d8ae3729b5f78_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9ea8631b9b348fc98164b8455c586a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55dcdd667a914130ac7f247f5ab8e970_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i50c68ef9e2c94e88bc900f8445716b7f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:CellTherapyProductsTotalCellTherapyProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15ca9a88790b41dab9dd09539fbfc66b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4cc8f9b08eb949459f8922ebc6ecd590_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i14d6f24068e64a7bb2e161b0ea089deb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie547a0920cc34aff9876297ca28ab3cd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9409f8c5614f464cac6ce5449dfc8a91_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibca6cbf239d149448f38489f25c6ac14_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3b79faef45f4559baf646714298411a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibeb51c8c4ffd41489bda5887c0250688_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68234a1374f84b4b93207cb00261676d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a896e7fa0ea4692ab85773273ce8925_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fd408517b934aa38aa102382fee39f7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i720140b50665423d9ecf9cc4d23c024c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d26f0693aed4c998637a007f2a4df73_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6bb9697cc7594310943f7cb04cffb997_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia3cca4b1510b45f0a81e6c1ee81cd735_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i43f061fd85154f68a9a577619edb8cf3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i23c6213e809147e69336a3f6284317f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id94a3128eb634eb9a869ba096d445597_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie527ccfe78524f97b3646d01e7cdd88b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab43b5a322744bf29d7a74c4096dac3f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icbdf5cd7eae14b92af352c6ab83988a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60a9443075964128a15a01c02e823b16_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib67c8b2793e440f6b65336fc0aedd433_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifca680403c8f440e980e85b1a1536764_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsAmBisomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5ffac4669e6141d693435ad3d4c6baa5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3e7eb9d47d3d45f1801328a82bcdb51c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i79138071f14346498db0bdc4d20f7898_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id8bf0dc9d6014d1b82589f892ae08671_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1cf42ac0f6b141f9b9a452ed3335a197_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i22b869318548494b9e06efac2a33eda5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d84e35cd15e4f45a75e3a912c6dc29b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a6ffb332c0e4d9fbb4397e67ceb91dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i738618c718414809ad145d0c367755aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icebf8365902241d8bdd0aa638c68bb3b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i62346343776542ffb3989e6fdfdb861b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id85501d9727f4bd3a90aad68a5047f39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsLetairisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7981271263a0497385c106ee1d8586d4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i11d9e7d23b4e44fca91e8f8a56cc640a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1fd5efc4fbfd4d47bbea341757531be6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6323c623d0145c9a4ab424c52f46d21_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i91ac289724a141efb05295c0ae0c3206_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibbde1bd79a61473584fdf4a131ea0893_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5901b8ecd56a493aab74941a2b2f9e23_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id160a09703b54e7685b93b162b95d162_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4729d87ad9f345eeadc62cb0f11ed0b5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64a427f3722a42e6afceb6d7c0ab324a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id402bd3c4ac1490b8201b3a308ef1e2f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib847a11c1e7f4aee9f52682db5c1f135_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91a7d5c54528430783128148bcd0b974_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia3e2f8a83b0f4ae497dc2e5c8ba4927c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idb1777596b9e486a9e19ecb95f8684eb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e0fa4aa3a554fbca7b6597772bae432_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i96b230c4abe241f88e888152fba0544e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icacf9afd500a448096edbd2f4cba2326_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i01748bbcf6c24a2e85eb82ac7163747d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ided586c3fc76418f9cab15dce3540cb0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i320ef6561a284511ac0240c964bc81a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia34d7b9624484238b55305a3f87daed8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib30d9baceb6a430eba29fc86bed3e18a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8000a2e754d4b178de03c4010ac094d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OtherProductsTotalOtherProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i191031ec2f8340fe8c4d6783e97231cc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i47cec898f169483d9a78d908ee8ac54b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c17ca18fe8b4685bc8dbff8b0024fca_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if4c0214e29ea4b9282808e79f896a82b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i878929f1d5d34534bbf9576f56d5bffc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ca736187a154121b6128d87c38b83ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1dbb6a36e59f4a65b7cd766dceaf5deb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3463ced19f543a6b038efda28937ed7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice19479778e74f7f859404303e2642b1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i122092ce94ac4c349bc55b92090d0c7a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i895482d8185045179df5923b9434a992_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4ded8cfb2f694a869b82b4f9ceb7481c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieb0d53388f4d42a58ab06e6add14cb87_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icbff194d4ca5433aa7e19eed529284a5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i343fb20119ca4a0e8613c7e22a4b527e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia90efc3a95e5478c9d184b269d0ceecc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i794d6401fe294df8a2c8c5f381e7766e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98fd41f3a3ce4161bf06001545fb251e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:RoyaltyContractAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie276f108be5d41f7bf6f6aec108cc38a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idbc48146b4d84e27bff9ab5d3c8388e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id83653adc14343229d0ecdf85dcc0b36_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i55695bcefff74f4a90f76506bacb48c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i44ec1db4248d428a8f326df992d5ba74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd5cf4c53b074c43b621eb8f8a9aa397_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6943cae579d9493b901bd4c64167f279_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4906ad8453c4207b906de6e1a183a7c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i92af14de4d6e45c28faa18feca763fe7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">gild:OtherInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86eb6bdf28e54e3cbf341a8b16bceb07_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0face3f5bfd147f59b55ecdd4534fa47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c332f0a85d243b0b2f856949a44e2d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:AmerisourcebergenCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28e35fde408143f1b5cdd3758261b912_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iee00e346b51a47dca4aa5cc9604337d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9e8f79ffaa54a4f8353a2e74e70d2fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib67a8beee1994fe2a9cfb4af6a2b4b81_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i133bd58bb3044e43b6e19b3c2019b2c9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b1a0954ab4c4c079b9fa4cff95a21bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">gild:MckessonCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88c34d1a31564a41b639cee23ce6e2a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf9113abd39d46f397a0870bd4c9cdc8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0bee5e30cfa2426f9d380bc5925fcac9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7cfca0b59b604750a7f306bd9362a183_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if6c99e845b70436ca2df28ab68166418_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a483101b0c448358a8bd230e176fff0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3808d9c4a2e146bc9d87fcf438476f8c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bf751057be34c59b162ff5ec611226d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ad0ba308ad04f38a0ff215fa0aacb6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c405fdc93ac4546907dd695172e2ce9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb6db70d966741b8be2616a8bd67d2e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd515e9c1c6b4b0b8621d96b2531c80d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3dcf159fc7b46349235521b48359fa2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20ebe72fb6da4c999fc461851f94ee96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2478182a4b4e4e1487d776c80659bc45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdd0a17887254d5a9c770861de71e83e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie157b97ed1b142c8bfb14e1fcd0d779a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37f394996de54d9db35d84fd2f8d9ef7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3900a5a96df424da8d5920aec948465_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4bdf8861d83422885dbc7a9b650a26b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib91c1acddeb04eea8c21245a6b6d170c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic45d2c331f304e139eb2373b4aeea8ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0983c44cb0734541a17aa9caaa5ab892_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8cb3270aa34d4ff1b804ace86710f83c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib94f769c7f244c9e88d0a8e925d81a3b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i488df48c29e54b3593d5488e3d330c61_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5db63b134cb94dcf9570583d7adafdf6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa4ad0ad8aba4b84beeeb124f4ea9111_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ea779af859f47d89962f097d7265f0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd1b17c5a8674218abaf2a1683840aaf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i618bd4f52005481f8b9ee51618d178c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbf59e9f2f2d4d67b113295c7b4d1089_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4374b3f59dcb41f88c069c68eef7cb1b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iedcb3258e37243aa808a6fa8be5a770b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib47bca5eb2de4839b8e148ae5a0de84f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib4eb920885a343a481088353353f3232_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88ec60685e024c9a9d982e1a4ff3ae64_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if92841c2bf314e908654618e08167aba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i773b7fbb6ae64c61836fd54bba47d25a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5bf409fd77ce4f9a90bb11514b042cff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i018a6b73fef648df813ad16b7e2eadb3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07414abcd214485880e84c068a03395f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie19dd55d40234f4aa0cb87ba2849918b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e2a4623b8824759a123ab21bf6411c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib084fcedcc844984a042bbb471e335d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i099761b72f8945b5941d06a0e1567729_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fcf55829c924deebe56a00be5ac0c2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf63565ba06a41a18d32952215669dc5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e733fc488aa402d8d8717e0955e5672_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic7e16303ba004af899fc51df2e60f7da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i02675adb1f704219bbfa6df72958ccf9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic14516a4cc9c4cf4b87bc4e6c89da010_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i944a69baa46241a78832dfd6edb03619_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i94e8996fcf904aefa7b45eb05d8a1b9f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41782720cc44450d8ecfa13b2c8eba6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39ea15b99df04bd1a91357ea2c784fb1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5c4c24154784954be6af020baa2783d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if72d0c8e59074c399a7a8d5de4a0d84c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69dc8a4d00924a239a188dc5ae14f7e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2c6ab0f463354216aaf151d6b3782c66_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaeb19fd2013648c5b7c1b740c697a80f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1382e07fb1b3414fa219beccffc330e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8cda06ee09b140cb827aed9e1a3df8bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f5633d790d049eb8451a5b270d77750_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied3cb02615a94f4a8ceb1be0e567f340_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d43b6e593fa4c628617fc5b9f8381e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0ca783d57092471f8f9c2a0e850ac09c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ea06efd22dd4661bfb5cd9adaff66df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if89553c3611c4e288ce130b8d3ac5113_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08fcddcda0ac40758fc2ee38e6741a4a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f315354a63246aca5ced4ec8972897c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i327c843055444377ab16bab2849e6c00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide95ae75ed8c423695c053ecd6b2da97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd60b83d9abb419d9f60987e3d02e8cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i894b79ae5fbe43b2a34999235fe34725_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i983c7f539ca14293b59e2fe55bbce4b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a6894a7e98f4519a8f9e29d935836aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a77b8962a7b4133b9c80ea7b093866e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff764d89cbbe483ba2bacb34b6224c68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb43dd0a466b491faff2c751f3a877c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38d985d4e3d9474ebcab3db7e6a6ee15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i21959734d0a54ddcb46382c2339b2f8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib378be3a5b704e4ebb3dc87fcddff125_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9701ad4aac1b429ba132c36256901aa8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86d573d5c055472aa3815285608a7bfd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i11ec8cf5f17e4fc1b6fbc896b8b377f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if89123ef0fcf45cebe2871f98a115ee8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56e6656d2b2349758ad1672abcde5f04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3056f9b6e43746a586f484704ba24280_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i177d34f888fa40768c93e77bd471d6ac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibf1408e9098f40baa057cd1cfc7888f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ce378a3eb1f4ebba108c7b8e6e3fd0b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib233c60e47c6477a9eb3e08f380cda48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b61ed2454aa4bc2a404ffa25a550770_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e4adf40d5824c4fbe26cd8dcbfbf227_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie454a27fc82f4874b5cda233495e0206_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:ForeignCurrencyDerivativeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie78f1ffe90f34e168923153a6356d08e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief9bc9ff381a4854850cbd8345981bc5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3770d09680134e1792a2afb46bb64c8a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i258640a7c57747aeb519ee9e07186999_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i39c7630058f7482b8663c73873f905cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if091fd24a2e744cc84af3abc98b8f3f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia14bcf8248ac4a89ac301d6111091e59_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1dd2083018754b229660065eb3c2d886_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfb7080a46984104933ddc77a231978a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a2c198018764025b669a401e4b72f02_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iccefd6d5263c4c06812886b75ec30089_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ca5b496a82144a99398868f529cc733_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i85d0914f5c72425b8a8d68428082805c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idcaa8320537e4f41a1cac571eb1d4c4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ac85363bb5744b9a9f23b5639f332c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedbbc78ef8e242f2b89fc61cceca1611_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08f3914c4bd548ffa8c16f9da7bd4df7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if7e357738293475089434472816fe934_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib93c734b7bfa468486822daca4f70209_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if172c306038b41f48386ed7ae399787a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i126cf5d37167408d897b7f47dbb2f508_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if398b36aa15c4bcdbd145f253add16fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2aa74cadbdb34ed3b2763fe749e4a969_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7609fb41a434a248c259460823ebb48_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifb2efdf458554bab8ef48f6d397f4e6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if21d9ac9e987485c9b496bfee383aafa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">gild:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia10224614a2c4100ba6f83973aa40b07_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3f06b3794e74e00a49aace81e6036af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cd161b557064dc88ec5537ac6193a18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2fdbe18128244987a1e36b0904391b66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99e1333e6d0f4c0a8d9fdea046b7eaf1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d0619bee4424bcc8f8609420f4cbb12_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50e2abe2412a45b18cf87a34c75a795b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ff5933035664d28975731dea852a94b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9084bff3951f442886fd602ca88f373d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0dc75bc453e4ab9a410488c8fa21a09_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia73cd273d0724e22a127a4de80a03fee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73bd05cee6434509a4a4f115c801d1c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01e13782ede9404eb98583a539f3ac04_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e9c57adbf444d65825f235837090240_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gild:ResidentialMortgageAndAssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b5ae4a796da464bb370d53bae12c455_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3e52c52611f24f8faac4fa92e65543f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i463626c5759146d08f5927f7e0b6683a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1634706b89014eebace618eae101eefc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3eaf91c6ed454ec2900cd809519f9ae0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if9928086fec14acfb7cf4385d987b680_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">gild:MarketableSecuritiesNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i198d532a8c074ac78f29a94fac0b9f33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4812222e45cd4cb69428c9cdba79819c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad7614ba24154118b1da72e576ca61e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1ad61301e5ed420bb158a038204db320_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica09543c00fe4598ac8ce750d8afb1ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9443f1a550be401b9c00363c5d93d604_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if99033cbc8c044d3a0561d49bbba36b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gild:EquitySecuritiesDonationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gild:GileadFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1cc9513c77541668e0695e24152fbdf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gild:EquitySecuritiesDonationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gild:GileadFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c84aa3ba61245188fa2fc51e8e98ac1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i485ded3cb94b411881b8ee607e8a95fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id81c22c85dbc4822a7ef92c8c72ce5b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i669cfd4e64c242c1a8ef8796fd28b7cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1bd1f9124d4d45ddb0aca9a2a42b8ae3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i66b2c501c7c4411197427bc2b905865c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c5dc98f71a34b989bdd92e74b03bcaf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i884916a0bf074d689e54307d3e38f85f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fedf80dcdf54b7ab0cf8db9b226197b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e415108242847aa9f7899559c4beb51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b1fc54addc74b608025b4442073733f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ddfa8ed452243918c264f684e03d322_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ff582c0bcd9440d8450644be10362de_D20220920-20220920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:MiroBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-20</startDate>
            <endDate>2022-09-20</endDate>
        </period>
    </context>
    <context id="ie636277d8cc8441891c35c55a8b0f84c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:MiroBioLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i83300a86394449e3b64aed1970eda7d5_D20210304-20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="icb5939cef17f48478fd4464ba9e5a0cc_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i510e50f0ac43478382e87ec9808db7ce_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i28808546af3a44b5b726f97b0be6b62c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61be0ceaa2ff4374a907d95021e07080_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8747b96d361f490595133641ce6801bf_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i3f715f66b49c4eb3866d26fc054558bb_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i5e0b94afcd4a4e969f87632c645d0ab6_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i000f39fad6fc4888bca218c81bd4367a_D20210304-20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="ie4dce94d4803432ea623df9764cf4027_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="i4513e5ea422e4a229b71a42e1b842c21_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic2d744e7509044cfb0669434445c9252_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="icab7b0de5a6c43d697d7858746732e0e_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:ThreeYearSeniorUnsecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i153abdf5024043579147bb4cf3dd2205_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8b805b1eef94fff97d2acef45332eaf_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i7e9d7f1885544506bd276d0c9126856f_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i13dee278e6454433be1edc4ce1da6ed1_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="ie6f1965ab97c42069eb90ab5238a2ecd_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="ia565affd511f4d70ae37392429f48f4a_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="ib4719e0d131f44a085886b933ab78bb6_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ifa9a93f5272a429bbdd06910a8637c97_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i32d561b8ae6b4a2f98da8f5dd0fa0d8a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic1048a20244b4ce5bb8bf7d3be281065_D20201023-20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="ie422be158b934364b7f415457625004b_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="ie215a497705b4a2fbfc864f7caeffd9d_D20200407-20200407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-07</startDate>
            <endDate>2020-04-07</endDate>
        </period>
    </context>
    <context id="ia971b5b9fb3d4bd384e45480e81c75f3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a7ef37e465543e5ad6a7b3828719842_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieff06bffa0844a9d8876ecd6c333e23c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i44d47c74025d4cfdba50d1a8b27fc2b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i492e0765e063418f871681e4d0901a65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0ba8e5a7781443694297bc65f7058d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdf3325b9c814697b37f4edbe5de04de_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MYRGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9c7754ade07946249e798f443a00c1b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i181901e26e3e4c91a24f93e978ab1945_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:IntangibleAssetSofosbuvirMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44ccd0f6f6894efbb8cbf39df662d267_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89be91f170784317b4d65294841f9a30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:AxicabtageneciloleucelDLBCLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf8e90e835654b89b0b240d8650e1eae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9d3cfbadc744a27b6406bc2824e189a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:TrodelvyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id42c17e537b943188ee815c6eb4724df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i59824532c8ca4a779f76468f950efb0c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">gild:HepcludexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d0b0fcb16144c1485e4bb100851404c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i525ebc96796c4ef3b6ad07db88affd7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57236ea81268491a97d91341f26ba286_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3cbbdf76bfd6400ebaa7f622c1e30073_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e1a6227be7f4425b549d4e5d0588c1c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i140e9b5aa60a4667b375867beadd9364_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">gild:InProcessResearchAndDevelopmentTrodelvyForHRHER2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i327df07e8ea64ce7a694e3e3b3ff882e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb58b983f5e14067bcbab9fc5db32341_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib9bc6f335dac4058a61472d6b15e5fa0_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gild:DragonflyTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DragonflyTherapeuticsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i771f1a1172d84395889aa09f42795a08_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gild:DragonflyTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DragonflyTherapeuticsCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic189333a47cb4e74a306f790f89b7e3d_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="i957b3f15755947a18bbf1e5b8d938645_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gild:MerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="ia428e1ccf59043d4b741292e75fe250f_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:OralFormulationProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="i35be91a902b1413ea429208ada936e60_D20210313-20210313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gild:InjectableFormulationProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-13</startDate>
            <endDate>2021-03-13</endDate>
        </period>
    </context>
    <context id="i49b7362839864e28ab937849b5b66936_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i59caa7a2fafd4bcebc5b55c3446ffe7a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0604404ad083494e87385971ee52a834_D20200713-20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-13</endDate>
        </period>
    </context>
    <context id="i7be52f10430343af827d91922fb036f7_I20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-13</instant>
        </period>
    </context>
    <context id="i8f866f4b5345461795270bb2919d3ffb_D20200713-20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-13</endDate>
        </period>
    </context>
    <context id="i6289804387bd4103907cc19f3c49ade8_I20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-29</instant>
        </period>
    </context>
    <context id="i740c686e35a541228a361dc29719f86c_D20200529-20200529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-29</startDate>
            <endDate>2020-05-29</endDate>
        </period>
    </context>
    <context id="i3837ec2ec53d40948208538478b144fd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2135143e0b8a42c79094487f8538db87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc5bf2b91bbf47619e2400e89b0617db_I20210208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-08</instant>
        </period>
    </context>
    <context id="i15aa5080eeeb4755b9ee289447ef8c62_D20200527-20200527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-27</startDate>
            <endDate>2020-05-27</endDate>
        </period>
    </context>
    <context id="i0f56f1023e494483ab5622ea9a93b454_I20211118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-18</instant>
        </period>
    </context>
    <context id="i156971f265ed4b789964f0e884da2478_D20211221-20211221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-21</startDate>
            <endDate>2021-12-21</endDate>
        </period>
    </context>
    <context id="i7645b620bfdd4f51895f7a3169f56f31_I20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-13</instant>
        </period>
    </context>
    <context id="icfb2a3f5c657473bb9004b07b586f56e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementAndStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i138aace7ae954687991de21bbcbf935f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ArcusCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i01d11dc0f9a54ca5b5c8a9bb3d0e5538_I20200619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-19</instant>
        </period>
    </context>
    <context id="i016d7a91b5e04c58945de8f96fb29672_D20200713-20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-13</endDate>
        </period>
    </context>
    <context id="i1c6ac8024c8e4d0dba576efa9455806e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i200b7ebaf9d741dda60fabffb43ff601_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic28bdc6a3eb0421bb098c47b028e6ed7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id73ecb9294534bdda3109b865875a37a_I20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:PionyrMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-13</instant>
        </period>
    </context>
    <context id="if7b11be3257e4f40a3e503c8bc3746c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie187f099f6884416a506c2273b834248_I20200713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:PionyrImmunotherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:ResearchAndDevelopmentServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-13</instant>
        </period>
    </context>
    <context id="i9841318d0cc04cdca6946b8f50b2d1e2_I20200717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-17</instant>
        </period>
    </context>
    <context id="i71a5441f80434f7fb81b3ead03db9f77_D20200825-20200825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-25</startDate>
            <endDate>2020-08-25</endDate>
        </period>
    </context>
    <context id="i2116fe68676542f08655b70510bcbc39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if64523d7bf4f4c6bbcf933b3fa695ad0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iafaadd0b51b8476e9b35ffba851e4d74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70ddfe12d2d14dcd90c45e6ba0df7567_I20200825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-25</instant>
        </period>
    </context>
    <context id="i57942f7799d54d7f9080cf71318c3ad9_I20200825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:TizonaMergerAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-25</instant>
        </period>
    </context>
    <context id="i81f791b61360445b9d059ca216fb9e27_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TizonaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:DevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TangoTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-17</startDate>
            <endDate>2020-08-17</endDate>
        </period>
    </context>
    <context id="i0c965202198f48ec9fd033a927a99823_D20200817-20200817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:TangoTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-17</startDate>
            <endDate>2020-08-17</endDate>
        </period>
    </context>
    <context id="if9369ae332d1495a882a011455d3dff2_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i32bd6912cab14eadbb3318f66acae3dd_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i98853617c7ee492bac67c931971fb5b8_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:JounceTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:LicenseRegistrationRightsAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iafbe177f342940c6bfb9527cc4113ba3_I20201215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-15</instant>
        </period>
    </context>
    <context id="i021e03a868e241539ef14f9a4a5d5eff_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i6a34cfded76c4d25931ccbc7eb146801_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="if22f3ebfb466459088b430f3aaf9fbe0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i561a20e735884dd09fd59922c428289f_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i2dd88b8c706745b7bfcd8184f6d34f23_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ff8d15cd938494a955c3470b06e15f7_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:GalapagosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GalapagosSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="id348a415186e4a219b8e1335dc1ce1ae_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="ic5f7160626e0482aa57280e46676f4b9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b27bce0f57f43408b5d6611ea6202b5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia93636a3c58c408fbe02ea53965397ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3809906dea34eddb658b6eb681b0746_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:JanssenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i8dc6ff7bbfe146f790e94a1bf140cf21_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i15224c301e61426ab8f8d27a3b9863f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d6fdb8767134660ae43cba1ca191838_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60eff7e7e8194d3ca2b0fe59c130421e_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:AgreementWithJapanTobaccoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1d267ec0240944fe98ab627640747acb_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:EverestMedicinesAndImmunomedicsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="ia4dccea757f34cada4ff7ad4f868097e_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gild:EverestMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:EverestMedicinesAndImmunomedicsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1b13652ec49d451b9134a37a2d7ddd69_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gild:EverestMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:EverestMedicinesAndImmunomedicsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i52460a4a2230491d8481379314fe3f77_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:EverestMedicinesAndImmunomedicsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e38b8bce9e8433699c11bb0d7911eaa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie041293ff2f94b94bb3eeae5382b1137_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica9f3e6a16e841fb807eb9deab1f16b7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:OtherCollaborationArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94f7d5f595874e31babd47d1f943f03f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e682eb04f72495694ed3396a628d82d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a5ea21b1a1b43f288b70665cfbd4480_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id423610de99f429cadafe5a4274a7579_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46a7ff031bd6498c94ca9dd5f3025f99_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9fbf6172d0c74ecf8b376de532d163ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72cca364459e4c9a9900d1ff55ebcbe1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife4410a1d3ac4f6db988c4f916e2bfec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A075SeniorUnsecuredNotesDueInSeptember2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfa5f7601c0344768c77f746163923e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if709c8f28db74549bd5a3161d97c21e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic140c268cb72480b99affba2d2903761_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0cddfe4bc224e0a87870c31c94df95e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68e57a3bf88e41bc8bcda7b3a61da0ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3619c4f682548ff8c69c3e69dd442e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42f508896a1f48ef818931672fc82b7f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4befda2944dd4e48bbf33cbb6a800b3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc01af360ccd4ed291a9c264b7a9d13d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d007723ea0d457f8381ae1dc771efe7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A120SeniorUnsecuredNotesDueOctober2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5968bcc3ccaf4e119907fba73d267d74_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i12e3ef865c8244a080b985b6a3939718_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A165SeniorUnsecuredNotesDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a23e70b82e64cc79b08ee71a5bd6b2f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie69a01e11be94336a2f8daa28bd70c35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4677adf6e0c14c858103e4db348e4694_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i30e53bc1666b4c059c137ce292a94b11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinSeptember2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6733ec0f5d1e4796b8f94c12c762b012_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i14a47de090294df9b57b1251ef9289b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A260SeniorUnsecuredNotesDueOctober2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i175eed19d77e4a91a2d341be010e07f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29d037f45ab54f7ca294996c4e283eb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueDecember2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72a08c81dba348df8500cc3742e5df5d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib9ed8ad260cf481f964bb009ba049509_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinApril2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1220d26ecab846bda8d60360ee0028bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3feeb01e0b754048b12295e1fbb184c9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinFebruary2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52789550e4a34d6a81d8f70c1e195b8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i120a62d356e74c158afb261bb2ae839c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fe59d0908e34a159160b1e26b01fb15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5dcdd5d44dfb41e08635c954c03f9520_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:SeniorUnsecuredNotesDueinMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31faa9b303f543e78b0b2176fa8247c9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i259c5faa64504524b5634abd51d1fc38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A280SeniorUnsecuredNotesDueOctober2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic33e120250c747548d29ff0a8b4ff7cc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8e2c900d6e514479b136e94cce379e22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">gild:SeniorNotesAndMediumTermNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d5cbf682a784526bc44e1be5f4b2591_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d2aa040eb2c451cbda18a7f0add00c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic270da4b44c84a5db419c3cd7630f579_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A195SeniorUnsecuredNotesDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="id302c14527e54b03b1462a8b781c544d_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:A325SeniorUnsecuredNotesDueSeptember2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i39f1a4a42b2e42c8b1adac714d4b3849_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9e6348bb4b5348819415c13456fd293e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i58df36e70f7647cf876057727793fb70_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i17fb44daa02d4c84b8bed20193956526_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i7184a423cb03437a853dc81095f40d56_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1ed58c535ccd4faa9176f654b65aaa5b_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7bab656927b94fc98bcf55c11d946976_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4655f4b3112c42b5817c56a6a39a9b66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gild:CreditFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89095e70e7fa45458393451ccf83e29b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5fb8687e8cd4caea5f84599504664c8_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="i381dbbaeb14842d0957d6f5cdf308d28_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib9689ea2698f49518e3f35ebf341d9d2_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:JunoTherapeuticsIncAndSloanKetteringCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i64a2deb2d3f347b89108aa1f51ac3e1b_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:PreExposureProphylaxisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ic183ba3839714584846a1a616db08cbd_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="i88bc63bfd5744353885db8517516f8c3_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5013c57ba1f641bd9a9a482a7a391bf2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:EuropeanPatentClaims2032ExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea228f095581408787a759595c70e968_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gild:ProductLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i27765a75461d4d2081b2a23a1daaf601_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia23032332ced4abab639e98fc3486e66_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2016StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="i3967341da57b4f3caa9d502babffc1d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">gild:A2020StockRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib808ed4dfe4e411999e03f92bc995798_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i14329a4081124b6fbf3b38e4aae01606_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifdde5e060f4745f89cb9aa85e12fd275_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id9ca1e84f12844d697f1ea6824ff7451_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i413b2fc67238496985ac43774e9116b6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iad684e32333e4d028165723fb0a3c25d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie85479b87980466db067faedfa50f2bd_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9ec4c04bdd21487da1fbeecdbf019611_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i925d522b8c534cdf821c642767a2b8c5_D20230202-20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="ifc0e2948c490453d8a2ebfca402b6cfb_D20220201-20220201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-01</endDate>
        </period>
    </context>
    <context id="ic65ba49cc6d24464998712864877bfbc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i75a52e5d45f44bd2b61d1cbfd645a700_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id39a3baccb6f4a489742ff823a82f45d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icb52f2212bb54664833a43b8f1d3e792_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b9945ce2eae4b4db8bf21445b6ff8a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i225f3dbf9ef040efa82ebde15cfdcbfc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7be022dd13814593bc19060ec3103aff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a8d242e2a254cb7a740cad8ec6484af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e2f8c526d704f298539af3a53a6ab31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4585b2391d2c42aaa5fcec24001b539d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i888ea767a9e646238e97fdafcff19aee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a43e9292cc34d47a7b84bc89666fdcc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if1282cebfa404d25b44e39c3dee052f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc18bb50e5fb4827a108a43362008dbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i703dc9a954254418a5cecf9488a563fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89ba96d4050347bdb58a1c83a817e40e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibc1baff673f642548027f1b6b5d8e4af_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if5b483b2ee2e42d5a938318ae558e2e2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i72eb2ca7a60f4cf19210a329bed5aa1f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia122869e81d74b249c7207040246de2f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41a0488268694a0ca64f483518e451cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id443da59986449869f984ba29bd052a0_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:GileadSciencesInc2022EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="ic8f202de25714586abb2bcfe7d406697_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gild:GileadSciencesInc2022EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13cf4d57dd80444a9615d435346a008b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i41cc17b6454144eebfb7455e16f8e439_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ief16c425ab394fcfaa9c8f247a26d1b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2061ba894de4be5b28c846ab2265609_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied34c0fde1d440f0a671f6e6ead42d05_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i580e59f939fd4c8388da4fdbdc6b58cb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i03e3e50cbabd4bef8487336a456c1552_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iba83b20f658a4a5b967cae95a8147d07_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3a53a5a5ed940069011952033f6937e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7e116706429d4b6489792bf2fee6c8ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i13414ce25cbc42b98829371034442897_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0fbfe8113ac4be684dbe7e6211e449f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gild:AcquisitionRelatedExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icca0a85ac6724ad4a26ba8cfb7d3e7aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gild:AcquisitionRelatedExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i71ed40d871ce41e2928bc9829eff5643_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gild:AcquisitionRelatedExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib345f0317e14471c87be46037d1c42bd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:MiroBioLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gild:AcquisitionRelatedExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09a809a0f4a64f36887c2d0d12f7975f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:ImmunomedicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gild:AcquisitionRelatedExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idb5b9f9fcb9e410b9600826b343149ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">gild:FortySevenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gild:AcquisitionRelatedExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3fd6c8b6cd2e488a9ef5cb0ed0ecd928_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifec682fbc5e74d0b9bb6f5a57a44ba23_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i767c3be8d79f4a58b2e54e5310c7404a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5bf67c25be264122919d5db5b2238804_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6786edd5a2f463ba624fe8629254698_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16f8cd4d572b4630890ba497cb7ba380_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91dd25449865431396ad590df47902c2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3d2e4dd234744ff0b8f9c4fbca89aac9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i246e5be9df34403b970d76a795c2a09e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia54f00a060494b7e8284daf41bb9942f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i306251c6f0a34cecb6731b34d196923e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb16b1a82cc04d97bc97982197e928b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b63e11ff4a246c388b2b8117a18b35f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd6b4cdafb5e493e8f88f2078b78eb38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05562b0ef6074645bd6d203b69cd9fe7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e2b914d4ec74b7d9487a6f371a25de3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf9a3708d6b74d5eb87c245216002834_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">gild:DeferredCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34b2763ca1054014af97296f08cfe8f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i016ea1213b884f66af6169c417c336f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie3f62493c696477b8cfbb9f960369e84_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcellxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GlobalStrategicCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i2425a97f760f4c49bd6815b72167f203_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcellxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GlobalStrategicCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i0056aa3d99a143b88dbc13d114cc84be_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">gild:ArcellxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gild:GlobalStrategicCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">gild:ArcellxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i0f0e85f937584323a180e6f5054512c6_D20230222-20230222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882095</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">gild:TmunityTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="country">
        <measure>gild:country</measure>
    </unit>
    <unit id="segment">
        <measure>gild:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="program">
        <measure>gild:program</measure>
    </unit>
    <unit id="agreement">
        <measure>gild:agreement</measure>
    </unit>
    <unit id="patent">
        <measure>gild:patent</measure>
    </unit>
    <unit id="opposingparty">
        <measure>gild:opposingParty</measure>
    </unit>
    <unit id="lawsuit">
        <measure>gild:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>gild:plaintiff</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN180L2ZyYWc6Y2VhZDQ0MTRhYjMzNDczZmIyYmZiODVhMTUwYmZiNjgvdGFibGU6ZmIwMTNmNmI2MmM2NGZmNGE3NGIyYmQ3ZTZmZjJmY2YvdGFibGVyYW5nZTpmYjAxM2Y2YjYyYzY0ZmY0YTc0YjJiZDdlNmZmMmZjZl8zLTEtMS0xLTE2NzY2NQ_6cdf0acf-f23c-4394-871b-de8600fa1a78">0000882095</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN180L2ZyYWc6Y2VhZDQ0MTRhYjMzNDczZmIyYmZiODVhMTUwYmZiNjgvdGFibGU6ZmIwMTNmNmI2MmM2NGZmNGE3NGIyYmQ3ZTZmZjJmY2YvdGFibGVyYW5nZTpmYjAxM2Y2YjYyYzY0ZmY0YTc0YjJiZDdlNmZmMmZjZl80LTEtMS0xLTE2NzY2NQ_e09c178b-6133-4aff-a32a-105047313bb8">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN180L2ZyYWc6Y2VhZDQ0MTRhYjMzNDczZmIyYmZiODVhMTUwYmZiNjgvdGFibGU6ZmIwMTNmNmI2MmM2NGZmNGE3NGIyYmQ3ZTZmZjJmY2YvdGFibGVyYW5nZTpmYjAxM2Y2YjYyYzY0ZmY0YTc0YjJiZDdlNmZmMmZjZl81LTEtMS0xLTE2NzY2NQ_d8ac8e9f-b5f9-4ac7-9700-b6f3dc72a135">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN180L2ZyYWc6Y2VhZDQ0MTRhYjMzNDczZmIyYmZiODVhMTUwYmZiNjgvdGFibGU6ZmIwMTNmNmI2MmM2NGZmNGE3NGIyYmQ3ZTZmZjJmY2YvdGFibGVyYW5nZTpmYjAxM2Y2YjYyYzY0ZmY0YTc0YjJiZDdlNmZmMmZjZl82LTEtMS0xLTE2NzY2NQ_e15a5759-80b6-4945-b206-1f0a345516e5">false</dei:AmendmentFlag>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtMi0xLTEtMTY3NjY1_2f4084d2-5259-4bc5-8b05-5f700b1f1a8a">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtNi0xLTEtMTY3NjY1_46ccc9b5-72b7-44ea-ba73-a4b1e8bd1b28">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtMi0xLTEtMjA2NjQ5_b7aba77a-d3a3-423b-9d31-3f7747775fae">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtNi0xLTEtMjA2NjQ5_bc98400a-c82d-4004-b4ed-25c8c3bfe4b2">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <gild:DebtInstrumentCallFeaturePeriodBeforeMaturity
      contextRef="i9e6348bb4b5348819415c13456fd293e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEwOTk1MTE2MzcyNzc_a58a2f1f-515b-4f40-ba1a-00d6cf2d5f1b">P2M</gild:DebtInstrumentCallFeaturePeriodBeforeMaturity>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_8de7020f-9548-47c7-9a1e-4746afc67ea4">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_b3559456-f5cf-4d45-8c2a-793a81b2aed1">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_37e207dc-5857-47ab-bc75-5d95f77eba00">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_566a40c8-fefd-4cc7-be50-3313dae89a4d">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_083b769e-0d49-49bf-952b-f91005031157">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_6a8cd158-cdc0-45a1-ba9e-3851203d9cab">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i13cf4d57dd80444a9615d435346a008b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTY3OTU_0304068a-3d69-42e3-a0cc-97d49217f440">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ied34c0fde1d440f0a671f6e6ead42d05_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTg2ODM_bb52c247-34d1-49f0-be7e-b07c8a217a78">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY184OQ_56aadc67-03e8-4df1-ad20-a4cccbf3ce57">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6ZGUxM2E3ZTYwMjM1NDBiYzhjYzZmNDg5N2YzYmJiN2QvdGFibGVyYW5nZTpkZTEzYTdlNjAyMzU0MGJjOGNjNmY0ODk3ZjNiYmI3ZF8wLTAtMS0xLTE2NzY2NQ_f4cccf8f-a633-4bf1-8cd7-51dd0945f4dc">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18xMDk5NTExNjMxODUw_9ddd0d2b-58ef-4145-b8a9-74b6263b7eb5">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18xMDk5NTExNjMxODUw_22cf6078-a46a-4af5-a3b6-fe02672587dc">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6YmU5MzUyMzUxMzI0NGE3ZDkyYWNlNGU5NDExOTM0ZjUvdGFibGVyYW5nZTpiZTkzNTIzNTEzMjQ0YTdkOTJhY2U0ZTk0MTE5MzRmNV8wLTAtMS0xLTE2NzY2NQ_c6c01a24-e4c1-47ac-a243-999984cc1669">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yMTY_054295ae-e76b-4e84-8e8b-bc8e6e445d92">000-19731</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yMjI_924b1e85-855e-435b-8806-2f2ca2c10539">GILEAD SCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6M2VkYjFhM2Y4MGYwNDJmYWI3YjI0MGE2NWQzMmY2NmEvdGFibGVyYW5nZTozZWRiMWEzZjgwZjA0MmZhYjdiMjQwYTY1ZDMyZjY2YV8wLTAtMS0xLTE2NzY2NQ_6e436a36-cad2-4ca1-8272-de0856faf3c6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6M2VkYjFhM2Y4MGYwNDJmYWI3YjI0MGE2NWQzMmY2NmEvdGFibGVyYW5nZTozZWRiMWEzZjgwZjA0MmZhYjdiMjQwYTY1ZDMyZjY2YV8wLTEtMS0xLTE2NzY2NQ_5906fb9a-ffa8-40f2-9956-46b35dfcbfc1">94-3047598</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yODY_7107fca2-5a34-4318-a3be-feb243c47464">333 Lakeside Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yOTA_c47e6cc2-1f61-40b2-9037-f76e627619cb">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yOTQ_dffd1ec8-2c19-41a9-a5de-f8fdc8c34c19">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yOTc_804d1b9c-36d8-4437-a9cb-274e5df191d2">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zNjI_d3cd0b44-e7fd-4bc8-b577-98149a12f3dd">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zNjU_20cbab9c-4c8a-4c63-a37d-8dfa91dc49c5">574-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6M2M0MTA5NmU5YmEzNDcxMTlhM2ZmZDE1NmVlMzNiZTIvdGFibGVyYW5nZTozYzQxMDk2ZTliYTM0NzExOWEzZmZkMTU2ZWUzM2JlMl8xLTAtMS0xLTE2NzY2NQ_f87d6025-c640-4dd9-a27d-718897dc6629">Common Stock, par value, $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6M2M0MTA5NmU5YmEzNDcxMTlhM2ZmZDE1NmVlMzNiZTIvdGFibGVyYW5nZTozYzQxMDk2ZTliYTM0NzExOWEzZmZkMTU2ZWUzM2JlMl8xLTItMS0xLTE2NzY2NQ_20ef86e1-822b-4d92-8bc5-947922bffdf1">GILD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGFibGU6M2M0MTA5NmU5YmEzNDcxMTlhM2ZmZDE1NmVlMzNiZTIvdGFibGVyYW5nZTozYzQxMDk2ZTliYTM0NzExOWEzZmZkMTU2ZWUzM2JlMl8xLTQtMS0xLTE2NzY2NQ_a4edd668-6010-485b-8477-1c83a93a35cb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY182OTE_0fc1bd0d-4c16-47f7-9f49-bbb12a352e7f">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY184NTA_7f5c3397-908c-4aab-a9bd-bad8de31ea98">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18xMTg1_4db28448-55e3-47ed-9bfa-11e71631d236">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18xNTEz_e2a99508-6003-4258-9691-10d55b7aad8e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18xODcx_f70301a1-64c6-412b-9b74-c62fdc799309">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zODY0_b47a8288-afa9-4c82-bd3e-ca6ee4ab4a90">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zODY1_c17c4d09-7431-4c0d-9782-33026816ea5a">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zODY2_1fbc6082-8fc4-42fd-beaf-2c6cdd38b6c5">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY185ODk1NjA0NjU0MTAz_3c2af349-ea84-4f84-b3d8-b5b40397ba37">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="if8b93d3ce3b74726be0d91eed3869725_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18yOTM1_97abcefb-4477-467a-a3f9-7e59ac775706"
      unitRef="usd">55900000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if2acd853399e42529979a83d303e38d1_I20230217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zMDE3_bc62645f-3710-42ef-b6bb-cc806ba2d0a9"
      unitRef="shares">1247105154</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xL2ZyYWc6NmRmODU5YjQ1ZjVmNDAwZmIwOGYwZWJmMmE0YmE2MmMvdGV4dHJlZ2lvbjo2ZGY4NTliNDVmNWY0MDBmYjA4ZjBlYmYyYTRiYTYyY18zODY5_ecc8f9c5-8565-42b0-952c-008fddfb0f1b">Specified portions of the registrant&#x2019;s proxy statement, which will be filed with the Commission pursuant to Regulation 14A in connection with the registrant&#x2019;s 2023 Annual Meeting of Stockholders, to be held on May 3, 2023, are incorporated by reference into Part&#160;III of this Report.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN182NC9mcmFnOjI1YmY4YmMzNjk4NTQ0MWQ5YzY1YTMzNTFjZDNmMzBhL3RhYmxlOjQyODBjZDA3Yjc2NzRlNDhhNzI5ZDY5MDVmYWI5MDkwL3RhYmxlcmFuZ2U6NDI4MGNkMDdiNzY3NGU0OGE3MjlkNjkwNWZhYjkwOTBfMC0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjo0ZmQyYzQxNjlkYmU0NzlhYmJhYzJiMWJkZWVkMGIyZV83MQ_5a14d9ce-16da-45fd-9896-568284a50afa">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN182Ny9mcmFnOjI4ZWM5NDY2ZGVlNzRkNzQ5NTQxOGZjYjNhNDIwYmE3L3RleHRyZWdpb246MjhlYzk0NjZkZWU3NGQ3NDk1NDE4ZmNiM2E0MjBiYTdfMzQzNg_3cf21250-d0f8-4df1-a87f-a898c601eac2">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN182Ny9mcmFnOjI4ZWM5NDY2ZGVlNzRkNzQ5NTQxOGZjYjNhNDIwYmE3L3RleHRyZWdpb246MjhlYzk0NjZkZWU3NGQ3NDk1NDE4ZmNiM2E0MjBiYTdfMzQzNw_d8329207-ace6-4e37-8e40-7629e108e516">San Jose, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNC0yLTEtMS0xNjc2NjU_87daa750-b12d-41f9-ab78-3ac5556c90e2"
      unitRef="usd">5412000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNC00LTEtMS0xNjc2NjU_af18e15d-bb32-474e-acf7-d300a63134ba"
      unitRef="usd">5338000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNS0yLTEtMS0xNjc2NjU_4405c21c-e9f1-4909-af5e-6850160e3c5d"
      unitRef="usd">973000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNS00LTEtMS0xNjc2NjU_ad0f39eb-18e6-4cff-9af8-c1afafd3bcd1"
      unitRef="usd">1182000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNi0yLTEtMS0xNjc2NjU_d1ab0282-f7a3-4f09-a4db-01b3844d1b0a"
      unitRef="usd">4777000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNi00LTEtMS0xNjc2NjU_5f102b34-a534-4932-8406-a9854340148b"
      unitRef="usd">4493000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNy0yLTEtMS0xNjc2NjU_9bdd67d9-d56f-4c1e-a35b-cbeaf4d32872"
      unitRef="usd">1507000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfNy00LTEtMS0xNjc2NjU_e005ec69-019a-4614-9edd-c225470c38a7"
      unitRef="usd">1618000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfOC0yLTEtMS0xNjc2NjU_94452874-fbb0-42b9-a0f7-bfb8e16f1685"
      unitRef="usd">1774000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfOC00LTEtMS0xNjc2NjU_a9870085-d735-46d1-90a3-c4821d7b3829"
      unitRef="usd">2141000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfOS0yLTEtMS0xNjc2NjU_dbc6d49b-831e-4922-a758-07ded9c291bb"
      unitRef="usd">14443000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfOS00LTEtMS0xNjc2NjU_bc975534-3807-44d3-a9f2-1cd47b246d59"
      unitRef="usd">14772000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTAtMi0xLTEtMTY3NjY1_2d29ef7b-2cd3-41d6-9596-89c2c369850f"
      unitRef="usd">5475000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTAtNC0xLTEtMTY3NjY1_0b0107e0-df06-477d-9fcd-8b3431105d1a"
      unitRef="usd">5121000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTEtMi0xLTEtMTY3NjY1_bc2111d1-b4e4-437a-8090-6f4ae07efb37"
      unitRef="usd">1245000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTEtNC0xLTEtMTY3NjY1_9b4e3a40-e657-4a5b-b3a9-4e5104dcf033"
      unitRef="usd">1309000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTItMi0xLTEtMTY3NjY1_d834cd9a-2f73-4dee-a2f6-37bcfc991b2a"
      unitRef="usd">28894000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTItNC0xLTEtMTY3NjY1_964c4036-4847-4a1d-b2b5-385eb4cd1db6"
      unitRef="usd">33455000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTMtMi0xLTEtMTY3NjY1_c588bd02-2bc0-4340-bb01-7df224ce08d0"
      unitRef="usd">8314000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTMtNC0xLTEtMTY3NjY1_16f902c8-2b22-4bc8-94e7-f0cda92cc5aa"
      unitRef="usd">8332000000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTQtMi0xLTEtMTY3NjY1_cc34d5a0-5b4c-4cf6-a041-77bd8b4605f2"
      unitRef="usd">4800000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTQtNC0xLTEtMTY3NjY1_f26b83c9-534d-412f-9c9f-3d77078768a0"
      unitRef="usd">4963000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTUtMi0xLTEtMTY3NjY1_575e195c-da7c-4809-a9a0-7416fca56d99"
      unitRef="usd">63171000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTUtNC0xLTEtMTY3NjY1_9d4c0f88-d793-4cfc-8fe1-42809d9d90c6"
      unitRef="usd">67952000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTgtMi0xLTEtMTY3NjY1_e85fa4ef-96a3-4efb-8a43-8010e32480f8"
      unitRef="usd">905000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTgtNC0xLTEtMTY3NjY1_a73011f2-a033-42ce-8185-c05a489c15b0"
      unitRef="usd">705000000</us-gaap:AccountsPayableCurrent>
    <gild:AccruedRebates
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTktMi0xLTEtMTY3NjY1_1be76dea-e1c6-424e-b0a1-5c59806a8b80"
      unitRef="usd">3479000000</gild:AccruedRebates>
    <gild:AccruedRebates
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMTktNC0xLTEtMTY3NjY1_370b9cdd-9148-4d85-aedf-47e9958a0f9f"
      unitRef="usd">3244000000</gild:AccruedRebates>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjAtMi0xLTEtMTY3NjY1_f056b6d8-9ff1-48d7-8a12-f277063f96ec"
      unitRef="usd">4580000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjAtNC0xLTEtMTY3NjY1_d56d74f5-ac45-414d-952a-7ffdc665830d"
      unitRef="usd">6145000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DebtCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjEtMi0xLTEtMTY3NjY1_bf3a023f-28dc-41e0-8109-01a4a5a78b07"
      unitRef="usd">2273000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjEtNC0xLTEtMTY3NjY1_7ead9847-c6e4-4b51-a757-593ba166e58d"
      unitRef="usd">1516000000</us-gaap:DebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjItMi0xLTEtMTY3NjY1_0e2f999f-2de6-4f53-94ea-a5b45188ba4b"
      unitRef="usd">11237000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjItNC0xLTEtMTY3NjY1_8493dcec-4b10-43b6-a7fc-c9cd5c31be97"
      unitRef="usd">11610000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjMtMi0xLTEtMTY3NjY1_76aac610-1a91-4b1d-96a8-377f89a61892"
      unitRef="usd">22957000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjMtNC0xLTEtMTY3NjY1_acc5582b-8131-43fc-b40f-af7c18e5015f"
      unitRef="usd">25179000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjQtMi0xLTEtMTY3NjY1_b8562ec0-84fb-4228-b462-ab737c570e88"
      unitRef="usd">3916000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjQtNC0xLTEtMTY3NjY1_e6e9b157-1a59-41b3-a712-cc8161da9797"
      unitRef="usd">4767000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjUtMi0xLTEtMTY3NjY1_897b98fa-9aa3-428b-92b9-7be774cd8625"
      unitRef="usd">2673000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjUtNC0xLTEtMTY3NjY1_871fdc84-40cd-47e8-9024-ac8ea1b064f7"
      unitRef="usd">4356000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjYtMi0xLTEtMTY3NjY1_958a9d58-048c-465c-976c-6f4b7eeeb9ef"
      unitRef="usd">1179000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjYtNC0xLTEtMTY3NjY1_9d86b7b9-a1aa-4f1c-af1d-0418ca798149"
      unitRef="usd">976000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjctMi0xLTEtMTY3NjY1_10ddafb5-dba1-4169-b1a1-cf389f880fef"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjctNC0xLTEtMTY3NjY1_06510c42-ab64-4182-926b-fa9bfc8c7cf6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZGVhMGQxNjI5MjIzNDcxNDk1Zjg3NzQwOTk1YjYzZjRfMzE_478df680-1bd0-4e02-934f-5fd056433f4b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZGVhMGQxNjI5MjIzNDcxNDk1Zjg3NzQwOTk1YjYzZjRfMzE_d845cf67-a431-4e45-acb3-5ac58a30994b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZGVhMGQxNjI5MjIzNDcxNDk1Zjg3NzQwOTk1YjYzZjRfNDU_1c820532-4735-4997-83f2-acd698936547"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZGVhMGQxNjI5MjIzNDcxNDk1Zjg3NzQwOTk1YjYzZjRfNDU_20f3f5c0-6381-4986-bdef-2be464a844a6"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZGVhMGQxNjI5MjIzNDcxNDk1Zjg3NzQwOTk1YjYzZjRfNjc_5a1a16d1-72ff-40c8-8c5e-a6b17991ddb5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZGVhMGQxNjI5MjIzNDcxNDk1Zjg3NzQwOTk1YjYzZjRfNjc_c9f5647c-18ea-472d-8348-4749e66b2a8f"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktMi0xLTEtMTY3NjY1_127c4bf0-3511-4d2c-8ef4-e5d0542b60ff"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMjktNC0xLTEtMTY3NjY1_5b612731-c387-4999-aab7-3ad1fb67afc6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfNzY5NjU4MTM5NDg0Ng_ae730a60-6908-4ba8-a59c-7f1e806f36ee"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfNzY5NjU4MTM5NDg0Ng_e7253b32-d29d-46ab-a140-613c94d00ecc"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfNzY5NjU4MTM5NDgzNw_03e53a8b-5490-4678-a5f7-ed02e91bcc8b"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfNzY5NjU4MTM5NDgzNw_06006b99-2755-49bd-a7b9-ed42aef3c933"
      unitRef="shares">5600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfMTA5OTUxMTYyODE3Mw_b814779b-a1a1-4382-b3b9-3e2a7ffc8ea3"
      unitRef="shares">1247000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfMTA5OTUxMTYyODE3Mw_f8a903c7-a253-449b-8df4-be990b0ab364"
      unitRef="shares">1247000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfMTA5OTUxMTYyODE2NA_5e7fdfdd-761f-4831-b537-b356b94fd7a9"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246MjJjNTlhNzMwMTlhNDhjMjgxOTIyYTZhYWY0NjcxMjlfMTA5OTUxMTYyODE2NA_84e8e54e-9c2c-487b-917e-42200f136b21"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtMi0xLTEtMTY3NjY1_2c502674-dc1b-4972-9e7a-afac17013e52"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzAtNC0xLTEtMTY3NjY1_13dd7a30-751a-4075-925d-006187e9e963"
      unitRef="usd">1000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzEtMi0xLTEtMTY3NjY1_86ed0f11-2ee6-446d-b429-82dcefaa27cb"
      unitRef="usd">5550000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzEtNC0xLTEtMTY3NjY1_b3f0dbad-8927-4882-aa5c-ac303c55cf1c"
      unitRef="usd">4661000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzItMi0xLTEtMTY3NjY1_37407bb8-59cd-4ff6-9c98-9153cbc1a3dd"
      unitRef="usd">2000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzItNC0xLTEtMTY3NjY1_f5cb02a7-69f9-4664-811e-b4c35cfeacc6"
      unitRef="usd">83000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzMtMi0xLTEtMTY3NjY1_0cae36f4-c3f0-4162-894c-ac07673dfb33"
      unitRef="usd">15687000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzMtNC0xLTEtMTY3NjY1_1cc3a661-a26c-4dca-bd6c-a2a417398166"
      unitRef="usd">16324000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzQtMi0xLTEtMTY3NjY1_125c8d22-7c28-41a3-af05-2147a44ba3c0"
      unitRef="usd">21240000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzQtNC0xLTEtMTY3NjY1_2e4e0601-ad34-406e-9a59-82477acb8982"
      unitRef="usd">21069000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzUtMi0xLTEtMTY3NjY1_e9aceb63-d57e-4931-8c28-99f38523d96f"
      unitRef="usd">-31000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzUtNC0xLTEtMTY3NjY1_104b7032-cda7-44ab-b8b8-a4aea275f677"
      unitRef="usd">-5000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzYtMi0xLTEtMTY3NjY1_18cbfa3f-6601-49de-9541-7fba0ecdbbba"
      unitRef="usd">21209000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzYtNC0xLTEtMTY3NjY1_0e6a54d5-f0fc-4238-925b-c636fcda34f4"
      unitRef="usd">21064000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzctMi0xLTEtMTY3NjY1_114334ff-4689-4066-a829-400afe0d35e8"
      unitRef="usd">63171000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183My9mcmFnOmQzMDQ0NWJkY2NlMDQ2YmZiMWUzZDgxMDVlOTMzMWNkL3RhYmxlOmZmNDU2M2UxNWY4ODQwOTU4M2I5ODg3MmM0ZjZhYWExL3RhYmxlcmFuZ2U6ZmY0NTYzZTE1Zjg4NDA5NTgzYjk4ODcyYzRmNmFhYTFfMzctNC0xLTEtMTY3NjY1_673d0f21-b626-44fe-88f5-19b200ba84b8"
      unitRef="usd">67952000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5776967eec2e40169c93026e3f869e40_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMy0yLTEtMS0xNjc2NjU_f8f420f2-9e66-48b7-a438-c72f2126dbab"
      unitRef="usd">26982000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdd0d2f0925f42e7889120dcf51249c1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMy00LTEtMS0xNjc2NjU_23acd1e7-c024-4a59-8f0b-eda9f0cfcfae"
      unitRef="usd">27008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i549c720f0be04d399b280dc53ff6498d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMy02LTEtMS0xNjc2NjU_c91b96b6-1677-41fe-acc6-734ae0da0cba"
      unitRef="usd">24355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3009f1cc5994ac0949727e755fef6fb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNC0yLTEtMS0xNjc2NjU_d823e876-ef13-4c9b-9d73-c76159013d06"
      unitRef="usd">299000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fd731dcc7c6442d9eb015fc7f92096b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNC00LTEtMS0xNjc2NjU_c97f6157-839a-45e1-af32-8f2bbbad3920"
      unitRef="usd">297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ce29476464948ef99a1d86b1a2d50bf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNC02LTEtMS0xNjc2NjU_567d789d-2564-44dd-be59-f4d09a851922"
      unitRef="usd">334000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNS0yLTEtMS0xNjc2NjU_705af443-5460-423e-b789-63214a755588"
      unitRef="usd">27281000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNS00LTEtMS0xNjc2NjU_a7da044c-85a2-4c65-8725-8dbf903dc400"
      unitRef="usd">27305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNS02LTEtMS0xNjc2NjU_73906abe-cb67-4960-b6df-934ab095fc4d"
      unitRef="usd">24689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNy0yLTEtMS0xNjc2NjU_f3748581-e597-4880-b053-ea248e6ae822"
      unitRef="usd">5657000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNy00LTEtMS0xNjc2NjU_b67d1c1a-a6f3-44a6-b9e8-2493609febfd"
      unitRef="usd">6601000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfNy02LTEtMS0xNjc2NjU_c62be3bc-27aa-4cfd-8b54-3e695e98cd40"
      unitRef="usd">4572000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfOC0yLTEtMS0xNjc2NjU_64555f28-8443-4d95-bb3b-310de7907283"
      unitRef="usd">4977000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfOC00LTEtMS0xNjc2NjU_07eca73e-90de-4525-a290-6a2da00cab75"
      unitRef="usd">4601000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfOC02LTEtMS0xNjc2NjU_31df9952-63f3-4dec-a92f-6467327e4468"
      unitRef="usd">4927000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfOS0yLTEtMS0xNjc2NjU_4e8861c2-d00c-4a3d-8355-2a91da19b90a"
      unitRef="usd">944000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfOS00LTEtMS0xNjc2NjU_c113cf23-28b9-448b-9dee-9cfd2b6bd631"
      unitRef="usd">939000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfOS02LTEtMS0xNjc2NjU_2f5697c4-f6d0-4758-9db9-aa67c99d275d"
      unitRef="usd">5968000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTAtMi0xLTEtMjAyODQ3_672db3f4-30b7-48ee-be18-720c9c57ee50"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTAtNC0xLTEtMjAyODQ3_7296e948-7ad6-467f-90f0-81029fe15726"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTAtNi0xLTEtMjAyODQ3_0d0646b1-b3b8-41a6-9403-45fa9ac06f28"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTAtMi0xLTEtMTY3NjY1_2823871e-2e38-4ba1-958e-85d66ef734e9"
      unitRef="usd">5673000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTAtNC0xLTEtMTY3NjY1_55542c46-d99f-41b4-a88f-f7603e38264a"
      unitRef="usd">5246000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTAtNi0xLTEtMTY3NjY1_81cf4990-a512-4c4e-a436-de550a7f51b0"
      unitRef="usd">5151000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTEtMi0xLTEtMTY3NjY1_908dc39b-f600-4b87-9905-a54b04b03e40"
      unitRef="usd">19951000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTEtNC0xLTEtMTY3NjY1_7d1c538d-4c15-45cd-bc18-5e6dc8bfb852"
      unitRef="usd">17387000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTEtNi0xLTEtMTY3NjY1_292e38a0-83f7-4d5d-b7df-6ccf6086684e"
      unitRef="usd">20618000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTItMi0xLTEtMTY3NjY1_df9bf41c-e840-461b-b176-53fda1c80f83"
      unitRef="usd">7330000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTItNC0xLTEtMTY3NjY1_c25914f1-69ae-4bc5-ba6c-fc19e0b88df6"
      unitRef="usd">9918000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTItNi0xLTEtMTY3NjY1_d3ee8612-e585-4ff4-a5c1-9dd6a3affddf"
      unitRef="usd">4071000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTMtMi0xLTEtMTY3NjY1_97763fc8-0c17-4517-91d6-fee83676ce83"
      unitRef="usd">935000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTMtNC0xLTEtMTY3NjY1_0e4f6961-ddd3-4bae-a3be-b6041729a795"
      unitRef="usd">1001000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTMtNi0xLTEtMTY3NjY1_05d6e8e9-1477-4db2-96f2-afbf149d8a4b"
      unitRef="usd">984000000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTQtMi0xLTEtMTY3NjY1_4b714edf-ac33-4acf-9de7-cb1ec51bf817"
      unitRef="usd">-581000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTQtNC0xLTEtMTY3NjY1_ce0aae50-83a4-487c-b93b-cb3586559c7c"
      unitRef="usd">-639000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTQtNi0xLTEtMTY3NjY1_5f6e88bd-9d1e-4469-b082-9d9a88f662eb"
      unitRef="usd">-1418000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTUtMi0xLTEtMTY3NjY1_f9c116bc-7741-4bc8-bd54-f247bbe7c24e"
      unitRef="usd">5814000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTUtNC0xLTEtMTY3NjY1_6a7a20e7-6ea3-468a-bed7-88d247d696ec"
      unitRef="usd">8278000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTUtNi0xLTEtMTY3NjY1_ed48e4ca-c767-49e3-a87f-1315f284c7a7"
      unitRef="usd">1669000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTYtMi0xLTEtMTY3NjY1_ee9076a5-fae3-43ac-b20a-8056b031c40d"
      unitRef="usd">1248000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTYtNC0xLTEtMTY3NjY1_d8ed3d19-da09-49ae-9038-2050af67e051"
      unitRef="usd">2077000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTYtNi0xLTEtMTY3NjY1_61330962-0c4d-4b12-85b2-bc8a70678d8b"
      unitRef="usd">1580000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTctMi0xLTEtMTY3NjY1_c740fe9f-facf-46c4-945f-a9d8b12b815d"
      unitRef="usd">4566000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTctNC0xLTEtMTY3NjY1_2e7e5d80-bd45-42dc-9d1d-122b882d76bf"
      unitRef="usd">6201000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTctNi0xLTEtMTY3NjY1_9f172a08-d204-439b-ba87-aafdb7a2a1e8"
      unitRef="usd">89000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTgtMi0xLTEtMTY3NjY1_019d1e28-9ef7-4bbb-8a55-ed7c82b16e53"
      unitRef="usd">-26000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTgtNC0xLTEtMTY3NjY1_0f0f01dd-db53-45a3-86d5-2f85ce198c46"
      unitRef="usd">-24000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTgtNi0xLTEtMTY3NjY1_dc2287fa-8384-4d57-af53-8b744fe32b59"
      unitRef="usd">-34000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTktMi0xLTEtMTY3NjY1_3e38e7a0-6350-49f1-85bc-192612afa8c5"
      unitRef="usd">4592000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTktNC0xLTEtMTY3NjY1_a0686f75-0cad-48e9-a6ca-34e5b986760b"
      unitRef="usd">6225000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMTktNi0xLTEtMTY3NjY1_c1438e93-8449-4b55-93ad-04d196782bd4"
      unitRef="usd">123000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjAtMi0xLTEtMTY3NjY1_f668b586-93b5-49df-aaa7-9e4a45a9963c"
      unitRef="usdPerShare">3.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjAtNC0xLTEtMTY3NjY1_d5333cdc-162c-4949-9b0d-615ec673b2e6"
      unitRef="usdPerShare">4.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjAtNi0xLTEtMTY3NjY1_9a03820a-297b-42d3-96ec-d80dc93c2475"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjEtMi0xLTEtMTY3NjY1_cba4dff9-cd21-45d1-9fbc-05899c037b86"
      unitRef="shares">1255000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjEtNC0xLTEtMTY3NjY1_ae2aee9e-3715-4661-98d8-a5ddeba71880"
      unitRef="shares">1256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjEtNi0xLTEtMTY3NjY1_d40dfe23-3dc3-4837-b05b-d98e4b90c858"
      unitRef="shares">1257000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjItMi0xLTEtMTY3NjY1_ae05e343-668d-4901-9934-b335f5efb1ac"
      unitRef="usdPerShare">3.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjItNC0xLTEtMTY3NjY1_2df4161e-f717-40fb-81fa-8656d0a4f2e3"
      unitRef="usdPerShare">4.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjItNi0xLTEtMTY3NjY1_d13b1542-1bd1-402c-b561-ed2fdc44a253"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjMtMi0xLTEtMTY3NjY1_c1b066c8-e937-4723-97d8-c24b6a08c0b2"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjMtNC0xLTEtMTY3NjY1_30bb3a54-d7ee-40de-8916-be130187f418"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183Ni9mcmFnOjc4YWI1MzQ3YmUyMzQwNzQ4ZGU1OTRlMGQ5NTYwNzkzL3RhYmxlOjhiMjM4YzYwZWYxNjRlNWJhMmVkNWQ2NjUxNmExNWEzL3RhYmxlcmFuZ2U6OGIyMzhjNjBlZjE2NGU1YmEyZWQ1ZDY2NTE2YTE1YTNfMjMtNi0xLTEtMTY3NjY1_e7d47d8a-838d-44f8-9320-53bd24569d57"
      unitRef="shares">1263000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMi0yLTEtMS0xNjc2NjU_c740fe9f-facf-46c4-945f-a9d8b12b815d"
      unitRef="usd">4566000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMi00LTEtMS0xNjc2NjU_2e7e5d80-bd45-42dc-9d1d-122b882d76bf"
      unitRef="usd">6201000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMi02LTEtMS0xNjc2NjU_9f172a08-d204-439b-ba87-aafdb7a2a1e8"
      unitRef="usd">89000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNC0yLTEtMS0xNjc2NjU_1e8d3a02-d163-466c-9d33-dc0af952da08"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNC00LTEtMS0xNjc2NjU_3bedcbc1-e60a-4758-bd71-9a204a9ae9e2"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNC02LTEtMS0xNjc2NjU_e79031ed-23f7-4325-94e1-c93d220113c9"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNi0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjpiMDcwYTRhZjRkZjU0NjFmOGQ3ZTRmZDM2MzQyMjNjZl80Mzk4MDQ2NTExMTU3_af0304d9-b8e2-4133-9cda-3ad0450aba99"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNi0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjpiMDcwYTRhZjRkZjU0NjFmOGQ3ZTRmZDM2MzQyMjNjZl80Mzk4MDQ2NTExMTYy_d6fbeabe-95b2-4601-bb0b-c570d6c5a58c"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNi0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjpiMDcwYTRhZjRkZjU0NjFmOGQ3ZTRmZDM2MzQyMjNjZl80Mzk4MDQ2NTExMTcw_ea398c2a-148c-46bb-83b0-41d4dc7db5d8"
      unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNi0yLTEtMS0xNjc2NjU_920617b2-0b45-4fdc-bf6d-f472980ac2b8"
      unitRef="usd">-30000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNi00LTEtMS0xNjc2NjU_b0697b31-3859-4aac-97da-21037595440e"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNi02LTEtMS0xNjc2NjU_a79f8852-db33-4d74-b1e6-6a90b79becfb"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNy0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjoyNTEyZWFlOWJhMDQ0NDVlYWJjMWU2NDAyMjVkOTE3Zl80Mzk4MDQ2NTExMTYy_0510c133-7f4c-46b8-a3da-05fbf5543a7c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNy0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjoyNTEyZWFlOWJhMDQ0NDVlYWJjMWU2NDAyMjVkOTE3Zl80Mzk4MDQ2NTExMTY3_07ebc29e-335c-412a-be42-2a601dead455"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNy0wLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjoyNTEyZWFlOWJhMDQ0NDVlYWJjMWU2NDAyMjVkOTE3Zl80Mzk4MDQ2NTExMTc1_a8272875-594f-4f03-b343-972eb4319de8"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNy0yLTEtMS0xNjc2NjU_43ee3911-cb69-4137-90b4-c3b5c2abe852"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNy00LTEtMS0xNjc2NjU_6a7e4587-96e6-435a-8e26-b7fb0e3ed4d3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfNy02LTEtMS0xNjc2NjU_95b50e6b-2234-4284-b171-9d60210b34b8"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfOC0yLTEtMS0xNjc2NjU_b36ed618-8f2c-4008-b049-cbdcd373cede"
      unitRef="usd">-29000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfOC00LTEtMS0xNjc2NjU_5a3e3b5e-922f-42b1-9365-bf07e1076897"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfOC02LTEtMS0xNjc2NjU_e5c84a04-54bb-4492-b342-10121a85956f"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YzE2NGI5ZWUwYWMzNDg1YThjY2JmMWY0YmQwYmJjZWJfNDM5ODA0NjUxMTE1Nw_0ce579de-1b5f-461a-9231-14d1b6a2c8df"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YzE2NGI5ZWUwYWMzNDg1YThjY2JmMWY0YmQwYmJjZWJfNDM5ODA0NjUxMTE2Mg_fcb88789-d3ba-438f-acac-80ef8e4ca2c3"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTAtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YzE2NGI5ZWUwYWMzNDg1YThjY2JmMWY0YmQwYmJjZWJfNDM5ODA0NjUxMTE3MA_f317b976-2227-4811-af0c-9cd0647123c0"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTAtMi0xLTEtMTY3NjY1_9feae780-847f-4520-8056-d92d004ad34e"
      unitRef="usd">130000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTAtNC0xLTEtMTY3NjY1_d178b666-af1b-40cf-a437-f8197d2be331"
      unitRef="usd">129000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTAtNi0xLTEtMTY3NjY1_64647083-aff6-4f3a-a652-5ede8de29b87"
      unitRef="usd">-103000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTEtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YWFhNGNmNzAwNTQ2NDBmOGI0NDA1NTI2Nzk3YzM5ZjRfNTQ5NzU1ODEzOTQ2_62a55e8c-8bf2-489f-ba40-27cf8beae971"
      unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTEtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YWFhNGNmNzAwNTQ2NDBmOGI0NDA1NTI2Nzk3YzM5ZjRfNTQ5NzU1ODEzOTUx_68402e2c-8526-424d-99d3-1f7436ffafc4"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTEtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YWFhNGNmNzAwNTQ2NDBmOGI0NDA1NTI2Nzk3YzM5ZjRfNTQ5NzU1ODEzOTYz_352712aa-15a4-4fa5-bf36-942ec771aac1"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTEtMi0xLTEtMTY3NjY1_36b96d38-cca4-4c17-9a6b-885f6cb59a48"
      unitRef="usd">171000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTEtNC0xLTEtMTY3NjY1_2b9ad264-a1ff-43ee-83d3-77dbe499386f"
      unitRef="usd">-58000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTEtNi0xLTEtMTY3NjY1_770a0d80-955a-4d2d-8835-f61cd3500f5a"
      unitRef="usd">41000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTItMi0xLTEtMTY3NjY1_1991781c-aa8a-4915-b7f2-bae6c1d92726"
      unitRef="usd">-41000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTItNC0xLTEtMTY3NjY1_577c542d-4da0-4fd2-b285-0c20b032584a"
      unitRef="usd">187000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTItNi0xLTEtMTY3NjY1_2c63da42-e0e7-4a31-8cb7-c72b360192c7"
      unitRef="usd">-144000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTMtMi0xLTEtMTY3NjY1_014a1dcb-5386-4a20-8dd5-c6efc0b6f3f8"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTMtNC0xLTEtMTY3NjY1_59e430f0-4960-4a17-9290-8fe2619bc0ce"
      unitRef="usd">143000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTMtNi0xLTEtMTY3NjY1_6b6abeac-31de-485f-8271-ad76c9babbba"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTQtMi0xLTEtMTY3NjY1_230725fd-4cdf-4d15-8a61-ecff3edccec1"
      unitRef="usd">4485000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTQtNC0xLTEtMTY3NjY1_f5c23953-b243-4ca1-a856-a768113dc6f2"
      unitRef="usd">6344000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTQtNi0xLTEtMTY3NjY1_636a0802-b229-4fef-9923-927dbd52d989"
      unitRef="usd">-56000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTUtMi0xLTEtMTY3NjY1_28e28955-11a5-4239-8138-5c24af49715a"
      unitRef="usd">-26000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTUtNC0xLTEtMTY3NjY1_0051e8f1-889c-4a35-a96a-91790f3566e7"
      unitRef="usd">-24000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTUtNi0xLTEtMTY3NjY1_95aa4b32-b5be-4115-ab4b-be6643385288"
      unitRef="usd">-34000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTYtMi0xLTEtMTY3NjY1_52df4481-8401-4dd1-a0ad-c1ede1b76a14"
      unitRef="usd">4511000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTYtNC0xLTEtMTY3NjY1_c2c40645-e512-4aa0-b467-488fe2a7c10b"
      unitRef="usd">6368000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN183OS9mcmFnOmFmMzEzYWNiNDc2ODQ3YTJiNTAwZjJjMGZiNDdmOGJiL3RhYmxlOjNjZGI3MWJhMTY1MTRlMTk5ODAxZWIzODA0ZTE4MTBiL3RhYmxlcmFuZ2U6M2NkYjcxYmExNjUxNGUxOTk4MDFlYjM4MDRlMTgxMGJfMTYtNi0xLTEtMTY3NjY1_91dba5ef-1420-46b6-a62b-0560567f96ca"
      unitRef="usd">-22000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iff509ac6299d48d6b6117ee9f80eea96_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItMi0xLTEtMTY3NjY1_4a63bdfb-51b5-4092-b27c-651930662aa0"
      unitRef="shares">1266000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff509ac6299d48d6b6117ee9f80eea96_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItNC0xLTEtMTY3NjY1_2c349409-756c-4dbf-949c-bd7356a191d1"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabc34cf4f8374f479afced7f51e2c9fc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItNi0xLTEtMTY3NjY1_15ff5e98-dbe2-42b4-a5dc-6ff76f3fac6a"
      unitRef="usd">3051000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bc9d4063e094f24aa7047cc3f2ade07_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItOC0xLTEtMTY3NjY1_09404535-6bfb-4381-944d-8f9fe295bfa0"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea5153cc41ac4ad3909784ec5a03b75b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItMTAtMS0xLTE2NzY2NQ_f1b7df98-d769-4394-8db7-54810e0e845a"
      unitRef="usd">19388000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e8a156a2c184ca39b4834ed03243876_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItMTItMS0xLTE2NzY2NQ_b7152085-ca1f-4f28-8a9c-3d174f934100"
      unitRef="usd">125000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0142ebb7458d4ec68ef2fa3254d6e76a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTItMTQtMS0xLTE2NzY2NQ_baa79540-acb1-4fc0-b8ed-1dd4dbccf0a1"
      unitRef="usd">22650000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc446f587b564d3da2a7e92adf1f9212_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTMtMTAtMS0xLTE2NzY2NQ_b800f0c0-c69e-424c-b063-1c6ec610efdc"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i605eee38c1414b2ebe50ecfda6aa08a7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTMtMTQtMS0xLTE2NzY2NQ_6aa4a2cd-a282-418c-b5c4-5db8bd495852"
      unitRef="usd">-7000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i0c07a715073b4180a3d6350999b7c927_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTQtMTItMS0xLTE2NzY2NQ_fa13ac76-1d46-4f08-9113-ac0cc648f102"
      unitRef="usd">-72000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTQtMTQtMS0xLTE2NzY2NQ_f7a7f3a1-c219-4a35-b33e-d24a6116952d"
      unitRef="usd">-72000000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:ProfitLoss
      contextRef="i9014eaa8515b42f5bf4fc221a5754f36_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTUtMTAtMS0xLTE2NzY2NQ_0b1cea1a-4c56-42fa-a284-e89135fbadd5"
      unitRef="usd">123000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0c07a715073b4180a3d6350999b7c927_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTUtMTItMS0xLTE2NzY2NQ_8fb9076d-8562-44ed-9506-dd2dd0d9a26c"
      unitRef="usd">-34000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTUtMTQtMS0xLTE2NzY2NQ_b8807bcd-a5e3-42ab-9625-d0e6d39ec010"
      unitRef="usd">89000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia7d244df84ac4dea867eed31d805f681_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTYtNi0xLTEtMTY3NjY1_41087402-55b7-4637-9c22-067ded300200"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i93bdf1e4730740ab8d4b26eb38235e1d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTYtOC0xLTEtMTY3NjY1_935c702d-8bf1-485a-984c-78a5e71f8d86"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9014eaa8515b42f5bf4fc221a5754f36_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTYtMTAtMS0xLTE2NzY2NQ_3d806d74-4f9e-478d-8a66-57e4e6f9588d"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTYtMTQtMS0xLTE2NzY2NQ_12f09e8c-1537-45a6-8c02-727d65899351"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ia7182ed726234760880abd2d15fcf97b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTctMi0xLTEtMTY3NjY1_be417f7d-74ab-4725-93dc-3a09b7b9c358"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia7d244df84ac4dea867eed31d805f681_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTctNi0xLTEtMTY3NjY1_64424599-0850-40f5-a6c0-e01c59bc52ae"
      unitRef="usd">100000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTctMTQtMS0xLTE2NzY2NQ_b6ac10bc-029d-47fb-b8a0-e039beb92dff"
      unitRef="usd">100000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ia7182ed726234760880abd2d15fcf97b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTgtMi0xLTEtMTY3NjY1_04d01c1f-49ad-4f96-902f-1799e378d8c5"
      unitRef="shares">11000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia7d244df84ac4dea867eed31d805f681_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTgtNi0xLTEtMTY3NjY1_d651c8e3-2e66-4afe-b48f-c4faff560dd1"
      unitRef="usd">156000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTgtMTQtMS0xLTE2NzY2NQ_b84bf5eb-466d-4fd0-a570-ac0757ac501f"
      unitRef="usd">156000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia7d244df84ac4dea867eed31d805f681_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTktNi0xLTEtMTY3NjY1_39140019-0cfd-405c-a088-51e5ebdc6c68"
      unitRef="usd">642000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMTktMTQtMS0xLTE2NzY2NQ_d5ec6a6a-f1d2-4afb-a85a-41e6ee9857fc"
      unitRef="usd">642000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ia7182ed726234760880abd2d15fcf97b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjAtMi0xLTEtMTY3NjY1_05c63084-cddd-45a3-a6b6-65e1c9ee991d"
      unitRef="shares">25000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia7d244df84ac4dea867eed31d805f681_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjAtNi0xLTEtMTY3NjY1_0b367277-551d-4fe3-8246-9354625176e0"
      unitRef="usd">70000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i9014eaa8515b42f5bf4fc221a5754f36_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjAtMTAtMS0xLTE2NzY2NQ_4c10a64c-0bb3-4b4e-807a-396f5ae963de"
      unitRef="usd">1658000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjAtMTQtMS0xLTE2NzY2NQ_0298c5a8-71be-4c3b-8d95-c2059956e883"
      unitRef="usd">1728000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjEtMC0xLTEtMTY3NjY1L3RleHRyZWdpb246ZmFmNTc2ZmRmYTk5NDkzMjg0ZWFkNzg0MWMwYjQ4NDZfMTA5OTUxMTYyNzgxNA_3d8cfe1a-254e-43c7-bf8d-4d8058f85828"
      unitRef="usdPerShare">2.72</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i9014eaa8515b42f5bf4fc221a5754f36_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjEtMTAtMS0xLTE2NzY2NQ_dfab5c8f-58c0-4676-85a7-94b0563560b0"
      unitRef="usd">3464000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjEtMTQtMS0xLTE2NzY2NQ_3684e62b-bb59-4f5f-94dd-64fa0a20a87c"
      unitRef="usd">3464000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8646b81d562c4764b295900f43b19e19_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItMi0xLTEtMTY3NjY1_b999b4ec-d766-4a72-9cac-4f63138234d1"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8646b81d562c4764b295900f43b19e19_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItNC0xLTEtMTY3NjY1_a2be2e9f-b4d8-4117-b7d6-9aa975b8d460"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i991524b7050f435c8e75c4ffc5a934c7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItNi0xLTEtMTY3NjY1_3be82dc3-6f4d-4b40-aeb6-8b37b4460893"
      unitRef="usd">3880000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6f649babc4c4963a34bead50d8785d8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItOC0xLTEtMTY3NjY1_559d51b6-fcae-467f-a392-b2bfb8cf9f9c"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i091822ada63940bfbcb5532bd0807fc2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItMTAtMS0xLTE2NzY2NQ_05b14760-2629-4bc5-8240-c56953d2dbb0"
      unitRef="usd">14381000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i831d6d8c42f147b3af3fa768e1980ac4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItMTItMS0xLTE2NzY2NQ_d00b1144-59ea-4df9-887f-8b5fc6f10a5f"
      unitRef="usd">19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjItMTQtMS0xLTE2NzY2NQ_f28d5ce5-a62d-44b8-8ac1-881a386e3155"
      unitRef="usd">18221000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ia8570b5642fc41c3b275ef064cd4fc5e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjMtMTAtMS0xLTE2NzY2NQ_fe49a12e-8e7f-4b78-a704-0f02997d7136"
      unitRef="usd">6225000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic2bbd0596e084172b456bf6e816df644_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjMtMTItMS0xLTE2NzY2NQ_5fbc0859-3334-44c9-bf51-1072ce8b17fe"
      unitRef="usd">-24000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjMtMTQtMS0xLTE2NzY2NQ_44665e0f-37fe-4742-b702-d5c0184b6973"
      unitRef="usd">6201000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i31982067c8ba46ccba2062f655093c96_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjQtOC0xLTEtMTY3NjY1_9dc41a8b-168e-4a14-a452-36bfe0d6792a"
      unitRef="usd">143000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjQtMTQtMS0xLTE2NzY2NQ_3ab32888-40f5-41c1-afa8-3604585e0a51"
      unitRef="usd">143000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i21d65b154d20435bba2da402431f2156_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjUtMi0xLTEtMTY3NjY1_f3217dbd-9f36-49e8-9cc6-91e3735c4a17"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id41cdbe8321640c0bef3e78a54d341e4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjUtNi0xLTEtMTY3NjY1_2ea5573d-7485-466c-8aea-b30ba257f786"
      unitRef="usd">111000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjUtMTQtMS0xLTE2NzY2NQ_9fa426ad-ed4f-4e97-a9cb-76923c16af6f"
      unitRef="usd">111000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i21d65b154d20435bba2da402431f2156_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjYtMi0xLTEtMTY3NjY1_ec0a479f-2e41-41a6-a5f3-93a9099836cf"
      unitRef="shares">9000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id41cdbe8321640c0bef3e78a54d341e4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjYtNi0xLTEtMTY3NjY1_789fdf10-613f-4acf-8a18-9dc6c3f3cb1f"
      unitRef="usd">58000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjYtMTQtMS0xLTE2NzY2NQ_79d6a14b-297a-4f5b-ab25-c4ea2c786f6e"
      unitRef="usd">58000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id41cdbe8321640c0bef3e78a54d341e4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjctNi0xLTEtMTY3NjY1_26abff26-3d56-4b50-bc13-dfe4a7761b6a"
      unitRef="usd">640000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjctMTQtMS0xLTE2NzY2NQ_b3b3aba4-57d3-4358-a770-6f5b0e166805"
      unitRef="usd">640000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i21d65b154d20435bba2da402431f2156_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjgtMi0xLTEtMTY3NjY1_b1441e6e-3fed-4f81-b08e-e0709b956e0c"
      unitRef="shares">11000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id41cdbe8321640c0bef3e78a54d341e4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjgtNi0xLTEtMTY3NjY1_84925146-c9d6-4250-8437-39f5281e20a2"
      unitRef="usd">28000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia8570b5642fc41c3b275ef064cd4fc5e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjgtMTAtMS0xLTE2NzY2NQ_b3c4b2e3-59ca-4762-92c8-c5455838df87"
      unitRef="usd">664000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjgtMTQtMS0xLTE2NzY2NQ_c4cce1ae-8aeb-43a3-8499-e225835caad6"
      unitRef="usd">692000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjktMC0xLTEtMTY3NjY1L3RleHRyZWdpb246YTVlMzEyMzVhMWU5NGRiZWIzODMxYjMzYTRkYmNmMWJfMTA5OTUxMTYyNzgxNA_1d1b17ae-cfc1-4d8c-afeb-f8406a3e132f"
      unitRef="usdPerShare">2.84</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="ia8570b5642fc41c3b275ef064cd4fc5e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjktMTAtMS0xLTE2NzY2NQ_eadff01c-3406-41ed-8158-a6e71b97cd3c"
      unitRef="usd">3618000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMjktMTQtMS0xLTE2NzY2NQ_3b518bc7-e430-49aa-9db8-fd66b01b5139"
      unitRef="usd">3618000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4f2b6090dbb84a0da94eda0da3c2c7e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtMi0xLTEtMTY3NjY1_89723d0f-6d06-446a-be75-d2d1f7e94b17"
      unitRef="shares">1254000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f2b6090dbb84a0da94eda0da3c2c7e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtNC0xLTEtMTY3NjY1_f2bf2bdf-f0ce-4ca8-9922-4c59ff61a160"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3255734b4164a248d1ae872f85437e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtNi0xLTEtMTY3NjY1_aa381910-ecb0-43d3-8765-0e019da0a5e2"
      unitRef="usd">4661000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33c6e110f0a74581baf5ef42159e7423_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtOC0xLTEtMTY3NjY1_ba89c354-857a-4d99-9428-7de000a80c5d"
      unitRef="usd">83000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i309e1278bed34922b7275c62cf3b74a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtMTAtMS0xLTE2NzY2NQ_2f286c4d-f0da-4faa-81c9-1795bd890749"
      unitRef="usd">16324000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e9c39969dfb47c9bad7061e5500bbb8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtMTItMS0xLTE2NzY2NQ_41d290ab-d167-49e0-8bad-b035dd7cb2cd"
      unitRef="usd">-5000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzAtMTQtMS0xLTE2NzY2NQ_33b9ee67-ae1c-4946-854f-f7dd8726dda0"
      unitRef="usd">21064000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0f97bc74e5b74cff8c8def5c5e9058ce_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzEtMTAtMS0xLTIwMjg4Nw_239d3da8-2c63-4552-b986-0ea7da4d0e94"
      unitRef="usd">4592000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a2c49aec7474f71b15b7ba23892c798_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzEtMTItMS0xLTIwMjg4Nw_90c86757-35eb-4ce5-ae87-5a55c978a79f"
      unitRef="usd">-26000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzEtMTQtMS0xLTIwMjg4Nw_50f97b2a-1518-4448-8a04-23c25963705d"
      unitRef="usd">4566000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i07be39de877c4dec919659b89dc15370_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzItOC0xLTEtMjAyODg3_948bcc4e-99f1-4ad9-9d56-9df0f373d0b5"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzItMTQtMS0xLTIwMjg4Nw_0901eb06-ad60-46fb-bbe0-084360a3207f"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ided187f87ec24a75b5f0f28661776608_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzMtMi0xLTEtMjAyODg3_e09d0ee3-53b2-44a9-a851-1b6a6130853a"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib24a5c6406f94acbab0fa346fc44c96d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzMtNi0xLTEtMjAyODg3_f5a6ae3f-e1d1-414d-9978-cf32bda1dc0a"
      unitRef="usd">103000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzMtMTQtMS0xLTIwMjg4Nw_90234629-7766-4926-b2c9-34e8c0511efe"
      unitRef="usd">103000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ided187f87ec24a75b5f0f28661776608_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzQtMi0xLTEtMjAyODg3_ae7e231d-cb0f-4f49-9ce9-4d5775686d96"
      unitRef="shares">13000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib24a5c6406f94acbab0fa346fc44c96d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzQtNi0xLTEtMjAyODg3_de20b6c6-03ab-4cf0-8cf3-2b6e8ce06760"
      unitRef="usd">211000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzQtMTQtMS0xLTIwMjg4Nw_48a26716-d230-4017-a83a-df8bdb2d608f"
      unitRef="usd">211000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib24a5c6406f94acbab0fa346fc44c96d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzUtNi0xLTEtMjAyODg3_f3deaae0-a708-4f27-97ae-d56f61d532b5"
      unitRef="usd">640000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzUtMTQtMS0xLTIwMjg4Nw_e5ff38d9-ba23-4ead-9e37-36e646d0fb0f"
      unitRef="usd">640000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ided187f87ec24a75b5f0f28661776608_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzYtMi0xLTEtMjAyODg3_b509f5ff-8922-4281-b9dd-5972f447ae7b"
      unitRef="shares">22000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib24a5c6406f94acbab0fa346fc44c96d_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzYtNi0xLTEtMjAyODg3_daa021bb-0550-496a-b52f-3d23b509115a"
      unitRef="usd">65000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i0f97bc74e5b74cff8c8def5c5e9058ce_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzYtMTAtMS0xLTIwMjg4Nw_59409f20-2d60-460f-a0db-52a60c1515e7"
      unitRef="usd">1504000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzYtMTQtMS0xLTIwMjg4Nw_73eb0a3b-7c17-4852-a213-07a04eef669b"
      unitRef="usd">1569000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzctMC0xLTEtMjAyODc3L3RleHRyZWdpb246ZmIyM2M5YTQxNzAyNDZhM2EzMzVkYjc2YmUxMmE5OGNfMTA5OTUxMTYyNzgyMQ_c0909df2-8a08-4d3a-924e-4674c6a21545"
      unitRef="usdPerShare">2.92</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends
      contextRef="i0f97bc74e5b74cff8c8def5c5e9058ce_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzctMTAtMS0xLTIwMjg4Nw_4844e8ae-3e4f-4f6e-9cca-a15549debc9a"
      unitRef="usd">3725000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzctMTQtMS0xLTIwMjg4Nw_f91a9240-6643-47df-8420-789407943127"
      unitRef="usd">3725000000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i22bb6ac875f8426a9e185ea79d9ed340_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtMi0xLTEtMjAyODg3_190d5c11-6069-489c-b627-00f764302f7b"
      unitRef="shares">1247000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22bb6ac875f8426a9e185ea79d9ed340_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtNC0xLTEtMjAyODg3_2e045493-a900-4e31-b13a-a796a7948bbb"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c9fd7dab9954496aabbca76c556ef25_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtNi0xLTEtMjAyODg3_29b2b5a0-22a1-4429-ba9b-bc0af29d8d87"
      unitRef="usd">5550000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic35cf517e1c44e6cb7eb51a11bc60ba9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtOC0xLTEtMjAyODg3_edb4c1d9-29d4-48c5-9264-9299744226c6"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if58ddd7e8b04461b92ae526d7f69766b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtMTAtMS0xLTIwMjg4Nw_eb534f5f-f2c7-48fa-9473-dd67356d668f"
      unitRef="usd">15687000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7cff17f8e033479dbe6df66c5418db1d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtMTItMS0xLTIwMjg4Nw_36c66ae0-940d-4858-abbc-bf137562078e"
      unitRef="usd">-31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184Mi9mcmFnOmJlNzQ2NTE2MWZjNzRmMjM5NDM2ODNmYzllYzQyOTgyL3RhYmxlOjE3ZmZjN2EwOTZkYzQwNmY5NmRmZWViZDdlNjBhNGNlL3RhYmxlcmFuZ2U6MTdmZmM3YTA5NmRjNDA2Zjk2ZGZlZWJkN2U2MGE0Y2VfMzgtMTQtMS0xLTIwMjg4Nw_c447e2ea-5674-4af1-9d23-a0fe3ae85b45"
      unitRef="usd">21209000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMy0yLTEtMS0xNjc2NjU_c740fe9f-facf-46c4-945f-a9d8b12b815d"
      unitRef="usd">4566000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMy00LTEtMS0xNjc2NjU_2e7e5d80-bd45-42dc-9d1d-122b882d76bf"
      unitRef="usd">6201000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMy02LTEtMS0xNjc2NjU_9f172a08-d204-439b-ba87-aafdb7a2a1e8"
      unitRef="usd">89000000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNS0yLTEtMS0xNjc2NjU_3477a2b8-8946-446b-acf2-88e4652f1e3e"
      unitRef="usd">323000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNS00LTEtMS0xNjc2NjU_9d6a0c8d-e6aa-4e82-a51a-3809631d5987"
      unitRef="usd">329000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNS02LTEtMS0xNjc2NjU_bea3c194-8c22-4b6e-bf2c-3f9acec3c67f"
      unitRef="usd">288000000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNi0yLTEtMS0xNjc2NjU_98717d8f-a274-427d-bc39-fd6a1989fbda"
      unitRef="usd">1780000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNi00LTEtMS0xNjc2NjU_3c00e29a-16cb-47f4-bfde-0a6442a820e0"
      unitRef="usd">1721000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNi02LTEtMS0xNjc2NjU_9dcaa3f7-5d6c-484a-be91-39ac8e4cbac2"
      unitRef="usd">1192000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNy0yLTEtMS0xNjc2NjU_faebf387-2cb7-4d9c-9f09-4ac4d494af88"
      unitRef="usd">637000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNy00LTEtMS0xNjc2NjU_29cfebaf-9bc5-4390-8313-4aa396998bc9"
      unitRef="usd">635000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNy02LTEtMS0xNjc2NjU_3d9dfcfc-e108-49dc-be22-3e271118d5c8"
      unitRef="usd">643000000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfOC0yLTEtMS0xNjc2NjU_88129b29-5727-4e52-9838-a7d55107acbe"
      unitRef="usd">-1552000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfOC00LTEtMS0xNjc2NjU_38ccbe62-db3c-4eb6-a3d7-42af2101ef57"
      unitRef="usd">-116000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfOC02LTEtMS0xNjc2NjU_013df50a-4e87-45a9-93a1-096cb90c1e85"
      unitRef="usd">-214000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfOS0yLTEtMS0xNjc2NjU_c21e380a-b68d-4709-b137-1025f2f654f8"
      unitRef="usd">-657000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfOS00LTEtMS0xNjc2NjU_f04ef4c8-d88f-4253-8c6e-4459bb9e261a"
      unitRef="usd">-610000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfOS02LTEtMS0xNjc2NjU_1b6d5d0f-dace-487c-825d-ee05f3a799a4"
      unitRef="usd">-1662000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTAtMi0xLTEtMTY3NjY1_a0833547-2c39-46bc-a692-da77c550199a"
      unitRef="usd">944000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTAtNC0xLTEtMTY3NjY1_8c1a2f56-2858-44f6-934f-40b51bb79d64"
      unitRef="usd">939000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTAtNi0xLTEtMTY3NjY1_0280b38b-5526-42ec-8a51-349099d653bc"
      unitRef="usd">5968000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTEtMi0xLTEtMTY3NjY1_c6134ae6-eb7a-400d-8d74-bc644a8bc13b"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTEtNC0xLTEtMTY3NjY1_d2da1e6f-a84f-45e6-8a22-68c97682f83c"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTEtNi0xLTEtMTY3NjY1_acbf7034-5720-4c06-af7a-2c62ad6cb298"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTMtMi0xLTEtMTY3NjY1_c1a37393-b8f6-47f2-a7b6-9fa74f5a6b71"
      unitRef="usd">-780000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTMtNC0xLTEtMTY3NjY1_f7c9dd06-e3a2-46df-8a87-7ab3bce80f0b"
      unitRef="usd">-576000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTMtNi0xLTEtMTY3NjY1_c486c075-683e-4794-b5b6-4a6c25b20f0d"
      unitRef="usd">-178000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTUtMi0xLTEtMTY3NjY1_b023be84-3548-42aa-9c22-d901f1aada42"
      unitRef="usd">406000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTUtNC0xLTEtMTY3NjY1_0c45255b-b353-42be-b716-691445f3c9ce"
      unitRef="usd">-313000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTUtNi0xLTEtMTY3NjY1_c2be6521-d1d7-4a52-9c87-dd4f55032be3"
      unitRef="usd">1171000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTYtMi0xLTEtMTY3NjY1_80b2dd89-6ee5-4aa9-a308-663e5667d87f"
      unitRef="usd">310000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTYtNC0xLTEtMTY3NjY1_fcbdcfba-01ca-486c-953c-228bfb77f147"
      unitRef="usd">-11000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTYtNi0xLTEtMTY3NjY1_530cc50c-958b-4fac-89d8-a40e3ea964c1"
      unitRef="usd">195000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTctMi0xLTEtMTY3NjY1_6d3a1e0a-8dcd-4b6c-8dc7-5d10fc0bc505"
      unitRef="usd">-70000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTctNC0xLTEtMTY3NjY1_9d0978cf-19f8-4209-bdcb-2682d029a37b"
      unitRef="usd">42000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTctNi0xLTEtMTY3NjY1_ae64263b-c816-4a99-9bbe-eaea26f0a945"
      unitRef="usd">214000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTgtMi0xLTEtMTY3NjY1_987e98bd-f2a9-47f1-9386-1850c2e370f3"
      unitRef="usd">226000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTgtNC0xLTEtMTY3NjY1_ae273035-60eb-4764-a588-76a3962060d8"
      unitRef="usd">-118000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTgtNi0xLTEtMTY3NjY1_3f2e9e7e-8d66-459a-b1be-ca04c1987fd2"
      unitRef="usd">80000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTktMi0xLTEtMTY3NjY1_d3bda90c-152d-4b8b-9ed4-6f31be362d6f"
      unitRef="usd">-568000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTktNC0xLTEtMTY3NjY1_295fde34-210f-4df1-8367-298190614218"
      unitRef="usd">-364000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMTktNi0xLTEtMTY3NjY1_a29431db-969c-4594-a8e6-f412a73dd142"
      unitRef="usd">-778000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjAtMi0xLTEtMTY3NjY1_9dbfd2c8-712f-48aa-b336-a144754da786"
      unitRef="usd">-775000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjAtNC0xLTEtMTY3NjY1_20b86392-2357-4e38-a8ff-4c36e8d649ba"
      unitRef="usd">689000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjAtNi0xLTEtMTY3NjY1_05b3b877-f7d1-42c2-8fe7-62f6c7813aa9"
      unitRef="usd">640000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjEtMi0xLTEtMTY3NjY1_29d9fbf6-7280-4544-9903-20ed86873ca8"
      unitRef="usd">9072000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjEtNC0xLTEtMTY3NjY1_fbc9bfd2-f69c-4eaf-a420-b64b312706c4"
      unitRef="usd">11384000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjEtNi0xLTEtMTY3NjY1_9ab69aa2-0dac-4d11-8717-a4fad2ea8779"
      unitRef="usd">8168000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjQtMi0xLTEtMTY3NjY1_5132eca6-a061-4ef2-b968-ef94c3b474be"
      unitRef="usd">1770000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjQtNC0xLTEtMTY3NjY1_edba330a-a319-46ca-9436-b6792f999b61"
      unitRef="usd">3517000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjQtNi0xLTEtMTY3NjY1_526d511c-2c0e-4ab8-8a54-7bfa817c9915"
      unitRef="usd">20315000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjUtMi0xLTEtMTY3NjY1_d47a29ff-5f8c-4216-87e8-123ca324f894"
      unitRef="usd">412000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjUtNC0xLTEtMTY3NjY1_c96f57cb-1f55-45f1-82ee-c88986ff3a91"
      unitRef="usd">730000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjUtNi0xLTEtMTY3NjY1_2cbadd41-c1d8-4e7f-b634-fd5219504530"
      unitRef="usd">23239000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjYtMi0xLTEtMTY3NjY1_eaa2c8fd-4bed-483c-af27-5b9cd004709e"
      unitRef="usd">1590000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjYtNC0xLTEtMTY3NjY1_c5be48d9-0d0e-4e0d-a34d-9003d41c36ce"
      unitRef="usd">2180000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjYtNi0xLTEtMTY3NjY1_1a14662b-8c4d-40db-b6c2-8c6b95d80c22"
      unitRef="usd">9479000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjctMi0xLTEtMTY3NjY1_517dba3b-1448-4ebb-a5ca-3cbcc22b1f9b"
      unitRef="usd">1797000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjctNC0xLTEtMTY3NjY1_ce7a357b-52ed-42c8-9c61-d3f64edaa791"
      unitRef="usd">1584000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjctNi0xLTEtMTY3NjY1_ce3916b8-64a9-45de-9b04-217a2b81569d"
      unitRef="usd">25920000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjgtMi0xLTEtMTY3NjY1_47284684-c11a-4a50-ab8f-6deee5459657"
      unitRef="usd">172000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjgtNC0xLTEtMTY3NjY1_39f2a576-9fbe-49b5-a567-f34935ccc4f8"
      unitRef="usd">380000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjgtNi0xLTEtMTY3NjY1_e7f1306c-3faf-4177-bd3e-207bba879ded"
      unitRef="usd">455000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjktMi0xLTEtMTY3NjY1_000e83b8-2d08-4857-8fde-7cc1a60765c7"
      unitRef="usd">728000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjktNC0xLTEtMTY3NjY1_8d014499-34b2-499f-8315-fc294bdc174e"
      unitRef="usd">579000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMjktNi0xLTEtMTY3NjY1_33eb5420-5156-48d6-874f-ec603b940c17"
      unitRef="usd">650000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzAtMi0xLTEtMTY3NjY1_2e9ba2a1-a76e-43ca-8866-48812b0d7548"
      unitRef="usd">1000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzAtNC0xLTEtMTY3NjY1_808c78b6-fbd1-4f0d-bcdd-af30b73e5978"
      unitRef="usd">-19000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzAtNi0xLTEtMTY3NjY1_e6d4170a-8cb2-451a-b89a-4c21458f66ef"
      unitRef="usd">-7000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzEtMi0xLTEtMTY3NjY1_68f68c72-bdf5-47df-859a-ef96ea6ce214"
      unitRef="usd">-2466000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzEtNC0xLTEtMTY3NjY1_c3ce40e5-6606-4286-8039-f0af9ad67ff2"
      unitRef="usd">-3131000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzEtNi0xLTEtMTY3NjY1_4e748026-10bb-4e22-be0d-90bf14a37e6c"
      unitRef="usd">-14615000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzQtMi0xLTEtMTY3NjY1_499eb82f-f903-4583-b1d1-6a83386c810a"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzQtNC0xLTEtMTY3NjY1_5809c445-52ce-4953-ab53-07e7032da5dc"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzQtNi0xLTEtMTY3NjY1_2ec15fec-0df6-468a-8632-9b2a302ec4df"
      unitRef="usd">8184000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzUtMi0xLTEtMTY3NjY1_0e731e0d-bd42-4f92-bbdf-2b103c39c54f"
      unitRef="usd">309000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzUtNC0xLTEtMTY3NjY1_ca9c5da2-d5a2-49d9-aa34-b2df62f47710"
      unitRef="usd">169000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzUtNi0xLTEtMTY3NjY1_25d362c6-77aa-4b9a-a808-bcb9bc7c89a9"
      unitRef="usd">256000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzYtMi0xLTEtMTY3NjY1_28c0a3fd-336d-47f8-a5dd-24cc27ebc781"
      unitRef="usd">1396000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzYtNC0xLTEtMTY3NjY1_5f71e82f-3dae-4017-97ae-34596a8cff99"
      unitRef="usd">546000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzYtNi0xLTEtMTY3NjY1_b20ae7b3-378e-454c-80ce-37f1a6a6a09a"
      unitRef="usd">1583000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfDebt
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzctMi0xLTEtMTY3NjY1_f4ff3cd8-0bca-4e05-a1b9-da56c261b2fc"
      unitRef="usd">1500000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzctNC0xLTEtMTY3NjY1_646a88dc-3dc6-40b6-ab52-bfef77c172db"
      unitRef="usd">4750000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzctNi0xLTEtMTY3NjY1_8396b8e9-9188-45d0-af6f-0d3ca029b846"
      unitRef="usd">2500000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfDividends
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzgtMi0xLTEtMTY3NjY1_309b8ab3-9339-4661-9685-75418b83cf29"
      unitRef="usd">3709000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzgtNC0xLTEtMTY3NjY1_6143a52e-08d5-499f-b9e0-23e1c5b0a8fe"
      unitRef="usd">3605000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzgtNi0xLTEtMTY3NjY1_1617f13d-b297-40b3-81d0-3f9185acacc7"
      unitRef="usd">3449000000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzktMi0xLTEtMTY3NjY1_bda7914a-49fe-4acb-9006-f7b540cc62b3"
      unitRef="usd">-173000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzktNC0xLTEtMTY3NjY1_aad8281a-0adf-445b-b41d-189dbad21f61"
      unitRef="usd">-145000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfMzktNi0xLTEtMTY3NjY1_4f1f3688-1b5e-47e3-9db2-6530181da6c4"
      unitRef="usd">-138000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDAtMi0xLTEtMTY3NjY1_4a28eb6e-64ad-4571-8ec2-0fe17e6e983d"
      unitRef="usd">-6469000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDAtNC0xLTEtMTY3NjY1_a4bc3dbd-5834-475d-b0be-dcd4a13c8a05"
      unitRef="usd">-8877000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDAtNi0xLTEtMTY3NjY1_56118792-2f76-4828-a1bf-997158c910fd"
      unitRef="usd">770000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDEtMi0xLTEtMTY3NjY1_13141be0-1dc8-48c7-b83b-3a35ebd7afdf"
      unitRef="usd">-63000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDEtNC0xLTEtMTY3NjY1_c517aac6-7fb5-4e2d-b60f-24cf0b00e777"
      unitRef="usd">-35000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDEtNi0xLTEtMTY3NjY1_9b1e7bab-5aef-470c-b90a-833177079cec"
      unitRef="usd">43000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDItMi0xLTEtMTY3NjY1_5e9e6d8c-8a3b-42f8-a27a-fe0ac9aba8e9"
      unitRef="usd">74000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDItNC0xLTEtMTY3NjY1_065d80f5-f4de-43c5-b6be-3b9053e63815"
      unitRef="usd">-659000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDItNi0xLTEtMTY3NjY1_07fc8b1e-30ee-4983-adc4-1e6cc640f96f"
      unitRef="usd">-5634000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDMtMi0xLTEtMTY3NjY1_ba403584-78b7-435c-8344-85a2828f05c1"
      unitRef="usd">5338000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDMtNC0xLTEtMTY3NjY1_90a0cf18-54f3-4ca0-a9af-b2186dec5a0c"
      unitRef="usd">5997000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0142ebb7458d4ec68ef2fa3254d6e76a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDMtNi0xLTEtMTY3NjY1_5541d488-a505-4e8b-ac74-9c560b4ce3a5"
      unitRef="usd">11631000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDQtMi0xLTEtMTY3NjY1_563fc159-b22d-4817-91e7-566a1fd4e7c9"
      unitRef="usd">5412000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDQtNC0xLTEtMTY3NjY1_ba403584-78b7-435c-8344-85a2828f05c1"
      unitRef="usd">5338000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDQtNi0xLTEtMTY3NjY1_59427aea-8126-4b7e-9c72-668b355abde0"
      unitRef="usd">5997000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDctMi0xLTEtMTY3NjY1_5033df35-c438-4033-a9a3-10522b31269f"
      unitRef="usd">907000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDctNC0xLTEtMTY3NjY1_ab833712-14c6-4e1d-8950-6f366cafb7b1"
      unitRef="usd">979000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDctNi0xLTEtMTY3NjY1_5f1f6a17-2651-427a-850c-9a84ef618fce"
      unitRef="usd">951000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDgtMi0xLTEtMTY3NjY1_51a4864a-65ba-4ad6-b398-76cfacbb3995"
      unitRef="usd">3136000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDgtNC0xLTEtMTY3NjY1_2adf4f60-df28-4103-b59d-d4da38a3e928"
      unitRef="usd">2509000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN184NS9mcmFnOjk3OGNjYjM3YzYxNzQzY2Q4NGM1Njg0ZDI4OTFiZDJlL3RhYmxlOmM2ZThlNzYwODZkZTQyODdhZDI5N2I5NDZlYTdlZDQ5L3RhYmxlcmFuZ2U6YzZlOGU3NjA4NmRlNDI4N2FkMjk3Yjk0NmVhN2VkNDlfNDgtNi0xLTEtMTY3NjY1_b718d35f-6d24-4c79-87c2-33bd4531dbe6"
      unitRef="usd">2639000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzODY_0fa02eb1-5fbd-44cc-95bc-e581c445472b">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead Sciences, Inc. (&#x201c;Gilead,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; or &#x201c;us&#x201d;) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of marketed products includes AmBisome&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Atripla&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Biktarvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Cayston&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Complera&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Descovy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Descovy for PrEP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Emtriva&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Epclusa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Eviplera&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Genvoya&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Harvoni&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Hepcludex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Hepsera&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Jyseleca&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Letairis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Odefsey&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Ranexa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Sovaldi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Stribild&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Sunlenca&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Tecartus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Trodelvy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Truvada&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Truvada for PrEP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Tybost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Veklury&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Vemlidy&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Viread&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Vosevi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Yescarta&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Zydelig&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The approval status of Hepcludex and Jyseleca vary worldwide, and Hepcludex and Jyseleca are not approved in the U.S. We also sell and distribute authorized generic versions of Epclusa and Harvoni in the U.S. through our separate subsidiary, Asegua Therapeutics, LLC. In addition, we sell and distribute certain products through our corporate partners under collaborative agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one operating segment which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. Our Chief Executive Officer, as the chief operating decision-maker (&#x201c;CODM&#x201d;), manages and allocates resources to the operations of our company on an entity-wide basis. Managing and allocating resources on an entity-wide basis enables our CODM to assess the overall level of resources available and how to best deploy these resources across functions and research and development (&#x201c;R&amp;amp;D&#x201d;) projects based on unmet medical need, scientific data, probability of technical and regulatory successful development, market potential and other considerations, and, as necessary, reallocate resources among our internal R&amp;amp;D portfolio and external opportunities to best support the long-term growth of our business. See Note 2. Revenues for a summary of disaggregated revenues by product and geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles and include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities (&#x201c;VIEs&#x201d;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates. Certain amounts and percentages herein may not sum or recalculate due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the second quarter of 2022, expenses related to development milestones and other collaboration payments made prior to regulatory approval of a developed product were reclassified from Research and development expenses to Acquired in-process research and development expenses on our Consolidated Statements of Income. Concurrently, we reclassified the cash payments related to these expenses from Other to Acquisitions, including in-process research and development, net of cash acquired within Investing Activities in the Consolidated Statements of Cash Flows. We believe this presentation assists users of the financial statements to better understand the total costs incurred to acquire in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects. Prior periods have been revised to reflect this classification, resulting in a reduction of previously-reported Research and development expenses of $762 million and $112 million for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from product sales when control of the product transfers to the customer, which is generally upon shipment or delivery, or in certain cases, upon the corresponding sales by our customer to a third party. Revenues are recognized net of estimated rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a financing component. Shipping and handling activities are considered to be fulfillment activities and not a separate performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Gross-to-Net Deductions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates and chargebacks are based on contractual arrangements or statutory requirements and include amounts due to payers and healthcare providers under various programs. These amounts may vary by product, payer and individual plans. Providers qualified under certain programs can purchase our products through wholesalers or other distributors at a discount. The wholesalers or distributors then charge the discount back to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates and chargebacks are estimated primarily based on product sales, including product mix and pricing, historical and estimated payer mix and discount rates, among other inputs, which require significant estimates and judgment. We assess and update our estimates each reporting period to reflect actual claims and other current information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Rebates that are payable to third party payers and healthcare providers are recorded in Accrued rebates on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distributor Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually-determined covenants such as the maintenance of agreed-upon inventory levels. These distributor fees are based on a contractually-determined fixed percentage of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allowance for Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the U.S., we typically permit returns six months prior to and up to one year after the product expiration date. Outside the U.S., returns are only allowed in certain countries on a limited basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Royalty, Contract and Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur. Contract and other revenues are recognized when the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are recorded when incurred and consist primarily of clinical studies performed by contract research organizations (&#x201c;CROs&#x201d;), materials and supplies, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations consisting of various support and infrastructure costs. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of Research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical study costs are a significant component of Research and development expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for R&amp;amp;D services prior to the services being rendered are recorded as prepaid assets within Prepaid and other current assets on our Consolidated Balance Sheets and are expensed as the services are provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquired In-Process Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired in-process research and development expenses are recorded when incurred and reflect costs of externally-developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront and milestone payments related to various collaborations and the costs of rights to IPR&amp;amp;D projects. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses are recorded when incurred and consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs related to sales and marketing, finance, human resources, legal and other administrative activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising expenses within Selling, general and administrative expenses, including promotional expenses, are recorded when incurred and were $778 million, $735 million and $795 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide stock-based compensation in the form of various types of equity-based awards, including restricted stock units (&#x201c;RSUs&#x201d;), performance share units (&#x201c;PSUs&#x201d;) and stock options, and through our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the &#x201c;ESPP&#x201d;). Stock-based compensation expense is based on the estimated fair value of the award on the grant date, or the first date of the ESPP purchase period, and recognized over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible or if an employee terminates due to death or disability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of RSUs is based on the closing price of our common stock on the grant date. For PSUs, depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. For stock option and ESPP awards, estimated fair value is based on the Black-Scholes option valuation model. Estimated inputs to that model include (i) expected volatility, based on a blend of historical volatility of our common stock price along with implied volatility for traded options on our common stock, (ii) expected term in years, based on the weighted-average period awards are expected to remain outstanding using historical cancellation and exercise data, contractual terms and vesting terms of the award, (iii) risk-free interest rate, based on observed interest rates appropriate for the term of the stock-based awards, and (iv) expected dividend yield, based on our history and expectation of dividend payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock outstanding during the period. Diluted earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents are determined under the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our marketable debt securities are classified as available-for-sale and carried at estimated fair values. We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. Unrealized gains and losses on available-for-sale debt securities are reported in Accumulated other comprehensive income on our Consolidated Balance Sheets until realized, at which point they are reclassified into Other income (expense), net on our Consolidated Statements of Income. Interest, amortization of purchase premiums and discounts, and expected credit losses, if any, are also recorded in Other income (expense), net on our Consolidated Statements of Income. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost bases. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in Accumulated other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and estimated credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities with readily determinable fair values, including those for which we have elected the fair value option, are recorded at fair market value, and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Any impairments or adjustments are recorded in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting, with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in equity securities are classified in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets, generally depending on marketability and whether the securities are subject to lock-up provisions. We regularly review our securities for indicators of impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;35 years or useful&#160;life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;useful&#160;life or lease&#160;term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;Impairment of Long-Lived Assets&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement contains a lease at inception and classify each lease as operating or financing. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions, including Goodwill, Intangible Assets and Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period, which may be up to one year from the acquisition date, with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the abandonment or completion of the associated R&amp;amp;D efforts, which generally occurs when regulatory approval is obtained. Goodwill and indefinite-lived intangible assets are not amortized and, instead, are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and, are also periodically reviewed for changes in facts or circumstances resulting in a reduction to the estimated useful life of the asset, requiring the acceleration of amortization. See &#x201c;Impairment of Long-Lived Assets&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the initial fair value of an intangible asset, or when quantitative analysis is required to determine any impairment, we use a probability-weighted income approach that discounts expected future cash flows to present value using a discount rate that is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. These cash flow models require the use of Level 3 fair value measurements and inputs, including estimated revenues, which, for example, include significant inputs such as addressable patient population, treatment duration, projected market share, assessment of the asset&#x2019;s life cycle, and competitive trends impacting the asset; costs and probability of technical and regulatory success, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value on our Consolidated Statements of Income until such time that the payment is made. Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and, therefore, no goodwill is recorded and contingent consideration generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are expensed as incurred on our Consolidated Statements of Income unless there is an alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset over its useful life to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Unrealized changes in the fair value of derivatives designated as part of a hedge transaction are recorded in Accumulated other comprehensive income. For our hedges related to forecasted product sales, the unrealized gains or losses in Accumulated other comprehensive income are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Using regression analysis, we assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize accruals for loss contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue the best estimate of loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax provision is computed under the liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance to reduce our deferred tax assets to the amounts that are more likely than not to be realized. We consider future taxable income, ongoing tax planning strategies and our historical financial performance in assessing the need for a valuation allowance. If we expect to realize deferred tax assets for which we have previously recorded a valuation allowance, we will reduce the valuation allowance in the period in which such determination is first made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (&#x201c;UTB&#x201d;) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax expense on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to account for the tax on Global Intangible Low-Taxed Income, enacted as part of the Tax Cuts and Jobs Act, as a component of tax expense in the period in which the tax is incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Consolidated Financial Statements are presented in U.S. dollars. The functional currency for most of our foreign subsidiaries is their local currency. Revenues, expenses, gains and losses for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities for such entities are translated using exchange rates that approximate the rate at the balance sheet date. Foreign currency translation adjustments are recorded as a component of Accumulated other comprehensive income on our Consolidated Balance Sheets. Foreign currency transaction gains and losses on transactions not denominated in functional currency are recorded in Other income (expense), net, on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply fair value accounting for all financial and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt"&gt;Level 1 inputs include quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt"&gt;Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt"&gt;Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTY0OTI2NzUzODIzMQ_b4376237-919e-4d70-a61e-8f331f1cc791"
      unitRef="country">35</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTA5OTUxMTcyNDMxNg_fd7a58ed-cf6e-4890-8cd5-960253a0ec1c"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE1MDU_60e460d1-e676-403c-bc37-57900bc821b3">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles and include the accounts of Gilead, our wholly-owned subsidiaries and certain variable interest entities (&#x201c;VIEs&#x201d;) for which we are the primary beneficiary. All intercompany transactions have been eliminated. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income or loss attributable to noncontrolling interests in our Consolidated Statements of Income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these Consolidated Financial Statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant accounting policies and estimates. We base our estimates on historical experience and on various market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Actual results may differ significantly from these estimates. Certain amounts and percentages herein may not sum or recalculate due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the second quarter of 2022, expenses related to development milestones and other collaboration payments made prior to regulatory approval of a developed product were reclassified from Research and development expenses to Acquired in-process research and development expenses on our Consolidated Statements of Income. Concurrently, we reclassified the cash payments related to these expenses from Other to Acquisitions, including in-process research and development, net of cash acquired within Investing Activities in the Consolidated Statements of Cash Flows. We believe this presentation assists users of the financial statements to better understand the total costs incurred to acquire in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects. Prior periods have been revised to reflect this classification, resulting in a reduction of previously-reported Research and development expenses of $762 million and $112 million for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i1aa84a6eecd341f092eaee39012ec26a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTA5OTUxMTY3NTI5Ng_815322e4-8d07-4a57-bdc6-2a09f60da762"
      unitRef="usd">-762000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic2269762347243d582b0adac2360f5d2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTA5OTUxMTY3NTMxMQ_501b0be8-a4cd-49f5-9088-d90059bb0d2c"
      unitRef="usd">-112000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0MDQ_244e003d-d349-4836-981c-74068c1e24cc">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue from product sales when control of the product transfers to the customer, which is generally upon shipment or delivery, or in certain cases, upon the corresponding sales by our customer to a third party. Revenues are recognized net of estimated rebates and chargebacks, cash discounts for prompt payment, distributor fees, sales return provisions and other related deductions. These deductions to product sales are referred to as gross-to-net deductions and are estimated and recorded in the period in which the related product sales occur. Our payment terms to customers generally range from 30 to 90 days; however, payment terms differ by jurisdiction, by customer and, in some instances, by type of product. Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Taxes assessed by governmental authorities and collected from customers are excluded from product sales. If we expect, at contract inception, that the period between the transfer of control and corresponding payment from the customer will be one year or less, we do not adjust the amount of consideration for the effects of a financing component. Shipping and handling activities are considered to be fulfillment activities and not a separate performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Gross-to-Net Deductions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates and chargebacks are based on contractual arrangements or statutory requirements and include amounts due to payers and healthcare providers under various programs. These amounts may vary by product, payer and individual plans. Providers qualified under certain programs can purchase our products through wholesalers or other distributors at a discount. The wholesalers or distributors then charge the discount back to us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates and chargebacks are estimated primarily based on product sales, including product mix and pricing, historical and estimated payer mix and discount rates, among other inputs, which require significant estimates and judgment. We assess and update our estimates each reporting period to reflect actual claims and other current information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks that are payable to our direct customers are generally classified as reductions of Accounts receivable on our Consolidated Balance Sheets. Rebates that are payable to third party payers and healthcare providers are recorded in Accrued rebates on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate cash discounts based on contractual terms, historical customer payment patterns and our expectations regarding future customer payment patterns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distributor Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our inventory management agreements with our significant U.S. wholesalers, we pay the wholesalers a fee primarily for compliance with certain contractually-determined covenants such as the maintenance of agreed-upon inventory levels. These distributor fees are based on a contractually-determined fixed percentage of sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Allowance for Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowances are made for estimated sales returns by our customers and are recorded in the period the related revenue is recognized. We typically permit returns if the product is damaged, defective, or otherwise cannot be used by the customer. In the U.S., we typically permit returns six months prior to and up to one year after the product expiration date. Outside the U.S., returns are only allowed in certain countries on a limited basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimates of sales returns are based primarily on analysis of our historical product return patterns, industry information reporting the return rates for similar products and contractual agreement terms. We also take into consideration known or expected changes in the marketplace specific to each product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Royalty, Contract and Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty revenue is recognized in the period in which the obligation is satisfied and the corresponding sales by our corporate partners occur. Contract and other revenues are recognized when the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzNTM_74b2fcf6-eb84-431d-996a-97dd5761c5c6">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are recorded when incurred and consist primarily of clinical studies performed by contract research organizations (&#x201c;CROs&#x201d;), materials and supplies, expense reimbursements to the collaboration partners, personnel costs including salaries, benefits and stock-based compensation expense, and overhead allocations consisting of various support and infrastructure costs. From time to time, we enter into development and collaboration agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of Research and development expenses.&lt;/span&gt;&lt;/div&gt;Clinical study costs are a significant component of Research and development expenses. Most of our clinical studies are performed by third-party CROs. We monitor levels of performance under each significant contract including the extent of patient enrollment and other activities through communications with our CROs. We accrue costs for clinical studies performed by CROs over the service periods specified in the contracts and adjust our estimates, if required, based upon our ongoing review of the level of effort and costs actually incurred by the CROs. All of our material CRO contracts are terminable by us upon written notice and we are generally only liable for actual services completed by the CRO and certain non-cancelable expenses incurred at any point of termination. Payments we make for R&amp;amp;D services prior to the services being rendered are recorded as prepaid assets within Prepaid and other current assets on our Consolidated Balance Sheets and are expensed as the services are provided.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE1MTM_706775f0-ea7c-44aa-9ede-40c281724557">Acquired In-Process Research and Development ExpensesAcquired in-process research and development expenses are recorded when incurred and reflect costs of externally-developed IPR&amp;amp;D projects, acquired directly in a transaction other than a business combination, that do not have an alternative future use, including upfront and milestone payments related to various collaborations and the costs of rights to IPR&amp;amp;D projects.</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0MTg_7d900cf1-efee-42a2-8be8-ca4be9ab6bff">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative expenses are recorded when incurred and consist primarily of personnel costs, facilities and overhead costs, outside marketing, advertising and legal expenses, and other general and administrative costs related to sales and marketing, finance, human resources, legal and other administrative activities. &lt;/span&gt;&lt;/div&gt;Advertising expenses within Selling, general and administrative expenses, including promotional expenses, are recorded when incurred and</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTI2Mjk_2e310bf2-90da-489e-9624-a3d1ec76b5a9"
      unitRef="usd">778000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTI2MzM_77f55146-fb70-42d5-98dd-0342869d7a2d"
      unitRef="usd">735000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTI2NDA_54e230f9-c623-4694-a24d-96a2ce3ff213"
      unitRef="usd">795000000</us-gaap:AdvertisingExpense>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTMxOTQxMzk2Mzk5OTg_c6ba9424-dbe4-4ce7-889a-ba574b4bfc22">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide stock-based compensation in the form of various types of equity-based awards, including restricted stock units (&#x201c;RSUs&#x201d;), performance share units (&#x201c;PSUs&#x201d;) and stock options, and through our Employee Stock Purchase Plan and the International Employee Stock Purchase Plan (together, as amended, the &#x201c;ESPP&#x201d;). Stock-based compensation expense is based on the estimated fair value of the award on the grant date, or the first date of the ESPP purchase period, and recognized over the requisite service periods on our Consolidated Statements of Income using the straight-line expense attribution approach, reduced for estimated forfeitures. We estimate forfeitures based on our historical experience. The requisite service period could be shorter than the vesting period if an employee is retirement eligible or if an employee terminates due to death or disability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of RSUs is based on the closing price of our common stock on the grant date. For PSUs, depending on the terms of the award, fair value on the date of grant is determined based on either the Monte Carlo valuation methodology or the closing stock price on the date of grant. For stock option and ESPP awards, estimated fair value is based on the Black-Scholes option valuation model. Estimated inputs to that model include (i) expected volatility, based on a blend of historical volatility of our common stock price along with implied volatility for traded options on our common stock, (ii) expected term in years, based on the weighted-average period awards are expected to remain outstanding using historical cancellation and exercise data, contractual terms and vesting terms of the award, (iii) risk-free interest rate, based on observed interest rates appropriate for the term of the stock-based awards, and (iv) expected dividend yield, based on our history and expectation of dividend payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTMxOTQxMzk2Mzk5OTc_73cc6df1-bfe4-4aa2-856c-63901c6b87f6">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock outstanding during the period. Diluted earnings per share attributable to Gilead is calculated based on Net income attributable to Gilead on our Consolidated Statements of Income divided by the weighted-average number of shares of our common stock and other dilutive securities outstanding during the period. The potentially dilutive shares of our common stock resulting from the assumed exercise of outstanding stock options and equivalents are determined under the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0NDM_886fea8e-422f-45cf-aa83-1b6a8fa68e3c">Cash and Cash Equivalents We consider highly liquid investments with insignificant interest rate risk and an original maturity of three&#160;months or less on the purchase date to be cash equivalents.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzOTA_e8ce618f-1286-4202-9533-b16649feb225">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our marketable debt securities are classified as available-for-sale and carried at estimated fair values. We determine the appropriate classification of our marketable debt securities at the time of purchase and reevaluate such designation at each balance sheet date. Unrealized gains and losses on available-for-sale debt securities are reported in Accumulated other comprehensive income on our Consolidated Balance Sheets until realized, at which point they are reclassified into Other income (expense), net on our Consolidated Statements of Income. Interest, amortization of purchase premiums and discounts, and expected credit losses, if any, are also recorded in Other income (expense), net on our Consolidated Statements of Income. The cost of securities sold is based on the specific identification method. We regularly review our investments for declines in fair value below their amortized cost basis to determine whether the impairment is due to credit-related factors or noncredit-related factors. Our review includes the creditworthiness of the security issuers, the severity of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost bases. When we determine that a portion of the unrealized loss is due to an expected credit loss, we recognize the loss amount in Other income (expense), net, with a corresponding allowance against the carrying value of the security we hold. The portion of the unrealized loss related to factors other than credit losses is recognized in Accumulated other comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzNzU_32f23dff-a2e8-4252-9b9d-14174fc222b7">Accounts ReceivableTrade accounts receivable are recorded net of allowances for wholesaler chargebacks related to government and other programs, cash discounts for prompt payment and estimated credit losses. Estimates of our allowance for credit losses consider a number of factors, including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns and government funding and reimbursement practices.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzMzU_b778f54a-e7af-4858-af81-adf4d150c689">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We periodically review our inventories to identify obsolete, slow-moving, excess or otherwise unsaleable items. If obsolete, slow-moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value through a charge to Cost of goods sold on our Consolidated Statements of Income. The determination of net realizable value requires judgment, including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others.&lt;/span&gt;&lt;/div&gt;When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#x2019;s judgment, we capitalize pre-launch inventory costs prior to regulatory approval. A number of factors are considered, including the current status in the regulatory approval process, potential impediments to the approval process such as safety or efficacy, anticipated R&amp;amp;D initiatives that could impact the indication in which the compound will be used, viability of commercialization and marketplace trends.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTMxOTQxMzk2Mzk5OTk_cd73af3c-7dc3-4d8b-9c17-7ef72bd0e67c">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities with readily determinable fair values, including those for which we have elected the fair value option, are recorded at fair market value, and unrealized gains and losses are included in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities without readily determinable fair values are recorded using the measurement alternative of cost less impairment, if any, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Any impairments or adjustments are recorded in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For investments in entities over which we have significant influence but do not meet the requirements for consolidation and have not elected the fair value option, we use the equity method of accounting, with our share of the underlying income or loss of such entities reported in Other income (expense), net on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in equity securities are classified in Prepaid and other current assets or Other long-term assets on our Consolidated Balance Sheets, generally depending on marketability and whether the securities are subject to lock-up provisions. We regularly review our securities for indicators of impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0NzE_25db9e22-c96b-476c-8f66-1ac337ee629e">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization are recognized using the straight-line method. Repairs and maintenance costs are expensed as incurred. Estimated useful lives in years are generally as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;35 years or useful&#160;life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;useful&#160;life or lease&#160;term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;Impairment of Long-Lived Assets&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <gild:PropertyPlantAndEquipmentUsefulLivesTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0NjQ_51933601-be55-4be2-8679-1be457cf0b58">Estimated useful lives in years are generally as follows: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Estimated&#160;Useful&#160;Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;35 years or useful&#160;life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter&#160;of&#160;useful&#160;life or lease&#160;term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gild:PropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic7fd9b86e7264c5c947746f574318575_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RhYmxlOjQwNTYyZGVhMzg5ZjRkYjViYzQ1ZTg2ZTIyZjVjNDgzL3RhYmxlcmFuZ2U6NDA1NjJkZWEzODlmNGRiNWJjNDVlODZlMjJmNWM0ODNfMS0xLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjo0MzA1N2E4N2I0MDc0N2MyOGQ1MGEzYjU3OTgzYmY2OF8xNQ_3335a893-056f-42da-975f-858f24eebb40">P35Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i390b60767b4e4998ba62331653915af0_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RhYmxlOjQwNTYyZGVhMzg5ZjRkYjViYzQ1ZTg2ZTIyZjVjNDgzL3RhYmxlcmFuZ2U6NDA1NjJkZWEzODlmNGRiNWJjNDVlODZlMjJmNWM0ODNfMi0xLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjo0ZDM4OWVmNzU4YjY0N2I2YTdhN2FkN2NhNzg3MDg1NV80_60971260-4fb9-403e-be1a-15f3a728742d">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i88a6a37544df4d67aec58fa3bb44848e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RhYmxlOjQwNTYyZGVhMzg5ZjRkYjViYzQ1ZTg2ZTIyZjVjNDgzL3RhYmxlcmFuZ2U6NDA1NjJkZWEzODlmNGRiNWJjNDVlODZlMjJmNWM0ODNfMi0xLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjo0ZDM4OWVmNzU4YjY0N2I2YTdhN2FkN2NhNzg3MDg1NV83_5cdeacbc-cdae-4f51-8092-5c307aeceae7">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i09e8c6458f804b75b3ac5c526d0da3b3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RhYmxlOjQwNTYyZGVhMzg5ZjRkYjViYzQ1ZTg2ZTIyZjVjNDgzL3RhYmxlcmFuZ2U6NDA1NjJkZWEzODlmNGRiNWJjNDVlODZlMjJmNWM0ODNfMy0xLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjowZTM0YWRmMTlhMDA0YWQ5YTNkMjI4MDM2NWRmNDNlNl80_10f07a11-a451-4069-bfac-37dee7043dc4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib71c43a2aa1f484d95e6e3501ae5b495_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RhYmxlOjQwNTYyZGVhMzg5ZjRkYjViYzQ1ZTg2ZTIyZjVjNDgzL3RhYmxlcmFuZ2U6NDA1NjJkZWEzODlmNGRiNWJjNDVlODZlMjJmNWM0ODNfMy0xLTEtMS0xNjc2NjUvdGV4dHJlZ2lvbjowZTM0YWRmMTlhMDA0YWQ5YTNkMjI4MDM2NWRmNDNlNl83_0339fd3f-7f41-4a59-a9ed-cddfdd4b38c0">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0Mzc_e3645aaf-6023-479e-b925-1b5e43b56a6c">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement contains a lease at inception and classify each lease as operating or financing. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of the lease payments over the lease term, which is the non-cancelable period stated in the contract adjusted for any options to extend or terminate when it is reasonably certain that we will exercise that option. Right-of-use assets are adjusted for prepaid lease payments, lease incentives and initial direct costs incurred. Operating lease expense for the minimum lease payments is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for lease and nonlease components in our lease agreements as a single lease component in determining lease assets and liabilities. In addition, we do not recognize the right-of-use assets and liabilities for leases with lease terms of one year or less.&lt;/span&gt;&lt;/div&gt;As most of our operating leases do not provide an implicit interest rate, we generally utilize a collateralized incremental borrowing rate, applied in a portfolio approach when relevant, based on the information available at the commencement date to determine the lease liability.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0MjE_1731823a-a4ea-4b8e-bcb0-9f50d06d3642">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions, including Goodwill, Intangible Assets and Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired, including IPR&amp;amp;D projects, and liabilities assumed be recorded at their fair values as of the acquisition date on our Consolidated Balance Sheets.&#160;Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period, which may be up to one year from the acquisition date, with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the abandonment or completion of the associated R&amp;amp;D efforts, which generally occurs when regulatory approval is obtained. Goodwill and indefinite-lived intangible assets are not amortized and, instead, are tested for impairment annually or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite useful lives are amortized over their estimated useful lives, primarily on&#160;a straight-line basis, and, are also periodically reviewed for changes in facts or circumstances resulting in a reduction to the estimated useful life of the asset, requiring the acceleration of amortization. See &#x201c;Impairment of Long-Lived Assets&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the initial fair value of an intangible asset, or when quantitative analysis is required to determine any impairment, we use a probability-weighted income approach that discounts expected future cash flows to present value using a discount rate that is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. These cash flow models require the use of Level 3 fair value measurements and inputs, including estimated revenues, which, for example, include significant inputs such as addressable patient population, treatment duration, projected market share, assessment of the asset&#x2019;s life cycle, and competitive trends impacting the asset; costs and probability of technical and regulatory success, among other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approval or sales-based milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value on our Consolidated Statements of Income until such time that the payment is made. Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones, changes in projected revenues or changes in discount rates.&lt;/span&gt;&lt;/div&gt;When we determine net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the transaction is accounted for as an asset acquisition and, therefore, no goodwill is recorded and contingent consideration generally is not recognized at the acquisition date. In an asset acquisition, upfront payments allocated to IPR&amp;amp;D projects at the acquisition date and subsequent milestone payments are expensed as incurred on our Consolidated Statements of Income unless there is an alternative future use.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE1MDQ_06e3b414-769a-45d9-954e-2ccb73794f0a">Impairment of Long-Lived AssetsLong-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset over its useful life to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzE0MzI_00ef8600-7bcd-4d00-876e-881b29e45cd5">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize all derivative instruments as either assets or liabilities at fair value on our Consolidated Balance Sheets. Unrealized changes in the fair value of derivatives designated as part of a hedge transaction are recorded in Accumulated other comprehensive income. For our hedges related to forecasted product sales, the unrealized gains or losses in Accumulated other comprehensive income are reclassified into Product sales on our Consolidated Statements of Income when the respective hedged transactions affect earnings. Changes in the fair value of derivatives that are not part of a hedge transaction are recorded each period in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Using regression analysis, we assess, both at inception and on an ongoing basis, whether the derivatives that are used in hedging transactions are effective in offsetting the changes in cash flows or fair values of the hedged items. If we determine that a forecasted transaction is probable of not occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzOTI_13843253-912a-4ffa-8541-2f7273a27456">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize accruals for loss contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue the best estimate of loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible, we disclose the possible loss or range of loss, or that the amount of loss cannot be estimated at this time.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMzEzNTE_8a7757d9-51bd-4f6b-bc68-a3e9b89f53a8">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax provision is computed under the liability method. Significant estimates are required in determining our provision for income taxes. Some of these estimates are based on interpretations of applicable tax laws or regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. We record a valuation allowance to reduce our deferred tax assets to the amounts that are more likely than not to be realized. We consider future taxable income, ongoing tax planning strategies and our historical financial performance in assessing the need for a valuation allowance. If we expect to realize deferred tax assets for which we have previously recorded a valuation allowance, we will reduce the valuation allowance in the period in which such determination is first made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by tax authorities based on the technical merits of the position. The tax benefit recognized in the Consolidated Financial Statements for a particular tax position is based on the largest benefit that is more likely than not to be realized. The amount of unrecognized tax benefits (&#x201c;UTB&#x201d;) is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by tax authorities, new information obtained during a tax examination or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to UTB in Income tax expense on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to account for the tax on Global Intangible Low-Taxed Income, enacted as part of the Tax Cuts and Jobs Act, as a component of tax expense in the period in which the tax is incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTMxOTQxMzk2Mzk5OTU_ad9a9d19-d4fd-4214-8cb2-7c5fdf94fefa">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Consolidated Financial Statements are presented in U.S. dollars. The functional currency for most of our foreign subsidiaries is their local currency. Revenues, expenses, gains and losses for non-U.S. dollar functional currency entities are translated into U.S. dollars using average currency exchange rates for the period. Assets and liabilities for such entities are translated using exchange rates that approximate the rate at the balance sheet date. Foreign currency translation adjustments are recorded as a component of Accumulated other comprehensive income on our Consolidated Balance Sheets. Foreign currency transaction gains and losses on transactions not denominated in functional currency are recorded in Other income (expense), net, on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185MS9mcmFnOmE1MTE0YmEyYTk5NjRlYmU5NWMzNDg2NTU0NzE2NTI4L3RleHRyZWdpb246YTUxMTRiYTJhOTk2NGViZTk1YzM0ODY1NTQ3MTY1MjhfMTMxOTQxMzk2Mzk5OTY_01b269ba-1fe3-41db-9f17-8a58627b8d79">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply fair value accounting for all financial and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the fair value using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt"&gt;Level 1 inputs include quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt"&gt;Level 2 inputs include observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:47.25pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt"&gt;Level 3 inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability. Our Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMjUzNw_b76287e3-688a-427b-a753-85de5d65dbd0">REVENUES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Disaggregation of Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Product sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HIV &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Hepatitis C virus (&#x201c;HCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ledipasvir/&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Hepatitis B virus (&#x201c;HBV&#x201d;) / Hepatitis Delta virus (&#x201c;HDV&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cell therapy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total cell therapy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents our revenue from cobicistat (&#x201c;C&#x201d;), emtricitabine (&#x201c;FTC&#x201d;) and tenofovir alafenamide (&#x201c;TAF&#x201d;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#x201c;Janssen&#x201d;). See Note 10. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes Atripla, Emtriva, Sunlenca and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes Hepcludex and Hepsera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes Cayston, Jyseleca, Ranexa and Zydelig.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Revenues from Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Revenues Recognized from Performance Obligations Satisfied in Prior Periods&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues recognized from performance obligations satisfied in prior periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue share with Janssen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; and royalties for licenses of intellectual property&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 10. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $171 million and $174 million as of December&#160;31, 2022 and 2021, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were $102 million and $79 million as of December&#160;31, 2022 and 2021, respectively.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMjU0MQ_34fd82c6-8ed9-4a7f-b1c0-5a2aa2f54e6a">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Other International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Product sales:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;HIV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Biktarvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Complera/Eviplera&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Descovy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Genvoya&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Odefsey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Stribild&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Truvada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Revenue share - Symtuza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HIV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HIV &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Veklury&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:4.5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Hepatitis C virus (&#x201c;HCV&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Ledipasvir/&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sofosbuvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sofosbuvir/Velpatasvir&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HCV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HCV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Hepatitis B virus (&#x201c;HBV&#x201d;) / Hepatitis Delta virus (&#x201c;HDV&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vemlidy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Viread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other HBV/HDV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total HBV/HDV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Cell therapy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tecartus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Yescarta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total cell therapy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;AmBisome&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Letairis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:17.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;26,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Royalty, contract and other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;19,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;24,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents our revenue from cobicistat (&#x201c;C&#x201d;), emtricitabine (&#x201c;FTC&#x201d;) and tenofovir alafenamide (&#x201c;TAF&#x201d;) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (&#x201c;Janssen&#x201d;). See Note 10. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes Atripla, Emtriva, Sunlenca and Tybost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes Vosevi and Sovaldi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(6)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes Hepcludex and Hepsera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(7)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Includes Cayston, Jyseleca, Ranexa and Zydelig.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic696402818f946ca8e766e2da5e21ac0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0yLTEtMS0xNjc2NjU_827b2b5a-c532-4917-b2c2-00a3d155a57d"
      unitRef="usd">8510000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i286ee669e6484c499ce3f18c039cd90c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS00LTEtMS0xNjc2NjU_85feae0c-4487-4f5c-a562-697676213d41"
      unitRef="usd">1103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00413e506af84cb6b520644367a012ce_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS02LTEtMS0xNjc2NjU_41a83750-0265-4246-af42-081c10343907"
      unitRef="usd">777000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ac7bcb2b4b64c279d885fb620928589_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS04LTEtMS0xNjc2NjU_ae963350-c204-42bc-a6de-f388e8740ff1"
      unitRef="usd">10390000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d7e0990ed454ca09ff79ece5703dfde_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0xMC0xLTEtMTY3NjY1_5973d02e-2cfa-4257-8d05-56b7d22444c2"
      unitRef="usd">7049000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56cc9ca37eb642478c269153aa683b08_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0xMi0xLTEtMTY3NjY1_ace66840-4a0e-4d24-9423-f93167460230"
      unitRef="usd">969000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f70e4e6502d40f395271bf5dacfb004_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0xNC0xLTEtMTY3NjY1_67445dbc-c81f-4587-8cc2-fee933f3346e"
      unitRef="usd">606000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f74fe4a143c4a2c9d6b59c1d6a92719_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0xNi0xLTEtMTY3NjY1_c8eb02a3-28b2-4907-919e-20fc83c470f1"
      unitRef="usd">8624000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70c25bac5ccf4ea4b63bb3ff8c487134_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0xOC0xLTEtMTY3NjY1_4204ba31-85cf-4a3c-b715-64be8aa93b8d"
      unitRef="usd">6095000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9e8df77801f4427b07c69bffbbb53f5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0yMC0xLTEtMTY3NjY1_ca143a7a-68eb-49e9-864e-3a3965996742"
      unitRef="usd">735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cca639743794954823700d44d77da39_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0yMi0xLTEtMTY3NjY1_91307338-28c5-461f-abf2-952e300f26c6"
      unitRef="usd">429000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cfd1d80d3ce4e1d81dd9cbad42783fb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNS0yNC0xLTEtMTY3NjY1_57429eb8-2e1c-4334-981c-0ba2f0b018d2"
      unitRef="usd">7259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb859e1c4b7140e1bce378f02656f04f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0yLTEtMS0xNjc2NjU_4aed647a-323c-4b5b-9c27-8974abe6a281"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e31ca129163441e8e9ea4ff5f95df21_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi00LTEtMS0xNjc2NjU_70cb8c4e-902f-4908-82e3-1fff3f29c2c3"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b5793c69ad54496bd31bcf75d0dc074_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi02LTEtMS0xNjc2NjU_a3601103-c837-4d0f-a498-d4e6c39064b5"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9fccc1142b74901bc9e73819cdd9125_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi04LTEtMS0xNjc2NjU_5788ad02-a56c-4a89-9ec0-9ba5fe01cd24"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b327175cb0442eab0262b47b930716e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0xMC0xLTEtMTY3NjY1_9f4634fa-edef-491e-887b-76b13bd50500"
      unitRef="usd">102000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93a83bfeca0b4653adb38d1116db35d0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0xMi0xLTEtMTY3NjY1_e4a54159-722a-45fd-8cd0-64e01f14fd4e"
      unitRef="usd">142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2f630b325964676ad13e1b62b9ace1d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0xNC0xLTEtMTY3NjY1_fe2be3cf-0f06-49ff-9ebe-09768f85b73e"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if440505f622045a0ab8e2f08a2a84ff4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0xNi0xLTEtMTY3NjY1_dabd8cd8-cc06-4d25-8a6a-9142f3900efe"
      unitRef="usd">258000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id47d4305b1ac49fcb94e0cdc18738baa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0xOC0xLTEtMTY3NjY1_1611efdc-3814-4137-aff5-a01e2649476a"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e56ec469d9f455285efc69b4c698e5c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0yMC0xLTEtMTY3NjY1_6d5ca99a-c963-4448-a22b-937eb2bd4bb9"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15076f57d5f940d28b2718517e8b16f3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0yMi0xLTEtMTY3NjY1_8b47e615-9d44-40cb-89fc-fda37082c5a5"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22c3f886b1e7454faf57898572502064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNi0yNC0xLTEtMTY3NjY1_1d8ab911-e47a-4658-b9e1-e0342697a243"
      unitRef="usd">269000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae0ac82ae7e44e389ab9b0b042115b90_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0yLTEtMS0xNjc2NjU_edf6c9b0-75c7-4695-bcbb-69150558788b"
      unitRef="usd">1631000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cd4f275449048bdae7a5e135ab9aadb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy00LTEtMS0xNjc2NjU_b0f4f9ad-88ba-4fe7-90c7-a0af69a43a72"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93fde66711574d6bbab8f82da5df47b6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy02LTEtMS0xNjc2NjU_cab9c392-6deb-4fb5-bf53-1dfb68de1f56"
      unitRef="usd">123000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e1da3ce22e34b9d8b83601cc4c715da_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy04LTEtMS0xNjc2NjU_e4cac694-8e7d-4c4b-ab18-4b8a4ffbdd38"
      unitRef="usd">1872000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i964d48496e5a432ba68cb1dba5f31cc2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0xMC0xLTEtMTY3NjY1_c676d774-5202-43cb-8519-4ac756f70cf1"
      unitRef="usd">1397000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0071404988114bf68fb32b3baae96596_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0xMi0xLTEtMTY3NjY1_0b84ffdf-e4ee-4eeb-9fb5-1119f7c7adb3"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69a61c1cbf1a41039ca8dd3bd871bccc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0xNC0xLTEtMTY3NjY1_aa1e61b5-f543-4f4c-8b33-fc8fd5b526d3"
      unitRef="usd">139000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f2cf5628f8640368fe1236801410db4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0xNi0xLTEtMTY3NjY1_e72108b8-3873-482d-b9bc-ec6f4baa321c"
      unitRef="usd">1700000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67f16390de4f49cf950cd63ea38a892e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0xOC0xLTEtMTY3NjY1_c313354a-7323-47ee-9588-4ba0f94045d1"
      unitRef="usd">1526000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if72733c8f57e48839a1cec90953d943a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0yMC0xLTEtMTY3NjY1_47323efc-3af7-4381-ad82-56e0f5056206"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad56bba1d8dd4206abdf2a2ec6754899_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0yMi0xLTEtMTY3NjY1_0db41350-a6b2-443d-b8af-a3754721a5f5"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i304b851b46d94cd2871b2b103c61252f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNy0yNC0xLTEtMTY3NjY1_c22e5856-0dd6-418f-9705-6a09a1f32872"
      unitRef="usd">1861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5ac5cc1e74843118ec886b8bf7ef582_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0yLTEtMS0xNjc2NjU_7e65c99a-df7f-449c-968a-0242d8e2fa29"
      unitRef="usd">1983000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c5f8cda4ab4437b9355aa4d0ac8a973_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC00LTEtMS0xNjc2NjU_0bf2630c-c620-4f9d-b42c-296615222aed"
      unitRef="usd">284000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i740c73c876d84ead9b478bfac1e5c406_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC02LTEtMS0xNjc2NjU_9ea2587c-e6d6-4989-b9ed-f52687a89104"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02057a68acd8487089bcc3e13994ef8f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC04LTEtMS0xNjc2NjU_61410fe3-3d96-47be-a0ec-ab09ef0825de"
      unitRef="usd">2404000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0ae81470ee244b1bd11b567115b6709_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0xMC0xLTEtMTY3NjY1_63e6a9d0-a959-454c-94c0-b83385c35bdd"
      unitRef="usd">2267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib23321b8060e4e9cb82713996e9cdccf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0xMi0xLTEtMTY3NjY1_dcdad6e8-8566-4e98-a142-3a005a7ad2d3"
      unitRef="usd">391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie28f325e4676479c9ae644fd3eb6dc67_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0xNC0xLTEtMTY3NjY1_7f5a4336-5822-4d63-a834-99649750a7d1"
      unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0339bfc0225743a98310d7e4676b63a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0xNi0xLTEtMTY3NjY1_dd8d0048-4e7a-4f7b-bdc1-e404ee485664"
      unitRef="usd">2879000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff0215260a554fe1a70899059d81b451_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0xOC0xLTEtMTY3NjY1_da7e7baf-5617-4278-bc74-dee811ad8943"
      unitRef="usd">2605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f3192435e8c448f8600dfb9c15a1180_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0yMC0xLTEtMTY3NjY1_298634a7-9765-453a-a74b-ce20808b6303"
      unitRef="usd">490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67f25f67445f4a4ab2ccdd05c60c4182_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0yMi0xLTEtMTY3NjY1_4f1ae97d-1474-4ffc-b762-850892035f35"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaee906e7856d488ca901f1010783b65d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOC0yNC0xLTEtMTY3NjY1_e5662574-d093-42ee-a7b3-c7ac1bbf82d3"
      unitRef="usd">3338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i887e5599e4c94395876541937b39df84_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0yLTEtMS0xNjc2NjU_ce3d4c6a-9764-4ffc-9678-9c7311f1ad2d"
      unitRef="usd">1058000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0505374d8f084ccba1175e3944dbd664_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS00LTEtMS0xNjc2NjU_1511eda5-87dd-48c5-a2a8-f9d0506171e2"
      unitRef="usd">364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida1cacafd04c44f093aad95b5b455f48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS02LTEtMS0xNjc2NjU_d1e3b328-9696-48d0-9443-077ad15e4219"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib31ee1b39fb5499c81d8735285addc93_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS04LTEtMS0xNjc2NjU_f2fb40d8-ba4a-49d2-8bbb-281ed445513a"
      unitRef="usd">1469000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbac4e022d8e464388f4a38bbf75756d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0xMC0xLTEtMTY3NjY1_72cf0a44-a6d0-47e3-b768-460468d04039"
      unitRef="usd">1076000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70473509ff904d01a46a345f05fea5da_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0xMi0xLTEtMTY3NjY1_2798cac7-7b45-4ea9-839d-a0d1ddf761ee"
      unitRef="usd">440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf7892154f17434fbf26b8d35f055731_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0xNC0xLTEtMTY3NjY1_b5e4052d-3bac-4ee7-a053-a9b3452b1c82"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee4be07fc0444b0c9a13b3199fe07055_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0xNi0xLTEtMTY3NjY1_d9fb428e-90bb-4042-8446-210dd493bc5b"
      unitRef="usd">1568000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3caa5600f3c42d6a90eb349e4bd514f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0xOC0xLTEtMTY3NjY1_0bdd966e-b271-4b43-a701-4f287cf609db"
      unitRef="usd">1172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idca9bbc5fc664235853309bcafe09958_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0yMC0xLTEtMTY3NjY1_c6733b4c-c4e5-4f86-9f1b-c4bfa97699dd"
      unitRef="usd">450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3622543706a4a2ead1afac3ba8a644a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0yMi0xLTEtMTY3NjY1_0233e8f8-bbce-4d96-adcc-187d1a7e644b"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18db965aef5240089858bc62cf910c9f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfOS0yNC0xLTEtMTY3NjY1_fe96776f-8761-4200-88ba-fcdf3932c107"
      unitRef="usd">1672000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd3b6a53fda1447db2fdec88c020c38a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMi0xLTEtMTY3NjY1_2719bbe3-b0ad-4368-99d5-0d4e8c35407d"
      unitRef="usd">88000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35737905b7f54f96b51c229ab96133ca_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtNC0xLTEtMTY3NjY1_2cf6b414-e2d9-4a89-be8d-c196baf61d64"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37d4b794616d455b92a951ae3e8edbdb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtNi0xLTEtMTY3NjY1_9770b6f6-789a-475e-b702-59926f40630c"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i036b934c4c424d27a375818415f5f565_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtOC0xLTEtMTY3NjY1_5214b750-9a94-4546-9159-20039c4286e9"
      unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10d92f1839624521878f4e8fe7a4145e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMTAtMS0xLTE2NzY2NQ_c6427abf-8a66-463d-8928-1f67ee2230c0"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0be6d27e8e284285916d1f631af87d93_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMTItMS0xLTE2NzY2NQ_1d099657-8c70-4341-b5b2-63f3843b0d00"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i272805c9851c4bfdb5a20f92f49d6fd0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMTQtMS0xLTE2NzY2NQ_ee77ac34-3cdb-4241-b0e0-95e686fe5177"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98e924509b7e456cbae02bc97a737eba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMTYtMS0xLTE2NzY2NQ_8cfb39f9-3470-4a5b-aaaf-3ce2a828ae18"
      unitRef="usd">189000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17e5067a7fe24c2489a2377a45fe5b95_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMTgtMS0xLTE2NzY2NQ_c0e2e879-c255-47ae-9f41-f67d0dd0dedb"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie19185ddfd4c49b9aca949d6f1a89ec6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMjAtMS0xLTE2NzY2NQ_2fec4cf4-2d2d-4c52-b473-e231aad5c21a"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied3bdd8ecc264a9cb8aabcb280063543_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMjItMS0xLTE2NzY2NQ_d176da59-b5d8-44a7-949a-8787f2cfe777"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i633428932b804629900634cfca66947f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTAtMjQtMS0xLTE2NzY2NQ_3703c28d-3122-4a95-8e3c-65295e146061"
      unitRef="usd">196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87e76c6ce2104589bb819a55da49f0a1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMi0xLTEtMTY3NjY1_53b28d84-de6d-400f-85d0-45f1f350266e"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i302fc8ea04774f47a2cf3fbb59d774c4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtNC0xLTEtMTY3NjY1_cac1a482-9f9e-4d01-a95c-893d4ead76a6"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68de7e98cbfe48278b7e8e7b1ec961b2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtNi0xLTEtMTY3NjY1_979ed947-a9f8-428b-88c0-05d4eb674759"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09ef539a43334ebf8e611cf6caa5b1d3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtOC0xLTEtMTY3NjY1_5c7db220-f2a7-45e4-a1db-19390351e0cc"
      unitRef="usd">147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e84d2367c3549a5bf92e42aa560380d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMTAtMS0xLTE2NzY2NQ_6bc7035c-65a2-47a5-a2d1-daf2dff0fa00"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i058ee4cbf024433382a4b9568255bf56_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMTItMS0xLTE2NzY2NQ_e7cf815f-182e-467d-bd13-01bdba5b4d19"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c7acb2c7cb04a5d8c5b81d0106790d3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMTQtMS0xLTE2NzY2NQ_779bfcba-e4cb-4f4c-8211-6e3324e0a4b9"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idba4864482334ff491facf75b1f78c6e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMTYtMS0xLTE2NzY2NQ_772af86c-ea4f-47bb-ac4f-36a3b2eec722"
      unitRef="usd">371000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53b547cdffc54b5d8fd971f88c4b405a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMTgtMS0xLTE2NzY2NQ_f89bf893-c65a-45aa-b781-094c36aea2ed"
      unitRef="usd">1376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36718df39e0a47c7a9984f2501ce84de_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMjAtMS0xLTE2NzY2NQ_8bd03f33-24e4-4ddd-97f4-4abc4bbc75e7"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied0db1516b674b75a73389a4c97b931e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMjItMS0xLTE2NzY2NQ_ac2d8fce-b2e2-4734-9af9-abd0000e887c"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9af6895f54f43d2b2aee375ef4268d5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTEtMjQtMS0xLTE2NzY2NQ_e6843c58-d5e1-4443-92b3-32e27c8f64dc"
      unitRef="usd">1448000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50a22c11bafe49b492afdf6f074bf51c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMi0xLTEtMTY3NjY1_539716b2-4587-44bc-8b5a-bb190951f02c"
      unitRef="usd">348000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56989cfa5ca9443592944384e4a662a3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItNC0xLTEtMTY3NjY1_afffd7b1-ff3b-4ccf-80d6-67f600cafa42"
      unitRef="usd">168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7d3d1785838487fa5864f6342945d52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItNi0xLTEtMTY3NjY1_383cfd68-867b-49bd-b5d0-ad488ea22b63"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i483ed774b8694c0e9f7537a56e3d8723_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItOC0xLTEtMTY3NjY1_7fb35664-3786-46b4-a911-c267c3b5c4f0"
      unitRef="usd">530000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33140238ec544db4bf188fc5d80572b9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMTAtMS0xLTE2NzY2NQ_a078e185-4682-46ec-a966-2fbb96116ce7"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f0fda03309d414a88c8d75b94de2c56_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMTItMS0xLTE2NzY2NQ_434fd464-9bda-42c7-b54a-0bad85711339"
      unitRef="usd">165000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic481237eae4e4a89a31528ac64b99866_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMTQtMS0xLTE2NzY2NQ_a8ce8ce0-1808-49e3-9b99-d9dad52d1cf4"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c625e43b4ea49c0aae317d5f95ced49_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMTYtMS0xLTE2NzY2NQ_2680cadc-1246-4037-8797-8efe6c1222ef"
      unitRef="usd">531000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id61421ab356146f5b9d4c0a367d00a97_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMTgtMS0xLTE2NzY2NQ_0087a5f6-f74c-4eb9-b951-8d7700bd0a19"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c3f9f82011a48019099652b6774bf3e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMjAtMS0xLTE2NzY2NQ_38aeb53c-7648-4260-b662-82852dbe1c02"
      unitRef="usd">149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36131c939960498fae7e0683985c0826_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMjItMS0xLTE2NzY2NQ_384f9b4c-d8e0-4285-8080-bd24f8890631"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic39482d1ab7947dfbee72e97e6c80cb9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTItMjQtMS0xLTE2NzY2NQ_88343f1a-4679-49dc-8b35-a4c67013f5fe"
      unitRef="usd">488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8417f39fd314af3973c6cffd12840ab_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMi0xLTEtMTY3NjY1_3b97f9f6-29f1-4133-999e-0edb77ca9ef9"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83cc8de84b324599b629478841ef5031_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtNC0xLTEtMTY3NjY1_fd8c220c-21c8-45b9-b54d-24b6b8556bf5"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibee89b9c9e4a4997a3e05c1360c968a3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtNi0xLTEtMTY3NjY1_1dc0f9ca-42dd-42b4-a0f8-7c1bfb3578a6"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2710bb1e4e1a4da2bd3c71ff3d63d766_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtOC0xLTEtMTY3NjY1_222e5db7-d992-4413-8dbd-ca96e9907b1a"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d50bd550a3e4eda851933980c3b6015_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMTAtMS0xLTE2NzY2NQ_83555d5a-1ecd-4b9b-8213-d143d75dcc23"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife622784ffa145f89df7c21f7e243720_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMTItMS0xLTE2NzY2NQ_b1d94015-fc09-4c05-8dca-31b1378eadee"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i995e08e1c0564adfa6e51134fcafcd8c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMTQtMS0xLTE2NzY2NQ_60988555-feb2-467e-b0bf-3381ecf8c3b0"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf67814543c7461d8fcb1cf0ed2a896a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMTYtMS0xLTE2NzY2NQ_7dcd5bd7-9de3-45d4-8d7f-7256153c4bdd"
      unitRef="usd">195000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i271f7c1121dc478784b60c3682272afc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMTgtMS0xLTE2NzY2NQ_2c0c3d5a-90b8-41fd-b418-a86f9dcba97e"
      unitRef="usd">332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c46fa85c0964613972809e212f5c052_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMjAtMS0xLTE2NzY2NQ_730550b1-ccab-4174-8bc5-52ac13f47d71"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdc70db5a1624cd9932fc54e3656a357_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMjItMS0xLTE2NzY2NQ_3458c40e-597d-426d-8259-ca531faf5f4c"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf397fbe91ff4afab6f6016ac4dfc728_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTMtMjQtMS0xLTE2NzY2NQ_bdbe522e-b883-4820-9aa2-b4f6c4050030"
      unitRef="usd">407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if27e01c3738343ae828ddd82be4d291e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMi0xLTEtMTY3NjY1_4d262d5b-b9e6-4568-b748-6f598a562f3e"
      unitRef="usd">13820000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d9a8f22db57427db018ee661e6611ec_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtNC0xLTEtMTY3NjY1_90748311-7068-4c96-805f-e83ed79e874d"
      unitRef="usd">2219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23826be9a15045c7bb6572cf25f0aa6f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtNi0xLTEtMTY3NjY1_9eff6b81-f3ef-43ee-bf64-4a80b2584f65"
      unitRef="usd">1155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe24bb9f9af9476b962e3e4255a2fca0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtOC0xLTEtMTY3NjY1_4af74f63-b631-4b3c-8c27-22529d0cd5c0"
      unitRef="usd">17194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5889f693afe94663b9bb93ada344fee3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMTAtMS0xLTE2NzY2NQ_389d11bd-f13d-48d5-8953-982d80ad33ef"
      unitRef="usd">12828000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i746f4ee74a48426283deb266e69bfe47_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMTItMS0xLTE2NzY2NQ_b703bc13-b535-404e-b60c-02531da828b4"
      unitRef="usd">2366000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25fb84b127124bc9a930a78d394ae9ba_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMTQtMS0xLTE2NzY2NQ_5d7c32b8-172e-4cf6-aa13-ee72825b5f7c"
      unitRef="usd">1121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a531ef2bfa647ae80f2e7f581cb250a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMTYtMS0xLTE2NzY2NQ_5d8d602e-19fb-4494-bb6b-610a9b6b770b"
      unitRef="usd">16315000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i038b1c841f2c4a1f99edae58948bfc95_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMTgtMS0xLTE2NzY2NQ_12977a20-99bb-41c2-9512-dce2b1eefaef"
      unitRef="usd">13651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8989bfdb504424e88c9fc5951e552e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMjAtMS0xLTE2NzY2NQ_7ceaec22-04f4-45f5-9dd6-56b474f687f2"
      unitRef="usd">2287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i747dd2095bd84387a1b2cef2a08d4ce4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMjItMS0xLTE2NzY2NQ_54a39fee-6227-44af-a36b-8299cb2f0e83"
      unitRef="usd">1000000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia623a13014414ceeb8b62e7b7d0307ed_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTQtMjQtMS0xLTE2NzY2NQ_eda8b178-b1ac-462d-8ac2-dee67ae19fe6"
      unitRef="usd">16938000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad8fc90a5cc743ac8164e9757643d7c7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMi0xLTEtMTY3NjY1_bb2dbe6b-3543-49f1-9fa0-8ef6d7bb89bd"
      unitRef="usd">1575000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ef9373aea4d45da839ba8bd983d6d41_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtNC0xLTEtMTY3NjY1_6c523ca6-fce7-4f0b-9c81-de57b297be19"
      unitRef="usd">702000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i159b36366579482e833ac889d1de99c8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtNi0xLTEtMTY3NjY1_c7dccec8-f0d8-47d4-b43d-06171d2c0556"
      unitRef="usd">1628000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib77dccfb87744dc0bd019148750e21d3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtOC0xLTEtMTY3NjY1_57ae2bfc-e3a9-4b9a-9591-6328c6cb42c1"
      unitRef="usd">3905000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i892ab04014c6452385a1231e4a398daf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMTAtMS0xLTE2NzY2NQ_403116b7-8d7f-4a75-ac99-27896b8b0bbb"
      unitRef="usd">3640000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic70bed0fa20348939ac81aac767a32c6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMTItMS0xLTE2NzY2NQ_8448884f-e660-4d23-9ca6-9a5f8afd2395"
      unitRef="usd">1095000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cdc513510df408a8c14ad0c77931ade_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMTQtMS0xLTE2NzY2NQ_78bf78ab-410c-46d5-b229-99bfc9f56572"
      unitRef="usd">830000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70e1551d2e994a7189a15b9f7e12f955_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMTYtMS0xLTE2NzY2NQ_830f31f1-014b-4100-bec3-3552beeae76f"
      unitRef="usd">5565000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3270ed2ab9af4df597819fe1d39f6066_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMTgtMS0xLTE2NzY2NQ_2b8213ed-d55f-4f39-a102-9ace3ceb92e0"
      unitRef="usd">2026000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if566c62d193d4045a5d0d0bc3b4f89a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMjAtMS0xLTE2NzY2NQ_0f2759a3-dc41-4d54-9efb-fe412549f6d3"
      unitRef="usd">607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8e5cf6644584b59bef073ec6d2e077b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMjItMS0xLTE2NzY2NQ_59bd01b8-7ebd-4760-aacc-7f4679b08c75"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if603e181b6c147c1be2e679da1361347_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTYtMjQtMS0xLTE2NzY2NQ_d6e264fb-7b35-44f0-85e3-cfbbfd60aadc"
      unitRef="usd">2811000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if161350d9f934bd5b9c69a9471693d6c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMi0xLTEtMTY3NjY1_5b84ff0e-bcc8-4be8-a123-e3a8a19dbf0f"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i224c38109cbc43f6bad2833a21c3d696_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktNC0xLTEtMTY3NjY1_f712cea9-e9ec-4e62-b4c7-7b4c6f83b3f1"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if3d5a1d3752041f4825d5ee38213b9f3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktNi0xLTEtMTY3NjY1_3560428f-2b88-4cb3-b5da-2bad0c2a49de"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1889ca3a09446d1a27ffe2aacdca6bf_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktOC0xLTEtMTY3NjY1_72539dc3-6c48-41f9-947c-5166e5d84447"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84af8bd3147d49149ce9becb6109e0f3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMTAtMS0xLTE2NzY2NQ_ddb5628b-ee9a-4a38-a466-08f9150a9de6"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7dae9fa70cf84bab9cf15d4dd1ab1c25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMTItMS0xLTE2NzY2NQ_12dde050-f78a-46c7-aff9-2b339ebc1030"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ca3edc2c8454bfe860b717853160f7c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMTQtMS0xLTE2NzY2NQ_a6ec9a44-72fb-4233-bb97-a6614eefac76"
      unitRef="usd">97000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i990aae18e5ac4dc19094dd84e771dffa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMTYtMS0xLTE2NzY2NQ_a8a84988-045a-4a0f-8e84-7cc604c018cb"
      unitRef="usd">212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1385fad94f9646459a09390bebc1818f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMTgtMS0xLTE2NzY2NQ_c2c7305d-88b5-4407-97c8-feeb6565a80f"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64774209bf234606bd852b8efadecec2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMjAtMS0xLTE2NzY2NQ_893b41db-efc3-4f57-8b39-646b4201d887"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i408f437468464bfb95a8a1c1592428a4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMjItMS0xLTE2NzY2NQ_d09c51bf-90e4-4579-a8ac-5cb51993b45e"
      unitRef="usd">151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a9586512d7c414fa31e0c58325277e9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMTktMjQtMS0xLTE2NzY2NQ_4f78f0ec-e065-4f33-889d-19a84471e54b"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i001f0a321e7a4cc9919c4b2d3cc488ef_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMi0xLTEtMTY3NjY1_f49a4c2b-f9d0-4446-af26-c257bedf241c"
      unitRef="usd">844000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a7970864108404b9398d1c10e32861e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtNC0xLTEtMTY3NjY1_c894f92c-e19c-4248-aeee-c4b3bc2248da"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ef5ab3d255d4d7d9f8adf8b51dc6060_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtNi0xLTEtMTY3NjY1_71677f7a-04ae-44a8-b94c-e75e9f4bb7b6"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d762459c913449eb0f5d2ffcf4a8ab8_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtOC0xLTEtMTY3NjY1_cdb1068b-c9fc-4326-8835-fd0701ebc17a"
      unitRef="usd">1530000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i842e95d3015c4566b5b99f7cd1c3766b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMTAtMS0xLTE2NzY2NQ_a17c944e-7577-47a9-979c-58a211e39dc4"
      unitRef="usd">815000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c8b88a32bcf490093fd7196fd827fdf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMTItMS0xLTE2NzY2NQ_99514b8b-77fb-42ec-b321-68cc3913ffd5"
      unitRef="usd">316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f6ac7fa58b641b9994e9e2ce1b1a394_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMTQtMS0xLTE2NzY2NQ_c3127ea7-2b3b-4341-95ce-41c25f718116"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e5ee028ea914344923f044cfd129a25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMTYtMS0xLTE2NzY2NQ_fd2dd724-0684-4e27-8b54-4c8ee88f0ae2"
      unitRef="usd">1462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e11ede728fc4b108eb991ae3d30fce7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMTgtMS0xLTE2NzY2NQ_2ac36d6f-eb9f-494a-afb0-7fe48a7b4e17"
      unitRef="usd">864000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7c70711ba3a452f8b82fa6d3959ed4a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMjAtMS0xLTE2NzY2NQ_295786fc-dc75-4333-b6c4-ab2614bac1da"
      unitRef="usd">337000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e58f04355584a7b83ab6050a0f2f05e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMjItMS0xLTE2NzY2NQ_9a428d08-51f6-42e3-b15c-582fa42f19c5"
      unitRef="usd">398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d165787a07f4f2b974d0947bb5841d2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjAtMjQtMS0xLTE2NzY2NQ_fe40d8e3-1503-4a9b-b845-a565ccf1a2f2"
      unitRef="usd">1599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if576a322818849af93ddf776061a8daa_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMi0xLTEtMTY3NjY1_577aa6bf-e18e-4a17-9f08-c31c59102dea"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13ecfda046a14b828b6b88d76ce34397_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtNC0xLTEtMTY3NjY1_da86bd29-b622-45bc-87f0-caedca23fc1b"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0cd547725ff48868a0a2427edbdb26c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtNi0xLTEtMTY3NjY1_c31d4780-e180-4d00-aaba-74ff1bf1c658"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie44bc2b667f640c0a49ef7f1c0d6afad_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtOC0xLTEtMTY3NjY1_c0422185-4905-42f9-a034-64a586526cb7"
      unitRef="usd">166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27d62848770f420584e5549e2f98494b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMTAtMS0xLTE2NzY2NQ_ead5d52a-de30-4eea-a8b9-e40a854caece"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb21c9712fc547089da1e6a2b9444cc9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMTItMS0xLTE2NzY2NQ_2016da1a-6e4d-4a67-a9b3-0029ea619592"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b6e79b7ca6d45d8865a7c9f5f63c09e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMTQtMS0xLTE2NzY2NQ_71f031eb-c231-4851-ac3d-63b588b008da"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e3cb062c5154c10a3316d587eff126e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMTYtMS0xLTE2NzY2NQ_18eb724a-dd46-4614-8b7a-0a456d4dfcf3"
      unitRef="usd">207000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54e8d61cf6b54f18a3832db879c16f70_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMTgtMS0xLTE2NzY2NQ_0f62b0a8-95e2-41bd-8625-46e564fd56e0"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id357c81bb4e5460ab1a7936bd0bc234a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMjAtMS0xLTE2NzY2NQ_0dcacdfa-799e-46b0-84ac-ad1c7d7e3c4f"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9303626ac8f847eba23eb95d3525b36f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMjItMS0xLTE2NzY2NQ_29151f3d-0370-41b8-bdf9-099598976921"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2436a0ce9352470798f7186a3a70c857_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjEtMjQtMS0xLTE2NzY2NQ_5abc435c-62ef-45d6-b814-205e56b41473"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8352ae8893d34956800ed3b7a48a48f7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMi0xLTEtMTY3NjY1_f47e3192-43f7-4508-89bf-d612f3ab8bb3"
      unitRef="usd">1005000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4a7fcc37bdb46a8b48ab66e6c59272e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItNC0xLTEtMTY3NjY1_f2322f3b-fb57-4207-a025-7b57f2483c0a"
      unitRef="usd">413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i316a0910d8e048a4843f027671f1598f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItNi0xLTEtMTY3NjY1_44ec99d9-1419-4150-93ed-6edfca6a1bea"
      unitRef="usd">392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f0ca5b4297e4ce5bb2fcad022831bd4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItOC0xLTEtMTY3NjY1_948d4018-df83-4e8f-a7e1-c8369028e104"
      unitRef="usd">1810000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46b71f3a3fd84ae7b5f5562467d87974_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMTAtMS0xLTE2NzY2NQ_77db6984-cd30-4424-9b08-a1758c48353b"
      unitRef="usd">1018000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab7e60f505e04d06b0aa3dda75663f1f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMTItMS0xLTE2NzY2NQ_97841aa7-cc78-4fb4-9287-498fde0c4e63"
      unitRef="usd">421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadec57d70f694b2c9aeef1696ac8ec12_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMTQtMS0xLTE2NzY2NQ_e5e2e69e-912b-4ecc-a567-6024d072785c"
      unitRef="usd">442000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3cb175d66081417f895e6a30847d0ec9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMTYtMS0xLTE2NzY2NQ_3960ece3-3767-47c8-9a89-9b23021158f8"
      unitRef="usd">1881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibee44c336571414b93118372858b768a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMTgtMS0xLTE2NzY2NQ_eab23075-7a38-4cb4-a260-d8dda92631e4"
      unitRef="usd">1088000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1cdd83824774e048ef83b228f4edbb4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMjAtMS0xLTE2NzY2NQ_4f5017be-7aed-498d-aa46-f9fba3c767c8"
      unitRef="usd">414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9306bcc0ca3a42b3b7c50ee626394174_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMjItMS0xLTE2NzY2NQ_a6972b3a-02f6-44bd-ad41-4e5fc38f6213"
      unitRef="usd">562000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccf53c215b7d4f7997810c9a06bcdd03_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjItMjQtMS0xLTE2NzY2NQ_a10abae5-1bd9-432e-8e72-c962ef927826"
      unitRef="usd">2064000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2dc553a8ada449298fffed4c28e2060f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMi0xLTEtMTY3NjY1_c5816b10-5bba-4974-b959-a12a781f0ff7"
      unitRef="usd">429000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic415777eefb04ed297d1241f612be3c7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtNC0xLTEtMTY3NjY1_b65ab1af-ae69-4a7f-b921-2662d31897b4"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie13c6aa1001243d89d2583a460ce4786_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtNi0xLTEtMTY3NjY1_798c6811-4d98-4b0c-8c21-d65646b24eec"
      unitRef="usd">379000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib64f820871db47e3a10f78b9550bb92e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtOC0xLTEtMTY3NjY1_8018446d-9e73-459b-881e-6994f87ee0e0"
      unitRef="usd">842000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42cd1fcad93c4c6ea52dce4ae9e6c75f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMTAtMS0xLTE2NzY2NQ_f3a1ca26-afb0-466d-888c-5acb76cb7981"
      unitRef="usd">384000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b2bdd0ef7d94c5d9c5937ce2afd82fa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMTItMS0xLTE2NzY2NQ_d721663a-7b6c-4ed8-9b45-9b908de7b1ee"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4aec2c5b53674a8e99a3fabeca154f63_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMTQtMS0xLTE2NzY2NQ_a464e41e-0327-493d-a4e2-f310f83dfd8f"
      unitRef="usd">396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib20a0912ba52411597d240f59ee8a970_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMTYtMS0xLTE2NzY2NQ_ba42df45-2186-4754-8bf6-c31ae9de174c"
      unitRef="usd">814000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if28852e0de5a4261bb649f5abaa6914b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMTgtMS0xLTE2NzY2NQ_830079d8-27e5-4619-942c-8ab89510754c"
      unitRef="usd">356000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ed29a62f86443fcb28feb3b67712b1d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMjAtMS0xLTE2NzY2NQ_69444ed9-5c08-4fb0-b875-66748c09f75e"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i752e7f4d5fcb4e0bbf8b49e33b38f59c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMjItMS0xLTE2NzY2NQ_88db67a2-f74d-4256-943b-6dacf1cab500"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id94daf83394e47f9bb26f578ef1b6fd7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjUtMjQtMS0xLTE2NzY2NQ_12d0f874-41a7-4d92-88e0-c4004ebd7a9d"
      unitRef="usd">657000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e7228c11db24e9aa0d0a7aa03dfbb82_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMi0xLTEtMTY3NjY1_f1d86168-14ab-40bb-abd2-e4be63cc1334"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44b50cd213f44bd3b7a2dc1a71945fa5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtNC0xLTEtMTY3NjY1_af172626-ad70-404c-9bd3-80f6351b9453"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9225d954d484582b9642b85bcf59293_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtNi0xLTEtMTY3NjY1_525ce84b-9d33-42f4-a0a5-f2a89aa34c5a"
      unitRef="usd">62000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib93f3e8abe7249e8bf7db00e4237ff24_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtOC0xLTEtMTY3NjY1_b3b06128-8364-4f17-a808-8ee6b2fc1712"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84c19876953f4ca6b7fa9b0c8fdf5a9e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMTAtMS0xLTE2NzY2NQ_ca79b763-db8c-45da-9306-ab6faff801c8"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25424faa0377487b93010e5bde98b80b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMTItMS0xLTE2NzY2NQ_e46dbc3a-e54a-45b9-94c4-40e4e60699d9"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f6d94f1fffe48978776b2d7573360e4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMTQtMS0xLTE2NzY2NQ_7c93f1e9-84b8-468a-a99e-4785a1910eaa"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53b03b0e23a24b88acb155327c8488ed_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMTYtMS0xLTE2NzY2NQ_44f73942-26fc-49c3-9a1b-1e776a17eea0"
      unitRef="usd">111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42a165571ecc4a6a81d1a6a559f0c569_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMTgtMS0xLTE2NzY2NQ_2742364c-797e-4a62-884c-b8daa0e6bc88"
      unitRef="usd">14000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icde54372e7c94f3cb372e6be0b78a13b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMjAtMS0xLTE2NzY2NQ_aae891a3-e416-48d2-a1e2-e216d781a49c"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id464c7738d154fe99637211d865d3a53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMjItMS0xLTE2NzY2NQ_cd957422-0dbd-4274-983f-99a144224c89"
      unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i152e0d6d305445e59681826b69d85467_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjYtMjQtMS0xLTE2NzY2NQ_f1927168-52ea-4305-b292-8db8c0a624bf"
      unitRef="usd">185000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c7a7e2316ac49c2a3524b858ab86c7e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMi0xLTEtMTY3NjY1_0fe881eb-8b64-46be-a5dc-87aa05da0fed"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7c74c57c8c0479082ce7a7dac084d27_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctNC0xLTEtMTY3NjY1_e53ba5f6-1ca6-424b-aa30-f1526d04a390"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib769b5b3d70b46e892db64fc00f73c4c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctNi0xLTEtMTY3NjY1_7fb47b1b-d2ac-4fd3-8df7-9793e31dbba1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ce38a9465334f39b1eb1623b8138d52_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctOC0xLTEtMTY3NjY1_9f21afb0-467e-4e4d-85c3-3570e3c93918"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if28c44bf664d40ecb1b0a3e548f23981_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMTAtMS0xLTE2NzY2NQ_d5cc2871-1272-4fce-bf8d-bf015684d8a0"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59e34f35279744a9b950cebad2d0bc39_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMTItMS0xLTE2NzY2NQ_e4dd746d-163e-4167-a485-552bac99db62"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09871c6ba3ae431c998271ba08136fe8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMTQtMS0xLTE2NzY2NQ_f7f325c5-408b-49dc-bf2a-989f6339f3a8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4170b5c1c1714d8f920993b6d2262d02_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMTYtMS0xLTE2NzY2NQ_156c5770-d47c-4dbd-9bd7-49a86a07d137"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6523d67294b4f8981a8e945c6b20785_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMTgtMS0xLTE2NzY2NQ_8a823840-1263-4ca6-9efb-d2d161e7077a"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6f3c5b346184ba1b39b0710a6321e5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMjAtMS0xLTE2NzY2NQ_ac1af59b-5143-4970-97c9-db8ad655e73f"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9d36441d753401c8d6ec0475559e780_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMjItMS0xLTE2NzY2NQ_4c09a757-3741-4846-a3da-4a180d38c7c4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ed527ac9bdd4205809a16ca629aec11_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjctMjQtMS0xLTE2NzY2NQ_b41227a4-9bf6-4f53-bd37-f49d806d31c2"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a9466b57eba44278c2bc11a50ea844e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMi0xLTEtMTY3NjY1_841680b4-5e61-4505-8ba0-06daed7f1235"
      unitRef="usd">435000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd2376deb7144bd59b534ed53871b5ac_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtNC0xLTEtMTY3NjY1_c15e5399-f480-471e-96a2-137b1d70ea64"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60812f2148b74064ae4b10afc339abc3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtNi0xLTEtMTY3NjY1_e18cbb0a-648f-4117-9038-990c50a2a3b4"
      unitRef="usd">441000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3b257573b924383a6fd7a367622f923_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtOC0xLTEtMTY3NjY1_34aa299c-bf66-40cf-81d2-9d102d1ab395"
      unitRef="usd">988000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie21e023844a745bb8a3684cb9d194638_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMTAtMS0xLTE2NzY2NQ_5bdc934c-9e24-4a6a-a2c2-a52a42340810"
      unitRef="usd">397000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idab285af921e41088931c917d2518003_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMTItMS0xLTE2NzY2NQ_7a6ad582-9eab-4257-be29-8d09ab1f2eec"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39beed2eccf74622bbc506893a5c1069_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMTQtMS0xLTE2NzY2NQ_2e18524b-412b-4d99-a0cf-d7f9e4e364d0"
      unitRef="usd">468000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4047a0aafd81455d991a4aeaa945def4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMTYtMS0xLTE2NzY2NQ_b8e68167-ee30-4502-b0a7-a511b76558c1"
      unitRef="usd">969000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7af0ff053a604ab5bda65ff903d0e784_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMTgtMS0xLTE2NzY2NQ_9bfa28a2-c212-4cfd-9aa1-cdd386e558d6"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0570a9882284918847527738da8a490_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMjAtMS0xLTE2NzY2NQ_ba1661c2-a087-4db2-90a2-4dd24ab0fc57"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4e1f9c9a4fe47a7bc9cbb56ef70b24f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMjItMS0xLTE2NzY2NQ_94e9bb2f-fdf0-47ba-826f-4759139a9c93"
      unitRef="usd">409000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7868f7368c3486d82227cdcaa76a33d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMjgtMjQtMS0xLTE2NzY2NQ_5bbd62c3-81c2-44df-a17f-35437da6b204"
      unitRef="usd">860000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2d7e48b21f4489189057ca3a20ee5a6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMi0xLTEtMTY3NjY1_7499048d-4fb0-423f-8df2-6fb6da23cb07"
      unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i552a5e98cd894d1f82b630e62cc1d7fc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtNC0xLTEtMTY3NjY1_2d825125-6d35-44f7-ab39-234325852f24"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3d02401452d436da34605e1e142fa23_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtNi0xLTEtMTY3NjY1_5beeab56-8a84-432b-a84d-cdeb42fbfa76"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57c3adbab8d849c5b912381e32fd4668_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtOC0xLTEtMTY3NjY1_63903fe8-ac59-454e-b51b-3a6c43a19bc4"
      unitRef="usd">299000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cb8d3f9aaf646d1ab94c2572cad9d97_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMTAtMS0xLTE2NzY2NQ_7dff59f3-70db-4a45-804b-9a391ab5f694"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd11072ce9b8438f822f1f5b0f101e9d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMTItMS0xLTE2NzY2NQ_753d7c27-56a5-41d9-ab6b-3406a67b46d7"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icacbf61077d141f49fe6cfb43f3d6a64_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMTQtMS0xLTE2NzY2NQ_d578bb2f-91e3-4aba-a0a2-58140c58f0ee"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia435f9794a6b429f9e917b58fca423ee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMTYtMS0xLTE2NzY2NQ_64a57eb6-7e17-4ecf-b4fc-ca3e72fe7953"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec37e2e6ec1a42e0a68b48238a81f664_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMTgtMS0xLTE2NzY2NQ_800e5ace-db88-4ee5-9ab4-276898234610"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36bfd55ed5a14a94977376f9736657ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMjAtMS0xLTE2NzY2NQ_d55b2dc7-4159-4dda-990a-60d3f7d41939"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9976f07ed0ea4180a61ff830dd781cd2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMjItMS0xLTE2NzY2NQ_4e43424f-6dcf-4d47-8343-7a176384e25c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9f3506be92642258438c218c9fefcab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzEtMjQtMS0xLTE2NzY2NQ_7b72cf06-ec31-4e7a-a6d1-ebeef6d4c9d5"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc7adbea5d984ceca881d04a7c590ecd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMi0xLTEtMTY3NjY1_97bf9295-5fe1-420b-b2f5-ee525b7bf07b"
      unitRef="usd">747000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic98c35b70a6d4caa9097cbd03988b94b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItNC0xLTEtMTY3NjY1_1525a7fa-87ab-40d7-b431-722040ed8c2e"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48bbf122b5a340cd9c41944387fcbf26_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItNi0xLTEtMTY3NjY1_4598cb32-400f-4df5-be56-6da79448ad92"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8be13c495ea743bdb150e8a637348840_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItOC0xLTEtMTY3NjY1_7020e8c3-1408-4e8c-a7a8-74427e652d00"
      unitRef="usd">1160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f58bf4910d04410b4d8f3dee38fa563_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMTAtMS0xLTE2NzY2NQ_4932a047-b32c-44af-9557-df46a12a7d3a"
      unitRef="usd">406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74057d7eaf294ff4a1f0ee3ed98656e9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMTItMS0xLTE2NzY2NQ_d343ab9e-2d7e-49d6-adb2-30aee184e9ff"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b1203b4aa444780be9b251625ed241b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMTQtMS0xLTE2NzY2NQ_9746d5f8-d403-4822-9b99-1c5bdb2ac899"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c1cdc8fffbe411cb0781c91d13f40bb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMTYtMS0xLTE2NzY2NQ_3cd0f3ab-f24c-4edf-81da-860a9a323e19"
      unitRef="usd">695000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3eae0aa7e3b54e74ba47f8e7d11af81f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMTgtMS0xLTE2NzY2NQ_1480ef5e-044f-4a69-9c43-399f527f8999"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71b57df694f24969abcc922725bd4116_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMjAtMS0xLTE2NzY2NQ_6f11a772-7414-4362-8f8d-8ec38a00a828"
      unitRef="usd">191000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4309bba638742288a3c3b3411782a64_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMjItMS0xLTE2NzY2NQ_cca5b219-b5b4-45c3-865e-4c1d607c3e72"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia68db9a0ea2f4c7390ec4cbc6e024d62_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzItMjQtMS0xLTE2NzY2NQ_154a79ec-aac6-411a-9a54-d5c0d21ce06f"
      unitRef="usd">563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f98a55a88cd4ff9a94405f8df480139_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMi0xLTEtMTY3NjY1_17c7e026-b31e-4d63-ade8-c6fd243c79cc"
      unitRef="usd">968000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10627c2c5eaf4c4a93e8853d80712680_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtNC0xLTEtMTY3NjY1_ed826572-2747-4d2c-a82c-971194e4df82"
      unitRef="usd">430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e0f9a67dff1450ea9e2f3abed91dfde_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtNi0xLTEtMTY3NjY1_5b7834d5-d7a6-4c89-94b5-a2730881474b"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bec111f16ad4191913cb9e0707b68d3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtOC0xLTEtMTY3NjY1_01cb5449-3329-4b07-a154-473265d29f13"
      unitRef="usd">1459000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idda1937d0695488d92eca8410b6b5ad0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMTAtMS0xLTE2NzY2NQ_d9993bc1-5a6a-4272-8597-3caccfee203f"
      unitRef="usd">542000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id43ed2f32ec54108b2052f7c81e8dd87_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMTItMS0xLTE2NzY2NQ_d46e5076-d409-44f7-b00c-120bb94ca226"
      unitRef="usd">293000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e173b6e94784412a1a9aba6693632f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMTQtMS0xLTE2NzY2NQ_ea465efc-2628-4e0d-b928-c51a007ee931"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20f103fc96db43f9871d8821af37e8d6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMTYtMS0xLTE2NzY2NQ_8fd91326-ff16-493e-9df4-0f649059b9ad"
      unitRef="usd">871000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe90cf240bcb4039827d8ae3729b5f78_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMTgtMS0xLTE2NzY2NQ_ee60d5f3-c459-442d-8432-f312007f8e6a"
      unitRef="usd">396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9ea8631b9b348fc98164b8455c586a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMjAtMS0xLTE2NzY2NQ_b0595877-ce8e-4e25-9a4e-183f6bc9b019"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55dcdd667a914130ac7f247f5ab8e970_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMjItMS0xLTE2NzY2NQ_0408c722-2312-40a3-84b0-d672274d2fd2"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50c68ef9e2c94e88bc900f8445716b7f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzMtMjQtMS0xLTE2NzY2NQ_fa0342a5-09e6-402e-9b6f-21e5dd2e6ef6"
      unitRef="usd">607000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15ca9a88790b41dab9dd09539fbfc66b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMi0xLTEtMTY3NjY1_6b3d9b3e-1edd-4d93-883d-73818ba986f7"
      unitRef="usd">525000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cc8f9b08eb949459f8922ebc6ecd590_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtNC0xLTEtMTY3NjY1_e915bd3a-1374-446d-accd-0a03012569be"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14d6f24068e64a7bb2e161b0ea089deb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtNi0xLTEtMTY3NjY1_e78675c6-ca86-4300-8329-aa25abc9afa6"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie547a0920cc34aff9876297ca28ab3cd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtOC0xLTEtMTY3NjY1_3337f757-8d5e-4546-845e-6d356e54a87d"
      unitRef="usd">680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9409f8c5614f464cac6ce5449dfc8a91_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMTAtMS0xLTE2NzY2NQ_83c4396c-0a32-4698-81a0-c63dd9fc8420"
      unitRef="usd">370000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibca6cbf239d149448f38489f25c6ac14_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMTItMS0xLTE2NzY2NQ_4c763554-2731-43e2-af04-fc5001b26785"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3b79faef45f4559baf646714298411a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMTQtMS0xLTE2NzY2NQ_81c2a3ea-7574-4393-9a6b-0d32730afe83"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibeb51c8c4ffd41489bda5887c0250688_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMTYtMS0xLTE2NzY2NQ_c4e82039-0f39-4c26-be5b-df9bce20fe40"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68234a1374f84b4b93207cb00261676d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMTgtMS0xLTE2NzY2NQ_204e24ba-eb8a-4bfd-a147-10adb06afdd3"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a896e7fa0ea4692ab85773273ce8925_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMjAtMS0xLTE2NzY2NQ_eed967a4-0f7f-43ce-abbf-1a377c6a13b1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fd408517b934aa38aa102382fee39f7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMjItMS0xLTE2NzY2NQ_94189d76-13dc-47ee-ae07-ca8b9420345e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i720140b50665423d9ecf9cc4d23c024c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzUtMjQtMS0xLTE2NzY2NQ_3dfabc3e-da64-4f9d-9623-ce604bce6929"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d26f0693aed4c998637a007f2a4df73_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMi0xLTEtMTY3NjY1_e6ab6faa-f688-41bf-830e-2d2ff6615dff"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bb9697cc7594310943f7cb04cffb997_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtNC0xLTEtMTY3NjY1_849598c2-655e-4ca7-b3a8-dbda9b03eafa"
      unitRef="usd">258000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3cca4b1510b45f0a81e6c1ee81cd735_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtNi0xLTEtMTY3NjY1_620b5fe9-aa32-4813-a667-de67ea866321"
      unitRef="usd">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43f061fd85154f68a9a577619edb8cf3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtOC0xLTEtMTY3NjY1_8f2c242b-c99f-4b68-b5e9-f55dda07adbd"
      unitRef="usd">497000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23c6213e809147e69336a3f6284317f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMTAtMS0xLTE2NzY2NQ_8fe4154a-d15a-4859-a246-10cc9f6cbd1e"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id94a3128eb634eb9a869ba096d445597_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMTItMS0xLTE2NzY2NQ_a5cc1135-fec2-424b-83dd-575e0db32730"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie527ccfe78524f97b3646d01e7cdd88b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMTQtMS0xLTE2NzY2NQ_b177aae5-e04f-4609-b50c-3c562dce8d84"
      unitRef="usd">227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab43b5a322744bf29d7a74c4096dac3f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMTYtMS0xLTE2NzY2NQ_a105ef09-f1e8-4274-af4e-f99f54bb0a45"
      unitRef="usd">540000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbdf5cd7eae14b92af352c6ab83988a6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMTgtMS0xLTE2NzY2NQ_a53324c5-d791-4ed7-9be9-37b76e7f816b"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60a9443075964128a15a01c02e823b16_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMjAtMS0xLTE2NzY2NQ_8d8f3001-a5df-496c-aa6f-ba824ea31a94"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib67c8b2793e440f6b65336fc0aedd433_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMjItMS0xLTE2NzY2NQ_9d31b681-442a-45cb-b18d-40904d1b3dea"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifca680403c8f440e980e85b1a1536764_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzgtMjQtMS0xLTE2NzY2NQ_f652dab5-0e3a-44b2-a133-4316cade640c"
      unitRef="usd">436000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ffac4669e6141d693435ad3d4c6baa5_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMi0xLTEtMTY3NjY1_6e6e9a57-9657-4b6f-9350-e71ac693d309"
      unitRef="usd">196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e7eb9d47d3d45f1801328a82bcdb51c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktNC0xLTEtMTY3NjY1_738518d7-59e7-4088-9ad8-c93293f2b8f8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79138071f14346498db0bdc4d20f7898_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktNi0xLTEtMTY3NjY1_98840739-7695-4234-baa0-1561008f87ec"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8bf0dc9d6014d1b82589f892ae08671_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktOC0xLTEtMTY3NjY1_d398394c-86ad-41f7-b69f-5b78b60230d2"
      unitRef="usd">196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cf42ac0f6b141f9b9a452ed3335a197_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMTAtMS0xLTE2NzY2NQ_c782bb1f-7d86-40f4-bd6b-386f5fada6d3"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22b869318548494b9e06efac2a33eda5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMTItMS0xLTE2NzY2NQ_992d9382-b648-4303-a9cf-54de3b3740e4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d84e35cd15e4f45a75e3a912c6dc29b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMTQtMS0xLTE2NzY2NQ_93945747-57c4-4c28-ab81-6639571809d4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a6ffb332c0e4d9fbb4397e67ceb91dd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMTYtMS0xLTE2NzY2NQ_79b48999-5b0a-4477-9459-3e0671467372"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i738618c718414809ad145d0c367755aa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMTgtMS0xLTE2NzY2NQ_a1a5e72f-cdfa-4b54-b077-d060af75046a"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icebf8365902241d8bdd0aa638c68bb3b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMjAtMS0xLTE2NzY2NQ_d478e3f1-665b-4d68-87f7-36099d7c0e52"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62346343776542ffb3989e6fdfdb861b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMjItMS0xLTE2NzY2NQ_9e4c4632-b89e-4163-b41c-6ec2719a3980"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id85501d9727f4bd3a90aad68a5047f39_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfMzktMjQtMS0xLTE2NzY2NQ_d609a241-c15f-4913-9ce5-ab76a2e0c814"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7981271263a0497385c106ee1d8586d4_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMi0xLTEtMTY3NjY1_5b5e0d0c-8cba-4313-a70c-e47f39b79dec"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11d9e7d23b4e44fca91e8f8a56cc640a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItNC0xLTEtMTY3NjY1_d18d43d5-0830-450c-a433-3fe5baff0b87"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fd5efc4fbfd4d47bbea341757531be6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItNi0xLTEtMTY3NjY1_58fcb52e-4285-4d34-9704-98edd26137c0"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6323c623d0145c9a4ab424c52f46d21_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItOC0xLTEtMTY3NjY1_9bcd36e0-7c34-4103-892b-cdd08cbc3837"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91ac289724a141efb05295c0ae0c3206_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMTAtMS0xLTE2NzY2NQ_cb916b98-5a36-46a3-8967-9ac1483d4122"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbde1bd79a61473584fdf4a131ea0893_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMTItMS0xLTE2NzY2NQ_5ac136e4-05d0-4429-928a-789b9253da39"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5901b8ecd56a493aab74941a2b2f9e23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMTQtMS0xLTE2NzY2NQ_0984f897-5fa2-4ebf-88cd-a7d4371fff15"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id160a09703b54e7685b93b162b95d162_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMTYtMS0xLTE2NzY2NQ_b245559d-4ea8-4c9f-88a5-990ba13ba4c8"
      unitRef="usd">281000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4729d87ad9f345eeadc62cb0f11ed0b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMTgtMS0xLTE2NzY2NQ_dce5a9aa-8716-4562-a9cc-3411d1e8504a"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64a427f3722a42e6afceb6d7c0ab324a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMjAtMS0xLTE2NzY2NQ_b60d0bb5-1945-4ab4-b992-bf5d4609f14e"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id402bd3c4ac1490b8201b3a308ef1e2f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMjItMS0xLTE2NzY2NQ_dcebbe65-004d-4539-9e56-bdaaaeccf0f5"
      unitRef="usd">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib847a11c1e7f4aee9f52682db5c1f135_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDItMjQtMS0xLTE2NzY2NQ_2f503bca-5b8d-4465-a263-2f6baf06f607"
      unitRef="usd">276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91a7d5c54528430783128148bcd0b974_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMi0xLTEtMTY3NjY1_e7da6159-db89-451a-b32a-9e79f8c6f666"
      unitRef="usd">388000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3e2f8a83b0f4ae497dc2e5c8ba4927c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtNC0xLTEtMTY3NjY1_d94acf53-5f86-4ace-bfdb-2b746c970162"
      unitRef="usd">323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb1777596b9e486a9e19ecb95f8684eb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtNi0xLTEtMTY3NjY1_30440272-dc0b-40f7-afd1-7b9de85a6251"
      unitRef="usd">235000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e0fa4aa3a554fbca7b6597772bae432_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtOC0xLTEtMTY3NjY1_a7bc4d8f-237a-4235-b448-4fcba88fe35f"
      unitRef="usd">946000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96b230c4abe241f88e888152fba0544e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMTAtMS0xLTE2NzY2NQ_ce628f2b-59c9-417b-b96d-c15e2bec1a38"
      unitRef="usd">381000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icacf9afd500a448096edbd2f4cba2326_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMTItMS0xLTE2NzY2NQ_71ea0d50-195b-4067-a980-7b22fcd24952"
      unitRef="usd">389000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01748bbcf6c24a2e85eb82ac7163747d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMTQtMS0xLTE2NzY2NQ_a7d6e580-c8c7-407a-8cc9-9ac410720294"
      unitRef="usd">257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ided586c3fc76418f9cab15dce3540cb0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMTYtMS0xLTE2NzY2NQ_e9378492-fea9-45f3-927d-0785e5501545"
      unitRef="usd">1027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i320ef6561a284511ac0240c964bc81a4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMTgtMS0xLTE2NzY2NQ_f4230767-7bac-4393-9dd4-64654f875429"
      unitRef="usd">551000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia34d7b9624484238b55305a3f87daed8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMjAtMS0xLTE2NzY2NQ_b2dcadbb-be2d-4db9-9e6f-b55784b80fa3"
      unitRef="usd">314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib30d9baceb6a430eba29fc86bed3e18a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMjItMS0xLTE2NzY2NQ_693ebf83-b36b-43c0-a533-018abdd63df7"
      unitRef="usd">161000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8000a2e754d4b178de03c4010ac094d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDMtMjQtMS0xLTE2NzY2NQ_d0f6f66c-c6c9-4cd8-95f4-8e332e821d40"
      unitRef="usd">1026000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i191031ec2f8340fe8c4d6783e97231cc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMi0xLTEtMTY3NjY1_66010dda-6add-4555-bfe3-e3c0613c2cb2"
      unitRef="usd">18716000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47cec898f169483d9a78d908ee8ac54b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtNC0xLTEtMTY3NjY1_a57f5d86-33b5-458b-9d4e-6077157d5592"
      unitRef="usd">4342000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c17ca18fe8b4685bc8dbff8b0024fca_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtNi0xLTEtMTY3NjY1_735774c4-e6fb-4e0e-86f9-f112fe97b02f"
      unitRef="usd">3924000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5776967eec2e40169c93026e3f869e40_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtOC0xLTEtMTY3NjY1_a2f94323-1bb7-4c37-a7d2-7e1672698613"
      unitRef="usd">26982000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4c0214e29ea4b9282808e79f896a82b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMTAtMS0xLTE2NzY2NQ_57b47bbd-a0be-43dc-a5e7-3fd8be38e971"
      unitRef="usd">19176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i878929f1d5d34534bbf9576f56d5bffc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMTItMS0xLTE2NzY2NQ_81bba0c2-b0c0-46b7-b56d-91171c07f3c6"
      unitRef="usd">4678000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ca736187a154121b6128d87c38b83ea_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMTQtMS0xLTE2NzY2NQ_d09264e7-77f1-4bb1-8ea5-b565746dec26"
      unitRef="usd">3154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdd0d2f0925f42e7889120dcf51249c1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMTYtMS0xLTE2NzY2NQ_8677190e-b1ec-4282-b93e-2cb41e3e4b64"
      unitRef="usd">27008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dbb6a36e59f4a65b7cd766dceaf5deb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMTgtMS0xLTE2NzY2NQ_c3a7eec2-3885-4bd5-b845-5dd4bf8c38b7"
      unitRef="usd">18141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3463ced19f543a6b038efda28937ed7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMjAtMS0xLTE2NzY2NQ_37774d97-e498-4fdd-b10d-fca066b9ee2c"
      unitRef="usd">3894000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice19479778e74f7f859404303e2642b1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMjItMS0xLTE2NzY2NQ_00503791-45f2-46db-a213-81d28821072e"
      unitRef="usd">2320000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i549c720f0be04d399b280dc53ff6498d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDQtMjQtMS0xLTE2NzY2NQ_b55d71cf-240e-4cfc-9d34-ca06832a8161"
      unitRef="usd">24355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i122092ce94ac4c349bc55b92090d0c7a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMi0xLTEtMTY3NjY1_c3e09c4d-d709-4f7a-8f95-350f18eb0f22"
      unitRef="usd">168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i895482d8185045179df5923b9434a992_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtNC0xLTEtMTY3NjY1_b948109a-12e9-4cd2-8c5c-69e3bd7ae433"
      unitRef="usd">127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ded8cfb2f694a869b82b4f9ceb7481c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtNi0xLTEtMTY3NjY1_810f48b1-29f0-4aa0-a6f7-4a9383bc9f52"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3009f1cc5994ac0949727e755fef6fb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtOC0xLTEtMTY3NjY1_00fcb2c7-7c38-4f46-bfe7-cd910a7877a4"
      unitRef="usd">299000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb0d53388f4d42a58ab06e6add14cb87_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMTAtMS0xLTE2NzY2NQ_09afb792-4a9c-4ab8-b31f-14337dac416b"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icbff194d4ca5433aa7e19eed529284a5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMTItMS0xLTE2NzY2NQ_4cf9d0c8-d220-4352-a9b3-12d4abf9b6e6"
      unitRef="usd">196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i343fb20119ca4a0e8613c7e22a4b527e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMTQtMS0xLTE2NzY2NQ_2167f1a8-9d53-4928-8b72-85c8f8c89c7c"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fd731dcc7c6442d9eb015fc7f92096b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMTYtMS0xLTE2NzY2NQ_6905cd3a-7522-4a93-896c-eeb4ea38868e"
      unitRef="usd">297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia90efc3a95e5478c9d184b269d0ceecc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMTgtMS0xLTE2NzY2NQ_775f1ae2-5bb5-4301-a785-ec06d02b931e"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i794d6401fe294df8a2c8c5f381e7766e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMjAtMS0xLTE2NzY2NQ_62f377f0-b36b-4d45-a6df-4429e498e0f3"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98fd41f3a3ce4161bf06001545fb251e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMjItMS0xLTE2NzY2NQ_a5fecfe3-c7d5-4e17-a820-4185a7b495a8"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ce29476464948ef99a1d86b1a2d50bf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDUtMjQtMS0xLTE2NzY2NQ_bb380e8d-a093-451f-9713-ff19521609aa"
      unitRef="usd">334000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie276f108be5d41f7bf6f6aec108cc38a_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMi0xLTEtMTY3NjY1_82e7478d-02d1-4644-8175-4bb5e11dec03"
      unitRef="usd">18884000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbc48146b4d84e27bff9ab5d3c8388e9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtNC0xLTEtMTY3NjY1_f636b5f0-6295-4860-a943-2a5c8dbc86ab"
      unitRef="usd">4469000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id83653adc14343229d0ecdf85dcc0b36_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtNi0xLTEtMTY3NjY1_11e366eb-1064-411a-8117-574904d62cc4"
      unitRef="usd">3928000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtOC0xLTEtMTY3NjY1_c957b0d4-f80a-4b3c-9067-1b8d32dbfe03"
      unitRef="usd">27281000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55695bcefff74f4a90f76506bacb48c1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMTAtMS0xLTE2NzY2NQ_fd2f77af-5502-4fdc-a331-7963613313f7"
      unitRef="usd">19267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44ec1db4248d428a8f326df992d5ba74_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMTItMS0xLTE2NzY2NQ_8d9bd720-5f8e-4a78-abf4-c5263942d61f"
      unitRef="usd">4874000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd5cf4c53b074c43b621eb8f8a9aa397_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMTQtMS0xLTE2NzY2NQ_4841b541-766b-4d53-908b-f156a4afd1b3"
      unitRef="usd">3164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMTYtMS0xLTE2NzY2NQ_f05cef92-001a-49f0-a582-05752f8bc1fc"
      unitRef="usd">27305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6943cae579d9493b901bd4c64167f279_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMTgtMS0xLTE2NzY2NQ_a431c02e-3a19-434d-b615-6792b3d152fd"
      unitRef="usd">18217000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4906ad8453c4207b906de6e1a183a7c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMjAtMS0xLTE2NzY2NQ_5d80b833-40cf-43f0-b2ff-be53815f69b2"
      unitRef="usd">4135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92af14de4d6e45c28faa18feca763fe7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMjItMS0xLTE2NzY2NQ_1422212c-f29d-4f7c-9929-2f172c20b03d"
      unitRef="usd">2337000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmIzYTFmYzVmNmVjMTQ3NTlhMGM4MzAwNTI4NmNmNTQ5L3RhYmxlcmFuZ2U6YjNhMWZjNWY2ZWMxNDc1OWEwYzgzMDA1Mjg2Y2Y1NDlfNDYtMjQtMS0xLTE2NzY2NQ_446ab151-a0ac-4113-9494-970d1a0df6aa"
      unitRef="usd">24689000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMjUzOA_63ad05c2-3bd1-4ac4-aa6f-5fd794be195b">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.699%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.702%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(as a percentage of total revenues)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i86eb6bdf28e54e3cbf341a8b16bceb07_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfMi0yLTEtMS0xNjc2NjU_67148e10-1022-400b-a20e-ca97def49b2a"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0face3f5bfd147f59b55ecdd4534fa47_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfMi00LTEtMS0xNjc2NjU_f412fd95-4f9c-44bf-8410-bc34cc3eb254"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2c332f0a85d243b0b2f856949a44e2d2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfMi02LTEtMS0xNjc2NjU_eb25157a-f2f4-4242-947f-fb8438d34e51"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i28e35fde408143f1b5cdd3758261b912_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfMy0yLTEtMS0xNjc2NjU_5798e691-410b-449a-81a7-2a0e267cae89"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iee00e346b51a47dca4aa5cc9604337d3_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfMy00LTEtMS0xNjc2NjU_8e929028-c889-4379-be3e-032bc9362b6b"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if9e8f79ffaa54a4f8353a2e74e70d2fa_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfMy02LTEtMS0xNjc2NjU_170b435f-1ac4-4882-8dbd-c78a3c55b487"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib67a8beee1994fe2a9cfb4af6a2b4b81_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfNC0yLTEtMS0xNjc2NjU_359e04b4-d6a5-442b-9793-093fb4863926"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i133bd58bb3044e43b6e19b3c2019b2c9_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfNC00LTEtMS0xNjc2NjU_e1beaa29-7cb5-4da0-9f46-15f975e722ca"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0b1a0954ab4c4c079b9fa4cff95a21bf_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOmU1N2U1YjYxOGQwMzQ0NTdiZTM1YTFkZDU1NGJkZjMxL3RhYmxlcmFuZ2U6ZTU3ZTViNjE4ZDAzNDQ1N2JlMzVhMWRkNTU0YmRmMzFfNC02LTEtMS0xNjc2NjU_99b24a6b-2ca6-47f1-b5e9-2e9fe0e00c65"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMTMxOTQxMzk1NDM3MTI_fb1b1af2-57e6-4a45-988d-cd0c357bd630">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes revenues recognized from performance obligations satisfied in prior periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue share with Janssen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; and royalties for licenses of intellectual property&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 10. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOjg2ZDNlMjExYWU4YjQzMjBhNmY1ZjBhN2UwNGEzYzFiL3RhYmxlcmFuZ2U6ODZkM2UyMTFhZThiNDMyMGE2ZjVmMGE3ZTA0YTNjMWJfMy0yLTEtMS0yMDQ5Nzc_2fe69acb-4739-4eb6-9860-e358cc03cf6b"
      unitRef="usd">783000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOjg2ZDNlMjExYWU4YjQzMjBhNmY1ZjBhN2UwNGEzYzFiL3RhYmxlcmFuZ2U6ODZkM2UyMTFhZThiNDMyMGE2ZjVmMGE3ZTA0YTNjMWJfMy00LTEtMS0yMDQ5Nzc_d99d6c46-01ce-4bcf-b314-6cb2e480dd20"
      unitRef="usd">851000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOjg2ZDNlMjExYWU4YjQzMjBhNmY1ZjBhN2UwNGEzYzFiL3RhYmxlcmFuZ2U6ODZkM2UyMTFhZThiNDMyMGE2ZjVmMGE3ZTA0YTNjMWJfMy02LTEtMS0yMDQ5Nzc_aedaf745-956a-41e4-9fc4-d53c8b291264"
      unitRef="usd">841000000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOjg2ZDNlMjExYWU4YjQzMjBhNmY1ZjBhN2UwNGEzYzFiL3RhYmxlcmFuZ2U6ODZkM2UyMTFhZThiNDMyMGE2ZjVmMGE3ZTA0YTNjMWJfNC0yLTEtMS0yMDQ5Nzc_c382604c-a102-43c7-be24-c7be522697c3"
      unitRef="usd">582000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOjg2ZDNlMjExYWU4YjQzMjBhNmY1ZjBhN2UwNGEzYzFiL3RhYmxlcmFuZ2U6ODZkM2UyMTFhZThiNDMyMGE2ZjVmMGE3ZTA0YTNjMWJfNC00LTEtMS0yMDQ5Nzc_f572a1ee-310a-423c-91ab-2a84ca0459fa"
      unitRef="usd">856000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RhYmxlOjg2ZDNlMjExYWU4YjQzMjBhNmY1ZjBhN2UwNGEzYzFiL3RhYmxlcmFuZ2U6ODZkM2UyMTFhZThiNDMyMGE2ZjVmMGE3ZTA0YTNjMWJfNC02LTEtMS0yMDQ5Nzc_08760180-18cc-4a38-98b0-36f1e59d7b53"
      unitRef="usd">101000000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMTA5OTUxMTYzNjE5Mw_e0a2bef9-96b1-4170-984d-3e80c5a8f40c"
      unitRef="usd">171000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMTA5OTUxMTYzNjE4Ng_06500c02-7409-498a-acb4-3c89f3d7014a"
      unitRef="usd">174000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMTA5OTUxMTYzODExNQ_4678f705-6461-4bb7-b7a4-123de810f95b"
      unitRef="usd">102000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185NC9mcmFnOjE5NmJiMDczNjI4ZTRlMWNhNzcwYWFhMDBhNTViZjZlL3RleHRyZWdpb246MTk2YmIwNzM2MjhlNGUxY2E3NzBhYWEwMGE1NWJmNmVfMTA5OTUxMTYzODExOA_02e5ab10-8f52-4a05-8b74-ed3095096b52"
      unitRef="usd">79000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfNzg0MA_3f9ceae0-c84a-41a6-be7d-09dcc9389b3f">FAIR VALUE MEASUREMENTS &lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos NV (&#x201c;Galapagos&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Arcus Biosciences, Inc. (&#x201c;Arcus&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for MYR GmbH (&#x201c;MYR&#x201d;) contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 10. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 2 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Derivative Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;amp;P Global Ratings, Moody&#x2019;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimated fair values of our senior unsecured notes, determined using Level 2 inputs based on their quoted market values, were approximately $21.9 billion and $28.6 billion as of December&#160;31, 2022 and 2021, respectively, and the carrying values were $24.1 billion and $25.6 billion as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 3 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our first quarter 2021 acquisition of MYR, we recorded a liability for contingent consideration, which is revalued each reporting period until the related contingency is resolved. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of Hepcludex.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the change in fair value of our contingent consideration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation assumptions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange remeasurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Included in Research and development expenses on our Consolidated Statements of Income and primarily related to increasing discount rates and updated probability rate estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Included in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability Related to Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded a liability related to future royalties as part of our fourth quarter 2020 acquisition of Immunomedics, Inc. (&#x201c;Immunomedics&#x201d;), which is subsequently amortized using the effective interest method over the remaining estimated life. The fair values of the liability related to future royalties were $1.1&#160;billion and $1.3&#160;billion as of December&#160;31, 2022 and 2021, respectively, and the carrying value was $1.1&#160;billion as of December&#160;31, 2022 and 2021. See Note 11. Debt and Credit Facilities for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, we recorded a partial impairment charge of $2.7&#160;billion related to certain IPR&amp;amp;D assets. See Note 8. Goodwill and Intangible Assets for additional information. There were no indicators of impairment noted during 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Fair Value Level Transfers&lt;/span&gt;&lt;/div&gt;There were no transfers between Level 1, Level 2 and Level 3 in the periods</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfNzgyOA_0b4f1b8a-297e-44db-a499-53fd208430e9">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Galapagos NV (&#x201c;Galapagos&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment in Arcus Biosciences, Inc. (&#x201c;Arcus&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability for MYR GmbH (&#x201c;MYR&#x201d;) contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See Note 10. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i88c34d1a31564a41b639cee23ce6e2a3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC0yLTEtMS0xNjc2NjU_869219cf-d25c-4eb0-afa2-3b1d8c0625ec"
      unitRef="usd">410000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iaf9113abd39d46f397a0870bd4c9cdc8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC00LTEtMS0xNjc2NjU_8fad10bd-4792-4873-b93d-ad3eb465ed51"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0bee5e30cfa2426f9d380bc5925fcac9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC02LTEtMS0xNjc2NjU_b2fd33b0-783f-40c8-a8e9-a2460c572a3f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7cfca0b59b604750a7f306bd9362a183_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC04LTEtMS0xNjc2NjU_7bbdff6e-c8d8-4b8d-a8fd-1423b91fbb6d"
      unitRef="usd">410000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if6c99e845b70436ca2df28ab68166418_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC0xMC0xLTEtMTY3NjY1_d7544d70-c865-4374-b7d0-41549d342245"
      unitRef="usd">407000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0a483101b0c448358a8bd230e176fff0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC0xMi0xLTEtMTY3NjY1_7d187e74-308e-4c93-9d4d-da5da20ad727"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3808d9c4a2e146bc9d87fcf438476f8c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC0xNC0xLTEtMTY3NjY1_bfde0625-a3f8-4351-8d46-94852d919363"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0bf751057be34c59b162ff5ec611226d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNC0xNi0xLTEtMTY3NjY1_7d02e998-3e31-4eeb-b9d7-9160c66a79b2"
      unitRef="usd">407000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2ad0ba308ad04f38a0ff215fa0aacb6f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS0yLTEtMS0xNjc2NjU_09a1ec28-4d5f-43c0-be9b-3ce351c74454"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1c405fdc93ac4546907dd695172e2ce9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS00LTEtMS0xNjc2NjU_7c7c7b8c-481b-4713-8bb2-2b6f8070bba2"
      unitRef="usd">35000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ibb6db70d966741b8be2616a8bd67d2e8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS02LTEtMS0xNjc2NjU_e3a4b2ef-b361-43a8-9113-910c9f6e1e5c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ifd515e9c1c6b4b0b8621d96b2531c80d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS04LTEtMS0xNjc2NjU_74700481-e8ad-4dfd-a9f2-ed27ece0894a"
      unitRef="usd">35000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id3dcf159fc7b46349235521b48359fa2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS0xMC0xLTEtMTY3NjY1_1f796aa5-1843-456c-82bd-718e90fbdf5c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i20ebe72fb6da4c999fc461851f94ee96_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS0xMi0xLTEtMTY3NjY1_c69ce711-65c6-4366-9b9c-a69a7874e867"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2478182a4b4e4e1487d776c80659bc45_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS0xNC0xLTEtMTY3NjY1_5ecf41c6-babb-459f-9c26-a6b3ca81bd9a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="icdd0a17887254d5a9c770861de71e83e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNS0xNi0xLTEtMTY3NjY1_4c62be33-3dd7-476d-a2e9-c764a5a4c774"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie157b97ed1b142c8bfb14e1fcd0d779a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi0yLTEtMS0xNjc2NjU_fb22c4f4-5553-456c-918d-8eb643ab14b2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i37f394996de54d9db35d84fd2f8d9ef7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi00LTEtMS0xNjc2NjU_b9ea8cb7-d20f-46a6-8fa3-7e21f0c72c7b"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id3900a5a96df424da8d5920aec948465_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi02LTEtMS0xNjc2NjU_22bb391f-1136-4763-a99e-49eb871c3587"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia4bdf8861d83422885dbc7a9b650a26b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi04LTEtMS0xNjc2NjU_eb9c6503-6272-4562-bab3-faa5eff1541f"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib91c1acddeb04eea8c21245a6b6d170c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi0xMC0xLTEtMTY3NjY1_7df58ee8-79b5-4b38-84bf-901aadf20d82"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic45d2c331f304e139eb2373b4aeea8ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi0xMi0xLTEtMTY3NjY1_c611d1d5-2e9e-4b8b-aef6-cb5303db4e53"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0983c44cb0734541a17aa9caaa5ab892_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi0xNC0xLTEtMTY3NjY1_d685c696-8bcd-45d7-9d6c-fb4f4ee40c4d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8cb3270aa34d4ff1b804ace86710f83c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNi0xNi0xLTEtMTY3NjY1_b436460d-d40e-405d-a84a-dda7490ff17c"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib94f769c7f244c9e88d0a8e925d81a3b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy0yLTEtMS0xNjc2NjU_a0ac2ec5-13ee-4424-8438-d62ee439ae76"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i488df48c29e54b3593d5488e3d330c61_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy00LTEtMS0xNjc2NjU_15ae8222-f3da-4974-ad20-30495ed110fc"
      unitRef="usd">54000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i5db63b134cb94dcf9570583d7adafdf6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy02LTEtMS0xNjc2NjU_3f9596d1-957d-4d99-a49e-bae5c27983f4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iaa4ad0ad8aba4b84beeeb124f4ea9111_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy04LTEtMS0xNjc2NjU_056e633e-f529-44d2-8541-15bc3fc3bc9b"
      unitRef="usd">54000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7ea779af859f47d89962f097d7265f0a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy0xMC0xLTEtMTY3NjY1_3ba930e4-0683-4c01-878e-2448888ab43b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ifd1b17c5a8674218abaf2a1683840aaf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy0xMi0xLTEtMTY3NjY1_57f2ccc6-1be4-421f-b112-a331ff6111cf"
      unitRef="usd">249000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i618bd4f52005481f8b9ee51618d178c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy0xNC0xLTEtMTY3NjY1_272b7c36-d4d6-453c-ad96-c30d4d752b2b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="idbf59e9f2f2d4d67b113295c7b4d1089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfNy0xNi0xLTEtMTY3NjY1_38205a07-b0ff-453f-b9a7-3036b9f8e515"
      unitRef="usd">249000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4374b3f59dcb41f88c069c68eef7cb1b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC0yLTEtMS0xNjc2NjU_be0dc90c-84b0-43d4-b8dc-7b11171ffb81"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iedcb3258e37243aa808a6fa8be5a770b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC00LTEtMS0xNjc2NjU_5510de87-18a9-4300-a1e7-9984ab52dba2"
      unitRef="usd">1427000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib47bca5eb2de4839b8e148ae5a0de84f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC02LTEtMS0xNjc2NjU_219467e4-c4e4-4559-a10a-7e8e7c3602c6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib4eb920885a343a481088353353f3232_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC04LTEtMS0xNjc2NjU_ea3006c5-e10e-4070-af04-d1a01b72129b"
      unitRef="usd">1427000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i88ec60685e024c9a9d982e1a4ff3ae64_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC0xMC0xLTEtMTY3NjY1_9adfcfee-2fd8-48c0-9981-8fc43da41a54"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if92841c2bf314e908654618e08167aba_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC0xMi0xLTEtMTY3NjY1_1749ac25-03a5-4f64-9369-6a48d7e22965"
      unitRef="usd">1363000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i773b7fbb6ae64c61836fd54bba47d25a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC0xNC0xLTEtMTY3NjY1_e54ff0ba-092e-4a29-80c6-d1a165550275"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i5bf409fd77ce4f9a90bb11514b042cff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOC0xNi0xLTEtMTY3NjY1_f01510fd-e3c4-4944-8e47-48bf1dcbc9a1"
      unitRef="usd">1363000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i018a6b73fef648df813ad16b7e2eadb3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS0yLTEtMS0xNjc2NjU_b95d7633-043f-4e10-96cd-4745505aa86e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i07414abcd214485880e84c068a03395f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS00LTEtMS0xNjc2NjU_8616656c-5742-4315-a6c3-25e403129ce4"
      unitRef="usd">333000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie19dd55d40234f4aa0cb87ba2849918b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS02LTEtMS0xNjc2NjU_d4bba44d-b48b-4d63-892e-b37f9e47fa02"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1e2a4623b8824759a123ab21bf6411c1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS04LTEtMS0xNjc2NjU_fd544916-9aa8-46cd-b9d3-d031e5d4c56d"
      unitRef="usd">333000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib084fcedcc844984a042bbb471e335d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS0xMC0xLTEtMTY3NjY1_4ff240ce-8b05-4b5b-82a3-3f9d7d89f8e4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i099761b72f8945b5941d06a0e1567729_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS0xMi0xLTEtMTY3NjY1_1fb52e21-e60d-40cd-abb3-19be5f901060"
      unitRef="usd">424000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0fcf55829c924deebe56a00be5ac0c2f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS0xNC0xLTEtMTY3NjY1_0ceea604-0e16-4ad4-97fe-080dc057b943"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iaf63565ba06a41a18d32952215669dc5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfOS0xNi0xLTEtMTY3NjY1_c8b391e3-765a-4e15-a30f-d531a7047a8e"
      unitRef="usd">424000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3e733fc488aa402d8d8717e0955e5672_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtMi0xLTEtMTY3NjY1_ea1bafc3-0394-4e41-be33-4be18d1fc909"
      unitRef="usd">3831000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic7e16303ba004af899fc51df2e60f7da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtNC0xLTEtMTY3NjY1_0ffef966-df94-4642-9c7b-bf36aac16d07"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i02675adb1f704219bbfa6df72958ccf9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtNi0xLTEtMTY3NjY1_f75104ae-a306-4c0a-8e34-8b4957c7d007"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic14516a4cc9c4cf4b87bc4e6c89da010_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtOC0xLTEtMTY3NjY1_3337784c-dc19-4b32-b706-875ba466037c"
      unitRef="usd">3831000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i944a69baa46241a78832dfd6edb03619_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtMTAtMS0xLTE2NzY2NQ_f24816f9-aa63-4b80-9736-8007f3c45aa4"
      unitRef="usd">3661000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i94e8996fcf904aefa7b45eb05d8a1b9f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtMTItMS0xLTE2NzY2NQ_85c7ed0b-a75a-49f6-b7a3-ef1524319380"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i41782720cc44450d8ecfa13b2c8eba6a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtMTQtMS0xLTE2NzY2NQ_d9f3fa94-0d7c-4680-ba1b-5283eb097fa2"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i39ea15b99df04bd1a91357ea2c784fb1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTEtMTYtMS0xLTE2NzY2NQ_6d604c0e-020b-4eac-9a4e-229178621070"
      unitRef="usd">3661000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie5c4c24154784954be6af020baa2783d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItMi0xLTEtMTY3NjY1_dd292c2b-1808-440f-ae49-d19d8daf28d0"
      unitRef="usd">736000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if72d0c8e59074c399a7a8d5de4a0d84c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItNC0xLTEtMTY3NjY1_2c219b6b-1502-4b94-b9e4-fa19bfdb7bfe"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i69dc8a4d00924a239a188dc5ae14f7e8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItNi0xLTEtMTY3NjY1_3c02a36a-8d91-4fb7-bb8e-f99b8d3359cc"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2c6ab0f463354216aaf151d6b3782c66_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItOC0xLTEtMTY3NjY1_5ced05d1-af10-46ca-a7c2-f8f89cdcb630"
      unitRef="usd">736000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iaeb19fd2013648c5b7c1b740c697a80f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItMTAtMS0xLTE2NzY2NQ_1a9a6ccc-0681-4d39-8fe0-175eb0560be9"
      unitRef="usd">931000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1382e07fb1b3414fa219beccffc330e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItMTItMS0xLTE2NzY2NQ_8de0924f-bfbe-489c-a134-1b57b815af75"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8cda06ee09b140cb827aed9e1a3df8bf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItMTQtMS0xLTE2NzY2NQ_95782666-0193-4169-b28b-17095078187e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4f5633d790d049eb8451a5b270d77750_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTItMTYtMS0xLTE2NzY2NQ_75472aa4-9c79-4f3c-bb03-6ff883fa4892"
      unitRef="usd">931000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ied3cb02615a94f4a8ceb1be0e567f340_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtMi0xLTEtMTY3NjY1_9e270e66-88db-470a-b66a-acc72be0761a"
      unitRef="usd">286000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3d43b6e593fa4c628617fc5b9f8381e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtNC0xLTEtMTY3NjY1_81d2e08a-66b6-4946-a41a-644f3d8ab327"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0ca783d57092471f8f9c2a0e850ac09c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtNi0xLTEtMTY3NjY1_dc0fcf9e-f4c3-43fd-9510-f436a59b7c4b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7ea06efd22dd4661bfb5cd9adaff66df_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtOC0xLTEtMTY3NjY1_6bb74321-3f34-4911-96b6-72efd53baebc"
      unitRef="usd">286000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if89553c3611c4e288ce130b8d3ac5113_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtMTAtMS0xLTE2NzY2NQ_eac93ce7-5e9c-4a87-a3f3-7d6a8ac55174"
      unitRef="usd">559000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i08fcddcda0ac40758fc2ee38e6741a4a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtMTItMS0xLTE2NzY2NQ_5c52847d-bdf2-43cc-9353-73ec81d294ce"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0f315354a63246aca5ced4ec8972897c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtMTQtMS0xLTE2NzY2NQ_1d866973-5d50-4ca0-acfb-99c57d14dd68"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i327c843055444377ab16bab2849e6c00_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTMtMTYtMS0xLTE2NzY2NQ_7a46a3dc-cbe4-4001-9615-431c28d2412f"
      unitRef="usd">559000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ide95ae75ed8c423695c053ecd6b2da97_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtMi0xLTEtMTY3NjY1_57c0357c-b57f-4e83-b666-1818d977a814"
      unitRef="usd">175000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icd60b83d9abb419d9f60987e3d02e8cd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtNC0xLTEtMTY3NjY1_f9dc5f4d-a738-4ac5-af5f-6d43badab813"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i894b79ae5fbe43b2a34999235fe34725_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtNi0xLTEtMTY3NjY1_6cd84751-a31b-4b2c-98b3-ecaa20bad567"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i983c7f539ca14293b59e2fe55bbce4b0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtOC0xLTEtMTY3NjY1_01c175be-0a56-4fe1-90b4-6e7483092ff9"
      unitRef="usd">175000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5a6894a7e98f4519a8f9e29d935836aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtMTAtMS0xLTE2NzY2NQ_3d1f4b4a-de7e-48cb-9752-674cc94a4b6c"
      unitRef="usd">331000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6a77b8962a7b4133b9c80ea7b093866e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtMTItMS0xLTE2NzY2NQ_f8002dcd-e7c6-4344-926f-ce99980267ef"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iff764d89cbbe483ba2bacb34b6224c68_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtMTQtMS0xLTE2NzY2NQ_83b3fa63-2596-4493-ad25-403d696e0e6d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icb43dd0a466b491faff2c751f3a877c9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTQtMTYtMS0xLTE2NzY2NQ_f26e8035-79fc-4dc0-86d3-1e2fd38ed592"
      unitRef="usd">331000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i38d985d4e3d9474ebcab3db7e6a6ee15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtMi0xLTEtMTY3NjY1_2bbb7370-031c-4eb7-bf4d-109030963e70"
      unitRef="usd">220000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i21959734d0a54ddcb46382c2339b2f8c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtNC0xLTEtMTY3NjY1_0d39ac8e-e758-4781-9d3a-38b7b120d3c8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib378be3a5b704e4ebb3dc87fcddff125_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtNi0xLTEtMTY3NjY1_08e06dd1-d869-4642-8f0d-3ff82bd70ee0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9701ad4aac1b429ba132c36256901aa8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtOC0xLTEtMTY3NjY1_39951f47-4251-47e7-95d5-76494517397e"
      unitRef="usd">220000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i86d573d5c055472aa3815285608a7bfd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtMTAtMS0xLTE2NzY2NQ_70f16f1d-121c-477e-b1c0-9f36f8b1068a"
      unitRef="usd">261000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i11ec8cf5f17e4fc1b6fbc896b8b377f5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtMTItMS0xLTE2NzY2NQ_c834794e-b525-4ea6-834d-a4c5a90abaab"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if89123ef0fcf45cebe2871f98a115ee8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtMTQtMS0xLTE2NzY2NQ_ef05455b-0a88-437e-bf84-547dd8631d69"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i56e6656d2b2349758ad1672abcde5f04_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTUtMTYtMS0xLTE2NzY2NQ_1b320656-2904-4ad7-92c5-8e5538938982"
      unitRef="usd">261000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i3056f9b6e43746a586f484704ba24280_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtMi0xLTEtMTY3NjY1_386c34d6-e6d2-4906-a9cd-439e15275bcd"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i177d34f888fa40768c93e77bd471d6ac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtNC0xLTEtMTY3NjY1_b2c80763-4956-40a3-9938-7c34d908226a"
      unitRef="usd">60000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ibf1408e9098f40baa057cd1cfc7888f5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtNi0xLTEtMTY3NjY1_a19a7d11-0634-4116-8959-73d01329aaab"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i1ce378a3eb1f4ebba108c7b8e6e3fd0b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtOC0xLTEtMTY3NjY1_cc07fab6-464c-493e-a32e-49dda4bf5050"
      unitRef="usd">60000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ib233c60e47c6477a9eb3e08f380cda48_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtMTAtMS0xLTE2NzY2NQ_a80d4556-3f90-41f4-8e22-555e7bb919b9"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i0b61ed2454aa4bc2a404ffa25a550770_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtMTItMS0xLTE2NzY2NQ_21367340-0ec7-436b-bdc5-1a6c3a540e2f"
      unitRef="usd">80000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i2e4adf40d5824c4fbe26cd8dcbfbf227_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtMTQtMS0xLTE2NzY2NQ_59db7701-c104-409b-94c1-c09b56a45d0a"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ie454a27fc82f4874b5cda233495e0206_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTYtMTYtMS0xLTE2NzY2NQ_23c0bab1-6719-4203-9eef-40cf8db12201"
      unitRef="usd">80000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie78f1ffe90f34e168923153a6356d08e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctMi0xLTEtMTY3NjY1_6afef008-f26c-40b3-a2e3-26f4a6290a06"
      unitRef="usd">5658000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ief9bc9ff381a4854850cbd8345981bc5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctNC0xLTEtMTY3NjY1_376a5460-36ab-47d2-9657-4d7e4275c85a"
      unitRef="usd">1943000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3770d09680134e1792a2afb46bb64c8a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctNi0xLTEtMTY3NjY1_10fdad66-0310-4d1c-a3a0-33880fff210a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i258640a7c57747aeb519ee9e07186999_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctOC0xLTEtMTY3NjY1_a9c4a984-d916-46c8-ad2e-ffa7e6c7d093"
      unitRef="usd">7600000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i39c7630058f7482b8663c73873f905cf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctMTAtMS0xLTE2NzY2NQ_b38101cc-a1b8-454c-99f1-284835fd1a25"
      unitRef="usd">6150000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if091fd24a2e744cc84af3abc98b8f3f5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctMTItMS0xLTE2NzY2NQ_f7073205-94e8-4417-8299-119bef9141da"
      unitRef="usd">2170000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia14bcf8248ac4a89ac301d6111091e59_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctMTQtMS0xLTE2NzY2NQ_9b7d01bd-55ec-43b8-b4e2-2a72ac1d4588"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1dd2083018754b229660065eb3c2d886_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTctMTYtMS0xLTE2NzY2NQ_d3e1ccff-f2f0-4c38-8aad-3f1cc83a8cb4"
      unitRef="usd">8320000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idfb7080a46984104933ddc77a231978a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktMi0xLTEtMTY3NjY1_8308f67d-a92a-4868-948d-cf06c9ed9428"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7a2c198018764025b669a401e4b72f02_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktNC0xLTEtMTY3NjY1_d7f9f0d5-e694-4a95-a15d-87bbbf8fd0c4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iccefd6d5263c4c06812886b75ec30089_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktNi0xLTEtMTY3NjY1_2a792249-1fa3-4ac9-a2c7-75d1b3004ace"
      unitRef="usd">275000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1ca5b496a82144a99398868f529cc733_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktOC0xLTEtMTY3NjY1_982352e8-d8e9-4ecd-888c-42465879fd6b"
      unitRef="usd">275000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i85d0914f5c72425b8a8d68428082805c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktMTAtMS0xLTE2NzY2NQ_2dbff62b-9827-4418-9075-bc4e45e6aa7e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idcaa8320537e4f41a1cac571eb1d4c4b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktMTItMS0xLTE2NzY2NQ_32dc0019-5041-4c37-ac71-999c9e9dc37b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6ac85363bb5744b9a9f23b5639f332c9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktMTQtMS0xLTE2NzY2NQ_58690734-cd32-435d-b390-410aace59ea4"
      unitRef="usd">317000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iedbbc78ef8e242f2b89fc61cceca1611_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMTktMTYtMS0xLTE2NzY2NQ_3401ddc4-2fa4-4991-bfbc-0bf7ccbee662"
      unitRef="usd">317000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i38d985d4e3d9474ebcab3db7e6a6ee15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtMi0xLTEtMTY3NjY1_fc55e3cb-03de-4c5d-bd51-679abc8c94f2"
      unitRef="usd">220000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i21959734d0a54ddcb46382c2339b2f8c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtNC0xLTEtMTY3NjY1_a11f31c7-cf17-48bb-a6df-8860dbcf4b72"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ib378be3a5b704e4ebb3dc87fcddff125_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtNi0xLTEtMTY3NjY1_5480c245-5c76-4bc5-bf39-f51e08c0a512"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i9701ad4aac1b429ba132c36256901aa8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtOC0xLTEtMTY3NjY1_d23d0d0f-c123-477e-97ae-e113d9d25237"
      unitRef="usd">220000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i86d573d5c055472aa3815285608a7bfd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtMTAtMS0xLTE2NzY2NQ_4c1ff52f-aea8-4a5a-b169-49df7b7efc5f"
      unitRef="usd">261000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i11ec8cf5f17e4fc1b6fbc896b8b377f5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtMTItMS0xLTE2NzY2NQ_846209e1-cef0-49ca-8686-5475361fbc7a"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="if89123ef0fcf45cebe2871f98a115ee8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtMTQtMS0xLTE2NzY2NQ_3ce5d923-a74e-4161-9552-f2126e02c037"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i56e6656d2b2349758ad1672abcde5f04_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjAtMTYtMS0xLTE2NzY2NQ_e6c415fe-346d-403c-b9b9-327c497a278f"
      unitRef="usd">261000000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i3056f9b6e43746a586f484704ba24280_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtMi0xLTEtMTY3NjY1_cba46e10-1dba-4866-ae09-455b87935b3e"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i177d34f888fa40768c93e77bd471d6ac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtNC0xLTEtMTY3NjY1_85696489-210d-489b-bf38-1f1c6d63d258"
      unitRef="usd">42000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ibf1408e9098f40baa057cd1cfc7888f5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtNi0xLTEtMTY3NjY1_d34d91a9-16b3-421c-a621-d931dad86a95"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i1ce378a3eb1f4ebba108c7b8e6e3fd0b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtOC0xLTEtMTY3NjY1_c8e6723f-b069-4881-a4fe-9a127514b8fa"
      unitRef="usd">42000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ib233c60e47c6477a9eb3e08f380cda48_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtMTAtMS0xLTE2NzY2NQ_74931c87-88aa-41d2-ba97-6bc0bc57b1c9"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i0b61ed2454aa4bc2a404ffa25a550770_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtMTItMS0xLTE2NzY2NQ_08227898-4f48-4b82-93db-3b67258fc1ef"
      unitRef="usd">5000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i2e4adf40d5824c4fbe26cd8dcbfbf227_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtMTQtMS0xLTE2NzY2NQ_d0ebd856-c216-4ef6-ad1c-ab788ecf5e59"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ie454a27fc82f4874b5cda233495e0206_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjEtMTYtMS0xLTE2NzY2NQ_00b3f51c-b986-4a06-b03b-5393e9ada7f8"
      unitRef="usd">5000000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie78f1ffe90f34e168923153a6356d08e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItMi0xLTEtMTY3NjY1_12120f28-0c8d-4445-961c-be7ecf93dc4c"
      unitRef="usd">220000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ief9bc9ff381a4854850cbd8345981bc5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItNC0xLTEtMTY3NjY1_cb803adb-91e7-45ef-bf4a-31fa7dee8cfa"
      unitRef="usd">42000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3770d09680134e1792a2afb46bb64c8a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItNi0xLTEtMTY3NjY1_e32136cc-75c1-4498-ac0f-30ea8c422acd"
      unitRef="usd">275000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i258640a7c57747aeb519ee9e07186999_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItOC0xLTEtMTY3NjY1_b0eee1d3-e0cb-4ef3-b912-8fd22d019a9c"
      unitRef="usd">538000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i39c7630058f7482b8663c73873f905cf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItMTAtMS0xLTE2NzY2NQ_2bfe8b3d-b9d0-4558-8b39-906f90775ec0"
      unitRef="usd">261000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if091fd24a2e744cc84af3abc98b8f3f5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItMTItMS0xLTE2NzY2NQ_f035706a-23ea-498b-b8ef-9cdf800ac345"
      unitRef="usd">5000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia14bcf8248ac4a89ac301d6111091e59_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItMTQtMS0xLTE2NzY2NQ_3f5b7ce0-1b2e-4bdd-9eff-0f7d000dbc05"
      unitRef="usd">317000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1dd2083018754b229660065eb3c2d886_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOmQ3MDEyN2I0ZTFjNjRkZDI4ZTM3MWUyZDUxMzFmOTA5L3RhYmxlcmFuZ2U6ZDcwMTI3YjRlMWM2NGRkMjhlMzcxZTJkNTEzMWY5MDlfMjItMTYtMS0xLTE2NzY2NQ_419e1716-9bc5-4f00-a4bb-75e1a6740da2"
      unitRef="usd">583000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfNzY5NjU4MTQxMzc1MA_b425bcb5-3b15-4f04-af27-2a4bdfc267cf">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 2 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our available-for-sale debt securities, we estimate the fair values by reviewing trading activity and pricing as of the measurement date, and by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Derivative Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our foreign currency derivative contracts have maturities within an 18-month time horizon and all are with counterparties that have a minimum credit rating of A- or equivalent by S&amp;amp;P Global Ratings, Moody&#x2019;s Investors Service, Inc. or Fitch Ratings, Inc. We estimate the fair values of these contracts by taking into consideration the valuations obtained from a third-party valuation service that utilizes an income-based industry standard valuation model for which all significant inputs are observable, either directly or indirectly. These inputs include foreign currency exchange rates, Secured Overnight Financing Rate and swap rates. These inputs, where applicable, are observable at commonly quoted intervals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Level 3 Inputs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our first quarter 2021 acquisition of MYR, we recorded a liability for contingent consideration, which is revalued each reporting period until the related contingency is resolved. The contingent consideration was estimated using probability-weighted scenarios for U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approval of Hepcludex.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i08f3914c4bd548ffa8c16f9da7bd4df7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfNzY5NjU4MTQxNTc1OA_de4fc7ef-142f-4590-96c4-d84157e3da42">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:LongTermDebtFairValue
      contextRef="if7e357738293475089434472816fe934_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTYzNzkxNA_33b427da-d33f-42b0-ad37-2e53d159b4e0"
      unitRef="usd">21900000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib93c734b7bfa468486822daca4f70209_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTYzNzkwNw_b3ea4678-cbaf-46be-9912-0578fe21d2a9"
      unitRef="usd">28600000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if172c306038b41f48386ed7ae399787a_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTYzNzk0MQ_1ff830db-4d48-4323-b80a-6fa866c69588"
      unitRef="usd">24100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i126cf5d37167408d897b7f47dbb2f508_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTYzNzk0OQ_e3ad324b-cdc1-408d-bf3a-a2d2d6eb1ebf"
      unitRef="usd">25600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTQyOTM2NTExODAzNjU_42fe3f36-7b1d-4ba9-a775-697db455fb3f">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the change in fair value of our contingent consideration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation assumptions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange remeasurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Included in Research and development expenses on our Consolidated Statements of Income and primarily related to increasing discount rates and updated probability rate estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Included in Other income (expense), net on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if398b36aa15c4bcdbd145f253add16fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfMi0yLTEtMS0yMDUyNzI_35b23a0d-90a2-41f1-8b58-9bd98aeba310"
      unitRef="usd">317000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i2aa74cadbdb34ed3b2763fe749e4a969_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfMi00LTEtMS0yMDUyNzI_d8a6e7bb-1270-42aa-9919-8cb506ced320"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="ie7609fb41a434a248c259460823ebb48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfMy0yLTEtMS0yMDUyNzI_e5f81b9e-8b4a-4af1-a46b-d443ddcc52bb"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="ifb2efdf458554bab8ef48f6d397f4e6a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfMy00LTEtMS0yMDUyNzI_82ae103d-09e7-4b4a-9a2b-24bbbba5eb29"
      unitRef="usd">341000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie7609fb41a434a248c259460823ebb48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfNC0yLTEtMS0yMDUyNzI_0471cb07-c8bd-458d-acf8-2c2fb7ddd2ea"
      unitRef="usd">-21000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ifb2efdf458554bab8ef48f6d397f4e6a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfNC00LTEtMS0yMDUyNzI_b881638b-847e-4a4b-aaa8-cfbf8645a7e4"
      unitRef="usd">-1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement
      contextRef="ie7609fb41a434a248c259460823ebb48_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfNS0yLTEtMS0yMDUyNzI_a78b2ea6-7171-4118-b901-4e9ddba6d6d1"
      unitRef="usd">-21000000</gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement>
    <gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement
      contextRef="ifb2efdf458554bab8ef48f6d397f4e6a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfNS00LTEtMS0yMDUyNzI_fddecdb0-efb1-4c8e-aea3-3037dc9c5cce"
      unitRef="usd">-23000000</gild:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if21d9ac9e987485c9b496bfee383aafa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfNi0yLTEtMS0yMDUyNzI_d5fcf8ae-1c10-4a01-bd6a-e2a92cf35d14"
      unitRef="usd">275000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if398b36aa15c4bcdbd145f253add16fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RhYmxlOjExNmY2ZGQ3OWQzOTQwZDZhMWM1MWRiYzQwYjk1MWRlL3RhYmxlcmFuZ2U6MTE2ZjZkZDc5ZDM5NDBkNmExYzUxZGJjNDBiOTUxZGVfNi00LTEtMS0yMDUyNzI_0ada7966-2394-469b-ae37-b016aa8bfe7f"
      unitRef="usd">317000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="ia10224614a2c4100ba6f83973aa40b07_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTY0MTExMg_b8b96e0f-d9a6-41d4-a5d9-c487587d40ba"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="ic3f06b3794e74e00a49aace81e6036af_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTY0MTEwMw_193fd1f5-2af7-44ec-8755-57918a3ddd11"
      unitRef="usd">1300000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i1cd161b557064dc88ec5537ac6193a18_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTY0MTEzMw_9a4ce6ab-c0c6-432e-a245-0c66f218090d"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i2fdbe18128244987a1e36b0904391b66_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTY0MTEzMw_f3d9cfc0-eb79-4288-b8b7-73ef37d20c57"
      unitRef="usd">1100000000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i99e1333e6d0f4c0a8d9fdea046b7eaf1_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN185Ny9mcmFnOmNiOThmYTQ2NzViOTQzMTY5ODRmZDljZTcyNjQ1NmM1L3RleHRyZWdpb246Y2I5OGZhNDY3NWI5NDMxNjk4NGZkOWNlNzI2NDU2YzVfMTA5OTUxMTY0NzEwMA_267cdb16-932b-4bbf-92e9-e25b2c54a72f"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzYyNQ_21cc43cb-c086-4318-ab19-645a157a0a91">AVAILABLE-FOR-SALE DEBT SECURITIES AND EQUITY SECURITIES &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No allowance for credit losses was recognized for investments with unrealized losses as of December&#160;31, 2022, as we do not currently intend to sell, and it is not more likely than not that we will be required to sell, such investments before recovery of their amortized cost bases. The unrealized losses were primarily driven by broader change in interest rates with no adverse conditions identified that would prevent the issuer from making scheduled principal and interest payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Securities Measured at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is classified in Other long-term assets due to certain lock-up provisions in our amended subscription agreement with them, which extend to August 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments and other equity investments without readily determinable fair values were $423 million and $338&#160;million as of December&#160;31, 2022 and 2021, respectively, and were excluded from the table above. These amounts were included in Other long-term assets on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unrealized Gains and Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net unrealized losses recognized on equity securities were $657 million, $610 million and $1.7 billion for the years ended December&#160;31, 2022, 2021 and 2020, respectively, and were included in Other income (expense), net on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Related Party Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022 and 2021, Gilead donated certain equity securities at fair value to the Gilead Foundation, a California nonprofit public benefit corporation (the &#x201c;Foundation&#x201d;). The Foundation is a related party as certain of our officers also serve as directors of the Foundation. The donation expense of $85 million and $212 million was recorded within Selling, general and administrative expenses on our Consolidated Statements of Income during the for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU5MA_978639d4-8b3b-4175-8c37-27ddedb17641">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItMi0xLTEtMTY3NjY1_28c58804-457b-414d-b8ed-702604f0f325"
      unitRef="usd">415000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItNC0xLTEtMTY3NjY1_b1a7fa53-671f-4d75-a0aa-619a02e958b7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItNi0xLTEtMTY3NjY1_8e51956e-55dc-4632-bc2f-5266e74ea4cb"
      unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItOC0xLTEtMTY3NjY1_3d28f61a-7e0d-46a1-b9b7-ee70eed1af80"
      unitRef="usd">410000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItMTAtMS0xLTE2NzY2NQ_d89ab38b-7c26-4b82-ba94-5cae607f1502"
      unitRef="usd">408000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItMTItMS0xLTE2NzY2NQ_330a2a95-2e9b-46e5-8a0e-a545c82e70f4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItMTQtMS0xLTE2NzY2NQ_a6948562-dba6-4ee7-badf-691fe3029692"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzItMTYtMS0xLTE2NzY2NQ_949f989a-1a17-4bff-8ebc-be8fd0a1f905"
      unitRef="usd">407000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtMi0xLTEtMTY3NjY1_38a0ecde-5c29-45c6-a452-a147f450f7a8"
      unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtNC0xLTEtMTY3NjY1_c2b8cb18-1032-4b65-b7c0-181b2e8aea4d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtNi0xLTEtMTY3NjY1_43fb472f-dad1-4974-aba2-7b75d7261557"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtOC0xLTEtMTY3NjY1_db0d7d45-cc01-4cd1-aede-b1737e51f757"
      unitRef="usd">35000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtMTAtMS0xLTE2NzY2NQ_82ae59a0-b613-4d32-92f3-ad1ea276689a"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtMTItMS0xLTE2NzY2NQ_4e28a50b-ae04-4ca3-af48-5f8dfd470eb8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtMTQtMS0xLTE2NzY2NQ_0a7935f9-41a7-4d31-93ed-30cc24d5e2fd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzMtMTYtMS0xLTE2NzY2NQ_a2b5c952-f798-4e91-9282-31a25ab1318e"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i4ff5933035664d28975731dea852a94b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtMi0xLTEtMTY3NjY1_41857e25-977c-4b26-b444-eb29913f9f8d"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4ff5933035664d28975731dea852a94b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtNC0xLTEtMTY3NjY1_9a9c0189-a57f-47ca-8b2b-e1e46d053dc4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4ff5933035664d28975731dea852a94b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtNi0xLTEtMTY3NjY1_b757d2ef-f3a6-4d4b-af9f-12ec2102448f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4ff5933035664d28975731dea852a94b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtOC0xLTEtMTY3NjY1_3c208ab1-e920-43ad-847a-741fde2a5266"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i9084bff3951f442886fd602ca88f373d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtMTAtMS0xLTE2NzY2NQ_65afb9b2-faaa-4338-827b-74532bb47fc3"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9084bff3951f442886fd602ca88f373d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtMTItMS0xLTE2NzY2NQ_405cc7e1-d2aa-4791-9b97-f0f2e050afca"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9084bff3951f442886fd602ca88f373d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtMTQtMS0xLTE2NzY2NQ_d0906b13-34ab-413a-89f9-f5b7d527d2b1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9084bff3951f442886fd602ca88f373d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzQtMTYtMS0xLTE2NzY2NQ_6e800454-f0e8-408c-b087-f9594f076b1d"
      unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtMi0xLTEtMTY3NjY1_0913744a-2ae2-47af-b572-9b688425a5f7"
      unitRef="usd">54000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtNC0xLTEtMTY3NjY1_c570b775-7ed9-48a1-bfc4-4fe2018dc200"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtNi0xLTEtMTY3NjY1_1bf6f2b4-22f6-4e76-a808-9e238a01788b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtOC0xLTEtMTY3NjY1_d7e02bb6-44c7-48bd-89c0-51d5a26d0244"
      unitRef="usd">54000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtMTAtMS0xLTE2NzY2NQ_b37bc0eb-1530-4b45-b8c0-54b7493dd747"
      unitRef="usd">249000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtMTItMS0xLTE2NzY2NQ_4d949d38-f117-4f29-926c-3665c0e8e6d0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtMTQtMS0xLTE2NzY2NQ_d529a0be-b868-4545-bb91-ae5b372e1af0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzUtMTYtMS0xLTE2NzY2NQ_380621ca-5ad1-484d-94f8-d5d35eaf9cba"
      unitRef="usd">249000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtMi0xLTEtMTY3NjY1_dee95293-086a-4c43-9ecc-96325727acf4"
      unitRef="usd">1452000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtNC0xLTEtMTY3NjY1_6e4de0d2-f8af-46ca-9fd4-93b6027e8ced"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtNi0xLTEtMTY3NjY1_842530cc-f5e8-42bb-8175-c5a4ca78a9d6"
      unitRef="usd">26000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtOC0xLTEtMTY3NjY1_393b4a9f-eb69-4fea-892f-666804f1b891"
      unitRef="usd">1427000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtMTAtMS0xLTE2NzY2NQ_07ecfba5-eb03-47ff-a768-453e7b963622"
      unitRef="usd">1365000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtMTItMS0xLTE2NzY2NQ_61aea05e-221d-4063-944c-32a9b8cd5409"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtMTQtMS0xLTE2NzY2NQ_508687ad-4f8b-4fd3-a561-a2988411735a"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzYtMTYtMS0xLTE2NzY2NQ_26b7cc37-9831-4773-b3d9-fa46fd24ee6b"
      unitRef="usd">1363000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctMi0xLTEtMTY3NjY1_5c511e94-8b5e-4408-9250-ae41a6ae0569"
      unitRef="usd">335000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctNC0xLTEtMTY3NjY1_24791286-7e5e-4445-97d6-0da951f0399b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctNi0xLTEtMTY3NjY1_a5131ac6-008c-4bf7-bc69-61cec63c3d5d"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctOC0xLTEtMTY3NjY1_3ef06817-6d36-4007-ba18-12f3502b863d"
      unitRef="usd">333000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i6e9c57adbf444d65825f235837090240_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctMTAtMS0xLTE2NzY2NQ_9f6c6d88-00a8-4165-a1d0-dc5674250b17"
      unitRef="usd">425000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6e9c57adbf444d65825f235837090240_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctMTItMS0xLTE2NzY2NQ_137c9f53-8b94-4414-9881-173fd091dd80"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6e9c57adbf444d65825f235837090240_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctMTQtMS0xLTE2NzY2NQ_afa4540a-0093-49af-8ffd-0522e2dbdaef"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6e9c57adbf444d65825f235837090240_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzctMTYtMS0xLTE2NzY2NQ_7bbcd9c0-adc6-475e-b744-144629e0d19c"
      unitRef="usd">424000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtMi0xLTEtMTY3NjY1_5766a1da-6dd2-43b8-ada6-50c50e1bed89"
      unitRef="usd">2325000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtNC0xLTEtMTY3NjY1_e6baf5cc-88cc-4669-b88a-884264f4bbc9"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtNi0xLTEtMTY3NjY1_1c1c94ed-5207-4f80-ba2d-f9ee50d3fd48"
      unitRef="usd">34000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtOC0xLTEtMTY3NjY1_71214195-c4d1-41aa-a0ab-2a2bac2505c1"
      unitRef="usd">2293000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtMTAtMS0xLTE2NzY2NQ_8d87639f-9b53-449c-9d51-52b4033707a5"
      unitRef="usd">2501000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtMTItMS0xLTE2NzY2NQ_099a05e1-6b5c-4b6c-8b63-fa7545976390"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtMTQtMS0xLTE2NzY2NQ_3f057684-4ac1-45c7-8841-2ef9b44455ca"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo5OTQ4MzNkNjU3NmU0ZTE4ODJlZjYwNjM3NWI0NGEzZC90YWJsZXJhbmdlOjk5NDgzM2Q2NTc2ZTRlMTg4MmVmNjA2Mzc1YjQ0YTNkXzgtMTYtMS0xLTE2NzY2NQ_3b4c0c1a-b117-4564-81c8-dfc10187b456"
      unitRef="usd">2497000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzEzMTk0MTM5NTQ3NDkw_98b997d3-c3d4-4202-9fe5-2b173678fd1f">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to available-for-sale debt securities that have been in a continuous unrealized loss position, classified by length of time:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzItMi0xLTEtMjYyMjU3_16780e92-b891-4e50-8dd4-e854a518fb50"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzItNC0xLTEtMjYyMjU3_7a5811b2-29a1-4cde-8c35-78bbf8d08038"
      unitRef="usd">174000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzItNi0xLTEtMjYyMjU3_c3ccdac3-4a09-4d32-bab3-39f9f9ec1fc9"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzItOC0xLTEtMjYyMjU3_7fe5417f-23f0-4617-8449-ee5fe6f5ef50"
      unitRef="usd">206000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzItMTAtMS0xLTI2MjI1Nw_b994f93d-36ee-4e55-a1e9-c8f9a4d24ab1"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i7d0619bee4424bcc8f8609420f4cbb12_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzItMTItMS0xLTI2MjI1Nw_1beaf047-c45f-4497-9cf5-b80ac891ed2d"
      unitRef="usd">379000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzMtMi0xLTEtMjYyMjU3_7838e10e-c50e-438d-b4b6-d307ea8f699a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzMtNC0xLTEtMjYyMjU3_ed821d04-7a2d-49ea-b4ef-0efeb263a9f3"
      unitRef="usd">21000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzMtNi0xLTEtMjYyMjU3_49da373c-1e6d-46c4-8648-f2eabc557e73"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzMtOC0xLTEtMjYyMjU3_158b3198-4e63-46db-b1e6-ac3f23fab198"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzMtMTAtMS0xLTI2MjI1Nw_ed164aaf-26f4-46cb-b3bc-f8e67dcca7de"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i50e2abe2412a45b18cf87a34c75a795b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzMtMTItMS0xLTI2MjI1Nw_6030941e-1e60-499d-a617-95546013a218"
      unitRef="usd">21000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i4ff5933035664d28975731dea852a94b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzQtMi0xLTEtMjYyMjU3_23695b22-ec02-4cd1-8885-808720fb2a68"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i4ff5933035664d28975731dea852a94b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzQtNC0xLTEtMjYyMjU3_3ae3a604-b986-4d53-b725-74442d11e6fd"
      unitRef="usd">31000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i4ff5933035664d28975731dea852a94b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzQtNi0xLTEtMjYyMjU3_9d44dab2-5856-4503-a612-a3a96ea21766"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i4ff5933035664d28975731dea852a94b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzQtOC0xLTEtMjYyMjU3_6c0123a5-a7c2-4a5b-85fd-fdc404df68f6"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i4ff5933035664d28975731dea852a94b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzQtMTAtMS0xLTI2MjI1Nw_bbe86d74-1d6f-44da-9423-16222bf0b0b1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i4ff5933035664d28975731dea852a94b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzQtMTItMS0xLTI2MjI1Nw_5b37b17f-9cd6-4eb3-ab0e-4661e3d5160a"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzUtMi0xLTEtMjYyMjU3_04eba7b3-be79-40d8-bb96-eb033acda702"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzUtNC0xLTEtMjYyMjU3_827c0117-afa6-4f88-a572-247b56941c6c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzUtNi0xLTEtMjYyMjU3_284cc675-8f3c-44d4-9212-30425d982cb2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzUtOC0xLTEtMjYyMjU3_453e174b-e8aa-4387-8a5a-29de82b78de2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzUtMTAtMS0xLTI2MjI1Nw_40fcf21b-6c75-4594-8efe-a492c9e56f4b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if0dc75bc453e4ab9a410488c8fa21a09_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzUtMTItMS0xLTI2MjI1Nw_5fb91fb3-745e-49d9-962a-f2bb855ff9c3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzYtMi0xLTEtMjYyMjU3_906fcc58-6c36-47e8-bb7f-3c561d011a5f"
      unitRef="usd">17000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzYtNC0xLTEtMjYyMjU3_afefca80-3f6e-4331-8b92-938c3d5f8e9c"
      unitRef="usd">774000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzYtNi0xLTEtMjYyMjU3_000b51f2-77db-4655-be02-e90f99eafb29"
      unitRef="usd">8000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzYtOC0xLTEtMjYyMjU3_f6a11ac4-b4f4-45be-bc14-f5811587d5bb"
      unitRef="usd">439000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzYtMTAtMS0xLTI2MjI1Nw_7f1c96b4-f6fa-418f-a4e0-2bb97b183d06"
      unitRef="usd">26000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia73cd273d0724e22a127a4de80a03fee_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzYtMTItMS0xLTI2MjI1Nw_ac281e76-a1fe-448b-baab-0ef80c0dff5d"
      unitRef="usd">1213000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzctMi0xLTEtMjYyMjU3_6a990e3f-438c-4076-a0e6-57cf70739b24"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzctNC0xLTEtMjYyMjU3_0ca3a8db-82b5-4bae-9c78-52c48d8830d8"
      unitRef="usd">205000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzctNi0xLTEtMjYyMjU3_2690e78a-1729-42ce-89ea-9b67c80513c3"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzctOC0xLTEtMjYyMjU3_a8aa4f7a-23e7-44f9-ba66-20d87eca7b92"
      unitRef="usd">56000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzctMTAtMS0xLTI2MjI1Nw_c0814cac-953e-4b11-8cd2-c43c2b94dfe2"
      unitRef="usd">3000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i01e13782ede9404eb98583a539f3ac04_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzctMTItMS0xLTI2MjI1Nw_f80939d4-d3f6-4ee3-ae31-4e01ba1c4e11"
      unitRef="usd">261000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzgtMi0xLTEtMjYyMjU3_bcba04f6-e9b7-424a-b2af-470293ba7a58"
      unitRef="usd">22000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzgtNC0xLTEtMjYyMjU3_cb485534-a1a3-4053-9104-cc6e16f86c48"
      unitRef="usd">1204000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzgtNi0xLTEtMjYyMjU3_9df5d633-d368-4c8f-bf68-db65618ea1ea"
      unitRef="usd">12000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzgtOC0xLTEtMjYyMjU3_86375094-9ea9-44f8-9235-bb5a95a71bc2"
      unitRef="usd">705000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzgtMTAtMS0xLTI2MjI1Nw_14674fe5-1adf-4ab8-86b0-920df3a9e494"
      unitRef="usd">34000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTpkZGRjZGNlMWFjZjE0MmY5YTRjYWZmNGE3YmIwMjNkMi90YWJsZXJhbmdlOmRkZGNkY2UxYWNmMTQyZjlhNGNhZmY0YTdiYjAyM2QyXzgtMTItMS0xLTI2MjI1Nw_6c20696d-be9e-4e5d-b4bf-24e5e78740a1"
      unitRef="usd">1908000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzItMi0xLTEtMjYyMjU3_e6a5fcbf-5258-4b5e-9519-9c2660e1c071"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzItNC0xLTEtMjYyMjU3_c7fe77bc-415e-4fb9-a55f-767080ad1cfb"
      unitRef="usd">402000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzItNi0xLTEtMjYyMjU3_17e3fbc8-11f1-485b-a8bb-57dd9ca2c5f0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzItOC0xLTEtMjYyMjU3_ef5137b8-9edb-4eac-8219-7099eff27399"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzItMTAtMS0xLTI2MjI1Nw_b9e2db9b-daed-46bf-a657-884366b89c3c"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i8b37c127a5104005a9d21dbbe7b0a74d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzItMTItMS0xLTI2MjI1Nw_d486fabc-9d33-476e-baa2-023856c9f78d"
      unitRef="usd">402000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzMtMi0xLTEtMjYyMjU3_489fc612-6268-4901-91c2-7b0f3d926fa7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzMtNC0xLTEtMjYyMjU3_9ab52359-0292-4fa3-bfd6-fab3f5606ca8"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzMtNi0xLTEtMjYyMjU3_8ca62030-7061-4304-b65c-7ee667d6149c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzMtOC0xLTEtMjYyMjU3_c26d2cc5-ffdf-4274-9792-e93df1bbb7ae"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzMtMTAtMS0xLTI2MjI1Nw_bc762072-78d5-4771-9089-ee530e28c0ce"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iebbbab8aa0c44e40a5ca859fc630dbb2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzMtMTItMS0xLTI2MjI1Nw_07a2e03c-0380-49e0-8070-829c6260c17f"
      unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i9084bff3951f442886fd602ca88f373d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzQtMi0xLTEtMjYyMjU3_61bee9af-3251-4774-af70-430ffc8ae66f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i9084bff3951f442886fd602ca88f373d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzQtNC0xLTEtMjYyMjU3_e46dfa4c-ebf7-482c-811e-d6752087e006"
      unitRef="usd">46000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i9084bff3951f442886fd602ca88f373d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzQtNi0xLTEtMjYyMjU3_69c72848-e873-48d3-a43f-2ae9700a5333"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i9084bff3951f442886fd602ca88f373d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzQtOC0xLTEtMjYyMjU3_804995fd-ee65-4e9b-b40c-b55ca9cf60cb"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i9084bff3951f442886fd602ca88f373d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzQtMTAtMS0xLTI2MjI1Nw_b3afe057-e19d-4020-ab4e-5bedba0400fc"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i9084bff3951f442886fd602ca88f373d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzQtMTItMS0xLTI2MjI1Nw_1ec88a1d-bda8-44e7-8a60-040b1ed97727"
      unitRef="usd">46000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzUtMi0xLTEtMjYyMjU3_5498c302-d4d0-4ac4-94b6-95f8044bb86c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzUtNC0xLTEtMjYyMjU3_0d4c4249-e5c8-4700-a6a7-e6237794f7d7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzUtNi0xLTEtMjYyMjU3_62216909-bbab-4ecf-8e92-c7256ecbb9e7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzUtOC0xLTEtMjYyMjU3_1d69640e-ad3d-4c66-814f-e695a2c65f6d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzUtMTAtMS0xLTI2MjI1Nw_cc536516-5ae6-4c05-9aaa-4020884fcfa1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia8dc8b4c28a44d80992e8a57ecb4e719_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzUtMTItMS0xLTI2MjI1Nw_b2a82faf-ea32-47a7-8af7-9f2824120c96"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzYtMi0xLTEtMjYyMjU3_d6be04c9-9079-4339-bbcb-004e6da25724"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzYtNC0xLTEtMjYyMjU3_06b530e4-138a-4df0-9547-89f9eee8b9bf"
      unitRef="usd">1159000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzYtNi0xLTEtMjYyMjU3_e4ca6a1a-7c0b-4a79-ba23-216b13dfa7c0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzYtOC0xLTEtMjYyMjU3_147305ab-0d3d-45ed-b653-fe93f048645b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzYtMTAtMS0xLTI2MjI1Nw_3f9a39c1-36e8-4c31-986b-ed024b1e9729"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i73bd05cee6434509a4a4f115c801d1c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzYtMTItMS0xLTI2MjI1Nw_83d57128-b59f-4fa2-a6b4-8e23dc52a5cf"
      unitRef="usd">1159000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i6e9c57adbf444d65825f235837090240_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzctMi0xLTEtMjYyMjU3_1f125f33-9318-4c69-acac-17f6e3bdcf62"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i6e9c57adbf444d65825f235837090240_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzctNC0xLTEtMjYyMjU3_5f8348a4-64a0-4f55-af9c-33cf7ca7a7f7"
      unitRef="usd">410000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i6e9c57adbf444d65825f235837090240_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzctNi0xLTEtMjYyMjU3_02dcdfac-56c5-4833-92b9-62da2f76229a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i6e9c57adbf444d65825f235837090240_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzctOC0xLTEtMjYyMjU3_dd0a574e-f5d2-4339-9355-cef3f7785df0"
      unitRef="usd">10000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i6e9c57adbf444d65825f235837090240_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzctMTAtMS0xLTI2MjI1Nw_f67a387f-ee68-497f-9470-f8ade9181edb"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i6e9c57adbf444d65825f235837090240_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzctMTItMS0xLTI2MjI1Nw_87155b75-58b3-49b7-bcdd-76482063a36c"
      unitRef="usd">420000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzgtMi0xLTEtMjYyMjU3_fd209151-eff7-4bd6-8c02-87e4d6d3e76a"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzgtNC0xLTEtMjYyMjU3_b05f2f15-a2f2-4b35-878b-a1a5e2c30808"
      unitRef="usd">2022000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzgtNi0xLTEtMjYyMjU3_d08d314b-7831-4cfd-9704-80074f6c1b2c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzgtOC0xLTEtMjYyMjU3_731a1bb5-c84e-4af9-862f-2504e08af069"
      unitRef="usd">10000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzgtMTAtMS0xLTI2MjI1Nw_9982e32b-120b-4e45-acd4-a7b3e560beee"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZToyYzNkODEwY2ViODY0YTM0YTZjNzg1YWJiYjhlOGQwOS90YWJsZXJhbmdlOjJjM2Q4MTBjZWI4NjRhMzRhNmM3ODVhYmJiOGU4ZDA5XzgtMTItMS0xLTI2MjI1Nw_aa0730d9-ebdc-4419-adea-52420cff046f"
      unitRef="usd">2032000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNTY2MA_0b2346d7-a4e8-4e69-93d8-c02c6324c741"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzEzMTk0MTM5NTQ3NDkx_aedb54e9-99fb-40f1-a9ce-b4177e5c644d">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our available-for-sale debt securities in our Consolidated Balance Sheets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6b5ae4a796da464bb370d53bae12c455_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzEtMi0xLTEtMjYyMjU3_3599b829-7db6-4123-be66-bc03ec0f42df"
      unitRef="usd">75000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3e52c52611f24f8faac4fa92e65543f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzEtNC0xLTEtMjYyMjU3_91c7f4d6-bf3b-4b0c-b494-e1f97bcdf59c"
      unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i463626c5759146d08f5927f7e0b6683a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzItMi0xLTEtMjYyMjU3_deece1be-280c-488f-955c-eb5990991794"
      unitRef="usd">973000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1634706b89014eebace618eae101eefc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzItNC0xLTEtMjYyMjU3_60c5e906-7711-49c2-b8a1-4e90e7d6cc8b"
      unitRef="usd">1182000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3eaf91c6ed454ec2900cd809519f9ae0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzMtMi0xLTEtMjYyMjU3_970c2e8c-72f8-4382-aeb8-d7d063cab9c9"
      unitRef="usd">1245000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if9928086fec14acfb7cf4385d987b680_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzMtNC0xLTEtMjYyMjU3_1b4ed19f-a847-49c1-ae91-72e6b4809075"
      unitRef="usd">1309000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzQtMi0xLTEtMjYyMjU3_3048d4d5-eecb-461a-bc99-266ab6d072c8"
      unitRef="usd">2293000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTphNzlmNzI1NzExMzg0MmFjOTdjNzJkYWUxNGFjNTI3ZS90YWJsZXJhbmdlOmE3OWY3MjU3MTEzODQyYWM5N2M3MmRhZTE0YWM1MjdlXzQtNC0xLTEtMjYyMjU3_f2bf0716-2458-4c88-8684-a250a8cadcb7"
      unitRef="usd">2497000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzEzMTk0MTM5NTQ3NDk0_02010b5a-9137-49f2-9ec5-51931bd6e0d9">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&#160;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzItMi0xLTEtMjYyMjU3_90c6cefc-0ff7-4487-851e-cccadd4f351c"
      unitRef="usd">1057000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzItNC0xLTEtMjYyMjU3_22a41993-dd49-4c70-ac1d-e4b69c9ce7db"
      unitRef="usd">1048000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzMtMi0xLTEtMjYyMjU3_0a7056f6-f8ed-4811-8e3b-5cd3cfe97a00"
      unitRef="usd">1260000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzMtNC0xLTEtMjYyMjU3_b70365fe-a183-4755-b7a4-05fde91fede4"
      unitRef="usd">1236000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzQtMi0xLTEtMjYyMjU3_c7325e12-5b46-4215-8070-6d58291aa42c"
      unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzQtNC0xLTEtMjYyMjU3_bcec14e8-a018-411d-a121-55a6b612e876"
      unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzUtMi0xLTEtMjYyMjU3_df36ca42-9b02-42c7-97ae-1d180af80776"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzUtNC0xLTEtMjYyMjU3_b60edb94-6c75-4de4-be6a-667245191929"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzYtMi0xLTEtMjYyMjU3_ef7ed3ba-343a-4372-89bb-c497e1d7c88d"
      unitRef="usd">2325000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo3ZjE1NTdjNTNhNWE0NDBkOGZmMDRhODcwZTVhNTc0Zi90YWJsZXJhbmdlOjdmMTU1N2M1M2E1YTQ0MGQ4ZmYwNGE4NzBlNWE1NzRmXzYtNC0xLTEtMjYyMjU3_a023e7b7-bfb3-44cb-9f90-ae68b71d6cba"
      unitRef="usd">2293000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzEzMTk0MTM5NTQ3NDky_09199428-feb1-43f2-b27c-aa0ccf90e64c">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Consolidated Balance Sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Prepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is classified in Other long-term assets due to certain lock-up provisions in our amended subscription agreement with them, which extend to August 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6b5ae4a796da464bb370d53bae12c455_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzEtMi0xLTEtMjYyMjU3_499cdf55-a935-4da9-89b4-48b2ede1f9a8"
      unitRef="usd">3831000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3e52c52611f24f8faac4fa92e65543f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzEtNC0xLTEtMjYyMjU3_e62218a6-6fd0-4f18-be91-3535daf28780"
      unitRef="usd">3661000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i198d532a8c074ac78f29a94fac0b9f33_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzItMi0xLTEtMjYyMjU3_6e573fcc-fa25-4e6a-aa7d-40293f8f5fc3"
      unitRef="usd">473000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4812222e45cd4cb69428c9cdba79819c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzItNC0xLTEtMjYyMjU3_bcd34361-bd16-43ef-974d-cd12e5d85db0"
      unitRef="usd">885000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iad7614ba24154118b1da72e576ca61e1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzMtMi0xLTEtMjYyMjU3_19ef6b71-b5f6-4299-9d72-e4b46f746938"
      unitRef="usd">943000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1ad61301e5ed420bb158a038204db320_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzMtNC0xLTEtMjYyMjU3_be904f78-704e-4f7e-8647-c77a43dc3b64"
      unitRef="usd">1197000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ica09543c00fe4598ac8ce750d8afb1ed_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzQtMi0xLTEtMjYyMjU3_83a2ee07-2745-4147-a023-b457afd6353e"
      unitRef="usd">5248000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9443f1a550be401b9c00363c5d93d604_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90YWJsZTo0OWEwZmRhN2I4NzQ0MDRkYjUyMGFlNjYyMzMwZGUxOC90YWJsZXJhbmdlOjQ5YTBmZGE3Yjg3NDQwNGRiNTIwYWU2NjIzMzBkZTE4XzQtNC0xLTEtMjYyMjU3_e3160a69-a6bc-46f8-bdd5-46b261954efc"
      unitRef="usd">5743000000</us-gaap:AssetsFairValueDisclosure>
    <gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzA3NA_cde0dc2f-f394-4d0c-80d9-2f80c8115459"
      unitRef="usd">423000000</gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount>
    <gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzA3OQ_4f828f67-8880-43f4-93a3-afb631790f48"
      unitRef="usd">338000000</gild:EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzI4OA_ada04443-91cf-46e0-83d1-206fd6b57e82"
      unitRef="usd">657000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzI5Mw_bd7c43f5-bd8f-4191-b2f7-cf411af2eece"
      unitRef="usd">610000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzMwMQ_1632791f-238f-4f22-87a1-f11e9e36fdc6"
      unitRef="usd">1700000000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="if99033cbc8c044d3a0561d49bbba36b3_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzczNg_744a239c-5ce3-402f-b93e-a53de9fa0d35"
      unitRef="usd">85000000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="id1cc9513c77541668e0695e24152fbdf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDAvZnJhZzo2Zjg0NjY0ODI5MmM0N2Q3OTBjYmY2Mzc4NTQwZDA1OC90ZXh0cmVnaW9uOjZmODQ2NjQ4MjkyYzQ3ZDc5MGNiZjYzNzg1NDBkMDU4XzU0OTc1NTgyNzc0NA_1ba3f57d-ef1c-431c-b0e8-91d67b814bc2"
      unitRef="usd">212000000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzMzNTE_be3cf38a-da8d-4bc0-bcae-7cbf4d4ccccd">DERIVATIVE FINANCIAL INSTRUMENTS&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The derivative instruments we use to hedge our exposures for certain monetary assets and liabilities that are denominated in a non-functional currency are not designated as hedges. The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of 18 months or less. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, we held foreign currency exchange contracts with outstanding notional amounts of $3.0 billion and $2.9 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts in our Consolidated Balance Sheets on a gross basis. The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtMi0xLTEtMTY3NjY1_2f4084d2-5259-4bc5-8b05-5f700b1f1a8a"&gt;Derivative Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtNi0xLTEtMTY3NjY1_46ccc9b5-72b7-44ea-ba73-a4b1e8bd1b28"&gt;Derivative Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives presented gross on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross amounts not offset on the Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash collateral received / pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount (legal offset)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtMi0xLTEtMjA2NjQ5_b7aba77a-d3a3-423b-9d31-3f7747775fae"&gt;Derivative Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtNi0xLTEtMjA2NjQ5_bc98400a-c82d-4004-b4ed-25c8c3bfe4b2"&gt;Derivative Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives presented gross on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross amounts not offset on the Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash collateral received / pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount (legal offset)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our derivative contracts on our Consolidated Financial Statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Accumulated other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) reclassified from Accumulated other comprehensive income to Product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of gains and losses related to the hedged forecasted transactions reported in Accumulated other comprehensive income as of December&#160;31, 2022 are expected to be reclassified to Product sales within 12 months. There were no discontinuances of cash flow hedges for the years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash flow effects of our derivative contracts for the years ended December&#160;31, 2022, 2021 and 2020 were included within Net cash provided by operating activities on our Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i08f3914c4bd548ffa8c16f9da7bd4df7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzEwOTk1MTE2MzE4NzA_9b9ad560-6454-4fce-b45a-75881d776717">P18M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzE2NDkyNjc0NDU3NDA_32cabc5a-f934-495c-974d-4d9dd971d5fd"
      unitRef="usd">3000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzE2NDkyNjc0NDU3NTA_612aa787-bfd0-4a10-82ea-73bc34d64949"
      unitRef="usd">2900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzMzNTU_9fc7cc56-d843-454a-8f44-14b5c5f9be0c">The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtMi0xLTEtMTY3NjY1_2f4084d2-5259-4bc5-8b05-5f700b1f1a8a"&gt;Derivative Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEtNi0xLTEtMTY3NjY1_46ccc9b5-72b7-44ea-ba73-a4b1e8bd1b28"&gt;Derivative Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives presented gross on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross amounts not offset on the Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash collateral received / pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount (legal offset)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.074%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtMi0xLTEtMjA2NjQ5_b7aba77a-d3a3-423b-9d31-3f7747775fae"&gt;Derivative Assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEtNi0xLTEtMjA2NjQ5_bc98400a-c82d-4004-b4ed-25c8c3bfe4b2"&gt;Derivative Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&#160;long-term&#160;obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives not designated as hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total derivatives presented gross on the Consolidated Balance Sheets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross amounts not offset on the Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative financial instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash collateral received / pledged&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net amount (legal offset)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i4c84aa3ba61245188fa2fc51e8e98ac1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzQtNC0xLTEtMTY3NjY1_cecd7926-c89e-4284-af09-4a280c203b7d"
      unitRef="usd">59000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i485ded3cb94b411881b8ee607e8a95fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzQtOC0xLTEtMTY3NjY1_462d25de-2250-4a90-bf4d-0afe00edcd5b"
      unitRef="usd">26000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="id81c22c85dbc4822a7ef92c8c72ce5b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzUtNC0xLTEtMTY3NjY1_3e8c6ac4-9d53-4f65-90e6-8da7ff8ff736"
      unitRef="usd">1000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i669cfd4e64c242c1a8ef8796fd28b7cc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzUtOC0xLTEtMTY3NjY1_829d5973-6da6-425f-baba-e34f497f8dee"
      unitRef="usd">9000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i1bd1f9124d4d45ddb0aca9a2a42b8ae3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzYtNC0xLTEtMTY3NjY1_6eab9b51-3341-41c1-9766-fe0a2ad375a3"
      unitRef="usd">59000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i1bd1f9124d4d45ddb0aca9a2a42b8ae3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzYtOC0xLTEtMTY3NjY1_2e38f7e7-dc79-40eb-9714-7c2ce5230fb5"
      unitRef="usd">35000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i66b2c501c7c4411197427bc2b905865c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzgtNC0xLTEtMTY3NjY1_4a14309e-8cab-4ad1-b545-87268992c913"
      unitRef="usd">1000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i66b2c501c7c4411197427bc2b905865c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzgtOC0xLTEtMTY3NjY1_cdf1e20a-f691-496e-852d-a70b5d5d1a4d"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i66b2c501c7c4411197427bc2b905865c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzktNC0xLTEtMTY3NjY1_c9b2cb57-b41e-40e5-bc63-77b7f3c1bb0d"
      unitRef="usd">1000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i66b2c501c7c4411197427bc2b905865c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzktOC0xLTEtMTY3NjY1_0636be3f-09b0-44af-943e-8753f5a9ffc9"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEwLTQtMS0xLTE2NzY2NQ_0053c2dd-470b-4216-9b2c-4426999fc7da"
      unitRef="usd">60000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEwLTgtMS0xLTE2NzY2NQ_e90a0b0e-ad53-44b2-9b7b-88ea4d5d94c2"
      unitRef="usd">42000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEyLTQtMS0xLTI2NTYzOA_baeff9ee-a236-41d6-b113-547c99542552"
      unitRef="usd">36000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEyLTgtMS0xLTI2NTY2MA_5b495abe-ccef-45a2-a04a-248b30da8a11"
      unitRef="usd">36000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEzLTQtMS0xLTI2NTY0OA_aa3f3bc5-6307-41da-b85b-3ba4d10f2b38"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzEzLTgtMS0xLTI2NTY1MQ_96bb18cf-c4fa-4b5e-adc4-a831e47048cc"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzE0LTQtMS0xLTI2NTY0NQ_114a2afe-eaf6-437c-a51b-caa19a2c3a20"
      unitRef="usd">25000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZToxOTRiMTdmMzRiMzE0MGQ4YWE1YjU0OTQ5Yzg2NjgxNS90YWJsZXJhbmdlOjE5NGIxN2YzNGIzMTQwZDhhYTViNTQ5NDljODY2ODE1XzE0LTgtMS0xLTI2NTY1NA_841c42de-8dd6-4322-a9f0-388fdcecfa78"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i8c5dc98f71a34b989bdd92e74b03bcaf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzQtNC0xLTEtMTY3NjY1_d1300c80-2412-4b98-8536-ed4588be79f2"
      unitRef="usd">75000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i884916a0bf074d689e54307d3e38f85f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzQtOC0xLTEtMTY3NjY1_6e990ca2-7062-4016-94ef-763798a7619d"
      unitRef="usd">4000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i2fedf80dcdf54b7ab0cf8db9b226197b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzUtNC0xLTEtMTY3NjY1_be042c40-059a-4eef-8887-df6c92e1c1f7"
      unitRef="usd">5000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i7e415108242847aa9f7899559c4beb51_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzUtOC0xLTEtMTY3NjY1_86260115-2e76-4468-9dea-54300b14461d"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i5b1fc54addc74b608025b4442073733f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzYtNC0xLTEtMTY3NjY1_1a985805-3bdd-4016-a481-e24f7ed01e90"
      unitRef="usd">80000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i5b1fc54addc74b608025b4442073733f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzYtOC0xLTEtMTY3NjY1_5664f946-5f62-4991-b5dd-7cb873dff41e"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0ddfa8ed452243918c264f684e03d322_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzgtNC0xLTEtMTY3NjY1_b27d1efd-36a7-4949-9acc-726f28afa9b3"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0ddfa8ed452243918c264f684e03d322_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzgtOC0xLTEtMTY3NjY1_fc2f6192-f7a6-4346-9b53-f72edfe8df4c"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0ddfa8ed452243918c264f684e03d322_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzktNC0xLTEtMTY3NjY1_5d355c87-c730-4e54-b3a0-69a15aa90350"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="i0ddfa8ed452243918c264f684e03d322_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzktOC0xLTEtMTY3NjY1_cac27dff-bbe9-4593-8bc1-e4841da3f87b"
      unitRef="usd">0</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEwLTQtMS0xLTE2NzY2NQ_22d99656-39a2-4309-ae88-2cad23c072f9"
      unitRef="usd">80000000</us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEwLTgtMS0xLTE2NzY2NQ_a5c69cd4-f1ca-4488-9ec5-d6c0b646d6ac"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEyLTQtMS0xLTI2NTc4OQ_abc40753-d714-48c9-9f16-f5a6da771e61"
      unitRef="usd">4000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEyLTgtMS0xLTI2NTc5Mg_08565978-eadd-46e0-a2bf-d9c628088aee"
      unitRef="usd">4000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEzLTQtMS0xLTI2NTc5NQ_56acd5fc-a927-488f-8f79-fd7d6f88611c"
      unitRef="usd">0</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzEzLTgtMS0xLTI2NTgwMQ_625211a6-0128-4b46-9b2c-2d9a7a7b0ca1"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzE0LTQtMS0xLTI2NTc5OA_47f01800-9489-4203-bd89-603bfa4d0751"
      unitRef="usd">76000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTo1MDQ3NWY3YmFmYWU0MTkxOGE1NzA0YjMxNzkzMjI2Zi90YWJsZXJhbmdlOjUwNDc1ZjdiYWZhZTQxOTE4YTU3MDRiMzE3OTMyMjZmXzE0LTgtMS0xLTI2NTgwNA_a4e080b8-76fa-48ca-a815-f9fe0f1dd6b9"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzMzNzM_9081a05e-faa7-4ee6-b25c-d3f42339037f">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the effect of our derivative contracts on our Consolidated Financial Statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Accumulated other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) reclassified from Accumulated other comprehensive income to Product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other income (expense), net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzMtMi0xLTEtMTY3NjY1_5c43220b-005b-45b4-8d02-2bf3bf27446d"
      unitRef="usd">150000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzMtNC0xLTEtMTY3NjY1_4b634e02-d33a-4d6d-8a04-2989d2c2fdd0"
      unitRef="usd">147000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzMtNi0xLTEtMTY3NjY1_51838a32-32d2-4076-82ae-e46a3aa571c3"
      unitRef="usd">-118000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzQtMi0xLTEtMTY3NjY1_d97dc191-fe81-4bbd-922f-506a636b1931"
      unitRef="usd">196000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzQtNC0xLTEtMTY3NjY1_4776dc01-d02a-477a-a0e1-d0ec51b760cc"
      unitRef="usd">-67000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzQtNi0xLTEtMTY3NjY1_5da06e2f-b788-4523-b3d1-feb363dbe586"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzYtMi0xLTEtMTY3NjY1_2e2562f2-6d21-402a-bedc-7cc7d834f5f0"
      unitRef="usd">67000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzYtNC0xLTEtMTY3NjY1_052f5d80-efef-475d-836a-f8a1d62b7a0e"
      unitRef="usd">21000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90YWJsZTphZDFkYjBlMGUwZGI0MzRlYTY5MDNhZjNlNjVjYTNkMS90YWJsZXJhbmdlOmFkMWRiMGUwZTBkYjQzNGVhNjkwM2FmM2U2NWNhM2QxXzYtNi0xLTEtMTY3NjY1_e445342f-f791-4db0-af41-1b6354b987e8"
      unitRef="usd">-51000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1
      contextRef="i08f3914c4bd548ffa8c16f9da7bd4df7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzEwOTk1MTE2Mzg5NzU_2e151778-4173-4ef4-953c-5226139d309a">P12M</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzE2NDkyNjc0NDU3MzM_135866ab-33d6-4df2-86d7-d28cfdaa8ed3"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDMvZnJhZzo0MjQ4NGM3N2YwMDA0ZWY0ODUyZmU2MWEyZjBiNzFjOS90ZXh0cmVnaW9uOjQyNDg0Yzc3ZjAwMDRlZjQ4NTJmZTYxYTJmMGI3MWM5XzE2NDkyNjc0NDU3MzM_321f3a7d-8e28-4452-beb5-748ad8e3cc96"
      unitRef="usd">0</us-gaap:GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEyMzcz_ecc406ea-80e4-459c-a697-8a8d1cd3d0bd">ACQUISITIONS&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;MiroBio&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2022, we acquired all of the outstanding share capital of MiroBio Ltd. (&#x201c;MiroBio&#x201d;), a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for $414 million in cash. As a result, MiroBio became our wholly-owned subsidiary. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for the transaction as an asset acquisition and recorded a $389 million charge to Acquired in-process research and development expenses on our Consolidated Statements of Income during 2022. The remaining purchase price relates to various other assets acquired and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;MYR&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2021, we completed the acquisition of MYR, a German biotechnology company. MYR focuses on the development and commercialization of therapeutics for the treatment of HDV. The acquisition provided Gilead with Hepcludex, which was conditionally approved by European Medicines Agency (&#x201c;EMA&#x201d;) in July 2020 for the treatment of chronic HDV infection in adults with compensated liver disease. Upon closing, MYR became a wholly-owned subsidiary of Gilead. The financial results of MYR were included in our Consolidated Financial Statements from the date of the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate consideration for this acquisition of &#x20ac;1.3 billion (or $1.6 billion) primarily consisted of &#x20ac;1.0 billion (or $1.2 billion) paid upon closing and contingent consideration of up to &#x20ac;300 million, subject to customary adjustments, representing a potential future milestone payment upon FDA approval of Hepcludex. The fair value of this contingent liability, estimated using probability-weighted scenarios for FDA approval, was $341 million as of the acquisition date. As of December&#160;31, 2021, the fair value of the liability was $317 million and was included in Other current liabilities on our Consolidated Balance Sheets. As of December&#160;31, 2022, the fair value of the liability was $275 million and was included in Other long-term obligations. See Note 3. Fair Value Measurements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The finite-lived intangible asset of $845&#160;million represents the estimated fair value of Hepcludex for HDV in Europe as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Hepcludex for HDV in Europe and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D consists of Hepcludex for HDV in all other regions without regulatory approval, including the United States. The estimated aggregate fair value of $1.19&#160;billion as of the acquisition date was determined by applying the income approach using unobservable inputs (Level 3 under the fair value measurement and disclosure guidance) to estimate probability-weighted net cash flows attributable to this asset and a discount rate of 12%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of MYR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $226&#160;million was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for MYR is not expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The one-year measurement period was completed in the first quarter of 2022, with adjustments recorded to the fair values of assets acquired and liabilities assumed of $18 million. See Note 8. Goodwill and Intangible Assets for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Immunomedics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we completed the acquisition of Immunomedics, a company focused on the development of antibody-drug conjugate technology, for cash consideration of $20.6 billion. Upon closing, Immunomedics became a wholly-owned subsidiary of Gilead. The acquisition was financed with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $1.0&#160;billion borrowing under a new senior unsecured term loan facility and cash on hand. In 2021, we repaid the borrowing under the senior unsecured term loan facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded share-based compensation expense of $289&#160;million related to the cash settlement of the accelerated share-based compensation expense attributable to the post-combination period, which was primarily recorded in Selling, general and administrative expenses and Research and development expenses on our Consolidated Statements of Income for the year ended December&#160;31, 2020. We also recorded other acquisition-related expenses of $39&#160;million, primarily representing closing costs and related fees, in Selling, general and administrative expenses on our Consolidated Statements of Income for the year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Immunomedics was accounted for as a business combination using the acquisition method of accounting. The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outlicense contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value step-up adjustment of $881&#160;million, included in inventories of $946&#160;million as of the acquisition date, was primarily determined by the estimated selling price of finished inventory less the cost to complete the manufacturing process and selling effort. The step-up adjustment was recorded in Cost of goods sold on our Consolidated Statements of Income as the inventory was sold to customers and in Research and development expenses on our Consolidated Statements of Income for inventory used for clinical purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The finite-lived intangible asset of $4.6&#160;billion represents the estimated fair value of Trodelvy for metastatic triple-negative breast cancer (&#x201c;TNBC&#x201d;) as of the acquisition date. The fair value was determined by applying the income approach using unobservable inputs to estimate probability-weighted net cash flows attributable to Trodelvy for metastatic TNBC and a discount rate of 7.0%. The discount rate used represents the estimated rate that market participants would use to value this intangible asset. This intangible asset is being amortized over an estimated useful life of 12 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired IPR&amp;amp;D assets consist of Trodelvy for hormone receptor-positive, human epidermal growth factor receptor 2-negative (&#x201c;HR+/HER2-&#x201d;) breast cancer, Trodelvy for non-small cell lung cancer and Trodelvy for urothelial cancer (&#x201c;UC&#x201d;). The estimated aggregate fair value of&#160;$15.8&#160;billion&#160;as of the acquisition date was determined by applying the income approach using unobservable inputs (Level 3 under the fair value measurement and disclosure guidance) to estimate probability-weighted net cash flows attributable to these assets and a discount rate of 7.0%. The discount rate used represents the estimated rate that market participants would use to value these intangible assets. Trodelvy for UC was granted accelerated approval by FDA in April 2021 and $1.0&#160;billion was reclassified to finite-lived intangibles from IPR&amp;amp;D. Trodelvy for HR+/HER2- breast cancer was partially impaired in the first quarter of 2022, but was subsequently granted approval by FDA in February 2023 and $6.1&#160;billion will be reclassified to finite-lived intangibles from IPR&amp;amp;D in the first quarter of 2023. See Note 8. Goodwill and Intangible Assets for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also recorded an intangible asset related to a license and supply agreement with Everest Medicines (&#x201c;Everest&#x201d;), which was entered into by Immunomedics prior to the acquisition. Under the agreement, Everest was granted an exclusive license to develop and commercialize Trodelvy in certain territories in Asia and make certain sales milestones and royalty payments to us. The acquisition date fair value of $175&#160;million was determined by estimating the probability-weighted net cash flows attributable to the outlicense and a discount rate of 7.0%. The discount rate represents the estimated rate that market participants would use to value this intangible asset. This intangible asset was being amortized over an estimated useful life of 15 years on a straight-line basis up until we reacquired the rights from Everest in the fourth quarter of 2022. See Note 10. Collaborations and Other Arrangements for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net deferred tax liability was based upon the difference between the estimated financial statement basis and tax basis of net assets acquired and an estimate for the final pre-acquisition net operating losses of Immunomedics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liability Related to Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust (&#x201c;RPI&#x201d;), prior to our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The acquisition date fair value of the liability was estimated as $1.1&#160;billion, which was primarily determined based on current estimates of future royalty payments to RPI over the life of the arrangement using the real options method and an effective annual interest rate of 2.5%. The inputs used for valuation of this liability are unobservable and are considered Level 3 under the fair value measurement and disclosure guidance. The liability related to future royalties was categorized as debt and primarily included in Long-term debt, net on our Consolidated Balance Sheets. See Notes 3. Fair Value Measurements and 11. Debt and Credit Facilities for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&#160;excess of the consideration transferred over the fair values of assets acquired and liabilities assumed of $4.0&#160;billion was recorded as goodwill, which primarily reflects the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill recognized for Immunomedics is not expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Forty Seven, Inc. (&#x201c;Forty Seven&#x201d;)&lt;/span&gt;&lt;/div&gt;In the second quarter of 2020, we completed the acquisition of Forty Seven, a clinical-stage immuno-oncology company focused on developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for total consideration of $4.7 billion, net of acquired cash. Upon closing, Forty Seven became a wholly-owned subsidiary of Gilead. We accounted for the transaction as an asset acquisition since the lead asset, magrolimab, represented substantially all the fair value of the gross assets acquired. During the year ended December 31, 2020, we recorded a $4.5 billion charge representing an acquired IPR&amp;amp;D asset with no alternative future use in Acquired in-process research and development expenses, and stock-based compensation expense of $144&#160;million primarily in Research and development expenses on our Consolidated Statements of Income.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <gild:PaymentsForAssetAcquisitions
      contextRef="i9ff582c0bcd9440d8450644be10362de_D20220920-20220920"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE2NjI0ODY_e116ea00-91f8-4d7f-8550-66aff5de3ae7"
      unitRef="usd">414000000</gild:PaymentsForAssetAcquisitions>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ie636277d8cc8441891c35c55a8b0f84c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE2NjI0OTM_c5b081eb-49bc-4439-89e4-b68f54a841fb"
      unitRef="usd">389000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i83300a86394449e3b64aed1970eda7d5_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3NzE0Nw_9dd12aa4-de4b-4b0d-8b92-01f78cee63ce"
      unitRef="eur">1300000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i83300a86394449e3b64aed1970eda7d5_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3NzE2Mg_812495fb-8aac-4cef-bfdb-d3e8dace0ffd"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i83300a86394449e3b64aed1970eda7d5_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3NzE3Nw_7a3cfd1c-b16f-4470-9722-c14e368c5e46"
      unitRef="eur">1000000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i83300a86394449e3b64aed1970eda7d5_D20210304-20210304"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3NzE5Mg_27aaadef-a5d4-47b9-9e5f-fff6dd96f03d"
      unitRef="usd">1200000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icb5939cef17f48478fd4464ba9e5a0cc_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3NzIwNw_93c834e2-009a-4a6e-8d9c-a382c08ccf6f"
      unitRef="eur">300000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
      contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3NzIyMg_9fceebd9-252f-42e5-bdee-e14eb1773202"
      unitRef="usd">341000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i28808546af3a44b5b726f97b0be6b62c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE3MTY_9b5d33d7-7131-4e4d-9154-0842691fe2cf"
      unitRef="usd">317000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i61be0ceaa2ff4374a907d95021e07080_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTgyMDY3NTA_ef4d6724-a958-4892-9ac0-de89f96e4f1c"
      unitRef="usd">275000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEzNzQzODk1NDIwMjc0_d56c66b6-3fc6-4f12-a7e0-01a18bb59e32">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of MYR was accounted for as a business combination using the acquisition method of accounting. The following table summarizes estimated fair values of assets acquired and liabilities assumed as of the acquisition date: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Immunomedics was accounted for as a business combination using the acquisition method of accounting. The following table summarizes fair values of assets acquired and liabilities assumed as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outlicense contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets (and liabilities), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i8747b96d361f490595133641ce6801bf_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzItMi0xLTEtMjcxOTI0_935c3a69-9bd6-4c63-b417-1e68bb6dd244"
      unitRef="usd">845000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i3f715f66b49c4eb3866d26fc054558bb_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzMtMi0xLTEtMjcxOTI0_9f8cf19e-1662-47c8-8e07-77ef4dfa58d7"
      unitRef="usd">1190000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzQtMi0xLTEtMjcxOTI0_78866feb-8700-4130-bcc2-6bf2c35b6d63"
      unitRef="usd">513000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet
      contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzUtMi0xLTEtMjcxOTI0_571b4353-b667-4e53-8324-c749a4b218f5"
      unitRef="usd">-187000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzYtMi0xLTEtMjcxOTI0_69e33ccb-a365-4aa3-8858-09c6b219058a"
      unitRef="usd">1335000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillGross
      contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzctMi0xLTEtMjcxOTI0_e8c808e8-ae86-43cd-b274-aeb0b6fda365"
      unitRef="usd">226000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTpkNmFhZDBiMDYzMjM0YzA2OWQ4NGM0MmJlZTQ1M2YyMi90YWJsZXJhbmdlOmQ2YWFkMGIwNjMyMzRjMDY5ZDg0YzQyYmVlNDUzZjIyXzgtMi0xLTEtMjcxOTI0_c4b585a5-17bf-4774-8c74-56e74ce156d7"
      unitRef="usd">1561000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i8747b96d361f490595133641ce6801bf_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2NTg_37892ae8-561f-442f-90bc-1b6d11da5854"
      unitRef="usd">845000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate
      contextRef="i5e0b94afcd4a4e969f87632c645d0ab6_I20210304"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2NjY_e781e30e-ee43-4fe3-a31b-6dcb5a2bee26"
      unitRef="number">0.12</gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i000f39fad6fc4888bca218c81bd4367a_D20210304-20210304"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2NzQ_865fd0b4-a419-4972-803e-406a01077f15">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="ie4dce94d4803432ea623df9764cf4027_I20210304"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2ODA_54754bc5-0e26-4114-bd73-6ff3db72eee4"
      unitRef="usd">1190000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate
      contextRef="i5e0b94afcd4a4e969f87632c645d0ab6_I20210304"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2NzA_e781e30e-ee43-4fe3-a31b-6dcb5a2bee26"
      unitRef="number">0.12</gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:GoodwillGross
      contextRef="i510e50f0ac43478382e87ec9808db7ce_I20210304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2ODc_44db19c2-a7c5-46d9-9550-2a4707807897"
      unitRef="usd">226000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i61be0ceaa2ff4374a907d95021e07080_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2OTQ_72f02a3c-c39d-4ab8-91f4-f6f2f2c7341b"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i4513e5ea422e4a229b71a42e1b842c21_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTgyMDM0NzQ_48812f59-ac1e-4ae6-a405-0b1943257e60"
      unitRef="usd">-18000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ic2d744e7509044cfb0669434445c9252_D20201023-20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg3MjkzMQ_c8d7d599-7af4-4fb7-ad9e-872c6e77a569"
      unitRef="usd">20600000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="icab7b0de5a6c43d697d7858746732e0e_D20200901-20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDExNTI_f24357ab-4975-4d9b-8b90-7fab82d59401"
      unitRef="usd">1000000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="i153abdf5024043579147bb4cf3dd2205_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDExNjE_04a6cd91-02fd-4cea-a1b4-05856a8c0a2e"
      unitRef="usd">289000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i153abdf5024043579147bb4cf3dd2205_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDExNjk_ef26c415-61d5-4386-b655-e1b810e5d8ad"
      unitRef="usd">39000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzEtMi0xLTEtMjcxOTQz_ede0c6c7-cc8f-40a5-9c3c-a57ecafc8e49"
      unitRef="usd">726000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzItMi0xLTEtMjcxOTQz_af0a55c1-d9ce-410b-99a1-cf1cedb1ce2e"
      unitRef="usd">946000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i7e9d7f1885544506bd276d0c9126856f_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzQtMi0xLTEtMjcxOTQz_3bb2b1f6-1626-4715-a421-654a9fd26c81"
      unitRef="usd">4600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i13dee278e6454433be1edc4ce1da6ed1_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzUtMi0xLTEtMjcxOTQz_f7cebb43-6136-4089-b39b-ebe312831040"
      unitRef="usd">15760000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ie6f1965ab97c42069eb90ab5238a2ecd_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzYtMi0xLTEtMjcxOTQz_6a650a75-7562-433d-85da-835f1bb115b8"
      unitRef="usd">175000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzctMi0xLTEtMjcxOTQz_2e7675b5-3e99-4ca3-b9d0-63d2791593f2"
      unitRef="usd">4565000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability
      contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzgtMi0xLTEtMjcxOTQz_844c85db-7eae-43f4-ad2e-8fec60665c50"
      unitRef="usd">1100000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet
      contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzktMi0xLTEtMjcxOTQz_463cd6c8-0974-40cf-9384-e2ed79ff56c1"
      unitRef="usd">64000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzEwLTItMS0xLTI3MTk0Mw_44c1ba33-befc-4bde-8133-975ab0bfae65"
      unitRef="usd">16606000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillGross
      contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzExLTItMS0xLTI3MTk0Mw_d987cfd9-29a6-4995-a11f-dd3a21903866"
      unitRef="usd">3991000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90YWJsZTphZjFmYTBjOTE1MTg0OTc1YmMwM2U0ZmFhMGMwYzYzMy90YWJsZXJhbmdlOmFmMWZhMGM5MTUxODQ5NzViYzAzZTRmYWEwYzBjNjMzXzEyLTItMS0xLTI3MTk0Mw_ff22d5ea-7025-4fe2-b706-a2194fa51fc4"
      unitRef="usd">20597000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory
      contextRef="ic2d744e7509044cfb0669434445c9252_D20201023-20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDExODU_797a7969-84ed-43bb-a160-0a1ad5e00333"
      unitRef="usd">881000000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDExOTI_e37092fe-1d23-4f1f-8687-ad5dae34f689"
      unitRef="usd">946000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i7e9d7f1885544506bd276d0c9126856f_I20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMDA_1c6b1d1f-faa3-4ec4-bb44-124fc4cef376"
      unitRef="usd">4600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate
      contextRef="i7e9d7f1885544506bd276d0c9126856f_I20201023"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMDg_5a65d244-e6f8-4735-a2bf-a89834913e86"
      unitRef="number">0.070</gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ia565affd511f4d70ae37392429f48f4a_D20201023-20201023"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMTY_db341be2-bbfc-4e3e-a4b0-c60dd473b098">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i13dee278e6454433be1edc4ce1da6ed1_I20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMTk_8f80d3a3-5046-4ce3-90dd-f94c452960ab"
      unitRef="usd">15800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate
      contextRef="i7e9d7f1885544506bd276d0c9126856f_I20201023"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMjk_5a65d244-e6f8-4735-a2bf-a89834913e86"
      unitRef="number">0.070</gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="ib4719e0d131f44a085886b933ab78bb6_I20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMzc_80f55b5f-6ac5-43f4-9348-23ea1bf0e758"
      unitRef="usd">-1000000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <gild:FiniteLivedIntangibleAssetsGrossReclassified
      contextRef="ifa9a93f5272a429bbdd06910a8637c97_I20210430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMzc_c70e4d75-38c7-4e77-ab0d-7213470a2a46"
      unitRef="usd">1000000000</gild:FiniteLivedIntangibleAssetsGrossReclassified>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="i32d561b8ae6b4a2f98da8f5dd0fa0d8a_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE0NzM_cdd8b0fe-3165-4963-a449-788d71587cb6"
      unitRef="usd">6100000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ie6f1965ab97c42069eb90ab5238a2ecd_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE0ODE_4841af04-56f3-4a9a-ac1c-bff4b4074a9c"
      unitRef="usd">175000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate
      contextRef="i7e9d7f1885544506bd276d0c9126856f_I20201023"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDEyMzQ_5a65d244-e6f8-4735-a2bf-a89834913e86"
      unitRef="number">0.070</gild:AcquiredFiniteLivedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic1048a20244b4ce5bb8bf7d3be281065_D20201023-20201023"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE0OTA_3a9d1dc8-1407-4e29-99d9-5f57c5a2b38d">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability
      contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE0OTM_a44728cd-e61f-4be0-9dd9-2bb3bcf539c9"
      unitRef="usd">1100000000</gild:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability>
    <gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput
      contextRef="ie422be158b934364b7f415457625004b_I20201023"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE1MDE_d65f7779-933b-41bc-840b-940ead1ff9fa"
      unitRef="number">0.025</gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput>
    <us-gaap:GoodwillGross
      contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2NDE_3efba176-a8b8-4e78-a505-15b8dc92073b"
      unitRef="usd">4000000000</us-gaap:GoodwillGross>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="ic8b805b1eef94fff97d2acef45332eaf_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2MzI_c99ce300-df0a-43e2-8f5b-864c3b301cf3"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <gild:PaymentsToAcquireAssetsNetOfCashAcquired
      contextRef="ie215a497705b4a2fbfc864f7caeffd9d_D20200407-20200407"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg1NjQ4MA_6bd0c24a-cd7d-4f84-8fbf-46f09f5dad87"
      unitRef="usd">4700000000</gild:PaymentsToAcquireAssetsNetOfCashAcquired>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia971b5b9fb3d4bd384e45480e81c75f3_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzU0OTc1NTg1NjQ5Ng_38efe009-6f32-4f13-9218-4b40b884d922"
      unitRef="usd">4500000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="i9a7ef37e465543e5ad6a7b3828719842_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMDYvZnJhZzplYzVmNzQxMTk0ZDc0NGJlYjY3MzI2ZjllZWRjNDI5NC90ZXh0cmVnaW9uOmVjNWY3NDExOTRkNzQ0YmViNjczMjZmOWVlZGM0Mjk0XzEwOTk1MTE3MDE2NTA_ab3c8b07-1a42-4270-bce4-26c6e612fc78"
      unitRef="usd">144000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzY3NQ_79bd1806-ddbb-4251-b0e6-ac5f12891377">PROPERTY, PLANT AND EQUIPMENT&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Property, plant and equipment, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements (including leasehold improvements)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes $104 million and $131 million of unamortized capitalized software costs as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net book value of our property, plant and equipment in the U.S. was $4.5 billion and $4.1 billion as of December&#160;31, 2022 and 2021, respectively. The corresponding amount in international locations was $973 million and $963 million as of December&#160;31, 2022 and 2021, respectively. All individual international locations accounted for less than 10% of the total balances.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzY3NA_b66ad555-5858-4cb3-89b1-88fe9479ed13">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Property, plant and equipment, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements (including leasehold improvements)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office, computer equipment and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Includes $104 million and $131 million of unamortized capitalized software costs as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:Land
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzItMi0xLTEtMTY3NjY1_2202f131-3589-4c1e-aebe-c930e5caee42"
      unitRef="usd">562000000</us-gaap:Land>
    <us-gaap:Land
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzItNC0xLTEtMTY3NjY1_807e3fa7-eb0d-4202-ba11-5e98a6c0078d"
      unitRef="usd">404000000</us-gaap:Land>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzMtMi0xLTEtMTY3NjY1_cceb8061-621d-43ba-95e2-3c151c59a329"
      unitRef="usd">4390000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:BuildingsAndImprovementsGross
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzMtNC0xLTEtMTY3NjY1_19fc50ea-e698-480b-ae3d-63ad886abd91"
      unitRef="usd">3794000000</us-gaap:BuildingsAndImprovementsGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzQtMi0xLTEtMTY3NjY1_b8fe0895-ba80-48c3-b057-e40f16a90d43"
      unitRef="usd">1110000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzQtNC0xLTEtMTY3NjY1_ff175146-c891-46f0-b56a-46eda231db0b"
      unitRef="usd">952000000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzUtMi0xLTEtMTY3NjY1_c07e0b27-8309-4462-bc93-81cd435e9671"
      unitRef="usd">880000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzUtNC0xLTEtMTY3NjY1_6062a307-638c-4a60-9fb3-9db43a6d4efd"
      unitRef="usd">807000000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:ConstructionInProgressGross
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzYtMi0xLTEtMTY3NjY1_21b1a14d-7b23-4dbe-9c4c-d9014c027c58"
      unitRef="usd">719000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzYtNC0xLTEtMTY3NjY1_a324a061-f5d3-4a3d-9851-3ab0b125358b"
      unitRef="usd">1057000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzctMi0xLTEtMTY3NjY1_141b397b-de28-4f81-bb82-29aa82a449c5"
      unitRef="usd">7661000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzctNC0xLTEtMTY3NjY1_d372c2c1-259e-461f-b636-0eda411a718c"
      unitRef="usd">7014000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzgtMi0xLTEtMTY3NjY1_31b1c8d3-957b-4935-9cc2-87f82996d7fe"
      unitRef="usd">2186000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzgtNC0xLTEtMTY3NjY1_4428c687-c38e-498b-b9f7-e93b797d9f1d"
      unitRef="usd">1893000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzktMi0xLTEtMTY3NjY1_2023ce59-50d3-4d73-8ccc-e3756979a371"
      unitRef="usd">5475000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90YWJsZTo3ZTAxY2EzNjNmMTc0ZmFhOGNmYmJjZTk2OTI2MDRhZC90YWJsZXJhbmdlOjdlMDFjYTM2M2YxNzRmYWE4Y2ZiYmNlOTY5MjYwNGFkXzktNC0xLTEtMTY3NjY1_fefb998d-f857-41bf-810b-e79ef0ba1dcb"
      unitRef="usd">5121000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzE2NDkyNjc0NDIzNTQ_71a609e9-73cd-49b9-bde3-7691648e3ffb"
      unitRef="usd">104000000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzE2NDkyNjc0NDIzNDY_9f5d5835-aa71-4347-9858-acaf4b53824b"
      unitRef="usd">131000000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ieff06bffa0844a9d8876ecd6c333e23c_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzE2NDkyNjc0NDIzNjc_777e03fa-e3db-45eb-81c1-d6bff404069a"
      unitRef="usd">4500000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i44d47c74025d4cfdba50d1a8b27fc2b9_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzE2NDkyNjc0NDIzNjE_83772223-eade-4d3f-bfec-e9b66acf8c9a"
      unitRef="usd">4100000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i492e0765e063418f871681e4d0901a65_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzE2NDkyNjc0NDIzODI_fda9ea37-6a8c-488a-846d-69cc5e3b9db7"
      unitRef="usd">973000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie0ba8e5a7781443694297bc65f7058d2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTIvZnJhZzo3MTJlNWM4NTgwMjk0NDU3YTk4MzNjMDg3MzA1NjY3ZC90ZXh0cmVnaW9uOjcxMmU1Yzg1ODAyOTQ0NTdhOTgzM2MwODczMDU2NjdkXzE2NDkyNjc0NDIzNzY_1de2a7b4-42c9-4e39-9cc1-fa0febd79099"
      unitRef="usd">963000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzM1MTI_c1c550ea-848c-4554-a117-37b657f2bb9f">GOODWILL AND INTANGIBLE ASSETS &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of Goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, goodwill decreased by $18&#160;million as a result of finalizing the amount of acquired net operating losses of MYR, which resulted in a decrease to the net deferred tax liability acquired. As of December&#160;31, 2022, there were no accumulated goodwill impairment losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; axicabtagene ciloleucel&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; Hepcludex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets &#x2013; IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&amp;amp;D intangible asset of $6.1 billion will be reclassified to finite-lived assets in the first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense related to finite-lived intangible assets was $1.8 billion, $1.7 billion and $1.2 billion for the years ended December&#160;31, 2022, 2021 and 2020, respectively, and is primarily included in Cost of goods sold on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment Assessments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No indicators of impairment were noted for the years ended December&#160;31, 2022, 2021 and 2020, except as described under &#x201c;2022 IPR&amp;amp;D Impairment&#x201d; below. The weighted-average discount rates used in our quantitative assessments for IPR&amp;amp;D intangible assets during those years, other than for the assessment described below, were 7.5%, 6.5% and 8.0%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 IPR&amp;amp;D Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Immunomedics in 2020, we allocated a portion of the purchase price to acquired IPR&amp;amp;D intangible assets. Approximately $8.8&#160;billion was assigned to IPR&amp;amp;D intangible assets related to Trodelvy for treatment of patients with HR+/HER2- breast cancer. In March 2022, we received data from the Phase 3 TROPiCS-02 study evaluating Trodelvy in patients with HR+/HER2- metastatic breast cancer who have received prior endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and two to four lines of chemotherapy (&#x201c;third-line plus patients&#x201d;). Based on our evaluation of the study results, and in connection with the preparation of the financial statements for the first quarter, we updated our estimate of the fair value of our HR+/HER2- IPR&amp;amp;D intangible asset to $6.1&#160;billion as of March 31, 2022. Our estimate of fair value used a probability-weighted income approach that discounts expected future cash flows to the present value, which requires the use of Level 3 fair value measurements and inputs, including estimated revenues, costs, and probability of technical and regulatory success. The expected cash flows included cash flows from HR+/HER2- metastatic breast cancer for third-line plus patients and patients in earlier lines of therapy which are the subject of separate clinical studies. Our revised discounted cash flows were lower primarily due to a delay in launch timing for third-line plus patients which caused a decrease in our market share assumptions based on the expected competitive environment. As of March 2022, there were no changes in our plans or assumptions related to our estimated cash flows for patients in the earlier lines of therapy. We used a discount rate of 6.75% which is based on the estimated weighted-average cost of capital for companies with profiles similar to ours and represents the rate that market participants would use to value the intangible assets. We determined the revised estimated fair value was below the carrying value of the asset and, as a result, we recognized a partial impairment charge of $2.7&#160;billion in In-process research and development impairment on our Consolidated Statements of Income during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzM1MTM_4fd911dd-13f2-42da-b282-e85c7e1f6834">&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of Goodwill:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzItMi0xLTEtMTY3NjY1_ba20cf8b-ddd8-41f5-b6f6-762f71b7f49f"
      unitRef="usd">8332000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzItNC0xLTEtMTY3NjY1_33e14fc1-a2cb-4540-9010-3f808f9fde2b"
      unitRef="usd">8108000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzMtMi0xLTEtMTY3NjY1_24a5b645-c663-44e2-99f4-de382095990e"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzMtNC0xLTEtMTY3NjY1_ff4a4a49-83bd-4220-89c5-f402aa017077"
      unitRef="usd">226000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzQtMi0xLTEtMTY3NjY1_153b4f8e-4005-4e56-ba92-bc5661f3229b"
      unitRef="usd">-18000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzQtNC0xLTEtMTY3NjY1_4e83d180-0b6e-4849-8a95-500b56e26f23"
      unitRef="usd">-2000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzUtMi0xLTEtMTY3NjY1_e7d43fae-1acb-4f9e-86c6-4bde8572795f"
      unitRef="usd">8314000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo3NmU2YTVlYzNiMjk0MmQ4YjNkYWZkZmQ2YzljODc4OC90YWJsZXJhbmdlOjc2ZTZhNWVjM2IyOTQyZDhiM2RhZmRmZDZjOWM4Nzg4XzUtNC0xLTEtMTY3NjY1_9a61f135-aabd-4c1d-b3fc-e510c49821e7"
      unitRef="usd">8332000000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="icdf3325b9c814697b37f4edbe5de04de_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NDU4MzM_6302e19d-04b3-47d9-9bec-79078e4d3c35"
      unitRef="usd">-18000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NDU4NDQ_8f516f5b-e892-4b36-be7e-bcc6202c4434"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzM0OTY_bbb18ef8-4dc0-4645-92b9-dcc089aeafb0">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; axicabtagene ciloleucel&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; Hepcludex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets &#x2013; IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2023, FDA granted approval of Trodelvy for use in adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. Accordingly, the related IPR&amp;amp;D intangible asset of $6.1 billion will be reclassified to finite-lived assets in the first quarter of 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzM0NzQ_d679a21c-b79d-492d-a488-13abe1b2b9cb">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Gross&#160;&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; sofosbuvir&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; axicabtagene ciloleucel&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; Trodelvy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset &#x2013; Hepcludex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(733)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived assets &#x2013; IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9c7754ade07946249e798f443a00c1b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtMi0xLTEtMTY3NjY1_83a4a5ea-eafe-45f7-8757-5760b912b120"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9c7754ade07946249e798f443a00c1b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtNC0xLTEtMTY3NjY1_905dec9a-e7b1-4b5d-afc1-ab93018934e4"
      unitRef="usd">6350000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i9c7754ade07946249e798f443a00c1b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtNi0xLTEtMTY3NjY1_26ff22c0-29c2-4eb8-9a53-fc63d7c44bc3"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9c7754ade07946249e798f443a00c1b4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtOC0xLTEtMTY3NjY1_1f7608e7-e7bd-4b83-8393-b9c8942139fd"
      unitRef="usd">4370000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i181901e26e3e4c91a24f93e978ab1945_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtMTAtMS0xLTE2NzY2NQ_8821d795-6970-4d8c-b65b-0107205e0102"
      unitRef="usd">10720000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i181901e26e3e4c91a24f93e978ab1945_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtMTItMS0xLTE2NzY2NQ_59d42964-97c3-4f9d-837f-d7acb2a1826f"
      unitRef="usd">5651000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i181901e26e3e4c91a24f93e978ab1945_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtMTQtMS0xLTE2NzY2NQ_0187e1dc-0d6d-4216-afbe-764db593170e"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i181901e26e3e4c91a24f93e978ab1945_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzMtMTYtMS0xLTE2NzY2NQ_c677af71-b875-4df4-b88b-8e3c9989bc4b"
      unitRef="usd">5069000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i44ccd0f6f6894efbb8cbf39df662d267_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtMi0xLTEtMTY3NjY1_7c047098-d93e-423f-bcfc-92a49c65bee4"
      unitRef="usd">7110000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i44ccd0f6f6894efbb8cbf39df662d267_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtNC0xLTEtMTY3NjY1_575b4a8c-4be4-49de-a203-603c34e3582d"
      unitRef="usd">1908000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i44ccd0f6f6894efbb8cbf39df662d267_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtNi0xLTEtMTY3NjY1_4911fc1e-a547-464d-a9f6-23dcd8f49b28"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i44ccd0f6f6894efbb8cbf39df662d267_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtOC0xLTEtMTY3NjY1_be215e66-bbad-463f-9202-a696f5389c7f"
      unitRef="usd">5202000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i89be91f170784317b4d65294841f9a30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtMTAtMS0xLTE2NzY2NQ_13c900d5-8875-4c2a-831e-dd0eb096346a"
      unitRef="usd">7110000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i89be91f170784317b4d65294841f9a30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtMTItMS0xLTE2NzY2NQ_c5583f90-4c28-4803-8a27-4e9b78783154"
      unitRef="usd">1501000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i89be91f170784317b4d65294841f9a30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtMTQtMS0xLTE2NzY2NQ_19e48863-85c1-4f38-99c0-6bb8c6eccf72"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i89be91f170784317b4d65294841f9a30_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzQtMTYtMS0xLTE2NzY2NQ_d359cc90-b8f6-4212-8b9f-e62fd1b17328"
      unitRef="usd">5609000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idf8e90e835654b89b0b240d8650e1eae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtMi0xLTEtMTY3NjY1_46ce8e21-8af3-4f0a-9c22-b445455e70c0"
      unitRef="usd">5630000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idf8e90e835654b89b0b240d8650e1eae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtNC0xLTEtMTY3NjY1_3836a418-abd3-45d0-9704-634f9fbab456"
      unitRef="usd">973000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="idf8e90e835654b89b0b240d8650e1eae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtNi0xLTEtMTY3NjY1_3404c127-03ac-41e5-a187-9acb7e6312e9"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idf8e90e835654b89b0b240d8650e1eae_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtOC0xLTEtMTY3NjY1_618d5d21-4e73-4a90-9a74-243f4f1e073c"
      unitRef="usd">4657000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic9d3cfbadc744a27b6406bc2824e189a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtMTAtMS0xLTE2NzY2NQ_672eebdf-5373-4da2-8c65-dead4fa9d644"
      unitRef="usd">5630000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic9d3cfbadc744a27b6406bc2824e189a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtMTItMS0xLTE2NzY2NQ_1c9a66c8-134a-4c0f-bdae-76fba9b6987c"
      unitRef="usd">507000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ic9d3cfbadc744a27b6406bc2824e189a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtMTQtMS0xLTE2NzY2NQ_3349b42c-8576-4514-8890-b51cd6135933"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic9d3cfbadc744a27b6406bc2824e189a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzUtMTYtMS0xLTE2NzY2NQ_c73584cc-abcb-43c7-82ff-51fed7b9db7d"
      unitRef="usd">5123000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id42c17e537b943188ee815c6eb4724df_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtMi0xLTEtMTY3NjY1_4bb63e61-512b-4692-a7e9-a14a7d9e1686"
      unitRef="usd">845000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id42c17e537b943188ee815c6eb4724df_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtNC0xLTEtMTY3NjY1_94213b6e-82ca-4507-a773-89f118fa7553"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="id42c17e537b943188ee815c6eb4724df_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtNi0xLTEtMTY3NjY1_5d8f2c13-85a2-446d-af7a-a00813acab1f"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id42c17e537b943188ee815c6eb4724df_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtOC0xLTEtMTY3NjY1_7643498a-1dbc-4078-82f6-e15526367cfe"
      unitRef="usd">687000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i59824532c8ca4a779f76468f950efb0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtMTAtMS0xLTE2NzY2NQ_46d1b36e-3625-49b3-9e13-6768670e1e8e"
      unitRef="usd">845000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i59824532c8ca4a779f76468f950efb0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtMTItMS0xLTE2NzY2NQ_77fab2f1-e2d0-4856-afa1-662de9a456fb"
      unitRef="usd">72000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i59824532c8ca4a779f76468f950efb0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtMTQtMS0xLTE2NzY2NQ_59a8bf3e-7df7-4245-8117-c776424e530d"
      unitRef="usd">0</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i59824532c8ca4a779f76468f950efb0c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzYtMTYtMS0xLTE2NzY2NQ_1cf97525-efb8-4173-923f-4398761c33af"
      unitRef="usd">773000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6d0b0fcb16144c1485e4bb100851404c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctMi0xLTEtMTY3NjY1_24e6d70f-6ad7-476c-a2fe-cb760f7f8c62"
      unitRef="usd">1489000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6d0b0fcb16144c1485e4bb100851404c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctNC0xLTEtMTY3NjY1_3c4f9988-10b4-49cf-ad25-098396d92f9d"
      unitRef="usd">733000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i6d0b0fcb16144c1485e4bb100851404c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctNi0xLTEtMTY3NjY1_d12d7c69-a3e0-4495-bbb9-d6e01001b0b9"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6d0b0fcb16144c1485e4bb100851404c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctOC0xLTEtMTY3NjY1_c37ef5b7-7e0a-4ff8-b973-b1d030df1642"
      unitRef="usd">758000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i525ebc96796c4ef3b6ad07db88affd7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctMTAtMS0xLTE2NzY2NQ_faa7103f-7ccb-406e-8215-45fe2168a0c6"
      unitRef="usd">1610000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i525ebc96796c4ef3b6ad07db88affd7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctMTItMS0xLTE2NzY2NQ_a5df5e36-e98e-4bc7-8790-102cef4a03ae"
      unitRef="usd">650000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i525ebc96796c4ef3b6ad07db88affd7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctMTQtMS0xLTE2NzY2NQ_1c48f376-85c9-4882-87bf-32c3b852a6fb"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i525ebc96796c4ef3b6ad07db88affd7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzctMTYtMS0xLTE2NzY2NQ_fcc4903b-ad63-4288-a69d-d73073e63457"
      unitRef="usd">961000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtMi0xLTEtMTY3NjY1_194f6f86-b28e-4ab6-9b75-dba91fb1da2c"
      unitRef="usd">25794000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtNC0xLTEtMTY3NjY1_2313bef6-62d9-449a-ae2e-713aeb0544fc"
      unitRef="usd">10121000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtNi0xLTEtMTY3NjY1_3c9d2d3e-ff14-4a2f-b05e-b3913b4d85fa"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtOC0xLTEtMTY3NjY1_3ef34012-9919-4eb4-8548-d04f9b6a1d0c"
      unitRef="usd">15674000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtMTAtMS0xLTE2NzY2NQ_150e4ef4-3e03-43db-b9db-8d16a5e771f9"
      unitRef="usd">25915000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtMTItMS0xLTE2NzY2NQ_3acf957c-3d91-42fb-9316-8c3648605ea1"
      unitRef="usd">8381000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtMTQtMS0xLTE2NzY2NQ_b2dcb7b7-7efb-49b7-9f3b-53eb50bd8891"
      unitRef="usd">1000000</gild:FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzgtMTYtMS0xLTE2NzY2NQ_6f53abd8-9a97-4d49-bdda-bb1af105790e"
      unitRef="usd">17535000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzktMi0xLTEtMTY3NjY1_a6cbdf29-1d29-49c9-b5b4-f240c6b28004"
      unitRef="usd">13220000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzktNi0xLTEtMTY3NjY1_f5740396-3506-4eed-82c9-0a9b2dbbea74"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzktOC0xLTEtMTY3NjY1_d2f907fe-157a-4435-bce2-78466d2e59cc"
      unitRef="usd">13220000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzktMTAtMS0xLTE2NzY2NQ_ca97a1b7-9b3b-410f-9b7a-85f639102cf8"
      unitRef="usd">15920000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzktMTQtMS0xLTE2NzY2NQ_9fde7392-84fc-4c34-afcf-18b110c8bc55"
      unitRef="usd">0</gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzktMTYtMS0xLTE2NzY2NQ_355fb979-0f39-4c7d-b113-0c2d8f19c585"
      unitRef="usd">15920000000</gild:TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTItMS0xLTE2NzY2NQ_8d1c65a1-76bb-4aaf-ab6e-e2a5525d2418"
      unitRef="usd">39014000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTQtMS0xLTE2NzY2NQ_9722d1b7-25c2-4450-ad54-070317611633"
      unitRef="usd">10121000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTYtMS0xLTE2NzY2NQ_d7693a8e-9152-4b77-9e96-28ab4fe35a8a"
      unitRef="usd">1000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTgtMS0xLTE2NzY2NQ_e13a726f-02af-4e61-8efa-79356016b01c"
      unitRef="usd">28894000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTEwLTEtMS0xNjc2NjU_82c8db73-3a74-4706-bb7a-1b4e0f97ee44"
      unitRef="usd">41835000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTEyLTEtMS0xNjc2NjU_49b49e79-1b33-493b-9053-edb88a7aa780"
      unitRef="usd">8381000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTE0LTEtMS0xNjc2NjU_23160cb0-4606-4921-bfeb-0e7a9ce6b086"
      unitRef="usd">1000000</gild:FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZToyNGQ0OTY0NGU1NTA0MDBlYjM1NmI0ZTUyMTNjMmY5My90YWJsZXJhbmdlOjI0ZDQ5NjQ0ZTU1MDQwMGViMzU2YjRlNTIxM2MyZjkzXzEwLTE2LTEtMS0xNjc2NjU_270dd8a2-7dc4-43bb-b1ec-4aacb04d3025"
      unitRef="usd">33455000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="i57236ea81268491a97d91341f26ba286_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzEwOTk1MTE2NTUzNjA_ab6b342e-db90-4eb0-b140-a7103f82e714"
      unitRef="usd">6100000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NDcwMzk_93b1ec22-4731-4fe0-8049-0d4c6bdb48a3"
      unitRef="usd">1800000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NDcwMzI_8b7f7a67-5369-4dc4-b4a8-f4075a5c0e3a"
      unitRef="usd">1700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NDcwMjU_469c7bab-1712-4091-8823-17d9ddea2e06"
      unitRef="usd">1200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzEzMTk0MTM5NTU4NzEy_31edd875-6518-4593-a992-062644c32311">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzEtMi0xLTEtMjY1MTky_b467bfdb-43cb-4506-8381-7650c30f306e"
      unitRef="usd">1777000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzItMi0xLTEtMjY1MTky_36ee1f8a-7ef1-4543-a744-4fb421d0f631"
      unitRef="usd">1777000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzMtMi0xLTEtMjY1MTky_10ddcf49-8930-4981-a57d-b45e18490186"
      unitRef="usd">1771000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzQtMi0xLTEtMjY1MTky_199ad010-1bcc-4c5e-8c35-8837f0a36ead"
      unitRef="usd">1763000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzUtMi0xLTEtMjY1MTky_7db85d3e-5c24-4a6a-95fb-feb150327437"
      unitRef="usd">1763000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzYtMi0xLTEtMjY1MTky_652ea547-9a55-46b0-bb3b-4d3cd1aff4c2"
      unitRef="usd">6824000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90YWJsZTo2M2U0ODg3OWRiM2Y0ZWU4ODBkZTE1MmEyNzJlOWI1YS90YWJsZXJhbmdlOjYzZTQ4ODc5ZGIzZjRlZTg4MGRlMTUyYTI3MmU5YjVhXzctMi0xLTEtMjY1MTky_f20b46c7-57b9-4252-adaa-32f4a06b5226"
      unitRef="usd">15674000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzU0OTc1NTgxNjEzMDQ_691e0f85-017b-43d0-9bdd-a485f65d5362"
      unitRef="number">0.075</gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate>
    <gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzU0OTc1NTgxNjEzMDk_f4d4b6a0-2750-48c1-b17c-0f57b0c4c23e"
      unitRef="number">0.065</gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate>
    <gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate
      contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzU0OTc1NTgxNjEzMTc_6a56f841-d5d3-4dac-8be9-13b0fc0dbeee"
      unitRef="number">0.080</gild:IndefiniteLivedIntangibleAssetsAcquiredDiscountRate>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="i3cbbdf76bfd6400ebaa7f622c1e30073_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NTQwNjQ_4ef79441-c50d-4cab-982b-29ad3bf1b3ee"
      unitRef="usd">8800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="i32d561b8ae6b4a2f98da8f5dd0fa0d8a_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NTQwNzE_e253de21-e65e-4a02-88e4-c72687b27b3b"
      unitRef="usd">6100000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <gild:IndefiniteLivedIntangibleAssetMeasurementInput
      contextRef="i8e1a6227be7f4425b549d4e5d0588c1c_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NTQwNzg_50142703-1aa8-4b96-b9f5-d780541f3719"
      unitRef="number">0.0675</gild:IndefiniteLivedIntangibleAssetMeasurementInput>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i140e9b5aa60a4667b375867beadd9364_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTUvZnJhZzo4Yzk3NGY4MTBmNGE0ZWU3OWExNDgyNzAxYThiNDU0Mi90ZXh0cmVnaW9uOjhjOTc0ZjgxMGY0YTRlZTc5YTE0ODI3MDFhOGI0NTQyXzE2NDkyNjc0NTQwODI_740d464d-d655-4c44-ac7c-5daf934da1c7"
      unitRef="usd">2700000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90ZXh0cmVnaW9uOjcwMDJhMDZmZGQwMTRjMjc4ZGFmZTdiZWE2ODVmNWVlXzE5MA_d903ab92-368f-456a-9635-f0938850c067">OTHER FINANCIAL INFORMATION&lt;div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of our trade accounts receivable arises from product sales in the U.S. and Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total inventories as of December&#160;31, 2021 included $294 million of fair value adjustments resulting from the Immunomedics acquisition. There were no fair value adjustments in total inventories as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:24.75pt;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Other current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual for settlement related to bictegravir litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;See Note 13. Commitments and Contingencies for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90ZXh0cmVnaW9uOjcwMDJhMDZmZGQwMTRjMjc4ZGFmZTdiZWE2ODVmNWVlXzE5MQ_b1bdb360-71aa-4418-85f4-5fe23e727f96">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Accounts receivable, net: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for cash discounts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowances for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzItMi0xLTEtMTY3NjY1_6c2a3b9a-0175-472a-9223-18af1a0ca1dd"
      unitRef="usd">5464000000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzItNC0xLTEtMTY3NjY1_6411ce4d-ff73-4dd1-bdbd-331bccf7793f"
      unitRef="usd">5278000000</us-gaap:AccountsReceivableGrossCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzMtMi0xLTEtMTY3NjY1_12c2ea2f-f421-4df1-a580-c6a8f116eeb3"
      unitRef="usd">549000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableChargebacksCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzMtNC0xLTEtMTY3NjY1_92ae8866-7302-455c-9404-25d7c806c8ed"
      unitRef="usd">671000000</gild:AccountsReceivableChargebacksCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzQtMi0xLTEtMTY3NjY1_94c45594-a953-4012-b764-e0369851df18"
      unitRef="usd">83000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <gild:AccountsReceivableCashDiscountsAndOtherCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzQtNC0xLTEtMTY3NjY1_dea7875f-f98a-438a-a15b-03f4369222c5"
      unitRef="usd">67000000</gild:AccountsReceivableCashDiscountsAndOtherCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzUtMi0xLTEtMTY3NjY1_a07a963a-ae5b-414e-9647-ce8db55f29f3"
      unitRef="usd">55000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzUtNC0xLTEtMTY3NjY1_a9e65bc8-a3c6-4892-bdf9-39e2877b9dee"
      unitRef="usd">47000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzYtMi0xLTEtMTY3NjY1_6f77dc52-20f5-4ee8-ab55-9091971a1077"
      unitRef="usd">4777000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTpkNzYwYTE0YTU2OWI0MTc2OGFjMzE5Y2IyZDU0ZTg5YS90YWJsZXJhbmdlOmQ3NjBhMTRhNTY5YjQxNzY4YWMzMTljYjJkNTRlODlhXzYtNC0xLTEtMTY3NjY1_66dc246f-d08c-4a21-a126-89b05b60174d"
      unitRef="usd">4493000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90ZXh0cmVnaW9uOjcwMDJhMDZmZGQwMTRjMjc4ZGFmZTdiZWE2ODVmNWVlXzEzMTk0MTM5NTM1NzI3_511d5587-6a47-4419-870e-fbf04d8fb5b0">&lt;div style="margin-top:4.5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our Inventories:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Amounts primarily consist of raw materials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzItMi0xLTEtMjA2ODEz_35d6e0da-8aee-48b2-9703-915998390dca"
      unitRef="usd">1177000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzItNC0xLTEtMjA2ODEz_43ae9104-87ea-4508-b747-30b9aaf5bcd6"
      unitRef="usd">1112000000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzMtMi0xLTEtMjA2ODEz_8aebed3a-1140-4791-9939-0c3e1866ed8d"
      unitRef="usd">577000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzMtNC0xLTEtMjA2ODEz_d2d50708-6fb2-4802-b4b8-e23ac167cf2d"
      unitRef="usd">590000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzQtMi0xLTEtMjA2ODEz_80eb9558-73a9-415f-87de-46e46f58983c"
      unitRef="usd">1066000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzQtNC0xLTEtMjA2ODEz_7cce3cbd-9b90-461f-9bf4-3a37412ce7b8"
      unitRef="usd">1032000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzUtMi0xLTEtMjA2ODEz_149c2019-5243-4ff5-a4d8-d1b9b8a191b9"
      unitRef="usd">2820000000</gild:InventoryNetAndInventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzUtNC0xLTEtMjA2ODEz_5c49ef2d-1c99-40af-a046-0970d5d65784"
      unitRef="usd">2734000000</gild:InventoryNetAndInventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzgtMi0xLTEtMjA2ODEz_dedf1f5b-4502-424d-96ef-87d93766d640"
      unitRef="usd">1507000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzgtNC0xLTEtMjA2ODEz_de6e4942-2ea3-4966-af2a-9f59f93727fa"
      unitRef="usd">1618000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzktMi0xLTEtMjA2ODEz_c99bb0e9-1653-46dd-8465-31396e7768bd"
      unitRef="usd">1313000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzktNC0xLTEtMjA2ODEz_38915212-a733-422e-a64e-52f75e26fd75"
      unitRef="usd">1116000000</us-gaap:InventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzEwLTItMS0xLTIwNjgxMw_1fb1164b-b682-4fa9-b545-77ddcdeab9c3"
      unitRef="usd">2820000000</gild:InventoryNetAndInventoryNoncurrent>
    <gild:InventoryNetAndInventoryNoncurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZTo2ZDgzYTFjOTMyNjQ0NWYwOWU2MGE3NDQxN2VmYWU4Yy90YWJsZXJhbmdlOjZkODNhMWM5MzI2NDQ1ZjA5ZTYwYTc0NDE3ZWZhZThjXzEwLTQtMS0xLTIwNjgxMw_8a2f8912-5cce-4a6f-bc24-3132d2279a16"
      unitRef="usd">2734000000</gild:InventoryNetAndInventoryNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i327df07e8ea64ce7a694e3e3b3ff882e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90ZXh0cmVnaW9uOjcwMDJhMDZmZGQwMTRjMjc4ZGFmZTdiZWE2ODVmNWVlXzU0OTc1NTgxNjc0NQ_403c6c88-1aa5-4c39-811c-e988c472d08d"
      unitRef="usd">294000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="ifb58b983f5e14067bcbab9fc5db32341_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90ZXh0cmVnaW9uOjcwMDJhMDZmZGQwMTRjMjc4ZGFmZTdiZWE2ODVmNWVlXzU0OTc1NTgxNjc2OQ_c46d172a-8953-4c1e-8684-2bdabaac1383"
      unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90ZXh0cmVnaW9uOjcwMDJhMDZmZGQwMTRjMjc4ZGFmZTdiZWE2ODVmNWVlXzE5Mg_720821a6-5c50-494d-878b-82bb86e26cd0">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of Other current liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrual for settlement related to bictegravir litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;_______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;See Note 13. Commitments and Contingencies for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzItMi0xLTEtMTY3NjY1_a8b49114-54cc-42cd-bc0c-f4f67c777397"
      unitRef="usd">1018000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzItNC0xLTEtMTY3NjY1_b1251b61-8bfc-4a52-804c-1cfa22e4cd7e"
      unitRef="usd">927000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzMtMi0xLTEtMTY3NjY1_aa1c50a8-b860-4b72-892d-14edcd904632"
      unitRef="usd">959000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzMtNC0xLTEtMTY3NjY1_2ab5c8e0-f001-417d-8bea-4735a6c72f8c"
      unitRef="usd">539000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzQtMi0xLTEtMTY3NjY1_2078ae20-b544-4294-ad39-0fbb4225610a"
      unitRef="usd">422000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzQtNC0xLTEtMTY3NjY1_965513f8-5d10-4481-af08-fb8830f61bd1"
      unitRef="usd">499000000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzUtMi0xLTEtMTY3NjY1_9d01031a-088b-4163-8968-69895949f9eb"
      unitRef="usd">0</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzUtNC0xLTEtMTY3NjY1_f7546071-793f-4505-976e-7a382b2d6ce7"
      unitRef="usd">1250000000</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzYtMi0xLTEtMTY3NjY1_ff05e6d7-a50f-42d5-8976-3ecc756f1eed"
      unitRef="usd">2182000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzYtNC0xLTEtMTY3NjY1_72460766-525c-4ca2-b489-361a9d2352f1"
      unitRef="usd">2930000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzctMi0xLTEtMTY3NjY1_691c7853-6b5e-46b4-998f-6cfd12c0b953"
      unitRef="usd">4580000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMTgvZnJhZzo3MDAyYTA2ZmRkMDE0YzI3OGRhZmU3YmVhNjg1ZjVlZS90YWJsZToxNzFmN2ZmZjNiZWI0ODRhODcxNTVmYTYyODE4N2U1OS90YWJsZXJhbmdlOjE3MWY3ZmZmM2JlYjQ4NGE4NzE1NWZhNjI4MTg3ZTU5XzctNC0xLTEtMTY3NjY1_995db15c-f830-45b6-a6d5-a17cafeacb99"
      unitRef="usd">6145000000</us-gaap:OtherLiabilitiesCurrent>
    <gild:CollaborativeAndOtherArrangementsTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzMyMTAw_364d8c8d-c1be-4abe-b9fd-9be8d4937246">COLLABORATIONS AND OTHER ARRANGEMENTS &lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. These arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements and equity investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the financial terms of these arrangements, we may be required to make payments upon achievement of various developmental, regulatory and commercial milestones, which could be significant. Future milestone payments, if any, will be reflected in our Consolidated Statements of Income when the corresponding events become probable. In connection with the regulatory approvals, milestone payments made will be capitalized as intangible assets and will be amortized to Cost of goods sold through the terms of these collaboration arrangements. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Dragonfly&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, we entered into a strategic research collaboration agreement (the &#x201c;Dragonfly Collaboration Agreement&#x201d;) with Dragonfly Therapeutics, Inc. (&#x201c;Dragonfly&#x201d;) to develop natural killer (&#x201c;NK&#x201d;) cell engager-based immunotherapies for oncology and inflammation indications. Under the terms of the Dragonfly Collaboration Agreement, we received an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001, as well as options, after the completion of certain preclinical activities, to license exclusive, worldwide rights to develop and commercialize additional NK cell engager programs using the Dragonfly Tri-specific NK Engager platform. Upon the closing of the Dragonfly Collaboration Agreement, we made a $300 million upfront payment to Dragonfly, and we made an additional $15 million payment related to a target selection in connection with an August 2022 amendment to the agreement, which were recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December&#160;31, 2022. These payments were classified as Acquisitions, including in-process research and development, net of cash acquired in Investing Activities on our Consolidated Statements of Cash Flows for the year ended December&#160;31, 2022. In addition, Dragonfly is eligible to receive performance-based development and regulatory milestone payments of up to $630 million related to the DF7001 program with further commercial milestone payments and royalties on worldwide net sales if successful. If we exercise our options on additional NK cell engager programs, Dragonfly would be eligible to receive opt-in payments and performance-based development, regulatory and commercial milestone payments and royalties on worldwide net sales on these optioned programs as well.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Merck &amp;amp; Co, Inc. (&#x201c;Merck&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 13, 2021, we entered into a license and collaboration agreement with Merck Sharp &amp;amp; Dohme Corp., a subsidiary of Merck to jointly develop and commercialize long-acting investigational treatments in HIV that combine Gilead&#x2019;s investigational capsid inhibitor, lenacapavir, and Merck&#x2019;s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir. The collaboration is initially focused on long-acting oral and injectable formulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Gilead and Merck share global development and commercialization costs at 60% and 40%, respectively, across the oral and injectable formulation programs. For long-acting oral products, if approved, Gilead would lead commercialization in the U.S., and Merck would lead commercialization in the European Union (&#x201c;EU&#x201d;) and rest of the world. For long-acting injectable products, if approved, Merck would lead commercialization in the U.S. and Gilead would lead commercialization in the EU and rest of the world. Under the terms of the agreement, Gilead and Merck would jointly promote the combination products in the U.S. and certain other major markets. If successful, we would share global product revenues with Merck equally until product revenues surpass certain pre-determined per formulation revenue tiers. Upon passing $2.0 billion in net product sales for the oral combination in a given calendar year, our share of revenue would increase to 65% for any revenues above the threshold for such calendar year. Upon passing $3.5 billion in net product sales for the injectable combination in a given calendar year, our share of revenue will increase to 65% for any revenues above the threshold for such calendar year. Reimbursements of R&amp;amp;D costs to or from Merck are recorded within Research and development expenses on our Consolidated Statements of Income. Expenses recognized under the agreement were not material for the years ended December 31, 2022 and 2021. No revenues have been recognized under the agreement for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will also have the option to license certain of Merck&#x2019;s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead&#x2019;s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for such investigational oral integrase inhibitor of the other company within the first five years after execution of the agreement, following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt out, in which case the non-exercising company will be paid a royalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, Merck announced the decision of the parties to stop all dosing of participants in the Phase 2 clinical study evaluating an oral-weekly combination treatment regimen of lenacapavir and islatravir following the decision of FDA to place clinical holds on the Investigational New Drug applications for certain formulations of islatravir. In September 2022, Merck announced that the study would resume under an amended protocol with a lower dose of islatravir.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Arcus&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 27, 2020, we entered into a transaction with Arcus, a publicly traded oncology-focused biopharmaceutical company, which included entry into an option, license and collaboration agreement (the &#x201c;Collaboration Agreement&#x201d;) and a common stock purchase agreement and an investor rights agreement (together, and as subsequently amended the &#x201c;Stock Purchase Agreements&#x201d;). In accordance with the terms of the Collaboration Agreement and Stock Purchase Agreements, which closed on July 13, 2020, we made an upfront payment of $175 million and acquired approximately 6.0 million shares of Arcus common stock for approximately $200 million. Of the total $391 million initial cash payments, including transactional costs, made under the agreements, we recorded $135 million as an equity investment which was calculated based on Arcus&#x2019; closing stock price on the closing date of the transaction. The remaining $256 million was attributed to (i) the acquired license and option rights of $175 million representing IPR&amp;amp;D assets with no alternative future use, (ii) $65 million of an issuance premium for the equity purchase and (iii) $16 million of direct transactional costs. These amounts were expensed as Acquired in-process research and development expenses during the year ended December 31, 2020 on our Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Stock Purchase Agreements, we have the right to purchase from Arcus additional shares up to a maximum of 35% of the outstanding voting stock of Arcus over a five-year period ending in the third quarter of 2025. We are also subject to a three-year standstill ending in the second quarter of 2023, restricting certain other activity on our part. On May 29, 2020, in a separate secondary equity offering, we acquired 2.2 million shares of common stock of Arcus for approximately $61 million. In the first quarter of 2021, we also acquired approximately 5.7 million additional shares of Arcus common stock for $220 million. As a result, we currently own a total of 13.8 million shares of Arcus, which represented approximately 19.5% of the issued and outstanding voting stock of Arcus immediately following the closing of the first quarter 2021 transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Collaboration Agreement, Gilead had the right to opt in to all current and future clinical-stage product candidates for up to ten years following the closing of the transaction. In November 2021, we exercised our options to three of Arcus&#x2019; clinical stage programs and amended the Collaboration Agreement. The option exercise and amendment transaction closed in December 2021, triggering collaboration opt-in payments of $725 million and waiving the $100 million option continuation payment which would have been due to Arcus in the third quarter of 2022. The net option charge of $625 million is included within Acquired in-process research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2021. The collaboration opt-in payments of $725 million were recorded in Other current liabilities on our Consolidated Balance Sheets as of December 31, 2021 and paid to Arcus in January 2022. Our payments to Arcus were included within Net cash used in investing activities on our Consolidated Statements of Cash Flows in the first quarter of 2022. Under the amended Collaboration Agreement, the companies co-develop and share the global costs related to these clinical programs. We recorded $187 million of such costs in Research and development expenses on our Consolidated Statements of Income for the year ended December&#160;31, 2022. If the optioned molecules achieve regulatory approval, the companies will co-commercialize and equally share profits in the U.S. Gilead will hold exclusive commercialization rights outside the U.S., subject to any rights of Arcus&#x2019;s existing collaboration partners, and will pay to Arcus tiered royalties as a percentage of net sales ranging from the mid teens to low twenties. Under the Collaboration Agreement, we may also pay an additional $100 million at our option on each of the fourth, sixth and eighth anniversaries of the agreement, unless terminated early, to maintain the rights to opt in to future Arcus programs for the duration of the contact term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Pionyr&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2020, we entered into a transaction with Pionyr, a privately held company pursuing novel biology in the field of immuno-oncology, which included entry into two separate merger agreements, one contemplating the initial acquisition of a 49.9% equity interest in Pionyr, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Pionyr (together, the &#x201c;Pionyr Merger and Option Agreements&#x201d;) and a R&amp;amp;D service agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 13, 2020, we closed the transaction and made cash payments of $269 million. We account for our investment in Pionyr using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Pionyr. Our investment in Pionyr, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Pionyr's net assets at transaction closing. We determined that the resulting basis difference primarily relates to Pionyr&#x2019;s IPR&amp;amp;D which has no alternative future use and that Pionyr is not a business as defined in accounting standards. As a result, we immediately recorded a charge for this basis difference of $215 million in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. The carrying value of our equity method investment in Pionyr was zero as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Pionyr is approximately $70 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount is recorded in Other long-term assets on our Consolidated Balance Sheets. We may choose to exercise our exclusive option to purchase the remaining equity interest from Pionyr&#x2019;s current shareholders for a $315 million option exercise fee and up to $1.2 billion in potential future milestone payments upon achievement of certain development and regulatory milestones. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Pionyr. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the R&amp;amp;D service agreement, we made an initial cash funding of $80 million and recorded a charge in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. In addition, we committed to provide additional payments of up to $115 million to Pionyr upon achievement of certain development milestones. We accrued $70 million in milestone payments, related to the initiation of two Phase 1 studies, with a charge to Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020, and the payment was made in the first quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Tizona&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 17, 2020, we entered into a transaction with Tizona, a privately held company developing cancer immunotherapies, which included entry into two separate merger agreements, one contemplating the initial acquisition of a 49.9% equity interest in Tizona, and the other providing us the exclusive option, subject to certain terms and conditions, to acquire the remaining outstanding capital stock of Tizona (together, the &#x201c;Tizona Merger and Option Agreements&#x201d;) and a development agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 25, 2020, we closed the transaction with Tizona and made cash payments of $302 million to Tizona&#x2019;s shareholders in accordance with the terms of the Tizona Merger and Option Agreements. We account for our investment in Tizona using the equity method of accounting because our equity interest provides us with the ability to exercise significant influence over Tizona. Our investment in Tizona, consisting of the transaction price noted above and transaction costs, exceeded our pro-rata portion of Tizona&#x2019;s net assets at transaction closing. We determined that the resulting basis difference primarily relates to Tizona&#x2019;s IPR&amp;amp;D with no alternative future use and that Tizona is not a business as defined in accounting standards. As a result, during the year ended December 31, 2020, we immediately recorded a charge for this basis difference of $272 million in Acquired in-process research and development expenses on our Consolidated Statements of Income. The carrying value of our equity method investment in Tizona was zero as of December&#160;31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our exclusive option to acquire the remaining outstanding capital stock of Tizona is approximately $41 million based on a probability-weighted option pricing model using unobservable inputs, which are considered Level 3 under the fair value measurement and disclosure guidance. The estimated amount is recorded in Other long-term assets on our Consolidated Balance Sheets. We may choose to exercise our exclusive option to purchase the remaining equity interest from Tizona&#x2019;s current shareholders for a $100 million option exercise fee and up to $1.2 billion in potential future milestone payments upon achievement of certain development and regulatory milestones. Such option to purchase will expire following the earliest occurrence of specified events, including the delivery of data following completion of certain Phase 1b trials by Tizona. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the development agreement, we committed to provide funding to Tizona of $115 million, which was recorded in Acquired in-process research and development expenses on our Consolidated Statements of Income during the year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Tango Therapeutics, Inc. (&#x201c;Tango&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 17, 2020, we entered into a transaction with Tango, a privately held company pursuing innovative targeted immune evasion therapies for patients with cancer through its proprietary, CRISPR-enabled functional genomics target discovery platform, which included entry into an amended and restated research collaboration and license agreement and a stock purchase agreement (together, the &#x201c;Tango Collaboration and Stock Purchase Agreements&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon entering into this transaction, we made an upfront payment of $125 million and a $20 million equity investment in Tango. During the year ended December 31, 2020, we recorded the $125 million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income. In the third quarter of 2021, we made an additional $13 million equity investment. Tango became a publicly traded company in 2021, and accordingly our equity investment has since been recorded in Prepaid and other current assets on our Consolidated Balance Sheets at fair market value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Tango Collaboration and Stock Purchase Agreements, Gilead has the right to option up to 15 programs over the seven-year collaboration for up to $410 million per program in opt-in, extension and milestone payments. For the products that Tango opts to co-develop and co-promote, the parties will equally split profits and losses, as well as development costs in the U.S. For products that Tango does not opt to co-develop and co-promote, we will pay Tango up to low double-digit tiered royalties on net sales. We will provide Tango milestone payments and royalties on sales outside of the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Jounce Therapeutics, Inc. (&#x201c;Jounce&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 1, 2020, we entered into a transaction with Jounce, a publicly traded company developing novel cancer immunotherapies, which included entry into license, registration rights and stock purchase agreements (together, &#x201c;Jounce License and Stock Purchase Agreement&#x201d;). In October 2020, we closed this transaction and made a total payment of $120 million. We recorded $64 million upfront expense in Acquired in-process research and development expenses on our Consolidated Statements of Income and $56 million as an equity investment in Other long-term assets on our Consolidated Balance Sheets, representing approximately 14% of the issued and outstanding voting stock of Jounce immediately following the transaction, which was calculated based on Jounce&#x2019;s closing stock price on the closing date of the transaction. In December 2022, we amended our existing license agreement with Jounce enabling us to buy out the remaining contingent payments potentially due under the license agreement for $67 million, which was expensed to Acquired in-process research and development expenses on our Consolidated Statements of Income and was paid in 2022. Going forward, we will be solely responsible for all further research, development and commercialization of the immunotherapy specified in the license agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Galapagos&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Filgotinib Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, we closed a license and collaboration agreement with Galapagos, a clinical-stage biotechnology company based in Belgium, for the development and commercialization of filgotinib, a JAK1-selective inhibitor being evaluated for inflammatory disease indications (the &#x201c;filgotinib agreement&#x201d;). Under the terms of the filgotinib agreement, as amended in 2019 (the &#x201c;2019 Agreement&#x201d;), we obtained an exclusive, worldwide, royalty-bearing, sublicensable license for filgotinib and products containing filgotinib. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, Gilead and Galapagos amended their agreement to allow Galapagos to assume development, manufacturing, commercialization and certain other rights for filgotinib in Europe. In connection with the amendments to the 2019 Agreement, Gilead agreed to irrevocably pay Galapagos &#x20ac;160 million (or approximately $190 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Of this total amount, Gilead paid &#x20ac;35 million (or approximately $43 million) in January 2021, an additional &#x20ac;75 million (or approximately $88 million) in April 2021, and &#x20ac;50 million (or approximately $60 million) in 2022. We accrued the full amount of this liability with a charge to Research and development expenses on our Consolidated Statements of Income for the year ended December 31, 2020. In addition, Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Global Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In&#160;August 2019, we closed an option, license and collaboration agreement (the &#x201c;Galapagos Collaboration Agreement&#x201d;) and a subscription agreement (the &#x201c;Galapagos Subscription Agreement&#x201d;), each with Galapagos, pursuant to which the parties entered into a global collaboration that covers Galapagos&#x2019; current and future product portfolio (other than filgotinib). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Galapagos Subscription Agreement, we purchased 6.8 million new ordinary shares of Galapagos and were issued warrants that confer the right to subscribe, from time to time, for a number of new shares to be issued by Galapagos sufficient to bring the number of shares owned by us to 29.9% of the issued and outstanding shares at the time of our exercises. We currently own 16.7 million shares or approximately 25.8% of the shares issued and outstanding at the time of last purchase in 2019. We are subject to a 10-year standstill restricting our ability to acquire voting securities of Galapagos exceeding more than 29.9% of the then-issued and outstanding voting securities of Galapagos. We agreed not to, without the prior consent of Galapagos, dispose of any equity securities of Galapagos prior to the second anniversary of the closing of the Galapagos Subscription Agreement or dispose of any equity securities of Galapagos thereafter until the fifth anniversary of the closing of the Galapagos Subscription Agreement, if after such disposal we would own less than 20.1% of the then-issued and outstanding voting securities of Galapagos, subject to certain exceptions and termination events. In April 2021, we amended the Galapagos Subscription Agreement to extend the initial lock-up provision for certain Galapagos shares from August 2021 to August 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to programs in Galapagos&#x2019; current and future pipeline, if we exercise our option to a program, we will pay a $150 million option exercise fee per program. In addition, Galapagos will receive tiered royalties ranging from 20% to 24% on net sales in our territories of each Galapagos product optioned by us. If we exercise our option for a program, the parties will share equally in development costs and mutually agreed commercialization costs incurred subsequent to our exercise of the option. We may terminate the collaboration in its entirety or on a program-by-program and country-by-country basis with advance notice as well as following other customary termination events. We have two designees appointed to Galapagos&#x2019; board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Janssen&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Complera/Eviplera and Odefsey&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2009, we entered into a license and collaboration agreement with Janssen, formerly Tibotec Pharmaceuticals, to develop and commercialize a fixed-dose combination of our Truvada and Janssen&#x2019;s non-nucleoside reverse transcriptase inhibitor, rilpivirine, This combination was approved in the U.S. and EU in 2011, and is sold under the brand name Complera in the U.S. and Eviplera in the EU. The agreement was amended in 2014 to expand the collaboration to include another product containing Janssen&#x2019;s rilpivirine and our emtricitabine and tenofovir alafenamide (&#x201c;Odefsey&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the amended agreement, Janssen granted us an exclusive license to Complera/Eviplera and Odefsey worldwide, but retained rights to distribute both combination products in certain countries outside of the U.S. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Complera/Eviplera and Odefsey.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are responsible for manufacturing Complera/Eviplera and Odefsey and have the lead role in registration, distribution and commercialization of both products except in the countries where Janssen distributes. Janssen has exercised a right to co-detail the combination product in some of the countries where we are the selling party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the financial provisions of the 2014 amendment, the selling party sets the price of the combined products and the parties share revenues based on the ratio of the net selling prices of the party&#x2019;s component(s), subject to certain restrictions and adjustments. We retain a specified percentage of Janssen&#x2019;s share of revenues, including up to 30% in major markets. Sales of these products are included in Product sales and Janssen&#x2019;s share of revenues is included in Cost of goods sold on our Consolidated Statements of Income. Cost of goods sold relating to Janssen&#x2019;s share was $483 million, $530 million and $570 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. We may terminate the agreement without cause with respect to the countries where we sell the products, in which case Janssen has the right to become the selling party for such country if the product has launched but has been on the market for fewer than 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Symtuza&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2014, we amended a license and collaboration agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen&#x2019;s darunavir and our cobicistat, emtricitabine and tenofovir alafenamide (&#x201c;Gilead Compounds&#x201d;). This combination was approved in the U.S. and EU in July 2018 and September 2017, respectively, and is sold under the brand name Symtuza. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2014 amendment, we granted Janssen an exclusive license to Symtuza worldwide. Janssen is responsible for manufacturing, registration, distribution and commercialization of Symtuza worldwide. We are responsible for the intellectual property related to the Gilead Compounds and are the exclusive supplier of the Gilead Compounds. Neither party is restricted from combining its drugs with any other drug products except those which are similar to the components of Symtuza. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of the party&#x2019;s component(s), subject to certain restrictions and adjustments. The intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation. As the license was deemed to be the predominant item to which the revenue share relates, we recognize our share of the Symtuza revenue in the period when the corresponding sales of Symtuza by Janssen occur. We record our share of the Symtuza revenue as Product sales on our Consolidated Statements of Income primarily because we supply the Gilead Compounds to Janssen for Symtuza.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of the agreement may be on a product or country basis and will depend on the circumstances, including withdrawal of a product from the market, material breach by either party or expiry of the revenue share payment term. Janssen may terminate the agreement without cause on a country-by-country basis, in which case Gilead has the right to become the selling party for such country(ies) if the product has launched but has been on the market for fewer than 10 years. Janssen may also terminate the entire agreement without cause. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Japan Tobacco, Inc. (&#x201c;Japan Tobacco&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2005, Japan Tobacco granted us exclusive rights to develop and commercialize elvitegravir, a novel HIV integrase inhibitor, in all countries of the world, excluding Japan, where Japan Tobacco retained such rights. Effective December 2018, we entered into an agreement with Japan Tobacco to acquire the rights to market and distribute certain products in our HIV portfolio in Japan and to expand our rights to develop and commercialize elvitegravir to include Japan. We are responsible for the marketing of the products as of January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are responsible for seeking regulatory approval in our territories and are required to use diligent efforts to commercialize elvitegravir for the treatment of HIV infection. We bear all costs and expenses associated with such commercialization efforts and pay a royalty to Japan Tobacco based on our product sales. Our sales of these products are included in Product sales on our Consolidated Statements of Income. Royalties due to Japan Tobacco are included in Cost of goods sold on our Consolidated Statements of Income. Royalty expenses recognized were $198 million, $250 million and $291 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2018 agreement, we paid Japan Tobacco $559 million in cash and recognized an intangible asset of $550 million reflecting the estimated fair value of the marketing-related rights acquired from Japan Tobacco. The intangible asset is being amortized over nine years, representing the period over which the majority of the benefits are expected to be derived from the applicable products in our HIV portfolio. The amortization expense is classified as selling expense and recorded as Selling, general and administrative expenses on our Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of the agreement may be on a product or country basis and will depend on the circumstances, including material breach by either party or expiry of royalty payment term. We may also terminate the entire agreement without cause.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Everest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, Everest and Immunomedics entered into an agreement granting Everest an exclusive license to develop and commercialize Trodelvy in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia (the &#x201c;Territories&#x201d;). Gilead subsequently acquired Immunomedics in October 2020 and assumed the Everest license and supply agreement, which provided for certain sales milestones and royalties payments to be made to Gilead and was recorded as a $175 million finite-lived asset as part of the purchase accounting. In the fourth quarter of 2022, we reacquired all development and commercialization rights for Trodelvy from Everest and terminated the previous agreement. Under the terms of the new agreement, Gilead will make $280 million in upfront termination payments to Everest, of which $84 million was made in 2022, with the remaining amounts included in Other current liabilities on our Consolidated Balance Sheets as of December&#160;31, 2022. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. We accounted for the new agreement as a contract termination, which includes the reacquisition of commercial rights and the settlement of our pre-existing relationship with Everest. As a result, we recorded an expense of $406 million in Selling, general and administrative expenses on our Consolidated Statements of Income, which primarily represents the upfront costs and write-off of the remaining value of the pre-existing asset related to the prior agreement. In addition, we recorded an acquired finite-lived asset with a fair value of $50 million for the commercial rights reacquired for products approved in the Territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Other Collaboration Arrangements That Are Not Individually Significant&lt;/span&gt;&lt;/div&gt;During 2022, 2021 and 2020, we entered into several collaborations, equity investments and licensing arrangements as well as other similar arrangements that we do not consider to be individually material. We recorded upfront collaboration expenses related to these arrangements of $86 million, $177 million and $129 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively, within Acquired in-process research and development expenses on our Consolidated Statements of Income.</gild:CollaborativeAndOtherArrangementsTextBlock>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ib9bc6f335dac4058a61472d6b15e5fa0_D20220401-20220430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0NDQ_c26df669-ef94-4e1d-908a-9ae47ce278b0"
      unitRef="usd">300000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <gild:PaymentsToAcquireAdditionalInProcessResearchAndDevelopment
      contextRef="i771f1a1172d84395889aa09f42795a08_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0NTE_dce5d32d-199c-4143-9072-f299336c454f"
      unitRef="usd">15000000</gild:PaymentsToAcquireAdditionalInProcessResearchAndDevelopment>
    <gild:PotentialFutureMilestonePaymentsMaximum
      contextRef="i771f1a1172d84395889aa09f42795a08_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0NTg_f1331a28-017b-4c30-9939-d81da5bc0bf4"
      unitRef="usd">630000000</gild:PotentialFutureMilestonePaymentsMaximum>
    <gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
      contextRef="ic189333a47cb4e74a306f790f89b7e3d_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0NjU_50a2d499-578d-4022-bd78-9fc8605dc926"
      unitRef="number">0.60</gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts>
    <gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
      contextRef="i957b3f15755947a18bbf1e5b8d938645_D20210313-20210313"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4ODI0ODg_7bc504c2-483a-4d8d-bd18-f4dc1d8ffa23"
      unitRef="number">0.40</gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts>
    <gild:CollaborationArrangementNetProductSalesThreshold
      contextRef="ia428e1ccf59043d4b741292e75fe250f_D20210313-20210313"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0NzM_d82bea8c-ed88-4665-b7cb-01b03a1d3a02"
      unitRef="usd">2000000000</gild:CollaborationArrangementNetProductSalesThreshold>
    <gild:CollaborationArrangementPercentOfGlobalProductRevenues
      contextRef="ia428e1ccf59043d4b741292e75fe250f_D20210313-20210313"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0Njk_5adffe54-d344-4bc0-ab76-205e40f1120a"
      unitRef="number">0.65</gild:CollaborationArrangementPercentOfGlobalProductRevenues>
    <gild:CollaborationArrangementNetProductSalesThreshold
      contextRef="i35be91a902b1413ea429208ada936e60_D20210313-20210313"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0Nzk_8bef2809-077e-4330-b828-47f20f507b7a"
      unitRef="usd">3500000000</gild:CollaborationArrangementNetProductSalesThreshold>
    <gild:CollaborationArrangementPercentOfGlobalProductRevenues
      contextRef="i35be91a902b1413ea429208ada936e60_D20210313-20210313"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY0ODc_af4fc720-46a1-448c-9ef7-fc666685ff8a"
      unitRef="number">0.65</gild:CollaborationArrangementPercentOfGlobalProductRevenues>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i49b7362839864e28ab937849b5b66936_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA2ODUyOA_4862f622-b883-4cbc-9e2a-53721e7c65f2"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i59caa7a2fafd4bcebc5b55c3446ffe7a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA2ODUyOA_89c244c4-1ca5-4382-a5fe-77d7faa97248"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <gild:CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod
      contextRef="ic189333a47cb4e74a306f790f89b7e3d_D20210313-20210313"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODAx_cf2e5cdc-218b-4433-ae6e-6bd30c735d99">P5Y</gild:CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1MDk_548193fa-ee07-4b37-a9ce-af6564217738"
      unitRef="usd">175000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <gild:InvestmentOwnedBalanceAdditionalShares
      contextRef="i7be52f10430343af827d91922fb036f7_I20200713"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1MTc_5373e7cd-9ae8-4471-968b-3fd4cf7b9109"
      unitRef="shares">6000000</gild:InvestmentOwnedBalanceAdditionalShares>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1MzM_467807e8-f624-4b3f-a9f6-61e95487f317"
      unitRef="usd">200000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <gild:TotalUpfrontPaymentsMade
      contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1NDA_bab39964-1250-4131-be04-e2b51f036a4b"
      unitRef="usd">391000000</gild:TotalUpfrontPaymentsMade>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7be52f10430343af827d91922fb036f7_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1NTg_79b65341-7b20-4133-a461-b61828ec75c2"
      unitRef="usd">135000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1OTQ_04a53a09-3bae-4493-bd29-3954d711f9d5"
      unitRef="usd">256000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY1NzY_a1805168-45d6-46d3-a746-fe69407d526a"
      unitRef="usd">175000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <gild:IssuanceDiscountPremium
      contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY2MTE_16ad0916-0a92-4b52-bb70-997da8adb0af"
      unitRef="usd">-65000000</gild:IssuanceDiscountPremium>
    <gild:PaymentsForDirectTransactionalExpense
      contextRef="i0604404ad083494e87385971ee52a834_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY2Mjg_998d0c56-81dd-4b5e-86c8-903be88da2ed"
      unitRef="usd">16000000</gild:PaymentsForDirectTransactionalExpense>
    <gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
      contextRef="i8f866f4b5345461795270bb2919d3ffb_D20200713-20200713"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NTgzOTU1MzU_5b963da2-ec78-40a0-b7ee-06aa9ee040f2"
      unitRef="number">0.35</gild:EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased>
    <gild:EquitySecuritiesFVNIPurchasePeriod
      contextRef="i8f866f4b5345461795270bb2919d3ffb_D20200713-20200713"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODEx_8d4f6f85-62f9-47db-ae6b-84d3c98f3e56">P5Y</gild:EquitySecuritiesFVNIPurchasePeriod>
    <gild:EquitySecuritiesFVNIRestrictionPeriod
      contextRef="i8f866f4b5345461795270bb2919d3ffb_D20200713-20200713"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODEz_8b072bc4-6b36-4b9a-82e7-89076fca9fad">P3Y</gild:EquitySecuritiesFVNIRestrictionPeriod>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i6289804387bd4103907cc19f3c49ade8_I20200529"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY2Njc_8d64ac87-4d5a-48e7-b7ee-41907a49f28d"
      unitRef="shares">2200000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i740c686e35a541228a361dc29719f86c_D20200529-20200529"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY2ODM_725c1ad6-48a7-4ae9-8073-00905654dcf9"
      unitRef="usd">61000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <gild:EquitySecuritiesFVNISharesAcquired
      contextRef="i3837ec2ec53d40948208538478b144fd_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3MDE_7a27dc37-cb8d-4b48-9458-0dead4d84067"
      unitRef="shares">5700000</gild:EquitySecuritiesFVNISharesAcquired>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i3837ec2ec53d40948208538478b144fd_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3MTk_ae091735-13e4-4d87-bae7-c7f80d40c37c"
      unitRef="usd">220000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <gild:EquitySecuritiesFVNIShares
      contextRef="i2135143e0b8a42c79094487f8538db87_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3MjY_1d3058b8-15c6-40fa-8a00-a9fe4db819d5"
      unitRef="shares">13800000</gild:EquitySecuritiesFVNIShares>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="idc5bf2b91bbf47619e2400e89b0617db_I20210208"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3MzU_df8151a4-7225-4748-8769-2a7b7e59c71d"
      unitRef="number">0.195</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <gild:CollaborativeAgreementOptInTerm
      contextRef="i15aa5080eeeb4755b9ee289447ef8c62_D20200527-20200527"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODE0_37ecfbf8-e7eb-4bae-84c6-3d955dc19d13">P10Y</gild:CollaborativeAgreementOptInTerm>
    <gild:NumberOfClinicalStageProgramsWithExercisedOptions
      contextRef="i0f56f1023e494483ab5622ea9a93b454_I20211118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3NDU_e20d7807-2ff7-42b1-a1dc-6d9c11069f0f"
      unitRef="program">3</gild:NumberOfClinicalStageProgramsWithExercisedOptions>
    <gild:PaymentsToOptInTheCollaborativeAgreement
      contextRef="i156971f265ed4b789964f0e884da2478_D20211221-20211221"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3ODI_e84f8f7f-d622-4cc1-8797-d3873b1ee181"
      unitRef="usd">725000000</gild:PaymentsToOptInTheCollaborativeAgreement>
    <gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries
      contextRef="i7645b620bfdd4f51895f7a3169f56f31_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4MjY_e4053f20-4ed6-409f-9452-dfbd4a397911"
      unitRef="usd">100000000</gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="icfb2a3f5c657473bb9004b07b586f56e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4MTU_b0044129-ef1f-45de-953f-f7e1ec138407"
      unitRef="usd">625000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:PaymentsToOptInTheCollaborativeAgreement
      contextRef="i156971f265ed4b789964f0e884da2478_D20211221-20211221"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY3NjQ_e84f8f7f-d622-4cc1-8797-d3873b1ee181"
      unitRef="usd">725000000</gild:PaymentsToOptInTheCollaborativeAgreement>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i138aace7ae954687991de21bbcbf935f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzQ5NDc4MDI1Nzk4Mjc_28f23885-d7a8-4198-af48-c148253f3545"
      unitRef="usd">187000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries
      contextRef="i7645b620bfdd4f51895f7a3169f56f31_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4MjI_e4337ec9-daf6-4639-8da2-f04b07b00ff6"
      unitRef="usd">100000000</gild:EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i01d11dc0f9a54ca5b5c8a9bb3d0e5538_I20200619"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4MzM_bf123352-07b6-4f59-aa87-da188575760a"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i016d7a91b5e04c58945de8f96fb29672_D20200713-20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4Mzc_102425f0-eee5-4bb6-8db8-3336fde1d52e"
      unitRef="usd">269000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i1c6ac8024c8e4d0dba576efa9455806e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4NDQ_f5410550-bfca-46b2-9936-85b49824d3ca"
      unitRef="usd">215000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:EquityMethodInvestments
      contextRef="i200b7ebaf9d741dda60fabffb43ff601_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4NTE_72485c4e-30d9-4ff9-a34f-336cbb15433f"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ic28bdc6a3eb0421bb098c47b028e6ed7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4NTE_931da3ff-c2f0-49cf-bf6c-1b524f959614"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="id73ecb9294534bdda3109b865875a37a_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4NjE_2465bd78-6f80-453c-bf4b-df36c019595f"
      unitRef="usd">70000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <gild:EquityMethodInvestmentOptionExerciseFee
      contextRef="id73ecb9294534bdda3109b865875a37a_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4Njg_26e489fe-50e9-40d1-b48e-ace40649858f"
      unitRef="usd">315000000</gild:EquityMethodInvestmentOptionExerciseFee>
    <gild:PotentialFutureMilestonePaymentsMaximum
      contextRef="i016d7a91b5e04c58945de8f96fb29672_D20200713-20200713"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4NzQ_71a7f699-4916-471e-96b5-701e840704bb"
      unitRef="usd">1200000000</gild:PotentialFutureMilestonePaymentsMaximum>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if7b11be3257e4f40a3e503c8bc3746c3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4ODM_fbccbee9-e078-4535-ad68-59a31b4bd74f"
      unitRef="usd">80000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:ResearchAndDevelopmentFutureMaximumPayments
      contextRef="ie187f099f6884416a506c2273b834248_I20200713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4OTA_3b1474d7-e0b2-45bd-bf4d-1c3060694066"
      unitRef="usd">115000000</gild:ResearchAndDevelopmentFutureMaximumPayments>
    <gild:AdditionalResearchAndDevelopmentInProcess
      contextRef="if7b11be3257e4f40a3e503c8bc3746c3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY4OTc_ed50fe09-5c42-4a40-bba9-1abb6cc5ea05"
      unitRef="usd">70000000</gild:AdditionalResearchAndDevelopmentInProcess>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9841318d0cc04cdca6946b8f50b2d1e2_I20200717"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5MDQ_9719f88b-07da-4b18-8256-b6857a8da681"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i71a5441f80434f7fb81b3ead03db9f77_D20200825-20200825"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5MDg_b1c6c563-b444-487e-aaf7-a27f893c65b5"
      unitRef="usd">302000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i2116fe68676542f08655b70510bcbc39_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5MTU_9403abbf-1ca6-449e-8c57-ebf55fa71610"
      unitRef="usd">272000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:EquityMethodInvestments
      contextRef="if64523d7bf4f4c6bbcf933b3fa695ad0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5MzQ_9423ab23-6fee-443b-90c4-2c6eeee9f346"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="iafaadd0b51b8476e9b35ffba851e4d74_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5MzQ_ed06ffb5-d969-45bf-8847-f26f90cc2e4a"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="i70ddfe12d2d14dcd90c45e6ba0df7567_I20200825"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5MjQ_c2893003-3213-489f-af6c-4da3af036b02"
      unitRef="usd">41000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <gild:EquityMethodInvestmentOptionExerciseFee
      contextRef="i70ddfe12d2d14dcd90c45e6ba0df7567_I20200825"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5NDE_7e443e89-1055-4805-ae38-19bea4ea6c7f"
      unitRef="usd">100000000</gild:EquityMethodInvestmentOptionExerciseFee>
    <gild:EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments
      contextRef="i57942f7799d54d7f9080cf71318c3ad9_I20200825"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5NDc_289c1849-f84e-4d92-87c0-ce9a642e7aab"
      unitRef="usd">1200000000</gild:EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i81f791b61360445b9d059ca216fb9e27_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzM4NDgyOTA5NTE4MzA_5e0f43ae-41da-4fd2-bcc0-338280eef251"
      unitRef="usd">115000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5NjQ_939ad9ab-e390-4aa0-bd46-1d99db1b83eb"
      unitRef="usd">125000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5ODY_3ff1195a-fe9e-47a9-87ec-5b636eefe727"
      unitRef="usd">20000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4OTUwMDQ_1a5511c8-ee81-48aa-ba0e-74c61ef5c357"
      unitRef="usd">125000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzY5OTM_5d3b731c-c829-4ffc-88d5-ccd31975606a"
      unitRef="usd">13000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <gild:NumberOfPrograms
      contextRef="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzcwMTA_926ef186-9cdf-40b2-ac49-a4a4658e2781"
      unitRef="program">15</gild:NumberOfPrograms>
    <gild:CollaborativeArrangementTerm
      contextRef="i0698725f2dc4457d8d4459defacd642b_D20200817-20200817"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODE1_0bf3a5a5-a342-4715-b60a-997913c48b49">P7Y</gild:CollaborativeArrangementTerm>
    <gild:EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments
      contextRef="i0c965202198f48ec9fd033a927a99823_D20200817-20200817"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzcwMDM_d940c99c-eae6-47f1-8903-05f41de9cc0f"
      unitRef="usd">410000000</gild:EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments>
    <gild:TotalUpfrontPaymentsMade
      contextRef="if9369ae332d1495a882a011455d3dff2_D20201001-20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzcwMzY_5fc8b2b3-4c7a-4bf3-a9d2-b24a164b10e2"
      unitRef="usd">120000000</gild:TotalUpfrontPaymentsMade>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if9369ae332d1495a882a011455d3dff2_D20201001-20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzcwNTI_839fd925-faa1-45d6-ab56-8c76884d9157"
      unitRef="usd">64000000</us-gaap:ResearchAndDevelopmentInProcess>
    <gild:CashPaymentsMadeRelatedToEquityInvestments
      contextRef="if9369ae332d1495a882a011455d3dff2_D20201001-20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzcwNjY_857f1203-3dad-4120-8f31-c19edce3c640"
      unitRef="usd">56000000</gild:CashPaymentsMadeRelatedToEquityInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i32bd6912cab14eadbb3318f66acae3dd_I20201031"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzcwNzg_36d9e786-3567-4a52-8808-58bf03f9f06e"
      unitRef="number">0.14</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i98853617c7ee492bac67c931971fb5b8_D20221201-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA3MDQxMg_04565a8a-3344-4c43-8a50-d2cba546c693"
      unitRef="usd">67000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts
      contextRef="iafbe177f342940c6bfb9527cc4113ba3_I20201215"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzczNTk_13db1d0f-e19b-42d9-8bc5-329bb77aee76"
      unitRef="eur">160000000</gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts>
    <gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts
      contextRef="iafbe177f342940c6bfb9527cc4113ba3_I20201215"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzczNTM_19d82e02-0d78-4079-9090-9200a7c31be5"
      unitRef="usd">190000000</gild:PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts>
    <gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts
      contextRef="i021e03a868e241539ef14f9a4a5d5eff_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzczNzg_0d46d5eb-4037-4668-a2e1-eb418837d198"
      unitRef="eur">35000000</gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts>
    <gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts
      contextRef="i021e03a868e241539ef14f9a4a5d5eff_D20210101-20210131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4NzczOTY_f8542c6a-a19b-4332-a8b3-c45b7f450544"
      unitRef="usd">43000000</gild:PaymentForAdjustmentsOfBudgetedDevelopmentCosts>
    <gild:AdjustmentsOfBudgetedDevelopmentCostsPayments
      contextRef="i6a34cfded76c4d25931ccbc7eb146801_I20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0MTM_0493c5f3-f0b1-4f61-a895-93a49ed5125f"
      unitRef="eur">75000000</gild:AdjustmentsOfBudgetedDevelopmentCostsPayments>
    <gild:AdjustmentsOfBudgetedDevelopmentCostsPayments
      contextRef="i6a34cfded76c4d25931ccbc7eb146801_I20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0MzA_369a3f99-704a-4821-8772-3cb0a6c27733"
      unitRef="usd">88000000</gild:AdjustmentsOfBudgetedDevelopmentCostsPayments>
    <gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths
      contextRef="if22f3ebfb466459088b430f3aaf9fbe0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0NDg_8b5f71ed-9c0e-4195-ac6a-d8330d73c369"
      unitRef="eur">50000000</gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths>
    <gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths
      contextRef="if22f3ebfb466459088b430f3aaf9fbe0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0NjU_94800c9b-c845-4134-bb50-80c7eba2bd7b"
      unitRef="usd">60000000</gild:AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i561a20e735884dd09fd59922c428289f_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA2ODUyMQ_1e4fe3dd-091f-4f89-b260-656ca72d4414"
      unitRef="shares">6800000</us-gaap:InvestmentOwnedBalanceShares>
    <gild:MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement
      contextRef="i561a20e735884dd09fd59922c428289f_I20190831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0NzI_8536326c-d623-41e6-99e9-81dc64a7208e"
      unitRef="number">0.299</gild:MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i2dd88b8c706745b7bfcd8184f6d34f23_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0NzU_20d1749c-51c9-4418-aeac-49f35b412c37"
      unitRef="shares">16700000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i561a20e735884dd09fd59922c428289f_I20190831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0ODM_a59f98e5-d60d-4bd5-bdbf-3e21cde9ff8e"
      unitRef="number">0.258</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <gild:StandstillRestrictingTerm
      contextRef="i5ff8d15cd938494a955c3470b06e15f7_D20190801-20190831"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODE2_60f650fe-0484-4cc8-af5c-72f77cede3b7">P10Y</gild:StandstillRestrictingTerm>
    <gild:MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement
      contextRef="i561a20e735884dd09fd59922c428289f_I20190831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA2ODMxNA_3ffdaaf0-47f6-4528-a6e2-078f7c4d41be"
      unitRef="number">0.299</gild:MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement>
    <gild:MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement
      contextRef="i561a20e735884dd09fd59922c428289f_I20190831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA2ODMxOA_bbdb1ae9-5f22-4c30-a4c3-16d332d41a04"
      unitRef="number">0.201</gild:MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement>
    <gild:PotentialOptionExerciseFeePerProgram
      contextRef="i561a20e735884dd09fd59922c428289f_I20190831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0ODc_d5b76d60-c68c-4795-9a2d-c3f8fe3d69f9"
      unitRef="usd">150000000</gild:PotentialOptionExerciseFeePerProgram>
    <gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage
      contextRef="i561a20e735884dd09fd59922c428289f_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc0OTY_719bc437-c6db-4e38-a39b-19a66973cfbb"
      unitRef="number">0.20</gild:PotentialSalesBasedTieredRoyaltyLowEndPercentage>
    <gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage
      contextRef="i561a20e735884dd09fd59922c428289f_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4ODI1MDA_ac2a3782-a67d-4879-872e-b0a92efec3b7"
      unitRef="number">0.24</gild:PotentialSalesBasedTieredRoyaltiesHighEndPercentage>
    <gild:PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage
      contextRef="id348a415186e4a219b8e1335dc1ce1ae_I20141231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1MDA_836a0f2b-3383-4c55-8371-248ece73158a"
      unitRef="number">0.30</gild:PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic5f7160626e0482aa57280e46676f4b9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1MjA_6e861952-ebc3-44d6-bd4c-54f093f18656"
      unitRef="usd">483000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7b27bce0f57f43408b5d6611ea6202b5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1MDU_bee14e3e-852b-4086-a95d-7207f6a55e9b"
      unitRef="usd">530000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia93636a3c58c408fbe02ea53965397ff_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1MTE_628dce1b-024f-4645-bba4-065f7d814adb"
      unitRef="usd">570000000</us-gaap:CostOfGoodsAndServicesSold>
    <gild:CollaborativeAgreementProductMarketPeriodSubjectToTermination
      contextRef="ic3809906dea34eddb658b6eb681b0746_D20140101-20141231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1Mjk_1d45515d-6d3a-4913-ab42-e6bf23271e87">P10Y</gild:CollaborativeAgreementProductMarketPeriodSubjectToTermination>
    <gild:CollaborativeAgreementProductMarketPeriodSubjectToTermination
      contextRef="ic3809906dea34eddb658b6eb681b0746_D20140101-20141231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1MzM_73c14033-b1ea-4ad1-857a-adfed21ed1b3">P10Y</gild:CollaborativeAgreementProductMarketPeriodSubjectToTermination>
    <us-gaap:RoyaltyExpense
      contextRef="i8dc6ff7bbfe146f790e94a1bf140cf21_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1MzY_28a8fef2-ab8c-40df-a50d-fd413f08169d"
      unitRef="usd">198000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i15224c301e61426ab8f8d27a3b9863f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1NDU_4de07801-db21-4c89-94cc-34988be5bd53"
      unitRef="usd">250000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i4d6fdb8767134660ae43cba1ca191838_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1NTI_c8b913e9-d3e4-4a87-8838-d9ddbc1334b4"
      unitRef="usd">291000000</us-gaap:RoyaltyExpense>
    <gild:InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan
      contextRef="i60eff7e7e8194d3ca2b0fe59c130421e_D20181201-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1NTk_90b587c3-3555-4e4b-ac19-5ed7913bb177"
      unitRef="usd">559000000</gild:InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i60eff7e7e8194d3ca2b0fe59c130421e_D20181201-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1NjY_04b7401c-6e98-4b83-b374-11f4b839bba4"
      unitRef="usd">550000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i60eff7e7e8194d3ca2b0fe59c130421e_D20181201-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEzMTk0MTM5Nzg0ODE4_cd56060f-2ea6-449e-8e55-bc0a5100081b">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i1d267ec0240944fe98ab627640747acb_I20201023"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzM4NDgyOTA5NjA3NDY_57626e88-6206-40bb-ac94-0544f03463cb"
      unitRef="usd">175000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <gild:UpfrontPaymentsToTerminatePreviousAgreement
      contextRef="ia4dccea757f34cada4ff7ad4f868097e_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzQzOTgwNDY3NzM0MDg_ca5a87e0-6e1e-464f-b452-2f8c401fe0dc"
      unitRef="usd">280000000</gild:UpfrontPaymentsToTerminatePreviousAgreement>
    <gild:PaymentsToTerminatePreviousAgreement
      contextRef="ia4dccea757f34cada4ff7ad4f868097e_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzQzOTgwNDY3NzM0MjI_b2b44cd7-a7b9-4fd0-ad5c-8da5966d3fab"
      unitRef="usd">84000000</gild:PaymentsToTerminatePreviousAgreement>
    <gild:PotentialFutureMilestonePaymentsMaximum
      contextRef="i1b13652ec49d451b9134a37a2d7ddd69_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzQzOTgwNDY3NzM0Mzc_9e6e58e5-3bac-442e-92c5-32679d040b16"
      unitRef="usd">175000000</gild:PotentialFutureMilestonePaymentsMaximum>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i52460a4a2230491d8481379314fe3f77_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzQzOTgwNDY3NzM0NTI_cc514772-cf52-479f-bd61-75de9c95b9ea"
      unitRef="usd">406000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i52460a4a2230491d8481379314fe3f77_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzU0OTc1NjA3NjYyMw_03d4c7a7-972b-4ac9-87b6-6e58182456d4"
      unitRef="usd">50000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <gild:UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant
      contextRef="i1e38b8bce9e8433699c11bb0d7911eaa_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1Nzg_b3273a4e-03fc-4fb0-b480-e217c47713cb"
      unitRef="usd">86000000</gild:UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant>
    <gild:UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant
      contextRef="ie041293ff2f94b94bb3eeae5382b1137_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1ODc_2e767835-352f-4f09-bfd0-71fe30e59c7f"
      unitRef="usd">177000000</gild:UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant>
    <gild:UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant
      contextRef="ica9f3e6a16e841fb807eb9deab1f16b7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjEvZnJhZzoyNmRmNmU0NDVjMjc0OGZlYWFlOTc0MTkyOGNjOTI5MS90ZXh0cmVnaW9uOjI2ZGY2ZTQ0NWMyNzQ4ZmVhYWU5NzQxOTI4Y2M5MjkxXzEwOTk1MTE4Nzc1OTE_407febeb-ffe9-4cfb-b946-8156729260d5"
      unitRef="usd">129000000</gild:UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzQ5NDU_e4784006-939c-474e-86f4-91604d2f4c61">DEBT AND CREDIT FACILITIES&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, we repaid $500 million of senior unsecured notes prior to the March 2022 maturity by exercising a par call option. Additionally, in July 2022, we repaid $1.0 billion of senior unsecured notes prior to the September 2022 maturity by exercising a par call option. No new debt was issued in 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our senior unsecured fixed rate notes may be redeemed at our option at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed and (ii) the sum, as determined by an independent investment banker, of the present values of the remaining scheduled payments of principal and interest on the notes to be redeemed (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semiannual basis at the Treasury Rate, plus a make-whole premium, which are defined in the terms of the notes. The senior unsecured fixed rate notes also have a par call feature, exercisable at our option, to redeem the notes at par in whole, or in part, on dates ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEwOTk1MTE2MzcyNzc_a58a2f1f-515b-4f40-ba1a-00d6cf2d5f1b"&gt;two&lt;/span&gt; to six months prior to maturity. In each case, accrued and unpaid interest is also required to be redeemed to the date of redemption. The $1.5 billion of 0.75% senior unsecured notes due September 2023 also have a different call feature, exercisable at our option, to redeem the notes at par, in whole or in part, at any time until maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event of a change in control and a downgrade in the rating of our senior unsecured notes below investment grade by Moody&#x2019;s Investors Service, Inc. and S&amp;amp;P Global Ratings, the holders may require us to purchase all or a portion of their notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest to the date of repurchase. We are required to comply with certain covenants under our note indentures governing our senior unsecured notes. As of December&#160;31, 2022 and 2021, we were not in violation of any covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Liability Related to Future Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Immunomedics, we assumed a liability related to a funding arrangement, which was originally entered into by Immunomedics and RPI Finance Trust (&#x201c;RPI&#x201d;), prior to our acquisition of Immunomedics. Under the funding agreement, RPI has the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of Trodelvy for each calendar quarter during the term of the agreement through approximately 2036. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over 16 years. The estimated timing and amount of future expected royalty payments over the estimated term will be re-assessed each reporting period. The impact from changes in estimates will be recognized in the liability and the related interest expense prospectively. The liability related to future royalties was primarily included in Long-term debt, net on our Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Revolving Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, we entered into a new $2.5 billion five-year revolving credit facility maturing in June 2025 (the &#x201c;2020 Revolving Credit Facility&#x201d;). The 2020 Revolving Credit Facility can be used for working capital requirements and for general corporate purposes, including, without limitation, acquisitions. As of December&#160;31, 2022 and 2021, there were no amounts outstanding under the 2020 Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Revolving Credit Facility contains customary representations, warranties, affirmative and negative covenants and events of default. As of December&#160;31, 2022, we were in compliance with all covenants. Loans under the 2020 Revolving Credit Facility bear interest at either (i) the Term Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) plus the Applicable Percentage, or (ii) the Base Rate plus the Applicable Percentage, each as defined in the 2020 Revolving Credit Facility agreement. We may terminate or reduce the commitments, and may prepay any loans under the credit facility in whole or in part at any time without premium or penalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Contractual Maturities of Financing Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate future principal maturities of our senior unsecured notes as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Interest ExpenseInterest expense on our debt and credit facilities related to the contractual coupon rates and amortization of the debt discount and issuance costs was $940 million in 2022 and $1.0 billion in 2021 and 2020.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzQ5NDY_1605f8eb-a8b2-4917-b110-23448888441f">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the carrying amount of our borrowings under various financing arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type of Borrowing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issue Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2011&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2046&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 2047&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior Unsecured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior unsecured notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other obligations, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i94f7d5f595874e31babd47d1f943f03f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzItNi0xLTEtMTY3NjY1_f8fb8fb4-5b3a-43ca-a7c4-39698850e8bc"
      unitRef="number">0.0195</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i94f7d5f595874e31babd47d1f943f03f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzItOC0xLTEtMTY3NjY1_cb18aea2-c480-4a8d-841f-55729efd4471"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i9e682eb04f72495694ed3396a628d82d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzItMTAtMS0xLTE2NzY2NQ_b070487c-afd3-4238-8358-e6f2c023d316"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a5ea21b1a1b43f288b70665cfbd4480_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzMtNi0xLTEtMTY3NjY1_ea7c97c7-d8ae-4d3b-b6c9-bccb6615ca27"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5a5ea21b1a1b43f288b70665cfbd4480_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzMtOC0xLTEtMTY3NjY1_091cbf8f-0f5a-446d-ad88-0362bcf17553"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id423610de99f429cadafe5a4274a7579_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzMtMTAtMS0xLTE2NzY2NQ_ed05c836-35ed-49e4-9bdf-a697cd906da2"
      unitRef="usd">999000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i46a7ff031bd6498c94ca9dd5f3025f99_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzQtNi0xLTEtMTY3NjY1_38b020f1-f838-44cc-b2a0-5ccfc355c6d6"
      unitRef="number">0.0250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i46a7ff031bd6498c94ca9dd5f3025f99_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzQtOC0xLTEtMTY3NjY1_9e93c330-8086-48cf-971e-ac85841d2182"
      unitRef="usd">749000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i9fbf6172d0c74ecf8b376de532d163ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzQtMTAtMS0xLTE2NzY2NQ_4dbabae6-fe40-4ebc-b3be-78c9466ac6ed"
      unitRef="usd">748000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i72cca364459e4c9a9900d1ff55ebcbe1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzUtNi0xLTEtMTY3NjY1_7ff7be04-bfde-4e37-8c9d-b3df83bb8007"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i72cca364459e4c9a9900d1ff55ebcbe1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzUtOC0xLTEtMTY3NjY1_9d6e85e7-fc81-49e7-9c2e-a8ffc803336e"
      unitRef="usd">1498000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ife4410a1d3ac4f6db988c4f916e2bfec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzUtMTAtMS0xLTE2NzY2NQ_0823aedb-c772-4168-b845-89d09c4d1faa"
      unitRef="usd">1496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icfa5f7601c0344768c77f746163923e9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzYtNi0xLTEtMTY3NjY1_81d5ea12-d313-40fa-8b6d-938d745ecb3b"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="icfa5f7601c0344768c77f746163923e9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzYtOC0xLTEtMTY3NjY1_592ba96a-f442-4e92-b7cd-fdeb75d79365"
      unitRef="usd">1748000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if709c8f28db74549bd5a3161d97c21e0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzYtMTAtMS0xLTE2NzY2NQ_c3111b46-43b5-4dca-a243-cd8e25934a8e"
      unitRef="usd">1747000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic140c268cb72480b99affba2d2903761_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzctNi0xLTEtMTY3NjY1_81a83cfd-5a1b-4add-be1e-d1d127a5c582"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ic140c268cb72480b99affba2d2903761_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzctOC0xLTEtMTY3NjY1_09e249b9-8612-4af3-a568-eef02f12365a"
      unitRef="usd">1748000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id0cddfe4bc224e0a87870c31c94df95e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzctMTAtMS0xLTE2NzY2NQ_54df0570-8c68-41d6-8969-e2b1c92d2155"
      unitRef="usd">1747000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i68e57a3bf88e41bc8bcda7b3a61da0ed_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzgtNi0xLTEtMTY3NjY1_6ece3d06-b3ee-4ce9-83b7-54399747a19e"
      unitRef="number">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i68e57a3bf88e41bc8bcda7b3a61da0ed_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzgtOC0xLTEtMTY3NjY1_9e0b5c3b-b84e-4406-8339-47ac7366ac97"
      unitRef="usd">2742000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id3619c4f682548ff8c69c3e69dd442e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzgtMTAtMS0xLTE2NzY2NQ_68085e32-43c6-445e-ba11-dbd62f60b65f"
      unitRef="usd">2739000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i42f508896a1f48ef818931672fc82b7f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzktNi0xLTEtMTY3NjY1_90e7f05a-2a91-44d4-acff-e15f11a1d5a8"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i42f508896a1f48ef818931672fc82b7f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzktOC0xLTEtMTY3NjY1_6c0d82b7-3a38-45c8-9e9a-36de6290e909"
      unitRef="usd">1247000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4befda2944dd4e48bbf33cbb6a800b3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzktMTAtMS0xLTE2NzY2NQ_c8de28e1-1e38-4883-9caa-9b7aa9957421"
      unitRef="usd">1247000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icc01af360ccd4ed291a9c264b7a9d13d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEwLTYtMS0xLTE2NzY2NQ_b2c38ed2-2418-4d16-86b0-d92c2835e2c7"
      unitRef="number">0.0120</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="icc01af360ccd4ed291a9c264b7a9d13d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEwLTgtMS0xLTE2NzY2NQ_ce613245-e8df-4076-b0a8-4f4302e8bf70"
      unitRef="usd">747000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0d007723ea0d457f8381ae1dc771efe7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEwLTEwLTEtMS0xNjc2NjU_6c716cb7-ed72-408b-a287-0048fe437b4a"
      unitRef="usd">746000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5968bcc3ccaf4e119907fba73d267d74_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzExLTYtMS0xLTE2NzY2NQ_b59f8324-7b56-4181-9868-cd7ded4de9d7"
      unitRef="number">0.0165</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5968bcc3ccaf4e119907fba73d267d74_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzExLTgtMS0xLTE2NzY2NQ_d373e988-33e7-4e22-a3a6-561af3938f01"
      unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i12e3ef865c8244a080b985b6a3939718_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzExLTEwLTEtMS0xNjc2NjU_ed9b369f-a318-461d-9837-429d4f2a9e46"
      unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9a23e70b82e64cc79b08ee71a5bd6b2f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEyLTYtMS0xLTE2NzY2NQ_7fddf2e8-78c2-48d6-b39f-31cfb0f30eb1"
      unitRef="number">0.0460</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i9a23e70b82e64cc79b08ee71a5bd6b2f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEyLTgtMS0xLTE2NzY2NQ_1866a6d6-84ea-4b16-b72c-a4e8271d996a"
      unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie69a01e11be94336a2f8daa28bd70c35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEyLTEwLTEtMS0xNjc2NjU_b198da0a-8737-4f90-868e-2e1b2810972e"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4677adf6e0c14c858103e4db348e4694_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEzLTYtMS0xLTE2NzY2NQ_05a825fc-80c4-407f-919e-0459b9395e8d"
      unitRef="number">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i4677adf6e0c14c858103e4db348e4694_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEzLTgtMS0xLTE2NzY2NQ_085d518e-55a4-4364-8b70-6e80c47f7b49"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i30e53bc1666b4c059c137ce292a94b11_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzEzLTEwLTEtMS0xNjc2NjU_4ce303ff-b972-4b50-adea-0a5cb95b1f69"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6733ec0f5d1e4796b8f94c12c762b012_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE0LTYtMS0xLTE2NzY2NQ_2fcc1003-0bcb-4c61-a17e-f868635d0b9a"
      unitRef="number">0.0260</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i6733ec0f5d1e4796b8f94c12c762b012_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE0LTgtMS0xLTE2NzY2NQ_a29be6a3-1a29-4194-aa49-77a5c490b9dd"
      unitRef="usd">988000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i14a47de090294df9b57b1251ef9289b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE0LTEwLTEtMS0xNjc2NjU_c08123e7-da42-4864-b077-1efa62fc1f1c"
      unitRef="usd">987000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i175eed19d77e4a91a2d341be010e07f7_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE1LTYtMS0xLTE2NzY2NQ_80a84e8b-546b-4b1f-a288-03af47907441"
      unitRef="number">0.0565</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i175eed19d77e4a91a2d341be010e07f7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE1LTgtMS0xLTE2NzY2NQ_59a4ee32-ecb5-4c2c-9c48-30b92eff4c4f"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i29d037f45ab54f7ca294996c4e283eb2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE1LTEwLTEtMS0xNjc2NjU_bcbc1110-4f2b-42ec-85b8-db587e8366c6"
      unitRef="usd">996000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i72a08c81dba348df8500cc3742e5df5d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE2LTYtMS0xLTE2NzY2NQ_d4e7b552-2b25-49fa-9504-d088d66a9d38"
      unitRef="number">0.0480</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i72a08c81dba348df8500cc3742e5df5d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE2LTgtMS0xLTE2NzY2NQ_e7379d6a-b3f5-4a41-bd7f-bf13a91d976b"
      unitRef="usd">1736000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ib9ed8ad260cf481f964bb009ba049509_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE2LTEwLTEtMS0xNjc2NjU_5a8b21eb-b2a7-4979-b6a4-887469cabeb2"
      unitRef="usd">1736000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1220d26ecab846bda8d60360ee0028bd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE3LTYtMS0xLTE2NzY2NQ_01d3477a-f051-43d5-a849-8a2253b0d197"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i1220d26ecab846bda8d60360ee0028bd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE3LTgtMS0xLTE2NzY2NQ_365c14af-c484-47f4-979d-f2a8cc7fa702"
      unitRef="usd">1733000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3feeb01e0b754048b12295e1fbb184c9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE3LTEwLTEtMS0xNjc2NjU_19dc53a9-39c7-4261-8f33-dfa47ce30e17"
      unitRef="usd">1733000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i52789550e4a34d6a81d8f70c1e195b8c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE4LTYtMS0xLTE2NzY2NQ_2a1bdcc2-672e-45a0-9536-27f4bb95e157"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i52789550e4a34d6a81d8f70c1e195b8c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE4LTgtMS0xLTE2NzY2NQ_a58c9cdc-a460-4a37-aac8-8af3cd60dfb3"
      unitRef="usd">2221000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i120a62d356e74c158afb261bb2ae839c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE4LTEwLTEtMS0xNjc2NjU_6b01d4a2-08f3-4841-9e19-6c9fd8cceeba"
      unitRef="usd">2220000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2fe59d0908e34a159160b1e26b01fb15_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE5LTYtMS0xLTE2NzY2NQ_9771590b-2162-45af-9f6d-d12e6f111ccd"
      unitRef="number">0.0415</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2fe59d0908e34a159160b1e26b01fb15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE5LTgtMS0xLTE2NzY2NQ_9f7f76a0-3ebb-43cf-973d-2ae8fecf6412"
      unitRef="usd">1728000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5dcdd5d44dfb41e08635c954c03f9520_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzE5LTEwLTEtMS0xNjc2NjU_879e9286-d522-4c2e-8760-19a1a33876f6"
      unitRef="usd">1727000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i31faa9b303f543e78b0b2176fa8247c9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIwLTYtMS0xLTE2NzY2NQ_c0bcd64b-1a32-483c-811e-6ab7c9b5f65f"
      unitRef="number">0.0280</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i31faa9b303f543e78b0b2176fa8247c9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIwLTgtMS0xLTE2NzY2NQ_4808a4de-0ce8-4590-a263-4f18fe8a8102"
      unitRef="usd">1477000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i259c5faa64504524b5634abd51d1fc38_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIwLTEwLTEtMS0xNjc2NjU_d27b33e0-d581-4138-80f6-5f4393211a92"
      unitRef="usd">1476000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic33e120250c747548d29ff0a8b4ff7cc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIxLTgtMS0xLTE2NzY2NQ_ee267dc2-c327-4812-920f-4f2cd5bc24ab"
      unitRef="usd">24088000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8e2c900d6e514479b136e94cce379e22_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIxLTEwLTEtMS0xNjc2NjU_e060dc3d-b5dc-42c2-98cf-8d3dbcfa598e"
      unitRef="usd">25571000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0d5cbf682a784526bc44e1be5f4b2591_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIyLTgtMS0xLTE2NzY2NQ_240a0d28-d58e-492e-96f2-610680e06ccb"
      unitRef="usd">1141000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i2d2aa040eb2c451cbda18a7f0add00c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIyLTEwLTEtMS0xNjc2NjU_20b56071-664e-4983-ae8c-c5c71a3897fb"
      unitRef="usd">1124000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIzLTgtMS0xLTE2NzY2NQ_a8270d34-7996-4ca1-9bfa-52e609cc1029"
      unitRef="usd">25229000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzIzLTEwLTEtMS0xNjc2NjU_e2436807-1305-44ec-a88a-1fc9eb3bf1e4"
      unitRef="usd">26695000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzI0LTgtMS0xLTE2NzY2NQ_f82f8b5b-0c01-4457-8c55-0ec9d3d4e51d"
      unitRef="usd">2273000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzI0LTEwLTEtMS0xNjc2NjU_e340d557-9890-4d8e-9ef7-69da24e0a792"
      unitRef="usd">1516000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzI1LTgtMS0xLTE2NzY2NQ_0895e003-2158-473a-85c9-bc73f81e1db9"
      unitRef="usd">22957000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTowYTVmZWU4N2ZlY2M0YTNmODg2MDVhMDU3MDFlZjUyYS90YWJsZXJhbmdlOjBhNWZlZTg3ZmVjYzRhM2Y4ODYwNWEwNTcwMWVmNTJhXzI1LTEwLTEtMS0xNjc2NjU_0a83f2b6-e250-4587-889b-2d3006de2f6c"
      unitRef="usd">25179000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:RepaymentsOfDebt
      contextRef="ic270da4b44c84a5db419c3cd7630f579_D20220201-20220228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDcxNTY_f969275c-5d0b-4c55-9693-2d231d0919b6"
      unitRef="usd">500000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="id302c14527e54b03b1462a8b781c544d_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NTExMjg_0fefaa1e-31c3-44b1-baf7-449b999fd1d5"
      unitRef="usd">1000000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDcyMzE_71d1140c-5508-4aed-978c-060b1157d12d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i39f1a4a42b2e42c8b1adac714d4b3849_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDgwNzA_4db154e7-ff1f-4fe3-941e-a74f07e67342"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <gild:DebtInstrumentCallFeaturePeriodBeforeMaturity
      contextRef="i58df36e70f7647cf876057727793fb70_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEwOTk1MTE2MzcyODE_233ba983-2139-4659-aa70-baabd3df9bd8">P6M</gild:DebtInstrumentCallFeaturePeriodBeforeMaturity>
    <us-gaap:LongTermDebt
      contextRef="ife4410a1d3ac4f6db988c4f916e2bfec_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEwOTk1MTE2Mzc1NTQ_47d602c8-335a-485f-930e-fd16cbc466f4"
      unitRef="usd">1500000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i72cca364459e4c9a9900d1ff55ebcbe1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEwOTk1MTE2MzcwMzI_7ff7be04-bfde-4e37-8c9d-b3df83bb8007"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i39f1a4a42b2e42c8b1adac714d4b3849_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDgzNDY_2d9b7996-f5de-40be-964b-97aa7260fda7"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput
      contextRef="i17fb44daa02d4c84b8bed20193956526_I20201023"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEzMTk0MTM5NTQ1Mjc5_11f1ec56-6197-458b-afb0-7917b81d752f"
      unitRef="number">16</gild:BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7184a423cb03437a853dc81095f40d56_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDg5Nzg_a61c4295-752a-4fd5-a223-557da6eb22f8"
      unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i1ed58c535ccd4faa9176f654b65aaa5b_D20200601-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzEzMTk0MTM5NTQyNTY1_b18bdb66-1119-4feb-bc95-c79c950dccca">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCredit
      contextRef="i7bab656927b94fc98bcf55c11d946976_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDg5OTg_4696b440-1045-4abb-a1d0-7d3a3f4a2f59"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i4655f4b3112c42b5817c56a6a39a9b66_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDg5OTg_93297201-e207-4e86-abb6-c5a9c8a59f09"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzQ5NTY_9b70c71d-45c2-46fb-bd29-1ab3eb0251c6">&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate future principal maturities of our senior unsecured notes as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzEtMi0xLTEtMTY3NjY1_13883864-ff19-4588-b701-21e4a03f06f0"
      unitRef="usd">2250000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzItMi0xLTEtMTY3NjY1_6bb4845b-bf4d-402b-845e-25ead5230235"
      unitRef="usd">1750000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzMtMi0xLTEtMTY3NjY1_c235dcf8-8147-46f2-8f8d-7d97a304acb2"
      unitRef="usd">1750000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzQtMi0xLTEtMTY3NjY1_837f58b9-6260-4f39-8d4a-ba0a153d318e"
      unitRef="usd">2750000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzUtMi0xLTEtMTY3NjY1_b0d34697-aee0-4290-a7f9-0c45edc59b6a"
      unitRef="usd">2000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzYtMi0xLTEtMTY3NjY1_7a67dcbd-3290-4c9d-bae6-8025d5eb04c6"
      unitRef="usd">13750000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt
      contextRef="i89095e70e7fa45458393451ccf83e29b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90YWJsZTpmMDllNDE3ZGViZDI0NWJmYWM3ZTFmYjYyMzY3OGQ4ZC90YWJsZXJhbmdlOmYwOWU0MTdkZWJkMjQ1YmZhYzdlMWZiNjIzNjc4ZDhkXzctMi0xLTEtMTY3NjY1_dbbc2a44-87e7-445e-bd47-2b270fd8629e"
      unitRef="usd">24250000000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDgwNTU_8bfacd4f-413b-43ef-b620-c2b64f746248"
      unitRef="usd">940000000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:InterestExpenseLongTermDebt
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjQvZnJhZzpmMzVkM2Y3N2IwOWQ0MzVkOTY3NWYyYzdhZjUyMzAyMS90ZXh0cmVnaW9uOmYzNWQzZjc3YjA5ZDQzNWQ5Njc1ZjJjN2FmNTIzMDIxXzE2NDkyNjc0NDgwNjM_7655fa54-227a-46af-8a48-d6b3b7a6f297"
      unitRef="usd">1000000000</us-gaap:InterestExpenseLongTermDebt>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzgxNQ_d41c12fa-6bc3-422a-8e33-cd5aa5ed7c3d">LEASES&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases consist primarily of properties and equipment for our administrative, manufacturing and R&amp;amp;D activities. Some of our leases include options to extend the terms for up to 15 years and some include options to terminate the lease within one year after the lease commencement date. As of December&#160;31, 2022 and 2021, we did not have material finance leases. Operating lease expense, including variable costs and short-term leases, was $162 million, $156 million and $171 million in 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes balance sheet and other information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except weighted average amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_8de7020f-9548-47c7-9a1e-4746afc67ea4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_b3559456-f5cf-4d45-8c2a-793a81b2aed1"&gt;Other long-term assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities &#x2013; current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_37e207dc-5857-47ab-bc75-5d95f77eba00"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_566a40c8-fefd-4cc7-be50-3313dae89a4d"&gt;Other accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities &#x2013; noncurrent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_083b769e-0d49-49bf-952b-f91005031157"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_6a8cd158-cdc0-45a1-ba9e-3851203d9cab"&gt;Other long-term obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes other supplemental information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total discounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzE2NDkyNjc0NDI0ODI_431444ff-1df8-45dc-b57f-3ebe3c571220">P15Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzE2NDkyNjc0NDI0ODY_f08dc8d7-5e7a-4677-9453-ae9e0a0fc1c4">one year</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:OperatingLeaseExpense
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzE2NDkyNjc0NDI1MDM_d396cd17-28f7-47da-baf0-a543dd0f506f"
      unitRef="usd">162000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzE2NDkyNjc0NDI0OTc_9ccf7652-9d11-425d-a851-a9b58e418f4e"
      unitRef="usd">156000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzE2NDkyNjc0NDI0OTA_dc37efb8-0dcf-4cf6-b03f-27a1f46b4872"
      unitRef="usd">171000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzgxMw_227a9bb0-9a08-4a1e-94d0-a5de6f2cf6ce">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes balance sheet and other information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except weighted average amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_8de7020f-9548-47c7-9a1e-4746afc67ea4"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItMi0xLTEtMTY3NjY1_b3559456-f5cf-4d45-8c2a-793a81b2aed1"&gt;Other long-term assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities &#x2013; current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_37e207dc-5857-47ab-bc75-5d95f77eba00"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtMi0xLTEtMTY3NjY1_566a40c8-fefd-4cc7-be50-3313dae89a4d"&gt;Other accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities &#x2013; noncurrent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_083b769e-0d49-49bf-952b-f91005031157"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtMi0xLTEtMTY3NjY1_6a8cd158-cdc0-45a1-ba9e-3851203d9cab"&gt;Other long-term obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes other supplemental information related to our operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItNC0xLTEtMTY3NjY1_5cba5616-6678-4bda-be0c-b34100c43e9c"
      unitRef="usd">505000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzItNi0xLTEtMTY3NjY1_fac64965-1cb1-416e-ac39-1b49d0c4fb64"
      unitRef="usd">542000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtNC0xLTEtMTY3NjY1_eb6ed2a3-706a-4776-9f68-a1cd0e9624d3"
      unitRef="usd">111000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzMtNi0xLTEtMTY3NjY1_31c62f41-bd53-4345-b549-7c17656fac9d"
      unitRef="usd">101000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtNC0xLTEtMTY3NjY1_7f928a72-9790-4f9e-926b-511e8851ce15"
      unitRef="usd">467000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzQtNi0xLTEtMTY3NjY1_4d41ee2c-58cb-4c49-a9b2-f778ee59ac08"
      unitRef="usd">489000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzUtNC0xLTEtMTY3NjY1_e11249f0-48e4-4b9b-9e3a-510b7d751358">P8Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzUtNi0xLTEtMTY3NjY1_2490d778-e987-4e4e-a052-8c640461b7b8">P8Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzYtNC0xLTEtMTY3NjY1_1231cd63-deaf-4f30-bc0a-f2726c71fbaf"
      unitRef="number">0.0280</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTplY2VmZDJiMDIzNDA0M2U3YTVhN2QzY2YxOTkyNDQ4Yy90YWJsZXJhbmdlOmVjZWZkMmIwMjM0MDQzZTdhNWE3ZDNjZjE5OTI0NDhjXzYtNi0xLTEtMTY3NjY1_e558ea2a-89d0-4eb6-b28b-eb0ec7c6b99d"
      unitRef="number">0.0300</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTpkMWFmMTkwN2RkNjY0OGYxYTU1Y2MzODYwOTY3ODZkNy90YWJsZXJhbmdlOmQxYWYxOTA3ZGQ2NjQ4ZjFhNTVjYzM4NjA5Njc4NmQ3XzItMi0xLTEtMTY3NjY1_ec943463-9b2d-43a4-aa73-f4b67df9fb55"
      unitRef="usd">98000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTpkMWFmMTkwN2RkNjY0OGYxYTU1Y2MzODYwOTY3ODZkNy90YWJsZXJhbmdlOmQxYWYxOTA3ZGQ2NjQ4ZjFhNTVjYzM4NjA5Njc4NmQ3XzItNC0xLTEtMTY3NjY1_b00e373a-fdb4-4ee6-bfef-96e341d64fec"
      unitRef="usd">123000000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTpkMWFmMTkwN2RkNjY0OGYxYTU1Y2MzODYwOTY3ODZkNy90YWJsZXJhbmdlOmQxYWYxOTA3ZGQ2NjQ4ZjFhNTVjYzM4NjA5Njc4NmQ3XzMtMi0xLTEtMTY3NjY1_b596cb6b-bde6-421e-90fd-96806ade8340"
      unitRef="usd">97000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZTpkMWFmMTkwN2RkNjY0OGYxYTU1Y2MzODYwOTY3ODZkNy90YWJsZXJhbmdlOmQxYWYxOTA3ZGQ2NjQ4ZjFhNTVjYzM4NjA5Njc4NmQ3XzMtNC0xLTEtMTY3NjY1_7bb8ab49-5c16-4be1-ab0b-3223535a294f"
      unitRef="usd">88000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90ZXh0cmVnaW9uOjI5YjM1M2JmY2M4MDRkZjViOTc3YThhNWNmZGQwNDNjXzgxNA_cebbd016-79f5-406f-92d6-d144ca7ca1ef">&lt;div style="margin-bottom:4.5pt;margin-top:4pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes a maturity analysis of our operating lease liabilities showing the aggregate lease payments as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total discounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzEtMi0xLTEtMTY3NjY1_e5b830ca-e360-4529-a109-0742a6680bce"
      unitRef="usd">117000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzItMi0xLTEtMTY3NjY1_deace6f0-b8b7-4df0-b4ce-32407720b82b"
      unitRef="usd">111000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzMtMi0xLTEtMTY3NjY1_b5706714-7633-4520-a1e9-ac51ee1947ed"
      unitRef="usd">79000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzQtMi0xLTEtMTY3NjY1_30ecd23c-d59b-415c-a7c5-9f7ff2683e17"
      unitRef="usd">56000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzUtMi0xLTEtMTY3NjY1_9a03c932-52c3-49a5-af48-9838c8065123"
      unitRef="usd">52000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzYtMi0xLTEtMTY3NjY1_2fb5b4a8-a4c6-4810-8eb0-1b6e1dc66ae9"
      unitRef="usd">236000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzctMi0xLTEtMTY3NjY1_7f84d911-2b78-43d2-8445-c7bf357f4152"
      unitRef="usd">651000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzgtMi0xLTEtMTY3NjY1_1eae4d78-659a-4818-a9e6-f00e8057e226"
      unitRef="usd">73000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMjcvZnJhZzoyOWIzNTNiZmNjODA0ZGY1Yjk3N2E4YTVjZmRkMDQzYy90YWJsZToxN2ZlNTlmNTdjMWQ0MTQ2ODVhYmUyZDM3ODBmMDViMS90YWJsZXJhbmdlOjE3ZmU1OWY1N2MxZDQxNDY4NWFiZTJkMzc4MGYwNWIxXzktMi0xLTEtMTY3NjY1_c37aa38c-13e0-4780-9935-d996c57a3117"
      unitRef="usd">578000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzI0NjMx_f4cf0f2a-7381-4c18-b44e-3b8bd444dc30">COMMITMENTS AND CONTINGENCIES &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions. Certain significant matters are described below. We recognize accruals for such actions to the extent that we conclude that a loss is both probable and reasonably estimable. We accrue for the best estimate of a loss within a range; however, if no estimate in the range is better than any other, then we accrue the minimum amount in the range. If we determine that a material loss is reasonably possible and the loss or range of loss can be estimated, we disclose the possible loss. Unless otherwise noted, the outcome of these matters either is not expected to be material or is not possible to determine such that we cannot reasonably estimate the maximum potential exposure or the range of possible loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not have any material accruals for the matters described below as of December&#160;31, 2022. As of December&#160;31, 2021, we recorded an accrual of $1.25 billion in Accrued and other current liabilities on our Consolidated Balance Sheets for the previously disclosed legal settlement related to the bictegravir litigation, which we paid in February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation Related to Sofosbuvir&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012, we acquired Pharmasset, Inc. Through the acquisition, we acquired sofosbuvir, a nucleotide analog that acts to inhibit the replication of HCV. In 2013, we received approval from FDA for sofosbuvir, sold under the brand name Sovaldi. Sofosbuvir is also included in all of our marketed HCV products. We have received a number of litigation claims regarding sofosbuvir. While we have carefully considered these claims both prior to and following the acquisition and believe they are without merit, we cannot predict the ultimate outcome of such claims or range of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are aware of patents and patent applications owned by third parties that have been or may in the future be alleged by such parties to cover the use of our HCV products. If third parties obtain valid and enforceable patents, and successfully prove infringement of those patents by our HCV products, we could be required to pay significant monetary damages. We cannot predict the ultimate outcome of intellectual property claims related to our HCV products. We have spent, and will continue to spend, significant resources defending against these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with the University of Minnesota&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The University of Minnesota (the &#x201c;University&#x201d;) has obtained U.S. Patent No. 8,815,830 (the &#x201c;&#x2019;830 patent&#x201d;), which purports to broadly cover nucleosides with antiviral and anticancer activity. In 2016, the University filed a lawsuit against us in the U.S. District Court for the District of Minnesota, alleging that the commercialization of sofosbuvir-containing products infringes the &#x2019;830 patent. We believe the &#x2019;830 patent is invalid and will not be infringed by the continued commercialization of sofosbuvir. In 2017, the court granted our motion to transfer the case to California. We have also filed petitions for inter partes review with the U.S. Patent and Trademark Office Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;) alleging that all asserted claims are invalid for anticipation and obviousness. The PTAB instituted one of these petitions and a merits hearing was held in February 2021. In 2018, the U.S. District Court for the Northern District of California stayed the litigation until after the PTAB concluded the inter partes review that it had initiated. In May 2021, the PTAB issued a written decision finding the asserted claims of the University&#x2019;s patent invalid. In July 2021, the University appealed this decision, and oral arguments before the Court of Appeals for the Federal Circuit were held in January 2023. The litigation in the U.S. District Court will remain stayed through the appeal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Litigation with NuCana plc. (&#x201c;NuCana&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NuCana has obtained European Patent No. 2,955,190 (the &#x201c;EP &#x2019;190 patent&#x201d;) that allegedly covers sofosbuvir. In opposition proceedings before the European Patent Office (&#x201c;EPO&#x201d;) held in February 2021, the EPO Opposition Division upheld the validity of the EP &#x2019;190 patent in amended form. The EPO has now scheduled the appeal hearing for March 2023. We continue to believe that the amended EP &#x2019;190 patent claims are invalid. Subsequent to the EPO opposition decision, we initiated proceedings to invalidate the U.K. counterparts of the EP &#x2019;190 patent and a related patent, European Patent No. 3,904,365 (the EP &#x2018;365 patent) in the High Court of England &amp;amp; Wales. NuCana has also filed counterclaims against us in the High Court of England &amp;amp; Wales alleging patent infringement of the U.K. counterparts and seeking damages and other relief. The U.K. case was heard in January and early February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, NuCana also filed a lawsuit against us in Germany at the Landgericht D&#xfc;sseldorf alleging patent infringement of the German counterpart of the EP &#x2019;190 patent and seeking damages and injunctive relief. In April 2022, we filed an action for grant of a compulsory license before the Federal Patent Court in Germany. In July 2022, the D&#xfc;sseldorf court determined that NuCana&#x2019;s German counterpart of the EP &#x2019;190 patent is infringed and granted an injunction. In August 2022, Gilead filed a notice of appeal regarding the D&#xfc;sseldorf court&#x2019;s decision, and a hearing is scheduled for August 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation Related to Axicabtagene Ciloleucel&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, &#x201c;Juno&#x201d;) filed a lawsuit against us in the U.S. District Court for the Central District of California, alleging that the commercialization of axicabtagene ciloleucel, sold commercially as Yescarta, infringes U.S. Patent No. 7,446,190 (the &#x201c;&#x2019;190 patent&#x201d;). A jury trial was held on the &#x2019;190 patent, and in December 2019, the jury found that the asserted claims of the &#x2019;190 patent were valid, and that we willfully infringed the asserted claims of the &#x2019;190 patent. The jury also awarded Juno damages in amounts of $585 million in an upfront payment and a 27.6% running royalty from October 2017 through the date of the jury&#x2019;s verdict. The parties filed post-trial motions in the first quarter of 2020, and the trial judge entered a judgment in April 2020. The trial judge affirmed the jury&#x2019;s verdict, enhanced the past damages by 50% and maintained the royalties on future Yescarta sales at 27.6%. In April 2020, we filed an appeal seeking to reverse the judgment or obtain a new trial due to errors made by the trial judge, and in July 2021, the appeals court heard oral arguments. In August 2021, the Court of Appeals for the Federal Circuit (the &#x201c;CAFC&#x201d;) reversed the jury verdict, finding the asserted claims of Juno&#x2019;s patent invalid. In October 2021, Juno filed a petition for rehearing with the CAFC. In January 2022, the CAFC denied Juno&#x2019;s petition for rehearing. In June 2022, Juno filed a petition for certiorari seeking a review by the Supreme Court. The Supreme Court rejected Juno&#x2019;s petition in January 2023, making the CAFC judgment final.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation Relating to Pre-Exposure Prophylaxis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, we filed petitions requesting inter partes review of U.S. Patent Nos. 9,044,509, 9,579,333, 9,937,191 and 10,335,423 (collectively, &#x201c;HHS Patents&#x201d;) by PTAB. The HHS Patents are assigned to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) and purport to claim a process of protecting a primate host from infection by an immunodeficiency retrovirus by administering a combination of FTC and tenofovir disoproxil fumarate (&#x201c;TDF&#x201d;) or TAF prior to exposure of the host to the immunodeficiency retrovirus, a process commonly known as pre-exposure prophylaxis (&#x201c;PrEP&#x201d;). In November 2019, the U.S. Department of Justice filed a lawsuit against us in the U.S. District Court of Delaware, alleging that the sale of Truvada and Descovy for use as PrEP infringes the HHS Patents. In February 2020, PTAB declined to institute our petitions for inter partes review of the HHS Patents. In April 2020, we filed a breach of contract lawsuit against the U.S. federal government in the U.S. Court of Federal Claims, alleging violations of three material transfer agreements (&#x201c;MTAs&#x201d;) related to the research underlying the HHS Patents and two clinical trial agreements (&#x201c;CTAs&#x201d;) by the U.S. Centers for Disease Control and Prevention related to PrEP research. Although we cannot predict with certainty the ultimate outcome of each of these litigation matters, we believe that the U.S. federal government breached the MTAs and CTA, that Truvada and Descovy do not infringe the HHS Patents and that the HHS Patents are invalid over prior art descriptions of Truvada&#x2019;s use for PrEP and post-exposure prophylaxis as well because physicians and patients were using the claimed methods years before HHS filed the applications for the patents. A trial for the bifurcated portion of the lawsuit in the Court of Federal Claims was held in June 2022, and in November 2022, the Court determined that the government breached the three MTAs. The Court also made findings of fact relating to the CTAs but declined to issue a decision on breach of the CTAs until after trial in the Delaware District Court. A trial date for the lawsuit in the Delaware District Court has been set for May 2023. A separate trial at the Court of Federal Claims to determine the damages Gilead is owed based on the government&#x2019;s breach has yet to be set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation with Generic Manufacturers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the approval process for some of our products, FDA granted us a New Chemical Entity (&#x201c;NCE&#x201d;) exclusivity period during which other manufacturers&#x2019; applications for approval of generic versions of our products will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#x201c;ANDA&#x201d;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of our products prior to their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#x2019;s approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, we received a letter from Lupin Ltd. (&#x201c;Lupin&#x201d;) indicating that it has submitted an ANDA to FDA requesting permission to market and manufacture a generic version of Symtuza, a product commercialized by Janssen and for which Gilead shares in revenues. In November 2021, we, along with Janssen Products, L.P. and Janssen (&#x201c;Janssen&#x201d;), filed a patent infringement lawsuit against Lupin as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Lupin asserting infringement of two additional patents in the same court. This second case has been stayed. Trial has been scheduled for October 2023. In September 2022, we received a letter from Apotex Inc. and Apotex Corp. (&#x201c;Apotex&#x201d;) stating that they have submitted an ANDA for a generic version of Symtuza. In October 2022, we, along with Janssen, filed a patent infringement lawsuit against Apotex as co-plaintiffs in the U.S. District Court of Delaware. We separately filed an additional lawsuit against Apotex asserting infringement of two additional patents in the same court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Starting in March 2022, we received letters from Lupin, Laurus Labs (&#x201c;Laurus&#x201d;) and Cipla Ltd. (&#x201c;Cipla&#x201d;), indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of Biktarvy. Lupin, Laurus, and Cipla have challenged the validity of three of the five patents listed in the Orange Book as associated with Biktarvy. We filed a lawsuit against Lupin, Laurus and Cipla in May 2022 in the U.S. District Court of Delaware, and intend to enforce and defend our intellectual property. Trial has been scheduled for December 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;European Patent Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, several parties filed oppositions in the EPO requesting revocation of one of our granted European patents covering sofosbuvir that expires in 2028. In 2016, the EPO upheld the validity of certain claims of our sofosbuvir patent. We have appealed this decision, seeking to restore all of the original claims, and several of the original opposing parties have also appealed, requesting full revocation. The appeal hearing was held in November 2022, but a final decision regarding the validity of the claims has not yet been announced.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to sofosbuvir that expires in 2024. The EPO conducted an oral hearing for this opposition in 2018 and upheld the claims. The original opposing parties have appealed, requesting full revocation. The hearing for the appeal has been scheduled for September 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, several parties filed oppositions in the EPO requesting revocation of our granted European patent relating to TAF hemifumarate that expires in 2032. In 2019, the EPO upheld the validity of the claims of our TAF hemifumarate patent. Three parties have appealed this decision. The hearing for the appeal has been scheduled for March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The appeal process may take several years for all EPO opposition proceedings. While we are confident in the strength of our patents, we cannot predict the ultimate outcome of these oppositions. If we are unsuccessful in defending these oppositions, some or all of our patent claims may be narrowed or revoked and the patent protection for sofosbuvir and TAF hemifumarate in the EU could be substantially shortened or eliminated entirely. If our patents are revoked, and no other European patents are granted covering these compounds, our exclusivity may be based entirely on regulatory exclusivity granted by EMA. If we lose patent protection for any of these compounds, our revenues and results of operations could be negatively impacted for the years including and succeeding the year in which such exclusivity is lost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Antitrust and Consumer Protection&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We, along with Bristol-Myers Squibb Company (&#x201c;BMS&#x201d;) and Johnson &amp;amp; Johnson, Inc., have been named as defendants in class action lawsuits filed in 2019 and 2020 related to various drugs used to treat HIV, including drugs used in combination antiretroviral therapy. Plaintiffs allege that we (and the other defendants) engaged in various conduct to restrain competition in violation of federal and state antitrust laws and state consumer protection laws. The lawsuits, which have been consolidated, are pending in the U.S. District Court for the Northern District of California. The lawsuits seek to bring claims on behalf of direct purchasers consisting largely of wholesalers and indirect or end-payor purchasers, including health insurers and individual patients. Plaintiffs seek damages, permanent injunctive relief and other relief. In the second half of 2021 and first half of 2022, several plaintiffs filed separate lawsuits effectively opting out of the class action cases, asserting claims that are substantively the same as the putative classes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These cases have been coordinated with the class actions. Trial has been set for May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, we, along with BMS and Janssen Products, L.P., were named as defendants in a lawsuit filed in the Superior Court of the State of California, County of San Mateo, by Aetna, Inc. on behalf of itself and its affiliates and subsidiaries that effectively opts the Aetna plaintiffs out of the above class actions. The allegations are substantively the same as those in the class actions. The Aetna plaintiffs seek damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we, along with generic manufacturers Cipla and Cipla USA Inc. (together, &#x201c;Cipla Defendants&#x201d;), were named as defendants in a class action lawsuit filed in the U.S. District Court for the Northern District of California by Jacksonville Police Officers and Fire Fighters Health Insurance Trust (&#x201c;Jacksonville Trust&#x201d;) on behalf of end-payor purchasers. Jacksonville Trust claims that the 2014 settlement agreement between us and the Cipla Defendants, which settled a patent dispute relating to patents covering our Emtriva, Truvada and Atripla products and permitted generic entry prior to patent expiry, violates certain federal and state antitrust and consumer protection laws. The Plaintiff seeks damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, we, along with BMS and Teva Pharmaceutical Industries Ltd., were named as defendants in a lawsuit filed in the First Judicial District Court for the State of New Mexico, County of Santa Fe by the New Mexico Attorney General. The New Mexico Attorney General alleges that we (and the other defendants) restrained competition in violation of New Mexico antitrust and consumer protection laws. The New Mexico Attorney General seeks damages, permanent injunctive relief and other relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages or could be subject to permanent injunctive relief awarded in favor of plaintiffs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named as a defendant in one class action lawsuit and various product liability lawsuits related to Viread, Truvada, Atripla, Complera and Stribild. Plaintiffs allege that Viread, Truvada, Atripla, Complera and/or Stribild caused them to experience kidney, bone and/or tooth injuries. The lawsuits, which are pending in state or federal court in California, Delaware, Florida, Missouri and New York, involve more than 26,000 plaintiffs. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. The first bellwether trial in California state court was scheduled to begin in October 2022, but is currently stayed while the California First District Court of Appeal considers the merits of plaintiffs&#x2019; theories of liability. The first bellwether trial in California federal court is scheduled to begin in January 2024. We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcome. If plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, we received a subpoena from the U.S. Attorney&#x2019;s Office for the Southern District of New York requesting documents related to our promotional speaker programs for HIV. We are cooperating with this inquiry.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A former sales employee filed a qui tam lawsuit against Gilead in March 2017 in U.S. District Court for the Eastern District of Pennsylvania. Following the government&#x2019;s decision not to intervene in the suit, the case was unsealed in December 2020. The lawsuit alleges that certain of Gilead&#x2019;s HCV sales and marketing activities violated the federal False Claims Act and various state false claims acts. The relator seeks all available relief under these statutes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Choice Advocates, LLC (&#x201c;Health Choice&#x201d;) filed a qui tam lawsuit against Gilead in April 2020 in New Jersey state court. Following the New Jersey Attorney General&#x2019;s Office&#x2019;s decision not to intervene in the suit, Health Choice served us with their original complaint in August 2020. The lawsuit alleges that Gilead violated the New Jersey False Claims Act through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the New Jersey False Claims Act. In April 2021, the trial court granted our motion to dismiss with prejudice. Health Choice has appealed the trial court&#x2019;s dismissal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health Choice filed another qui tam lawsuit against Gilead in May 2020 making similar allegations in Texas state court. Following the Texas Attorney General&#x2019;s Office&#x2019;s decision not to intervene in the suit, Health Choice served us with their original complaint in October 2020. The lawsuit alleges that Gilead violated the Texas Medicare Fraud Prevention Act (&#x201c;TMFPA&#x201d;) through our clinical educator programs for Sovaldi and Harvoni and our HCV and HIV patient access programs. The lawsuit seeks all available relief under the TMFPA. In September 2021, the Texas Court of Appeals for the Sixth Court Appeals District granted our request to stay the Texas litigation pending final judgment in the Eastern District of Pennsylvania lawsuit filed in March 2017, as discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We intend to vigorously defend ourselves in these actions. While we believe these cases are without merit, we cannot predict the ultimate outcomes. If any of these plaintiffs are successful in their claims, we could be required to pay significant monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunomedics and several of its former officers and directors have been named as defendants in putative class actions filed in 2018 and 2019, which were consolidated in September 2019. Plaintiffs filed a consolidated complaint in November 2019 and an amended complaint in July 2021. Plaintiffs allege that Immunomedics and the individual defendants violated the federal securities laws in connection with Immunomedics&#x2019; Biologics License Application for Trodelvy, and seek certification of a class of shareholders, damages and other relief. The consolidated lawsuit is pending in the U.S. District Court for the District of New Jersey. In June 2022, plaintiffs filed their Motion for Class Certification, and Immunomedics submitted its Opposition in July 2022. The parties have agreed to settle this litigation. A motion seeking preliminary approval of the settlement was granted in February 2023. The court has not yet entered a final order approving the settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to various legal actions that arose in the ordinary course of our business. We do not believe that these other legal actions will have a material adverse impact on our consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationReserve
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUyNTQ_93f83c85-da20-49d6-9c00-dfb5209b9378"
      unitRef="usd">0</us-gaap:LitigationReserve>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ib5fb8687e8cd4caea5f84599504664c8_D20220201-20220228"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUyMzQ_204660a6-58f4-4a74-827c-848e08856752"
      unitRef="usd">1250000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationReserve
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUyMzQ_67ccb8f7-dbf4-4d47-9ec8-d98f49dd4607"
      unitRef="usd">1250000000</us-gaap:LitigationReserve>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i381dbbaeb14842d0957d6f5cdf308d28_D20191201-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUyNzQ_9190ebd6-4a8c-47b9-8005-dcdc5c38e7c3"
      unitRef="usd">585000000</us-gaap:LossContingencyDamagesAwardedValue>
    <gild:JudgmentRoyaltyRateFromOctober2017
      contextRef="i381dbbaeb14842d0957d6f5cdf308d28_D20191201-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUyODU_a83af996-1a8f-43ac-a790-c9be2c039dcf"
      unitRef="number">0.276</gild:JudgmentRoyaltyRateFromOctober2017>
    <gild:JudgmentEnhancedDamagesOnPastSales
      contextRef="ib9689ea2698f49518e3f35ebf341d9d2_I20200430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzMDE_02dba917-7e7c-40cb-9566-fcd92d734942"
      unitRef="number">0.50</gild:JudgmentEnhancedDamagesOnPastSales>
    <gild:JudgmentRoyaltyRateOnFutureSales
      contextRef="ib9689ea2698f49518e3f35ebf341d9d2_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUyOTM_274843b6-85a8-4acb-a6fe-4c5b972659f3"
      unitRef="number">0.276</gild:JudgmentRoyaltyRateOnFutureSales>
    <gild:LossContingencyMaterialTransferAgreementsNumber
      contextRef="i64a2deb2d3f347b89108aa1f51ac3e1b_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzMDU_ac727347-40d7-47c3-ac52-5978ca427f10"
      unitRef="agreement">3</gild:LossContingencyMaterialTransferAgreementsNumber>
    <gild:LossContingencyAdditionalPatentsAllegedlyInfringedNumber
      contextRef="ic183ba3839714584846a1a616db08cbd_D20211001-20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzMzA_1fa58f5a-53a3-49ff-95d7-014469853b8d"
      unitRef="patent">2</gild:LossContingencyAdditionalPatentsAllegedlyInfringedNumber>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="i88bc63bfd5744353885db8517516f8c3_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzNDM_b36f9b03-6e50-48bf-b6ec-ea8d7feab38c"
      unitRef="patent">3</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <gild:LossContingencyNumberOfPatents
      contextRef="i88bc63bfd5744353885db8517516f8c3_D20220301-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzNDc_e4ebaa28-8521-4a00-b487-e37bb24df8f7"
      unitRef="patent">5</gild:LossContingencyNumberOfPatents>
    <gild:LossContingencyPartiesAppealedNumber
      contextRef="i5013c57ba1f641bd9a9a482a7a391bf2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzNzM_8d06d6ca-7497-46ba-b010-afa6c37cfdb1"
      unitRef="opposingparty">3</gild:LossContingencyPartiesAppealedNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="iea228f095581408787a759595c70e968_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzODA_701a1db9-4fd9-4e6a-b214-4d7079523d44"
      unitRef="lawsuit">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="iea228f095581408787a759595c70e968_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzAvZnJhZzpjNmNlMzc3YzEwMjQ0MjQ1ODIwMGQzOGE5ZjY4MzJkYy90ZXh0cmVnaW9uOmM2Y2UzNzdjMTAyNDQyNDU4MjAwZDM4YTlmNjgzMmRjXzEwOTk1MTE3NDUzODY_661eb1d9-71a9-4040-8562-99b64e0f0bc2"
      unitRef="plaintiff">26000</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzI3Mjg_9bfef954-6802-42b0-9924-6350ba48e096">STOCKHOLDERS&#x2019; EQUITY &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Stock Repurchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, our Board of Directors authorized a $5.0 billion&#160;stock repurchase program (&#x201c;2020 Program&#x201d;). Purchases under the 2020 Program may be made in the open market or in privately negotiated transactions. The $12.0 billion stock repurchase program authorized by our Board of Directors in the first quarter of 2016 was completed in the fourth quarter of 2022. We started repurchases under the 2020 Program in December 2022. As of December&#160;31, 2022, the remaining authorized repurchase amount under the 2020 Program was $4.9 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock repurchases through open market transactions under these programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares repurchased and retired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to repurchases from the stock repurchase programs, we repurchased shares of common stock withheld by us from employee restricted stock awards to satisfy our applicable tax withholding obligations. These shares are excluded from the table above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the par value method of accounting for our stock repurchases. Under the par value method, common stock is first charged with the par value of the shares involved. The excess of the cost of shares acquired over the par value is allocated to Additional paid-in capital based on an estimated average sales price per issued share with the excess amounts charged to Retained earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes cash dividends declared on our common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our RSUs and PSUs have dividend equivalent rights entitling holders to dividend equivalents to be paid upon vesting for each share of the underlying unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February&#160;2, 2023, we announced that our Board of Directors declared a quarterly cash dividend increase of 2.7% from $0.73 to $0.75 per share of our common stock, with a payment date of March&#160;30, 2023 to all stockholders of record as of the close of business on March&#160;15, 2023. Future dividends are subject to declaration by our Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have 5 million shares of authorized preferred stock issuable in series. Our Board is authorized to determine the designation, powers, preferences and rights of any such series. There was no preferred stock outstanding as of December&#160;31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Accumulated Other Comprehensive Income &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in Accumulated other comprehensive income by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i27765a75461d4d2081b2a23a1daaf601_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzE2NDkyNjc0NDQ0NzM_aaec4085-5121-4311-b875-d62a23a99cf5"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ia23032332ced4abab639e98fc3486e66_I20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzU0OTc1NTgyMTEzMg_808bbcc4-914f-40aa-82cf-e27d067f24ef"
      unitRef="usd">12000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i3967341da57b4f3caa9d502babffc1d5_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzE2NDkyNjc0NDQ0ODA_2c69e01b-9428-4f08-81ca-0bb89bc233bd"
      unitRef="usd">4900000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzI3NDA_5a6eb522-f90b-4769-8b43-a46805f2037f">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our stock repurchases through open market transactions under these programs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares repurchased and retired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average price per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzItMi0xLTEtMTY3NjY1_f22cdc03-a2d7-4d6c-be30-f8c07ec39a38"
      unitRef="shares">19000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzItNC0xLTEtMTY3NjY1_e02b3b08-1300-403d-9cb6-25903edc458b"
      unitRef="shares">8000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzItNi0xLTEtMTY3NjY1_ba8af475-2dd8-46da-9874-5575498b100e"
      unitRef="shares">22000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzMtMi0xLTEtMTY3NjY1_c276dfb9-66db-4227-9cb7-7dea4df941cf"
      unitRef="usd">1396000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzMtNC0xLTEtMTY3NjY1_ead07804-716d-45c8-992c-9cc72b5f2a64"
      unitRef="usd">546000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzMtNi0xLTEtMTY3NjY1_664d79bb-487a-496d-b76c-0347ae4c4c7e"
      unitRef="usd">1583000000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzQtMi0xLTEtMTY3NjY1_50fa55bb-1bf4-4606-9d35-cdb94c2ba6aa"
      unitRef="usdPerShare">73.77</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzQtNC0xLTEtMTY3NjY1_63964f0a-2c8d-410f-985a-a539644dd439"
      unitRef="usdPerShare">66.58</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2MDc5ZTY4Y2FlMjU0NWM1ODI3N2YxZWJhODE4NWI5Ny90YWJsZXJhbmdlOjYwNzllNjhjYWUyNTQ1YzU4Mjc3ZjFlYmE4MTg1Yjk3XzQtNi0xLTEtMTY3NjY1_b8992b18-2e1b-461b-b7e5-3cfb376c575d"
      unitRef="usdPerShare">70.64</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:DividendsDeclaredTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzI3NTg_e261d37b-1be6-4dd9-8109-b729b72b3edc">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes cash dividends declared on our common stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dividend Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;First quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Second quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fourth quarter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DividendsDeclaredTableTextBlock>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ib808ed4dfe4e411999e03f92bc995798_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzItMi0xLTEtMTY3NjY1_b8369dab-efc2-4e33-9e9e-baa6c6b01b5e"
      unitRef="usdPerShare">0.73</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ib808ed4dfe4e411999e03f92bc995798_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzItNC0xLTEtMTY3NjY1_e2472282-1e76-4770-bbd2-b4d3192ffbc4"
      unitRef="usd">932000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i14329a4081124b6fbf3b38e4aae01606_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzItNi0xLTEtMTY3NjY1_9c456134-b7cb-4476-b586-8c76d055f4ae"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i14329a4081124b6fbf3b38e4aae01606_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzItOC0xLTEtMTY3NjY1_5919a7f7-cae0-4462-82c6-271957262879"
      unitRef="usd">906000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ifdde5e060f4745f89cb9aa85e12fd275_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzMtMi0xLTEtMTY3NjY1_27ce4a42-cc9a-4daa-8582-9fcb7cbed4a1"
      unitRef="usdPerShare">0.73</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ifdde5e060f4745f89cb9aa85e12fd275_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzMtNC0xLTEtMTY3NjY1_8dfdca4b-2444-49c1-82d5-9cd78ceebc55"
      unitRef="usd">932000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id9ca1e84f12844d697f1ea6824ff7451_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzMtNi0xLTEtMTY3NjY1_e06117aa-3dd8-4bc9-811b-4a2bfedb6675"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="id9ca1e84f12844d697f1ea6824ff7451_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzMtOC0xLTEtMTY3NjY1_001590a2-ea64-4e18-80c4-97474447a139"
      unitRef="usd">903000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i413b2fc67238496985ac43774e9116b6_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzQtMi0xLTEtMTY3NjY1_4eb5d2e9-eeae-4cc8-8c0c-c3e79f5d868b"
      unitRef="usdPerShare">0.73</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i413b2fc67238496985ac43774e9116b6_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzQtNC0xLTEtMTY3NjY1_f40da00a-b844-46e9-b225-30604612b3f1"
      unitRef="usd">933000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="iad684e32333e4d028165723fb0a3c25d_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzQtNi0xLTEtMTY3NjY1_4b079be2-02ca-4e5f-899a-b42768cbcf44"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="iad684e32333e4d028165723fb0a3c25d_D20210701-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzQtOC0xLTEtMTY3NjY1_04da6a3f-22ec-48bd-98ba-50687816f838"
      unitRef="usd">905000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ie85479b87980466db067faedfa50f2bd_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzUtMi0xLTEtMTY3NjY1_95c8defc-6742-45bf-bed6-fd34723cddd5"
      unitRef="usdPerShare">0.73</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie85479b87980466db067faedfa50f2bd_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzUtNC0xLTEtMTY3NjY1_98a0e99c-820b-4478-926e-13c262c466ca"
      unitRef="usd">928000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i9ec4c04bdd21487da1fbeecdbf019611_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzUtNi0xLTEtMTY3NjY1_9a3ff3bb-4037-4ebe-98a9-ede7049802ae"
      unitRef="usdPerShare">0.71</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i9ec4c04bdd21487da1fbeecdbf019611_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzUtOC0xLTEtMTY3NjY1_27092290-a365-4987-bc06-ef76883f962c"
      unitRef="usd">904000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzYtMi0xLTEtMTY3NjY1_84e1de31-291d-4048-9a88-466f94667c90"
      unitRef="usdPerShare">2.92</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzYtNC0xLTEtMTY3NjY1_f6f63e40-6037-4f25-aa70-ec48dae51dd0"
      unitRef="usd">3725000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzYtNi0xLTEtMTY3NjY1_b6344430-1abe-4ea3-afe8-1996a10500df"
      unitRef="usdPerShare">2.84</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTo2ZjIwNjUwMzkzNGM0ODk0YTAwNmM5ZDdmZDgzYWU3NS90YWJsZXJhbmdlOjZmMjA2NTAzOTM0YzQ4OTRhMDA2YzlkN2ZkODNhZTc1XzYtOC0xLTEtMTY3NjY1_0b156839-5fd9-4897-ab23-dd732e255e3e"
      unitRef="usd">3618000000</us-gaap:DividendsCommonStockCash>
    <gild:ChangeInDividendsPercentage
      contextRef="i925d522b8c534cdf821c642767a2b8c5_D20230202-20230202"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzU0OTc1NTgxOTY0OQ_509f6d6c-dd7b-4cc3-ae49-e5fac5697c79"
      unitRef="number">0.027</gild:ChangeInDividendsPercentage>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ifc0e2948c490453d8a2ebfca402b6cfb_D20220201-20220201"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzU0OTc1NTgxOTY0Mg_673ede39-0c96-4b63-b0a7-787cb6ba243a"
      unitRef="usdPerShare">0.73</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i925d522b8c534cdf821c642767a2b8c5_D20230202-20230202"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzU0OTc1NTgxNzIyNQ_8caf0f12-6afa-476a-a424-9d3103c7c730"
      unitRef="usdPerShare">0.75</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzE2NDkyNjc0NDQ0OTI_5a1dcaf5-d237-468b-9ea2-40a6d9b818bf"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzE2NDkyNjc0NDQ1MDA_42b52ee4-f861-4c8b-bc62-66590ccec517"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzE2NDkyNjc0NDQ1MDA_cea36019-1048-4a6e-a6fc-2ea43f431a70"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90ZXh0cmVnaW9uOjgwMDM2ZDNkY2VjNDRkODFiMDdjOWNjMzY4MjQ0NGMyXzI3NTk_3dc0d424-1c4f-42d8-9100-a0bebf01f3e5">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in Accumulated other comprehensive income by component, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net unrealized gain (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassifications to net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic65ba49cc6d24464998712864877bfbc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEtMi0xLTEtMTY3NjY1_0fefc82c-7584-463e-ad10-146506bc4df5"
      unitRef="usd">53000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75a52e5d45f44bd2b61d1cbfd645a700_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEtNC0xLTEtMTY3NjY1_62868ff7-beb8-468b-b08d-dfbe4de25ea5"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id39a3baccb6f4a489742ff823a82f45d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEtNi0xLTEtMTY3NjY1_22bcda5b-6315-481a-ab38-08dc788e234d"
      unitRef="usd">31000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5bc9d4063e094f24aa7047cc3f2ade07_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEtOC0xLTEtMTY3NjY1_b0edf419-21dc-46f6-ba42-04cfa5a9272b"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="icb52f2212bb54664833a43b8f1d3e792_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzItMi0xLTEtMTY3NjY1_be5badf1-05e1-4366-ab81-8fb57fb0edb5"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i0b9945ce2eae4b4db8bf21445b6ff8a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzItNC0xLTEtMTY3NjY1_e52c0113-9f96-45fc-8526-36935be1af5f"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i225f3dbf9ef040efa82ebde15cfdcbfc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzItNi0xLTEtMTY3NjY1_81085c05-bfc3-40d0-83d2-e9ebc6e58509"
      unitRef="usd">-103000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzItOC0xLTEtMTY3NjY1_4997875d-94b6-468a-9406-17632f45f0f9"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="icb52f2212bb54664833a43b8f1d3e792_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzMtMi0xLTEtMTY3NjY1_2f4903d6-a168-4ad2-beb3-dd22d99ddf12"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i0b9945ce2eae4b4db8bf21445b6ff8a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzMtNC0xLTEtMTY3NjY1_7464e080-5e30-4c1d-a2c7-34ba7f9aa17a"
      unitRef="usd">42000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i225f3dbf9ef040efa82ebde15cfdcbfc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzMtNi0xLTEtMTY3NjY1_39e90a3d-5570-4e2f-acf8-f22f3138582a"
      unitRef="usd">41000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzMtOC0xLTEtMTY3NjY1_86775091-f98c-4c6d-a5ae-0301c0c27814"
      unitRef="usd">83000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icb52f2212bb54664833a43b8f1d3e792_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzQtMi0xLTEtMTY3NjY1_55b91b52-41d2-4475-9504-06b35818adba"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0b9945ce2eae4b4db8bf21445b6ff8a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzQtNC0xLTEtMTY3NjY1_0c8303e9-705f-408d-be0f-727619fd3b95"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i225f3dbf9ef040efa82ebde15cfdcbfc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzQtNi0xLTEtMTY3NjY1_846c9d46-4860-4e39-a01a-a7bb6666be00"
      unitRef="usd">-144000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzQtOC0xLTEtMTY3NjY1_a2bc9d99-f58e-4047-880a-0541a66bbc78"
      unitRef="usd">-145000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7be022dd13814593bc19060ec3103aff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzUtMi0xLTEtMTY3NjY1_a3104504-2a2f-4fd2-b867-ec2823977260"
      unitRef="usd">51000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a8d242e2a254cb7a740cad8ec6484af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzUtNC0xLTEtMTY3NjY1_8519d8f3-1a21-499a-8ae6-f03be90d110f"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e2f8c526d704f298539af3a53a6ab31_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzUtNi0xLTEtMTY3NjY1_fd76e8f2-ce88-44da-a292-24d43ea282a9"
      unitRef="usd">-113000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6f649babc4c4963a34bead50d8785d8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzUtOC0xLTEtMTY3NjY1_98c47778-a56d-4b59-a782-831013911fb0"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4585b2391d2c42aaa5fcec24001b539d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzYtMi0xLTEtMTY3NjY1_fdeee50f-fd20-444c-b0bf-344c126a5b5a"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i888ea767a9e646238e97fdafcff19aee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzYtNC0xLTEtMTY3NjY1_08e9418f-5bef-4808-a515-fb8031baea36"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6a43e9292cc34d47a7b84bc89666fdcc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzYtNi0xLTEtMTY3NjY1_05906d2a-18be-4be1-af04-430d84ba59ec"
      unitRef="usd">129000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzYtOC0xLTEtMTY3NjY1_febaa9e6-1b1d-43f3-9509-105852e39f37"
      unitRef="usd">85000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4585b2391d2c42aaa5fcec24001b539d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzctMi0xLTEtMTY3NjY1_888ec807-4305-485f-acba-063827b2d467"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i888ea767a9e646238e97fdafcff19aee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzctNC0xLTEtMTY3NjY1_4395a885-58b2-4bf7-84a1-644c0f7d3aa3"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6a43e9292cc34d47a7b84bc89666fdcc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzctNi0xLTEtMTY3NjY1_9f018601-a41c-4bde-a5ff-49a7074971c4"
      unitRef="usd">-58000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzctOC0xLTEtMTY3NjY1_d670e857-6e7b-4d0a-8faa-4f3a7929de77"
      unitRef="usd">-58000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4585b2391d2c42aaa5fcec24001b539d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzgtMi0xLTEtMTY3NjY1_bc9831c0-5d56-422d-b0cf-ce9e605b2a89"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i888ea767a9e646238e97fdafcff19aee_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzgtNC0xLTEtMTY3NjY1_d55de0f2-e26b-4dd1-9e4b-88d253fd4508"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6a43e9292cc34d47a7b84bc89666fdcc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzgtNi0xLTEtMTY3NjY1_84b29b1b-5816-467d-83de-bbb1dd19c6fc"
      unitRef="usd">187000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzgtOC0xLTEtMTY3NjY1_1a596c91-09ac-49ff-9564-bf68a6288269"
      unitRef="usd">143000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1282cebfa404d25b44e39c3dee052f3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzktMi0xLTEtMTY3NjY1_76fcdba4-8ffe-4b11-a513-1eae6c48720f"
      unitRef="usd">13000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icc18bb50e5fb4827a108a43362008dbb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzktNC0xLTEtMTY3NjY1_96dc67c7-db72-463b-bcf7-415d6681ef61"
      unitRef="usd">-4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i703dc9a954254418a5cecf9488a563fa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzktNi0xLTEtMTY3NjY1_121d5d40-e06c-44ee-86c7-5a94bcefe50d"
      unitRef="usd">74000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33c6e110f0a74581baf5ef42159e7423_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzktOC0xLTEtMTY3NjY1_af8d93b4-31e0-4b35-aeb4-bff301d9d55c"
      unitRef="usd">83000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i89ba96d4050347bdb58a1c83a817e40e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEwLTItMS0xLTE2NzY2NQ_d4ef1006-49d1-4814-8204-4e1e3e367c41"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ibc1baff673f642548027f1b6b5d8e4af_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEwLTQtMS0xLTE2NzY2NQ_54564d22-a681-4537-ad9c-4306ad23b4f5"
      unitRef="usd">-30000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="if5b483b2ee2e42d5a938318ae558e2e2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEwLTYtMS0xLTE2NzY2NQ_f91dffe0-6bb4-454c-85ae-d39bab5fb815"
      unitRef="usd">130000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEwLTgtMS0xLTE2NzY2NQ_80f9acc1-292a-4ea2-81cd-87484d4f21a8"
      unitRef="usd">88000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i89ba96d4050347bdb58a1c83a817e40e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzExLTItMS0xLTE2NzY2NQ_61d28c1a-510c-4dcd-a7ba-f7f6c4332aa2"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ibc1baff673f642548027f1b6b5d8e4af_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzExLTQtMS0xLTE2NzY2NQ_4884d601-120b-4232-9ec8-a5d0d222a668"
      unitRef="usd">-1000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="if5b483b2ee2e42d5a938318ae558e2e2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzExLTYtMS0xLTE2NzY2NQ_46984f84-f43a-4ca1-b3d5-372bfb6437d4"
      unitRef="usd">171000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzExLTgtMS0xLTE2NzY2NQ_d9594a52-22d9-4ec3-b607-991afdea9a80"
      unitRef="usd">170000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i89ba96d4050347bdb58a1c83a817e40e_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEyLTItMS0xLTE2NzY2NQ_a24ded8a-0541-4017-b5f0-e12269c8d50a"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibc1baff673f642548027f1b6b5d8e4af_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEyLTQtMS0xLTE2NzY2NQ_02fed9bb-a248-462e-946c-b70fbdc0a931"
      unitRef="usd">-29000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if5b483b2ee2e42d5a938318ae558e2e2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEyLTYtMS0xLTE2NzY2NQ_01c27f5a-aed6-4d79-bb50-a2eb779eae9f"
      unitRef="usd">-41000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEyLTgtMS0xLTE2NzY2NQ_813f88c4-28c4-4b05-8faf-26d0009ddb9c"
      unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72eb2ca7a60f4cf19210a329bed5aa1f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEzLTItMS0xLTE2NzY2NQ_2b7417ad-110e-428f-b866-0a104230fc35"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia122869e81d74b249c7207040246de2f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEzLTQtMS0xLTE2NzY2NQ_81c463e8-dbe8-4ab3-9056-ec91e4b10b1d"
      unitRef="usd">-33000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41a0488268694a0ca64f483518e451cd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEzLTYtMS0xLTE2NzY2NQ_3616ab3c-6bab-4dad-a577-6fe98acc78d8"
      unitRef="usd">33000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic35cf517e1c44e6cb7eb51a11bc60ba9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzMvZnJhZzo4MDAzNmQzZGNlYzQ0ZDgxYjA3YzljYzM2ODI0NDRjMi90YWJsZTplY2FhMjk1ZTM2Njc0YTUzYWI3MGYzZWZhYmQyYThhZi90YWJsZXJhbmdlOmVjYWEyOTVlMzY2NzRhNTNhYjcwZjNlZmFiZDJhOGFmXzEzLTgtMS0xLTE2NzY2NQ_7d6046e7-8537-4296-9830-86a188b822f7"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzk4NTU_afd318db-519d-4d5c-b6e8-4dbf9ede5238">EMPLOYEE BENEFITS &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Incentive Plans Summary&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2004, our stockholders approved and we adopted the Gilead Sciences, Inc. 2004 Equity Incentive Plan (as amended, the &#x201c;2004 Plan&#x201d;). As part of our acquisition of Forty Seven in 2020, we assumed the Forty Seven, Inc. 2018 Equity Incentive Plan, which we subsequently amended and restated as the Gilead Sciences, Inc. 2018 Equity Incentive Plan (as amended and restated, the &#x201c;2018 Plan&#x201d;). As part of the Immunomedics acquisition, we assumed the Immunomedics Amended and Restated 2014 Long-Term Incentive Plan, which we subsequently merged into the 2004 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, our stockholders approved and we adopted the Gilead Sciences, Inc. 2022 Equity Incentive Plan (the &#x201c;2022 Plan&#x201d;). The 2022 Plan authorized the issuance of a total of 132 million shares of common stock. No awards may be granted under the 2004 Plan or the 2018 Plan since the approval of the 2022 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These are broad-based incentive plans that provide for the grant of equity-based awards, including RSUs, PSUs, stock options and other restricted stock and performance awards, to employees, directors and consultants. As of December&#160;31, 2022, a total of 101 million shares remain available for future grant under the 2022 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant time-based RSUs to certain employees as part of our annual employee equity compensation review program as well as to new hire employees and to non-employee members of our Board. RSUs are share-based awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. RSUs generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTY3OTU_0304068a-3d69-42e3-a0cc-97d49217f440"&gt;three&lt;/span&gt; or four years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;PSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant PSUs that vest upon the achievement of specified market or performance goals, which could include achieving a total shareholder return compared to a pre-determined peer group or achieving revenue targets. The actual number of common shares ultimately issued is calculated by multiplying the number of PSUs by a payout percentage ranging from 0% to 200%, and these awards generally vest only when a committee (or subcommittee) of our Board has determined that the specified market and performance goals have been achieved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option grants are designated as either non-statutory or incentive stock options. The exercise price of stock options may not be less than the fair market value of our common stock on the grant date and no stock option may have a term in excess of 10 years. Employee stock options generally vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTg2ODM_bb52c247-34d1-49f0-be7e-b07c8a217a78"&gt;three&lt;/span&gt; or four years. Stock options may be settled in cash or in shares of our common stock, including a net issuance using shares otherwise purchasable under the option to pay the exercise price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ESPP Summary&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our ESPP, employees can purchase shares of our common stock based on a percentage of their compensation subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of our common stock on the offering date or the purchase date. The ESPP offers a six-month look-back feature. ESPP purchases are settled with common stock from the ESPP&#x2019;s previously authorized and available pool of shares. A total of 79 million shares of common stock have been authorized for issuance under the ESPP, and there were 3 million shares available for issuance under the ESPP as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize total stock-based compensation expense included on our Consolidated Statements of Income as broken down by award type and by expense type:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense included in total costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Accelerated post-acquisition stock-based compensation expense of $8 million related to the MiroBio acquisition in 2022, and $289 million and $144 million related to the acquisitions of Immunomedics and Forty Seven, respectively, in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense included in total costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value of RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of RSUs as of the respective vesting dates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was $948 million of unrecognized compensation cost related to unvested RSUs, which is expected to be recognized over a weighted-average period of 2.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;PSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our PSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:right"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value of PSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of PSUs as of the respective vesting dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2022, there was $29 million of unrecognized compensation cost related to unvested PSUs, which is expected to be recognized over a weighted-average period of 1.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize activity and other information related to our stock options: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;br/&gt;(in dollars)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest, net of estimated forfeitures as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the stock option awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected terms in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was $48 million of unrecognized compensation cost related to stock options, which is expected to be recognized over an estimated weighted-average period of 2.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our ESPP activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount paid by employees for shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value of ESPP shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of ESPP shares as of the respective vesting dates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the ESPP awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected terms in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Deferred Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a retirement saving plan under which eligible U.S. employees may defer compensation for income tax purposes under Section 401(k) of the Internal Revenue Code (the &#x201c;Gilead Sciences 401k Plan&#x201d;). In certain foreign subsidiaries, we maintain defined benefit plans as required by local regulatory requirements. Our total matching contribution expense under the Gilead Sciences 401k Plan and other defined benefit plans was $176 million, $166 million and $144 million during 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a deferred compensation plan under which our directors and key employees may defer compensation. Amounts deferred by participants are deposited into a rabbi trust. The total assets and liabilities associated with the deferred compensation plan were $220&#160;million and $261 million as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="id443da59986449869f984ba29bd052a0_I20220531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzU0OTc1NTgxNzU3MDY_2ec0e47c-4c0f-4221-883e-26c6e5582498"
      unitRef="shares">132000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic8f202de25714586abb2bcfe7d406697_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTkxMzg_f853368c-03d2-4ab2-a89a-68c345f7b56b"
      unitRef="shares">101000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i41cc17b6454144eebfb7455e16f8e439_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzc2OTY1ODE0NDY3ODM_3079b50e-e08b-4706-bdc6-f5637f56fd2b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage
      contextRef="ief16c425ab394fcfaa9c8f247a26d1b8_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTc3MTc_e2981404-7aa0-4b43-a51f-c9d148bbf7a5"
      unitRef="number">0</gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage>
    <gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage
      contextRef="ic2061ba894de4be5b28c846ab2265609_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTc3MjQ_f61c17cc-7c10-494d-984a-3995117c58c2"
      unitRef="number">2</gild:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzQzOTgwNDY1NTg2MzU_2bf9c02f-5c0e-4eb1-8f4d-f6e2b5fa9069">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i580e59f939fd4c8388da4fdbdc6b58cb_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzc2OTY1ODE0NDY3ODQ_86c9649d-6372-424e-8e81-e9d596611be3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjI5MTk_230f9129-9f39-4f00-bdcf-592d65cbb901"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i03e3e50cbabd4bef8487336a456c1552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjI5MjM_a042383b-f17f-41fa-96df-59e1fb406c1d"
      unitRef="shares">79000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i03e3e50cbabd4bef8487336a456c1552_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjI5Mjc_89276b5f-c1b9-452f-bcf3-3c1e3baf8fef"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzEx_36a76df3-6a66-4ba7-a57f-d741e671ca8a">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize total stock-based compensation expense included on our Consolidated Statements of Income as broken down by award type and by expense type:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense included in total costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Accelerated post-acquisition stock-based compensation expense of $8 million related to the MiroBio acquisition in 2022, and $289 million and $144 million related to the acquisitions of Immunomedics and Forty Seven, respectively, in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense included in total costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzItMi0xLTEtMjM5MzQy_a72547b2-a26f-47a1-a6b2-7de22b45527c"
      unitRef="usd">557000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iba83b20f658a4a5b967cae95a8147d07_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzItNC0xLTEtMjM5MzQy_d1e7e64b-a1be-4a93-ada7-9e7016d6643c"
      unitRef="usd">558000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib3a53a5a5ed940069011952033f6937e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzItNi0xLTEtMjM5MzQy_e35afc95-28d5-4bb5-92ad-5d76eef648f5"
      unitRef="usd">546000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzMtMi0xLTEtMjM5MzQy_387d51ff-eaad-4e46-9319-7a62ad0648f7"
      unitRef="usd">25000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7e116706429d4b6489792bf2fee6c8ae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzMtNC0xLTEtMjM5MzQy_9a43c148-4779-452f-af7d-5853e832cff5"
      unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i13414ce25cbc42b98829371034442897_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzMtNi0xLTEtMjM5MzQy_67b450ec-b2ad-4368-a7c8-ef7d278a0336"
      unitRef="usd">25000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzQtMi0xLTEtMjQwMzIw_f4e40486-c9d8-40f9-8586-9671f85452c5"
      unitRef="usd">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzQtNC0xLTEtMjQwMzIw_80966f5f-8066-4f9b-8bad-62b44185d4fd"
      unitRef="usd">29000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzQtNi0xLTEtMjQwMzIw_958e19c6-2f90-4a7c-8025-82e2e92f265b"
      unitRef="usd">44000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzQtMi0xLTEtMjM5MzQy_250c5bf0-0c7f-4b0d-acb1-4bc9fa818923"
      unitRef="usd">26000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzQtNC0xLTEtMjM5MzQy_e4f14cdb-6881-4e65-a3a8-ac4a553a1674"
      unitRef="usd">31000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzQtNi0xLTEtMjM5MzQy_479c2e75-1728-482c-ae87-accb5a99cfe7"
      unitRef="usd">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib0fbfe8113ac4be684dbe7e6211e449f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzctMi0xLTEtMjQwMzIw_b2a90c57-1320-4b80-b349-ac58b336c532"
      unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icca0a85ac6724ad4a26ba8cfb7d3e7aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzctNC0xLTEtMjQwMzIw_d65f4274-9ac5-4cd9-945f-cc926997e4e9"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i71ed40d871ce41e2928bc9829eff5643_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzctNi0xLTEtMjQwMTMz_77222ffb-40e4-4fdf-b3b5-caa5f2ac2041"
      unitRef="usd">433000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzctMi0xLTEtMjM5MzQy_0f89a66a-e5a6-452e-8d8d-4d343d3617d6"
      unitRef="usd">645000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzctNC0xLTEtMjM5MzQy_2a2753b3-1123-4da1-b629-fefa411e92c3"
      unitRef="usd">635000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo0YTJmYzZmNTA2MjY0ZjcyOWViZmJlYTUwYmY3MWQxNC90YWJsZXJhbmdlOjRhMmZjNmY1MDYyNjRmNzI5ZWJmYmVhNTBiZjcxZDE0XzctNi0xLTEtMjM5MzQy_e7e08df8-6e01-45ba-82df-1db1b1db5785"
      unitRef="usd">1076000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib345f0317e14471c87be46037d1c42bd_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjU0OTU_10a56fec-6698-4af2-bb1e-d1be4765df8f"
      unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i09a809a0f4a64f36887c2d0d12f7975f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjI5Mzc_85d9c69a-20c5-4e31-be6e-651f68ea2c3a"
      unitRef="usd">289000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idb5b9f9fcb9e410b9600826b343149ed_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjI5NDU_b407976a-3b14-488a-94db-4d7e40ed8757"
      unitRef="usd">144000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3fd6c8b6cd2e488a9ef5cb0ed0ecd928_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzItMi0xLTEtMjM5Mjkz_d8f39057-d4a0-4a20-bd34-cfe02e27f547"
      unitRef="usd">46000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifec682fbc5e74d0b9bb6f5a57a44ba23_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzItNC0xLTEtMjM5Mjkz_19020b79-178b-422d-b8a8-231514b01a12"
      unitRef="usd">40000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i767c3be8d79f4a58b2e54e5310c7404a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzItNi0xLTEtMjM5Mjkz_adf39458-7083-4bb0-b4d2-ed9640e702e4"
      unitRef="usd">109000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5bf67c25be264122919d5db5b2238804_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzMtMi0xLTEtMjM5Mjkz_4da69965-f033-4fd8-8870-a761a4469a2f"
      unitRef="usd">285000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie6786edd5a2f463ba624fe8629254698_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzMtNC0xLTEtMjM5Mjkz_38364301-7a59-4328-b259-9903ca1b7ecc"
      unitRef="usd">287000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16f8cd4d572b4630890ba497cb7ba380_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzMtNi0xLTEtMjM5Mjkz_81150701-dcd0-4f45-920c-abee5ce436ed"
      unitRef="usd">462000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i91dd25449865431396ad590df47902c2_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzQtMi0xLTEtMjM5Mjkz_acb81c42-76b2-4ff1-a1ea-f55b3861f24a"
      unitRef="usd">313000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3d2e4dd234744ff0b8f9c4fbca89aac9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzQtNC0xLTEtMjM5Mjkz_1ee7c03c-bf22-4043-bf13-f07e7aa4f879"
      unitRef="usd">308000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i246e5be9df34403b970d76a795c2a09e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzQtNi0xLTEtMjM5Mjkz_72586197-b92b-4772-b04a-d21b7a8e3a6f"
      unitRef="usd">505000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzUtMi0xLTEtMjM5Mjkz_53ca98f8-a97b-4b2c-8e17-ca84ea8b1bad"
      unitRef="usd">645000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzUtNC0xLTEtMjM5Mjkz_e67ef0ed-05b8-4c75-a038-b818532a324c"
      unitRef="usd">635000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzUtNi0xLTEtMjM5Mjkz_53a012f6-14f4-46ff-a08f-afb75987f4aa"
      unitRef="usd">1076000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzYtMi0xLTEtMjM5Mjkz_9d67feae-9d63-4ae1-ae3c-69aa1a815aa1"
      unitRef="usd">91000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzYtNC0xLTEtMjM5Mjkz_1b19a728-1cd1-4727-84d2-36e4c8ed0b84"
      unitRef="usd">100000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzYtNi0xLTEtMjM5Mjkz_96ef1231-6237-4b01-9041-78bd34c66bd2"
      unitRef="usd">222000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzctMi0xLTEtMjM5Mjkz_732ad64a-fce7-4df9-883f-cc226cd92593"
      unitRef="usd">553000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzctNC0xLTEtMjM5Mjkz_95328e17-df5a-4f83-ae4b-f5c37795516c"
      unitRef="usd">535000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4NTJkZTk2MzNiYTA0YTk2OTA2ZGU3ZmMzYzA5YjVkYS90YWJsZXJhbmdlOjg1MmRlOTYzM2JhMDRhOTY5MDZkZTdmYzNjMDliNWRhXzctNi0xLTEtMjM5Mjkz_021fce42-8b35-4c11-b0b1-b0dfce30cc71"
      unitRef="usd">854000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzk4NjI_bde64c41-a633-456f-a378-af045435933f">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value of RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of RSUs as of the respective vesting dates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia54f00a060494b7e8284daf41bb9942f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzItMi0xLTEtMTY3NjY1_3be8081b-c39e-4fc7-a45b-52f3655acd8f"
      unitRef="shares">20900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia54f00a060494b7e8284daf41bb9942f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzItNC0xLTEtMTY3NjY1_de5b827b-cde3-4972-9223-cf912633e961"
      unitRef="usdPerShare">67.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzMtMi0xLTEtMTY3NjY1_9238844d-5b28-40ab-818f-01f85d945d30"
      unitRef="shares">13700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzMtNC0xLTEtMTY3NjY1_56ee7dde-5f83-4499-bd31-6ece39546ea4"
      unitRef="usdPerShare">60.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzQtMi0xLTEtMTY3NjY1_4c6bf93e-4dbb-40a0-9505-b80e5b727472"
      unitRef="shares">8900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzQtNC0xLTEtMTY3NjY1_617f04b9-7c9d-42e2-b733-63cd48e23e3f"
      unitRef="usdPerShare">67.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzUtMi0xLTEtMTY3NjY1_903ab704-6e87-49e1-a9b2-5b57ef688c8e"
      unitRef="shares">2200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzUtNC0xLTEtMTY3NjY1_f85086e6-27a6-4d8b-8228-e9347c6498b2"
      unitRef="usdPerShare">63.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i306251c6f0a34cecb6731b34d196923e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzYtMi0xLTEtMTY3NjY1_509e63be-3b6b-4a87-b763-80e086585017"
      unitRef="shares">23600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i306251c6f0a34cecb6731b34d196923e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo4YTU4OGY3YmI1Mjc0YjU3YTJkNjlhYzAyM2U2ODI1Ni90YWJsZXJhbmdlOjhhNTg4ZjdiYjUyNzRiNTdhMmQ2OWFjMDIzZTY4MjU2XzYtNC0xLTEtMTY3NjY1_b98d02e8-cb4d-4952-9b57-d52f7412fe50"
      unitRef="usdPerShare">63.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjYTczNDVlZTUxMDY0NmY3YWIxM2NlZDZkZWU1NzZkZC90YWJsZXJhbmdlOmNhNzM0NWVlNTEwNjQ2ZjdhYjEzY2VkNmRlZTU3NmRkXzItMi0xLTEtMjE1MjYw_09163fcf-2a5d-49f2-97a7-0b745e7ab153"
      unitRef="usdPerShare">60.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iba83b20f658a4a5b967cae95a8147d07_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjYTczNDVlZTUxMDY0NmY3YWIxM2NlZDZkZWU1NzZkZC90YWJsZXJhbmdlOmNhNzM0NWVlNTEwNjQ2ZjdhYjEzY2VkNmRlZTU3NmRkXzItNC0xLTEtMjE1MjYz_64006f07-3de4-45f1-8809-d88e272e1617"
      unitRef="usdPerShare">65.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib3a53a5a5ed940069011952033f6937e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjYTczNDVlZTUxMDY0NmY3YWIxM2NlZDZkZWU1NzZkZC90YWJsZXJhbmdlOmNhNzM0NWVlNTEwNjQ2ZjdhYjEzY2VkNmRlZTU3NmRkXzItNi0xLTEtMjE1MjY1_75b951f1-d7fd-4235-ad7f-0bb3c67a601a"
      unitRef="usdPerShare">70.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjYTczNDVlZTUxMDY0NmY3YWIxM2NlZDZkZWU1NzZkZC90YWJsZXJhbmdlOmNhNzM0NWVlNTEwNjQ2ZjdhYjEzY2VkNmRlZTU3NmRkXzUtMi0xLTEtMjE1Mjgz_dceb7ff3-28c0-466e-b079-6e62c23cf340"
      unitRef="usd">554000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iba83b20f658a4a5b967cae95a8147d07_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjYTczNDVlZTUxMDY0NmY3YWIxM2NlZDZkZWU1NzZkZC90YWJsZXJhbmdlOmNhNzM0NWVlNTEwNjQ2ZjdhYjEzY2VkNmRlZTU3NmRkXzUtNC0xLTEtMjE1Mjg1_cb0f7022-031a-4aff-afa2-23bd9c4a5ecf"
      unitRef="usd">463000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ib3a53a5a5ed940069011952033f6937e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjYTczNDVlZTUxMDY0NmY3YWIxM2NlZDZkZWU1NzZkZC90YWJsZXJhbmdlOmNhNzM0NWVlNTEwNjQ2ZjdhYjEzY2VkNmRlZTU3NmRkXzUtNi0xLTEtMjE1Mjg3_207bc713-a62c-4bb9-b639-ab98b6dd0178"
      unitRef="usd">444000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i306251c6f0a34cecb6731b34d196923e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjI5NjE_414f6d47-90bd-4c77-a21e-3ca2c2329f63"
      unitRef="usd">948000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzE2_c30983c4-86fa-4c3e-88b1-93747fd2ae7c">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzE0_d3265644-4351-4d60-9fab-084242a4052f">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our PSU activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:right"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value of PSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of PSUs as of the respective vesting dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ieb16b1a82cc04d97bc97982197e928b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzItNi0xLTEtMjM5NDI4_32bfcce5-cc29-4afb-b45c-b4aae540c703"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ieb16b1a82cc04d97bc97982197e928b8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzItOC0xLTEtMjM5NDI4_e3f84372-4b3e-45d1-a28f-ad20ca4d5a66"
      unitRef="usdPerShare">79.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzMtNi0xLTEtMjM5NDI4_21630d8d-7243-4410-85c3-fd9a405bdbdf"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzMtOC0xLTEtMjM5NDI4_97e02b44-97d9-4138-a03c-36e0101aab20"
      unitRef="usdPerShare">60.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzQtNi0xLTEtMjM5NDI4_d1568258-3df5-4163-bbbc-3b0d8480c13d"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzQtOC0xLTEtMjM5NDI4_b78b9876-ccb8-4dd6-84a6-bd300ad7f28a"
      unitRef="usdPerShare">68.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzUtNi0xLTEtMjM5NDI4_5b4d814c-21b0-47cf-83b6-837c0d14d1c8"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzUtOC0xLTEtMjM5NDI4_637cc218-2b40-4e06-9737-6355614d769c"
      unitRef="usdPerShare">59.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1b63e11ff4a246c388b2b8117a18b35f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzYtNi0xLTEtMjM5NDI4_bc2d3347-c7ce-4494-8bd2-fcab99751c84"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1b63e11ff4a246c388b2b8117a18b35f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2Nzk2ZDA5ZjY2MzM0ZWYyOWM3MmRhMmZmYmIyYWNjOC90YWJsZXJhbmdlOjY3OTZkMDlmNjYzMzRlZjI5YzcyZGEyZmZiYjJhY2M4XzYtOC0xLTEtMjM5NDI4_b9123ec4-1a24-4954-a711-e147afac8bd1"
      unitRef="usdPerShare">64.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZGQ3OTYwNmEwNWQ0ZDAyYmY1ZjUyMmVkZjYyZWJkNS90YWJsZXJhbmdlOjZkZDc5NjA2YTA1ZDRkMDJiZjVmNTIyZWRmNjJlYmQ1XzItMi0xLTEtMjM5NDI4_12148a14-da46-4125-b813-1c969d7db755"
      unitRef="usdPerShare">60.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7e116706429d4b6489792bf2fee6c8ae_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZGQ3OTYwNmEwNWQ0ZDAyYmY1ZjUyMmVkZjYyZWJkNS90YWJsZXJhbmdlOjZkZDc5NjA2YTA1ZDRkMDJiZjVmNTIyZWRmNjJlYmQ1XzItNC0xLTEtMjM5NDI4_d221c9e5-fdd0-4ca4-8320-f7109ab3f504"
      unitRef="usdPerShare">71.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i13414ce25cbc42b98829371034442897_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZGQ3OTYwNmEwNWQ0ZDAyYmY1ZjUyMmVkZjYyZWJkNS90YWJsZXJhbmdlOjZkZDc5NjA2YTA1ZDRkMDJiZjVmNTIyZWRmNjJlYmQ1XzItNi0xLTEtMjM5NDI4_71ff8f7a-d95f-49d6-a014-3f90a3693bae"
      unitRef="usdPerShare">83.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZGQ3OTYwNmEwNWQ0ZDAyYmY1ZjUyMmVkZjYyZWJkNS90YWJsZXJhbmdlOjZkZDc5NjA2YTA1ZDRkMDJiZjVmNTIyZWRmNjJlYmQ1XzUtMi0xLTEtMjM5NDI4_14dcfe21-37a9-4a25-b6f3-a0f11a1ebed5"
      unitRef="usd">14000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i7e116706429d4b6489792bf2fee6c8ae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZGQ3OTYwNmEwNWQ0ZDAyYmY1ZjUyMmVkZjYyZWJkNS90YWJsZXJhbmdlOjZkZDc5NjA2YTA1ZDRkMDJiZjVmNTIyZWRmNjJlYmQ1XzUtNC0xLTEtMjM5NDI4_8b9c13d4-1697-40bc-93f9-58eae68e37aa"
      unitRef="usd">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i13414ce25cbc42b98829371034442897_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZGQ3OTYwNmEwNWQ0ZDAyYmY1ZjUyMmVkZjYyZWJkNS90YWJsZXJhbmdlOjZkZDc5NjA2YTA1ZDRkMDJiZjVmNTIyZWRmNjJlYmQ1XzUtNi0xLTEtMjM5NDI4_acedcec5-6635-4752-8b36-9e0aad1b202f"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i1b63e11ff4a246c388b2b8117a18b35f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjMwMTE_8daab2f0-3f6a-4ccb-9f91-4cb232fa9fb3"
      unitRef="usd">29000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3309414c3d884642ba85e5b11341a37f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzE4_7bf48d29-e764-4e56-a5f4-6844bf244f42">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzIw_b2288ade-851f-4d59-9911-e3109505cf61">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize activity and other information related to our stock options: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;br/&gt;(in dollars)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest, net of estimated forfeitures as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Aggregate intrinsic value represents the value of our closing stock price on the last trading day of the year in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifd6b4cdafb5e493e8f88f2078b78eb38_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzEtMi0xLTEtMjM5Mzc5_0651d6d4-cbc6-4e00-96e7-cc044537eb7c"
      unitRef="shares">16800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ifd6b4cdafb5e493e8f88f2078b78eb38_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzEtNC0xLTEtMjM5Mzc5_c953e709-cf95-40c0-8764-0fbf3db91ed7"
      unitRef="usdPerShare">70.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzItMi0xLTEtMjM5Mzc5_9a7beb50-157a-4ee1-a3cf-593e175d2190"
      unitRef="shares">4100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzItNC0xLTEtMjM5Mzc5_69adfac8-cfb5-4095-8f28-b75f5fa23137"
      unitRef="usdPerShare">58.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzMtMi0xLTEtMjM5Mzc5_c7540644-2e1a-432b-8022-03dde59d29d4"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzMtNC0xLTEtMjM5Mzc5_2b4b02f0-8112-4b36-982b-bf3ea9ccfbd2"
      unitRef="usdPerShare">62.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzQtMi0xLTEtMjM5Mzc5_a971bf41-b2d6-49de-8ece-a88fd34105ee"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzQtNC0xLTEtMjM5Mzc5_915dcb68-6d01-440b-b728-f6f2772a58b9"
      unitRef="usdPerShare">82.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzUtMi0xLTEtMjM5Mzc5_6fefef9f-d46d-4391-b62b-43f31c909761"
      unitRef="shares">3500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzUtNC0xLTEtMjM5Mzc5_3a407e62-28a9-4e00-97d3-bdbbc2b0923b"
      unitRef="usdPerShare">61.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzYtMi0xLTEtMjM5Mzc5_32325902-e682-4daa-b882-46ea19a5c9a8"
      unitRef="shares">14400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzYtNC0xLTEtMjM5Mzc5_7cc3551c-1cc7-4409-8c0e-f65dd7193605"
      unitRef="usdPerShare">67.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzYtNi0xLTEtMjM5Mzc5_787826ad-5df6-41e5-ae1b-0516f554f8df">P6Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzYtOC0xLTEtMjM5Mzc5_020729cf-5a8c-49b2-bb2d-63addfcbffaa"
      unitRef="usd">271000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzctMi0xLTEtMjM5Mzc5_5140be8a-f985-4d71-8aa7-02dd45ae3864"
      unitRef="shares">7900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzctNC0xLTEtMjM5Mzc5_10190672-1c3c-4d8e-aa0d-34d665ef57a8"
      unitRef="usdPerShare">72.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzctNi0xLTEtMjM5Mzc5_2ba52ac1-da10-40a9-a7d8-0b87eb9f74f6">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzctOC0xLTEtMjM5Mzc5_f205603b-18c2-4ccf-bde6-111588dfc98c"
      unitRef="usd">115000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzgtMi0xLTEtMjM5Mzc5_beda5a71-1ae9-46a7-a8b7-b8229d4c3ded"
      unitRef="shares">6200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzgtNC0xLTEtMjM5Mzc5_d1f6b89d-4bcd-4b62-9c76-bf0fb4ff80ec"
      unitRef="usdPerShare">62.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzgtNi0xLTEtMjM5Mzc5_0647139e-87fd-4317-8f08-12c9dd03fd89">P8Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowZDBkYzEwMjUwZGU0YmJlOTE2OTIxODg3NzI4NjlhZC90YWJsZXJhbmdlOjBkMGRjMTAyNTBkZTRiYmU5MTY5MjE4ODc3Mjg2OWFkXzgtOC0xLTEtMjM5Mzc5_9ada1f80-3e90-4985-9244-03a1913417bc"
      unitRef="usd">146000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjZDMzNjJmNDljM2E0NmU1OTgzYmM2ZWVmYjhiYTk0OC90YWJsZXJhbmdlOmNkMzM2MmY0OWMzYTQ2ZTU5ODNiYzZlZWZiOGJhOTQ4XzItMi0xLTEtMjM5NTUz_ad11643a-7249-4b2b-a9e8-ebaad03d65b1"
      unitRef="usdPerShare">9.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjZDMzNjJmNDljM2E0NmU1OTgzYmM2ZWVmYjhiYTk0OC90YWJsZXJhbmdlOmNkMzM2MmY0OWMzYTQ2ZTU5ODNiYzZlZWZiOGJhOTQ4XzItNC0xLTEtMjM5NTUz_fdc56a93-381b-4bbd-9bfe-c960cc870d7b"
      unitRef="usdPerShare">10.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjZDMzNjJmNDljM2E0NmU1OTgzYmM2ZWVmYjhiYTk0OC90YWJsZXJhbmdlOmNkMzM2MmY0OWMzYTQ2ZTU5ODNiYzZlZWZiOGJhOTQ4XzItNi0xLTEtMjM5NTUz_015b9772-d75c-4af8-8a07-2f6fbf286b7c"
      unitRef="usdPerShare">11.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjZDMzNjJmNDljM2E0NmU1OTgzYmM2ZWVmYjhiYTk0OC90YWJsZXJhbmdlOmNkMzM2MmY0OWMzYTQ2ZTU5ODNiYzZlZWZiOGJhOTQ4XzMtMi0xLTEtMjM5NTYw_1e3eeedc-7275-46e3-b42d-858cfd3973c8"
      unitRef="usd">59000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjZDMzNjJmNDljM2E0NmU1OTgzYmM2ZWVmYjhiYTk0OC90YWJsZXJhbmdlOmNkMzM2MmY0OWMzYTQ2ZTU5ODNiYzZlZWZiOGJhOTQ4XzMtNC0xLTEtMjM5NTYw_d80166ed-214c-41de-820e-319f23195a62"
      unitRef="usd">48000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTpjZDMzNjJmNDljM2E0NmU1OTgzYmM2ZWVmYjhiYTk0OC90YWJsZXJhbmdlOmNkMzM2MmY0OWMzYTQ2ZTU5ODNiYzZlZWZiOGJhOTQ4XzMtNi0xLTEtMjM5NTYw_358d5a22-0139-4c4f-abac-1eae6f074c7a"
      unitRef="usd">179000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <gild:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzIx_48c3017c-7695-433c-a031-db363c1faa32">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the stock option awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected terms in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used the following weighted-average assumptions in the Black-Scholes model to calculate the estimated fair value of the ESPP awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected terms in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gild:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzItMi0xLTEtMjM5NjEy_e1631257-6a37-4014-ac6e-d0f8e07df21b"
      unitRef="number">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzItNC0xLTEtMjM5NjEy_8dcab7b0-e229-4625-8fba-b9aaa7ebe821"
      unitRef="number">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzItNi0xLTEtMjM5NjEy_58b4b5f2-03f4-403c-99a4-f0479a48b170"
      unitRef="number">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzMtMi0xLTEtMjM5NjE2_2b741f4d-462e-49d3-8ffc-2f9041e3fcfd">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzMtNC0xLTEtMjM5NjE2_a8176ef9-fa38-4cc8-a588-8ffe86e8e10f">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzMtNi0xLTEtMjM5NjE2_9e0a9ae0-83d2-4371-87ae-b8ab62ed8941">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzQtMi0xLTEtMjQwMjMz_69b9eae6-2e35-4fda-8a49-066394104657"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzQtNC0xLTEtMjQwMjMz_e5f7c432-8c22-401e-86d3-456fd7c698fa"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzQtNi0xLTEtMjQwMjMz_32472b5b-12c3-4c1e-8e7c-b7a0e4cb5318"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzUtMi0xLTEtMjM5NjIy_57bfc228-48ef-4ffb-8000-078f7cfa3ffc"
      unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i263a55ae9f204f7c9c63fbda8803d5a0_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzUtNC0xLTEtMjM5NjIy_dcf3bade-7977-4170-b438-6e51f9c04a95"
      unitRef="number">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3f7fc90707144498b3995178ebc2d42f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTowYTU0MmNiMTEzMjQ0YmEzYmY4NmE1ZTE0OTdmMTZiNS90YWJsZXJhbmdlOjBhNTQyY2IxMTMyNDRiYTNiZjg2YTVlMTQ5N2YxNmI1XzUtNi0xLTEtMjM5NjIy_492516cf-49ac-42c2-b792-5d04f8ca1f81"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i05562b0ef6074645bd6d203b69cd9fe7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjMwNzY_cf398a68-886d-48ed-ba80-ed13887bd1b5"
      unitRef="usd">48000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzMTk0MTM5NTcwNzIy_6f85888f-045a-400e-ba55-6a42942e5088">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEzNzQzODk1Mzg0NjEx_226e7cea-c25b-4907-b4b2-91d0af926040">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our ESPP activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount paid by employees for shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value of ESPP shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of ESPP shares as of the respective vesting dates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzItMi0xLTEtMjY1ODQz_155f421a-a132-430b-a80e-f9675060743d"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzItNC0xLTEtMjY3MzI3_5d8236be-961d-44dd-b389-c81bd0a92413"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzItNi0xLTEtMjY3MzI3_ff0b1e1c-da25-47d3-9e94-3ea5a6addb83"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzMtMi0xLTEtMjY1ODQ2_780dd00c-22e8-4313-8bbc-0501b1044532"
      unitRef="usd">103000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzMtNC0xLTEtMjY3MzI3_7456b5e9-d9bc-49d2-a44e-09765d43df18"
      unitRef="usd">111000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzMtNi0xLTEtMjY3MzI3_f1cb300f-b03a-444e-a65d-345e99345ae0"
      unitRef="usd">100000000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <gild:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare
      contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzItMi0xLTEtMjM5ODAy_ef855703-1601-44c3-8053-6eda1a4a5295"
      unitRef="usdPerShare">13.40</gild:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare>
    <gild:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare
      contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzItNC0xLTEtMjM5ODAy_2201f8d6-14ba-4210-98ba-ed7b71175735"
      unitRef="usdPerShare">14.58</gild:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare>
    <gild:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare
      contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzItNi0xLTEtMjM5ODAy_0d348dfb-75ce-4bc3-b744-a505815e4367"
      unitRef="usdPerShare">15.09</gild:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzMtMi0xLTEtMjM5ODAy_7fda62be-b9bb-4ba0-8ae5-8edbf5a3a755"
      unitRef="usd">21000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzMtNC0xLTEtMjM5ODAy_ad2f273a-85c0-4865-bd8d-4381e3fee584"
      unitRef="usd">23000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo2ZjlhM2ZlNTUwZWQ0NzgwODJkMjE2NGZmYzk1NzIwZS90YWJsZXJhbmdlOjZmOWEzZmU1NTBlZDQ3ODA4MmQyMTY0ZmZjOTU3MjBlXzMtNi0xLTEtMjM5ODAy_a456634f-6b84-4884-abbf-9e3b0f16b75d"
      unitRef="usd">24000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzQtMi0xLTEtMTY3NjY1_8dbbd317-b162-42df-a189-60b13c98b61b"
      unitRef="number">0.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzQtNC0xLTEtMTY3NjY1_6f73cbea-cf4d-4adb-a12c-baff4faae1d5"
      unitRef="number">0.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzQtNi0xLTEtMTY3NjY1_33525411-aa05-4411-b785-6144f09c4eb3"
      unitRef="number">0.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzctMi0xLTEtMTY3NjY1_31d48970-54e5-47f1-8ef3-54ff3cc60580">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzctNC0xLTEtMTY3NjY1_6a7f5040-6d99-47b7-b3a8-d22fd423eb70">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzctNi0xLTEtMTY3NjY1_f2d7de4b-a248-450e-a43b-1c9397fb3957">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzEwLTItMS0xLTE2NzY2NQ_d3fa5ecf-936f-48ce-9c7c-ddbfb53221e4"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzEwLTQtMS0xLTE2NzY2NQ_1a87762f-9606-49a6-b7db-62f224d5e348"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzEwLTYtMS0xLTE2NzY2NQ_cfb00a5f-79d5-4168-95a5-94d9e9e8b01e"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzExLTItMS0xLTE2NzY2NQ_3f0cd206-2d67-4816-b934-451c55b99ad2"
      unitRef="number">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5a3bcf261b6340a0bb9bcf41631899a6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzExLTQtMS0xLTE2NzY2NQ_b3c67694-79a9-45f7-b578-c71434db7696"
      unitRef="number">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9ab0b3a2f0804372984fc607e6a270b6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90YWJsZTo5YTE4Njc2NzBmMWE0ZTY2OWY5MGRiNTkxNTAzNDc4Zi90YWJsZXJhbmdlOjlhMTg2NzY3MGYxYTRlNjY5ZjkwZGI1OTE1MDM0NzhmXzExLTYtMS0xLTE2NzY2NQ_65c4ee6f-1e0c-4501-89aa-c7454317ecc9"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjMxMTU_a60ac989-9d8b-45b6-9f05-861457c2ad98"
      unitRef="usd">176000000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjMxMjM_f924cce1-237d-4097-955c-2ce60fb9cfd0"
      unitRef="usd">166000000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjMxMzA_488eceda-73d1-4ea1-83d1-4609a2eee5e4"
      unitRef="usd">144000000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0e2b914d4ec74b7d9487a6f371a25de3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzU0OTc1NTg1MTMwNQ_e0294ed2-1056-43b1-957f-a901ecb21b16"
      unitRef="usd">220000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idf9a3708d6b74d5eb87c245216002834_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzYvZnJhZzoxODQ1NDY1ZDc4NGQ0ZTlkYjE1ZjlmM2RiNjg0Y2I3ZC90ZXh0cmVnaW9uOjE4NDU0NjVkNzg0ZDRlOWRiMTVmOWYzZGI2ODRjYjdkXzEwOTk1MTE2NjMxNDU_26e7775e-f310-437f-8fdc-51fbb76fdbe2"
      unitRef="usd">261000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90ZXh0cmVnaW9uOmYxYWU1YTkwZThiMDRiMjVhNGQ5MDE1ZTY5MDk5MzNhXzk3Mg_543be3c0-d332-4685-973a-bfcfbe7b3678">EARNINGS PER SHARE&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculation of basic and diluted earnings per share attributable to Gilead:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in basic earnings per share attributable to Gilead calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in diluted earnings per share attributable to Gilead calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential shares of common stock excluded from the computation of Diluted earnings per share attributable to Gilead because their effect would have been antidilutive were 12 million, 15 million and 13 million during 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90ZXh0cmVnaW9uOmYxYWU1YTkwZThiMDRiMjVhNGQ5MDE1ZTY5MDk5MzNhXzk2Nw_d05e62fb-541c-4773-bdd7-b3c1cded8113">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the calculation of basic and diluted earnings per share attributable to Gilead:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in basic earnings per share attributable to Gilead calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of stock options and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used in diluted earnings per share attributable to Gilead calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Gilead&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzItMi0xLTEtMTY3NjY1_3e38e7a0-6350-49f1-85bc-192612afa8c5"
      unitRef="usd">4592000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzItNC0xLTEtMTY3NjY1_a0686f75-0cad-48e9-a6ca-34e5b986760b"
      unitRef="usd">6225000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzItNi0xLTEtMTY3NjY1_c1438e93-8449-4b55-93ad-04d196782bd4"
      unitRef="usd">123000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzMtMi0xLTEtMTY3NjY1_cba4dff9-cd21-45d1-9fbc-05899c037b86"
      unitRef="shares">1255000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzMtNC0xLTEtMTY3NjY1_ae2aee9e-3715-4661-98d8-a5ddeba71880"
      unitRef="shares">1256000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzMtNi0xLTEtMTY3NjY1_d40dfe23-3dc3-4837-b05b-d98e4b90c858"
      unitRef="shares">1257000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzQtMi0xLTEtMTY3NjY1_39cddccc-2877-4f52-8388-941ec701097e"
      unitRef="shares">7000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzQtNC0xLTEtMTY3NjY1_6d454dfd-438f-4b36-8c8e-cba3d5d04bf2"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzQtNi0xLTEtMTY3NjY1_a481d49b-1380-495e-83f0-24b820b1058c"
      unitRef="shares">6000000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzUtMi0xLTEtMTY3NjY1_c1b066c8-e937-4723-97d8-c24b6a08c0b2"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzUtNC0xLTEtMTY3NjY1_0f82b954-a474-4676-b096-7a775f06e778"
      unitRef="shares">1262000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzUtNi0xLTEtMTY3NjY1_e7d47d8a-838d-44f8-9320-53bd24569d57"
      unitRef="shares">1263000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzYtMi0xLTEtMTY3NjY1_7810b9a5-71be-4f17-996f-e950fe61dc78"
      unitRef="usdPerShare">3.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzYtNC0xLTEtMTY3NjY1_d5333cdc-162c-4949-9b0d-615ec673b2e6"
      unitRef="usdPerShare">4.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzYtNi0xLTEtMTY3NjY1_9a03820a-297b-42d3-96ec-d80dc93c2475"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzctMi0xLTEtMTY3NjY1_5110ccb8-7038-4d12-bc10-9526946bd1ce"
      unitRef="usdPerShare">3.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzctNC0xLTEtMTY3NjY1_2df4161e-f717-40fb-81fa-8656d0a4f2e3"
      unitRef="usdPerShare">4.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90YWJsZTo2YzIxNDVjMzQ2YjE0MzYzYjhjYWU2ZDhiZmQ0YWVmYy90YWJsZXJhbmdlOjZjMjE0NWMzNDZiMTQzNjNiOGNhZTZkOGJmZDRhZWZjXzctNi0xLTEtMTY3NjY1_d13b1542-1bd1-402c-b561-ed2fdc44a253"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90ZXh0cmVnaW9uOmYxYWU1YTkwZThiMDRiMjVhNGQ5MDE1ZTY5MDk5MzNhXzEwOTk1MTE2Mjk1Njk_d4211531-ec92-4ac6-9296-725a870be9f1"
      unitRef="shares">12000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90ZXh0cmVnaW9uOmYxYWU1YTkwZThiMDRiMjVhNGQ5MDE1ZTY5MDk5MzNhXzEwOTk1MTE2Mjk1NzU_b32dc9ac-f2dd-4d46-925d-55d093b88852"
      unitRef="shares">15000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xMzkvZnJhZzpmMWFlNWE5MGU4YjA0YjI1YTRkOTAxNWU2OTA5OTMzYS90ZXh0cmVnaW9uOmYxYWU1YTkwZThiMDRiMjVhNGQ5MDE1ZTY5MDk5MzNhXzEwOTk1MTE2Mjk1ODM_5734d427-32a4-453f-bb50-86bb86196331"
      unitRef="shares">13000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQ3MTM_2318eef3-bdf6-4ae3-be3d-75c4e47087c4">INCOME TAXES&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the federal statutory tax rate applied to Income before income taxes and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings at different rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US tax on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement of tax examinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D &amp;amp; related charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-taxable unrealized loss on investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves and accruals not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess of tax basis over book basis of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront and milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess of book basis over tax basis of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance increased from $520 million as of December&#160;31, 2021 to $599 million as of December&#160;31, 2022, primarily due to unrealized losses on our equity investments which are subject to a full valuation allowance, and increased from $398 million as of December&#160;31, 2020 to $520 million as of December&#160;31, 2021, primarily due to California research and development tax credits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we had U.S. federal net operating loss and tax credit carryforwards of approximately $199 million and $7 million, respectively, which will start to expire in 2023, if not utilized. In addition, we had state net operating loss and tax credit carryforwards of approximately $2.7 billion and $879 million, respectively, which will start to expire in 2024 and 2023, respectively, if not utilized. Utilization of net operating losses and tax credits may be subject to an annual limitation due to ownership change limitations provided in the Internal Revenue Code of 1986, as amended, and similar state provisions. This annual limitation may result in the expiration of the net operating losses and credits before utilization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file federal, state and foreign income tax returns in the U.S. and in many foreign jurisdictions. For federal income tax purposes, the statute of limitations is open for 2016 and onwards and 2013 and onwards for California income tax purposes. For certain acquired entities, the statute of limitations is open for all years from inception due to our utilization of their net operating losses and credits carried over from prior years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax returns are subject to audit by federal, state and foreign tax authorities. We are currently under examination by the Internal Revenue Service and Irish tax authorities for our 2016 to 2018 tax years. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We periodically evaluate our exposures associated with our tax filing positions.&lt;/span&gt;&lt;span style="color:#acacac;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the total unrecognized tax benefits, $946 million and $800 million as of December&#160;31, 2022 and 2021, respectively, if recognized, would reduce our effective tax rate in the period of recognition. Interest and penalties related to unrecognized tax benefits included income tax benefit of $3 million, income tax expense of $41 million and income tax benefit of $82 million on our Consolidated Statements of Income for the years ended December&#160;31, 2022, 2021 and 2020 respectively. Accrued interest and penalties related to unrecognized tax benefits were $215 million and $218 million as of December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022, we do not believe that it is reasonably possible that our unrecognized tax benefits will significantly change in the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a rollforward of our total gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to current year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to prior years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Tax Cuts and Jobs Act, we recorded a federal income tax payable for transition tax on the mandatory deemed repatriation of foreign earnings that is payable over an eight-year period. Federal income tax payable for transition tax was $3.5 billion and $4.0 billion as of December&#160;31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the anticipated timing of payments associated with this transition tax as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQ3MTY_b7003666-2ed9-4d9b-aa11-0fef31702b49">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzItMi0xLTEtMTY3NjY1_adf8e152-d033-4865-b312-2fff51891c3d"
      unitRef="usd">4439000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzItNC0xLTEtMTY3NjY1_74364703-07de-4393-889d-1418142b63e9"
      unitRef="usd">8587000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzItNi0xLTEtMTY3NjY1_ca23e288-2561-4621-87ee-33395ec6ee20"
      unitRef="usd">2505000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzMtMi0xLTEtMTY3NjY1_c6675add-9d9d-4417-9c38-66ec901e8cf8"
      unitRef="usd">1375000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzMtNC0xLTEtMTY3NjY1_61e270ec-abd8-4e15-a179-ddcac67e6d42"
      unitRef="usd">-309000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzMtNi0xLTEtMTY3NjY1_eec28579-b72e-4c01-89f0-4dae5a04f7f9"
      unitRef="usd">-836000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzQtMi0xLTEtMTY3NjY1_e6737d8e-1310-4782-8e01-43bd0e158f09"
      unitRef="usd">5814000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzQtNC0xLTEtMTY3NjY1_ba72beca-6a3d-40a5-80ea-2b75bbc084f4"
      unitRef="usd">8278000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTphMzllZGI0YmUyYmE0MjQ3YTkyMjRjNmQ5MThmMmZhMS90YWJsZXJhbmdlOmEzOWVkYjRiZTJiYTQyNDdhOTIyNGM2ZDkxOGYyZmExXzQtNi0xLTEtMTY3NjY1_c11e8300-a2cf-400f-9ceb-0cc7836d7d9f"
      unitRef="usd">1669000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQ2OTQ_6ecee9e3-40bb-4e47-a764-f9350f721372">&lt;div style="margin-top:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,539)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzMtMi0xLTEtMTY3NjY1_a99a1184-d0dd-454e-9f70-320cd938bce7"
      unitRef="usd">2539000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzMtNC0xLTEtMTY3NjY1_90250e3d-6d92-43ba-9530-d79edb586ad1"
      unitRef="usd">1776000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzMtNi0xLTEtMTY3NjY1_53051f67-eb03-4c8a-9464-51c7dc1b2eae"
      unitRef="usd">1450000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzQtMi0xLTEtMTY3NjY1_3993bd51-662c-4c73-ba41-2a8048ba93f1"
      unitRef="usd">-1502000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzQtNC0xLTEtMTY3NjY1_afaaddeb-8e28-4226-9aa6-5b93fe4c3b88"
      unitRef="usd">-250000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzQtNi0xLTEtMTY3NjY1_8e9ccbe2-8e41-447d-890f-057803e1eea0"
      unitRef="usd">-164000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzUtMi0xLTEtMTY3NjY1_293498c9-b41e-45fd-ac00-d9cc53615f1f"
      unitRef="usd">1037000000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzUtNC0xLTEtMTY3NjY1_ec092d55-d2b6-4397-8855-6d9419e03173"
      unitRef="usd">1526000000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzUtNi0xLTEtMTY3NjY1_459aa33e-aec0-4ec2-a193-191b33c40011"
      unitRef="usd">1286000000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzctMi0xLTEtMTY3NjY1_0ac1e851-6852-48a6-9d8d-7ae95818e135"
      unitRef="usd">32000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzctNC0xLTEtMTY3NjY1_affc473d-f922-4a9f-9524-e300715c5238"
      unitRef="usd">228000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzctNi0xLTEtMTY3NjY1_f18309e3-c43b-4194-bc8d-3425754648e2"
      unitRef="usd">198000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzgtMi0xLTEtMTY3NjY1_4eb1babd-30c5-4008-bece-dfda66b4bd39"
      unitRef="usd">-154000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzgtNC0xLTEtMTY3NjY1_aa7a204f-8c34-4bbd-8b1a-cf90bc2d0d66"
      unitRef="usd">185000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzgtNi0xLTEtMTY3NjY1_f3416cf6-5927-4b08-89f6-f163eca7a584"
      unitRef="usd">-97000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzktMi0xLTEtMTY3NjY1_b7a9430f-ccca-4dfa-afa5-29ba62650dc0"
      unitRef="usd">-122000000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzktNC0xLTEtMTY3NjY1_fb449a86-9476-430d-a37e-0ef38bee24c8"
      unitRef="usd">413000000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzktNi0xLTEtMTY3NjY1_c904a6c1-f803-4b7e-bb76-239548237ef6"
      unitRef="usd">101000000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzExLTItMS0xLTE2NzY2NQ_664a2267-c9aa-49d4-aeec-43955b468290"
      unitRef="usd">232000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzExLTQtMS0xLTE2NzY2NQ_9af2dbf9-4e4d-4ece-a349-306f24f3490a"
      unitRef="usd">185000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzExLTYtMS0xLTE2NzY2NQ_e678655e-8dc7-4be7-bebe-fe4233774fa5"
      unitRef="usd">155000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzEyLTItMS0xLTE2NzY2NQ_8d16b6c4-6f9d-4cf6-a0dd-99d7fb80cccd"
      unitRef="usd">101000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzEyLTQtMS0xLTE2NzY2NQ_cc7f2d88-ade8-4e7b-9fc7-ac0f34c70575"
      unitRef="usd">-47000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzEyLTYtMS0xLTE2NzY2NQ_cdb50c1d-1e32-4a45-938a-5ae0034c7c7b"
      unitRef="usd">38000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzEzLTItMS0xLTE2NzY2NQ_cb3ed1fc-5d10-40b8-9631-ed34f3c0d806"
      unitRef="usd">333000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzEzLTQtMS0xLTE2NzY2NQ_44faf781-6fa6-458f-8434-32d083768fed"
      unitRef="usd">138000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzEzLTYtMS0xLTE2NzY2NQ_aea4da12-1802-4427-b3e7-bfcb9392c0e2"
      unitRef="usd">193000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzE0LTItMS0xLTE2NzY2NQ_07e0beb2-a2c5-4618-8006-865b7419f982"
      unitRef="usd">1248000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzE0LTQtMS0xLTE2NzY2NQ_9e6d2583-d8e5-4124-bdc0-831624a4be9d"
      unitRef="usd">2077000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxNGI0MmZjN2VlNzc0OGU5ODQxZWIwZjdkNThmOTE5MS90YWJsZXJhbmdlOjE0YjQyZmM3ZWU3NzQ4ZTk4NDFlYjBmN2Q1OGY5MTkxXzE0LTYtMS0xLTE2NzY2NQ_7e52b9ed-e72a-4799-a7e3-63673ba90a89"
      unitRef="usd">1580000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQ3MTQ_9631442b-78d2-40ce-b27f-8ad61172c918">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the federal statutory tax rate applied to Income before income taxes and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings at different rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US tax on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlement of tax examinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D &amp;amp; related charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-taxable unrealized loss on investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzItMi0xLTEtMTY3NjY1_a761d3bb-4899-41e5-b136-b5be4e592bc0"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzItNC0xLTEtMTY3NjY1_d2f0cb54-7874-4207-9bda-bf06e5e7502c"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzItNi0xLTEtMTY3NjY1_577aefa7-7d55-436f-a7b6-cf631b736c59"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzMtMi0xLTEtMTY3NjY1_5c23c934-d516-4322-adea-48dd3ac122eb"
      unitRef="number">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzMtNC0xLTEtMTY3NjY1_027f8fc8-0b2c-4517-bb62-c055bb7aa255"
      unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzMtNi0xLTEtMTY3NjY1_588c5747-7ed7-4b4d-99d3-28aa06ec2691"
      unitRef="number">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzQtMi0xLTEtMTY3NjY1_dd588e1b-6c3c-47e5-8c0c-13e04fbb3822"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzQtNC0xLTEtMTY3NjY1_eed6c81e-8116-4323-9b12-dcda7a436172"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzQtNi0xLTEtMTY3NjY1_3e653599-0ece-49d7-85b0-ffd3e8d16a2e"
      unitRef="number">-0.100</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzUtMi0xLTEtMTY3NjY1_2eaee813-9acf-43ed-9938-7e285540ed24"
      unitRef="number">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzUtNC0xLTEtMTY3NjY1_c5aa1cb0-ebe0-4dc7-aa94-efed3fac136d"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzUtNi0xLTEtMTY3NjY1_5e00f817-a8e4-4196-8899-f904b1bb27fe"
      unitRef="number">0.069</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzYtMi0xLTEtMTY3NjY1_ba0becb2-9e0a-42a5-88cd-3b9e154ed9f3"
      unitRef="number">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzYtNC0xLTEtMTY3NjY1_850417bd-1a8d-4170-916a-1be0743ffbce"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzYtNi0xLTEtMTY3NjY1_63233ae3-2cda-4f60-ac41-d61371f0466c"
      unitRef="number">0.072</us-gaap:EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzctMi0xLTEtMTY3NjY1_5b79de84-ae03-4651-aee1-070c29284ea3"
      unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzctNC0xLTEtMTY3NjY1_14420dd9-4c6f-48a3-b5b7-dbd7085ca803"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzctNi0xLTEtMTY3NjY1_4ea32d71-7f38-4588-b5ba-457c10ccab99"
      unitRef="number">0.080</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzktMi0xLTEtMTY3NjY1_1ebe54c0-897a-4570-99d3-cefc454c2e49"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzktNC0xLTEtMTY3NjY1_265b52a5-2dae-49c3-a829-4582e4dc142b"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzktNi0xLTEtMTY3NjY1_bcad329e-4ab1-45a1-ad89-1dda15fda518"
      unitRef="number">-0.102</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEwLTItMS0xLTE2NzY2NQ_71ebf9b3-bd29-496b-86b9-5cf3f99e4434"
      unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEwLTQtMS0xLTE2NzY2NQ_1aadff04-3c8b-48f8-b542-61847536cd93"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEwLTYtMS0xLTE2NzY2NQ_4d764d3e-3011-4789-815c-f1f4b044ff66"
      unitRef="number">0.562</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzExLTItMS0xLTE2NzY2NQ_e1b7339f-b9e9-466f-a584-f6f09be23f79"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzExLTQtMS0xLTE2NzY2NQ_fe4191df-484d-44e2-8350-d696f4a0ea39"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzExLTYtMS0xLTE2NzY2NQ_e213c275-ba53-4619-b748-d6d310353bba"
      unitRef="number">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEyLTItMS0xLTE2NzY2NQ_3816604a-fad2-4ec8-9a90-35f1f9325c9b"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEyLTQtMS0xLTE2NzY2NQ_27fbf2e4-a5ec-4001-8575-9df8185e6c17"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEyLTYtMS0xLTE2NzY2NQ_e1e44706-a070-4577-93e0-e399e831e4ba"
      unitRef="number">-0.230</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEzLTItMS0xLTE2NzY2NQ_01c91d4b-3d4c-4296-9d19-426d93cb8b1d"
      unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEzLTQtMS0xLTE2NzY2NQ_c69e9a5d-e478-48c4-a5f8-79b5589240fa"
      unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzEzLTYtMS0xLTE2NzY2NQ_02e22243-7eb2-4b32-9210-2b874bb1c1f4"
      unitRef="number">0.115</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzE0LTItMS0xLTE2NzY2NQ_50905175-fbe0-48c0-99c5-8a387997fd27"
      unitRef="number">0.215</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzE0LTQtMS0xLTE2NzY2NQ_d17a057c-e1f3-41a6-b45d-234556455e3e"
      unitRef="number">0.251</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToyMTdhOTJhMDg1NTA0Mzg5YmYxMDBjOWMxOGIwNjAwYi90YWJsZXJhbmdlOjIxN2E5MmEwODU1MDQzODliZjEwMGM5YzE4YjA2MDBiXzE0LTYtMS0xLTE2NzY2NQ_7ad47998-30eb-4afd-b17e-b3ab9ca5bc0f"
      unitRef="number">0.947</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQ2OTM_453c2481-d7fc-4e0d-9b23-2dd16fdb94c4">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves and accruals not currently deductible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess of tax basis over book basis of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront and milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and other credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability related to sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess of book basis over tax basis of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzMtMi0xLTEtMTY3NjY1_82d51e21-bd46-47b2-a2be-8362725cfbf8"
      unitRef="usd">430000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzMtNC0xLTEtMTY3NjY1_a1bf8e1b-3ff8-4f04-afc0-8842787af418"
      unitRef="usd">413000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzQtMi0xLTEtMTY3NjY1_956c8660-de8e-4e82-9a89-e64e33f3edb2"
      unitRef="usd">95000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzQtNC0xLTEtMTY3NjY1_bcd16378-3b61-4d49-93ad-fa6fae5d4b1b"
      unitRef="usd">117000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzUtMi0xLTEtMTY3NjY1_48f3f308-13fa-4949-ac31-aecf00c131c2"
      unitRef="usd">645000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzUtNC0xLTEtMTY3NjY1_8c82bce7-eacc-40b6-b269-348e89f84cb2"
      unitRef="usd">700000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzYtMi0xLTEtMTY3NjY1_91c082ba-63d1-43dc-9d60-c760104cb122"
      unitRef="usd">1067000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzYtNC0xLTEtMTY3NjY1_e4abcb7e-cbbf-4832-859d-155c5a05b9c3"
      unitRef="usd">1157000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <gild:DeferredTaxAssetsUpfrontAndMilestonePayments
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzctMi0xLTEtMTY3NjY1_a616c696-7311-4da8-9b5d-72332d55d512"
      unitRef="usd">1298000000</gild:DeferredTaxAssetsUpfrontAndMilestonePayments>
    <gild:DeferredTaxAssetsUpfrontAndMilestonePayments
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzctNC0xLTEtMTY3NjY1_b7ce6042-4ec1-4f3e-9250-33e67cc19dcb"
      unitRef="usd">1310000000</gild:DeferredTaxAssetsUpfrontAndMilestonePayments>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzgtMi0xLTEtMTY3NjY1_556075a1-14ca-40c8-ad0e-f6c5f4a47a1a"
      unitRef="usd">233000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzgtNC0xLTEtMTY3NjY1_1fca0b37-876d-40cf-991c-ce312560a2ef"
      unitRef="usd">249000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzktMi0xLTEtMTY3NjY1_ae4d3cfa-7d4c-4fed-b061-c4729cff8f23"
      unitRef="usd">196000000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzktNC0xLTEtMTY3NjY1_e41c303e-fc89-4c94-81f9-fe30106c6a0e"
      unitRef="usd">129000000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzEwLTItMS0xLTE2NzY2NQ_a109fd9b-198b-4218-bb1f-91384b86ad26"
      unitRef="usd">278000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzEwLTQtMS0xLTE2NzY2NQ_20b25271-e47d-450a-8b76-b0d5df9e757e"
      unitRef="usd">274000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzExLTItMS0xLTI1NDA0MA_a13288eb-8388-4a4d-b38b-182ccf6c3db5"
      unitRef="usd">784000000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzExLTQtMS0xLTI1NDIzNA_1b6b9ffe-c3e1-406d-b950-8c0c7e9468a8"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzExLTItMS0xLTE2NzY2NQ_cad6b4a9-0c88-417a-9ff3-841c90d40ac1"
      unitRef="usd">263000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzExLTQtMS0xLTE2NzY2NQ_0a6e0e6b-c587-44a4-baec-8e839374adc0"
      unitRef="usd">292000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzEyLTItMS0xLTE2NzY2NQ_e53361b8-e94a-4bb6-a2e6-c4194343060d"
      unitRef="usd">5289000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzEyLTQtMS0xLTE2NzY2NQ_ea28c1c8-acf3-4b91-8c78-fe2b3c5e13e2"
      unitRef="usd">4641000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzEzLTItMS0xLTE2NzY2NQ_e179e3c3-4ac3-4fa3-92f9-b72d6f422861"
      unitRef="usd">599000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzEzLTQtMS0xLTE2NzY2NQ_c24247b9-d402-4c6d-a1a4-6053fe93207f"
      unitRef="usd">520000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE0LTItMS0xLTE2NzY2NQ_54031278-7285-4bc8-93ca-f1d698ce9b59"
      unitRef="usd">4690000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE0LTQtMS0xLTE2NzY2NQ_87ccb388-c70f-4be0-a81a-a4e9bd9bda46"
      unitRef="usd">4121000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE2LTItMS0xLTE2NzY2NQ_8bdb572b-a8ca-442f-9359-e031d00013be"
      unitRef="usd">234000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE2LTQtMS0xLTE2NzY2NQ_527c4b96-4614-43ae-bc89-165be4f2193d"
      unitRef="usd">227000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE3LTItMS0xLTE2NzY2NQ_f15b523f-7e9d-4e49-84af-a82d68275100"
      unitRef="usd">5728000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE3LTQtMS0xLTE2NzY2NQ_c549de3d-7a98-4a0e-82e0-d31be852e1dc"
      unitRef="usd">6719000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE4LTItMS0xLTE2NzY2NQ_d96ed39f-615c-4e66-93d8-44021600f470"
      unitRef="usd">160000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE4LTQtMS0xLTE2NzY2NQ_97130312-2a0f-45c7-9d6d-1489ec520da9"
      unitRef="usd">192000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE5LTItMS0xLTE2NzY2NQ_eac2143a-8cf5-4e60-a38a-9802effd8002"
      unitRef="usd">6122000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzE5LTQtMS0xLTE2NzY2NQ_a24ea961-2e7d-4c88-a6d9-fab628c372e2"
      unitRef="usd">7138000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzIwLTItMS0xLTE2NzY2NQ_96429529-b4b5-4946-8933-700f04d7baef"
      unitRef="usd">1432000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZToxYzI5ZTIyOWE2ZTU0MTU4OWFlZTRkYTRmNGMwMjQzNi90YWJsZXJhbmdlOjFjMjllMjI5YTZlNTQxNTg5YWVlNGRhNGY0YzAyNDM2XzIwLTQtMS0xLTE2NzY2NQ_4b599afb-d8b5-4fcb-a905-6ee5e2ca3b55"
      unitRef="usd">3017000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzU0OTc1NTgxNTMzODY_63b0e600-5e40-4b4d-9925-f11e0a31a579"
      unitRef="usd">520000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1ODU_b088dbb4-fbb3-4ef9-add6-aa000bd92bc4"
      unitRef="usd">599000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzU0OTc1NTgxNTM1MjA_3eaf6e9e-d557-41b2-a68a-6257b5791318"
      unitRef="usd">398000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1Njk_63b0e600-5e40-4b4d-9925-f11e0a31a579"
      unitRef="usd">520000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i34b2763ca1054014af97296f08cfe8f9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1MjY_f5ffc73b-4892-419f-970f-3a5cbb38df66"
      unitRef="usd">199000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i34b2763ca1054014af97296f08cfe8f9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1Mzc_e61aa6f0-c4e0-4ef0-803f-d341a18a3282"
      unitRef="usd">7000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i016ea1213b884f66af6169c417c336f8_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1NDQ_4aee8f16-6afa-4d64-9fd0-4ec93df1dc41"
      unitRef="usd">2700000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i016ea1213b884f66af6169c417c336f8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1NTM_a7cec877-c1d1-45f2-89ae-0ca23f1d9bf1"
      unitRef="usd">879000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1MTc_bc8f49a5-85d6-4195-9348-04246f2e3f6c"
      unitRef="usd">946000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY1MTA_72f51cd8-9d06-4637-8efe-0769c575697d"
      unitRef="usd">800000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQzOTgwNDY1MjU0MTI_c7d4c936-6ee8-42d7-b15e-7ef9e7cca0e6"
      unitRef="usd">-3000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY0OTQ_c7ed80ed-5dcf-401b-b07d-ab5c060199ad"
      unitRef="usd">41000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY0NzM_6407ed55-9e08-474e-872e-0cdfa9c84ac7"
      unitRef="usd">-82000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY0NTA_905e5891-6377-43bc-a07a-4daa6a92b163"
      unitRef="usd">215000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzE2NDkyNjc0NDY0NDM_55c6a949-3e25-45a2-a062-0f87b6722dc8"
      unitRef="usd">218000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzQ3MjA_e5324b71-892c-4454-b074-7860006986d4">&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a rollforward of our total gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to current year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax positions related to prior years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzItMi0xLTEtMTY3NjY1_38e8a4e3-75c7-44cf-9a6d-b013742662ee"
      unitRef="usd">1713000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzItNC0xLTEtMTY3NjY1_89bf7ee2-3596-4ea0-89b6-182bf04d7323"
      unitRef="usd">1614000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0142ebb7458d4ec68ef2fa3254d6e76a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzItNi0xLTEtMTY3NjY1_38d02b4c-b5d9-4e37-889c-a06132c91853"
      unitRef="usd">2031000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzQtMi0xLTEtMTY3NjY1_6ee8ac76-4743-4028-b60e-f67686361d28"
      unitRef="usd">129000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzQtNC0xLTEtMTY3NjY1_642a4e9a-4718-4e52-9394-b2dbf37d92da"
      unitRef="usd">147000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzQtNi0xLTEtMTY3NjY1_578619d3-6674-4c07-9e55-6906b6dc1fd1"
      unitRef="usd">121000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzUtMi0xLTEtMTY3NjY1_e1adc627-ccf3-4644-a57a-6c0b6c629568"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzUtNC0xLTEtMTY3NjY1_0eb0e9b6-7662-4114-941a-49080d8b09d4"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzUtNi0xLTEtMTY3NjY1_a6a5d5a5-e656-469d-8d90-2ecb5230ae66"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzctMi0xLTEtMTY3NjY1_a8fd930f-0ce4-4308-84cb-e829d113db2a"
      unitRef="usd">225000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzctNC0xLTEtMTY3NjY1_838d925e-ab92-4dde-a7f3-2413af982aea"
      unitRef="usd">161000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzctNi0xLTEtMTY3NjY1_655b83bc-2626-4c6a-8cdb-9874dc98160c"
      unitRef="usd">398000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzgtMi0xLTEtMTY3NjY1_c6bb8dee-c83a-4356-9699-c078554fd2d3"
      unitRef="usd">31000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzgtNC0xLTEtMTY3NjY1_adc7f210-509c-43e4-a79b-26cdb3a48988"
      unitRef="usd">179000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzgtNi0xLTEtMTY3NjY1_4d843855-b0be-45ac-b40f-869119adf764"
      unitRef="usd">481000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzktMi0xLTEtMTY3NjY1_5bd517ba-0aba-4379-acc6-d724901550f2"
      unitRef="usd">10000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzktNC0xLTEtMTY3NjY1_f40afb7f-fdf9-4095-bfa6-5ef4dafe138f"
      unitRef="usd">28000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzktNi0xLTEtMTY3NjY1_cb94168b-1d12-4768-87e3-1c567210da1d"
      unitRef="usd">454000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzEwLTItMS0xLTE2NzY2NQ_bb731164-b23c-4f4d-90e0-34c3bfdc3172"
      unitRef="usd">68000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i6e7ebe801cbe46ffb5e9cd5ddabdd381_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzEwLTQtMS0xLTE2NzY2NQ_2370e718-dded-4dd6-b49a-f20441020fac"
      unitRef="usd">2000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i6074f89fe0ca4bcca3bd95ac1b273b53_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzEwLTYtMS0xLTE2NzY2NQ_15f21b47-089b-41d1-842c-18874c72375d"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzExLTItMS0xLTE2NzY2NQ_165fabb1-01ed-4271-be4a-a3ed071def85"
      unitRef="usd">1959000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzExLTQtMS0xLTE2NzY2NQ_d4c24ebe-c6af-41e5-ac80-829ac58fdeb6"
      unitRef="usd">1713000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2c49c0902f5d45b4881bbd5f032acaf0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTplNDJkYzdmMzMxYzY0ZTFlODdmMzY0MGJkOWJjOThiYS90YWJsZXJhbmdlOmU0MmRjN2YzMzFjNjRlMWU4N2YzNjQwYmQ5YmM5OGJhXzExLTYtMS0xLTE2NzY2NQ_88d20275-1588-4043-803d-6fabbc1dedd0"
      unitRef="usd">1614000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzU0OTc1NTgxNTM4ODQ_4a607926-30a5-4942-8204-4efebfc6e94a"
      unitRef="usd">3500000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="ie98b1de291f04339b19d38631b6c5007_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzU0OTc1NTgxNTM4OTI_5d5f8e09-3b61-4515-9c8e-a66630ebcbaf"
      unitRef="usd">4000000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <gild:ScheduleOfTransitionTaxTableTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90ZXh0cmVnaW9uOjAxMTNjYzM1NWExMjQ0NjdhMDI0ODIwZDYwNGM0MjJhXzEzNzQzODk1MzU3Mzk5_7dcf2cd1-e391-4fa5-83d2-9b15e5574c5b">&lt;div style="margin-bottom:4.5pt;margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the anticipated timing of payments associated with this transition tax as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</gild:ScheduleOfTransitionTaxTableTextBlock>
    <gild:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTo0MDhjNGE3NTkwNDY0MjMzOGIxMzg2ZTk5MTZmZTM2NC90YWJsZXJhbmdlOjQwOGM0YTc1OTA0NjQyMzM4YjEzODZlOTkxNmZlMzY0XzEtMi0xLTEtMjIyNzUz_6b9818e2-af38-49dc-9b8d-e2b566b08ced"
      unitRef="usd">886000000</gild:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne>
    <gild:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTo0MDhjNGE3NTkwNDY0MjMzOGIxMzg2ZTk5MTZmZTM2NC90YWJsZXJhbmdlOjQwOGM0YTc1OTA0NjQyMzM4YjEzODZlOTkxNmZlMzY0XzItMi0xLTEtMjIyNzUz_b528040d-0dfd-4e97-a823-c75d54bb326c"
      unitRef="usd">1182000000</gild:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo>
    <gild:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTo0MDhjNGE3NTkwNDY0MjMzOGIxMzg2ZTk5MTZmZTM2NC90YWJsZXJhbmdlOjQwOGM0YTc1OTA0NjQyMzM4YjEzODZlOTkxNmZlMzY0XzMtMi0xLTEtMjIyNzUz_18117b23-a339-465d-9df9-66bbb3da6952"
      unitRef="usd">1477000000</gild:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="i36be9f39e0e143cf97505efaec9d56a4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN18xNDIvZnJhZzowMTEzY2MzNTVhMTI0NDY3YTAyNDgyMGQ2MDRjNDIyYS90YWJsZTo0MDhjNGE3NTkwNDY0MjMzOGIxMzg2ZTk5MTZmZTM2NC90YWJsZXJhbmdlOjQwOGM0YTc1OTA0NjQyMzM4YjEzODZlOTkxNmZlMzY0XzctMi0xLTEtMjIyNzUz_b8062da8-182b-4d0c-97af-2f750a3399c7"
      unitRef="usd">3546000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i2a52280e791949799892ada047e34d67_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN181NDk3NTU4MTU1NjgvZnJhZzpmZTZhYTdlYzY5OWU0YzA2ODJkNTI1ZDRkYWQwOTAxNy90ZXh0cmVnaW9uOmZlNmFhN2VjNjk5ZTRjMDY4MmQ1MjVkNGRhZDA5MDE3XzEzNzQzODk1MzYyOTcx_a63f703e-67fb-4d89-bba2-a075e9dc65e4">SUBSEQUENT EVENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Arcellx&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, we closed an agreement to enter into a global strategic collaboration with Arcellx, Inc. (&#x201c;Arcellx&#x201d;) to co-develop and co-commercialize Arcellx&#x2019;s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Under the terms of the agreement, Arcellx will receive an upfront cash payment of $225&#160;million and $100&#160;million equity investment as well as other potential contingent payments. The companies will share development, clinical trial, and commercialization costs for CART-ddBCMA and will jointly commercialize the product and split U.S. profits 50/50. Outside the U.S., we will commercialize the product and Arcellx will receive royalties on sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Tmunity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, we closed an agreement to acquire Tmunity Therapeutics (&#x201c;Tmunity&#x201d;), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. Under the terms of the agreement, we acquired all outstanding shares of Tmunity other than those already owned by Gilead for approximately $300&#160;million in cash consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ie3f62493c696477b8cfbb9f960369e84_D20230101-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN181NDk3NTU4MTU1NjgvZnJhZzpmZTZhYTdlYzY5OWU0YzA2ODJkNTI1ZDRkYWQwOTAxNy90ZXh0cmVnaW9uOmZlNmFhN2VjNjk5ZTRjMDY4MmQ1MjVkNGRhZDA5MDE3XzU0OTc1NTgzNDAwNQ_5be2a6b4-e961-4a9e-aff3-0a22dc238bde"
      unitRef="usd">225000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="ie3f62493c696477b8cfbb9f960369e84_D20230101-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN181NDk3NTU4MTU1NjgvZnJhZzpmZTZhYTdlYzY5OWU0YzA2ODJkNTI1ZDRkYWQwOTAxNy90ZXh0cmVnaW9uOmZlNmFhN2VjNjk5ZTRjMDY4MmQ1MjVkNGRhZDA5MDE3XzU0OTc1NTgzNDAwOQ_0764a6fd-a442-4a8b-bd34-faa32e881633"
      unitRef="usd">100000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <gild:RevenuePerformanceObligationPercentageOfUSProfits
      contextRef="i2425a97f760f4c49bd6815b72167f203_I20230131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN181NDk3NTU4MTU1NjgvZnJhZzpmZTZhYTdlYzY5OWU0YzA2ODJkNTI1ZDRkYWQwOTAxNy90ZXh0cmVnaW9uOmZlNmFhN2VjNjk5ZTRjMDY4MmQ1MjVkNGRhZDA5MDE3XzU0OTc1NTgzNjgwNw_93ca0d94-9bb8-4937-b1e2-7ec422b6975c"
      unitRef="number">0.50</gild:RevenuePerformanceObligationPercentageOfUSProfits>
    <gild:RevenuePerformanceObligationPercentageOfUSProfits
      contextRef="i0056aa3d99a143b88dbc13d114cc84be_I20230131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN181NDk3NTU4MTU1NjgvZnJhZzpmZTZhYTdlYzY5OWU0YzA2ODJkNTI1ZDRkYWQwOTAxNy90ZXh0cmVnaW9uOmZlNmFhN2VjNjk5ZTRjMDY4MmQ1MjVkNGRhZDA5MDE3XzU0OTc1NTgzNjgxMw_19706b49-1655-4015-ad73-152c0a93fc62"
      unitRef="number">0.50</gild:RevenuePerformanceObligationPercentageOfUSProfits>
    <gild:PaymentsForAssetAcquisitions
      contextRef="i0f0e85f937584323a180e6f5054512c6_D20230222-20230222"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjZkOTZjNzI3YmQzZTRhMTA5NjliYmY2YTg0ZDY0Y2U3L3NlYzo2ZDk2YzcyN2JkM2U0YTEwOTY5YmJmNmE4NGQ2NGNlN181NDk3NTU4MTU1NjgvZnJhZzpmZTZhYTdlYzY5OWU0YzA2ODJkNTI1ZDRkYWQwOTAxNy90ZXh0cmVnaW9uOmZlNmFhN2VjNjk5ZTRjMDY4MmQ1MjVkNGRhZDA5MDE3XzU0OTc1NTgzNDA0OQ_2d3b9251-9f0c-46f2-b805-48904e485479"
      unitRef="usd">300000000</gild:PaymentsForAssetAcquisitions>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>119
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MY0Q]]^%[] &%";H-HPA^%'X]$' )>>+ +^1N<SFG0<YVT">:B"U'=TE @KK
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M!/A^3:DX[,@+E"7WD_\ 4$L#!!0    ( $V"5E;1*&9,.P(  +P%   8
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M<FMS:&5E=',O<VAE970S+GAM;*V9VV[;.!"&7X5PBZ(%DE@D=;!S,) ZV;9
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M'BX3,'^0/]>7-P]S</L57-U<W%Y?@D/P;9Z SY^^ +[$C'"0E^ Z+PJ9-7X
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M-IR\>)<5Q4L-/C3C;W@IYE/!]N,\%<.IV]I13P2!;TAF;L&'3 Q"6N:9$*P
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M-2?><T B'RC[$[E?]R'_COZ[W3!.Q=[[?T6T=[E[I]I=GD=N6(H]&&KBP,&
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MKD"E0/R_)82?&O(!92UL_P!02P,$%     @ 38)65O,@:R7%"   72L  !D
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MW J01[Z.J$BXT]^&MNK*:L%L!Q_$"V9S&@@('9*JB?8%^A#[K6=.)*BMOWU
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MQJI#I2N$Z9OJVJ"14GAXK?O*U^5L2ASM8\&E9 JXB%[>4Y,3*,VU6/36%9?
M.E>D^[ ,?@'^L7RQ]1H^&-=+2Y,DE@%I79UAQW>IX/K(B_>6[PQW]-P.**49
MR"S! "T"VDW+)4,IY="JQF JP]Q(/5#I^?^W<R=#M<0CHEG9>3 -I23Z=JQ0
M>;&I1$Y+'-\PU8#%>@.JD/6&_^B]M'-F3S'E@N($L<@Y\]9;@9\J:+&;M,,6
M/7Z?Y;NDY"BAC_]X;5;ZG&H+@$]6:PH9P/<EY8JZWN2ZJL8&AS(V)OYG<QVC
MY:"#T8(#>8U(E>)T% Z2V)"2"I5ST3 B!</U#90I-$?&!BKT1(AP7OEY#]Y"
MO+(LDA*?*O$I<[%41Y'E7F-_U E(GA-T>J2=MFTK#F],:3"V@B+Z^3J-%,LK
M .\#&)>24%05O4)%!]N'L=";<GREQTL0^=USS&XN,0R>!\$&QJ<&&YJX8Q&T
M@M0[2P5^,W7R*73%JD1.!7-9DD\EO)MMZ]<XZ^':QU:2NX,L6)U>%PH?5?E(
M4R$%DF#MO7IOZ;HHN/Q>R@5HIV_$F/V+%&;=NQSW0DB7BA# &4W-B,E$!V5:
M#:+^8L)Z9E0(.A)@+U>]8'7&]N:>'4]**MGDY->!_*-$.DC I:N"U\H#NRIF
MHU#!]8D>5290&!W+JUNJ].*0IN2]E>^75&J)05C.>!DS;HZ30226+FCT'*B0
MRGPRL)5';+<+-I14+9GK5;3%&9<G&H-8@@T2N/@%^WHFO^1LI$ >.\_)AJ7G
M=P#4FB-5:DLPRK#3IALHY<*?@O*(8@H]W<@Z>K6F"8=B6W2,AL+@O70,F_4U
M?*-O5710:L>OJR^^WK-O@Y$R;8[0JC.-/1];=NZ70;J D+JP!%; GKP&V_]D
M!1:5'%$J-?4SC8YM[L8UDS0?>\FX$)ABX=1$QB5QMQ/]+"5Y;'+2Q:(!1V)K
MJHOCX#;Q5H #5#??>BH3Y(HTEH*;&4<?)F#O)P)/4Q7/AU3%\Q%=@]2C:.I[
MLD"5E)BZ5"#!C89:.9)5<YG#I'),8]YHF=H]ZI%'M5L9(FRKBV@SEQ5WY&B+
M]H0SYI@@VP:D_(TD(*W3D57WSFQQ7JSB&74)V6*"<7V0&F-:-S*CI%Z6O0D4
MI=!F-M]<5VU(>,285VHHEE:X8/CAKA(C;L)-E[,<A-!)MYOL,-P'QDFIL^A"
MRG20X^V_\SR(MA/OM-BUH])XI""F>:(N8AGA-GK$V(WD#E.TZJ1J9O(O;)V2
M:H_/:O9*J<I(2RA80'ZB8_;HY@5,*LV*#B [V81KBNCZ&\IR9"4S0X,4S9V8
MH.NX^/?.]\=O<3&+.I<22FR]M'+%% 1E'F+^-Q5"V8981VDU?U)BS0=VOTY@
M,D8U7:S!#*"Y626O N4=41O_,9VN=Q(-D<FM8WNBUC]:;LKK5F@Z2[-/;*<%
M8EGQCA"OUN"4?D.E\OHW M%Y::?%" @*$DVI-9'VI>\>>\.JY*XDKM'E^&J[
MA:<D@JG_5"6EO'0P)J)*0H5*BZ3P7>/&\EYD8JF1P-=L?(2[#L7FC*92*NZ+
MK:T)O3O4/=NJI[?0*#RIW=!@=THLI./<R6T=:Z /#@7AJ*K;WB07CC&:9?J)
MA/ZGVN$D@3C+Q92G&6RIY&3\>*2'SBU]3\$_C_,SW (-6%AF46V)9C6%5F$G
M$*5@I,B4X[6F.1A%]2)F*E)U$E4[#&@.B8V#!7(XQ\C,>CB\\I1[XMJJ'I/!
MJ(DHR6&=/_G$&$DDZ[2%,[(6I<&3$Y=C/'0^[^@G,\]+$P,1F0G!2AO"6!S3
M(\(-(G:I<N\65\Q1IYKT0WPU-V$:)2C8[\)*?J:41=A06$%J8$U65_4.N?/)
ML#?.$%592$Z!Q33MR1%54TR'.Z(GD@U'P)=8M:"6-A5^UDE1<]!A=P\9]L!Q
MS=Z 0XJ#(=G$^,G7]\[>A!RPJDGS"BBYDU-7'DU9 OK1GIH/,8V^07<^)H2T
M7V*9C8907J$5\:4[:'9'_,<I+J82]@?)Z(R=XS-3W6SKI"C05.^YFS&;'($.
M:3:@P88.O@YZWP^'Z#T@]%&0YUYE(:T F":SW+M@9&;J;;),CH9[6,19;W#L
M*+8T"NHW:B -:(]^.1FVIOWON*=N5B%&80$<N*,V43\UM( =AVD03)ZR\D89
MP14FZ=MM_-;';[%XL^=.P-[PNC.N$!P<F*E*Q&C#*J?%J]N^'M>2'DM<:M3B
M UYFJ[4)J= ]U=K9TAW-^-O\$9 _C@ZJ295IYF54.N40H^CB=#_2A+FVXK14
M6N43K_*V6OKBY5#5)47(R678T' QIM$K26;"A3S]3K9"(U9A@+??<C6+)BC
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M#A7I+A<X,"O# OC]OL7FMS?L8'CK>?I?4$L#!!0    ( $V"5E;D.\P?* H
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MG2D<7-A=M;L+PS*E"@?D;,G*D2!-:JF5T\8N]*EMPU9=O(8C*&$$P:SYR1R
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MSYN<FTO<=)2E!9A?&$A3=^B ]CO7T7\ 4$L#!!0    ( $V"5E; ]>;C_ @
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MKPCK-EZ3H9>^41BC2X8?F@PG,*'+YI$G2&%);Z0I1-;\]^?$/K\#U2KGOBI
M#^1X:]\+[';ML\1"Z)G[^ *C4GK[+Q05M?J^,_*?-3;3_<>ACUS/*&U3,<72
M3FO0:S#M/[CX!ZMR]Y%CHJQ5"W<[%]3@TP2,3Y6RZP?:H/KJ=?%?4$L#!!0
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M K53H.^E4O9AXQSTOU.6_P%02P,$%     @ 38)65G9T2N >"@  4!D  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULK5F+;MLZ$OT5PC>W:+&*;<G/
MI&D )^DC0!]!DMUBL5@L:(FV>2N)*DG%<;_^GB$E64Z<M"BV0!.)(H=G7F>&
MS,E:Z6]F)81E]UF:FS>=E;7%<:]GXI7(N.FJ0N3XLE ZXQ:O>MDSA18\<8NR
MM!?U^^->QF7>.3UQ8U?Z]$25-I6YN-+,E%G&]>9,I&K]IA-VZH%KN5Q9&NB=
MGA1\*6Z$_6=QI?'6:Z0D,A.YD2IG6BS>=&;A\=F0YKL)_Y)B;5K/C#29*_6-
M7BZ3-YT^ 1*IB"U)X/AU)\Y%FI(@P/A>R>PT6]+"]G,M_9W3';K,N1'G*OTJ
M$[MZTYEV6"(6O$SMM5I_$)4^(Y(7J]2XGVSMYXX&'1:7QJJL6@P$F<S];WY?
MV:&U8-I_8D%4+8@<;K^10WG!+3\]T6K--,V&-'IPJKK5 "=S<LJ-U?@JL<Z>
MOE<J6<LT93Q/V&5N>;Z4\U2PF3'"FI.>Q1XTLQ=7\LZ\O.@)>6'$/JG<K@Q[
MFR<BV170 [@&850C/(N>E7@AXBX;A &+^E'TC+Q!H_' R1O\EL;L0IHX5:;4
M@OUG-C=6(V[^N\\.?I?A_ETHEXY-P6/QIH-D,4+?B<[IBS_"<?_U,SH,&QV&
MSTG_#:_]1-Z7+Q=?+S]^9+//%^SR\^WL\_O+LX]OV>SFYNWM#6NVNUT)ME I
M,EGF2V8Y[>G36?X0AEE\CE< @V>9^U>N]88F\TR5N65JT4@[9G"MR.9"._>^
MQ(H,P\A5\\HYFWZ$[$PL99Z3B#E/>1X+=L"FP6 0N=]A?[J%!T,C&6GJ0JL,
M&?^]E$92]AOVXH]I%$:O612-V2?!R<'@%LL*H:5*&$_^0K+1B&$OP^DK]C)Z
M12'\:-]PV.Q_F3N8 5O6 !(1@QF-2-A\PP["::T0XX;Q"AZ98"%SGLH?SH@P
MTM8V#K+&^AQ\#.;5W*F#@#2P*29\^O=UP-8K&:\J<9@+P_%F:V:5DTD"P$Y"
MDS3+[UDJ^5RFTFZ:3;J(%Y*YXP:O$20@ =;T(U=8$)=9F7+:K-%59@67VMG0
MP^ONR::?!(PJ=7L1=XL"PG[\&-6CD?!!S+S7P,%F+; @;M!RSLY+F"&/-^Q6
M\]S@&_EDUKB<?8:QSNM(G7EO_'^EO9.YM.(P10E**CV/'ZGN@S1\S8Q:*#,O
M[Z1&L(7]8!+U\?!R' Q&_5=XJH/Y@ V#P:2_,VD4C$?A[J11T!\?/;T;OY<Q
MGUO4X!P)*U.5BC(6*9L$8=A'-@1'?21$+6X4P/3;;Z-^V/XV[C^ST:U6B4CO
M-C1O@-5'D\%V[1"X)_6747_2EAI&@Z>E?A!%G):)N&?3X0B01BVPX^G$CTZB
M[>!D,F!?*,)9& RG1_@X (Z03493C(Q)KS'9.61'XY#=*LM3RMB'_F/1*)@<
M#;%C'P!#FA\"_F1('XY"; J:F/KQ23 :C* ",G*/H%J3RZOK%SPK7E] )I8-
M@@@NK5'7OZMA;'6T[ZL?]J#EP]1"+ R.@K[CL 8V@@?_HVDP/:+Q81A,@?6@
M@>^_#P;!<#1B_WO^GP,.7GPGYKI$DT=I.@C8NXL96R)9*(MX46AU!W1@GB8@
MT%VR$N1%5)8021;(*D?&:VE7K,RIAL:>/U(5\S0%C25W1,L)P]I,6&XLUL3L
MP_4_>A_>7D>';$Z$:%&",$N#-!5;\3L!WHR%L[[($Q5KE,+#N>-L"@E>;%Q1
MY6 UM]JNP7])XJH(0)N-L2+#-GZRW%:Z%@28FFB[2^RA--60=.,X%7M[*MEZ
M^J&/R"P'XV[(YE7I<&0[=[!3S) +25#5WHBLH"RD!O+O<("%XA!(7N@2%6DK
M?WB^>GN/OAX6GRV76BP!BJK0]K.H/M> 'V[X.+36J'$'87=: P_H;=*H04;%
M0-0,D,L)[$9P;<@7D+JG$CF>I\5XZ =4] KA.GDR*8U+PPHMJ:(@)F3NJ,#5
MQ'-EG#6I8AE0:HI(R5W).4>Y4*E,G&8W\)GPA1^3+_-89:+[*YV.,!;;DHA%
M::E?W&M 6$?%TDUSH4S[_\22?']5/GY0[JK*0KZE' TFDPF]#+>/(_<8TN.8
M'L<#>IQ4C[=4X_F"0F0<3+'.D\9!S6*7VP)/U=P8;Z3/"I 35 RKM /::@2J
MAL'9Y+?<*^YC45BR0"(,<G..5276:D=P4?^U:P2VV;/%Z+Z#0^=TSO3^6[LC
MF4@.D?4:U8TEZ.V=S=!6P8FE\8%"+D&RY%92^MYY/]3JDAY/9RMPEMJW<<I4
MR@9,N>)BT0DW9MB*;&GFL ;>:I/NZ,^ C?'3F6/:[?^Y&^U=]J3NQ+BQRO/J
MI-O$6:L!=K&=966.Z(;S'%5XDZ\!+B5.=>3,"HIA/Y]P%Z5&1P_5D&.Q:RZ;
M%O49JX!KB.7O77X@+0^F6UYP1$%$MLP]KSQGW1;][-0*B\CUS19P[M:*)_B?
MNE/VB4.;*O+6K4H )N#^S$ Z7SF%D2#77Z[D^<TAVAUCRV3#!,I6Z3OR!@WL
M^-3^K8KPLU($ZT*KIB#5I2A@\2;&8>TP$06E$/3]AJ,#T U[8VR]DG/ITI!"
MABH5T31YG@YX+CGI$D?5A>UEE41V)75R2'-8D9:F4:#*H5===N8*8D67M=K;
MJ/#F\ <04]'PXQ!T\:-%P?7.8CK\Y*!$%-,M]=9YLE.ZG)/*PO.T0U)1;B,*
M"< (G1NA&5OK/U-B8:6=$NL)UP='34U=]N7!AJW-'',@5[2:5X>JPYILJ 0A
MQWR;PV.R GJ)FGF,JPMQJVC$W*S8 CQ@ZI.;NR^ I]U6V\.>RSI?>:A3 J"/
M KR .&T!R[8G6U.YI2C)1;XP4N1NRY;&^KP4^!JC5%9^;.GDK"SB50ZR]U<-
MZ!3H+*30V)DRCL%HGFD;I5K:-*6X->92[!<2Q$?#_B#U*.L7A!TX-Y6B%?-U
MN'O+<2U\S);SOP"2)A@?DS ^UCCE** E'6')Z;"+) ?73MO5P;$UGK#CMN](
M2L^-(/>4.U)(>9F3]V7F[B.>4\CCC'D55<U)OBI-V.(;@M:L2!,$<)D5_DIC
M7B>IW7&!R@J!4D:%3.0X0JJ<PJ$^[+<I</>4W[JYH6V+%(=;ZJW;6[;XN)V/
MNT[&FK9_'+HG?-1E7YMLVJG.-&?<G: :>NO(A^HV.S^J\G'5]\5HS]W1#7C(
M*#RG;MTQ$X)\(5.\&;@GY;K2QU1!7F6@3S:'QB5QY0C$#B)60A[Y3I7H*TM_
M[^)SD!;MJ8A0-!$@-<2#/VLT<=9J)+>93%72]0>[UV@-V=5-A27,0?N"J2YM
M:IFC5W4\18CYSI4-G*V73M!!U.K2X:[+_!#FH=PF><*%"YDE(;91A5O=$O2K
M+?6V42(+:0&N\O?$OC5\0+[[[DA[K5ON3  ]W>4;YF+&7W@WH\V?"V;^EGP[
MW?^M ;LM)<(Y%0LL[2/..DS[^WO_8E7A[LSGREJ5N<>5X.A#:0*^+Q2:W.J%
M-FC^B'+Z-U!+ P04    " !-@E96K4+'DYT$  #/"@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6R55MMNVS@0_96!&A0MX+5U]26U#3AI@AIH+DC2
M[<-BL:"EL<V&(E62BI-^_0XIQ>MB8S?U@W6;.7/FS'#(\4;I>[-&M/!8"FDF
MP=K:ZKC7,_D:2V:ZJD))7Y9*E\S2HU[U3*61%=ZI%+TX#/N]DG$93,?^W;6>
MCE5M!9=XK<'49<GTTPD*M9D$4?#\XH:OUM:]Z$W'%5OA+=HOU;6FI]X6I> E
M2L.5!(W+23"+CD]29^\-_N2X,3OWX#)9*'7O'N;%) @=(1286X? Z/* IRB$
M R(:WUO,8!O2.>[>/Z.?^]PIEP4S>*K$5U[8]208!E#@DM7"WJC-)VSSR1Q>
MKH3Q_[!I;)-1 'EMK"I;9V)0<ME<V6.KPX[#,-SC$+<.L>?=!/(L/S++IF.M
M-J"=-:&Y&Y^J]R9R7+JBW%I-7SGYV>F57:.&<RZ9S#D3,)=-H4FQ<<]2 &?6
MRUNPDP8LW@,6Q7"AI%T;.),%%C\#](C9EE[\3.\D/HCX$?,N)%$'XC".#^ E
MVW03CY?\?KKPUVQAK*8V^?NES!O<]&5<MW2.3<5RG 2T-@SJ!PRF;]]$_?##
M =;IEG5Z"/UWB_0+L+M/9S=P/K^<79[.9Y]A?GE^=7,QNYM?7<(LSU4MK:'E
MEB-_8 N!'9 T&N[6"$LE: ESN0+K/K3KF/]  ZK6>WV/@8J(Y8(R<(5\QR7U
ML1#$W;SW975_T4ON< 19)^VG_AH/AO 9C3D&YFB0$A279(!\S?0*%RR_-Y"E
M(^@/HCV&S*RAX*:-PV0!R@L[3,AICX_&@EL0RAAZDV60#O:+= 1I9S 8^&LZ
M2KQH)?NF-+=/H)9>)6JP FD6_3]9DM+%6&I50J554><6#!/TBA0CGO"E>]OU
MK,]J34.Y2VWP@-(2/-F\HD [YJ^LR0W;4 (6-36=H;2B3N33HRLM]:\T;ATW
M(DMRD3KT+1N%KD\Y#:0"5DH5AHS#?M_])S'<*4OM>P1Q9QB'_CI(4KC!2FE+
M#HR([2;E(F5A$[$?#:%9!T+)U1]$JB1[@R3BN^@]&211XHGU]T3YY_#/H\S*
MIBR5YDXY\00Y2<*-=>73NVITVRA\ARXSSNPG9;V,7.:BIGD(1_$H?1;:F2X9
MU_# 1$W5+[[1L*?=SC>%H3W%U=$W@ZO]O"QKJ4IJQISBY-]K;KA;_EU7>(VP
M<7]2[4-T'?1*NG&WE3FOM29;$)PMN*!HO^XRQS179:6DCTKH>Z%>V8&GA$8G
M@&9 N]['LA+J"1$6*'');=,D(37'$8SB ;4/$4"B]DA\*O;D*8ZR$63)"&;/
MB]NO[69Q:;2UE@92"IF.1FYUZYJ4\A9HK4 G(9D)YEK4*ECPW.)*LP>2VB6S
M:MBY_GG[9AA'\0=B%&=AFSQS@.2YJV/<B8:486>4A ?4=G,D&[H.[G>B-'M5
M!]^2-)?*(D1)UZE7\K8%G'BGM#E3X9!VD7:^L:+P?>1;8[NI=%_:LWH[AXP2
M:>2ZHY0!/\B:\\;V[?:T-FL.*?^9-T>]"YK8G#07N"37L#O( M#-\:EYL*KR
M1Y:%LG0 \K=K.G&B=@;T?:DHQ?;!!=B>8:?_ E!+ P04    " !-@E96=WV$
M;5HC   7A0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6SM75ES&T>2
M_BL=''K6B@!  #Q$V9(B:!T>^9 4HC1^V-B'0G<!**O1A>F#,/WK)X\Z^P!!
M6?8H8N=AQB+074=F5N:71R4>[W3YL5I+62>_;?*B>G*TKNOM-R<G5;J6&U%-
M]%86\,U2EQM1PY_EZJ3:EE)D]-(F/YE/IQ<G&Z&*HZ>/Z;.WY=/'NJES5<BW
M95(UFXTH;[^3N=X].9H=V0_>J=6ZQ@].GC[>BI6\EO6'[=L2_CIQHV1J(XM*
MZ2(IY?+)T=7LF^_.\'EZX)]*[JK@WPGN9*'U1_SC5?;D:(H+DKE,:QQ!P']N
MY#.9YS@0+.-?9LPC-R6^&/[;COZ2]@Y[68A*/M/Y+RJKUT^.+H^23"Y%D]?O
M].X?TNSG',=+=5[1_R<[?O8,'DZ;JM8;\S*L8*,*_J_XS= A>.%R.O#"W+PP
MIW7S1+3*YZ(63Q^7>I>4^#2,AO^@K=+;L#A5(%.NZQ*^5?!>_11VDXN%+@72
MJ$I$D25OZK4LDZNR%,5* OWKZO%)#5/A"R>I&?8['G8^,.QLGORLBWI=)2^*
M3&;Q ">P1K?0N5WH=_.](SZ7Z20YG8V2^70^WS/>J=OX*8UW>O?&;^3 OI/_
MO5I4=0F2\W]]). )SOHGP-/T3;45J7QR!,>EDN6-/'KZ][_-+J;?[EG^F5O^
MV;[1/YUO=PS[YJ>?KKY[\^[J_:LWKZ^3J]?/DS?O__'B77+U[MW5Z^]?_/SB
M]?OKY!>9P/ PF2IJG>0JQ4-:K&@52*]:KE2:I-TE:EIBI38J%V4B0E+O5+U.
MZK4JLV0KREK)*@&5 Y](.&0WH#RV^!R-DNK-1I:I$KGZG09/]#))95F##DJV
MI<Z:M.;YS!])"G^H#-9539+W:V!&//=&W,)6;G0.DE#O= +S;G0IW4)V:PTO
M2*-"^.-4;06^"U/B&D%+XD:1"/B0HO=@6?A=1 A:%PXF?]OJ2F8)4+!2JT(M
M%:RR3DI5?>3%EW(GRJR"[8,&SG!H79CQ[/Y!EZ:IK-Q,?NX]^TSS)I-)H8LQ
M*,"FR,0BETFS799P8&%OM_3L"-<';)6P#+59-&5EQ@#:V&>2Q6W2,)OTEID,
MFQ'IOQH%^[,,*5$OPG@I# ^;0";J1:Y61BS\&%M=PY>XJS;#2[EJ<E'K\A94
M8"Y!*1;2KP*>.('7*P'?C%%#9SU/C9)2WXJ\O@T_@6F*1M*62KU4];A:BY)X
M&% -5U[U?T6+D[#=FN0'IJ2/)\D'4'HLNTM5B()8!>=E8QG58LPHV4EBS@+)
M3>0CN=B(C\$^FRU9L;6"91-I8*P;6)1NJI!B(A^%!(L/C*<,3KI6Z1J^;/(,
M9PZD<)*\;.H&F-A'2+6$06_A=97GO.(EVEA8,G!;-V7R#/BJ<SIO67)=PW^,
MZ"R35P6L1<+,THIR";H1-D;RC?Q L9+T$/!D@;(Y@;=0>@ICR(VFD-$NM_#T
MC<AA>3T2LA$@\':YJ=BJ&E4'+$[@^:V!#PK/@*@J:9AJ'Q:@!VIZ%-CQ#.0
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MUA8ET?9?\4&!8:X"['CG[I[A."_!J_9(>?_V(JOCA0U4NP0\1B806&:40 *
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M2HEGBX33AH*,TU^%6@C<+CHYX/.HGB>KIMP"" A1YSB3N'5%2A56%$JE#2N
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M"#SO(S (&L[,)&'+"-:A 7>#%1U&13:LT4 UU)KSL!C; $0&ZA9I+]LS7Y6
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MN82/..?Z[.I(H9JIV^+'*OYLBTMK0A+=ES>/]B?ZPP<N]^9,-H\=L*NII;@
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MGWU"<LE-.IZP>*:3-797T2Y]PRY)X;/1OG!PHW/,7P)TB,262;IA<I4>1/R
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MVM( O)\9T_H?M$'X;/O+_P%02P,$%     @ 38)65B7FJK; !P  :Q,  !D
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M54CFPN/\=_33@-W/VO+!C<<7*Z$*-O<-RN_-/4H4<,P<MZ':H/%+(/]KT/R
MT_0;TJZXD*Z! GV0V>();^@[EZ(0B.'ST&-RP93"?9';8<)_TY&743\J7D Q
M':(DX/IA?$3#A ZC08+%&*L[3G-KU1PS0!C)D%Z,70.J?ZN(W]+A$,2'PPA_
M4_"RCM3CYSN^TJ]&9D<[3HUH.#SB_]'1Z]YA<H-W[!3WW<,H@EY<QX.C5UU,
MINP:-,7'C,;W.MA>,</A]]?\VZJ>3B@"SJ^[QYY%'+S#(3LVX>,$D^8KOGD4
M_"49''ENAF@Z_6XG&?T)QS":#/YJ$-F"P_AXFPW1M\(8MQ%,? "3Q*^?>['N
M[WP *24F&_[,PR]4F C"MY#M[O9+TD7X@/)('CY#H=TON. *.0<KGT&=T +;
MA=-+_SEEIIW3I;_-)=XU#1/@^5QKURY8P?;[VOG_ %!+ P04    " !-@E96
MG*?..S$-   A)P  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6S%6@MO
MVT82_BL+-REL0*9)ZND\#-BIVPO0M$*4-"@.AP-%KJ0]4UQF2=K6_?K[9G9)
MD;)EJ[T4;5":6N[.SN.;QP[YYDZ;FV(E92GNUVE6O#U:E67^ZNRLB%=R'16>
MSF6&)PMMUE&)GV9Y5N1&1@DO6J=GH>^/SM:1RHXNWO#8U%R\T569JDQ.C2BJ
M]3HRFRN9ZKNW1\%1/?!1+5<E#9Q=O,FCI9S)\G,^-?AUUE!)U%IFA=*9,'+Q
M]N@R>'4UH/D\X3<E[XK6O2!)YEK?T(_WR=LCGQB2J8Q+HA#ASZU\)].4"(&-
MKX[F4;,E+6S?U]1_9-DARSPJY#N=?E%)N7I[-#D2B5Q$55I^U'?_D$Z>(=&+
M=5KP5=S9N8/^D8BKHM1KMQ@<K%5F_T;W3@^M!1-_SX+0+0B9;[L1<_E#5$87
M;XR^$X9F@QK=L*B\&LRIC(PR*PV>*JPK+Z[7>:HW4HHKF<F%*HLW9R7(TL.S
MV)&XLB3"/22"4'S06;DJQ'66R*1+X S\-$R%-5-7X9,4?Y"Q)_I!3X1^&#Y!
MK]\(V6=Z_3WT9JO(R-,K&"\1TV@#3)7BTI@H6TJ^_^?EO"@- /*OQZ2WM >/
MTR:G>57D42S?'L$K"FENY='%]]\%(__U$YP/&LX'3U$_S#S/D/@P_?G7WZ^O
MQ=7U+]<_OO\T$[-2QS=.'>_T&OY=1.PBUU\K56[$^RR&5N L8II&62%FUF$Q
M+CY$&QC%'_2$KN#:1&BETT2:0D1Y;O0M2$99(NZDB!*=E_A9KJ3X2:4(&&(6
M*PG:18^V\)C0XWN*XP@$81O@J<<4OO]N$H;^:UY",_AW\/K$$Y>%R"-3"KU@
MGJ(8! O%\F (K@OJ,WDK,Z$R I3?8^X*A"''76M.PUDP>9PS+%ZI>$4DBFI>
MR*\5'J:;FED6'C H(Q(=0CPE_;X]VM)W".ZH NOWJH(FOE^OJTQ#2A47;;T\
M4$!GXF5KXX^U)-AL('[6V?+TDS3K W6REF:)M2HK-6_3&,_;0BD,OQ&4PG"?
M,CLZP[2NSCXQ8VY81%6YTD;]UVVFH*0(Y$BCD2AU&:5T&_1#Q.(T)8P5%%L*
M&HWU>DT#)(DG?M$BNHM,4B!:;\1<BB7B#0E10;NFJP^AZP%G4E$HVI7&K"[L
MOF6;5V:]P 0CQ=SH*#F=LT>K1OR<O;=<1:4@&BJ18N%V8F:(I&2=N:66X1Z1
M2*M$94OQ<?89OZ=\9<$$+ &Q"S:-!BG#Z#0J)MGL%'J42\,5 XE1DP4,I(MG
M^)4H@\RLC245@R82*;@J&,=@#5E KN?8H,X$O8X-_&#7!D92%2*BVTBET3RU
MTBZJLC*UP&W=-VHD&<67>DJ)DL.I@Q^ Z5B:D@@WS)-C=V).EE7@JG[NE$J
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M&@!@OH[33,4"L8,WZ:BX$,\P)4B\@X?H5"4<)&94H5+^8"91_*&0)8Y1$]U
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M>'V"VCCPD'T1<.!:CX-W>C!X R)(!4 P/ BXX?G_B=OIM\-MX UJW'9/9\\
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MI=MRJ<MSW3(>3D2R98_#*L&_)'[M] ::0(8HS"$'\8P-%1"<;!S;M4!+1MD
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M#1NPOC)(33L(#KH_H>G_4$L#!!0    ( $V"5E:9[9(6CR<  )J&   9
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M^/7\ZKQ8^]8'US1[_-GO<$J78+\+-4R^:P#ZB)[PH1DK7PRRI1$7@_W^4#?
MD\JB&T-QL^E@MK/NIH6I^G'1UU7M0BTS+'T8@%L5U_"56S0>IAP\G'8H8./U
M0(C]M[]\<WGYZ,F_WKSJZ<^+)Y\7P %AYGJY*6Y@Z<!;@-T1M2S@#$ IL,S^
MO'C6-#RI0*P E&E[1VS(0L8W-5 TPO"\ !93+"U4XV9N-K [7!/.4\!3N+2_
MW74]/#1T!0"FAZVXMKAX].@_$!2X+P]S==MZV9<X,G@$>]$"DP?X=5N/\S0=
M#'3#$.K%.! @8+:V@]_;(0  $?@*FAXO#T&;7;RY;ECV#<_L?Q\!$V J @_
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M,0.<#G[&6?& <#U(B$![KEF.B'9%-=+=!!A? <3.B^=^7;<M\WT"9H\T7Q7
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M%8=%U%"6&Q?6\'GY 39 Q(WJ! L%1 PX.4AFY34E_LHZ/_RV\KAKWAZHWF-
M<ZT#/"=!GLEY5E04F7M2NX!1I6_P//D]\"D V$JI -H .N'9T)WAD<Q87(H,
MFWA$UH_0;F%K0,P)%++PB>\J:N5&+/#2I)6#+H4*,1^\ ):RI4WJ!=B+!JQ8
M"RX]?H0/_?U14;E]_Z38@#Y]C>B1SR.2&N[TMS'4?54OF?KABWC!K-4# J%=
M5+=1S4%39K_SS!!HU^;J#_$Y<NXCP"LCNA"LNA;.(\CM;U&#!C2S^B)23H"9
M%:JL09!H&+<H?5$Y5_(R6 B4@9H$[&U!:AP,8.,'49QH#F<;6Z$)L&^ ,7;
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M*P.=<[ !5N+RS<0VX$=2YYHTANUS<2V*8D6NI;WPH>Y2<G2_OM\L)5IV?6J
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M L5<4\@,?Y-3&5>7R,-M1*#'A$(+S\.<^<M<4?O(JP@AB"+W+&,$/N(?<9(
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MRK  ?G]HX>KFAA<87N6>_@=02P,$%     @ 38)65@UMA8G#!0  6 \  !D
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M@J8%.)\JS /5@ ZH']/S_P!02P,$%     @ 38)65GFNF!_)!@  #!<  !D
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M:,K,& JIA6%A5P:2O&#2(1/M4JI"*I3Q,$68VP]"K^$]\(:'1/)&^.L/P];
MH:7X["-H$:-!@J>, CM'5UFHXQ@N<S3ET2W&JFVMWQ+C'^*WSP*O1<,@!%[
M;J1!D4^9U_<]"J%+ ?*#0TOR)KY]AHY[/X+U># 9L1T0$#80$/Y$"'B;HV/1
M$WDIRT[JLBN*$Q;5)D38J<4/(8+(JXU&U?-36S!&[@$2S"0(90E? )L"Y"B(
M<1:MS2K79J5D5E&;U6=1BB''W,21Z1U+(9^;A#R']0J;H.<=X/2;A.=LW<G6
M;U*AV_(Y3J@2X3XL?1<Z_#KF';A#%8)).PILVMJL=(8-_OBCR5X8TQ2MVZGC
MUM C^-* REJ(WT::;9BR;<5MS^VH<N".#MD(?7$PQN+V)RM@\=P? !#RK.>$
M%BC"H76N-W0;O#CP*L_W/<?ZWK6?(R=<XX?;GR#R=UO?_SPCZ^[FW4/,;O?S
MOBLSPZWI$.Z;ET&WD;:&?D-VVF;FAMU>N1[Y_BRE-N:N>SB^5IW-66=JW:P(
M#-N!L'N39M#W=G6R8=/)AOMV,H.=X[+&ZJCJ$'OUMTV-:^>B/]2X2+NHH]U^
M&UQJ5L2)75C+5,2V."YXRO,(V#6=[7 /?+]L]]D17W*=V%A'] )XA%O@XKFA
MHAH1K Q1..;$D0&5X:%2W4)EUD/U)B.?TFGL62!YE!TA+ AIF^5,6KNAU=;G
MD2W.J$F,T4_<XF!CIRT.G==*U.<]-S1RMRDU=B[["T\YI&/4TC&K==RT!=EY
MUFFAZA=A$LJM'-@=<&5;B!..JF<P9N<SC.5ZV"1*EO.$S<2BHMA8#AWZQ5-#
MQ=T:7/$;W&]5%!__*[8U;8C_#S?%53KL2(-QDP;C?=.@<T>Q*;J[I?UPC4.U
M=BN:F6UE&!/<E<XH(@L;$;J(PHTMLBE:8LJUT'VB_N;Z]_MCW[7/(>Y!KA04
M7,266:*5BI&"MH52FZB[ J+ >!RR#Y8A;9"@Q3()+%!@A:\"'B(6C.USA&/_
M//)GA3RJ# UL44+D45K&T(Y)!B:1,8XL0)O,FH^>/%=164EZ@WXN^%QB&+"@
M"[#7A.E='Q-!L64BHH0M@=EK1*B4XD61TFF!TJ$=VJ*Z9]3$/P5DP4+!AC_%
M=>G^DB14.53F,:CTCA( L.1E)B)==S@-;4V/V0<T9$T@S1M]F=#MLPL.;7%*
MC,KA&2K"#0E'KE1&MT=EP0HE%X(N5YO^PW&-F+8#Y51'2M3VS!6 77R):$(Z
M9OW:+_ -J]R>S\[+>8E68MH%QYNJ>M"ZH<Q S>T]+*HOR]Q4EY4-M;GJ/:]N
M.-?LU3WQ>Z[F=-&2P@RG.L<C/(2JZNZU^C"RL/>=4VF,S.QK AP]3@PX/I/2
MK#YH@>8"_.P_4$L#!!0    ( $V"5E:J/EADH 0  /<.   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;-U746_;-A#^*X1:%#:0199LV8YK&TB<IBVP
M;D&3=1B&/=#222)*D1Y)Q>E^_8Z4+,N)[7I8NX<]F!;%NX]WQ^].O.E:JL\Z
M!S#DL>!"S[S<F-7$]W6<0T'UN5R!P)54JH(:G*K,URL%-'%*!??#7F_H%Y0)
M;SYU[V[5?"I+PYF 6T5T6114?;D"+M<S+_ V+SZR+#?VA3^?KF@&=V!^6=TJ
MG/D-2L(*$)I)012D,^\RF%Q%5MX)?&*PUJUG8CU92OG93MXG,Z]G#0(.L;$(
M%/\>8 &<6R TX\\:TVNVM(KMYPWZC?,=?5E2#0O)?V6)R6?>V",)I+3DYJ-<
MOX/:'V=@++EV(UE7LD,4CDMM9%$KHP4%$]4_?:SCT%(8]PXHA+5"Z.RN-G)6
M7E-#YU,EUT19:42S#\Y5IXW&,6$/Y<XH7&6H9^;7H-@#M9$A-TQ0$3/*R7NA
MC2HQ]$:3SCU=<M#=J6]P.ZODQS7T504='H .0O)!"I-K\D8DD.P"^&AG8VRX
M,?8J/(IX#?$YZ0=G).R%X1&\?N-\W^'UO^Y\VV4J$O(.DHR)C%Q:UC##0)-K
MIF,N=:F _'ZY1'%DU!_[PE)M.MB_J<VRB5[1&&8>II$&]0#>_-6+8-A[?<2E
M0>/2X!CZ_*Y*+B)3LN!4:Y:RF%;\1Z]N*%/D$^4E6('][N_SZ.B>^SVZSX&D
MDF/2VS :2Z(Z\]E?&$R#R_%S U-KX(,U4%L+DZV%;&OA&4YB7B8.&'%6TN!K
M2UQ(4\QVJRG35(,Q*#)!/V,HEJ :ZK0]O]0HI]MO?F1TR7AUYATF,.LX1_MT
M]VE$6]$\O+(%UNB.9IF@!A)"-<F18J G!*L+U@Z!V:X4B/@+@<<XIR+# &'Z
M6)9I<JM@15GB8B319U5+&P1R]K\DT07Y>6>%M_QX2<+A21M5$%R*[ <#JMC
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M2>ZPI%9"AZ40O&]6/E&--DY\ZP59S&83 IS-1W ?T"AC<3X=AR^CY/[S'[]
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MJOEHT=P8.7,?"L;2&%FYX922@BHK@.NEE&9]8QVT7X[._@%02P,$%     @
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M1*M[T(Q-W/C@3'74I)RL."@+J^E6$IV=+:Q*;W-59*C-+_#V2RWM(_1OQ+)
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MPA'$+E#.T/Z<-P8:1)&FW098)5?(7N@R>M3PQ18*O#B'WU=&&PP#+<8L@/<
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MG$6GA*&5$KH3PQX80Y=:ZX(HFSG;O33M+(XS;W8$%4F/BN35J+B2&R@JZD*
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M="LX.DQ:@/<;I<SAA@[H?QV>_P=02P,$%     @ 38)65B.ZVYH[!0  :2(
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MP2C$3%T@SZ\H%?L=-4#Y=<GL/U!+ P04    " !-@E96M3"GTHX@  "AF@$
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M/NLON^-Q=_/PRT_C^GK<WQ><_ON'W>[X_)O[O^#K;O_KP\=^\_]02P,$%
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M(0\EDJ.-5 \Z!S#DL>!"C[W<F/+*]W6:0T'UI2Q!X)>%5 4UN%5+7Y<*:.9
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MY(9Q;BU&OL%(+)^?UEXGE=?H!:]A1&ZD,+DF7T0&V3Z!CQ(:'=%6QR0ZR9A
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M98H_8;2&#=DQO1#-'71ZQI:O$$RY+VI:W_$8HV*GM*@ZL,F@HKQ=R5-7AR-
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M//CYP:=TO1'5!Z/IU2Y9LQD3#[O[0KX;M2K+=,OR,N4Y*MCJ>O &O[Z)PVI
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M3%,.)(:Y(3-(<L4, TVH2,GG'SDS3_O2,S)-4V9S1SFY$64!VDR^C\$@IOZ
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M2V(>B?DD%I"8(#%)8B&)1206DYB",*W,3^_+_/1ESG>=DCV"Q%P2\TC,)[&
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M5;[<_GB=)O.T:#:H__TRSZN[OS0#?,V++]N'<_[_4$L#!!0    ( $V"5E9
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M'V=9^?BD^J*"S3=9]/\'4$L#!!0    ( $V"5E8A5[T<S (  +@)   9
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M===0-S&R;D_RF31X+[3#)=[<H*P!OI]+:5XF]G+H_POD?P%02P,$%     @
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MO+R(JORE;"\\5(O;:O'\9KCYRTF$OY]TKODY.73N =5&J*:BFH9J8U334<U
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MEBM93KH2_AV=#MZ48#TXXP4.>>%2_JC3'6Q*G+:>O?A3M)K,;I:KZ?V]LC[
M:C&]7DUGM\JJ6CPT5SIV5 +E1BRGLIS&<F.6TUG.8#F3Y2R6LUG.83FWZZ^
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MR$%G0Y<*45[(=YNA<W*0G\Y!;N1@& [8-%_9%]]I$OHYB)?,&Y6#Q*H&U.5
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MG>,QJ'ITUALC*S=,YM+@:'++ O\V0%D'?+Z0TNPV-D#[_Y+\ U!+ P04
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MOKF=J\5Y10J9,4ANU)PN@:S=X";-F5RBM_LF'_V7/J[V?+P,&0SV;(0[%[]
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M?0<<RW%:&C2_7&ZWR/W+Y5:+/.B6/T':*0\OEMM>1R[=:O2XBN>>X<U3R-0
M*4;&U[_$>?"9HXS]TV9U >NWP^0]])ZM882FAKA),D2WR)A]_,WVK$]M-NF$
M^3IA@4Y8J G6L+=?V=OOHL\6Q02FU<T@!C"/19EC*HYOQ,PNYOAMF]L%VU-L
MN<!M9_9X8F[K'IZ&C)H1_FF$G+3UD*"S#]>F6Q.LD>Y!E>Y!9[H?,K+)>5LJ
M"]VPGDIW[%GJ<Y32T]!!OS72;X$.1FY;:-#9[FM3K G62+%7I=CK3O$64?'
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M$94!XOR2$+XOR M4_V#,_@-02P,$%     @ 3H)65F29-D&\!   C",  !D
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M^;AGB(T-P_2 C?[OO]E-ZR_5!0H)&T#"AI"P$21L# F;0,*FD+ 9)&P."5M
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MX9S$Z>$6>P&F4B!^7Q/"3R>R@^(%G/X/4$L#!!0    ( $Z"5E9DJSU;/@(
M - %   9    >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;*U476_3,!3]*U:0
M8)-&G:1I026)M'4@> !5JX 'Q(.;W#96G3BSG6;CUW/M9*&%[DLB#XD_[CD^
MYSKWQJU46UT &')3BDHG7F%,/:-49P643(]D#17NK*4JF<&IVE!=*V"Y Y6"
MAKX_I27CE9?&;FVATE@V1O *%HKHIBR9NKT (=O$"[R[A2N^*8Q=H&E<LPTL
MP7RM%PIG=&#)>0F5YK(B"M:)=Q[,YI&-=P'?.+1Z;TRLDY646SOYE">>;P6!
M@,Q8!H:?'<Q!"$N$,JY[3F\XT@+WQW?L'YQW]+)B&N92?.>Y*1+OK4=R6+-&
MF"O9?H3>S\3R95)H]R9M%SO!X*S11I8]&!64O.J^[*;/PQX@B.X!A#T@?"I@
MW /&SFBGS-FZ9(:EL9(M438:V>S Y<:AT0VO["TNC<)=CCB3+HW,MH44.2C]
MBKR_;KBY):_) I,)2D%.7  YN03#N-"GN*<+ID#'U.#QEH1F_5$7W5'A/4==
M0C8BX^",A'X8'H'/GPX/#N$430_.P\%YZ/C&SW'^11H@/\Y7VBC\P7X>,]FQ
M1L=9;='-=,TR2#RL*@UJ!U[Z\D4P]=\=L_R?R X2,!X2,'Z(/?USQ]JFXHRP
MQA12\5^X<L*K_IY/C^6@(YXZ8MLG=NG$=T],=_OV'H\[4!X-RJ/G*<?VI VK
M<EYM'I,>_2/I;]$/171RZ5Z]V5[WF:D-KS01L$:,/WHS\8CJ^D<W,;)V);B2
M!@O:#0MLN:!L .ZO)?YW_<16]=#$T]]02P,$%     @ 3H)65E)C:^,T!@
MSB,  !D   !X;"]W;W)K<VAE971S+W-H965T.#8N>&ULS5I=;]LV%/TKA%=L
M+5#7(B5_)',,)%8_ JQMD+3;P[ '6J)MH9+HDG3<[M>/DA7)HJX8.]-#7AI+
M/O>(AU>\]Y3F=,?%-[EF3*$?29S*B]Y:J<WY8""#-4NH?,,W+-7?++E(J-*7
M8C60&\%HF <E\8 XSFB0T"CMS:;YO1LQF_*MBJ.4W0@DMTE"Q<\K%O/=10_W
M'F[<1JNURFX,9M,-7;$[IKYN;H2^&I0L892P5$8\18(M+WJ7^-QWO2P@1_P9
ML9T\^(PR*0O.OV47U^%%S\E&Q&(6J(R"ZC_W;,[B.&/2X_A>D/;*9V:!AY\?
MV-_EXK68!95LSN._HE"M+WJ3'@K9DFYC=<MW'U@A:)CQ!3R6^;]H5V"='@JV
M4O&D"-8C2*)T_Y?^*";B( "/6@)($4#, *\EP"T"W&,#O"(@G^K!7DH^#SY5
M=#85?(=$AM9LV8=\,O-H+3]*L[S?*:&_C72<FMTI'GQ;\SAD0OZ&WG[?1NHG
MZJ/YFJ8K)E&4HLL@V";;F"H6HL]JS02:\T2_8^LL^?<,7:<!3QAZZ3-%HUB^
MTM%?[WST\L4K]"*+_QC%L<ZPG Z4'F_VU$%0C.UJ/S;2,C9,T$>>JK5$;].0
MA76"@19:JB4/:J^(E=%GP1ODXM>(.(0  YH?'XZ!</_X<,>BQBUSY^9\;@O?
MY>?Y=3;]\3:,TA6ZX2)?2I=*B6BQ5701,Z0X^L1UAE(EN,Z#AEVGB@DFU6OT
M29<5OD1?Z _T]ZW^%NF5M*,B_ =*U7XH'CR4K#J=RPT-V$5/OQJ2B7O6F_WZ
M"QXYOT/3W"69WQ%9+05>F0+/QCZ[8JLH3;-I7="8I@&#IFY/,<XILCI\/R/8
M&7G3P?WAG#11>$*RU^P0Y0-<9#1T2E1-Q;!4,;2JR%Z$;:K;1AS]JU?Y2K<+
M]#+F4KZ"Y.RY1@=#F$P,+0!D: AI0OHC LL8E3)&5AFW+(BIE-$R"FBV$F3V
M]J=:6Y27*$C+J#D*/'8,-4W0T!#L SP3%U8S+M6,K6KVM3:HU=JHJ+6MN1D#
MXS!>H7D3@SW7T /P8&\("YJ4@B960;J(/[)0)HVG$DR<,V/\$*JQG/PFJKZ<
M:A+.2@EG5@E?N*(Q-')KV*G5L4LROR.RVG1AIW(7SO-I4<58.LI"IVQ^5VSU
M/!RX//S_^U3!42O;1F&8 YC^R"B8/D344CPPJ220[NMAP6DOB "H61$AIM:2
MB"L+AZWVY(BB6!#4ZITIH DQ$^<#F,/$U8=?V1]L]S]Z.>K_6:5HOA6"I<%/
M]$705,9Y^P7%6.E.7J)=LOE=L=6GLO)@>/B,2J75$)Z<AR[9_*[8ZGFH3"2V
MN\CC2F73\.%&J01\HVGG(4R+;\25<<1VYWB:G<>0UVN42 #DFB88 K58>ER9
M1FQWC4\P];CI_4Q+_SC$MT+J8BK[B.W^\6D][.R8! &@9H( 4$N"2&7QB-6Z
M'-'!"@);!P,@YGKR <RPQ<^3RA@1NS'Z6JV3]WJ=2$33$/VA4\$DRJKO/8WB
MK/3VEUST[ZBNP3Y;*'3'@JV(5,3D8>$%Q5N??VJE[93-[XJM/O>5HR/D^70\
M8G67)^>A2S:_*[9Z'BH/2NP>]*B.1P#_:&YA 1AB+N(FI&T-5R:4V$WH:?VN
M(*M72K,_0*"1*:6)\5IZ-ZE<(+%OQ3VAW9'F5IK9'0"(V>X 2-]K:PZ5F2)V
M,_6DAD> W31B[@)!H$:& )?6HJ@R5\1NKHYH=Y!7,LTA!#*WL !,6T(J.T7L
M=NJ1?C>G<HW>Q9KU PM71W0WZ]-.KJI=LOE=L=5GNO)ZY.P9=;=.-R [9?.[
M8JO_1E;Y4]?N3X_J;F[36X[-[@9@M \W72J <EN*CENY5-?N4D_K<&YS^PTW
M.AP$,HNL#X#ZV&EI<FYE_%S[5MX3FIP+;;^-S3X'H!H_U4!,7EN&#GZ*M7NH
M)S4Z%_)4#4V 8YJ,35$ $_:\%E65LW+MSNKQ9N<V?Y!L]#H 8RXN'\#4%M=>
MP.#@H$/"Q"H_,"+UM&]3M3\%4-XM#Z5<YD<QC/M7^-S?'RVI:/8G73Y2L<KZ
M8LR6FM)Y,]:^2.P/C^PO%-_DQRD67"F>Y!_7C(9,9 #]_9)S]7"1/: \PC/[
M#U!+ P04    " !.@E96G_81=S,(   (40  &0   'AL+W=O<FMS:&5E=',O
M<VAE970X-RYX;6S%G%UOVS84AO\*X0U#"W2U1<E.TB4&FHC%"BR#T:#;Q; +
MQJ9MH?KP*#H?PW[\2$DQ35NFH^$=?-/:BOB(.J]YI/>(XN5C(;^52R$4><K2
MO+SJ+95:?>CWR^E29+Q\7ZQ$KO\R+V3&E?XJ%_UR)06?58VRM$\'@U$_XTG>
M&U]6VR9R?%FL59KD8B))N<XR+I^O15H\7O6"WLN&+\EBJ<R&_OARQ1?B3JBO
MJXG4W_H;RBS)1%XF14ZDF%_U/@8?V'!@&E1[_):(QW+K,S&G<E\4W\R7S[.K
MWL#T2*1BJ@R"Z_\>Q(U(4T/2_?BK@?8VQS0-MS^_T#]5)Z]/YIZ7XJ9(?T]F
M:GG5.^^1F9CS=:J^%(\_B^:$AH8W+=*R^I<\-OL.>F2Z+E61-8UU#[(DK__G
M3TT@MAK0X8$&M&E =QH$T8$&8=,@?&V#J&D0[38(#S08-@VJ4^_7YUX%+N:*
MCR]E\4BDV5O3S(<J^E5K':\D-S^4.R7U7Q/=3HU9MDJ+9R'(M<C%/%$E^9'\
MRJ7D1C_R)A:*)VGY5F_]>A>3-]^_)>622U&2)">W29IJL<MWY/OMKY=]I3MF
M\/UITXGKNA/T0"<"2FZ+7"U+PO*9F+F OCZCS6G1E].ZIEYB+*;O21B\(W1
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MTAB*YKYZ:"UX=.JI]Q%TZCV4%D-I#$5SI;1./SHR];[C0\<C.,]\"G_+SB)
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M?CBP_7&=W.FPADTI:G?Y5Y$<ZV.OO4#^FTE,T$IGLKW)9&R%GO5W,A:Z*3>
MU+1;,&<=:*]^FQI:K-)?\Y=P-MNHG/-/EM3IF'$=2H/,L+:Q.*43A!3XVIS$
M"+1D.RJS3^FBMSCMN3-G'+7^>WT*9$XFCC+9$=(CYBHI"41@I2159:+<XMFI
M3'8CV=:<4[PQ*5EJFAO ,7 ]0#U?,2;?;_0$Q=G8_%]02P,$%     @ 3H)6
M5O?KC1G]!0  8R4  !D   !X;"]W;W)K<VAE971S+W-H965T.3$N>&ULM9I=
M<YLX%(;_BL;;V4EG$D"R#7;6\4QBNKN]Z#23;-IK!62;*2"OD)WFWZ_X,"#
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M,FNK3R+"-MDJG@1X=!_S?"%&>;1<*72?K8]I''^ MVZ^WJ>2R9<??<%L(SB
MD*R%I&4XXD' \A4]^0ZGNVR-RROEG$;9YI9@G["T@3B_II0?=](.RG55R_\
M4$L#!!0    ( $Z"5E9Q6<G'SP,  .@0   9    >&PO=V]R:W-H965T<R]S
M:&5E=#DR+GAM;,5876^C.!3]*Q8KK7:D;?D(2=-N$JD)'>U(.U+4:&8>1O/@
MPDVP:C!C.TGS[]<VA 0&:%HAS4L"YIZ#S[EPK\UDS_BSB $D>DEH*J96+&5V
M9]LBC"'!XIIED*HK:\83+-4IW]@BXX C TJH[3G.R$XP2:W9Q(PM^6S"MI*2
M%)8<B6V28'Z8 V7[J>5:QX%'LHFE'K!GDPQO8 7R2[;DZLPN62*20"H(2Q&'
M]=2Z=^\"U]< $_&5P%Z<'2,MY8FQ9WWR*9I:CIX14 BEIL#J;P<+H%0SJ7G\
M+$BM\IX:>'Y\9/]HQ"LQ3UC @M%O))+QU!I;*((UWE+YR/;_0B%HJ/E"1H7Y
M1?LBUK%0N!62)058S2 A:?Z/7PHCS@#NJ 7@%0"O#O!; (,",+@4X!< 8[6=
M2S$^!%CBV82S/>(Z6K'I V.F02OY)-5Y7TFNKA*%D[.')*/L (#FD,*:2(&N
MT$H]7-&6 F)K="_4$Y'I% GT14"$)$,+3,,MQ1*0C %]Q(2CKYAN\_@]YI%
M?P4@,:'BP\26:I;Z7G98S&B>S\AKF9'KH<\LE;% #VD$497 5O)*C=Y1X]SK
M9 P@O$8#]V_D.9[7,*'%Y7"W 1Y<#G<ZU S*C T,G]_"MY(L?$8LSTF3O9UP
M74?N1(9#F%JJ4 C@.[!F?_[ACIQ_FJSIDRSHB:QBFU_:YAOV09MM,>9PI4M$
MA!8L47538%-Y[CG'Z094+9/HZ8#.XY;X8(;-0XV^_Z<HT2<)B?C1Y+O?I^]]
MD@4]D55\'Y:^#SL?UX>73)5X9>:.J9)!*)&')O-R$M<Q++I9[6;.M7<SL7?G
MKC1'W5:C@M>B*CI&I8[193HD\$0@DJ(#8-[X G83#5N!B_<"@W< *R;<E";<
M=#(]$O%\M>:J79!4^0!"(J[Z0),).9'K5I+@N+5<+9K#G'$MI:^&5>2,2SGC
MRW(:D1V)((W0@0"-FN2,&R?@#VIR6L+\FIQQTQ/J^,UJ;DLUM]UJ5LMET]0[
M46^M2WV2!3V15=QRG=/*Q_G-':&80$_6]\H6],56-?]LV>GVT18*EGHMK[]V
M+6'#VFO7$M9215SO),;KJS>\PC1"B5G[-N;_W=#@7="J&:?EJ=N]/GU#CRB8
M?FD2XWIZF^,<MY[?EKA12X)/:T>W<XGTED91,/W2 H9U32UQ]59QC'NE5]AG
M6\ $^,9LI04*V3:5^4ZI'"VWZ_=FDUH;G^MMO-E:GFCR;P"?,=\0M0VDL%:4
MSO6-6F?Q?%N=GTB6F8WF$Y-JVVH.8\ 1<!V@KJ\9D\<3?8/RX\;L?U!+ P04
M    " !.@E96I75/DJ<#   T#0  &0   'AL+W=O<FMS:&5E=',O<VAE970Y
M,RYX;6S%5VUOXC@0_BNC7'5JI2UYX:6T!TA >KI*5PDMU]L/J_O@)@.)ZM@Y
MV\#R[\]V0C:P(=N56-T7B.UY'L\\]DPFHQT7;S)!5/ EHTR.G42I_,%U991@
M1F2'Y\CTRHJ+C"@]%&M7Y@));$$9=0//&[@929DS&=FYA9B,^$;1E.%"@-QD
M&1'[&5*^&SN^<YCXF*X392;<R2@G:URB>LD70H_<BB5.,V0RY0P$KL;.U'\(
M?<\ K,7?*>YD[1E,**^<OYG!4SQV/.,14HR4H2#Z;XMSI-0P:3_^+4F=:D\#
MK#\?V'^WP>M@7HG$.:>?TE@E8V?H0(PKLJ'J(]_]@65 ?<,7<2KM+^Q*6\^!
M:",5STJP]B!+6?%/OI1"U #^X P@* '!*:!W!M M =WW GHEH&>5*4*Q.H1$
MD<E(\!T(8ZW9S(,5TZ)U^"DSY[Y40J^F&J<FCUE.^1X19LAPE2H)M_"X7"Q@
M:@XD57NX#E&1E,H;O?*R#.'ZZ@:NP 69$($24@8O3.,^U":>4TKUH>JYJ_IP
MY"KML=G7C4KO9H5WP1GO_ ">.5.)A$<68WQ,X.I0JWB#0[RSH)4QQ*@#7?\#
M!%X0-#@T?S_<;X"'[X=[+=%TJ]/K6K[N&;ZED?S6W/L8YCS3Q4 2FTY3(0A;
MHTY0!:][J-LMR-Y.3W=$Q/#Y3TT)3PHS^4_3^13[]YKW-T7I0>8DPK&CJXY$
ML45G\NLO_L#[K4G;2Y*%%R([TKU7Z=YK8Y\\2;DA+-*W?:/OI0 \9)'.U^@-
M\HV($BTVY)2P)E4+]CO+;BKS=N)[W9&[K8O58./[QS9A$X]7V1R%UJ]"Z[>&
M9I*_R>56U(]>A$N2A1<B.U)K4*DU^)\3<'!)W2])%EZ([$CWNTKWN]9;NBS?
M-3H/3U\+A6P%?%#+C. DO[YK$;99''D]K+P>_M2R,7Q'V6BP^:9L-/&<*1OW
M56CWK:%]L@T6QK=DBT(WC+#6]U]!3!3"BJ0"MH1N$/BJZ"[*7L$:Z92XUEU"
MS"DE0D*NA;'+-TT2%%[<UUWO=GHG&C08]3K]X8D*#5;]CG??K(/O?6VHO%8E
M_N**T):8B30S*D'=-LL<;=\+6Y0J96NK5W.?Y'US9L')L<Z;;$ZN1]ADTSL)
MV:VUDQF*M6W+)41\PU31:56S5>L_M0WOR?S,?!+8-O4K3?$]\4S$.F42**XT
MI=>YTT5<%"UZ,5 \MTWK*U>Z!;:/B?ZL06$,]/J*<W48F VJ#Z7)?U!+ P04
M    " !.@E96C[(Y]7T#  #3"P  &0   'AL+W=O<FMS:&5E=',O<VAE970Y
M-"YX;6RU5M&.XC84_14K'54STI2$$,(P!:2![+;[,*O1HFD?JCZ8Y +6.#%K
M.[#]^UX[(0U)8!EI^P*V<\Z-S[GVS9T<A'Q36P!-OJ4\4U-GJ_7NT755O(64
MJI[8089/UD*F5.-4;ERUDT 32TJYZWM>Z*:49<YL8M=>Y&PB<LU9!B^2J#Q-
MJ?QG#EP<ID[?.2Y\89NM-@ON;+*C&UB"?MV]2)RY592$I9 I)C(B83UUGOJ/
MT=C@+> /!@=5&Q.C9"7$FYE\2J:.9S8$'&)M(E#\V\,".#>!<!M?RYA.]4I#
MK(^/T3]:[:AE114L!/^3)7H[=1X<DL":YEQ_$8??H=0S-/%BP97])8<2ZSDD
MSI46:4G&':0L*_[IM]*'&J$?GB'X)<%O$H(SA$%)&%Q+"$I"8)TII%@?(JKI
M;"+%@4B#QFAF8,VT;)3/,I/VI9;XE"%/SSY0F;%LH\@+2++<4@GD%[+$PY7D
M'(A8DS;@GLRI8C&A64(BQG,-";F-0%/&U1VR7Y<1N;VY(S?$)<H0%&$9><V8
M5O>UA6?&.68>UV[JTXFK49;9G!N7$N:%!/^,A+Y/GD6FMXI\R!)(3@.XZ$=E
MBG\T9>Y?C!A!W".#_CWQ/=_OV-#B>GJ_@QY=3_<NJ!E4*1[8>(/K4_S7TTII
MB7?N[RZ[BW!!=SA3AQ[5CL8P=;#0*)![<&8__]0/O5^[K/J1P:(?%.S$QJ"R
M,;@4??89:S#+8I$"H5I+MLHU7>$=T8+\QCA6W"XKBY C&])4X/TL&([Q2.WK
M%K5!H>\/3T%1&]3W!Q7F1-&P4C2\J&A9W,5<X07&&[BRMQJ.IV6'I\7>UC-R
M24QYG'-JR_<M\HNK?==E0[&/\&3SPX;"12<H;-C0"1IU^Q!6/H07?;!%#+\^
M!-9K_!R9JH=U-WXC8F?$*5OIX&O.]I1#IM7WU(:M/8X:4MN(ILY+B!.1HTKD
MZ#W)3LK"_;^D>]21I+!YZJ\!19V@,\?^H7+BX:(3\W>><R,V$9Q360-WZB[>
M.Z[M=M +&YE=M$%!;]Q,?QOD]?K=LL>5[/'W3_F[,GZ]\'&7\* AO U"X8.&
M\#:H+=RMM3LIR(UM&Q6)19[IXB-?K5:=Z9-MR!KK<^Q8BP;SOS!%N_M,Y8;A
MS>>PQI!>;X1U1Q8M9#'18F>;JI70V*+9X18] VD ^'PMA#Y.S NJ/G[V+U!+
M P04    " !.@E96T7)ZBXH"  #,!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Y-2YX;6RM5=]OTS 0_E>L(*%-@N576]!(([7+$#P,59N !\2#FUP::XX=
M;*<M_SUG)PW=E%5]V$MLG^_[?'<^?TEV4CWJ"L"0?<V%GGN5,<VU[^N\@IKJ
M*]F P)U2JIH:7*J-KQL%M'"@FOM1$,S\FC+AI8FSK52:R-9P)F"EB&[KFJJ_
M2^!R-_="[V"X9YO*6(.?)@W=P .8[\U*X<H?6 I6@]!,"J*@G'N+\#J;6'_G
M\(/!3A_-B<UD+>6C77PMYEY@ P(.N;$,%(<MW #GE@C#^--S>L.1%G@\/[!_
M=KEC+FNJX4;RGZPPU=S[Z)$"2MIR<R]W7Z#/9VKY<LFU^Y)=[QMX)&^UD74/
MQ@AJ)KJ1[OLZ' '"V0N J =$SP&3%P!Q#XC/!4QZ@"NUWZ7BZI!10]-$R1U1
MUAO9[,05TZ$Q?2;LM3\8A;L,<2:]I4HPL=%D!8H\5%0!>4^^4:6HO0]RD8&A
MC.M+M&J[JP\#$^2.<8YWIQ/?8"26S\_[4Y?=J=$+IX81N9/"5)K<B@**IP0^
MIC#D$1WR6$8G&3/(KT@<OB-1$$4C =V<#P]'X-GY\.!$-O%P*['CB\^_E5^+
MM38*G\GOL7)W=)-Q.BL=U[JA.<P]U 8-:@M>^O9-. L^C97J-<FR5R)[4L;)
M4,;)*?9T(0PK&&]=*VO(6\4,P]Z%?<Y;[#M2*EF37-9-:ZB3(5D2.-2^P=J[
M9B<7V.Q=VU^.%;\+8N:"L#*[Q?Y._.UQ24=<ID]=LA&7>'#ITO>/WGD-:N/T
M4F,"K3#=4QFL@R0OG!(]LR]1JCME_4_3Z?P=51LF-.%0(F5P]6'J$=5I9[<P
MLG%JLI8&M<E-*_S=@+(.N%]*:0X+>\#P TO_ 5!+ P04    " !.@E96.E3G
ME=$"   I"   &0   'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6RM5EU/VS 4
M_2M6AB:0!OE. TLC4;)I2$-"=&P/TQ[<Y+:U<.S.=EOV[V<[:=:/T/' 2^./
M>X[/N4[N;;;FXDG. 11ZKBF30V>NU.+*=64YAQK+"[X IG>F7-18Z:F8N7(A
M %<65%,W\+S$K3%A3I[9M7N19WRI*&%P+Y!<UC46?T9 ^7KH^,YFX8',YLHL
MN'FVP#,8@WI<W L]<SN6BM3 ).$,"9@.G6O_JDA,O WX3F MM\;(.)EP_F0F
MM]70\8P@H% JPX#U8P4W0*DATC)^MYQ.=Z0!;H\W[)^M=^UE@B7<</J#5&H^
M=%('53#%2ZH>^/H+M'YBPU=R*NTO6K>QGH/*I52\;L%:04U8\\3/;1ZV '[R
M B!H <$^('H!$+: \+6 J 5$-C.-%9N' BN<9X*OD3#1FLT,;#(M6MLGS%S[
M6 F]2S1.Y;>LY#6@;_@9)#I'8_U:54L*B$]1NW7ZE4MYAD:@WS% ._&G!2A,
MJ-X]1X_C IV>G*$31!BZ(Y3J6Y69J[1&<Y);MGI&C9[@!3U^@.XX4W.)/K$*
MJET"5YOK' 8;AZ/@*&,!Y04*_0\H\(*@1]#-Z^%^#[QX/=P[XB;L[BNT?.%_
M[PL51):4RZ6^E9_7$ZF$_H9^]66\88SZ&4U=N9(+7,+0T85#@EB!D[]_YR?>
MQ[YLO259\49D.YF,NDQ&Q]CS0N=1*E+V9:Q!#BS2%,Y5'D7A9>:NMC-Q&)3&
MZ6 WJ#@,"F(O[H)VE,>=\OBH<EWP=#EC?<(;8+)UG!\.XCWAAT'GH;?GKN@)
M2L.D7WC2"4^."F]?WDE32D@S4Z:4]'E)#E(7IWZTY^4P* T&Z9Z7PR _22[W
MO+A;1;0&,;/-2**2+YEJJDVWVO6[:UOF]]9'N@\V;>L?3=-$[["8$281A:FF
M]"X&.LFB:4S-1/&%+=43KG3AM\.Y[N4@3(#>GW*N-A-S0/?O(/\+4$L#!!0
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MM3-1=Z?U0/%]U:^]<*6[O^IRISMZ$"5 /]]PKDZ#\@7M_PA6_P-02P,$%
M  @ 3H)65G,4RH:<!   31$  !D   !X;"]W;W)K<VAE971S+W-H965T.3@N
M>&ULK5A=;]LV%/TKA(85&=#8HOR9U#806RV6AVY!LFX/PQYHZ=HF*I$N2=GI
M?OTN)5FV-4K*0_,02_(]QSSWBY>:':7ZJG< AKRFB=!S;V?,_K[?U]$.4J9[
M<@\"O]E(E3*#MVK;UWL%+,Y!:=(/?'_<3QD7WF*6/WM2BYG,3,(%/"FBLS1E
MZOL2$GF<>]0[/7CFVYVQ#_J+V9YMX07,E_V3PKM^Q1+S%(3F4A %F[GW0.]#
M.K* W.)/#D=]<4VLE+647^W-8SSW?+LB2" REH+AQP%6D"26"=?QK23UJM^T
MP,OK$_NG7#R*63,-*YG\Q6.SFWM3C\2P85EBGN7Q5R@%Y0N,9*+S_^18VOH>
MB3)M9%J"<04I%\4G>RT=<0&@XP9 4 *".F#8 !B4@,%; <,2,,P]4TC)_1 R
MPQ8S)8]$66MDLQ>Y,W,TRN?"QOW%*/R6(\XL'D4D4R!_L%?0Y):\8%[%60)$
M;DC(-QM0("(@2S!' $&>E#SP/.3H='*%92(FGR &Q1+R8IC)C%3?+TS(,S-
MC#P]6@(F+5PP;NJ,-R$8QA/]RZQO4*E=;S\J52T+54&#*AJ0SU*8G28?10SQ
M-4$?753Y*3CY:1FT,H80]<B OB>!'P2.!:W>#J<.>/AVN-^B9E!%?9#S#3JC
MCE'642)UAK'X^V&MC<)*_,?E\8)QZ&:T[>E>[UD$<P_[CP9U &_Q[B<Z]C^X
MO/4CR<(?1';ER6'ER6$;^^*4\KI*>85Y[O)?P4/]G,BVX\/"[]ED.%PZYDU6
M89?5E911)674*L56+5:HK;WW1."6@SU@4\I;@X --RY=[:0W0<_W?W:5\*H
M4GHEP@]&-:UNLV'@%CNNQ([;XX;-AV\% :8$%UOL7X;$9<,S>0RU2VP[Z8W?
M&S>([00.W,"P TA]AW^O/#*I/#)II7K&VF JVN6=7)H=*!(IB+EQ.J*="Z,^
M:7!$!Y V>3#L (Y[=^U^F%9^F+8R?7FQ-4"*'>DJ1UQ^F+J3>%(K:[<9K=>U
MVVQ"[Z[^W)E_5^F[>TOFWV)AX\05$RX,$UN^QDV?%]L"[IA9/I6Y!+>3WPQZ
MTX; =P"; ]\!G'85 /7/LY#?W@'!F 12VP&P]]DL@%>&0Q>SSG"&OX,0ZSIH
M<$<WLJ&"PBXD=?WHM4<NID/:2O80?<LX=@'R^/3\CJ7[#R')/W#D3[!'QB3:
M,;5U]\J2^G])/ZS5QLGN:C>K%8:;:S3&X\WYKV'_H\%9;="J=K7#2L#)DPMR
M8$G&BI-)@F<CAE.P4V/@UAC4-3;8U3>[!KOQI$':>>"CK5/0XC<I;C&AF2WS
M3. ),>'_8OAP\M.VU7%Q &ULYCM5#IRK\NM=KL&.3NLJ!\[Y9= @\CR+T?9A
M['>[:SD%#)T+&TSK MQV]90-W7;T(IS7"LXC&&T?ES[B!)*?A//NTS1*4N=,
M%-2S:=5@-ZIO.VZ[NV$]Z_H7Y\P4L.[M>5V32&;"%$>IZFGU3N A/PG7GB_M
MNX+\_'JF*5XT?,9VPH4F"6R0$IL@+DT59_?BQLA]?II=2X-GX_QR!PPW,VN
MWV^D-*<;^P/5&Y3%?U!+ P04    " !.@E96UO+KN#L%   C&   &0   'AL
M+W=O<FMS:&5E=',O<VAE970Y.2YX;6RU66UOVS80_BN$5Q0M4->B),MVFAAH
MK0TKL&Y!TG:?&9F.B5*B1M)QO%^_HZQ8"LFPGI%\B?5R=[KG.?+XD#G?"OE#
MK2G5Z+[DE;H8K+6NST8C5:QI2=1[4=,*WJR$+(F&6WD[4K6D9-DXE7P41U$V
M*@FK!O/SYMFEG)^+C>:LHI<2J4U9$KG[1+G87@SPX.'!%;M=:_-@-#^OR2V]
MIOI;?2GA;G2(LF0EK103%9)T=3'XB,_RN'%H++XSNE6]:V2@W CQP]Q\7EX,
M(I,1Y;30)@2!GSNZH)R;2)#'/VW0P>&;QK%__1#]MP8\@+DABBX$_YLM]?IB
M,!V@)5V1#==78OL[;0&-3;Q"<-7\1=O6-AJ@8J.T*%MGR*!DU?Z7W+=$]!QP
M^H1#W#K$QSHDK4-RK$/:.J0-,WLH#0\YT61^+L4626,-T<Q%0V;C#?!99>I^
MK26\9>"GYY^K0I04?27W5*$ANH9QM=QPBL0*Y71%I:1+\Q)]5(IJA4BU1'\P
M<L,XTPP\WN14$\;56_#]=IVC-Z_>HE>(5>@+XQSJJLY'&K(TWQH5;4:?]AG%
M3V24T^(]2O [%$=Q['%?'.^./>[Y\>[18_<14'O@-S[P&S?QDB?CM21J()$T
M))[Y.-E'2?U1S.0_4S4IZ,4 9K>B\HX.YJ]_P5GTP<?0<P;+GRG8(_:2 WM)
M*/K\3VA\T.(DT:RZ15PHA0HBY0[ZW9;(I7=T[2-.FHBFZ]W-TP0J>=<GR&.#
MD\<V>3"S$W&G!]QI$/>U%L6/H>EG2P3S$YJ\(J9-^O#N(V4]++.Q!=<UP7AB
MP0TF="+<\0'N. CW:A]QWUY(4<@-X0I50D,'A,E3:;Z#7K[<P!IQPZF/A+&#
M,$MM%ER;260-C#R8YXDL9 <6LB +O]X7% 8X=%[3*Z#X#&[N**QKL&H^W*^@
MN6I2W1HBVG[BXR-S*QYE5LD7'B,\ML=%,.<3&9D<&)D$&?E6KZ2H=#,L2L8I
MK(851379@?#PXYZXD.+9U,+M,4JP/1*"F9V(>WK /?WI?""R6#? A5[#&"A@
M#6'ZY]UOZF"+$ZNS+3PVZ<R"'TSP1/BS _Q9>"+\LV%Z!P,=6H)^LM0SMXJS
MS$+JL8EMI,%<3D2*HTY^14&L#V)J!R*:$VV$@D"*[!78:J,WDB(I=H0;N>45
M4Y%;S8D]XKU&J45$.--3F>@)41QD8D%JI@EG_P('5Z])67_($;V'I0_&/;#@
M!X_=GCY-;?"ND3W9PZF="KW3B#@HHN9_F2G^#E54>T'&;O$R>T[[C&:Q#?,E
MM!SNQ!P.J[FO NIK-F6V(D8W%'H:17>$;\A^.\AA0TJJPKO8MY_I8QW'TYG-
MB&N59BFV*7D)F8<[G8?#0N_[D8A=!3<<SQS$/JO8&>NI(WZ'26^-?(RDDW X
MK.&>+*X7CZO%TFQFJW2?%8Z="KZ$9L.=:,/9\1L\WFV-O;L\_$QJJN7G.:/E
MSQ7M,8^=U,-AK7<IS49/[]ZAFI-6\U$0 K41 %XN71DWC!.G^?NL8EODAG,[
M%7LG]W!8[W7*OR_UC?3O[02.5/[857?#\21V%(''+)M@6QR%$S^5F$X(XK 2
M;!9&+TI7V0WAJS9(GY6[*KZ$ HP[!1B'%:"G<?;:B/>LR%5SPPS'%JZ%SVR"
M$VLDY.'T3H7?R;XX+/O,$8]/$KSID?#6RP)VUS&<)@X+'K,D<HX_PEG^7Q9&
MO0-9<WS^A<A;5BG$Z0K"1^\GL&;)_8GT_D:+NCFCO1%:B[*Y7%.RI-(8P/N5
M$/KAQAS['OXO,/\/4$L#!!0    ( $Z"5E9Z%@@E+@0  !X4   :    >&PO
M=V]R:W-H965T<R]S:&5E=#$P,"YX;6RU6-MNXS80_15"710)T$07R[:<V@*2
MJ$4#;-I@TVP?BCXPTMAF5R*])!T[_?J2DB+K%B(.E)=8I&;.\)R11I.9[QC_
M)M8 $NVSE(J%M99R<V';(EY#AL4YVP!5=Y:,9UBJ)5_98L,!)[E3EMJ>XTSL
M#!-JA?-\[XZ'<[:5*:%PQY'89AGFSU>0LMW"<JV7C2]DM99ZPP[G&[R">Y /
MFSNN5G:%DI ,J"",(@[+A77I7D3N1#OD%E\)[$3M&FDJCXQ]TXN;9&$Y^D20
M0BPU!%8_3W -::J1U#F^EZ!6%5,[UJ]?T'_-R2LRCUC -4O_(HE<+ZS 0@DL
M\3:57]CN-R@)C35>S%*1_T6[PG8\LU"\%9)EI;,Z049H\8OWI1 U!T6TW\$K
M';RV@_^*PZAT&+W5P2\=_%R9@DJN0X0E#N><[1#7U@I-7^1BYMZ*/J$Z[_>2
MJ[M$^<GPAL8L _0GWH- 9^AWS#G6F4 G$4A,4G&J=A_N(W3RZ11]0H2B6Y*F
M*F-B;DL57Z/8<1GKJHCEO1++]= MHW(MT"\T@:0)8*N#5Z?W7DY_Y1D1(XC/
MT<C]"7F.Y_4<Z/KM[FZ/>_1V=\? 9E3E8I3CC5[!^V,#6GRZ0I^9$.A:Y>)9
MO=D[S!.!_OZLK-&-A$S\TR=] >WW0^OJ<2$V.(:%I<J# /X$5OCC#^[$^;E/
MMB'!HH' &I+ZE:2^"3W\BM,M+@I,JDH<IC'TB5> 3',072F?PO%L-K>?ZIKT
MV.BLUVVBKLUH%E0V#0;CBL'8R."!<HC9BI+_($$2[]$C4%@2V?O^%5"36OR9
M/VGQZ-H$3IN'\4CO3-FD(CPQ$BXKDJ:J/FXXE415)DP357LDJ' 2G902G"+8
M*Q/1F]))A^;9J*5$U\1W6T),.@D]"[S^A$XK?E,CO\LXYENHT2FX=4GWL9IV
MCNRYXQ:M/IN@Q<MXQ'<F.*@$"-XD (<-EIP4KR=;(E7JU%>:(L"<JB+8RS_H
M<!N-.T]XT$F:[W0><>,9WZG K%)@9E0@4KD6DL1YOO%6KADG\KF/KQ'GV*H^
M)%@T$%A#/]<Y="W.QWTJ2^R!5!T4+1H*K:EKK1MTC4_F0==4ZQK7=>V5TNV\
MD&[GRVF.>;1" Z$U%?(."GE&A52GC&(."9$-=7K%\3KB3-O2&(,=+<U :$UI
M#NVK:VSEPGN))>2?LY3%.$7_;CD1"<G_P>O59]">=5"T:"BTII2'MM7U/["^
M&7OBHW4=$BT:"JVIZZ&9=LW=]-'UK=LM>]-V+W%M#GJT1!_1?;N']MLU]]_'
M%+AN>QQ,.]7?&.YH<09"*\2Q:X.3#/@J'T"IQX)MJ2RF$-5N->2ZS$<[K?TK
M/?S*!S('F&)R=HOYBE"!4E@J2.=\JK++BV%4L9!LDX]G'IF4+,LOUX 3X-I
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MX*6G"?Z'=AOGPV=^B#N\KEU&X:3S;F8NJV3:\^:%!SU9.,A?=]N*@NZNE3N
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M\CFX]3SRUL\IK_EW>O074$L#!!0    ( $Z"5E:7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 3H)65E$46A4I!P
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M<' N>&UL4$L! A0#%     @ 38)65JG.#DGM    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 38)65IE<G",0
M!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " !-@E96(F-BX,P'  !^+P  &               @($,"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 38)65M$H9DP[
M @  O 4  !@              ("!#A   'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( $V"5E8(DBS;A 8  ,H;   8              "
M@7\2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !-@E96
M@Z@?2-4"  !W"0  &               @($Y&0  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ 38)65CC1L7DG!@  XQT  !@
M     ("!1!P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M $V"5E9= 8//W@0  $@4   8              " @:$B  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " !-@E96[H$(ZR@#  !_"@  &
M            @(&U)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ 38)65HD/KJ?#"@  JV\  !@              ("!$RL  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $V"5E;):[2#=P,  !</
M   8              " @0PV  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " !-@E96\R!K)<4(  !=*P  &0              @(&Y.0
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $V"5E;Q5L2_
M3RH  (:&   9              " @;5"  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ 38)65HCTF2.G"0   14  !D
M ("!.VT  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !-
M@E96Y#O,'R@*  #S&@  &0              @($9=P  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $V"5E; ]>;C_ @   $;   9
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M970Q."YX;6Q02P$"% ,4    " !-@E96K4+'DYT$  #/"@  &0
M    @($IL   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M $V"5E9W?81M6B,  !>%   9              " @?VT  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ 38)65B4!V'IV"@  *1L  !D
M             ("!CM@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " !-@E96ZP8EH+8$   %"P  &0              @($[XP  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $V"5E;[RC,QG!T
M ,)=   9              " @2CH  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ 38)65B7FJK; !P  :Q,  !D              ("!
M^P4! 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !-@E96
MG*?..S$-   A)P  &0              @('R#0$ >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( $V"5E9\4ZEY5@,   T(   9
M      " @5H; 0!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ 38)65GY/WR@4"P  2!T  !D              ("!YQX! 'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !-@E96<L!NDBL$   5"0
M&0              @($R*@$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( $V"5E:9[9(6CR<  )J&   9              " @90N 0!X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 38)65E@2"@'&
M @  $ 8  !D              ("!6E8! 'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " !-@E96^W^&D<0)  #6%0  &0
M@(%760$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( $V"
M5E8-;86)PP4  %@/   9              " @5)C 0!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ 38)65GFNF!_)!@  #!<  !D
M         ("!3&D! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    " !-@E96JCY89* $  #W#@  &0              @(%,< $ >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $V"5E9=U#%_N ,  $()
M   9              " @2-U 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ 38)65ORWJ#!+ P  * <  !D              ("!$GD!
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !-@E963-H/
MA[8%  !%$@  &0              @(&4? $ >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( $V"5E;IUR3W- 0  &X*   9
M  " @8&" 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M38)65@4+UD'/!   VPP  !D              ("![(8! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " !-@E96I.]-8?,#  #6"0  &0
M            @('RBP$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( $V"5E:/C U[U@0  *X,   9              " @1R0 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 38)65MKN3C&]!P
M5Q@  !D              ("!*94! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " !-@E96D.)%V/4"   ]!P  &0              @($=
MG0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( $V"5E9!
MSRX<O0<  $84   9              " @4F@ 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ 38)65B.ZVYH[!0  :2(  !D
M     ("!/:@! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $V"5E;.1CM4_A    BW   9              "
M@6;7 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 38)6
M5D/X$7 -!   5A8  !D              ("!F^@! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " !-@E96]U;CU2<#  ##"   &0
M        @('?[ $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( $V"5E9UNZ)C?04  #PB   9              " @3WP 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ 38)65B\:]8SJ!@  L#
M !D              ("!\?4! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " !-@E9614N).Y@#  #)#   &0              @($2_0$
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( $V"5E;Y=,\>
M*@,  %<-   9              " @>$  @!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ 38)65E[MJB\X P  1PT  !D
M ("!0@0" 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !-
M@E96X,_ _FH#   +#P  &0              @(&Q!P( >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( $V"5E:WNTK?3@,  (<*   9
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M970V,RYX;6Q02P$"% ,4    " !-@E96#TVNDTL#  #Y"0  &0
M    @(&=,@( >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M $V"5E:<"2SIWP(  !L+   9              " @1\V @!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ 38)65K5, C3$ @  GP<  !D
M             ("!-3D" 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    " !-@E962JA'8'\%  #-)   &0              @($P/ ( >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( $V"5E;A#!FK  @
M -5"   9              " @>9! @!X;"]W;W)K<VAE971S+W-H965T-C@N
M>&UL4$L! A0#%     @ 38)65B%7O1S, @  N D  !D              ("!
M'4H" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " !-@E96
MVP^P";("  #9!P  &0              @($@30( >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;%!+ 0(4 Q0    ( $V"5E9XS,38NP(  !<(   9
M      " @0E0 @!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%
M  @ 38)65I7W^A-J @  )@<  !D              ("!^U(" 'AL+W=O<FMS
M:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " !-@E96=7.P"/T"  "*"
M&0              @(&<50( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+
M 0(4 Q0    ( $Z"5E9P@CJS8D0  )K;!0 9              " @=!8 @!X
M;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ 3H)65CR6,(!U
M"0  4U$  !D              ("!:9T" 'AL+W=O<FMS:&5E=',O<VAE970W
M-2YX;6Q02P$"% ,4    " !.@E965]V+[7<(  "+60  &0
M@($5IP( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( $Z"
M5E8Z7FO,#P,  $,,   9              " @<.O @!X;"]W;W)K<VAE971S
M+W-H965T-S<N>&UL4$L! A0#%     @ 3H)65I-L9>BT @  RP@  !D
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M=#@R+GAM;%!+ 0(4 Q0    ( $Z"5E85UQUX- 0  ,T8   9
M  " @3/& @!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @
M3H)65F29-D&\!   C",  !D              ("!GLH" 'AL+W=O<FMS:&5E
M=',O<VAE970X-"YX;6Q02P$"% ,4    " !.@E969*L]6SX"  #0!0  &0
M            @(&1SP( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4
M Q0    ( $Z"5E928VOC- 8  ,XC   9              " @0;2 @!X;"]W
M;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ 3H)65I_V$7<S"
M"%$  !D              ("!<=@" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX
M;6Q02P$"% ,4    " !.@E96(G6'EU,&  !C,P  &0              @(';
MX ( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( $Z"5E:;
MO*$@* 0  !X3   9              " @67G @!X;"]W;W)K<VAE971S+W-H
M965T.#DN>&UL4$L! A0#%     @ 3H)65@ZT^9 C!   )Q,  !D
M     ("!Q.L" 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $Z"5E;1<GJ+B@(  ,P&   9              "
M@>H! P!X;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L! A0#%     @ 3H)6
M5CI4YY71 @  *0@  !D              ("!JP0# 'AL+W=O<FMS:&5E=',O
M<VAE970Y-BYX;6Q02P$"% ,4    " !.@E96^K'15M,#   O$   &0
M        @(&S!P, >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0
M   ( $Z"5E9S%,J&G 0  $T1   9              " @;T+ P!X;"]W;W)K
M<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ 3H)65M;RZ[@[!0  (Q@
M !D              ("!D! # 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6Q0
M2P$"% ,4    " !.@E96>A8()2X$   >%   &@              @($"%@,
M>&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"% ,4    " !.@E96URQ/
MR.X#  #:#@  &@              @(%H&@, >&PO=V]R:W-H965T<R]S:&5E
M=#$P,2YX;6Q02P$"% ,4    " !.@E96&$F\S' "   Q!P  &@
M    @(&.'@, >&PO=V]R:W-H965T<R]S:&5E=#$P,BYX;6Q02P$"% ,4
M" !.@E96,R=8<G8#  !'#@  &@              @($V(0, >&PO=V]R:W-H
M965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    " !.@E96+'*E"VL#  "J%@
M#0              @ 'D) , >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $Z"
M5E:7BKL<P    !,"   +              "  7HH P!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( $Z"5E91%%H5*0<  *U#   /              "  6,I P!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !.@E96"DA2;NL"  "&/   &@
M            @ &Y, , >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " !.@E96A'6;AV,"  !A.@  $P              @ '<,P, 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     ;P!O (0>  !P-@,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>845</ContextCount>
  <ElementCount>590</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>188</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Available-for-sale Debt Securities and Equity Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecurities</Role>
      <ShortName>Available-for-sale Debt Securities and Equity Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Derivative Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstruments</Role>
      <ShortName>Derivative Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Collaborations and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CollaborationsandOtherArrangements</Role>
      <ShortName>Collaborations and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Debt and Credit Facilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilities</Role>
      <ShortName>Debt and Credit Facilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/Revenues</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Available-for-sale Debt Securities and Equity Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesTables</Role>
      <ShortName>Available-for-sale Debt Securities and Equity Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecurities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Derivative Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsTables</Role>
      <ShortName>Derivative Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DerivativeFinancialInstruments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/Acquisitions</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OtherFinancialInformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Debt and Credit Facilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilitiesTables</Role>
      <ShortName>Debt and Credit Facilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/DebtandCreditFacilities</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/Leases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/StockholdersEquity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Employee Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsTables</Role>
      <ShortName>Employee Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/EmployeeBenefits</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/EarningsPerShare</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gilead.com/role/IncomeTaxes</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Revenues - Disaggregation of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails</Role>
      <ShortName>Revenues - Disaggregation of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Revenues - Summarized Revenues from Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails</Role>
      <ShortName>Revenues - Summarized Revenues from Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Revenues - Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesPerformanceObligationsDetails</Role>
      <ShortName>Revenues - Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Fair Value Measurements - Summary of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails</Role>
      <ShortName>Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails</Role>
      <ShortName>Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails</Role>
      <ShortName>Available-for-sale Debt Securities and Equity Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails</Role>
      <ShortName>Available-for-sale Debt Securities and Equity Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of Classification of Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails</Role>
      <ShortName>Available-for-sale Debt Securities and Equity Securities - Summary of Classification of Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Derivative Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Derivative Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails</Role>
      <ShortName>Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Property, Plant and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails</Role>
      <ShortName>Property, Plant and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Other Financial Information - Accounts Receivable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails</Role>
      <ShortName>Other Financial Information - Accounts Receivable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Other Financial Information - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails</Role>
      <ShortName>Other Financial Information - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Other Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails</Role>
      <ShortName>Other Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Other Financial Information - Other Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails</Role>
      <ShortName>Other Financial Information - Other Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Collaborations and Other Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails</Role>
      <ShortName>Collaborations and Other Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/CollaborationsandOtherArrangements</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails</Role>
      <ShortName>Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Debt and Credit Facilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails</Role>
      <ShortName>Debt and Credit Facilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails</Role>
      <ShortName>Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Leases - Balance Sheet Location and Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails</Role>
      <ShortName>Leases - Balance Sheet Location and Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Leases - Supplemental Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Supplemental Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Leases - Summary of Operating Lease Liabilities Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails</Role>
      <ShortName>Leases - Summary of Operating Lease Liabilities Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/CommitmentsandContingencies</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Stockholders' Equity - Repurchases of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails</Role>
      <ShortName>Stockholders' Equity - Repurchases of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Stockholders' Equity - Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityDividendsDetails</Role>
      <ShortName>Stockholders' Equity - Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Stockholders' Equity - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Employee Benefits - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails</Role>
      <ShortName>Employee Benefits - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Employee Benefits - Summary of Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails</Role>
      <ShortName>Employee Benefits - Summary of Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Employee Benefits - Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails</Role>
      <ShortName>Employee Benefits - Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Employee Benefits - Performance Share Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails</Role>
      <ShortName>Employee Benefits - Performance Share Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Employee Benefits - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails</Role>
      <ShortName>Employee Benefits - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails</Role>
      <ShortName>Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Employee Benefits - ESPP Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails</Role>
      <ShortName>Employee Benefits - ESPP Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails</Role>
      <ShortName>Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Earnings Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Income Taxes - Schedule of Transition Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails</Role>
      <ShortName>Income Taxes - Schedule of Transition Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="gild-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gilead.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gilead.com/role/SubsequentEvents</ParentRole>
      <Position>103</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: gild:DebtInstrumentCallFeaturePeriodBeforeMaturity, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  gild-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="gild-20221231.htm">gild-20221231.htm</File>
    <File>gild-20221231.xsd</File>
    <File>gild-20221231_cal.xml</File>
    <File>gild-20221231_def.xml</File>
    <File>gild-20221231_lab.xml</File>
    <File>gild-20221231_pre.xml</File>
    <File>gild2022form10-kexhibit211.htm</File>
    <File>gild2022form10-kexhibit231.htm</File>
    <File>gild2022form10-kexhibit311.htm</File>
    <File>gild2022form10-kexhibit312.htm</File>
    <File>gild2022form10-kexhibit32.htm</File>
    <File>gild2022formex1050offerlet.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gild-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1998">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>125
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gild-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 41,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1998,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 845,
   "dts": {
    "calculationLink": {
     "local": [
      "gild-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gild-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "gild-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gild-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gild-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gild-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 967,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 12,
    "http://www.gilead.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 17
   },
   "keyCustom": 82,
   "keyStandard": 508,
   "memberCustom": 112,
   "memberStandard": 63,
   "nsprefix": "gild",
   "nsuri": "http://www.gilead.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.gilead.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000010 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "10",
     "role": "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ie98b1de291f04339b19d38631b6c5007_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails",
     "shortName": "Income Taxes - Rollforward of Total Unrecognized Tax Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i0142ebb7458d4ec68ef2fa3254d6e76a_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gild:ScheduleOfTransitionTaxTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "gild:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Income Taxes - Schedule of Transition Tax (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails",
     "shortName": "Income Taxes - Schedule of Transition Tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gild:ScheduleOfTransitionTaxTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "gild:TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i0f0e85f937584323a180e6f5054512c6_D20230222-20230222",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "gild:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.gilead.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i0f0e85f937584323a180e6f5054512c6_D20230222-20230222",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "gild:PaymentsForAssetAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Revenues",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.gilead.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.gilead.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Available-for-sale Debt Securities and Equity Securities",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecurities",
     "shortName": "Available-for-sale Debt Securities and Equity Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Derivative Financial Instruments",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstruments",
     "shortName": "Derivative Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Acquisitions",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.gilead.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Property, Plant and Equipment",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.gilead.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Other Financial Information",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.gilead.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.gilead.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborativeAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Collaborations and Other Arrangements",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.gilead.com/role/CollaborationsandOtherArrangements",
     "shortName": "Collaborations and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:CollaborativeAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Debt and Credit Facilities",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.gilead.com/role/DebtandCreditFacilities",
     "shortName": "Debt and Credit Facilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.gilead.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.gilead.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.gilead.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Employee Benefits",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.gilead.com/role/EmployeeBenefits",
     "shortName": "Employee Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Earnings Per Share",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.gilead.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.gilead.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.gilead.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "29",
     "role": "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gild:PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Revenues (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.gilead.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.gilead.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Available-for-sale Debt Securities and Equity Securities (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesTables",
     "shortName": "Available-for-sale Debt Securities and Equity Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Derivative Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsTables",
     "shortName": "Derivative Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Acquisitions (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.gilead.com/role/AcquisitionsTables",
     "shortName": "Acquisitions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Property, Plant and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.gilead.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Other Financial Information (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.gilead.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Debt and Credit Facilities (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.gilead.com/role/DebtandCreditFacilitiesTables",
     "shortName": "Debt and Credit Facilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.gilead.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.gilead.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Employee Benefits (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.gilead.com/role/EmployeeBenefitsTables",
     "shortName": "Employee Benefits (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Earnings Per Share (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.gilead.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.gilead.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Revenues - Disaggregation of Revenues (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails",
     "shortName": "Revenues - Disaggregation of Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ie276f108be5d41f7bf6f6aec108cc38a_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i86eb6bdf28e54e3cbf341a8b16bceb07_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Revenues - Summarized Revenues from Major Customers (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails",
     "shortName": "Revenues - Summarized Revenues from Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i86eb6bdf28e54e3cbf341a8b16bceb07_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Revenues - Performance Obligations (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.gilead.com/role/RevenuesPerformanceObligationsDetails",
     "shortName": "Revenues - Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Revenues - Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.gilead.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
     "shortName": "Fair Value Measurements - Summary of Assets and Liabilities Recorded at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i258640a7c57747aeb519ee9e07186999_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "if7e357738293475089434472816fe934_I20221231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "if398b36aa15c4bcdbd145f253add16fb_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Fair Value Measurements - Summary of Contingent Consideration (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails",
     "shortName": "Fair Value Measurements - Summary of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2aa74cadbdb34ed3b2763fe749e4a969_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
     "shortName": "Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities at Estimated Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
     "shortName": "Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails",
     "shortName": "Available-for-sale Debt Securities and Equity Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
     "shortName": "Available-for-sale Debt Securities and Equity Securities - Summary of the Balance Sheet Classification of Available-for-Sale Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i6b5ae4a796da464bb370d53bae12c455_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
     "shortName": "Available-for-sale Debt Securities and Equity Securities - Summary of Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i6b5ae4a796da464bb370d53bae12c455_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Available-for-sale Debt Securities and Equity Securities - Summary of Classification of Equity Securities (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
     "shortName": "Available-for-sale Debt Securities and Equity Securities - Summary of Classification of Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i6b5ae4a796da464bb370d53bae12c455_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Derivative Financial Instruments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Derivative Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails",
     "shortName": "Derivative Financial Instruments - Summary of Classification and Fair Value of Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails",
     "shortName": "Derivative Financial Instruments - Summary of Effect of Foreign Currency Exchange Contracts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Acquisitions - Narrative (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
     "shortName": "Acquisitions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "gild:FiniteLivedIntangibleAssetsGrossReclassified",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ifa9a93f5272a429bbdd06910a8637c97_I20210430",
      "decimals": "-8",
      "lang": "en-US",
      "name": "gild:FiniteLivedIntangibleAssetsGrossReclassified",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i510e50f0ac43478382e87ec9808db7ce_I20210304",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Acquisitions - Summarized Fair Values of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i510e50f0ac43478382e87ec9808db7ce_I20210304",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Land",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedComputerSoftwareNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Property, Plant and Equipment - Narrative (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
     "shortName": "Property, Plant and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedComputerSoftwareNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ie98b1de291f04339b19d38631b6c5007_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2c49c0902f5d45b4881bbd5f032acaf0_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillPurchaseAccountingAdjustments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Summary of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Estimated Future Amortization Expense of Finite-Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Other Financial Information - Accounts Receivable, Net (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails",
     "shortName": "Other Financial Information - Accounts Receivable, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Other Financial Information - Inventories (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails",
     "shortName": "Other Financial Information - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ifb58b983f5e14067bcbab9fc5db32341_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Other Financial Information - Narrative (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails",
     "shortName": "Other Financial Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Other Financial Information - Other Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails",
     "shortName": "Other Financial Information - Other Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Collaborations and Other Arrangements (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
     "shortName": "Collaborations and Other Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ic189333a47cb4e74a306f790f89b7e3d_D20210313-20210313",
      "decimals": "2",
      "lang": "en-US",
      "name": "gild:CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails",
     "shortName": "Debt and Credit Facilities - Summary of Debt Carrying Amount (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Debt and Credit Facilities - Narrative (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
     "shortName": "Debt and Credit Facilities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
     "shortName": "Debt and Credit Facilities - Contractual Maturities of Financing Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i89095e70e7fa45458393451ccf83e29b_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.gilead.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Leases - Balance Sheet Location and Other Information (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails",
     "shortName": "Leases - Balance Sheet Location and Other Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "iff509ac6299d48d6b6117ee9f80eea96_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "iff509ac6299d48d6b6117ee9f80eea96_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Leases - Supplemental Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Supplemental Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Leases - Summary of Operating Lease Liabilities Maturity (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails",
     "shortName": "Leases - Summary of Operating Lease Liabilities Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.gilead.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Stockholders' Equity - Repurchases of Common Stock (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails",
     "shortName": "Stockholders' Equity - Repurchases of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ifc0e2948c490453d8a2ebfca402b6cfb_D20220201-20220201",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Stockholders' Equity - Dividends (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.gilead.com/role/StockholdersEquityDividendsDetails",
     "shortName": "Stockholders' Equity - Dividends (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ie85479b87980466db067faedfa50f2bd_D20221001-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStockCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Stockholders' Equity - Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.gilead.com/role/StockholdersEquityPreferredStockDetails",
     "shortName": "Stockholders' Equity - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ie98b1de291f04339b19d38631b6c5007_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Employee Benefits - Narrative (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
     "shortName": "Employee Benefits - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Employee Benefits - Summary of Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
     "shortName": "Employee Benefits - Summary of Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ia54f00a060494b7e8284daf41bb9942f_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Employee Benefits - Restricted Stock (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails",
     "shortName": "Employee Benefits - Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i5a7854cb487a40a28225b2ee2dcecfbe_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ifc0e2948c490453d8a2ebfca402b6cfb_D20220201-20220201",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ieb16b1a82cc04d97bc97982197e928b8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Employee Benefits - Performance Share Awards (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
     "shortName": "Employee Benefits - Performance Share Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i3309414c3d884642ba85e5b11341a37f_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ifd6b4cdafb5e493e8f88f2078b78eb38_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Employee Benefits - Stock Options (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails",
     "shortName": "Employee Benefits - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gild:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
     "shortName": "Employee Benefits - Schedule of Assumptions Used to Calculate the Fair Value of Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "gild:ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "ibcf6404ac03d4ae1b5d298ceda016a56_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Employee Benefits - ESPP Activity (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails",
     "shortName": "Employee Benefits - ESPP Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i9a7b6cfca7fd4ebbac1b45c5d56240aa_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails",
     "shortName": "Earnings Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Earnings Per Share - Narrative (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.gilead.com/role/EarningsPerShareNarrativeDetails",
     "shortName": "Earnings Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails",
     "shortName": "Income Taxes - Schedule of Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Difference Between Provision For Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i2a52280e791949799892ada047e34d67_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "gild-20221231.htm",
      "contextRef": "i36be9f39e0e143cf97505efaec9d56a4_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 188,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r867",
      "r868",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r867",
      "r868",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r867",
      "r868",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r867",
      "r868",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r870"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r867",
      "r868",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gilead.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gild_A075SeniorUnsecuredNotesDueInSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.75% Senior Unsecured Notes Due in September 2023",
        "label": "0.75% Senior Unsecured Notes Due in September 2023 [Member]",
        "terseLabel": "0.75% Senior Unsecured Notes Due in September 2023"
       }
      }
     },
     "localname": "A075SeniorUnsecuredNotesDueInSeptember2023Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A120SeniorUnsecuredNotesDueOctober2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.20% Senior Unsecured Notes Due October 2027",
        "label": "1.20% Senior Unsecured Notes Due October 2027 [Member]",
        "terseLabel": "1.20% Senior Unsecured Notes Due October 2027"
       }
      }
     },
     "localname": "A120SeniorUnsecuredNotesDueOctober2027Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A165SeniorUnsecuredNotesDueOctober2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.65% Senior Unsecured Notes Due October 2030",
        "label": "1.65% Senior Unsecured Notes Due October 2030 [Member]",
        "terseLabel": "1.65% Senior Unsecured Notes Due October 2030"
       }
      }
     },
     "localname": "A165SeniorUnsecuredNotesDueOctober2030Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A195SeniorUnsecuredNotesDueMarch2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.95% Senior Unsecured Notes Due March 2022 [Member]",
        "label": "1.95% Senior Unsecured Notes Due March 2022 [Member]",
        "terseLabel": "1.95% Senior Unsecured Notes Due March 2022"
       }
      }
     },
     "localname": "A195SeniorUnsecuredNotesDueMarch2022Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A2016StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Stock Repurchase Program [Member]",
        "label": "2016 Stock Repurchase Program [Member]",
        "terseLabel": "2016 stock repurchase program"
       }
      }
     },
     "localname": "A2016StockRepurchaseProgramMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A2020StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Repurchase Program [Member]",
        "label": "2020 Stock Repurchase Program [Member]",
        "terseLabel": "2020 stock repurchase program"
       }
      }
     },
     "localname": "A2020StockRepurchaseProgramMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A260SeniorUnsecuredNotesDueOctober2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.60% Senior Unsecured Notes Due October 2040",
        "label": "2.60% Senior Unsecured Notes Due October 2040 [Member]",
        "terseLabel": "2.60% Senior Unsecured Notes Due October 2040"
       }
      }
     },
     "localname": "A260SeniorUnsecuredNotesDueOctober2040Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A280SeniorUnsecuredNotesDueOctober2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.80% Senior Unsecured Notes Due October 2050",
        "label": "2.80% Senior Unsecured Notes Due October 2050 [Member]",
        "terseLabel": "2.80% Senior Unsecured Notes Due October 2050"
       }
      }
     },
     "localname": "A280SeniorUnsecuredNotesDueOctober2050Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_A325SeniorUnsecuredNotesDueSeptember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.25% Senior Unsecured Notes Due September 2022",
        "label": "3.25% Senior Unsecured Notes Due September 2022 [Member]",
        "terseLabel": "3.25% Senior Unsecured Notes Due September 2022"
       }
      }
     },
     "localname": "A325SeniorUnsecuredNotesDueSeptember2022Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AccountsReceivableCashDiscountsAndOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Cash Discounts and Other, Current",
        "label": "Accounts Receivable, Cash Discounts and Other, Current",
        "terseLabel": "Less: allowances for cash discounts and other"
       }
      }
     },
     "localname": "AccountsReceivableCashDiscountsAndOtherCurrent",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccountsReceivableChargebacksCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Chargebacks, Current",
        "label": "Accounts Receivable, Chargebacks, Current",
        "terseLabel": "Less: allowances for chargebacks"
       }
      }
     },
     "localname": "AccountsReceivableChargebacksCurrent",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AccruedRebates": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Rebates",
        "label": "Accrued Rebates",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AcquiredFiniteLivedIntangibleAssetsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Finite-lived Intangible Assets, Discount Rate",
        "label": "Acquired Finite-lived Intangible Assets, Discount Rate",
        "terseLabel": "Discount rate of finite-lived intangible asset acquired"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsDiscountRate",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_AcquisitionRelatedExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition Related Expense",
        "label": "Acquisition Related Expense [Member]",
        "terseLabel": "Acquisition-related expense"
       }
      }
     },
     "localname": "AcquisitionRelatedExpenseMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AdditionalResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Research And Development In Process",
        "label": "Additional Research And Development In Process",
        "terseLabel": "Additional acquired in-process research and development expenses"
       }
      }
     },
     "localname": "AdditionalResearchAndDevelopmentInProcess",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AdjustmentsOfBudgetedDevelopmentCostsPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments of Budgeted Development Costs, Payments",
        "label": "Adjustments of Budgeted Development Costs, Payments",
        "terseLabel": "Additional payment for adjustments of budgeted development costs in 2021"
       }
      }
     },
     "localname": "AdjustmentsOfBudgetedDevelopmentCostsPayments",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months",
        "label": "Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months",
        "terseLabel": "Payment for adjustments of budgeted development costs in 2022"
       }
      }
     },
     "localname": "AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_AgreementWithJapanTobaccoIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with Japan Tobacco, Inc. [Member]",
        "label": "Agreement with Japan Tobacco, Inc. [Member]",
        "terseLabel": "Japan tobacco"
       }
      }
     },
     "localname": "AgreementWithJapanTobaccoIncMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and Restated Research Collaboration and License Agreement and Stock Purchase Agreement",
        "label": "Amended and Restated Research Collaboration and License Agreement and Stock Purchase Agreement [Member]",
        "terseLabel": "Tango collaboration and stock purchase agreement"
       }
      }
     },
     "localname": "AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Filgotinib License and Collaboration Agreement in December 2020",
        "label": "Amended Filgotinib License and Collaboration Agreement in December 2020 [Member]",
        "terseLabel": "Amended 2019 agreement"
       }
      }
     },
     "localname": "AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AmerisourcebergenCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Corp [Member]",
        "label": "AmerisourceBergen Corp [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourcebergenCorpMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcellxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcellx, Inc",
        "label": "Arcellx, Inc [Member]",
        "terseLabel": "Arcellx, Inc"
       }
      }
     },
     "localname": "ArcellxIncMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Biosciences, Inc.",
        "label": "Arcus Biosciences, Inc. [Member]",
        "terseLabel": "Arcus"
       }
      }
     },
     "localname": "ArcusBiosciencesIncMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Collaboration Agreement and Stock Purchase Agreements",
        "label": "Arcus Collaboration Agreement and Stock Purchase Agreements [Member]",
        "terseLabel": "Arcus collaboration agreement and stock purchase agreements"
       }
      }
     },
     "localname": "ArcusCollaborationAgreementAndStockPurchaseAgreementsMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Collaboration Agreement",
        "label": "Arcus Collaboration Agreement [Member]",
        "terseLabel": "Arcus collaboration agreement"
       }
      }
     },
     "localname": "ArcusCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ArcusStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arcus Stock Purchase Agreement",
        "label": "Arcus Stock Purchase Agreement [Member]",
        "terseLabel": "Arcus stock purchase agreement"
       }
      }
     },
     "localname": "ArcusStockPurchaseAgreementMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.gilead.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gild_AxicabtageneciloleucelDLBCLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "axicabtagene ciloleucel (DLBCL) [Member]",
        "label": "axicabtagene ciloleucel (DLBCL) [Member]",
        "terseLabel": "Intangible asset \u2013 axicabtagene ciloleucel"
       }
      }
     },
     "localname": "AxicabtageneciloleucelDLBCLMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Future Royalties, Liability, Measurement Input",
        "label": "Business Combination, Future Royalties, Liability, Measurement Input",
        "terseLabel": "Liability related to future royalties, measurement Input"
       }
      }
     },
     "localname": "BusinessCombinationFutureRoyaltiesLiabilityMeasurementInput",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Future Royalties Liability",
        "negatedTerseLabel": "Liability related to future royalties",
        "terseLabel": "Liability related to future royalties"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFutureRoyaltiesLiability",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net",
        "terseLabel": "Other assets (and liabilities), net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health Inc [Member]",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health, Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CashPaymentsMadeRelatedToEquityInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Payments Made Related To Equity Investments",
        "label": "Cash Payments Made Related To Equity Investments",
        "terseLabel": "Cash payments made related to equity investments"
       }
      }
     },
     "localname": "CashPaymentsMadeRelatedToEquityInvestments",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CellTherapyProductsTecartusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Tecartus",
        "label": "Cell Therapy Products, Tecartus [Member]",
        "terseLabel": "Tecartus"
       }
      }
     },
     "localname": "CellTherapyProductsTecartusMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CellTherapyProductsTotalCellTherapyProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy Products, Total Cell Therapy Product Sales",
        "label": "Cell Therapy Products, Total Cell Therapy Product Sales [Member]",
        "terseLabel": "Total cell therapy"
       }
      }
     },
     "localname": "CellTherapyProductsTotalCellTherapyProductSalesMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ChangeInDividendsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Dividends, Percentage",
        "label": "Change In Dividends, Percentage",
        "terseLabel": "Percentage of change in dividends"
       }
      }
     },
     "localname": "ChangeInDividendsPercentage",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period",
        "label": "Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period",
        "terseLabel": "Option period to license certain inhibitors"
       }
      }
     },
     "localname": "CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_CollaborationArrangementNetProductSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Net Product Sales Threshold",
        "label": "Collaboration Arrangement, Net Product Sales Threshold",
        "terseLabel": "Net product sales threshold"
       }
      }
     },
     "localname": "CollaborationArrangementNetProductSalesThreshold",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Percent Of Global Development And Commercialization Costs",
        "label": "Collaboration Arrangement, Percent Of Global Development And Commercialization Costs",
        "terseLabel": "Percent of global and development and commercialization costs"
       }
      }
     },
     "localname": "CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_CollaborationArrangementPercentOfGlobalProductRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Percent Of Global Product Revenues",
        "label": "Collaboration Arrangement, Percent Of Global Product Revenues",
        "terseLabel": "Percent of global product revenues"
       }
      }
     },
     "localname": "CollaborationArrangementPercentOfGlobalProductRevenues",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_CollaborativeAgreementOptInTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Opt-In Term",
        "label": "Collaborative Agreement, Opt-In Term",
        "terseLabel": "Opt-in term"
       }
      }
     },
     "localname": "CollaborativeAgreementOptInTerm",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Product Market Period Subject To Termination",
        "label": "Collaborative Agreement, Product Market Period Subject To Termination",
        "terseLabel": "Period subject to termination"
       }
      }
     },
     "localname": "CollaborativeAgreementProductMarketPeriodSubjectToTermination",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_CollaborativeAndOtherArrangementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and Other Arrangements [Text Block]",
        "label": "Collaborative And Other Arrangements [Text Block]",
        "terseLabel": "Collaborations and Other Arrangements"
       }
      }
     },
     "localname": "CollaborativeAndOtherArrangementsTextBlock",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Collaboration term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_CollaborativeandOtherArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative and Other Arrangements [Abstract]",
        "label": "Collaborative and Other Arrangements [Abstract]",
        "terseLabel": "Collaborative and Other Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeandOtherArrangementsAbstract",
     "nsuri": "http://www.gilead.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gild_ContingentConsiderationLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Liability",
        "label": "Contingent Consideration, Liability [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_CreditFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility Due June 2025",
        "label": "Credit Facility Due June 2025 [Member]",
        "terseLabel": "2020 revolving credit facility"
       }
      }
     },
     "localname": "CreditFacilityDueJune2025Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DebtInstrumentCallFeaturePeriodBeforeMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Call Feature, Period Before Maturity",
        "label": "Debt Instrument, Call Feature, Period Before Maturity",
        "terseLabel": "Call feature, period prior to maturity"
       }
      }
     },
     "localname": "DebtInstrumentCallFeaturePeriodBeforeMaturity",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_DeferredCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Compensation Plan [Member]",
        "label": "Deferred Compensation Plan [Member]",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "DeferredCompensationPlanMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DeferredTaxAssetsUpfrontAndMilestonePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Upfront and Milestone Payments",
        "label": "Deferred Tax Assets, Upfront and Milestone Payments",
        "terseLabel": "Upfront and milestone payments"
       }
      }
     },
     "localname": "DeferredTaxAssetsUpfrontAndMilestonePayments",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_DevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Agreement",
        "label": "Development Agreement [Member]",
        "terseLabel": "Development agreement"
       }
      }
     },
     "localname": "DevelopmentAgreementMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DragonflyTherapeuticsCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dragonfly Therapeutics Collaboration Agreement",
        "label": "Dragonfly Therapeutics Collaboration Agreement [Member]",
        "terseLabel": "Dragonfly Therapeutics Collaboration Agreement"
       }
      }
     },
     "localname": "DragonflyTherapeuticsCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_DragonflyTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dragonfly Therapeutics, Inc.",
        "label": "Dragonfly Therapeutics, Inc. [Member]",
        "terseLabel": "Dragonfly Therapeutics, Inc."
       }
      }
     },
     "localname": "DragonflyTherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EquityMethodInvestmentOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Option Exercise Fee",
        "label": "Equity Method Investment, Option Exercise Fee",
        "terseLabel": "Option exercise fee"
       }
      }
     },
     "localname": "EquityMethodInvestmentOptionExerciseFee",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Option Fee And Potential Future Milestone Payments",
        "label": "Equity Method Investment, Option Fee And Potential Future Milestone Payments",
        "terseLabel": "Option fee and potential future milestone payments"
       }
      }
     },
     "localname": "EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount",
        "label": "Equity Securities And Equity Method Investment Without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments and equity method investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesAndEquityMethodInvestmentWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesDonationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Donation",
        "label": "Equity Securities Donation [Member]",
        "terseLabel": "Equity Securities Donation"
       }
      }
     },
     "localname": "EquitySecuritiesDonationMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries",
        "label": "Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries",
        "terseLabel": "Additional option fee on fourth, sixth, and eighth anniversaries"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased",
        "label": "Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased",
        "terseLabel": "Maximum percentage of outstanding stock allowed to be purchased"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments",
        "label": "Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments",
        "terseLabel": "Opt-in, extension and milestone payments"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_EquitySecuritiesFVNIPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Purchase Period",
        "label": "Equity Securities, FV-NI, Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIPurchasePeriod",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_EquitySecuritiesFVNIRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Restriction Period",
        "label": "Equity Securities, FV-NI, Restriction Period",
        "terseLabel": "Restriction period"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIRestrictionPeriod",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_EquitySecuritiesFVNIShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Shares",
        "label": "Equity Securities, FV-NI, Shares",
        "terseLabel": "Number of shares (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIShares",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gild_EquitySecuritiesFVNISharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Shares Acquired",
        "label": "Equity Securities, FV-NI, Shares Acquired",
        "terseLabel": "Additional shares acquired (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNISharesAcquired",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gild_EuropeanPatentClaims2032ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "European Patent Claims 2032 Expiration",
        "label": "European Patent Claims 2032 Expiration [Member]",
        "terseLabel": "European Patent Claims 2032 Expiration"
       }
      }
     },
     "localname": "EuropeanPatentClaims2032ExpirationMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EverestMedicinesAndImmunomedicsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Everest Medicines And Immunomedics Agreement",
        "label": "Everest Medicines And Immunomedics Agreement [Member]",
        "terseLabel": "Everest Medicines"
       }
      }
     },
     "localname": "EverestMedicinesAndImmunomedicsAgreementMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_EverestMedicinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Everest Medicines",
        "label": "Everest Medicines [Member]",
        "terseLabel": "Everest Medicines"
       }
      }
     },
     "localname": "EverestMedicinesMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement",
        "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Remeasurement",
        "terseLabel": "Effect of foreign exchange remeasurement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeRemeasurement",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "totalLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "gild_FiniteLivedAndIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FiniteLivedIntangibleAssetsGrossReclassified": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Gross, Reclassified",
        "label": "Finite-Lived Intangible Assets, Gross, Reclassified",
        "terseLabel": "Reclassified intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGrossReclassified",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Rate Senior Unsecured Note Issued September 2020",
        "label": "Fixed Rate Senior Unsecured Note Issued September 2020 [Member]",
        "terseLabel": "the \"2020 Fixed Rate Notes\""
       }
      }
     },
     "localname": "FixedRateSeniorUnsecuredNoteIssuedSeptember2020Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ForeignCurrencyDerivativeContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Derivative Contracts [Member]",
        "label": "Foreign Currency Derivative Contracts [Member]",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeContractsMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_FortySevenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forty Seven, Inc. [Member]",
        "label": "Forty Seven, Inc. [Member]",
        "terseLabel": "Forty Seven, Inc."
       }
      }
     },
     "localname": "FortySevenIncMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GalapagosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galapagos, a clinical-stage biotechnology company based in Belgium",
        "label": "Galapagos [Member]",
        "terseLabel": "Galapagos"
       }
      }
     },
     "localname": "GalapagosMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GalapagosSubscriptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galapagos Subscription Agreement",
        "label": "Galapagos Subscription Agreement [Member]",
        "terseLabel": "Galapagos subscription agreement"
       }
      }
     },
     "localname": "GalapagosSubscriptionAgreementMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GileadFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Foundation",
        "label": "Gilead Foundation [Member]",
        "terseLabel": "Gilead Foundation"
       }
      }
     },
     "localname": "GileadFoundationMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GileadSciencesInc2022EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Sciences, Inc. 2022 Equity Incentive Plan",
        "label": "Gilead Sciences, Inc. 2022 Equity Incentive Plan [Member]",
        "terseLabel": "2022 Equity Incentive Plan"
       }
      }
     },
     "localname": "GileadSciencesInc2022EquityIncentivePlanMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_GlobalStrategicCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Strategic Collaboration Agreement",
        "label": "Global Strategic Collaboration Agreement [Member]",
        "terseLabel": "Global Strategic Collaboration Agreement"
       }
      }
     },
     "localname": "GlobalStrategicCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Product Sales",
        "label": "HCV Product Sales [Member]",
        "terseLabel": "Total HCV"
       }
      }
     },
     "localname": "HCVProductSalesMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsLedipasvirSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Ledipasvir/Sofosbuvir",
        "label": "HCV Products, Ledipasvir/Sofosbuvir [Member]",
        "terseLabel": "Ledipasvir/Sofosbuvir"
       }
      }
     },
     "localname": "HCVProductsLedipasvirSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HCVProductsSofosbuvirVelpatasvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HCV Products, Sofosbuvir/Velpatasvir",
        "label": "HCV Products, Sofosbuvir/Velpatasvir [Member]",
        "terseLabel": "Sofosbuvir/Velpatasvir"
       }
      }
     },
     "localname": "HCVProductsSofosbuvirVelpatasvirMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Product Sales",
        "label": "HIV Product Sales [Member]",
        "terseLabel": "Total HIV"
       }
      }
     },
     "localname": "HIVProductSalesMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsBiktarvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Biktarvy [Member]",
        "label": "HIV Products, Biktarvy [Member]",
        "terseLabel": "Biktarvy"
       }
      }
     },
     "localname": "HIVProductsBiktarvyMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsCompleraEvipleraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Complera/Eviplera [Member]",
        "label": "HIV Products, Complera/Eviplera [Member]",
        "terseLabel": "Complera/Eviplera"
       }
      }
     },
     "localname": "HIVProductsCompleraEvipleraMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsDescovyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Descovy [Member]",
        "label": "HIV Products, Descovy [Member]",
        "terseLabel": "Descovy"
       }
      }
     },
     "localname": "HIVProductsDescovyMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsGenvoyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Genvoya [Member]",
        "label": "HIV Products, Genvoya [Member]",
        "terseLabel": "Genvoya"
       }
      }
     },
     "localname": "HIVProductsGenvoyaMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsOdefseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Odefsey [Member]",
        "label": "HIV Products, Odefsey [Member]",
        "terseLabel": "Odefsey"
       }
      }
     },
     "localname": "HIVProductsOdefseyMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsStribildMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Stribild [Member]",
        "label": "HIV Products, Stribild [Member]",
        "terseLabel": "Stribild"
       }
      }
     },
     "localname": "HIVProductsStribildMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HIVProductsTruvadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIV Products, Truvada [Member]",
        "label": "HIV Products, Truvada [Member]",
        "terseLabel": "Truvada"
       }
      }
     },
     "localname": "HIVProductsTruvadaMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product [Member]",
        "terseLabel": "Total HBV/HDV"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Other",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Other [Member]",
        "terseLabel": "Other HB/HDV"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductOtherMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Vemlidy [Member]",
        "terseLabel": "Vemlidy"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]",
        "label": "Hepatitis B Virus / Hepatitis Delta Virus Product, Viread [Member]",
        "terseLabel": "Viread"
       }
      }
     },
     "localname": "HepatitisBVirusHepatitisDeltaVirusProductVireadMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_HepcludexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepcludex",
        "label": "Hepcludex [Member]",
        "terseLabel": "Hepcludex",
        "verboseLabel": "Intangible asset \u2013 Hepcludex"
       }
      }
     },
     "localname": "HepcludexMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ImmunomedicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunomedics, Inc. (\u201cImmunomedics\u201d), a leading company in antibody-drug conjugate (\u201cADC\u201d) technology",
        "label": "Immunomedics, Inc. [Member]",
        "terseLabel": "Immunomedics, Inc."
       }
      }
     },
     "localname": "ImmunomedicsIncMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_InProcessResearchAndDevelopmentTrodelvyForHRHER2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In Process Research And Development Trodelvy For HR+/HER2-",
        "label": "In Process Research And Development Trodelvy For HR+/HER2- [Member]",
        "terseLabel": "In Process Research And Development Trodelvy For HR+/HER2-"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentTrodelvyForHRHER2Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-Lived Intangible Asset, Measurement Input",
        "label": "Indefinite-Lived Intangible Asset, Measurement Input",
        "terseLabel": "Discount rate, measurement input"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetMeasurementInput",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetsAcquiredDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-lived Intangible Assets Acquired, Discount Rate",
        "label": "Indefinite-lived Intangible Assets Acquired, Discount Rate",
        "terseLabel": "Discount rate of acquired IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsAcquiredDiscountRate",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "label": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss), Cumulative Gain (Loss)",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial consideration for acquisition of rights to market and distribute certain products in Japan",
        "label": "Initial Consideration For Acquisition Of Rights To Market And Distribute Certain Products In Japan",
        "terseLabel": "Cash paid"
       }
      }
     },
     "localname": "InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_InjectableFormulationProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Injectable Formulation Product",
        "label": "Injectable Formulation Product [Member]",
        "terseLabel": "Injectable Formulation Product"
       }
      }
     },
     "localname": "InjectableFormulationProductMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_IntangibleAssetSofosbuvirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sofosbuvir [Member]",
        "label": "Intangible Asset - Sofosbuvir [Member]",
        "terseLabel": "Intangible asset \u2013 sofosbuvir"
       }
      }
     },
     "localname": "IntangibleAssetSofosbuvirMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_InventoryNetAndInventoryNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Net And Inventory Noncurrent",
        "label": "Inventory Net And Inventory Noncurrent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNetAndInventoryNoncurrent",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_InvestmentOwnedBalanceAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Owned, Balance, Additional Shares",
        "label": "Investment Owned, Balance, Additional Shares",
        "terseLabel": "Additional shares acquired (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceAdditionalShares",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gild_IssuanceDiscountPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Discount (Premium)",
        "label": "Issuance Discount (Premium)",
        "terseLabel": "Issuance discount (premium)"
       }
      }
     },
     "localname": "IssuanceDiscountPremium",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_JanssenPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the collaboration with Janssen Pharmaceuticals",
        "label": "Janssen Pharmaceuticals [Member]",
        "terseLabel": "Janssen pharmaceuticals"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_JounceTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jounce Therapeutics, Inc.",
        "label": "Jounce Therapeutics, Inc. [Member]",
        "terseLabel": "Jounce"
       }
      }
     },
     "localname": "JounceTherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_JudgmentEnhancedDamagesOnPastSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Enhanced Damages On Past Sales",
        "label": "Judgment: Enhanced Damages On Past Sales",
        "terseLabel": "Enhanced damages on past sales"
       }
      }
     },
     "localname": "JudgmentEnhancedDamagesOnPastSales",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JudgmentRoyaltyRateFromOctober2017": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Royalty Rate from October 2017",
        "label": "Judgment: Royalty Rate from October 2017",
        "terseLabel": "Running royalty rate from October 2017"
       }
      }
     },
     "localname": "JudgmentRoyaltyRateFromOctober2017",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JudgmentRoyaltyRateOnFutureSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judgment: Royalty Rate on Future Sales",
        "label": "Judgment: Royalty Rate on Future Sales",
        "terseLabel": "Running royalty rate on future sales"
       }
      }
     },
     "localname": "JudgmentRoyaltyRateOnFutureSales",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_JunoTherapeuticsIncAndSloanKetteringCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center (collectively, \u201cJuno\u201d)",
        "label": "Juno Therapeutics, Inc. and Sloan Kettering Cancer Center [Member]",
        "terseLabel": "Juno"
       }
      }
     },
     "localname": "JunoTherapeuticsIncAndSloanKetteringCancerCenterMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, Registration Rights and Stock Purchase Agreement",
        "label": "License, Registration Rights and Stock Purchase Agreement [Member]",
        "terseLabel": "Jounce license and stock purchase agreement"
       }
      }
     },
     "localname": "LicenseRegistrationRightsAndStockPurchaseAgreementMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_LossContingencyAdditionalPatentsAllegedlyInfringedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Additional Patents Allegedly Infringed, Number",
        "label": "Loss Contingency, Additional Patents Allegedly Infringed, Number",
        "terseLabel": "Number of additional patents allegedly infringed"
       }
      }
     },
     "localname": "LossContingencyAdditionalPatentsAllegedlyInfringedNumber",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyMaterialTransferAgreementsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Material Transfer Agreements, Number",
        "label": "Loss Contingency, Material Transfer Agreements, Number",
        "terseLabel": "Number of material transfer agreements"
       }
      }
     },
     "localname": "LossContingencyMaterialTransferAgreementsNumber",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyNumberOfPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Patents",
        "label": "Loss Contingency, Number Of Patents",
        "terseLabel": "Number of patents"
       }
      }
     },
     "localname": "LossContingencyNumberOfPatents",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_LossContingencyPartiesAppealedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Parties Appealed, Number",
        "label": "Loss Contingency, Parties Appealed, Number",
        "terseLabel": "Number of parties appealed"
       }
      }
     },
     "localname": "LossContingencyPartiesAppealedNumber",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_MYRGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MYR GmbH (\u201cMYR\u201d), a German biotechnology company",
        "label": "MYR GmbH [Member]",
        "terseLabel": "MYR"
       }
      }
     },
     "localname": "MYRGmbHMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Current [Member]",
        "label": "Marketable Securities, Current [Member]",
        "terseLabel": "Short-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MarketableSecuritiesNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Noncurrent [Member]",
        "label": "Marketable Securities, Noncurrent [Member]",
        "terseLabel": "Long-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrentMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Ownership Percentage In Galapagos Based On The Terms Of The Subscription Agreement",
        "label": "Maximum Ownership Percentage In Galapagos Based On The Terms Of The Subscription Agreement",
        "terseLabel": "Maximum ownership percentage"
       }
      }
     },
     "localname": "MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_MckessonCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corp [Member]",
        "label": "McKesson Corp [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "MckessonCorpMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MerckMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck",
        "label": "Merck [Member]",
        "terseLabel": "Merck"
       }
      }
     },
     "localname": "MerckMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck Sharp &amp; Dohme Corp License And Collaboration Agreement",
        "label": "Merck Sharp &amp; Dohme Corp License And Collaboration Agreement [Member]",
        "terseLabel": "Merck Sharp &amp; Dohme Corp"
       }
      }
     },
     "localname": "MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement",
        "label": "Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement",
        "terseLabel": "Minimum ownership percentage"
       }
      }
     },
     "localname": "MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_MiroBioLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MiroBio Ltd.",
        "label": "MiroBio Ltd. [Member]",
        "terseLabel": "MiroBio Ltd."
       }
      }
     },
     "localname": "MiroBioLtdMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_NumberOfClinicalStageProgramsWithExercisedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Clinical Stage Programs With Exercised Options",
        "label": "Number Of Clinical Stage Programs With Exercised Options",
        "terseLabel": "Number of clinical stage programs with exercise options"
       }
      }
     },
     "localname": "NumberOfClinicalStageProgramsWithExercisedOptions",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_NumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Programs",
        "label": "Number of Programs",
        "terseLabel": "Number of programs"
       }
      }
     },
     "localname": "NumberOfPrograms",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gild_OralFormulationProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Formulation Product",
        "label": "Oral Formulation Product [Member]",
        "terseLabel": "Oral Formulation Product"
       }
      }
     },
     "localname": "OralFormulationProductMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_OtherCollaborationArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Collaboration Arrangements [Member]",
        "label": "Other Collaboration Arrangements [Member]",
        "terseLabel": "Other collaboration arrangements"
       }
      }
     },
     "localname": "OtherCollaborationArrangementsMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]",
        "terseLabel": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.gilead.com/20221231",
     "xbrltype": "stringItemType"
    },
    "gild_OtherHCVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other HCV",
        "label": "Other HCV [Member]",
        "terseLabel": "Other HCV"
       }
      }
     },
     "localname": "OtherHCVMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other International [Member]",
        "label": "Other International [Member]",
        "terseLabel": "Other International"
       }
      }
     },
     "localname": "OtherInternationalMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsAmBisomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, AmBisome [Member]",
        "label": "Other Products, AmBisome [Member]",
        "terseLabel": "AmBisome"
       }
      }
     },
     "localname": "OtherProductsAmBisomeMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsLetairisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Letairis [Member]",
        "label": "Other Products, Letairis [Member]",
        "terseLabel": "Letairis"
       }
      }
     },
     "localname": "OtherProductsLetairisMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Other [Member]",
        "label": "Other Products, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProductsOtherMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsTotalOtherProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Total Other product sales",
        "label": "Other Products, Total Other product sales [Member]",
        "terseLabel": "Total Other"
       }
      }
     },
     "localname": "OtherProductsTotalOtherProductSalesMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_OtherProductsYescartaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Products, Yescarta [Member]",
        "label": "Other Products, Yescarta [Member]",
        "terseLabel": "Yescarta"
       }
      }
     },
     "localname": "OtherProductsYescartaMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for Adjustments of Budgeted Development Costs",
        "label": "Payment for Adjustments of Budgeted Development Costs",
        "terseLabel": "Payment for adjustments of budgeted development costs"
       }
      }
     },
     "localname": "PaymentForAdjustmentsOfBudgetedDevelopmentCosts",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsForAssetAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Asset Acquisitions",
        "label": "Payments For Asset Acquisitions",
        "terseLabel": "Cash consideration"
       }
      }
     },
     "localname": "PaymentsForAssetAcquisitions",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsForDirectTransactionalExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Direct Transactional Expense",
        "label": "Payments for Direct Transactional Expense",
        "terseLabel": "Direct transactional costs"
       }
      }
     },
     "localname": "PaymentsForDirectTransactionalExpense",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Additional In Process Research And Development",
        "label": "Payments To Acquire Additional In Process Research And Development",
        "terseLabel": "Additional payments to acquire in process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInProcessResearchAndDevelopment",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsToAcquireAssetsNetOfCashAcquired": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Assets, Net Of Cash Acquired",
        "label": "Payments To Acquire Assets, Net Of Cash Acquired",
        "terseLabel": "Total consideration, net of acquired cash"
       }
      }
     },
     "localname": "PaymentsToAcquireAssetsNetOfCashAcquired",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsToOptInTheCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Opt-In The Collaborative Agreement",
        "label": "Payments To Opt-In The Collaborative Agreement",
        "terseLabel": "Collaboration opt-in payments"
       }
      }
     },
     "localname": "PaymentsToOptInTheCollaborativeAgreement",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PaymentsToTerminatePreviousAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Terminate Previous Agreement",
        "label": "Payments To Terminate Previous Agreement",
        "terseLabel": "Termination payments"
       }
      }
     },
     "localname": "PaymentsToTerminatePreviousAgreement",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PionyrImmunotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pionyr Immunotherapeutics, Inc.",
        "label": "Pionyr Immunotherapeutics, Inc. [Member]",
        "terseLabel": "Pionyr"
       }
      }
     },
     "localname": "PionyrImmunotherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PionyrMergerAndOptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pionyr Merger and Option Agreements",
        "label": "Pionyr Merger and Option Agreements [Member]",
        "terseLabel": "Pionyr merger and option agreements"
       }
      }
     },
     "localname": "PionyrMergerAndOptionAgreementsMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PotentialFutureMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments, Maximum",
        "label": "Potential Future Milestone Payments, Maximum",
        "terseLabel": "Maximum potential future milestone payments"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsMaximum",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialOptionExerciseFeePerProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Option Exercise Fee Per Program",
        "label": "Potential Option Exercise Fee Per Program",
        "terseLabel": "Potential option exercise fee"
       }
      }
     },
     "localname": "PotentialOptionExerciseFeePerProgram",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Payment for Adjustments of Budgeted Development Costs",
        "label": "Potential Payment for Adjustments of Budgeted Development Costs",
        "terseLabel": "Potential payment for adjustments of budgeted development costs"
       }
      }
     },
     "localname": "PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Sales Based Tiered Royalties High-end, Percentage",
        "label": "Potential Sales Based Tiered Royalties High-end, Percentage",
        "terseLabel": "Payment of tiered royalties, high-end percentage"
       }
      }
     },
     "localname": "PotentialSalesBasedTieredRoyaltiesHighEndPercentage",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Sales Based Tiered Royalty, Low-end, Percentage",
        "label": "Potential Sales Based Tiered Royalty, Low-end, Percentage",
        "terseLabel": "Payment of tiered royalties, low-end percentage"
       }
      }
     },
     "localname": "PotentialSalesBasedTieredRoyaltyLowEndPercentage",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_PreExposureProphylaxisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Exposure Prophylaxis",
        "label": "Pre-Exposure Prophylaxis [Member]",
        "terseLabel": "Pre-Exposure Prophylaxis"
       }
      }
     },
     "localname": "PreExposureProphylaxisMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability",
        "label": "Product Liability [Member]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsOtherHIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Other HIV [Member]",
        "label": "Products, Other HIV [Member]",
        "terseLabel": "Other HIV"
       }
      }
     },
     "localname": "ProductsOtherHIVMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ProductsRevenueShareSymtuzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products, Revenue Share-Symtuza [Member]",
        "label": "Products, Revenue Share-Symtuza [Member]",
        "terseLabel": "Revenue share - Symtuza"
       }
      }
     },
     "localname": "ProductsRevenueShareSymtuzaMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_PropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant and Equipment, Useful Lives [Table Text Block]",
        "label": "Property Plant And Equipment Useful Lives [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Price Of Goods Less Specified Amount, Maximum Percentage",
        "label": "Purchase Price Of Goods Less Specified Amount, Maximum Percentage",
        "terseLabel": "Purchase price of goods less specified amount, maximum percentage"
       }
      }
     },
     "localname": "PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_ResearchAndDevelopmentFutureMaximumPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Future Maximum Payments",
        "label": "Research and Development Future Maximum Payments",
        "terseLabel": "Research and development future maximum payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentFutureMaximumPayments",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_ResearchAndDevelopmentServiceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Service Agreement",
        "label": "Research And Development Service Agreement [Member]",
        "terseLabel": "Research and development service agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServiceAgreementMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ResidentialMortgageAndAssetBackedSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Residential Mortgage And Asset-Backed Securities [Member]",
        "label": "Residential Mortgage And Asset-Backed Securities [Member]",
        "terseLabel": "Residential mortgage and asset-backed securities",
        "verboseLabel": "Residential mortgage and asset-backed securities"
       }
      }
     },
     "localname": "ResidentialMortgageAndAssetBackedSecuritiesMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_RevenuePerformanceObligationPercentageOfUSProfits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Percentage Of U.S. Profits",
        "label": "Revenue, Performance Obligation, Percentage Of U.S. Profits",
        "terseLabel": "Percentage of profits earned"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPercentageOfUSProfits",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_RoyaltyContractAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Contract, And Other [Member]",
        "label": "Royalty, Contract, And Other [Member]",
        "terseLabel": "Royalty, contract and other revenues"
       }
      }
     },
     "localname": "RoyaltyContractAndOtherMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ScheduleOfInventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Inventory [Line Items]",
        "label": "Schedule of Inventory [Line Items]",
        "terseLabel": "Schedule of Inventory [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInventoryLineItems",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and ESPP, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share-Based Payment Award, Stock Options And Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions to Calculate the Estimated Fair Value of Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsAndEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_ScheduleOfTransitionTaxTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Transition Tax",
        "label": "Schedule of Transition Tax [Table Text Block]",
        "terseLabel": "Schedule of Transition Tax"
       }
      }
     },
     "localname": "ScheduleOfTransitionTaxTableTextBlock",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gild_ScheduleofInventoryTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory.",
        "label": "Schedule of Inventory [Table]",
        "terseLabel": "Schedule of Inventory [Table]"
       }
      }
     },
     "localname": "ScheduleofInventoryTable",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_SeniorNotesAndMediumTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes And Medium-Term Notes",
        "label": "Senior Notes And Medium-Term Notes [Member]",
        "terseLabel": "Senior Notes and Medium-Term Notes"
       }
      }
     },
     "localname": "SeniorNotesAndMediumTermNotesMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueDecember2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due December 2041 [Member]",
        "label": "Senior Unsecured Notes Due December 2041 [Member]",
        "terseLabel": "5.65% Senior Unsecured Notes Due in December 2041"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueDecember2041Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinApril2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in April 2024 [Member]",
        "label": "Senior Unsecured Notes Due in April 2024 [Member]",
        "terseLabel": "3.70% Senior Unsecured Notes Due in April 2024"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinApril2024Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinApril2044Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in April 2044 [Member]",
        "label": "Senior Unsecured Notes Due in April 2044 [Member]",
        "terseLabel": "4.80% Senior Unsecured Notes Due in April 2044"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinApril2044Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinFebruary2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in February 2025 [Member]",
        "label": "Senior Unsecured Notes Due in February 2025 [Member]",
        "terseLabel": "3.50% Senior Unsecured Notes Due in February 2025"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinFebruary2025Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinFebruary2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in February 2045 [Member]",
        "label": "Senior Unsecured Notes Due in February 2045 [Member]",
        "terseLabel": "4.50% Senior Unsecured Notes Due in February 2045"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinFebruary2045Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2022 [Member]",
        "label": "Senior Unsecured Notes Due in March 2022 [Member]",
        "terseLabel": "1.95% Senior Unsecured Notes Due in March 2022"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2022Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2026",
        "label": "Senior Unsecured Notes Due in March 2026 [Member]",
        "terseLabel": "3.65% Senior Unsecured Notes Due in March 2026"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2026Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2027 [Member]",
        "label": "Senior Unsecured Notes Due in March 2027 [Member]",
        "terseLabel": "2.95% Senior Unsecured Notes Due in March 2027"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2027Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2046",
        "label": "Senior Unsecured Notes Due in March 2046 [Member]",
        "terseLabel": "4.75% Senior Unsecured Notes Due in March 2046"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2046Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinMarch2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in March 2047 [Member]",
        "label": "Senior Unsecured Notes Due in March 2047 [Member]",
        "terseLabel": "4.15% Senior Unsecured Notes Due in March 2047"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinMarch2047Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2022",
        "label": "Senior Unsecured Notes Due in September 2022 [Member]",
        "terseLabel": "3.25% Senior Unsecured Notes Due in September 2022"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2022Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2023 [Member]",
        "label": "Senior Unsecured Notes Due in September 2023 [Member]",
        "terseLabel": "2.50% Senior Unsecured Notes Due in September 2023"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2023Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2035",
        "label": "Senior Unsecured Notes Due in September 2035 [Member]",
        "terseLabel": "4.60% Senior Unsecured Notes Due in September 2035"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2035Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_SeniorUnsecuredNotesDueinSeptember2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due in September 2036",
        "label": "Senior Unsecured Notes Due in September 2036 [Member]",
        "terseLabel": "4.00% Senior Unsecured Notes Due in September 2036"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueinSeptember2036Member",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Intrinsic Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in millions)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Shares Issued In Period, Weighted Average Price Per Share",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Shares Issued In Period, Weighted Average Price Per Share",
        "terseLabel": "Weighted-average grant date fair value of ESPP shares granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodWeightedAveragePricePerShare",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "gild_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted- Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted- Average Exercise Price (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Pay-out Percentage",
        "terseLabel": "Payout percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOtherthanOptionsPayoutPercentage",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gild_StandstillRestrictingTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standstill Restricting Term",
        "label": "Standstill Restricting Term",
        "terseLabel": "Standstill restricting term"
       }
      }
     },
     "localname": "StandstillRestrictingTerm",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gild_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_TangoTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tango Therapeutics, Inc.",
        "label": "Tango Therapeutics, Inc. [Member]",
        "terseLabel": "Tango"
       }
      }
     },
     "localname": "TangoTherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year One",
        "label": "Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearOne",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year Three",
        "label": "Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearThree",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year Two",
        "label": "Tax Cuts And Jobs Act, Transition Tax For Accumulated Foreign Earnings, Liability, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "TaxCutsAndJobsActTransitionTaxForAccumulatedForeignEarningsLiabilityYearTwo",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_ThreeYearSeniorUnsecuredTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Year Senior Unsecured Term Loan Facility",
        "label": "Three Year Senior Unsecured Term Loan Facility [Member]",
        "terseLabel": "Three year senior unsecured term loan facility"
       }
      }
     },
     "localname": "ThreeYearSeniorUnsecuredTermLoanFacilityMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TizonaMergerAndOptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tizona Merger and Option Agreements",
        "label": "Tizona Merger and Option Agreements [Member]",
        "terseLabel": "Tizona merger and option agreements"
       }
      }
     },
     "localname": "TizonaMergerAndOptionAgreementsMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TizonaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tizona Therapeutics, Inc.",
        "label": "Tizona Therapeutics, Inc. [Member]",
        "terseLabel": "Tizona"
       }
      }
     },
     "localname": "TizonaTherapeuticsIncMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TmunityTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tmunity Therapeutics",
        "label": "Tmunity Therapeutics [Member]",
        "terseLabel": "Tmunity Therapeutics"
       }
      }
     },
     "localname": "TmunityTherapeuticsMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount of assets (excluding financial assets) that lack physical substance, excluding goodwill, having a projected indefinite period of benefit.",
        "label": "Total Indefinite Lived Intangible Assets Excluding Goodwill",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "TotalIndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_TotalUpfrontPaymentsMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Upfront Payments Made",
        "label": "Total Upfront Payments Made",
        "terseLabel": "Total upfront payments made"
       }
      }
     },
     "localname": "TotalUpfrontPaymentsMade",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_TrodelvyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trodelvy",
        "label": "Trodelvy [Member]",
        "terseLabel": "Trodelvy",
        "verboseLabel": "Intangible asset \u2013 Trodelvy"
       }
      }
     },
     "localname": "TrodelvyMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gild_UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Current Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Current Period Tax Positions [Abstract]",
        "terseLabel": "Tax positions related to current year:"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsCurrentPeriodTaxPositionsAbstract",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Prior Period Tax Positions [Abstract]",
        "terseLabel": "Tax positions related to prior years:"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPriorPeriodTaxPositionsAbstract",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Up-Front Collaboration And Licensing Expenses Related To Other Collaboration Arrangements That Are Not Individually Significant",
        "label": "Up-Front Collaboration And Licensing Expenses Related To Other Collaboration Arrangements That Are Not Individually Significant",
        "terseLabel": "Upfront collaboration expenses"
       }
      }
     },
     "localname": "UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_UpfrontPaymentsToTerminatePreviousAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payments To Terminate Previous Agreement",
        "label": "Upfront Payments To Terminate Previous Agreement",
        "terseLabel": "Upfront termination payments"
       }
      }
     },
     "localname": "UpfrontPaymentsToTerminatePreviousAgreement",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gild_VekluryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Veklury",
        "label": "Veklury [Member]",
        "terseLabel": "Veklury"
       }
      }
     },
     "localname": "VekluryMember",
     "nsuri": "http://www.gilead.com/20221231",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r348",
      "r349",
      "r480",
      "r508",
      "r817",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r279",
      "r355",
      "r361",
      "r368",
      "r428",
      "r594",
      "r595",
      "r596",
      "r623",
      "r624",
      "r656",
      "r658",
      "r659",
      "r660",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect from the adoption of new accounting standard"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r279",
      "r355",
      "r361",
      "r368",
      "r428",
      "r594",
      "r595",
      "r596",
      "r623",
      "r624",
      "r656",
      "r658",
      "r659",
      "r660",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r279",
      "r355",
      "r361",
      "r368",
      "r428",
      "r594",
      "r595",
      "r596",
      "r623",
      "r624",
      "r656",
      "r658",
      "r659",
      "r660",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r406",
      "r838",
      "r931",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r467",
      "r557",
      "r739",
      "r775",
      "r804",
      "r805",
      "r834",
      "r848",
      "r859",
      "r928",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r467",
      "r557",
      "r739",
      "r775",
      "r804",
      "r805",
      "r834",
      "r848",
      "r859",
      "r928",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r406",
      "r838",
      "r931",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r403",
      "r741",
      "r836",
      "r857",
      "r923",
      "r924",
      "r931",
      "r998"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r403",
      "r741",
      "r836",
      "r857",
      "r923",
      "r924",
      "r931",
      "r998"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r467",
      "r549",
      "r557",
      "r585",
      "r586",
      "r587",
      "r715",
      "r739",
      "r775",
      "r804",
      "r805",
      "r834",
      "r848",
      "r859",
      "r919",
      "r928",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r467",
      "r549",
      "r557",
      "r585",
      "r586",
      "r587",
      "r715",
      "r739",
      "r775",
      "r804",
      "r805",
      "r834",
      "r848",
      "r859",
      "r919",
      "r928",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r348",
      "r349",
      "r480",
      "r508",
      "r819",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r280",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r383",
      "r429",
      "r430",
      "r624",
      "r657",
      "r659",
      "r660",
      "r661",
      "r688",
      "r702",
      "r703",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r280",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r383",
      "r429",
      "r430",
      "r624",
      "r657",
      "r659",
      "r660",
      "r661",
      "r688",
      "r702",
      "r703",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Reclassification, Adjustment"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r404",
      "r405",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r837",
      "r858",
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r404",
      "r405",
      "r788",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r837",
      "r858",
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r19",
      "r856"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r299",
      "r407",
      "r408",
      "r812"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r3",
      "r241",
      "r263"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r5",
      "r241",
      "r263"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r246",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Future royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r117",
      "r288"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r314",
      "r324",
      "r325",
      "r645",
      "r821",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Cash Flow Hedges, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r314",
      "r324",
      "r325",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Unrealized Gains and Losses on Available-for-Sale Debt Securities, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r38",
      "r40",
      "r41",
      "r300",
      "r768",
      "r781",
      "r785"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r323",
      "r324",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r37",
      "r41",
      "r193",
      "r703",
      "r776",
      "r777",
      "r878",
      "r879",
      "r880",
      "r893",
      "r894",
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r36",
      "r41",
      "r193",
      "r324",
      "r325",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated useful life of finite-lived intangible asset acquired"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r11",
      "r856"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r594",
      "r595",
      "r596",
      "r893",
      "r894",
      "r895",
      "r977"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r65",
      "r109"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r154",
      "r155",
      "r559"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r598"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r589"
     ],
     "calculation": {
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Stock-based compensation expense, net of tax"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r301",
      "r411",
      "r431"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Less: allowances for credit losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r65",
      "r102",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense related to finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r972"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r239",
      "r262",
      "r292",
      "r343",
      "r393",
      "r397",
      "r401",
      "r427",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r641",
      "r646",
      "r675",
      "r856",
      "r926",
      "r927",
      "r988"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r283",
      "r304",
      "r343",
      "r427",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r641",
      "r646",
      "r675",
      "r856",
      "r926",
      "r927",
      "r988"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]",
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "After five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r83",
      "r415",
      "r765"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "After five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r83",
      "r414",
      "r764"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "After ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r83",
      "r416",
      "r766"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "After ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Amortized\u00a0Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r83",
      "r413",
      "r763"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r203",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingsAndImprovementsGross": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Improvements, Gross",
        "terseLabel": "Buildings and improvements (including leasehold improvements)"
       }
      }
     },
     "localname": "BuildingsAndImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r636",
      "r846",
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r173",
      "r174",
      "r636",
      "r846",
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill expected to be deductible for tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related expenses"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r181",
      "r182",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Acquisition consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r180",
      "r183",
      "r639"
     ],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Liability for MYR GmbH (\u201cMYR\u201d) contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r186",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory",
        "terseLabel": "Fair value step-up adjustment of inventories acquired"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability",
        "terseLabel": "Fair value of contingent liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Deferred income taxes, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Aggregate fair value of acquired IPR&amp;D",
        "verboseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "Intangible assets:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Finite-lived intangible asset",
        "verboseLabel": "Finite-lived intangible asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Combination, Separately Recognized Transactions [Line Items]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Table]",
        "terseLabel": "Business Combination, Separately Recognized Transactions [Table]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions, including Goodwill, Intangible Assets and Contingent Consideration"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "auth_ref": [
      "r806"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.",
        "label": "Capitalized Computer Software, Net",
        "terseLabel": "Unamortized capitalized software costs"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r67",
      "r286",
      "r810"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r60",
      "r67",
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r60",
      "r230"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r343",
      "r371",
      "r375",
      "r377",
      "r379",
      "r387",
      "r388",
      "r427",
      "r468",
      "r470",
      "r471",
      "r472",
      "r475",
      "r476",
      "r506",
      "r507",
      "r510",
      "r514",
      "r521",
      "r675",
      "r807",
      "r873",
      "r888",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r27",
      "r247",
      "r269"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r121",
      "r461",
      "r462",
      "r790",
      "r925"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Capital shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividend Per Share (in dollars per share)",
        "verboseLabel": "Dividends declared (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r893",
      "r894",
      "r977"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending period (in shares)",
        "periodStartLabel": "Beginning period (in shares)",
        "terseLabel": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10",
      "r856"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.001 per share; 5,600 authorized; 1,247 and 1,254 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r43",
      "r319",
      "r321",
      "r330",
      "r760",
      "r772"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Gilead"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r190",
      "r191",
      "r196",
      "r319",
      "r321",
      "r329",
      "r759",
      "r771"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r189",
      "r196",
      "r319",
      "r321",
      "r328",
      "r758",
      "r770"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Office, computer equipment and other"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r75",
      "r76",
      "r227",
      "r228",
      "r406",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r75",
      "r76",
      "r227",
      "r228",
      "r406",
      "r786",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r75",
      "r76",
      "r227",
      "r228",
      "r406",
      "r789",
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r75",
      "r76",
      "r227",
      "r228",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r75",
      "r76",
      "r227",
      "r228",
      "r406",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r523",
      "r525",
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r523",
      "r524",
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r835"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Changes in estimates"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenues recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "verboseLabel": "Revenue share with Janssen and royalties for licenses of intellectual property"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "auth_ref": [
      "r932"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.",
        "label": "Contract with Customer, Refund Liability, Current",
        "terseLabel": "Allowance for sales returns"
       }
      }
     },
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r843",
      "r845",
      "r1000"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r48",
      "r741"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r891",
      "r966",
      "r969"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "negatedTerseLabel": "Current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r891",
      "r966"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "negatedTerseLabel": "Current"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r891",
      "r966",
      "r969"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "negatedTerseLabel": "Current"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r74",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r125",
      "r341",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r493",
      "r500",
      "r501",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt and Credit Facilities"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r240",
      "r243",
      "r260",
      "r351",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r489",
      "r490",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r687",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r4",
      "r243",
      "r260",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Short-term and long-term debt",
        "verboseLabel": "Total senior unsecured notes"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r24",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, stated percentage",
        "verboseLabel": "Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r25",
      "r351",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r489",
      "r490",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r687",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Redemption price, percentage of principal amount repurchased"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r25",
      "r131",
      "r134",
      "r135",
      "r136",
      "r231",
      "r232",
      "r234",
      "r258",
      "r351",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r489",
      "r490",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r502",
      "r687",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r905"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r422",
      "r442",
      "r827"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Longer"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r422",
      "r442"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "12 Months or Longer"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r422",
      "r442",
      "r827"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less Than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r422",
      "r442"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedTerseLabel": "Less Than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r905"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      },
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "netLabel": "Total",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Fair Value",
        "verboseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of the Classification of Available-for-Sale Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r420",
      "r439",
      "r827"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r421",
      "r440"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "auth_ref": [
      "r438",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r419",
      "r827",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt Securities In Continuous Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleUnrealizedLossPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Compensation Expense",
        "terseLabel": "Matching contribution expense"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r891",
      "r967",
      "r969"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r891",
      "r967"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r65",
      "r168",
      "r621",
      "r627",
      "r628",
      "r891"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r242",
      "r259",
      "r616"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r891",
      "r967",
      "r969"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsEquityMethodInvestments": {
     "auth_ref": [
      "r166",
      "r965"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.",
        "label": "Deferred Tax Assets, Equity Method Investments",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "DeferredTaxAssetsEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Excess of tax basis over book basis of intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r617"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r166",
      "r965"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized R&amp;D expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r964"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r166",
      "r965"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r166",
      "r965"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r164",
      "r166",
      "r965"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and other credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r166",
      "r965"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r166",
      "r965"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Reserves and accruals not currently deductible"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": {
     "auth_ref": [
      "r166",
      "r965"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies",
        "terseLabel": "Liability related to sale of future royalties"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r618"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r159",
      "r964"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r166",
      "r965"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Excess of book basis over tax basis of intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r166",
      "r965"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r166",
      "r965"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r65",
      "r115"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r305",
      "r820"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement",
        "terseLabel": "Derivative Assets"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r33",
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "terseLabel": "Net amount (legal offset)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r32",
      "r34",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "negatedTerseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative asset.",
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative asset, statement of financial position"
       }
      }
     },
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r34",
      "r211",
      "r307",
      "r818"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset",
        "terseLabel": "Cash collateral received / pledged"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r34",
      "r211",
      "r307",
      "r818"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset",
        "terseLabel": "Cash collateral received / pledged"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r216",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period for the anticipated transfer of gain (loss), net, from accumulated other comprehensive income into earnings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimate of Time to Transfer",
        "terseLabel": "Time estimate for gains (losses) to be reclassified from AOCI to product sales"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimateOfTimeToTransfer1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r207",
      "r976"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gain (loss) recognized in Other income (expense), net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement": {
     "auth_ref": [
      "r305",
      "r820"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and elected not to be offset.",
        "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement",
        "terseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r33",
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "terseLabel": "Net amount (legal offset)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r32",
      "r34",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "negatedTerseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative liability.",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative liability, statement of financial position"
       }
      }
     },
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r974",
      "r975"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Outstanding notional amounts on foreign currency exchange contracts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Maturity on derivative instruments"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r206",
      "r208",
      "r209",
      "r212",
      "r214",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r198",
      "r199",
      "r201",
      "r202",
      "r210",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r544",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r562",
      "r590",
      "r591",
      "r593",
      "r597",
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Employee Benefits"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r137",
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsDeclaredTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.",
        "label": "Dividends Declared [Table Text Block]",
        "terseLabel": "Schedule of Dividends Declared"
       }
      }
     },
     "localname": "DividendsDeclaredTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic tax authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r331",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r369",
      "r371",
      "r377",
      "r378",
      "r379",
      "r383",
      "r660",
      "r661",
      "r761",
      "r773",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Gilead (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r331",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r371",
      "r377",
      "r378",
      "r379",
      "r383",
      "r660",
      "r661",
      "r761",
      "r773",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Gilead (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r676"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r346",
      "r605",
      "r630"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r962",
      "r970"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Changes in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion": {
     "auth_ref": [
      "r962",
      "r970"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for extraterritorial income exclusion.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Extraterritorial Income Exclusion, Percent",
        "negatedTerseLabel": "Foreign-derived intangible income deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsExtraterritorialIncomeExclusion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary": {
     "auth_ref": [
      "r962",
      "r970"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent",
        "negatedTerseLabel": "Non-taxable unrealized loss on investment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r962",
      "r970"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign earnings at different rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r962",
      "r970"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Acquired IPR&amp;D &amp; related charges"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r962",
      "r970"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r962",
      "r970"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent",
        "terseLabel": "US tax on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r962",
      "r970"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r962",
      "r970"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Research and other credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r962",
      "r970"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Settlement of tax examinations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofDifferenceBetweenProvisionForIncomeTaxesandFederalStatutoryIncomeTaxRatetoIncomeBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r960"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r589"
     ],
     "calculation": {
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "negatedTerseLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r130",
      "r279",
      "r323",
      "r324",
      "r325",
      "r352",
      "r353",
      "r354",
      "r357",
      "r364",
      "r367",
      "r386",
      "r428",
      "r522",
      "r594",
      "r595",
      "r596",
      "r623",
      "r624",
      "r659",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r703",
      "r776",
      "r777",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r97",
      "r394",
      "r874"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity investments balance"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r59",
      "r99",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r293",
      "r672",
      "r813"
     ],
     "calculation": {
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Marketable equity securities",
        "verboseLabel": "Equity investment"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "terseLabel": "Unrealized loss on investment of equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r95",
      "r261",
      "r860",
      "r861",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Other publicly traded equity securities",
        "verboseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r491",
      "r674",
      "r830",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r662",
      "r663",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r217",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r217",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r491",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r663",
      "r712",
      "r713",
      "r714",
      "r830",
      "r831",
      "r843",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r217",
      "r222",
      "r491",
      "r830",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r662",
      "r663",
      "r665",
      "r666",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r491",
      "r830",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r491",
      "r550",
      "r555",
      "r663",
      "r712",
      "r843",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r491",
      "r550",
      "r555",
      "r663",
      "r713",
      "r830",
      "r831",
      "r843",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r491",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r663",
      "r714",
      "r830",
      "r831",
      "r843",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r218",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Change in Fair Value of Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r667"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Changes in valuation assumptions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r491",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r712",
      "r713",
      "r714",
      "r830",
      "r831",
      "r843",
      "r844",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r662",
      "r663",
      "r665",
      "r666",
      "r668",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r669",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value, recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r203",
      "r206",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r344",
      "r604"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "negatedTotalLabel": "Federal income tax expense (benefit), continuing operations"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Federal:"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r417",
      "r418",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r441",
      "r443",
      "r444",
      "r502",
      "r519",
      "r654",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r827",
      "r901",
      "r902",
      "r903",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Amortization useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r290",
      "r456"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r452",
      "r455",
      "r456",
      "r458",
      "r742",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r108",
      "r743"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r103",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r108",
      "r742"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofFiniteLivedIntangibleAssetsDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "terseLabel": "Foreign currency derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation and Transaction"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r933",
      "r1000"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non-U.S. government securities"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "negatedTotalLabel": "Foreign income tax expense (benefit), continuing operations"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Foreign:"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net gain (loss) reclassified into earnings when foreign currency cash flow hedge is discontinued because it is probable that the original forecasted transactions will not occur by the end of the original period or an additional two month time period.",
        "label": "Gain (Loss) on Discontinuation of Foreign Currency Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net",
        "terseLabel": "Gain (loss) on discontinuance of cash flow hedges"
       }
      }
     },
     "localname": "GainLossOnDiscontinuationOfForeignCurrencyCashFlowHedgeDueToForecastedTransactionProbableOfNotOccurringNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r289",
      "r448",
      "r756",
      "r828",
      "r856",
      "r907",
      "r914"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r450",
      "r828"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill resulting from acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r449",
      "r451",
      "r828"
     ],
     "calculation": {
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r449",
      "r451",
      "r828"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment losses"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r170",
      "r913"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "negatedTerseLabel": "Decrease in goodwill",
        "terseLabel": "Measurement period adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r201",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r887",
      "r918"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "In-process research and development impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In Process Research and Development Expenses"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r345",
      "r629"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r45",
      "r237",
      "r248",
      "r272",
      "r393",
      "r396",
      "r400",
      "r402",
      "r762",
      "r826"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r345",
      "r629"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r346",
      "r606",
      "r614",
      "r620",
      "r625",
      "r631",
      "r633",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r347",
      "r366",
      "r367",
      "r392",
      "r604",
      "r626",
      "r632",
      "r774"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "negatedTotalLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r322",
      "r600",
      "r601",
      "r614",
      "r615",
      "r619",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r61",
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r336",
      "r423"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedTerseLabel": "Net loss from equity securities"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r379",
      "r561"
     ],
     "calculation": {
      "http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive effect of stock options and equivalents (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r454",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure": {
     "auth_ref": [
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure",
        "terseLabel": "Indefinite-lived intangible assets, fair value"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r105",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross\u00a0 Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r101",
      "r106"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Including Goodwill) [Abstract]",
        "terseLabel": "Intangible Assets, Net (Including Goodwill) [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r233",
      "r251",
      "r326",
      "r391",
      "r686"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseLongTermDebt": {
     "auth_ref": [
      "r250",
      "r807",
      "r808"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of interest paid or due on all long-term debt.",
        "label": "Interest Expense, Long-Term Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r335",
      "r339",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid, net of amounts capitalized"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r100",
      "r814"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails_1": {
       "order": 3.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r303",
      "r811",
      "r856"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": 1.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r876"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": 2.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Other long term assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r285",
      "r302",
      "r385",
      "r445",
      "r446",
      "r447",
      "r740",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r100",
      "r816"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails_1": {
       "order": 1.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r100",
      "r815"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails_1": {
       "order": 2.0,
       "parentTag": "gild_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r273",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Shares of common stock acquired (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r426",
      "r997"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Marketable Debt Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt Securities by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r238",
      "r254",
      "r274",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Available-for-sale Debt Securities and Equity Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Land": {
     "auth_ref": [
      "r875"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.",
        "label": "Land",
        "terseLabel": "Land and land improvements"
       }
      }
     },
     "localname": "Land",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Supplemental Information Related to Operating Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r986"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating Lease Aggregate Future Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r699"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r699"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r699"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r699"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r699"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r699"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r699"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r699"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Termination period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r984"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease term extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r15",
      "r245",
      "r267",
      "r856",
      "r890",
      "r904",
      "r980"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r284",
      "r343",
      "r427",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r642",
      "r646",
      "r647",
      "r675",
      "r856",
      "r926",
      "r988",
      "r989"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r4",
      "r243",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Amounts outstanding under the facility"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r27",
      "r920"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Accrued litigation"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r243",
      "r264",
      "r490",
      "r505",
      "r830",
      "r831"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total debt, net",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Less: Current portion of long-term debt and other obligations, net"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Short-term and long-term debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r123",
      "r351",
      "r929"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r123",
      "r351",
      "r495"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r123",
      "r351",
      "r495"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r123",
      "r351",
      "r495"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r123",
      "r351",
      "r495"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r123",
      "r351",
      "r495"
     ],
     "calculation": {
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Total Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r25",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValueCurrent": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.",
        "label": "Loss Contingency, Accrual, Current",
        "terseLabel": "Accrual for settlement related to bictegravir litigation"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r920",
      "r921",
      "r922"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r921",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of claims filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r921",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [
      "r921",
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents challenged"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment, Gross",
        "terseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of Equity Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r979"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r979"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r979"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MediumTermNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instruments with maturities ranging from five to ten years.",
        "label": "Medium-term Notes [Member]",
        "terseLabel": "Medium-term notes"
       }
      }
     },
     "localname": "MediumTermNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r31",
      "r244",
      "r266",
      "r343",
      "r427",
      "r468",
      "r470",
      "r471",
      "r472",
      "r475",
      "r476",
      "r675"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage by noncontrolling owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "terseLabel": "Change in noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r60",
      "r63",
      "r66"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r46",
      "r66",
      "r249",
      "r271",
      "r282",
      "r317",
      "r320",
      "r325",
      "r343",
      "r356",
      "r358",
      "r359",
      "r361",
      "r362",
      "r366",
      "r367",
      "r376",
      "r393",
      "r396",
      "r400",
      "r402",
      "r427",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r661",
      "r675",
      "r826",
      "r926"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Gilead",
        "totalLabel": "Net income attributable to Gilead"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r192",
      "r195",
      "r317",
      "r320",
      "r366",
      "r367",
      "r880"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r187",
      "r522",
      "r893",
      "r894",
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Liability related to future royalties"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "terseLabel": "Number of countries in which entity operates"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r393",
      "r396",
      "r400",
      "r402",
      "r826"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r983"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r690"
     ],
     "calculation": {
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total discounted lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesSummaryofOperatingLeaseLiabilitiesMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r690"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities \u2013 current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease, current, statement of financial position, extensible enumeration"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r690"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities \u2013 noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease, noncurrent, statement of financial position, extensible enumeration"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r692",
      "r695"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r689"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease, right-of-use asset, statement of financial position, extensible enumeration"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r698",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r697",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesBalanceSheetLocationandOtherInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r71",
      "r77",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]",
        "terseLabel": "Available-for-sale debt securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax [Abstract]",
        "terseLabel": "Available-for-sale debt securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax [Abstract]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r309",
      "r310",
      "r312"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r41",
      "r44",
      "r324",
      "r677",
      "r679",
      "r683",
      "r878"
     ],
     "calculation": {
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Net unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r308",
      "r312"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r308",
      "r312"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Net unrealized gain (loss), net of tax impact of $20, $18 and $(15), respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r308",
      "r312",
      "r649",
      "r650",
      "r653"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain (loss) recognized in Accumulated other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "terseLabel": "Tax impact of net unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r312",
      "r315"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to net income, net of tax impact of $25, $(9) and $6, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r312",
      "r315",
      "r651"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Gain (loss) reclassified from Accumulated other comprehensive income to Product sales"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofEffectofForeignCurrencyExchangeContractsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax",
        "negatedTerseLabel": "Tax impact of reclassifications to net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Net foreign currency translation loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r130",
      "r318",
      "r321",
      "r327",
      "r677",
      "r682",
      "r683",
      "r757",
      "r769",
      "r878",
      "r879"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r38",
      "r42",
      "r94",
      "r316"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassifications to net income, net of tax impact of $0, $0 and $12, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r39",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "negatedTerseLabel": "Tax impact of reclassifications to net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r309",
      "r312"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gain (loss), net of tax impact of $0, $(1) and $12, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r39",
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Tax impact of net unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Other Accrued Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r856"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/OtherFinancialInformationOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other liabilities.",
        "label": "Other Liabilities, Fair Value Disclosure",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "OtherLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other\u00a0long-term\u00a0obligations"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r881",
      "r882"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Payment of dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r53",
      "r638"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid for acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisitions, including in-process research and development, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire equity method investments"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r336",
      "r423"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "terseLabel": "Payments to acquire shares"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "terseLabel": "Payments to acquire in process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchases of equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.gilead.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.gilead.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r9",
      "r856"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r877"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofClassificationofEquitySecuritiesDetails",
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsSummaryofClassificationandFairValueofDerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt financing, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuances of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r883"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Debt issued"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r56",
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Total fair value of ESPP shares as of the respective vesting dates"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-Term Lines of Credit",
        "terseLabel": "Borrowing under the senior unsecured term loan facility"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r80",
      "r332",
      "r333"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r884",
      "r886"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r52",
      "r80",
      "r332"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "verboseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r282",
      "r317",
      "r320",
      "r337",
      "r343",
      "r356",
      "r366",
      "r367",
      "r393",
      "r396",
      "r400",
      "r402",
      "r427",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r640",
      "r643",
      "r644",
      "r661",
      "r675",
      "r762",
      "r826",
      "r853",
      "r854",
      "r880",
      "r926"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r120",
      "r792",
      "r793",
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r116",
      "r287"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r118",
      "r268",
      "r767",
      "r856"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails",
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Other, Gross",
        "terseLabel": "Office, computer equipment and other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r792",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r41",
      "r44",
      "r324",
      "r677",
      "r681",
      "r683",
      "r878"
     ],
     "calculation": {
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassifications to net income"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r556",
      "r704",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r278",
      "r704",
      "r705",
      "r987"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "Donation expense"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r556",
      "r704",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r987"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r885"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayments of debt and other obligations",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "negatedTerseLabel": "Decrease in research and development",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails",
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r137",
      "r265",
      "r780",
      "r785",
      "r856"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r279",
      "r352",
      "r353",
      "r354",
      "r357",
      "r364",
      "r367",
      "r428",
      "r594",
      "r595",
      "r596",
      "r623",
      "r624",
      "r659",
      "r776",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r389",
      "r390",
      "r395",
      "r398",
      "r399",
      "r403",
      "r404",
      "r406",
      "r543",
      "r544",
      "r741"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/RevenuesDisaggregationofRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r406",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r548",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r533",
      "r534",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "auth_ref": [
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "terseLabel": "Revenues Recognized from Performance Obligations Satisfied in Prior Periods"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r696",
      "r855"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/LeasesSupplementalInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Accounts Receivable, net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r41",
      "r981",
      "r982"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated OCI by Component"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "verboseLabel": "Available-for-Sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Debt Securities at Estimated Fair Value"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r84",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryoftheBalanceSheetClassificationofAvailableforSaleDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r173",
      "r174",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsSummarizedFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r973"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r25",
      "r131",
      "r134",
      "r135",
      "r136",
      "r231",
      "r232",
      "r234",
      "r258",
      "r830",
      "r832",
      "r892"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Financing Arrangements"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r204",
      "r208",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Effect of Foreign Currency Exchange Contracts"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Classification and Fair Value of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r897"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Difference Between Provision for Income Taxes and Federal Statutory Income Tax Rate to Income Before Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r150",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-based Compensation Expenses -Included in Consolidated Statement of Income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesSummarizedRevenuesfromMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r103",
      "r107",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r103",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r828",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income (Loss) Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r16",
      "r17",
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Contractual Maturities of Financing Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Summarized Fair Values of Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Summarized Revenues from Major Customers"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r558",
      "r560",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of employee stock purchase plan activity.",
        "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "terseLabel": "ESPP Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r144",
      "r145",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Activity Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r126",
      "r128",
      "r129",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r296",
      "r297",
      "r298",
      "r387",
      "r506",
      "r507",
      "r508",
      "r510",
      "r514",
      "r519",
      "r521",
      "r834",
      "r873",
      "r888"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock Repurchases"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r127",
      "r128",
      "r129",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Stock Repurchases"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r852",
      "r963"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated Future Amortization Expense of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/DebtandCreditFacilitiesContractualMaturitiesofFinancingObligationsDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesNarrativeDetails",
      "http://www.gilead.com/role/DebtandCreditFacilitiesSummaryofDebtCarryingAmountDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.",
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "terseLabel": "Accelerated stock-based expense"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AcquisitionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of RSUs as of the respective vesting dates"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common stock authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, beginning balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r582"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Expected to vest, net of estimated forfeitures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Expected to vest, net of estimated forfeitures (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Expected to vest, net of estimated forfeitures (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails",
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails",
      "http://www.gilead.com/role/EmployeeBenefitsPerformanceShareAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsRestrictedStockDetails",
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails",
      "http://www.gilead.com/role/EmployeeBenefitsSummaryofStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.",
        "label": "Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]",
        "terseLabel": "PSU Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected terms in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsScheduleofAssumptionsUsedtoCalculatetheFairValueofAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares (in millions)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Expected to vest, net of estimated forfeitures"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock (percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r891",
      "r961",
      "r968"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "negatedTotalLabel": "State and local income tax expense (benefit), continuing operations"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "State:"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and local jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r343",
      "r371",
      "r375",
      "r377",
      "r379",
      "r387",
      "r388",
      "r427",
      "r468",
      "r470",
      "r471",
      "r472",
      "r475",
      "r476",
      "r506",
      "r507",
      "r510",
      "r514",
      "r521",
      "r675",
      "r807",
      "r873",
      "r888",
      "r896"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r29",
      "r130",
      "r279",
      "r323",
      "r324",
      "r325",
      "r352",
      "r353",
      "r354",
      "r357",
      "r364",
      "r367",
      "r386",
      "r428",
      "r522",
      "r594",
      "r595",
      "r596",
      "r623",
      "r624",
      "r659",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r703",
      "r776",
      "r777",
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r386",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r9",
      "r10",
      "r130",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuances under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r9",
      "r10",
      "r130",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance under equity incentive plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r10",
      "r130",
      "r137",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/EmployeeBenefitsStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r9",
      "r10",
      "r130",
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuances under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/EmployeeBenefitsESPPActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r9",
      "r10",
      "r137",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances under equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "verboseLabel": "Stock repurchase program, remaining authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r9",
      "r10",
      "r130",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Shares repurchased and retired (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r9",
      "r10",
      "r130",
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "terseLabel": "Amount"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r9",
      "r10",
      "r130",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchases of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r9",
      "r10",
      "r130",
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r13",
      "r14",
      "r79",
      "r856",
      "r890",
      "r904",
      "r980"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Gilead stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r187",
      "r188",
      "r194",
      "r279",
      "r280",
      "r324",
      "r352",
      "r353",
      "r354",
      "r357",
      "r364",
      "r428",
      "r522",
      "r594",
      "r595",
      "r596",
      "r623",
      "r624",
      "r659",
      "r677",
      "r678",
      "r683",
      "r703",
      "r777",
      "r778",
      "r890",
      "r904",
      "r980"
     ],
     "calculation": {
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.gilead.com/role/StockholdersEquityChangesinAccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.gilead.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r139",
      "r342",
      "r507",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r520",
      "r522",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r684",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r684",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r684",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r684",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityDividendsDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r706",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": {
     "auth_ref": [
      "r971"
     ],
     "calculation": {
      "http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability",
        "terseLabel": "Accrued repatriation of foreign earnings",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails",
      "http://www.gilead.com/role/IncomeTaxesScheduleofTransitionTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r409",
      "r410",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r417",
      "r418",
      "r502",
      "r519",
      "r654",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r901",
      "r902",
      "r903",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Average price per share (in dollars per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/StockholdersEquityRepurchasesofCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r973"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails",
      "http://www.gilead.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r824",
      "r843",
      "r996"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agencies securities",
        "verboseLabel": "U.S. government agencies securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r824",
      "r843",
      "r845",
      "r996"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesInContinuousUnrealizedLossPositionDetails",
      "http://www.gilead.com/role/AvailableforsaleDebtSecuritiesandEquitySecuritiesSummaryofAvailableforSaleDebtSecuritiesatEstimatedFairValueDetails",
      "http://www.gilead.com/role/FairValueMeasurementsSummaryofAssetsandLiabilitiesRecordedatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r599",
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "negatedTerseLabel": "Reductions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r609"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r607"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and income tax penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r607"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Income tax penalties and interest (benefit) expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r610"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r612"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesRollforwardofTotalUnrecognizedTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r613"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CollaborationsandOtherArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r370",
      "r379"
     ],
     "calculation": {
      "http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in diluted earnings per share attributable to Gilead calculation (in shares)",
        "totalLabel": "Shares used in diluted earnings per share attributable to Gilead calculation (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r369",
      "r379"
     ],
     "calculation": {
      "http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in basic earnings per share attributable to Gilead calculation (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gilead.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.gilead.com/role/EarningsPerShareScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1002": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1003": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1004": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1005": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1006": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1007": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1008": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=SL65897772-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.8)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(ii)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL108322424-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r863": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r864": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r865": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r866": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r867": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r868": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r869": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r871": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r872": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130611-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126960272&loc=d3e32014-111567",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>126
<FILENAME>0000882095-23-000007-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000882095-23-000007-xbrl.zip
M4$L#!!0    ( $Z"5E9B>8*Q2CX% (8R/@ 1    9VEL9"TR,#(R,3(S,2YH
M=&WLO6M['47.+OQ]_PI>WJ_;0QU451+7#/L"$G@R&SL#!!CGRUR22I4X^)#'
M=D*<7[_53APFP/ $".G5O=; X'7H=>K[;NF65"7]]?\\.SE^[ZF=7QR=G?[M
M_?B7\/Y[_^>CO_Y_>WO__.2K+]Z[=:9/3NST\KU/SXTOK;_WP]'EP_>^ZW;Q
M_7OC_.SDO>_.SK\_>LI[>]>O^?3L\=7YT8.'E^^ED/)/GCS_,&;L5&K<*Z.6
M/9 T]B1HV6-4H88U4:C_^\&'71!1J>Y1D+ '6OL>AH![0!W1>D;E]K_[A[53
MU9::]&S ,5 ED5$9H5=0:]/'/KST7^>_\/3B0SU[<GIY?O6W]Q]>7C[^\(,/
MGLGY\5\N3/_RX.SI!R^?_,"_=GK_Y0N.GKTZ]H<??OC+]?%GYP_\F)@_.#H]
M/CJUZ1S='/[LXNBUXW_(+X\.\8-_[G_QM3ZT$]X[.KVXY%.UFU==G%^^>M7@
M"[E^C3_XVC?I=O3+7]N?>.W !T?'_;4OX0\8][_HV<GU<3'E^.K[^AL=_:=?
M&*9?^/HW]=_[_:\</CTM?/'J\"<7>P^8'__\Q[U\XO53?7$&*;9?^S8OCO@1
MF\M?/OA'7#ZX/.?3BW%V?L*7SNWI\\)>2'OQU:<^^]E/>HE9)*(/KI_]M\_;
M\Y/^VL$W(/S:1\:RY\1]==+_\X=-1/UW9/I/$']Y(NH'+YZ\/O3#8SY]\+?W
M[73OFZ_?=ZX[TA_]]<0N^;WIE7OVWT^.GO[M_4_/3B_]"MZ[=_78P=$7]_[V
M_J4]N_S@^E,_^.A__:__]=?+H\MC^V@BT-X-4_[ZP8L'__K!B[>6LW[UT5_[
MT=/W+BZOCNUO[_>CB\?'?/7AZ=FI^1<X>O;A=*"=O[AYU+N=7M_TYP_<C)P?
MZ8O/?W;YE8V_O7^4N*2$P1I% FI$2(D[!VB6_2)N_[HU?9400]S[D;VG?#)]
MM!U]>/O4O]_5I_YSSOGXSFFW9__7KMY_[\@O@:.>O[V26V=/OTA?/3W,^T_Z
MH]M/[W].C^X^NO_]W7OW'QT\OY,/3[Y\?O_>5P_W[WU<#AX='QV>'*;#>P_"
M_5N'X3!]D[_(!\>'S\_2_5O?I\/G>G60_O[]?OHF'-Z[_</=>X?E\.3O)P<G
MM^'@\R_3P><'QP<1PQ?I_M7A=UH/T[</[]_Z,NS[^Q\^VG]^<$N?WS^Y<W5X
M<O_H[JUO_3._^6&Z??#HP=/^^6='\ODWU9__8?_>@;_GG;1_LN_O>?_DX//;
M^>#SZ75?YOOW[I_<?_3WZ5N^?,VW_EGE]/Z]QR>'CSY^MI_\F4>'5X?/#\/]
M$_\-]S0</OK[T?U;_?C@Y/[)OK_Z_C$^_^+>[<O]K\,S_YL.GA^F@R__5;6/
MP#KV1LJZ!YE@#UN4O6Y80Q@<N>'['P7_'V(*5/[ZP6NP_IDHW[B@SXXNE(\/
MC<\_\T<N=CC_3SB'7\#9 FEL*'LUYKP'/,8>Y\1[,13'(\<LXCA/,,R&\#_\
M_<_Z#N,WPCC^ L8=6='(M549Y!AKVZ,6PI[4D;L+)HZYO/_19X?O$.&/'=Y^
M#?$Q/]BA^C^AFG[IRHV%2ROD4EBJ2V$H>Y)"W8MNMS.4$JLYJH./+^RW )NK
M.%4R6; (60>U$HH--J5>*L._[OP4SY?Z[<-;_F9/7><\M8\O+NSRZTN/#R:(
M[X[/CDY=.![YI7QV<30)H=O/7'-<',FQW3Z=OL2U.IJ7!L_V;^T_O7_Z]X?W
MGY^%_4=?^G/[^2 =_K!_Z^-P_[O#</?6-U?W3[Y)^]_=OKK_Z).C@^>?/;K[
M-87#[_Y^<?_>V;.[][XZVK_73_:?^]_GM\/^YU_"X7>WX^&C;\+=>U^6P^</
MDE/GV<'-:_[Y]X=RTH_O/KI=G"[/_+.>^]_G^_>^_.'^K8</#^]]>W3@KSNX
M=?SH[JW#=/?6[?C/YTZ#HVL:7.[?.\P'CP[CO]* X"%.VBO)V0#B\1-**!Y3
M^44N<41&?O^C7U/=___=RX=V?HW:Q<'9J3XY/Y]"O%]]R3_.[3$?]=O/'CN2
M]O%I_[?W^/3%&[QKVGUQQ')T[ IP1[T_AWH'/Z4>5%4E*7LM2=L#,-X3;GF/
M0:*A]"@)WX1Z-\@=V0UW?IU\/WW1CZ3]+9PS0HG=$KG)A)Q)(O6,-4>I6D)H
MUYR+.U/W4[[%_5M?YH/O#OV[?79R^-TW[C&_?W;W\]OQX/G'[KWVGQT\__[Y
M_J,[Z?[13_GVS0_N5>/]1_WH\+O[#^_?^]*Y>QL.[WV3]V]=<S??O;=_M?_H
M_LEKIN[1Q\[?+\N_I+'SJ_%>S^QJ-679<\CB7AZM06NMN,'8>%/W-FBWK:;N
MG5'OX&?44T((@?<44]_S6[ G8'TO%47-,@PD;:ZI(ZL94 2D^%]TS1Z+1I>)
M=?1$V7Y%KD\9(&>>7-XYO;@\OX[+/N7CX\^,+Y^<VXO@[!,;9^>V/SWBG)R;
M8H^^?$FQQ^X1O_7CW5NE.S_<_<ZUO=^_.WFO[R;-W1_>?_3-U?[SCZ_VG6+W
M__DPZ,FWI_P=/;E[XA[Q._]NCS2[3B\>%TSW_3M.%/K[HX/TV<G!/?>8M^X\
M<[KX=_D^[KLVWY^^XW/]%Q?D-.+8*['('KA"<\<8>2^$7G6D7D:4]S_Z1]I_
M-QKI[N/KJ__TP1?&%_;5E)"_.[ZY^"W>ZXNCB\O9@=4;VW%U][L[SP_N'1QY
MN.42Q6W'YX<N=[YWH*=K^EN_BK_ZWFW%\\.K&]OQ^-@#O)/[M_Y^Y*!Y</=Q
M\,_+?NS#@^3'I4.W!]]?'=QRZ73U$]MQXN_WW?WO]Z=@[]%^F-[W_KW^\."[
MV_G^K8-']UU&W;UW)QS<>OCHG\_O_%RA8[<64AA[5 #WH$T!.$?S6U!Y:&W&
M\'O<UKOQ.CORS$H>R:5X<%_W1M&Q!]WC?-3$>XTRHPMLMA[_;/*\+<OS2K:\
M='T[]KQ5]NS_G#VY60JMZU[!XA&:Z^<]T5;V2J?BHMF$0_A]LF4.X[/CS[OF
M3ZE^>0?%O6'#9:^ZZQ(K82_GF#L;$D/_\_GSUNW/CV9P1Z&W2J$O?TZA@%E:
M)=L+'6@/2"8=E&1O4 RAA!QC:;^10O-*H!V+9F!19=0>"^YIU[ 'A:-'5$ZJ
MC"6FD#LIRSMA473[ [VTWC$  %.-I4/VN+JZ+T7YE5#ZADY?/^1S^\29U#\]
M.YF22M>9F8_/S_GTP36+/KGZ\9!_\-7TT,<_\'F__L^W=C%1\47D'>?FT_/#
M&SX]NWOKRWAPZS#>OZ73,>'^O>/O#Q_=]H#Y^&0_?345SOQS[N3[G_XDV'[D
M[WGKFW#PZ-OO#YY/W^>KX[O?32GM;T_N?G?X_/[G=]+=6U\].GS4OW=N/+][
M[\$/T^<<.#?NWOOF7R$'"!5Y+_?J!B99WN.@ND?-#4Z*;0"XQOE'_DT%3NL9
M-(QNL?O+1^#:XJA6C3ND'LH.YG<'\P-_?/]?(B5I@K:7H4?W(R.X%&FV)Z$I
MLN-\O23EEV#^X/751^<VS*]ZM8M?6#0U+?+Z\.)Z;9X3X;WK15\?7EX]=EPO
MCDX>'T_KV:X?>W@^\>2U]5%_>7;A8NBO'[S^'B\^_\</??D=+LZ>G%_?NUYW
M]^%+\KV ^?=4UV_>R*X70=W<.^K3_7%DY^]=?R'[Q15KG][YOZ\OYOGIBS^Z
M>>CU=W]\3<Z;>Q>7?'YYRQWA]7J1/?]R(=Z\[L?G7GW-_N.A,>WE^.-'O'CF
MYO[-AWSPVHGZQ?,V4"CWK.:* UIRU1@Z19N6B%9JJ;S0B:'FL &GZ\5ZRLN7
M)ZONY?#JC5X^\V9GX,GIT8N?_^2:?2\>/'&A\N3</GJY3/+#;[Z^=?/RFZ=N
M[D^O_^6SF5@[%E=*9)!*(F<BHY_?D"UCC]=G,X=I%>9&G<U\O:JS_<&S>3&9
MYHN?G="7=+Y^\C>?T=\0QVS4&?W)%?K;SNAK9^ W:/"-.@/QCYR!?[]"W9]?
M._U7/Z\?/?6O]>^''KPHUIV=_\Z+^6>OGQZ\9:=G)QZ:_,+;OBFE7WN+#U[_
M]O\3\TOS$+ V,TT&(592<LM1+0^WS/[(#![MY<^V!Y/N>G&W^X<]>WQ\I$>7
M^W8B_A']Z&0*WJ:M$!?GEQ_^X_RL/]'+N^=?V_G3([6/GQVYB;@1?"^???'2
MOW[PB^_XZE2]^N!%>%;I/?0T J4R7&$W1/*PJ^OPZ M(XS5^\0:_=W(!+Q6_
M^.;XQ;>&7W&06O(XQB41=/?HXOJR:\EC5"#LU_B%&_S"#K__C%]X<_S"6\./
M<P@THFHA M8PA06I62MEV*CC%[,.B\'O>HG!5V=7?'QY->U..6>]O%EFLT9C
MFD9O.7;5IA4@=3()L0QM@_QD5UFT,9T1S%DLJT>;B:!5<#L*:(.(8\<JD5,O
M0<:B+>N,8,YB9JLU$\,050SJ&%*,M)?>V050QCEDSB(N@AH:#*1A01E$E;-T
M*JQ14LM2\@P7P2+X-D8)Q%H340?L56J,'B31P&#&5*=P.-(FVHQ72>Z;RM?M
M_WXR%>;/3AZ?G?K=B]>EF3]^<G;Z]>69?O_V[<:/<7JDMY:I8-$,.IS6V;D-
MC7BH]>8!CR6EH:N!YN/>K^N4?/P//NIW3C_EQT>7?+P0F(JH7SJA9G--/!(P
MMP!--8_$W5XDE-8!D^J3DR?'4].%:_<['7=N#Z=W>VIW3O7LQ!8"F7&)):M"
M9 7V8#100S M'+*T(JN!["N[Y*-3Z[?Y_/3H],'%0O!)AAQ+Y:01P5TY"6 &
MZR$GR-C6XY2F!0"3J#T[/G9X[O@I.+>+/R%]\*>@%"(D$VE0L/O%4SWT2(-S
M*M!=Q59^=RC-=09$P35ZP2:E0L^=$S>;"J4C>B =TVIX^AOMR!O%>Y^^<";N
M.VZ/87KY8IW!W?%Q/WM\O4SA^AN\T9']T9.+R^E7+.3*J:&864:-$$'\(K(2
M3$?GRAR0-U@R;#EP04/C%DOPF!(B!LZ]9@^@B*0II;: 5,N&>JCY(V%R?V;,
M.&V8@C2*>.2E*<6IQP&,7->'[9^O#N='E5M/ 'T@N-3OQCB5@'N.'4,9]64^
M;56HOK-H>GYP*8M++8.60X/ XCI44C7)F'*QN(2:XA)B\/F!=I^+R7I+-65H
MU<^_H]U3GVI6@YJL#^@_-5TY/Z!8H0K&7FK2J70EB0J%,"!+)(MTO0IKA^,;
M:]R?0O,'-"Y1+ FDA3+!412M%84QM#!ET+8::&9(.[]%F+A.ZV:$14&!:N8,
M8MQ+Z-BP=%P/3/.FG=\B9('<BTW+Z&LF"#)$I92<I <,S6.-U4#V+M/.;Q$?
M]+"@=E2/_B(TR3SRX%;1_9'K#875X//NT\YO$247#*2!@H?H'3Q41XPBO8R0
M$RN/\.Y0FLWT8VEA2CFGH1 U2VK%1JB@'=Q-VP)6;VV<09E_!8LFIW$H5"T@
MQ)8$2I51#6/M[NIA?:C.DEN<9XF>>Y 4:E,4GEH6"ON]-&HI@;)271^V\R<J
M9@$ZN8(H$@OT%#QX$@>Z,X0$.8X4RPJ!?G>)BED [>Y@NQCF%"L$#6(C6T-V
MA#-$6Z%5GB=_/ NX,))4EY)=!(%#9P+KT]^L29O1N]L+N.2+]&UM4GS]NLNI
ME)9!P*\[3H ]LF%+ POD9F4UT,R1A7I[,.6LU6*<VE-,ZX"B\/!0!-S5D35(
M>3TPS9R%>HN0!;*8&LK48(12DN;AH]:D8^I9P.N![)UFH=X>/F"DF:A2'P)-
M2;BW4*-YK!#$'=5J\)DA"_7V4 I3V5$;6/&+1L= Q6ZC:#$*!?47^QDO&ZYW
MG(.995]DY"F[R.; -A@M>B0GS6.XC.2"D'!]J,Z2@YD%V]#$,G47D6U:":04
MJ182I*ZQY+:$!A!+T"SS ]VM1VP#FVD";D7*""-AK;&U6L,*+^)WEX.9I_6'
MP^@*%4(=4^L!80F#,]2A $JUKP_0>7(P\[0B2"*5%5L9"*FR!R=8C!MUF@*4
M\.XZ4BWY(OU36F5%I=%;9R$J %29191;U5*JC9MF=BN 9HX<S-N#27.9NB U
MBVX/K:HTDQ(Y1M$:A&D],,V<@WE[D(V"O?=F* &@1J'$5E+M;51RC2*K@>R=
MYF#>'C[-(_KH$M)"SN"N2&RJP;OA@XA=8E\-/C/D8/X02J\:&>K9$__:5S_K
MCGG=+^;EDS?O\6O=,7_LMOGBU_SR&[Y\\DW>\"?Y!$;@:J93M7!J7F=L'H6&
MF#PXJ;R ZN&TC^\KY\1+.OVXN>\K>WHT'7)W_,,1.W^QM^\KTV.^N/#/4OZS
M=_C-7S_4E"9[/>U)2)![P22!.VO*-8S2TP*V)2P$WEDV*6@;G02KM51!BQ*T
M-NWW;I ]1FF_V(%]P^#]M\:$_L,OK_YQ[+;VX],^>87'TWM\<G7OZO%/NAA^
M\L1MGKL#/^[FYAU76F=/KRFRRL2OFV2IH=4F8$"$PGY5YUA+IEBF1:4KA7J?
M]:'KL_.K?S_P;>SN_VH:,?"C-=D_.CTZ>7*R1NH@<N7<RK3+=&J-SZ8%!V<1
M  1<4B5H,ZG#S]9*G4"&6L'I@@&FQD.9W<U,@>"T!DGR JCSNZ_U/X>44YSS
MQ(.8-R7D(FDC+2ID3LQQN(GI5*Q:+B&R%0%:@B[YW=?YCC:_7\Y6JA 21AP$
M51FMU6JI<[$469>@<2:>O,IL?&YG#\[Y\4./18Y?P/DR[O_PFZ__F ?ZE5:T
M_W7GVY?/7GQR]+WC]O1JC5Q)'O58K635#8RZ(E;+(Z*&3-HIZ$*X\E:!_*/L
MG)Z^_60R2VMD3 @0LY50>3ACI$I)H0)D%\0AID4LB/H?\+NFS77AX3I/>LHO
M2D9O@S4[@P.L3522@%30U*@CEB'5L4U8D!9"GQV0J3<+1,$Z%% .-$8C4RLM
MY#[Z$C:G;J/*F&<F3%4EY=S,+_H$#355BB4S5\SR<J76YG-E.U7&3#NV6C"P
M6D+J$$:FDEJ443KK$)<@"V',3F7,0Y\P&@P#GF8? B>E[CJ5-/;*Y$2BA=!G
M!V0+FHI,V5(=8.RB,8OD:1L&8(L9%E)YW3:5,4L95\BPC]8PQ &0VC2NN9*,
M(2(EC[(0KFRGRIB%,4%UZM'5(#<"*H IMQ Z0&^M<Z:%,&:G,N:BS^A3@^%I
M#CB8WXJ]DPIW-SZ8QQ*ZE>Z O/8<@H6F9=72(@2+HI8;CI!JJ2/ 6%52:JJ!
M'=LYWWYZ=/WW3_8@;Z!O%IG_RI:C<DP4:P:(AD:N3\<H@TH?*>XXLP#5,4\%
M14JC[-*4^_5V&^G9+<YHI8>NH<%"F+/)JN,W\G61-!HT5#5&2-* @E.(K&6,
MI*Y"8EK*ZI =H*\6&$I.+;:BTV:A9"RN/Y) $\JAQ;J4BLI&>I1WH$)FR8]1
M9LPR3#D(U)*Y2\8>8ZQ^PQW*CC,+4"$S[6D9-0<W.84JU%:YQ^R1CUL<8KV9
MJ;+YS-FID'EI- !"F48LN=2 PM-P'DLC("=&CX:64JC; ?IC(]36(8<BT\Q<
MEYA"8$&[1G1Q*<RK2FJM3X7,DC^+5JHI5.HTH)2$Q<94>@'_#UK1'6<6H$+F
M84X);=IIV<L@"#VA> B$4Y,+E%A'7@AS=BID7AJEI'D@5HG6H,!@IQ02EI9*
MF)8G+X1&.T!?C3ZQP(J)K1F 9206DB !7$(6H:7L87DS0&_9A9[]Z:7\M19B
MTC0-)TW[<BD 2G?.<+&8BU.&N<N.*INK.68A#.71K=;FEJ1!KR(>LPZ<]L?U
M 4WJ0@BSR9KCS6BZ2/8$B]/<"$O),@AU%,PU1%70%DOGA;!GZW&D"AT0J%IA
MR$FXHDKLPF5D1S.M*G&U&H4QSVKR,"T+ D*,$614'.*$R<)L4VOI)0Q[VC2J
MK+NV4HEKU*@R(D.<]E(S]IZE8XNBJ@LAS$YAS#-$<"0=I287I15"=G-CSI"*
M(3J7NJRKI+)B'&L;L68*W6  Z: 2M-=LG)&1DJTJ*;4:A3%+NFNTU')6'*49
M(&;BJ*;D*.9.D-=5=%N9PI@G/]K+E+B(W74%I%!9^DB<3&LK@+3;N;(4SS0+
M>W( P1(%JEL7[6F2I4E<J&J-J:2Q$/9L/8Y<KG?&3D4OA!PCFDY%,)31;!1,
M"\E%;<SNV,_M].G9U3H7%VL9J)V!!2!/:XI+888^E=F8VE):4+Y-'!>C,&8A
M3(.@S25IJQW!N)- <\/";FV*0MA527;FYM=2IBF4QA59G3W8 I*H9HN9"&S@
MNG94KAC'$=@P0@MF"4"B]!BE7-=.I;:PE$8J6Z8P9DEW2<HY1<%0I\Y-I(*I
M3==[]=M==2R$*ENI,&8AC"4<.16;=I] (R6V"C!Z-JE=:UL(878*8YZB;,XD
M0]W937-:F##'T-LUF:1FC@MAS];C.(:_6TDU<"DP+/(D%BD4ZA@%2EQ(+FK+
M%,8LZ2YW%Y$2Y&*H %-Y-(0^A#06CA'#0JBRE0IC%L+4-E(9M0&4 5/J*ZGV
M'HK6H!!Q*7/;=@ICICT(1J%:PU([("I3B&-2% VSU-(7PIZMQQ&Q62E$!DJ0
MJ6"K!2+E)IGZP*7TVWDS'.]V&Q>V@G48\Z0M2RBY0<<1$%3%944KE@F@2Z]U
M1Y4-5ABS$*9S5%8>/8!+TA$H,W<J4CQT<<V!.\*\(TFS2/9(CF;1W="0,LU>
MPMBQY6G_//>NM*ZB[)NQ9Y$X#F$%\W?L:% A(WJXD5%DM-)</:XJ%[4:A3%3
M0WOP*WR:ED,!>H@,E;.'IZ$,XYOM8SNJ;*3"F*>L-AI2B@5&;)!AR$A5L.>)
M,J7E=>6YUZPPYJFQ&8B%-C0 @ 0ECME5!]'P1YU 6\B>1>+(69E+#6%DA32-
ML0DF&<CA[27"NE;LKD9AS)+NZLHDHF5HK9!RP9)S(/$@=9K75W!'E<U5&/-,
M/\@UI0*YA<K R;A''JQ9&+D"K&OST9H5QCP=W+ +U<(V2@+'E+"@:$TZ*+K>
MV$;/M$@<I6>I7/+H' %:ES3ZM)U$_4,TX[KZFGQ]>7XD_MCR)<8\LT\\\&P4
MBK3A<2E5*5%3FGJTU9A=J>ZXLL$:8Q[&M [2"&JL'4H12DPELF5#Z[*8)FV;
MO!+C#7FZ2/J$7(4RJ/^3H*?&N16,"+$,_Z>N:];)FH&,H5,:$3/5!"5%;#C
M<%ACB%#6->-D/2ICGA7>8M6O=?<0"2%A(?<=<=3LT2FV_K(ZNN/*9JJ,61B3
M6L)0U$/0:9;CZ%(XA>$&!ZC7L9AI.#N5,=,P)31RKQ1(FD&I*FPAB5)C#W=,
MUE6;73.0L5D)U6$;ED 3(''*S25&&>:QQ[HF@:]'9<R2][)($4OOHWMP0=/P
M*Z9K=Q$9R;3NN++!*F,>QDR=/#N::JK TT9G9E%QZ1%J+K";6;(8YS3/IJ2<
M/9JAG 0#U$0TT09T*-=*T-95,%DSD-BL5:UJK@FA((E@)"ZE,] (O)0)X!NS
M<_7>^9.GW%?91B6'-!2- [0& QHG'7F(%.K^@*YK7\F;X;@8C3$+82IV:T:H
M,@PP-90I#]8DFE*-LH+.?K-KC!6;FT V2B:&[%K#9*#5&'74:0VAQ+ZN?24K
MQK$:0D^Y-O6XPJ6%#$H&Z7HE:,:PE'TE6Z8PYBF6%#0#=Q<AP7398V(0*A53
M<=J4=<TH69G"F"='JHU5DC:5 %PZ:O'XI3M#:J/0EU)=VRF,>::$"P-6<&GJ
M"F,,H#A81W-U,1IJ75<=?\4XEBP%FO8QM("X%1B=6AR("@*A+&7M]Y8IC'F&
M!M06L8],%M@ITY@(8:02HDXR=5WC;%:F,&:JDX0NL<0JM8&TPBU/@YQ!:6H_
M'Y="F)W"F(<]Q*,BE6F%.>2>)+%9;L4&I(I]737\%>-8 J>D,0H/ Q*@Q*./
M.H+;A%&B+B07-:_"N.')5_;43I_8UP_YW+Z^.KE\\GR5>:]2"4D'EVDM!N1"
M:?J#8,"U)EY!_O+W [H8S3%/1Z76<X\-"^9I[H13R*/443,X@THON[K)S@"]
M"8T LTV56<%*H,%HM)(;EVJY8TM;;8 6"6C.$4+*:%JF7HXN/2+BT-(QE)9D
M-\=DLSDS2VX,1AB=P]0]HT,$1E3LK0A!MZ1K**EL@0J9A3D*Z&QHQC9)5B3.
ML21DK2!$6)?"G)T*F;M$5Z?Q.%G &$@#L^78>AE4U#HLQ6GM 'U5-:L14F3)
MQ6_4X:ZDN[KD7%L/@:DM)*>UK2IDGOXZF@<-QR]&!@R1 E$M2>H4GHR\E"SZ
M=JN0F0IV,4>E:01? ,+!UBQ4S(1% Z:E[&S:J9!Y::29 %-WM]4(6A]BUI)1
MLZH8]&7HO/DTV@'Z2H4@Q#8RC9X]JO4;+6O5,7I,"(&7THOG#0"]-@W_=>?;
M/]F-K+7-%V95[(8@.4$ADIK< J#3QT8)>2D;G#:'*"NOO9@A"2D9>+A*C;.%
MHC'7H%1Q,56[C=4;;TC217(GM1A$HH%YE-,Y2<_:XABYU]S;RXS9YG-GVU'L
M)4@O)?BE#]892Z3L\4;0+#7$%72;7Y^RF&?HK]64&L(8'*$,I#Z:ICB:)<@M
M+:51T^809=WU%*)B 2UJ*!6X#ZY68LPPE(=VU(709=N5Q3R3,T9MZ$8&7%!
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M4F*S$2M-^0K3F!;"EBU7%?.,UE")K?1: T:(;2 5JYP#0NO!UE YW0(0Q0Q
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M+W-*+@U-W?67KAHD;VW;YD6"64JE(FICC 8#7/Z/5DNHPBJ &I<?,JYU1S:
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M5%>B=%XOSUD(EJ%*B:Y$^K0>B8LJU0 YM[Z$R4L[;F\^MV?1)8,,1Z,QG-+
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MH[98M/R&#6.AL4O")LO/=7NU)[P\A0&G>_/%ZA />6=6UH?^B/D7+H-SJ50
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M$L-N9<LXM'YB:$F$L@&G8\LDJ=EICMR$P "T\S^X'$YFAW=Y.3F<?4*9G;_
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M7 NA4T5C)!-JJT/4WWT?MXU!AQV8DF$5O&/E+>A8Q8KYJ!E*2\A W^,>9E_
MX+WMX<^&4F*/%6&4*26$J$'<E00F!<K>5=&FL?1XLWYOP.BPUGZIUAH1E%G
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M@9+8OAB9HW;9,T$P4.HFCJ++;AOKRS!R20:,LZT1 8(XQ:D&#S[6)):NDAI
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M$%!'HJK9411G(WIP(]I_UJ04GOSPD ]QNKN^31<O9A/)A& BZYRK2R)H"E
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MAG V&47CML\?] W%RYB$4XC^K'+8,")=G'_BMG&7FW\^./1*&9S:5_;1!^_
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M\K5@LTC1H<4(*N4HKFJA  X2%=<Z:^N20FXE 09L,;XU4G1H*5I2K!$#0<%
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M7V.V9\K!GBL'VS\89$JQEU<.MJ-U(J5M=H'$-'G05,0#0VC9:.*,::KK666
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M3<X*2@J44TC1Z!2XK63&P8Z6F]TVW=TX:1E8K'6M@#)I91LC&8I:!]21K!M
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MPT_&<(I0PB^N1J$_\D0J*7MUDB83 ,,4'X6_PQ3>PTWB+REO%EZY5LX/=O*
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MZBW[1%J!]/%:61E)@-=K002@SR=T<OIBH"_093PIW0_)!X17'"=XJ7RBPBS
MGX,Z$;+F!+_ #ZZY'3(/&>Z@]J1AGQ#",YC&=X7&LB3I@_JV?AT^$P.FA\5
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M:ONRI&1_.OK>\L#\A%V.)!AYP..5=B.@#DB[8:DCZ?3VP+U-CQK7IJCZT$&
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MY EU#R$$<I(KLT8XZ-""7$^5=@!7.L48;D7DL*>4N#5E>,)QL8!+WX_&^J)
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M*13ZBO1O; !;X1 6Q?D?9G:.?H9"(GIZ!H6XFWR/1V4 GP$KPC1\+ -W21G
MW #NN ^P ]02FM3FI,/%Y 0E5YH3G@7R$L,$NY?5T]4DC\9)C$1+3>G1"S>:
MX@17;35;_];>)^O=>OW[IQ/O8YKD$^_H#1F_.$R0FUU[\H=,?0Q$^F*"KORI
MZ1D.VJ95':^25''K?5.64)<>EHD VZN&44V!/'?GUI5L;G47E8E5:KCPY,4K
MX2AZ,F;-KD4_C&#3/Y>X\HS:<']([%0B,1SB3+Y,%H,2Q1@G%? X'B=_+BL:
MJRA@YC2W3/013D)Y5VA5"\6HE&0\S9#&!BJ!C<TY*L_#JB@33W=O,$9,,5!1
M2>E] 7'@==>\4]Z1G5Z%GU,K^7U@[4E$TP@#9Y[K6?U@K/*\V)V%AA.MR$T?
MQ=X!4/VX#\#FSNM7<HZ*C_3PE%K-&<XCB_V'RNC9J+I*;N?RW+C6M'M D?"@
MHNQI-4FX;H$"09<_Z[X-\(D*@U(5LZ<SN%&Z\9!2E'68 <-3&F=#P"KO^SD(
M1ZECP&N>0:_ZI..Z9C*J5?*ST'2V["KT91MS'J.I*S,G]LTUS2=&$H[H/H_]
M0 %FD@)?.L&2M@&R.PL#;"]JID-DU06?J>5-*RX^0$5S=N]L1)79<(MD@UN.
MOR+L%X<38<<?/=I"&AFK.']*8QW<ZV7(LR.+'"\CC15!B!YWL;80F&DR%1&-
M5.3QO5F?)K?P7&"6G0F-2LE 1DL>48IV&? $=\+*1$S-B%XM'7B+.(_5'3JL
MS+2F, W:$X&+X'_A? I;Y.)@6X'-U5H\(0HQ& 3VS#*\BFYEYDJE^H/7=LXN
M9K)B>4$2F[F]9]-QEO\MO->!2'-J</"V6.$M+/ 6?DP<9TYO%SOR.!F/4074
MS0:*5ITTZ,E59VHV;781\E#;KZX^Q) 252_J/&";3I_N;3'('7VIL[X&>E'I
MQP5=[3FSH1]?FVJ*<QV>L+&RQ;G/<?38OD/"1?3BP!G'NCJBAG)AN,4EM;4$
MO&&&QO/[-!RT1>;.H&?=@WIET@1;4QRE_6/U8^QX E<QJ2EUFAKK$8":H=DW
M9U*,B2N]9;6.LNMBWS'N':EBR[=PGBQ'L-))0E*T$#@G=2^ /8V1(Y9&V9LM
M<?X?<'X9<5 ,Q\W3RR>CJ0(A(1 BQEF 8W;)/Z$<YLLC"6EB&NJ&F,JF2"*P
MF,>TIB%.'Z<-S#T2LF#Y [L?D-3#J^3)A#.;)Q\EG"U-0XJE<;] F].-<\W#
M)"!&#!BUYATG*K/]R<"\UTS<3%E4LKP1?09:UI$^ES1]#'BY\OHRNY(\^-K]
M*8%$3Z5$*=<W65;X^1CG8>N_]2AHW'LE^"C=,^*?Q:GL>5=E^!D@B"(W";J^
M;&TB4%=Q6Q9;W7ZU%DG0A-!83'/Y1@D0LL!$$J#-6$9KWD&>\BQX2759Z/P#
M2!H/ ,<:>]@\A%P!=!<_0IRO#$OO[/ZCL@W-*4J]<^.@\K.MGOT9.W[L=,M"
MV:7A;'KP/0[^Y'(.N_]4_>+M826)@E5\^5ZF6$RRK\F=LG'V11I0J<(GHCT]
M^Q1W<^S_)A4V-7>>)V*L@W45QJ;O+W$7,YX35&B:O5?,EL-QU&5D+>S"EDDA
MO([GM>:S 2*Z&<:V",H_1DCA#N)V(K-PM>2J,]%54)4,C4G7!T4V&>/LRABY
M;$4H\E/2]3$4J('9KY<BC"BCVOZ$4Y6Y2@>=!H#9Q2Q*)082A\)B.ENJO=(M
MROV8\"1)G-*9T AVP$OT@J,WG]/2:#-1B(\5WU%Z/+P,/PMCE:>T2B'J4AF.
M^V#'D0CQ:/HG:*:M\CQ[9O=:>^")O&CT#@0LI>!6*7-$;T C!_N*@20(Y9'J
M>)XPBQ@>+6JC$:5AD-(?Q5AO&1JOLLU8*2Z$P9VC+1JJ\D!)2@=3P!O]D4G@
MY:;A2E8V9,P[9E:5<<BXE7Z8V-U,]8!D_"%U%$ QILW&RD\Q)T:1T0_[TKP#
M,7TB"=TC+D=+AI*^<3!'Y?ZH> V8D'F*GZ-VAC@@ LI;AUL$*.1:LQOBC<4\
MD128JF_VIZW(O!]1^1XAW"7B>)(.8?F_M0$)^A&"C66XAAK"&XQ.ZBJ,ZP(4
M,^WKPAQN^%8J]->%:E11)X1KA+*V4=R9>T/%Q90Z  A59N @@?)4XR]?,D@"
M^$1[5\R1"*^E5B(=@$S$5%+I<D:EBPI3.(G$*:ID;')$R%AFEO43L130IUW%
MP&KZ<+: \PU-3X*2;HQ9I@E/=H5_)K#YOPA<2#:*!Z)J@O;H6]:>[-D*&M,^
M!HWV@@;$RF"QB,5S%!FG!K'(,"M(?T7DQTGN<!R.>A;<S0123VD^RX$-IHY#
MCEN&Y)\Q<Y?=GQ?#FXV%5RI8H1G)B+[4\7)VXG))3I6V9'1^G@?MYV5IQ'.:
M89%B.GII6G,8#R(QUCE_YAE^&2I"N",+#(7C;C)@T K/*>,A<"@[J<&<>3H#
M,U@"Z6T,(M#/S=#D6;& [4)0M[L*,<D:312 9#%*F.?,U\Z/UC.'-3!Y,5S$
M0OS&8=G:/0A\A=YJ4B_-D'JRL1VY"! AQ9<N6YOMD:=Q K0/=*CE,7F(N6;E
MAWZDKV>JE^"CW<G$1H(4CV9.J46U+KG22KM98V5"GN=S-0@L)0K(S:DTLEZ"
MJ J'M11$DB:<4* ,\5/E?0PP(51-)A&G'.!*>:S;XF8DF5F=F/.U52S :HLB
M0'M^GTV#H$Q9DJH)@ Q=Q #G&0$AXS3!1'93<C"S MD<(%83X"3Z9ZCOQ0-Q
M"4P854[RP8#6\)\<I22_EL4@(:+*"?&\ 0NZ*DQ=.[& JQO!&(!NBS/O4)Q)
MX#^"WV'GEIA*=*"221)BDA>KMP!MA59CJ=2<K*KJ <UT<.1H])HD %SD[KR8
M6E+S(U:NT&5"E.Q4_ND,96]/D0J <*"XA!:T>4Q (\" OJW4((^T'1!);5K.
MO"NV/>+]<$+N=?304!%["W>"X8L([/;W@GNTE&\!@$FF)M]A))D74=#>4= +
MUPIW12(<"Q+J *"-U+F791H?B'AJM O#'@L\=5D5S2/3RF$2EW)"]+URM-5J
M1QJ 8W&![6=H7*(<8G$IZ,>F\3+Q>LTB%\(R+QQP1J"--<%K^@!7^'$I:&-"
M31$FIE/;!&Q7P(T>B.MC:(K@6.:R%?HGBD[E@#3M.5O"4\;801K?5$41)XK4
MTJUQ9O$J!?4HG[ 7S &YD0/DI"@S"0PC4XP/KBI/4\F"!S]E1D7?!Z75$/]X
M&)T5.AI+[7ML.-+V\T+T$,I8AT:\$ECUICG"B.Q4AY@T8I$1IC4*<PTE"[B
MU!K/U701@#+3$?)D%B$_G;:T)@P[NC571X;D!86+S'T5+(;[6!5?(]A--MVG
MJ/P@]0*A0RHBNO*X^K9T_U;H"3\%QJ.=V+8W&JN6P+( =%=Z>$8^)D8^GUYM
MH#:D<84@''MLB0_M!%6X*?ZF6\>R$8_QVHH@A>D!9ZH6+D,TPGB@#OR /7L
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MV8CC)">>8=\X[X>NS<;IS78>8$V.[D$JADD\ *YT7IS E&;@Y"@]##'&2:
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M495T6-0$T*4!_]NR9BQP&5"7@AP#4JC7Q5E8J%_&Z>Z^=E6TJA-'8:G5K'0
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M-'.9[*2>0^35:[KNCIS[:17^?HHT([XDQ7;9H7>%$$;"!Y@5FVR54[=T4 ?
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MIQ>&XRXE!B>JVG;L*).S7QFVYG(B4YP5LJ=(.2I8@RI/BBJ'D7<FAZ #)[?
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M<2*YE1M>0")3!@ VA!*V8YM38>VTW:$Q(3.*;7$9)-+1T:[1G:^2$"^/*;V
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M0S%4$JU#7%A44@!I-8H#]BVZK]+0K:,!=\#R<:8E2VNX^58-ZC$Y8'\)%+^
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MGG.^M"T<U\1C&C2B4P#KLV?,$4ZF,]T>K*2U?/2# (HZQ\;+VC-I'"IXLZ9
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M;G'W]%"\[2;=T\]Z&/*GHF(.H6*84O9&'=2W/^P(D"_>!@X3S5&"S[G*:@6
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MU55G+G#K]-5V\MQW!FB8;]0V61Z$8E<SQ!;-4T\B&$@8VP7U1#6_GK]X0S3
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M(X(,<DQX..<,M@'M7C"PV<2\]$#1IU*'[_#-!YC+PCR5M2ID(<##V8*^PE?
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MN#N(, 2+<IFA9QL57S504'RFFE-KG!JNL[9M+K'[W8^INB0HC5#W(\C<;(@
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M$0:I46Z-*E/I6B]X>K@@E4&WO6FOU-!\B+QE*X!C@LEK[CDK(B_0/0#U^]I
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MB']M)[_#H DQ[QPY6V3,74@\I[,7_HL99UF@3-LL?-WJRH)I0LNZ4]@BM.?
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M=\GS#$A70$!DS$-%052A6RMAC/Z(:R^9MT!EFJ&T ,+#T/$ZBB+?3@X5MEY
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M(XU2@ :8?1LE.T&T8LJ8]O0EP'";\FE.#Z@5R8W$,LOY0YSB.&OH51PIH><
M-#FC$R>KZ%2EH^ZR:<DNX <QBNJL:&95 4!&/L,XMN)X6K+\@O4WW5_6=7,A
MP+ VE$YL-IR78A'PRY*JG!1;/"Z2GEJMOX*Q'=/$G]G_./XC32Y*1@X^+V;T
MW'DIVFW,*/\M1B.'%< Q_0?O/TA #=.R.L2'D$M7Z)?3)^8*-(E)>]YTC#EY
M6,Z7:7)(TDC?7)?91X+^WSHY/BTY/+>WL_LD5> _[-AR3%;'J)0S%5Q-(QST
M#1E-/Y)D\?SO[OQO@1%5.X+9*<@DR6:E+BO]#6;0:$DOV-]Y2O?RS;B,I9IY
M(2S,UHIU0_->2[!O?-Z4X^(I_DSWT8UY4=$[6HGA*07#!1!:0-G3T=1F0K=C
MYNV,1E_ROVF::I:(U]$7SMJRT4.1!9F.TGW<.2J69&FD#,A=,5(U?>LY66>7
M!<BV^=-L*//S!B"@.E,I2__/F*(I8\G0.B0UV45;S 240,H73%_17,[/=3;<
M=25M:4'=KAKR[#-!R"89?ZJ?7[R?B>.3N]>S?5:SI)PM+=;9\>47/]+T9=.9
MF$I)4=,N:6KS";"#G*GEPIPV+$PX/:$MI@VO>];2/@&12-+-"K'DBO=D3PA&
M[69L@S_]VIH'.6;AH;U/D^8^EV<\2]B3(,>T;$1CD+:HH!WR8D;_A 2QCS0_
M#[45/8XDB96T3+3A7/-!H=K,/YATT7E)FX,4VJPI.U&D)/<SV3M.0H!D#ZA?
M[R@+9#P#[U9%G8VS64:KK^3P6=4!)?ZR(*5-_YOV0H.Q3:=,I995$:$;="G-
M%<Z<:</R0RX&;Q6\(^OF6_PM>*F)X8@DB]3Z4(C[*QMB'VBJ_%HLDU]T\,GO
M,U"%;89L/UM 70NH\6412*([G85$+1 _<B*+\@*'O@D.&19M0W-S09YAL^A4
MU\,D8;67X6P6YAVPYI#PG!4-N'I*IO^C+:91&O469?><+FJ2TW$6O)()!$6"
M[>4&! U?A@603ND+FJDMF M3V:/,S58@[\/CH#V\@+C[G>$AJ8\6+5D&F0/*
M=N\9+7&5^WW /_+N$>-F2P3*/WE^2:?6%G\>,\-UBQ$ICJPN>,)XASL33"@@
MY+WLZ[/E5'5-O#BCMB&;K Z.U>PB*RL<<:77_</+!=LL=/?]VM A\,^B&]-A
MFV&=WA;\WXLN=4$9.0MM5NCZMVU#I\Y%@/_K9IZS;SFYXO[ Q\(N:CJ!Z?C$
M:*N&= CGYD3<<C9WI\6<5$C&\G-.*H<<9GS';-ZT6Y*IN""C['PQY2-L1BJ9
MU%)EVG."^(N[(=G;JHLS,4)LH?YQ\K]_^L?1R=Z6,Z=9+=,:B7U(*K81TT9F
MC['7:W+*6]Y (^079=[%>V&K%'<SD58PK]V2SH@I?8-?)!76X/NZ8L[*^D9*
M\?8K%,;/I\60-"I],F=I::U)A< 3ZJL8852P\\X."+/1:*>,S]6JN2BJ9@:9
MLC4\ </#,[>"LW*&M+<C<<S&_UZ47>EUSI@AH4?J87=K-I:=\:$IJ6Q>'G.>
M3#;Z0$\0(?'0#"P1#FQ^0Y8TCK6?TR\5_RILEO/L'2DA),7)5:.EXY SD/9Y
MY]1SYEQC]@A28R=DS1@))NEB6O#L3*:<K-^2Q@IO,7Z(UVF-B,AE,:(5+7C+
M<<SL#,[T-ADI0E3 *UD(L:= ]&N10>YNS!L-M;(-1W[A@A_F2P4\$<]5%#R(
MA5X90/ZDM?\F"WU5!.H/\A'X-/FHTIK[CU";?6T:\IL*.;3(PZ^4\QNN\(G*
MD6#^'O=8*: _?0D++)[G32..W[-V<98<Y%.RR>'&AG;)\V<'GFLJ.+G-P$HE
M9T.^:IT%.1LD+C+2C:3_6"NV676O^S$=/N?)A-G:Y<R!\6O59HGYZ[9"2PR&
M@1H$4_K/<BOG3R %4#)1\[S_Q!MMJ3OI^YS2YW"%!J0/MO!AQ'W#SK^F6[U)
M">'$N8P?82_#_B3#[W(K;SKF\8(E.'<'ZR_ENWG6KK,HV5@FZ;H0I52*]=@M
M9C@[Z-WC\[+*257#BN/3QMEG>YJ*8DU_5BC79\FF@EVQ>S]Y=S-;[$[2OI:D
MD?:*M-8?Q;0J\S7",2;CKV:WP85]?V%)(1_+V?Z__.&#Z*&ZFI$#EG$YG_=6
M=DUBD%&&+0A]Q5%VDF78!A)OTRCTG>A\==$Q6.A!'<6 W$4[?I<(?_%AL]U+
MQ^#7B(A1TS<6\^/T]A2QM;)-WH#P9H^^>T$"*)4 7%BAS(HDH_.&)L.XBOFB
MR_+_9^]=F]LVDH7AOX+R\>[CU"$8W @"]EE7R9+L*+%D1Y:3U_Z2&@!#$38(
M<'&11/_ZMWMF ()7D30E@M1DMQ*;) 8S?;]-=X1)?Q(5F&RHYMJ)>D^D:-@J
M')M^!RF6I#R%4RGB,6VG]!I R;+NU9Y9?CS,(J!:'LG+N5A%,N4+!BP(79VJ
M>J@6_Y.3IR:J"JV#G3PEQ<XVQ<Y1<5V@2;% ZH!IA-G7ZQ0L6?B,!Q/KP^(X
M?Z,.J\*<+VI<^<LRVT<HK37-=DR%K6!SUY0B;@&,J($2YN@6CZN3T$$&WN89
MM#SASG1:^#E+MG%+#.-MN N>AA7B2^K'1R?4WXMH-";3*J")N2H>2%62(3B-
MB0CC5/'M\RH/?W0-Y#FJ=$<5[3X?>Y7'(JW/"PC$HX#VCVD2 %GPD/-O+%[[
M.1O'88]_._]8K8$_^0NT5I&.1 R\Y)Y> 3IT&0O-FH$)F(&$&W["-&.9[/&;
M/_QU=J+J;LT4++F#A72#)**9/PY9#V-:#,"RQ&3$?XN0I4V0TB-6F(-J_&X$
M8!(/<RX#]R-(&*_P9^CB)[B7$L984($^3(J%A!ABY(%/]C;X(_RLW+CDI$?G
M)!SMLL _B<)>+ISB*BV*P6,T(UE.@P<DSZ9L/]PM#]SPRT'<YDO&]F(8?ZOR
M)+64+>,F$-5CFF<E$BG%" NK4T5;=-@?1>0NS*;R7&22G47T550$9WF2EKXQ
MJR7*0R_$'#:.ZR:L!J&V#[Z]2O6@*1R!.13CUF\P9\S&SS*Y @<">PA$#CLG
M\'9$5DP%2R+>JMTR3,-(D/'8LV8*84(ZX1QC9AR0&FG61?1<N3O'A^9>DCX5
M>YG[]%JR;6^BYQ]$+K:9AUI8"S&?K(^Q/.2*)S\E\^X^'<!\919P%7<\KE/*
M:X7Q[SXW.ZX&18PB_&I<EY%-AD'$+\:3Q\E8CV5XI: <%5X5YXE"T[(<B84Y
MRMQI41I-8&V6JTQ4#)45:?4J*-B\V Q)L2 S*,M?CX\NE2L%7QJ+>K:(Y"Q4
M7!6YHB09)ICZ0Z53%5!$H:AD894I%"" 0@:78S5K-.Z+8B9PA'(P[])JEO%$
M*13F[M&%BPLL+> E,W "'\/-8D)Z;6:ZPN]HL )1ZJ4%29G58$I=USAVJ15\
M3M0&<.H]2GT@@+NI@*'XM/(;F/>K"CM=F$WJN&H.ZS>!XJ[4('AS?'Z$C(7W
M:53.5&/N %)B=1#U2H>Y.I*Y[4,L7!W!#P=D&?W]#B0KR:]!Y#>9/N,5TKRF
MF54%+?%PJZ(LAE8\(;.J3T@(TC=4/I'X^RCA\>WW>=!&LA2![#_:?[3Q*4D$
M#2&"<0BF3&HQ5"(%G//L/=-3O[$+%8!.$$L%KX'_FT8]#!6,::!.&:6X@#6X
M&JR+#8S9#S->79?27LIJY$;C8JI?+RN)%@$I4.6-BG).B4:#81] 4_WR_9OC
M]U65HR2GG6>[*FJ:*ER]1XP4&9T."&<4+P&K+%>/_5GP)XCM^M50K%P]/5XI
MK%U6CBXK"P6R*PD-;<4BS9@-AD59G/"\B&18)1G1XCL=A&,R/'K_OF:LQDS=
M'9.8!&02*M6]9K(\@CC!1;@MC)F$>%<VG>6!M]6[%9;^886?Y<6IB,5,L2?-
M9/GG2')+XV/?/*+-PF(8FEZ9CJM@AV'/EIB _(87,1:;2^] RI(T=D :,16D
M@65,911L1IO>6\R..'W[OA0$[,*D% 7-P_?"N&?]AA//5K&JM9S5&V,4E 4,
M.-.65?^3L0#X$P^1H\L/WB7LVO_>4L[!]8I  $AD[QS9I;U26=S@'HVON61S
M3&9^169L'*$AQ.--858WH/.$6]3,NN:_!2K0#1  <=YGS,]N_W"SRN_301(.
M!D6<K",)&A\5_H"GD63^V&0^$5^<5X6"M(_QT4K8/>Q=K>I:U7Y<IY+$N%6#
MJA9LG%L1=<YI$<2OZ-U$E*O1D"IG9RP\SWTQ$0H[KURUHPE7[6@J&;D6/4^0
MLJ1<2;F+X[0\<1:(6V0#$K)6(RF_^(:QU4^J[NAZBZ7<,'UT?'SIL#]Y23 J
MH_C\YMCOC LFDF]3.07^BXE"J!E:YKVR699*EDTT(.XVEF[WI)'.\7+\.QK/
MHKWV33V=5.:2O# ;4C_LX25Z3EBB>PIOA%->MN>22N0AQ^E?T5T-R]F48MA+
MX=@@"4?L.][*&(CJN:TI ,%(E!W5-B0Z*2KTCG4$89$2=J;2E(:?XQJQ<O[N
M1#.LUKS2]N,37?1-.3XQ:^>1]-N@<N6)H@%&L:=8:)CEM0K0JN23?U.GUBJ)
MA==WZ]E+44%6Y4%%.\&Q".7IJ0DM#EKQ'>OLE"K'X$>1EO(I ?VO_)' IZU:
M7\>C+*PBW4O$X9.\P="1-QBD2%@S2+*L-*+JQ#"IW*:$QDE*KI.X%XV6&3K5
MC^;INYCD!5X5^ X*"5B<!=QH? V$F@I;NQXY*5MS5>V%>!*H%Y&!Z%Q::VLB
M%<X.BJ619.;HF[)?;)7TYI?J3.7J\L/'\/B3JI7WZT05-%K>=0TQ&9\8>VZ#
M-\?,7ZM<-=;$;>RPE:Y:2_%'6'BC!G1(&0J!Y&)2OY9P\D=%H-:O-KRT'WHA
M-O7E77# NP.Z[;$>766(GX7VFAW4V[!^]:S&5)*/&A16(=,2F=VT]_&2/>:X
MIXRZOS[\N4PTX_=UJ5QV_RH_9TE1O%2 A92XH0L2)]B;N5Z9.==S3?NT .I)
M0KSGDO?3JAEG5 P+*9H?GZ0^T6$^%?# :MZ(EE=8:IV3V'WC,$W>A DO+*N<
M5_[A1-#BN:5;E3^)=Q-)UF]7C[..M9_;?[2%-A>5Q()TRL:UO<0O,GYC!EV-
MA&78F.+'AI,1HTE^V00LB3!#7P+KE?+:SRIQ/:J:@*W<=+ 969;%?0C'+<]%
MD_.9<[W^/Q[@K#P9-G2-28IA1E^6?W@5@#L>D='+,&9O8@^]$L 0[L^<\:$,
M//SKL2O0UK@[(";!BC>+K]OLJZDA<OP[6V^[NK[P:ZV]Z7>F8VWTY++-ZEJ[
MXW8>8+,=<_%+&[?9!X*LK:VVH7L&#F\Z5WBK_#T]'6V&F1FSO,"^TUQ4@BJF
M=RBG)D8XB)$.HJ^<&/0PGMB[>$+@&L,$E\"+QS":!#%45D_[^/H3/OXQFTHQ
M 8"UIX^+R>?KS2%M]+QA-GJ\;!^>K4 >]XZ#7WE&\_K /+01SAM H-G#?XUN
MRW#6'4N^$5,]Z'!?2=&2HL<4;6KK#BW?.XKV5YEI?O^I&CJO?/5:1*V,NNC&
MJZWC_&<1W@SH_.OG+*BI6>/[(/TN*&_F/, 6.WD:>@6/CU0IZ(VLIGL&MZ\#
MP$-3(O..N',V67HVJ]5QC34%QGQ.>% M(&GN@&C.;AG&NH9)\VAN)<MC5?K;
M!_WYPK!G8G /C*]F'/PG#8<I"W8?I,])B/5>@4))BM6_63T:NSU#XB>=U4,6
MZO..N'.V67HVLVU;FSD>#?(F)<GM$\E9;=?<>Y);)X#Q],R([>"K&0>?8T;\
MRM3HWH_)FLC$*+?8J_>YT6WCO8>J( 93F&*Z&=XI8M60O!(]&BD]^!,O@TGY
M_0K,^+6PBA$ @7-T@H+RH6EEE^",1/PJ&9MW/'%#G<WN$T63+27I];"_F#<2
MTP'X@VR6!FOF>2"CRNX-]2BW)%.>6VV[0@I6+:'65H)UK;T2GZT)G#VWV\;$
MXBB?-UY<Y[=Z LHQSK8_0P_YQ("V,*>#3(EI+JY2AOQV.BOM(G<*"!+JYR_%
MS+.037]413/#^V?NG7V<GKJ'LXG#E/W([[/&47BMR&AW*R $O$D"*PMDW3'$
MS7@^,H.7"9M YXPWJJTFO"5>-G$;CY4,G[$B<#8M<[J&L?Y5O;$W+*UAY[WG
MEF97]6EBN[4WLBW2=%"VTQ=W4:O:XZ7U[^6E&00=#LD#! M8L?FC,9M0+F".
MDSXJCH1MZ6VC4\%+[(O/2,)+H;PE;WVC7NCG])K/_(C"\L+5>#QAD?+9PSBI
M'$^!E,0OX09A(!J2#REK.,[ /H?]P^ _ST([<&V_:W2]P*06T377=CVO9Q/'
M"FS+I]U_+/M9LRKJEM3/+2MQ%K5T"*L/;"P\5N4<0,7@Y71AP%Z+]\E)E*+*
ML1B@-/Q!11-86#D)U 284>5_1GZ*K[F:Q(+]23W]<F7(/-NCNDJ]V[;L[IY4
M_]F@?1VYUZWOU6T[]F:K2KC*O4IZ/12XPE[MK197KU%9NCC.H^]G%>H7\(^4
M4^:Y5%U#2N=E&\6Y!PB7!RI:GOCIT[D6L.4+ &O4.S6; '$8]BKYMQ7.^Y3
MQIM&2\"M#3C6\5 YB_FT*];N1D)Q;2@R9_S1)-K>@>?GA=KV"&OO@+<-T?:$
MP;=U ?>$8?D 8FZOSK_!W;T]N*+GKE2?(2;@\I3KRYWHNFTX[/*E\J7RI0_H
M9:\3SUBK1$@WFRT@?SO[ZXD7SJX&I[TL8ESM:+K9<@QM[ZL8)<GM#\D9+4-W
M)<5)BGL\(=?2.QO>1)<4)REN$XKKMG17WD>1)/>()&> )>=(DI,D]XB6G&G;
MDN(DQ3VF)6=LV"5+4IRDN$THSFZ9^OX[#^,RM_VZYEDAB2VX^F7'W6"L$4=_
MD#Y3>Q'/%E<J'Z*KU$K\T\!N*ZNJU4Y7=L1I-HZZVO[WR3IL#.DM>VT'7.+H
M<7%DMMRUFY)*'#TVCFQKW92DQ-%CRSK-E7S4;!PYIN2B9F.HT^K8DHMVCJ,U
M'>P7IK;7C2AW%%CXR3Z4*XZGTXWM-\E8L9KN>%Q-Q^?IROC=ZM;$IJ,"9(SU
MD7!DZ;+98;,Q9*[=25UBZ+'EG*/O?['MH>-(T_>_C.:P<60=0!' @6/(DKJH
MV1@"7;3IP#F)H]W%'JR];EXM:QK6CBJ\^>O7WTXVNZ=WZ'&[Y1K(E)'59F-(
MUV5%0[,Q9%GK6@@20X^+(=>1%2?-QI#I=B6&&HTA75OWII[$T"/K(5M*N69C
MR+77O=(O,;1KIWHWUG<CCOX@I0Q[$4\XQE%55WQ4U4,T_]G[@-P]8DZFAIJ-
M(6OMHD>)H<?%D"T1U&P$Z2VKL_\-F@X;1QV97VTXA@PY'+CA&#+WOW?)82/(
MZ<H"A9UC:$W/>D<.4B/._G2K%,I!O;),86U#SI!E"LW&D&ZM:\A)##TRAF0=
M2;,19#OR)G*S,61V)8::C:&U+PY)!#TN@O[]/XZA&Z\DEAJ-)5.JHMUC:$V_
MNKN;VI)&G/WI5BJP,8BR1&%] 2=+%!J.(4-FAIJ-(6/MNT,20X]<B&7)Y%VS
M,63*V\6-QY"L\FDVAHS.NG>')(8>NU9.,R2.=HZC-9WJ%X[LHK#5^@2CT^Q8
MPE4",%*&]8'PNRY56&4R=:-X;+D<=%I=?5V3?$U([%'4];"0:[7,M<N-)6[W
M [=FRS4VO/XL<=MPW!IVRW4DXQXF<G6WI7>EQCU,Y%HMN[MARP.)VX;CUFSI
M':EQ#Q.W1K>E:9)Q#ZGX9)=E78T P&['?NR B2^3$8GR40O.%^<I\7.%Q(&2
M8#F*DM(;&A<;1H\./0I[SR!E69?2< S)3$;#,;2NV2CQ\\CFGRLSZLW&D"N+
M4IJ-(-V5A5T-QY#LW]1L!!EK=QR6&-JUD[T;M=2(HS_UJI2?"BG<$ZQ;,>;(
M@8##5)4@*;R(*N79EP0E5XK0-@WDSS>,RFX'0KOFS/M*>!SGYQ(36X'2CN/;
MDF4DRZR>IK4V[7LN.49RS!/D&"PW^[G\J.08R3%/B6.,;LM8^RJ=9!G),D^7
M972W9=@;3MV2+"-9Y@FRC-5RNM+WEQPC.6:-,EY;<HSD&,DQ:W@RIK9AM^L#
M8AE90"T+J'_-"1 O_#<(;U[_'_RKW&3M9-^*+ ][HVV?HGL?KQJXYW_N^:<Z
MTO0!!B2]#F/&AU/]!7=ZGD^4*A=)3A6CK5R*A*N2])2\SS_/E#Q1CI.820V2
MTT!Y&\8D]D,2*9]R^&! XSQ3PMB/B@"^#6/E##Y4'+Y(F"E'<5S CR_I,$ES
M)8F5MTDZ4'1-_4/I):G2*U)60!Z$&;F^3NDUR4/X$3PM\K^*-RH;%+17@:[5
M[CP*?'5M!0#S?0343U)VKI? R33%7SU[_=O97S]S'OY1".O%^4O#P%_MY(CL
M(),M)) <4DHRH = 7N=?2$//]6[;4+PPBA"]0":&9AAXE6 P)"G\$'X"G^@M
M6"F$T\,NE0"0#Q_C;8,0""%0^O!2)!4ZP(L'2#UOPN\Y26]&RFV21L%M&%!V
M)Z%';@#@J 9A-1_DI!*,8CBZG\'Z!$0BB6#]I-?+:(Y;1&H/82-P $'[49(Q
M/J!W0-A9>!/F(_;"J[2X(0'! ^#//K<_M>$0?1+'-((/@6+S)!U5KV.[*>+Q
M?F - %VL^$6:TM@?X0O@Z>OR_6WE(TG9+I(B77(.X(ZLB) ?>VDR4+)^V&-L
M6.UE$-ZUV-MO*;QC2.%HM:\0KBF $1[(0B )D@J4F(MY3.#<,MI=I,AADH6,
MI%,: 6W?T%< _KPO9'O]06&<:.-'B ?RI,@7/U(C=Q] 2M,=D;9I3X*C_N]^
M6NYF2*ZIZ@'%?U=)#S;[DD2W9)0]^W62IX&AIV X?7Q^R-?_YZ7PZ"(\3"OY
M9XN?.@@Y^1?]'A7IZ#!DI3C,E+R$@X_EI:EQ@6FVW8WD993<CH5DD )GQK@L
M/%3X*$23;,A,M!]<TP+ F<2NY!F3&J=%F@SI?&DY*8;A2=:16#E#/HW9HB1J
M*Y_8R4"0E4>^IC%-V5(I[44HD(X__'5VHNJNPD0([(WO!5?-0/FG*'1A@3#N
MP:]A6?[5U % I),,I%P4X7_Q$.2&@$0#T(5X6:T8YN0[5PNTQQ8"@% NW6^(
M#U*5C-<FD3C##8 24))S\P8E?[G9MG($OQ7RMP7V2UZD5."Q=EI $M@TO5[H
MP\\0+4- 0"CNS W("-X-O\J 2$/X#8ES@ L3Y4D,TA[.GC <XWEB(-X#,WV.
M#\7T.9XV?298V1*F3]O9B)/7,1R $BGR_1" #6 !0 #GSMH?TW;$@='5F[^4
M7Y7?3@Z%NN XB$ XT#(#V^!4YCH.F';K4]FL5?T7'8"W-V+O1@$TML!)D Q+
M_^PW.F1.WQV^C>N+PZ*F8]0I5P ;,CP0ZX.=*.<GFJ2HEG+;#_U^Z<@K7VCF
M@P AC :N*/ZY@!]-T)WME.*MLY%XFR6\ZJVPS.6OE\K[-\?O%YHF-:W//#.Q
MR?+9H_?OA:X%W0HTC#^-1H-A'\!X6'0Z,V1RKVFT/,TRB==U.>79CK:1R%L@
MU&") <T)J,X\],'^"X<156,6D@)[$!V\#+QH$OLT74"5AT58DY-&]IJJN(NR
MQ%03LLRU[%F* @FSKM^%$NEH\";,D@'W/18%E-X#P85I>&"&V+L4C@M;5B_
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MM UN G])G8BGN50(WNHUI>,*NY8]+F=Z7#H'V^-R;URVJKSD7:V\Y&BRO.3
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MM4XZK ".E;2.RR9Y&[3GW;9=377 !^ #1YEL#7I"?3KP:,IMO[*A(/LUE_S
MAT.N,J)16\'M"#:=W-%4IZ;NN'DX*^R<^QH=F7C^!GA'PR7%ADBX53O 6O>?
ME8H)9]"^HW)"L";:&F^0MFX]H:&U37>SRK9ERW; 3S0?HFM+QURM"<A:Q73P
MY88M2W:R6=U9;;-SHSKVLRFR+#L/-K789_W:0%D'^)2/K]]?!C?# X=0[79!
M<Z[)JD:!H$!?B&ZSO[S<+E%L#K?F17'FAZLD?); YSZN6B=JHQMMH]-PWOK
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MN0) C)+XFO]EAI\/1:8I>-66B^F:?JK)+:8$ HHX1UC""T>H7(#M)^2/5^2
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MWU$D!A15[5@TME#!WU(P2^&_4Z] FP -5F''DKI-.G_SP!$>C4)Z(ZBWQA0
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M=<OT>VZWHW5HCU#?#3HVL?XY&\<& ^J' Q)E_WFFVF6DL,C4:T*&+Y$BC^(
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M/=XYW#C9_? &I^<AO>V-]&P;>&>[%[LGZ*2*.+Q#Z3M<_MR/445&4,P-T(4
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MOOD 9 %\&P!?,W@H]E%K3D#0[,!(RPI&DPB""4F)#(P)59WPI$TG_%.+MUP
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M/=@E@\_VX*C?77=?=M+:[!Z\_;1[\![U#EZF>WU#TWH=[JYW2??TS4DWW^]
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MH=HR15GPB)*D6\CB.6P[!VY>YD K,2=(<7 &1T@JOP)EM /JL6114Y;V2.)
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M?HN4;C<AC(<0J'*8869)L(&CX*(WPABDS"^2$ K]MHM^:PZ5)$%FB/-@B"+
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MEQ*[+!'F(J4BI2*E(J4BI<64TH,ZY+[ICL7Z:U21K#O>?#26.Q6!*X> "2E
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M&S:V(AG2<"U,G*4DDB(E5.62Y";(">62*II3;K)L:X?%#P68UGLWUX]6']S
MZ&GU(6AU.5<PET8+;D@N9(*Y.P')XC &6N5QSH#%"IDCK2YWVNII=6-H]:'-
MAYY6'X)6E\R#6.7*2".)#K'O/%@+8!Y$$8EUE(9AF*E$HEREZQ37_YEB$GO:
MZ+($RZ!.JN-?==4')6Z[C#^XR^<5&*'U9A[8O3SA7_>=A?>;'FM3/!/ NN?
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MUMO<N&G8]97;SIYWW8IWG2X;%'F6ZCP3BIB(YUCJ$Y(\SA@)LR20D8[3P,3
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MS[QNSKR^K6A#%.E<\(B'A*=,$QI+3K(,6SAG61B)0*4)Q5[KZ^'[Z.EW[6I
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M:9AD,@\# ^I!FBYG?=T-$>O'X6%O;"^B?6.TM/E@^JL\X^-3/2CY5 _<[]4
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MO;SVV&[MV&. 1[-;(;PAJJ$U,+J@$&U5-/"BI@AZT%9!.U52:(U:-FKPSGC
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M!=W)=NS-1FX@HLB9K\!SVVNM1;Z #N+7R2HJOOBNDY=MZX9\L-!)DQ7W5G7
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M_HW#PYI<#CW+@BIT^-;U&3/+.8R/G0!8+])/3]O?CD]V/^A,:A9FAH11QH#
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MTKYGS46GI?;IL@B#-< TF%&]1&TK=[BGIMYV>[I4U=(3HBHUDM<F#?N4Y'F
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MZJI[R:]X^<0;%"VOL8WMV]FBJY^C#+904!/;[@FCJ9?=B[R< <G+O54H, B
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MH6\LH2=,RESR_\_>V_98=N1VGE]%R $&'D#1C@B20;(;R!=C&]L&=FT,[&W
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M6">#%.UC:*ET.+X?QQ>5/K&(C5QW,5T$UB::=/:<U(W6S*6/BD_/-;]:HG]
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M);CL-UI3CN6SE.N>/8$>EF!@23AI=9#5:H&G9_IH\]V.)7@T2]#[(NBUD//
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MT6*0)I:64$9-5F9-LY8V6(J%I_X89>4'Y=NB/#!,.3/(V&7D4[4%RV6+AFB
MT2>:)G)0_D"4+_M>?2B%8ZXI#]\Z><:D BMIQ-D87\<N&EX97JVM/2S?EN7R
M4H?:!F1"I$G:I$AMWG0(83LZ^7NR?-GX6D4K;\UFK*<EC.5,7K=8?A]/Y0BX
MT5>P+*_NC/JSL_P .OGWUQ+\:&W\^.(/[_3C3_OZ7Q=^T=C_,C;EK[_[^_G-
M9[_]K[_[T]_^^>]^N%L^ZO/ 7Q']B*?RFZ^_^O:+?>?^^IOYI7WWQ1_F;_8
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M9(57@CU$++))KQF?GJ6]^<SCML4G/USR/8GP8H[>_UW^7:-U+CV7GDO/I6_
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M,T+PH5%6#7 SSY&G89'PRF4M@3P&2^FCGL%C;PKQZ^"QB8 55VHC@FX<R$D
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M29$XN@5X.[&\N5CVW<N*#'TA(R&C<K6Q-AG-FZ"6EWMELP_73<'X^CDD^\)
MOEMII-%_&HQP[O8:2P6%A+;B5-^;CW,LA!5"+BY4;!@DA0K"SN=8LN</%(8_
M<7Y%.%\[H^0NRD/"9$+*.%IVD1$E9V($#LF1Y3)Q?@MP3A);4P"?.[$7;JH(
MG&I,N2J[4J8V7R2>UT+T$RL2,W?'VHZ8@Y1,!S@;Z/HL.8P)DI_:?+.QG+HC
MYBAW]A[--"U+<1B*S1!3"D%DQ@\M$LOK(?I.0DV^F5S:Z,H7NI]M.Z"+C59:
M"A:C;.^ >^\TV(GEQ6*YF]]&$ -;[]$5TE*L2 3*D51!9U.OFX3Q]=C]@HDJ
MM"&X@QHLD0REE@Q$RUQ25V/!3_V]^3B/'C "0DJCS]>0XDQ<8RNM:+?F$^<W
M"^?K^VD5<Y]@;[1/JT$7P2BZ;&+-/CF6/MUVXGSS<5XH!.L*)Y\::@'A;LX[
MZTM7<ZD!3VV^2#RO[9N5;I^E*S*371@Y=PX,YQJ,:(KBJ\WD\&9H\PV([3\_
M_^'"\?QE[Y=7]WYY"S.N_\2E55[ Q^&4W_7*N=+WQ[LA7. 1/GUZ>+PW5NPG
M1W5?3O9^J9^.!DS&WT5\NCZ8<ES'';9W_I+^Z_7B[B,[<\2N*?:17!<./H)8
MY!$1FYV-M787,5 L.*.B%F9''MS_<CU7(>@H:&:SH:PR\L+ 2.H_UI46T,1E
MQ#@ZF-F>FXMDU]5@3<6#8D5L6=A5:ET0QIPC6IE(7B"2UW(2BJ."4(*Q!-;@
MJ' F"&"@U:#2FE5*VSMQ GF#@=Q*J"UCTU:P8%*M NA22 &<UCB!O$0@KYED
M:EF#KP8]!8,%T'"R_0O54GQTD++=W@DP@;RQ0*X15D7!H5B'(;.@*(Y:6;YA
M+'YF'"P1R&L9!ZRY0*S6I-PQC,Z"(1ZE_DNQ76YG($BCW\Y$\N8BF9UD3YP\
MBD-7F]K@.8RB2#:#MW%&-2T0R>=E'"B[J$PF"$2#40:68S(LV2%!0>=']M -
MJ*0RL?S.%<ZT5*<EL42'"0)A*ZWC&EP52PP3RXO$\MI):.B8[789C0W%CC)G
M;-B3F$2LW,UQ$1CU.=QTE3<7RX&M4ZJYA"C((*()&9UX]8VKGUA>)I;73D$M
M=Q;N^LJ$)MY@'<UI*1<CJ2 DU]>Q"]L[L_#H!D.Y](D4R\F"!JPI4E >Q8.]
M<NA_\Q/*BX3R6N* >@PA<.DH%C*8>4!9@F&VVD66"F;J[C+-@N";BV5,G@LE
M*=P 0ZU2<O19;7.N%JMA!B<M$LMKB0,EUR L8BBY[BZ'Z$?R;C: SA57*5@<
M1833=)<W%\L1!7UJD+SOW]0H+5>-(Z)<%#S.)*!%8GD]04"C[=2KP3C&8,9)
MA%%F;[2%,KII-8=U>X=F*[S-A7)!Z[5 QK';V>48=;@J"%BJS57?)I07">6U
MG:]NEE5K#,9:[#H[ !NN(1HM(E)S;K9U;]E-J[RY4%;"),YE5U-#J95;\)%\
MT9!=<S 5]C*AO+;QY5NPH%E,T-&< SNHQ4<POD659F.+=APNWP"%O0'A_W^0
M(N%Q\:7]'QV>R/[6*MQ_ZV.7]]?#HU*/S(CSMW?[N&T='^[OE:U78[#1U,Q.
M4@DY8/ TFJ+1Z"3ND#1W_<UI1M0OCYIWUR/J:RH276!3E+AK+">FN[O2A5;B
M1KD3<XS;.T!T17E9ET#,#4K!O,T\(-!=*A("M4.B(:>2?0V95)!]^D"] R8/
M7(H'UN/QN7O++8 );=0HE5R-MJ+&:\*8.5D7?><!_][1?Y,'-I0'RNA</UJC
M*E>D*%P=UZP\%A1AU<D#2^2!LWH +*+UR9N2K8Y:Q<E(*\XDY5(I2/3!C=ZH
M[QUM-'E@0WG 5ML$14!"P-9]_J0Q<*<&KUT=@)\\L$ >6,L&Z+.6L5 S'I*,
M;B+!*([*QBVK$+4*H6WO,%Y57<3) YO& UT(>+ 91:M'UX@J$;G@FXH-B'4&
M.BV0!\[+):C14_-J F<VZ)(:Y5A&(9?JM68G0&.'X+T#G283;"@3Y.Y9<E>1
MP5K!46 UUJ+%-^RFQ(.?647+9(*U\]@T,D?Z+!K'H_:BC=TW8++=-_"^Y>*1
M1^U%()Y,,)G@?-_ )235W&+V*+X[E%7)2TXN0L(TJZ8ODPG6CG,EE5A#AWZF
M/#J*=A>!<E<'+!F=37WN&$>N<)I,,)G@_-W"6@+%#"VGB(X:9U$72NY^)=JL
M]L/W23EX]L24PQ/S\DTF35R:)M9R)"I#(F1O6I5QN-C L$_%V-2)?]3U##@"
MN.Y8/XEB$L5;6I-[6UL,T8DG#,Y)MKXS!$?43$YP1H MD@O6<BP:>K"INPRI
M+W.#P)T+2D$3,09LE )ZWMX)86XC3"9X6Z !EJ0</2+UQ40: M@@T!=/D5IH
M,L$2F>"<# U?LA15H]47@T5'6'=LIL]G5PM*M@E<92GHR02;Q@0*MG ?F:I1
M$&Q5\=PR1:T%JJ.9J[5,)EC;4(P,JW8]1B%JUP39&@D QO8YU%(BE)9&@L?4
M!),)SF>"1OU)Q-<N'PNJ2U2JA8P=^MU/8"P?O@W,W$9X7YI8[QUAVXA#SB;'
M<0*9"QD.#0U5 %_)NX+V=!OAQD<C;$!VR1]DX#BX":DE3X\.R[/<Y[SC]OB=
M,DQF=M\%*T"SL^!J]ET#H&V5,I:8""JG3M3Y X6.3_:^*O;^:CV_),8^?:6(
MB7TAFU$RQVBK8&H7>]%!]EE')4JZDV8>[P8C'5.NF9B:BSP*D+)TJ<:6:B7)
M 3]0</A$^M4A?2V#1$)JH5 T !HZTDD-%ZPFVI1<2"4$[DC'.X!^ GUC@<[9
MI2R.NC%7',7M,A5MC=1:/YJU3*#?.*"?->D)0DJ8T=38U&"UU5!L;)ISOG7I
MIM:W[1VXPWX6V=E<H/<U$#FFVM5[1=O->F;H#GB%1I'[;R;0;QK0UW- ?&,$
M#\:I)H,9TBA4ZTVJ+B8?F;J W][Q\0[3-.F;B_2&V7J'U7,55/;DJ0OW41Z
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MGRW7A_<__^W!5S]@3-22#29B['35#:?1)&CZ^)=*SK;1ZJT[)NM;Q8NDJ[D
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M\?T*WRZC#:UD!LE]SB/;5$KDX)*O/M=K#R.9.+X,CM>BVU+N_U7*!LFIP>3
MD*HWOE,SV615I>MA"!/"FPOA<?:NR1:.,:%3TNJCB^/@(*;BZPQ<O1'07HL$
MJR"HOC:C,%JP@9 9 <K]B\W<8G4UY&FB;P&^6PDN5,XN1T6U2M&[#G;U 5PF
M6Z:)7A*.UT.G,%G;S;.IW8?J>KL5(]R\J<6GFJLE'IT_IXG>9 @7*+FYP*V+
M-8R ["$$[W0<\7,3/X_);@*TUT.07$L<18)QA& PQ&S(:S')467;M+1IHV\%
MP+VM6I-O78H+9N:.=(Q]9;O&6"O'>:ZT+""?/5?*D7--SID8<NQB.T;#RME(
M9$F4L%),VSOKS;DGA#<'PIC(D>].%U:L#BF5E&(7V#&P9@S31M\(:*^%LH2:
M&W;?R:BH=AO-S7#VL4-;(0LY+2S31M\"@.=2K+A$E'S $H1S2I:B*YWX*T&=
M-GI90#YKHS%'KQ7 0"G)8(K=D?:534X1)739E1+>!!N]O*B">>7RK[QM9:8>
M'!Z8L]$?UUMLZD*6\J(!H#?:4E87DG*JQ:E#GTE;_[>ZEHOMFIAEGB@MWX+N
MK0=]-/4^8T,30GBY6\6.BJ&J$4'Z'(_@R8T-ZI[X?IVUD1HP,L=2NQ+FHA *
M82N^4>':TCQ16A*.UX(^E*M0UF2*M\U@E&BH"9A4O6LV)Y^3;N_ >ROA">'E
M0K@ 6]N]GH[AAAZ+4 GLK=3,2!C#--$W =IK01_>JP*[9IR#.'Q<,,)<#7)5
M2BY#H$W.$YWX?EV-$+4T&KM3-"H9$(6B.0EK#%9\U&FBEX3CM:"/JIS[3(&)
M/ODAM?W8?H:^K"3TQ>L"NC9-]&9#6-EE)[F4JA;KD&P=KQ@D:BPNV9D;?2.@
MO1[TD4H+5"N9Q!H,*I AU&;8.I'2O"TTW>C; /",H?@,X!IT@#OH&LU# D49
M:)=K!_@$\N6 O![TX5QQ)1A?A\164B.U19,U@(6B6 -L[X0-K&DW,?RZ(  3
M9,2L-@%V528NB7"6KM-$B6=DYLW ]EK41XD4<N1H2'/I GS4""@QFZ;8NAA#
MF[%,(WT+ $Y9P2<K EBP>UY*%B6/>#YG6\?^--++ O)9(ZT($:,MIJ#M1MJ&
M47D6Q90B"=GV&4WY1ACIY844S"N7?^5M*_CQV7B6UI_FI-_SL'5*?GIXO'<R
MBWQ<[TX5MA0YI^:[%.9*5.SH.N!#(2=P[9O-4P2_O^U\OA[O(5:RKSD8![6;
M3O1H"(%,B;XK8&"I*<[(YUN ;^R ;DC9<PVH$!A*Z+^K4 !LCFX>)BT)QVOQ
M'BY()>^]:5#$("<T4KPU8)%#+:X[,D,"+S_R>4+XG2$<BD90!YB[L2ZY<4@V
M$)0D15II<9KHFP#MM7@/Z!/)L3C3YW,4!V V@ER-2@W9)R9HLP[7;<"W"$H7
MW85$!950:ZWJ_-BL%'9NFNA%X7@MWL.&6"- -2UX[E*[>$,!G7%!,[0,FEFG
MB=YL"*<J(SFB4>"&J1!S],UR*LG'T*S,HZ2; .WU> ]08; 5C8T$!K-UAA)5
MX['[4-0)&T&GC;X% &\C'RKE(!03>C=,=?/B^JH@M")M'B4M"\AGCY)":C[G
M'(W3CN8^@\UHGRXC(X2GQ:ZR<MO>\<@3Q)L+XNA("W:99FU <HV4:PVN_[JX
M1-E-*WTCP+T6\.&3UY0AFH(E&@R0C12.)H/MOTG!JY]6^C8 O&@+7+GYYL=2
M2)WBP7,8E?>*L\332B\+R&>M-)"W06PR:EL;0.Y6FB49L!"5&W6R#C?#2B\O
MFF!>N?PK;UNAC\\.CYX>'LE)[6RLL\;'!SL3AH0*W526K-AE,&4;.4?J'SUE
M=3/F8_GF\^%GZS$?6FW);/-(2;(&H:!1*MD,&>12=W.5W(Q[O@7XKF4$/@>J
MD#R""%F2V(2T!DG)?E!\'SQ[8LKAB7GY/A/DEP/Y6D!(",Z62LDX$NX@M]:(
MJ\DP$XH&7U9=7]P=],OO@S@A_NYAFY@T2ZCJ2T4"5AIE:Z4#?*P.G+W9;@2Z
MUVN .,:8*IJ,8YLZ!.[HMF)2I3IVN*S/5Q>V.?&]9'Q796^)@D WX4BN?P\!
M^O\:>/#3A-\8D*\7")%NM6,.IKI56E/J)KQ9-,6)=9KZK(Z D6G"-QSB1#5'
M&RE4ZS&S<&'RU0FV!E(CSM.HFX#N]9@1EM)RJ]7X5L@@93O$N3/4<O?)!9U<
M87_5"?#E KRQ)W39:P.'E2W%,!K#5$LN)M$/&A0V;?A[HOSL495+R))],!8D
M&&P1#4-D$[M6*ZEZSS$,(PX1)L8W%^,I@::F&H?%SAW=$%L)J"J8B@\S\/-F
MP'LMI*2&+L.LBK'LNT87SX9LCD.CNQA"L#Z%:<1O <"#-K3<2DJY8NLJW:HZ
M%QRJ19_;M0=^3B-^A2@_:\2;[3-I6S$5,AID1$,54Q?MVES)VKTR=U.,^/*B
M&>:5R[_RMM48^;H>[Y5Z<+(G^UM/#H].?I0?ZY8<E"TY/JXG9GS>6MXW$&7&
M:UZT I\CB9J@U>X_46GD0(KKOZF^2E&8IUC+MZO?G!.(PJ&D"& L0C-8G34<
M1RF^A%TY!Q&*=<9CWP9\)W0HFHMWB!2(;"7,-I)8  [7?DH]<7P9'*_%FE!T
M,8Y642&A-P@N&(D9C \5+3C/W27:W@%X;W$\,;Q<#%?'I810T'K AB(V*R45
M3\CL: :+W@ALKT6:E-4>)1:CW=DU6"(8&EM="JEQ]X&;V*NK9#_QO5Q\N^H%
MHP<E\I@"2X>RJ'?:);ES>58?612.UX))QFD#LHN&NZPV.&2V<@%3NH&NG;5S
MB&7:Z W'L%K"EFO)F?IB(!2+7E4QN0H0BIVG4#<!V^NA)-B:1YNK(;6CW4Q0
M0U[ 0.,RJLPTJK-$V&T N&5.<<0&-F(,&AA=L5%L=2&FY&=B\\* O!8MTC3X
MZIVIHYQ]AW0QH@K&L=;0V#H;[?8.^EDD;)-!W'(+@3QG]EAJ[5/?(6Q'5E:V
MV7_0H^1II=\9W&NQ(MU 5XD63:?C:% *&DZM&DNV9!N2,L*TTK< X-(BA!A4
MNFD>[:2HC.HCW7D.,7+)85KI90%YK2D<C0;,%4R*0<:Y53 "MID2P$FRF(3J
MS;#2RPLTF%<N_\JK+#^2[J:EQX)\_G^?[9T\?R/8XY-K+3LR[S'O,>]QV^^Q
M/-:?5R[_RML6IKG;/_OSK2=R]',]V6K]<\U S&OU7*$F@):12 2M+U0HN50M
MAU!#3!<N-W JJ?[CNW[QRX.]F<-P54[K[G!6SSJM59Q*RV L,':G%9W1"F!0
MZZAKW#);WMZ!.P1N\6[K1/ [(SBGZB)84+$6I1%SR\&5YFNT+16Y.@3/K>-W
M!N_ZUG%KM7&,IK0!WHC><$YJM$$4R2X6F^;6\2V K_4Q!2GJ6K+H':LVB:4E
MSX%R;CSANP3XKN4/IN ZV]:Q31Q'>Q@Q5 $-*7)(.14[X7LKX)L=!A<%<^:,
MN>&(D,Y88R8N8IV=^GDI&'ZXUN()("7";$IVW%4S>*.IHYE24,$8+:0\]?/&
M(Y@1);+*B(5&)XD(?&DEUJ(6HKMPA-5$\+5[P(_NK2*@.XK[\WWG'WSU0_-(
M+C8V(G%XOF0-)^@8[O:W0<;0IW5@.,:)X8W&<!V=%UO7RT.5-4F*H:H-A<0I
M7SC :HKH:X7OEV?A2R&G6JP:22/N@EOL)EC U.:"1W ,9*>,O@4 1I?()V]S
M1L1@"]7<Q('Z3%4E7KB:U@3PM0+XJ[, +MR@":.Q)66#L=M?[8QK@B?H_,NI
MR4PFO T !J[B@C*79E&+$W804A6?NXO5],(=%J>*OGX4?W<6Q;%$B]E68WVW
MQ5@E&Q:LQGONO!R]L\G>%!6]O"/\>>7RK[RB ,@+AU:4O5]>W?OE+<RX_A/G
M5B$:'S<N<N_@EWI\\J0>G/1OM_XN^_)4?CSL[_*OK;\,4^[MIZ]_N?K9??I?
MKPC@2A\[W@T7>.Y/GQX>[PTN^N2H[LO)WB_UTY/#IY\86+WZ[ S(<1TWV-[Y
MBWO]T'_MTW%-\5^WOHQF#1FS1Q>P"P$.J#5*&W9&Q">"\GX;Y-/V7\+V?[D>
M0U**9Y^]&D>6#*)M1BJR*8X+%6F>2K?\">+BJV!.B+Y[N?KDB^V.=F";, .S
M)*$22D7IGCCF>02] .BN]S[/(UH@=N@&ZPUJ=\*5*_;5U'_=BB9M5U=K;\)W
MN? =&88D6*QEC^*!Q1&5'*0Z;*G2A.\2X+O6\3Q;+Q#%4&%GL&DRJE1-8U8J
M (%SGO"]!?#U.8K:AK'/.7H719H+KD2%1/UO<0KD#PC3M2"1D&NQH3C39\6.
M*EMB)&5O&C7B7+)&F )YTR$J51VWXJV#B)2#INPTH<V1NU*V[WF\/"%Z.1]V
M/0K$"4O,.1L;J=O2 FRH56M<6@4!1*N5MW?X_>.X)DB7"U('Y*M-39T"=N4K
MPSVJ.;>6 6R%>82\"/"NQX"4.AR79K1I-=BMJA$':)R&I.2"M-EP:8$ YBOO
MBIJ+V%C[8E"'H]2T3U(+5R=0&NF,X5H&?M="0#AT/R7&:*QC,.@B&_6DW?A:
M#C:1HS3WH9:'WVN(X6JA^[ EL2T6N2IA<!+4)UM22N'"M6BG2KX2H*Y%>:2
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M;<5S-@RA@Q=J'CXN8[ZZH^()X 4#N($+$% B>(R298398E\$G'S_?YX 7@2
MUV(]7*$8.8$))5B#6:R1W-0PYY"*PU(B30#? @"#3YD0; B(""F)NJBBG=VY
MQFQGK,>'!>IZK(=T6H623=;:?5EKAR_K0K>Y+GLJ'IUO-T,F+R^.8%ZY_"NO
MLJ'936B;\O#D<3W:>OI,]_?R_O.MDR,IM6S5LWW.KK7-V:T/@"R5@]04:J&,
M'B*';$-W;4I47X33W-[]8$;QJ_7XAY"RA?[%:$C-8"48\0_1.')4N$L8<KB]
MXU)8?/CCA.B[EVLOT2I!85%%QX5;M$RI0K&^4G[/:C33\;P2Z*[%/[310[EA
M,9* #$H.1EIH)HYH%BFBY*ZNS_:$[W+A2XR:6&IHW:T!]0+(S!Y"JX#)APG?
M)<#WK.6-N1"FX(R 4X/JLV%2,#6+C$)@)<2K"U^:\%TN?)D@IQ: LSCT#!JX
M^E9#4,T5=08(?TB8KL4_6)>[^M5JK(1HL%5GV"J:6!,26/:M\13(&P[1(+$;
M64F5J6%P+-0Z1KM0AD"C,]W<V/V0/NQZ_ ,4UU!13*EI9,MG-9R"-S&-%E0H
MJ'$T+;H!27P3I.]>\4U24N+H1Y\3!Z"<R=;^@V6@&.L\/ET$>-?B'_Y_]KZU
MJ<TC:?NOJ*BMMW:K/.P<>D[.4U0YQLGCK04_3NQD[2^NGI,1!HF51!S\Z]\>
M"3#FQK%D!$@PNPD!Z3[,Z;JZ>[JGNSC.98J)91M)PBH YJ4I+&:R8ERM!)E+
M4X0? (!+L0:2\S&0'>M40$D#$121MY00C6L 7@D =^(?:*I4J97&I/8$8/"*
M89*: 5?)>)-Y-JD!^ $ . 90*?%:)C* %P5+D=%J410Z:^,UBP8VH"X(U$[\
M0Y$F.ZXTL[Y$!BERYDQ23&19DG(YZ9KK8AW4Y-7SK;<K5__*)>6Z6)OXA^U<
M\FB4:V</C_)@C%,"IV$9?%?(0XL#G#<.T"7O=(*LD@<+.40,*@6;#9J<Q34=
M,DT.+B '7W=#'F0(P2K+&5>"I&"N.<:K&U5PSQ7W1N5:UTM*OO)1@ VBWY]?
M7'CMK0+25C6D1)JK44Y&J90/LKAV9GP5H-L)>>!)>8PNLVRU8V"=8#XI9,H%
M&X2DKV.+M'\(\*UE $)6J(/ED(G#2;Y&9^L!N%)$"WE8#?A>EKS<96Y2$BPY
MXQD8D,P5GI@JQ<F0+,^Y%;9^"/#UE@M,@!A% .D#"B6C,E(;3U_@-8OS-)@N
M!--.R(/R7HL"EH'4@J1LMLSKI)DUX$$+JWS-7=P4Y'L-46>2MBK58/U9AESE
MA)9.&^[0AI+:7NYMVK#=D ?+BS!%D-DJJQ5K;69!1,Y\4::X(+AQ-7'A&M2F
M;B#]_NH>(D<7BR["9B@D3$T)T7D3'"G(MNCF,5T)\'9"'J)38#T09'7UDV8T
MC#Y)#"%J]!P#8LM]]A  7)PG=.924^&!CCEDZ:PHWJ$0.N<6\K : .Z$/-",
M:= Z,([.,5!5^A8'C%2E1,:M$LGX!N ' &!MLC':)!FD F^UPR0,J<LAIJP+
MAZ8FWRI0.R$/(BC):8*8]!P88");5D;-7-9:.4__.+D>:O+JN=/;E:M_Y3)3
M/MA-N^H1#S\-1_3GH$<T.LJ#>$*<.^K_,:V),>7M"NZ6[^%F@Q^X-L4'DTDK
M H/:F0(.+(> $J2;^SC;Z50^/9W)IZ>S]V0\SI.?L#_Z#0^.\W9_' ^&X^-1
M;MKN4H3HFVZ\A'(FDG%J6"8UAX'GAJ&/B;1>GX665I.NT\)['P"RA;5)07'.
M%01NC8M>96M# DOV#LX=,[$PLAN"%T)P)VPBR.AHOA2!MYYAY:B8)]67V8IK
MSYV4!C>VS+7].0V\JPO>4 1PESVO1UAY0.3:QB1BB;8">NZ(B2:6[PC4E\4R
M"H\V"<&XJ8GYA3#,>>V958D+)3TN<P^Y(7MUD2UB5M:ARD&4&@F%@KMH@\LF
MJY)X:&)Y-1#<B;.(D=N"M7:5@4BR666&2F;Z+26$4#37O(GE^PW>()6*AF>P
MT8"UZ'-0F;NB'(^T".9V #6Q?$?6<C<R QU/H$G15L5S$LP%F,M2,JUUMB%X
MX</R?$,-VZN+;1Z,R$F"!B0ZCY*,9B@%I4:MN;5SIP-O@OFF,=P)T)!"&:N
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M2^.Z-Y>YSH,OG@QB)E!8,H9+82Z'R$)V)7$4Q?,:+L.7G!#_)BGOMNNCWEE
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M>*#Y5F\4X!W?JL>@I=*>%"$O&114+)1D:+T%5;3AAJ9Y8ZL5"&O0;M["^\$
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M7.^-'MO.>MX&TW;",1"Y53QYED.*#$!XABDCTQ(DCX5FO!:^EX^XND\[NM.
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MZ[:<B]%<D*FY>&SIQ!U!@(WJV/2GZ9[EEKE+OR0_Y0>H+##,7[#"HHSPOJT
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M(\T,0R9:6$2I<>0ITYO=%G\8R4VN1X=%.<5[PRJE7*B2&,PJ^O1Z#E(A;T0
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MP7+0PD/0PHM *_FH\%N)7FN%7G,6%U%,&481HYXBCF6&%#4!@:HRS!@AB6.
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M2S56M+UXD@GO)Z]8Q%M\T.:Q+[L+XK+,L_$2;[7#SL3R/:>NB,\"%7=GC3H
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M_/Q3EN(J%W-FMJX)X+%%3-;SGGUSX>9M$S"FC'C<0DYC-H0D]ZGCA-4A0CY
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M!=&("\.0-88B+*GDW#-8 EB#""I]#JO0[P[BVL\9;7Q#/9W5=I"-[TZKU;D
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MF@]<GV*CD#, W/0[C5;3QW8O\P-E>.KU00'B<5&NL3YTVA5V=4J\J->$,5G
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MSRQH[6BXL.,U^QG_2N/MC,.P#LVLR%5KOC)CHXLM@%F_7 K+\4>G8EH^[G0
M6^ 5X=,3\,B.J^%,+? 4=$TL=WFAD>5YT]K#X*^#6]'! HWM1JI6IZI[@?48
M(_=$]NFLF!7LG-P!8BA8-YJH">&LB*;7&R>="UB4+BQZ;Q*%BB@6[/;5"8:/
MD](X'%ZUG",Y.[& _[9Q FH"XGK<C>4K@_80[/J7"Q-4SFK^RE%1;G?M<:>=
M6I<O \] 7K?.N\U6(1(M$EN,F*+R>=^:,%U G:/M%ERY)O]YP8N0_3/+3<Y\
MI/BW\30U_KAV]=;HZG(=^>T_*Z6_NCRSZ(+E.@!C @0,4&6C\<_I>XZ_"R,<
MXB/X'""9 (-?0+\!H4??V?M_XXM]!,V/[6-[G&,J94ML%C+??GGDR+CJM//<
M'U?X"JYCRYZ=#2U>P#)?[= ;C:N-8!(=&C]\[S+'W>@C&$T 4VTP*<#VZ,%O
M\)=.MQ4NF@!IE?D8*]KAJWN.C#]QP%$?Q"P6XZK:98?&0_9W)][J,B/(<=>>
MK3>VWX"LD_4,C1=Y*C*E;&6AP&>9]'S,7-F*LP9D]" \.5XP84^M-\:6;IS_
M'I6=,[E.T[9JG/34]_[?M54:C1UVR&)*7Y_@@VX3]<ZCSSB:O_EZ]"4 RNSP
MPQJ-P,RW.N4&=UJDLK?8.U&*.^.\3(R)8#W'0EM),@6U=$1$D2P>>LM\Z"UC
MSO#MD=Z_AAO=06=(V+S3_JO;R=;M^Z$V@D^]?64B/),0\*/[VGDL7\CN00[W
M'L*SWAUY*D.2TJ"8#$<\$O"XL;;(V,B5CU1IA]<V&9X]'QOSAD^Y!UG*QY*U
M7AD;(REJ3TKY721**9*()02D2'-FA-;&6FP2I\H(B_7<^,N-W7!FQ&EK/*I:
ML)8A6 >OCX*/(K#,^&",1YQP!H*E*$K4&,:DYX*GM4TR>T8PEJN1/$V8?+91
MP7VC%UM#8[DY:SJ#F&T-CL'$*+LYV'K@(H\DLWC"$_A6++="5M_-=DZHC/P1
M+3S\C,XK>;C:][-$3WJA0V>XV*V+>0=AT!WA^"7<$W ^/_<&5O.ALSZV]<M@
M?0ML>4#\RL3?NN+?S^Y+\>*K'?&'HU]OM&.QB[WMG8S\\S('.]5V"K?9FHA:
M_/ 5_\CW>=/J7%S%:!9XQVO^PM6^!$9Y!(.Q."^P>$-[H7$>NT4-P;0>6C!W
MBPIDL_P\W_ )(6@4T*C\T-W1($?0M&N_-<\&9S7>+(8WQT>),$8LU0@3Y7(#
M#(P : P*F@0KG,<N\;5-.2<E< PXUWW+H:$X,KXJ:$F#;I76-B?@<"WJ=-V=
MO;($L[:-O=IAA"X-6J !J7@=W_)=0=VSEHT"9YWV(L;AI-Y<C$(>\[0';HN:
M[>NCO56C%@JWW/'M*XNT%X<O&<.5D3LTS%^2M[P+L_6E\7_LV?EO@)U3_ESY
MX\@]>QGN]'Z[L5MV&\*JUD3S7.J1QU1)U'Q?NBA=-7L?3FSW?#B'VYT3V$;_
MZ'3/-]:S<SYPO69H6A!/@/;J<GC$:0>>!-IPL\_5ZK2/48:!.>YCOQOM52N2
M_][Y&P36]O,-'+QOXRT(O@VEP%']UIOYMK?G,"3X^*3IFJ XZXU6;%OX-!=+
M5U;Q>-WGWJ ]\*T([EKV'G.$"B:JWX4E\=WF>=^.?FMU_,@I'S^HV0-5+479
M5?#K^MPV\Z.:>><ICK0?9&6'SR>GHI,C")7??PJ&53D$R/"0,:"X_;/'QW6S
MM<EF:^RE-EO[X<'EU$&G95@';:3W5G).G,U90CDE4\?H,3;/^*#SALC7A'-1
M0<25KC?R.5%L'+<Z;LY!UNS)93Y;@NVP?W,?+3 (P9B>,E0]T>!A,0O^N^-1
M<5@#F93!21NG(@O%4,W%VPR-?I@T5.E-B0N=]D3"PE\P5/C/?GI;WF;"10:'
M^8_I5\D'"[VQN8KHKVZOGGX\$MC2P(U!0NF .'@,R 6ED4E>2RR"-U2"O3IK
MKOZC2,O=1,((Y1@HKA+"<&6)=BZ1*)P.AFG)12T23RD2^]LY??/X2 &@8NXI
MXII9Q /(A0M$H\2#)T&G9&G.5I\C$ME"SS'@O*&6H)OO=GI5"Z8?[.5CLWNC
M\0;<]1DK8'3P5IV*ED/(&,;05OD9Y<=9^!IF/WS<^+ Q8? L])W7@V[G/ *F
M?VSG3T>6\NN/XU.,RLGOC8[T*A]C]ATF7OJ&-UE\4/E%RG/O\/*O/]XTTGML
M']4#1U8MO,!9S@,<GE:,NAU>'95.#WMTB%$EVIS9TYS*8KM?8CFPG?1&B[5>
M/>W:EC5*F1DF1_0FS?/X[T$Q*0>P_<^YLC?HGEL0R8F3%/"5\JLWB_,'(YJ4
MRE'Z!;B0W=[P!"-_/Z_I78(VEE,=B?=)&,Q9X$YQ0@V-2J1(!4X_ #ZD%T*^
MO=C_JWKA#]FY/3B!]3[IM,)BT1OS"T-?V0V_[QX%35VTVJ,8M$9<2H$<F"\(
M$X>9)8%93-<VZ<:<Z(T;1F] J')X821Y59AA%((L6#:I)7"U;1P#7(*9!5>V
M@^V6..5ZB;Q44I][3@_EL%*&9MN#N=XKT92[;< _*8?L/AOP4"3?#U6PWFNO
MS*\O1\*&E*+@*+!,&>D\1M8I";,O(L>)@(UOP?R:/9[X1Y56W;Z\PC98BZ\5
M#O='FE^1I@UREL"D=/T$DC'AHB'68.H()RR"1!F*M0W6,!DEKI%L!03K^Y<C
M[6*B&AN$E8J(,X:1TQ0P326*D\#**1 LMC'GX&LA))NP:'X&SW+ZU_WA[">%
ML8:S94K=_K8_LHDGKRB&K=.23*3ID8E)H>0E_$^+E/2#P-G[J03@U'A?(K3;
MP^!%OR1,E_2=RDRTDR>MV7P$P7V_M)/5C<;KT5>ZXZ[?C<'8U)X(+.=3U':G
M#Q8P&*'-(<WEZ+2R-W5<V1B=5)8A9I'>N$MS<VZ<8I)J9L#9CE1;9YC2\*EP
M4H+&_.#H<&?OS2(DM6-ZVJ&*7/4]7WT:Q$=7H6'_\M,MNK_]\7)_ZXAK29/,
M41BM<_]RES6(6B28HB0J+T6B=ZIR%<9;JRQ--H&]YV..E@KAP=R08'DH.\3(
MX:+/E+O6B_X(BZZ-IYQ[CHBW C9K39$%BQPI%52RUBC*]=KFWFS3^MG->PR?
M)0W8Q=C^$03=$7!>QLG@IZ'M 3+>J::JJI IVC211CD.5J0?G),5SZ[9+CS$
MO7AU#G8MV[(D"5T92R5L,7$>E_<QW\RI,CF$,8X)Y7$N-L0?' ;>>XR31WFO
M;<DY/CO/FW7.IQ_G"C3[HQ36JWUZT2&,XDZ=45I#N?UP8Z[J.[J]\0G$W-K(
M>YTW+&#__5G-\WXW9^4-![XSGKK]\L)@(S8[UZ$.)-._"H/N!=@8O=C^Y4#N
M]7>X%]QO%_YV#,;AUK<CGV@4/GA$22;K!:<$V2@CDBXP[!43(9?LIYP<4L!H
MN@)RF!<- N<'HY3HJ6!EZN2&)=FIO9XY?25"?YUDP2.-<0)UOYA=Y1K;GR>;
M0V_Y*B<FU^4,)7U]G*5MVZ4,+RMK[QQVPFL6Y/ (K81@*WQ>!RQNQ6%P/!>Z
M#6\_&GH6_[P+AUA9K^=],#W[.:MN5$Y4/*:;OSRJK#FWS0 ^V;"T[(7 ]T[[
M:HNJ\CJ&9GV[W<F5+F%8E)GGY$H 1K62N9RQGQ,Q8(;".!5]7LED)2ST2EAZ
M_4$ R/MJ6X-A*66[8!H,-WYI75Z#SG'F1LY;@K<OXYB ^^HX9 RM$[([/?@W
MVUNE5*EE?;P:2_:(1AE,HS3),=#FB=[N#H[S$4-K5"=1<'FT7TQF4N2'3((\
MS.^'>-X?3S"=-\&@+?G)U914D4GPTT!7AV9&3K,^J^P)V-/Z'1".86)L ]X3
M+H"YCU-/?D')5EM=/^B]#'4K>527#:J*,8CG95&5-" [D?U<7C]G19T/' @@
MZ 9<$DJ23U71@T99/Z[9.3^QL''Z4F=41<C/J]+' G7#>N"0G]F]'#[Q"H$7
M2>":+(;Z40E4J7XN9VF=/-,=$/OS0=<7*+BZ8[FJ/31P0*V&M363C^P<QVS.
M5*>.ME?RP^*_![&<FXU48V)@'\JS_AH]:SRRWFAH58*RSV&+TI-K7*%Y[>SN
MAO<KH[CQ$>,JU59GF(GU/P,8Y3!Q#J]/%D],5UK <^\20L82<XZY#5@S;GC4
MBFEA%(E14 L?%4,-8U49:N6'NBSGT>-Y9'?[RY'@FAB6+(H1*\0=4\@:'Y%-
M4D@.7@8LW=HF4;>43Q39'^7SE_/N;\T<[ +ANE%F2IRX-YWX[F)F5,U56HPS
MFS15P1!#:7*8@:5?Z+IFI45<,_)WQB7P^Q?M&'ZWK:Q(5W4W'X9/K@5D 0$Y
M\$>"*1:5#[E02X-)KP@R$HQ[E@+W23E#<G*=G'=@.A*0:K$SB)0MXSKPEJCP
M-:%9+:1Y79@5/H!#TBV5*6^^[C5KZ5E(>K[O'G&I-%8@.$G2?/K)$L!+DDB2
M: !Z5&)$K6W26ZK^-AK[U:;7[_3O6,NW-.$HP'*0G_^QVABOBF="K(5A$6'8
MV]XZ<M8Q8R1'A J,.&$$N8@YBM0)D@#B+7=KF\R0FZ%DF%%>%9%-$&F,*]$F
MK-1B9O;RGXM9,R<RVAL5AU>G1'<JTKK?7C6#-S6\W%NB#HZ/E'%2,$Z0<K1(
M%$.62Q K2335T2OA*5@O[#;KI5=( :;Y<T8%F_!GF&X_J JVJHJE;'/GC6P8
MAAU7NP\]B6XS<WA<+X3/)XDCZWU"1*NZB6X\ W?]KGD:2]_ZYIO28TN[ELI%
MI'+_X-T1+(I@%AO$G(U@,AF&7*#P*VQY01&23!"PZ0EYLU1FN;/]?K?I!L-"
MP7\V_W/(KC6TM">=XF%0?NBAUM[:2Y0L^/\C2S061((=+H)$7 ; .\4E2E$:
MCE405-H?>&O=>)Y+M L!46/GKU$6Q9"QJ<0;VIV&;?5CMUWJID8<1(->7 <I
M!#%\9.'*W$WPTW4OK]<;9+]NN]GSF6#I+\#09EW%O) D4?CO$9&P)(9(A*VA
M8)@+BIQ3N919!:MMII9,<_-XQH)4'9(TAPN1\ZSS"HP/FX<[ZE5<#6 *I.?Q
MQ6<.'<>;3G<;8,GW#R:MQ6%&3RU#"\G0Z?&1,3I@+R32)(0L0Q%IZ34RF+FH
M=; TM[HBMVQS($.A+,0\NWW,'EE1J%695,-,K2LVBCN39]S.B3'*A\"+IX*]
MC!. JS*1VR+(\2I/H1@;Y=!J=&7)OJM"/!,T L/H3\6#8<$7*WP3>?[NE@JJ
MDY8R@90Q+L#&5T90A9VC)I/ZI^1^  772\MFW*Z_]W:&3!C#;%!['/?3_J#?
MZ]M"J5AF92N?W\5PT/D]CN8G_,KYH<,\IX/C[_L''\GN]X]'PAG)0/,1.%]@
MIF"+D5,Q(BRM-1&\?9RSV^8X9/\8)XA<S7GC:Z=_Y5B-XX>=K_GL\=94D7L)
MRP_D8[3B=2K(#U-!7G\[TH$GF;1 DB:#N HNIX(XI'E@WNC$HI!5*@C*,#R3
M"7)>9KDQ)!T>GM97U,S_'MAN3A,!@8#%$QN-3[%B1LZI7KV!.RT;2N<)1 3\
M&_#9?)TPM)B4?#_2#BOJ/$?2,7!HG+%(TZB0-EC)Y*U)%DR(G!Y^@Y@4J("M
MM/#43(H*S'6G/2TKK-2O5DN4,VFN%2H.>18O1SM_3A?9:(Q.QLWHF+040/0B
M_#7'=*K'9$*0H<';22EF Z-LEF-G_6X'89)JHS%G6KG "68P&=X3DS+W@0U1
M#X.+@IKY!V$C1WS^65A] K:XF;MWZ@'))+=>*\2#L(AK$,^RI7$"ZV*Y253G
MCJX;L_U<YYR 73O[&N]H/W<(ICCV4LO(A!6<4*HMDR1X"GZ2 9#S0R0#<4%S
MY:8^!'LX =K?WCU25'AB<\!&6Y B&PW26#&$L<%""AY\RD>H-Q][E*R0JP3'
MZYA641Z5O6\II_!,,Q4]C5ZPP+'AFF(MF.9*.\)Y"E/E!)A-T<^)'^Z2%0"-
MO+=:CA:0([:[_?I(6:J"9PIYEYD\' =7FPN-<(@V\* YEFIM4VRH6TX[9ORR
MFT_E[U0T^I-"4T/0 XK.P9<C&[$AB@E$6.29\0/V, L;F5=)8U@QD"H/>QB]
M[1Q^JY>SC&-OT*KXFH<==P%@.A?9)JH.Z&_SZ^?B#25,$,XB=MIRZI4!\<F9
M 5E^@M,W->E;%&9J&5E(1DX/CTA@6&BG$1$>]BJ<P!:W&.>$C<AA)4@YMB)L
M0R^<ZC/*.1P?.BR^-\V- 04O7*+.$.<25Y*82#G&41N'P8,+KI(5L''TW"K@
M$;CL-ML=D)/+G9+AVBO6<;=WTCR_BOW\?KF7TUC;_6X'WJQ]7%WR*\=ZI@3F
M^\>CD#01Q'*D*!7@XL-^I)4$(],J,)"%\8KD^*^94X(^CO;D\X-8<<_\./#3
M/#N+H5D)SO5<^BG"^>MV4I:)ZZ?N-:W@[;2"_*72"OZ0)G"*5M!$P2RC$AOC
M.)?*82^H2-KZ5/H)/&-:P;\&W7QT-R8KO[$UPY >ZL2&ZW'_7+'4+(6*N<QF
M: T431Z>&(_J6% O(^J</FC%S*P.!FZ+U!%AK< :QQ@=5T(X$R/58"6HF+27
M=.S?JI%_JV[IB3AZL?WS_D[[(';/ZAC=;3$Z?)0M^^221E%%!VZ'C4ASL!!8
M,$($#V8!86N;_=B^H:;O5J2^!LO@Y>YUODX6?4TP58=K5-6W,8D,F>:FCY*3
MD EL S" LX')K!.2TFB--<QQP8=V)B'ZANKX(DM[Q2S93W\,9?M#%NV_AM1V
MN5[^]6BX5=UH;U:ZP+(92]?0G,"_GIQ=LR;VMC\>18I#3A9&-"6%.'4$61(\
MDL%X0K T":=A*'C6_AR9"%<I>>-ROB'T#"F_<ZW"1%W.#:!7Y>4-LZK&9:'C
M+U<]'B;JH88U-<V9HL4^H.5QB0=/%2Y-<Z/?,6>+"&D4252*F#F^=$ZK36 (
M:QXL!:^[\K<)I2/.![I8FY(*%$_B?,BL?:E%A'E_>^<H:IYT4@F%S/3!O2=@
M&IO_S]Z;-[=Q9/FB7P6A-W-?=X12D_MBSU.$;$E]Y6M2MD6W1_Z'D2L%&21X
M 4(R]>G?.5E56 B0(BB*@JCJ:-L@EJJLS+,OOV-($M:(P')FEH&=Q3_25O/>
M#]]U@G.KB+#&<>F<AI*2+(I9IXKQ@@$3@1 4[&/5R9?ZU(L^FD:\/<_YY<GS
M,0XK> 4T@85]S] ^@!<G0P03]Y-A[X-?BVXD^N!94B4*UC)GC!=35S#$QTDJ
M(4DOG'&,X6SI*[IM6JFU8OMV?7QM47/MY%W AZ191>9J?:S+,ZW-B)AFCDM[
MDS<X)6=;X076!/>BJ*B5D< .P5$J S5!60WTF3\"6--7+G\>\COX_3# 02!>
M),F%%2PRS<0!/9)B,LN1"2NI>?!87R6V*NQ_V\W;HGM\YB%'5TS_Z:JYV*8!
M!;T*OJ^T+/;?_GH;*GAM7-?+!KRF=75'+2369?.JVGS[X-6;7*?A5A);(\UF
M+ YB>"S+X)\\R.[)>2MV7\Z6!E[/OU:7=Y'9]O-9TQTU:RW2X7R\UO)0\&W&
M:PTO3S[R97SISK"^-)*PBJ02QV1Y8$H#'8E?:4&@&TB5M3F\<]-^ 2C^QPV;
MN$"@>1^S\=B,J($Z'$N9LQ!B*$ZH<NU)6U<KHK:P^-G?;9-:)P_G"@HAZGO&
MWLS8OZK]IU'N/7W!]C_\!392/.2V<&&M(LEXBU48EO@B+8E,6@[:2BB)>0I[
M11IT7%J0R4IBMXH,N=4PNK*$^(43X\<CL+81A+4=3KYI,/=&0"+@I0M#7INA
M\!4IO>&L9KK\*EI[!S!? <@0?G,^5'8#TGS7730[J\."%I#[RR5WB.\Y[T):
M=LFG<.UA(X=6U3"666%NY>%B7#A.[)Y+.41FS\N#OK U"LL#VTP-WF@Q[@M!
MO? >M189EWB,@A6LW"HW09P-SMYC\TM>&2E\]5C:\Z:Z E?U"8-%>Y?L:Q W
M%UTR<.6EP BH(\D7[+D2CF!K RF-ST)I*?HC+ID_6XI=HB3)"+'7Y:KJ40$7
MX6$U?%N/"Y&8%N>U 0FM@Q>KHPVJ/ *)@ZB"0.C84%I+&^<1^^EJR+X-T3<L
M-@^/=;(KS3H;N;32!JZ&')YQS/,]@G#Z!?X^G]R/#HZ7B.ASD@?,;0'BU&Q
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MD7VB(@57C&DM?I!RI'O1U_#=I=(Y.@PLZJBT(, KDDAK,O&^&.*Y*=:)J%4
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M@*&4<0N0PR;CQI:%[1Z_/SF:^)0[ZP]#VV!/P8_&FUS%9G=#'HW?+]O9S27
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M>E>Z(*[K@A1"Y%Y*8DU&8%J524C2$!ZXH259S1TZ\?+VD\T]R/]7!O)OZ3T
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M:78NF*F:*T]$(1E(*FZPEY324I<ZE#!\[\77S-1[]72E)_[2'</K[#4</3-
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MJ$O%3V?6= /6CF<889[I= 2Q6W!5!#PE9\8\S10%E-NH1O6F<E]G)V*MM+P
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M1$ W+*B%W;,:5 [ZPP5P6WY=(WZ]0N8J;[G%W#A'"9>ETR08[ZTS 1-5D.I
ML.;;;U>R;F7N7;#PDLP%BR&PV/T$LQ+,?./!:M *>>=+S &"Z6VE/[0\O$8\
M?+N\V\K<.V/8)3.?EEA1JC#2K! (.+1$QN("^5 64K*@0/!&,_^'BSNOWV%^
M9CNZ1<6:F_R'@['N/6 UD:I (H,E<X-)++=8S[E-V;K5)7J\ N">VB2U2MRM
MRX2C9<>)Y)XXSV!/%'&@R7&PP[2,C=B+H.!':17>V*9;ZI9S]F^%B1Y'DFL+
MJ2VD/G!S]:MUZI^A/^A]@>MR+$L1"N8Y1D6RD ,52.L2(S"9I-->$.< 7-EF
M26_K9*U%UQ9=6W1]F/YYK<)Z%YBZ5$"O8)QSAA'1QB/N-4,Z>(F(4H4F6&#L
M0E18Y6VUJ&HAM874%E*_T>/^QZ"T55@?!ER7 \$,$85D"HG@%.)2E4@;RI!S
M):.>"N&9CPIK06ZK,>DZH.OW-Q!<^VYC!Y-AY_6;MZ..CF70XR\G^I.?=NOI
M^/],NI^ 9_KC3EJH40=^[8Y[L=%/;.'GAZG9WXKKT^?&IVY>G<DYX,.GV+RK
MZEOFM3VI6B)4O<-RTZK+>$$$DJWOZ@2T?NO;[[SP9CC1P\M,_W2S PC'4O=%
MW>\#Q=O8A^Q$CU,SI-\&>ICZO.UVA]Z.!\-&OR1=!_KU+N=[*G6Z?1M[H*:U
MO!*5 0R-'RZ>SE'A!*5&6L&X=4%28HL8AEWJ]&$"9H;A!ZI_:0(SJW'YN-MS
MOSP[T?UC_[+?U&YCJ7I]/.N]BN@CQ=[O;__U%A\ GNX?'G^&,>&#OSX(K$+A
M"AMAT\2<,U!1/5?(BZ"M*%1I8^DLNK7<=/Z_<B/,__L]18@L]E1Q:;G"7# G
M-?4F6,TQ-84-IO(9T3K%"7YIK9G;VO2]XP]%R;SS(#JQ507B8*8@@W6)2EE:
M4QA-.=-71"!&)/V>+?]!YFZW_'NW'.9TN?_7!VEUP(%05.B@$2\+C32G'"G'
M"&86V)SAM.7+WKU&RR# ],4V>9NYL:4&X7IY%F6ST^-TX9X>VI,L:!C.DB82
MC^[U\HVUR(9+A[%?) B56?/.WB!+$#,9@1R+73W[S0<2D1^XU7DQ&4^&OM'2
M+PYS-#&G(+&2-I!H(;=K-9=7R+5K"?A'TF7SU= '/XPR.C''[:DN/'7:?2#=
MY9W/RN"5R)/;O"Z #BN,5X$ICSWAS 95"BQ\T-XJ)PK-/[Q<=23Q<O_%(MI,
M%S6M:0*9T<YD?#*(727=H[?EOA]GGM/]W8^7^Z<6GO478,[+#T(3!U@CD*/Q
M'*&0!BFO*>)8%TX9261LB;P"9:I.98W>WWJZPIWS*577O8)'D]1@LPLW $G%
M1L,'4]Z.#7UG]R84 %7U#*@JH8OS(Z#RQ#F;G?/!!:#09O4&#RIP-D J$R,.
MHW\)B!)MA.I%AR<^]O,%N%HC<CR8C$=C&#@8+?..A]#][!WZXH>#EDXSG1)X
MYP=.C:#><Q1D04#Q!3HUM@#Y6 B%P>"W@I1?\2NMW&"OI"$.5%L2,&=,&0+B
M51:,@%8K,"[3!B]YE-H-OI,-MEZS A.%2 P4X;KP2!?!(NHU9X$SHDO0>/J#
M)21:H0 MH,]@MA65T@(JIX\F;:7OD*2>T 0D<<N?5!_O'6LG9Y->ZGQ^ '@Z
M[( R#DMTXONC+LCHEWW0#_W"C.^VR_<;>^+=I.</0F-P:6QS0\LC^W,P&K5=
MP \_?F#.8A>- &)Y0)PZB13!&&EL? R)#LR+FW<!7U/OUS<:@R>K(_F,1E&G
M:-+X(-&XG:/Q;J9QL"CBYX,^3&^ST_?C9,#HSX^J=SAL^1;.IR@W;A[.MUAQ
M-\W#KW[I=W>-)EM$?M]C'V"P;(N5=]./^TY6MBS$8QDLWI+J>H-]FJV@;[GA
M\Z/J#?MB,(0_^YUGDV&T]2X[AT-X6"_I.#_QLKSM#SV,(EK+O^MN/UO 44_R
MR?.V\TEW>U&\(+ [T!LP,4#A->/.&V\GP^X8C.)-&$@2?H?Z<[N.5ZUCC KH
MO  5I/,O[X[;5;LRC^AG[]?\F^[IOO4+QF4GVY5$M1V<VRY8]Q0M90MA-%?6
M%HYR7G"PSDM"9<%E69I@;'1I$?7M(*DWC2.?Y_^9=,>78(SW)G'%7@V&<10[
MX_&P:R;)C#D<[ _Z<1Q#,';@DI<1LOQH_.@=7#EJZKQW1%^<[)U^).\/]VAT
M6AT=OOUR].XEV_O]Z,O[=^]/8,R71X<G)^^["U%39W^?'KU[?GEP^'</3'JZ
M_^7UR?[A_LG1J;V V?;>G[WHOM_]X^3@]Q=G__[R?#F'"@<?K*06E4+&DI7,
M(^T(1H07 A?&<A?$QK9H.SJW^-?B'P!,*;2@7C@N N?&45,01ZP)KN!"@SK3
MXM]:X]]2FE,!LDN&4"+CC<S'DP9+AUPPGCM/A=> ?VT3U!;^6OA+^*(T@R6Q
MI@A<QR!K3D.0E&E) Q>NA;_UAK^E1H+46*>%004C G%)--*&2000:$LI/67<
M;6RS%O]:_&OQ#P!&&*L<QV F8<4#Y3$EFI?6LD"U\SFBH\6_M<6_I:0A@[T+
MG"A$B;.@_H4"F=A7%7,;M-"*EM1L;,M;3G%_!(VB'TW1J>@QG\S<[,>ZV^_\
MHS<87>M8JZV=MW L>!-/H!$TQ/ ;8P0O"BX9TYP9&8B+_8EH"M/!=9@.7H6)
M,>P2?EL$QZ\%ZOSFPV#H7\<H[M&H&V#AXCA'0 4'X5!_;A'Q1HCX<MDA:+PP
MV@6"L/ $<584H!%*@F0PH@P1+PT8Q,L5E9;8K:V(N2Y<?0.FQD8I+JRG7GMN
MN#/2!$HX%V#O!:G5-9BZY>6'XN4EYY87U&)"&%(AYG6)8)$4M$"L4$P83W00
M86.;MW7E'QM'WT1.4RH"<R8H'S#'/FA)O7&>"!N<-<&V<OI1\/92\4."I;!8
M(-A"ACAV&$GF*/+*&UMX(056&]MD17?;5E(_";XN<,F#5,%CJ[FQ5C/CE-"6
M&%HR(UC+UX^!KY<\$ERI4I;"(<5-$0^D-/R&"T3*@D47>\ !^+I8$P7\9RMQ
MO43X,9LPQOGG!("VF_6=QA[]N,=A'N@6=_/%<'!VC82A'"P\?@43'K@9\CW1
M'+S[1<2]98\$H)["S!5(DR(F[H&28[R)A9TH=4HY%PC= )-% F7\ND9=_EK^
MOVV5Y]:]$[<+ "VCWXC1E]P5)2^XQQ(CX1E&W!*'-+4E8MSH,BBM2:DWMOF/
MJ#XM>Z\Q>]^"IZ)E[_5A[T4YSI176#.'A"B!O3T-2-L@$:AT@1$FA:21O9=C
M35KV?A+L?0L.BY:]UX:]EQP7LBA+@15!04D+TKL Z2VT1YAA8K&EI21\8UO^
MB#]R_5IP/QK'10R3L)GP8_TVH/ROU3%8CP"*'XVQ>]QP^3#Q%2T>?A<>_K7L
MMA#"* )[B#AQ-'8)%D@)S!$N#!.22.V,OI5 BC4*JFV9_Q&&8;0L_YTLO^3
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MO'8".UE*X62+@H\#!9=<HTI:7I:E1%H4#G$C%-*EI$B"F4R8(B08,(<+_"A
M\&>,'EO/(CN-S5[1@/V)'Q=Q(86AP#R.6DZUUB)8;RD\F!C0'ETZ+B+U<=%2
MH[DV!7@-H/)HV7,8G/=>X(""HQ@41FZ1P28@!K\16FAAA-[89O)6#Y&^P3V/
M\PCYYX,$*:77L8NV\@4O*)->E<'I8$,@2GO?0L)C@(3ER#+81TYD0,+X@+C$
M48\B @4C,2-&Q]Z6H#VUB/!S(,)-0DHT9UY11:UEW/%2ET9R8Z4JBB(X:Z\!
M""T./!@.++7K$ H7CFI$I/%@17F"=, <<08&,C=:*&\WM@E5MQ]CVL+!DX #
M7WKC)2;6>%Z$8(17U@GGM'&.2=+"P1K#P9)3)7BCHZ:'B"$.0""PF&,26UR#
M94@]4X&5MU&^^-[0H*TGU-83NC<LO 7W25M/:,U!TRZ[5Z*);"4NH](4>UZ(
M6(? :(0+)FEIJ.-%V=83^@GX_Q9\)2W_KSW_+_E2.%-"2RF0D(:"#15*)+DF
MJ.#<XE ZIC5K^?\GX/];<(U<X2MM*Y,\),,O"GP5,)$%[*+FQ +#.X] U0N(
M*UWBDJN26+ZQ+9;/4UI>?SJ\_N-^CY;7UX_7ESPBKBBQEZ)$L.$&<8<UDD%K
MQ /3)6"]\V6Y9KS^,P:3M*6('GH7UC_.I 7%[P+%XQ4]G:R2C%B,A!,%XI0Z
M9+ -R'JP?#%LK9;JU@-*'CH N>7^1QU2TG+_=W+_DK_#">$\#A1Y6D25R!&D
M/#=(2D<%"XX++&\[=J1E_C5F_G6-'FE9_GM9?KD,D:'*$(.$)+&)3.EB<RB/
MC#$$^%_9(L0P$5FVI<A:SE^#0)&6\[^3\Y?\'T0+55A%$%;:(JY"0$H4')E0
M2%U0*6D1DPUOK>?C.B;;/+DR1*0M0]1F8-X3[@=");7>!,TQ!P/!\%C%T(+V
MX+&@@:4$S&O ?9MW^0 "X>.R[Z<$5<\9S9$,(48,$Q(S!Q@B7OO"<EG26(9C
M1?)Y6X>CQ;^G@G\WJKMOB31&8"^"X9*6FF )5C K*,;2&7,U +89Z.N$A$M^
M,%4X6Y2V1,Z4%(QB9I"QH42<"%<4DOA0D(WM'ZG,VV)@BX%KBX$W*46)F;-*
M*\&IX)Q(+:RW07$)OQ4LZ%8'7&_D6]0!"25..(Z1QX5%H-![) L 0J$5-]8'
M+[#;V"Z7H:_5 5O\^PGQCS%;^%B?$.N2"TF,#L('3HE0ON2TM8'7&_^6R[('
MZ10S'#'B,=C 3"#M372*!H:)4TX(N[(UW=KBW\\8,W9_!8CN.(%X[5;W^E+A
MY@NPWD+A1G$PRFBP(3D6F/'2.".D)E8R+4GI.<YQ,+0^$:-M:94U% [/+_X\
M?#G>>Y,$!%P+U__UP7$?@!P*Q)4CB$O"D:2QJ((GGGE6E):36*#S)ZJNTB)@
MBX#+"&AL5(5#4;)01-> Q+0,Q!1&..ECB?86 1\% OZUB(""BX([2I$N)""@
M8"723MF8(5UH1T%U#F)CF_U(<<X6 5L$7$\$O,GAN#!<,D.]IYY3)[1BDA&I
MO1 2/J+7 , 6]QX.]XX6<2\HXD+P&!7&@+XGN$4R]JQW+):@%L%($ANVK@"^
M=2V@TZ)?BWYWA7Y4"THE]J4BBJM2*:FH=AKSTC/NBK)%O[5&O^-%]),X*&TM
M[!;L(UB[FB))K$.RY)(['BC1<F-;_G"N;%L]K*T>]O0"Y&_!'=A6#UIWV/R\
MPEU8$$>E)1H)@L%$=H"8NC0:A3(4EC-&M:9M_:"?  'NSAW6UA1Y4)9?\H]Q
M"0I1K"!$*#:(4T:1\C;68'?844IU4<2^WBVS/S)FOXGS^]9]/RV3/RB3+SF#
M>*$D#Y*CP!F80U839)@3B)74!%-P5CH.3%[^R#E@R^%KS.&W[M]H.?Q!.7S)
MX>&44!PV&5'J%.+>,F0*7"*EB [.:Z4ECAQ^"TWHVB"OMC#8XZP1L/XA42TD
M?A\D7JYP9FC*G7=2(RPX01R3$AD1,/*$TD)9Z036MQ[[]-!9 2W_/^J H);_
MOYO_ESP;F ;OE#$(@$ B7E"/%"\L,B4.QED,5B[9V%[13ZKE_Y;_;\,GTO+_
M??+_DM,#$PN0+332WA6(NU*AF/P.<.!-62JOO0H;V[R5_RW_WXW'I.7_^^3_
MY1@0PH*4EB,:?W"#1:R7'A M')"9<LZHF!KW./B_K11&'[!26%Z65;$];1KU
MK2[1>LN/F]29 "6#6EWJ @=N U&48,VH,AY424U"RK.^AI^]S;-^"''R984[
MB9J2DU([1 CVB%,9D)%%@; FF%.&@V4"S,G;3;2^%:YZ')4H6HQM,?:&.KHF
MH*(7RDOB2FXH5[:DN,0<4UXX3[\"LFT]L_5"VR7GG226%\Q+Y S\X-HPI+ H
MD+>*>&X(-L1M;+/ENA;?6]*L1=H6:7\NI+U)ER2B,8\%M@%MN<96%SQPR021
MG@MB7:O-KCF^+CE'64$* %6+"J-CYQ30:[4H2U0$KZ2VMI1.KL375IUM0;8%
MV;L 6; ?;1"D]*#Z<%]84WHCB";$V (;K5J077.07?) EZ[ O/ EDK'L!*>J
M0$HRC&2AB91&4AK*I^4R2&[J?R;"@O^Z[J?M>G+[DS/@()O_CO36[4]2Y.CV
M_\)E]>0JWN%TJXPA?>>#43=>\\O0]^#B3_[7BZX;G]2\U;BQFC6>W:(-3&\R
MOOJ6QLRLCU1__Q!!XYAD,=WIO&"-GW&XB?L*IPJP;DOCF.>:8%4H8T*A8_(&
MM[[\0%BQ4=]U,JSG<*Z//3)#KS\B'6"*O^C>A;X<;?QS;B7.NGVTL/*+BY:7
M9OM_S1!NG1ONZA5-M+)Q]5U+]Y[IX3$,(Q(G85L+\9RGD]&X&R[O?(/*E1M$
MQ%8]^(>@CXP&RS_O9TRKE^1_YYCZ%DY.YT78;G=D>X/19.@/0CPI]?U1PHK7
M/D67/QN,QJ,W)WKH?],C[U[IRS-@X-$A#.&W'@B_!Y=81[7$^GRP^Q?9WSTB
M[W=MO :_/^Q]/#I]3MZ?]L[VZ.ON_NDQO.<E>_],X??_/L'V[.^^?J<F!Z?P
MS-VW>/_T[X_[7^)X7O<.WKWN[AW^?7;P#B37[R]!VKT^/3IU'__]Y2/?/WS[
M00?'B'0&":(<Z/3"(E-$[XDS07GG!64RZQR O=[MQ!3:4M+2:6I$Z00O(Z[8
M$OZQ@G/)M;0;'0]ZP'ED[N'$;VP_WWOUY\'1\^>=WY[O/W_Q\O!-9QG@FWR^
M /9Y8[[]TOE!!LT$MTXHY@G7(F@NF%'<T;(4FA*\<162J/6!D3P.T-L&P[02
MOX  ]\-XU<9VTMA0HN5.D]RO!-H'G&)ZXB_=,;S.7@,HL@+: 0T4.#2&N+_J
MP?,[;R9G,(?+ZTR07R$,\D==6,7^^!?*D]AZ( G^LM_9TY<=BC'?[ PF4?K.
M5/"./C\?#C[!UNJ^ZUSXCG:#<P"QSOC$=W[O]KQVG3>VZV&%1IMQH;;2@SHK
M5Z[S#PT/!+1SWFVF)\1D;(I_3;?$*]+?Y-?_V>KLC#KG>CB.9^EQ3-K" [-N
M%#]Z :; 9>>-_^2!*?OQ@!UOIM&-1L#(>72-:Z8C(W+UR.#FDZX]B8\83<S(
M_V<"7_8NZ\&FR4>[(N)W/.'_VNRO>D=S]G,/7%@*N/_*I8@7OCP[F_0',,NN
M'37796D!YB[<:;SX=3T3>!GO_#GH'Z-#/SR[YIH 4![#O=W^>)!>,]V\K:?&
M$)3>$D-0>A5)S.T\7#:_\X=I>:N/.WHR/AD,4YWE>%L7MCI%G !=Z,YX * 6
M?[W29A]%E6.T8+8[SIG3 M0<$%_P0P4EN=%4&8<%U3B;[5A\TVR?ZC--$; S
M'.K^L8_ZS6^72RK/SH4>.A"\Q@\/0OIVM#.=XGRAC/[D#+E!DD!Q"&MDWM^W
MLO06'QQ:LG]X_'G_RUNVMWOT@7J+/2\MXA:'V$2>("F91[2P18SWI;"OL5;:
MLJ7> >;I11K)I!&IQP[.SN('D>*W.OO_/WMOVM36LF2!_A4%K_O%O1$N;LV#
M;P<1/@>.'R=:PH.P+WPA:C0""=&2,,.O?UE;8I*$S2"!!-4#!PMI:^^JRE69
M69EK=6LV3U*_U@&#<+'V ^8S+_9J^[]M_;7NY0LC *OU6WEUYM>&-C-<GX.;
M:_JU0 88:A\>LQ=KKM>U ;G*&VI=&?MQY3<,]NV@ED>B%6)>WM585$.:!R96
M"#'ZZ'#8W^5+#)-?M2]?M^'?GZJ?U?34 '<J;J$,1,-^O+RC@!>;9VCXEORG
MX]BK3*DJ3AM=%J [=H[;W?.842JT>M$/NKWAI0 ?^B?M =Q5O]I[;E2S#4.W
MRY*V=X^'':\37"%$*A3A0DOK''4^114XEM*H>V<+9P0[/VVKG=,^X#-\S/-1
MT&<Z^GR^V&K^.,W?TV@>PO?_V$M:,":U1Y@%FH^Z*;+:6 0O,2Z2<D(Z0!\\
M6:@ZCCZ]V,GJ ?9R+BH+22<#B*-'1G(3=1X"("\42$V#BE\%4MG"7PD>?K^<
ML@%<=01I^?$R\/C8&^2)O@*@[%#?\O6/(-YN7_U]!(Q5L_&EA<-B^=F"6P4P
MA>_IY"N<QG:[<LTST]II;1\P[>97 +#EOW2/T-5U.Q6F]2^_]H\NX,+J\#8S
MDE?+\A8<#P$\0_J@/=S8ADYAOC(@:,Q(GWHQ@I,\Z-E0+>+KK35_Q\WMM79R
M#+_^!,@&>!]][X]X%'NV#1?(K]? S^S5;DT@3(A'K3.TWPHPS>_?*/3LL*WF
M]AYF&'8+;1$+TH#C$QFRV'MD8!<QE*C$.5Y9&^S#C(S,*OLHOTK^<>(]44YR
MP4E6XW+)*2Y$)#+IR)FY1_+OT3M2]>/;<#4,&2;(K5THS_S[<-([[<)*C$=O
M;NOQ%.Z%;*UO8/@NMK5>WV-8F:P'BB+6#G&%)7+!2Y2$9 I^I$!AZTG9[LZC
M[?7'<WU@J]U.9<8!HN%LHA5FO:8MY=,KW%(^5?M(1N(*(RL4K8(,O]^*/RL;
MRW/9/P9O+;4 O.$Y#^,@V_Y-5_A'%WS*RQR'[YZTP\C9OKQ2=KHO'=P*Q4=@
MWXO@DAQ5VQ&\6&TK%C:B"%,PB+T.W'CVN>&-^9SS.'_M]?5Z.1MU GL'#'W,
M_G6SNO%!WN^.*I?T9A VW#K %P>O<Y!WE1SRY[BB7P,'U _):FKNO-;)[SEN
MG^>OR$-Q?:EJL. =<(?VO'M2\7?DH,3^B+4,2?D3E1G<Z;\/KS7FO\=$I.=4
M6,<,3SY9:[)+SY6E,A"GI_OO[!(L?[3:88B4[A=(Z<ZOWW(3*:L6-%@ 1UO#
M .A3]62?KA[LRC]'],VAY,U=TK-ZT^]%:C3AF"-E;=98XRSKC"?D32!<.Y>4
M%2MKD\PZ_YT7]L-6A:=8$@?N/P^1NR@<U5YS".XHE4+B.VI RJIX[E5Q\'DO
M20*>#CA+RA-8%3!CR&@.KI0Q@L ?A/9T98WB*>OBW="9'F8\AG[QN-MZ!+^=
M[D<(YBHL:PT&X&[_ Y"P?^*N7OCG+<>[M@^^^PT$K0 ^8]D$CH_G-"H@AX^#
M\^UB_L[A/@"N_"O:R*M#MMIH:;^2'7WX-,-=?1ARA9A;&RX/66*K2FKEF"V?
M5YP,NKWSO)U>I]5NY<&&FVD\ XMOP=(\!A>O<NIN)\MR(O.H.\C)S';L5X[$
MT'U(MM6[7&(_;?LD3HW91K[&T!.IW,:\'(^ZM[ZE^I)J08+_D ]6<K1[YO/7
M76?*I@8@SB<)6&T]9H';2)P( -\^!HN)M$+>-P#Y%8#^<0> ;IP=MX8+;QA^
M3(T^LB/]IN'S!ZU?;.]1EXS'-"'A<SM== 3I!!B:9*1.)&NP-#GK-1%R5('(
M:FWC,@=Q>W&6\/^><Y##/^<$]>!R(L:S.J!)&+FH(G)8>6TA_K=*/RS\%QI'
M89)A)@7N-=,Z6)Y"#BH=;(BNA/^+$_Y_WM/2&\E-0!#M4\0ICTA'35 T01@I
M"7&1_2K\7ZU]G=@98%?HQ\&@71W>0)#5WQ]N.+](X]T\H[%#D8?+@]F3?G[Q
M\J-Y,SNM=J:3G@=OITH/7J>T1UL'.-T0J56OW-[*%M.=>6A!S==/GUY9^<QV
M-8-Y5>2'>W<CY^SA9D9S_<L\\##%W,W>\HWH?'A4VNK=SGN# WT0_>!F'KW=
M G]ZY/U<?=W0^X'+#;\XIPSB_^4LPZAHH]T]'28('A;A&:N<],E;!0@9G;.>
M."Z\"$)2CJW]#:\,FYFS\FGTH)_R<U9EEC">E3V/(KZW'.[E>SDD]5S*?[ I
MZLW#O=SA;P@UR"1F$$\8YU0IN"^&!BF\<P:3E34MIF0!1D?V#W*/NRF!,0'V
M#1.K0X"[6IOYQ>%RK>"@>C/X_[4^.#9PJ<$^K,[N(<JM K44;3X 7!V^]?(2
MHP.:$5*?0IQP^S:N$KOY4Y7@A_IW/^?H?K:Z)_U<UW5=2I/]]^LSQ^-NMSK.
M'IKK:NW#8T^X,8LL"NR==8&[F#37BC%IN9">"$'O>\)]8V7_:8\ST Z/K+]
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MSOGN!5U3!N[U0=>CFL +=#TS='V^$31\/JU?;)[N)8@3,-<R<ZN \X&305K
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M1P5N'5]9(WA65(!%S60V J2Q'VW/[U>G-B'^C.WN<5:AGVO#2^%#N2(S<@D
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MPK_Z_1A.VG$K33?Q+[$_@._-$)#S.]L /OT/I[87/F1:^-;@O)DGK@FW] =
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M+3Q#*9B<3'?!A92]S44BX2UU>:4N[UZDC4^#M=*@]VI@;\(]A)@ 4\<Y,BI
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MY-X)1G0!GK=ZB!-:/ULA'H7:>2NVYT)K<B\ OF\[[>*MG5<4<EXNBO71FB@
M_'  WAX[XMD\WQ/*)?#Y-.(Z)@@YDT,:UB3"2H-+F"Q+R:^L\56V&#VG+P_
M!7C>6,A9@&<6P'/[M N )_C$G T1*:,4XD1AY#C32$9!DO&P#1F1@8<7X"G
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M^4__[_^C(<K\]\=6.]I0^^I;\<C#U>#SA[7,ZU+]G?S[GZMPD9H'@\G/!?<
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ML[X'HZ1C3%EO+TGPA"+\%EE 2G@>N<):>3XNZ"@<Y<%+*3E-G&'I.*,&P(S
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M!#,!L*LIJD*L<)B$DJ$PY2!UF+@"8<K'<ZZB-(E]*:5ZJL'/104MKG?_!:H
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M,($H87)Z)$4B)MR(;8 D2F)&$@,G,VB^Y^#$P<F")0TZ.'DBG$Q$/$FA*.&
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M8QJG&^_)I#G5\?=J\/=<=1+'W[/F[PE;8L(9#N,$884)8E$8HQA$,X1E$$8
MW$I@TPXJF*SE-!<&7X>0PS]-(7A3F7YZ5V?G,UD)A67H!+N!>';Q#]/M3J<%
MLY>T]'%%!(?IGT,2<+#W(-C;N_CS9+][<&RACS1@E(TO/Y(DHAB')FF<2L1
MFD'<USZB3-(D59+B"!27\"F"C3.V+C"?OY3BXOC\1?G\RSB?$QH!F.,8*:65
M"?8*4<*X0"GQ&<,@LJ9"@@+CV'Q%V?R%]!?'YB_*YM_'V1P'*<$)BY ?\P0Q
MT&90S(A$.(XC)B- @0#T&.=B>3$FW6NKI[93^(V5YG?7U54TZZY9%-9*Y3W3
M@ZO_\FM<C?<YIFBQ-XW%Z=GKRO7.<"^XG*+:X3!(19)@Y&,C\I$((Y#Q!1)4
M*S_"2J=Q8"J4\^#)Y?^>@8_F;/MVJ.I0U;6Y<:@ZH4@K)@G3B48R%"E(V#I
M0L8^B@D7,HA3I9-P1HUN'*HZ5'6HZGKIK!ZJ3M@MXEC! D4!PD$<(P8[(XI]
MJE!H)%@)^Z52_HRZZ2P0JEH#R!O;W/I]O\7\C2[QR]MP?+]M&+2M*\Z]R+I-
MK]O4GJDCL]/KEIYH*^^//"F];=G=]"ZT9_BN,(V!A9=JF'C1\K*VS,^U;3[>
M$5>V;SBPH=<M8%PV*ML>,O_ G6'$2G3SX@KX6Y_#?0K=$=TBL[9%XSN&2V&
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MTM@9LYB=?;DX!.GP.Z@'AR?;(#E^N3JX/F#?S_9 2OR[=7CR\[)Q_G?+6-Y
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MHNQZQ[U.IV5]J8!ACP%-;[9XZ;T:%A0VWF ;8SDR@MLBKAV@+B2@TE4&5.8
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MZ8Z B]3AXOKA8M]H2/P@9-0:#0FFD1_;(B^@Z?Y&*"1D.O@Y9%LJ9%OAO$-
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MO1>S3*Z#I^KN.5[&V,'9SX++V%S*K9&L=B$/O-8IFSA8]*WQ[A'.)BEI),#
M)B61T'QJYVNV0\Y_JA=HHYS_9/2SU-R$]"?$%#TT&0=N1G(7][2$HM2J1Q*[
M_.Z%%J7F$JMI\L:(%9WT2XE3$Y'#+@9JR7!RQ:VQ+M-[?7'R%AL9'JLBV=&%
MZ0LC .6\LBD*[8D+4:@12$3>R?&1]RD7K?*I(5#.)+=D^+C:98*PR^%=7WR\
MI4X0IO/#QX<6"G)EU.:-CZM=*(BL=<8N)HN.CW>/<";M9B;*LV!C%\2=L@<
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MI'Z0*7YQATBY,WKN?2RNXQ!:Z_#>UQU;K_8<7NIJXJ1:OW]=8VV[+ TP6\/
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M\$;8D5L\0:(4"?OEN]G;/8>.8?*!73 DE+!WU)T@2@;L_W:/*'/8[0:@W)8
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M>BQE6+XK61&KL,QGL8X>YXAJ.6#*ETDNW>.UOHM.A9$4OY)YJ')Q%1,P9GT
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MW;#R#L. 2_&O9,8&@%+>7,6ULNP21?Q,31*TD!@/-[_#F6SLH]IAVFL=INI
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MWW\XH\O7WBVH_L?W_%6%02@EU0;"_WO_E_WP&5W&LWQ^MIZ,G_GGBZ]L8'H
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MWDI]>W2'MY3F-96G:ZE-K*1D;/% ,9E-Z2#Z8(%"$$:HBM;TSA]>?_Z8S-1
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MQ/FW^;S\,3T[>W(7WE]I-7%5RL)B@;2^=ET5 4C$_+:BEI"D11TZ*X.!AC)
M XEM8-T[LR*(Q#-I01K1LB]&0%#5@L.*3I:B$O9.V74>PI@T]!CXOT7'BJ,Q
MIEL$>#E#Z\-T$QF2J*RC(;>K5HW+;)V48 BFHC R)@J].Z)\ 6!,6;0Q4FY_
M:0W9:.<@UA.'H8&2!$HHP%0*D%3E.3')2"V5EZEWB^U!]>3V,]J\HJY8UIW
MUIH$28O:CG1[7\%XPS&UK1Z\=U*398?V9F.CVQ[:8.B^ ;/2A<R7:WL<-!BE
M?G@Q6^'L[90_O)R(8IT*%4$&H]I=$ZSL>%J!J)9"R@:MQJPGK@WE&S!R71?
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M;E9Q[;:Z9_/SM*KG9[>?=SEX#F?(Y9+:X&NK7TH0H^9IR%YI6U(*J??&Q4X
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M#SQJ0(]GET%VVBU:/_+:LZY2:)2MJ<J#TY7Y8&. I*,$Z57-+N404'9>L?=
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M-:9JI&^)K[O*>TN']>+U]D?")?WGO_W_4$L#!!0    ( $Z"5E9Z]H( J<(
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M[4L<SL+\1U</)9U"R((.)3KN&=E^D5 SQVLS)!9+3B:'W.UUW>[!#_<P[E'
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M9[J@;WTZ'H8NMXS^.BQ;MM%"#RRYI17S,I:1F;6."PB1'& 5D('7RD-1DFP
M2YYVM\FQ[;ID'RJ7IJT^M^N+?0=E]&"8KWE=SB?D296<9JY D<J2SU!GK19!
MWW*60K9"2$S]6S5+.-\-FMTTU/ J<".T2[.OND#;EQG3]S3*.U@P=U/A;=38
M4?[[L%LN0;362]I>+0AA>'5%$WA'QW%RG'D32Y9*/'1J;&^M],Z,;<3>!R/.
M=LMK$)<]MWAT0F4)W&D!JC92<TPZ4*;(P&GAL5LC_6U8<3.D>V"7W%5]J[1H
M*/O&MY573]*%I1ZD]IZ,+Q-Y;5@0>;74#?!(MKIW.:;48CS5]2<_-5.C@?P;
M#R#\-1R3%*Y@6OKC'4 U3#3:"&3_B4:[:FC<EW@;9QAM!N=D*CZ@ ULSZ)2U
M"KPU$I*U&'1,]>[VX>G\A@RCO:A\&ZFV3FUX1C &T_'))"&=/Y]Q]&(\^;JL
M'/;>I)@SV%)GXEF/X(,WP JZHJ*QTG4KYKGA(?M-<&BD@W$/ FP]:^%%F.3!
M* S_CF$X^_)ZE)85?XQEHU2!K+("Q5R$4(-Q.@;$6+04IENGF T/>/ *;2&X
MUF_IV_0[3J?CJ]Q2Q0EIP.A0S0Q#W.+.@(_)NMJY"(7LI,?KG_W@5;BCN/:1
M;O1S&$S^$88G^!;#]&0RORX]2Y<Y'9<ZJ6\V#:/\9A#B8$C/PND'3!5-#K/S
M?[M#'E+3Y^^<H-2?-%8RE[*UDAEA2M)129:\8='(J!G]$7WQ1TV1[.:GGW_<
M\S ,Y"Y^_((X^V4R/OE*/L?/M$6-TB ,SW.@7X2O5>S3-^>9!J58EADW$$QD
MM&-A@&A-!.VL$=&9(&+K:X9=,>\:VU@HZ%F<SJ/]1RYGTC3M&RA\)%?=,7#:
M&,@L"&Y](B^[=5K 503[CUSLE36KX8T=Q-_#U<I+C+./F$XF\_?TV3=Z)ZN'
M_O-X4DO_+L:BIC0YP3Q/4L7I[$@BCU'0R>ZL)=1.D #J#53B3&%T(214C4ES
M-Z3[)]<N^ET=2-J_<GJ(G;[ZU\E@=GJ!^^=OOPZ.K!<B2.G!&T-V"KU X%D*
MH&T4]/^U?K235[Q-3ND:' ^:#CL+MH?;->(B#CZ/7IQ,)CA*%Y6@==479_U@
M6C/AR%0X"@*-X<J!=T+4814(4>H(!EE*G(?HF&U]WFX'\4%3I$]U-(R>7EWY
M.F"66RSUVH"IR$&A2+4C,+&<.(U>D#EJ6E^[;03SH!G11L0-V[4N@5UR#\X7
M6AO!.,L5L-KL0?FD(=A4P(;";=*)A]66RSMK?0V,)V:0[JJ('DR(YR=36MJT
M#@J,@T515-W*2!AU];3R 3TG+#SH!?C3([12HV*UVU.BK2RG""&;3"NP!8-'
MA=C:C[D#S/US:V?UCO>KFQ[H-"^PNR2'=;NA=NB4+0&RM;H.&261"!9(+M)J
M85B*V-I [0#KX=.EM>SW9\-.S_F[UG+*T69RM,"D>GJ2I02N3BPMEIRO+&OI
M]$V5Y@T-V1MQ/GP"]:Z='NS:6_B>4 CTQ8')Y*63Y<4@>B>!!8RL1%UX:LV=
MQ[[--)1X#[;NA7UWNL["6R3%8$HF6:;!8]%U8BZ#H&4"CJD(GS"0P=Y;*'HS
MKGW5!A[4!FZNH/M2%7AI89=N:WZ>X+].ZFXZS]8(498L2X22N*RWM@E\"0&D
M,B648%S4K8.Y'6 =*K^M/14V<ZV)2GHPF-?=\)T#/+MY[@*QI]SY#O .DT/?
M7+6;J--8+P>BD C28:9W1V1/![ZD S\BDI7&I$L,N0M,/Q;JW))C?Q^8LXTZ
M]L28FCE AC_MN\ONOR(4:84"(XJIA[R%&&VI?2*2B4F%['N[K[\!UP%#AJT4
MVH$P.VFCA\OK2R_-^9=_'^"$'O+E] U^PT6C.^$]8>'D31B'BZD 3D8%PF1)
M_J#E*%I7'7=#]A1,G%:*Z2/NLX[BU_$N7Z8.8/=H[VP$>G#+IYG&N^Q(3=6U
MKT-M(^@H,$IN:KX&.E!8,D0>Z>U3 FVMC5&\4S'1P^)6=]/H?E!K&RWU2:G7
MHZ\GM6D^28 O.ZI+)QFW$FP6M1Q3U?GV4D+4T3ANDL;<J;OU70AT'<[]L(H:
M*7(397;40I]FT25H8MG)0>I,*V9@F*L)'S5Q" E:L8%>E"0S_6@/!!%/DR!W
MT<*>=A"YG Q==(Z6"6 RI,K=##YBA,"\5<H+S58GXO9"$/DT"7(7+?1I&5^)
M1CP/T\&BOH_7 S46#Z744#NR!-[7\JV(*BEE,8G6N1:W0'H*KM3.JNCAIO-]
M+>\F,5]D%ZZY?CLC=1>H/7E06\ \N/^TNYK'^]51GR?4!<!ZR??LN#:M7XZM
M$2;(8J(%C5H1PN0@.A? 9"_)![#1J-8->[O@.K23U)P_S971 V&VX7C008AY
MD:22!#75<4<\)Z#=V)")KFTVK;WL ^T_6YH\S?2[PP:TC7)Z\)U>36>#XS##
M=Z4#5A=%\?,)*D74+C?5SY-! X_1LXQHR69K7=2R!;X#C/WL2]&KE3!]::G/
MH^SYZ3P7_\4P3!=[,HM(YGP.A$32GFRT( FH CQI9F)).>G>HGVK8)Z"_;R#
M^/O,"5M4:)R=VOG=Z/R2;7YZ_S8:QRE.OE5!S!W%6DL]2H/A8)YC?7E59SMU
MEW7U?5'1>$T'M\EWH<XF0MX'O?>YW[5>'YT./(;:5,@P67LB&_ Y9"A8A.9U
M4 [V%IEZ$'SN[B(\!#IOH^X>:/S;QT^3^5HN%=PN#0K.9)#2D4%!AYS"Y,'Y
M.IR8"\5B%EKHUBV'-Z,YH+MP4(V/>U%7#Q[%;Q]_&7_#R:CZX\\^(TD IU<+
M^\]P>H?DAWL#43,!RKL"SI@,,82HM):*R];F8%=LWTG6GRK[.((7)3,78->"
M%(BL%&9 JSJ>66NRKR4*L*H(HWD)0K>N>.L$[#O9>E)B'\W5D1S^,J!?P^F[
M\A*_CJ>#V?ET]\25%QF"++E"J\F!A$][C"P6:V6WSKA;\.L&.-]9U51A/5PE
MU4YTXPD!6TMT*WT(V0G G(CHPB9P=4 <LS%Z85#ETIQ--P'ZSJ?&2FL88IDW
M./R M1)]-!N$X=OQ9/8Y?,9GHSQ?_/.0?L=\#6TTRJ.*"GS(')2DH]LQST$'
MB2EB1BU7\H0WM(O<^M%/G$Q[T-=U=NE=]ZNWXQ&>O@V3WW'V\\DH+U$9$XKF
MT0'YT@J4*QHJT!J[C+Y$\C98ZPRK]4B>.*D:JNDZ>4SK)FG+ZW<9<T0TD%AV
M==!2;:"+&9)C3$87=?OV6.N1?"=/*S5=)X_=Z5Q[B04G))@7X^.O.)K.5_U^
M&$;+:S4>N8@B :LW:LHS!Z&.ZM).)\R*W +LUKOZYN<\<7ZTUL1UDKB=2++2
M-.,E3@;?"-\W/&^?L0R..6ZQ9H-(A@F4=06\X &<$BH[C41RU8DN79_XG3@]
M:><ZA7RK-ES/$FV#TX6:YLE$LFBCBP*,->A YR4XHQPQNR074^+%M;Z)V0#E
MT5Y;MQ!]#S;O.ECURPDN)S]U =C3[?.MX YSC=Q$E1WHL;L>>NSDMQEH88GL
M)YW!JCHJ+'$+WM1NQ2(8&TO(N&JP/%2BW'(_>QB>;"/^YB,[_OO#+\?Q[V>'
M70DBD&ED "TC))F0A*P-!,:43X(QN^HX;YK6<?EC]V]O-);YN(G &@_"NS0$
M;NXAO<79EW%^/?J&TUF]J[C^4\0ZQ&1.:,UJ1R9N0'M#5HU0$3RG%<A@K2PF
M!8\M1N;M@O'1V15[55K#>$G%O0G7V=O4!5G#87LWH]G_Q+W]:77<JTH:#^B[
M!6$.3DG)$PBO:MM\1H<J!@XNFYR4UB5BIRCM/23+#:/Z[B-7MM%$:P/D%]IC
MOX;/XZ6_C<8R5@*96D'3B2IBH)TU1V J6!=]*-S83B;(R@?O=UI82X&/&TFK
M]>@^DMS)]/E@/$T#I%-R>C&#3N52G*E=CJ*KIR/SX(F>H&6,"I7+4?!..MSX
MB,>AS382W/A&]CT'[EG.\X\-P]>C,IX<SX-TK8>]W?B0?B:Z=5_7ZM@VB2P:
MYW5A0FD9?+W3TCSDF(6/R:RO;+_Q<4T3P9]=F0BW)@I+O_#K>#2Y$I1]<][=
M%67@S*D,1=1!\]X*\)9%0):U<*Z(('MK_-9B ;L/ZEH&B3]@??%K$[8PJ]=2
MI_RH^!*SHOU7\KH3<WIW@T%%2V+,D:?IA6L=0[D)S\%C_'ODVO6978WTU$,J
M\ILQN9 X.:ZY.N<2._+,,J&Y!1ZS!Y5, )\3?>5#"B(HF7)I3)ZU0)XR:W;7
M3 ^QVPKF]6@ZFYPL&FY/)J=5"/.RX",K6>;H%9B4,R@C>6W]Z" GBR'98*5K
MW53Q)CQ/F3S-]-1#@O#9;,(/X],PK()9W'G.%L)(BV^.@K!D5IIJN3*D;=%9
MB%YK8"7G['6R7#4?0=H!UU/F5'.]]9 P_/KX*\FK<OY=>3V:A='G01R>B>[U
MZ$Q?.*2C.)_/ROQE/,Y_#(;#(\[)^,?B@ 0D0%D2D^/)@#.VY@]&*7/KYB&[
MX'W*7-R;GONO\KZ3%)=1?YFCK<T+,"M0VE6O/)!7S@SCK'I\_74+V!7\WF>(
M')RSA]'[_9XZ<M&-"'-PVM/[F+$:MCX*B"11B(P%AII6Y)]:_[C]\F3+)G/;
MZ.O S9VZ0/W>9*Z!FG?H\707'1VJR9QQ(D:?$@3''*CBR'Y Q<$)C4IX';7I
M+>[XT)K,[<*?YLHX\#XDE%(AAP!>Z7I;&C3$4K._92&OF]E:?_(X]I^&3>:V
MTN\.&] VRCETD[FL1 G1UNNW0$ZV21EB)*S)%*9R3FAUZ]C^XVDRMY6B=VDR
MMXV6>MB9ED&_#_B5I(-Y\5K=(!?MB[ D%\M2'=QC#+URG+Z2,@F,C%;1>M#Z
MEA ?+Z_ZU%6_O<!O&K_AR?5@M7V4K7ZR2IED$RQY(SISQ4/MZ=AZF^J&[+MG
MUUA[!Y_$U 7L]TE,+36^T[B<NZCKX).8T"F>1*YI5?.!T3Z!CTD ,UEYP=$7
M;-WC[1YPJ\TDIOU1:QLM[6F.RG+$"WDPI3A:M2VR=AW6$1SYP!!\U-ID+VS\
M/FCG;HK<8M#.-EK8TR2FY8B7(@59D,(#JIIE68(%SWP!%03S*6B5;&\&T\,;
MM-.:('?1PI[*(^L6ZD0PACL!0L]+?!2#J&4$C=Y9X8I0V+HWWWVML#ZH^=Q"
M/SUD/MQ>8M@%X/<R[*U5N75Y[5WT<)@R;*MM\;0'VEI"2MN>!I]2J@&LD@AM
M#,VO9!]6&7:_/-E&_*VKH%X?'Y^,QL>8!^E2%8AU*DIC,UA>V]?0*4L;J UT
M1A:MZ=1,.G4KQU[[\?>R+'L;'8R;"K#?X>CK1L0O2OI"](C2 ,IZWV(4>6K)
M!2A",*T9LW1T[B4/XPJLIVURM-9;GTEMZP N2X [0-QCD&X%WL%#<VU4VR%X
MTD(O>XK&K4*5,1<N<B: )M*)&PM$'Q44>HTLYRAL?QF/^Z;.G3(O]LN<;=2Q
MK_CMY?UWF5Q4.+*0)*2H:T?T[""@MQ"2<(PEQK/K+;?P9FCW(\:RDUJ[1&MW
MU,E&4ZCOBN*/)\?'87(Z+K4+'V&OM33C46U*/.FEN+CK\_JI,[[3:E=*C@7Z
M4#,;9$A)11M=J6/\I!!&D8Y1K.='UR<?/O'^S7DJN"^N:&L]Y* 96?":#+K$
M.42&CA5KHVT_*^,^51^?@[D90Y=&FB_",)T,YU]^& ^'/X\G?X1)/@J>N<(]
M0@PNU_GIOAK/#NIHJIK^H)SH[<*MKT4]]**=;5B_\6BX%XSIT[^^M+?]<S#[
M<FTQTZNKF7Y8D?9"/*>+DE\5M'1,"2BYWD<X<AIC)/?1>J<M2HQ*M&X WLM"
M#DC]^T&X#I;2?MFR)Y.\RZ(VK.G]R21]"5.<'KG@A76U7D]97?NK:XC)6; :
M.?W/2>WC/7D+;EO+]Q?A'G)F3REL.ZSK%]+TF_&TAI.')V1QOQZ]"I/:3&1Z
M9$J6#(VA-28%RB*#*.9=N)S1-=V!5'._7X[-B_O^MCP$5C6\T5[TPV^[RK/V
M^J_^I)V!W,L/]'GG'TM'IG)*Z B,<TDVK97@?$:0)5I,11FINK6'VR/H[V_%
M R#+GNY9=C<:48A8E*:EN'E.7""'SM4;JJ2E2,H&)EI7INW!Q3A,A&AQW6>9
MXX8K"])'6?N@2 @R:+"1">6+H<VTMY#STVS-T"0RL5>]W\/6#.>OT\4D>+*?
MK=*"=F4DT[GN;Q!RHF]C0%XL2USVYGBM _3P4P&VXLCF5( ===6G\[^[B;"Z
MO&7N7(<%]IU"T-?B#IZ L"NA^@OW-F3#@Z1]XJZ6+ 30N79T]M:"$SF *0FS
MB"R:H+_3?;NDB0?']FU(T#H?=,.][#G.\PFJ/FHC(O"4R 8S@LPOX06HG(I3
MW&#IZ$EW>]Z#=H);:'G<KXIZN"+;E$H=O$1&*ZP=/F+MR4<VD1$%LDO(4S9&
MA'V,_'KR]F4+_?002K\]4[L+P._5+5NK<NNJA;OHX2#5+:A$UEDR8'P>\RH%
M7$P!5/#>6TZ;9+>18_>?*'>L;NF7)]N(O^<A@XG[C#H#:OI#"1G)ZG,*8O8R
M*,,CFM#):+GW0P:WDOD-0P:W$-@^4C>??0N#83WYRG@R#4.LS<\OYK.'45X=
MV7Z>;GCY7WZ\_B]GRWY/^:(5S]TS/@\!<^=$T8/+=B6_E+8ACX+;Y()302>?
ME(I>LJ"%C27RHT, WNVHNIC =H[@YP6"BZ=?A+EY2(XV9 X<'8)RMD!TON[/
MFEE9O):\=1.)K0"VF#!Q\;&K#WQV7#MR_1OSB_%T=M[9^ZPS_>O1#"<XG3TK
M]-]GP^'XCSHMD_[E"[*<![-ZRWVDDM+1VP1!.4=[UWP+U'44@HZ%:Y2N>=9N
MORO:_SG3'U_73;&X)USHP15>7<_*:E,Z.:Z7Y)A_F1#:W\C5"\.ZW)JQ\;QN
M4O@I_'D4F!7"90T* _GSW)"5QHV%)*2(,F8;3>O08!/@CYFW^]=L#Q[471=1
M7ZV+10CMF68%P4=+8M2I3@A- APSV6>/-C7?;YL _T[/EIKM(2)T\]FPZ3@X
MTBY+QV4!Z2Q)*XI0*\XX>%<'U^:0C&V=3'\WI(^9@'O070\==KK(9Q& 3<R6
M:)."H'FJ9;=()D:QH"T/AKP6@[HUR3J#VU=RS_[8U(]>[DURSF!$ENN@#F-=
MCG-;=%14H0HL Z-5T<N $0)S&40H1I X.<;6[9HW0#G4A4E/>E^]UVT@_QZL
MLT^3,)H6G-1[HH\X^39(M&&^*VO03C_11T[7_]6R'6N'M?1T=])R'0=*H&E!
MD/$]T^Y]9RSSCGG,$L@DR&1\L@1.Q@"<:5U0.)5]ZQ/V_C/UMMR7^T[4;93:
M T%_^_AI,K]FOQ0</KOQ4$8PM-Q *99<<:\+N,0MP3.\=EC)4;2>#+D9S?X]
M@\-I>=R+BGH(YOWV\9?Q-YR,YF_59Z2UX_2JFW.&4RNILF$><JQC(AP9)-&Z
MVA',QRAY0>>P.96Z87O2Q.I!?7VDFBY*DR[ K@7IT&6AZ^C=5,B;DLE7RY<D
M$4J6 ;V*I?4@[D[ GC#!VBNNAYC:"YS,!F5 OU8E\1*_CJ>#V;)UI;4&)3.0
M'/>UKX""FHH(3J!&EF+DS;M0W #G"3.IE9)ZB)"]&$^^CB<$;"VY;0Z(6G(0
MI9@Z#TM#Y"8"AB!0:9>C:GUS?2.@I\RA9HIJ6.(ZSS3Z@#5U>32C);\=3V:?
MPV<D8<U38I^']#OF:VAC#-SE4("XKT$EC^",2F"SUU&F3)9?M_2MK1_]! FT
M!QU=9Y1^,!ECKT>++/R3\<G*O=G[\2(C[Q[FCW4'?6^SR>XH]Y7<,CU/*DN:
MH6<J957SR3 73]\IB<+WEEO6'7[;*_T+!+<]_Z(X(=(V$M+L*)&@1"8#PTM!
MIH85&CR)$I(,16BCT.369<$-X;=.CN@.Y=+U>OWQN3RECZR0B0\8$P<ELJ+=
MV KP,2NE)4L)6Q? -%_$_@_$0S'ZMI2*_?*AAWC6S5?TMRWJ#4ZGG[Z$$1=O
MZ3>_3%<6>23K&"6;&<3 )/FY"NO45 ')T-+X/%;7NCM&KPMZ2,1O0KBM$CKV
MR98>8FZ[+6ZYJ'>3-^/19YRL+L[$[ 1M,*"8K/6>+I)IC//;%V9J)Y[(6[?>
MZ75!WU^%^\*6O2?==1+RD>0I*D6'JXF"@5+(P26#P!A/)B;ELF]] =( ]G=:
M[U?S/40G-RRAW+B$<]EQQIP7U1KT" HMR8Z[ B4%3QZZ<JRT#E[N@O<AT;6M
M);XW+=\[2V/5C#H24N;DHX;$3*+WW3$(5EK0QB5EDPVL>=>8MBO8/XOWQYY>
M+>BM5'_OB+QJ!!TQ&:SE:$&1A&LE.AT<G(P@(80T3*&WL?4@B+8K^$[D?:C^
MGAB\1PR%=>240K&<C'3).,1$TC1&1)FE5T'NM\9T/<[OI&RGQOV9JS=B/C>E
M%GGOVL80'>$VN9X"3&L(RDJP5I"U3;:54/?!U;J*>E\%*O?<8.U+S_>]KD5@
M-C5G$TH1L?8G8W7#K_M_E,@+1V_4XZYKV3<A.A:\;*.8^UX^T&4MWPM>-O"S
M"4'ZK".XBW;O.V-S8$G;@I"BG9=%JMH6T@-R);E&GU3SZ_;[S]0[%KS<&Z)N
MH]3]%KRXX$TR64$2EH-*.4/TTM;&N-E&5K)E['O!2P]:[E[PLHV*#EGP8JR4
MAEXM"*FZ49;,XAA1@-').&.\L,WO>YY(P<MNQ.I!?0<K>!%!9D3DX LY8?/9
M'P%9!)EUR2%8QU/K^KRG4/"R"\':*V[/!2\F%J,B[:\\!"0?BIPWIQE"9+3Z
M+*+GHG41U>,M>-F%2:V4M/>"%\Z=C-9EX+4D1VG-(#IC00HR,0M7.O/F#'K$
M!2\[<:B9H@Y?\&*2+1X)*,;@R/!C&3PSBJP_EKBW%HU?N5[X7O!R9P+M04?W
MLN#E6<[S1U8YTK\Y#OLN7KD1P/X+4;K+8Z6HQ-LD4PH,G?=*>N:E#]D3/6Q1
M*>:R?5')C5!V.\\^X#Q;ZWV8S$[GKUY(9Y(]Z],E,FDUA@@.G0 E=$WA8@FD
MYZSH4(25K>,"MV':]0S?\/D?<4C_XO,O.,))&-;7/1\3T>J%SVSP#5_]^15'
M4YS^3%O6I7\UK2,L+W_B$<=";W_*4'R0H#RSX$I,4%@H(:ML9?.JUWY7M/]#
MH"DK5RV#>Z3^'J(T%SW2-JQS^OSTRM_,KX]0)AXD.M">DSVDHB>?WTO@(AIK
MN=:.M:Y%NA/0?5T5]TK _E5T7ZY\-ZQO'I.WB-9;0YZ_*!EJ9V[PR7.0T80H
M!8LVM<Z9N0'.X5L:]L:%;MO?UCKI(?2W =J9,=\%7$]7N#<".\R=;#,U=J/'
M#CK8.U%DR,P$'L!S27LS^?K@?9W?7I3G3C 63.ODT0,0Y):KT,/P8QO1MY[Q
MM.HUO22'J4([<]#12:_(-(,L!#GH=>BG-Z6 -JJ0SQXL.GN;3]OA.??&6+Z+
M1L;]B+,',[?;:3EGN^1)2^,8,,7K_,L@(%IOZ ^RR.FDM(GMR1];@^[)VQV[
M:JR'.Z++>)9O40=$>[ ][J'!L;/^;J#)#L+OV>A8-E02TI.CIP$E+[7+$8<8
MYJV54'GC- ;9.G5U7W2XFWFQ!S9L(_/6)L8O\Z#RS^.34;Y\%GIF='0N BVT
MCM_5"1Q:VB %]TQ&'9A5G4R+]9]_6)/B+F(?MY79_1XI.?N"S\.P#AO[^ 5Q
M-A_MO;B])D"W-8(Z2'>P)H@/V!JLO<17KG"D\,R9Q-'RH&)144III15>"\6+
MCCOT!6N"?9_C)T-Q(>GB:V&I!Q7)Y ^!WE;A(N>:C#[?O%W)/1H_N7$T42DF
M:E/(F\JYYC%9!8&37Y495T(3=XQH'3%_G&.EMN%7H[%2V^BNURN:V\;8!%T8
M.? )I*VUL&@=."X,V"*3#SX:W7QB^0,?*[4+F_K1RWVYB[E\ZKP9+\Z;17%$
M#"(8)<%CK/:<R!"9RL!3(+M=&R.Q=6NV35@.'PUIJOEQ#QKHP;%=AVM96-4!
M64]QC\VH#A/_:*.]#I380?1[)H?R7)=4VX0;K -8"&O)%H2Q"G42FJO6.?C[
M)L4M49"]<V(+B?? A1=A^N79*-?_5/_F&^V/H]GT_$+ "QE"!%G+ZY0+@; 1
MRAPPLZ!]T;:UK7(3GOV;O:WTMIK(W$KH#2W9>6#G;9C\3OYHO-)(X60R(7A+
M=)RL,40!4:($I8*#*(0$S@L=G\$SQ58HL2$N=NNC'KRV>Y!HZ^#G.G2_CD?I
M"L"<)/<UNJM2'>O*/$+$@(#61YV8EIK+.ZM\]6F/5^L[R77CE=B]")>N1KRN
MW3,?(B+:%=0!@YYWDMM*7)-K);4I1"6OE,O"2Z)5*#K9P-&&O$-<LRN\'8M#
MSQOQU%*,6B/R9A#B8'A6B5'KIC&_&WVHCYW4R,\HTZLT67[[/$P'EX(%*7&6
M9!;@9:X3!"6#F+T'3$HQ6>\D2NO09M,%[&K/K>KHYV^_#HZ"3:H4%<'[5+MN
M.4-'3(V5:6]"J+VW9>MPP#H<^]_;#\>M59-O9[WT$+1<".5<1B\'TQJ\(I$<
MT8I20:=!Y2#H#^6![! '.7+-G60EJ-:&_T8P3YDU;3341T5_ Q$MHF_2,/*B
M&0,C:S);2@4"&@LL1,N=M86EYF,N6X'?5[S\_A#R,'J_+_'V\]4_/YVO?VX@
MS8-#3,I$_D'-=? 6E-$9O&$2<LX\!I:CXZV[-&\$<ZB(^X&XL8FA.^FH_RUS
MC4#F$OAM-(Y3G'RK@G@]^GHRH[\FSY'$.+?"+Z]JF<;385T]!?3[6M.!>N*U
MH<[-6^9A]?Z0>)VYYPE9@5@R6<?<2+*.F0$18[0J^B!9\WY #XK/MW7.>UAT
MWD;=/=!XU4%;!NFT*)B] 1*))#L[2_ *596<$+*8A,US@M8C.;@;="!-W^)'
MWT%-/7C2&R\-E9;DPQL!VG(.*IH T69>,VYY3HR)I%L/7+]OB1CWPRQLHJ$>
M"E-NN'WH@NRI)VILI;WNE_)W$?U^$S4P^H)&T(;'>":$+$)4.@ &IIW*.J/<
MQ\9R'Q,U>N+$-A+?=Z(&G7$ZA<0A":RY*;& ,[4W<G32N9AXDJT;2S^81(VM
M]+9-HL8V0N_!YG@_P:]AD)=-; CFN]D7G)PE%RQMMCE2S0J+Q4D(U<I7WAGP
MS'KPKAB&(3*.K3>+[N@>#5EZ4D@/>\D<UT4^PA5HS*,P5G"RGR,YB,@=2< P
M*-IJSB)ZW;RT^@8XCX8<K42^CT20ESBAK:YVR%K7A[%U4\$=GK9SZD:KE:[D
M9%1"&..THS- <5*@,2(536Z+8\DZ=K3#<W>MC%H^^.(^*%@F+98(*F!M<YD#
M>,D2.,]CR$QXEMM/F+P&8_>:K^5'?L#ZMI+K^#;,:I3@E!])[J6T :$D57/L
MR"Z,AGFP(OCB/%/6M#X ;\)SB*%MN^G]>I56(VGW8!A=8/MUO'B-GAV/3T:S
MHV11*:<J+E/[IJ"'F'F-'XCD>:&]'5N7]F_"\I@8L(.4>YE:NL1U:4?]A214
M)VU]P'0EIZUV?KPTX/K=B]>?QJ]'=#S@J^EL0!LOOBN?R"/]-%[V,.9'L=CB
M2V9@E+9T6B<'@3-3V:V(W9PG;#]$NM\U/28VW@.M]Q F7"[EW:CF "U&&\[7
M\JZ<S6A8N!GIM/JJ/P_'?_P=\V=\>4*+J+^0PI16>JFKQ_O).-:@ZKM"K^^[
M=!9L_17I_4V98122_%BEH::4 BG  5>D Y:3#UPTYO?^5O?PF7Y/F=#+[-2E
MY!;A_T+OFU"N@+"Q@*I-WYU(%D**4B3%#!>MVU:O0-A7OE=_N^/VDCQT[M5T
M,COZ$$:?<=%X*"JT5M':A:NFI=<0;1# G32)RT"V9:?-B3[UDO[INPO=7WG@
MX<:'[J"Q\:Z2:VB6G8,XBW5T@;'-I5871;8/)=U^<[6#\%?5MX/D>E2D8@FS
M=AY89AQ4*>3D:;**9$XE:Y6UB)U2Q ^MP VW3.WUMXW &NOM;?AS<'QR? 8D
MF8+)1 N:V=JFRWCPJIJR,08TM)N8;E6]MVCNRD/W9W?M)/9Q"YGMH[79S0'$
M#15<893/DS'&9:W+U%L<=W=(/0=[&\ML)2*<G?%%^A!R026X"46K*+6D[\B-
MQ'Q+1'AW<*U,\8MBE O3U&AMG,%"NR.GET-BAE!2!B8,ZB*L3LW'&M\(J)WC
M,;^F.7_ +Q/RN^8_>CTZ:T-%+M/'D_@_F&:?QF^K9S4AQVE6LY@FD[H)51T<
M*4Q98_!DMR&"RC8"[1J9]J'@BM&JM/>H&R_AD&[SKHS;[ SM7[N]1KOGV*L/
M7PI]\7X\'*13\L(6G<,QG\R_.-)"V3K.!'(A%U()2Z)C4@,*1E8,8Y;I_KSH
M3A ?,=F::J?7X/F+\; &1R=A^"X.!Y_GQ\VG\0><G4Q&-;!TI&K"I70. @KR
M2%$;"+(.X\LBD*LJ'$OMFR5V1?<X*=14)ST$J3?MK O*/_M,<IS.+A9!>^D\
MYGCK%GOU93EBV9$5KA%,<084.5\0:X"2QY(8<Q9+\XK1_:SL<;+VWG"AUQ#U
M,J?]]*H]<?[C[6P*QX/F=9J+\HDD[SA)WBNL$[6M8:+0*=&ZBT5/2WF<G#Z<
MMAM.+KYA6;?;*4DJGU6 (O6\<P4'[XV$(N@(4EER'5IW%+D#S$=.OJ9:VCC
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MO:P)F.]\V_++>)S_& R'B^"8=#IQ# 6,)--5I2!K(HL%J9%V?8\AI];9(E<
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M8=&#8UQ9],Y$5P;K*SA$S]R5A-]?SM)GF..KM-Q Z]U^_N_+^6)YN3\"KI0
M#PQ,H-<LFU"[811FD@K%<>6A>:/@3L">1<+X8=S85F'=3A$#'&DKD&\OOL"R
M#T!*EQ>7YV2*Y:MO+?WY6B(.7')+;S9AY,@T1W+E@R/7RQ/(DKFTKG67A\[@
M3I U;14R0*3LU<5TMAC_[W*7?E<>M$/S 0I8Z^N\OLRT-V2J)1Z8X5G&DD$5
MTSH^]CBB$^)(0]$W3-FZJI%Y_+)T5<Q_=T#HJ"BRYA4DYF(DO"A)*,$3I8UP
MFDP)&5'NLJ(.7?P$6'$4N0^0='7,YHP%HH@UR5V%ZE5 G5G*?6')U4$?8#+\
M: 7Z++:VYTJ*AAWA.N:5_/)G3;@G:W%E$=Q,&ZDO\?FT3L\=>9]*EG3\BX"Q
M-K53+!3IF,PH42H>A&C-ZP:P3XBOQU9BPW9P'<Z-]2'-(V>UE(8,BF1)2AIK
M,UZ"QSR)J'"5G);0X*A>7_<$"#.TM ?HO7;K;SPT,F^?Y+P^R0.>CSB6Y+W@
MC&?:5[44@=$&:YESWF4EK$=H79[7!^\),.SH:AN@$=S>10I8@HC<2>:#J7E$
MWK)@:S%:"+9H)Y,OK4N$OLLF6GT(-:A2GCHAX[&^$5>3JJ.%VGTL@ZZS*-&1
MD2@5.=-1*Q"AI-@ZS_Y[;Z*UE_H[-M':1PU/TA.I"\ ?3;3V5N7>S9$.T</3
M--'25EDKZ14L)C.=Z,SUN6@FBLS9"JYS>=E-M(;ER3[B'[:)5B+;*@=.FV3@
MADPN[NB0UH)% W5TB$S!VDX^U?-OHK6/S+<WT=I'8,=JHA6C]J*VE'*IMD^V
M+#H(K'!>(ZS.9;TS#^ [:Z)UJ"K["_#X!9@/*@9SM Z3+8Q[7QNG$-Q 5@_3
MP221= +E6]^>GVJ5>1]C<4BU';^7P<9"PBZ0?U29#TB#!O6^A^CPF529^RQ]
M\";46#1!%Z8P4,$S)61M"A*<+JWKY)X-[1I7F1^;=?NHKK6!NZ.$>=5_Z,UT
M]N\?_OV7#_+:"L HP!;%6? U^.@!6(@UT3NCTXK,?H%=;Q<.6?_[*"W?2Z_3
MXRIE@ 2U]4N13_3?+=\G5P?.24YR$+9V($/!@C".&8R&%T/_3YUJI?;8FK9A
M>1'&5A-%#)!&L@G7]:O2!=E QM-V5$]C([717@=*]!#] #;/(PAY[6Z9ZY6J
M*74(FPPLDKO)>)TWDHNS4K>^H#PV*798,,?FQ#X2/P(7[N;"W315L1B@#NT%
MPJ53C2QQ#BP5+;3CRIKF(]9WHSJ^6=)*ASNHT5,! Q@;-]DY9+W?@GTSP_^Y
MQ$GZMGPYN(;@!9VA5BM!]E>-?-D4F2]%8Q%:*]>Z7*0#K!=A@K16SP!)?3<0
M-P%<O4,=( [5*'TWO"=JCMY:M=NHTU@O0S1"[P#5)*MU#97'8CS3.2H6;0%F
MBR@Q65]B;)WV\F34V=7P_!DP9Q]U'(DQ\]^GDQFFR]EL/#E;N?(Y@@5$EKPE
M,6AN:=O-]<LDE;'%V.8]_3I">X+NRJW5VH$V?75RC#Y^CQ3H?KR\N(#9M^F#
MK,)AJI]W+C=D!?1^S[I6!0T1)!2T(2FAA0RAH!+):9V+]]GSQZJ@=RX\V)2-
M7V^2!;T)@"X(%CE*IF6AG5+QVL=2FQ1XK%F@K?>)#K@&G#!R/059"\-MR62;
MUKGLT1=Z%S$Q$:VPR63M]1&?^XDF3C=GR!Z30_97PQ!.X&-E=#?%N'=K,$?<
M:J,@1Z:6;3"6E70V>%:$$=D*6;)L/<IW?Y0OBTHM5-7Z6NP1N&^F,QR?35Z3
M;5 -D$\SF,S/EXC_1I*N]=ZOKQZ'_N/5=T9&)&X#5ZP4D4ETCLQ:>D>8]S:#
MCT$:*78=P$, .R&F/;G>CCO8K7;@!"V >\.9K5.V=;"110R)04@I9>\=YM:5
M^X\C.B$Z#:""XX_#>% U]"K.%S-(BU$25AA-?G8!JPAWJA<'#IF7HB3)<W%/
M7HZZPGJ"I#J*VIY!(?3(&-2\5*FX6,AGM@05E6,V9CK;@RBY>0A^7XS/+I>D
MD?9[4FXOU;7/2GH4[$%'>1):DX?BF'<QU7I)VJ2]4[1QRP ^^&*@14'T=V*&
M'96#ST*GK?OG?)HN:O^[/=\J>J64MEDQGHVL3=.1$-=V8LE")M.R*-&M@\Y!
MR[\$G@VOET'LN >FY=O)-M'XDFT*9&]862<RB%S-39Y9-,$6F0&\:7VEM ^^
MD[37!E)/PR8AV[ N(W4/"8_.@ ),+/-4N[=:S0 $,(M%<.FU<ZY]OG@79$^Q
M1PVEW1TT:J":XX[WWA:JD[19.U?S@((BH9146#"V,!EMR+$8<H*/..&[4U3U
M\(#@J\FN?E6'A9HX<&5+8"Y@#7?&VJ#9:^:-12X+)F^ZC;H>'.H)OJ'/4,?'
ML3(>[CX@C$2G$T-?T[Y4Y"PH*UF0,CN#=&:N\W (Z^(E'PN]U?(,(C^;NJ<9
M%[T7PK*8I6/:DDD?G3$L"B)^,M$KW_KN[;ML@??LPH]]E3E Q[/;;-9'I'65
MQ^IUED)C+7LGD%H:8,&YQ(SAA@LEM1*M8Y#=T1VKY=3@G!I((<^EZ=0C#_6@
M?M0B>*F<94(LPZ=T%D0%9*H)D4*R.F;?VK7: ][3YY^W)4CW^[I>BCJNH[6Q
MGK0+W*&RT9]#F??.S/2A5-^=8LWT]@SH)K1T*HC"(*8ZK1H<69S2,D.>?I+.
MN*);CY%X%C3;E<7^3%FVC[K:W]?= _AQ6J;S>/EU/%NE3I-EP<D)8M8H11MZ
M0 8&#;DQ107-T7K1L>O2XPL]*UN]OY:F XFX=:LMXGJ"N( SG& :GY/X+A.>
M__SK3Z]_O4870,D0<DW-KX,N)'H20#1,%(M&\,!EZD: G4N=, 7:BKGU'K#J
M2K&J#_4\*B<Y4Q#)/PRRL!"%85Z"SD@;8(1N&K__N2>LWAX";'VW_>_XI88
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M)-<&:)<7U5J]BX]GY0P/A8E8VSQ#,+73 V<N!"W .F\[3@KIL-AWK>)!)#K
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M@S-\/9TO".J2X2/.(XH4"W,\U.E[T3(21&19<VE2RCY*W9@U7;&= F4&T<,
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M2PAGKLA0"_S12G(B6!W<S@5$BM.CDLZDL%/F=XOF?OC2P]W)>XE]TD)F#4/
M!2'XUR-"LJOCG5" *+GV3J8$OA175[+G;&42KNSDIF]3WN,O/4'EO5AF?41<
MMW[=XB1QJ; B$ATB 0WY7ZCH)$$/6<2@&;+B?.M-LX^__VUZ0GMKHH?N]Q5O
M?Q=J>BJ7#*'0\7+-K%'Q'F+M\0BXI4J4F+R,'@I3'I3W KRP#E)*VA45O&X^
M8F8 58&^=-Q%FJU?G_ZZF.3Z.8[R..;9^W&L@K]??$0GU^A[?O0&,K)D'478
M%'T71GXDB^"X$^""L0:55-FO/.%9\QJUV_<>/B.RCXHFAY%O+VMF;W=4+-[3
MTEU7TR\+N*>2E#0J$#D";_N5<^*0R0%1/"D>=6EL\6N)>=L^0!L=]3"6Y#$]
MMV:S"T4].05/J3GR J#]U+4ZLZ:-K'OP%)ZAS(64G3=UE'L*=;*>!A>C!)V-
MXEQ&643KEUJ'TOZN.W_Z5GX7$?>A](<12K<76:#;T41'M'!O027KZR"Z HQQ
MRW6T(C1O2GU"Q.&]AGTULWXRU0O$>K >E$6?S@+5*@7!:VG8+G*-=:]X8!Y!
M1JZT*4QPW=MSW>=)>MN^0DM]]3"TZ7ZCZCV=]S_\/)K5[GJB^!;YNY#:5WYA
M=S*'U(?R0C6OQJH]ZZC/SH(' NOTB8OKR0U9V]W33Q9]-)8#T4R1%J]+9D)B
M4)*(V17/>>ZM&64#70/J1FF#G^;*Z".[U0'C:"UG5E9W#24HQA""H @]VA@Q
M.$[!>^L9]T<Z?SHVIC33[QX'4!?E]. >O9O-1]?D\7\L.]#*4E"<O$"ZTHVL
M640$7ZR!9*R-B;Q";UKG4+O0=X246U^*7GU;U)>6UIY,/>X'^WQS?8W3OR?+
MF..)F]EP:]B.W]1\E]A+.%S9,!9U9%(7%,44%8QR6(I$5:2D7T,03S:,[?B=
M!QA9>G&U^"#ZZ6-9G2E9ITT^VF?OA-<LU;#0L4*'K*5;.BL-/!I62LS"&=W7
M$\8V+.S=(+C\IIR>)^1NK&$6/!<G!3@*ORF(5A1$9UO+Z8ZK[)C3+C<6U&Z4
M'6';\!$Q^*2EL+WV^KCC=Y'8%_SK]BCYA43^'!<RRRB(8G"JMM(J31Y121$\
M1U\R_:$4> QCW4KYV\;H$;3?QZKDG2SMMSS_6(B7R^#)?4<6(2 %?:K&@-XP
M R(0]<[&ZHD=Y;R\H_!M8[)';?;0@O&0&&TCPV625(3D)=<<N/:U;IX2!!,*
M9..EJ6ZZ9LW+TWTP<JA1KD/"[_$1,909K\LMV/=%PP^W?"YR<%JAHS 7(3JZ
M+51M?@G)%"C:VY)T$=:U1O@&<HY?5CD:5B;]Z*R':WX-:7?M63L0UU-!92-A
MQRFA-%/C;O#80P<'!PHJK@(3!5S$VD!BZF87Y^DG%C,19U"T7EIU!(!L*9$<
M!Q]=1-_Z9>A%_/?-:+:0[*=\5?W+6T_R-C,J%6HN44(TA>)PD1CYD<%!"5G(
MH(6Q<:5_:LU3T"U?='CGOJ%.)CT)M(?$1KT//Y;/>'7?K(T8K"XVD%.G6>54
M N8Z[LL6+%HRK6WKA.(3(EZ#]MM(N(=SOVZXHP_\=C%./^?O^6KR9^7X1U2J
M9%(J%H%H)89C1/"6 D>;<D9G7%:A=6/\#F2])EBTUD(?07N^HG_U]=<\SE.\
M(D(OTC5)?#:O&VB_YUM:[U!=,#C#3(;,E -E"-HA. ;6,2L\#]'(UJ_ .A'X
MFL#3GV9ZF-/WXU@MHYA+F!""UK4GV0GZ*3HPJ.IP")3)O/(!CD.)85^NES[.
MFCYFD>S"TWF88Z=ACIU@<HBI>"_1\<D,<Y0^1&L-E,(M*+KTP2L*,35&&X3E
M]3Q_L[CM-,QQ<+#MHMI^8H!-L]XD2<@BW27(#"A4!=!Q!*/HOR9&%USK1VIO
M8CA?%YUW&\[706$])!'6S7V+7),?8LG@C"6&F?! E 3011/C*A3FS\/Y#H6@
M%DKJ>ZSL#S/?E"+41IM :TMAD:RG=S$<+$HNF>5&Y=89Z%<_G&\/_+115-_C
M'6])\B)J9[0!CA%K93H1J.OKL?J,5TG'<VSM.;WBP<2M4/,"Y?20C_C'S6PT
MSK/9H\S\<K:',4'S.B4Y%PUT\&GZ21",O9:LZ"0<;WW>K"'EG*-HJ:L#0:C^
M.,WW$WQV(+"GU,-6XHZ31VBBRAW@L;\>>O!RMA,J6,DN*0F2 M.Z(1,!6:0S
M5QO4(>J84NN*RY& LB5P/PY.NHB_=<W]GZ/IY!^CR8=YNKT@G5<I!!DA1*SS
M S,#M)I!#@&S"9BB7NDV7%-D7_WDPSLDC24_:26VAE'P@ICWU]<WX\EU3J-8
MYSW=4D3*L$)K#TRF0E<?N4_(M 43<XD\%NZ<V$F1SW[\J]+F_@)L;9:_3*;S
MOS_G[WG\0(_1T<A"OF_R-5@./H-GI=0G_"A$28P;MI-"G_GP5Z7.?86W-D[L
ML:MR)<?6L(MRS2<W[YK<A8.5+DD;G(A!"!D0%><B,*VSSA@#$\DX]Z1+<LUW
M]%P^61>V?KA_C,Z"]D%3E,J+,J!\5!"0P":8T[GBU#7?1;0_U;V7G=91<#>,
MD'1YL\@+?)Q_R],OWW"\3.W,?IN,OY.F<_HTN;HB:Z[_I\O 49:Z$TL603*.
M@8X#B0Q*\!B$CYB:%P8.R^$ ,S9MD=^YN'4\ /4QZ;)_;G^[6=QU2<CLD6Y*
MSF-=&\\$A! 86&1!HA,\R9WV# S+4I;,G9"1' "EAS>H%T#L&"\>7LSHK_01
M<PH"EIG$2^6+8<I%,,)P4"PK\D&%!QYD=HQ9HU3K1M1#\7:VI*-8TAX .\;3
MMQ?S^:^%/N[Y9"S&'%@ [1<'A@X0BC<@A=*2/'[!3>L)&(?B[6Q(1S&D/0#6
M0U6F/SY)"R6/?F!5&HG%<0BB-G)86]MV2!],QV#H?UJ)T_'OGK!W-J>CF--^
M,&NX_N[PSFST.@LT$I(KID[&9G7!8P:?14Q>(4^Q^2B'X\1+';/0"Q+"!BK#
MWP]_93N5\P<J_SN/OGXC(B^^YRE^S>_^RM,XFN7?IZ.8']M*+DP*%QTH3=&%
M"KF "V0P.5J?-<_.QK M(3H,5D[H6-LONS,,<7="SDE%J/<&OB*)16#Q,\X?
M1DM>*DW,%T'WBS.UXY.N&]32TIV3)9-)"=-\)/X0^#Z<J9TBU@^?,VH+U),R
MUA^C_>V"T$ZQ8HV %&7=^I0=A!K48/0V)J9R^W?'@V'^;+:#,-L^(7O"&:SM
M@B!^E< 8B/T206'6X(.0BT,L^^"MWFW/["!LMR/S9]L=A.WV"=E33)K=3/.J
M1I^1@F?,$=<6K+-U1H&S@,EJP!*3*5YJB0=O=3T(YV>K'835]@;6T\S*;9>!
M,5B\E@X*5Q0DV&#!&\7 U[7RFA4?Q>N/:X>DNQ_OG2^3.5X]:*M8Q] &,C69
M4BUQDK:T56"Y1^/J)>-.1UN;.'TS*;X3 E2O\Z1?WO&X[$XC/B(=8Q)<(FZ4
MY0E\CG5.MHS(=7+!-G\VVHKX0\V-/C;$CZ+LH8R'_G&0B0[%*:X#D M2HP5&
MT8+S"J34I7B&T;'6=>>!C<\Z* 8VCLSJHHN3&3FT T_GD5F=1F9U@LE!9@^]
M0,>G@E_I>$3O!&B=<AVPFB%0L :1>Z.US8(UGUY[.KCM-#)K<+#MHMJ#C\Q*
MRF?NB2YO4IW I,D?EM& "ZQPDT0)NG71Z"V,S.JD\TXCL[HH;&TG2H_-B*OC
MFA9"FC7L2=S\!<U;$SOPL[K',:@2,@N2HU>V,%>RR0*S3\:PY.*3#L7-7W7T
M1D7"FN&">\BF6%"%&4(>';'%A"@E-T7)P=27/YQHHR*/0J*U&2RK[R8%UL6!
M=&X4540,.AI13N>I^ZMI5.R"_",W*G8!T&DW*MJL I,!@I1U.E-=8Q*3 TS(
M/5>A"'LZ#]G?6J-B)Y0>KU&Q \1.^&79)6=)%F,U.%N'9>0@ :6@B$E[*[+G
MC!@^&5-Z8XV*P[2D/0!VPL^\+HO*SO.B(%@M:C,(!T<!&81Z;' >+&N^)OG<
MJ/BJ#6D/@)WBFZM'K*8H<U"</&W#Z[#50%Q&QD%I7RPK16/[^N:Y4?&5F]-^
M,#O-)U&WSJR4UB1%1T<261&C%,WZ)")$C%I+)Q3&$\PLO(I&11>4\PD99%&?
MI,F8P7N30(M(,4?AS,G=QF8>G943.M;VR^X,0]R=D'-2$6J'!YTA>FFB+J 2
M&HK2$2%X%H"%B")YG213IW>PG=]?[X7U(38J=@'J21EKYZXO9804P=5']!3%
M2&,!!6<@12H>41IQ^+<.YT;%-V6V?4+VA#-8VP7A@BY><(H;!'?U$.. +DG@
MQ?+DE;2R^8+EP3!_MMU!V&Z?D#W%I-ENO5_,E:@"!K!*4OSO11U4)#(8QQ/3
M+-J@3\=PSXV*)V>UO8'U-+-RVV60>"DVU:83)CG)P(>Z9]V"Y72:226DSJ?3
M6?SJ&Q65I%LD,P8^+'8)4G#G70C 8V*<>^:8/9T)\Z^N47&8#[B: 6K0C8HQ
MN1BU=: =2_4<0W"Y,!!.9 Q"^R";1_MOL%%Q+X@?1=G#;%1,R1J/Q('U"PXX
M<6 -N5 %O0ZYK@XZ-RJVP\#&1L4NNCB51J]=>#HW*G9J5.P$DT-T?+U$QZ>"
M7Z(>L:XH3+*V(0>*SQ:L.K1%&9:%]>'-XK93H^+@8-M%M3W =;7]:7;;\68S
MKTLP+=37;Z!$-N#JUHN(1@24+%O;>L3V&E(&&/OTKN=)>R4=HRUQT4IY&W<U
M;$9\[F.;MR!NI7VE\9 I5W1$%9WS%$:*4') D;F3@>E@GS8>/O<%1V\W9-YQ
MA=)"8#R JB-],6*"5(I2/C$3<3 9E0]-VPTW98__L29[_/S#N%MG?O8X/<R,
M2U(D#T4@!V426;_' H;,/K*@BE:]R+57K@9X,K=%^+,.P'" ,J16PEL./][,
M9W,<I]'XZ^T36!=3W?/CB*'ZPE?P#$Y( Z)X%U';5,)@ANRN8^)(0!\0TEJE
M9YO 9$COM)Y]VO+K=#*C4"-[BBEB@:*U(I:B O+U B3#H@\Q"^4'<Y>N9^.,
M_<;8WQ<J0WKI]+3,_-!^&(NB@)KN6<LR*.4DH#=U-U40EB>-83BUN?5LG-'?
M&/W[0F5(;X5N67KWUY^CZ>+_\\ 29FET*@)\M@PH)M<0G"6^T"ED7EO6/'W2
M QMG]#=&_[Y0Z>/934U#O)_-;G+Z^69*#MF2K*7<'N<H[IX^I<OL+--!<6"<
M40@E'5FN\0Q\RCPFI0)WS9L_.E-YQNXJ=OM5]%-HZF,?S$^CC%+79*1$#%GB
M2JGDH'I78(T2F4P-<3B+(W8+1H]QW2W@4:O.]U+U+C-5()=:4W$\@LM<0PS>
M."VRQ=6=CT>7ZA,FWF8NZV@P&& (OWP8=C%.=$GG.@CRRZ3^T3.IBFQ%Y#*"
M+?2+TD+4<= >;(A*>'31\Z%%-KOR=K:"(8"F882_W^OX)9.[/H'G.A:C<X2D
MZ]MI8A0\XPFRM-;YP%Q1*Y=KZX[Z3O2^&:P/%0,##.4?V>TFCB^+%M(Y<H<C
MY@(J"O*)ZVPMRR4O/CGR) <S)Z<;:Z?2N-,C+/NK=33#U*#>K>W2W?LCJ\D&
M$Z2B4RPJ5Y_9&_!U VDF$3#KBF/NX&-$V[%W-J%V#^?ZQ=8Q2BG;6'TF0;Z1
MWZP4*L$03$F^)L\M.)X<\!@U.9B%9SSX));&/)X-JKE!]8FR8_AUV_A])O&^
MA5\GC2.5F&AYW:XKP(NXZ L+R23%LC[XX+;&/)ZMJKE5]8FR8W1<;^=WR<UN
MW$JW>.'#P&6TH! +(-W5]:5#\BB#"/S@+\&:<GBVJ!XLJB^$#;M>M9%-YU,H
M0D<('B.H9.DG2;](YH-(*'C00WM<\*+LPU%K6QLU$%F)11H&S-:%ML86<%A(
M%\7Q@,PDFX>6_]F1M3>3%1TR9(8T767G0L=&[KD,OF!B8+THQ+.L'7<Z P]U
M*#*))9>A%=[WX_AL1\,%V)"N_JWS2BY26@ 'KWX>S>J$AAJS7P3Z^QCGER9Y
MEW5P8)(DC66#%#PD"M-)6=D(U%A.9P[O1E;/!C5 2#VU)'/L9KSU!\:G7-5.
M?_[39+Q@]0:OON3IM;C4Q*JWM22?A*F'!_W$LX9HO>;19)[TT+KS7L#F"5G0
M(2'<N,>O;_SU5?K;@^7U+O ZEOFE]K9P;1QPM C*R00^>@K5N>5"2L$CEP,S
MN1>P>3:Y0YA<W_@;8,?5=F_YXNO7:?Z*\_R>.!^-9Z.X''%G4E;":0XZUBF?
MJ>:<7?(07:Q,&TQF, N%]V7V;'X[F]_@L=BPJOB0/=^#ZQ]9N5>$U<Y85 %\
M71*OHBH4AS(/==UB,89.',-W?P39G+X3LHA6CQZ/J^.GL+7'OCL>&>:*/2J6
MM#5DC]FS6EA0"ES2'H)$IJ1SAJ6AO6Q?R\PQBG%'AEI_#Q?WP,FPXY4?&>.7
M22:M)3IB)2=05FK 1(>.T-8[ABK3<3/<L&2%F[,)# 0I?040>W#6.=V^/I3"
M[-!*C,"-S*!,1KJ>8X#BC,<@5'&JE\U2@^#^;&/#T44G) ZP^Z3K?BQO!5>R
M1"BZMF<GE@"=K[LKM&=<!RGYT-Z!#'9QVZD7?0X H:<6XXYM,4^>ARWV.:QX
MJU;K+*2EJSER.MRL4Q"(,5 \"CKI,.K(!V8FN_!UMHUC@^6I0?CA; !!]#H%
MI<%PB639]4$$MXY^RYCG.D9K36O4O\$-('L!^BC*'N8&$$PF>B$D1!YE;3#1
MX&I26!2MA?:5@=9EB1\(./T-()TPL'$#2!==#*H3=</X]5UX.F\ Z;0!I!-,
M#K%*X24Z/A7\"JVXE][5O8RY+D1FX)V*A+:HN3!)9'5P)W8PN.VT 61PL.VB
MVA[@>K>7X-$(N-OU$E(+Y;VQX$I=69$U!8>6"'.8T7KAR,-IG=A;2\P HYW>
M=3WI0U%'V0-RZ^1,RL5L=G.]#,?^(*G-)S_A5;RYPGF>?WM(2]#?JR)LNC-D
M3Q+:[Q=I*9.5722..Y=C]"4I5%*DX+SG*N88ZOG&Y=-=)'L2<_2])5Q;R^IY
MKF,='\]8!O*'/00AG-6$_Y &,X+P0].])2^AX%Z/C[1]EWW_UX24/;H:S?_^
M1$J_%#S(5$0 6Z(&A76H'WH)B21;O$C.Q<$T&.S.U@!OD[88;Y8[ZPDJ?:TN
M>4D=:A.+R[H2TU$$YNE^%8M;V]?)EDE!0LV-9]9[[*5SO1=NWB;VCP^,(8T\
M?8ZS3Z/9__PRS?6A0Y[FV7QATUSXS'06$)TTM3!LP9,/ :BB]RQI9&(P?9N[
M,O4V#6 P,!G2:_I-%O[SZ/LHD5>]8) IXW1"#H)\:5""?B&>&& NP19=+,^#
M>36_*U-G.S@J3/IX@-*LF% <%XA.0TPFD9@+ V\4!VD*SPQ19=$\W?@&JX=[
MH?DHRAYF]=!QY,5%!QI+E:-2]>&7A62TYSDP89D_5P^;86!C];"++DZE^K(+
M3^?J8:?J82>8'*(,\Q(=GPI^14I6&\R0-1TL*M,5XQ>[R$M.4F<K,CNX^SH8
MW':J'@X.MEU4>]#J88[)AQ@"A%R;A'00X*Q,4%BTVCL;F6K=2O/JJX===+US
M];"+HGK(V_Y V"U)W&D;12228HK+@F9@:,$9F5S2A8O<>CK$,V2<4;.W<M:>
M.#U6F]]]_OWWBSBGN'S^=\,*\G,?V[PJO)7VE4JO2(QA42)(652(.=1:"^/6
M<U.'=+,GE=[GON#HU5N611 F!0J#DZ)+-1A FS@=2)(51)W1#2;+W*YZNVD?
MXP]V]_O--'XC.JI=SRZ#<([+NM$@UB:GY#7X4#+8["+CP7%R1UH+ZV6D#O#\
M;(O%3BLV&ZFTC\KI\V0O,IYKJ;X4Z$*."L$*)D&98L''*"!QG3UG0OOV@V1>
M0N@9A<W5V3".V*^K=6E92U[7-+TMQH/2OUG\U4MO2\I*<7)N"P/ELP;'7 "K
MDL@B%V=UV.88');D-P/? 2.AAY+E[]-)S#G-?B'Q5ZIQ'.^RN+,_R,&;OJ<_
M&).?5AWZYZ6RO#NX-DEGZ2$+FT A16](_B&$E'*(J@3/6_M.K6A_,] ^JM('
M76?DOBC+3 )) 0LH13\%[A&20_*"?(KA7&<\MCMQ%&4/L\[(-,J2F '-'2>[
MLP*<= :*2TP:E103K9MJ7UF=L1,&-M89N^CB5.HTN_!TKC-VJC-V@LDA"C8O
MT?&IX+>N68J&9[ .,Z@8++A8Z+)QUHE0K!#YX&T8@\%MISKCX&#;1;5]UQGO
M"A%2:\;(J^%FL0>+2_*"M0-D%G-2H:!NW9OR>JM$G?2[2Y6H@W(.T9-(H=7D
M.G_!O_+L-YS6+8W?\Q[5H4T?MW=5:&=:5_O^DLK:9&E*LLI:[CT*I@T6[E-!
MX2XW??!^]OF1O$GZN/'7#Y/9["?Z[+_+<G_@["$*R:1YGI@%9FN;:D@9O,H.
M>,E>:N^%EMC87G<@:]^3Z>=<\G2:R;_]ZV(VR_-93;0N+?+J:O+_:HQ_:2R6
M)(PCDZJ]OZ&^CP^F ,7QTIJ 6F#K]XD[D'7XDZLU2E8/HM:ZZ*'8LEX$ERFF
M6) QR#I;4,)X"+8.%$(O T,98VS=;[^>FM<'CD:2[\&Y(;C^1*@=S1]3=7$]
MN1G/+^G;LU.RD/MG&"BG,CBM IAD8W0^^-*\-KZ!G->'BE:R[Z%&\,=XFN/D
MZWCT_Q<GVMT3CB_?</[?DYNK]/[Z3XSS=Z7D^J"C7NN+)I18*#I@UD)PM0G%
M\P@A6P4YHTM%DF?G6T]Q?QFEKP],!]!8#^G\-53?.XN_YS%>S4=Y1E'#7=M?
M;7\:S_*ES$8'J1&D4(E,A->!)B0MKYPQT>1L>.N,Z![DOAG$-===#RMI7T+Z
M18S3FYPN'2._C3D&)!\$52RY<UY)R*HPQB3]PULGFO8@]PR[E^JNAU6M]<*_
MF5?"_FL29A=Q_K$(QNV7*8YG"ZW07_AE,B5J;ZX7@V\2_2Z/OH[?X;1.'2<)
M8EA,O;BT$3')7""&6E9+WH"ST1)V%+K@C52V-0K;4?_Z0'DDS?:P!'6]I)95
M-".$TR(XHJ>0PT#D  JK0?#('+<DL.8+2[>0=*AB^/&"Q.Z2'TH-^_Y4OKB9
M?YM,"=^+$D/FO-C"'6")=8,),@A21F*%SF!FB_2N]?J YRDY5E6[J:XGS67>
M0Z+A*56WV?]=Z.JI\+R.IN,4CUOH;2L4]A#Z(4&!DO/(A08?#:\KCB1X+048
M+"EF@=*R_@^((U9D#XF%+K+N 0-$!7GHH_A3S7M-_[ZKX9DBC346O(BU,S"3
M%\2\!NFSR\9(1_^T+EL\1\CA7=4V>EJM3NPMY%Z:/\@1)I?Y _W-J_^ZF8YF
M:10?=8>ZF+@VID!QM7LP6 ].%PE.L9@L=^A$\R<=FTEZ)6AH*?A#M%E^O@FS
M_.\;\D???:]O#/8HGJ_[J+T+YSO1N%(T]\%GH]%HRX-B:()TR1I9,+"Z 4E?
MKOO0/>WNQT]]B%Z"B]'5(4":9;F<,."E8H"88W*<96-;]SZOHV7O)H?ETY/9
ME\E%_/?-:)K?CQ=/X&>S3WF6":[?"/\_Y^_Y:O)G_8L4=JM8%GOHO*6P.]L"
MGI$H'/<V.6VS4,V;&3K2>(3G/BV0\J05H4_5]'!-/:%WN3#]<XYT<M9$XR_?
M?QM=1JMXRMY!2+XVL6DZF9FC $X8XX)E@MO6O;$[$?9:0;.W$EIW$GXBQ(YO
M:I<7A?+7B_Z:<#7ZNFR=R=/:78-?\\?RQV=">\U87Q*J0RE)@17DPRO#".$E
M&4")KF3'G$IRVWWVLJ\^<5 <0-X-:^H+:N_P6Y/ ]7G0 L7+U/#LTD0CO.,%
MN#,&E N*_"V1(&DZX;13A:UNTUP#A$W?\AITWDR*?72F_<CM,H\G!=9YB@HH
M;*]U3J2K*]8F9^ZREM:ZF)N/EWB&CH/UB_5Q].\MV*$DPU<9N1_L);@)7A:P
MC-<1QCX ZAR!A.:SYQ)]:;Y,]WE2CM;DM;>*MV#F):+NH_/E*5EW(P!W(*RO
M]JMU1!TG#=Y$==OAL(?<#PH,Y)A$4@DXX[I6@@I@T!8,2I6C]$*%YK-.#@N(
M+:GPP^*AB[C[Q\%M/LY'641$"8&1/Z.D\G5O'"?*N(TQ!L%"\U;UYP@YN@OY
M4D5M5O\+I-PPS3";SA\U.2_#VG_F^;=)>C_^GF?SZGD\_=.<:P/5PA"*L^1;
MZ4!AC:*PQGJ21 U_D^0N*N:)J9W<!R+D$3+H=P^HV)?&D_<K#JJDAK%GI7L=
M77?==SM0UL7SV *CS=0<UN4XK%8GO:JDX66T X5.8HQ&1O"J=C(E[2$884%:
M%[21"5/8*=LY0+"L<4>&BI4NFFB=\B1!YZNKO]Z/X^T5:IB2H7@$PV)]_F8"
M.)<%62 K/J/E7F^MT#W[R8?S/%J+?-)*7CU4-JH[];$\ZMY>/C+1G@5O/&B7
MJV.=$R CRE+2,=6V$&=:]P(^2\C).PWMQ-Q#NO)QS_[%./TV&>/#GRS>+>/B
M2<#L;E3W#N3VE*#H2.IQTA8-E+PZ<^@ &NHAA.U,=F:R%.N!2X.@-!VI+E?:
M8TH)0Y(NM@YN!P&H+6F/ >"I@V):>Q:_7DT"7GV>3W&>O]9G:U?T-R;393_]
MUVE>T'QWB5K'K4<%E@DZD#-=S(Z$1&&\0X_(O/:[#5;M\*6'SX3TJKW) 43?
M@_^R6@-<F$CT.@2CL;9*>Z()ZR"9.F?5)4WFH^FN;ITP?8Z.5^.]["WD'OHW
M5VFZ=<QWH:HO'^59BHXTA6YOC6V!P![B[L/A>)XZ(YC//$C(2+\H'ST@E@*6
M0C6#-9M;\@F#8-M(MP-AH(N46SL)7ZYO2))_?_F6I_AGOIF/XMWE1P3QY+D%
MS@*Q%^@GY,&!+25X(2++R>SD$JS]BB,X  T4,&DNO8:W>LJCRP_Y*UZ]&\_O
M&EX8]X9Y^FZ3Z\Q6F15X7CCP6N6KK3!QX_2J68[_]^OD^W_01R_MEWYX,-MG
MOO#D;^U]A=BPZ[V2LJ3B;OSH#G3L<#UO5^KC;SWL%;RW^"<-9=?PO'U"#WHZ
M'%(=V^$]G1&*<7 4;P +F6>944K<-'QE"#I<<X/VIL(N(NL]4U^X4(L;(UJA
M*3R,'.HFOL6;>J=C<FYU(.+@,O7["7AC7KZ+=%I/$'WB>"YD0:'[]7^\J^U#
MLQ'=#>_&-]=Y&9-_&,WF.[1"=7!NZQ?.'JRQ?G6W_J@&+-QW2C6(#68783:?
M8NPEYGOX\'T';\S)$UM^Y&^3<;R93NN3T[84/_\=QW%EGVCER3R,30+I(8[\
M?9K_Q%&Z'5%U,4Z/"/BI%W7L\HT#54X'8?4PGO!N6DZ=\M2/;3_W#2T,_-'G
M]H.I==]R<!QMT-&SEKY>,CW8^NHW]GOB/O]%IZ2170Y@L='MN?WC^DO 6?[/
M__._4$L#!!0    ( $Z"5E:_0N_+0ZP  $0+ 0 4    9VEL9"TR,#(R,3(S
M,5]G,2YJ<&?LO 58E%O7,'S#4-(M2)<@W1VB2$I*=PI(]X!(2O<@((V @#12
M$M+2(=W=S0 BS3><I]YSGN?1\\;__^_U?VZN=7'/S)I[[]5KK[7ON9FX60"P
M925E) $X.#C $/8'W"QB[ST!6SX' 'EY@!$  !0  4X(@(==H<->R 99 @BP
M:SC8M7I*ZNU_@ @ L/NW2 %DV'LP'$ 4!@#IUF_?_35^C5_CU_@U?HU?X__2
M(6MG2RGGZ&)F;N8( (C1H-^R"7Q8UI =C?#WZT^0F-^N00)\  "!_./Z'YD%
MRMO;N_W*+'Z-7^/7^#5^C5_C_^[!R<[))<C.*<C!0\DN(,C))\C.\R_?@^4@
M@!U@"U "<H CX *8 >8P@&4CP,TB&KF%L[.](!N;K1.KD:F=L1FKB9T-&]C(
MGHV#E9T-$!8#VQN96)DY4QJ;F5O:BM#OUS724UJ:BM!K\,BSR]L_-K.PE/9P
M-'OFH:!JXF%E(F!*+R:*@2H,%@3;V-N8.1M1@FVL;9T$P2+4O]U=$'9]^S8;
MM:BPH^ES014)R;]BP%Z)4/]U+6YN;JQN7*QVCN9L' (" FSLG&R<G"PP#!8G
M=UMG(S"+K1/-7V\@8>9DXFAI[VP)R[)N7QL9V[DXBU"[N%B:"CXW>LYC;&K*
MPV)LQ&7*PL%A:L1B9,K%P6+*Q67*Q\/!S_F<PYCZK].;FOQ]=GL71^O?YC8U
M83.S-K,QLW5V@G&#@XV:[7]V3AB+_C[IOV0_C$88CN!C1S,C9S,)&(C>BI>%
MG9.%@T?U;^)E%>#C%F;[ YXPVQ\6^O\!MT2%34T$36[79.?XE^F?F3G\]Z1M
M;2GZ']+IOQ )>^\O%["[PU3OSIT[PFS_<>)_Y@3;7S4/=O5W/85]D_+_A?%K
MDE^3_)KDUR2_)ODUR:])_G=-\H]<U\P6EN"ZP3+9FVG@,8",B(B$B(",A(B$
M@HR,@HJ#!LLQ4 FPL-%QB CN$1,1$-TE(:>G(B&C([M+1,U*3<?P@(F9Z1XE
M&Q<;(R<](Q/C[4W@D%%04.^@XJ.AX3.2$I$R_J?'31. @P)O K(%P5$#\#AP
M(!RXFS:  @#@$.%^&W_;%,#!@Q 0D9!1[J"BP1 JL0%X.! ('@&$B(B  /OT
M%>QS  $'$9>*0QP)3]D(F=H!G],WYAT*S:.R9@*5P0-:+F-'OSNHA'>)B._1
MW:=G>,#(S</+QR\@^%CBB:24M(SL,U4U=0U-+6T34[/GYA:6+YR<75S=P.X>
M_J\# H."0T(AL6_BXA/>)B9E9F6_S\G-^Y#_L;RBLJKZ4TUM2VO;E_:.SJ[N
MH>&1T;'QB<FIQ:7EE=6U]8W-+>CAT?&WD^^G9^>W=,$!(+B_C7])%PZ,+G@$
M!! "\BU=</!NMP@X"(A4'$BXXLK(1@YXU)R^*/B/8MZ5-=^AX5(Y(#!V'$0E
MI.5>I(/>DO8;97^.,+__$F5_)^P?=$T!Z" XF/! .( 8<"X9RA0&K0YTWM77
ME%#^ ,5H&ZR,6-<J'.)[M$_B(@$J9B=.>7"QH(1L^<3]R9)WYE;# P[_)31O
M_,=F=@*ZG:5H>1F$6Q[!<[RT>0N):"YK86TWP)-13Q43Y#;":X; [CG'FAC#
MN\H/64:^X=1;RR@W<Q)N]P$>G_$G:7$D#MF-\]X'JS';BP KZ4:Z+9=/OFIO
MR:F%Z?+A9'9"L; ,]M6,FS6CZ"EQP^'V*\[O 5L6Q7;7>'TTUYZ7XC? Z[5W
M-T [ ^SB2/H&2!?#]EX4R/.&A@*;#+_0_J?0&)G2@VLQ4@NK-6*LHG5: F7,
M$EK'MV+RB)G;6GT 8MJOR,^>.'D?I%E2'*TO85W2\V!=<TA=TB=)79Z=^M\
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MYC1D=.=#Q5:,#\RO K-O@.%7JX#SF]_A3]P 7<_&O7?0<FZ C8NM3:;DLAL
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ML=CN"\4A!YCONE7%>[/AL%9V[5(9=N.[_F([//37R?L,H.S?H=MV7,NFU=T
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M=B=F13K+DLY,0DF.BQ00D2D1&?G6I]A^_CI)+$!./)=JVL5+'"XHX^1DZU6
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ML1[2BU3"BE##K^35U[V,[*8D0Z+ *5D'5=+BM9@2,$+%1]9X@Q2].Y=[11)
MP4L"L1=5ZVJ_K4RPC(=*):]LG#]>C'[2J![G5HRY-+_188E,!!+H6C%!7%MO
M:_!"BGWO;F Y77>A(C\GZ74M.O =>DG<<>'R6]W99<E_U7U*-+K&#7=W]+U-
M/C A=<X^(],OWL[.KL./DN#%R$21F&6QU4[/B3BZ2F5*/)%U11(GQJKCQVE?
M%.FZD8'^V&VI*"*"1&IV)1!TH:]+[,A9<\$WVZZP5P/8$'?2WA+AF4HB]1PU
MD'VJ/I\XF*3Y!I#D!U9 _0MP5$Z^U;!]J<AXR&L(RG$$7;1" ;&-NI(VJYL
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MBYN<\&20?Y)<>=DLF<W]08@(G'^4M]Y_K(1-[/S5%@D1U65;UZVQV;< 4X4
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M+?7UZ-"RM"_ZYW.RU&,LB97%L%9O7]:8HR"9N#QTT^:)%5O9MJ_";/#'-+<
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M4;:="@JP*4Q0@?)%N SJ'/-$RV7NJD1*!WQED&7I-1*_'_V0,L @9GQ;98I
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M[1AJC\YWT7Z2'TZL952*&:3/T6V<!;60NN+M4$-/'C-\;'$TP$:TP,OKT7Z
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MJAH?,XG&_BNY,G<FMD:K&>'6U*[1AHA"=]E3J086&MR8?1%ANTPV#CF^6'_
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M<N^R!9__UXK?:5O_<_Y,%M7S9R7!I^6[5:7.K)KZRSGWO3@5000I3A*(8AK
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M>W&P3:XT7US("7%\K2BL-07;:( M. !]!MN?:R$!-28ST*"R=;XN08T+T,"
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MV&M!%5\OZLJQ5=[%X1:=-C/PL%$#U'I8,-$URV; \B,MQL#\ORY'MZ7&K M
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M!$\(\7TB;1P%;L2:VHM_PWDCF)W7P-$:F7D6QD=^8*[95JB.E.Y4JN/7:J7
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M!?BE(D5EQK%34,V&//85'(Y'MA+@9X"*NVQ95P2G9%$;IM]G2\#SQ8(4I2[
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M$ R"((:()102%C$8",$#[#,BJ-6Q_ I9ID90N\V+UU'$K0IVQ'3-$IEQUDC
M#QUOL(7Y1H_C*P"^;[7Y89!2[ Z!=42&UT@R*D\Z@&R?0ET,>2V[OE'GXR?2
MQ(Z755$;^^7[Y;H\ZR?9E@HBB]N\S.I(<I(5?R&+U=;K[(=AQ#DGD/A8J'-P
M0&&*:0!#768U%AC'9K&6 \DW.19>/3R0XKDFA 4IRTQF;4EB?=FBY0>U OH#
M&P# %@)]F=K-<MNR]^B+."*C'U\?'=ZTJ3BM/K96$'0:SK87>ARR=[H.SC<
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M5%#E76P-V$CK/"S5%!E7W>PN33=N*SM#Y0_ZV)D^YXA<VG(L^@JQ_L/<#WA
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M'ZD/*H%T*+'"9F$9=^IZ]<UH\P77=&"*-6@_4O<[T!J"6L49^*E>\_/-26:
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M-)N!C6[U$5[ILU._I@O^ZA2<;6(/VOP#I>4++:6%J?Q"2SJ2%?T22VMG:@^
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MV1(%4 #-VHF8+J<M N<\$!\<X-S6\E$NMZ[9D;W@#HR"&0C9Z!$PN[AM+6G
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M$I6E,,D3G),XB].\<.&+H8),C4Z^W\FUK,X&;APR>"'L*&8,> ,SD%$!&AV
M4:+;AZ;38\;([(^5+D7-$VD-%F-43KL4K.>4=_%X@]/.Z^9D7U:+.7_:7WN+
M*$=8R11&!&G&2V5ADLP9Q*2(L<J%TL<VQR3SHQ--C='V_?ML0Y'.0FG'63X
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MUR>Y^:R^TQ^S%(D4$9E S+1=CZ(LUMLK2K1)'Q.$I8@0<RH+&T;,J9T$M%Q
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M1(0EFB1,FB0N")/Z#S%VZE5Q9K[)\06_DV*[J#(6=J*#5G;'*+\S4-O1B$<
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M#H/FA:]UX##N-;I^I3_F]]O[)H^!XHC)+$(0$].SD)N"NCF*H:#Z')EQT]S
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M0>$,R4OGA/L0 P-G:7EG/!_Z/^^U^?A(%Z8FUO7F+5VOG_1,]=NC>2I-HDS
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M#5B47<[T>[-.C^G3LTTX:A74RX)<T-'^,ES"]!> ^Z9,OT'4*=/O0^N"Z2^
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M2AUH<)ELN5P:M_;#+\+@-&J+O\VMON5"&-SQ#[\@(]WX#_!BF%W]7X9D;R"
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MTR,P14(>+E&"<)HF610QB\9;)C)HO?WC=]VJQ:ORM@96OJ#S5=VD.%_ -B4
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M!TROPMFYB:9&55MR@EI0H"2U.H>?Q%:/CEP@-C#UV(%E3#3GD'!$*B>G&95
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M*NU'Q)E@"6<1FBU5'T4]XML9W8C1UG,,]Y))X52!?U5&"R^794Y6R]H9M"S
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M DF,$40T""#.0A]&'B<I12@)F6]T0]L[W=3(H9,6E&MQ#2]:^]'5O#UUAMG
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MJV&%X9/@ZA&8$\@&YJD-6IM+]1_GT#*O-GP."5>5AT_.,VX5XG/J'E0D/ON
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MALTVS>=.S]_C:2JF66IZ^+O^&LI9\[Z'_\T._KT2X--E^,U[=UHCZ*JAI[D
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MBQPBGF9QGG <<Z/@@C/CS(T6/G_]U7!-/@>@WL?O !;?KJ:]A+LFIL[/F"[
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M&>6.8O;.76?;_19OFI2J3^)#N<(K6N+EYW7+)KLZ>1D3+(IQ B/&) MP+OF
MD!PR@HE(\RS$5&MG9S+HW)AA)[,ZH-A)#7JQ=8KDV4^ 'H&XAM4[J5R-J$5#
M8GV(G+4EUAARXN;$^B <MR@VN->V=6@73_8%__&+'*V20]1-%9@OO.;5$Z\7
M! =108,(8D;D_BT+<E@$10A#%!6$T92GQ"@,^/*0<Z,C*2AXZ"4U[=UY$5\]
MOG&+FF>VV0E[ Q1V.WEWA\Z]S"Z[8^KBXZS)Y<4!)^Y5J0O <<M)[3OM:^?W
MH:S/G5>29B)/\@!!D5#5%"25_!)' E)4D#3B',6!@5?HY!ASHY%.RETL^7F7
MI#:*.HZ@J['Q[0)Z"<L5M>]?XF->\/X*G*:M<J_Q&EF5LS\#@$X-^Y>W3EZX
M_HSLIZK5G[O4/#CU=LM*":NJD;0(PCC(@X3!-%.^;D$BF*.B@"0N$,%Q%H2A
M5NKZB^?.C<DZT8"233_H= C4.'%=H;YGLM+2W"B8](2>5@&DP^=,%C1Z0OAA
MH.BI/]OM4[YPNL1U78J2-O2JFF,/PK&:]I0GZEFVV06;S]*F6;.^N.5NIU_0
M%%&&0UA$J>I)*T*(B;1!\ABE&8T3$K+ 9&?C0\C9??J?WM[9EY\=1IV"W[_(
MOZIS"U5MSM"3X^5]T-N)O?8L^V:XR2?8>*_G<P8<[0Z]B#CI?M(GR"]WH%['
MLEMPND8<JWL5Y?L65]6S:-_C>H$X0U%.$8RDJ0<123@L:)C"! <"HSCF*3$J
MS7%^J+F1_TY2H(K% SJ4U8R_1^#58V$WH'GFTCU>2DKP5@LO8SJ\#(4C4AL9
M:%)JNJSP2X+1N,/&M;7>J.1MO/R*E[QNJNA^*^4RR+ZLG_%R\_SS^H_W*R;I
MB2JOP#U?9"B,6)JD,!:4J*A-"@FG,8S3(BQ$D@B4<GVGE^'H<R.3+K1"&0N;
M1FY0-8*7*CEIN?X#\A4#CSOQ39Q!IO.BXT;SB+9O!ULO.FAD!XWPH)4>=.+?
M2(9J$+\!GR>!W,0SYQ'ZJ7QVSJ? T+=G">&XU\_TH1/Z RWU/?04VC[$)KI?
M/N5?JAC[X[OU=VG9KJO'GTNJ6L2I7DQC%:23'*4IBAG$F5I3,(D@SIF <227
MFC@N6!+I'Z18BS&WQ:51I&G_^@C^ S\\_ATT"@&ED4DDO?6T:"PIDX#M>6T9
MPQETVH!;U1#.77UU^TDQ28688G*F2INX<I)<I4Y<"^EXFH7UTR=,R;@6@</T
MC:N?9N<:494&^O)5W_"?70_3^FY%*RX7R?H+K[=+M=E2;IS/5;FN6@^-O+:/
M7JH7),0"TQQ!5H011(0DD 1R/R0P3[(",[D3,NHXZD*HN2UBMXR9I$$XG1\]
M+\S4J'M>S8;J-![L7J&FXUZC$MBI!-3'#1JE0*M5<\M.+W<.'I<H.W(%.1%I
M4J>12Q!?NI></MOV@+3>5"7=<-;D#_RZDN-_^?IK7R&"<YRF80+#+"&J0@2'
M19"DDG(1SE@J*9@8U?$;'6UN-"H%,V30<3!UCPD=0>29\_9R@D90T$@*?E"H
M_>BA3(T6+LY.X<;&FO@X34/MXW,QG9LLW V2>-YN-[6T$__OFM2W=-/4[6N(
M2/Y));OM3]^Z2HWO<;62#%;O J?^P7'U:<47H8CR+"8(!HQCB(I(6G(T*2 F
M&<5)P2@.M-+67 LV-QJ2;V=LL,MU.44:SHA7 MXSN2F#3*G5[&Z58D!J=@/V
MNC4F6Y,Z>Z(V::_@S3[6\@8H)8'4\I6FTL"%\4I3.I%3XS6FULS?X0'_40^(
MR_&F\XEX0.G 2^+C^98)WW(OL*T:/\S=ZG&[^5+6__I0<=['3GV1(G0F9E8D
M>9&*  I:<-7^E$"2L@PFE(FP0%G(B%DJN/;0<ULU!Y*#1O0;H(0'2OI=U!E0
M\AOFC>M/AIZ][P=B[^Y[770][ 3,$7.5?*X_\+1IZ<: '"6LFS_!,I7]4F_I
M<ZVE/STVWH[?I#!-BX/W?SYRM<'YME:_^B29>H-7*O+TX[;Y^+"0E!<QW/8!
M1!$M)!.2%!8D) FG,2E"H^S3J02?&X_VXJK8W:<F4'?5!NK*?Y</C6TDUI7@
MY4:^/W+[7ZY K7"H?S1,L9_JQ=!CY3E.MV=.;_2!;83)4&DPT!J09S"\KH_%
M:E2_ 9WR-Z!5ORDE/7R!?FM>H $(-Z"%P6'Q@(DGSE4!@JG$GK:(P<23<50(
M8>KQ;=K9\D<IU::LW_Q65MMZ]^,[^<+@YE==YF%G5:9%$DA;/H<TC3*(>,YA
M'J<"YD648LQBN;1I+6PV@\]M<?JVWN E^.\WO_WG?[_[S:2UJR'F&GXPCTAZ
MYOV=J. -: 0%_PGVOVOD[W[?9Q#;--,U1-RDQZX_Y*=JO6LZ ZZZ\=HA-]ZD
MU_"9$_;NM=/VL*6OY3-L*OE3NMZN-O473GGYI-+G5%W0=V7=_EHN2FUZ4YO+
MM,!ABL.$"9@D!9*;'B(@B=(4JD4A"PG.HT3_-,5L[+FM"C_SNOXO@)?+]1]8
MOA:UVJ  JHJJLEZ#QC)=*QU,JLR;S8C&HN$/9\]K1B\XV$O>M2QY=P!Q(_Y-
MUZQ-LT*C#=8F-?V]83[1:N$8>\/R_E;HC1?X-WODA"7^K70]+/)O]PC+U-/J
M'J_*_VU>O[=R][)>EJS=\*S89_D&]J_FH"K<KE)<K61:KI434%[]M;Q?-4FU
M<CO4:B"W.I_E\^A!&W24TR(1&,M=2!Q#A!(*<9[*G4E$DB3$09;QU"BA=6(%
MYK9P#?5O/N%!/_N!1F"O$NAU,LRBG?I-T7.ZS7G^/2^H0]4E9P^5;]Z$H?J'
MI3CW"( ]!.W;,_[*@-\5$*!!PN'IS&M-HJM<Y:G%GS8#^I4FYRBO^K7DL#RU
MVI*:_[^M'/R]*GE8F];\/7/[C/AG+R)H9?13V?<"$*Z<Z>>&F=;Y?4'9(V?U
MI>LMK<(S15#:B@:#%H1]:\);(6V=EY55Y)?V#?^Y"(.<QC'',&"JU4".5,=
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M*KOO=3R[]><=%[RJ5,:9W*?+47^6;^FR70WEXJ8":%8U[S)<%RQ%><9R!O-
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MS>/8J*CSF7'F]F5_W3X^+AOO5F,0-26YVX9=O,T*VZQ?MGXV/'4Y![@> SB
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M5L<W;9V# 7/HP\$=*KD^@$3C9MV'@_ D'3_@HX/FOC4MY2ZFCU0SP0LD\[B
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M%=U*BCRC><2AR!71K$)R2&0<0\1PG.4I-K48? *Y0P@W-;I_6ZW+QSJ1K5$
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M:,8&9L>+=>>VN?G@HP*-:F!/M[JPW8EVX/4+SJ&#/?I"<SF2*3OJG+J9Q ,
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MNL+;R_!BO=^=8>KK\.[^L%O[N._M5']=KM_(JGQ8F*'NJ[])\5 N'O8NZ )
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MKB],*Y55!30I-Y7V'6/BK.8 %WI['#$$E11Z#G*101HG$N8X9GD<140RJY.
MH69@#&KN!#7G=TVY^_'PMV/NT*@.3.2-N*"6]PYL);[; 6Q.5J_TI/&(9[$'
M*5@4B\60(\>NV(-P&K'B<*_?NM!%D&VW;ZDV!C%.8E@PBK0%B!7$.1$P05(O
M EG.4N*4FG$\P-2XII//<9M\@IL=;]R"QL <L8TE'&(O>DGO0)_]R>-'_<0O
M*7?\.5^\SM,+7R[*M?Q@HIK>;X.:F@PN4XI2&PM%PK4A4<A40<1SXR9+$<RX
MXHACE,N"N^1&]@_G]%F/E2SIZ'#OQ]/2WQX,I8$_]T906$L*=J*"+J\R:#%.
M.U1".=[[!QO7[VZE^(G;W>XNS[S,U5(;T.OG3_IU,+T>3:FDNN_CF[+B\[KZ
MQU?Y8_U*J_&/&8NQ?GUB"EF:%'HW$B%(6,XA5FDA*!$1IYE3HJ;#X%.S%#K9
MM=5LI*\]OEOY'1,W7>; CGB&0G9@&NH%%>QD![\;Z4$M?D"[Q >U4"F@+D./
MFQ/J <I)DJC/,T;N8]DV$/NX65>:9$5=<7B]*A=5R>M#SUF1HTCFB,,,<6U"
M$1/'0#,.(R$(DE&A>.04QS"8I%.CRCU!1^I%>74N+8\EIS!#0Y]7WMYG<MM)
M<D_?.[#5&-0J3Z"EI.VLO'0#R:MR_FNTB[2%.UAS2.L! YO*7_7SWBP?:;F8
M11+12,4$IBBC$$518BSD%#*]SV8XSF@LG-8(BS&GQO:]-MP=,(*#WQO1'0]7
M;2;@1O/8#]:!*;INI=ALS;\>;,ROXQC.!#Y%9FC+=V_$:1B\IQ!8V[EG;O7(
M._BOS6+Y]9M<T2>Y69>\>K_@>I O\R5=_!^YUA^WIKS7IB_<ZK4>4ZZZ@H&4
MIE+Q HI426VX4@*IJ:(9<\3C+"5*,:MM^PTR3(VDC!8.<?>>P/>3T4AP#DQ.
M1@&PKX&Q_/B?:]JOU0!;/4"C"&@T\:F5Z?L!V&='##\?(^5.^,_+3WPYGS>Y
MD7.]BO_'O^$DB?YJGE?_&/_U\D&[6_+%;5CWIF9X/GJ\Q(W;=#](Z[CQ49['
M35)?ZQ2S.*-%FJ6*4)CFVD!&G$>0R(3!*$ESE>CU"6?1MFR!PTF4LR167^M1
M;8(1#JE:1;I"!&OZ \@N8IAM(X;Y+F)XN=7(\6C+?>XLC[N&F8J1CL!:^#T"
MM@,>C7DC&.JXS%V <8_0O $Z.5;S?])P16 ^RR>Z7C4_?U1MM9*W=+70@E0S
MF4N21RJ#>8(Y1(KGIB9^"I6@$>(BPKFP2B\.)M'4S/K?OM2TN5R8VJ!&4"!;
M2<-7<^F?*CO"''4"!N9/^ZHM^QJ9*I.M3J!3ZH4JM5@!/6)UEGYY)E>1Q0H^
MGRHL=@_V#82OUI5QU#3D7\WR/,Y1CC&,4Z0@$E$!B3GSTZ@5@G*4I7GF$B=U
M/, D(Z.T4:FEK+>&K<7IR)<G,-K1WRW@#,QFK[>(O+V&B$<D]'FU@T4]'SU^
MY CG\\J=1C-?N,[O0];,\7I3/_"_EJRZY^N/*HGBHN[S7K:U235U[/79/"*2
M;>V_6:P84C3!$ L4051D&!*>:J-+X#RE2(B,.9WAA!-M:N:6%GFUD0*LCA;T
MVXRO@%,I1,P26@A(*-4&,TH4I*F(8,*+1-O0$>$X=V'S%YK*:4;(!IPGN^7B
M9= ?>*$Q5K+1JEYKC%Y *W8'=DK5=K1I=;#?"/K49-[J%FZ="H]WH!4NH&"C
MKHWA 3U>50<8P6\]?B/9^OVB6J_JLXX/Y4*^7\M';5\C66 F]&K*"((H3U+(
M,"D@R]),%BA#-'5*:+PPSM162B,FV,D)?C>2@EI4QR"(2\#:46@ N ;F0R^D
MG*GM"@Z!>.K2**.2SA55CQGDVN5^=-!577R]?&1ETWQ9<U0=Q'+/_V=3-N3D
MF#[G]M )O>.=X&!/\GK];Z)Z]H0?)/W.#[= WX3CX*-^*G[ '']!GD_Q=&"9
M!AP?59T5O%L,8L8CFJ,41G$F((KB"#+%%61,)3PO%$L2M[(!YT:9VAI;"VFV
MG[68-RRQYS&U=&G=BM30?BT/D-P=7'T@A/)RG1UC7%=7GYHG_J[>BSV" 3]I
M$GE>O7]\W"R6Z\/PCS;L28DDP@G-H<0QADA%IB">2"".4T)40F*26!7$LQMN
M:G30".P07'8=T'X*" _3P%S0R I.A6U#Q3P"]*YCZ!"+%Q3+D<+NKF :*'+.
M&IG>(+GK3QDO'LY:HX/0-_N[?&N2:K9^7U4;*=YL3!S=)[DJEZ)./ZG.YZG,
MI$RC/$Z9)ERI_T/S'-+<-":CE$8Q3B/EUI/,0X:I4;&1W@0@@LU"8P^D-H+7
MSR;.37^/)F#@25]=U46=ZD).KMTE?6;)SIH;&/N!^;T1$S3RWS49?-7=^4R^
M77;5':#*A &_6ZZ4+->;5<C4/7\\@]4==9=@Y%*CWA"=5A?U?Y2'0?IS.9=4
MO%OJC[Q^5KO@9PCC&,49)")--2G&!60XS;05&L6IC!"*8RL^[!EC:GS72 EV
M8CI84!=0M# ];\=F8#XZ@<7'PKR CX-9>3M.(]F2]J^1F_78#T"OR7CAUO'L
MQ'[9#XS#*Y=ZEDQNHH$7#Q^DYL[=";9*E(B1Z?>C$E,J.34Q!S&!$<LQ5:J0
MB"9NQ5(OC.3RGHY3'[4)(1-EQ374YG!Z;@3>-@)R+*!\ 5\[>RT 9@-SX%9"
M4(LXR+G]%11"U5&^,,JXE93[53VII7SE<C].^.W+STO]J2WJ0@0/<L%+69EC
MM"^2:[-KK?_6+E*2(I7E6005)1%$@G%(5)Q 1;!B6,2TR'*7K:'MP%.SCW[[
M\Y<_@X>MZ("VLH-J*[@;:UC/ &51SED20QHQ/0,1+J!F:089PE&:QC3BF+G1
M]!!S, YOO]PLV)'Y$,@.S.Z_?0$[F4$G-*AC&G9B7S=[G2G?%:M :X#UL*,N
M"JY@'*\2SO?[+1L?Z$+,$$,Q)HEF()HD$"&!(2U(;,Q(34XTX85R:K9A'CHU
MNC<RU>$-<_.?\O%II>'UL UKP.RXPQ6&@7G!B!/N8]]7+M"'7#]RU(]T7XGC
M#_#@WSP\47\S\>CZ0ZU>_;U<;:KM7]]H$&C]JT^KI6GM_'?Y."_%<^>IHI$H
M$")0YD1") 6".)$Q+# 5D6*%_AZMS+,;9)C:I]L*Y^"?\<3>PK\U/*(#L\!6
M8O *U/*"OX#=[VHUVM^WBMR!5A4?1YGG1#@XTH:?D)$<;4-.C)MK[C9(>UUW
MGH\>S[5WF^X'KK\;'Q6\ O_]XW*U+O]9O\9MPMO_E73U]8_EC,4%88FDVO;+
M$$2ITCM2B164(I*F8C]5E#IUQ_618FK+CGY[4;!R_3W@VQF3@T,Z\+K36]S_
MKDYPY<9ONZ_,'3!Z *W(*'7_K^,X?#N 'AFFTB7@.DP.S0,L'C90">[J2@77
MG_65Z^K]HCFO_F]9/GS3[^>]WI/3!_GVAUSQLI*?5B67LY1$>9*E.2P48Q 1
M69BBW 54A> IQFE$L5-)E!%EGQKIUI(':FXWYBM@1^(3G=B!J=^FNG=E6]Z[
M00#HUZ/!X YT*( 6!M#A &H@1JSY'7[VQJH"'E#R:=4%#S\ESI7"!Q#!-QU6
MR=5*BJ_T1[/XZA^ZW[5K[V=9R=5W:7)WZ[H*=%[-$IH45"5$[PM,^\\H+R 3
M::27.)SE.):1S".W;%D?,::V4'4BUCYEV@H)%LLUX!NMR6(]?P9"FNV=,79<
MTVN])LIN#1H>_H&7DT[8NB9!UQO,_+S]AU8-4^1K;Y(Z54(F\-X"9;#\7B\A
M1D[_O06HT^S@FY[FN9_@W_37/)<?U7G"?_OX-%\^2UG'NW[2[_HW?84IP7YO
M2HN5Z^>Z9?9>&[,$%[E !10%$A#%$D,2(PQ3%>7<Q*,2Y1:A'U:^J='MVR^?
M/H%.5,=M0."9LS3U7VX^AC;G6\WJ!,X+IOT=Z/1K<SP[#>M^''?;F02_UVJ"
M03JI#30%H6SRP-*-:W</ ^V);3W0,)ZQ$LO%PU>Y>C1A&+_0=1N&82I#-D&F
M'Y6VTA>\?#(%?8T7ZYW^YF8Q2FE"4P$3%D<098I"G)F@NURH)$_SC&;**;C"
M1XJIT;G^&G+'N LO\"T#-8:&=.C(#M.;QRA0!WG=@5:'Y]9_;J0-&/AQ"UBA
M(D6\9!@WM.06F$YB46YZF$?PRGV<1%_DHERN?EO4D9A2_+I<R^K-1G[DZR63
M*STG17M:SYA2*<TD3$2*(&*)@#AG$8SU?^*41BIC5H4^G$>>&JO%?TZB_P4:
MZ<%6?%#+#[0"H-4 &!4<HBB<9L,BB&4HC >F.2=X?:)5G'!VB%$9"N^1(E/"
MO-9N,2@^D/5&GC@]<+QX$Q\]#Z),O![@9_^^7WR7U;I><.I",J4JI7CU;+I4
MF")2&SKO#(\W="V/_1VJB"@S:6DH9]H,SA7$:9+!)(_C7.@50D1.U:!N$69J
MZ\:7S>,C73V;#?7]=UK.C;!0+5?P"]5[X^/ ??8,]K3<&GMNYO1-<VEG58\U
M0P.O.GMJ@)T>EV8!&%T&]6J$@#60&7Z3**-:XR% .S;*@SS3CXG_)L5#N7AX
M(ZORH2WN]Z.L9C@7:2JX@%S51>,)AE@Q#G%"TSQA64:1DT_Y_#!38\]62K G
M)OC=".I8<>\"J'9D=SM4 ].8!TK.U-0/0B#2N3#(J'32K^@Q45RYVHT"A"QG
M]QM1ZIGX8";$;#[RO,@P%CG$4FD#*\<*DB+&D!6,YRQ-XCRR"M\]\^RI?>RM
M>*"3S^X3/P=:_W=](Q0#?\S6*%A_PCWZGOEN]4;CSP_+[W_1=S6?K/YA]Z6>
M>]8HGV>/$MTWV7>)^X?X=K'6R_N[<BY7K_4:_[!</<]0G-,$80K3C.N-#L<<
M,IDQF$98\8)B(9B5O__"\Z?V038B@EI&T EI_U6>0_#ZEWDC+@-_G6Z0.'VB
M/8I[?:;GGC?:I]JCS/[GVG?9#145ORWG^H[J;5T'\/V"SS4K+!X^F7!TO4"O
MUZN2;=:UT;[\5>MBK/KE7#_TX;WI7ZPM_VVA>*JBG&&,(56)A"A",20*IQ"G
M!*4H59H/G%P;8<6;&F'L:V=Z><?%7]MBC/_I47$QW"S:V?DO-S<#D]:^8O\;
M-*K5Y6(;Y4"K'=A7#ZR7X%!!T&DX2,^ 8< /6=0QG'#CUWL,#NS94I#A1_'L
M6=!$Z;8-F$]:+\\HD4C%A,*8Q!0B$L<0YY&$A>D1'T4"*2FVC>(=FACT#VM%
M"$==X<?H:M!([=C!X K"=H0; K"1NAHTDH*NA_O9YNT!^QO8 1.JT\&5T<;M
M>6"G^DGW \O;W BE+CBH=RV_?9DAD0J%509I$6&(4BXAD7H3R&/*,L0+AJ+4
MKK#7[J$N+_AX);OLF& /FKS((Q8G"#)1< T-X9!0:?J9(J(WQ@DCF95KV@^8
M4>K)F1Q7 ;ZL-2E;UA3:PZ>?#/VT'ICO?OOU_=>W;\"7K_=?WWZYG==.=>S9
MT;87-\S5_F5'6GN/&H673D7OJ.?,O_B9*_?S&CDI+@3"-DPV2WFN/[(,P4+&
M"*)$,DBE4C#F64I-,2],G4Z [(:=VJ=8&YJ0U5'I?#_AM&TL;JK^:[M3_VNY
M .L@S<<MY\?.Y@F/^M";QVO5_%N1PUD_;A %,H(L!QW5%G(#XM@D<KS;(Y*T
MV>CMPE=,M_7Z5[_(];>EV!VB_W>I_[Y9?Y94E//G-U(3Q6.Y,#O!=[1<_9W.
M-_+^T=#I+)-482(CF(E80*1R##%C#.8\HY2@+$TYLHXW#2_?U-CP;=?I9!?'
M4O-<\^O'6LV#?_VCT12L&E6!V-,5**TL^&ZTM63(H=Z"?BJ=P-P.?<K0S-]>
M8)A6KW7<@49!L-,0M"J"5D>PKR0P6H):S3O0*/JR<^L06_NR<SQ2!.X+S;5;
MR.YP,]$;V#O L..%_PZ'V4&0\(##>'I?EX^/9;/<:%E,R%RY:(L<SZ)4"210
M N/<1 I3I/<P" N(36ETD<59G#I5(^X9:VI+]9ZH]1K-]X4%/YG ;A"GCF60
M^K"V],&&07!H_^L1> =R!O2[7@<CE,^U9Z1Q_:W753[QM5K<XAYOTS+8\]L?
M_)O97/ZJ7X<9$T)RKA3,F$)Z.X +B+GB4 J>J8AF$:%6]6DN#3 UDNAD!)V0
MP$AI'W)S%L1^(@@!S= N"#=4G*)N^E3W"KLY^\#1XF[ZU-D/O.F];J"JC%=J
M97W<K*NU)G=-)KWE^(3*4\:)-A]BJCDA3C)("8HADX3DC)"4Q6CVU'0B7-/5
MVLZ2&$EZEZ_J6(?A/K ]X>\ DP_E8F$"/AB=UUU51RG8&.CMH!&B!44%9'DD
M($JI?CMDRB'/.4%1PO(,%>W;\78A_L7?C4Z#D=X,6?_Y+_E:V!G#$YSH$;W[
ME^IWVI;O/'A7IE.Y,^R<C56U,Y#4TZK8&78JG*MU!AY^9#.I"ZNKUJM-4QG$
M=*3_JLVW5OY[(4KS YV_*2L^7U8;S13;&%@>J0SE60Q3DSN(XHA#1F,%2202
MA;,X2F(2M)#U,'I,;<?6O2FPX[G/\I&6M?FTGT-<5_#YZ5GJM7*L%?+&]V7@
M%7.\MV#Z*VCK[-\# ]1H@+6&8[>^[A !>Y ,$XW]LM/ZTHOLC5K\:RRZ8:8J
MV"(<2!S/$"RN1U])T=/-XL@D^*V2:C/_4"HYRT1*(L0R2)!)S8_T?V@A8B@B
M%J<X93+%3D6T;Q%F:LOCVVI=/IH@%+"I901S+:0IAJ*:GC'SNF=,N>L90XU^
M@+80. 9JW3*+EN%;(\W-P(M6IP;H;=U3G=G&->H HT_ B*\ J(:* [M%E'&C
MPP* =A(S%N*9GMW-ND/H5XU[Z<LW*=<_KY:;)VU+:WGT[THZKT.PS?+PFC:K
MPH=R(=_K7U4SA7(5<X(@*50.D4PE9!$64'*44T0*D@KLU.CL1H&F1L4'P2'U
M5-9'J5V3>N=NW#=/F!WCCCD- [/N_@RTVH!:'=#I<P>V&H&M2J#3"?QNM *U
M6@&-_5 (A^J@=JLXXS93"P3>25^U4,_U8^/:^#86_$I^TT:\7@C>+_CR47Y8
M5M5K6GU[-U_^86K?R)]IN3"__"QY6RBKJ;QQKS2G?:4_9C3G,B)<PB)"*43:
M,H8TEQ2FN,@95C(AA'DD6P83T(H?QD_+/!:W,@G9"TT59:WF7?VSMJ/7](?I
M>*ZW0.9O_YYD=^#??R)_JJG]W_,[H&4RW1<U/G/',H+A7@$[HA]W1L=A_,:-
M<Z 4:+0"/QD5_G0'C&K Z 9JY>Z 46_[K\<ZW@%JM#0)J.$6@.#(!UH)PLDU
MZI(0',[CM2'\ 'Z+Q&?Y72XV\IU&H/-UFR#3UYMJK:59O?W15@ PUJ;^/]/4
M9\8S;8T7'$'!8P91H?^#8\HAQTI)FA0XRS,7*]U#AJD9YE_K++55HXBC$>XS
M!2I7/!<Q@4E>4!,B44"L!($YY[DI)R?T&FV7RCS2)(R3^SSV--BMB@-#._#Z
MUTH/#$ENS\/J)"30:6 2"+M"-)T289>W&R ,M)#Y2##JDG4#1,>+TRV/\LA!
M[)K#[9\VF"Y!;27_0E*NTDQ!@5"BN2Z2$$<*0R0CSC,J)(E2ZWS"_K&FMJQL
M6R8>I$D_Z6L<$L"NP-O/88%!&YBKMG@=G.(:47WZ35P!SB$++AR (V6TW0*D
M6UJ:'32]*697'C%>NIB=+@>I7Y:W^+#JBCXL%VK^_%7O-.B3W*Q+7KTVL9YL
MN6JV$ \K67N>VA<Z*HH<1]JNYQ&/(%),0<;R&!92%9&@(HV)?:,@Y^$GQ[V=
M F!? W"@ MCJX$(KSA-C0]%#PCTT:SLA[<7DSI"[D/N0T(_%]V%>=D?J]P6N
M?S5P?NJ("X2OQH=KAO=3_+.!EXNZ:L]K^E3J+78=_E.U79S%N^7JW6:]6<GW
M5;4Q!QVS-,Y2F2,&99X:#Q$S[HDT@PD6I$ 1XSAS"E1UEF!JBTDK=9-?41F/
M?BTW4,L54+7DH&Q%KW,RFNL\,HG=YLG.?S$H^@.O+8WL39=CXZAOIJ&1O^L_
MWTQ#HP+H= B;D>P%7\ \9;?Q1\]>]H+G7$ZSWX,\:9%6WTSRM/[#!#Y^IW,3
M\MC:#ZF()&<2P2@6&409RB!5*(5*,2)R$D<B<:KTUC?8],BN^M;41S _R)VX
MCG36AZ\E<P5";6B2Z@"K?]B3-.!FVP624,33-]2X'&.A] F=V-SC7B/A]?*[
M7&TS-(325A(G*421-%MNP2')\@(J0@7AF4Q2:64HG3QY<IQ@A+/)<[@"6/]W
M?Q,,@ULBE@@XU3XXJZU7T8/#)XU6[>"L OME#LY?X.$0:X_<][=)NY2&;EU1
M6/ TRO22'>>Y7K<%@32/<LA3E22,BS0GTMH'9C/BU#[4)MR%'VS\Z9[4#EX7
M*\ M?%NA81SX0^\"A@Y<)WL"^SBPK*!T\%F%AG0D-]7MT+IYJ%Q@ZG5*63UH
M/#^4BUX'KB>G&STX^@O_)L5F+C^JK_JQ59TL]I7^.&Y6G0HJ8XY@%B<,(DPI
MQ!(G$#%"J3::,,)6)>CLAYP:2W="FX#1G=B],1>^8%L0=' (!V;HR^BYM(;V
M!=2!IH,#.Q)/>[R>;L3L!$PO,]L]:3QJ=M+L@)O=[O3MIOGWY7RCWY]5T_&O
MFN649)06&,HB*R!*BQQBE4F(DTPQ%HN81<*MG^;1"%.CWD9(L)6R:21I:1=?
MQO'ZQO9F= 9F55=@/#IK7E#^AMZ:QT\<N;OF!85.^VM>NM##QOK;^[]_6BW%
MAJ^K+Z:?F_Y=NX'@1:14+!(8,VXZ94H!:9QCR*1I52)%@N+"VJZZ.,S4/NA.
M.H>%_C*$%M92$& &_I:UC* 3\@YT8OKL7"]#Y6 '!8%L)-O'%SHW ^@J(KU&
MS^6[QS-TKFIP8-Q<O]KO$.^M4DUJ79-^H^VESW0M/TNC03DO:6M$O5Y)4:ZK
MF9[]F,<<0TPC;>V0 D%*DAR*B,N$Q"C*2-%E0O9SI)\ 5N_[8:;CP.QI3E<U
MZLWYU;)Q'C:RNIWV.4Y$/\\.".Y(ME0G>)=J:/:F1G9P*/Q=_0^-_'?@D]3#
MAPC/N@V_0,>'CH./>J#H!\SQ$:/G4P;)]-OY)Q**%4,1@4D2:2NPX"DDN) P
MCA0B>JLGT]QJ1^<Z\-3LPL]#I)'9^M6&!&]@[K)(& ._VSC80F>)77 ,#9T:
M-K(7R1<,QR2P6SU*QU;=J_(?>GO[_;G='#"5QS'G&10*<VUHF9I ""&H1!9%
M^KW+);<*C.@?9FJ4TTGGM[\Z@M!M*^H/S*A;T4[,&[>B1U#Y;47](7N1K:@]
M=-Y;T?.(V&Y%C^Y^D:WH>0TN;44O7.UIH"V?Z=RT\VAZT?(TSCCC"8P$IQ A
M$XE",@4+E$J><ZD4LXI$.?_XJ3%?*UW7WM?1YCI$SM*R\L9C:/NIA2)X4][S
M&H<R@@X?/JZI<U:Q$X/F_%4CEX#?->JKJLUC4_'K<UG]X]U*ZFV@_M1DM3:[
MP!DIB$IH%L-84/W]QUA!&F<(\B+CVOA!!6'C%'NWE7ARE*)EA$H+:6K3UE*"
ME19SI-+MUO-LQU:3FKV!"3! .?9=F4:PI_<=,)H#HSKH=*^]:A.HNNXZ3R]=
M7]U:WG^-2NJN\ >KF>X\L,<V^V<ZIT_T8=D%BL914B1*KR4YY]RD9\:01@Q#
M'"%EVK-G,DVL-]='#Y_:*K 5SV&C>(R7Q4[Z!A0&9M.M9#Y;YF,D'#;*-R R
MTO9X*^$=H(#K04I.Y[!:FQKIK%RN)?^V6,Z7#\]U^1VZ> :L7FO*!7@EYP_E
MYC'0#OH"5+W[YN-[QMLM7Y#V8(]\Z1KWJ+,W[;M0F3.2U9.).I;BU?-G4S=%
M:F%W#O4B1T1QSB!+6*(WS'D":5*8,N*:X%#$(BJL<ZFL1YT:W6T%!_N2&VMI
M*[M]I)H]]OT,.1BB U.G!9B!3S*\D/(*?[,?9;20.&?%]\/DW&_VV_COU=J_
M7X@ZV_S;<J[OKYKN-S,J4J'2(H**YQ%$ A/(F#:S<,XCGO!4Z+=NMC:%*NWV
M[=<&=&*@[;##?31-#<[Y3NHZ,J3:D_L__@TG<?'7.C-\[5C1^BK\=MOID* .
M3$(?CI!\VX^:\X[5%HI &\ZKPXVZ7[15_GB[9WV?3PZ4:6!9K<OY_+/>^ZU*
MOBX7#Z;YX(S&"8MSI;E$<*PM'%5 8IR#."=Y(7,FF;+J4M4_S-1,FIV@IFY.
M)RG00U^VOUU0M=C=!<%J:*_9#J8](>NNE4%@<DE;"@'76*E*'K YYBI=0Z,_
M/^GBW2/F)%W3X# /Z>K5?I;7I]622RDJ$Y'2E?#YJ)H:/[\M]'.TY:??E_*[
M-)1\UA]G*FM6,UG$2LE(045E75!80,KB#*J<1HHQHO_=J=E?*,&F1KR-):>,
M*_U[[4I?*O#VRZ=/714S6M7=2[[)O0XEX+N><_,!"6U_.X;.!9M@.QOP):9M
MX#6@4^EN6\;,S%"CTMWY\Y*=AWJ_BGO3KW/;\/UR;HRSN1D:]4!F:3"Q1C5?
M0X-Y;.8&?[Z'.:P7D5*80>C\E^5J_4 ?S&!U][M7E/]#BB^2;U:U*=[%#F).
M9)Y*: H60Z1( 6DD&"01DC*CA)#4WDQV'GYJ++ZG 'AL-:@WDG6;5LAJ)4"U
MU<+!6'2?&I)$1 I,38YP 5&2IY!DBL&HT%8/RXG(4V77MV3XR1FG9<FDIL=B
M*S0HY ,OC_M8=\(#+7W32Q,V\H.= CXG9NZ@.VRL!@5_I U7^$EPVXYY8]B[
M37-_ZGC;-V^-#[9U_D_Q=+0O%P_&Q_-&LO57_8C['V4URR0C"",,69$@B*A*
M(!91"N,X)31+19(AJUXP?8-,;0$W,D(C)#!2W@$C)_C=2&K)2[V(6OK+;\1I
M:!^Y@>BK&T3NCO(>#$(YQ\\-,:Y#O$?)$R=XW[4>EGZ[)ZV^+ML>YO="U%5L
MZ/S]HMZ*5%67;JRIYXW\+N?+)W/++,HQ2>-<P (7B>D,E4-:9)&)F,\BCK*,
MY[FUR>\OQ]2H8R<X>&J5,CUH::.6"61Y:M2I*])OT[C%3B,'R^>&Z;.P.\>9
ME*'],]TD?%V"5@VP-T?O%Z#5!&S3ZHUE]&;L^7 P2<>9EY%LTP'GQ\U(O1W5
M7FOUAL>/9[;>CL&!_1K@<9ZI(N9T^+-\TB_I-UI)/=3#BCY^EH^T7)@FBIOU
MM^6J_*<4NVON'Y>;Q3J>(95@&O,4YBS'$!&>099)!..($QKA.%:J<&OSZB_,
M]%PGM2YZY>H$-8N9T<9T3&_U 72K$*"U'H[I'_YS9V=8CS,?@Q\]FXG820@^
M=1.Q503L--F_\+Y_3MS3+VZ&,U1>A;\@XR9,W S822;$[4_TX]FNE>)7^J/V
M2E0_+Y?BCW(^UVS^7IL.BX>2S67S3[.$"<QPA(R#M8 H3F.]8<@+F#"J$KU]
M2%%.71P)+H-/;9?P]D=MTIBS7/K#Q+B7^B^F60%;+O_1_5V9++I6C<8W[7BZ
MZS0]=N0Y%.@#T^6VN:JIW=1(=P<ZT>L-V$[X]M_#,:0/9H$XT6GH45G0!Y1C
MWO-ZAA_3_;I<_-:='B182JQD ?,44X@*S#21"0%%$L<Q00FBJ97GX\RSI\93
M6C3]IQOK[$-E1RJ>  S,&8WN _2#.J-NH,]]_\FC?LUG5#K^6,]=<EO]HH]"
MJDIV!65DDF&2%0RFG,401:F"5'$!HRR)]>_C/$9>Y8L.1IG:]]D*YU>1YQ _
M"X=@"%0&_F@/Z^^T4MY8N>@0)[_"1=YXO4C=(FO<O,L6G<7#MFK1X<TO4K3H
MK/R7:A:=OSC4EFNUK*H9*62&<(Q@%L4$(I)$D"1"0LIPDA.I,BPREQ2H\\,X
MT=]HB4^B,^[-7JK9)P$FU7(EZR#:MJ'6?+[\H[?+K O<OILE5Q!?9%MDA!QR
M][,/PF#[G'J0%][1["MZ?>]R<+7W+D7(JGQ8F$S,=KV*$$V2C*=ZHY()B# J
M($:40)XG(A%,4H&=XC?.C#$UJ^C7Y1KL9#1!\]^D># NT7)1K5<;^U.]/F"M
M]S:WP#7X'F<-WAP@];<6J?=;I(;9 5T")=Q.Z&2$L7=$EU0\LS.Z>*GG^=>V
M+U%3YOI5O1IN2UZ_T7]4ZY+?+TR';JE'/NJ7E> TS0O-%+E*$FU-1-J0B'(%
M54091['*J+3J2A)(GJGQRWZOK;98_$\?-'O_"32*[560=TW(N77F+(_ QIN/
MH<_!3J>"'<_!'>@4JCV]K4HN?>?<#\7" !SJ9.Q&:<8]'@L#W<D96:#'>O8\
M>7R:+Y^E_")7WTLN+Y0NF]<OEO[IHS(="1X6YLSNDUR52WU=M:X^E OY?BT?
MJQG.68JC(C8!"M34ZBX@R;B$@F810RF*LIB[$'1@^:9&V)UZH-6OS<MC)_4.
M[\!.24,I.S5!HR>H%06_&U5!K:MC1'#H-\&.\%]P?H=> *YG6-;%9T7-_:_I
M4[FF<Z/771L)83>7[GU<AD$\5*.7P-*-VPEF&&A/6L4,-(S?"O+;8K5]O%ZO
M7LF%5&53>JE>P#[)!9VWQ5&Z(I;WG*\V4LSB.%$RU\M#A*@Y&E&F/A)+88&3
M(HFR1++8JOAD %FFMC*T8NWJ%1N6*!O3T;@3GSI5W%C^EMFR8_21YF!@]M[7
MHG9"=GK<[7?AVNK216HT4]6J$XZS V :B)]OD614+@X V3'OAGBD'\?>?Z?E
MW)C]>@OPA<[E+KW.Y-O\0M?MW[Z4BX>Y;/_^_(:N33C=:FT$-IS_RH1OW;.J
M;N S4UCFL:G\&\=Q#E&1YL;_&D$N4_UK&1.!G$SU(82<'"MWDO['O\5Y]%<C
MKQO_#C*3=L3\TO,S^)$16^^E"FLKNM,7Z@TU-!K?@4ZK[7:J-;\;G;?_#(S6
MM1W>Z%UOKL#OG=8!K?$A)R40Y0\BXJAKP9 @'R\2@X[EF3TMJTK*CT]R14TY
MI@]2[Q6ZHH7/ORU$67&SWY2B"?YM=I^S6"I,"\F@*-)(V^9$09I(# 56&4Y4
M$DGE%$SH)<74^-\H\9^@?'S:K/=L<\?4:Z_IL./XP4$>F,0;^>_ 5@-0JW '
MMDK<@7TU0!NO'CIWY"8<0R6 >\DP;H;X+3"=I)#?]#!/]S==F424ZI-<U6Z4
M-^7<?-DSE<N4$!+#HI ((N.B("I2$&=Q+HF(.99.#9<NC#,U>FO% K(5%^C)
M:"K\ ;HVK=8WZ_IH:KT$/Y=S207XJ5P L9S/Z6KOXC\Y>IXO3(*E!_EV: <F
MM4Y"XZEO'/QWH)4RH%NW'X90[MD+HXSK9NU7]<1=>N7RD9N^U?_Y>U,9LW''
MQC->)"F/$84\5A0B20C$5'&HA.(RSA*1ZXO&Z.]V1KBI<5238+ILNB-M2XP^
MU<*.U,_MW!1:QC>\T,2,>-;EV:6M_@.T&K9GFA-HQ=:#^TMW73LGVK]&@[4>
M4(/U4NL;PS? ?55^IZ; Z=8J_76Y_JA4)=>?EO.2/[^=F\+'R\4;::+K319&
MFNA--,DPC%BN(,(1@SC/<A@1K I"\U3Q9+:0#\81]=4EP]A9%"NV( U;G @T
MI->NTP2H<D$7W)0"W 7#.N<5NT^1'7$/A?A8OM$MRGL;Z2\;]O^TS,::_X56
M>NT&O\IU3;\'<0I;A4S<R;OM).W%X9I@W0:*D-'YWH '"]UWEV#DN'YOB$Z#
M_OT?=6LD<&W0O7I^/:=5M1?IRW$D2!Y!640"(E.]F49"0IS2F/)<J2AW:GE^
M9;S)6;E[X:/')56\(W?/(VUIN8;#;VAC] 0Z;7G6THX46=L+4/#(V?.CO5!D
M;*_JER-?^V\;X-2C*P#V9B/_KZ2KKW\L9R*G!4]0#$D6%1!EA8!4R@(JK)(T
MIIAPY)1:X#C^U A(OW$HX+G&&< #G&C<!N,$SC*TZ<6DW@J7>@=L- !:A9%.
M,2YC-\;YQ9G1IW-R<1D:IS.+GL<,&P9TKS1#?)4+,VJU;2H^2VD:LYQS2,U1
M!DH*!8D4"*89PS(O:%(PISI7MXDS-<*KI01KN0#/1LYAPGHNS(P=%8Z']^#;
M48M0'2,XJ"5W#=NA]4S6=!I'XX?J],,_<E#.!6$F&7[3#YQOH,V5I]ZZ>[TL
M1KW7F$4HB6B&$UA(GD.41QQB4FC2I4IR;7$JSIC?/O;*R%/CU_UMV>'W7FGA
M#YI\U/([IB_9SXCK?C<@SB/N?$\IU07B&W:_EG %WP=?&_>%=L26<%S>&]L^
M(&CVS@SEHB %3V$LHECOAA,$J> 2TC3*(FU&HHRA67/H^F5-5VL[\KHPFLLG
M=#SF<%_3*_E0+NIZQ8S.W0OT7$(VCE ALRR"&2;:"J<1A8PH#!-.2"(RSIGJ
MD'V[$"/CVHTX8##,0@2'U([1 X T,']?3#H:/),H,"M?&F4*&4"7&/?:Y8&J
MHOTJU[,LDQ+GYC!#\@0BEF)(LT2OU#EGB5!1QG%^4TTT/8B3^?>2%=%N+'MF
M\+3[_F]%:?!-\9F29UI$8\S]?5LM[OYJM;C;ZZ#MX3)4%30SQ,O60-M3\FH%
MM/UK;Z:!SCVH#;B>JM G5=")2#&BB3)QR-H@2V0*69)D,(U1C$RY-,RE5R3)
MC8)--*YD5\=^OW"]*62_5]<^9!U[SVEUIJX!9^D%>&Y/F[N1*MW?!F!X0O24
MYZ78\S;X>JCVQ@=[YG_\SZ9</Y^TX8V4D$7,,50<28B$HI#P&,%",D82I"@B
M3B<EYX>9FH?NX_J;YL>G#9N7?/X,UBLJ3"Y(+;MSU^DK"%-,BCA7!411GD&4
MI07$+&.F72,I6!QCGL1NW:QNQWB<3E6-G'O.N"!XVJTCMV,T\.)P LX -3[[
M00B5*'-^D''S9'H5/4F3Z;_:HR/"E\WC(UT]?U1?2KVM5B6G"U,/PZ3MF:!L
M$U:X=<ISE5*9Q00FL:8"E$H)&9,"QCQ)(T0P3@NK2D"N T^.@U</=%'^L]WL
MF2/.1A?P48$];<!.'=#IXW9NXCQ#_0PS).Y#GYJT""]?&F&'!@X#(3U23X>
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MB@U6^W*[Q)Z-^!I8F)P3G=R!N74_J'[_L,]H?B9XOCJ)GC^)N-\BL(M3ZT
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M'$$:[@SGS)O<XI+\]M7W@TCWB<@&HNT"(AOK]R*L\62Q_#Y)+)6B2P+.DZ7
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MBA<01M52*8R$$HHJLM;.&9.]4:W;]3Q%*]B]MV#QBGE-IX .M4U@DA3>,ZG
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MZDB^VB_599G(U^<)7,D<0C11:Q<\MI\_?R<UXYJC-MJ^!4(-1-\!B#Z0-HB
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M:=W/9D!VQGXUT-CP]:'V+H[8,Q;/=O!S"DG*=#U)#B,Y! Y4)'>!V(@U%>W
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M[5"]=IQ=/K14:%.UJB//Z TAT(3:=!'!H:7#IQ #GHXW(UJ_>QN C3XO8P8
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M)*_$!&#!9.$MLUJU=MSV(&O<D<V#@:VM.CI V)OY9H;F:G4[;V=,"<6Y"+F
M*X9\5&0>8J1?&E09,27R4MOWY]^#L''G[@V$LO8JZ0!G'W%&?W3R%YSC,M2G
MEL_RE^E\6L55'Q^<[:'5=7NMI/3">(287 15'SF$ZC=H<ARBL4Z%YN,A#Z-T
MW+EV R'Q"936 33ONEF\X3LPP3AC :)TG@)U<AL"YQ&"JYT,> S&\\98W).T
M<2?.#02^(=32 =JNWSM=9\>$8+F3FR' %E0QCOP'14Y$D.2HJFA%:.W./4#2
MN'/A!D)72S5T@*JS.7;7!XM>9\HI*5(PD)VM71*T D>L04HEDML:0KS^@OUX
M"[8/8>/.>QO*?C5720<XNVQ*>YT1'37G3@FB7-4::);((*?:SAMC,1&S<,.U
M%3X$3_X'PU,;T7> H=J@^/*U\598%.LDI#T29^=QM,3 -C7U.KDZ:#'7ABN.
M$X\LB9Q%LK'U5*F]"-LO@<M^,'"UUTD'0*L[9DY_Y48BF@YR%K*.@$+4NL#D
M(8B"(#*RY'T=J=?:D[^+EOW@]*-="#21? <(VA;>_X+KSW4^^T4_]K/M4+NE
M:VL41)%J3P07P*$H8.G@+B5F;GGKA_+W$K0?EGZT#'\['70 J#O;)]ZX*_/&
MQDAAK'1&4%2K"P3:(,"<4$J+())H;:+VI6T_F/UHN?U!--,!XK;OL;?/L*^S
M@E9G+E4&E%C+79.!@"0Y[HI5)MK@FU]9WD/.?KCZT;+YK>3? 91N:4U];H:)
M$^9LML ]6CK7HX# L@/Z+9&-+12&M/;6[Z9F/R#]:,GX1M+O $=OOGP-TV6U
MK>^6+Z>KKXM5F+TK;Q?SD[?3;[AMJWYCKT1ON-'>T3;1"10C1H.TFD3G3-+.
M<12MJY@.H7,_[/UHN?C!-=8!*B\GA-SD1%C/5,J@C2 [+1.CJ 4S2.&4#)Y"
M8-;:NMU-S7X(^]'R\8VDWP&.[ND=<2,:IO@$O8F016VJ%[0#CX&#\URCT,QP
MV?JN9W_J]L/9#Y>5'T8['>#NXFG*=3Y$[<&O0^U5'0K989_ ,9<@&"%1T/\,
MML]VW4[+?ICZ\3+S#23? 8)>+Y8X/9F_.*6UY\3',LQ7))OJ:-)>V?QRMNMW
M[KQ\\HS"XB @>U:?7X8,,:4 #(-+B7Z:L/6;^H.)W:\,]D=+X#^-[GH Z?D\
MX7?EMD&*YU68J+4C1Q/D9N<)PVM/%'(<9'$BR"21M^Z*L1=A^X'O1TOWM]=)
M3T#;F<E^^[N&3)ZHD"R#0>M!)1UH!Z$$+C'DS*-+H75HNC=Q^P'N1[L3&$8W
M?Z#7=9_JK>W3O:T[6VZLEW6W<3O\NSHM)<6>P4'0&&MW&0'!6P>,\9 QE9IY
M:[SMV[^KV_2!O_/NXV\K+*>SFN/9RGCGU2HO'(6Q8'EM.N:10T!)0;G4]6E-
MQB+20U [<.UNG] ]!A!7^O /+/\^[=K9RZTC3-6U+S2P/O?1U,B@//!@[0),
M14E4JCCP6I&W5"?U.9,8**5LDKHH;%YMOB=I#1JXA9.3)9YLU/.NG"U[#> \
MHA+U;LR38PC*10U.T0]UXDWT7/LB6K<SV8NP<:W/$.BYI>M:8_UTX,U_3)\Q
MG\[P@IWGWW\)_V>Q/)?<ZOGW#_AUL:R&_2.>;!O)7>4XFV =9@?.U2G@BKS6
M:+P#K:+UUDAC3>MRG^.I'O?1[U/ ]8DUVP&6S_C\@%_"M#YB>(_+S;2P><)W
M<3;=[MOZ."NM,7^:?J&_\JY\I-]=E6U*Z!K[FOG$(BN$OV2!5&$H,">O(DJ>
MG'9%!FQ]O=68A7%?&S\%RL?4>9_^XVTY@".<R?L^U\"SW)O:1F[FQ7J7C<HN
M Y5@N W:)L!D)! B)84L"L$;'SU9.Z5C\W3]/?2T.]LO5ME6)% H]78:XMD,
MK3/)YW?S#YA.ETO:(IO&)==V1M26MF/6D#,%5<IBAJ B@V#0T\D@&8^M'>^F
M#(SKH#;#W=W'_%,KN8,3_X+E/3C]VWP15[C<O-MX,_]ZNJ8_7LSK(+D-"':J
M#WG@Q@4/$84 93 0^]R <<E$I3$GW7H>]Q!\C.OA#H;WT57>YZG_[%N8SBJ?
MY/VLP@SKP+F/51@; 85M[FS]_?*W#O<(#EVJ@;?0A,M6&?!S6EXOEA^)ELM%
M+W".VFO!=(&LO0>%QM0^S J8BY&,:62IM*XC?YBJ=E[%W6M=VV=7SQAO;-+!
M12!7NDY10W+W!5*0&5UQR@82F!C,D3B,YI%3ZVV1=K<'\00*[<!IN&HTKO/\
MM_D2PVSZWT368K5ZOUAM1I!?G#K76#=9E"*M!5FB([G7T!5=J;6\64G-D?/6
M3G%#\D?N?#<LK,=2<_<(O[Y[;3%>U.H[7I-\@I$?Q@H#%J*QV7!FK]]8#@SA
MGE)8HV+T"$5U ,*=-ZDO9F&UFI8IYN??SS.!IV'V2UA7SK^_#.OKO)9 WB:)
M%4*H0PI#;0,ME(1BLQ*9AT3A0O/:W,/I';G?WK @?3)%=@#:7\+R'[BN+.S$
M$)?)88ZBU)R(,@5K>CJ Y]Z"RS(JZ9V+OG7UY+T$C=Q<;UC8M5-%GQ'[Y<N>
MVVI##P_/]_IN@UC\\?2W&@QXL?#.>L_F^:^83Z;SDV>)_FB#EEMFG$@=2F*H
M06=7';G"(2I3R[NS(]SDG%7SJ8"'D]LN5+^5B#?SCZ3VS97+3H'R35]XQPU.
MIBB-D$L6M.DT@QB< !)IXLG;VEYUL,B]"0LCCPQ\(N3>'>$_/0XZ.-0?8/\O
M83JO0> =8KB\4-YYP)2%,%%GP*0U*"8<!"8I*$PQ>?I!6=%\\DUK)L8-_CO=
M"@-CX>#-\ V7<3'@[4'ZY^ETN]V/N1BX^946.?\':&OD5=S21J(V=JY7J3L4
M[ Q+D](I;L 9ED!Q5:<3"0'(%4_,!&&;EV$^CL*6A8%I<3*OJ;(WF12X"?_.
MKICKL@3AJU?-]&>TF?*U0#!H*WCV'(R1 90,2"$ADQ SH]^A'[QH[7DU9F%<
MWV% ?-Y7.?C4JN\S5KOR$"'L/$0XW%@^],D&EO-15#<RHW<^V;A )C>"%<LL
M8*Y]R5F6X%G6P%+,!AUG/K<>7? @48.UK]M)6/B<R#7F4#PGGQE5Q3]FX$EP
MZ1QWT;0>%?(P5>.:M+98V;MQW6$ZZ=,P_66QR+]-9\1B?E/W^,F4=O;60A]N
MFA[^: /C]$C*&YFG\U6?W5SUED!#*YO(O;<@C"^@C*W3$X( %Z*53 7O8FM3
M]2@"V_EXY\ONO&,I+(A8FV?+4ANPJP#1I<UCEJRT*(;QUL7O]Y SKJ$:#C5W
MNU['::2KK,L;VKAE.I^N<=,5[=;MOG/-*5UR*CB0QEI0N4Z8J((,C$Z#***,
MKOEHH\-('3>#,@8HA]-D5X!]O3>+5@;+HPV@?16KLIN9Z11KE9+09Q9\:7U/
M?0"9X]90C '48338$4@7]['X^G1=1?JE/N[[[XL74//5]<OY2"YND()!4C'1
M!M6ASIRU4#C]+D\Q"-NZ04M+^L>MNGAZ6#^YSON,>3:S.';NG#<I^8NRU,.:
MNSSPR18-7!Y#]9'1SJ9YQIT+7F#2LR1L,@F8VW2CK8]];"3_DBRB5@%9C/HA
MR>VW5,.:\[,9++\NUKAZNPB;-FYG2\]/+B>S[ ;YIK@D): JL=X6%7 <%1AA
M C>V*!_88$?TH\D=)] 9 ##W5)D/JL*.SNCJ+Y_->]GV'UQ?L\5.RQ UZMKX
M4H/2M8C)8 %KO=$HN"YFR%#G/MK&B6V>%(<-E=,!Z#92.^-DYT;F^O-V$0V3
M3D$2B4Y_FP+$HA!06PS%&1=2Z_<*>Q$V3H3R!'!KKY8^G;):R1[F^041,UV_
M#FF7SP/+&._[8)/ZQ;TI;E:X&->WA :>E<(QDXW)C$(#&R+X8A RA9ZA$,!,
M\U/@=DI:UEG%]6XQZ&4YN$P*C>40>9W(D;P"9P,#'K@2BE.T/6 5P%U4C5T4
M>#0J[BMR:J"(#DZW2X[.WAK03MT.VOB$RR^5R^NMBUP.==PZ"%?(9C.RWC[S
M""4'Y"9D7_QPKM5^-(Y=@#<@[ 904I_'WG9^U>&GW)5_W^!0NYN>1F?8=H$+
MN&2TB#H1/I*OD[JT!1>4)UO"K=%&(#G1C;?950J.'P-'7WNQ6%V'IO<Z1LRD
MKL0S[0-#C$4"J50860C2"M]^!-RMI(Q[.AVA[YL3WXX7=0='T79PW;NON RU
M==Z&JW//_OOY2[@;L60RPC !5@0)BMM"8JME+2+Z@)@T:_YPX@ RQSV0FB)M
M6!7U>19]7!,?GQ<S4M-JVP?E\'/ISF\U.*/VH[/1>75SL9IVO$"9*4I)\GZA
M:(&@@D?PLEB0FF)P5E3DS=\9WT]1.T=YL\[S[YLGN[M334J)Q!@8'XEA67)M
MZ5F?D^LB4E'9V-:CM1X@:=SSK2$^[G:'CU=%!^?>R^FW::8MN7J):4:RO5[E
MG5PJ,I,S7P>9@]*1@V=,@[0QL)2+<LWK>A\@:=SS;$!DM51%!\BZ<C5T^N5T
M%M:8MXG3Q1<BZC/.5YMG6G6<6'V==8U=&6.125K(HK;<ME@S]24 #UD([[G.
MNO5;G"-)'K<@YTELWO"J[-,+>T7NU>([XG.<8YD>4X9]QY<:>&#[T-@JYWV1
M8GI7*@1(_QMR/^ &&C4<7'W\3+"-Y*/G]^'[]B'HQ5-/9@7WA$ L@?"0LX"0
MT$&P3.=:RB+\ -,.CJ"XG2T\5])'7'Z;)MPL^;PNN4O4L]GFDV?S",X?:[W'
MY72QI73GT78T/"86P6XZL2#%-KXV>36,;V9V:E3#%70W9F;DC/W38?IN^SHF
M/+KR&6[G_ .2M*>UZ?OFM/O;G,S<L]_",I^]++\>_M.Y9CF97BC*.%"^OI=$
M[B%%Z^C_7 QQP+BH!0LC7R?TL">>'@H][(1;F=YI5;#Y"UN.WYVN5_72^[+#
MPG7F$PJ?.$4-LK;Q5$)F\,([2*;H0FXAL]B\6JXE ^-ZUF/N@M%@T,,>>, $
M;#;^NZ_;L;]W<)Q4%+7<*]EDZODGP1>G2 ",>5$P13-<9<*A5(]; =^QS6^L
M\!$AOJE1NXW=,WEN-O05=N?YPC>LO_W^=)D^TS^H[Z!K'Z<M/&JCAJ^7/55V
MW@?$.J>L*&"1CD#%= +/T0 7.7.TJ$V)#T6N3TSSN&T01]@%/6/B!S@-[A3%
M'99"2A&RB RR$ZX>AAY\HI_QX&..-@7-AGM!T(2%O7:(^0/MD!Z@T&E^,BSK
MG+05>88;D1R1G[S]2RWRDWO0V"@_>7VIR_H#8SW+M1X@2[)YP21P/$5P(1,&
MG.-<MO8'[Z*E84[QV@IU2DZBP^'E=':ZOG&-Y&VL$TL#(!8+B@M?YS8GJ 41
MR>M<!T(.ES%\#*GCY@.;8.B>3-]@2NO30FTOASZ%WX\IK+SYD09VZ0'*&IFD
MBU5N*<]-V2A=ST*I"4QT_D@(N98JY5HW)R57KG7CT7O(:?E0KB[RO,YUPLL%
MZ3^K]0;KK^GWIR?7!\_06:QUB JR()$H[QS$%!@X4PQML(09ATO:'D3RN(:J
M%;+N>U,WM!Z[BB^J*[F85V_UG'5B]^S=_=GEZO677H5<5ZT]I%#+&GDD!])J
M#:D.N2TQ9=6\8/H(<L>]4Q@>KL/JKRNHOBH%T_JB]H+X_$#!U[USO2PW.D7I
MP&0?0)G P7LC(*$R.;.8S)#^WZ/I'3?U/SQ8!]9@5VA]>48 ,7G;--OKJ5QF
M=+ &Z]!N71O,<I(O6O :&1=..M-\"MN!I(Z;L!\>H\/IK2MXUNEQY]44Q.IY
M'=6'Q6Q&'D[-OEX_-H)GW,D"V9D(*NHZNTL+,"I&7:3.6@Z70GPLM>/FTX<'
MZ:#:Z^>JZ-,RS+==P8G):QQAC-;QI*#D4KN>R0 N( .1;1(\BZ+,@R'V_LN-
MFWYN#:B!Q-QG,N;=\B3,SQJ*A7G^>/KE2UA^7Y2/%,5-RS35WLK;?C[3^<G[
MQ6R:ZLP.7(?I[+!.7,>LUZ)-5S-^6XV9OK':97HQI.(UL\"C\G1\ZDSH"@:<
M#]Q&GKUEK6/)NZDYSFAMQ?SN?C%O-M=$9FV+%A)TJ8]EO!)UZ%L@(8B:3V7^
MQFC(NTS7_HN.//^Y#02NVJ^!)#[B\;=:KB<?POP$G_T^74U<]HI94\#$^HJA
M6 $^T>F-S#%C==%1[/7DEKZZLS'H5Y>;XLJ"(S9N&TR7BV,%VP,:?L$O$9<3
MGG*6"8E8P3*=],F #]F#EMD58UTVO!D>MDN.@X@CE'5=W0=(;F2%_S*=3[^<
M?CDC7,:,)@1RVZ,GMSU;"B^+X 3]K(Q0SG*^5]#U@,JO+#JRT@]1V:*%_,96
M?/A]AW"+2FV&S5ID E10M5XIR-JU+7GGK,>RU[W00XK?772<5'DSQ1\LOP[R
M,G=.>GG^_1-]8F,(61%!>L[HR$L2%#E)$+ASP'QA60=R#8UL["OO0=:(73:'
M=AJ&4D[/>*L,O5Q\"=/Y)#E&6RA&VCB,'/,B$CAC%"3E@\=DM6G^CF(/LCJ=
M]W0H%/:>^'287CJ VO-3DFA]IC'/YS]]\^7K<O%M,YIT=6:O@[29I6Q!QEKS
MXVEKAI(<V.*\4JX(8JXQV/8BK%.X'0J'Q="ZZ0!POP22ZAR7WW<%=L9*??W/
M@^. 1>1:!EX@YHS52W!&B: B:]WAXQYRQJU-&!I<K?30 :1JD<4I?>XZ&^2H
M:EE;3 A49.^YE^ M_2"538XGG:UJ_;;_#E+&K1P8&DHMY#]V(@=7Y^.X-UZ"
MQ1ARM:+:.E&GJ63PC@(4H41AUD3D?J\+_X>2.5>7';%)^9.D^(X0<C_XN-@P
M(CM-_,<2:TLM=."25N!U<49X*WG8JW_G_@@9T\,^6GVWP^  68X.A&_3U:;=
MQ?OE=+'<=KKX4+MDK5:;;;/11/X_IZOUCB543F;&5 235,V2I@)D5#T8+#FQ
MQ%7:KRG>@V Y@+@N '4($!9/J96QJRYVKXV?75P;/V"NWY*#]X8$O)KD'!.&
MN)DZYXC5G" (25LW9Z9(Q*Q</\_NFL1T%!WC5*<]R0'WU%KJP._^];1NHUKD
M3 PMB9,W\[]_GJ;/KXB]]?=M=UQ<3;2C_REN 26KPY4XAR@9_:!,="HAG1>M
M>Q/O1]F8H[">$"B+P;76$18O>C)_Q)--EF0B2D(*7PH46RB8=4A6/FL)-D:R
M;%RP6,1 \+M!S)A#K\9'W'&ZZ0!DY+ @$?"YOHW$;SA;;*+=L^<<KWY/L]-M
MQQN*@Y=U@"8%W@E7J_K^?,)0H!0B@+0J43"<*1C6T4.(.7BC=>*E=0KU"'+'
M')<U'E"?2K^/A[+?0GF.)[6AP:=FB'Z6O^%R3;[S_.2,S8F.5ED=#'#4Q(C2
M!8+4$61(-O&D$N.J,5!O4C&BHS@B_H[41@<6\LY4X]]66$YG;Z<%)\BU",(H
M0&--'1!,$F(F@I E8N QF-)Z\LD>9(WS)F%LQ+765Y\UYA_(F,]/L8[-#B<G
MRVI$Z7N+<O'[AY>3[_OI!I7C!W'1J$C\;(W7!-P7B_FF-/COT_7G%Z>K]>(+
M+B_*A7DM"W8<(;+,*6IP'F(=/H!!(G<L(6\^\'U/THZ?3K K]7?G4M\F#*(+
MM WHR!?:BGK3H2$XIH$9%V@;>NM$ZZX)]]$S[K7X$%BY.:"@D39&3B>3_<VG
M:?UN>=9E>9-8C[D^!LL9* *BJ"@P!IZ,.-B2;"[&1E_VVD0/9(MO6WOTOM>-
MM+IH*.(^(%(?NIYQL#K+EGNCC*DMM$/M^:,B[2)GI8$BC199!4QQKY+#_7!R
MDX#Q;@Z.U^E-@!PIX#Z<[\K(V>T&"TRD(C7(I$@<GB('KV(!R3-W.I;@9>O)
M4U<(&!T=QRKTIJM\H'0/A@9%@W'1XO;HKV_^ZXS\CV&&YY5C1A?OA+1UY-VF
M!S."<YQ!PN0\Y]X4IA[R?^_^_.BU>8=J:]%4<&-?'%YRL'H^_<<Z++]]/Q>*
M3C)KK$V1$L6-.D2(EAOZI='9<8KM8GFD^J\M,>(%2P/%W8Z#8Z38$19JS=8,
ME^'5M^GFO^<E6SDPK2QMC__+WILVMWDC:Z!_Y=;]WN=@7ZKN%]N)$U?9<<IV
MYM1\4F%IV)Q0I \I>:+Y];=!B=HL2ESP\H6<4Y.Q+5DF>GD:Z 9Z<4R13U[(
M.^>!@7 9#9/2>K?=._&32XWX%#(<-AI(M2.,_(3+-+\&.AJM(U<)@I+U@CM@
M;?EHP1CO':) 9G>&QIT51GQS& X1^\NP(R#\@K-O\XLUF@MJ]+6?CE&U>*MZ
M4MX&"9I;RPO#4NY?=CP-A#LKC'CY/QP0]I=A1T!XG[$L<8UF&VW1W%@HD2%Y
MTX%#+-:"4$$$'[VP8;M._IM6&/%.?C@@["_#CH#P\6PQB?2]ZTQO7U\_';AL
MZ8 +3H)+GMRA("-QDB7:M"L2[BXQ3H>?@:%P@!0[PL*GQ?FWD-<[F]4F6^XL
MA5JFCCGW&8(T BC,+CH$#$:87:%P9X6MD&"?&1+VE^'80%AS<'57NVH@_O'B
M].S\/VMN1&'.*0S 94WJM5I<CGM-/L5D@LYTYFV%B">7V@H:[CE HZU4>\'(
M:DXO26H-<U.$UYYVN4"QD=*.6+#*@4B,2PS$S9:GQL.?OQ4:_'-"PP'R&QL"
M_\ _I^>+ZTL3F3QG.8-*:"^KS7PR'HPTS$06O;\_^V*#YN]\[.@%FRUN'/<7
MU-@J_O750Z"W.N<D"@?I5@V"LH-09U_F9*-#;3-M7=OY P]]_.B%E4TNF0\6
M7#^J7[[%//D:EM\FBX_S,E_&<_K3%4<N>D1M&&3#/>U76@/%-P:B\J*4Z(P1
MNT+AD>7&O'P^7*$/XZ.5=#O"RPT?_\#IUW"V8NZ*)2V%P*P4!*\Y^<%TRH40
M/"#WP<HB4*@M8XFMUAOS2GHPQ+22[]B0N?1]7JU]'V5<EIHA!%,"*)0*8B%?
MBH=@A5>HBA1;0>/NYXYY!]T6 @?(:VQ5_XJ$T\G99/GR'Y/%^?+ZRY]P>A96
MW[I[\.H40A9T\)([Q,BOCL0E<[QFP;)8<C(YY.VVB=T6'K?7?BOG8T!A/QL@
M_0-/IY.\=KH%2I-RC, TJX-[*:2*=4 U<2XX0X.F;-< >+_UQW1<A@3#7JC;
M7S//!WR3!8;U';!6$GF.%.&I>D<0>$TG4+1/ZQR,\)&)$!IC[];R8WI _4%O
M7[T\&^2M?(3K\($9[A*'A)(8Y$9"D%9!*=FG;$10;,O'O#U6']/MZ@YW^VIE
M;-B]PNGT$Y$>OEY</VO,S\+T^^_?=G Q2"=M9*"#<Z"2,."]2$!NJO0V^2BV
M[$RQU_+C3J)IY,(-+_@>H84I+,[.U]PP[0I6'J)+U2S)1B)S"%JJ[% X^FV[
MNZ4GEQK1/3N"HI_"U?Y2'QM#JVUUS<<_<5D963^F&:NXP#J6!U-M^%($1"E8
M[6RE12&,Z"W3'A]99$3?ZLBX:27IL1'SB5C Z77RGJ?@PSGMP-4+&"7)!0S5
M!^#,:XPY21:V>ZZ\^[GCSJYJ= 0=(*JQM7P'K2NSN/V=VP:1HF%61P'65:YL
MR(3B>I%&%I%1U':6VUU';[WD.+DNC;$QC("[@LV+TY>3Y?QT/21!:JMY*+3)
MB4 [ITL:/#.: @6MC8O"&;==8<TCBXS9O&H8A6[$S '2[0HE;VN!_F*R%H[(
M(025%'"O L5V.D",%.!QVB5%B3JS^T-$MD')W47&;#AU9)0<(-VN4'([_!?*
MA")10;#5!<M<@M-! ^&?N2!2UF&/C:2/BY=CXV-?N8X-C@_SBS ]NUBW4G@Q
MR[<YT:FF^Z4 /(M0F[-H<$D&T+Z8B-G*(MU6"'ETF?%F#[6MY6TLT)$[ WQ<
M=\_]!>>?*8C[,DEA>MF:V7-G B?2V6HL;'3D?R>D^"TR,I9@N&_1&6 C >-F
MX@W21J*-L,=&S&7CQ=LL7%D32AF,TAFD\8K$0BY^P(Q02#9&U!P!O55[PJ<0
MLXF \;H%-%+LO+641X3*JM?8XN+DCX\G09 CQ:R#;,G/5G02D[---L,IOF?:
M1L/O/PO=P<42TW]]GG_[[ZM/O(3&U1<WR+A9;T08M%':_" )CMHIHDKAY_/:
M$.[J*(PZ1-H0B5U!T*]S7\A+*@F0"^(["CIM6XPXN+WF>(Y&6_T?),NQ/<Z5
M._1F1I\VNQQ3/ET[XD+X4J2OK?^0?",6P#OM(>0B:G\=+^(.U^0/K#!..-)>
M_>W$V$%;H0WNU-OK!I2*2^9#G3L6,[G,5K Z1<B",XHG55B2Z4C=[][N-&A@
ML+J Y@[H(*KH %I/M J\:;F\7"+]ES^%OTZ8,]9D2P>H\#63E1OPRI-_EI4H
MM1]IMJT'7^Y!9I>-]/;$R7==LH=56D,G:) NLI?]>2?_P;S^3E7 N_"O^6(M
M@Q8=97=9IF%WV;VY.W*G698Y]W18@JRX59)^"49:,$+$Y&46]GX[FN?2:?9C
M^H+Y?(KOR^5(CO^99+Q:^N7%746\O/B 7^>+VS,5+@^9.JE1"(:06)URRPNG
MT-4)**%H58BSH%M/TFQ ]O/H6[L+\N[OG<?6;0=G/,DR815GU>.'R?+/EQ<O
M<9:^T"[SY^J:I52Y19;!&*Q].Q6%1A(#T*%4^QU$)G/KR1A/T30N$(\.DN_F
M>3;46)<(7'-S%>)Q)9,1OG90X!20!8K*G)$((J1 ;I$NZ%OOED_1-"X"VR+@
M27@=H(X.X/7$N;&^ ,K,6L<%>=P4^:N Y'%KY:$H:9*W@1SO(X<M/;1I;8N%
MW0*5/133 =H>,,TZQGEEE5(EIYDK4*0BSR0'":$(^I*S%+(50F(:_B1=DS/N
M(V"'A^A>>NH1<K?FAEOK)5FH!2$,!Z5L N_H-$B.,V]BR5*UGJ[W"#F];69[
MJOPI*.TI_QZ@=&5SW[&T;H''HQ,J2^!."U"U)Z)CTH$R109.@HK;C;[8!4Z/
MD]09I/95_7U(-=3#R#D-=_?R2^\T2.T].0TF\MK7(O+JG1K@D?Q3[W),J<6X
M[>]7'O?98:PCKX$61L;0;^&4I':'ARLC<S(5']"!K6\TREH%WAH)R5H,.J;Z
M9-< 2AL)&"\AXE"-SEN+=^QG\1=$]F0Y/U\DI"WR,\Y>S1=?UW6ZWIL4<P9;
MZBAYZQ%\\ 9805=4-%:Z[4I#'EED/"@TTM]\ &&.#8I789$GLS#]%</T[,N;
M65K7N3&6C5(%LLH*%'.1XDN60<> &(N6PFS7DV;# N,ER@P AA9"'!L([]*?
MN%S.[^)8%2>D :-#/4L-X9@[ SXFZVH_)A1R*PQ\_]GC)<H,H/X#1==!6/.=
MOW5'/C?/[E%KFX+2@%IC==D+!.X0A#;)<Z%\N-_=Y>#P9DO2QNUE-?9ES1#Z
MZP"6WT5WO^.B?B-\1GY29!8!K:V=Y3RH' -XQAGMM3$B\EAB:?V _A@]X\;9
M@P#@J6N<?;71]Y!EXJK,%Z>!F'T?IY/+%*06"3&/?W##%)@=.#ARTDM 6734
MJ;;XSK7T51+\9($D6'0V*I^,:FRS1TIZ>>BS']3#1_IU62:8W\Q^7^"WR?R\
MZFLRSR?1&IND962,C*)3X1-X(PI8%@63GAS)L-6MSVX;VH%4/X^4EUUP]\"V
M=TS-CEI"\1C/;R<A3J9TRKPZ/SV?$J_?\%4X2U_^^/HB_XM^IKHRG^97&GGU
M)<P^XYO9S\NSR6DX(\?HTR+,EO21)*C?%Y.$)RY(IIF-=8J<J4_P!9R7""Q*
M7H1B0;G6#\I'8&O<1\.Q[&%,;/3M3?P6%HN5/!HX$-]]5D.?X7$ZC^PF:!VC
MX,A!ECH;)M%6&9@CM](X0F@-H/$'<A-JGOG9;WAV$A46F;0 ELDE5ZS(6JG#
MH7AO$T:+2CQ6J]AJ1US3\SR.]EVPLLU6MI<V^HB5-V_+)XY8"63 X*4C#R12
M9!8X>A"J9"UM%>$ F36;"7H>QV1K;.VGCSX/N-=ALOA'F)[C.PS+\\6J OVJ
M^.)B7E96M RSO&9Y@LL/F*IB<SB[_K<''(I-UV]PD XGCT:'[\TBDV6:SBN-
MRVNDRY*]]2R X4%1A%+JO9"7H'TL 8LF[["U,_X8/8=NAM>?_?+B99C6,.WC
M%\2S7Q;S\Z^3V>?+"U=,R23+-'ABL XS)AO4,@''5"A$PV"Y'8KG1^@:]]AM
MAI+[^V%SE71PYM[BZ9;5OU[@_Y[C+%VL<@Y")*G1^0$E<5G? "GV+R& 5*:$
M$HR+NK4ONP59G8"L&18V@ZV)8GK"VD,,7;U@BB =G2<,1*Y5JN2]0D1$*$RZ
MQ)"[P/106-M,5C=8:P.%35!KI)=.H5:]E?/%@JQSW<52A"*M4&!$(=^8H848
M;:FO/LG$I$+V@WD,C]#5"=A:@6$+L!VDF9[0]O+B^H^_3G!!1'VY>$N1VF4S
M*^$]T<XUD#GB93=O)Z,"8;*T/%J.HG6-VW:4C1O*'O,H;:6>GD!WVY"^Y^_*
M9*/ *+D)0']PH+!DB#R2))5 6],S%&_],K<3@9UL>@T1LLV^UT1=/6'QS>SK
M>>T#3!+CZT:OTDG&K02;12V[477DMI00=32.FZ0Q;]4(<Q_D?4].)SAK#X)-
M<#M0(YV"2ZPK1Z7.)"$&ACD!*DA/!P2Q4FP@HTPRT[>. "[1P_3S<<&UCT8Z
M!9=<#WXM.D?+!# 94K63##YBA,"\5<H+S>X/H1P$7+*'.>OC@FL?C?0$KCN!
M^\NPG%P6\_#J-,3BH93(2$R,@G9?ZRTBJJ24Q21:YR(_05(G(#ONI=I^"ND)
M7S<WW35']L5I;7V[;M(N3)#%1 L:M2).DH/H7 "3O20WUD:C6B<9;T-7)XY8
M"R!L EDKK72 M-]KNC^IYN:=[P$NKS;IH(,0JZH3)8FU5*<"\)R [-.0BZEM
M-JU#S1W(ZP1WS; Q/XZB.L#@3;+=%KRY*(I?-8XOHE;FUQA'!@T\1L\RHB6_
MH769SP[TC8O"P4!ROZ9G*(UU@,9;)\@J,^+5-"POSPX6D=S1'(AR26>'T8(D
MI@KPI)F))>6D![MJNT_,N#5EQ_3G#E!"3VBZS+*Y\DGR^]GUR\C*-_EC-H]+
M7'RK@EN%1S4!9Y8FT\E*I[>EL*X(Y9G'4/L%&"9K&K(!GT.&@D5H7GN@XV Q
M;&->.CFY#X/:)@"/J?<.\/_'QT^+%>\7'ROCJ^2R];G *=B7TM&Y$,D!Q^3!
M^3I*C@O%8A9:Z-9YGYNIZ02#HZ)E/HCJN@#A+_-ON)C54/#%9R2)X?(GC&??
M\>4=4@CH#43-!"CO"CAC,L00HM):*BY;G_#;TM;)%71? !U K1W ]?5\@9//
MLQOF'F1*(+)2F &MZC ]K<G1DBC JB*,YB6(^Q.3#W< MB&LDYO&GH#:7J$=
MH/054JQ9)O1CN'Q??L*O\^5D/<]:J,25%QF"++FR4M-\B!_M,;)8K)7;-8G;
MI:1C,SF=Q$H](;*5\GK X7SQ=;X@1AXT*BM]"-D)P)S(J(1-X&H#"&9C],*@
MRO<'03<H+GJ$H*VPJ/]>6&RFP+'[5'W Y223&B9A^FZ^./L</N.+65X)ZV5(
M?V+^CKMHE$<5%?B0>9UW02$F\QQTD)@B9M3;CAC>=>FM@&C^%D \@NXZV"??
MS6=X\2XL_L2SU^>SO.;"F% TCPZB9 J4*QHJ8_72+OH2*9)CK1-M'J9D*T#:
MOP4@&ZJL ^#]_+_GD[/O[Q"XC#DB&D@LNSH;H#8@Q S)$0W11>U8ZQ*WARG9
M"GCN;P6\!BH;^RS^Z6K-5_/3KSA;KJ3T^S3,UJ]?/'(110)6'[Z49PY"G4RA
MG4Z8%85<N%T/T<?7V0I;_F^!K=9:&1M@5T']*Q+DJH(&%Y-OE]UEKJKKKR]+
M';=8$TTDPP3*N@)>\ !."96=1C(HM174MEUQN[ML]O=!W2"JZN!D?7F^G,QP
MN7R1:+^F +YJ>)7D)(LVNBC 6&^2R"FHPT<=F5%)+J;$BVO]-KB!E$["W:&>
MJ5LHH%,<U3\N<#T/H[!$I[W.8%6=AY&X!6_($I,(QL82,MX_+@=!U!VBQGVR
M:Z+Z+>"TOQ[&/B#?_?/#+Z?QUZNMM001Z!0W@+;V&<Q$><C:0&!,^42+V_MQ
MYJ:&W;<_MC\,'*"O>1/AC3SNXU:[Z540\0[/OLSSF]DWO&RU]_UW$6O?\Y7Q
M:.:L$=R ]H;.7Z%B'9W-009K93$I>&PQ7.80&CNY-VM]HAU5=2-#=!,?5S:;
M@U-2\@3"*Q)?8;2#8^#@LLE):5TB;G4C]@0('Z=BO($DQT/!?!"5C'WL_4)V
M^35\GJ]C"C26L1+((0BZ-MB-@:PQ1V J6!=]*-S8K0Z^>Q\\'D):*FO>2')C
M:YUD?KY\.9DOTX1"3%S>#%I1N11G:A.-Z.INS#QX,@70,D:%RN4H^%;ZW[C$
M>/-JAD)"&VEV$%G=G-</G-:O)S/ZWB1,/Y*V5G5*K\+753_\M]=#$4JQ+#/:
M4(.I]4H, T1K(H43M,]&9X*(@[6RV9/F3AYRAD]-/X)*.X#PY2W>=9\]EW-)
MVM*F+'P$I1P#IXV!S(+@UB?N=.O2UKL4=)*I>Q3MSYNIH@,@W4WO>/$M3*;5
M&%_/%Q_#%'_^*TW/,PGQ14J+\SJH@%:F ^5$(H]1L S.6N+2B5I\7D-HSA1&
M%T)JWG![/TK'!>8AV)@?75%=3)*X_\KY^MMODQ/KA0BR-K<PIOHLQ8)G*8"V
M4=#_,HK<.JWV(3K&3?=N"*:#A=S!SG7O_6C]:K22T@-UCR=!H#%<.?!.U%8I
M#B%*'<$@2XGS$-NG-NQ(XKA)V@WA-:1JNMBD+F7U$"ODHV*ID\F9BA0>HT@0
MO":;(@M"+V341@SBB>V+I\%2K!OBJ8VX]]^SYF=AV@0WMYJYWXS6\1*=Y0H8
MUP&43QJ"305L*-PFG7B0K1'S !F=5#*-X< ?JI0.SL+UF]>K^6DD:57AU$V7
MA%>E19*:D/ZN)A2L)TJ@E1H58\!9HDTWIP@AFTP<VX+!HT)L'3/N0>:X_OO!
MT-CPECR4GCJ XONS+S=S2ZIK^<"NK1TZ94N ;"UYFCJ0" 4+)$=IM3 L16SM
MSF]!UKA;8&NHM=9#!]#:X%8NKVWE0=\R1YLI" :3JH= OB0X(A^*I< X2VZ<
M:STC:Q\ZQ_7]6X-O<$UU@,8G;"NA$.B+ Y/KQ$04#*)W$EC R$K4A:?6N&NP
MO0T6#;1&6$/I-XL+AA^7]2+G54)3F+Z9K>;)UB]:S\1Z=)&A!E]MS]DQIELQ
MPS3WT4.*S@$=D1Y<H>C"AU""E(FKX6;P##G=ZBHFOS-5[(%4</J!W^:SQ9W,
M\/4;G:1=NC8+PZS(8W#UI3<8T"0QSI268;AN6X<2W\D;U:%X>Z*IT9&4V\$!
M_%174<S!:9\%T&;AZ7B) J(@\4;& D-R=KWOL=_OL?H9'0LH.S8%WD5K/8'P
ML1:CQHD8?4H0'"/S+BZ3Y!0')RBR%UY';8XP+/&9-07>"0C[- 7>12L=(&V7
M-J)"*15R"."5KAF?%-C'4DOV9$DV,%N+E1L#[L=J"KP3-@YH"KR+HCK X$XM
M9K,2)41;TP #@C(I0XS$6S*%J9P36MVZ/.G'; J\$T@.:0J\B\8Z0..KL%A<
MD&?R ;^2-#%?FO C<M2^"$MRM"S5.7?&D'F3EZW(PQ88&7'=^J5M1Q+'O8(^
M%B:'U%L'L-QRO)DG!YK5'K;66U%;?9,L@R6?6F>N>*C]OEMOC]M1ULE3<"]1
M2BL=]H3,K<8*H5,\B5P+!59WJ#Z!CTD ,UEYP=$7;-T*>"<".W$C&R+DH"&&
MNZBK)RP^,-6,G.Y2'$G)%EF'$^@(CD(^"#YJ;;(7-O8V9ZZ3(88[@6"'.7.[
M:*13<*VGFA4IR'$1'E#58J42:IJK+Z""8#X%K9(=[-S=<\Y<)T,,6X-K'XUT
M *Y-32:<",9P)T#H5?V28A"UC*#1.RM<$:IY5LLA#5Z.U>UY) ^NA98Z!=N]
M;A96V^+)<&QM/D&VHL&GE&K07A)Q%4/S9XYGV@5F)]7OW@5F!SV,71C]YO3T
M?#8_Q3Q)M\IXK5-1&IO!\MKHC?9T,CP;:BF(UK1')YVVZP;SX,?WAXD#]#=O
M*LP.]IF'7V->+_!_SVL&UV4?B1 ]HC2 LEZ*&T6Q3'(!BA!,:\8L;=='>5"]
M0U97C>3'OZYHHKV> /D00U<F*V,N7.1,C)A(&WHL$'U44$AFEG,4=KALE,UD
M=1(OMH+"%I<2A^BE4Z@M;UOINO5)X<A"DI!BS5?4V4% ;R$DX1A+C&<W6$+)
MXZ1U KE6D-CF'NQ _?0$NP..CK?7%5 H V=.93)B94'5VT9O601D60M'SFV0
M@^68M&"@DZ:D?1SC1T=$!^9PTP#X ]8MH]IU.*L%ZA?\I/@2LXH!)*]=IS@B
M!(.*,,F8PZB]<*U=S\?HZ62_/3Y,OFM*T4AG751UOYW//G_"Q6EMM7$MXQ//
M+!.:6^"QYJ$E0\Y23C4C+:0@@I(IM\ZE>I"03FZ*1\?<X5KJ8K.+9V]FR[/%
M^64]\V5"Q&4BQ(F5+'/T"DPBATD9R2%&ZR GBR'98*5SS3>[S?0\_]OD5IM=
M(YUU@+^K-D$?YA=A6@5Y6:EW=BF\=/G%21 6E3.U/R!#VL"=)9]=:V EY^QU
MLEPU[RJV!5W/_\*G#1Z;Z[ #7+XY_4KRK?;UOKPAK<X^3\BIOA3UFUG&0C[&
M&4[)X<C7+:]^F<_SOR?3Z0GG0G L#DB@ I0EL3J>##ACZ_BO*&7FC?%Z"+W/
M/^)I@^.CZ;P9OH<O]/QX?GH:%A?SLJ$]1.N:SVW7&ZK\<R]^CU$)RCE: G<$
M69L<*\0$D<<$@6/VW$NGW-^S$M0RQPTG8Y<^RGJP2 @R:+"1">6+L<@&NPS]
M@2M!=\';<)6@NRBW Z_AUIO'=8>)U8RJRV?_+*S2 B$B>3_DFBL(.=&7,2 O
MEB4NFW< >8R@3M!W7)!L?K \4&,]P>]Q26XW8.VN.*Y>3Q)W-?LR@,ZU9[NW
M%IS( 4Q)F$5DT00]%(2'8JH3,S@<@)N@W04:QLXT>JJ]V?7T7%];-4;@*3$2
MN."7;8I53L4I;K"H[>8Q;+=>)]CK R'S8=75P0:]*2&P-B!B))%:X!MK\$@G
MF!$%LDO(4S9&A&,,T/N!:JX.\0E::*E3L-W--$0ELLZ2 >.K8HI2P,440 7O
MO>5D6=L-5/OQ,W9W4OW.&;N[Z&'L<_3>Z,'$?4:= 37]HH2L/4&=@IB]#,KP
MB"9L=5P^J[F-.^GKD;F-.PBO@_VD[46M+ZYH:SWDH.GD+K57=N)T?#-TK%@;
MK6Y=I'+\-*&N'R,;!L]'1T1/YG"X\_PJ3-/Y=/7'#_/I]/5\\>^PR'3H,%>X
MIV@O.-H?E/ UE\M1+,A6?0B4$X/5/0_%5"<!S_$!.UQPW@ ]/9G3K=>8_YF<
M??F.^>5=[I<?[FGG*D"\S,9104O'E("2:T6G"P9B=!ZL=]JBQ*A$\UDK0S#2
MB=GT =8MLK*/BYR]S><K+B;S_/$L+,Y&-:(-DOC]?)&^A"4N3USPPKKZL*UJ
M@_: &F)R%JQ&3O\YJ?U@3Q>->>GDAN.',J6F^'G&A]$&.?Q"0>/;^;(694[/
M<QV*]W-8U!SEY8DI%$>B,223I$"1MPU1K(8:.Z-KJPM29=^&M9FY3D*DOX.E
M-4+8V)=+C:5R-?WAY[]H%YI]KJ4!-Q]+![QR2N@(C',*?(N5X'Q&D"5:3*6^
MM6WWTG-$HCO)..W*HKH&SC,^RQYWCU&(6)0FUMWJ"C10V.MJB5G24B1E Q.M
MBU'&"ZR&SWWMRJ+Z0<Z!@=7/LSQ4LNSUW.,R7RS#%.].10ZS?'^R[75BZ>U_
M^?'[?WFV;I2;;]+S]L^Q'8/,!JFYHTNW44;O_>G8M^9FK_,L<\2H-&9P@B=0
M"0MX;CTDH9/CV:+4S6M;GJ3JT#/G8_J"^7R*[\OFM2Z?'Q*S=&R28QIT9=\H
MA$!'*FC+@U%!&]2M+^BV)F[DD>UML7-_<Q]&13WX.^LIK3<E<I<-4,EO*R05
M8,00*!(=!$9GH@C%"!X2Q]BZZ?8&4L;%U4"*O^\[--!"!V#ZM BS):U<GXH^
MDLLS2>35O"\/<+?\1!^Y?/BOKM(&F'?,8R;/)TORQ31+X&0,P)G6!853V;?>
MZUK2/_(;1 M S3O1;@?(_N/CI\7*K;_E15WEI2@C&%INH ZS!N5U 9>X)78,
MK_V:<A2MRQ<W4S,NZL9#R'P0=74!O%_FWW Q6UGP9R19X?*NEW[%EU929<,\
MY%@G.S@Z@Z)UM96-CU'R@LYA<QAN1]NX;T@=@7( 57;1@>7J O"&O0?9<NBR
MT+62/14$)9.OKA+)+I0L WH52^O^&%L1-N[#2S?P;*_$#K;/5[@XFY0)_5B5
MW$_X=;Z<G*U;O5IK4#(#%/WYFK.@H!984'B(&EF*D3?/=GF$G'$?*[I!82N%
M=;$OOIHOOLX7Q,J#IF1S0-22@RC%U+%=&B(W$3 $@4J['%7K<1F/$C3NY7X_
M"&RFM%$QN'KH^X"U&&QV1D)Z-U^<?0Z?D<2[2N=\&=*?F+_C+\; 70X%R-8T
MJ.01G%$);/8ZRI3)/]ZN1&'GI;>"G_EAX7<$?76Q)VYSH?;V.FF8A^3JA05P
M=.1N.%L@.E]KBC2SLGBRQ-9[Y$X$CAO:'.=R<CB-=0'(N]O\?19?G-;IBO_!
M_&J^/+ON8W35P^O-C#Q57)Z]*/3[B^ET_F_:$>J_?$6,3,YJBM&)2DI';Q/)
MN\Z(%ZOJ)UT;SNE8N$;IFE?N#,M1__?Q>X+Q@;Z!G>!B_T!J?A:F;3H/WN/_
MGG12.C^M^128?UD0=W_,%ABF53PUU>YE?5[&3^&OD\"L$"[3086!@>)&0N#&
M0A)21!FSC:9U0XPFA/>_S;?!_/&UW,$=P;Y,5S.^85IHSS0K"#Y:$KM.$3Q/
M APSV6>/-C7?YYL0/N[M5__0WE_+NT/;7T)[AI\K(4?P;C8=7"<4R$K'90'I
M+,DWBE#',7#PSG/&<TC&MKX;VX_2<:_->O%&FNBQSSZ;0R6WO9E=-LTYGY_?
ML_;?YY=M##I,)-R>Z([3"O>4_/&2#"V+3FII(%.@3,$RLQ!"1L@8A+=:2AM;
M;W[#)QD^OH$\K(?KK,_+2P1M8XB.<3#9)%!,:PI>K 1K15)."B]4ZR?FPZGN
M/BUQ%[3M=BHT5VH'SOJFQ":!V=04#BA%Q-K:C('CQ=:151)YX>A-\X:_/>8K
M'AL16R8R[J*>#E#6]#4@!Y:TI9@A1;MR]E3MZN<!N9)<HT\JMZX&__$3&7<"
MU)")C+MHMP-D/Y(9YX(WR60%25@.J@Y$B5[:VDPUV\A*MJSU*+J_12+C3@C9
M/I%Q%W5U ;PML]^,E=*0&5.@RG6MP":^(@HP.AEGC!?6_U\BX\B@'$"5'4!T
MNPPX$61&1 Z^!'79QRH@BR"S+CD$ZWAJG>_]=TMC/ 2<[978 3(?RXHSL1@5
MZ1S@(2"YZQ'!:880&4DKB^BY:)U6^_=(8SP$A:T4U@/V'LV'X]S):%T&7A,S
ME=8,HC,6I" 7O'"E,V^.OK])$N-!^&NFM+&;W.R>$F>2+1Z),8S!D6/,,GAF
M%'G'+'%O+1I_[R7V_U(8FX#O"/KJ8#_<?*7[U+/&33_5]=UO4DF+3!Z(E\*3
ME(4&G\E+3C(4H8U"T_QJJ"'YXX9#(]]TC@6#9VT!M](LZK>O!2!]9"4@;2\Q
M<5""G",GZS!*<I.4EBPE;#W1HSD3O3XT#0S'9F;1 AL=&,?CV])30GB+R^6G
M+V'&Q3OZR2_+>T(YD2EH93/Y:X%)4%(A>*4%)$.BX*OBY=;];P9EZ+D:31.P
M[O28>TSD')JY]JD3:UK+XOWB[7SV&1?W96)B=H+V-#KZ99VWY2(X@ZMN&.2
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MW?DIYAO9W(@C>ZF$$05"X+7K',\4%KH /!>7,Y.EJ-:/% .S].Q2W0:SA=&
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M$>?>4/B&BS@?8)(JN0I%9;202O7^:EP1;23O+U@*+R)B"'XK+#SG2:I[0^$
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M>U/3&##XF)&ZXZ7HZ+W( I!)<G(]TC&M? 8T7A699)'8''+/T#-,/&T0,^M
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M7-]>[3]VG*%!BZEXP.!K5_M@(2J5H38)I3L]"Q5:!ZZZ4S?JM(]CD-:3@D8
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M I6L)W%P"8$GQKQ59'%UZC7]PI7PV-K#YM2-R+XX6C'C -;FB>::@^5VQZ6
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MG^O'O\3TOR[FW_^#/OI:\_3-K=(?67#8$HR1W!/'*F)@#%U3O;6\3.'<NVC
M>Y]I&PE'WR421[&R..%S=,^U@'T90'=7&^;0.%I=\P:R&]H'V70(V"4VI"(-
MWSA+KM!E28=>B"0+X\CH#DIJTS$/Z<Z'#J?:PU7RH(/" ?(900NLW73QS=CP
MY70C\XIQJXWS2)>CL\2+LHR#,X(\YL1B3F)SNW4Q"PZ8"'^/E&&+K$9R:[14
MUTA1=SVW?M>2SFG+8D@>DG:6W.W (; @P659I,TJ,MYZRN.+1 W;D*B)ZCO
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MT1E%LOL1]D@A=!-85;O :LZ9*^8Y[8::)(Q&@&/6@S"AD"]1O.C8B:CKBMT
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M24^80BXE[096JVN4Y :<EQH2T[1;5$'F6S]=/$_1J,.&^Z#C0;.X=HH812K
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MG5<U-T9A*R-H HEG9!-?<'I5CZ27\\7?Z=^N)J%8\OE2 L.LJ*L]$)PSAO[
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MYIX6',E'"8R!Q%5J'5_6X(.0ZV,S^^"M+H,L#N^!^7$RR3_M?B3X/FN[WR8
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MV/W/40"7;O=#PO=9V_U!'=7,E:@"!K!**E!>U+F$(H-Q/#'-H@WZ<HS^YRB
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MXHO0K9]*GB!I7,2="QGSX=1T..K\!G6S]7[@.IZJ$?A^W7[ZXT*=\)RM+#%
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M1NDCBCR:LJ4,1:AC,+XHK K3&TC@FF<;!H+8 OU0NST@&X&5 8H>L4]E@((
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M0L$^K^0U\ /RL41N^)^:JR7HY2^E@OD>X&6>^ /7\9^A"[[&R93:!X60TPF
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M7[>_D'J_S0[/#MK@JZ,N^,O_OCJ*W[3V_%[?]>]O/_A+IL'-#X.[GS<NQEX
MXQ8YHW:0YPX0K>B*V+)%;,G\1R*V]-<7&H.=.T<?@SVW>,3E-Q,E4_9N54/>
MASYVU_=-S\D;I'](07AR!UWH< G?"U_F9G+G5GKM><_YK?44/H+S2[<[Y1,7
MV=5ON%;W%_Q7_P502P,$%     @ 3H)65F^-UA!I!0  K1(  !T   !G:6QD
M,C R,F9O<FTQ,"UK97AH:6)I=#,R+FAT;=U8;6\B-Q#^WE\Q1]1<(L&^ 8$
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MS9\^Y661DU6/"YN''=1?HQA+K>6B9XKTUBQE"<G73JP_)U[SB^.N=]0UV_-
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M/>25JY/UTUWDV"NEDW\ 4$L#!!0    ( $Z"5E;\MY'(1QD  "IO   >
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MPF(.\_!&=7<&17[>@ 5VRFTPBQ-= ?/0%'"<"XPF?@&=*\J1K(>P? TKI_"
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M05'!YL@L,S:GZ"-FO5 \M:,5>'NW498''6!4&9 *S3$-O@+32(WY$702S)S
M%BH646^ -WY>53ML0W/FJS3 A\AQRFWBPI)PC]\+!JN9AR04QEF%"B4S4W',
MC?]FTT?9'EIU*!Z42F*G16S>2/F=5+ONH@U?',N"N+J11F2\0)%D8P91*4 /
MAXP%JP=&S*<*BB4\"2:I*)#4[4LCPYP,4L^L4GV0'5@:B(,VM"L9_*RK!GW$
MQN4+,$I,>P7:SH,0QQR+6F=[: \E2-Z-+IN2S"4M%3:57NEU'0=7OECPV-#1
M6H!7*\@/ER#CNB*=GVYP\PD8-%(^!">M=+=9 7)HQ9(:@UAXMQ@H#8Z> 0IL
M9&]5Q%F:$AGUP>_]Y3OH[OW%F-6 WO-:L*[?G$UA>WJ&TP ?V&@B&SQ'T.C5
MOJ*.9?E*W6JK/UUAW1P97L#$_;>5>(UY]H<(P"^I%<*INHMYN0;@DRA4 T"A
M_15(N)?V3&2*Q!1WNT_P*Y-NAE6&4"1X@%SK0X;H::S;D8B5\+OS780'<ZF#
M;:!09V&\JTL-@(<TE"U//D=F)Q%39\A0S[?^-=@?"QY%9#,%-@E\D(-I5!4!
M?I)9 &'I>"EO>-:M"^?F'?CZ*K^+KI:H-O%_%TW\% @R")QU5-^>K!#K6WL
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MIZ9+WDH9 ].DVWNU&II$/NUJ.\M(F(#QO>%N(@BD'6&X& JS(0(XB T87 W
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MM6)N+LF^B=YD8X\.9G@PR"($Z'_OS*>R.)X]5YFOIK_DVS?@*;Z%0=:-57R
M3(A4V;N_C^3./X^!']_),K(B_?,G9(4_E;;&"B'V7PC\K3_\BRCN]><!^AM^
MLPVZ]R^U^41.+^WQ;Y&CWV?WU?\!4$L! A0#%     @ 3H)65F)Y@K%*/@4
MAC(^ !$              ( !     &=I;&0M,C R,C$R,S$N:'1M4$L! A0#
M%     @ 3H)65N?N&XSF(0  V94! !$              ( !>3X% &=I;&0M
M,C R,C$R,S$N>'-D4$L! A0#%     @ 3H)65HV6YB ?.P  !7T" !4
M         ( !CF % &=I;&0M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M $Z"5E9Z]H( J<(  '6U"  5              "  >";!0!G:6QD+3(P,C(Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " !.@E96OT+ORT.L  !$"P$ %
M        @ &\7@8 9VEL9"TR,#(R,3(S,5]G,2YJ<&=02P$"% ,4    " !.
M@E96ACO@WK?; 0 \L!, %0              @ $Q"P< 9VEL9"TR,#(R,3(S
M,5]L86(N>&UL4$L! A0#%     @ 3H)65F_SG:#1( $ @%(- !4
M     ( !&^<( &=I;&0M,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( $Z"
M5E8%]#'$PP<  ,R=   >              "  1\("@!G:6QD,C R,F9O<FTQ
M,"UK97AH:6)I=#(Q,2YH=&U02P$"% ,4    " !.@E96V=66P P$  "F"@
M'@              @ $>$ H 9VEL9#(P,C)F;W)M,3 M:V5X:&EB:70R,S$N
M:'1M4$L! A0#%     @ 3H)65J#G2F*^!P  82   !X              ( !
M9A0* &=I;&0R,#(R9F]R;3$P+6ME>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    (
M $Z"5E:/2;E8N0<  #L@   >              "  6 <"@!G:6QD,C R,F9O
M<FTQ,"UK97AH:6)I=#,Q,BYH=&U02P$"% ,4    " !.@E96;XW6$&D%  "M
M$@  '0              @ %5) H 9VEL9#(P,C)F;W)M,3 M:V5X:&EB:70S
M,BYH=&U02P$"% ,4    " !.@E96_+>1R$<9   J;P  '@
M@ 'Y*0H 9VEL9#(P,C)F;W)M97@Q,#4P;V9F97)L970N:'1M4$L%!@     -
-  T DP,  'Q#"@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
